,nct_id,primaryOutcomes,secondaryOutcomes,otherOutcomes,startDate,status,study_type,phases
0,NCT03646721,Adverse event,HbA1c,Assessment of key metabolite(s) of DA-1241,2018-08-29,COMPLETED,INTERVENTIONAL,['PHASE1']
1,NCT02275845,incidence of gestational diabetes mellitus in both groups,Neonatal outcomes,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
2,NCT02331147,proportion of ulcers completely healed by the allogenic dermal graft protocol of care to the standard protocol of care in the management of indolent diabetic ulcers at 6 weeks,Mean time to healing,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
3,NCT02682121,The primary outcome will be gene expression levels of mitofusin 2 and uncoupling protein 2,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4,NCT03747978,24-hour blood pressure,night blood pressure dip,,2016-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5,NCT01814735,"Changes in fasting blood glucose, lipids, and blood pressure",Feasibility and cultural appropriateness,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
6,NCT03386097,Cholesterol level in skin biopsies,,,2018-01-10,COMPLETED,OBSERVATIONAL,['NA']
7,NCT00295633,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8,NCT06281301,Number of participants that showed Macrosomia knowledge greater than 50 percent as assessed by the score on a survey,,,2024-01-30,RECRUITING,INTERVENTIONAL,['NA']
9,NCT00004266,,,,1993-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10,NCT01271231,Glycated hemoglobin,Probing depth,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
11,NCT02058160,Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30,Percentage of Participants With Severe Symptomatic Hypoglycemia,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12,NCT03176472,Change in Mean Average Pain Intensity (NRS),Change in Non-pain Neuropathic Signs (UENS),,2020-12-07,COMPLETED,INTERVENTIONAL,['PHASE2']
13,NCT01275820,Glucose blood level,Dosage of Insulin,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
14,NCT03878758,Injection Site Pain for BD Nano PRO Needle Compared to Each of Three (3) Commercially Available Comparators,Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Force),Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Total Injection Time),2019-02-07,COMPLETED,INTERVENTIONAL,['NA']
15,NCT02148861,Number of treatment emergent adverse events,area under the glucose infusion rate - time curve at steady-state,,2014-05-26,COMPLETED,INTERVENTIONAL,['PHASE1']
16,NCT01001104,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks,Percentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
17,NCT02157480,Mean CGM glucose from a 6-day CGM recording,HbA1c,cardiometabolic stress test,2014-09,COMPLETED,INTERVENTIONAL,['NA']
18,NCT03660384,BCVA,,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA']
19,NCT04841720,Tmax,AE/serious AE,,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
20,NCT00527254,HBA1c Glycosylated hemoglobin,"Blood glucose, Total Cholesterol, HDL Cholesterol,LDL Cholesterol, Triglycerides, BMI, systolic and diastolic blood pressure and system adherence",,2003-10,COMPLETED,INTERVENTIONAL,['NA']
21,NCT04734158,corneal epithelial thickness,,,2019-08-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
22,NCT04407819,prevalence of sarcopenia in patients with T2D and in the control group,fat mass,,2018-03-20,COMPLETED,OBSERVATIONAL,['NA']
23,NCT00520065,Positive area under the curve (AUC) for plasma glucose and mean glucose level,Adjusted peak values for plasma glucose and serum insulin concentrations and positive AUC for serum insulin concentration,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
24,NCT03378635,Time to Plasma Glucose Recovery,Time to First Rescue Infusion of IV Glucose,,2017-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
25,NCT03662997,% of Participants With No Strike-through After 7 Days Wear Time at Day 7 and 21,Mean Difference in Score in SF12 Health-Related Quality-of-Life Questionnaire,,2019-03-19,COMPLETED,INTERVENTIONAL,['NA']
26,NCT03205436,Time to initial closure of diabetic foot ulcer,Mean cost to heal,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
27,NCT03580330,Mean HbA1c,,,2014-04-17,COMPLETED,INTERVENTIONAL,['NA']
28,NCT01307904,Dates Glycemic Index,,,2010-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
29,NCT04742023,Average Daily Glucose,Total Insulin Use,,2020-04-21,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
30,NCT03741660,change in systolic blood pressure,change in apoB:ApoA-1,,1991-01,COMPLETED,INTERVENTIONAL,['PHASE2']
31,NCT05919667,Change in blood glucose level,Change in plasma amino acid concentrations,,2022-02-28,COMPLETED,INTERVENTIONAL,['NA']
32,NCT01302327,beta cell function,,,2011-03-01,WITHDRAWN,INTERVENTIONAL,['NA']
33,NCT05123963,Change in glucose control.,Change in plasma cytokine levels,,2021-09-15,RECRUITING,INTERVENTIONAL,['NA']
34,NCT03878706,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.,Comparison of liver steatosis level between treatment groups,,2017-11-03,RECRUITING,OBSERVATIONAL,['NA']
35,NCT00657800,Quality of Life (QoL),Emergency Room visits; admissions,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
36,NCT02802644,Neointimal coverage assessed by optical coherence tomography,Biomarkers,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
37,NCT04659330,glucose variability,Insulin dose in patients with and without lipohypertrophy,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
38,NCT01051674,Weight,Hemoglobin A1c,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
39,NCT00721084,Total energy expenditure,Physical activity related energy expenditure,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
40,NCT04442334,Detailed Characterisation of the NAFLD Patient Phenotype,Health Related Quality of Life: NASH-CHECK,,2015-05-01,RECRUITING,OBSERVATIONAL,['NA']
41,NCT00849576,Postprandial time course of Asymmetric dimethyl arginine (ADMA) after injection of insulin VIAjectTM compared with regular human insulin and insulin lispro.,"The secondary objectives are to evaluate the postprandial time course of arterial elasticity (pulse wave analysis; PWA), blood glucose, insulin, intact proinsulin, nitrotyrosine, glucagon, ICAM-1, VCAM, E-selectin.",,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
42,NCT03761446,Mitochondrial Respiration,Physical function,,2019-03-18,RECRUITING,INTERVENTIONAL,['NA']
43,NCT00973830,Diabetes knowledge,Change in HbA1c reading,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
44,NCT03544541,Carotid Intima-Media Thickness,,,2018-01-05,COMPLETED,OBSERVATIONAL,['NA']
45,NCT03219411,Fasting plasma glucose at 12 weeks,Area under the curve-glucose during OGTT (oral glucose tolerance test),,2017-08-28,COMPLETED,INTERVENTIONAL,['PHASE2']
46,NCT05668325,Home Based Mini Trampoline Exercise Tracking Form,,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
47,NCT00734383,"Perioperative Plasma 15 f2t isoprostane, a biologically active marker of oxidative stress","Perioperative (includes coronary sinus levels) plasma antioxidant concentration; ET-1, TNF alpha, Troponin I, peroxynitrite; gene and protein expression of eNOS and iNOS; hemodynamics",,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
48,NCT02644590,"blood pressure monitoring , pre and post treatment with melatonin",,,2016-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
49,NCT00456300,"Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone",,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
50,NCT05746975,Peripheral DR lesions characterization,Correlate and analysed DR findings in each imaging technique with disease severity,,2023-04-03,RECRUITING,OBSERVATIONAL,['NA']
51,NCT00607139,Glucose level at which counter-regulatory hormone response is achieved,Accuracy of the Guardian-RT continuous glucose monitoring device,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
52,NCT02225379,Positive Predictive Value of the hypo-Sense,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
53,NCT01784289,Measure of blood Interleukin 7,Count of blood lymphocytes T,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
54,NCT02589730,change in glycated hemoglobin levels,change in scores measured by MKT,change in scores measured by self anxiety scale,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
55,NCT04014023,Change from baseline in HbA1c,"The proportion of patients who achieve HbA1c < 7.0%, HbA1c < 6.5% and HbA1c reduction >0.5% from baseline",,2019-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
56,NCT00566319,2-hour glucose,"Pedometer counts, Fasting glucose, total cholesterol, HDL-cholesterol, LDL- cholesterol, TNFα, IL-6, CRP, systolic and diastolic blood pressure, body mass, waist circumference, BMI, physical activity, psychological determinants",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
57,NCT04853537,gestational diabetes,any associated comorbidities questionnaires,,2021-08,UNKNOWN,INTERVENTIONAL,['NA']
58,NCT04181307,Number of Participants Who Are CW-Compliant and CW-Noncompliant,Number of Total Prescription Encounters,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
59,NCT01479933,Insulin sensitivity,Adipose tissue gene expression,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
60,NCT06073756,Neutrophil-to-lymphocyte ratio and platelets to lymphocytes ratio,HbA1c with good glycemic control and have HBA1C lower than 7and poor glycemic control and have HBA1C higher than 7with prescence or abscence of vascular complications,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
61,NCT00361153,"To evaluate the effect of 8 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method, i.e., placebo-corrected change from baseline in M-value.","To evaluate the effect of treatment with WelChol on HbA1C, insulin, fasting plasma glucose, and fructosamine.",,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
62,NCT01293318,Association between copeptin level and severity of pancreatitis (according to Atlanta classification),"Determine whether change in copeptin level from day 0 to 2 is associated with organ failure, necrosis and/or superinfection",,2011-03,COMPLETED,OBSERVATIONAL,['NA']
63,NCT04019938,Serum Cystatin C,Bone mineral density,,2019-07-04,UNKNOWN,OBSERVATIONAL,['NA']
64,NCT02653599,Change in HbA1c from baseline at 12 weeks,Pulse,Change in glucagon-like peptide-1 levels from baseline at 12 weeks,2015-12,COMPLETED,INTERVENTIONAL,['PHASE2']
65,NCT02220296,Incidence of adverse events,"t1/2, the terminal half-life of insulin 338",,2014-08-20,COMPLETED,INTERVENTIONAL,['PHASE1']
66,NCT01103284,Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months,Mean Number of Days With at Least One Hypoglycemic Event,Percentage of Subjects Requiring a Daily Insulin Dose ≤ 0.5 IU/kg at End of Study,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
67,NCT02340260,Glycosylated hemoglobin (HbA1c),,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
68,NCT03291834,Occurence of hypoglycemia or hyperglycemia,Measures taken to prevent hypoglycemia or hyperglycemia,,2017-08-15,COMPLETED,OBSERVATIONAL,['NA']
69,NCT03714646,Plasma acetate concentrations (microM),"Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK)",,2018-09-05,COMPLETED,INTERVENTIONAL,['NA']
70,NCT00166803,"Vulnerable plaque analyses by PET: Define plaque location and activity at baseline, and compare with the follow-up scans site by site.","2.Biomarkers:hs-CRP, MMP-1, MCP-1.",,2005-06,SUSPENDED,INTERVENTIONAL,['NA']
71,NCT04812262,Number of participants with clinically significant abnormalities in 12-lead ECGs,Number of participants with antidrug antibodies (ADAs),,2021-02-24,RECRUITING,INTERVENTIONAL,['PHASE1']
72,NCT03722225,"The percentage of the glucose values spent in target range, defined as 72-180 mg/dl.",,,2016-01-20,COMPLETED,INTERVENTIONAL,['NA']
73,NCT02862431,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change From Baseline for Glucagon,,2016-07-12,TERMINATED,INTERVENTIONAL,['PHASE1']
74,NCT00674986,Change From Baseline in Hemoglobin A1c (HbA1c) at Month 12,Glycemic Variability Pre and Post-Prandial Excursions at Each Meal,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
75,NCT06020664,Proportion of subjects with complete wound closure during the 12 weeks of the Treatment Phase,Changes in Wound-Q Health-Related Quality of Life outcome during the 12 weeks of the Treatment Phase as measured by changes in the subject response to the Wound-Q Health-Related Quality of Life scale,,2023-08-16,SUSPENDED,INTERVENTIONAL,['PHASE1']
76,NCT04124354,Change in Shannon Index (Alpha-Diversity) as Reflected in Change in Operational Taxonomic Units,Change in Body Fat Percentage,,2020-02-10,TERMINATED,INTERVENTIONAL,['NA']
77,NCT03859193,Change in nutritional knowledge,Patient Satisfaction with Care,,2019-09-27,COMPLETED,INTERVENTIONAL,['NA']
78,NCT03574935,Wound healing rate,,,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
79,NCT00553020,To assess the duration of the metabolic effect of a sc injected single dose of either insulin glargine (LantusT) or NPH-insulin (ProtaphanT) on blood glucose control in patients with type 2 diabetes,"To evaluate the effect of insulin glargine (LantusT) and NPH-insulin (ProtaphanT) on suppression of endogenous glucose production, endogenous insulin secretion, and lipolysis",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
80,NCT01642394,Change in Glycated hemoglobin,Change in the diet composition,,2011-10-01,COMPLETED,INTERVENTIONAL,['NA']
81,NCT02512068,Number of Participants Who Had One or More TEAE Occurred After 1st Dose of Trelagliptin 25 mg Tablet,Number of Participants With Markedly Abnormal Values of Clinical Laboratory Parameters Before the Start of Study Drug Administration in Treatment Period II,,2015-08-07,COMPLETED,INTERVENTIONAL,['PHASE3']
82,NCT01029288,"Decisional quality (knowledge, decisional conflict, and satisfaction)",Patient medication adherence,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
83,NCT06171412,Mean hours per week CGM worn,Mean count Barriers to Device Use,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
84,NCT02518022,• Number of hypoglycaemic events <70 mg/dl per arm from begin of consumption until lunch next day (12:00 am),• Max. alcohol in expiratory breath,,2015-09,WITHDRAWN,INTERVENTIONAL,['NA']
85,NCT03117543,Percentage of hOGTT venous plasma equivalent glucose (hOGTT-VPEqG) results within ±10% of paired venous plasma glucose measured on a YSI analyser (VPG-YSI) (reference standard).,Specificity of HbA1c for screening for GDM versus gold standard of 75g OGTT and VPG-YSI measurement (IADPSG 2010 criteria).,Serum insulin concentration at 60 min after 75g oral glucose in pregnant women of Black (Black African and Black Caribbean) compared to White European ethnicity.,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
86,NCT05574023,Less time spent in hypoglycaemia using Predictive Alarm vs Alarm on Threshold,Better glycemic metrics using Predictive Alarm vs Alarm on Threshold,,2021-05-10,COMPLETED,INTERVENTIONAL,['NA']
87,NCT01676116,"Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)",Change From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).,,2012-08-29,COMPLETED,INTERVENTIONAL,['PHASE3']
88,NCT02631148,Change in Systemic Renin-aldosterone-angiotensin System (RAAS) Activity,Change in Central Blood Pressure,,2016-01,TERMINATED,INTERVENTIONAL,['PHASE2']
89,NCT04144920,Glucose variability (mean amplitude glycemic excursions),Physical and Emotional feeling states,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
90,NCT01932866,Change in abdominal circumference,Change in diabetes risk score,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
91,NCT01883804,The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment.,The Change in Insulin Use From Baseline to Study Completion.,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
92,NCT00512538,Time to complete wound healing (full epithelialization with no drainage),Incidence of complete healing,,2000-10,TERMINATED,INTERVENTIONAL,['PHASE3']
93,NCT00119041,A1c,Patient Satisfaction,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
94,NCT01754337,Percentage of time of plasma glucose levels spent in target range.,Percentage of overnight time of plasma glucose levels spent in the high range,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
95,NCT02115711,Absolute reduction in average number of cigarettes/bidis smoked per day amongst smokers,"Absolute mean reduction in weight and waist circumference, for those who are overweight or have increased waist size at baseline, at the end of 2 years.",,2014-04,COMPLETED,INTERVENTIONAL,['NA']
96,NCT01889706,Body fat content and anthropometric parameters,Insulin requirement,Assessment of skin AGE,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
97,NCT01741467,Differences in blood glucose,Changes in medication use,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
98,NCT02562326,Pharmacokinetics: AUClis 0-30min,Local tolerability,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
99,NCT01354262,Change in serum levels of Hemoglobin A1c.,,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
100,NCT01051102,Area under the Glucose Infusion Rate curve after a single dose,Area under the insulin aspart concentration-time curve after a single dose,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
101,NCT05922280,Douleur Neuropathique 4 Questionnaire DN4,,,2023-02-15,COMPLETED,INTERVENTIONAL,['NA']
102,NCT05110092,blood sugar control-HbA1c,,,2016-12-14,UNKNOWN,INTERVENTIONAL,['NA']
103,NCT00666718,Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24,Number of Injections of Insulin at Week 24,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
104,NCT00889668,Clarke Error Grid,User Satisfaction,,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
105,NCT00707031,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Quality of Life: Change From Baseline in Patient's Satisfaction to Treatment (PAGI-QOL) at Week 24,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
106,NCT06234332,Numbers and morbidity of participants with adverse pregnancy outcomes,Incidence of depression in adolescents,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
107,NCT00287456,,,,2006-02-02,WITHDRAWN,INTERVENTIONAL,['NA']
108,NCT06035367,Value of absolute photoacoustic signal on the participant arm,assess the tolerability of the investigational device by a usability questionnaire,,2023-07-06,RECRUITING,INTERVENTIONAL,['NA']
109,NCT05013229,Change in HbA1c,Weekly insulin dose (total),,2021-11-30,COMPLETED,INTERVENTIONAL,['PHASE3']
110,NCT05118061,Analytical verification of StatStrip glucose/ketone meter system - ketone comparison,,,2022-05-25,COMPLETED,OBSERVATIONAL,['NA']
111,NCT03800875,Total percentage of time (22:00-22:00) that the glucose concentration remained within 3.9 and 10.0 mmol/L,Mean glucose level,,2019-02-08,COMPLETED,INTERVENTIONAL,['PHASE2']
112,NCT05399446,Change in Eating Disorder Symptoms,Change over time in Diabetes-Related Quality of Life,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
113,NCT05416580,Change in inflammation marker level: high sensitivity CRP,Change in body weight,,2022-09-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3']
114,NCT05414409,Changes in the gut microbial metabolites in obese youth with type 1 in response to metformin,Changes in measures of beta cell function using a timed mixed meal tolerance test,,2022-09-30,RECRUITING,INTERVENTIONAL,['PHASE2']
115,NCT03526536,Change in blood glucose level,,,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
116,NCT02739906,BG1h,Local tolerability (Number of injection site reactions),,2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
117,NCT00171717,% of patients whose diabetes resolves 6 months after the conversion (fasting glucose < 1.26 g/L without hypoglycemic treatment).,Incidence of acute and chronic rejection treated at 6 months and at 1 year.,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
118,NCT01337440,the difference of haemoglobin A1c (HbA1c) and glycoalbumin (GA),change from baseline in autonomic nerve function,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
119,NCT00715221,"Physiological measurement; Differences in tissue insulin-stimulated glucose uptake used by PET imaging among normal weight, obese and patients with type 2 diabetes",,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
120,NCT05671679,Percentage of time with sensor glucose in the target range,Percentage of postprandial time with sensor glucose in hypoglycaemia,,2023-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
121,NCT02002221,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks Between Treatment Groups,"Number of Participants With Adverse Events, Serious Adverse Events and Death",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
122,NCT02585778,Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs),Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - On-Treatment Analysis,,2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
123,NCT00659477,The change in blood glucose variability,Comparison of dose of insulins NPH vs Lantus,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4']
124,NCT03785236,Hepatic uptake of 68Ga-NODAGA-exendin-4,Islet graft function,,2016-06-06,TERMINATED,OBSERVATIONAL,['NA']
125,NCT01213784,Left ventricular function,Muscle strength and mass,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
126,NCT05317585,Large for Gestational Age Infant,Maternal Patient Satisfaction Survey with Glucose Monitoring,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
127,NCT02747680,Brain activation during hypoglycemia (low blood sugar) using functional MRI,,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
128,NCT02693392,Glycosylated hemoglobin (HbA1c),Post-prandial Blood Glucose,,2016-01-17,COMPLETED,INTERVENTIONAL,['NA']
129,NCT02804620,Change in HbA1c%,ApoB,Weight,2014-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
130,NCT05313529,Change of cognitive function,Change of general cognitive function,,2022-10-08,RECRUITING,INTERVENTIONAL,['NA']
131,NCT03474601,Treatment outcome of pituitary diseases,Complications of pituitary disease,,2015-03-15,RECRUITING,OBSERVATIONAL,['NA']
132,NCT05872009,Number of neonates with adverse neonatal outcome,Percentage of participants with pathological placenta histology findings in case and control groups,,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
133,NCT04527107,"Mean change in best-corrected visual acuity (BCVA) ETDRS letter score from Baseline, in subjects in Part B of the study",Incidence of systemic and ocular adverse events (AEs) and serious adverse events (SAEs),,2020-07-31,COMPLETED,INTERVENTIONAL,['PHASE2']
134,NCT05125185,Change of VCAM-1,,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
135,NCT03568630,"Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.",,,2018-07-26,RECRUITING,OBSERVATIONAL,['NA']
136,NCT03700528,Committed Action Questionnaire (CAQ-8),Work and Social Adjustment Scale (WSAS),,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
137,NCT01030601,Central Retinal Thickness,Best corrected visual acuity and incidence of laser treatments,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
138,NCT05647083,Means of diabetic foot risk score,,,2022-09-09,RECRUITING,INTERVENTIONAL,['NA']
139,NCT02729441,24 Hour Ambulatory Blood Pressure Monitoring,,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
140,NCT01237119,Liver Histological improvement,NAFLD Activity Score,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
141,NCT01730534,Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.,Subjects Included in the Endpoint of All-cause Mortality.,,2013-04-25,COMPLETED,INTERVENTIONAL,['PHASE3']
142,NCT02848833,Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug,Number of Participants Per Final Effectiveness Assessment Category at Last Visit,,2016-08-10,COMPLETED,OBSERVATIONAL,['NA']
143,NCT01032395,Differences in the Seroconversion Rates or Significant Increase by Visit (Vaccine With Adjuvant - Vaccine Without Adjuvant),,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
144,NCT04728620,User Experience,Order Completion,,2021-05-06,COMPLETED,INTERVENTIONAL,['NA']
145,NCT05395442,Collection of Post-Test Data,,,2022-06-03,COMPLETED,INTERVENTIONAL,['NA']
146,NCT00993473,"Event Rate of ""All Hypoglycemia"" Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)",Average Daily Blood Glucose (BG) Based on CGMS Values: End of Treatment and Change From Baseline to End of Treatment,Nocturnal Blood Glucose Variability Based on All On-treatment CGMS Values,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
147,NCT01633762,changes in postprandial GLP-1 secretion,changes in metabolomic profile,,2012-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
148,NCT02829593,Change in Euglycemic GABA level in hypothalamus using MRI,,,2019-10-31,COMPLETED,INTERVENTIONAL,['NA']
149,NCT04064996,Pain assessment With Visual Analog Scale,Albumin levels,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
150,NCT05473767,Change in postpartum weight retention,Change in physical activity,,2022-11-18,RECRUITING,INTERVENTIONAL,['NA']
151,NCT04974333,HbA1C,Waist circumference,,2021-10-04,UNKNOWN,INTERVENTIONAL,['NA']
152,NCT04316429,Change in Endothelial Function (EF) Assessment:,Change in Physical Activity,,2020-06-09,COMPLETED,INTERVENTIONAL,['NA']
153,NCT03552991,Quantitative insulin sensitivity check index (QUICKI),Lipopolysaccharide (LPS),,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
154,NCT02081989,glucose uptake into peripheral skeletal muscle,,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
155,NCT06269419,Urinary creatinine ACR,,,2024-02-25,RECRUITING,OBSERVATIONAL,['NA']
156,NCT03174522,Complete healing of all ischemic ulcers on the index leg.,,,2017-04-25,TERMINATED,INTERVENTIONAL,['PHASE3']
157,NCT02627287,Injection success (full dose delivered s.c.) (yes/no),"Grading of bleeding, redness, bruising and swelling at the site of injection",,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
158,NCT02542774,First occurrence of cardiovascular disease,All cause mortality,,2015-08,UNKNOWN,OBSERVATIONAL,['NA']
159,NCT03205865,Diagnosis of Type 1 Diabetes,Detection of Islet Autoantibodies,Detection of Transglutaminase Antibodies,1993-12-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
160,NCT02774876,Area under the curve of sensor glucose levels,Coefficient of variation of glucose levels,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2']
161,NCT03985098,Adherence Measure,,,2019-05-29,COMPLETED,INTERVENTIONAL,['NA']
162,NCT05653050,Time in target glucose range,"Total, basal, and bolus insulin dose",Human Factor assessment,2023-02-20,RECRUITING,INTERVENTIONAL,['NA']
163,NCT02594033,Maximum concentration of insulin aspart measured in serum,,,2015-10-27,COMPLETED,INTERVENTIONAL,['PHASE1']
164,NCT01705899,Change in measured creatinine clearance,Change in glycemic lability score,,2006-11,SUSPENDED,INTERVENTIONAL,['PHASE1']
165,NCT04155996,Data collection - Sleep hours,Data collection - Medical treatment information,,2019-01-20,TERMINATED,OBSERVATIONAL,['NA']
166,NCT01980264,To noninvasively provide real-time imaging of cutaneous histopathology and molecular changes.,To provide a diagnostic tool for diseases.,,2009-08-05,RECRUITING,INTERVENTIONAL,['NA']
167,NCT03635671,Perfusion density,Retinal layer thickness,,2018-09-01,TERMINATED,OBSERVATIONAL,['NA']
168,NCT00696995,"The number of serious adverse drug reactions, including major hypoglycaemic events",Fasting plasma glucose at visits,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
169,NCT02482610,Vascular Endothelial Function,Oxidative Stress Biomarker (Malondialdehyde; MDA),,2016-06,COMPLETED,INTERVENTIONAL,['NA']
170,NCT01401751,To evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.,Safety Evaluation,,2011-07-01,COMPLETED,INTERVENTIONAL,['NA']
171,NCT05194592,Change (%) in LV mass index,Change (%) in mean 24hr ambulatory systolic and diastolic blood pressure,,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE4']
172,NCT05941468,Plaque Control Record (PCR),Oral Health Related Quality of Life(OHRQoL),,2023-03-28,RECRUITING,INTERVENTIONAL,['NA']
173,NCT04075110,Visceral Adiposity Index,leukotriene B4,,2019-07-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
174,NCT04072523,Prevalence of Left Ventricular dysfunction,Correlation of Left ventricular dysfunction and heart failure,,2019-12-03,COMPLETED,OBSERVATIONAL,['NA']
175,NCT02093702,Mean Change in Diastolic Blood Pressure,Mean Change in Adherence to the Canadian Diabetes Association's Clinical Practice Guidelines Resistance Exercise Recommendations,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
176,NCT01689142,Change from baseline in HbA1c,Number of patients with various types of hypoglycemia events,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
177,NCT03686436,measuring visual acuity by snellen chart,,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
178,NCT06056167,The percentage of blood glucose readings at the target glycemic control 140- 180 mg/dL (7.8 -10 mmol/L).,Intensive care unit (ICU) length of stay,,2023-05-17,RECRUITING,INTERVENTIONAL,['NA']
179,NCT06111664,"Prevalence of hypophosphatemia, DPi and SSL at the population level.",,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
180,NCT01809431,weight (body mass index),breastfeeding,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
181,NCT00427401,The primary end point is glucose lowering (24 hour mean glucose concentration).,Fasting blood glucose,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE2']
182,NCT02368704,Show an increase in markers of ER stress in fasting patients with type 2 diabetes,Lipolysis on insulin,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
183,NCT04275479,Share data with the current SBDS Registry,,,2020-01-10,RECRUITING,OBSERVATIONAL,['NA']
184,NCT05764850,Cluster analysis to decipher underlying mechanisms of type 1 diabetes,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
185,NCT03901248,"Interrelationship of adipokines such as adiponectin, apelin, visfatin and vaspin in different glycaemic stages",Change in HbA1c,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
186,NCT00911625,Average Blood Glucose Over 6 Days,The Number of Participants Who Experience at Least One Blood Glucose Level Below 70 Milligrams Per Deciliter,,2009-01-21,COMPLETED,INTERVENTIONAL,['PHASE4']
187,NCT00425269,"Plasma Glucose, 2-h, Post-test","Intake of Fish, Post Test",,2006-04,COMPLETED,INTERVENTIONAL,['NA']
188,NCT00395148,Metabolic parameters,,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
189,NCT01089205,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
190,NCT00059254,Oxygen consumption,excess Post exercise oxygen consumption (EPOC),,2000-09,COMPLETED,INTERVENTIONAL,['NA']
191,NCT01765894,"Glucose homeostasis in controls, type 2 diabetics without medication and type 2 diabetics in metformin treatment.",IL-6 and incretins,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
192,NCT05260931,Ventricular sphericity indices,,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA']
193,NCT03251079,Safety Endpoint,,,2017-07-25,COMPLETED,INTERVENTIONAL,['NA']
194,NCT05618756,Postprandial Triglyceridaemia,Postprandial Insulinaemia,,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
195,NCT02661165,The self-management Interviews to identify if and how patients' spirituality influences their diet and exercise.,,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
196,NCT05629806,Blood glucose fluctuation,,,2022-04-10,RECRUITING,INTERVENTIONAL,['PHASE3']
197,NCT03736668,Measurement of left ventricular ejection fraction,Comparing the volume of the left atrium in Simpson biplane and in 3D,,2018-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
198,NCT01263132,Mean Neuropathic Pain Score at Visit 6 (Week 4),Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
199,NCT02470403,"Part 2: Number of Patients With Any Adverse Events, Serious Adverse Events and Death",The Apparent Volume of Distribution of LIK066 During the Terminal Elimination Phase Following Extra Vascular Administration (Vz/F) in Part 2 of the Study,,2015-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
200,NCT05166122,Referral adherence,Assess AI performance,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
201,NCT03802877,Recruitment,Completion of evaluation procedures,Breastfeeding,2019-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
202,NCT01881958,efficacy will be measured by comparing Hemoglobin A1c,Safety will be evaluated calculating number of Adverse Events.,,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
203,NCT02121717,Change in HbA1c from baseline after 24 weeks of treatment,Percentage of patients who use rescue therapy,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
204,NCT04358263,Percentage of time in hypoglycemic ranges,Changes in glycated haemoglobin (HbA1c),,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
205,NCT00226330,Body weight,Patient reported outcomes using the Medical Outcomes Study Short Form-36 (SF-36),,2005-03,TERMINATED,INTERVENTIONAL,['PHASE3']
206,NCT05299177,"% time spent in target glucose range measured by continuous glucose monitoring (3.9-10mmol/L, 70-180mg/dL)",Change in weight (kg),Productivity lost,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
207,NCT04587336,"Aim1: Differences in Diabetes Distress Scale score by HbA1c level (HbA1c < 9 and HbA1c 9) and by medication regimen (no insulin, insulin).",,,2020-08-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
208,NCT00704652,Morphologic changes in the retina detected by HD-OCT following darbepoetin alpha therapy compared to control patients,"Changes in blood count, chemistry, Astrup and blood clotting following darbepoetin alpha therapy compared to control patients.",,2008-05,TERMINATED,OBSERVATIONAL,['NA']
209,NCT00206349,,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
210,NCT06081231,proportion of time spent in the target glucose range,concentration of HbA1c,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
211,NCT01169090,Change in HbA1c from baseline to Week 16.,Change from baseline in Fasting Plasma Glucose (FPG),,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
212,NCT00359775,Impact on Family measured by the Impact of Family Scale.,,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
213,NCT05036343,Glucose,Change in Self-Efficacy for Managing Chronic Conditions - Managing Medications and Treatment Score,,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
214,NCT04117763,Arrhythmogenic burden,,,2019-10-04,RECRUITING,INTERVENTIONAL,['PHASE4']
215,NCT04029103,self-efficacy,,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
216,NCT00001985,,,,2000-01,COMPLETED,OBSERVATIONAL,['NA']
217,NCT02449850,Food allergy to any intervention allergen,Rhinitis/Allergic rhinitis,Any other allergic disease,2014-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
218,NCT03307850,"Impact of Stress and Exercise on CGM Glucose Levels, determining how these factors affect time within target glucose range 70-180 mg/dl",CGM Glucose Levels greater than 180 mg/dl,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
219,NCT05611944,SSI rate,patient satisfaction,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
220,NCT01217073,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event During the 66-week Extension Period,Change From Baseline in FPG Levels at Week 78,,2010-10-08,COMPLETED,INTERVENTIONAL,['PHASE2']
221,NCT00001368,,,,1993-10,COMPLETED,INTERVENTIONAL,['PHASE1']
222,NCT05941286,"Time in range (3.9~10.0mmol/L, %)",Glycemia risk index (GRI),,2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
223,NCT00168857,Change from baseline after one year of treatment in proteinuria (ratio of protein to creatinine as measure in spot urine sample).,Change from baseline after one year of treatment in the following: glomerular filtration rate; serum creatinine; macroalbuminuria; sodium excretion; high sensitive C-reactive protein; serum aldosterone; and other renal and cardiovascular measures.,,2003-07-09,COMPLETED,INTERVENTIONAL,['PHASE4']
224,NCT01667185,System Performance Effectiveness,System Performance at Alternate Wear Site,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
225,NCT02332434,"production and clearance rates of intestinal and hepatic TRL, in 2 groups of obese patients (15 patients per surgery procedure), before and 6 months after the surgery.",,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
226,NCT03617393,Survival at 1 Year,Humoral Immunoserologic Indexes,,2017-07-10,UNKNOWN,OBSERVATIONAL,['NA']
227,NCT00499707,Change from baseline in hemoglobin A1c (HbA1c) at week 32.,"Key Secondary Measures: Change in FPG HbA1c and FPG responders Change in insulin, C-peptide, free fatty acids, lipids, insulin sensitivity and beta cell function Adverse Events Vital Signs Weight 32 weeks",,2003-10-08,COMPLETED,INTERVENTIONAL,['PHASE3']
228,NCT00042042,,,,na,UNKNOWN,INTERVENTIONAL,['NA']
229,NCT00859755,Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.,Assess the excretion of the study drug and metabolites in urine following dosing.,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
230,NCT05801614,non diabetic HbA1c,Changes in Insulin secretion,,2022-02-28,RECRUITING,INTERVENTIONAL,['NA']
231,NCT02130284,Rescue Events During In-clinic Procedues,,Device Metric/Performance - All Device Deficiencies,2014-10,COMPLETED,INTERVENTIONAL,['NA']
232,NCT04104711,Costs via frequency of complication-related hospital admissions,,Sociodemographic and disease-related characteristics of patients with diabetes,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
233,NCT05766774,Change in fasted plasma Eh[CySS] from baseline,Change in fasted plasma Eh[GSSG],,2023-06-28,RECRUITING,INTERVENTIONAL,['NA']
234,NCT01244152,Weight change,Hemoglobin A1C,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
235,NCT02607007,Subjective Appetite,Food Intake,,2015-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
236,NCT05394532,HbA1c,self management,,2020-10-02,COMPLETED,INTERVENTIONAL,['NA']
237,NCT05556161,HbA1c change,Social support,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
238,NCT04356898,Area under the curve (AUC); ((mmol/L)*h),High blood glucose index (HBGI),,2018-04-15,COMPLETED,OBSERVATIONAL,['NA']
239,NCT03786146,Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) and expressed in micrometers.,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
240,NCT05417841,HbA1c,Time Above Range,,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
241,NCT03805191,The extent of change in MAGE,The control rate of HbA1c,Gene polymorphism,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
242,NCT05532553,Assessment of carotid atherosclerosis,,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
243,NCT00361907,Primary: Assessment of effect of Pulsatile Intravenous Insulin therapy on circulating blood markers for diabetic patients.,,,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
244,NCT00668785,Mean Change From Pre-PRP Best Corrected Visual Acuity (BCVA) at 3 Months as Expressed as an Early Treatment Diabetic Retinopathy Study (ETDRS) Score (Number of Letters Correctly Read.),Percentage of Patients That Maintain Pre-PRP Visual Acuity at the 3 Month Time Point,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2']
245,NCT05446493,Serum YKL-40 and platelets indices in erectile dysfunction,Effect of tadalafil on Erectile dysfucntion patients,,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
246,NCT04284033,"Number of infusion set failures due to ""unexplained hyperglycemia""",Duration of infusion set wear,,2017-02-14,WITHDRAWN,INTERVENTIONAL,['NA']
247,NCT01938521,Fasting and postprandial Clock Genes expression in peripheral blood cells (PBC),Fasting HbA1c,"fasting and postprandial glucose, Insulin, GLP-1, asymmetric dimethylarginine (ADMA),and lipid plasma levels",2013-09,COMPLETED,INTERVENTIONAL,['NA']
248,NCT01473953,Number of Treatment Emergent Adverse Events (TEAEs),Number of Subjects With Antibodies (Positive) or Without Antibodies (Negative) Against Liraglutide Observed at Pre-dose and at Last Follow-up,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
249,NCT03214367,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Change From Baseline in HbA1c at Week 52,,2017-07-17,COMPLETED,INTERVENTIONAL,['PHASE3']
250,NCT03557541,type 2 diabetes new onset,HOMA-B (homeostasis model assessment B cell function),,2014-05,COMPLETED,INTERVENTIONAL,['NA']
251,NCT03672422,Length of time from progression from Acute Recurrent Pancreatitis to Chronic Pancreatitis,Number of subjects with abnormal oral glucose tolerance test (OGTT),,2017-06-30,COMPLETED,OBSERVATIONAL,['NA']
252,NCT03244579,Fasting blood glucose,Shoulder dystocia,,2017-08-20,UNKNOWN,INTERVENTIONAL,['NA']
253,NCT02735044,Change From Baseline in HbA1c to Month 6,Percentage of Participants With Any Hyperglycemia With Ketosis at Month 12,,2016-04-14,COMPLETED,INTERVENTIONAL,['PHASE3']
254,NCT00442325,Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.,"The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment. Change from baseline in apol",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
255,NCT04552600,To evaluate safety of Nuvastatic - Letter Score,To evaluate short-term visual outcomes on DRSS,,2019-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
256,NCT04670198,Glycated haemoglobin (HbA1c),Acceptability of Intervention Measure (AIM),,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
257,NCT00054925,Change in Weight,,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
258,NCT05753436,Heart Rate,Serum Ferritin,,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
259,NCT02035644,change in HbA1c levels,blood pressures,,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
260,NCT00862602,Glucose tolerance,Insulin,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
261,NCT00831779,Adjusted Mean Percent Change From Baseline in Insulin Sensitivity at Week 12 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Insulin Secretion at Week 12 (Last Observation Carried Forward [LOCF]),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
262,NCT01462864,we aim for a 2000 steps increase in Number of steps per day,Brief Illness Perception,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
263,NCT00623610,Evidence of clinically relevant beta cell function.,,,2000-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
264,NCT05007977,Change in glucagon between euglycemia and hypoglycemia,Change in cortisol between euglycemia and hypoglycemia,Symptom score during hypoglycemia,2021-07-08,TERMINATED,INTERVENTIONAL,['PHASE1']
265,NCT01302639,postprandial fat oxidation,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
266,NCT03423589,Alterations in Plasma-Induced Transcriptional Analysis,Intestinal Microbiota,,2018-04-23,COMPLETED,INTERVENTIONAL,['NA']
267,NCT04867629,Proteomic biomarkers,Oxidative stress biomarkers,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
268,NCT06330194,Percent time in sensor glucose target range (3.9-10.0 mmol/L),Frailty,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
269,NCT04019821,Postprandial Glycemia,Time in postprandial glucose range between 70 to 180 mg/dl (4.0-10.0 mmol/L),,2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
270,NCT03913793,Six minute walk test distance,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
271,NCT01665989,Change in weight (percent weight loss from baseline to 6 months),Cost effectiveness and savings,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
272,NCT04305587,Number of Participants With Abnormal Electrocardiogram (ECG),Renal Clearance (CLr) for PF-07081532,,2020-03-16,COMPLETED,INTERVENTIONAL,['PHASE1']
273,NCT01644201,HbA1c,,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3']
274,NCT06186245,Length of stay in the medical intensive care unit (in days).,mortality,,2023-12-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
275,NCT06226727,Cmax,,,2024-02-14,COMPLETED,INTERVENTIONAL,['PHASE1']
276,NCT01344668,Improvement in A1C at 12 months,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
277,NCT01095822,How therapy with valsartan (160mg/daily) in combination with aliskiren (150-300mg/daily) affects platelet/coagulation/fibrinolytic biomarkers in recently diagnosed hypertensive patients with type 2 diabetes mellitus.,"Whether combination therapy is superior over monotherapy with aliskiren with regard to the improvement of hemostatic biomarkers (platelet aggregation, expression of GP IIb/IIIa, and plasma levels of antithrombin-III).",,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
278,NCT04190199,Nutritype signature of T2DM risks in women post-GDM,Smoking habit and exposure,,2020-05,UNKNOWN,OBSERVATIONAL,['NA']
279,NCT03920683,Toe-brachial index,Coronary angiography,,2019-07-08,COMPLETED,OBSERVATIONAL,['NA']
280,NCT03497390,Change in glycemic control,Change in waist-hip ratio [WHR],mortality,2012-07,COMPLETED,INTERVENTIONAL,['NA']
281,NCT02990299,Hemoglobin A1c,Diabetes Self-efficacy,Health Coach Satisfaction,2017-03-24,COMPLETED,INTERVENTIONAL,['NA']
282,NCT03546062,Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
283,NCT00628056,The primary end point of the Perhexiline intervention study will be the change in cardiac PCr/ATP ratio.,,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
284,NCT05586594,To see how many patient with diabetes diagnosed at early age with features not suggestive of type 1 or type 2 are found to have MODY monogenic diabetes (commonest subtypes) among young Emirati patients,To find out the antibodies present in young patient with diabetes and if they are helpful in ruling out monogenic diabetes,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
285,NCT05056376,Achievement of CDC's benchmark for type 2 diabetes risk reduction as a binary outcome (yes/no),Correlation between self-reported and measured physical activity,,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
286,NCT01490151,Safety and Feasibility of TTR Closed-loop Control System as Measure by the Count of Successful Hospital Admissions,,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
287,NCT01802541,insulin resistance,,,na,COMPLETED,INTERVENTIONAL,['NA']
288,NCT03343366,Glycated Hemoglobin (HbA1c),HOMA-IR,,2018-01-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
289,NCT04603885,BDNF DNA demethylation in percentage,Processing speed,,2020-10-27,UNKNOWN,INTERVENTIONAL,['NA']
290,NCT01916694,Glycosylated haemogloblin,Neonatal hypoglycaemia,Economic evaluation,2013-09,COMPLETED,INTERVENTIONAL,['NA']
291,NCT01853332,Social Adjustment Scale,Health Risk Factors,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
292,NCT02777060,Change in Balance,Change in average of longest walking bout,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
293,NCT00254124,"- prespecified per protocol analysis: same outcomes as above, looking at patients who were >=80% compliant with the intervention",- change in blood pressure,,2004-04,COMPLETED,INTERVENTIONAL,['NA']
294,NCT04943692,Change in HbA1c,Incidence of adverse events,,2021-08,SUSPENDED,INTERVENTIONAL,['PHASE3']
295,NCT05476016,Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control),"Analysis of safety outcomes, included suspected de novo DM diagnosis based on HbA1c",,2022-08-29,COMPLETED,INTERVENTIONAL,['NA']
296,NCT00596973,Treatment sucess based on patients' glycemic control,,,2008-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
297,NCT05237271,CPV-measured cost difference,CPV-measured Assessment of use case types,,2022-03-15,COMPLETED,INTERVENTIONAL,['NA']
298,NCT03341312,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr),Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm,,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1']
299,NCT02262832,Serum hemoglobin A1C,Bone mineral density &amp; metabolism,,2014-10-09,RECRUITING,INTERVENTIONAL,['PHASE3']
300,NCT05065892,Neutralizing antibody level,Adverse events following vaccination,,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
301,NCT00798915,"The effects of GIP, xenin-25, or a combination of GIP plus xenin-25 on insulin secretion and blood glucose levels",The effects of xenin-25 on GIP action in persons with type 2 diabetes,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
302,NCT02020616,Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint,"Pharmacokinetics: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC [τ,ss]) of LY3053102",,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
303,NCT01403961,Compare incidence of immediate post surgery complications in diabetic patients with HbA1c > 7 and patients with HbA1c ≤ 7,,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
304,NCT06110728,Number of missed behavioral health visits,,Changes in weight,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
305,NCT00229268,,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
306,NCT06180655,Study Feasibility: Intervention safety,Objective measures using an Oura Ring: Heart Rate Variability,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA']
307,NCT01997424,Steatosis,Steatosis (serum),,2013-05,COMPLETED,INTERVENTIONAL,['NA']
308,NCT00379652,"Potential outcomes for the future intervention include systolic blood pressure, diastolic blood pressure, and hemoglobin A1c",,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
309,NCT02987751,Changes in HbA1c,Number of participants treated related to adverse events,,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE4']
310,NCT04786340,"Incidence of Treatment Emergent Adverse Events as assessed by dermal assessment (Draize score 0.0-4.0) score of skin erythema, edema pruritus and dryness score) of the dosing area",Neuropathy Total Symptom Score-6 (NTSS-6),,2020-11-20,COMPLETED,INTERVENTIONAL,['PHASE2']
311,NCT01399385,"To develop, implement, and optimize new non-invasive methods for characterization of the micro-environment in the thoracic and abdominal area utilizing specialized techniques",,,2011-07-06,RECRUITING,INTERVENTIONAL,['NA']
312,NCT00809705,"Tmax, log (AUC), log(Cmax)of paracetamol",Multiple dose pharmacokinetics of Taspoglutide,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
313,NCT03566511,Change in Arterial Spin Labeling (ASL) signal measured using 3T MRI from 2 hours post dosing to 4 hours post dosing,,,2018-06-12,SUSPENDED,INTERVENTIONAL,['PHASE2']
314,NCT06201806,Glycemic Responses (GR),Assessment of Appetite:,,2019-01-02,COMPLETED,INTERVENTIONAL,['NA']
315,NCT05152121,AUC,hypoglycemia epizode,,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
316,NCT01104701,Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population,Number of Chemistry Laboratory Values of Potential Clinical Importance Observed During Treatment Period - ITT Population,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
317,NCT00970567,"glucose metabolism, time course of positive ketone bodies",,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
318,NCT01572389,Change in Patient Health Questionnaires-9 During Intervention,,,2012-11-01,COMPLETED,INTERVENTIONAL,['NA']
319,NCT03513939,"To assess the safety of the Cell Pouch following implantation, and islet transplantation, by evaluating the incidence and severity of adverse events (AEs) determined to be probable or highly probable to the Cell Pouch",Proportion of participants with a reduction in HbA1c >1mg%,,2019-02-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
320,NCT03186560,Microcirculatory flux in the lower limb of the different subgroups with geko device on.,Adverse Events,,2018-02-12,TERMINATED,INTERVENTIONAL,['NA']
321,NCT02020850,Toe-Brachial Index,Ankle-Brachial Index,,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
322,NCT05233592,Total Daily Insulin Resistance (TDIR),Change in Time in Hyperglycemia,Post-hoc t-test,2022-03-08,COMPLETED,OBSERVATIONAL,['NA']
323,NCT03859856,ovarian volume,,,2018-11-25,COMPLETED,OBSERVATIONAL,['NA']
324,NCT06283576,Cancer detection,Overall survival,,2024-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
325,NCT00529191,Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1 Diabetes Mellitus,HDL and LDL Cholesterol Levels in Participants Stratified by the Preservation of Islet Cell Function,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
326,NCT04616391,Between group TIR difference,Between group difference in the Diabetes Quality of Life (QoL) questionnaire score,Number of Severe Hyperglycemia episodes,2020-11-02,UNKNOWN,INTERVENTIONAL,['NA']
327,NCT00687999,"Sustained virological response (SVR) rate, HCV RNA seronegative by PCR throughout 24-week off-treatment period; biochemical, virological and histological characteristics of CHC patients; HOMA-IR change after combination therapy",,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
328,NCT02657213,Assessment of the Minimed 640G insulin pump with Smartguard activation in preventing the number of severe and non-severe hypoglycaemia in patients with diabetes type 1 at risk of severe hypoglycemia,Study of average cost per patient for each therapeutic strategy supported from the point of view of society,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
329,NCT05859165,24h AUC of Nutren Diabetes group with Fresubin Diabetes group,Albumin,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
330,NCT04569994,Number of treatment-emergent adverse events (AEs),Maximum observed serum NNC0363-0845 concentration after a single dose,,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE1']
331,NCT02833389,Percentage of Participants with Adverse Events,Serum Concentration of UTTR1147A,,2016-11-14,COMPLETED,INTERVENTIONAL,['PHASE1']
332,NCT03542370,Blood Pressure - Systolic Blood Pressure (randomized and non-randomized controlled trials),Inflammation - C-Reactive Protein (randomized and non-randomized controlled trials),,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
333,NCT03751735,Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires,,,2017-01-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
334,NCT01497561,Area under the glucose infusion rate curve,Terminal half-life,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1']
335,NCT04809311,Patient with at least 70% unblinded FGM (flash glucose monitoring) data,Coefficient of variation (CV),,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
336,NCT00315939,Frequency of Severe Hypoglycemia,,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
337,NCT01175629,Determine the prevalence of lifetime and current psychiatric conditions including PTSD in Vietnam Era Twin Registry members who served during the Vietnam Era.,Characterize the level of current disability in Vietnam Era Twin Registry members who served during the Vietnam Era.,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
338,NCT03184662,Renal Function Decline,Safety of HIPA performed by e-coaching in the context of COVID infection,,2018-02-12,UNKNOWN,INTERVENTIONAL,['NA']
339,NCT00198510,Resolution of Vitreous Hemorrhage,Visual Acuity,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE3']
340,NCT05951270,Apple polyphenols and glucose homeostasis in prediabetics,Apple polyphenols and fecal microbiota composition,,2022-01-14,TERMINATED,INTERVENTIONAL,['NA']
341,NCT05988957,Describe CGM data use,Describe overall experience of receiving a NFA during CGM initiation,,2023-08-01,COMPLETED,OBSERVATIONAL,['NA']
342,NCT01950676,Change in glycemic control (HbA1c) between the intervention and the control group,Treatment satisfaction as measured by DTSCs and DTSQc,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
343,NCT03782636,Differences in slopes of DBS (Dried Blood Spot) C-peptide over the 6 month-treatment period between the active and placebo groups.,Change in HbA1c and daily insulin requirements during the trial period.,,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
344,NCT00649246,autoantibodies against the pancreas and type 1 diabetes,Risk factors for type 1 diabetes,,1997-07,COMPLETED,OBSERVATIONAL,['NA']
345,NCT01580475,"Changes from baseline in glycemic control measurements (follow-up for 21 months) at training (9 months), detraining (3 months) and retraining (9 months)",Measurement of muscular strength in patients with type 2 diabetes,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
346,NCT00845559,Whether treatment with exenatide attenuates post-prandial glycemic excursions as assessed by oral glucose tolerance testing (OGTT) and continuous monitoring system (CGMS) technology.,Change in body mass index (BMI).,,2008-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
347,NCT02246400,Change in measure of Health-related quality of life from baseline to 6-months follow up.,Body weight,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
348,NCT02094846,Glycated hemoglobin,Physical activity,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
349,NCT05609279,Proportion of enrolled participants providing serum samples for metabolomic analysis,,,2021-02-18,RECRUITING,OBSERVATIONAL,['NA']
350,NCT03036800,Weight loss of ≥15% at 52 weeks,Patient quality of life,Waist circumference,2017-11-28,UNKNOWN,INTERVENTIONAL,['PHASE4']
351,NCT00602953,Disposition Index (DI),,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
352,NCT05104944,Quality of life and resource data collection - patient diary.,Progression of foot deformity as documented by measuring radiological foot alignment angles.,Economic Evaluation - Reported through a patient diary,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
353,NCT02291250,Plasma Glucose Area Under the Curve,Plasma Insulin Area Under the Curve,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
354,NCT01496365,Mean Change From Baseline to Week 5 in Average Daily Pain Score (ADPS) Following Treatment With DS-5565 Compared to Pregabalin and Placebo,Drug-related Treatment-Emergent Adverse Events (n ≥2 Participants in Any Treatment Group) Following Treatment With DS-5565 Compared to Pregabalin and Placebo,,2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE2']
355,NCT05385575,Number of participants with abnormal clinically significant electrocardiogram (ECG),The efficacy of KN056 by analyzing HbA1c (Glycosylated hemoglobin) changes,,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1']
356,NCT01510223,Gastric emptying by 13C octanoic acid breath test,Food intake by buffet meal,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
357,NCT00863954,Reduction in blood glucose and A1c levels at endpoint compared to start,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
358,NCT04045184,Compare hemoglobin A1c levels between groups with high versus low dietary fiber intake,,,2018-10-20,RECRUITING,OBSERVATIONAL,['NA']
359,NCT05186389,Metagenomic analysis,Clinical associations with metagenomic analysis,,2022-01-26,UNKNOWN,OBSERVATIONAL,['NA']
360,NCT04007640,fibroinflammatory lesions at histology in obese patients,Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma,,2019-06-18,RECRUITING,INTERVENTIONAL,['NA']
361,NCT00134524,Subject tolerance to the MME procedure,"Quality of Life assessments at baseline, post-procedure and 6 month follow-up",,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
362,NCT02098733,Number of Participants With Adverse Drug Reactions,Fasting Insulin Level,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
363,NCT00974090,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
364,NCT02967406,Dementia,Blood lipids,Cognitive function,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
365,NCT01594060,,,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
366,NCT05610722,HbA1c,Percentage of sensor readings below 54 mg/dl,"The time required to review insulin and glucose data, make and send recommendations",2022-11-06,RECRUITING,INTERVENTIONAL,['NA']
367,NCT05740514,"The effect of T1D on skeletal muscle health, quantified by physiological parameters (detailed in description)","The effect of a detraining period on skeletal muscle health compared to baseline, quantified by physiological parameters (detailed in description)",,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
368,NCT06074601,Clinical validation of cell-free RNA-based biomarkers of adverse pregnancy outcomes,Discovery of multi-omic biomarkers of adverse pregnancy outcomes,,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
369,NCT00676767,Glycemic Response,,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
370,NCT01349114,Change in Flow-mediated Dilation,Mean Central Aortic Pressure at 3 Months,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE4']
371,NCT03475108,Hemoglobin A1c,Quality of life (primary care giver),,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
372,NCT02993614,CVD REAL1 Incidence of hospitalization for heart failure. / CVD REAL 2 All-cause mortality,"CVD REAL1 All-cause mortality; CVD REAL 2: Hospitalization for heart failure (HHF), stroke, myocardial infarction (MI) and including composite endpoints",,2017-11-30,COMPLETED,OBSERVATIONAL,['NA']
373,NCT00263419,Progression of albuminuria,Cardiovascular risk factors,,2005-01,UNKNOWN,INTERVENTIONAL,['NA']
374,NCT02767336,Marketing Claims Evaluation questionnaire.,,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
375,NCT01399346,"tmax(ins), time to maximum observed serum insulin aspart concentration","t10%max(ins), time to reach 10% of maximum observed serum insulin aspart concentration",,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
376,NCT03330548,Change in Low-density lipoprotein (LDL),Change in Hemoglobin A1C (HgbA1c),,2015-07-09,COMPLETED,INTERVENTIONAL,['NA']
377,NCT02977130,Glycated hemoglobin (HbA1c),,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
378,NCT05814393,HbA1c (24 Weeks) lowering effect,HbA1c lowering effect,,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE3']
379,NCT00438321,Insulin sensitivity,Intramyocellular fat,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE1']
380,NCT06246175,Area Under the Concentration Versus Time Curve (AUC) of HRS9531 From Time Zero to Infinity (AUC0-inf),Incidence and severity of adverse events,,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE1']
381,NCT04387422,Glucose kinetics during hyperglycemic clamps before and after induction of IAH,Antecedent physical activity - sleep quality,,2020-08-12,RECRUITING,INTERVENTIONAL,['NA']
382,NCT04978376,Body weight,HbA1c,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
383,NCT04195191,Adherence to treatment,Satisfaction with the service,,2019-01-18,UNKNOWN,INTERVENTIONAL,['NA']
384,NCT03389607,SCUBE-1,total antioxidant capacity,,2018-01-08,COMPLETED,OBSERVATIONAL,['NA']
385,NCT01885208,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Subjects Who Achieve HbA1c Equal to or Below 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target: (Yes/no),,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
386,NCT03959514,Area under the glucose infusion rate-time curve of insulin aspart,Area under the serum insulin aspart concentration-time curve from 0-60 minutes,,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE1']
387,NCT05223556,Accuracy in the diagnosis of referral retinal lesions,Satisfaction of participants as measured by questionnaire,,2022-02-01,COMPLETED,OBSERVATIONAL,['NA']
388,NCT00044395,Reduction in neuropathic symptoms,"Vibration sensation;Neurological signs;Electrophysiology of peroneal, tibial and sural nerves;Relief of symptoms as measured by VAS;Composite scores of nerve function;Clinical global impression of change",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
389,NCT02465021,Food intake,Blood insulin,Food Recall,2015-03,COMPLETED,INTERVENTIONAL,['NA']
390,NCT02939118,Incidence of adverse events reported during the study.,,,2016-11-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
391,NCT04021602,Introduction of Solid Food,Baby's Height,,2019-09-18,COMPLETED,INTERVENTIONAL,['NA']
392,NCT00279084,Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period.,Quality of life: SF 36 auto-questionnaire,,2004-01,UNKNOWN,INTERVENTIONAL,['NA']
393,NCT02048904,Change in Microalbuminuria Level,,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4']
394,NCT04769765,"Number of patients on the basic diabetic program, included in the study, who have completed at least three of the four scheduled follow-up visits.",Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. Number of follow-up visits per patient per center.,Complications,2022-05-04,RECRUITING,INTERVENTIONAL,['NA']
395,NCT05215210,change in fasting plasma glucose concentrations,change in HOMA-B levels,change in creatinine,2022-03-23,COMPLETED,INTERVENTIONAL,['NA']
396,NCT04244110,Usability of the Diacare platform,,,2020-01-17,COMPLETED,OBSERVATIONAL,['NA']
397,NCT03555994,To assess the effect of MEDI0382 on hepatic glycogen levels versus placebo after 28 days (Part A) and 35 days (Part B) of treatment,Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300μg (Parts A and B) by assessment of changes in haematology and clinical chemistry parameters,,2018-05-31,COMPLETED,INTERVENTIONAL,['PHASE2']
398,NCT05958602,Change in HbA1C of Participants,App Engagement,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
399,NCT01510522,Change from Baseline of Patient self-reported subjective compliance as assessed by Haynes-Sackett test at Month 6,Rate of reported adverse events,,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
400,NCT04674384,Occurrence of Serious Adverse Events (SAEs) deemed potentially related to the dietary programmes.,Percentage of contacts with Dietitian conducted face to face after baseline (for ILED and CLED),,2022-01-19,RECRUITING,INTERVENTIONAL,['NA']
401,NCT05989256,Inpatient hypoglycemia event rates,Number of Inpatient hospitalizations with a hyperglycemic event,,2024-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
402,NCT05046158,Incidence of wound closure,Clinician Acceptability,,2021-08-16,RECRUITING,INTERVENTIONAL,['NA']
403,NCT04828512,Survival,major complications of cirrhosis,,2007-01-02,UNKNOWN,OBSERVATIONAL,['NA']
404,NCT04979130,Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups,Differences between treatment groups in plasma hs-CRP,Exploratory: determine the effect of semaglutide as compared to placebo on intestinal microbiota in relation to changes in intestinal permeability and inflammatory markers,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
405,NCT01000545,macroalbuminuria and serum creatinine,adverse events,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
406,NCT03915990,the diagnostic value of Umbilical artery Doppler indices [Resistance index (RI)& pulsatility index (PI)] in predicting the adverse neonatal outcome among diabetic patients.,he diagnostic value of MCA Doppler indices [Resistance index (RI)& pulsatility index (PI)] in predicting the adverse neonatal outcome among diabetic patients.,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
407,NCT01330121,Adherence with discharge diabetes medications up to 120 days following pharmacist counseling during hospital stay about diabetes self management,Change in lipids after 90 days,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
408,NCT05478252,Change in Glycated Haemoglobin (HbA1c),Anti-semaglutide Antibodies Level (Measured as Titre),,2022-08-03,COMPLETED,INTERVENTIONAL,['PHASE3']
409,NCT05647798,Initial neonatal glucose post delivery,Mother's childbirth experience score,Intrapartum insulin dose (total),2023-05-22,RECRUITING,INTERVENTIONAL,['NA']
410,NCT03338010,Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®),Rate of Total Symptomatic and Nocturnal Hypoglycemia Events (Adjusted by 1 Year),,2018-03-22,COMPLETED,INTERVENTIONAL,['PHASE3']
411,NCT03307486,Occurrence of type 2 DM after GDM,Fetal weight at birth vs eating habits,,2015-09-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
412,NCT04071977,Changes in concentration of total antioxidant capacity (TAC) after intervention from baseline.,"Correlate the levels of total antioxidant capacity (TAC) in systemic samples, aqueous humor and vitreous humor with the glycosylated hemoglobin value of patients with proliferative diabetic retinopathy.",,2020-03-25,COMPLETED,INTERVENTIONAL,['PHASE2']
413,NCT01835431,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%),Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L),,2013-10-17,COMPLETED,INTERVENTIONAL,['PHASE3']
414,NCT01928329,Change From Baseline in HbA1c Levels,Major Hypoglycemic Event Rate Off Drug,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
415,NCT02407132,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c (%) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention.","Change in Mean Triglycerides From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention",,2015-06,COMPLETED,INTERVENTIONAL,['NA']
416,NCT05415683,Data Collection,,,2022-06-22,RECRUITING,OBSERVATIONAL,['NA']
417,NCT01690091,insulin sensitivity,heart function,,2012-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
418,NCT03770728,Change From Baseline to Week 30 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,,2019-08-01,TERMINATED,INTERVENTIONAL,['PHASE3']
419,NCT01399645,To determine liver fat fraction evolution induced by liraglutide and insulin,,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
420,NCT02053103,Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo,Change from baseline in very low density lipoprotein (VLDL),,2014-03,TERMINATED,INTERVENTIONAL,['PHASE2']
421,NCT04794283,neonatal hypoglycemia on day 0 of life will be meassured,Hyperbilirubinemia during the first week of life will be meassured,,2021-03-01,UNKNOWN,OBSERVATIONAL,['NA']
422,NCT00339703,,,,2004-11,COMPLETED,OBSERVATIONAL,['NA']
423,NCT02900417,The changes of the composition of gut microbiota before and after the use of sitagliptin,"Changes of fasting plasma glucose levels, lipids levels and insulin sensitivity",,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
424,NCT02709031,Time to potassium rescue,Average levels of magnesium in patients on cicletanine with and without magnesium,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
425,NCT03228420,Composite of Safety and Effectiveness,Hemoglobin A1c,,2017-07-20,UNKNOWN,INTERVENTIONAL,['NA']
426,NCT00760578,Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test,Change From Baseline in HDL,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
427,NCT06129994,Ecological Momentary Assessment (EMA) methods for measuring depression,Hemoglobin A1c,,2023-11-07,RECRUITING,OBSERVATIONAL,['NA']
428,NCT01570946,Progression to diabetes,Improvements in Quality of Life,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
429,NCT04994327,Glycemic control,Compliance,,2021-05-07,COMPLETED,INTERVENTIONAL,['NA']
430,NCT00755287,Absolute change from baseline in HbA1c,"Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
431,NCT00225264,Absolute change from Baseline in carotid intima-media thickness.,"Incidence of cardiovascular events as a composite of cardiovascular mortality, nonfatal MI, nonfatal stroke, coronary revascularization, carotid endarterectomy/stenting, hospitalization for unstable angina and hospitalization for CHF",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
432,NCT00239538,Changes from baseline in the mean SBP and DBP as measured by ambulatory blood pressure monitoring (ABPM),Metabolic and inflammatory marker changes from baseline,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
433,NCT01089790,"To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG",To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose.,,2010-03,TERMINATED,INTERVENTIONAL,['PHASE3']
434,NCT01022619,apnea-hypopnea index,growth and development during the 1st year of life,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
435,NCT04938557,The time spent with glucose levels between 3.5-7.8 mmol/L based on CGM measures (Time In Range TIR 3.5-7.8mmol/L),Hospital length of stay (infant).,,2019-09-26,COMPLETED,INTERVENTIONAL,['NA']
436,NCT00823992,Absolute change from baseline in HbA1c,"Safety:Adverse events,clinical laboratory tests, vital signs,physical examination, ECG, anti-taspoglutide antibodies\n",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
437,NCT04071535,Assessment of small fiber neuropathy in Chinese patients with diabetes by calculating intraepidermal nerve fiber density (IENFD) via skin biopsy,Evaluation of diagnostic sensitivity and specificity of sudoscan in Chinese diabetic patients with small fiber neuropathy compared with intraepidermal nerve fiber density (IENFD),,2015-12-01,UNKNOWN,OBSERVATIONAL,['NA']
438,NCT02214654,circulation endothelial cell,,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
439,NCT04547023,Number of Participants With a Positive Gestational Diabetes Mellitus (GDM) Screen (>= 140 mg/dL) on the 1 Hour 50-g Oral Glucose Tolerance Test (OGTT),Number of Neonates Exclusively Breastfeeding at Time of Hospital Discharge,,2020-11-02,COMPLETED,INTERVENTIONAL,['NA']
440,NCT03137316,intact parathyroid level,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
441,NCT02123901,Change from baseline in vascular reactivity,Change from baseline in blood chemistry,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
442,NCT06178250,Ductus venosus volume in ultrasound,,,2021-09-22,COMPLETED,INTERVENTIONAL,['NA']
443,NCT05405244,Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water,Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water by TaqIA Allele Status (A1 vs. A2/A2),,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE3']
444,NCT04034511,Change in hemoglobin A1c,Change in Hemoglobin A1c,,2020-01-21,COMPLETED,INTERVENTIONAL,['NA']
445,NCT03118713,The percentage of change of Urine Albumin-to-Creatinine Ratio (UACR),Change from baseline in Quality of Life as measured through Audit of Diabetes-Dependent Quality of Life-19 (ADDQoL-19) questionnaire,,2017-04-25,TERMINATED,INTERVENTIONAL,['PHASE4']
446,NCT03939793,Adherence Rate,,Change in Glycosylated Hemoglobin,2019-05-15,COMPLETED,INTERVENTIONAL,['NA']
447,NCT03960463,Change in tissue oxygenation from baseline to 4 weeks,Presence of scar tissue,,2017-05-18,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
448,NCT01493115,Glucose infusion rate,"Safety-related parameters including electrocardiogram, vital signs and laboratory tests",,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
449,NCT05783700,BIOIMPEDANCEMETRY,Resting heart rate,,2023-10-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
450,NCT06000722,Delphi Round 2,,,2023-12-05,RECRUITING,OBSERVATIONAL,['NA']
451,NCT00927394,Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8,"Number of Patients With Adverse Events, Serious Adverse Events and Death",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
452,NCT00446381,"Levels of intravitreal VEGF, TGFbeta, ET-1, PDGF, IGF-1,angiopoietin, HIF 1 alpha, HIF 1 beta pre and post injection of intravitreal Macugen.",Effect on concomitant diabetic macular edema post injection of intravitreal Macugen,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
453,NCT03299010,Factors that have sufficient power to classify Chinese DM patients in primary care into risk group in terms of total CVD and all-cause mortality,,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
454,NCT01240759,Change from Baseline to Week 12 in Hemoglobin A1c (HbA1c),Safety assessments,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
455,NCT05105620,Fréchet inception distance (FID) score.,,,2018-08-01,COMPLETED,OBSERVATIONAL,['NA']
456,NCT03681054,Child: Neonatal body fat%,Percentage of participants on GDM medication,,2018-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
457,NCT00344136,,,,2000-09,COMPLETED,OBSERVATIONAL,['NA']
458,NCT06330948,Hematology Test,,,2024-03,RECRUITING,INTERVENTIONAL,['NA']
459,NCT02459561,HbA1c reduced by 20%,To estimate the cost-effectiveness of the EndoBarrier device compared with conventional treatment.,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
460,NCT01407640,Validation of cutaneous insulin tests,Immunogenetic of patients with IA (Insulin Allergy),,2012-02-06,COMPLETED,INTERVENTIONAL,['NA']
461,NCT05842993,Change in glycosylated hemoglobin (HbA1c),Safety measurement,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
462,NCT04460573,Adherence to offloading,Physical Activity,,2021-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
463,NCT02772679,Survival of Tregs,"Analysis of general immune response as assessed by, for example, viral tetramer+ CD8 cells and effects of Treg infusions on peripheral blood cells measured by flow cytometry including T cell subsets, B cells and other innate cell subsets",,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1']
464,NCT03342495,Health services utilization,Variation in SF-12 Scores,Youth/Caregiver Satisfaction,2018-02-06,COMPLETED,INTERVENTIONAL,['NA']
465,NCT00468676,"Glycated Hemoglobin (HbA1c) at Baseline, 6 Months and 12 Months",Health Care Costs,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
466,NCT04933851,Diabetes Distress Scale,Diabetes Support and Isolation Questionnaire,Body Mass Index (BMI),2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
467,NCT04442529,Perceived stress,Mothers and Babies Skill Utilization,,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
468,NCT03484741,Adverse events,Blood insulin level,,2017-04-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
469,NCT03638362,TCJ and hsCRP,fasting triglycerides,,2009-08-21,COMPLETED,INTERVENTIONAL,['NA']
470,NCT03959501,Change in serum ketone levels after treatment,Change in homeostasis model assessment 2 steady-state beta-cell function,,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE4']
471,NCT02309424,Muscle glucose uptake following meal ingestion (area under the glucose uptake versus time curve-AUC),Number of participants with adverse events,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
472,NCT04351880,Anxiety and Depression measured through the Hospital Anxiety and Depression Scale,Re-hospitalization and Emergency Department Visits,,2020-04-16,COMPLETED,INTERVENTIONAL,['NA']
473,NCT06152887,Change in numeric rating scale (NRS) scores in pain diary,Quantitative sensory testing,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
474,NCT06184568,Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss,"Percent Change from Baseline in Triglycerides, Total Cholesterol, LDL-c, HDL-c, non-HDL-c",,2024-02-29,RECRUITING,INTERVENTIONAL,['PHASE3']
475,NCT03940482,Change in glycaemic control of patients as measured by >= 5% reduction in glycosylated haemoglobin (HbA1C) over a 12 week period.,Change in a levels of ketonemia (Serum Beta-Hydroxybutyrate 0.5-3.0 mmol/L) over a 12 week period.,,2019-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
476,NCT03428945,Change from Treatment Assignment Glucose Tolerance to Abnormal Glucose Tolerance or Diabetes,,,2018-08-15,TERMINATED,INTERVENTIONAL,['PHASE2']
477,NCT01418911,,,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
478,NCT02357043,Accuracy - Blood Glucose Level Obtained by Layperson With the Dario Meter Compared to Blood Glucose Level on Yellow Springs Instrument Obtained by Nurse/Technician,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
479,NCT00438126,increased self-reported leisure physical activity,resting blood pressure,,2002-01,COMPLETED,INTERVENTIONAL,['NA']
480,NCT00237588,Insulin sensitivity assessed with hyperinsulinaemic isoglycaemic glucose clamp(GDR),Microalbuminuria,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE4']
481,NCT00198926,caloric compensation,,,2000-05,COMPLETED,INTERVENTIONAL,['NA']
482,NCT02597127,Percentage Change in LDL-C From Baseline to Day 180,Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
483,NCT00671008,Glycaemic control as measured by HbA1c,Change in body weight,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
484,NCT05702463,"Among initial ASA non-responder participants, define the proportion of participants that remain ASA non-responders with different formulations and dosing regimens of ASA.","Platelet response levels to various agonists not directly related to the pharmacological target of ASA, including ADP, collagen, epinephrine and thrombin receptor-activating peptide (TRAP).",,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE1']
485,NCT02135549,Postprandial serum glucose area under the curve in mg*hr/dL over four hours,Peak blood serum excursion at 2 hours from baseline in mg/dL,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
486,NCT00520962,,,,1997-06,COMPLETED,OBSERVATIONAL,['NA']
487,NCT00855608,The main outcome measure will be visual acuity improvement (3 lines),central foveal thickness and angiographic lesion size,,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
488,NCT01002235,Dose limiting toxicity,Pain Levels,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
489,NCT03804658,Glucose variability,Health Literacy,,2019-01-13,RECRUITING,OBSERVATIONAL,['NA']
490,NCT01861756,"Overall Decisional Comfort (0-100, 100=no Conflict)",Glycemic Control (HbA1c),,2013-05,COMPLETED,INTERVENTIONAL,['NA']
491,NCT05530356,Spatial Metabolomics,Age-corrected composite fluid cognition score,,2022-09-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
492,NCT04303364,Assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy,Explore the pathophysiological and potentially causal pathways characterizing diabetic cardiomyopathy,,2020-10-02,RECRUITING,OBSERVATIONAL,['NA']
493,NCT01870713,"different proteins detected between obese persons, type 2 diabetes patients prior to surgery, 10 days after surgery and 3 months after surgery.",evaluating the change in glucose between the baseline evaluation and the follow-up evaluation.,,2010-10,UNKNOWN,OBSERVATIONAL,['NA']
494,NCT02455414,Change in regional brain volume,Change in disease severity score,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
495,NCT01762085,occurrence of plantar foot ulceration wound,Visual Analog Pain Score,Incidence of falls during the study,2013-06,UNKNOWN,INTERVENTIONAL,['NA']
496,NCT01487382,Hypoglycaemic events,Adverse events,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
497,NCT01698112,Fasting fructosamine,adiponectin,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
498,NCT02327429,Change in Cholesterol Intake (3-day Food Record),Change in Fasting High-density Lipoprotein Cholesterol,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
499,NCT01351701,Risk factors associated with different grades of severity of DFI,Percentage sensitivity to different empiric antibiotics,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
500,NCT03867942,Gemigliptin Cmax,,,2019-03-21,UNKNOWN,INTERVENTIONAL,['PHASE1']
501,NCT04957173,The primary outcome of this study will be weight loss in the participants.,,,2021-10-14,WITHDRAWN,INTERVENTIONAL,['NA']
502,NCT06330233,Electrophysiological examination of the peroneal nerve of the lower limb,infrared thermography testing,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
503,NCT05437848,Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs,Change in coefficient of variation as measured by CGM over 7 days,,2022-02-25,COMPLETED,INTERVENTIONAL,['PHASE1']
504,NCT02130687,Norepinephrine (NE) Concentrations,24hr Urinary Testing for Sodium,"Aldosterone, Angiotensin II, and Plasma Renin Activity (PRA)",2014-06,COMPLETED,INTERVENTIONAL,['NA']
505,NCT03959306,Effect on Markers of Endothelial Dysfunction(The change in the level of soluble intercellular adhesion molecule ( ICAM) in serum using ELISA kit),Effect on Quality of Life ( Using Diabetes-39 questionnaire ),,2019-04-24,UNKNOWN,INTERVENTIONAL,['PHASE2']
506,NCT01196546,HbA1c reduction,"To evaluate the effect of combination therapy of vildagliptin (50 mg) plus metformin (500 or 1000 mg) twice daily on FPG and BMI, safety and tolerability profiles",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
507,NCT04831216,"Hemoglobin A1c (HbA1c), %",,,2021-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
508,NCT01395290,nasal staphylococcus colonisation,,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
509,NCT00935441,Glycemic control (HbA1c),Systolic blood pressure control in patients with elevated blood pressure at baseline,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
510,NCT00108524,Change From Baseline in Body Weight at 48 Weeks,Change From Baseline in Blood Sugar at 48 Weeks,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
511,NCT02178501,Change from Baseline in endothelial function status 3 months,Change from Baseline in glycometabolic control at 3 months,Safety Measures,2013-01,COMPLETED,INTERVENTIONAL,['NA']
512,NCT04790604,Acute care service use,Medication adherence,,2021-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
513,NCT01412710,Blood Lipid,Glycemic Control,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
514,NCT02276742,Urinary sodium will be determined from a time 24-hour urine sample,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
515,NCT06081413,improvement in obesity-related diseases,,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
516,NCT03403699,Differentiate iPSCs into CD34+ cells and mesoderm,,,2018-01-11,RECRUITING,OBSERVATIONAL,['NA']
517,NCT01350102,Hgb A1c Level,Wound Area Measurements,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE4']
518,NCT04790006,Safety and tolerability assessed by incidence and severity of adverse events,Apparent clearance (CL/F),,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
519,NCT06067399,To assess the correlation between RDW and HbA1C levels in patients with T2DM before and after glycemic control.,To determine if changes in RDW levels correlate with the presence of other comorbidities and complications.,,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
520,NCT02064647,Time spent with postprandial glucose level in target range,Frequency & duration of postprandial hypoglycemia,Satisfaction/ease of use of Trend Arrow Adjustment Tool,2014-07,COMPLETED,INTERVENTIONAL,['NA']
521,NCT01494987,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
522,NCT02477865,HbA1c,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2014-03-23,UNKNOWN,INTERVENTIONAL,['PHASE3']
523,NCT02383238,Microcirculation,Macrovascular circulation,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
524,NCT01332149,Change From Baseline in Mean Pain Score at Endpoint,Change From Baseline in HADS Depression Total Score at Endpoint,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3']
525,NCT00737269,,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
526,NCT03418415,Changes in glucose metabolism from baseline to 6 months,Changes in renal function up to 2 years,,2018-01-18,UNKNOWN,INTERVENTIONAL,['NA']
527,NCT04487678,Change in venous blood pH,Gastro-intestinal distress symptoms via a questionnaire,,2023-08,WITHDRAWN,INTERVENTIONAL,['NA']
528,NCT02068989,Percentage of Subjects with an HbA1c greater than or equal to 6.5%,,,2013-02,TERMINATED,OBSERVATIONAL,['NA']
529,NCT03126786,Mean Change From Baseline in Best Corrected Visual Acuity Letter Score,Mean Change From Baseline in Central Subfield Thickness,,2017-07-11,COMPLETED,INTERVENTIONAL,['PHASE2']
530,NCT02634229,Identification of novel predisposition gene,Correlation between genotype and HbA1c,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
531,NCT00707993,Change From Baseline in Glycosylated Hemoglobin at Week 52.,Incidence of Glycosylated Hemoglobin Decrease From Baseline.,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
532,NCT03785522,Change in HbA1c (mmol/mol),"Reason(s) for discontinuing treatment with Tresiba® during the treatment period, if applicable",,2018-12-23,COMPLETED,OBSERVATIONAL,['NA']
533,NCT04362540,The primary outcome measure for the study will be the mean difference in values of the HOMA-IR (as a surrogate for insulin resistance) in those with NAFLD vs. those without NAFLD 6-12 weeks post partum,MRI scan to confirm the presence of NAFLD at 6-12 weeks post partum.,,2019-05-05,RECRUITING,OBSERVATIONAL,['NA']
534,NCT05346250,Incidence of type 2 diabetes,Serum lipid change,,2011-07-01,COMPLETED,OBSERVATIONAL,['NA']
535,NCT04147637,Percentage time in range 4-10mmol/L,Change in dose of insulin,,2020-10-14,WITHDRAWN,INTERVENTIONAL,['NA']
536,NCT05666596,Body mass index(kg/m2),,,2021-01-07,COMPLETED,OBSERVATIONAL,['NA']
537,NCT05207774,obesity,omental and subcutaneous fat inflammation,,2020-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
538,NCT00992641,Glucose metabolism,Transcriptomics and metabolomics data,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
539,NCT05567692,Type 2 diabetes incidence in Descendance population,Study of interactions between risk factors on type 2 diabetes incidence,,2023-02-10,RECRUITING,OBSERVATIONAL,['NA']
540,NCT01499108,Change in ambulatory blood pressure,Washout analysis,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
541,NCT03437421,Change in longitudinal strain,,,2018-02-04,COMPLETED,INTERVENTIONAL,['NA']
542,NCT04219215,Change in rate of glucose disappearance,,,2020-02-01,COMPLETED,INTERVENTIONAL,['NA']
543,NCT03618420,Glomerular Filtration Rate (GFR),Renal Oxygenation,,2018-10-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
544,NCT03049605,Motor and sensory conduction velocity of the lower limb nerves,,,2014-01-25,COMPLETED,INTERVENTIONAL,['PHASE2']
545,NCT04661358,Worsening of diabetic retinopathy,Visual acuity loss from any cause,,2021-03-05,RECRUITING,INTERVENTIONAL,['PHASE3']
546,NCT01754181,Time spent in glucose reference intervals,"Measuring glucose sensor 2h, 3h and 4h post-prandial and AUC, in every situation tested to evaluate the efficacy and safety (time spent in hypoglycemia)","Comparison of glucose sensor 2h, 3h and 4h post-prandial and AUC in conditions identical meals for each trigger level (50 or 75%). Measuring AUC during and 2 hours after physical activity, then to lunch time, during dinner and throughout the night.",2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
547,NCT01492465,Subject incidence of anti-AMG 876 antibodies.,Pharmacodynamic parameters:,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE1']
548,NCT05663606,TIR,HbA1c,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
549,NCT01368978,Efficacy,,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
550,NCT00223574,glycated hemoglobin,diet satisfactio,,2002-01,COMPLETED,INTERVENTIONAL,['NA']
551,NCT04222894,Plasma Lipids,Food Acceptability: The Food Acceptability Questionnaire,,2020-06-26,COMPLETED,INTERVENTIONAL,['NA']
552,NCT06197360,Hypoglycemia fear worry,The self-management attitude scale for diabetes patients,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
553,NCT03260881,EAT inflammation,EAT GLP-1R,,2018-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
554,NCT01783210,Gestational diabetes mellitus.,Mode and timing of delivery,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
555,NCT05372809,Incidence of index ulcers closed,Wound infection,Incidence of adverse events of the index ulcer,2022-04-28,TERMINATED,INTERVENTIONAL,['PHASE3']
556,NCT02916251,PD endpoint: Plasma glucose profiles above baseline: tmax,Safety endpoints: Antidrug antibodies incidences,,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2']
557,NCT04259112,Serum cystatin C (CysC) level,Renal tissue oxygen saturation,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA']
558,NCT00656851,Myocardial Fatty Acid Esterification,Fasting Glucose Insulin and HOMA,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
559,NCT05937373,Disparities in Continuous Glucose Monitoring (CGM) accuracy - serum and arterial glucose values,Disparities in Continuous Glucose Monitoring (CGM) accuracy - interference amount,,2023-08-04,RECRUITING,INTERVENTIONAL,['NA']
560,NCT02359617,Mean absolute relative difference between sensor readings and capillary glucose readings,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
561,NCT00120328,"To determine the effect of each dose of avosentan on time to doubling of serum creatinine, end stage renal disease (ESRD) or death when administered on top of standard treatment in subjects with type 2 diabetes mellitus and diabetic nephropathy.",unstable angina,,2005-07,TERMINATED,INTERVENTIONAL,['PHASE3']
562,NCT04404556,Barriers to Diabetes Adherence questionnaire - Youth report Time Pressure/Planning Subscale,Type 1 Diabetes and Life -Parent Report,,2020-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
563,NCT04236609,Rate of Target lesion failure TLF,Bleeding,Target vessel revascularization (TVR),2020-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
564,NCT01196533,Comparison of the TensorTip Accuracy Against Hospital Periodical Readings.,,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
565,NCT00307749,Nerve Conduction Studies,Clinical Global Impression,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
566,NCT00928876,"to determine the effect of Interleukin-1 receptor antagonist on insulin sensitivity, as derived from glucose infusion rate measured by euglycemic hyperinsulinemic clamp",systemic inflammation,,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
567,NCT01541215,Change in HbA1c (Glycosylated Haemoglobin),Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 156,,2012-11-13,COMPLETED,INTERVENTIONAL,['PHASE3']
568,NCT05943886,AUC,Assessment of the incidence of anti drug antibodies (ADA) developed against HEC88473 after dosing,,2021-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
569,NCT01876563,erytrocyte thioredoxin reductase,GENE EXPRESSION OF TBP-2,,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
570,NCT06185348,Body mass index (BMI) variation after 6 months of treatment with hybrid closed loop (HCL),description of metabolic parameters at 24 months,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
571,NCT04791267,Acute care service use,Medication adherence,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
572,NCT05645653,Medication Adherence,Treatment burden,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
573,NCT04409171,incidence & risk factors of worsened DM,characteristics of new-onset and worsened DM,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
574,NCT00846300,Change in blood pressure,,,2001-08,COMPLETED,INTERVENTIONAL,['NA']
575,NCT03745157,Change in local laboratory measured glycosylated haemoglobin (HbA1c),Change in selected patient reported outcomes: Diabetes Therapy Related Quality of Life (DTR-QoL),,2018-11-21,COMPLETED,OBSERVATIONAL,['NA']
576,NCT03085771,Endothelial precursor cell account (EPC),,,2017-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
577,NCT01129258,PD Endpoint: glucose excursion (change from Day -1 baseline) in response to a liquid meal test (MMTT) on Days 1 and 14.,"Lactate (change from Day -1 baseline), at times specified in the SOA.",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
578,NCT02392117,Change in the number of any hypoglycaemic episodes,"Change from baseline in HR-QoL (health-related quality of life) questionnaire scores (PROs (patient reported outcome): SF-36 (short form 36), and DTSQ(Diabetes Treatment Satisfaction Questionnaire ))",,2015-03-16,COMPLETED,OBSERVATIONAL,['NA']
579,NCT02513641,Insulin Sensitivity,2-hour Insulin Area-under-the-curve Via Oral Glucose Tolerance Test,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
580,NCT02212951,Post-standardized meal glucose exposure (AUC),Draize injection site erythema and edema scoring,,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
581,NCT01201278,"Insulin tolerability, PK, and PD",,,na,UNKNOWN,INTERVENTIONAL,['PHASE1']
582,NCT05699759,Adverse Events,Mean change in best-corrected visual acuity (BCVA) at other study timepoints,,2023-02-28,RECRUITING,INTERVENTIONAL,['PHASE1']
583,NCT06130215,Time above Range (>180mg/dl and >250mg/dl),Diabetic Ketoacidosis,Ped Quality of Life Survey,2023-11-15,RECRUITING,INTERVENTIONAL,['NA']
584,NCT03955107,time in range at Week 8 after enrollment,adverse pregnancy outcomes,,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
585,NCT02185755,HbA1c Levels before and after intervention,HbA1c levels remain at 8% or higher,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
586,NCT01186562,Insulin Independence,Acute C-peptide Response (ACR) to Glucose,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
587,NCT01345500,Total weight loss,Biochemical/social outcomes,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
588,NCT02786979,Number of participants with abnormal laboratory values and/or adverse events related to treatment,Change from baseline in value of TNF-α,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE4']
589,NCT01165983,Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside,"Absolute Change in Inflammatory Cytokines and Growth Factors, TNFα, pg/mL",,2009-11,COMPLETED,INTERVENTIONAL,['NA']
590,NCT05115747,Mean changes in the glycosylated hemoglobin level (HbA1c) at six months.,Mean changes in the health-related quality of life at six months.,,2021-01-15,COMPLETED,INTERVENTIONAL,['NA']
591,NCT03070106,Number of subjects in each study arm discontinuing insulin use with Hemoglobin A1c <7%,Change in the subject's score on the Medical Symptom Questionnaire (MSQ) in each study arm,,2017-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
592,NCT04227431,Change in glycosylated haemoglobin (HbA1c),"Reason(s) for starting Tresiba®, at time of switch/add-on, if available",,2020-01-17,COMPLETED,OBSERVATIONAL,['NA']
593,NCT02899390,Body weight change,Change in the Perceived Stress Scale (PSS) -14 score,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
594,NCT00094991,The change from baseline in insulin medicated glucose disposal after 16 weeks of treatment with Muraglitazar,,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
595,NCT02161094,Change in HbA1c,Score on the Diabetes Quality Of Life,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
596,NCT05303857,Central (aortic) pulse pressure assessed by Sphygmocor XCEL,Renal perfusion of both kidneys assessed by Arterial Spin Labeling MRI,,2022-03-03,RECRUITING,INTERVENTIONAL,['PHASE4']
597,NCT04652999,Patient satisfaction with the relaxation intervention,Heart rate,Clinical Data,2019-03-19,COMPLETED,INTERVENTIONAL,['NA']
598,NCT00700765,Major hypoglycaemic events,Variability in fasting blood glucose (FBG) and average plasma glucose level,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
599,NCT01299246,Number of the residents in detecting the early neurovasculopathy,,,2009-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
600,NCT02160275,Mean sensor glucose concentration,Time that the control algorithm is inactive,Glucagon use,2014-06,COMPLETED,INTERVENTIONAL,['NA']
601,NCT05735340,A1C,,,2023-04-15,RECRUITING,INTERVENTIONAL,['NA']
602,NCT03297879,The change of HbA1c,,,2013-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
603,NCT03347890,Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system,BOLD in brain regions involved in the reward system,,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE4']
604,NCT00316537,Assessment of ulcer size as determined by weekly ulcer tracings,"Assessment for complete wound closure. ""Complete wound closure"" will be defined as full epithelialization of the wound with the absence of drainage and lack of dressing requirement for an interval of at least 2 weeks.",,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
605,NCT03242005,Compare Pro-set® vs. Quick-set® for non-inferiority for set insertion failures (set removal) due to either occlusion alerts or hyperglycemia,Compare Pro-set® vs. Quick- set® for duration of wear,,2017-09,WITHDRAWN,INTERVENTIONAL,['NA']
606,NCT00238550,"Improvement in pain symptoms, including pain perception and sleep quality, utilising daily diaries and validated pain questionnaires during 12 week treatment period and after 3 month cessation of treatment",MR spectroscopy of the chemical constituents in the deep nuclei of the brain will be analysed before and after 12 week treatment period.,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
607,NCT03087266,Levels C-Reactive Protein,Endothelial Function,,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
608,NCT02071979,Wound Size,Wound recurrence,,2014-04,TERMINATED,INTERVENTIONAL,['NA']
609,NCT00481286,Change in systolic blood pressure; change in Hemoglobin A1C; change in low density lipoprotein,"Attainment of benchmark levels for SBP, A1C, LDL; self-management performance (self-report); completion of group clinic",,2007-04,COMPLETED,INTERVENTIONAL,['NA']
610,NCT01778556,Total Body Insulin Sensitivity,Endogenous Rate of Appearance of Palmitate,,2013-01-26,COMPLETED,INTERVENTIONAL,['PHASE2']
611,NCT05275400,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Status Version (DTSQ),,2022-03-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
612,NCT00916604,"Safety by assessment of adverse events, BP, pulse rate, plasma glucose, safety laboratory variables and ECG","Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide).",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
613,NCT02215408,The mean percent of applicable Guideline Advantage standards of care that are met at 12 months,The percent of intervention group patients who rate the intervention as helpful (versus not helpful),,2015-01-20,COMPLETED,INTERVENTIONAL,['NA']
614,NCT05482789,Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose,Area Under the Plasma Concentration Versus Time Curve (AUC) of exenatide,,2023-04-12,RECRUITING,INTERVENTIONAL,['PHASE4']
615,NCT04024631,Glucose response to an oral glucose load,Disposition index,,2019-06-17,RECRUITING,INTERVENTIONAL,['NA']
616,NCT00946426,Insulin sensitivity,Hepatic glucose output,,2009-07,WITHDRAWN,OBSERVATIONAL,['NA']
617,NCT05815342,Change in HbA1c,Coefficient of variation,,2023-04-11,COMPLETED,INTERVENTIONAL,['NA']
618,NCT05235425,Change in HbA1c,Change in HbA1c,,2022-03-20,RECRUITING,INTERVENTIONAL,['NA']
619,NCT00236210,The percentage of patients who attained a significant reduction in their global cardiovascular risk at 6 and 12 months. This was determined a priori by the investigators to be an increase in the ACTION Score of 5 or more.,"Secondary outcomes were change in the average ACTION Score, change in individual risk domains as measured by the ACTION Score, patient satisfaction, and quality of life, all after 6 months and 12 months, comparing intervention versus control.",,2004-08,COMPLETED,INTERVENTIONAL,['NA']
620,NCT00355680,Regression of new vessels,Bruch's membrane rupture,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
621,NCT00467675,,,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
622,NCT01039324,Emergency department encounter rates among patients in the study population.,Provider satisfaction among providers with contact with patients for whom intervention was appropriate.,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
623,NCT03683368,Time to infusion set failure due to an occlusion,Glucose variability,,2018-10-09,COMPLETED,INTERVENTIONAL,['NA']
624,NCT01339520,Change in total score,HbA1c,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
625,NCT01728740,AUC(0-tn) of metformin,,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1']
626,NCT06271382,Ankle Brachial Index,,,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
627,NCT00657605,Change in Weight,Change in Glucose Levels,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
628,NCT02093676,change in self monitoring of blood glucose,change in parental monitoring,,2014-07-30,COMPLETED,INTERVENTIONAL,['NA']
629,NCT03358797,Change in physical activity engagement,Change in Self-Rated health,,2016-12-29,RECRUITING,INTERVENTIONAL,['NA']
630,NCT05333055,Aqueous Humor Levels of Angiopoietin-2,Aqueous Humor Levels of Additional Disease State Biomarkers,Correlation of Biomarkers,2022-04-11,UNKNOWN,OBSERVATIONAL,['NA']
631,NCT01743014,Reduction in albumine to creatine ratio after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy,Change from baseline in carotid intima-media thickness after combined therapy with ramipril and clopidogrel and after ramipril monotherapy,,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
632,NCT02708758,incidence of large for gestational age,incidence of cesarean section,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
633,NCT04361552,30-day mortality rate,Length of hospital stay,,2020-04-07,WITHDRAWN,INTERVENTIONAL,['PHASE3']
634,NCT04281784,Proportion of Patients With EHR Documentation of Goals of Care Discussions,All-cause Mortality at 1 Year (Safety Outcome),,2020-04-23,COMPLETED,INTERVENTIONAL,['NA']
635,NCT01405547,Infant growth,Getational hyperglycemia and insulinemia (insulin resistance/sensitivity),,2009-03,COMPLETED,OBSERVATIONAL,['NA']
636,NCT02789722,Evaluation of transcriptome analysis.,Clinical evaluation: weight.,,2016-08-15,COMPLETED,INTERVENTIONAL,['NA']
637,NCT02213003,procedural complications,,,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
638,NCT04030013,Evaluate the effect of diabetes education given to renal transplant recipients with new onset diabetes after transplantation .,comparison of type of diabetes education,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
639,NCT05114590,Change from baseline to week 16 in the percentage of Time in Range (TIR),Number of participants with adverse events,,2022-01-27,COMPLETED,INTERVENTIONAL,['PHASE4']
640,NCT01657474,Mean time to healing,Percent change in wound area,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
641,NCT02617732,Change from baseline in mean amplitude of glycemic excursions (MAGE) and mean of daily differences (MODD) at 12 weeks.,Renal Function Examination,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
642,NCT00700817,Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78,"Hypoglycaamic Episodes, Weeks 52-78",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
643,NCT03378271,Accuracy of CGM and FGM,The evaluation of patients preferences and experience of the two glucose monitoring systems.,,2016-05-05,COMPLETED,INTERVENTIONAL,['NA']
644,NCT02484209,Difference in hypoglycaemia occurrence (mild-moderate category) between treatment arms,Duration of Hypoglycaemia,,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
645,NCT01954147,HbA1C,Fasting Blood Glucose,,2013-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
646,NCT01554293,"Pharmacokinetics Variables (Cmax, tmax, AUC, t1/2, kel, CL/F & Vz/F)",Exploratory markers (plasma DPP-IV activity and GLP-1 levels),,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
647,NCT00820378,,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
648,NCT02390167,Percent of Self-Test Fingerstick Blood Glucose (BG) Results (From Subjects WITH Diabetes) Within +/- 15mg/dL (<100mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Percent of Self-Test Alternate Site Palm Blood Glucose (BG) Results (From Subjects WITH and WITHOUT Diabetes) Within +/- 15 mg/dL (<75 mg/dL) and Within +/- 15% (>= 75 mg/dL) of Laboratory Glucose Method,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
649,NCT02406443,Percent Change in Fractional Excretion of Sodium (FENA),Change in Effective Renal Plasma Flow (ERPF),,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
650,NCT01121029,C-peptide levels before and after the hematopoietic stem cell transplantation,Serum levels of Hb A1C before and after the hematopoietic stem cell transplantation,,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
651,NCT02733302,IPAQ-SF questionnaire for measure of Physical Activity,,,2016-04-04,UNKNOWN,INTERVENTIONAL,['NA']
652,NCT01068730,Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax),Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis,Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]),2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
653,NCT03819127,Evaluation of cognitive decline,Rate of Glycated hemoglobin (%),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
654,NCT00698932,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients Achieving a Therapeutic Glycemic Response Defined as HbA1c <7.0% at Week 24,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
655,NCT05663554,Change in HbA1c% at 12 months,Change in weight bias at 12 months,,2023-01-15,WITHDRAWN,INTERVENTIONAL,['NA']
656,NCT01774500,"Combined hospital admission, seizure recurrence, or death at day 7",Recurrence of seizure,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
657,NCT02099981,The vascular response to flicker,Contrast sensitivity,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
658,NCT03248401,Change of carotid artery atherosclerosis,Change of carotid artery atherosclerosis 3,Body composition,2016-09-26,COMPLETED,INTERVENTIONAL,['PHASE4']
659,NCT03524404,Program engagement,,,2018-03-28,COMPLETED,INTERVENTIONAL,['NA']
660,NCT04916093,Changes in HbA1c (%),Changes in Renal function tests,,2019-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
661,NCT06242106,Perceived stress scale:,,,2023-03-15,RECRUITING,INTERVENTIONAL,['NA']
662,NCT02715258,Change in HbA1c From Baseline at Week 24,Change in Body Weight From Baseline at Week 24 in Subjects With a BMI ≥ 25 Kg/m2,Proportion of Subjects Who Achieve an HbA1c < 7%,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3']
663,NCT01293396,Area Over Basal for Postprandial Triglycerides,Area Over Basal for Postprandial C-peptide,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
664,NCT03805412,Percent Body Fat Change at 14 Weeks,MAGE Mean Amplitude of Glycemic Excursion,,2019-01-10,COMPLETED,INTERVENTIONAL,['NA']
665,NCT05760118,Revised Osteoporosis Knowledge Test,Osteoporosis Health Belief Scale,,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
666,NCT02607566,Feasibility as measured by study completion,Diabetes Self-Care,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
667,NCT01297062,"Comparison of LS Mean Changes From Baseline in QTcP Intervals Between Exenatide and Placebo on Day 3 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 500 pg/mL)","Plasma Exenatide Concentrations at Steady State on Day 1, 2 and 3",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
668,NCT01296412,Change From Baseline in Hemoglobin A1c (A1C),Percentage of Participants Reaching A1C Goal of <6.5%,,2011-03-11,COMPLETED,INTERVENTIONAL,['PHASE3']
669,NCT02917902,Change in HbA1c (measured as part of routine care),"Change in Body Mass Index, measured in kg/m^2, weight in kilograms, height in meters",,2015-01,COMPLETED,INTERVENTIONAL,['NA']
670,NCT02444156,Change in Cardiac function,Change in Sample size in a full-scale trial,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
671,NCT02015429,Blood glucose,Subjective appetite,Palatability of treatments,2007-12,COMPLETED,INTERVENTIONAL,['NA']
672,NCT03653013,Improved Glycemic Control measured by assessment of glycemic control (HgbA1C),,,2019-07-16,COMPLETED,INTERVENTIONAL,['NA']
673,NCT03267576,Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 2,Change From Baseline in Percentage of 2 Consecutive Glucose Readings With < 70 mg/dL,,2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE4']
674,NCT00679042,Number of Subjects Reaching the Efficacy Goal,Reduction in Hypoglycemic Severity Measured by %Reduction in HYPO Score,,2007-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
675,NCT00195884,hemoglobin A1c (HbA1c),quality of life (QOL),,1999-09,COMPLETED,INTERVENTIONAL,['NA']
676,NCT02269735,Number of participants who discontinued study drug due to an adverse event,Number of participants with anti-drug antibody (ADA) formation,,2014-11-26,COMPLETED,INTERVENTIONAL,['PHASE1']
677,NCT03124134,Safety and Tolerability,Post prandial insulin,,2017-04-18,COMPLETED,INTERVENTIONAL,['NA']
678,NCT01059799,Change in Glycosylated Haemoglobin (HbA1c),Mean of 9-point Self Measured Plasma Glucose Profile (SMPG),,2010-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
679,NCT01505036,"Rate of patients who attain,Hemoglobin A1C ≤ 7.0% and Blood pressure ≤ 130/80 and LDL-Cholesterol ≤ 100 or LDL-Cholesterol ≤ 70, all at 12 months.",Changes in Blood Pressure,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
680,NCT06160817,Healing time,Clinical characteristics of the ulcer: Local Clinical Signs of Infection,SINBAD classification of diabetic foot ulcers,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
681,NCT01860599,"Measures of Endothelial Function by studying number, function and gene expression of endothelial progenitor cells (identified as CD34+ cells)",Measures of Vacular Reactivity,Measures of Insulin Sensitivity by measuring inflammatory molecules as a surrogate of insulin resistance,2010-03,COMPLETED,INTERVENTIONAL,['NA']
682,NCT01215968,Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy,Number of Participants With Clinically Significant Effects,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
683,NCT00556244,Snellen BCVA and epiretinal membrane formation measured with OCT,central macular thickness measured bt OCT,,2007-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
684,NCT03437551,prevalence (percentages) of the stages of diabetic retinopathy (DR),mean NEI-VFQ 25 score,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
685,NCT04907838,Leg blood flow,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
686,NCT02777073,Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin,Change in Ghrelin Concentrations,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
687,NCT05897372,urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline,incidence of symptomatic hypotension,,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
688,NCT03186300,"Change in the percentage of time spent in hypoglycaemia (glucose level below 3, 9 mmol/L or 70 mg/dl)",Evaluation of usability and the treatment satisfaction of PEPPER system by using non-validated questionnaires.,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
689,NCT00855374,,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
690,NCT01484457,Restoration of Euglycemia,Average percent-of-time-in-range (80 - 180 mg/dL),,2008-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
691,NCT03828890,Family Physicians Screening for Diabetic Retinopathy - Number of photographs that are interpreted accurately by the family physicians when compared to the retinal specialist,Screening Impact - Percentage increase in the screening rates for Diabetic Retinopathy using retinal imaging.,Patient Satisfaction,2019-06-12,COMPLETED,INTERVENTIONAL,['NA']
692,NCT03220425,The change in the level of glycosylated haemoglobin(HbA1c),,,2001-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
693,NCT04805853,the change level of cardiac extracellular volume (ECV),Changes in score of Patient Health Questionnaire-9(PHQ-9),,2020-02-20,UNKNOWN,OBSERVATIONAL,['NA']
694,NCT01524809,Area under the serum insulin curve 6-14 hours after dinner at day 15,Adverse events,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE1']
695,NCT06167616,LADA,Type 2 diabetes,,2010-09-01,COMPLETED,OBSERVATIONAL,['NA']
696,NCT05031000,Analysis of system accuracy based on DIN EN ISO 15197,,,2021-09-03,COMPLETED,INTERVENTIONAL,['NA']
697,NCT06043843,Compare first incidence rate of hypoglycaemia or severe hypoglycemia between intervention and control groups in Ramadan,Compare the weight changes after Ramadan as compared to pre-Ramadan weight,,2021-02-16,RECRUITING,INTERVENTIONAL,['NA']
698,NCT03997773,Change in quality of life,Change in moderate to vigorous physical activity patterns,Changes in health literacy,2019-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
699,NCT01468181,Percentage of Participants With Hypoglycemic Episodes,Change From Baseline in Updated Homeostasis Model Assessment (HOMA2),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
700,NCT03804892,IMTG utilisation during exercise,,,2019-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
701,NCT02964715,Change in serum FGF 21,Change in MRI features of NASH,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
702,NCT00806975,"HbA1c change rate from the start to 12 and 24 weeks are investigated and compared. Furthermore, using a questionnaire sheet ""IDSQ-J"" related to the insulin infusion device, the patient's usability and satisfaction with KwikPen® or FlexPen® are performed.","As the secondary endpoints, the incidence of hypoglycemia, changes in body weight (BMI) and blood pressure, and the dose of insulin are investigated and compared before and after the changeover.",,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
703,NCT04304729,Vascular structure (Pulse-wave velocity),Hypertension,,2017-01-12,SUSPENDED,OBSERVATIONAL,['NA']
704,NCT04646746,Postprandial glycemic response,Postprandial GIP (Glucose-dependent insulinotropic polypeptide) response,,2021-02-08,COMPLETED,INTERVENTIONAL,['NA']
705,NCT00340613,Hemoglobin A1c,Urine microalbumin,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
706,NCT03236116,Homa-Percent Beta,Compliance,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
707,NCT02485132,Total incidence rate of hypoglycemia episode,,,2016-03,TERMINATED,OBSERVATIONAL,['NA']
708,NCT00433069,Early virological response,Improvement (vs. baseline) of glucose tolerance parameters after 12 and 48 weeks of therapy and after 24 weeks of follow-up,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
709,NCT05575206,Insulin secretion capacity,Glucose tolerance status,,2023-09-15,RECRUITING,OBSERVATIONAL,['NA']
710,NCT05887271,Change in the distance walked during 6 minute walk test (6MWT),Exploratory outcome: change in fibroinflammatory biomarker panel,,2023-03-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
711,NCT03962686,methylase status,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
712,NCT05478291,Effects of vitamin D supplementation on physiology of atherosclerosis,,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
713,NCT02876393,Presence of DMO evaluated from the optical coherence tomography (OCT) images,,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
714,NCT03403556,Mean percent change from baseline to week 24 in low-density lipoprotein cholesterol (LDL-C),Mean change from baseline to week 24 in HOMA-B,,2018-03-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
715,NCT05004428,Percentage of Type 2 Diabetes Mellitus (T2DM) patients with Chronic Kidney Disease (CKD) in database.,Annual average costs among patients,,2021-08-14,COMPLETED,OBSERVATIONAL,['NA']
716,NCT00264927,Serum sodium,"Safety: Physical examination, vital signs, adverse events, ECG, hematology, serum chemistry",,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
717,NCT04924777,HbA1c Levels,,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA']
718,NCT04537923,"Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)",Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score,,2020-10-19,COMPLETED,INTERVENTIONAL,['PHASE3']
719,NCT00106340,Time to HbA1c >8%,Change from baseline in body weight at 5 years,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
720,NCT03212950,Time within range 3.9 - 10 mmol/l (70 - 180 mg/dl),,,2017-07-10,COMPLETED,INTERVENTIONAL,['NA']
721,NCT05692388,Self-Care Behavior,,,2023-01-23,RECRUITING,OBSERVATIONAL,['NA']
722,NCT03040414,Non-inferiority for Percent of Time <54 mg/dL (3.0 mmol/L) During the Entire 24-hour Period.,Key Safety Outcome 3) Number of Severe Hypoglycemia Events,Human Factors and Diabetes Technology Attitude and Human Factors Questionnaires,2019-06-03,COMPLETED,INTERVENTIONAL,['NA']
723,NCT00224237,,,,2005-12,COMPLETED,OBSERVATIONAL,['NA']
724,NCT01191320,Change in HbA1C,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
725,NCT03019510,fasting glucose level,beta cell function,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
726,NCT05820295,Number of emergency department visits or hospital admissions,"Efficiency, as measured by the total number of care-coordinator hours used",,2023-05-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
727,NCT03848793,HbA1c,Change in Body Weight,,2019-03-06,COMPLETED,INTERVENTIONAL,['PHASE2']
728,NCT01475734,Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure,Number of Participants With Any Treatment-emergent Serious Adverse Event (SAE) and Treatment-emergent Non-serious Adverse Event (AE) During the Clamp Period,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
729,NCT00974740,C-peptide after a liquid mixed meal stimulation,plasma CRP,,2004-03,TERMINATED,INTERVENTIONAL,['PHASE1']
730,NCT01334034,Number of adverse events,Area under the glucose infusion rate-time curve,,2011-04-11,COMPLETED,INTERVENTIONAL,['PHASE1']
731,NCT03470961,Incidence and severity of adverse event,,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
732,NCT05101473,4x10-meter fast-paced walk test,,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
733,NCT03072901,Evaluation of Effectiveness of the EndoBarrier GI Liner upon weight loss,,,2010-12,TERMINATED,OBSERVATIONAL,['NA']
734,NCT02655770,Change in diastolic properties as assessed by CMR.,Echocardiographic indices of diastolic dysfunction,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
735,NCT04764968,Difference in percentage of time in range between the two study periods,Percentage of participants with treatment-induced or treatment-boosted anti-dasiglucagon antibodies,Number of device failures/malfunctions,2021-04-27,COMPLETED,INTERVENTIONAL,['PHASE2']
736,NCT04547790,Change in HbA1c,Change in weight,,2020-12-23,COMPLETED,INTERVENTIONAL,['NA']
737,NCT04905485,Difference in VIOME's Type 2 diabetes risk score,,,2021-05-21,UNKNOWN,INTERVENTIONAL,['NA']
738,NCT01597843,Registration for MHV,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
739,NCT04060056,Adverse birth outcomes,Number of participants developing type 2 diabetes,,2019-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
740,NCT04765982,Incidence of developing pre diabetes in patient with post operative stress hyperglycemia,other morbidity measures,,2021-12-01,RECRUITING,INTERVENTIONAL,['NA']
741,NCT00832390,Change From Baseline in A1C at Week 24,,,2007-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
742,NCT01819493,Body Mass Index,Blood Pressure,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
743,NCT05024656,Incidence of complete wound closure,,,2021-09,WITHDRAWN,INTERVENTIONAL,['NA']
744,NCT05866497,CAVI measurements,,,2022-06-10,COMPLETED,OBSERVATIONAL,['NA']
745,NCT00406133,Time With Glucose Level <=70 mg/dL (for the Cohort With Baseline HbA1c <7.0%),Total Costs: Direct and Indirect Costs,26-week A1c Level <7.0% (for Cohort With Baseline HbA1c <7.0%),2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
746,NCT00976495,Adjusted Percent Change From Baseline in Glomerular Filtration Rate (GFR) at Week 12 (Modified Last Observation Carried Forward [MLOCF]),Adjusted Mean Change From Baseline in Nighttime (0100 to 0600 Hours) Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF]),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
747,NCT01733524,Glycemic control,Self Management of Diabetes in Adolescents,Health care burden,2012-10,COMPLETED,INTERVENTIONAL,['NA']
748,NCT01214824,Change in HbA1C From Baseline to 6 Months,Proportion of Time in Hypoglycaemia (<3.9mmol/L)-Unmasked,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
749,NCT03435328,salivary volume,Eight-item visual analogue scale xerostomia questionnaire,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
750,NCT00448487,"same as in ICARE: composite major CVD outcomes (non fatal MI, Stroke and CVD death)",,,2005-04,COMPLETED,OBSERVATIONAL,['NA']
751,NCT00589680,Hospital length of stay,Time to correction of glucose level and anion gap,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
752,NCT00434538,Percentage of subjects with closed ulcers at week 12,Reduction of incidence of clinical signs of infection.,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE3']
753,NCT03001999,Feasibility of study procedures,Changes in SDSCA Scores,Hemoglobin A1c,2017-01,COMPLETED,INTERVENTIONAL,['NA']
754,NCT03352596,insulin,Blood pressure,,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
755,NCT01237301,Percentage Change in Hemoglobin A1c,Change From Baseline in CGM Glucose Variability,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
756,NCT00933101,Determine the impact of glycemic control on vascular oxidative stress/inflammation in adolescents with Type 1 diabetes mellitus,To determine the impact of glycemic control and vascular oxidative stress/inflammation on vascular health in adolescents with T1DM,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
757,NCT01809093,Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
758,NCT00785577,Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks,Number of Participants With Neurological Treatment Emergent Adverse Events (TEAEs),,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
759,NCT01486966,Change From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment,Incidence of Hypoglycaemic Episodes,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE4']
760,NCT01299844,Hemoglobin A1c,Diabetes Knowledge Test Score,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
761,NCT05999773,SGLT-2 inhibitors related adverse events,Adverse events classification,,2023-07-15,RECRUITING,OBSERVATIONAL,['NA']
762,NCT03826290,Per-patient change in Hemoglobin A1c (HbA1c) levels from beginning to end of evaluation period,Cost of diabetes medications prescribed,User opinions of the diabetes dashboard,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
763,NCT05803772,Change from baseline in AUC0-2h values of Oral Glucose Tolerance Test (OGTT) as measured in blood samples,Number of Participants Reported with At least One Treatment Emergent Adverse Event (TEAE),Change from baseline in AUC0-2h of OGTT as measured by Flash Glucose Monitoring (FGM),2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
764,NCT02401243,Percentage of patients reaching fasting SMPG ≤5.6 mmol/L without nocturnal (midnight to 6:00 am) hypoglycemia (confirmed or symptomatic or severe),Percentage of patients with adverse events,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3']
765,NCT00532610,Continuous holter monitor & ECG each treatment period:,"12-lead ECGs, vital signs, adverse events, and clinical laboratory tests.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
766,NCT00923975,Number of Participants Out of 50 Rated Successful (<=3) by Healthcare Professionals When Participants Performed Specific Software Tasks,Number of Participants Out of 50 Who Rated Their Satisfaction With The Following as Good to Excellent (>=3),,2009-06,COMPLETED,INTERVENTIONAL,['NA']
767,NCT02119754,Clinical Response,,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
768,NCT01408095,Change from baseline to 12 week endpoint in glycosylated fraction of hemoglobin A (HbA1c),"Pharmacokinetics: Area under the curve of concentration-time curve for one dosing interval at steady state (AUC0-tau, ss) of LY2608204",,2011-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
769,NCT05123248,Gestational Diabetes Mellitus (GDM),Plasma glucose measures from OGTT,"Applicability, acceptability, compliance of the unblinded CGM device use in a GDM pregnancy",2018-10-16,RECRUITING,INTERVENTIONAL,['NA']
770,NCT04444570,Rate and type of complications,Cardiovascular events and/or surgical site or implants complications,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
771,NCT01938807,Diabetes Management,Hemoglobin A1c,Satisfaction and usability of the mobile application,2013-10,COMPLETED,INTERVENTIONAL,['NA']
772,NCT02899949,change in HbA1c value,Evidence of urinary tract infection (UTI) documented,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
773,NCT00240422,Change from baseline of renal plasma flow (RPF) in response to L-NMMA infusion at the end of treatment.,Changes from screening in ECG at the end of the study,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
774,NCT05407233,Change in Pain assessment,Analyze cost-utility,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
775,NCT01555788,Percentage of time spent with blood glucose between 3.9 and 8.0 mmol/L (79 - 144 mg/dl),Percentage of time spent in hyperglycemia,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
776,NCT03579797,Eye health management,,,2015-01-01,UNKNOWN,OBSERVATIONAL,['NA']
777,NCT04464772,System Performance,,,2020-07-10,COMPLETED,OBSERVATIONAL,['NA']
778,NCT05566847,HbA1c<9%,Hypoglycemia events post-intervention start,,2022-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
779,NCT00304538,"1) Evaluate the safety and tolerability of VLD-glucagon in doses of 2, 4 and 8 ng/kg/minute when infused overnight 2) Evaluate the PK profile in plasma of VLD-glucagon 3) Evaluate the pharmacodynamic activity of these doses by measuring glucose levels",Compare the number of times and amount of time subjects have glucose levels < 70 mg/dL when treated with VLD-glucagon vs. the control infusion,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
780,NCT02874612,Evidence of a correlation between negative diabetes health outcomes and psychosocial functioning over a 1 year period,Number of participating rating themselves as having diabetes quality of life as assessed by the PedsQL Diabetes 3.2 measure,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
781,NCT00535886,"The primary outcome measure will be the ratio of total to high density lipoprotein (HDL) cholesterol. Blood draws will take place at screening, three weeks, and five weeks.","Related secondary outcome measures include concentrations of low density lipoprotein (LDL) cholesterol, HDL cholesterol, triglyceride (TG) and Lp(a) measured at screening, three weeks, and five weeks.",,2005-11,COMPLETED,INTERVENTIONAL,['NA']
782,NCT00342992,Cancer,Causes of mortality,,1995-03-03,COMPLETED,OBSERVATIONAL,['NA']
783,NCT01473576,Muscle protein fractional synthetic rate,Plasma nitrate,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
784,NCT01992133,Change in glucose metabolism as assessed by change in Insulin sensitivity index as calculated by HOMA -IR28,Change in plasma 25-OH- Vitamin D level pre and post replacement,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
785,NCT00790088,Percentage of Patients Achieving HbA1c < 7.5%,Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs),,2009-02,COMPLETED,OBSERVATIONAL,['NA']
786,NCT00412906,"Gene expression evaluated by measuring mRNA via RT-PCR. Plasma cytokine content, PLasma PAI-1 content, endotoxemia score","Mean Arterial Pressure, heart rate, Temperature,",,2006-11,COMPLETED,INTERVENTIONAL,['NA']
787,NCT03195400,Hepatic glucose fluxes,,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
788,NCT02666807,Change from Baseline in NF-KB at 10 weeks,Change from Baseline in insulin (µlU/ml) at 10 weeks,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
789,NCT03689738,Change in the Matsuda insulin sensitivity index (MISI),Change in the total AUC for breath hydrogen,,2018-09-24,COMPLETED,INTERVENTIONAL,['NA']
790,NCT04071808,Blood norepinephrine content,,,2019-10-01,COMPLETED,OBSERVATIONAL,['NA']
791,NCT04050098,bioequivalence study,,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
792,NCT03106246,Determine whether these EVs contain islet-specific antigens,Mutivariate analysis will be performed with patient parameters and EV parameters,,2016-12,UNKNOWN,OBSERVATIONAL,['NA']
793,NCT03845868,Incidence of cardiovascular diseases,,,2013-04-16,RECRUITING,OBSERVATIONAL,['NA']
794,NCT01397279,M Value in hyperinsulinemic euglycemic clamp,Insulin-suppressed endogenous glucose production (liver insulin sensitivity),,2011-07,COMPLETED,INTERVENTIONAL,['NA']
795,NCT00541450,Change in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks,Change in Fasting Plasma Glucose (FPG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks,,2008-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
796,NCT05849701,Wound volume,Wound volume,,2022-03-10,COMPLETED,INTERVENTIONAL,['NA']
797,NCT00760292,,,,2008-05,UNKNOWN,OBSERVATIONAL,['NA']
798,NCT02709629,Change from baseline in diabetes self management as reflected in the diabetes self-management questionnaire,Change from baseline in diabetes self-management as reflected in scores on the diabetes self-management questionnaire at 35 weeks,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
799,NCT06273020,Blood-Brain-Barrier Permeability after 10-14days of cerebrolysin in patients with AIS of the middle cerebral artery,"Comparison of cognitive impairment, using Montreal Cognitive Assessment in patients with and withouth cerebrolysin",,2022-11-17,RECRUITING,INTERVENTIONAL,['PHASE4']
800,NCT00569959,LDL-Cholesterol,Other lipid parameters,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
801,NCT02682680,Proportion of subjects who achieve target HbA1c and LDL cholesterol,Absolute change in creatine kinase (CK),Mean dose of colesevelam,2016-01-11,COMPLETED,INTERVENTIONAL,['PHASE4']
802,NCT03729479,Systolic blood pressure,Weight loss,,2018-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
803,NCT03116009,Large for gestational age or macrosomia,Glycemic control,,2017-03-19,TERMINATED,INTERVENTIONAL,['PHASE3']
804,NCT02556398,area under the curve (AUC) above target (> 180 mg/dL),,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
805,NCT02157155,Insulin signaling expressed as a CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.,Cytokines and stress hormones,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
806,NCT01589757,SUB-STUDY (n=75): Oxygen Radical Absorbance Capacity (ORAC) (Antioxidant Capacity) of transitional and mature breast milk.,MAIN STUDY: Change in behaviour from baseline (pre-class) to 6-8 weeks after delivery.,,2011-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
807,NCT05646017,Change in Time in range,Change in Hypoglycemia frequency,Change in Percentage of patients attaining the the International Consensus on Time in Range (ICTR) goals,2022-12-15,COMPLETED,OBSERVATIONAL,['NA']
808,NCT03863535,Change in best-corrected visual acuity (BCVA),Foveal avascular zone,,2019-01-18,UNKNOWN,INTERVENTIONAL,['NA']
809,NCT02347020,Food Intake,Cardio-metabolic risk profile,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
810,NCT06268977,Effect of adding SGLTi on BMI,,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
811,NCT04863872,Self-reported severe hypoglycemia,,,2022-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
812,NCT04131582,Change from basal fasting and post2h OGTT glucose levels at 6 and 12 months,Change from basal Weight at 6 and 12 months,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
813,NCT00775684,Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (pg/mL),PG 50 (the Plasma Glucose Level at Which Half-maximal Insulin Secretion is Achieved During the Glucose-potentiated Arginine Test) at Baseline and 6 Months,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
814,NCT01696266,Incidence of any hypoglycaemic event,Incidence of probable symptomatic hypoglycaemic events,,2012-09-05,COMPLETED,OBSERVATIONAL,['NA']
815,NCT03859934,Change of insulin signalling,Change of assessment of resting energy expenditure (REE),,2019-09-26,COMPLETED,INTERVENTIONAL,['PHASE1']
816,NCT00370084,Gastric emptying assessment,"Glycemia, relief of upper gastrointestinal symptoms, intragastric meal distribution",,2005-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
817,NCT03929601,C-Peptide Response to 2-hr MMTT at 24 months post-randomization,Analysis of changes in immune responses to known diabetes antigens and a neoantigen over time by treatment group,,2023-10-30,RECRUITING,INTERVENTIONAL,['PHASE2']
818,NCT03643692,Time in Range (%),,,2019-02-26,COMPLETED,INTERVENTIONAL,['NA']
819,NCT01673204,Changes in renal function with proteinuria,changes in sTNFR and TNF-related proteins,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
820,NCT01358929,Safety: Incidence of adverse events,Change in meal tolerance test,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
821,NCT01479062,Change from baseline in diabetes risk markers,Change from baseline in physical activity and dietary factors,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
822,NCT06187493,prevention of the development of DKD and alter its natural progression.,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
823,NCT02663661,Test the hypothesis that immunological abnormalities are associated with abnormally high glucagon responses to a meal and reduced glucagon responses to insulin induced hypoglycemia.,Correlate metrics derived from a minimally-invasive Continuous Glucose Monitor (CGM) home test with glucagon responses to a meal and hypoglycemia measured in the hospital.,,2016-03-16,COMPLETED,INTERVENTIONAL,['NA']
824,NCT04082000,Adverse Events (AEs) and Serious Adverse Events (SAEs),Improvement in sleep disturbance,,2019-04-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
825,NCT04607915,Feasibility - Delivery of Intervention (Coach strategies),Virtual Care Team experience and satisfaction via semi-structured interview,Exploratory Outcome - Diabetes self-management,2021-05-04,COMPLETED,INTERVENTIONAL,['NA']
826,NCT04663659,length of stay in intensive care,,,2020-03-15,COMPLETED,OBSERVATIONAL,['NA']
827,NCT01025973,Foetal HbA1c,Foetal acetylated Hb,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
828,NCT02886013,Prevalence of the FTO rs9939609 and PPARy rs1801282 polymorphisms.,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
829,NCT00476710,Bile Acid Pool Size and Kinetic Parameters,Resting Metabolic Rate,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
830,NCT01667614,Urinary albumin excretion,Serum potassium concentrations,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
831,NCT03751007,Incidence of Treatment-emergent Adverse Events (TEAE),C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 2 Hour Mixed Meal Tolerance Test (MMTT) at 12 Months,Incidence of Treatment Emergent Adverse Events up to 12 Months,2018-10-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
832,NCT01248286,Homeostatic model assessment (HOMA) index.,Sirtuin 1,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
833,NCT04191902,differences in glycemic control,,,2021-01-05,UNKNOWN,OBSERVATIONAL,['NA']
834,NCT00338949,Change in Visceral Fat Mass From Baseline to Week 26,,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
835,NCT01931982,Change in coronary flow reserve (CFR),Change in Endothelial function:,Change in waist circumference,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
836,NCT02813668,Number of Participants Reaching Two or More Cardiometabolic Risk Goals,Number of Patients With Prediabetes or Newly Detected Diabetes That Achieve Normoglycemia Rates,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
837,NCT04981808,CGM time in range,Time above CGM range,Health-related quality of life,2021-08-18,COMPLETED,INTERVENTIONAL,['NA']
838,NCT01187576,"to examine whether an extended multi-professional PAR intervention, based on SDT, is effective in increasing and maintaining the self-reported physical activity level in patients with newly diagnosed type 2 diabetes or hypertension or both.",,,2010-11,WITHDRAWN,INTERVENTIONAL,['NA']
839,NCT02418884,the Density Score of Coronary Artery Calcification in CAD patients with Diabetes Mellitus,the volume score of CAC in CAD patients with diabetes mellitus,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
840,NCT03939065,Differences in CGM percent time over 140 mg/dl,Statstrip glucose,beta-cell function,2020-06-12,TERMINATED,INTERVENTIONAL,['NA']
841,NCT05654831,"Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations",Pharmacodynamic Parameters: Fasting plasma insulin homeostatic model assessment,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE1']
842,NCT01295775,Hard exudates,Intraretinal microvascular abnormalities (IRMA),,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
843,NCT04207853,plantar pressure,,,2019-08-08,UNKNOWN,INTERVENTIONAL,['NA']
844,NCT05986253,Postprandial blood glucose area under the curve (AUC),Postprandial serum insulin concentration,,2023-08-07,RECRUITING,INTERVENTIONAL,['NA']
845,NCT03832790,BMI,,,2019-12-04,COMPLETED,OBSERVATIONAL,['NA']
846,NCT02094534,"Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements","Mean Nighttime, Daytime, and Fasting Glucose Levels",,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
847,NCT02718950,Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans,Evaluate the effect of liraglutide administration on body composition in humans,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
848,NCT01024244,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks,Change From Baseline in Heart Rate at 12 Weeks and 16 Weeks,,2009-12,TERMINATED,INTERVENTIONAL,['PHASE2']
849,NCT00542633,change in HbA1c,,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
850,NCT06181227,Safety of AVD-104,Treatment effect - vision,,2023-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
851,NCT00846144,Identify humans with marginal Cu status that may benefit from copper supplementation and normalize their GSIS.,,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
852,NCT01531517,Healing of the Ulcer,local reaction that may be due to study drug,,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3']
853,NCT02877186,Taxa abundance before and after one-week of three times daily diet soda consumption,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
854,NCT02060240,Insulin mediated skeletal muslce blood flow and capillary recruitment,Quantification of endothelial derived Vasodilators,"Correalte changes in fitness to vasodilators, blood flow, and insulin sensitivity",2014-02,COMPLETED,INTERVENTIONAL,['NA']
855,NCT00004983,,,,1999-09,COMPLETED,INTERVENTIONAL,['NA']
856,NCT01774968,Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c),Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4']
857,NCT05294653,Occurrence of Atherosclerotic Cardiovascular Disease(ASCVD) high risk rating,Occurrence of subclinical ASCVD(coronary artery calcium),Occurrence of rheumatic diseases,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
858,NCT04599920,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification.,Changes in the concentrations of N-nitroso compounds in feces.,,2020-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
859,NCT05152589,Hearing Loss,diabetic mother,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
860,NCT04972175,Incidence of adverse event,,,2021-07-28,UNKNOWN,INTERVENTIONAL,['PHASE1']
861,NCT02621008,blood pressure,stress mindset scale,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
862,NCT02972996,Blood Pressure,Hemoglobin A1C,,2017-01-19,COMPLETED,INTERVENTIONAL,['NA']
863,NCT04591015,Glycosylated Hemoglobin (HbA1c) - Change From Baseline to 180 Days,"Knowledge, Attitudes and Practice Toward COVID-19 Survey - Change From Baseline to 180 Days",,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
864,NCT04714411,Clostridioides difficile Infection,,,2020-11-05,RECRUITING,OBSERVATIONAL,['NA']
865,NCT02228122,A measure of the presence/absence of biofilms in over five weeks when exposed to Aquacel Ag+ Extra dressing.,Size of the wound and an indicator of healing,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
866,NCT02456428,Hospitalization for incident heart failure,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
867,NCT01683409,Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24,"Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady State (AUC,ss)",,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
868,NCT04940897,Measure incidence of adverse events,,,2021-10-25,COMPLETED,INTERVENTIONAL,['NA']
869,NCT02575937,Change in Glycosylated hemoglobin (HbA1c),Food Frequency Questionnaire（FFQ）,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
870,NCT02102958,Frequency of foot examination at home,New foot problems discovered at home,Total new foot problems,2011-07,COMPLETED,INTERVENTIONAL,['NA']
871,NCT01334684,Fasting glucose change after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells,Change in fasting insulin levels after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
872,NCT05902546,Insulin Resistance (Homa-IR),,,2023-01-07,COMPLETED,INTERVENTIONAL,['NA']
873,NCT02344329,Time to closure of a Diabetic Foot Ulcer using Human Amnion Allograft and Total Contact Casting vs Standard Wound Care and Total Contact Casting.,,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
874,NCT06061991,GDM diagnosis,Stillbirth,,2024-01-30,RECRUITING,INTERVENTIONAL,['NA']
875,NCT00454662,"Composite of following events: Sudden death, Cerebrovascular events, Coronary events, Renal dysfunction","All deaths, Death from cardiovascular events, Glucose metabolism, Incidence of primary outcomes events, New onset of atrial fibrillation, Safety, Withdrawal rate",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
876,NCT02730741,Compare number of treated patients who have had diarrhoea in the verum group and in the placebo group between Visit 2 and Visit 5. Diarrhoea evaluated using the Bristol stool scale (types 5 to 7),,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
877,NCT03462589,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,C-peptide secretion following single dose of SY-008,,2018-08-02,COMPLETED,INTERVENTIONAL,['PHASE1']
878,NCT02235519,Blood pressure,Renal function improvement.,,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
879,NCT01514838,Change in HbA1c from baseline to end of treatment,"Safety assessed by the incidence of adverse events, vital signs safety labo-tests and 12-lead ECG",,2012-04-23,TERMINATED,INTERVENTIONAL,['PHASE3']
880,NCT06256523,Changes from baseline in hemoglobin A1c (HbA1c) at the end of the study,HbA1c control rate (proportions of subjects with HbA1c < 6.5 % and HbA1c < 7.0 %),,2022-06-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
881,NCT04754581,Individual steps of muscle glucose uptake (post-exercise),,,2021-03-30,RECRUITING,INTERVENTIONAL,['NA']
882,NCT02039934,Improvement of Insulin sensitivity by high intensity interval training,,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
883,NCT03519217,Evaluate possible risk factors among diabetic infants,Detection of gene mutation responsible for infantile diabetes through gene sequencing,,2020-06-05,UNKNOWN,OBSERVATIONAL,['NA']
884,NCT05633810,"First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization.",MoCA Scores Assessed Over Time,,2022-12-21,RECRUITING,INTERVENTIONAL,['PHASE3']
885,NCT00480779,Change in Weight,Change in Triglycerides,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
886,NCT00770679,Change in Endothelial Function as Measured on MRI in the Legs,,,2008-06,TERMINATED,INTERVENTIONAL,['NA']
887,NCT05255497,The effect of biodex balance training on motor nerves,,,2017-09-02,COMPLETED,INTERVENTIONAL,['NA']
888,NCT04964388,Trabecular bone score,Sclerostin and Bone formation markers,,2021-11-09,RECRUITING,INTERVENTIONAL,['PHASE2']
889,NCT05415826,CRT,Intraretinal hemorrhage,,2022-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
890,NCT01171248,Ambulatory blood pressure (AMBP),Diabetic late complications,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
891,NCT01804049,Change in Total Lean Mass From Baseline,Change in Muscle Characteristics,,2014-04-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
892,NCT01131650,Prevalence of diabetic retinopathy,associated risk factors of diabetic retinopathy,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
893,NCT04700436,"Triglyceride (TG) change rate (percent, %)",Electrocardiogram (12-lead ECG),,2020-01-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
894,NCT01619332,Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test,Change from baseine in Gastric inhibit polypeptide (GIP) (Part III),,2012-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
895,NCT01820273,changes in incretines in the bariatric patient,Diabetes control,,2013-04,WITHDRAWN,OBSERVATIONAL,['NA']
896,NCT01872299,"Prevalence, incidence, persistence and phenotype of obesity, cachexia and type 2 diabetes in patients with chronic heart failure.","Changes of metabolic status in patients with heart failure and type 2 diabetes, obesity and cachexia",,2010-03,COMPLETED,OBSERVATIONAL,['NA']
897,NCT02473991,Placental Thickness at 3rd Trimester,,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
898,NCT03700801,HbA1c,Rate of hypoglycemia,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
899,NCT06250049,Number of individuals with diabetes who have received individual education related to diabetic foot care.,"Number of diabetic individuals referred to podiatry, vascular surgery, and traumatology and orthopedics.",,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
900,NCT03030729,"Comparison between retinal measurements, done by the RTOCT device and a commercial OCT",,,2017-03-14,COMPLETED,OBSERVATIONAL,['NA']
901,NCT01712594,Amount of time spent in the target range defined as 3.8-8.8 mmol/l (70 to 160 mg/dL) YSI glucose during in-clinic overnight visits,Glucose AUC above 8.8mmol/l (160 mg/dL) YSI glucose obtained during in-clinic overnight visits,All descriptive endpoints stratified by the accuracy of the sensor based on mean absolute relative difference (MARD) overnight,2013-05,COMPLETED,INTERVENTIONAL,['NA']
902,NCT04924673,HbA1c,Stress,,2020-06-17,COMPLETED,OBSERVATIONAL,['NA']
903,NCT02536820,glycosylated hemoglobin (HbAc1 %),Follow-up lost,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
904,NCT03481361,The relationship between OSA and cardiac autonomic neuropathy (CAN) in patients with T1D.,The potential mechanisms for the relationship between OSA and diabetic-related complications,,2018-02-14,COMPLETED,OBSERVATIONAL,['NA']
905,NCT05703152,Change from baseline in quality of life on the short form-36 questionnaire (SF-36) at 8 weeks,Body Mass Index (BMI) measurement,,2022-10-31,COMPLETED,INTERVENTIONAL,['NA']
906,NCT03415139,Plasma IL-33 levels will be measured among patients who do or do not develop PTDM (multivariable analysis).,,,2019-03-12,RECRUITING,OBSERVATIONAL,['NA']
907,NCT01253733,Health related self-efficacy,Quality of Life,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
908,NCT05979779,"Percent change from baseline in liver fat, as assessed by magnetic resonance imaging liver proton density fat fraction (MRI-Liver PDFF) at 6 months (26 weeks)",Change from baseline in HbA1c at 6 months (26 weeks).,,2023-09-05,RECRUITING,INTERVENTIONAL,['PHASE2']
909,NCT04631289,Incidence of AKI,,,2020-08-01,COMPLETED,OBSERVATIONAL,['NA']
910,NCT03742219,Triglycerides,24 hour dietary recall,,2017-06-05,TERMINATED,INTERVENTIONAL,['NA']
911,NCT05180721,Change in A1C value,Health care engagement - negative,,2022-10-03,RECRUITING,INTERVENTIONAL,['NA']
912,NCT01633177,Incident type 2 diabetes,HbA1c levels,,2010-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
913,NCT01925248,Blood Glucose Level,Change in Urine glucose level,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
914,NCT00623194,Insulin Detemir-insulin Aspart Cross-reacting Antibodies,Vital Signs: Pulse,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
915,NCT00638872,reduction of ulcer rate,safety and tolerability of the compound,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
916,NCT01903356,Incidence Rate of Adverse Events (AE),Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment.,,2013-07-11,COMPLETED,OBSERVATIONAL,['NA']
917,NCT03394456,Glycemic control,longitudinal outcomes,Access to care,2018-01-13,COMPLETED,INTERVENTIONAL,['NA']
918,NCT01951651,Hepatic Fat Content,Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%),,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
919,NCT00206362,,,,2004-07,COMPLETED,OBSERVATIONAL,['NA']
920,NCT03881254,Percentage of index ulcers healed at 12 weeks,"Changes in peripheral neuropathy using Semmes Weinstein Monofilament ""10""point discrimination test",Visible Graft Take at each visit,2019-04-02,COMPLETED,INTERVENTIONAL,['NA']
921,NCT05367024,Change in glycated haemoglobin (HbA1c) after broccoli and courgette soup interventions,Treatment effects on whole blood gene expression from RNAseq,,2021-09-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
922,NCT00357890,Beta Cell Function,Percent Body Fat,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
923,NCT00928057,Percent (%) Absolute Change in Fructosamine,Relative Injection Pain Score Assessed by Subject,"Reported Injection Site Leakage Events, by Pen Needle Type and Droplet Size",2009-06,COMPLETED,INTERVENTIONAL,['NA']
924,NCT00870818,"The Number of Participants Who Experience an Adverse Event, Serious Adverse Event or Adverse Event of Special Interest.",Human Anti-human Antibody (HAHA) Levels,,2009-02,TERMINATED,INTERVENTIONAL,['NA']
925,NCT02077803,Plasma concentration of metformin following the single dose of drug administration,Number of participants with adverse events as a measure of safety and tolerability,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
926,NCT01265537,Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection,eGFR at 6 Months,,2011-06-24,COMPLETED,INTERVENTIONAL,['NA']
927,NCT03870971,measurement performance,,,2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
928,NCT04489043,Oral glucose tolerance test (OGTT),Anthropometric measures,,2019-09-05,UNKNOWN,INTERVENTIONAL,['NA']
929,NCT02536248,Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period,Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period,,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
930,NCT01945060,Low Blood Glucose Index (LBGI),,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
931,NCT03194100,serum METRNL concentration,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
932,NCT00111228,Hemoglobin A1c (HbA1c) - Change From Baseline to End of 3 Month Study Period,"Average Blood Glucose - Change From Baseline to End of 3 Month Study Period, Calculated as Average Blood Glucose at 3 Month - Average Blood Glucose at Baseline",,2004-10,COMPLETED,INTERVENTIONAL,['NA']
933,NCT06285396,Motility index,Integrated area under response curve (AUC),,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
934,NCT06034574,%MARD lab phase,%MARD home phase,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
935,NCT01360697,Percentage of patients who attain 2 or more of the 'ABC'targets,Default rates at the end of the study,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
936,NCT05322369,: Prevalence of Periodontitis in diabetics of Egyptian outpatients of faculty of dentistry cairo university.,,,2022-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
937,NCT00595374,HbA1c,Incidence of hypoglycaemic episodes,,2003-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
938,NCT01079637,treatment failure rate,Foot temperature,,2010-05,TERMINATED,INTERVENTIONAL,['NA']
939,NCT05084079,The time to glycemic goal,Change of insulin dosage,,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
940,NCT05307120,Acceptability,Health-related quality of life,Health literacy,2022-01-13,RECRUITING,INTERVENTIONAL,['NA']
941,NCT05073237,change in beta cell function,change in serum lipidomics,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
942,NCT03039569,Eat >= 5 Servings Fruit and Vegetables,Degree of Concern of CVD Event in Lifetime,,2017-02-28,COMPLETED,INTERVENTIONAL,['NA']
943,NCT00351676,"Improvement in proportion of quality indicators achieved, for target diseases as a most responsible or primary diagnosis, between groups.",Qualitative evaluation of the impact of the intervention via interviews with the participating pharmacists and physicians.,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
944,NCT03630263,Metabolic fuel utilization,Self reported satiety scores,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
945,NCT01435642,Mean HbA1c (glycosylated haemoglobin),To quantify quality of life,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
946,NCT00336349,VAS of pain,blood flow of feet,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
947,NCT03573102,decrease in proteinuria,,,2018-06-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
948,NCT01551381,Platelet aggregation,Renal function,,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2']
949,NCT01154933,Fasting Insulin,Intranuclear NFκB Binding Activity,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
950,NCT03658655,Total daily insulin,HbAlc,,2018-06-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
951,NCT03908606,clinical attachment level,,,2018-04-11,COMPLETED,INTERVENTIONAL,['NA']
952,NCT00634673,postprandial serum fatty acids,serum endothelin serum fibrinogen,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
953,NCT03979352,Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy with placebo,Number of technical adverse events,,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
954,NCT01056887,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
955,NCT02711124,The level of preoperative HbA1c that will be a predictor of the higher prevalence of platelet resistance to the aspirin,"The level of HbA1c, that will represent the reliable predictor of platelet hyperreactivity and MAACE",,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
956,NCT02610530,Reduction in glycated hemoglobin (HbA1c),Weight Control,,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
957,NCT03530644,Performance evaluation,Safety by paucity of adverse events,,2018-08-28,COMPLETED,INTERVENTIONAL,['NA']
958,NCT00474630,Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease,Change in Food Craving Inventory Carbohydrates Subscale Score,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
959,NCT01113658,Frequency of complaints about device use and operation,,,2010-03,WITHDRAWN,INTERVENTIONAL,['NA']
960,NCT02183415,Number of patients with abnormal changes in clinical laboratory parameters,Plasma glucose levels,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
961,NCT03172247,Combined endpoint of diabetic hospitalized patients,,,2016-12-01,COMPLETED,OBSERVATIONAL,['NA']
962,NCT05754190,[General Study] Acute-Chronic Pain Transition Probability,[Sub-study] Treatment outcome prediction in chronic low back pain and failed back surgery syndrome patients,,2023-06-20,RECRUITING,OBSERVATIONAL,['NA']
963,NCT05283538,Statin prescription indication based on the patient's LDL cholesterol value and the LDL cholesterol target determined according to the cardiovascular risk level according to the ESC/ESA 2019 recommendations,,,2022-03-28,RECRUITING,INTERVENTIONAL,['NA']
964,NCT02678676,Percentage of Participants With First Occurrence of Macro-vascular Event or Death,Incidences With Malignancies,,2004-11,COMPLETED,OBSERVATIONAL,['NA']
965,NCT05540249,Peri-operative Change from baseline HOMA-IR,High-sensitivity C-reactive protein (hs-CRP),Mechanical ventilation time,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
966,NCT03662334,Part 3: Time to Achieve Plasma Glucose >90 mg/dL After Release of Hypoglycemic CSII Clamp,Part 3: Insulin Analog Serum Concentration as a Function of Time Following Termination of Insulin Infusion,,2013-10-03,COMPLETED,INTERVENTIONAL,['PHASE4']
967,NCT03062592,Blood glucose,c-peptid,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
968,NCT02866539,Number of pre-diabetes achieving euglycemic status,,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
969,NCT01220804,Optical reflectivity as measured by optical coherence tomography,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
970,NCT04377321,colchicine for treatment of type diabetes patients,,,2019-10-10,COMPLETED,OBSERVATIONAL,['NA']
971,NCT03752567,Percent of Participants With Adherence to the PDTA,Economic Impact,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
972,NCT04313088,Proportion of days with improved bowel movements,Nocturnal diarrhea,,2022-07-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
973,NCT04293731,insulin sensitivity (%S),cytokines levels,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
974,NCT02748434,Blood glucose levels,,,2016-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
975,NCT05718375,Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baseline,,,2023-01-25,RECRUITING,INTERVENTIONAL,['PHASE2']
976,NCT05987410,Six Minute Walking Test (6MWT) distance in meters,Peak Oxygen Uptake (VO2),,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
977,NCT00806858,"The change in subjects' satisfaction with insulin therapy, measured by change from visit 1 to visit 2 in subject treatment satisfaction scores on the DTSQ (Diabetes Treatment Satisfaction Questionnaire)",Number of clinical technical complaints,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
978,NCT05556291,Change from baseline in bodyweight & BMI,Percentage of patients who discontinued investigational drug due to adverse events,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
979,NCT03950245,iAUC glucose,Beta-cell glucose sensitivity (β-GS),,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
980,NCT00703755,"The percentage of normalized patients at V4 (fasting glucose < 6.1 mmol/L, TG < 1.69 mmol/L and HDL-C >= 1.03 mmol/L in males and >= 1.29 mmol/L in females)",Blood pressure.,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
981,NCT06140030,Anxiety Symptoms,Glycemic control,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
982,NCT00575471,Change in HbA1c from baseline for rivoglitazone compared to placebo,Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to placebo,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
983,NCT02001051,Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),Correlation Between Dermal Thickness and Patients With Subclinical Hypercortisolism,,2013-11-27,TERMINATED,INTERVENTIONAL,['PHASE2']
984,NCT02309502,"prevention on the developing of proliferative diabetic retinopathy (assessed with slitlamp, color fundus, and fluorangiography)",Pain assessment (questionnaire),,2012-10,WITHDRAWN,INTERVENTIONAL,['NA']
985,NCT01181674,Normoglycemia on Therapy,Number of Participants With Severe Hypoglycemic Episodes,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
986,NCT03165084,HbA1c,eHealth literacy,,2017-05-05,UNKNOWN,INTERVENTIONAL,['NA']
987,NCT04655690,Number of adverse events (AEs),"t½, NNC0471-0119: Terminal half-life for NNC0471-0119",,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE1']
988,NCT02565940,dermal sample,,,2014-12,UNKNOWN,OBSERVATIONAL,['NA']
989,NCT04009980,Changes of Retinal sensitivity and contrast sensitivity function after topical citicoline use in patients with diabetic retinopathy,Morphological retinal changes after topical citicoline use in patients with diabetic retinopathy,,2015-09-23,COMPLETED,INTERVENTIONAL,['NA']
990,NCT05754775,Remission,Weight loss,,2023-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
991,NCT05153070,Treg variation,incidence of adverse events at month 24,,2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
992,NCT04847778,Number of daily insulin injections irregularities,Change in Insulin Treatment Satisfaction Questionnaire (ITSQ-change) Score.,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
993,NCT00968006,Change in circulating CD34+KDR+ endothelial progenitor cells,Change in SDF-1alpha concentrations,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
994,NCT03630458,Glycemic response,Appetitive response,,2018-06-11,COMPLETED,INTERVENTIONAL,['NA']
995,NCT01574508,Glycated albumin levels,Number of participants with adverse events,,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
996,NCT02548299,Investigator-Designed Cooking Skills Questionnaire - Change from Baseline to 6 months,"Dietary Fiber, Fruit and Vegetable Consumption Questionnaire - Change from Baseline to 6 months",,2015-05,COMPLETED,INTERVENTIONAL,['NA']
997,NCT02858830,Lower body muscle strength measured by knee extension,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
998,NCT00666094,HbA1C,"body composition, C-peptid, BP, Cholesterol (LDL, HDL), Triglycerides",,2008-08,COMPLETED,INTERVENTIONAL,['NA']
999,NCT03388697,Gestational Diabetes,NICU admission,,2017-12-15,COMPLETED,OBSERVATIONAL,['NA']
1000,NCT04304261,Changes of cognitive function assessed by cognitive function scale after 12 weeks,,,2020-04-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1001,NCT05446753,Change in cardiovascular health risk indicators,Change in body composition,,2022-06-17,RECRUITING,INTERVENTIONAL,['NA']
1002,NCT01025934,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
1003,NCT05240274,Diagnosis of post-transplant diabetes,diagnosis of PTDM in OGTT screen fails,,2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE2']
1004,NCT02169167,Wound healing,Eradication of bacteria,Wound healing and infection,2014-06,COMPLETED,INTERVENTIONAL,['NA']
1005,NCT01631929,Time to Achieve Patient Stabilization,,,2012-08,TERMINATED,INTERVENTIONAL,['NA']
1006,NCT03720080,Adjustments of basal rate insulin infusion 670G,,,2019-05-16,TERMINATED,OBSERVATIONAL,['NA']
1007,NCT00736879,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants,Number of Participants With Marked Laboratory Abnormalities in 24 Week Double Blind Treatment Period - Treated Participants,,2008-09-22,COMPLETED,INTERVENTIONAL,['PHASE3']
1008,NCT02470260,Cognition,Depressive symptoms,,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1009,NCT00458133,Hemoglobin A1C,"metabolic measures, including serum cholesterol and triglycerides",,2007-04,COMPLETED,INTERVENTIONAL,['NA']
1010,NCT02850224,Number of participants with improved health-related quality of life as assessed by the PEDsQL.,,,2017-04-20,COMPLETED,INTERVENTIONAL,['NA']
1011,NCT01947075,"Proportion of patients with each disease among all febrile patients, overall and stratified by HIV status","Proportion of febrile patients with acute respiratory infection infected with a certain respiratory pathogen, compared to the proportion of healthy controls infected with the same pathogen.",Strength of association between each febrile disease and diabetes mellitus and between acute respiratory infections and indoor air pollution,2013-07,COMPLETED,OBSERVATIONAL,['NA']
1012,NCT03998436,"Proportion of Subjects Achieving Target Ulcer Closure Within 12-week Treatment Phase, as Assessed by Blinded Investigator","Proportion of Subjects Achieving Target Ulcer Closure Till End of Study, as Assessed by the Blinded Investigator.",Proportion of Subjects With Treatment Emergent Adverse Events (TEAEs),2018-12-26,COMPLETED,INTERVENTIONAL,['PHASE3']
1013,NCT05481021,Identify any self-reported stressors associated with burnout,To compare any change in presence of burnout from previous cross-sectional study (5 years ago),,2022-07-05,COMPLETED,OBSERVATIONAL,['NA']
1014,NCT00129792,weight loss,Cortisol levels,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
1015,NCT03815006,HbA1c Level at 24 Weeks,Glucose Monitoring Satisfaction Survey Score,,2020-01-09,COMPLETED,INTERVENTIONAL,['NA']
1016,NCT00961025,To characterize the pharmacokinetic/pharmacodynamic of DA-1229 in healthy male subjects,To evaluate the safety and tolerance of DA-1229,,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
1017,NCT05562063,Changes in Left Ventricular mass in CMRI,Changes in The Kansas City Cardiomyopathy Questionnaire (KCCQ),,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4']
1018,NCT04255433,"Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)",Cumulative Number of Primary Composite Events of CV Death and Total (First and Recurrent) MI and/or Stroke,,2020-05-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1019,NCT04545567,Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range 70-180 mg/dL in the Unannounced Meal,Units of Insulin Injected Outside of the Study Dinner Sessions,,2020-12-16,COMPLETED,INTERVENTIONAL,['NA']
1020,NCT03196895,change in medication,change in psychological functioning (attitude towards glucose monitoring questionnaire),,2017-06-28,COMPLETED,INTERVENTIONAL,['NA']
1021,NCT00883558,Postprandial Glucose Excursion,Number of Participants With Hypoglycemic Events,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1022,NCT05281029,Change from Baseline of HbA1c at 24 weeks,The rate of subjects who reached the target value of less than 7% (reasonable HbA1c goal) of HbA1c.,,2021-06-24,UNKNOWN,OBSERVATIONAL,['NA']
1023,NCT02947828,Presence of painful diabetic polyneuropathy,,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
1024,NCT04481737,Change in average fidelity scores,Change from baseline level of cardiovascular disease risk to 3-months and 6-month follow-up,Change from baseline patient satisfaction to 3-months and 6-month follow-up,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
1025,NCT04658264,Reduction in 2 hours post meal blood sugar,,,2021-01-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
1026,NCT03394859,Impact of return of clinically actionable results on patient treatment,,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
1027,NCT05578352,Insulin autoimmune antibody,T cell,,2022-08-05,RECRUITING,INTERVENTIONAL,['NA']
1028,NCT03648554,Responder's proportion difference between the two groups (dulaglutide (TRULICITY®) on top of dietary reinforcement vs. dietary reinforcement alone),Weight,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1029,NCT02883829,"Changes in attitudes, beliefs, and intentions about alcohol",,,2017-04-04,COMPLETED,INTERVENTIONAL,['NA']
1030,NCT03942081,Foot Ulcer Size,Quality of Photos: 1 - 5 scale,,2017-09-05,RECRUITING,INTERVENTIONAL,['NA']
1031,NCT05533996,Diagnosis of gestational diabetes (GDM),Labor dystocia,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1032,NCT02230137,HbA1c level,Satisfaction survey,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
1033,NCT03510000,Comparison of mean glucose levels between AP with empagliflozin with simple meal announcement strategy and AP without empagliflozin with carb-counting.,Morning capillary ketone concentration,,2018-05-15,COMPLETED,INTERVENTIONAL,['NA']
1034,NCT05159570,Differences in lipolysis rate,Changes in signaling in muscle and adipose tissue,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
1035,NCT06161701,Incidence of steroid diabetes in nephrotic patients after glucocorticoid use,"Cumulative use time of glucocorticoid, cumulative dose of glucocorticoid and drugs that may affect blood glucose in combination with steroid diabetes",,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1036,NCT01363791,Non-Alcoholic Fatty Liver (NAFL) Analysis,,,2009-05,UNKNOWN,OBSERVATIONAL,['NA']
1037,NCT01402362,Percent of patients with Diabetes Mellitus or impaired glucose tolerance,Prevalence of hypertension and hyperlipidemia,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
1038,NCT01708694,Insulin Sensitivity and Secretion,Hunger,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
1039,NCT01268267,Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Numbers of Forearm Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
1040,NCT04653545,What is the prevalence of glucose intolerance (diabetes and IGT) in patients presenting to an acute medical emergency department?,Diabetes control in those with known diabetes,,2022-02-01,RECRUITING,OBSERVATIONAL,['NA']
1041,NCT02384265,Change from Baseline in Hemoglobin A1c at 12-months,Change from Baseline in Systolic and Diastolic Blood Pressure at 12-months,,2012-06-21,COMPLETED,INTERVENTIONAL,['NA']
1042,NCT05172401,Frequency of adverse device effects and frequency of serious adverse device effects,,,2022-09-15,WITHDRAWN,INTERVENTIONAL,['NA']
1043,NCT03071016,To record the mean change in HbA1C from baseline,To record the change in blood pressure,,2017-03-04,COMPLETED,OBSERVATIONAL,['NA']
1044,NCT01804478,Muscle Blood Flow,Skin Blood Flow,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
1045,NCT05560412,Change in GLP-1 AUC,Insulin Levels,Blood Pressure,2023-01-10,COMPLETED,INTERVENTIONAL,['NA']
1046,NCT02009995,Testing of Strength,EuroQOL EQ-5D questionnaire,,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
1047,NCT00327015,"Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy",,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1048,NCT01317979,,,,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
1049,NCT03820635,correlation coefficient between serum level of osteoponton and the rate of different aspects of vascular affection as discussed previously,,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
1050,NCT02920801,flow-mediated dilation,renal function test,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1051,NCT04499287,postprandial insulinemia,postprandial oxidative stress,,2014-09-17,COMPLETED,INTERVENTIONAL,['NA']
1052,NCT03341559,Perfusion in lower extremities,,,2018-03-20,COMPLETED,OBSERVATIONAL,['NA']
1053,NCT02288273,Change in 24-hour Mean Weighted Glucose,Change in HbA1c From Baseline to Day 22 and Baseline to Day 70,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1054,NCT03724526,"Combined changes in HbA1C, SBP and LDL-cholesterol levels, simultaneous modeled using a scaled marginal model.",Change in ACC/AHA Risk Score of CVD,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
1055,NCT00553592,Pain and Safety,"Clinical Global Impression of Improvement, McGill Pain Questionnaire, Amount of Rescue Medication Used for Pain, Quality of Life Survey (SF-36), Patient Global Impression of Change",,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
1056,NCT03415880,The effect of a LiPA intervention program on increasing carotid distensibility in patients with type 2 diabetes.,The effect of a LiPA intervention program on microvascular function,,2018-11-08,COMPLETED,INTERVENTIONAL,['NA']
1057,NCT01128894,Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32,Mean Change From Baseline in Body Weight at Week 32,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1058,NCT01381926,Determine Changes in Bone Turnover Markers by Tartrate-Resistant Acid Phosphatase 5b (TRACP5b) During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.,,,2011-02,TERMINATED,INTERVENTIONAL,['PHASE4']
1059,NCT03434288,Time for identification of bacteria responsible for foot osteomyelitis,Time for identification of sensitivity/resistance to antibiotics of the bacteria responsible for foot osteomyelitis,,2018-02-08,COMPLETED,OBSERVATIONAL,['NA']
1060,NCT02587741,The incidence of diabetic retinopathy,oxidative stress,Metabolic indices,2015-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1061,NCT02388815,Point Accuracy,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
1062,NCT03840850,"Feasibility of implementing the intervention in primary care: Binary outcome (feasible / not feasible), as judged by the investigators",Change in self-management behaviour,Rate of missing data,2017-09-15,COMPLETED,INTERVENTIONAL,['NA']
1063,NCT01775059,Safety endpoint,Accuracy endpoint,Accuracy endpoint,2013-03,UNKNOWN,INTERVENTIONAL,['NA']
1064,NCT02001766,Glucose metabolism,,,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1065,NCT03354286,Time spent in blood glucose range,Health care utilization,,2017-11-07,COMPLETED,INTERVENTIONAL,['NA']
1066,NCT05378282,Differential Expression in blood and urine of diabetic patiens with and without diabetic nephropathy assesed by RNA seq,"Molecular data, Whole messenger RNA sequencing",,2021-09-03,COMPLETED,OBSERVATIONAL,['NA']
1067,NCT04299763,HbA1c,,,2018-06-19,COMPLETED,INTERVENTIONAL,['PHASE2']
1068,NCT00298740,Glucose Control as Assessed by Mean Glucose Levels,,,2003-02,COMPLETED,INTERVENTIONAL,['NA']
1069,NCT03676465,Family Communication Inventory Questionnaire,Change of Insulin Parameters,,2019-01-18,COMPLETED,INTERVENTIONAL,['NA']
1070,NCT00567047,• Pharmacokinetic measures,• Safety and tolerability measures,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1071,NCT01026688,Patient is receiving a statin,Change in treatment recommended following an LDL-cholesterol level above 2.0 mmol/L,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
1072,NCT05560568,Sleep efficiency,,,2023-01-20,RECRUITING,OBSERVATIONAL,['NA']
1073,NCT02792400,Difference in postprandial glucose excursions,Resting energy expenditure,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
1074,NCT01381887,Plasma concentrations of glucose,Adverse events,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1075,NCT00970528,Glycosylated hemoglobin (HbA1c),High Sensitivity C-reactive protein (hs-CRP),,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1076,NCT04539769,Diabetes remission rate,,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1077,NCT02310724,cardiovascular risk lipid values,healthcare usage,,2014-03-01,COMPLETED,OBSERVATIONAL,['NA']
1078,NCT01709929,Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemic events,Treatment satisfaction as assessed by Insulin Treatment Satisfaction Questionnaire (ITSQ-22),,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1079,NCT02358408,Evaluation of System Accuracy according to ISO 15197 (see description),,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1080,NCT05523362,Change in glucose variability as measured by continuous glucose monitor,Glucose Monitoring Satisfaction Survey,,2022-01-15,COMPLETED,INTERVENTIONAL,['NA']
1081,NCT02581488,Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment.,Target Ulcer Infection Rates in Each Treatment Group During the Treatment Period as Determined by Investigator-reported Adverse Events,Time to Closure for Ulcers Achieving Closure by End of Follow-up,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1082,NCT05983120,Determining the effect of SCLT-based education on Quality of Life,Determination of Body Mass Index (BMI),,2021-08-19,COMPLETED,INTERVENTIONAL,['NA']
1083,NCT06189417,Mean and proportion increase in glycemic control,Acceptability of a community-based club intervention led by Health Extension Workers,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1084,NCT00753142,First-Phase Insulin Release (FPIR),Number of Participants With Beta-cell Failure,,2004-03,COMPLETED,INTERVENTIONAL,['NA']
1085,NCT00798486,Number of A1C Results Either Equal To Or Within +/- 13.5% of the Laboratory Method (ACCURACY),Number of Participants Who Provided These Ratings For Overall Testing Experience With A1C Test Kit,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
1086,NCT04412746,Diabetes-related factors risk,,,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
1087,NCT02909725,Change in Time Spent Sedentary,Maternal Insulin Resistance,Maternal Body Weight Change,2016-02,UNKNOWN,INTERVENTIONAL,['NA']
1088,NCT03254446,Change in Joint British Society recommendations on the prevention of cardiovascular disease 3rd iteration (JBS3) risk score,Change in HbA1c,Safety profile of TRC150094,2018-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
1089,NCT03200795,Cholesterol level Change is being assessed,Quality of life Change is being assessed,,2018-03-15,UNKNOWN,INTERVENTIONAL,['NA']
1090,NCT04283942,Change of liver fat content in %,Change of lipid profile: free fatty acid,Change of brain functional MRI,2020-07-30,COMPLETED,INTERVENTIONAL,['NA']
1091,NCT00214825,Coronary microvascular function assessed by myocardial perfusion reserve measured by MRI,Proteinuria,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1092,NCT02390050,Change in HbA1c After 12 Weeks of Treatment,Change in HbA1c Over Time,,2015-05-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1093,NCT04721509,change in HbA1c of experimental group,No change in HbA1c of control group,,2021-02,UNKNOWN,INTERVENTIONAL,['NA']
1094,NCT00555217,"A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73m*m in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73m*m, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death","A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD.",,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3']
1095,NCT03111004,Change in length of the hospital stay,Carer perception of service utility according to eCCIS (selected questions),,2014-09-01,COMPLETED,OBSERVATIONAL,['NA']
1096,NCT05870293,Diabetes potentiation scale,,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA']
1097,NCT00918801,,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
1098,NCT01766245,"Cmax, the maximum plasma semaglutide concentration",Hypoglycaemic episodes,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1099,NCT03798080,Change in HbA1c,Immunogenicity (antibody variables),,2019-02-19,COMPLETED,INTERVENTIONAL,['PHASE3']
1100,NCT05884814,Change in interstitial glucose time in range,Change in interstitial glucose time in hyperglycaemia,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
1101,NCT06097065,Number and types of proteins/peptides differential characteristic peaks,ROC curve and area under curve AUC of clinical predictive diagnostic model,,2022-05-20,RECRUITING,OBSERVATIONAL,['NA']
1102,NCT05565716,Feasibility: Acceptability of SMART-HABITS-4-Health,Reach,,2023-08-21,RECRUITING,INTERVENTIONAL,['NA']
1103,NCT00529399,The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1104,NCT00473733,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE4']
1105,NCT01838122,Prevalence of HbA1C in both arms of the cohort of subjects,,,2013-04,UNKNOWN,OBSERVATIONAL,['NA']
1106,NCT02839174,Hemoglobin A1C,patient-physician relationship,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
1107,NCT04962139,The proportion of subjects with complete closure of Target Ulcer,The proportion of patients with Target Ulcer recurrence,,2021-08-10,RECRUITING,INTERVENTIONAL,['PHASE3']
1108,NCT04369001,Change of Depression Scores,Change of Diabetes Quality of Life,,2020-12,WITHDRAWN,INTERVENTIONAL,['NA']
1109,NCT04503239,Collect Device Data - Activity Tracker,Collect Current Subject Lifestyle and Treatment Regimen,,2020-07-22,UNKNOWN,OBSERVATIONAL,['NA']
1110,NCT05704075,Wound Size,Identification of regulatory cytokines for peripheral blood mesenchymal stem cells (PB-MSCs) mobilization,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1111,NCT05659147,Frequency of genetic mutations in patients progressing to diabetes vs. those not,,,2023-01-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
1112,NCT02099513,"Perception of perceived usefulness, attitudes, and experiences",,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
1113,NCT00814190,The primary endpoint is the A1c level or the change in A1c level.,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours.",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
1114,NCT01468376,Glucose and insulin response to the Oral Glucose Tolerance Test after administration of GLU-xx formulations,Safety and tolerability of GLU-xx formulations,,2011-02,TERMINATED,INTERVENTIONAL,['PHASE1']
1115,NCT01488383,change in capillary blood glucose levels,"Adverse reactions of treatments (nausea, diarrhea, vomiting, allergic signs)",,2013-09,WITHDRAWN,INTERVENTIONAL,['NA']
1116,NCT03857191,Difference in OSA risk before and after nutritional and psychocomportemental rehabilitation,To assess the effect of Weight loss on OSA,,2019-03-22,COMPLETED,OBSERVATIONAL,['NA']
1117,NCT00160160,Blood pressure reduction,Comparison of responder rates,,2004-10,COMPLETED,INTERVENTIONAL,['NA']
1118,NCT01646320,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1119,NCT03387683,Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment.,Adjusted Mean Change From Baseline in Myocardial Efficiency at End of Treatment.,,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
1120,NCT01268696,,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
1121,NCT04045938,HbA1c,Inflammation - C-reactive protein (CRP),,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA']
1122,NCT03683784,Prevalence of diabetes in Fayoum,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
1123,NCT05183191,Diagnostic accuracy of the hypoglycemia warning system using in-vehicle data to detect hypoglycemia (blood glucose <3.9mmol/L) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Technology acceptance of the hypoglycemia warning system,,2021-11-29,COMPLETED,INTERVENTIONAL,['NA']
1124,NCT01195259,Time to first occurrence of a serious adverse event of malignancy (excluding non-melanomatous skin cancers),,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
1125,NCT04373265,Dose-limiting Toxicity (DLT),Plasma Concentrations of Relacorilant in Combination with Pembrolizumab in Patients with Advanced ACC and Glucocorticoid Excess,,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE1']
1126,NCT00044746,,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1127,NCT00916188,"Insulin Sensitivity, oxidative Stress, lipid Profile",,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
1128,NCT01498939,Area under the insulin detemir concentration curve,Adverse events,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1129,NCT04916457,The incidence of developing into diabetic foot among the groups,,,2020-12-18,RECRUITING,OBSERVATIONAL,['NA']
1130,NCT01515384,Pancreatic uptake and clearance of 18F-AV-133 tracer as determined by SUVR,,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE1']
1131,NCT02947568,Association of genetical factors with NFS and HSI,Association of pathological tyrosine isoforms with hepatic setatosis indices,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
1132,NCT01561976,Area Under Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC (0-infinity)],Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2012-01-30,COMPLETED,INTERVENTIONAL,['NA']
1133,NCT04175665,Change in HbA1c,Proportion of patients who achieve weight loss ≥10%,Weight change in patients prescribed semaglutide as fourth line therapy (excluding insulin use),2020-01-06,COMPLETED,OBSERVATIONAL,['NA']
1134,NCT04228822,Dyslipidemia,Glucose variability,,2020-11-10,COMPLETED,INTERVENTIONAL,['NA']
1135,NCT01374594,GLP-1 secretion,,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
1136,NCT01828931,HbA1c levels,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
1137,NCT01544309,Change in HbA1c Level,"Change From Baseline in 1,5-AG Level",,2012-03,COMPLETED,INTERVENTIONAL,['NA']
1138,NCT01867502,Change in Glycemic variability,"Change in Hemodynamic response to exercise: Cardiac output (Q), Stroke Volume (SV) and blood pressure (BP)",Change in Oxidative stress (F2 isoprostane 8-iso prostaglandin F2α);,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
1139,NCT03641170,Blood glucose,,,2018-04-03,COMPLETED,INTERVENTIONAL,['NA']
1140,NCT04784650,"Presence of foot problems (no = 0, yes = 1)",Indication of peripheral arterial disease (PAD),,2021-01-31,COMPLETED,INTERVENTIONAL,['NA']
1141,NCT01578980,Percent Time of Active CTR,Frequency of Unplanned System Resets or Restarts,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
1142,NCT01977833,"Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test","Postprandial Plasma Glucose levels after breakfast, lunch and dinner meal challenge","Postprandial Insulin plasma levels, after breakfast,lunch and dinner meal test",2013-10,UNKNOWN,INTERVENTIONAL,['NA']
1143,NCT01257776,"Major adverse event (death, target limb amputation)",University of Texas Classification at target limb,,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1144,NCT02818322,time of ulcer healing,,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
1145,NCT02097615,Unlike the ultimate determinations for the initial surface of the ulcer obtained in square millimeters.,,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1146,NCT05477017,Variation in HbA1c values (% -point),Evaluation of the main side effects and the withdrawal rate,,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1147,NCT01934660,Our primary outcome of interest is vascular inflammation measured by standard uptake values from PET/CT and PET/MRI imaging with FDG,"As a tertiary analysis, we will add novel biomarkers to the above models including HDL efflux, HOMA-IR and inflammatory mediators to understand the association of each biomarker on vascular disease markers",,2013-12-02,COMPLETED,OBSERVATIONAL,['NA']
1148,NCT02510521,insulin sensitivity measured by the reference euglycemic hyperinsulinemic clamp technique,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
1149,NCT01357876,"To investigate the relationship between the glucose lowering action of metformin and lipid metabolism including, but not limited to, fasting lipids and prandial TGs",To measure sparse metformin profiles on the days when the PD endpoints are measured,,2010-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1150,NCT00870831,OGTT will be performed every 6 months for 5 years in subjects with a functioning Islet Transplant,The OGTT reflects the function of the Islet transplant and could be used as an indication of Islet Transplant function,,2000-10,TERMINATED,OBSERVATIONAL,['NA']
1151,NCT03164785,Change in urine albumin creatine ratio (ACR).,Incidence of Treatment-Emergent Adverse Events,,2017-07-24,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1152,NCT00462436,Primary Outcome: Reduction of total and LDL cholesterol,"Improved markers of glycemic control - fructosamine, HOMA",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1153,NCT01307371,Number of patient death during the follow up period,six-min walk distance (6MWD),,2007-03,UNKNOWN,OBSERVATIONAL,['NA']
1154,NCT06333665,Disease-free survival,perioperative 90-day mortality,,2024-02-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1155,NCT01895179,Change in Glucose Tolerance,Change in Inflammation and Metabolic Markers,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
1156,NCT04810026,Change in mean glucose time in range from baseline at Week 16,Change in self-reported blood pressure,Change from baseline in abbreviated Medical Outcomes Study Sleep Scale,2021-05-03,COMPLETED,INTERVENTIONAL,['NA']
1157,NCT04141241,hs-CRP (high-sensitivity C-reactive protein),Body Temperature,,2016-03-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1158,NCT00723411,Meal stimulated C-peptide (area under the curve),Insulin Dose,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3']
1159,NCT01854593,Reoperation,Silicon Oil Tamponade,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1160,NCT05687474,Feasibility - reliability,To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
1161,NCT00845897,Plantar Flexor Muscle Strength,Barefoot Plantar Pressure,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
1162,NCT00842556,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,To assess the safety and tolerability in healthy subjects,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1163,NCT01766570,Change in cardiometabolic statute from baseline to the end of intervention.,Change in anthropometric measurements from baseline to the end of the intervention.,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
1164,NCT05346978,Lipid profile,Atherogenic Coefficient (AC),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
1165,NCT05476861,Insulin omission,Waist circumference,,2022-11-01,COMPLETED,OBSERVATIONAL,['NA']
1166,NCT01161797,glucose variability,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
1167,NCT04531176,Change in A1C,Mean total cost of care,,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
1168,NCT03212755,The number of patients with high level of immunoglobulin in serum,,,2017-08,UNKNOWN,INTERVENTIONAL,['NA']
1169,NCT03204552,Change in BMI,,,2007-10-15,COMPLETED,OBSERVATIONAL,['NA']
1170,NCT00760110,Death,Macrovascular complications,,1997-11,COMPLETED,OBSERVATIONAL,['NA']
1171,NCT03369067,Percent time spent in glycemic zone (70-180mg/dl),,,2017-12-18,COMPLETED,INTERVENTIONAL,['NA']
1172,NCT01787617,Change in insulin response to an oral glucose tolerance test over 5 months.,Quality of Life Measures,,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
1173,NCT00105846,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
1174,NCT04625595,Change in total daily insulin use,Cytokine level from in vitro presentation of antigen by HLA-DQ8,,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1175,NCT02990832,Infection assessed as per Infectious Disease Society of America (IDSA) guidelines,Safety and complications (incidence of adverse events),,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
1176,NCT03460964,Glucose measurements,Acceptability of sensor,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
1177,NCT02421198,Change in percentage overweight,Waist circumference,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
1178,NCT02320461,Myocardial infarction (Incident cases),,,2008-08,UNKNOWN,OBSERVATIONAL,['NA']
1179,NCT02868788,change in plasma dipeptidyl peptidase IV enzyme level from baseline,change in plasma incretin level from baseline,,2016-06-14,UNKNOWN,INTERVENTIONAL,['NA']
1180,NCT04124848,To determine the severity of obstructive sleep apnea,Body composition,,2019-10-25,RECRUITING,OBSERVATIONAL,['NA']
1181,NCT01844479,Plantar Foot Temperature Changes in Regions-of-interest in Response to Walking,Gait Speed Variability Dual Task,Sudomotor Function,2012-12,COMPLETED,INTERVENTIONAL,['NA']
1182,NCT01342497,Rate of healing of diabetic foot ulcers (% reduction in area from baseline),Safety and tolerability of BBR-012 as assessed by reported adverse events and safety laboratory parameters,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
1183,NCT04960514,Referrals,,,2021-11-22,RECRUITING,OBSERVATIONAL,['NA']
1184,NCT03335371,Sentinel - Time to Maximum Concentration (Tmax),Change From Baseline in Basal Insulin Use,,2017-10-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1185,NCT00353587,Evaluate safety of MBX-102 with particular emphasis on endpoints of weight gain and edema,,,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1186,NCT03704389,Diabetes overtreatment in the elderly,,,2019-01-17,COMPLETED,INTERVENTIONAL,['NA']
1187,NCT02422446,Change From Baseline in Endothelial Function at 12 Weeks Using Reactive Hyperemia Index (RHI),"Change in Endothelin-1 (ET-1), High-sensitive C-reactive Protein (hsCRP), and Oxidized LDL Between Baseline and 12 Weeks",,2015-04,TERMINATED,INTERVENTIONAL,['PHASE3']
1188,NCT01244646,Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire,"Investigator-asked Symptoms of Hypoglycemia, hypoglycemic events, weight, compliance",,2010-12,TERMINATED,OBSERVATIONAL,['NA']
1189,NCT03527277,Endogenous glucose production,non-high density lipoprotein cholesterol (non-HDL-C),Eating motivation,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
1190,NCT05134025,"Comparison of TIR in blood glucose values during, and 1-hour after, dynamic physical exercise.",,Comparison of the maximum iG concentration,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
1191,NCT02318108,Hemoglobin A1c,,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
1192,NCT03159494,Blood pressure,Physical acitity,,2014-02-14,COMPLETED,INTERVENTIONAL,['NA']
1193,NCT04877730,Time in Range (TIR) 70-180 mg/dL From Breakfast Time + 5 Hours,Units of Insulin Injected Between 2 Hours Before and 5 Hours After Dinner,,2021-05-21,COMPLETED,INTERVENTIONAL,['NA']
1194,NCT03689530,Change in Body Weight at 6 Months,Change in Controlled Motivation to Prevent Diabetes Using the Treatment Self-Regulation Questionnaire (TSRQ - Controlled),,2018-10-02,COMPLETED,INTERVENTIONAL,['NA']
1195,NCT05433584,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in the IWQOL-Lite-CT - Physical Functioning Domain,,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
1196,NCT05908708,Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system,Sleep quality as assessed by a questionnaire,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
1197,NCT05459285,Area under the plasma concentration-time curve from time zero to ∞ (AUC0-∞),Elimination constants (λz),,2022-05-31,COMPLETED,INTERVENTIONAL,['PHASE1']
1198,NCT04889157,Maximum observed plasma concentration,Number of participants with laboratory abnormalities,,2021-07-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1199,NCT01926457,Umbilical Cord C-Peptide >90th percentile,Return to prepregnancy weight,Diagnosis of Preeclampsia,2013-07,COMPLETED,INTERVENTIONAL,['NA']
1200,NCT00950040,Percentage heavy drinking days,HbA1c levels,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
1201,NCT03436498,Infusion set occlusions,Number of patients with hypoglycemic events,,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1202,NCT01072565,Evaluate the efficacy of SMBG for clinical decisions related to the management of type 2 diabetes.,Determine the incremental benefit of CGM for clinical decision-making.,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
1203,NCT06277466,Correlation between T2DM susceptibility gene expression and clinicopathological features,Baseline LDL-C of controls with different genotypes,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
1204,NCT03938740,Basal/bolus ratios during the last 2 weeks of the treatment period,,,2019-03-18,COMPLETED,INTERVENTIONAL,['PHASE2']
1205,NCT01755572,Change in plasma ANP level at 21 Days,Office-measured heart rate;Treatment difference for liraglutide compared to crossover with placebo,Change in HDL,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1206,NCT04579900,Microbial signature,,,2021-02-01,RECRUITING,INTERVENTIONAL,['NA']
1207,NCT03695731,brown adipose tissue activation,Energy expenditure,,2018-10-15,UNKNOWN,INTERVENTIONAL,['NA']
1208,NCT03043859,Change in Hb A1C,Changes in BMI(kg/m^2),,2017-05-09,COMPLETED,INTERVENTIONAL,['NA']
1209,NCT05637749,Flow Short Scale (FSS) scores,,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
1210,NCT01480297,Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1211,NCT05778370,Correlation between HBA1c level and thickness of both macula and choroid in patients with type II diabetes mellitus,,,2023-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1212,NCT01230632,intravenous glucose tolerance test (IVGTT),insulin sensitivity,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
1213,NCT05261373,Assessed changes from Body composition: Fatmass and Fat-free mass.,Assessed changes from blood pressure,,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
1214,NCT05806502,Endothelium-dependant increase in forearm blood flow,,,2018-11-01,RECRUITING,INTERVENTIONAL,['NA']
1215,NCT03571139,Detecting changes in the retinal vascular plexuses and choriocapillaris after cataract surgery in type 2 diabetes mellitus patients with and without diabetic retinopathy using OCT angiography.,,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
1216,NCT01752985,Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment With BMS-813160,Dose-Response Relationship Using Change in Baseline Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment,,2013-03-18,TERMINATED,INTERVENTIONAL,['PHASE2']
1217,NCT00915707,Disposition Index reflecting Diabetes Risk as a result of decreased sleep duration and/or quality.,,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
1218,NCT02065791,"Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death",CV Composite Endpoint,,2014-02-17,COMPLETED,INTERVENTIONAL,['PHASE3']
1219,NCT03786133,Total bacterial load,Genotypes of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans,,2016-06-10,COMPLETED,OBSERVATIONAL,['NA']
1220,NCT03865901,Negative predictive value (NPV) and positive predictive value (PPV) of the Mellitus GCD59 ELISA for gestational diabetes mellitus screening,Sensitivity and specificity of the GCD59 ELISA to that of glucose load test (GLT) using two or more abnormal oral glucose tolerance test (OGTT) results,Sensitivity and specificity of the GCD59 ELISA across relevant subgroups,2019-05,WITHDRAWN,OBSERVATIONAL,['NA']
1221,NCT01829464,Change From Baseline in HbA1c at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3']
1222,NCT04769141,Medication dosing optimization,(CURATE.AI) pilot deployment using prospective data,,2021-08,UNKNOWN,OBSERVATIONAL,['NA']
1223,NCT02846233,Change in A1c at the End of Study Period,Changes in Treatment Satisfaction Scores (DM-SAT Total Score),,2016-08,COMPLETED,INTERVENTIONAL,['NA']
1224,NCT00157924,LDL-C lowering efficacy,Safety,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1225,NCT01035320,"Compare the effects of simvastatin + ezetimibe with those of simvastatin alone, on thrombogenic mechanisms, in patients with diabetes mellitus type 2.",Compare effects of simvastatin alone with those of placebo on thrombogenic mechanisms. Compare the effects of simvast. + ezetim. with those of simvast. alone on inflammatory variables. Assess how the treatment effect relate to renal function.,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1226,NCT00621608,"Freedom from having, or meeting the criteria for, a major amputation (below knee amputation, or metatarsal level) up to 12 weeks after randomization.",Cost effectiveness of HBOT: calculate the incremental cost per amputation avoided and the incremental cost per quality-adjusted life-year (QALY) gained,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1227,NCT03057158,"Proportions of differentially methylated CpG sites between cohorts, from Illumina EPIC chip",Gene expression (from PCR),,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
1228,NCT05488002,Cholesterol LDL-cholesterol Triglycerides Cholesterol LDL-cholesterol Triglycerides,Medication adherance,,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1229,NCT01273584,Birth Weight centile (z-score),2nd trimester miscarriages,,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1230,NCT01029704,Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4,Change in FPG Following Cessation of Treatment,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1231,NCT04257370,Wound healing at Week 16,Percentage of ulcers healed 50% or more at 12 weeks,,2020-07-09,COMPLETED,INTERVENTIONAL,['NA']
1232,NCT00394524,Mean Blood Glucose (BG) in mg/dl Among Glucommander Group Compared to Standard Insulin Infusion,Mean Hospital Length of Stay in Days Among the Glucommander Group Compared to Standard Insulin Infusion,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
1233,NCT01736124,Diabetes Self-management,Prospective Memory,,2015-04-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1234,NCT02853630,Changes in Insulin secretion rate,Number of participant treated related to adverse event,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1235,NCT00200018,Mean excess weight loss and percent excess weight loss,Diabetes status and use of diabetes medication,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
1236,NCT02477163,Changes in the value of laboratory investigations,,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
1237,NCT02989142,"prevalence of participants with at least one of the following four complications: pregnancy-induced hypertension, gestational diabetes mellitus, caesarean section, large-for-gestational age baby",Number of women who gave at least 6 months breast feeding,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA']
1238,NCT04380584,prediction of diabetic nephropathy,,,2019-11-30,COMPLETED,OBSERVATIONAL,['NA']
1239,NCT03916211,amputation rate,Wong-Baker Faces Pain Rating Scale,,2019-04-20,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1240,NCT00300287,Change from baseline in HbA1c at 108 weeks,Change from baseline in body weight at week 108,,2006-02-20,COMPLETED,INTERVENTIONAL,['PHASE3']
1241,NCT04690270,Insulin secretion,,,2021-01-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1242,NCT06154915,Determine the functional contribution of macrophages to diabetic chronic foot ulcers,,,2022-09-09,RECRUITING,OBSERVATIONAL,['NA']
1243,NCT04027062,"Percent of change of knowledge, attitude and practice of primary healthcare physicians",,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
1244,NCT04807374,Change in CGM Time in Range (TIR),Semi-structured interviews with youth and parents exploring the overall experience and barriers to expanding access to hybrid closed loop technology,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
1245,NCT02024750,"Change in Parent Quality of Life (QOL) for Usual Care and Tailored Resources (Intervention) Arms, During and Post-Intervention","Change In Parent Fear of Hypoglycemia (FOH) for Usual Care and Tailored Resources (Intervention) Arms, During and Post-Intervention",,2014-09,COMPLETED,INTERVENTIONAL,['NA']
1246,NCT00356109,To test that preprandial AIR Insulin is non-inferior to preprandial injectable insulin (insulin lispro) with respect to mean change in HbA1c from baseline to endpoint.,To assess rate and incidence of hypoglycemia,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1247,NCT01496339,Glycosylated hemoglobin (HbA1c),The random glucose level,,2012-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1248,NCT01219803,HbA1c,"Ins(0h,1h,2h),blood lipids",,2010-08,UNKNOWN,INTERVENTIONAL,['NA']
1249,NCT04949958,Body fat percentage,,,2022-04-15,COMPLETED,INTERVENTIONAL,['NA']
1250,NCT02501616,Reactive hyperemic index to measure endothelial function,Urine β2 microglobulin,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
1251,NCT00082316,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
1252,NCT04328896,CGM-Tele-monitoring effects on hypoglycemia,CGM - Tele-monitoring effects on HbA1c,,2018-06-15,COMPLETED,INTERVENTIONAL,['NA']
1253,NCT03049709,agreement of diastolic central blood pressure measurements,,,2015-05-01,COMPLETED,OBSERVATIONAL,['NA']
1254,NCT01279161,Identification of the effect of the FTO gene polymorphism on the development of overweight/obesity in insulin treated children,• Comparison of frequency distribution of FTO gene polymorphism involved in the pathogenesis of obesity in children with diabetes versus children without diabetes.,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
1255,NCT00388518,Absolute change from baseline in Hemoglobin A1c (HbA1c),"Adverse Events (AEs), laboratory parameters.",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1256,NCT04098549,Positive incremental area under the glucose curve (PI-AUC) (using the plasma glucose concentration before glucagon administration as basal level),Number of subjects experiencing vomiting,,2019-09-12,COMPLETED,INTERVENTIONAL,['NA']
1257,NCT01814995,percentage change in weight in participant,Change in mindful eating,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
1258,NCT02122250,user engagement,Diabetes and Physical activity knowledge,Single item: whether you would recommend the website to others,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1259,NCT04988204,Number of participants in the program at the end of the study,Bilirubin level,,2018-10-03,COMPLETED,INTERVENTIONAL,['NA']
1260,NCT04075513,Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis,Number of Hypoglycemic Events Per Participant Year During the On-treatment Period,,2019-10-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1261,NCT04101396,Clinical characteristics of participants,Participants' satisfaction,,2019-10-25,COMPLETED,INTERVENTIONAL,['NA']
1262,NCT01219959,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1263,NCT00348179,Vascular abnormalities as measured by the SyphmgnoCor equipment,,,2004-04,COMPLETED,INTERVENTIONAL,['NA']
1264,NCT01812122,Cardiovascular disease risk factor,hypoglycemic index,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4']
1265,NCT03707379,HbA1c,LDL-C,,2016-03-01,RECRUITING,OBSERVATIONAL,['NA']
1266,NCT03529903,Change in Physical Activity,,,2018-08-10,COMPLETED,INTERVENTIONAL,['NA']
1267,NCT00786019,"Ejection Fraction: Percentage of Blood Leaving the Heart Before and After Exercise at Baseline, After a Vitamin C Infusion, and After Exercise Training",,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
1268,NCT00901472,Improvement in glucose tolerance,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
1269,NCT02932475,Number of Participants With Composite Adverse Neonatal Outcome,Neonatal Safety Based on Treatment Emergent Adverse Events,,2017-05-25,TERMINATED,INTERVENTIONAL,['PHASE3']
1270,NCT03843840,Test retest reliability,,,2019-02-15,COMPLETED,OBSERVATIONAL,['NA']
1271,NCT00607503,Safety of bedtime administration of the epinephrine simulating β2 adrenergic agonist terbutaline to reduce the incidence of nocturnal hypoglycemia without compromising glycemic control in youth with type 1 diabetes (T1D).,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1272,NCT02003872,Excess weight loss,liver fat infiltration,,2015-01,TERMINATED,INTERVENTIONAL,['NA']
1273,NCT02156349,The mean HbA1c change by means of Generalized Estimating Equations (GEE) methods,Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods,,2014-05-14,COMPLETED,INTERVENTIONAL,['NA']
1274,NCT03253328,Stump Healing using the Bates-Jensen Wound Assessment Tool,Determine effect size to power a larger trial,Stump Healing,2016-12-15,SUSPENDED,INTERVENTIONAL,['NA']
1275,NCT02784275,Change of Body Weight From Baseline,Change of Score in Audit of Diabetes-Dependent Quality of Life Questionnaire From Baseline,,2016-06-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1276,NCT00294723,Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156,Hypoglycaemic Episodes,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3']
1277,NCT00786721,Near Infrared Spectroscopy to assess muscle mitochondrial OXPHOS function.,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
1278,NCT01329822,Fetuin-A,cardiovascular risk factors,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
1279,NCT04132401,Area under the receiver operating characteristic curve of the algorithm,,,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
1280,NCT02496390,Improvement in Homeostasis model assessment [HOMA] score.,Modulation of lipid and hormone metabolism,,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1281,NCT03049631,Changes in gut microbiome composition as measured by 16S rRNA gene sequencing in 12-week intervention of active treatment vs Experimental,Changes in blood pressure in 12-week intervention of active treatment vs Experimental,Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs Experimental,2017-05-18,COMPLETED,INTERVENTIONAL,['NA']
1282,NCT03456271,fracture,,,2017-07-01,TERMINATED,OBSERVATIONAL,['NA']
1283,NCT02765399,Change in ApoCIII Level,Mean Fractional Catabolic Rate of VLDL2-apoB100,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1284,NCT00390273,Lactate production following exogenous lactate overload,Parameters modelizing elimination of lactate following muscular exercise test (bi-exponential model).,,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1285,NCT06154746,aeffect of risk factors in progression of diabetic retinopathy.,,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1286,NCT01957696,Surgical complications,Non-surgical complications,"Scheduled, conventional, percutaneous, ultrasound-guided pancreas graft biopsies at 6 weeks and 12 months post-Tx [Amendment 2; Approved by Regional Ethics Commitee]",2013-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1287,NCT00522327,Adherence with care,care parameters,,2004-11,COMPLETED,INTERVENTIONAL,['NA']
1288,NCT02520258,Blood glucose,C-peptide,Interval changes in frequency distribution of microbes found in stool samples (Phase II - cohort 1),2015-08,COMPLETED,INTERVENTIONAL,['NA']
1289,NCT01560546,Lean body mass,Sexual function,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
1290,NCT02577900,Number of Participants With Complete Healing of Ulcer During the Observation Period,the Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
1291,NCT00313001,Superiority as assessed by HbA1c reduction,Patient satisfaction,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1292,NCT03765112,Perfusion density,Change in perfusion density in patients with moderate or severe non proliferative diabetic retinopathy (DR) or low risk proliferative DR over the follow up of one year,,2018-09-20,UNKNOWN,INTERVENTIONAL,['NA']
1293,NCT01392677,Adjusted Mean Change From Baseline in HbA1c Levels,Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1294,NCT05602441,Change in glycated haemoglobin from baseline to 12 months post intervention,Change in diabetes distress measured by Diabetes Distress - Screening Scale 17 (DDS-17) from baseline,,2021-01-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1295,NCT00904020,"Average daily pain intensity (Brief Pain Inventory [BPI] Questions 3, 4, 5, and 6)",QoL: Patient Global Assessment of Patch Satisfaction,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1296,NCT04241575,Action on suspected advanced liver fibrosis,Confirmed diagnosis of advanced liver fibrosis,,2020-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1297,NCT06112925,"Change in percentage of of glycemic control, blood pressure control and medication adherence among adult patients comorbid with diabetes mellitus and hypertension at outpatient clinics in Southwest Ethiopia",,,2022-03-27,COMPLETED,INTERVENTIONAL,['NA']
1298,NCT02987348,Changes from baseline in composite outcomes of HbA1c<=7.0% and weight reduction,Health care utilization,,2015-06-30,COMPLETED,OBSERVATIONAL,['NA']
1299,NCT00279201,ADDENDUM: 24-Week Endpoint HbA1c,ADDENDUM: HbA1c at Specified Visits and Endpoint,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1300,NCT05803421,"Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]",Pharmacokinetics (PK): Plasma Serum Concentrations of Orforglipron,,2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE3']
1301,NCT01994746,Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir,Time to Maximum Change From Baseline Concentration (Tmax) of Glucose,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1302,NCT06240273,Fasting glucose level will be assessed before and after the trial.,,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1303,NCT02474823,Result of ESAP testing,Result of PSG testing,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
1304,NCT04084418,Daily blood glucose standard deviation,Effects on physical activity (steps/day),,2019-10-15,TERMINATED,INTERVENTIONAL,['NA']
1305,NCT01100125,The change of HbA1C,the change of insulin dose,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1306,NCT02351232,Change in HbA1c,Change in anxiety and depression as measured by Hospital Anxiety and Depression Scale,,2015-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1307,NCT00781547,Glucose tolerance,Progress of atherosclerosis (IMT),,1999-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1308,NCT04869761,Adverse events and/or serious adverse events,,,2021-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1309,NCT05939271,- What is the incident amputation rate in persons with and without DM in the Netherlands in the period 2011-2020?,"- Does the presence of a formal multidisciplinary foot clinic / team in a hospital make a difference, especially when comparing previous and actual macrovascular complication rates?",,2022-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1310,NCT02989961,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection,Assess the efficacy of autologous Resticutis injection by clinical examination,,2013-11-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1311,NCT05354245,Peripheral insulin sensitivity,Stool consistency,,2022-09-08,RECRUITING,INTERVENTIONAL,['NA']
1312,NCT01676272,"Proposal for a multi center site randomized, prospective controlled head-to-head clinical trial comparing a bioengineered skin substitute to a human skin allograft.",,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
1313,NCT00533559,"we will measure insulin secretion, calculate disposition index and insulin clearance during a hyperglycemic clamp. We will also measure insulin sensitivity during a euglycemic hyperinsulinemic clamp","During the hyperglycemic clamp we will also measure Free Fatty Acid, C-peptide and triyglycerides. During the euglycemic hyperinsulinemic clamp we will determine the insulin sensitivity index and the disposition index.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1314,NCT02003677,Area under the glucose infusion rate curve,Maximum observed serum insulin aspart concentration,,2013-11-29,COMPLETED,INTERVENTIONAL,['PHASE1']
1315,NCT03917784,Matsuda index,total bilirubin,,2019-02-25,UNKNOWN,INTERVENTIONAL,['PHASE4']
1316,NCT02290067,User performance of blood glucose monitoring systems indicated by patient [questionnaire],,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1317,NCT03337828,Homeostatic model assessment (HOMA) index change after each alcohol-free beer phase.,Micriobota change after each alcohol-free beer phase.,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
1318,NCT05227105,Objective accelerometry,Objective accelerometry,,2023-05-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1319,NCT02994966,Foot ulcer recurrence,Determinants of ulcer formation,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
1320,NCT04263311,Change in BP control,Barriers and Facilitators to Implementation Adoption and Implications for Scalability,,2020-07-20,COMPLETED,INTERVENTIONAL,['NA']
1321,NCT03199716,Daily frequency of blood glucose monitoring (BGM),HbA1c levels,Responsibility for diabetes care,2014-09,COMPLETED,INTERVENTIONAL,['NA']
1322,NCT01115621,Effect of dietary intervention on the development of islet autoantibodies,Effect of dietary intervention on the development of Type 1 diabetes.,,2001-02,UNKNOWN,INTERVENTIONAL,['NA']
1323,NCT02851745,Increase in LV systolic function,Changes in diastolic LV function,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1324,NCT00337038,endothelial function,blood pressure and glycemic control,,2006-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1325,NCT03660553,Hemoglobin A1c (HbA1c),Incidence of Severe Hypoglycemia,,2018-10-10,TERMINATED,INTERVENTIONAL,['PHASE4']
1326,NCT00150085,"Proportion of patients who no longer require a hypoglycemic agent, or who move from insulin to an oral agent, or who no longer meet the American Diabetes Association criteria, or a relative improvement in mean glycosylated hemoglobin at 12 and 26 weeks","Safety assessed by death, graft loss, biopsy supported clinically manifested acute rejection, change in kidney function, change in liver function, serious adverse events and adverse events at 12 and 26 weeks",,2004-02,TERMINATED,INTERVENTIONAL,['PHASE4']
1327,NCT00094263,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
1328,NCT06007014,HbA1C,Fasting C-Peptide,,2023-10-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1329,NCT03393715,24-hour blood pressure profile,Night time blood pressure dip,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1330,NCT03037918,Whole body insulin sensitivity index,Microbiome analysis,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
1331,NCT02157298,Adjusted Mean Change in HbA1c Levels,Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1332,NCT03481530,Hypoglycemia rate,Comparison hypoglycemia rate,,2018-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1333,NCT01904422,Glycated hemoglobin (HbA1c),Tumor Necrosis Factor (TNF),clinical attachment level (CAL),2013-03,COMPLETED,INTERVENTIONAL,['NA']
1334,NCT04682067,Number of participants with >80% completion of daily ecological momentary assessments (EMA) completed,Number of participants with biochemically verified abstinence at 4 weeks post quit,,2021-01-08,COMPLETED,INTERVENTIONAL,['NA']
1335,NCT02974413,Glycemic control,Weight,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
1336,NCT00825695,functional transcranial doppler measures,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
1337,NCT02701257,Insulin Area Under the Curve in the 3.5 Hours Following the Insulin Bolus,PG AUC in the 3.5 Hours Following the Meal,,2016-03,TERMINATED,INTERVENTIONAL,['NA']
1338,NCT06195566,"Validation of the Mission T2D (MT2D) algorithm outputs, that predicts the real time risk for developing pre-diabetes.",,,2024-01-29,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1339,NCT01676233,Change in 24-hour blood glucose profile measured by continuous glucose monitoring,Change in HbA1c from baseline to each treatment end by treatment,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1340,NCT03437798,Correlation of CDC-AAP periodontal condition questions vs. periodontal disease diagnosis,,,2018-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1341,NCT04127890,Weight loss,,,2017-03-07,COMPLETED,INTERVENTIONAL,['NA']
1342,NCT06046560,Proportion of patients with prescriptions of SGLT2i or GLP1-RA at any time,Short-form Patient Activation Measure (PAM),Change in laboratory measured HbA1c,2021-03-22,COMPLETED,INTERVENTIONAL,['PHASE4']
1343,NCT04664764,to compare the effectiveness of insulin degludec to insulin glargine and NPH,,,2019-02-21,UNKNOWN,INTERVENTIONAL,['PHASE4']
1344,NCT05066152,HOMA-IR,Dietary cholesterol,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
1345,NCT03587623,Serum Copeptin concentration,,,2018-07-04,COMPLETED,OBSERVATIONAL,['NA']
1346,NCT01562782,Fold Change in Plasma Very Low Density Lipoprotein (VLDL) Triglyceride Palmitate,Peak Glucose in 2 Study Groups,,2012-04-02,COMPLETED,INTERVENTIONAL,['NA']
1347,NCT03605329,study of heart rate variability (HRV),monitoring of blood pressure,,2018-09-05,TERMINATED,INTERVENTIONAL,['NA']
1348,NCT01647542,Change From Baseline in HbA1c at Week 24,Change From Baseline in 2-hour Postprandial Glucose (PPG) Following Oral Glucose Tolerance Test (OGTT) at Week 24,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3']
1349,NCT00191282,Number of Participants Who Experienced a Primary Combined Outcome,Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18,Summary of Reasons for Deaths,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1350,NCT05909800,Differences in AUC in C-peptide stimulation test,Genetical analysis,,2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2']
1351,NCT02559479,Change in insulin resistance (HOMA index).,"Change in lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, non HDL cholesterol, triglycerides and apolipoproteins).",,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
1352,NCT00005419,,,,1992-03,COMPLETED,OBSERVATIONAL,['NA']
1353,NCT01565564,The Rate of Macrosomia.,The Rate of Pregnancy-induced Hypertension.,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
1354,NCT04799938,Level of Growth Diferantiation Factor-15,Level of VO2max,,2021-04-15,RECRUITING,INTERVENTIONAL,['NA']
1355,NCT01714986,"Intervention with Affect School with Script Analysis and Basic Basal Awareness Therapy in patients with diabetes, psychological symptoms and high HbA1c",Self-image,,2009-03,WITHDRAWN,INTERVENTIONAL,['NA']
1356,NCT05298735,Pancreatic calcium-handling: Rate of change of pancreatic T1 values with manganese-enhanced magnetic resonance imaging,,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
1357,NCT01759823,Reduction of insulin requirement by ≥ 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function,,,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1358,NCT06116149,Difference in mean 12-month weight reduction (primary health-related outcome),Difference in proportion of participants meeting intervention goals at 12 months,Sustainability (Participants): comparison of the proportion of participants maintaining DPP goals at six months after their participation in the DPP has ended,2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
1359,NCT04605991,Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0 Millimoles/Liter [mmol/L]) (Both Inclusive) During Daytime Period at Week 12,Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) - Glycemic Control Domain Score at Week 12,,2020-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1360,NCT04688359,Measurements behind the Icelandic heart association risk calculator,Hip-to-Waist ratio,LDL cholesterol changes from start point to endpoint in both groups,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
1361,NCT00067626,Homeostasis Model Assessment for Insulin Resistance (HOMA-IR),endothelial function measures as percent flow-mediated dilitation (FMD).,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1362,NCT00382564,,,,2006-09-25,COMPLETED,OBSERVATIONAL,['NA']
1363,NCT00789711,"Number of all (Major/Minor/Nocturnal) hypoglycaemic events, reported as serious adverse drug reactions.",Number of major (including nocturnal) hypoglycaemic events,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
1364,NCT00832182,Number of hypoglycemic episodes and adverse events,9-point blood glucose profile,,1999-12-22,COMPLETED,INTERVENTIONAL,['PHASE3']
1365,NCT02107326,Effect of Webdia Software use on HbA1C,Effect of Webdia Software use on the incidence of hypoglycaemic events,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
1366,NCT02252224,The number and incidence rate of adverse events and serious adverse event including unexpected adverse drug reactions,Changes in 2-hr PPG before and after administration of Forxiga,,2014-09-23,COMPLETED,OBSERVATIONAL,['NA']
1367,NCT00785005,,,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
1368,NCT03107208,Rate of Rebound Hyperglycemia,Evaluation of CGM and POC Glucose Monitoring During DKA Treatment in Children.,,2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE4']
1369,NCT00953914,autonomic modulation assessed by heart rate variability,,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
1370,NCT04653454,CGM accuracy - mean absolute relative difference (MARD),Readmission rate at 30 days,,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1371,NCT00424762,Peak Oxygen Uptake (VO2),Percentage of Patients Developing New or Worsening Peripheral Edema,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1372,NCT02710448,"the percentage of patients in stage 1 of chronic kidney disease (CKD) each category of renal function whose rate of erythrocyte metformin remain within the therapeutic range, at each stage of treatment.","the percentage of patients in stages 3-5 of CKD each stage renal disease with a blood erythrocyte remaining within the therapeutic range or higher, and but without significative hyperlactatemia (≥ 2.5 mmol / l) in the latter case.",,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1373,NCT00006162,,,,1994-10,COMPLETED,INTERVENTIONAL,['NA']
1374,NCT00159731,Adverse events,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1375,NCT02292290,Composite,HbA1c only,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1376,NCT04571723,Change in Health Mindset,waist circumference,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
1377,NCT03528031,Visceral adiposity,24-hour diet recall,,2018-06-19,COMPLETED,INTERVENTIONAL,['NA']
1378,NCT04999189,Change in blood pressure,,,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA']
1379,NCT01088594,Time-course absolute urinary sodium excretion calculated on the Day 1 of each study period,Creatinine clearance calculated on Day 1 of each study period,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1380,NCT03570138,Prevalence of cardiac arrythmic events during a 14 days Continuous ECG Monitoring,Prevalence of ventricular extrasystoles,,2018-06-29,UNKNOWN,INTERVENTIONAL,['NA']
1381,NCT00620282,Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF),Number of Hypoglycaemic Episodes,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1382,NCT00073255,,,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1383,NCT02624583,Changes in platelet reactivity between the three time points,Changes in the lipid profile between the three time points,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
1384,NCT05925946,Reversal of diabetes,Insulin Resistance,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1385,NCT00791453,Hgb A1C and BMI measurements will improve,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
1386,NCT01947855,Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1387,NCT01079364,Self Measured Blood Glucose (SMBG),Adverse Events (excluding hypoglycemic events),,2010-01,TERMINATED,INTERVENTIONAL,['PHASE4']
1388,NCT03947073,Total number of women who failed management with diet alone,Total number of neonates with a preterm birth,,2019-06-12,COMPLETED,INTERVENTIONAL,['NA']
1389,NCT03864744,Change in hepatic lipid content (steatosis) after total pancreatektomy or pancreaticoduodenectomy,Changes in NAFLD/NASH biomarkers,,2019-01-30,UNKNOWN,OBSERVATIONAL,['NA']
1390,NCT01594281,Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS),Number of PRP Laser Spots Until EOCS,,2012-12-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1391,NCT02986984,Rapid progression of kidney function loss,Serious Adverse Events,,2016-12,RECRUITING,OBSERVATIONAL,['NA']
1392,NCT05561855,The change of HbA1c from baseline,The change in depression severity from baseline,,2022-10-07,COMPLETED,INTERVENTIONAL,['NA']
1393,NCT01486862,Percentage of subjects achieving HbA1c (glycosylated haemoglobin A1c) below 7.0%,Adverse events,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1394,NCT02773095,Price of Novartis Access medicines and equivalents at alternative for-profit drug sellers,,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
1395,NCT04292509,blood ketones > 0.6mmol/l.,severe hypoglycemic episodes,,2020-02-15,COMPLETED,INTERVENTIONAL,['NA']
1396,NCT02634216,Effect of Capros on Blood Glycemic Index,,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1397,NCT00567112,Half Life (t½) for OCT (Fasted) and DFC (Fasted),t1/2 for OCT (Fasted) and OCT (After Meal),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1398,NCT05632029,Malondialdehyde,Glutathione,,2022-10-20,RECRUITING,INTERVENTIONAL,['NA']
1399,NCT02000024,Changes in weight,Changes in HDL-cholesterol,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
1400,NCT03670641,Change in Baseline A1C and A1C Measured at 3 Month Intervals up to 12 Months,Number of Participants Achieving Euglycemic Glucose Targets Within a 4 Week Period,,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE4']
1401,NCT02768818,Glucose metabolism changes,Admission to Neonatal Intensive Care Unit (NICU),,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1402,NCT04450693,Complete wound healing,Patient-reported mobility,,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE3']
1403,NCT03376789,Change in HbA1c,Change in 8-point SMBG,,2017-11-29,COMPLETED,INTERVENTIONAL,['PHASE3']
1404,NCT06084052,Device questionnaire,Reduction in CO2 comparing carbon dioxide emitted due to ulcer treatment vs carbon dioxide emitted due to device manufacture,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
1405,NCT05756712,The Change of Blood Glucose Level in mmol/L based on OGTT (Oral Glucose Tolerance Test) after Intervention,The Change of Fast Blood Glucose Level in mmol/L based on OGTT (Oral Glucose Tolerance Test) after Intervention,,2023-03-06,COMPLETED,INTERVENTIONAL,['NA']
1406,NCT05733455,Fasting serum C-peptide,Fasting serum low-density lipoprotein (LDL) cholesterol levels,,2023-05-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1407,NCT03970889,Change in the number of missed meal boluses,Positive predictive value of a Klue meal alert,,2018-10-12,COMPLETED,INTERVENTIONAL,['NA']
1408,NCT03226990,pressure areas,denture retention,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
1409,NCT05660928,Composite outcome of proportion of patients with controlled disease,Number of glycohemoglobin measurements,Program adherence,2022-12-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1410,NCT04784130,Clinical Outcomes-A1c,Behavioral outcome - medication adherence; questions,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
1411,NCT01729078,Changes in liver fat content after 12 weeks of intervention,Change in glucose metabolism after 12 weeks of intervention,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
1412,NCT04950634,To assess the role of sex on the progression of subclinical atherosclerosis in patients with T1D.,To identify novel circulating markers of subclinical atherosclerosis,,2018-09-01,RECRUITING,OBSERVATIONAL,['NA']
1413,NCT06077162,Hemoglobin A1c,Dietary intake - 24 hour recall,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1414,NCT00542009,Body weight,"Change in following parameters: Post-prandial and fasting glucose, and insulin",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1415,NCT05747118,Adherence,Change in triglycerides,,2022-08-15,COMPLETED,OBSERVATIONAL,['NA']
1416,NCT01814748,Percentage of Participants Who Discontinued Study Drug Due to an AE,Percentage of Participants Who Required Glycemic Rescue by Week 24,,2013-05-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1417,NCT01868542,Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline.,Incidence of Adverse Events,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1418,NCT05531838,Incidence of diabetes,HbA1c increased by 0.5%,,2022-10-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1419,NCT03820752,"Proportion of adult chronically ill patients correctly vaccinated diphtheria, tetanus, pneumococci, hepatitis B and influenza according to Belgian recommended vaccination schedule","Proportion of adult patients with antibodies against diphtheria, tetanus and pertussis.",,2014-10,COMPLETED,OBSERVATIONAL,['NA']
1420,NCT04613076,Depression change,Proportion of participants with change in glycosylated hemoglobin,Utilization of health care services,2019-09-03,COMPLETED,INTERVENTIONAL,['NA']
1421,NCT02261194,Change in depressive symptoms,Change in life space,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1422,NCT02805283,Condition-specific treatment satisfaction,Self-reported body weight,,2016-06-22,COMPLETED,OBSERVATIONAL,['NA']
1423,NCT00069836,Change from baseline in HbA1c,"Insulin dose, FPG,glycaemic responders, beta-cell function, hypoglycaemia, treatment satisfaction",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1424,NCT00843232,"Distinctive curves of glucose, C peptide, insulin, glucagon, GLP-1, GIP and ghrelin during a standardized mixed meal tolerance test, in T2DM subjects after sixty-five years old in comparison with middle-age T2DM subjects",Distinctive DPP-IV activity as measured by spectrophotometer in T2DM subjects after sixty-five years old in comparison with middle-age T2DM subjects.,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
1425,NCT00556114,Medical exam tool,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
1426,NCT01105923,Intervention acceptance,Quality improvement based on problem list accuracy/completion,,2010-05,UNKNOWN,INTERVENTIONAL,['NA']
1427,NCT05318183,Change in fasting plasma glucose,Intestinal whole wheat phytochemical: phenolic compounds,Gut microbiota relative abundance,2022-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1428,NCT00494988,Remission rate,HbA1c,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1429,NCT03512184,Determine if Liver Fat via Fibroscan Controlled Attentuation Pattern score has decreased as a result of YMCA program,"Measuring the effectiveness of the YMCA Program, as per metabolic blood work that's analyzed",,2018-01-03,COMPLETED,INTERVENTIONAL,['NA']
1430,NCT04643873,Muscle mass amounts in the trunk and extremities,6 minutes walk test,,2020-01-06,UNKNOWN,INTERVENTIONAL,['NA']
1431,NCT00743756,Weight Loss in the elderly african american population,Endothelial Function (assessed by pulse-wave analysis); sympathetic activity; insulin sensitivity,,2006-04,TERMINATED,INTERVENTIONAL,['NA']
1432,NCT01086137,Salivary Biomarker Levels,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
1433,NCT05788341,Positive Islet Autoantibodies,,,2023-05-30,RECRUITING,OBSERVATIONAL,['NA']
1434,NCT00701090,Change From Baseline in HbA1c at Week 30,Percent of Patients With A1C <6.5% at Week 30,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1435,NCT03965013,Number of treatment-emergent adverse events,Maximum observed serum NNC0268-0965 concentration after a single dose,,2019-06-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1436,NCT02713841,Bioavailability,,,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1437,NCT01257087,Percentage of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose of Less Than 5.6 mmol/l and/or HbA1c of Less Than 6%,Number of Participants With Microvascular Events,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
1438,NCT05076955,Healing Rate,Wound Closure,,2021-03-31,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1439,NCT01117350,Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period,Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1440,NCT02810691,Plasma glucose area under the curve,Post-meal peak plasma glucose,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
1441,NCT01788930,Response to antiplatelet therapy,Effects of CPAP treatment for severe obstructive sleep apnea on aspirin efficacity in type-2 diabetic patients,,2013-02,TERMINATED,INTERVENTIONAL,['NA']
1442,NCT01051011,Glycemic control assessed by HbA1c,"Meal tolerance test (in a subset of patients): Glucose, insulin, C-peptide, glucagon values",,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3']
1443,NCT00972283,Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1444,NCT01983215,number of patients with infections,infection rates,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
1445,NCT05335629,Effect on ST2 (suppression of tumerogenicity 2) level in the acute phase after myocardial infarction,Echocardiographic changes due to intervention,,2022-06-01,COMPLETED,INTERVENTIONAL,['NA']
1446,NCT00821977,Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM by assessing changes in HbA1c from baseline to 24 weeks.,Measure: To evaluate the body weight change from baseline with vildagliptin compared to placebo after 24 weeks of treatment as monotherapy in patients with T2DM,,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1447,NCT00502515,Rate of epidermal nerve fiber regeneration,"Safety: physical examination, clinical laboratories, adverse event reporting",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1448,NCT03155867,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,,2017-04-05,COMPLETED,INTERVENTIONAL,['NA']
1449,NCT06169982,Pharmacokinetics (PK): Area under the concentration curve during one dosing interval at steady state (AUCss) of LY3209590,"PK: Total amount of glucose infused during one dosing interval at steady state (Gtot,SS) of LY3209590",,2023-12-07,RECRUITING,INTERVENTIONAL,['PHASE1']
1450,NCT02530866,Change in baseline maternal glycemia at 32-36 weeks gestation,Lipid profile measurements,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
1451,NCT00089557,,,,na,TERMINATED,INTERVENTIONAL,['PHASE2']
1452,NCT00103935,"Assess the safety, tolerability, and pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC) injection in subjects with type 2 diabetes (T2DM)",Change in seven-point glucose concentrations from Baseline to Week 14 and Week 15,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1453,NCT01057693,Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase,Patient Global Evaluation of Study Medication (GESM) (Double-Blind Phase),,2010-03-31,COMPLETED,INTERVENTIONAL,['PHASE3']
1454,NCT04724967,Number of Participants at Each Dry Skin Scale,,,2021-03-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1455,NCT01564719,Metabolic Syndrome,Stress,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
1456,NCT03443180,Change in the plasma-induced transcriptional assay,Leukocyte analyses,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
1457,NCT05791942,MyChart letter opened,Completion rate of one screening/test,,2023-03-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1458,NCT04375020,gaba improve c peptide levels,,,2019-11-01,COMPLETED,OBSERVATIONAL,['NA']
1459,NCT01841398,Effectiveness of a 12 Month Culturally-Specific Multi-media Intervention on Heart Health Risk,Change in Hypertension Status,,2012-06,UNKNOWN,INTERVENTIONAL,['NA']
1460,NCT00215735,,,,2004-06,TERMINATED,INTERVENTIONAL,['NA']
1461,NCT00490893,Hormone response to hypoglycemia (glucagon) Symptom response to hypoglycemia,"Hormone response (epinephrine, growth hormone, cortisol) to hypoglycemia",,2006-03,TERMINATED,INTERVENTIONAL,['PHASE4']
1462,NCT05893927,"""Self-Efficacy for Diabetes Scale""",Blood pressure,,2024-02-15,RECRUITING,INTERVENTIONAL,['NA']
1463,NCT06079008,The proportion of cardiac valve calcification between survival group and mortality group,,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
1464,NCT01948037,Change from the intensity of numbness and cold feeling at 4 weeks. Change from the improvement of the pain index at 4 weeks.,Change from ankle-brachial index at 4 weeks,Change from flow velocity values at 4 weeks,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
1465,NCT03530579,Change in hip-to-waist ratio measurements,,,2014-02-13,COMPLETED,INTERVENTIONAL,['NA']
1466,NCT04323462,Wound Healing,time to ulcer healing,amputation,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1467,NCT01588743,AUC75-120 of Glucose Infusion Rate (GIR),AUC0-10 of Acute Insulin Response (AIR) during IVGTT,,2008-10,UNKNOWN,INTERVENTIONAL,['NA']
1468,NCT02276950,All-cause mortality,Composite,,2011-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1469,NCT02278939,Count of Participants Who Completed the Study,Change in Body Mass Index (BMI),,2014-11,COMPLETED,INTERVENTIONAL,['NA']
1470,NCT00308451,Primary(baseline versus final): AUCg as recorded from a 2-hour OGTT with 75 g glucose beverage; fructosamine; fasting plasma glucose.,"Secondary (baseline versus final): Lipid panels (Total-C, HDL, LDL, VLDL), lipid ratios , apolipoprotein A and B.",,2003-11,COMPLETED,INTERVENTIONAL,['NA']
1471,NCT00241904,HbA1c,Patients' Satisfaction With Care and Health Care Utilization,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1472,NCT05103306,Changes in HbA1c From Baseline to months 36,Percentage of patients with at least 1 episode of genitourinary tract infections,,2017-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1473,NCT05023798,Exploratory Usability Objective,,,2021-09-15,UNKNOWN,OBSERVATIONAL,['NA']
1474,NCT03804970,Proportion of scheduled eye care visits attended over 1 year,Visual acuity in the better seeing eye.,,2019-08-15,COMPLETED,INTERVENTIONAL,['NA']
1475,NCT01394510,Fasting Urine F2 Alpha Isoprostane Levels,Oral Disposition Index,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
1476,NCT03719911,Change in Hemoglobin A1c,,,2018-08-05,COMPLETED,INTERVENTIONAL,['NA']
1477,NCT00657943,Carotid intima media thickness,adverse events,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1478,NCT03445702,Lactate to pyruvate ratio,Genomic testing,,2018-10-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1479,NCT00442884,change of glucose measurements after stress test in the fasting and fed state,,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
1480,NCT01117831,Lipids goal achievement,Achievement of National Clinical Practice Recommendations among Puerto Rican Population with Diabetes Mellitus,Achievement of National Clinical Practice Recommendations among Puerto Rican Population with Diabetes Mellitus,2010-03,COMPLETED,OBSERVATIONAL,['NA']
1481,NCT01455142,Maximum observed serum insulin aspart concentration,Maximum glucose infusion rate,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1482,NCT05365438,Volume of carotid artery plaque,Changes of gut microbiota,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE4']
1483,NCT02931773,Sympathetic hyperactivity in recently diagnosed DM2 patients,,,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
1484,NCT04269668,Percentage of time of glucose sensor readings below 54 mg/dl,incidence of DKA,INSPIRE questionnaire measures,2020-07-19,COMPLETED,INTERVENTIONAL,['NA']
1485,NCT04529889,Change of obesity status during childhood and adolescence,Change of type 2 diabetes during childhood and adolescence,,2012-02-01,RECRUITING,OBSERVATIONAL,['NA']
1486,NCT02061124,Incremental and total area under the Concentration-Time Curve (AUC 0-240 min),Incremental and total area under the Concentration-Time Curve (AUC 0-240 min),Visual analog scale score,2014-02,COMPLETED,INTERVENTIONAL,['NA']
1487,NCT05271045,serum HbA1c (mg/dL),TAC (mg/dL),,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
1488,NCT06152536,Physiopathology of glucose after two different meals,Physiopathology of insulin after two different meals,,2022-06-09,RECRUITING,INTERVENTIONAL,['NA']
1489,NCT04391088,number of diabetic patients up to date with their mandatory and recommended vaccinations,number of patients vaccinated during hospitalization,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
1490,NCT06334133,Change in incidence of Level 2 or Level 3 hypoglycemia,To assess the incidence of adverse events,11-item/Short Form Hypoglycemia Fear Scale,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1491,NCT05407831,HOMA Index and Beta cell function,MODY probability >25%,,2022-03-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1492,NCT05338567,Validation of the accuracy of the predicted length of the small intestine,Building prediction formulas through machine deep learning,,2019-10-02,RECRUITING,OBSERVATIONAL,['NA']
1493,NCT01236365,Hs-CRP Levels Assessed at Randomization and 6 Months,Descending Aortic Strain,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1494,NCT03622359,Lower extremity perfusion,Limb salvage,,2017-02-17,RECRUITING,INTERVENTIONAL,['NA']
1495,NCT00286494,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1496,NCT03743779,weight,adherence,,2018-09-09,COMPLETED,OBSERVATIONAL,['NA']
1497,NCT01092806,The primary objective is to compare insulin secretion (Secr2.phase) between the two different formulations of Tac.,insulin sensitivity,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1498,NCT06322212,Assess anxiety in T2DM adults with thiamine treatment.,,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1499,NCT06123871,Statistical analysis and target gene prediction of misexpressed mirnas and enrichment pathway analysis,,,2020-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1500,NCT02432586,Change in Hemoglobin A1c one month pre-camp to one month post-camp Session 2,Change in Behavioral Pediatrics Feeding Assessment one month pre-camp to one month post-camp Session 2,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
1501,NCT05543720,Death and/or all-cause unplanned readmission,Days alive and out-of-hospital,,2022-10-17,RECRUITING,INTERVENTIONAL,['NA']
1502,NCT05873049,Artificial dermis (AD) or split-thickness skin graft (STSG) take rate,Vancouver scar score on 180 days,,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1503,NCT02324842,Fasting Plasma Glucose (FPG) at 4 Months,Body Mass Index (BMI) at 4 Months,Change in 24-hour Blood Pressure at Study End Compared to Baseline.,2014-11,COMPLETED,INTERVENTIONAL,['NA']
1504,NCT03830216,CGM time in range,Change in patient reported outcomes - HCS,Number of insulin dose administrations,2019-05-30,TERMINATED,INTERVENTIONAL,['NA']
1505,NCT04789993,Type of additional autoimmune diseases at type 1 diabetes diagnosis,Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto,,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA']
1506,NCT03279627,"Patient understanding of discharge instructions for home diabetes therapy according to presence or absence of hypoglycemia (defined as BG < 70 mg/dl), hyperglycemia (defined as BG > 250 mg/dl), or BG 70-250 mg/dl at time of hospital discharge",Association between patient understanding of home diabetes therapy and frequency of ER visits and hospital readmissions at 30- and 90-day following the index hospitalization,,2017-08-28,COMPLETED,OBSERVATIONAL,['NA']
1507,NCT00705861,"Erectile Function domain score (sum of Question 1,2,3,4,5 and 15) of the International Index of Erectile Function (IIEF) Questionnaire","the score from : 1) IIEF Q3 & Q4, 2) other domains of IIEF, 3) Sexual Encounter Profile(SEP)Q2 and Q3, 4) Life Satisfaction Checklist, 5) Global Efficacy Assessment Question(GEAQ)",,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1508,NCT01867970,Physical activity,Physical activity in daily life,Health status,2013-04,COMPLETED,INTERVENTIONAL,['NA']
1509,NCT00433823,,,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1510,NCT01538485,Increase of regulatory FOXP3+ T cells,serum calcium level,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1511,NCT05639478,Change From Baseline of the Foot and Ankle range of motion at 12-week,Implementation at 12 weeks,,2023-03-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1512,NCT05435677,"Dose-normalised AUCSema,0-tz: Area under the plasma semaglutide concentration-time curve after a single dose divided by dose",Adverse events,,2022-06-22,COMPLETED,INTERVENTIONAL,['PHASE1']
1513,NCT04738591,Glycated Hemoglobin (HbA1C),Retention rate,International Physical Activity Questionnaire (IPAQ),2020-12-30,COMPLETED,INTERVENTIONAL,['NA']
1514,NCT01664676,Glomerular Filtration Rate (51Cr-EDTA plasma clearance),Plasma concentrations of various hormones,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1515,NCT00285909,PPAR-gamma activated gene expression,Postprandial changes of HPA-axis activity,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
1516,NCT00534105,Cholesterol,LDL,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
1517,NCT05099367,Exploring PGI2 pathway in skin microvascular reactivity,role of PGI2 pathway on cell migration in vitro,,2021-10-01,RECRUITING,INTERVENTIONAL,['NA']
1518,NCT05129735,Improvement of quality of life score from baseline to 12-weeks,Improvement in LDL cholesterol levels from baseline to 12-weeks,,2022-09-15,UNKNOWN,INTERVENTIONAL,['NA']
1519,NCT00322621,Change From Baseline (Week 8) in Brief Pain Inventory (BPI) 24-hour Average Pain Item Score at Week 34 Endpoint,Change From Baseline (Week 0) in Vital Signs: Weight at Week 34 Endpoint,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1520,NCT01787396,HbA1c,,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1521,NCT03034798,Blood glucose concentrations,Participants estimated blood glucose concentration,,2015-01-14,COMPLETED,OBSERVATIONAL,['NA']
1522,NCT02841553,Changes in C-peptide levels in participants,Changes in best-corrected visual acuity in participants measured by Snellen optotype,,2011-07,RECRUITING,OBSERVATIONAL,['NA']
1523,NCT00969007,5% weight loss,,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
1524,NCT02807974,Change from baseline in sitting systolic and diastolic blood pressure,Time course of urine-albumin-to-creatinine ratio,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1525,NCT05431140,Diabetes Treatment Satisfaction Questionnaire (DTSQc),Time spent by the HCP,,2022-06-20,RECRUITING,OBSERVATIONAL,['NA']
1526,NCT03278587,Cataract surgical rate,Number of cases of ocular disease detected,,2018-05-31,COMPLETED,INTERVENTIONAL,['NA']
1527,NCT01432938,Pharmacokinetics: Time to Maximum Concentration (Tmax) of R-warfarin and S-warfarin,Pharmacodynamics: Maximum Observed International Normalized Ratio (INRmax) of Warfarin,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1528,NCT03467503,Maternal inflammation,Maternal dietary intakes,Maternal metabolomics,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
1529,NCT06336239,The prevalence of albuminuria,Evaluate the management of patients with type 2 diabetes mellitus and cardiovascular disease across different levels of cardiology departments in hospitals.,Exploratory Objective,2023-12-21,RECRUITING,OBSERVATIONAL,['NA']
1530,NCT02556918,Number of Patients With Persistent Hyperglycemia,Number of Subjects Returning to the ER Within 30 Days,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1531,NCT00202618,A 50% reduction in UAE from the baseline,A change in high sensitivity C-reactive protein (hsCRP) from the baseline to the end of the intervention period,,2003-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
1532,NCT00615368,Cognitive function,Hypoglycemic hormonal response,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
1533,NCT00797615,The primary outcome measure will be the between-group differences in BMI and body fat.,Secondary outcomes will include dietary intake and physical activity.,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
1534,NCT01421966,Proportion of patients with complete healing/closure of their target ulcer at any time during the 16-week double-blind core treatment period with sustained complete closure for 4 additional weeks of follow-up.,Proportion of patients whose Target Ulcer completely closed during the core double blind treatment phase and remained closed at the FU12 follow-up visit.,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1535,NCT06085703,Change of olfactory brain activation by fMRI,Change of metabolism,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1536,NCT01690208,Glycemic control as measured by HbA1c compared to baseline,Control of BMI and other obesity indices compared to baseline,,2012-05,UNKNOWN,INTERVENTIONAL,['NA']
1537,NCT06203002,Change from Baseline to Week 8 in Average Daily Pain Score (ADPS),Change from Baseline to Week 8 in Total Neuropathic Pain Symptom Inventory (NPSI) Score,,2023-11-29,RECRUITING,INTERVENTIONAL,['PHASE2']
1538,NCT03821675,Change in Wound Size in Response to Electrical Stimulation Therapy,Change in Tissue Oxygen Saturation in Response to Electrical Stimulation,Change From Baseline in Skin Perfusion in Response to Electrical Stimulation,2019-02-28,COMPLETED,INTERVENTIONAL,['NA']
1539,NCT05992974,Number of participants with gestational diabetes,,,2023-08-31,RECRUITING,OBSERVATIONAL,['NA']
1540,NCT00635492,Estimates of Probability to Remain on Initial Injectable Treatment at 12 and 24 Months.,Percentage of Patients Hospitalized Between Baseline and 24 Months,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
1541,NCT03755752,Endothelial cell density,Mean corneal thickness,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
1542,NCT02515461,Changes in glomerulus basal lamina assessed using transmission electron microscopy.,Protein concentration in urine,,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
1543,NCT01610518,postprandial blood glucose,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
1544,NCT01535495,Area of retinal neovascularization on fundus photography,Early Treatment Diabetic Retinopathy Study visual acuity in study and fellow eye,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1545,NCT03169413,Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive potassium channel gene in diabetic patients diagnosed under the age of one year.,dentification of possible demographic and environmental risk factors associated with increased risk of diabetes in diabetic patient under the age of one year.,,2018-01,UNKNOWN,OBSERVATIONAL,['NA']
1546,NCT00129233,"Composite cardiovascular events including fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, admission due to heart failure, coronary intervention and sudden cardiac death",renal function,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1547,NCT00947726,Decrease transepidermal water loss and foot dryness in study subjects.,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
1548,NCT02465411,HbA1c in venous sample,Number of self-reported severe hypoglycaemic events per year,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
1549,NCT05683392,Number of other serious device-related adverse events,Number of interventions for study meal challenges,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
1550,NCT04144374,Omadacycline Tissue Penetration.,Omadacycline Area Under the Curve (AUC) in Tissue,,2020-02-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1551,NCT01951729,Insulin secretion rates during each treatment.,Plasma pancreatic polypeptide levels during each treatment.,Plasma xenin-25 levels during each treatment.,2013-03-13,COMPLETED,INTERVENTIONAL,['PHASE1']
1552,NCT01268813,Development of Diabetes or complication,,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
1553,NCT03039933,Decrease in scores on the Hypoglycemia Fear Survey,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
1554,NCT06230276,Difference in an area under the curve of a glucose concentration change 4 hours after a meal (30 g and 50 g of carbohydrates) with a missed premeal bolus between individual HCL systems.,Difference in CGM parameters after a meal (30 g and 50 g of carbohydrates) with a missed premeal bolus between individual HCL systems using insulin aspart.,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
1555,NCT05368220,Impact on clinical decision-making and clinical trajectories,,,2022-05-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1556,NCT05072353,Healing,amount of adipose stem cells used for grafting,,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1557,NCT00706693,To determine if sucrose and fructose are equally effective as glucose in the treatment of spontaneous hypoglycemia in children with type 1 diabetes.,To determine preferred mode of treatment for hypoglycemia after completing the study.,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1558,NCT02444910,Change from baseline of the 2 hour oral glucose tolerance test (OGTT) at day 28.,Change in Insulin Sensitivity Based on Euglycemic Clamp Study,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1559,NCT06105931,Change in triglycerides from baseline to 1 year,,,2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE1']
1560,NCT01634464,"Long-term evidence of early human programming of obesity measured biochemical perinatal biomarkers, and the offspring growth and development.",,,2007-03,UNKNOWN,OBSERVATIONAL,['NA']
1561,NCT01725815,Health Related Quality of Life (HRQOL),Medication Adherence,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
1562,NCT05002933,Mean change in HbA1c from baseline to week 24,Mean change in body weight from baseline to Week 12 and Week 24,,2021-05-20,COMPLETED,INTERVENTIONAL,['PHASE4']
1563,NCT03323294,Fatty Acid Oxidation in Type 2 Diabetes with metformin,,,2017-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1564,NCT01454284,Hemoglobin A1c (HbA1c),Rapid Assessment of Physical Activity (RAPA),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1565,NCT00145925,Composite of new or substantially worsening nephropathy or microvascular eye disease.,"Includes cerebrovascular disease, coronary heart disease, heart failure, peripheral vascular disease, cardiovascular and all-cause mortality, microalbuminuria, visual deterioration, new or worsening nephropathy, cognitive function, and dementia.",,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1566,NCT00732511,"Effect of Coreg CR compared to Toprol XL on endothelial function, vascular compliance, and parameters of oxidative stress from time of randomization to study drug termination",,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
1567,NCT06248775,Acceptability of the VITAAAL intervention,Morning void urine,,2023-11-16,RECRUITING,INTERVENTIONAL,['NA']
1568,NCT00138541,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1569,NCT01149421,Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP),Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1570,NCT01752803,Hb A1c,inflammatory markers,Lipoproteins,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
1571,NCT01392560,Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia,,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1572,NCT03387826,Platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods,"VerifyNow P2Y12 assay % inhibition, using the TRAP-induced response at the end of the 2 study periods",,2018-01-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1573,NCT02061488,"Assessment of time spent in target range (glycemia between 70 and 145 mg/dl) and in hypoglycemia (glycemia <70 mg/dl), during the night (11 PM to 8 AM)",Assessment of glucose values during the night (glycemia and interstitial glucose values),,2014-03,COMPLETED,INTERVENTIONAL,['NA']
1574,NCT01803828,Change from Baseline in Left Ventricular torsion (°) at 5 months,Effects of PDE5i on Body composition,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1575,NCT01811849,Time to 1/2 maximal insulin concentration,AUC 0-30 and AUC 0-60,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1576,NCT00736515,"Decreasing value of FPG and HbA1c, dosage of insulin and control rate of FPG",Weight change,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1577,NCT01909687,Analysis of system accuracy,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
1578,NCT05139784,To define the frequency and phenotype of autoimmune T lymphocytes reactive to islet antigens in the different study groups.,To define the differences between lymphocytes in the blood and those in pancreatic lymph nodes.,,2022-10-24,RECRUITING,OBSERVATIONAL,['NA']
1579,NCT03560271,Change in Glycosylated Hemoglobin (HbA1c) from Baseline at Week 24,Proportion of subjects with decrease in HbA1c of ≥ 1.0% from Baseline at Week 24,,2018-06-18,COMPLETED,INTERVENTIONAL,['PHASE2']
1580,NCT04163757,type 2 diabetes,,,2019-01-20,COMPLETED,INTERVENTIONAL,['NA']
1581,NCT03761134,Change in hemoglobin A1c (HbA1c),Adverse events,,2018-11-30,TERMINATED,INTERVENTIONAL,['PHASE3']
1582,NCT03851848,Talocrural joint dorsiflexion ROM will be measured using a universal goniometer,Foot plantar pressure distribution (FPP) will be measured using Platform Pedography system,,2019-03-03,UNKNOWN,INTERVENTIONAL,['NA']
1583,NCT03654313,Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability of MEDI6570,Immunogenicity rate,,2018-09-28,COMPLETED,INTERVENTIONAL,['PHASE1']
1584,NCT05882071,"Proportion of patients with a history of cardio-vascular events including heart failure hospitalizations and lower limb amputation, renal events, ketoacidosis, Fournier's gangrene over the two years before the index date (initiation of SGLT2i)",Time from drug initiation to death all cause,,2023-11-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1585,NCT02587780,Blood glucose response,Body fat percentage,,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
1586,NCT00960882,DMMET-01 Plasmatic concentration,glycated hemoglobin,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1587,NCT00476931,"Total Neuropathy Score (TNS),Evoked nerve conduction velocity (NCV), Quantitative Sensory Testing (QST), %of subjects with conversion of unmeasurable to measurable NCV and NIS-LL",Safety,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1588,NCT00693511,Insulin sensitivity,Change in visceral abdominal adipose tissue,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
1589,NCT04257877,"Targeted proteomic analysis in children with DT1 (levels of certain plasma proteomics such as sorbitol, fructose, myo-inositol, scyllo-inositol, serine, lysine, tertadecanoic, palmitic, stearic, eicosanoic fatty acids)",Electrophysiological study,,2018-11-20,RECRUITING,OBSERVATIONAL,['NA']
1590,NCT05762653,Degree of impairment of exocrine pancreatic function,Factors associated with pancreatic fibrosis,,2022-02-03,RECRUITING,OBSERVATIONAL,['NA']
1591,NCT01365091,"AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets",Number of Participants With Death as Outcome and Serious Adverse Events (SAEs),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1592,NCT03730610,Effects of exercise training - brain inflammation,Effects of exercise training - ectopic fat,,2019-01-30,COMPLETED,INTERVENTIONAL,['NA']
1593,NCT00976937,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24,Percentage of Patients Requiring Rescue Therapy During 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1594,NCT05878444,Presence of our bacteria in feces,Adverse effect,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1595,NCT04641312,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3457263,,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE1']
1596,NCT05053828,"Calculate MedWise Risk Score (TM) of <10, 11-14, 15-19, 20-30, >30 for T2D patients to examine patient risk for adverse drug events.",,,2021-09-20,COMPLETED,OBSERVATIONAL,['NA']
1597,NCT01316484,"Qualitative, Content Analysis of Cognitive Debriefing Data",,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
1598,NCT01025557,Food intake,Blood glucose,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1599,NCT06120881,Feasibility of Higher Metformin Dose measured with the Feasibility of Intervention Measure (FIM),Co-efficient of variation of glucose,,2024-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1600,NCT02716519,Target Ulcer Complications,"During the post-acute phase, weekly surgical procedures for target ulcer treatment",,2016-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
1601,NCT04291391,Differences between groups in circulating C-reactive protein (CRP) at Week 4,Change from Baseline in Phospholipids Classes Quantifications in Red Blood Cells at Week 4 and Differences Between Groups at Baseline and Week 4.,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
1602,NCT02421393,Effect of intervention on bone quality (trabecular bone score),Effect of intervention on fracture incidence (history or medical records and vertebral morphometry),Effect of intervention on coronary heart disease 10-year risk,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
1603,NCT02750111,Blood Glucose,,,2016-05,UNKNOWN,OBSERVATIONAL,['NA']
1604,NCT00989079,Apparent volume of distribution (Vz/F),Urinary recovery of Ertugliflozin,,2009-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
1605,NCT05774015,Fasting Blood Glucose (FBG),Serum creatinine,,2023-09-25,RECRUITING,INTERVENTIONAL,['NA']
1606,NCT01038895,Antiproteinuric effect as well as antihypertensive effect of aliskiren 300 mg / daily versus ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria.,"Average night, systolic and diastolic blood pressure",,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
1607,NCT03970031,"Change in the weighted average of standardized AST, CK-18, and HbA1c values (standard deviations) from baseline to Week 26","Time to first event of death or adjudicated non-fatal MI or USA hospitalization, adjudicated hospital admission for HF, adjudicated nonfatal ischemic stroke, or liver event in all randomized subjects.",,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1608,NCT00442988,,,,2000-10,COMPLETED,OBSERVATIONAL,['NA']
1609,NCT00414999,"Part B: Safety & tolerability of 2 concentrations of TG100801 (ophthalmic examinations, ocular comfort ratings, ocular/systemic adverse events, lab tests) when administered twice a day for 14 days, assessed up to 7-14 days following dosing.",Systemic pharmacokinetics (Part B only),,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1610,NCT01472432,Capillary Density,iNOS,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1611,NCT02613897,Change in Endogenous Glucose Production (EGP),Change in Free Fatty Acids (FFA),,2016-01,COMPLETED,INTERVENTIONAL,['NA']
1612,NCT04634500,Change from baseline in HbA1c,,,2020-11-18,COMPLETED,INTERVENTIONAL,['PHASE3']
1613,NCT02672280,Percentage of wound closure as determined,Percentage area of re-grafting as determined,,2016-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1614,NCT06254014,HbA1c,blood pressure,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1615,NCT03312439,Non-communicable disease assessed by the Swedish national patient register,,,2012-06-01,UNKNOWN,INTERVENTIONAL,['NA']
1616,NCT01650129,Glycosylated haemoglobin A1c (HbA1c),Insulin doses,,2000-12-13,COMPLETED,INTERVENTIONAL,['PHASE3']
1617,NCT01439672,Insulin Sensitivity,,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1618,NCT04105348,effect of IBD on DM,,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA']
1619,NCT02523222,Treatment failure of at-risk infants,,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
1620,NCT01251510,GLP-1 secretion,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
1621,NCT03485092,left ventricular global longitudinal strain (GLS),Intensification of diuretic therapy,DNA and epigenetics,2018-03-16,COMPLETED,INTERVENTIONAL,['PHASE4']
1622,NCT04053712,Number of carbohydrate interventions to treat hypoglycemia,Mean Borg scale level during exercise (RANGE:0-10),,2019-07-16,COMPLETED,INTERVENTIONAL,['PHASE4']
1623,NCT02942069,Blood glucose response measured with CGM,,,2016-12,COMPLETED,OBSERVATIONAL,['NA']
1624,NCT05546138,Progression and regression of neuropathy,Correlation between central and peripheral measurements,fMRI as a marker for progression of neuropathy,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1625,NCT00740519,Incidence of serious adverse drug reactions including major hypoglycaemic events,HCP time used on titration training,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
1626,NCT00308386,"% of patients at goal for all three parameters (HbA1C <7, BP <130/80, LDL <100)",Physician satisfaction - survey filled out by physician,,2006-08-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1627,NCT05516966,Incidence of Adverse Events (Safety and Tolerability),Immunogenicity: anti-HRS9531 antibody,,2022-10-12,RECRUITING,INTERVENTIONAL,['PHASE1']
1628,NCT00306436,composite criteria reflecting a good glycemic and arterial pressure status. Success defined by all measurements of HbA1c < 6.5% and of systolic (diastolic) pressure <=135 (85) mmHg if proteinuria is < 1g/24h or <= 125 (75) if proteinuria is => 1g/24h,,,2006-05,UNKNOWN,INTERVENTIONAL,['NA']
1629,NCT04894903,Number of Diabetes Care Gaps at 12 months,Reported Services Completed Outside Vanderbilt System,,2022-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1630,NCT04831697,Change in Glycemic Control from Baseline to 6 months,Change in Health Related Quality of Life from Baseline to 6 months,,2021-12-14,RECRUITING,INTERVENTIONAL,['NA']
1631,NCT01888796,Change in left ventricular diastolic function,Change in serum NT-pro BNP levels,,2013-09,TERMINATED,INTERVENTIONAL,['PHASE3']
1632,NCT04383015,Time in glucose target range during exercise intervention,Recovery Interstitial Glucose,,2018-10-31,COMPLETED,INTERVENTIONAL,['NA']
1633,NCT01427699,Safety and Tolerability,Preliminary Efficacy,,2011-06-30,COMPLETED,INTERVENTIONAL,['PHASE2']
1634,NCT05443334,Change in HbA1c,"DTSQs, change in absolute treatment satisfaction",,2020-11-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1635,NCT02500186,Change in blood glucose level using CGM,Adverse events,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
1636,NCT04001231,Ctrough,The presence and titer of anti-exenatide antibodies,HbA1c,2020-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1637,NCT04556760,Change in glucose AUC(0-4) versus baseline compared to prednisolone following a standardised MMTT,Safety and tolerability of AZD9567 by assessing the number of participants with adverse events,,2020-11-26,COMPLETED,INTERVENTIONAL,['PHASE2']
1638,NCT03350191,Glucagon receptor occupancy,Change lipid biomarkers,,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE1']
1639,NCT03968354,Measure of RANKL mRNA expression in the liver,NF-kB pathway in hepatocytes and Kupffer cells,,2020-02,UNKNOWN,OBSERVATIONAL,['NA']
1640,NCT02130180,Mean Optic Nerve Sheath Diameter,,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
1641,NCT02302599,The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D,safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1642,NCT02298556,Absolute change in systolic blood pressure,Blood pressure variability (daily or hourly) in home blood pressure measurement,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
1643,NCT01403831,Hemoglobin A1C at 6 months,Diabetes knowledge,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
1644,NCT02745613,Insulin sensitivity,Myokine concentrations,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
1645,NCT01801631,Change in Diabetes related distress,Change in Biomedical variables,Change in Spousal support,2011-10,COMPLETED,INTERVENTIONAL,['NA']
1646,NCT01326598,The primary objective is to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the five categories of baseline treatment.,To describe changes in participants' weight from the beginning to the end of the study.,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
1647,NCT01115205,Change in haemoglobin A1c (HbA1c) levels,Compliance with walking sessions,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
1648,NCT03294915,Insulin sensitivity,Glycemic control,,2018-10,UNKNOWN,INTERVENTIONAL,['NA']
1649,NCT02801448,Delta-HbA1c,Delta-fasting blood glucose,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1650,NCT03213093,the rate of incidence of diabetic foot ulcer,Neurovascular response to pressure,,2017-12-01,RECRUITING,INTERVENTIONAL,['NA']
1651,NCT00576277,Pharmacodynamic profile,Correlation between plasma concentrations of AV411 and pain intensity assessments,,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1652,NCT05654805,change in insulin resistance (Matsuda),change in IGF-1 and its binding proteins,change in faecal excretion of BCAA metabolites,2022-12-15,RECRUITING,INTERVENTIONAL,['NA']
1653,NCT01289587,Aerobic fitness,Adherence/Attendance: Number of physical activity sessions attended,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
1654,NCT03603990,Visual acuity,,,2018-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
1655,NCT00933998,Epidermal Nerve Density Count,,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
1656,NCT04428606,Blood glucose effects of dietary supplement: Metabolic Rheostat vs. Butyrate Ultra,Impact of Metabolic Rheostat and Butyrate Ultra on food addiction and cravings,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA']
1657,NCT01271517,HbA1c,IGF-I,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
1658,NCT00208221,Microalbuminuria,systolic blood pressure,,2006-08,TERMINATED,INTERVENTIONAL,['PHASE3']
1659,NCT06084468,Incidence of heart failure,Number of Participants with admission with stroke,,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1660,NCT01165190,,,,2008-05,UNKNOWN,OBSERVATIONAL,['NA']
1661,NCT00643110,Completion of 6 subjects.,,,2008-04,WITHDRAWN,INTERVENTIONAL,['NA']
1662,NCT02029924,Area under the curve (AUC),"Safety and Tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1663,NCT05574231,Effect on medical diseases,,,2022-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1664,NCT05448105,User Experience - Acceptance,Change in Diabetes Readiness for Change,,2022-12-22,COMPLETED,INTERVENTIONAL,['NA']
1665,NCT02195856,Hepatic perfusion,Plasma incretin concentration,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
1666,NCT03190798,Change in Pulmonary capillary wedge pressure (PCWP),Change in Pulmonary capillary wedge pressure (PCWP),,2017-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
1667,NCT00790205,Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population),Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population),,2008-12-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1668,NCT03593746,Glycemic control,Other Biochemical Analyzes,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
1669,NCT01083212,PK of AZD1656 when administered with placebo or following repeated dosing of gemfibrozil by assessment of AUC and Cmax.,"Safety of AZD1656 when administered with placebo or following repeated dosing of gemfibrozil by assessment of electrocardiogram, weight, pulse, blood pressure, laboratory variables including 24-h plasma glucose, physical examination and adverse events",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1670,NCT02252965,Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period,Percentage of Subjects Who Are Compliant to Treatment,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1671,NCT00252018,Improvement of endothelial function as measured by FMD,,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
1672,NCT06288269,1 year survival death,,,2023-11-01,COMPLETED,OBSERVATIONAL,['NA']
1673,NCT02150109,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Number of Subject Responses That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
1674,NCT06277258,Number of Participants with adequate glycaemic control,Maternal satisfaction,,2023-01-31,RECRUITING,INTERVENTIONAL,['NA']
1675,NCT01604213,Reduction in serum levels of Interleukin 6 (IL-6),Improvement in other markers of athero-thrombosis and inflammation:,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1676,NCT01856790,Peak Post-prandial Venous Glucose Levels,the Incremental Meal-related Glucose Area Under Curve (AUC),Mean Nocturnal Glucose Levels,2013-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1677,NCT00945711,define general characteristics of the diabetes and eating disorder population,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
1678,NCT03607604,Urinary C-peptide Creatinine Ratio (UCPCR),Prevalence of MODY,,2015-04-01,UNKNOWN,OBSERVATIONAL,['NA']
1679,NCT02358096,Mean change of log transformed urinary albumin to creatinine ratio (UACR) from baseline to end of treatment,Proportion of subjects with either >30% or >40% or >50% reduction in AER from baseline to end of treatment,,2015-03-17,COMPLETED,INTERVENTIONAL,['PHASE2']
1680,NCT04646473,HbA1c,Problem solving,,2021-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1681,NCT00787605,Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP),Evaluate the Safety and Tolerability,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1682,NCT02188186,Change of HbA1c,Lipid profile,Body composition,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1683,NCT00145288,,,,2003-10,UNKNOWN,OBSERVATIONAL,['NA']
1684,NCT02573662,Change in insulin sensitivity,Change in insulin sensitivity,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
1685,NCT03135015,Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours,ISSI-2 Index of Beta-cell Function,Effect of Capsules vs. Tablets,2017-04-26,COMPLETED,INTERVENTIONAL,['PHASE1']
1686,NCT01339208,Change in HbA1c % from baseline,Patient satisfaction,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
1687,NCT00767741,Insulin blood level with and with out the intervention,,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
1688,NCT00844194,Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12,Change of Pulse Rate From Baseline at Week 12,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1689,NCT05917132,Fasting and postprandial lipid metabolite production in response to dietary lipid intervention in abdominal obesity and type 2 diabetes,Gut microbiota in response to a 2 day dietary lipid intervention in abdominal obesity and type 2 diabetes,,2023-06-12,RECRUITING,INTERVENTIONAL,['NA']
1690,NCT00376181,Change from Baseline in Glycosylated Hemoglobin.,Change from Baseline in Systolic Blood Pressure,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3']
1691,NCT00927524,Insulin levels,,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
1692,NCT02179281,Significant between-group difference in number of hypoglycemic events,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1693,NCT06199440,Primary Outcome,Secondary Outcome,,2022-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1694,NCT05759637,Hidden Hypercortisolism prevalence in a sample of Obese patients,,,2022-05-06,RECRUITING,OBSERVATIONAL,['NA']
1695,NCT02650726,anti-inflammatory ability of HDL,endothelium-dependent flow-mediated dilatation (FMD),,2014-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1696,NCT03109951,Abnormal Glucose Levels After Colonoscopic Preparation,Number of Participants With Self-treatment and Relief of Hypoglycemic Symptoms,,2017-03-25,COMPLETED,INTERVENTIONAL,['NA']
1697,NCT02040025,Change from baseline in TCOM (Transcutaneous oximetry measurement) values,Change from baseline in hemoglobin A1C laboratory values,,2014-04,TERMINATED,OBSERVATIONAL,['NA']
1698,NCT06054841,Two hour glucose tolerance test,Primary care,,2023-05-22,RECRUITING,INTERVENTIONAL,['NA']
1699,NCT01270061,HIV testing rate,Linkage to care,,2012-04,WITHDRAWN,INTERVENTIONAL,['NA']
1700,NCT00951119,The effect of the breathing device on SBP is the main study parameter,Secondary endpoints include diastolic blood pressure (DBP) and quality of life.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1701,NCT00911482,Spillover of free fatty acids from chylomicrons,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
1702,NCT00241605,Change from baseline in HbA1c at week 48.,Change from baseline in FPG at week 48. Time to glycemic control. Change from baseline in C-peptide and insulin at week 48.,,2003-06-25,COMPLETED,INTERVENTIONAL,['PHASE4']
1703,NCT00749190,Change From Baseline in HbA1c After 12 Weeks of Treatment,Trough Concentrations of Empagliflozin in Plasma,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1704,NCT03700645,hs-CRP,Diastolic function,,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1705,NCT02000700,Plasma concentrations of canagliflozin following multiple oral doses of canagliflozin,Number of participants with adverse events as a measure of safety and tolerability,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1706,NCT05441072,Ptosis,,,2022-12-19,RECRUITING,OBSERVATIONAL,['NA']
1707,NCT00557518,Change from baseline in albumin excretion rate (µg/min),"Albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, AGE related markers, 24 hour blood pressure determinations",,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2']
1708,NCT03217409,Low density lipoprotein cholesterol (LDL-C) (%),Fibroblast Growth Factor 21,,2017-08-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1709,NCT02924064,The Changes in HbA1c at Week 24,The Changes in Fasting Plasma Glucose (FPG) at Week 24,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1710,NCT01967992,Hemoglobin A1c,Hemoglobin A1c,Body weight,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1711,NCT00694070,Number of Participants That Could Answer at Least 85% of the Comprehension Questions Correctly (Comprehension of the Program Reports),,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
1712,NCT05263310,Any incidence of hypoglycemia,Medication-Related Outcome: Aggregate measure of diabetes medication deprescribing,,2022-04-25,RECRUITING,INTERVENTIONAL,['NA']
1713,NCT04514523,Acceptability - Clinicians,Feasibility 3,,2020-04-28,COMPLETED,INTERVENTIONAL,['NA']
1714,NCT01675271,VO2max,mental health,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
1715,NCT02131948,Endogenous glucose production,,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1716,NCT00001963,,,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1717,NCT01869933,Ocular Safety and Tolerability,Systemic Safety and Tolerability,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1718,NCT01004757,myocardial diastolic function,"triglycerides, insulin resistance",,2008-02,UNKNOWN,INTERVENTIONAL,['NA']
1719,NCT01997762,Change in beta cell function,Change in insulin sensitivity,change in plasma levels of resveratrol and resveratrol metabolites,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
1720,NCT01244971,Glycemic control,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1721,NCT00660998,Sexual Encounter Profile Question 3,Safety and Tolerability,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1722,NCT01088165,The influence of adalimumab treatment in comparison to treatment with fumaric acid esters on the functional integrity of the endothelium will be monitored by flow mediated dilatation (FMD),Influence of adalimumab in comparison to fumaric acid esters on biochemical cardiovascular and metabolic risk factors,,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
1723,NCT00338104,Percentage of Blood Glucose Values Between 80 - 140,Percentage of Glucose Levels > 180 mg/dL,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1724,NCT03687840,Step Length,Symmetry Index,,2017-02-14,COMPLETED,INTERVENTIONAL,['NA']
1725,NCT01156974,change in number of care goals met,Kinds of patients who benefit from working with a care guide,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1726,NCT04657367,Plasma microRNAs,,,2020-02-03,RECRUITING,OBSERVATIONAL,['NA']
1727,NCT00979394,Evaluate characteristics or co morbidities being existent for patient with T2D at GP,,,2009-10,TERMINATED,OBSERVATIONAL,['NA']
1728,NCT04581421,Liverfat,Insulin clearance determined during steady state insulin infusion,,2020-12-03,COMPLETED,INTERVENTIONAL,['NA']
1729,NCT05396079,Assessment of Flow-Mediated Dilatation,,,2023-03-28,COMPLETED,INTERVENTIONAL,['NA']
1730,NCT00841919,Pre and post- prandial glucose levels,High excursions of blood sugars (>300 mg/dl).,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1731,NCT02355145,Change in the frequency of usage by physicians of the main criteria for selecting the add-on therapy in patients with inadequately metformin-controlled type 2 diabetes,Number of years until starting the add-on therapies after diagnosis,,2015-04-02,COMPLETED,OBSERVATIONAL,['NA']
1732,NCT03993145,Adherence,Changes in HbA1c,Participant satisfaction,2020-02-07,COMPLETED,INTERVENTIONAL,['NA']
1733,NCT02984514,Activity of brown adipose tissue in correlation to exogenous insulin needs using the tracer 18F-deoxy glucose in positron emission tomography measurements,Glucose uptake in muscle in correlation to exogenous insulin needs; assessment using the tracer 18F deoxy glucose in positron emission tomography measurements.,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
1734,NCT00111631,Absolute change from baseline in HbAlc\n,"AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n",,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1735,NCT04253613,IL-10 level in GCF,,,2013-01-15,COMPLETED,OBSERVATIONAL,['NA']
1736,NCT05526157,Descriptive summary of patient comedications,Descriptive summary of temporal changes in the baseline characteristics of medication-specific cohorts,,2022-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1737,NCT03960255,Proportion (%) of patients with complete wound healing at 24 weeks,Proportion of patients who Die,,2021-02-20,RECRUITING,OBSERVATIONAL,['NA']
1738,NCT00102388,Change from baseline in HbA1c at 104 weeks,Patients with reduction in HbA1x >/= 0.5% after 104 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1739,NCT00707668,The incidence of diabetes,Insulin sensitivity and resistance of Korean subjects,,2007-05,UNKNOWN,OBSERVATIONAL,['NA']
1740,NCT04847219,TIme in range,calorie intake,,2019-10-09,COMPLETED,INTERVENTIONAL,['NA']
1741,NCT02304718,the risk of gestational diabetes mellitus,pregnancy outcome,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
1742,NCT02457858,"Islet yield using BMX-010, compared to current standard islet isolation data",AE/SAE morbidity within 1 month post-transplant,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1743,NCT01538589,Adverse events,Total dose of insulin infused subcutaneously,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
1744,NCT01715818,"Time to first occurrence of any component of the composite event (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke) as adjudicated by the Clinical Events Committee (CEC)","Time to first occurrence of a composite with components as adjudicated by the CEC: all-cause mortality, non-fatal MI and non-fatal stroke (in each of the subgroups with or without evidence of T2D at baseline)",,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
1745,NCT05887895,Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS062）,Incidence and severity of adverse events (AEs),,2023-05-23,COMPLETED,INTERVENTIONAL,['PHASE1']
1746,NCT03187145,Number of patients with full stomach,the mean gastric emptying time of clear liquid and light meal,Correlation of diabetes mellitus complications with delayed stomach empty,2017-06-15,UNKNOWN,OBSERVATIONAL,['NA']
1747,NCT01269034,The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.,"Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls.",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1748,NCT05655117,The detection rate of macular oedema in the intervention group vs. control group.,The screening rate for macular odema,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1749,NCT04949568,Glucose Variability data from continuous glucose monitor (CGM) will be downloaded directly from participants provided (blinded) FreeStyle Libre Pro,"Diabetes Distress Scale (DDS) (17-item), using Numerical Rating Scale: 0-6",,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1750,NCT02150707,Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio,Albumin:creatinine ratio,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
1751,NCT05422092,The activity of CEPT in pmol/mL/min,The activity of CEPT in pmol/mL/min,,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1752,NCT02638246,Percentage of days conducted at least 4 tests per day.,Feasibility,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
1753,NCT05473325,Signal to Noise,,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1754,NCT02546401,Area Under Curve (AUC) of glycemia,Area Under Curve (AUC) during 4H after a high-fat meal,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1755,NCT04266171,Change in HbA1c from baseline,Compliance/Satisfaction Questionnaire,,2020-01-16,UNKNOWN,INTERVENTIONAL,['NA']
1756,NCT04853810,Percentage of skin intolerance to adhesives in diabetic patients,Evolution of lesions,,2021-05-17,COMPLETED,OBSERVATIONAL,['NA']
1757,NCT05058690,Number of participants identified with pre-diabetes/type 2 diabetes mellitus when fasting blood sample test results are compared against FatHealth algorithm results,Number of participants identified with pre-diabetes/type 2 diabetes mellitus when oral glucose tolerance test results are compared against FatHealth algorithm results,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1758,NCT05762120,Weight Loss,,,2023-02-03,RECRUITING,INTERVENTIONAL,['NA']
1759,NCT05624762,pain score,Neuropathy Deficit Score (NDS),The sensory nerve conduction velocity (SNCS),2022-07-07,RECRUITING,INTERVENTIONAL,['NA']
1760,NCT03604419,The change from baseline value of HbA1c will be compared between treatments,"The change from baseline value of Fasting Plasma Glucose at Weeks 2, 4, 8, and 12",,2018-06-13,COMPLETED,INTERVENTIONAL,['PHASE2']
1761,NCT05000762,Platelet aggregation,,,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA']
1762,NCT04475380,Target lesion failure (TLF) at 2-year follow up in all-comers,Clinically indicated target lesion revascularization,,2018-09-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1763,NCT00877890,Change in HbA1c From Baseline to Week 24,Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1764,NCT01454401,Ulcer Healing Within 20 Weeks,Ulcer Healing Within 12 Weeks.,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
1765,NCT02589626,Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment,Change From Baseline in HbA1c After 52 Weeks of Treatment,,2015-10-29,COMPLETED,INTERVENTIONAL,['PHASE4']
1766,NCT06011512,"Proportion of participants developing diabetes mellitus during the study period, measured in changes of HbA1c.",Duration and cumulative glucocorticoid dosage,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
1767,NCT03907618,HbA1c,,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
1768,NCT00121355,,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1769,NCT02603510,Frequency of infusion set occlusions,Number of adverse events,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1770,NCT02307110,prevalence (percentages) of the stages of diabetic retinopathy (DR),mean NEI-VFQ 25 score,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1771,NCT04617405,"Association between the level, content and bioactivity of exosomes in serum and plasma Versus Insulin sensitivity at five times during pregnancy.",Association between the body weight Versus Insulin sensitivity at five times during pregnancy.,,2021-01-11,RECRUITING,OBSERVATIONAL,['NA']
1772,NCT02275091,small LDL particles,,,2014-10,UNKNOWN,OBSERVATIONAL,['NA']
1773,NCT04149054,Sallis Self Efficacy for Physical Activity Scale,Body weight,,2014-07-22,COMPLETED,INTERVENTIONAL,['PHASE1']
1774,NCT01474772,DPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period),Euro QoL-5 Dimensions (EQ-5D) - Health State Profile Utility Scores at the End of Each Treatment Period (Week 6 of Each Treatment Period),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1775,NCT00082407,Change in Glcosylated Hemoglobin (HbA1c),Change in Rate of Hypoglycemic Events,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1776,NCT00955903,Change in Abdominal Fat Mass,Weight Change/Maintenance,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1777,NCT05813652,"Medications (appropriateness, comprehensiveness)",,,2022-10-05,RECRUITING,OBSERVATIONAL,['NA']
1778,NCT00490672,Proportion of patients able to reach treatment goals.,The safety of the drug product used in the study will be assessed using the procedure for adverse drug reactions reporting for marketed medicinal products regulated by the Malaysian regulatory authority.,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4']
1779,NCT03816488,Feasibility: recruitment rate (total number per month),Number of participants with inflammation,,2023-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1780,NCT02312843,Change in cognitive performance from baseline following 6 month of high or low intensity exercise regimen,Change from baseline in blood sugar concentration and cerebrospinal fluid glucose measures during an oral glucose tolerance test following 6 months of high or low intensity exercise,Change from baseline in brain network connectivity using brain imaging,2013-03,COMPLETED,INTERVENTIONAL,['NA']
1781,NCT00417729,Oxidative stress,Adiponectin,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1782,NCT04232995,Berg Balance Scale,,,2019-03-12,COMPLETED,INTERVENTIONAL,['NA']
1783,NCT03390179,glucose concentration,glucose concentraion,,2017-09-04,COMPLETED,OBSERVATIONAL,['NA']
1784,NCT00548197,Best Corrected Visual Acuity,Anatomic Status of the Retina,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1785,NCT05369065,Device success,Change of anti-hypertensive medications,,2022-01-27,RECRUITING,INTERVENTIONAL,['PHASE1']
1786,NCT01341795,differences of sitagliptin and metformin trough concentration according to genetic variations of transporters,differences of HbA1c change according to genetic variations of transporters,,2011-07,UNKNOWN,OBSERVATIONAL,['NA']
1787,NCT01022762,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1788,NCT03232294,The relationship between fetal abdominal wall thickness and macrosomia,,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
1789,NCT05404178,Diabetic Foot Self-Care Questionnaire,Foot Care Behavior Scale,,2022-06-10,COMPLETED,OBSERVATIONAL,['NA']
1790,NCT00539409,"Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect Metabolic Integrity in patients with Diabetes Mellitus. Monitor results of QOL questionnaires, Hgb A1C levels, medications to see if patients complications improve",,,2006-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1791,NCT05163912,Acceptability,,,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1792,NCT01443143,Percent of time in euglycemic range,Percent of time in hyperglycemic range,,2010-12,UNKNOWN,INTERVENTIONAL,['NA']
1793,NCT03638102,Sleep duration,Depressive symptoms,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
1794,NCT03147677,Changes in 24h urinary protein quantity by comparing visits at week 20 with the baseline,Changes in urinary albumin / creatinine (UACR) of morning urine by comparing visits at week 20 with the baseline,Incidence of all adverse events (AEs) and serious adverse events (SAEs),2016-07-28,COMPLETED,INTERVENTIONAL,['PHASE4']
1795,NCT00754689,Change from baseline in A1C,Percent change from baseline in HDL-C,,2008-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
1796,NCT01319357,effect of saxagliptin compared to placebo on endothelial and vascular function of the retinal circulation,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1797,NCT01151293,,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
1798,NCT05752929,Number of paticipants with Glicemic control,Number of participants with hypoglycemia,,2016-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1799,NCT03614039,liver stiffness (LS),cytokines levels,,2015-09-15,COMPLETED,INTERVENTIONAL,['NA']
1800,NCT00567489,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1801,NCT04184947,3 point major adverse cardiovascular events (4P-MACE),Revascularization,Occurrence of adverse events,2014-03-01,COMPLETED,OBSERVATIONAL,['NA']
1802,NCT00964587,HbA1C,Barriers to Self-Management,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1803,NCT00606112,"Safety and Tolerance of a single intravenous dose of trodusquemine (MSI-1436) in obese, type 2 diabetics",,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1804,NCT04591925,Days of successful insulin delivery through the SteadiSet™ insulin infusion device versus a commercially available insulin infusion set,,,2021-02-05,TERMINATED,INTERVENTIONAL,['NA']
1805,NCT01360567,Percent change of HOMA insulin resistance and TG,Percent change of HbA1C and Cholesterol,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1806,NCT02180646,Plasma Glucose Level Post-meal (AUC [0-4]),Post-meal Level of Glucose-dependent Insulinotropic Peptide (GIP) (AUC),Post-meal Glucagon-like Peptide-1 (GLP-1) Level (AUC ),2011-12,COMPLETED,INTERVENTIONAL,['NA']
1807,NCT00518102,"The number of reported cases of cancers of all kinds, grouped by organ site in patients who have used REGRANEX (becaplermin) and patients who have not used not used REGRANEX (becaplermin).",The number of reported deaths from cancer in patients who have used REGRANEX (becaplermin) and patients who have not used not used REGRANEX (becaplermin).,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
1808,NCT00741585,"To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.","To evaluate the impact of changes in ambulatory BP in vascular, metabolic, and renal risk assessment.",,2008-09-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1809,NCT02942914,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics: Average Glucose from 8-Point Glucose Profiles in Participants with T2DM treated with Placebo or LY3209590,,2016-12-20,COMPLETED,INTERVENTIONAL,['PHASE1']
1810,NCT04016012,Change in Blood glucose levels,Change of Body Mass Index (BMI),,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1811,NCT02461394,Acceptance criteria defined by ISO 15197:2013 (see description),,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
1812,NCT04622371,SF-36,,,2020-01-10,COMPLETED,INTERVENTIONAL,['NA']
1813,NCT03230266,"Collection of catheters for intra-peritoneal insulin infusion from implanted pumps presenting obstructions or not : collection of biological and device samples (blood, catheters, insulin)",Associated conditions related to the patient and to infused insulin,,2017-06-02,TERMINATED,INTERVENTIONAL,['NA']
1814,NCT00662857,Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1815,NCT00349427,glycemic control at treatment 24-week measured by HbA1c (Glycosylated hemoglobin),"glycemic control at treatment 24-week measured by fasting plasma glucose and daily insulin dose, proportion of subjects who reduce total daily insulin dose after treatment of 8, 16, and 24 weeks",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1816,NCT05022615,"Number of Ungradable ETDRS Images within the 7 standard fields of Clarus, Optos, and Standard 7 Field imaging",Reason Image Quality is compromised per image grader,,2021-09-29,COMPLETED,OBSERVATIONAL,['NA']
1817,NCT04964713,major adverse cardiovascular events,,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1818,NCT02481466,Change from baseline of the maximum vessel wall volume of the carotid arteries by MRI at year 1 and 3,Atrial Fibrillation and heart failure,Cognitive Assessment,2016-11-25,COMPLETED,INTERVENTIONAL,['NA']
1819,NCT04784975,High-resolution peripheral quantitative computed tomography (HRpQCT) strength of cortical and trabecular bone.,Glycemia,,2021-04-23,COMPLETED,OBSERVATIONAL,['NA']
1820,NCT03804879,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Change From Baseline in Waist-to-hip Ratio,,2018-12-17,COMPLETED,INTERVENTIONAL,['PHASE2']
1821,NCT03914404,Changes of Total Symptom Score(TSS),Changes of EuroQol-5 Dimensions(EQ 5D),,2016-01-26,COMPLETED,INTERVENTIONAL,['PHASE4']
1822,NCT05472441,Change in Hemoglobin A1c,Change in food security assessed using the 18-item U.S. Household Food Security Survey Module,,2023-02-06,RECRUITING,INTERVENTIONAL,['NA']
1823,NCT02320526,Glycemic control,"Rate of dissappearance during a 2-step (pancreatic + hyperinsulinemic) hyperglycemic clamp, as a measure of glucose effectiveness + insulin sensitivity",Resting energy expenditure and respiratory exchange rate,2014-11,COMPLETED,INTERVENTIONAL,['NA']
1824,NCT02290600,"Accuracy of continuous glucose sensor output by individualizing sensor bias in subjects with type 1 diabetes, assessed by quantifying the improvement in CGM accuracy as measured by MARD (mean absolute relative difference).",Continuous Glucose Monitor sensor failure,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
1825,NCT04943926,Diabetes remission,Changes in quality of life,Changes in appetite/satiety and ketones from baseline,2022-01-04,RECRUITING,INTERVENTIONAL,['NA']
1826,NCT03644199,Glucose levels,Evaluation of gastric emptying,,2011-03-30,WITHDRAWN,INTERVENTIONAL,['NA']
1827,NCT03929679,Change in Glycated Haemoglobin A1c (HbA1c),Patient completed the study under treatment with semaglutide (yes/no),,2019-05-28,COMPLETED,OBSERVATIONAL,['NA']
1828,NCT01892917,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-09,TERMINATED,OBSERVATIONAL,['NA']
1829,NCT04289948,Work Package 3,Work Package 3: Impact on the bacterial microbiome of systemically chosen antibiotics and of anti-staphylococcal phage gel.,,2019-03-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1830,NCT05651490,Change in HbA1c over 18 months,Cost-effectiveness of PST-D,,2020-03-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1831,NCT01658579,Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]),Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline Up to Week 16,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1832,NCT05291351,Change in postprandial glycemic response,Treatment palatability,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
1833,NCT01394887,presence of inflammation,presence of type 2 diabetes,,2002-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1834,NCT04692415,Changes from baseline in arterial stiffness after treatment,Changes from baseline in CRP,,2018-12-15,COMPLETED,INTERVENTIONAL,['PHASE4']
1835,NCT01407289,Mean blood glucose,Number of glucose measurements in hyperglycaemic ranges,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1836,NCT02520921,"first main vascular event occurring within the 18 months after randomization among the following: Death (any), Myocardial infarction, Stroke, Urgent coronary revascularization and/or stent thrombosis, Acute arterial thrombotic event","Death, myocardial infarction, stroke, urgent revascularization, stent thrombosis, acute arterial thrombotic event and major bleeding analyzed specifically and separately",,2016-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
1837,NCT01740817,Muscle Insulin Sensitivity-M Value,Extracellular Signal-regulated Kinase (ERK) Phosphorylation in Muscle,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
1838,NCT00598793,HbA1c,Insulin dose,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1839,NCT01213940,Change in Late Outgrowth Endothelial Progenitor Cells,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
1840,NCT06169033,Area under curve (AUC) of the T2DM remission prediction model after 1 year,Area under curve (AUC) of the T2DM relapse model,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
1841,NCT05251116,System Performance,,,2021-12-11,COMPLETED,INTERVENTIONAL,['NA']
1842,NCT01824043,Gain in visual acuity and transparence of vitreous in treated eyes.,,Serum glucose levels will be compared with the visual outcomes,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
1843,NCT03260673,Comparison of the corneal endothelial cell density before-after cataract surgery,Comparison of the central corneal thickness(CCT) before-after cataract surgery,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
1844,NCT01271062,Acute insulin response (AIR) to glucose during IVGTT will be used as a primary variable characterizing the beta cell function,• Plasma concentrations and adipose tissue expression of selected adipokines and inflammatory cytokines characterizing the adipoinsular axis,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
1845,NCT00930956,Blood glucose,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
1846,NCT04616066,The effect of phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes,Determine whether date phytoestrogens affect insulin resistance,,2021-10-10,COMPLETED,INTERVENTIONAL,['NA']
1847,NCT01212133,The number of serious adverse drug reactions (SADRs) during the study period,Frequency of hypoglycaemic episodes,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
1848,NCT00604396,HbA1c,Insulin antibodies,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1849,NCT02173457,Change in HbA1c from baseline after 24 weeks of treatment,Percentage of patients who discontinue the trial due to hyperglycemia,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1850,NCT02722499,HbA1c,Resource Utilization and Cost,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
1851,NCT06074965,Event rate of lipohypertrophy (LH),Cohort analysis by duration of diabetes,,2022-10-05,COMPLETED,INTERVENTIONAL,['NA']
1852,NCT01331681,Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF),Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF,,2011-05-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1853,NCT04219800,Sitting time,Musculoskeletal problems,General self-efficacy,2020-12-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1854,NCT01219400,Glucagon response to hypoglycemia,Catecholamine response to hypoglycemia,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1855,NCT04134650,Change from basal fasting and 2 hours glucose levels during the oral glucose tolerance test at 12 months,Change from basal insulin sensitivity at 12 months,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1856,NCT05081817,Difference in glucose measurement,,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
1857,NCT03599401,Change in Glycosylated Hemoglobin levels,Change in Clinical attachment level,,2016-10-15,COMPLETED,INTERVENTIONAL,['NA']
1858,NCT03849612,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2019-02-21,COMPLETED,INTERVENTIONAL,['NA']
1859,NCT02098447,change in local blood perfusion index (BPI) related to physiological state (diabetics/healthy),Adverse effects of stimulation,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
1860,NCT02129946,Fasting and postprandial insulin,Satiety-producing effect,3-Day food records,2014-01,COMPLETED,INTERVENTIONAL,['NA']
1861,NCT06151821,Diabetes distress scale,Number of hypoglycemic and hyperglycemic episodes,,2023-08-01,COMPLETED,INTERVENTIONAL,['NA']
1862,NCT00006160,,,,na,COMPLETED,INTERVENTIONAL,['NA']
1863,NCT02912728,Time in glucose range 70-180,Satisfaction Questionnaire,,2017-01-30,COMPLETED,INTERVENTIONAL,['NA']
1864,NCT03506711,Change in coronary cross sectional area (mm2),,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
1865,NCT01574365,Adverse event collection and assessment,Profile of Pharmacokinetics,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2']
1866,NCT06257966,HbA1c,blood pressure,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1867,NCT03243058,C-peptide response,C-peptide response,HbA1c level,2023-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1868,NCT02218268,Determine the Difference Between Acute Effect of a Mixed Meal on Radial Artery Stiffness in Subjects With Type I Diabetes Mellitus Who do and Who do Not Take an Additional Bolus of Insulin.,,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
1869,NCT00991380,Physical Activity,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
1870,NCT02486341,Intraday glycemic variability measured by the average of MAGE index (Mean amplitude of glycemic excursions) everyday of exploitable recording by the participant.,Fragility level (Rockwood criteria),,2016-03-31,COMPLETED,INTERVENTIONAL,['NA']
1871,NCT00489242,"To assess the difference in CFV/CFR (coronary flow velocity/coronary flow reserve) in diabetic versus non-diabetic patients and to correlate CK-MB, TnI and HsCRP release after otherwise successful coronary stenting.","Correlation of CK-MB, Troponin-I and HsCRP release with CFR<2.0, FFR<0.8 in diabetic vs non-diabetic group. Evaluation of 30-day Major Adverse Cardiac Events (MACE) defined as death, MI, or urgent revascularization.",,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1872,NCT05768945,Time to dementia onset,Time to Alzheimer's disease onset,,2022-11-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1873,NCT02333864,Accuracy Verification of the POGO® BGMS: Minimum outcome of 95% of results within 20% of reference measurement.,,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
1874,NCT00653510,Metabolic changes,Left ventricular function,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
1875,NCT00950677,Glucose,exenatide concentrations,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1876,NCT01824862,foveal sensitivity,Retinal thickness,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
1877,NCT00359879,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12,Changes in self-monitored blood glucose (SMBG) profile from Baseline through Week 12,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1878,NCT02261545,Serum Fasting Blood Sugar(FBS),Serum HDL cholesterol,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
1879,NCT00228891,Measure the stabilization or reduction of the decline of diabetic neuropathy by pt questionnaires and diagnostic tests,,,2004-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1880,NCT05434754,To test the effect of a text message-based T1D transition intervention compared to control at 12 months in the Self-Efficacy for Diabetes management scale. A higher score indicates better self-efficacy.,Evaluate the impact of this text message-based intervention costs compared to usual care costs,Evaluation of intervention fidelity,2022-01-16,RECRUITING,INTERVENTIONAL,['NA']
1881,NCT04142229,Time in target glucose range,Socially evaluated cold-pressor test (SECPT),Questionnaire Score,2019-10-25,COMPLETED,INTERVENTIONAL,['NA']
1882,NCT02779556,Hemoglobin A1C (HbA1C),Diabetes Knowledge (0-13),,2016-11-07,COMPLETED,INTERVENTIONAL,['NA']
1883,NCT01991548,User Acceptance of the New MiniMed 640G Insulin Pump and Guardian Link Transmitter,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
1884,NCT03283566,Quotient of Stimulated C-peptide/Glucose Level Normalized for IEQ/Kg Infused in Response to MMTT,Ratio of C-peptide AUC to Glucose AUC in Response to MMTT Adjusted for Infused Islet Cell Mass,,2017-10-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1885,NCT05352022,Glycemic control (HbA1c),Quality of life as measured by the Short Form Health Survey (SF-12),,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1886,NCT05870280,The hypoglycemıc attıtudes and behavıor,The risk perception,,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1887,NCT01295385,"To quantify the myocardial blood flow at rest and after ""cold pressor test"" in a population of healthy volunteers",To estimate the metabolic and structural abnormalities in this population,,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
1888,NCT05375695,"Participants' experiences, needs and barriers",Sexual functioning,,2022-04-01,COMPLETED,INTERVENTIONAL,['NA']
1889,NCT05408416,central retinal thickness,reoperation,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
1890,NCT02729246,Change from Baseline of beta cell function,Change from Baseline of beta cell function,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1891,NCT01159184,,,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
1892,NCT02928939,Patients with diabetes mellitus and systemic corticosteroids,,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
1893,NCT04076384,Patient Activation Measure (PAM-13),The Finnish Diabetes Risc Calculator (FINDRISC),,2019-08-19,COMPLETED,INTERVENTIONAL,['NA']
1894,NCT00703599,Lowering of insulin-dependence and anti-hyperglycemic medication dosages,"No detrimental change seen in kidney function tests, liver function tests and other haematological parameters.",,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1895,NCT04025320,Pain Quality Assessment Scale,Sensory organization test (SOT),,2019-09-27,COMPLETED,INTERVENTIONAL,['NA']
1896,NCT06205030,HOMA-estimated insulin resistance,Inflammatory biomarkers,lipid profile,2024-06-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
1897,NCT00101764,,,,2005-01-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1898,NCT00917930,"to evaluate the effective prevalence of glucose metabolism alterations in patients with chronic ischemic heart disease and stable chronic heart failure, without previous diagnosis of diabetes mellitus",to evaluate the potential beneficial effect of physical training on the glycometabolic state,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
1899,NCT06229236,Percent of participants whose Diabetes Technology Utilization Score (DTUS) increases (based on review of last 14 days of CGM and insulin pump data),HbA1c change,Provider reported Feasibility of Intervention Measure (FIM),2024-02-13,RECRUITING,INTERVENTIONAL,['NA']
1900,NCT01939782,"Metabolic Clock Gene Expression in Peripheral Blood Cells(PBC),",Serum Cortisol,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
1901,NCT02747108,Weight Change From Baseline to 12 Months,Change in Mental Health,,2015-12-02,COMPLETED,INTERVENTIONAL,['NA']
1902,NCT03582956,Peripheral Sensitivity to High Dose Insulin,,,2019-01-01,TERMINATED,INTERVENTIONAL,['NA']
1903,NCT00491465,fructosamine,3 days CGMS & SBGM profile,,2007-07,UNKNOWN,INTERVENTIONAL,['NA']
1904,NCT05268705,The primary endpoint is the difference between study arms in difference from start to end plasma glucose concentration during 45 min fasted cycling (assessed by YSI (Yellow Spring Instruments 2900 STAT Plus)).,Change in plasma glucose from injection of glucagon to peak plasma glucose assessed by YSI during observation phase 3,,2022-02-03,COMPLETED,INTERVENTIONAL,['NA']
1905,NCT01288898,"Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests",Pharmacodynamics assessed by the ASP1941 glucose concentration changes in blood and urine,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1906,NCT03999125,Best Corrected Visual Acuity,Injection Count,,2019-06-25,UNKNOWN,INTERVENTIONAL,['PHASE4']
1907,NCT02748330,P2Y12 reaction unit (PRU),Non-coronary artery bypass graft (CABG) related major or minor or minimal bleeding,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1908,NCT03439592,cardiac deaths,,,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA']
1909,NCT05356884,Change in Adult Waist Circumference (WC) 6 - 12 months,Change in Adolescent Waist Circumference (WC) 6 - 12 months,,2022-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1910,NCT04273412,incidence of gestational diabetes mellitus,feto-maternal,,2018-10-13,COMPLETED,INTERVENTIONAL,['NA']
1911,NCT04028427,Change in Diabetes Self-Management Questionnaire,Change in HbA1c level,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
1912,NCT00000542,,,,1993-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1913,NCT04648618,Cytokines,,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
1914,NCT02126605,Percent agreement between DAD alerts and glucose readings,"Psychosocial variables (quality of life, fear of hypo-/hyperglycemia, diabetes distress, self-efficacy, and DAD experiences)",,2014-07,UNKNOWN,OBSERVATIONAL,['NA']
1915,NCT02401880,• Change in glucagon release (AUC0-180 min) during Liquid Meal Test (LMT) from V3 to V4 between the two treatment groups (Linagliptin vs. placebo),• Change in glucagon release (AUC0-180 min) during LMT from V2 to V3 during treatment with Empagliflozin (V2 vs. V3),,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1916,NCT05483140,Program Effectiveness,Medication Usage use,Quality of Life (QOL) SF-12,2022-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1917,NCT04569721,Number of Procedure Related Complications,Change in Fasting C-peptide Levels,,2021-02-19,WITHDRAWN,INTERVENTIONAL,['NA']
1918,NCT02795052,Change in Neurologic Function,,,2016-06,RECRUITING,INTERVENTIONAL,['NA']
1919,NCT02532088,Blood Glucose Level,Beta Cell Function,,2020-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1920,NCT04217161,Blood glucose measurement,Hypoglycemia events,,2020-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1921,NCT00561132,Changes on insulin sensitivity assessed with a euglycemic-hyperinsulinemic clamp technique,Changes on anthropometrical measures,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1922,NCT02162550,Change in carotid plaque volume,Change in carotid plaque composition,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
1923,NCT04184622,Percentage of Participants Who Achieve ≥5% Body Weight Reduction,Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide,,2019-12-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1924,NCT01841073,Glycaemic Control,Food Intake in Gram at 9 Weeks,Percentage Change in Body Weight,2011-03,COMPLETED,INTERVENTIONAL,['NA']
1925,NCT02229487,GLP-1 Levels in Response to Oral Glucose Tolerance Test,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1926,NCT00882336,"Gender, age, patients with diabetes and/or hypertension (%), smoker status, family medical history.","Biomarkers: Apo-A1, Apo-B, Hs-CRP, Creatinine, albuminuria, uric acid, glomerular filtration rate.",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
1927,NCT00816608,The development of diabetes,DM complication,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
1928,NCT03027219,Flow change,,,2017-01-31,COMPLETED,OBSERVATIONAL,['NA']
1929,NCT06298799,Genetic variants and miRNA expressions associated with changes in BMI.,Genetic variants and miRNA expressions associated with changes in A1c.,Demographic parameters that affect GLP1 AG therapy.,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
1930,NCT04865809,Change in BOP - Bleeding on Probing (percentage),,,2021-05-12,COMPLETED,INTERVENTIONAL,['NA']
1931,NCT00094757,Change From Baseline in A1C at Week 18,Change From Baseline in FPG at Week 54,,2004-10-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1932,NCT03555565,Percentage of Participants Who Had One or More Adverse Events,Change From Baseline in Fasting Insulin Level,,2017-02-28,COMPLETED,OBSERVATIONAL,['NA']
1933,NCT01021826,Occurrence (and severity) of hyperglycemia following primary hip or knee replacement,Prevalence of glucose metabolism disorders and metabolic syndrome,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
1934,NCT05824572,Patient Activation Measure-Short Form,Patient Satisfaction Questionnaire-18,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1935,NCT05260814,changes in HbA1c,cytokine changes,,2022-03,UNKNOWN,INTERVENTIONAL,['NA']
1936,NCT02760017,fasting glucose levels,Plasma endothelin-1 levels,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
1937,NCT05553145,Prevalence of autoimmune antibodies in patients with Type 2 Diabetes,Prevalence of autoimmune antibodies in patients with T2D managed by primary care,,2022-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1938,NCT00641550,"Maternal outcome: preterm labor, weight gain, preeclampsia, gestational diabetes Perinatal outcome: birthweight, Apgar scores, body composition, admission at neonatal intensive care unit","Doppler flow velocimetry indexes: pulsatility, resistance and A/B relation (uterine arteries, fetal middle cerebral artery and umbilical arteries)",,2008-04,UNKNOWN,INTERVENTIONAL,['NA']
1939,NCT03810846,Rate of Enjoyment,Medication,,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
1940,NCT03818711,Glycemic control (A1C),Quality of Parental Involvement,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
1941,NCT01935349,The proportion of HT/ DM patients who have achieved the target blood pressure.,"GOPC consultation, SOPC, A&E and hospital attendance rates in the past 12 months.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
1942,NCT04723550,Glucose control (HbA1c levels),Change in biological parameter: e-GFR,Cost effectiveness,2021-01-05,UNKNOWN,INTERVENTIONAL,['NA']
1943,NCT03235362,"YHR1705, YHR1706 Css, max",,,2017-08-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1944,NCT05038761,Mean absolute relative difference (MARD%),AE with special concern: erythema/edema under the adhesive patch or at the insertion site,,2021-10-08,COMPLETED,OBSERVATIONAL,['NA']
1945,NCT04970940,"Css,max of AJU-A51R1 and AJU-A51R2",,,2020-07-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1946,NCT02354911,Change from baseline in the mean 2-hour area under the curve (AUC) for plasma c-peptide at 12 and 24 months,Change from baseline in Total Daily Insulin Dose,,2015-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1947,NCT01500005,arterial stiffness,blood pressure holter,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1948,NCT04935671,Depression,Tryptophan,,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1949,NCT00578604,diffuse near infrared spectroscopy measurements,,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
1950,NCT02561078,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Body Weight,,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3']
1951,NCT04348565,Self-efficacy level in diabetes management,Quality of life Measurement,,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA']
1952,NCT00908271,Absolute oral bioavailability,Electrocardiograms (ECGs),,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1953,NCT04170998,Change from baseline in HbA1c (%) After 24 weeks,Change from baseline in 7-point SMBG After 24 weeks,,2020-01-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1954,NCT00339313,,,,2000-01-12,COMPLETED,OBSERVATIONAL,['NA']
1955,NCT00812591,Ratio between the plasma glucose level and the glucose concentration at the subcutaneous insulin delivery site,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
1956,NCT05383859,Change in Physical activity recommendations (mean),Change in HbA1c (Mean percentage),,2022-05-01,COMPLETED,INTERVENTIONAL,['NA']
1957,NCT03209258,Shift ('improvement') in functional recovery (death or disability) defined by the modified Rankin Scale (mRS),Residence,,2017-12-12,COMPLETED,INTERVENTIONAL,['NA']
1958,NCT00419497,area under the curve for insulin (AUC Insulin0-120) at the oral glucose tolerance test,120-min plasma insulin,,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1959,NCT00425178,Pharmacokinetics,Wound improvement,,2005-09-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1960,NCT04765358,Time in Range (TIR),,,2020-08-24,UNKNOWN,INTERVENTIONAL,['NA']
1961,NCT05480657,Efficacy - Insulin independence,Efficacy - Durability of insulin independence - long term,,2022-09-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1962,NCT05095259,Glycogen concentration,Hypoglycemia awareness status,,2019-12-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1963,NCT00099619,Change in HbA1c (glycosylated hemoglobin) from the baseline of the first period (16-weeks of exenatide or insulin) to the end of each 16-week period.,Change in patient-reported outcomes from Baseline to the end of each 16-week period,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1964,NCT05696964,Changes in perceptions of the patient-clinician relationship by patients of participating residents.,"Changes in the ""spirit of motivational interviewing"" rating given to the resident by the facilitator in role plays in motivational interviewing practice.",,2024-02-01,WITHDRAWN,INTERVENTIONAL,['NA']
1965,NCT05951621,2-h postprandial plasma glucose,"Self-Rating Anxiety Scale, SAS",Maternal and infant complications during childbirth,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1966,NCT00791661,Number of Participants Who Discontinued Treatment Due to an Adverse Event,24-hour Weighted Mean Glucose (WMG) Concentration,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1967,NCT02954692,Mean change from baseline in HbA1c,Mean change from baseline in Diabetes Treatment Satisfaction Questionnaire (DTSO) scores,,2016-11-30,COMPLETED,INTERVENTIONAL,['PHASE4']
1968,NCT02393573,Change in fasting blood glucose,length of hospital stay,,2015-11,TERMINATED,INTERVENTIONAL,['NA']
1969,NCT01512108,Incidence of Treatment Emergent Adverse Events (AEs),Change in FPG From Baseline to Week 52,,2012-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1970,NCT01115257,,,,2001-10,COMPLETED,INTERVENTIONAL,['NA']
1971,NCT04040426,Percentage of index ulcers healed at 12 weeks,"Changes in peripheral neuropathy using Semmes Weinstein Monofilament ""10""point",,2019-08-06,COMPLETED,INTERVENTIONAL,['NA']
1972,NCT04256486,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c(%) From Baseline at various time points",,,2022-04-21,RECRUITING,INTERVENTIONAL,['NA']
1973,NCT00001223,To develop a database and collection of samples obtained from patients with CF during their clinical care to allow for future research,,,1988-01-01,RECRUITING,OBSERVATIONAL,['NA']
1974,NCT05140798,Change in resting metabolic rate,Change in serum cortisol,,2016-04-25,UNKNOWN,OBSERVATIONAL,['NA']
1975,NCT04906213,Number of Genital infections,Changes in Hemoglobin A1C as measured by blood work,Adverse events will be collected form the medical record and patient report,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2']
1976,NCT01137058,Target goal of HbA1c (< 7.0%) without hypoglycemia,Body mass index (BMI) changes,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
1977,NCT01144338,Primary Safety Outcome MACE Events,Secondary Efficacy Outcome Hospitalization for HF,,2010-06-18,COMPLETED,INTERVENTIONAL,['PHASE3']
1978,NCT04345120,GIP concentration changes before and after meal.,"Stable Valley concentration (ctrough, SS).",,2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1']
1979,NCT04711083,correlation between nocturnal oxygen desaturation and glycemic control,,,2020-04-20,COMPLETED,OBSERVATIONAL,['NA']
1980,NCT02344433,Accuracy of family members identified (defined as the agreement of first and second degree relatives identified by both the tool (VICKY or MFHP) and the genetic counselor),Family and provider communication (Communication of family health history with family members and health care providers),,2016-11,COMPLETED,INTERVENTIONAL,['NA']
1981,NCT01767441,change in glucose response (pAUC) to mixed meal test between baseline and 1 month after undergoing bariatric surgery or being put on low calorie diet,changes in active GLP1 systemic bioavailability during a mixed meal test between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.,change in HbA1c between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.,2013-02,COMPLETED,OBSERVATIONAL,['NA']
1982,NCT02236793,Incidence of complete wound closure.,Treatment emergent adverse events.,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
1983,NCT00157508,Cardiac and renal hemodynamics after 4 weeks of treatment,,,2003-03,TERMINATED,INTERVENTIONAL,['PHASE2']
1984,NCT05477433,Measures frequency of psychiatric problems with diabetes mellitus type 1,,,2022-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1985,NCT03805633,Change in glucose during oral glucose tolerance test (oGTT),Hemoglobin A1c (HbA1c),,2018-02-02,WITHDRAWN,OBSERVATIONAL,['NA']
1986,NCT01046721,superior mesenteric (SMA) blood flow,Peripheral resistance,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
1987,NCT04507685,Change in Matsuda index for whole body insulin sensitivity,Change in Faecal characteristics- including short chain fatty acids (SCFAs).,Change in dietary intake (diet checklists),2020-10-19,COMPLETED,INTERVENTIONAL,['NA']
1988,NCT03472846,detection of microRNA concentration in serum,microRNAs and changes in bone metabolism under treatment,,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1989,NCT02852980,Glycemia realized after childbirth,Percentage of women who have pursued the dietary and hygiene rules,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
1990,NCT05185518,glucose sensing accuracy,user satisfaction,,2025-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1991,NCT04459936,Responders (Dichotomised: responder/non-responder),Serum Urate,Hospitalisation,2020-11-24,WITHDRAWN,INTERVENTIONAL,['NA']
1992,NCT03002675,The effect of exenatide on BAT activity and energy expenditure in healthy young South Asian compared to white Caucasian men,Visualisation of BAT as measured with MRI scan compared to FDG-PET CT,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
1993,NCT00965302,Diabetes remission,c-reactive protein,,2009-08,TERMINATED,INTERVENTIONAL,['NA']
1994,NCT01114763,,,,2003-06,COMPLETED,OBSERVATIONAL,['NA']
1995,NCT01846767,Peak Delta over baseline in 13CO2 breath enrichment,Per cent dose recovered,Diabetes classifications and measures of insulin resistance,2012-04,COMPLETED,INTERVENTIONAL,['NA']
1996,NCT01267448,"The proportion of responders in each arm. Responder: FBG 70-300 and/or PPBG <400 mg/dl (week1-6), FBG 70-250 and/or PPBG <300 mg/dl (week 7-12) and without metabolic exclusion criteria, repeat ED visits, hospitalization or significant hypoglycemia.",The number of fold increase in beta cell function in the 2 arms.,,2014-09-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1997,NCT01888315,Safety and efficacy of renal denervation,Safety and efficacy of renal denervation,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1998,NCT05741125,Acceptability (Satisfaction): The Percentage of Participants Who Were Satisfied with the Delivery and Content of the Intervention,Changes in Binge Eating Episodes,,2024-01-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1999,NCT02868931,Changes in Glycemic Control Measured by A1c,Severe hypoglycaemia,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
2000,NCT01809327,Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26,Number of Participants With Treatment Emergent Adverse Events (AEs),,2013-06-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2001,NCT03577119,Changes in insulin sensitivity and β-cell function: OGTT,Changes to Colonic microbiota structure: relative abundance,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
2002,NCT00087516,Change From Baseline in A1C at Week 24,Change From Baseline in 2-hr PMG at Week 104,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2003,NCT01977495,Enrollment and participation rates,Uptake of Device Usage,Change in Hemoglobin A1c,2013-12,COMPLETED,INTERVENTIONAL,['NA']
2004,NCT03420040,Change in fasting blood glucose between baseline to week 4,,,2017-11-27,UNKNOWN,INTERVENTIONAL,['NA']
2005,NCT05967260,Probability of overnight hypoglycemia,Change in weight,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
2006,NCT01817777,Change From Baseline in HbA1c Values at Week 28,Number of Participants Withdrawn From the Study Due to the Following Reasons: Withdrawal of Informed Consent; Lost to Follow-up,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4']
2007,NCT03908762,Change in A1C,Rate of Hypoglycemia,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
2008,NCT01389362,Resolution/progression of foot ulcer based on PEDIS,Hospital admission/attendance/stay,,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2009,NCT06049420,physical activity,Self-efficacy,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2010,NCT03078764,Diabetes related distress,Fasting blood glucose,Self-efficacy (for nurse),2017-06-09,COMPLETED,INTERVENTIONAL,['NA']
2011,NCT04200391,"Glucagon treatment success, defined as an increase in glucose level to ≥ 70 mg/dL or an Increase of ≥ 20 mg/dL from glucose nadir within 30 minutes after receiving 1 mg glucagon IM",Plasma glucose levels following glucagon administration,,2020-01-03,RECRUITING,INTERVENTIONAL,['NA']
2012,NCT05349591,Adverse Events,Stimulated C-peptide level,,2022-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2013,NCT02332005,change from baseline in peroneal motor nerve conduction velocity,change from baseline in VPT conduction velocity measurement,,2014-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2014,NCT04082390,Change in Fasting Blood Glucose (FBG) at approximately 4 weeks of the GFL System Diet with Release supplement versus GFL System Diet with placebo supplement,Change from baseline in Heart Rate between the 2 groups,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
2015,NCT01984827,ECG Analysis,Proportion of Participants with Adverse Events,,2019-02-10,COMPLETED,INTERVENTIONAL,['PHASE1']
2016,NCT04055428,Change in energy expenditure after natriuretic peptide augmentation,Impact of Natriuretic Peptide Genotype on Study Endpoints,Change in Metabolomic Profile,2020-08-15,RECRUITING,INTERVENTIONAL,['PHASE2']
2017,NCT00810420,,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
2018,NCT00521937,Complete wound closure at week 12,Time to complete wound healing,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2019,NCT03462420,Change of shoulder performance from baseline to 6 weeks after physiotherapy,Physical activity level,,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA']
2020,NCT03989908,Change in insulin response,Change in satiety rating,,2019-01-13,COMPLETED,INTERVENTIONAL,['NA']
2021,NCT01579136,change in blood pressure over time,,,2011-12,TERMINATED,INTERVENTIONAL,['NA']
2022,NCT04664205,Change in Fat Metabolism,Change in Continuous Glucose (Area Under the Curve),,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
2023,NCT00600262,,,,2005-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2024,NCT05285449,High-sensitivity C-reactive protein,,,2022-02-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2025,NCT01424046,HbA1c,Microalbuminuria,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
2026,NCT05790317,"Presence of post-operative nausea, vomiting and retching",,,2022-02-14,COMPLETED,INTERVENTIONAL,['NA']
2027,NCT00449930,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Number of Patients Who Reported 1 or More Episodes of the Adverse Experience of Vomiting,,2007-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2028,NCT00335101,Quality of diagnostic information,Diabetes mellitus,,2006-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2029,NCT05073068,Nocturnal respiratory exchange ratio,Blood glucose levels following the exercise intervention measured continuously using a continuous glucose monitor device,Feet sensitivity based on a clinical foot assessment,2022-01-25,RECRUITING,INTERVENTIONAL,['NA']
2030,NCT00629434,A1c,Diabetes Treatment Satisfaction Questionnaire,,2001-06,TERMINATED,INTERVENTIONAL,['NA']
2031,NCT00793754,Thrombin generation,C-reactive protein,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
2032,NCT05248776,Efficacy in lowering plasma glucose during the Oral Glucose Tolerance Test (OGTT) after 2 weeks of CPL207280 treatment,CPL207280 concentration immediately prior to dosing (Ctrough),,2022-01-21,RECRUITING,INTERVENTIONAL,['PHASE2']
2033,NCT06054126,Cardiac function evaluated by echocardiography,Cardiovascular events,,2010-01-01,RECRUITING,OBSERVATIONAL,['NA']
2034,NCT01846377,Change in fasting insulin from baseline to immediate post intervention (approximately 3 months post baseline assessment) and 2-months post intervention (approximately 5 months post baseline assessment),Change in Fruit and Vegetable Intake,Change in Moderate to Vigorous Physical Activity,2014-04,COMPLETED,INTERVENTIONAL,['NA']
2035,NCT03309254,Glycemic response,Respiratory quotient and fat oxidation,,2016-01-18,COMPLETED,INTERVENTIONAL,['NA']
2036,NCT01122316,Health-Related Quality of Life (HRQoL),Creatinine Level as a Measure of Renal Function,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
2037,NCT01984762,Rate of resolution of type 2 diabetes,postoperative complications,Glycemic control mechanisms,2012-09,RECRUITING,INTERVENTIONAL,['NA']
2038,NCT00148538,HbA1c at the end of the 6-month exercise period,quality of life,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2039,NCT01886170,For Phase II of the Study: Change in Hemoglobin A1C,For Phase II of the Study: Understanding of diabetes control,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2040,NCT02529449,Safety assessed by Adverse events,,,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2041,NCT04281069,glycaemia,Hemoglobin A1c,systolic and diastolic blood pressure,2019-03-01,COMPLETED,OBSERVATIONAL,['NA']
2042,NCT00289354,Pharmacoeconomic outcomes (as deduced by changes in HbA1c),"ANCOVAs: Treatment outcomes based on treatment group compared to gender, ethnicity, age, co-morbidities, Rx medications, glycemic states at entrance, lipid status at entrance.",,2003-03,COMPLETED,INTERVENTIONAL,['NA']
2043,NCT01063868,Number of Subjects With Treatment-emergent Adverse Events (TEAE),,,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3']
2044,NCT01499095,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12,Change in HbA1c From Month 6 to Month 9,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2045,NCT05823337,five-day second hour postprandial glucose average,,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2046,NCT01883037,Does HemoCue Glucose 201 RT provide lab-quality results in the analysis of glucose values during oral glucose tolerance tests?,Is HemoCue Glucose 201 RT method cost saving relative to the traditional laboratory method for analysing glucose values taken during oral glucose tolerance tests?,2. To see if the HemoCue Glucose 201 RT offers sufficient advantages to make it a viable alternative to conventional testing,2013-06,COMPLETED,OBSERVATIONAL,['NA']
2047,NCT05031429,"Safety, as indicated by hypoglycemia","Impact on activities of daily living, as indicated by Munich Chronotype Questionnaire (MCTQ)",,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
2048,NCT00141453,Renal Composite Outcomes,Reciprocal (1/Serum Creatinine) of Serum Creatinine,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2049,NCT05497960,Program satisfaction,Perceived Stress Scale Center for Epidemiologic Studies Depression Scale (CES-D),,2022-09-01,COMPLETED,INTERVENTIONAL,['NA']
2050,NCT02795559,Serum acetate response,Post-lunch ghrelin response,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
2051,NCT01620476,Area under the plasma liraglutide curve,Adverse events,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2052,NCT01213888,To evaluate the effect of a copper chelator in suppressing post-PRP macular edema in eyes with retinal neovascularization.,,,2010-11,TERMINATED,INTERVENTIONAL,['NA']
2053,NCT00738153,"The incidence of serious adverse drug reactions, including major hypoglycaemic events",Sub -group analysis of hypo risk,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
2054,NCT00786136,An absolute increase in SCr >=0.5mg/dL（>=44.2μmmol/L）or a >= 25% increase in SCr from baseline to 72h after the procedure,"The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes.",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2055,NCT02104466,Change from baseline in average weekly pain on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at week 12,Patient satisfaction,Use of medications at baseline and throughout 12-week intervention period,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2056,NCT05808699,Sensitivity and Specificity Corrected for Enrichment,"Observed Sensitivity and Specificity, Level II",Precision substudy,2023-03-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2057,NCT01864239,Self-reported medication adherence,Serum Cholesterol Levels,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
2058,NCT01792986,Difference in Mean Glucose Level Between Baseline and the End of the Sixth Week.,Difference in Red Blood Cell Count Between Baseline and the End of the Sixth Week.,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
2059,NCT03664583,Mental Health Using the Short-Form 12 Health Survey Version 2 (SF-12v2) - Mental Component Summary score.,Collaboration Using the Partnership Self-Assessment Tool (PSAT),,2019-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2060,NCT01346085,The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion,Any Adverse Event Throughout Follow-up,,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2061,NCT05747664,AUClast of DWP16001,,,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
2062,NCT05765292,C-peptide,cytokines levels,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
2063,NCT04968171,Partial clinical remission time,Albumine to creatynine ratio ACR [mg/g],,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
2064,NCT03130244,Mean change in HbA1c,Mean change in diabetes medication,,2019-09-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2065,NCT03544892,Time in Range,Diet Quality,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
2066,NCT00556465,Proteinuria,"blood pressure,serum creatinine,GFR,c-reactive protein,",,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2067,NCT01979471,The difference in change in estimated cardiovascular risk between advanced care and usual care groups,"Achievement of individual and the ""triple target""",,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2068,NCT00225849,"Composite event of cerebro/cardiovascular (CV) death, nonfatal cerebral stroke (of any cause) and nonfatal myocardial infarction (MI)",Severe side-effects that lead to interruption of the study medication.,,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
2069,NCT01542450,The ratio of area under the glucose infusion rate curve (AUCGIR) 0-5 hours to AUCGIR 0-24 hours,Adverse events,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2070,NCT01588639,Occurrence rate of serious adverse drug reactions including severe hypoglycaemic events,Number and ratio of missed injections,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
2071,NCT02445170,Health-related quality of life measured by the HRQoL score,The 15D health-related quality of life instrument,,2015-07,WITHDRAWN,OBSERVATIONAL,['NA']
2072,NCT02566330,Excess Weight (%),C-peptide (nmol/L),,2015-10,COMPLETED,OBSERVATIONAL,['NA']
2073,NCT01940770,Adverse event incidence,Mean change of lipid metabolism,,2013-10-18,COMPLETED,OBSERVATIONAL,['NA']
2074,NCT04091516,Weight loss,Body Composition,,2019-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2075,NCT02315287,Change of HbA1c,microalbumin to creatinine ratio,Body weight,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
2076,NCT03016910,Changes in plaque morphology stratified by cardiovascular risk factors.,Impact of asymtomatic CAD in diabetes on future events.,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
2077,NCT03471104,Change in Diabetes Distress Scale (DDS),Change in Glycosylated hemoglobin A1c (HbA1c),,2018-01-15,WITHDRAWN,INTERVENTIONAL,['NA']
2078,NCT02218099,"Part 2: Safety and tolerability of ASP8232 measured by nature, frequency and severity of AEs, vital signs, safety laboratory tests, routine ECG",Part 2: 24-hour urinary albumin excretion rate (UAER),,2013-09-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2079,NCT03835923,Change in HbA1c,"Number of the combined endpoint ""4P-MACE""",,2019-02-12,COMPLETED,INTERVENTIONAL,['NA']
2080,NCT02150824,The percentage of patients with drug- related adverse events,Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2081,NCT00390520,Glucagon counterregulatory response to hypoglycemia of the last 30 min of the 2.5 mM hypoglycemic clamp after 4 weeks treatment,"Safety based primarily on frequency of adverse events, number of notable abnormal laboratory values, and frequency and severity of hypoglycemic events",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2082,NCT05019274,Hemoglobin A1c,Food security score,,2021-08-09,COMPLETED,INTERVENTIONAL,['NA']
2083,NCT01629199,"At 12 weeks, wound closure rate of diabetic foot ulcers",average size reduction of diabetic ulcer,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2084,NCT01877200,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
2085,NCT01054092,HbA1c,"Safety assessed by adverse events, vital signs laboratory tests and 12-lead ECGs",,2010-01-14,COMPLETED,INTERVENTIONAL,['PHASE3']
2086,NCT02600377,HbA1c,Diastolic blood pressure,,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
2087,NCT04538352,Change in HbA1C ≤ 7.5%,Total daily insulin dose,,2021-01-18,COMPLETED,INTERVENTIONAL,['PHASE4']
2088,NCT03571100,Patient Comfort,Patient Comfort,,2018-05-07,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
2089,NCT03646916,Post-operative blood sugar,,,2020-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2090,NCT03744975,Plasma cGMP Response,Renal response,,2018-05-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2091,NCT05649891,Degree of indication of interventions performed thanks to Do-Confirm Emergency Manual use,Structured interviews,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2092,NCT02240680,Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.,Change From Baseline in Fasting Plasma Glucose (FPG),,2014-09-23,COMPLETED,INTERVENTIONAL,['PHASE4']
2093,NCT00404599,Reduction in oxLDL levels,Reduction in plasma endothelial function parameters such as soluble Vascular Adhesion Molecule (sVCAM) and von Willebrand factor,,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
2094,NCT06139913,Estradiol blood test,,,2023-03-15,COMPLETED,INTERVENTIONAL,['NA']
2095,NCT02670928,Number of Patients With Clinically Significant Weight Reduction (>5%) Compared to Baseline at Month 12,Percentage Hange From Baseline in Body Mass Index (BMI) at Month 12,,2015-07-20,COMPLETED,INTERVENTIONAL,['PHASE4']
2096,NCT06283797,Glycated hemoglobin (HbA1c) level,Number of needed interventions by the parents/guardians or care providers,"Severity of treatment-emergent SUSARs, SAEs, ARs and AEs",2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2097,NCT03410277,Neurochemical response to HG before and after induction of IAH,Antecedent physical activity,,2018-05-24,RECRUITING,INTERVENTIONAL,['NA']
2098,NCT04854083,HbA1c,"Change in the oxygen uptake and perfusion in subcutaneous and intra-abdominal adipose tissue, brown adipose tissue, skeletal muscle, gut and liver",,2022-02-17,RECRUITING,INTERVENTIONAL,['PHASE4']
2099,NCT03643783,Change in T2DM parameters and sPRR after surgery,,,2018-09-11,COMPLETED,OBSERVATIONAL,['NA']
2100,NCT01504724,Central macular thickness,Retinal nerve fiber layer thickness,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2101,NCT04411277,Primary outcome is time in range (TIR),-Glucose Variability,,2020-08-05,COMPLETED,OBSERVATIONAL,['NA']
2102,NCT02629263,HbA1c (%),HOMA-IR (mU/mmol/l),,2015-09,COMPLETED,OBSERVATIONAL,['NA']
2103,NCT04689971,Improvement in Brief Pain inventory at week 8,,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2104,NCT01754792,To assess hidrocarbonated metabolism parameters before and after pinitol/placebo administration,To evaluate oxidative stress on mitochondrial function before and after pinitol/placebo administration,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2105,NCT02035995,Retinal evaluation,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2106,NCT01295073,Change in retinal thickness measurements by Optical Coherence Tomography (OCT) from screening to Day 28 between subjects undergoing surgery with and without Trientine use.,Secondary analyses will involve evaluations of the change in visual acuity and fundus photography results from screening to Day 28.,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2107,NCT02982330,Incremental area under the glucose curve (continuous glucose monitor),Mean Blod Glucose (continuous glucose monitor),Satiety VAS 100,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2108,NCT01531933,Change in 15-minute post prandial insulin level,Adverse events,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
2109,NCT05088993,Change from baseline postural stability at 3 months,Change from baseline functional capacity at 3 months,,2021-02-15,COMPLETED,INTERVENTIONAL,['NA']
2110,NCT02957838,Changes in Mitochondrial Function,diabetic late complications,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2111,NCT04470310,HbA1c,The change in lipid profile from baseline at week 12 and 24,,2015-12-31,UNKNOWN,INTERVENTIONAL,['PHASE4']
2112,NCT03609463,Feasibility (Acceptability of Intervention),% Weight Change,Change in Health-Related Quality of Life,2018-03-27,COMPLETED,INTERVENTIONAL,['NA']
2113,NCT05580536,Understanding Health Implications of Genomics at 6 months,Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months,,2023-02-17,RECRUITING,INTERVENTIONAL,['NA']
2114,NCT02906930,Change in HbA1c,PGI-C Item: Scores of the Two Individual Items (Used for Validation of the IWQOL Questionnaire),,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
2115,NCT02925299,The primary outcome is the centralised measurement of glycated haemoglobin (HbA1c) at 6 months.,"HbA1c <7.0%, HbA1c <7.5%, Relative reduction ≥10% from baseline. o Absolute reduction ≥0.5% from baseline o Absolute reduction ≥1% from baseline o Absolute reduction ≥1% from baseline or HbA1c <7.0%",Health Economic Evaluation,2017-05-12,COMPLETED,INTERVENTIONAL,['NA']
2116,NCT02159014,Activity adherence rates,10 year risk of developing diabetes mellitus,Life quality,2014-08,COMPLETED,INTERVENTIONAL,['NA']
2117,NCT00318214,"Changes in electrocardiograms (ECGs), vital signs, and clinical laboratory values.",Time to closure and percent reduction in surface area of the target ulcer.,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE2']
2118,NCT00904761,exercise capacity,,,2001-10,COMPLETED,INTERVENTIONAL,['NA']
2119,NCT01964833,Change in the clinical attachment level at 180 days.,Cytokines in the crevicular fluid,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2120,NCT04232293,eLift and FibroMeter sensitivity for the diagnosis of advanced hepatic fibrosis,Complication of diabetes,,2021-06-25,RECRUITING,INTERVENTIONAL,['NA']
2121,NCT01990092,Change in plasma methylmalonic acid (MMA) levels,Change in neuropathic symptoms as measured by the Neuropathy Total Symptom Score-6 questionnaire (NTSS-6),,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
2122,NCT01849289,Change From Baseline in HbA1c (%) (Analysed by Central Laboratory),Number of Treatment Emergent AEs (Adverse Events),,2013-06-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2123,NCT05791201,Part B and Part C: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT),Part C: Change in HbA1c values,,2023-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2124,NCT00703482,Evolution of the E'/E septal ratio,Evolution of the PV doppler parameters,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2125,NCT05203653,percent time spent in hyperglycemia,capillary glucose,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
2126,NCT04446754,Diet intake,Lean mass,,2019-04-10,COMPLETED,OBSERVATIONAL,['NA']
2127,NCT02338193,Change in Body Weight,First Phase Insulin Secretion (IGI/HOMA-IR),,2015-09-22,COMPLETED,INTERVENTIONAL,['PHASE3']
2128,NCT00387452,Time and frequency domain measures of heart rate variability,Linear transfer-function analysis of cerebral autoregulation during upright tilt,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
2129,NCT02200965,Assessment of change in completion of nine key care processes in diabetes,Assessment of change in surrogate markers that define hard outcomes in diabetes,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
2130,NCT05628597,Glycated hemoglobin,Compliance,,2021-11-23,COMPLETED,INTERVENTIONAL,['NA']
2131,NCT00577174,Examine the relationship between mitochondrial function and insulin resistance in obese and non-obese children,"Evaluate the relationship of obesity, timing of puberty and related changes in hormone levels to mitochondrial function and the development of insulin resistance and/or impaired glucose tolerance in longitudinal analyses",,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
2132,NCT04034524,"Time until first composite CV event (myocardial infarction, stroke)",Time until first episode of acute cholecystitis,Change from baseline HbA1c,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2133,NCT03750695,Percent Change in Endothelial Function,,,2018-11-20,COMPLETED,INTERVENTIONAL,['NA']
2134,NCT05160142,% Change in Hemoglobin A1c,Change in primary caregiver self-efficacy for healthy meal planning and eating score,,2019-09-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2135,NCT03603704,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose,,2018-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
2136,NCT00232362,annular tissue Doppler velocity,,,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE1']
2137,NCT04579016,Weight loss,"Questionnaire data pertaining to physical activity, General Health and Well Being, Motivation to change and Risk Perception Survey for Developing Diabetes",,2020-01-13,UNKNOWN,INTERVENTIONAL,['NA']
2138,NCT03310944,Assessment of PK Parameter: Maximum plasma concentration (Cmax),Adverse Events,,2017-10-18,COMPLETED,INTERVENTIONAL,['PHASE1']
2139,NCT05754424,Area under the glucose infusion rate-time curve of insulin aspart,,,2023-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
2140,NCT06112418,The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.,The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.,The safety objective is to assess harm with the 2 prevention strategies,2024-03-06,RECRUITING,INTERVENTIONAL,['NA']
2141,NCT03356262,Body mass index (BMI),Dyslipidemia,,2005-07-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2142,NCT03714451,Change in glycemic variability,Change in glucose levels,Eating behavior,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
2143,NCT06301191,Comparison of liver stiffness difference among treatment groups,,,2022-03-01,RECRUITING,OBSERVATIONAL,['NA']
2144,NCT04201912,Toll like receptor 2 activity,Toll like receptor 4 activity,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
2145,NCT03731637,Determine sensitivity and specificity of serum CA 19-9 in pre-symptomatic pancreatic ductal adenocarcinoma in subjects with new-onset hyperglycemia and diabetes,,,2018-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2146,NCT03055169,value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of hyperglycemia,Insulin Resistance (HOMA),Number of patients with genotype TCF7L2 by PCR,2012-04,COMPLETED,OBSERVATIONAL,['NA']
2147,NCT00287183,Primary endpoint of efficacy will be assessed by comparing the treatment groups based on the change in urinary albumin-creatinine ratio (UACR),To evaluate the effect of treatment with TTP488 on UACR,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2148,NCT05814107,Incidence of Treatment-Emergent Adverse Events in CT-996 participants,Effect of a High-Fat Meal on Plasma Concentration of CT-996,,2023-05-09,RECRUITING,INTERVENTIONAL,['PHASE1']
2149,NCT00943059,lipid accumulation in ectopic tissue (cardiac and skeletal muscle),oxidative stress markers,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
2150,NCT05249062,Participants' engagement with the SHAPES app during the pilot,Exploration of user engagement behaviors,Economic impact of the intervention,2023-02-09,COMPLETED,INTERVENTIONAL,['NA']
2151,NCT00559286,Changes in Elongation-Index (EI) Method: To determine the elongation index (EI) we use the Laser assisted optical rotational cell analyzer (Lorrca).,Decrease of RBC aggregation (using Laser assisted optical rotational cell analyzer (Lorrca),,2007-12,TERMINATED,INTERVENTIONAL,['PHASE4']
2152,NCT03224533,Diabetes Outcome- Combined Definition,Sex Interaction,,2015-06-01,COMPLETED,OBSERVATIONAL,['NA']
2153,NCT03156478,Change in body weight,Usage of the Internet intervention,,2017-04-10,RECRUITING,INTERVENTIONAL,['NA']
2154,NCT01178476,The frequency of severe hypoglycaemia event,"The frequency of clinical hypoglycaemia (sensation of hypoglycaemia and BG<3.5mmol/l), biochemical hypoglycaemia (BG<3.5mmol/l), and nocturnal hypoglycaemia (waking up with a sensation of hypoglycaemia and BG<3.5mmol/l)",,2009-11,WITHDRAWN,INTERVENTIONAL,['NA']
2155,NCT00419484,,,,2004-03,COMPLETED,OBSERVATIONAL,['NA']
2156,NCT04686552,insulin,lipids,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
2157,NCT02815748,The area under the plasma concentration-time curve (AUC) of SP2086 acid,The number of volunteers with adverse events as a measure of safety and tolerability,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2158,NCT01342614,Blood pressure measurement,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
2159,NCT04237493,Hyperglycemia,Hyperosmolar hyperglycemic state,,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
2160,NCT02287506,Time to optimum treatment following diagnosis.,Mean glycaemic control,,2015-08-28,TERMINATED,INTERVENTIONAL,['NA']
2161,NCT00935766,Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.,Change in hsCRP,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3']
2162,NCT03867851,Other AEs/SAEs after islet transplantation,Change in C-peptide / (glucose x creatinine) ratio (CPGCR),,2021-02-08,RECRUITING,INTERVENTIONAL,['PHASE2']
2163,NCT01046110,Change in Glycosylated Haemoglobin (HbA1c),Change in Fasting Plasma Glucose (FPG),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2164,NCT05017571,Change in Homeostatic model assessment of insulin resistance (HOMA-IR),Change in Matsuda Index,,2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
2165,NCT02067923,Mixed Meal Tolerance Test (MMTT) C-peptide levels,Safety experience,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
2166,NCT02612675,Area under the blood glucose curve (AUC 0-240),,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
2167,NCT05088265,System Usability Scale,,,2021-10-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2168,NCT04560998,Change in maximum walking distance on a constant load treadmill test,Change in Short Form 36 (SF-36) physical functioning domain,,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2169,NCT05092620,Biospecimens collected,,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
2170,NCT03094819,Qualified eye examination rate,Participant perceptions,,2016-03-17,UNKNOWN,INTERVENTIONAL,['NA']
2171,NCT03957603,Change in Fasting insulin concentration from Baseline at 2 months,The incidence of macrosomia infants,,2019-05-16,COMPLETED,INTERVENTIONAL,['NA']
2172,NCT02520050,Absolute and relative change in HbA1c,Absolute and relative change in energy intake,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
2173,NCT02738086,Study-Related Adverse Events,"Late Life Function and Disability Scale, Limitation",,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
2174,NCT03696810,LOR ratios,Retinal Thickness,,2018-10-30,COMPLETED,INTERVENTIONAL,['NA']
2175,NCT04141891,Decisional Conflict Scale (DCS) Scores at Day 0 (Post-intervention),Occurrence of self-reported crashes,,2019-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2176,NCT05165706,Change from baseline in plasma inflammatory cytokine levels in serum samples as measured by Luminex immunoassay,,,2019-01-31,RECRUITING,INTERVENTIONAL,['NA']
2177,NCT05461560,Changes in maximal incremental capillary blood glucose level (iCmax) between baseline and endpoint within the intervention group vs. control.,Changes in area under the curve of incremental capillary blood glucose levels (iAUC) in the intervention group vs. control,,2021-12-05,RECRUITING,INTERVENTIONAL,['NA']
2178,NCT02363907,Point Accuracy of CGM ISF Readings to Blood Glucose Measured by a Reference Device,,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
2179,NCT03235219,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change From Baseline in Insulin Sensitivity as Assessed by Homeostasis Model Assessment for Insulin Sensitivity (HOMA-%S),,2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2180,NCT00895921,Change in Glucose Disposition,Akathisia,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2181,NCT02829268,Number of Participants With Treatment-related Adverse Events as Assessed by Liver Function Tests,Changes in Neurological Functions in Participants Assessed by the Wolfram Unified Rating Scale (WURS),,2017-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2182,NCT03934970,Comparison of diagnostic accuracy of Diffusion tensor imaging of peripheral nerves in comparison to Diabetic Neuropathy Examination in diabetic patients.,Identifying cut-off value for abnormal diffusion tensor apparent diffusion coefficient in diabetic neuropathy.,,2015-04-30,COMPLETED,OBSERVATIONAL,['NA']
2183,NCT04820348,Adherence to wearing continuous glucose monitoring (CGM) devices to measure glucose levels.,Feasibility of assessing the comorbidity of depressive/anxiety symptoms and type 2 diabetes and the impact of depression and anxiety on diet-medication adherence and lifestyle choices.,,2021-04-09,COMPLETED,OBSERVATIONAL,['NA']
2184,NCT01175928,Nerve Conduction Studies,Quality of life questionnaires,,2010-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2185,NCT05170867,HbA1c,Proportion of subjects losing more than 50% of baseline excess weight,,2022-01-14,RECRUITING,INTERVENTIONAL,['NA']
2186,NCT01087866,Percentage of fetal macrosomy,,,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2187,NCT02835287,Incidence of composite major cardiovascular disease events,Cost-effectiveness,,2016-10-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2188,NCT00856011,"Nerve morphology (Fascicular area, myelinated nerve fiber density, endoneurial capillary density and subperineurial space",,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
2189,NCT05504226,Changes from baseline HbA1c at week 24,Changes from baseline in BMI at week 24,,2022-10,RECRUITING,INTERVENTIONAL,['PHASE3']
2190,NCT00797212,Number of AST Results Within +/- 15mg/dL or +/- 20% of Fingerstick (FS)Blood Glucose Results,Percentage of Participant Ratings for Overall Testing Experience With This Meter,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
2191,NCT00656422,To describe changes in hepatic fat content between groups.,To evaluate safety between groups.,,2007-11,TERMINATED,INTERVENTIONAL,['PHASE3']
2192,NCT04007133,Compliance rate with statin measured by the Girerd test,Compliance rate with statin according to risk factors,,2018-01-31,TERMINATED,OBSERVATIONAL,['NA']
2193,NCT01764919,Assess the Sensitivity and Specificity of [124I]FIAU PET-CT Scanning in Detecting Osteomyelitis as Determined by Bone Biopsy in Patients With Diabetic Foot Infection.,Assess Any Additional Information That [124I]FIAU PET-CT Scanning Provides Compared to MRI,"Explore the Performance of [124I]FIAU PET-CT Compared to MRI in Detecting Osteomyelitis by Chronic Kidney Disease (CKD) Stage (Stage 1+2, Stage 3, and Stage 4+5).",2013-04,TERMINATED,INTERVENTIONAL,['PHASE2']
2194,NCT00321542,Death or acute myocardial infarction,"Composite of the primary outcome and the onset of new symptoms of coronary artery disease with proven myocardial ischemia (supported by treadmill, nuclear scan or stress echo findings) or the need for a revascularization procedure.",,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
2195,NCT05440968,"Attendance of patients with knowledge of their risk for diabetes type 2 to a confirmatory test, oral glucose tolerance test",Describe the causes of non-performance of the confirmatory test throughout a brief questionnaire,,2022-06-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2196,NCT02294175,"Total Bacteria Colony Forming Units (CFUs; Natural-log Transformed),With Phenylethyl Alcohol (PEA) Plating","Satisfaction: Wound Pain, Day 8",,2015-01,COMPLETED,INTERVENTIONAL,['NA']
2197,NCT02282475,Assess visceral adipose fat and intrahepatic lipid stores change during pregnancy,Compare glucose tolerance in pregnant women with gestational diabetes to those with normal glucose tolerance,,2014-11-30,COMPLETED,OBSERVATIONAL,['NA']
2198,NCT00042601,Change in food intake of participants on Pramlintide,Effect of pramlintide on postprandial metabolic and hormonal responses,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2199,NCT04883086,The extent of root dental caries,Measuring the vitamin D levels,,2020-12-15,COMPLETED,OBSERVATIONAL,['NA']
2200,NCT00437606,AUCo-inf and Cmax of plasma and urine GK Activator (2) and M4. AUC0-6 of plasma glucose.,"AEs, laboratory parameters.",,2007-03,TERMINATED,INTERVENTIONAL,['PHASE1']
2201,NCT04066959,Hemoglobin A1c,Blood glucose testing,,2020-11-16,RECRUITING,INTERVENTIONAL,['NA']
2202,NCT03457168,New-onset CKD,Cardiac events,,2019-02-01,RECRUITING,INTERVENTIONAL,['NA']
2203,NCT06315725,"Mean plasma glucose, basal and bolus insulin changes in individuals with T1D on AP following beverage consumption.",Resting Energy Expenditure (REE) and nutrient partitioning changes in individuals with T1D on AP following beverage consumption,,2024-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2204,NCT05798637,Rate of platelet activation,Rate of platelet heterogeneity,,2020-02-10,RECRUITING,OBSERVATIONAL,['NA']
2205,NCT00755547,Insulin sensitivity measured from Bergman's frequently sampled intravenous glucose tolerance test,1H-Magnetic resonance spectroscopy-derived measure of lipid content in liver and muscle tissue,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2206,NCT00713830,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2207,NCT03533478,Macular retinal thickness,Visual acuity,,2015-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2208,NCT03449784,number with dyslipidemia,number of patient not achieving LDL-C target according to cardiovascular risk,,2012-05-01,RECRUITING,OBSERVATIONAL,['NA']
2209,NCT00132288,"Change in physical activity of those allocated to the intervention group compared to ""wait-listed"" controls as measured by the Seattle-Rapid Assessment of Physical Activity questionnaire",Determinants of choice in favor of study participation,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
2210,NCT01525784,to examine prospectively frequency of hypoglycemia,To examine prosectively the effect of rt-cgms on glycemic control,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
2211,NCT02014220,blood glucose,food intake,satiety,na,COMPLETED,INTERVENTIONAL,['NA']
2212,NCT02531386,System accuracy criteria (see description),,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
2213,NCT00999856,demonstrate correlation between the fluorescence reading of the insert and capillary blood glucose measurement,duty of care,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2']
2214,NCT02754817,Change in HbA1c (Hemoglobin A1c),Percentage of responders for HbA1c below 7 percent (53 mmol/mol) with no hypoglycaemic episodes,,2016-04-26,COMPLETED,OBSERVATIONAL,['NA']
2215,NCT02056431,Change in Patient Quality of Life at Baseline and 8 Months,Number of Participants With Minimally Effective Dose in 12 Months,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
2216,NCT05268237,"Incidence, nature and severity of adverse events",Serum concentration of liraglutide,,2023-04-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2217,NCT00907114,center subfield mean thickness using Stratus OCT measured in microns,"macular volume using Stratus OCT, measured in cubic millimeters",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2218,NCT01900470,Change in standardized score,Patient Activation,Medical Adherence,2013-07,COMPLETED,INTERVENTIONAL,['NA']
2219,NCT02496221,Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion,Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick,,2015-06-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2220,NCT03007329,change in hepatic lipid content measured with magnetic resonance spectroscopy in %,change in glomerular filtration rate,change in cholesterol,2017-03-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2221,NCT05887180,"Rate of adverse cardiovascular and cerebrovascular events (MACCE ""Plus"" events)",Incremental cost-utility relation (societal perspective),,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2222,NCT01230034,Size of the reduction of urinary albumin in 24 hours to the various controls,"1. Size of the reduction of mean 24-hour average daytime and nighttime average. 2. Size of the reduction of central blood pressure. 3. Magnitude of changes in plasma concentrations of angiotensin II, bradykinin and BNP after 24 weeks of treatment.",,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
2223,NCT05898750,Blood glucose level,Insulin level,,2023-04-22,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2224,NCT05322304,neuropsychological function,,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
2225,NCT04131049,Postprandial glucose response by continous glucose monitoring,,,2019-06-24,COMPLETED,INTERVENTIONAL,['NA']
2226,NCT04030364,Program retention,Hypothetical program cost per patient,,2019-09,UNKNOWN,INTERVENTIONAL,['NA']
2227,NCT04051632,Successful implementation of hybrid closed loop technology,Assess impact of hybrid closed loop technology on glycemic control by analysis of sensor glucose data.,,2018-06-13,COMPLETED,OBSERVATIONAL,['NA']
2228,NCT00169832,Change in plaque volume in one SVG (by IVUS),14 Fluid retention,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2229,NCT04208620,Clinical laboratory evaluations,Proportion of subjects achieving > 5% body weight loss,,2020-01-21,COMPLETED,INTERVENTIONAL,['PHASE1']
2230,NCT02058641,Macrophage cell count and surface expression of markers of M1 and M2 polarization in blister fluid,Time to healing of cantharidin-induced blisters,,2014-02-26,COMPLETED,INTERVENTIONAL,['PHASE1']
2231,NCT01866748,Part B: Number of treatment emergent adverse events (TEAEs),Part B: Change in body weight from baseline,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2232,NCT05719675,Health-related quality of life,,,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
2233,NCT06158503,Bone remodeling improvement,HbA1c change,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2234,NCT03136484,Change in HbA1c,Change in CoEQ: Individual Items,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE3']
2235,NCT01498367,HbA1c levels,Economic Evaluation (Cost-Effective Analysis- Cost Utility Analysis),,2011-03,COMPLETED,INTERVENTIONAL,['NA']
2236,NCT03487887,Glycemic variability,Hypogliaemia,,2018-03-19,COMPLETED,OBSERVATIONAL,['NA']
2237,NCT00364312,Quality of life,Self-efficacy,,2004-05,UNKNOWN,INTERVENTIONAL,['NA']
2238,NCT04092023,Glycemic control,QOL: Audit of Diabetes Dependent Quality of Life (ADDQoL-19),,2018-10-02,COMPLETED,INTERVENTIONAL,['NA']
2239,NCT01292018,Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months,Control of dyslipidemia by all commercial available brands hypolipidemics drugs,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
2240,NCT04897802,Change in oxytocin concentration (pg/mL),Alexithymia assessment,,2021-09-13,RECRUITING,INTERVENTIONAL,['PHASE4']
2241,NCT03677609,Patient adherence: Vaccine and screening recommendations,Physician mindset: Mindset Beliefs Survey,,2018-01-04,COMPLETED,INTERVENTIONAL,['NA']
2242,NCT00285194,"-Immune activity and pharmacokinetic assessments included hOKT3γ1 (Ala-Ala) level and half-life, monoclonal antibody coating and modulation of CD3 on peripheral blood T cells, and anti-hOKT3γ1 (Ala-Ala) antibody responses.","-Proportion of subjects with slet graft loss will be defined as a return to insulin therapy for >30 days, absence of basal and arginine-stimulated C-peptide, re-transplantation, or patient death;",,2000-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2243,NCT01022177,retinal perfusion by HRF/OBF/RVA,,,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
2244,NCT04849845,Post-prandial Glucose Excursion,"Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose",,2021-04-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2245,NCT04364087,the prevalence of diabetes and prediabetes in infertile women with PCOS,Factors associated with diabetes and prediabetes,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
2246,NCT00701831,Time to dose titration,Physician Satisfaction Questionnaire,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
2247,NCT03651531,Hgb A1c,Incidence neonatal hypoglycemia,,2018-01-03,TERMINATED,INTERVENTIONAL,['PHASE3']
2248,NCT01392573,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change in Body Weight,,2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE3']
2249,NCT04107259,IRAPe,,,2019-01-19,COMPLETED,OBSERVATIONAL,['NA']
2250,NCT00167830,Improvement in fitness measures,Improved family cohesiveness,,2003-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2251,NCT02431234,Serum RANKL concentrations,,,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
2252,NCT00631488,Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels,Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2253,NCT02330484,Hypoglycemic Medication adherence rates using electronically monitored adherence (MEMS cap) data,MEMS cap data compared to PHQ-9 and AIS assessment,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
2254,NCT00700830,Assessment the incidence of the Serious Adverse Events including the major Hypoglycaemia.,Weight,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
2255,NCT00417131,,,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
2256,NCT02958956,Number of 10 Most Common Cancers Associated Cases,Number of 10 Most Common Cancer Cases By Dose of Pioglitazone,,1997-01-01,COMPLETED,OBSERVATIONAL,['NA']
2257,NCT00286637,Number of Participants who Show Evidence of Glaucoma Progression,,,1995-01,COMPLETED,OBSERVATIONAL,['NA']
2258,NCT04028960,Percentage of Time With Dangerous Hypoglycemia,Glucose Management Indicator (GMI),,2019-10-23,TERMINATED,INTERVENTIONAL,['PHASE2']
2259,NCT04817228,Change from baseline in wound biofilm presence before and after treatment,,,2021-04-21,COMPLETED,INTERVENTIONAL,['PHASE2']
2260,NCT04863235,Changes in self-compassion from pre-intervention to 12 week follow-up (20 weeks),Personal Growth Initiative as a potential mediator,,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA']
2261,NCT00873561,To assess the effect of repeated administrations of NBI-6024 on endogenous insulin production as measured by C-peptide levels in adult and adolescent patients with new onset type 1 diabetes mellitus,"To examine the effects of repeated administrations of NBI-6024 on insulin usage, glycemic control, and immune function (immunodynamics and pharmacodynamics) To examine the safety and tolerability of repeated administrations of NBI-6024",,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2262,NCT00454623,,,,2006-03,UNKNOWN,INTERVENTIONAL,['NA']
2263,NCT05046015,Change from Baseline in Overall Dry Skin Score,Skin barrier,Cracks/ Fissures,2016-09,COMPLETED,INTERVENTIONAL,['NA']
2264,NCT04569409,Proportions of subjects who achieved complete wound closure,Change rates in wound size and depth compared to baseline groups,,2020-07-14,RECRUITING,INTERVENTIONAL,['PHASE3']
2265,NCT03462017,Change in Flow Mediated Dilation (FMD),Assessment of PK parameter: AUC0-24,,2018-03-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2266,NCT01585506,Frequency and level of difficulty in introducing changes in compliance with the guidelines for biphasic insulin analogue use in subjects previously treated with biphasic human insulins,"Correlations between the difficulty in introducing changes in compliance with the guidelines for biphasic insulin analogue use in subjects previously treated with biphasic human insulins, and psychosocial factors",,2010-09-20,COMPLETED,OBSERVATIONAL,['NA']
2267,NCT00819325,"The primary IVUS endpoint of the study was the change in three-dimensional neointimal plaque volume within the stented segment at follow-up, compared to baseline.","The secondary IVUS endpoint was the change in the two-dimensional NIA within the stent, using the cross-sectional slice showing the smallest LA on follow-up and comparing it to the corresponding baseline slice.",,2002-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2268,NCT01774149,Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12.,Change in HbA1c,Empowerment,2013-03,COMPLETED,INTERVENTIONAL,['NA']
2269,NCT00410800,,,,1996-08-19,COMPLETED,OBSERVATIONAL,['NA']
2270,NCT04132739,Changes in strength,,,2019-03-01,TERMINATED,INTERVENTIONAL,['NA']
2271,NCT03257449,Body fat percentage change,,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
2272,NCT01990638,left ventricular diastolic function,exercise capacity,,2004-11,COMPLETED,OBSERVATIONAL,['NA']
2273,NCT02327754,Change from baseline in urine albumin creatinine ratio,"sUA, eGFR, L-FABP, HbA1c, SBP, DBP, TC",,na,COMPLETED,INTERVENTIONAL,['PHASE2']
2274,NCT00755404,To assess the efficacy of L-Carnitine containing PD solution on insulin sensitivity evaluated by measuring insulin requirement,To assess the efficacy of L-Carnitine containing PD solution on hematological parameters (hemoglobin and EPO requirements),,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2275,NCT02820558,Stage A Safety: Side effects reported for entire cohort,C-Peptide Levels (large cohort),sP Longevity,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
2276,NCT03205904,glycemic improvement after nutritional orientation in patients with cystic fibrosis in the pre-diabetic phase,To evaluate anthropometric data of the patients before and after the intervention.,,2016-12-12,COMPLETED,INTERVENTIONAL,['NA']
2277,NCT02589314,Evidence of alteration on pro and anti-inflammatory cytokines by CBA,,,2015-11,TERMINATED,OBSERVATIONAL,['NA']
2278,NCT03437694,Hypertension,,,2018-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2279,NCT00069784,"Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)",Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG,Number of Patients With First Occurrence of Any Type of Cancer,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2280,NCT03015480,Change in 24-hour urine sodium,Change in Net Endogenous Acid Production (NEAP),,2017-02-13,COMPLETED,INTERVENTIONAL,['NA']
2281,NCT02438397,MAGE: mean amplitude of glycemic excursion/MODD: mean of daily differences,,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
2282,NCT02069197,Change of body mass index from baseline in 9 months period,To evaluate safety of ketogenic diet as a treatment of obesity.,,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2283,NCT01798238,Glycosylated hemoglobin,Glycosylated hemoglobin <6.5% subject percent,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
2284,NCT06290349,Change from the baseline in HbA1c (%) after 24 weeks,Change from the baseline in weight after 24 weeks,,2024-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2285,NCT05610865,Interview and visual inspection of ulcers recovery rate,Percentages (%) of wound closure rate (with respect to time) will be assessed.,,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE1']
2286,NCT05985291,Average change from baseline to 3 months in treatment responder rates,Average change from baseline to 6 months in treatment responder rates assessed by Visual Analog Scale (0-10 cm),Assessment of subject outcomes satisfaction as measured through Patient Global Impression of Change (PGIC) (1-7 where higher scores mean better outcome) at 3 months and 6 months.,2023-07-03,RECRUITING,OBSERVATIONAL,['NA']
2287,NCT00604656,Insulin aspart antibodies,HbA1c,,2003-05-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2288,NCT01368536,Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) After 12 Weeks of Treatment Ending With the Combination of Valturna and Amlodipine Versus Valturna Alone,"Number of Patients With Adverse Events, Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone",,2011-05,TERMINATED,INTERVENTIONAL,['PHASE4']
2289,NCT00787215,Glucose intolerance status by OGTT,Glucose intolerance status predicted by Chinese University Diabetes Risk Score validated by OGTTT,,2008-11,UNKNOWN,OBSERVATIONAL,['NA']
2290,NCT04980014,Percentage of Participants With Abnormal Laboratory Findings Reported as AEs,Change From Baseline in Diastolic Blood Pressure,,2015-10-02,COMPLETED,OBSERVATIONAL,['NA']
2291,NCT02208921,The proportion of T2DM patients with Chronic Kidney Disease (CKD),Frequency of patients with HbA1C less than 7% in T2DM patients with and without CKD,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
2292,NCT01967901,Quality of life,Kidney function,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
2293,NCT04503564,Rate of Infusion Set Survival at End of Day 7,,,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
2294,NCT01577719,Effectiveness of a 6 month culturally-specific multi-media intervention on Heart Health Risk,Change in the MI risk score and clinical events,,2009-06,UNKNOWN,INTERVENTIONAL,['NA']
2295,NCT00607737,laser doppler blood flow,insulin detemir specific antibodies,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2296,NCT00074633,,,,2000-01,COMPLETED,INTERVENTIONAL,['NA']
2297,NCT00944450,Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin),,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2298,NCT00229918,Central macular thickness,Increased intraocular pressure,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2299,NCT00934336,"Assay of isoprostane-F2, an indicator of lipid peroxidase derivative production, in the 24 hour urine",,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
2300,NCT04426474,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug,PD: Change from Baseline to Week 12 in Fasting Insulin,,2020-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2301,NCT04907708,Mean morphometric diffusion capacity for oxygen (MMDC) in placental tissues,Percentage of immuno-antigens present in placental tissue,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
2302,NCT06053359,Semi-structured and Open-Ended Interview Questions,Social Determinants of Health Questionnaire,,2024-04,WITHDRAWN,OBSERVATIONAL,['NA']
2303,NCT01956162,"Evaluate the efficiency of ""Orthèse Diabète"" compared to ""conventional"" removable devices, in terms of the proportion of diabetic patients whose principal ulcer will heal completely.",Patients satisfaction with the prescribed device,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2304,NCT03569735,Cognitive disorder (occurrence of cognitive disorder),Usual gait speed,,2018-05-26,RECRUITING,OBSERVATIONAL,['NA']
2305,NCT04828785,Hemoglobin A1c at Month 6,Frequency of self-reported severe hypoglycemia at Month 12,Stress Score at 12 months,2021-07-02,RECRUITING,INTERVENTIONAL,['NA']
2306,NCT03952143,Change From Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants With HbA1c <7% and ≤6.5%,,2019-05-27,COMPLETED,INTERVENTIONAL,['PHASE3']
2307,NCT00403481,Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM.,Change in Ambulatory BP (Diastolic) From Baseline to Week 12 During the Last (Week 12 ) 4 and 6 Hours of the Last 24-hour Dosing Period.,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2308,NCT05155917,the rates of hypoglycemia,ICU Mortality rate,,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2309,NCT04735640,Change in fasting plasma glucose,Maintenance of acquired dietary and physical activity changes,,2021-04-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2310,NCT02035891,The incidence of overt nephropathy,Death from any cause,,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
2311,NCT03829800,Change from baseline Subjective appetite at 180 minutes,HbA1c,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
2312,NCT00328393,Median of systolic 24-hour ambulatory blood pressure,Median of 24-hour diastolic ambulatory blood pressure,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2313,NCT01860547,Serum Alanine aminotransferase (ALAT),Body composition,"Subclasses of serum lipoproteins, serum fatty acids and lipid classes of serum",2008-06,COMPLETED,INTERVENTIONAL,['NA']
2314,NCT05670366,Database which contains food intake data (type of food) retrieved from the diary app.,,,2022-09-26,RECRUITING,INTERVENTIONAL,['NA']
2315,NCT02695706,Skin acceptability through the self perception of patients.,Instrumental Performance Measures,,2016-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
2316,NCT00921570,Flow mediated dilatation,"TWEAK, PTX-3, Systolic Blood Pressure and Diastolic Blood Pressure",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
2317,NCT02386020,Change in Clinical attachment level,Change in Probing depth,,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2318,NCT05505994,Change from baseline in HbA1c,,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2319,NCT05703386,Progression of cerebral small vessel disease,,,2022-11-08,RECRUITING,OBSERVATIONAL,['NA']
2320,NCT03785951,Change in fasting and day long insulin levels,Change in body composition,Metabonomics,2018-12,UNKNOWN,INTERVENTIONAL,['NA']
2321,NCT04125784,Changes from baseline in diabetes mellitus type II prevalence,Changes from baseline in therapeutic regimes within those patients who were identified as having diabetes mellitus type 2 in the first study in 2014,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
2322,NCT02818192,Change in albumin excretion over time.,Change in estimated glomerular filtration rate (eGFR) over time.,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
2323,NCT00806585,Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE2']
2324,NCT02355717,Bone strength-strain index,Serum C-terminal telopeptide of type 1 collagen (CTX),,2014-12,UNKNOWN,OBSERVATIONAL,['NA']
2325,NCT02361138,Plasma glucose concentration of SHR3824.,Serum creatinine,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2326,NCT05529108,Change in bile acid concentration,Change in dietary,,2022-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2327,NCT00876213,,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
2328,NCT02306681,The percentage of patients who experience at least 1 hypoglycaemic episode,DSQOLS (Diabetes-Specific Quality-of-Life Scale) scores,,2014-10-30,COMPLETED,OBSERVATIONAL,['NA']
2329,NCT02994277,System connectivity,Meal composition's effect in the efficacy of the system to control glycaemia,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2330,NCT00210847,Change in the average of daily pain score recorded in the IVR system from baseline to the patient's final week of treatment with study medication.,"Efficacy measured by Brief Pain Inventory, Visual Analogue Scale, Short-Form McGill Pain Questionnaire, Profile of Mood States, SF-36 Health Survey, Physician and Subject Global Impression of Change, average daily sleep interference",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2331,NCT05213988,Glucose tolerance,,,2018-07-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
2332,NCT04265261,Percentage of Participants with Adverse Events (AEs),Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye,,2020-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2333,NCT00700154,Plasma glucose levels,laboratories for inflammation and oxidative stress,,2011-11,TERMINATED,INTERVENTIONAL,['NA']
2334,NCT01914302,Blood Volumes measured in microliters,Pain rating measure on a 0-20 Gracely Scale,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
2335,NCT01455441,HbA1c,Myocardial echocardiography,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2336,NCT03377946,Changes of gut microbiota composition,"Composite changes of weight, waist circumference and BMI",Changes of Intestinal endocrine function,2017-12-21,UNKNOWN,INTERVENTIONAL,['NA']
2337,NCT04905459,Specificity of ARDA mtmDR for detection of mtmDR in UWF images,,,2021-09-30,COMPLETED,OBSERVATIONAL,['NA']
2338,NCT03848767,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
2339,NCT00539396,Change in blood glucose following a standard meal,Mean change from baseline HbA1c,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2340,NCT03795662,Number of participants who develop diabetes,Number of participants who are readmitted,HbA1c to assess the average blood glucose levels 3 months before admission,2019-01-07,RECRUITING,OBSERVATIONAL,['NA']
2341,NCT02290184,Feasibility for Participant Enrollment and Retention,Change in Waist Circumference,,2014-11-01,COMPLETED,INTERVENTIONAL,['NA']
2342,NCT01488916,incremental areas under the curves of plasma glucose after meal challenge,"Meal-related glycemic excursion indexes (∆G, ∆T, BR)from the meal test",,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
2343,NCT00698126,Number of major hypoglycaemic events reported as serious adverse drug reactions,Quality of Life (QoL),,2007-10,COMPLETED,OBSERVATIONAL,['NA']
2344,NCT06236672,change in HbA1c (%),,,2023-02-15,COMPLETED,OBSERVATIONAL,['NA']
2345,NCT02333539,Frequency of Insulin Pump Adherence Behaviors,Change in Glycemic Control (A1C),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
2346,NCT04020822,Accuracy of Sensor Glucose Before and After Acetaminophen Administration,,,2019-07-29,COMPLETED,INTERVENTIONAL,['NA']
2347,NCT01418716,Quality of the cardiovascular preventive care,Use of public programs,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
2348,NCT03741153,the percentage of diabetic patients with pseudo-exfoliation syndrome,,,2019-01,UNKNOWN,OBSERVATIONAL,['NA']
2349,NCT01487811,Maximum drug concentration of the two formulations (Cmax),Frequency of adverse events,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2350,NCT03325569,The main outcome was difference in fasting and after load GLP1 levels between two groups,"The secondary outcome was to evaluate the between group difference in beta cell function, and visceral adipose tissue.",,2017-02-13,COMPLETED,INTERVENTIONAL,['NA']
2351,NCT04021251,Validation of predictive algorithms for determining blood glucose levels,,,2018-12-20,UNKNOWN,INTERVENTIONAL,['NA']
2352,NCT01030744,Self-Monitoring of Blood Glucose,,,2015-12,WITHDRAWN,OBSERVATIONAL,['NA']
2353,NCT03426709,Diabetes control measured by VR d= Hb glucosidal,System Usability Scale (SUS),,2018-11-26,COMPLETED,INTERVENTIONAL,['NA']
2354,NCT05945576,The morphometric characteristics of IDs in pediatric and adult's patients.,Analyse of (epi)genetic mutations transmission in proband and relatives.,"Description of different scientific rational for transferring a therapeutic approach (clinical guidelines) from an ID to another (identification of common phenotype, i.e. metabolic profile).",2017-03-10,RECRUITING,OBSERVATIONAL,['NA']
2355,NCT00698230,Change from Baseline to Week 12 in hemoglobin A1c (HbA1c),Change from Baseline to Week 12 in fasting plasma glucose (FPG).,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2356,NCT05658991,Retinal function amplitude,Retinal function latency.,,2022-12-11,RECRUITING,INTERVENTIONAL,['NA']
2357,NCT05744856,The acceptability of the self-care intervention,Self-care of GDM,Costs,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
2358,NCT00179777,Number of Participants With Type 1 Diabetes Mellitus,Number of Participants With Diabetes Associated Autoantibodies,,2002-05-06,COMPLETED,INTERVENTIONAL,['NA']
2359,NCT00711217,Wound healing,Clinical outcome data,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2360,NCT03539627,Systolic blood pressure,Dynamics of renal function (proteinuria detecton),,2018-11-07,COMPLETED,OBSERVATIONAL,['NA']
2361,NCT06198543,differential proteins of exosomes,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2362,NCT01475552,"Peak cardiac enzyme level (CK-MB,troponin-I)",The rate of periprocedural myocardial infarction,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2363,NCT05266742,Patient Identification Form,,,2019-12-15,COMPLETED,INTERVENTIONAL,['NA']
2364,NCT00185159,Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine,Safety and tolerability,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2365,NCT00411333,Change in retinal vascular density from baseline on fluorescein angiography,Safety,,2006-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2366,NCT01687582,Improvement of PASI score,Evolution of BMI,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2367,NCT00592735,weight loss,,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
2368,NCT00283218,"• Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between BIAsp 50 vs BIAsp 70, BIAsp 30 vs BIAsp 70, BIAsp 30 vs BIAsp 50 and IAsp vs BIAsp 30, 50 and 70.","AUCins: The area under insulin aspart concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulin aspart preparation: IAsp (NovoRapid®), Biphasic insulin aspart 30, 50 and 70.",,2006-01,COMPLETED,INTERVENTIONAL,['NA']
2369,NCT05580978,Change in percentage of CGM glucose readings > 120 mg/dL,Motivation and Attitudes Toward Changing Health,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
2370,NCT05416060,Change from Baseline in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months,Change from Baseline Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 6 months,,2023-03-23,RECRUITING,INTERVENTIONAL,['NA']
2371,NCT05588258,Assessment of the skin quality of participants' feet before and after the cream application intervention using a validated questionnaire.,,,2021-11-02,COMPLETED,INTERVENTIONAL,['NA']
2372,NCT01455922,Change in HbA1c,,,2013-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2373,NCT00228878,Researchers will assess whether pulsatile IV insulin therapy can successfully reverse the abnormal underlying metabolism in diabetic patients to the point of improving their quality of life.,,,2003-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2374,NCT01614379,,,,2012-06,WITHDRAWN,OBSERVATIONAL,['NA']
2375,NCT02891928,Anteroposterior displacement amount of the center of pressure with regard to the center of mass.,,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2376,NCT00413348,Change in inflammatory response to E. coli endotoxin injection,,,2006-11,UNKNOWN,INTERVENTIONAL,['NA']
2377,NCT06109311,"Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)",Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Domain and Summary Scores,,2023-11-10,RECRUITING,INTERVENTIONAL,['PHASE3']
2378,NCT01372852,"plasma adiponectin concentration, isoform distribution and activity.",,,2010-05,UNKNOWN,OBSERVATIONAL,['NA']
2379,NCT01831336,Target Lesion Failure (TLF),Target Lesion Failure (TLF),,2013-02,COMPLETED,OBSERVATIONAL,['NA']
2380,NCT05591664,eicosapentaenoic acid,,,2022-10-17,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2381,NCT05984459,Diabetes remission,Decreases in poglycemic drug treatments,,2023-01-30,COMPLETED,OBSERVATIONAL,['NA']
2382,NCT04802044,Correlation of HbA1c with Clinical Disease Severity,Proportion of Long COVID Syndrome,,2020-12-08,UNKNOWN,OBSERVATIONAL,['NA']
2383,NCT00746460,Feasibility of using health care providers other than physicians within a GMF to conduct a CV risk assessment and intervention on primary prevention patients,Satisfaction of the patient,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
2384,NCT03399994,In-stent neointimal volume,Procedural success,,2018-05-21,COMPLETED,INTERVENTIONAL,['NA']
2385,NCT01180712,Oral Glucose Tolerance Test,Fasting blood glucose/insulin,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
2386,NCT05508425,Abdominal bloating after glucose solution administration,,,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
2387,NCT02568384,"Percent of Responses From Persons Who Performed Each ""Software Operations"" Task and Rated Each Statement as Strongly Agree, Agree, or Neither Agree Nor Disagree.",Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Clarity and Utility of User Instructions For Onyx Glucose Meter and App System,Average Change in Total Daily Insulin Dose From Study Start to End of Study,2015-10,COMPLETED,INTERVENTIONAL,['NA']
2388,NCT03001323,Reduction in frequency of diabetic ketoacidosis,Basal insulin requirements,,2017-01,TERMINATED,INTERVENTIONAL,['NA']
2389,NCT03672656,Pain assessed by NRS,Satisfaction assessed by the VAS,,2008-01-01,COMPLETED,INTERVENTIONAL,['NA']
2390,NCT00309465,Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery,,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2391,NCT04618458,Parent BMI,Child stress,Child tanner stage,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
2392,NCT01848795,Glycated hemoglobin,,,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
2393,NCT00663884,Change of HbA1c before and after administration of test drug,"Change of CRP, 8-OHdG and Nitrotyrosine before and after administration of test drug",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
2394,NCT04897113,Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count,"scales of the ""Health-Promoting Lifestyle Profile""",,2021-05-12,UNKNOWN,INTERVENTIONAL,['NA']
2395,NCT04847999,Blood glucose incremental area under the curve,Blood glucose total area under the curve,Taste Questionnaire,2020-11-20,COMPLETED,INTERVENTIONAL,['NA']
2396,NCT05160272,Circulating C-peptide by iAUC of C-peptide during an IVGTT,Ctrough-ss (Day 28) and the change from baseline to Day 28,,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE2']
2397,NCT00013598,,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2398,NCT05524259,The incidence of PCOS patients in the two study arm that give birth before 37 completed weeks of gestational age.,"The incidence of neonatal outcomes in the two study arms (e.g. incidence of neonatal intensive care unit (NICU) admissions, incidence of Neonatal hypoglycaemia).",Cost-effectiveness of myo-inositol supplementation using Health Technology Assessment (HTA) analyses.,2019-06-21,RECRUITING,INTERVENTIONAL,['NA']
2399,NCT04791787,Hepatic Fat Content,Fructosamine level,,2020-11-25,COMPLETED,INTERVENTIONAL,['NA']
2400,NCT03144050,Clinical risk category,Ulcer incidence,,2017-04-14,UNKNOWN,OBSERVATIONAL,['NA']
2401,NCT02501538,Tissue Perfusion as Measured by TCPO2,Percent Wound Area Reduction,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
2402,NCT02452632,Change from baseline in HbA1c at the end of treatment,Percentage of subjects achieving the target HbA1c(<6.5% and <7.0%) at each visit,,2015-06-22,COMPLETED,INTERVENTIONAL,['PHASE3']
2403,NCT01975428,Participant Perceptions of Utility of Monitoring,Total Health Care Utilization and Costs.,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
2404,NCT04043260,Percentage of readings below 54 mg/dl,Change in HbA1C post study treatment,,2019-11-27,COMPLETED,INTERVENTIONAL,['NA']
2405,NCT05620251,humoral immune response after second vaccine dose,Adverse events,,2021-09-03,COMPLETED,OBSERVATIONAL,['NA']
2406,NCT02578498,Peak glucose value,Plasma glucose variation,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2407,NCT05539963,Number of participants with no clinical need for further additional surgical procedure or debridement to treat infection at the index site,Number of systemic antibiotic free days since trial surgery,,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2']
2408,NCT00211510,Change in A1c From Baseline to 26 Weeks,Problem Areas in Diabetes (PAID) Questionnaire Assessed and Compared Between Groups,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
2409,NCT01699100,plantar pressure of region of interest,Plantar pressure of non-region of interest,plantar pressure of midfoot area,2011-09,COMPLETED,INTERVENTIONAL,['NA']
2410,NCT04198948,Gliclazide AUC,Insulin,,2019-03-04,COMPLETED,INTERVENTIONAL,['PHASE1']
2411,NCT05351879,"Number of Clinically Significant Abnormal Results From Laboratory measurements (hematology, clinical chemistry) and Urine analysis.",Change in time in hyperglycemic range > 10 mmol/L,,2022-05-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2412,NCT02728687,BPI pain interference improvement 3 months,incidence of side effects,,2017-03-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2413,NCT06296251,Body fat mass,AST,,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2414,NCT03555656,Incidence of foot ulcers,incidence of foot ulcers,,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
2415,NCT05971524,Glycemic control,Triglycerides,,2023-05-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2416,NCT03189407,Change in estimated glomerular filtration rate,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
2417,NCT04555421,Fat percentage,Blood tests changes - glycemic control,,2020-10,UNKNOWN,INTERVENTIONAL,['NA']
2418,NCT02916680,Absence of ophthalmic complications,Change in total number of hypoglycemic events,,2016-03,RECRUITING,INTERVENTIONAL,['NA']
2419,NCT03297294,Change in Weekly Mean 24-hour Average Pain Score Using the 11 Point Numerical Rating Scale (NRS) From Baseline to Week 12,Treatment Emergent Adverse Events During Urgent Safety Measure (USM) Follow-Up,,2018-03-14,TERMINATED,INTERVENTIONAL,['PHASE2']
2420,NCT03025451,Weight,Fasting Glucose,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
2421,NCT00065312,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
2422,NCT05662189,pancreatic beta cell function (BCF),,,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
2423,NCT01593059,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-08,TERMINATED,OBSERVATIONAL,['NA']
2424,NCT01302756,Gestational diabetes,Gestational hypertension,,2012-04,WITHDRAWN,INTERVENTIONAL,['NA']
2425,NCT01828970,Mean plasma glucose level measured 3 times just before the first hemodialysis session,Deaths and major cardiovascular events,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2426,NCT01098253,Hemoglobin A1C,Nine Item Patient Health Questionnaire (PHQ-9),,2009-01,COMPLETED,INTERVENTIONAL,['NA']
2427,NCT01223456,Clinical Response determined by cure rate,,,2010-10,TERMINATED,OBSERVATIONAL,['NA']
2428,NCT02800044,accuracy,acceptability,,2017-03-14,TERMINATED,INTERVENTIONAL,['NA']
2429,NCT03032354,"Area under the curve (AUC) during fasting and at 30,60,90,120 min following the start of the meal",Fasting c- peptide concentrations in ng/ml,,2017-07-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
2430,NCT00849563,Percentage of weight loss,Change in HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR),,2009-04,COMPLETED,INTERVENTIONAL,['NA']
2431,NCT01331343,Difference in Change in A1c (%) between continuous use of CGM and control,Difference in change in A1c (%) between biweekly use of CGM and continuous use of CGM,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2432,NCT03680079,HbA1c,Depression screening,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
2433,NCT02754739,Insulin resistance assessed by HOMA-IR (homeostatic model assessment index for insulin resistance),"Biomarkers predicting cardiovascular diseases, assessed by plasminogen activator inhibitor-1 (PAI-1) (ng/mL)",,2014-04-15,COMPLETED,INTERVENTIONAL,['PHASE4']
2434,NCT01575080,Number of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<100mg/dL) or Within +/- 15% (>=100mg/dL) of Laboratory Glucose Method,Number of Subject Responses That 'Agree' or 'Strongly Agree' With Questionnaire Statements,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
2435,NCT05412264,Increased pedometer steps,Waist circumference,Questionnaire,2014-01,TERMINATED,INTERVENTIONAL,['NA']
2436,NCT00005140,,,,1977-09,COMPLETED,OBSERVATIONAL,['NA']
2437,NCT01663207,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
2438,NCT02593032,Percent of Participants With Adherence at Month 6,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
2439,NCT04579406,adverse cardiovascular events,"NPY, CGRP, SP and TRPV1",,2020-10-15,RECRUITING,OBSERVATIONAL,['NA']
2440,NCT02619877,Proportion of re-epithelialization,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2441,NCT00270608,,,,2007-03,UNKNOWN,OBSERVATIONAL,['NA']
2442,NCT06028139,HbA1c,Healthcare cost as measured by WPAI,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2443,NCT01781884,C-peptide value,HbA1C level,Daily dosage of insulin (units/kg).,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
2444,NCT01764373,Change in aerobic fitness,Change in pain experienced,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
2445,NCT03821753,Macular capillary density in the external deep capillary network,Oxidative stress markers,,2019-01-07,UNKNOWN,OBSERVATIONAL,['NA']
2446,NCT02130505,Postprandial change in leukocyte activation,Correlation between acute glycemia and leukocyte activation,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2447,NCT00803777,Number of Duplicate Subject BGM Results Within +/- 15mg/dL or +/- 20% of Healthcare Professional Capillary Results,Average Within Replicate Coefficient of Variation CV (Precision),,2008-12,COMPLETED,INTERVENTIONAL,['NA']
2448,NCT01642355,Reduction of Non-HDL cholesterol,Cardiovascular events,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
2449,NCT06190405,Large-for-gestational age,Rate of hypertensive disorders of pregnancy,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2450,NCT01617304,change in AGE levels in skin from baseline to 4 weeks,change in HbA1c from baseline to 4 weeks,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
2451,NCT00506272,average blood glucose,,,2007-12,UNKNOWN,INTERVENTIONAL,['NA']
2452,NCT01498159,Hemoglobin A1c,LDL Cholesterol,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
2453,NCT00903500,Dexa scan,"Questionnaires on psycho-social determinants of physical activity, on environmental determinants of physical activity and a motivational questionnaire",,2007-07,COMPLETED,INTERVENTIONAL,['NA']
2454,NCT00839150,,,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
2455,NCT01987674,HbA1c,Postprandial glycemia,Homeostasis model assessment of insulin resistance (HOMA-IR),2014-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2456,NCT00964184,HbA1C,insulin,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2457,NCT00782717,Percent of Patients Who Developed Macular Edema (ME) Within 90 Days Following Cataract Surgery,Percent of Patients With a Decrease of More Than 5 Letters in Best-corrected Visual Acuity (BCVA).,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2458,NCT00997763,Angiographic in-segment late loss at angiography,Angiographic pattern of restenosis,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2459,NCT00864838,Intraocular pressure (mmHg),,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2460,NCT02136758,Body Mass Index,Blood Lipids,Exercise Capacity,2009-04,TERMINATED,INTERVENTIONAL,['NA']
2461,NCT02015806,Optimal medication adherence to all cardiovascular or non-depression chronic disease medications,Optimal adherence to cardiovascular medications among subjects who are suboptimally adherent to these medications at time of randomization,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
2462,NCT02684565,Change in glucose tolerance and body composition that Are Related to Low protein BCAA Treatment,Change in glucose tolerance and body composition that Are Related to High Protein BCAA treament,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
2463,NCT00703209,"To determine if nerve decompression of lower extremities in patients suffering from painful symptomatic diabetic neuropathy with chronic nerve compression, has a significant impact on alleviation of pain, and improvement in quality of life.","To measure changes in quality of life. This includes medication changes, pain relief, restoration of sensation, etc.",,2008-01,COMPLETED,INTERVENTIONAL,['NA']
2464,NCT01684709,12-month glycemic control,Secondary effects upon adjustment to diabetes,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
2465,NCT02322762,Anti-diabetic treatments prescribed by physicians in a real-world setting.,Use of Healthcare resources.,,2014-12-30,COMPLETED,OBSERVATIONAL,['NA']
2466,NCT06031389,Detection of intestinal flora difference between intervention group and control group with diabetic nephropathy by bacterial 16srDNA sequencing,Statistical analysis of the degree of proteinuria relief in intervention group and control group.,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2467,NCT03588104,Change in glycemic control,Patient Assessment of Chronic Illness Care (PACIC),,2018-12-03,COMPLETED,INTERVENTIONAL,['NA']
2468,NCT03654521,Fetal interventricular septum thickness,,,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA']
2469,NCT02266030,Coronary artery stenosis,Lipid metabolism,Heart rate,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2470,NCT01042769,"Effect on cardiovascular death, non-fatal myocardial infarction and non-fatal stroke",Tolerability and long-term safety profile,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2471,NCT01415115,SCOUT Comparison,Hypertension,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
2472,NCT03891927,change of fasting glucose after intervention by extra virgin olive oil,"change at Lipid profile (cholesterol, TG, LDL, HDL) after intervention .",,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA']
2473,NCT04011683,"Incidence of cardiac arrhythmias during hypoglycaemia, euglycaemia, hyperglycaemia.",Mean amplitude of glycaemic excursions (MAGE) and cardiac arrhythmia.,,2018-12-01,COMPLETED,OBSERVATIONAL,['NA']
2474,NCT01506895,Change from baseline in Spectral Domain Optical Coherance Tomography,Plasma concentration versus time curve (AUC) of study drug,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2475,NCT00837408,Type 2 Diabetes,,,2009-02-03,COMPLETED,OBSERVATIONAL,['NA']
2476,NCT00114998,,,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
2477,NCT04954313,Association between changes in oral health and changes in systemic health (Flow-mediated dilation),Impact of treatment on triglycerides,,2021-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
2478,NCT05046886,Mean Amplitude of Glycemic Excursion (MAGE),HbA1c Levels,,2021-12-14,RECRUITING,INTERVENTIONAL,['NA']
2479,NCT03179280,post-prandial euglycaemia (PPG),,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
2480,NCT03453281,Central macular thickness,Uncorrected visual acuity (number of letters),,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2481,NCT01999374,Duration of sustained islet allograft function,,,2013-03,RECRUITING,OBSERVATIONAL,['NA']
2482,NCT01040962,,,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
2483,NCT05379686,Percentage of time in target glucose range (PG: 3.9 - 10.0 mmol/l) during and for 1-hour after dynamic physical exercise,Coefficient of variation in PG concentrations,,2022-09-21,RECRUITING,INTERVENTIONAL,['NA']
2484,NCT04888780,Quality Criteria for Consumer Health Information (DISCERN) Website Evaluation Scale,,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
2485,NCT04547244,CRTd responders rate,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
2486,NCT01306110,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
2487,NCT02010242,Albuminuria,Glucose metabolism,Neuropathic pain,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2488,NCT05199454,Brachial artery flow-mediated dilation (percent vasodilation) in 60 obese diabetic subjects,Glycosphingolipid content (ng/ml) in adiposomes from 60 obese diabetic subjects,,2022-05-16,RECRUITING,INTERVENTIONAL,['NA']
2489,NCT06018324,DTSQc,Treatment costs,,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2490,NCT04754919,"The rates of diabetes related hospital episodes, including Diabetic Ketoacidosis, between the 2 study groups before and after transition",To compare the proportion of young people in the study groups who fail to attend at least one out-patient adult diabetes appointment during the first year after transition,,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA']
2491,NCT00261352,The change in HDL-C from baseline to the end of the randomized treatment period.,"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2005-03,TERMINATED,INTERVENTIONAL,['PHASE3']
2492,NCT02879409,Determination of the variability of HbA1c (by measurement of standard deviation of HbA1c) between the 2 diabetes treatment thresholds,Comparison of HbA1c (percent) for each subject at baseline and following sample storage of 2 years to assess HbA1c measurement stability.,,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2493,NCT02918591,Change of Soluble Klotho,Change of HbA1c,,2017-11,UNKNOWN,INTERVENTIONAL,['NA']
2494,NCT02445079,Baseline prevalence and incident change in carotid intima media thickness,Baseline prevalence and incident change in chronic obstructive pulmonary disease,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
2495,NCT00288977,independence from insulin injections with adequate control of blood glucose in subjects with Type 1 diabetes at one year post final transplant,,,2000-09,COMPLETED,INTERVENTIONAL,['NA']
2496,NCT00305604,Change From Baseline in HbA1c (Hemoglobin A1c) at Week 24,Rapidity of Onset of Action as Determined by Home Glucose Monitoring After 1 Week,,2006-03-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2497,NCT04216849,UACR,eGFR,,2020-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2498,NCT01174381,Proportion of participants who change their lifestyle characteristics related to NCDs,Proportion of participants with decrease in Body Mass Index following lifestyle modification programme,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
2499,NCT04569630,Accuracy of the HEADWIND-model: Diagnostic accuracy of the hypoglycemia warning system (HEADWIND) in detecting hypoglycemia (blood glucose < 3.9 and < 3.0 mmol/l) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Perceived working alliance with IVA,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
2500,NCT04976426,multidimensional network biomarkers,,,2022-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2501,NCT02945332,Miles walked,Waist circumference change,Food consumption change,2016-10,COMPLETED,INTERVENTIONAL,['NA']
2502,NCT06062069,Compare the effect of CT-868 versus placebo on change in HbA1c (%) from baseline,Change in insulin doses from baseline when comparing CT-868 to placebo.,Time in hyperglycemia as per CGM metrics.,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
2503,NCT02224742,Healing,,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2504,NCT01521520,,,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
2505,NCT00922194,Change in Glycosylated Haemoglobin (A1C) From Baseline at 12 Months or More,,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
2506,NCT04049149,Incidence of any diabetes-related micro/macrovascular endpoints (Part 3 of study),Changes in patient's Depression Anxiety Stress (Part 3 of study),,2020-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2507,NCT03072407,"the number of AEs and the finding from the physical examination, the abnormal lab results",Disposition Index,,2015-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
2508,NCT00878891,Percent of time in normoglycemia (0.8 - 1.10 g/L),Adverse events due to the device,,2009-04,TERMINATED,INTERVENTIONAL,['NA']
2509,NCT01461330,Change from Baseline in Blood Pressure at 4 weeks,Change from Baseline in glucose control at 4 weeks,,2011-02,TERMINATED,INTERVENTIONAL,['NA']
2510,NCT01037842,the change in HbA1c from randomization to endpoint,the proportion of subjects with HbA1c <7% after 16 weeks of treatment and the change in FPG and 2-hr postprandial glucose (PPG) from baseline,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2511,NCT03349684,Absolute change in the levels of glycosylated hemoglobin (HbA1c),Number of participants with adverse events,,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2512,NCT01591681,Hypoglycemia Outcome: Percentage of Nights With Sensor Glucose Value </=60 mg/dl,Percent of Nights With Sensor Glucose >250 mg/dL,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2513,NCT05409391,mean daily blood glucose concentration,glycemic variability,,2022-06-15,COMPLETED,INTERVENTIONAL,['NA']
2514,NCT04697485,Change in NT-proBNP,Compliance,,2021-01-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2515,NCT04677127,Glycemic Control Change,Self-Efficacy Questionnaire,,2019-06-17,COMPLETED,INTERVENTIONAL,['NA']
2516,NCT05954819,Change of Diabetes Self-Management,,,2023-07-28,COMPLETED,INTERVENTIONAL,['NA']
2517,NCT02838784,Ulcer recurrence,Number of grafts and graft size(s),Health economic outcomes,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
2518,NCT03486223,Insulin Sensitivity,Renal Plasma Flow (RPF),Soluble Epoxide Hydrolase Activity in Tissue,2018-05-17,COMPLETED,INTERVENTIONAL,['PHASE2']
2519,NCT01814137,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Fasting Plasma Glucose (FPG),,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2520,NCT03208751,Change in VO2peak in ml/kg/min,Change in max. Watts/kg bodyweight,,2011-04-01,UNKNOWN,INTERVENTIONAL,['NA']
2521,NCT02977598,"Atherogenic index of plasma (AIP) values compared with glucose metabolism parameters like HbA1c, Fasting Plasma Glucose and 2-hour plasma glucose levels.",,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
2522,NCT01223651,Accuracy of continuous glucose monitoring system (CGMS).,The effect of altitude on the recognition of hypoglycaemic symptoms.,,2012-01,TERMINATED,INTERVENTIONAL,['NA']
2523,NCT00653185,Change from baseline in glycosylated hemoglobin,Body weight,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2524,NCT03636243,Reactive Hyperemia Index (RHI),study of the peri-aortic and peri-brachial adipose tissue (TAPV),,2019-10-15,RECRUITING,INTERVENTIONAL,['NA']
2525,NCT05559515,A1C,return to normoglycemia,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
2526,NCT00390637,For adults: body weight loss maintenance,For Children: Change in BMI-Z-score,For adults: Identify traits gene - diet interactions that determine responses to the dietary intervention.,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2527,NCT02790957,Wound healing rate,Incidence of adverse events and reactions,,2016-06,TERMINATED,INTERVENTIONAL,['PHASE2']
2528,NCT03694145,Proportion of patients accurately diagnosed with retinopathy,,,2018-10-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2529,NCT02176278,Attainment of at least 3 treatment targets,Incidence of all-diabetes related endpoints,Changes in albuminuria,2014-06,COMPLETED,INTERVENTIONAL,['NA']
2530,NCT00622271,"Enroll patients and their families into either a treatment group or a wait list control (WLC) group to determine the impact of a peer and family-based group intervention on improving adjustment, coping, and functioning among adolescents with diabetes.",Diabetes-related medical improvements from baseline to post-treatment and maintained at 4 months and 6 months post-treatment.,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
2531,NCT01111955,Lowering of fasting plasma glucose (FPG) throughout the study to see if there is a decrease from baseline,"Pharmacodynamics (measuring daily glucose, glucose AUC, HbA1c, lipid profiles, HPA markers, free testosterone, and SHBG)",,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2532,NCT02173067,varition in blood glucose levels during oral surgery with local anaesthesia (lidocaina and lidocaine with epinephrine),Hemodynamic effects during the surgery with local anesthetia (lidocaine and lidocaine with epinephrine),Anxiety levels during the oral surgery with local anesthesia (lidocaine and lidocaine and epinephrine),2009-09,COMPLETED,OBSERVATIONAL,['NA']
2533,NCT00277277,Body weight at 8 weeks; Body Mass Index at 8 weeks; Diabetes outcomes at 8 weeks,Hip/waist circumference at 8 weeks; Energy and nutrient intake at 8 weeks; Physical activity at 8 weeks,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
2534,NCT02257190,Glycemic control,Insulin sensitivity,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
2535,NCT05081921,Change in the International Knee Documentation Committee (IKDC 2000),Change in ultrasonographic findings in knee joint,,2022-01-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2536,NCT02111226,Blood Pressure,Blood Pressure,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
2537,NCT01908348,Endothelial function,,,2013-07-18,COMPLETED,INTERVENTIONAL,['NA']
2538,NCT03785275,Beta cell mass,Beta cell mass vs. beta cell function,,2017-12-06,TERMINATED,OBSERVATIONAL,['NA']
2539,NCT06222775,Glycated hemoglobin,Changes in Medication cholesterol,,2023-12-04,RECRUITING,INTERVENTIONAL,['NA']
2540,NCT00629304,Comparison of HbA1c mean between the 3 groups,"Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2541,NCT00717288,Patients With Morning (AM) Glucose Between 80-130 mg/dl on Day 2 and 3,Reversion to Intravenous Insulin for Failure of Glycemic Control,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2542,NCT01038648,1. Rate of conversion of IGT to diabetes. 2. Relative reduction of incidence of diabetes by Sitagliptin among people with IGT compared to Placebo. 3. Increase in reversal of IGT to NGT,1. Beneficial effects in beta cell function. 2. Changes in insulin resistance 3. Improvement in cardiovascular risk factors by Sitagliptin.,,2011-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2543,NCT04604548,Treatment Emergent Adverse Events (TEAE),Heart rate (bpm),,2021-08-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2544,NCT04104243,Comparison of Engagement and Retention of Men vs Standard Diabetes Prevention Program,Compare change in hemoglobin A1c over 6 months,,2021-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2545,NCT01077570,Number of serious adverse drug reactions (SADRs) including major hypoglycaemic (low blood sugar) events,Change in postprandial blood glucose (PBG),,2010-03,COMPLETED,OBSERVATIONAL,['NA']
2546,NCT01552603,Mean Percent of Time in Target Blood Glucose Range,Mean Deviation From Target Blood Glucose,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2547,NCT03490942,Plasma Epinephrine,,,2018-03-15,TERMINATED,INTERVENTIONAL,['PHASE2']
2548,NCT01217476,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Origin After a Maximum of 12 Weeks Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition to Best Local Cares",Relative Wound Area Regression of 40% or More at 6 Week,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2549,NCT00854503,Glucose tolerance assessed by HbA1c and fasting glucose,insulin-resistance assessed by clamp. Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers.,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2550,NCT01354015,Change in HbA1c,Change in HbA1c Over 3 Months,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
2551,NCT00353600,,,,1994-08-19,COMPLETED,OBSERVATIONAL,['NA']
2552,NCT01996995,complete cure of the target nail,Change surface healthy target nail / all clinically infected toes patients free of hyperkeratosis,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2553,NCT02101151,glycemic control,Obesity Parameter,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
2554,NCT04588259,Change From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol]),Number of Treatment Emergent Hypoglycaemic Episodes Classified Both According to the ADA Definition and NN Definition: Hypoglycaemic Episodes From 2 Hours (Exclusive) to 4 Hours (Inclusive) After Start of Meal,,2020-10-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2555,NCT02973477,Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride.,Change in B-type Natriuretic Peptide With Each Intervention as a Measure of Left Ventricular Function,Glucose Variability,2017-01-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2556,NCT06064058,HBA1C,,,2023-01-30,COMPLETED,INTERVENTIONAL,['NA']
2557,NCT05762432,Reduction in Wound Area,Dressing Changes,,2024-02-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2558,NCT01122979,Proportion of patients that reach the target of HbA1c ≤7% without confirmed nocturnal hypoglycaemia in each treatment group and the respective CI 90%.,Creatinine clearance variation,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2559,NCT03528707,liver stiffness (LS),cytokines levels,,2015-04-14,COMPLETED,INTERVENTIONAL,['NA']
2560,NCT06236334,Diabetes risk based on HbA1c level (mmol/mol),"Habitual food intake (frequencies, number and grams)",,2024-02,RECRUITING,INTERVENTIONAL,['NA']
2561,NCT00067678,,,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2562,NCT00732524,The primary outcome was the patients' ability to avoid repeat ED visits or hospitalization in either of the discharge regimens.,The secondary outcomes included the number of subjects who reached a fasting or pre-meal BG goal of 80 to 130 mg/dl and assessment of the beta cell function at the beginning and end of the study as measured by C-peptide levels during OGTT testing.,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2563,NCT00367445,Variability of blood glucose over a period of 72 hours,Insulin pharmacokinetics,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2564,NCT01809288,"Determine if there are differences in African, African-American and white women in the relationship between triglyceride levels, (a frequently used screening test for diabetes and heart disease) glucose tolerance status and insulin resistance.",Determine if there are race or ethnic differences in the pancreatic secretion of insulin relative to the degree of insulin resistance.,,2013-09-26,COMPLETED,OBSERVATIONAL,['NA']
2565,NCT00486629,Excessive weight gain during pregnancy,"macrosomia, requirement of delivery procedures",,2004-07,RECRUITING,INTERVENTIONAL,['NA']
2566,NCT05276401,To Assess the Number of Participants With Treatment-related Adverse Events After Nu-3 Gel Use on cDFU as Assessed by CTCAE v4.0,,,2022-03-11,TERMINATED,INTERVENTIONAL,['PHASE2']
2567,NCT06002997,Number of pregnant women with Periodontal disease,Percantage of HbA1C (Glycosylated haemoglobin),,2012-05-03,COMPLETED,OBSERVATIONAL,['NA']
2568,NCT03002116,Mean foot tissue temperature,,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
2569,NCT04880291,Safety and tolerability following single ascending doses of GFB-024,Characterize the incidence and persistence of immunogenicity of GFB-024 following repeated doses,,2021-05-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2570,NCT02480465,The mean percent change of HbA1c,"Safety evaluation - physical examination, vital sign, laboratory, adverse event",,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2571,NCT00529815,This study will determine if a real-time continuous glucose monitoring system is a more effective method of improving glycemic control in patients with type 2 diabetes than is episodic self blood glucose monitoring in the both the short- and long-term.,"The results of this study could also provide information on the impact of the two methods of glycemic monitoring on number of hypoglycemic and hyperglycemic events, and quality of life.",,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
2572,NCT00690638,To demonstrate changes in HbA1c,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2573,NCT05219812,Change in weekly mean 24-hour average pain intensity score using the 11-point Numeric Rating Scale (NRS) from baseline to the end of intervention,Number of participants with treatment emergent adverse events (TEAE),,2022-02-16,COMPLETED,INTERVENTIONAL,['PHASE2']
2574,NCT02081014,Serious Adverse Events,Glucose Tmax (Post-insulin),,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2575,NCT00214786,Achievement of Insulin Independence at 12-month Post Transplant,The Quality of Life of the Recipients Measured With the RAND 36-item Short Form Health Survey,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
2576,NCT01137812,Change in HbA1c From Baseline to Week 52,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2577,NCT00044148,,,,2002-07-16,COMPLETED,INTERVENTIONAL,['PHASE2']
2578,NCT00468117,Proportion of patients w/HbA1c </= to 6.5% and an absence of severe hypoglycemic events or a reduction in HbA1c of at least 1 point and an absence of severe hypoglycemic events,"Reduction in insulin requirements, HbA1c, MAGE, LI, HYPO score, fasting glucose, beta score, serum creatinine, c-peptide levels, MMTT, Clarke Survey, FSIGT, CGMS, number of hypoglycemic events, renal impact, cardiovascular impact, and quality of life",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2579,NCT02808182,whole-body organ-specific DFA partitioning,Lipoprotein lipase activity,,2017-01-17,COMPLETED,INTERVENTIONAL,['NA']
2580,NCT03689374,Change From Baseline in Glycated Haemoglobin (HbA1c),Change From Baseline to Week 52 in Diabetes Quality of Life Clinical Trial Questionnaire (DQLCTQ-R): Scores From the 8 Domains,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2581,NCT04159922,Score of the Bortner self-questionnaire,,,2019-12-03,COMPLETED,OBSERVATIONAL,['NA']
2582,NCT01242137,HbA1c,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
2583,NCT06134986,Change in percent body weight,Change in ketones,,2023-11-20,RECRUITING,INTERVENTIONAL,['NA']
2584,NCT04335565,Postprandial glucose levels,Subjective feelings of satiety,,2020-03-03,WITHDRAWN,INTERVENTIONAL,['NA']
2585,NCT01364298,Change From Baseline in Average Numeric Pain Intensity Scale (NPIS) Score at Day 84,Number of Participants With Adverse Events (AEs),,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2586,NCT00427986,"Retinal thickness estimated by the fast protocol of the StratusOCT (0, 2, 4, 8, 10, 15, 20, 30, 60, 90, 120 and 180 min).","Side effects during the three-hour examination period, to evaluate if caused by galactose per se or by an increase in intracapillary osmotic pressure.",,2007-01,TERMINATED,INTERVENTIONAL,['NA']
2587,NCT01751360,Blood Glucose,,,2013-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2588,NCT03509441,Assessing level of edema via T2 mapping,Urine test for creatinine levels,,2015-01-15,COMPLETED,OBSERVATIONAL,['NA']
2589,NCT01232946,Myocardial Fatty Acid Esterification Rate,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2590,NCT01094418,Nerve conduction parameters,Clinical neuropathic scoring system,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
2591,NCT04023539,Glycated hemoglobin,Blood pressure,,2019-09-04,COMPLETED,INTERVENTIONAL,['NA']
2592,NCT03328845,Oxidative stress markers with the new slow insulin analogues,Diabetes treatment satisfaction questionnaire (DTSQ).,,2017-01-20,COMPLETED,INTERVENTIONAL,['PHASE4']
2593,NCT04297592,Periprosthetic joint infections,Wound complication,,2020-06-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
2594,NCT02695082,Incidence of Acute Kidney injury (AKI),,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
2595,NCT01294423,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Body Weight,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2596,NCT05610046,Glycaemic response (Matsuda index),Gutt insulin sensitivity index,,2023-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2597,NCT02169570,Change in chest X-ray,Change in Random Blood Sugar (RBS),,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
2598,NCT06252038,Weight change across 12 months,CDC-NDPP Physical Activity Goal,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2599,NCT03522870,Glycosylated Hemoglobin A1c,EQ-5D-5L,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
2600,NCT06140485,Comparing the mean change in HbA1c levels between the experimental arm and the active-control arm,Comparing the mean change in weight between the experimental arm and the active-control arm,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2601,NCT00881543,"secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets",Washout of dipeptidyl peptidase IV inhibitors after one month without the drug,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
2602,NCT00875459,The frequency of occurrence of hypoglycemia measured quarterly over one year.,"Changes in total daily:prandial insulin dose, insulin dose, body weight, insulin antibody titers, the effects of insulin antibodies on glycemic control, individual and group mean %HbA1c measured quarterly and over one year.",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2603,NCT00603499,Reduction in the systolic and diastolic blood pressures,Average increase of serum magnesium levels Changes in lipid profile,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2604,NCT02256293,Acceptability,Diabetes self-management,,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2605,NCT05757713,"Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)",CD3 receptor occupancy,,2023-07-25,RECRUITING,INTERVENTIONAL,['PHASE4']
2606,NCT01114438,Change From Baseline in SF 36v2 Quality of Life Assessment,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
2607,NCT06265181,Type 2 Diabetes Self-Management Scale,Introductory Features Form,,2024-03-27,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2608,NCT02347553,To measure changes in electrolyte levels and QT interval on electrocardiography between hypoglycaemic and euglycaemic states,,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
2609,NCT05581043,Blood glucose following the OGTT,"Plasma concentrations of 3-OHB, insulin, C-peptide, glucagon like peptide-1 (GLP-1), cholecystokinin (CCK), acetaminophen, free fatty acids along others.",,2023-01-12,COMPLETED,INTERVENTIONAL,['NA']
2610,NCT00707434,Mean Relative Difference in Patient Glucose Monitoring: Continuous Glucose Monitoring (CGM) Device as Compared With Point of Care (POC) Glucose Testing,,,2008-06,TERMINATED,INTERVENTIONAL,['NA']
2611,NCT06232421,Number of patients with trophic ulcers cured,percentage reduction in the non-epithelialized area of the wound surface in relation to the initial one,,2024-02-08,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2612,NCT00318656,Episodes of Hyperglycaemia (>126 mg/dL) at Baseline Compared to After 12 Weeks on Treatment,"Glycaemia According to CGMS (MAGE), mg/dL",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2613,NCT02730949,efficacy of DCI oral supplementation on metabolic control,Insulin Requirement (I.R.) IU/kg,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2614,NCT00381134,Change in 24 hour urine albumin to creatinine ratio after 12 months of treatment,plasma aldosterone level,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2615,NCT01756196,episodes of systemic reactions after spinal steroid injection,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
2616,NCT06117358,Prevalence of Pre-Diabetes in Overweight and Obese children and adolescents in Assiut governorate,,,2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2617,NCT04537520,Wound area,,,2020-07-02,COMPLETED,INTERVENTIONAL,['NA']
2618,NCT04089462,Percentage of time spent in the hypoglycemic range (CGM <3.9 mmol/l),Question about patient preference regarding the two study arms,,2019-09-30,COMPLETED,INTERVENTIONAL,['NA']
2619,NCT06218992,MMP-9,Thermal imaging: Ocular surface temperature (OST),,2023-12-30,RECRUITING,OBSERVATIONAL,['NA']
2620,NCT04176276,Urine expression of miR-25,,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
2621,NCT04738799,"Change in time in range, under controlled conditions","Change in satiety, as measured by Visual Analog Scale (VAS)",,2021-04-29,COMPLETED,INTERVENTIONAL,['NA']
2622,NCT00385697,Mean HbA1c Change From Baseline in Segment 1,Mean HbA1c Change From Baseline in Segment 1,,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2623,NCT02057861,reversal of diabetic patients,hemodynamic changes,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2624,NCT03721874,Change in nightly substrate oxidation measured as respiration quotient (RQ) during the sleeping period,Change in systolic and diastolic blood pressure,,2019-04-30,COMPLETED,INTERVENTIONAL,['PHASE4']
2625,NCT04945070,HbA1C,Treatment Satisfaction,hsCRP,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
2626,NCT04810676,Cmax of CKD-383,CL/F of CKD-383,,2021-04-16,COMPLETED,INTERVENTIONAL,['PHASE1']
2627,NCT00442845,Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.,Change from baseline in apolipoprotein-B (Apo-B) and change from baseline in glycosylated hemoglobin (HbA1c) was assessed at 12 weeks.,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2628,NCT02007577,Quantification of Insulin Action With the Insulin Suppression Test (IST),Quantification of Insulin Clearance With the Graded Glucose Infusion Test (GGIT),,2010-07,COMPLETED,INTERVENTIONAL,['NA']
2629,NCT01148238,T-reg,"HLA, anti-GAD, anti-IA2, white blood count, CRP, fasting C-peptide, HbA1c",,2012-08,WITHDRAWN,OBSERVATIONAL,['NA']
2630,NCT05950282,"Assessment of Fasting Insulin levels and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores among different groups stratified by age, sex, race/ethnicity, BMI, and PCOS (Polycystic Ovary Syndrome) diagnosis.","Identify any significant interactions or relationships between the primary outcomes (Fasting Insulin and HOMA-IR) and the demographic and clinical factors, including age, sex, race/ethnicity, BMI, and PCOS diagnosis.",,2023-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2631,NCT02481596,Adherence to Diet - Problem Eating Behavior,Diabetes Self-efficacy,,2016-05-23,COMPLETED,INTERVENTIONAL,['NA']
2632,NCT00414986,HEDIS-like measures of acute phase management of depression,Patient report (by survey) of their primary care experience,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
2633,NCT01850810,Hunger,Prospective Consumption,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
2634,NCT00288678,"Through the health manager's coordination and consultation, diabetic patients will have better glycemic control for fasting plasma glucose, HbA1c, and blood cholesterol level.","Patients in the intervention group will have better health status such as lower hospitalization rate, shorter length of stay in hospitals, and fewer diabetic complications.",,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2635,NCT00888836,"To assess the efficacy of bariatric surgery in inducing partial or total remission of type 2 diabetes mellitus, as compared to standard medical anti-diabetic care (STC).","Secondary endpoints include percentage change of fasting plasma glucose levels, glycated hemoglobin, weight, waist circumference, blood pressure, cholesterol, HDL-cholesterol and triglycerides, hard cardiovascular risk and quality of life.",,2009-04,COMPLETED,INTERVENTIONAL,['NA']
2636,NCT06137469,Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.：(AUC0-300min),Immunogenicity indicators: anti-Noiiglutide antibodies,,2023-12-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2637,NCT00380445,To explore whether vildagliptin augments insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal in patients with type 2 diabetes,To measure the effects of vildagliptin on tissue carbohydrate metabolism (skeletal muscle),,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2638,NCT03416127,Glycosylated Hemoglobin (A1C),Diastolic Blood Pressure,,2018-01-30,COMPLETED,INTERVENTIONAL,['PHASE2']
2639,NCT00730392,The primary end points of this study are percent change from baseline for HbA1c and C-peptide area under the curve (AUC).,"Secondary end points are insulin dose and number of insulin injection discontinued, if any",,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2640,NCT03640221,Muscle sympathetic nerve activity (bursts/minute),Arterial baroreflex gain.,,2018-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2641,NCT00104182,HbA1C,Blood glucose,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2642,NCT01980524,MYCL,Ejection Fraction,Stroke Volume,2013-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2643,NCT05187806,Comparison of the pretest-posttest Diabetes Self-management Instrument-35 scores,Comparison of the pretest-posttest HbA1c values,,2017-02-07,COMPLETED,INTERVENTIONAL,['NA']
2644,NCT00350103,Change in Average Daily Pain Score From Baseline Week to the Last 4 Weeks of the Maintenance Phase,Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale Scores at Visit 8,,2006-06-30,COMPLETED,INTERVENTIONAL,['PHASE3']
2645,NCT04673656,Changes in HOMA-IR,Changes in fasting insulin,,2021-04-18,COMPLETED,INTERVENTIONAL,['NA']
2646,NCT05334173,Excess Weight Loss (%EWL),Remission or improvement of Obstructive Sleep Apnea Syndrome,Quality of life after surgery,2019-01-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2647,NCT05257460,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on continuous glucose monitoring (CGM),Total bolus insulin dose (units/day),Utility evaluation is the frequency and duration of use of the closed-loop system at home,2022-01-25,COMPLETED,INTERVENTIONAL,['NA']
2648,NCT03631108,Iris Vessel Geometric Characteristics,,,2018-10,UNKNOWN,OBSERVATIONAL,['NA']
2649,NCT00287404,,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
2650,NCT01102959,Number the answers correct or incorrect on carbohydrate counting in portions of real food,,,2010-03,UNKNOWN,INTERVENTIONAL,['NA']
2651,NCT05944549,Percent weight loss,Change in food security as assessed by the National Health Interview Survey(NHIS) Food Insecurity Screener,,2023-05-12,RECRUITING,INTERVENTIONAL,['NA']
2652,NCT02568280,Mean change in plasma glucose concentration,Area under the serum insulin aspart concentration-time curve,,2015-10-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2653,NCT02012972,NCDs and NCD risk factors in the study population by time on ART,Changes in NCD risks or prevalence,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
2654,NCT02715791,Diabetes self-efficacy,Physical Activity,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
2655,NCT00424411,Primary outcome is 24 week change in baseline in HbA1c.,Patient satisfaction and preference.,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2656,NCT00157729,"Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on metabolic function as measured by insulinemia, fasting serum glucose, glycated hemoglobin, and triglycerides.",mean changes in creatinine,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2657,NCT01473147,Mean amplitude of glycaemic excursions (MAGE),homeostasis model assessment(HOMA),,2011-10,COMPLETED,INTERVENTIONAL,['NA']
2658,NCT05810545,Maternal health - Gestational diabetes mellus,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
2659,NCT00717158,Health Care utilization and costs using claims data,Change in quality of life,,2001-05,COMPLETED,INTERVENTIONAL,['NA']
2660,NCT05333393,Blood Glucose Levels,Regulating the Nutrition of Children according to their blood sugar level,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
2661,NCT01643967,Evaluate the efficacy and safety of ozone released by the device Philozon Medplus in the treatment of patients with diabetic foot.,Evaluate the release of ozone in the environment by equipment MEdplus after insufflation rectal in patients with diabetic foot.,,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
2662,NCT01005069,Reduction of venous Fasting Plasma Glucose from baseline,Change in lipid profile from baseline,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2663,NCT00207233,Change in expression of selected adipocyte metabolic genes,,,2004-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2664,NCT02672748,Adult BMI change,child BMI z-score change,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
2665,NCT00482976,"Improvement in selective measurements of oxidative stress, endothelial activity and vascular abnormalities which will correlate with PKC activity in the peripheral monocytes.",Safety of ruboxistaurin,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2666,NCT02181842,Blood Glucose-Related Laboratory Parameters (HbA1c Values) at Each Time Point,Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs),,2009-01-26,COMPLETED,OBSERVATIONAL,['NA']
2667,NCT03562767,Percentage of Participants That Are Enrolled and Attend the Study the Study Sessions Compared to Enrolled,Change in Diabetes Health Belief Scale,,2018-12-05,TERMINATED,INTERVENTIONAL,['NA']
2668,NCT04005287,"Incidence and Treatment-Emergent Adverse Events as assessed by a dermal assessment (Draize score (scale 0.0 - 4.0) score of skin erythema, edema, pruritus and dryness score) of the dosing area",Norfolk Quality of Life Measure (QOL) Patient Questionnaire,Patients' Global Impression of Change,2019-10-15,COMPLETED,INTERVENTIONAL,['PHASE2']
2669,NCT01106677,Change in HbA1c From Baseline to Week 26,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2670,NCT06251895,SII,readmission,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
2671,NCT02322268,Glycemic control,Lipid profile,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
2672,NCT01542489,Change in HbA1c (glycosylated haemoglobin),Number of adverse events,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
2673,NCT05038137,Assess feasibility and adherence to time period of eating recommendations in both study groups.,Continuous Glucose Monitor (CGM) derived metrics,,2022-05-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2674,NCT01449019,The incretin effect,Plasma concentrations of Glucose-dependent insulinotropic polpypeptide (GIP),,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2675,NCT02073188,Proportion of participants performing at least 30% of the recommended Self-Monitoring Blood Glucose tests after 6 months from randomization,Type of overall contacts between centers and participants,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2676,NCT01923389,Number of Participants With Positive Anti-PF-05231023 Antibodies and Neutralizing Antibodies.,Observed Accumulation Ratio (Rac) for Cmax and AUCtau of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold),,2013-09,TERMINATED,INTERVENTIONAL,['PHASE1']
2677,NCT05377385,Usability of and problems encountered with the Omnipod Dash insulin administration system,Metabolic control of type 1 diabetes mellitus,,2022-04-13,COMPLETED,OBSERVATIONAL,['NA']
2678,NCT03528720,The earliest and most frequently occurring fundus quadrant of diabetic retinopathy in fundus fluorescein angiography.,,,2017-06-13,COMPLETED,OBSERVATIONAL,['NA']
2679,NCT02308254,Blood Pressure,Blood glucose concentration,Stroke volume,2013-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2680,NCT02308800,"Compare clinical outcomes (time to wound healing, number of surgeries) with Negative Pressure Wound Therapy with irrigation and Negative Pressure Wound Therapy without irrigation.",Compare quantitative cultures (bacterial load as measured by qPCR) and number of clinical infections in patients treated with NPWT with irrigation compared to conventional NPWT.,Compare responses to the HR-QOL questionnaires of patients treated with NPWT with irrigation compared to conventional NPWT.,2015-01,WITHDRAWN,INTERVENTIONAL,['NA']
2681,NCT06028503,Reduction in Hemoglobin A1C,Health literacy,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2682,NCT04725630,Blood glucose levels via hemoglobin A1C,Diabetes Competing Demands scores,Proportion of energy from ultra-processed foods,2021-05-29,RECRUITING,INTERVENTIONAL,['NA']
2683,NCT00845156,Insulin Resistance,,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
2684,NCT06068205,"In 48 subjects with type 1 diabetes with and without microvascular complications, the average stiffness of red blood cells, measured using atomic force microscope and quantified using Young's modulus, will be measured.",,,2023-09-29,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2685,NCT01755494,Area under plasma concentration time curve (AUC) for metformin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets,"Safety and tolerability assessment based on medical review of AE reports:physical examination, ECG, heart rate, blood pressure, lab test",,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
2686,NCT00521820,Progression of Congestive Heart Failure.,All cause mortality.,,2000-06,TERMINATED,INTERVENTIONAL,['PHASE3']
2687,NCT05847075,Plasma HSP72,Inflammatory/anti-inflammatory markers,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2688,NCT04595370,Percent change from baseline in UACR at 12 weeks,Percent change from baseline in UACR at 12 weeks to assess dose-response relationship,Change from baseline in eGFR over time,2021-01-26,COMPLETED,INTERVENTIONAL,['PHASE2']
2689,NCT05050266,Engagement in virtual care for preventive services,Participation and engagement: ROSE,,2021-10-21,RECRUITING,INTERVENTIONAL,['NA']
2690,NCT00466362,,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA']
2691,NCT06190808,Mean Absolute Relative Difference (MARD).,Adverse event nature and frequency,,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2692,NCT02150889,Differences in insulin sensitivity between groups,Differences in fitness level between groups,Differences in body composition between groups,2014-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2693,NCT01518166,Area under the curve of digoxin,Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2694,NCT00713011,Change in Proteinuria,Change in index of glycemia (HbA1c),,2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2695,NCT05524987,Effectiveness outcome: Systolic Blood Pressure,Effectiveness outcome: HbA1c,Implementation outcome: Sustainability,2023-03-20,RECRUITING,INTERVENTIONAL,['NA']
2696,NCT02463500,Adverse Events,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
2697,NCT05961163,"Composite index of nausea, vomiting, tiredness/fatigue, vertigo, circulation problems/syncopes, muscle cramps, headache, extrasystoles, palpitations, edemas, shortness of breath, depressive mood, anxiety, mental confusion","Reasons for drop out (eg, bad health condition, hospital admission, death)",,2023-07-24,TERMINATED,OBSERVATIONAL,['NA']
2698,NCT04542148,Time In Range,Umbilical cord blood surfactant protein D (SP-D),,2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE2']
2699,NCT00373269,FVIIa,TF-PCA,,2001-10,COMPLETED,OBSERVATIONAL,['NA']
2700,NCT04536285,Prognosis of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.,Presentation of diabetes and its acute complications among pediatric and adolescent patients with type 1 diabetes during COVID-19 Pandemic in Egypt,,2020-05-01,COMPLETED,OBSERVATIONAL,['NA']
2701,NCT01962701,Fetal plasma copeptin concentration,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2702,NCT02212665,Changes in insulin sensitivity,Patient-reported outcome measure,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2703,NCT02556554,Change(s) in Behavior and/or Concerns of Diabetics.,Evaluation of Maternal and Fetal Outcomes.,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
2704,NCT00295555,Normalization of high blood pressure,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2705,NCT03436693,The proportion of subjects with a decline in estimated glomerular filtration rate (eGFR) from baseline at Week 104,Change from baseline in urine albumin-to-creatinine ratio (UACR) at each assessment time point,,2018-02-15,COMPLETED,INTERVENTIONAL,['PHASE3']
2706,NCT05631054,Best corrected visual acuity at the last follow-up,The occurrence of vitrectomy for the fellow eye,,2022-11-10,RECRUITING,OBSERVATIONAL,['NA']
2707,NCT05230589,Change in Glycated haemoglobin (HbA1c ),"DTSQs, (Diabetes Treatment Satisfaction Questionnaire, status) change in absolute treatment satisfaction",,2022-01-11,RECRUITING,OBSERVATIONAL,['NA']
2708,NCT00325962,To compare oral 6R-BH4 to placebo with respect to change from baseline in arterial systolic blood pressure after 8 weeks of treatment in subjects with poorly controlled hypertension.,To assess the safety of oral dosing of 6R-BH4 in subjects with poorly controlled hypertension,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2709,NCT01789021,Differences in accuracy between blood glucose monitoring systems across the overall tested glucose range by comparing the mean absolute value of relative (percent) difference (MARD) between the meter value and the reference value,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
2710,NCT03928340,2 hours post prandial blood sugar measurement.,neonatal Intensive care admission,,2019-04-29,COMPLETED,INTERVENTIONAL,['PHASE4']
2711,NCT05398783,Mean difference and limits of agreement between measured and predicted BSA,,,2022-10-25,RECRUITING,OBSERVATIONAL,['NA']
2712,NCT03654989,"Comparison of wound closure between the 3 groups: iontophoresis of treprostinil, iontophoresis of placebo, and standard of care, over12 weeks.",Evaluation of safety via the appearance of the wound,,2020-01-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2713,NCT01463449,Low grade inflammation in adipose tissue after weight loss induced by gastric bypass,Quantity of fat in the liver,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
2714,NCT01206647,percentage of patients with stable HbA1c,impact of the switch on:,,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
2715,NCT01610219,Change in Dietary Intake,Change in Parent BMI,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
2716,NCT05441267,Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+),Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE),,2023-03-13,RECRUITING,INTERVENTIONAL,['PHASE4']
2717,NCT03580967,Change in depressive symptoms measured by Hamilton Depression Rating Scale (HAM-D),,,2019-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2718,NCT05204134,Severe Hypoglycemic Events,Patient Reported Outcomes,,2022-03-24,COMPLETED,INTERVENTIONAL,['NA']
2719,NCT02207777,Changes in hepatic insulin sensitivity,Changes in fat free mass,,2014-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2720,NCT06037538,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-04-19,COMPLETED,INTERVENTIONAL,['NA']
2721,NCT00343603,,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
2722,NCT00517465,Glucose AUC,Pharmacokinetic parameters,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2723,NCT01852968,alterations in hippocampal glucose transport kinetics,alterations in hippocampal neurochemistry,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
2724,NCT05147324,Change in percent time in range,Change in hemoglobin A1c percentage,,2021-12-13,COMPLETED,INTERVENTIONAL,['NA']
2725,NCT03992248,Hepatic glycogen,Insulin sensitivity,,2019-01-31,COMPLETED,INTERVENTIONAL,['NA']
2726,NCT05481944,Left ventricular myocardial longitudinal strain measured by MRI (%),Epicardial fat volume measured from ECG gated Dixon MRI images,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2727,NCT01580917,Latency time after occlusive loading,Response time to Maximum Flow,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
2728,NCT01074801,The primary outcome measure is time spent with plasma glucose concentration in the target range (3.9-10.0 mmol/L) between 24:00 on Day 1 to 08:00 on Day 3.,Secondary outcomes will include: (i) Total and basal insulin delivery between 24:00 on Day 1 and 08:00 on Day 3 (36 hours) (ii) CGM glucose levels between 24:00 on Day 1 and 08:00 on Day 3 (36 hours),,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2729,NCT00636766,Ultrasound and immunohistochemical parameters of plaque stability; novel cardiovascular risk factors,Long-term cardiovascular outcomes,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
2730,NCT03813316,The percentage of participants achieving an A1C value of ≤ 7% at 24 weeks,The percentage of participants on antihypertensive therapy at Week 24.,,2019-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2731,NCT01398423,Safety,Efficacy,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2732,NCT00439101,To determine if daily administration of megestrol acetate (MA) for 3 months compared to placebo prevents weight loss or improves weight gain in children with cancer-associated anorexia-cachexia.,To evaluate toxicities associated with MA in pediatric oncology subjects.,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
2733,NCT00485056,The primary endpoint will be the TDI E' ratio which is the relatively preload independent measure of ventricular diastolic function.,E/E' measured by TDI (a non-invasive measure of preload).,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2734,NCT01689051,Femoral artery blood flow,Leg glucose uptake,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
2735,NCT02108353,Efficacy (AUC),Efficacy AUC insulin 12 weeks,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2736,NCT01086150,Pain Scores From Composite Visual Analog Scale,"Keratinocyte Immunoreactivity of Nav1.6, Nav1.7, CGRP",,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2737,NCT03165240,Percentage of patients with drug related Adverse Events (AEs),Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in daytime (10-hour) urine,,2017-10-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2738,NCT03718715,change from baseline in the fecal microbiota composition by detecting bacteria families with help of relative abundance (%) and diversity metrics,correlation between microbiota and beneficial glucose lowering response,,2019-02-20,UNKNOWN,OBSERVATIONAL,['NA']
2739,NCT00398853,Insulin Sensitivity as assessed with hyperinsulinemic-euglycemic clamps,"body weight and fat distribution, myocellular and intrahepatic lipid content as assessed with MRS scans",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2740,NCT03887416,Changes in nighttime blood pressure,Changes in HBA1C,,2019-04-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
2741,NCT06217887,Change of olfactory brain activation by fMRI,Change of metabolism,,2020-05-10,RECRUITING,INTERVENTIONAL,['NA']
2742,NCT00949169,We compared prevalence of large artery stenosis according to carotid IMT group and evaluated whether maximal IMT ≥ 1.0 mm could predict for significant CAD by MDCT.,We performed invasive coronary angiography in some patients (N=14) and analyzed association for degrees of CAD between two angiographic methods.,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
2743,NCT05924516,Use of coping strategies,Usability,Energy level,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2744,NCT02109978,Response to diabetes therapy and rate of diabetes progression,Collection of samples for analysis of potential biomarkers,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
2745,NCT00280085,Pancreatic perfusion,,,2005-12,TERMINATED,INTERVENTIONAL,['NA']
2746,NCT01874431,Ratio of UACR at Day 90 to UACR at Baseline,Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale),,2013-06-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2747,NCT04800536,QTc interval,Plasma glucose decline rate and symptomatic response,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2748,NCT01953224,Change in Physical Activity From Baseline to 12 Weeks,Change in Motivation From Baseline to 12 Weeks,Number of Participants With Adverse Events,2014-09,COMPLETED,INTERVENTIONAL,['NA']
2749,NCT00479791,"Insulin, and glucose",Triglycerides,,1997-04,COMPLETED,INTERVENTIONAL,['NA']
2750,NCT05198895,Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control),"Analysis of safety outcomes (AEs, SAEs), including any safety outcomes listed in the comments, such as potential, suspected de novo diabetes diagnosis cases based on HbA1c readings",,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
2751,NCT00361738,Change in Mean Plasma Glucose (MPG) from baseline to week 4.,"Glucose parameters (change from baseline to week 4 in fasting and post prandial plasma glucose) ; Change in HbA1c and fructosamine ; Safety: physical examination, adverse events, ECG, laboratory tests",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2752,NCT00988689,Appetite,Palatability of treatments,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
2753,NCT02682940,"Aggregate reduction in the rate of mild hypoglycemia (biochemical and logged) as measured by meter or logged home blood glucose values <56 mg/dL at 3 months, compared to the monthly rate of hypoglycemia in the baseline period.",Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).,"Average ratings of ""acceptable"" or better from self-reported survey clinician feedback on the utility of Vigilant in managing patients.",2016-05,TERMINATED,INTERVENTIONAL,['NA']
2754,NCT03542240,Change in intestinal barrier function,,,2018-09-19,COMPLETED,INTERVENTIONAL,['NA']
2755,NCT05662826,Satisfaction,System usability,,2023-01-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2756,NCT00622284,HbA1c Change From Baseline at Week 104,Change in Baseline Lipid Parameter Triglyceride at Week 104,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2757,NCT01863810,Numerical pain rating scale (NRS),Adverse events,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
2758,NCT00566813,Number of Participants With HbA1c Less Than or Equal to 6.5 & Free of Severe Hypoglycemic Events,,,2004-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2759,NCT01046435,"Serum levels of C-reactive protein, fibrinogen,erythrosedimentation rate and white blood cell count","Clinical periodontal parameters: probing depth, bleeding on probing, clinical attachment level",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
2760,NCT03961542,blood glucose measurements after with or without chewing,,,2017-12-22,COMPLETED,INTERVENTIONAL,['NA']
2761,NCT01855243,Mean BG After First Day of Hospitalization,Mortality Rate,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
2762,NCT05979077,Participant Tool and Workflow Survey,To evaluate the impact of a patient-facing EHR-enabled questionnaire on glycemic control and visit efficiency.,,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
2763,NCT02402504,Subjective Appetite,Physical Comfort,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2764,NCT03466177,Retinal biomarkers for AD: receiver operating characteristic (ROC),Retinal biomarkers for AD: disease progression by measuring the change from baseline at 2 years and more,,2018-03-01,RECRUITING,OBSERVATIONAL,['NA']
2765,NCT00922389,Adverse events and laboratory parameters,Trans Cutaneous partial pressure of Oxygen: TCpO2,,2009-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2766,NCT03345004,Change in Stimulated C-peptide During a MMTT,Change in Body Mass Index (BMI),,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE2']
2767,NCT03437720,Resolution of Non-alcoholic steatohepatitis (NASH),Assessment of PK parameter: Ctrough,,2019-05-23,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2768,NCT01487109,To assess the change in urinary albumin to creatinine ratio,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2769,NCT03935919,Sensor accuracy in the perioperative period,Standard deviation of sensor glucose levels in the postoperative period,,2019-08-13,COMPLETED,OBSERVATIONAL,['NA']
2770,NCT05333822,blood glucose improvement in type 2 diabetic patients by continuous glucose monitoring.,insulin C-peptide gastric emptying,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
2771,NCT05881616,Content of serum metabolomics,,,2023-07-18,RECRUITING,OBSERVATIONAL,['NA']
2772,NCT05813912,Change in glycated haemoglobin (HbA1c),Relative change in weekly insulin icodec dose,,2023-09-22,RECRUITING,INTERVENTIONAL,['PHASE3']
2773,NCT01971047,BG concentration differences at 1 and 2 hours post intervention and post operatively,Number of perioperative complications,,2013-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2774,NCT01444443,Number of hypoglycemic events,Time spent in euglycemia (3.9-8.0 mmol/l); mean blood glucose level; LBGI,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
2775,NCT05423938,Postprandial glycemic response,Postprandial insulin response,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA']
2776,NCT03250403,pain,Conduction velocity,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
2777,NCT04634214,Severity of COVID 19 among people with and without diabetes,Length of hospital stay,,2020-11-16,UNKNOWN,OBSERVATIONAL,['NA']
2778,NCT01276288,Urinary Sodium Excretion Over 24-hour run-in Periods,"Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2779,NCT00678990,Safety,,,2019-01,UNKNOWN,INTERVENTIONAL,['NA']
2780,NCT03639545,Arterial function,Glycemic control,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2781,NCT00013741,,,,na,COMPLETED,INTERVENTIONAL,['NA']
2782,NCT03579420,Treatment success at 6 months,Waist circumference,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
2783,NCT00412126,Volume of intimal hyperplasia in the stented segment by IVUS at 6 months following PCI,"Late loss in minimal luminal diameter of stented site in coronary vessel evaluated by QCA at 6 months post-PCIb) Rate of clinical events at one year (hospital admission for unstable angina, CHF, MI, stroke, revascularization, and death)",,2002-07,COMPLETED,INTERVENTIONAL,['NA']
2784,NCT00793273,Change in FPG (fasting plasma glucose) of treatment,Insulin dose and concomitant oral antidiabetic medication time period between diagnosis of type 2 diabetes and insulin initiation,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
2785,NCT00642538,AUC 0-240 min post-prandial serum glucose,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
2786,NCT00258115,glycemia,,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2787,NCT01183013,Change From Baseline in HbA1c After 30 Weeks of Treatment.,Incidence of Rescue Therapy During the First 30 Weeks of Treatment,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2788,NCT06198725,The 2h C-peptide level of the MMTT test,Triglyceride,,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
2789,NCT05673837,volumetric Bone material density (vBMD),Trabecular area,Other structural and remodelling measures from bone histomorphometry,2021-12-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2790,NCT04413357,Area under the blood glucose curve,Insulinogenic index,,2020-05-18,COMPLETED,INTERVENTIONAL,['NA']
2791,NCT03092752,Percentage of Comorbidities by OAD Classes.,Number of Prescriptions of OAD by Each Renal Impairment (RI) Stages,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
2792,NCT00546702,Change of HbA1c.,"Blood glucose parameters, hypoglycaemic episodes and dosage of the mealtime and basal insulins.",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2793,NCT02984813,Flavoprotein fluorescence index,Humphrey visual field testing (24-2),,2016-04-15,TERMINATED,INTERVENTIONAL,['PHASE1']
2794,NCT05609266,Incident type 2 diabetes,,,1990-01,COMPLETED,OBSERVATIONAL,['NA']
2795,NCT03193125,Liver mitochondrial fatty acid processing,,,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
2796,NCT05933161,Estimated average glucose (eAG) values based on fructosamine lab values,Number of hypoglycemic unawareness episodes,,2023-11-10,RECRUITING,OBSERVATIONAL,['NA']
2797,NCT00131287,Percent reduction of glycated hemoglobin (HAb1C) and insulin resistance(HOMA-IR),"Glucose, cholesterol, triglyceride, leptin, adiponectin comparisons",,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2798,NCT02728414,change from baseline in glycosylated hemoglobin change at 3 months,change from baseline in c peptide at 3 months,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
2799,NCT01538576,HbA1c (glycosylated haemoglobin),Adverse Events,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
2800,NCT02426099,Efficacy (Blood pressure reduction),Creatinine (Change in serum creatinine),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2801,NCT05157815,Change in plasma HbA1c concentration,Change in Fasting Insulin (mIU/L).,Change in TNF alpha,2021-10-04,UNKNOWN,INTERVENTIONAL,['NA']
2802,NCT02676648,HbA1c,Body Weight Percent Lost,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
2803,NCT01043770,The proportion of people in the intervention and control groups with prevalent metabolic syndrome according to the IDF criteria.,Changes in general self-efficacy as measured by GSE,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
2804,NCT03551925,Change in Adherence to Refills and Medication Scale (Seven-item) (ARMS-7) Score,Change in Blood pressure,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
2805,NCT04501991,Lipid profile,,,2020-03-11,COMPLETED,OBSERVATIONAL,['NA']
2806,NCT05946148,>30% Liver Fat Fraction reduction,Shearwave Elastography (SWE),,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
2807,NCT00790348,,,,2008-07,UNKNOWN,OBSERVATIONAL,['NA']
2808,NCT04480801,Percentage of patients developing a foot ulcer,Change in foot care practices,,2020-09-15,COMPLETED,INTERVENTIONAL,['NA']
2809,NCT04141475,change of LVEF between before and after 12 weeks of treatment,,,2020-11-24,TERMINATED,INTERVENTIONAL,['NA']
2810,NCT05407662,Baseline all-cause healthcare costs by place of service,"sMRA continuing user questions - Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM v1.4) - validated PROM the evaluates patients' perception of sMRA treatment effectiveness, convenience, and overall satisfaction",,2022-11-02,COMPLETED,OBSERVATIONAL,['NA']
2811,NCT06284785,Difference in kidney oxygenation before and after bariatric surgery,"Difference in kidney oxygenation between obese, hyperfiltering men and women with T2D versus non-diabetic lean controls",,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
2812,NCT00908921,Change in glycosylated hemoglobin (HbA1c) rate,Percentage of patients achieving HbA1c <7.0,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2813,NCT04791358,Referrals,,,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA']
2814,NCT02551640,Differences in the change in physical activity levels between control and intervention groups as measured by daily physical activity measured by the Gear Fit device provided to participants in both groups,Differences in the change in C-reactive protein between control and intervention groups,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
2815,NCT05695170,Study protocol feasibility,Partner support.,,2022-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2816,NCT02590094,Visual Acuity,Time,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
2817,NCT03726983,Newborn baby weight,Change of Health Promotion Scale,,2017-01-05,COMPLETED,INTERVENTIONAL,['NA']
2818,NCT05164523,BDNF concentrations,,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
2819,NCT06146699,prevalence of diabetic retinopathy,,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2820,NCT03202095,Change from Baseline in Hamilton Depression Rating Scale,,,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2821,NCT00143520,Change in HbA1c,"FPG, Lipids, hsCRP, Adiponectin",,2004-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2822,NCT06325670,Number of binge eating episodes,HbA1c,Blood Pressure,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
2823,NCT04509856,Diabetes knowledge level (DKL),Blood pressure,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
2824,NCT01345734,Incidence of serious adverse drug reactions (SADRs),"Change in HbA1c (glycosylated haemoglobin)""",,2011-09-01,COMPLETED,OBSERVATIONAL,['NA']
2825,NCT05948969,New prescription of a SGLT2i and/or GLP-1RA,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
2826,NCT02107976,Whether acute changes in glycemia and/or red blood cell ascorbate (vitamin C) modify RBC deformability.,Whether RBC vitamin C concentrations can be increased by vitamin Csupplementation over several weeks in diabetic subjects.,,2019-06-14,RECRUITING,INTERVENTIONAL,['PHASE1']
2827,NCT01903044,"Wound healing (wound size, wound stage) - monitoring the healing of trophic lesions",Survival without amputation,,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2828,NCT02487537,"change in combined levels of glucose and insulin, expressed in calculated indices for insulin sensitivity",,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2829,NCT00764244,Percentage of patients with visual gain ≥ 3 ETDRS lines at 2 years,Evolution of visual field in each group,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2830,NCT04302974,"Incremental cost-effectiveness ratio per DM/HT-related complication or all-cause death avoided, and per QALY gained by RAMP or PSCC",,,2019-08-01,RECRUITING,OBSERVATIONAL,['NA']
2831,NCT01000922,To compare the maximal post prandial blood glucose concentration and the time to maximal post prandial glucose concentration between the different treatments,"To compare the ppGlucmax for all treatments, the ppTGluc-max, the AUCGluc 0-180 and the AUCGluc 0-360, CGluc-baseline for all treatments.",,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2832,NCT02765347,HbA1c,,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2833,NCT03623607,Patient acceptance of diabetes self-management education delivered via an e-learning platform.,To conduct iterative rapid-cycle usability testing of the enhanced Diabetes To Go program content and processes and establish a Diabetes To Go program toolkit for widespread implementation,Implementation effectiveness evaluation,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
2834,NCT01748305,Need for medication for diabetes,Mode of delivery,,2012-12,TERMINATED,INTERVENTIONAL,['NA']
2835,NCT01137903,Number of healing patients,Quality of life,,2010-04,UNKNOWN,INTERVENTIONAL,['NA']
2836,NCT00441129,Difference in HbA1C From Baseline and 6 Months,Change From Baseline in Total Daily Dose (TDD),,2006-06,COMPLETED,INTERVENTIONAL,['NA']
2837,NCT01298154,Food Intake,Blood Glucose,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2838,NCT02816099,Comparaison of linear correlation coefficients between plasma concentrations of apoC1 and CETP activity,,,2014-11-20,COMPLETED,INTERVENTIONAL,['NA']
2839,NCT01002547,"Liver Histology (Kleiner's et al Criteria, Hepatology 2005)",LDL-cholesterol,,2010-06-24,COMPLETED,INTERVENTIONAL,['PHASE4']
2840,NCT05876273,Percent of Time-in-Range (TIR) on NAP versus UMPC.,Participant Feedback,,2023-05-30,COMPLETED,INTERVENTIONAL,['NA']
2841,NCT05355090,Change in HbA1c,Change in body weight,,2022-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2842,NCT01507597,Plasma Glucose response to the GLP-1 infusion / glucose clamp,Food Intake,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
2843,NCT02627534,Probing Depth,Clinical Attachment Level,Gingival Recession,2014-04,COMPLETED,INTERVENTIONAL,['NA']
2844,NCT03421262,Large for gestational age,Medical cost,,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA']
2845,NCT04313998,Early Child Development,,,2016-06,UNKNOWN,OBSERVATIONAL,['NA']
2846,NCT01688986,,,,2012-08-25,COMPLETED,OBSERVATIONAL,['NA']
2847,NCT01511042,Frequency of Intermediate Phenotypes in Subjects with Diabetes Mellitus versus Hypertension,Frequency of salt sensitive subtype in Diabetics versus hypertensives,,1999-12,TERMINATED,OBSERVATIONAL,['NA']
2848,NCT00630617,Body Mass Index,Knowledge and attitudes,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
2849,NCT01505426,Change in HbA1c from baseline to end of treatment,"Safety assessed by the incidence of adverse events, vital signs safety labo-tests and 12-lead ECG",,2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE3']
2850,NCT03101930,Change in Plasminogen Activator Inhibitor-1,Fasting Insulin,Change in Weight,2017-05-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2851,NCT01858506,Change in lifestyle knowledge,Weight and waist circumference,Medical regimen for diabetes management,2014-08,COMPLETED,INTERVENTIONAL,['NA']
2852,NCT02681497,change in HbA1c value,Evidence of urinary tract infection (UTI) documented,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
2853,NCT05044130,VLDL-triglyceride uptake in adipose tissue - Measurement of fatty acid concentration and specific activity in adipose tissue biopsies,Insulin sensitivity,,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
2854,NCT00759889,To analyze and image wounds using microscopy and molecular techniques,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
2855,NCT03774069,Percentage of readings below 54 mg/dl (3.3 mmol/l),Number of physician override Advisor recommendation,,2020-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
2856,NCT00456027,"The development over time of safety variables, i.e. injection site discomfort, vital signs, laboratory values and AEs/SAEs as well as development of diabetes status, i.e. HbA1c, C-peptide, blood glucose and insulin requirement.",,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2857,NCT06299800,Glycated assessment at first visit,"Tumour characterization in the considered population, detected at the first clinical visit",,2024-02-04,RECRUITING,OBSERVATIONAL,['NA']
2858,NCT02842359,Change from baseline in flow mediated dilatation,Rate of change from baseline in T-cell induced inflammatory factors,,2016-08-23,COMPLETED,INTERVENTIONAL,['PHASE4']
2859,NCT02974504,HbA1c,HbA1c response rate,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2860,NCT06331338,glycemic control (HbA1c),Diabetes Self-Care Behavior Scale,,2024-02-14,RECRUITING,INTERVENTIONAL,['NA']
2861,NCT01421355,Change in Brachial Artery Diameter,,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2862,NCT02148523,Statin Adherence,Morisky Medication Adherence Scale (MMAS),,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2863,NCT06231225,Post-COVID-19 Functional Status scale,Dyspnoea-12 (D-12) scale,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2864,NCT00298428,Primary biological end-point: To compare SIPA levels in DM vs. MS vs. no DM/MS patients,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
2865,NCT04938843,Glycemic control,Liver fat function test GGT,,2021-08-16,UNKNOWN,INTERVENTIONAL,['NA']
2866,NCT02316665,change in mean nocturnal glycemia,Change in mean heart rate after intervention,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
2867,NCT04329871,Glycemic control while using the Medtronic MiniMed 670g system,Efficacy of Quality of Life and satisfaction while using the MiniMed 670g system,,2020-03-24,UNKNOWN,OBSERVATIONAL,['NA']
2868,NCT05928260,HbA1c,Quality of Life,,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
2869,NCT06032325,biomarkers,,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2870,NCT00254800,Assessment of Pharmacokinetics profile of exenatide measured by AUC and Cmax,"Safety and Tolerability assessment by Adverse events, clinical laboratory evaluations, vital signs, ECG blood glucose, body weight, physical examination and exenatide antibodies.",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2871,NCT01579981,Beta cell glucose sensitivity,Ad libitum food intake,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
2872,NCT03862690,Change in glycosylated haemoglobin A1c (HbA1c),Change in health-related quality of life (EQ-5D),,2020-05-28,WITHDRAWN,OBSERVATIONAL,['NA']
2873,NCT02477761,Plasma glucose concentration,Plasma glucose-dependent insulinotropic polypeptide concentration,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
2874,NCT04846673,visual analogue scale (VAS),"3 level version of Euro-Qol-5 dimensions, EQ-5D-3L",,2021-05-14,UNKNOWN,INTERVENTIONAL,['PHASE4']
2875,NCT02537587,Incremental area under the blood glucose response curve,Insulinogenic index,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2876,NCT03825562,Glycemic control,Psychological flexibility assessed by CAMM,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
2877,NCT02643225,The Number of Participants Who Were Diagnosed With Fetal Macrosomia (Birth Weight),Interventricular Septum Thickness,,2015-04,COMPLETED,OBSERVATIONAL,['NA']
2878,NCT03496597,surface of the central retinal avascular zone,,,2018-02-23,UNKNOWN,OBSERVATIONAL,['NA']
2879,NCT01264497,Change from baseline in relative insulin response,Number of subjects with a change in the control of diabetes,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2880,NCT03481335,HbA1c,Cost-utility,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
2881,NCT05143827,60-min glucose,AUC glucose 180 min,,2021-11-20,RECRUITING,INTERVENTIONAL,['NA']
2882,NCT00569426,Overall needle preference,Handling and acceptance of needles,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2883,NCT04744714,Neonatal outcomes,annual follow-up results,,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
2884,NCT01330251,Changes in fecal microbiota,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
2885,NCT01458210,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Ortho-Cyclen - Ethinyl Estradiol (EE),,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
2886,NCT00035906,,,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2887,NCT00971503,Significant increase in C-peptide levels after transplant in 70% of the patient.,Normalization of the hemoglobin A1C after transplant in 70% of the patients. Normalization of blood glucose levels.,,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2888,NCT02302443,Incidence and severity of treatment emergent adverse events,Area under the concentration-time curve (AUC) of HM12470 following a single dose,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2889,NCT02051647,Change in copeptin levels upon examination stress comparing copeptin levels prior and after examination,Correlation to cortisol as the classical stress marker,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
2890,NCT01212120,Presence/absence of the same S. aureus genetic profile in the nose and on the foot lesion.,,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
2891,NCT03862716,Proportion of participants achieving drug-free diabetes remission,Proportion of participants achieving drug-free diabetes regression,"the change in time range over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear",2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE3']
2892,NCT01806727,Predicted Cardiovascular Risk,Predicted Cardiovascular Risk,Health Costs,2013-04,COMPLETED,INTERVENTIONAL,['NA']
2893,NCT00300911,"Plasma Brain Natriuretic Peptide levels, echocardiographic measurements were made before the treatment and repeated after three months and six months of the treatment",,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2894,NCT01588587,Frequency of cancers,Receptor for AGE concentration,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
2895,NCT04530292,Measurement of HbA1c (%) one year after the discovery of diabetes.,Percentage of time spent wearing the sensor for patients with Freestyle sensor,,2020-09-28,COMPLETED,INTERVENTIONAL,['NA']
2896,NCT03362398,Human plasma concentration of 12 participants will be measured after 1.5 h,,,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
2897,NCT02637973,Change in liver fat content,,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2898,NCT03447275,The difference in serum vitamin B6 concentrations between cases and controls,The difference in serum and urine vitamin B6 vitamers between patients with advanced global vascular risk versus those with a low vascular risk,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
2899,NCT01824355,Percent of Self Test Fingerstick Blood Glucose Results Within ±15 mg/dL (< 75 mg/dL) and Within ±20% (≥ 75 mg/dL) of the Laboratory Glucose Method,Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
2900,NCT01908530,Difference to the Venous Blood Glucose MARD,Acceptability Questionnaire,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
2901,NCT01277913,Mean isometric hand grip force,"% patients with vitamin D hypervitaminosis (>200 ng/ml (500 nmol/L) and or hypercalcemia (>2.7 mmol/l) assessed at summer,spring, autumn, and winter",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2902,NCT06170515,HbA1c Performance,Type of errors as displayed,,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
2903,NCT00993187,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants With HbA1C < 7.0% at Week 30,,2010-05-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2904,NCT00338702,Time to definitive closure,,,2008-03,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2905,NCT01145742,Blood pressure,LDL Cholesterol,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
2906,NCT00286741,Systolic Blood Pressure,"Cost-effectiveness, Proportion of Patients With LDL < 100, Health Services Utilization, Quality of Life (as Measured by DQoL), Patient Empowerment (as Measured by DES).",,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2907,NCT02746861,Average reduction in HbA1c from baseline,,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
2908,NCT00308347,"Combined endpoint of doubling of serum creatinine, ESRD or death.",Secondary parameters: number of cardiovascular events and changes in proteinuria. Tertiary parameters: quality of life and healthcare resource utilization.,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2909,NCT05344690,Association of EPO gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis,The association of confounding factors on the incidence of diabetic retinopathy,,2022-05-20,COMPLETED,OBSERVATIONAL,['NA']
2910,NCT03902288,Cortisol hormone measurement,Serum total antioxidant activity measurement,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
2911,NCT00940173,"To establish preliminary evidence of the efficacy of DIABECELL(R), as measured by a reduction in serial HbA1C levels",To determine whether DIABECELL(R) causes an improvement in quality-of-life,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2912,NCT03526289,food intake,bone turnover markers,,2017-11-08,COMPLETED,INTERVENTIONAL,['NA']
2913,NCT03382015,Average Daily Glucose Levels,Triglycerides,,2018-01-09,COMPLETED,INTERVENTIONAL,['NA']
2914,NCT00528918,Hypoglycemic events,,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2915,NCT05768191,To compare improvements from baseline in patient HbA1c when aggressively treated with insulin human isophane plus rapid acting human insulin vs treatment with Premix human insulin,"correlation between patient QoL and glucose variability as measured by CGMS (baseline, week 16 and week 32)",,2023-06-15,RECRUITING,INTERVENTIONAL,['PHASE4']
2916,NCT03104829,HbA1C,Diabetic self-care behavior score,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
2917,NCT01944124,Systolic Blood Pressure,,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
2918,NCT03175120,Change in HbA1c,Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1,,2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE3']
2919,NCT01194830,Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks,Change From Baseline in 2-hour Post-prandial Glucose (PPG) After 24 Weeks,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2920,NCT03921242,Heterogeneity of Treatment Effect Via Pre-specified Sub-Group Analyses,Difference in Laboratory-Measured eGFR (mL/min),,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
2921,NCT02895672,A1C,,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
2922,NCT01371266,"Area under the curve glucose, response for OGTT. Glucose-120 min OGTT-AUC",Serum Lipids,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
2923,NCT00315614,A Reduction or Absence of Rejection Episodes,Number of Subjects With Reduction of Severe Hypoglycemia and Improvement in Hypoglycemia Awareness,,2000-12,TERMINATED,INTERVENTIONAL,['PHASE2']
2924,NCT00381719,Reduction in Daily Pain Score,Quality of Life questionnaires,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2925,NCT03154073,Insulin Sensitivity Index (μmol·kg^-1·min^-1·pM^-1),Change in 24-hour Glycemic Control (glucose AUC),,2017-07-20,COMPLETED,INTERVENTIONAL,['NA']
2926,NCT02934737,Markers of progression of diabetes,,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
2927,NCT00673231,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Fasting Plasma Glucose (FPG),Proportion of Participants With Lack of Glycemic Control,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2928,NCT00829387,Numeric Rating Scale (NRS) Pain Intensity,Beck Depression Inventory (BDI),,2010-03,COMPLETED,INTERVENTIONAL,['NA']
2929,NCT00135057,Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2930,NCT03138746,insulin sensitivity,change in inflammatory cytokines,,2018-08-13,COMPLETED,OBSERVATIONAL,['NA']
2931,NCT00127296,Combined measure of accuracy and precision between target and measured amounts of insulin dispensed (mean square percent difference),Precision (coefficient of variation),,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2932,NCT04625452,Loss-to-follow-up at 24 weeks,"Change of TTT sub-scales means from 12 to 24 weeks in the ""Theoretical Model of Change"" scores",Means change from baseline to 24 weeks in the level of triglycerides (TGC) (mg/dl).,2020-08-13,UNKNOWN,INTERVENTIONAL,['NA']
2933,NCT01326026,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2934,NCT06281899,Time to the First Occurrence of Any of the Components of the Composite: ≥30% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death,Changes in the quality of life,Compliance to carbohydrate intake,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
2935,NCT00946972,"Adverse events, laboratory values, vital signs, ECGs",Incretin levels,,2009-07,TERMINATED,INTERVENTIONAL,['PHASE1']
2936,NCT00703417,,,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
2937,NCT06310980,Time in range,DIDS,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2938,NCT00320502,Safety,Myocardial ischemia by 24-hour continuous 12-lead ECG,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2939,NCT01254084,"Fating plasma glucose, Steady state plasma glucose in Somatostatin-Insulin-Glucose Infusion Test","Body weight (BMI, hip-waist ratio)",,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2940,NCT03717207,syncope recurrence,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
2941,NCT04504370,Change in HbA1c,Change in Body Mass Index,,2020-04-27,COMPLETED,INTERVENTIONAL,['PHASE3']
2942,NCT03252080,ADDQoL score at endpoint,HbA1c at endpoint,,2017-08,UNKNOWN,INTERVENTIONAL,['NA']
2943,NCT01995539,Change From Baseline in A1C at 3 Months,Number of Serious Adverse Device Effects (SADE).,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
2944,NCT01627977,Visibility of the membrane after injection of the dye,Usefulness of the dye,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2945,NCT03241303,Plasma glucose,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
2946,NCT03834610,"Improvement in Penile Doppler parameters after treatment including peak systolic velocity in (cm/sec), end diastolic volume in (cm/sec) and resistive index (RI) that = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity.",,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
2947,NCT03878745,BD Nano™ PRO Pen Needle Compared to Terumo Nanopass® (Injection Pain),BD Nano™ PRO vs Terumo Nanopass® (Leakage),Compare BD Nano™ PRO vs Terumo Nanopass® (Needle Breaking),2019-02-11,COMPLETED,INTERVENTIONAL,['NA']
2948,NCT00729079,The primary outcome measure is weight loss with a goal of 7% of initial weight.,;Fat intake less than 25% and saturated fat less than 10% Fiber intake of at least 25 grams per day;Fasting blood sugar < 100 mg/dL; Absence of tobacco use,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
2949,NCT03372824,Glycated albumin reference interval in pregnancy,Admission to neonatal intensive care unit,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
2950,NCT00377858,Hemoglobin A1c (HbA1c) at 36 Week Endpoint,Change From Baseline in Absolute Body Weight at 36 Week Endpoint,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2951,NCT05124405,To evaluate the feasibility of the ( PA) Physical Activity intervention.,,,2018-05-24,SUSPENDED,INTERVENTIONAL,['NA']
2952,NCT02580591,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD)),Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,,2015-12-22,COMPLETED,INTERVENTIONAL,['PHASE3']
2953,NCT02212522,Genetic and environmental risk factors of T1D predisposition,"Undertake a prospective research of G and E risk factors of ""death in bed"" syndrome in diabetic adolescents",,2004-11,UNKNOWN,OBSERVATIONAL,['NA']
2954,NCT02690467,Fructosamine levels,Number of episodes of insulin leakage at injection site,,2016-09-06,UNKNOWN,INTERVENTIONAL,['NA']
2955,NCT04225455,To compare the data generated from the continuous glucose monitoring system (CGMS) Dexcom G6® with their routine self-glucose monitoring in pilots with class 1 and class 2 certificates,Previous 6 months logged data,,2019-12-05,RECRUITING,OBSERVATIONAL,['NA']
2956,NCT00034788,Time to complete ulcer healing.,Incidence of complete ulcer healing and reduction in total ulcer area at end of study. Incidence of adverse events throughout study.,,2000-12,TERMINATED,INTERVENTIONAL,['PHASE3']
2957,NCT04920279,Validity of the Turkish Version of Activities-specific Balance Confidence Scale in Patients With Diagnosis of the Diabetes Mellitus Before.,,,2018-06-11,COMPLETED,OBSERVATIONAL,['NA']
2958,NCT02098395,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2959,NCT01993511,Change in beta-cell function after RYGB.,Change in insulin sensitivity after RYGB.,Change in insulin clearance after RYGB.,2010-06,UNKNOWN,OBSERVATIONAL,['NA']
2960,NCT05444842,healing rate,,,2022-07-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2961,NCT01035879,Evaluate the effect of MBX-2982 on the absolute and percent change from baseline and placebo in mean weighted average of 14-point blood glucose levels associated with a standardized breakfast and lunch,Evaluate the effect of MBX-2982 on additional glycemic parameters.,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2962,NCT03199261,Bioequivalency between the 2 formulations of rE-4,,,2016-12-23,COMPLETED,INTERVENTIONAL,['PHASE1']
2963,NCT00362960,proteinuria (total urinary protein excretion) from baseline.,Evaluate safety and tolerability of all treatments.,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2964,NCT03475069,Quality of life,Body mass index,,2013-10-20,COMPLETED,INTERVENTIONAL,['NA']
2965,NCT02411825,Number of adverse events,Change from baseline in HbA1c,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
2966,NCT03660631,Effect of physician/pharmacist collaboration on implementation fidelity,Development of payment contracts,,2018-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2967,NCT05261906,Change in HbA1c from Baseline,Change in rapid insulin use from Baseline,Participant Feedback,2022-09-26,RECRUITING,INTERVENTIONAL,['NA']
2968,NCT00571935,HbA1c,Quality of Life (QoL),,2003-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2969,NCT01972113,Change in beta-cell function,"Effects of sex, race, bone age, and pubertal stage on changes in glucosemetabolism (insulin sensitivity and beta-cell function)",,2013-09,UNKNOWN,INTERVENTIONAL,['NA']
2970,NCT01393808,Changes in urinary albumin excretion from baseline at 4 month.,Ambulatory and 24-hour blood pressure profile.,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2971,NCT00911404,Need of insulin treatment for GDM,Fetal morbidity,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
2972,NCT06071208,prevention of diabetic complications,,,2023-10-14,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2973,NCT03899402,Change in HbA1c following dapagliflozin,Diabetic ketoacidosis assessment,,2019-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2974,NCT06021145,Percentage of time of glucose levels spent in the target range (empagliflozin vs placebo),Fasting ketone levels,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE4']
2975,NCT00819455,Progression to diabetes,Acceptability of text messaging as tool to prevent diabetes.,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
2976,NCT00905255,"Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring",Change From Baseline in Fasting Plasma Glucose (FPG) for All Patients at Week 52 and 76,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia for All Patients During On-Treatment Period,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2977,NCT00593424,Paired t-test or Wilcoxon signed rank test will be used to evaluate the change in fasting triglycerides with the diets.,Post-prandial lipids will be evaluated by t-test or Wilcoxon signed rank test for AUC of triglyceride and remnant lipoprotein measured by immunoseparation.,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
2978,NCT04311853,Implementation of new evidence-based nutrition practice guidelines,Improved health outcomes,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
2979,NCT05968222,Five times Sit To Stand (5STS),,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2980,NCT01346033,Validation of SCOUT DS algorithm for detecting known type 2 diabetes,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
2981,NCT00013299,,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2982,NCT00465881,,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
2983,NCT03755934,Change in the weekly average of the average daily pain scores,To characterise the dose-response relationship of MEDI7352 on chronic pain in subjects with PDN,,2018-11-19,COMPLETED,INTERVENTIONAL,['PHASE2']
2984,NCT04749030,Number of adverse events of severity grade 2 or more assessed by CTCAE v5.0 during the first week after first intervention (FMT or placebo).,Blood samples.,,2021-06-15,COMPLETED,INTERVENTIONAL,['NA']
2985,NCT05996380,Safety endpoints: Number of Adverse Events,,,2023-06-09,RECRUITING,INTERVENTIONAL,['PHASE1']
2986,NCT01140932,ERG,Retinal Vessel Caliber,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
2987,NCT02964572,changes in the secretion of IL-1 beta from peripheral blood mononuclear cells,"Changes in protein expression pattern (western blot, relative to control) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride",,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2988,NCT05767177,Glucemia following a Mixed Meal Test:,Enteroscopy: mucosal glucose-transport capacity,"Glucemia, insulinemia and GLPi-emia following the Mixed Meal Test",2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
2989,NCT04132908,blood samples,,,2016-10-01,COMPLETED,INTERVENTIONAL,['NA']
2990,NCT02671656,Uricemia,"Haematocrit, glucose and lipid levels, medications",,2016-03,WITHDRAWN,OBSERVATIONAL,['NA']
2991,NCT00320970,Urinary carboxymethyllysine,,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
2992,NCT01315756,"Improved glycemic control, HbA1c","Lipids, self-care, lifestyle changes, complications, quality of life.",,2011-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2993,NCT00167284,Lipids,Patient and physician barriers to diabetes care,,2001-10,COMPLETED,INTERVENTIONAL,['NA']
2994,NCT05176795,Gut microbiota composition,Fecal contamination with nanoparticles,,2022-03-16,RECRUITING,OBSERVATIONAL,['NA']
2995,NCT05415644,The PK parameters of retagliptin and metformin in the blood plasma on fasting and after meals area under the drug-time curve (AUC0-∞),Adverse events,,2022-07-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2996,NCT04533659,Glycemic control,In-home self-monitoring of blood glucose,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
2997,NCT05888688,Volumetric quadriceps skeletal muscle mass (cm^3),Sarcopenia assessment,quadriceps musculoskeletal Biopsy Analysis,2023-12-06,RECRUITING,OBSERVATIONAL,['NA']
2998,NCT06322940,Change in whole-body insulin sensitivity,Change in lipid profile,Change in total energy intake,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2999,NCT01932944,Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System compared to venous and capillary glucose,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
3000,NCT01352663,Change in HbAlc from baseline till the end of treatment period.,Percentage change in immunogenic response.,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3']
3001,NCT02806739,Number of Participants With Adverse Events That Are Related to Treatment,Effects of Soy Intake on C-reactive Protein (CRP),,2013-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3002,NCT03216564,Urinary albumin creatinine ratio (ACR) measured biochemically,Blood pressure,Patient Reported Outcome: Quality of life,2017-05-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
3003,NCT01589835,HbA1c Progression to diabetes,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3004,NCT02831361,changes from baseline HbA1c at week 25,Changes of HOMA-β at week 25,Changes of Triglyceride at week 25,2016-10-17,COMPLETED,INTERVENTIONAL,['PHASE3']
3005,NCT02435329,Impaired endothelial function in patients with type 2 DM with/ without diabetic neuropathy and Charcot foot compared to their healthy counterparts as measured by:,Impaired bone metabolism in patients with type 2 DM with/ without diabetic neuropathy and Charcot foot compared to their healthy counterparts as assessed by:,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
3006,NCT00021944,,,,2001-04,COMPLETED,OBSERVATIONAL,['NA']
3007,NCT04882332,Correlation between Metformin Usage Index and Vitamin B12 status among Egyptian patients with type 2 diabetes,,,2021-05-05,UNKNOWN,OBSERVATIONAL,['NA']
3008,NCT00135070,Glucose control,Length of stay,,2005-07,TERMINATED,INTERVENTIONAL,['PHASE4']
3009,NCT06131372,Change in urinary albumin-to-creatinine ratio (UACR),"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3010,NCT06120556,"Difference in HbA1c change from baseline (%) among SIDD, SIRD, MARD, MOD subtypes","Difference in percentage of patients reaching HbA1c below 7% among SIDD, SIRD, MARD, MOD subtypes",,2023-06-10,COMPLETED,OBSERVATIONAL,['NA']
3011,NCT01566981,Change From Baseline in HbA1C at 1 Year.,Change of the Following Parameter : HbA1C,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
3012,NCT00820703,To evaluate the safety and clinical effect of Nexagon® administered topically to diabetic foot ulcers.,To pilot the collection of data that may be considered useful in planning future studies of Nexagon® administered topically to diabetic foot ulcers.,,2009-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3013,NCT01333592,Incidences of Adverse Events,Change From Baseline in HbA1c at 52 Weeks,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
3014,NCT02439879,Total Symptoms Score,,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
3015,NCT03951168,Diabetes Specific Quality of Life,HDL-C,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
3016,NCT01469065,Change From Baseline (Day -1) in Mean Daily Glucose at Day 14,Change From Baseline in Fasting Lipid Parameters at Day 14 and 16,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3017,NCT01880372,Decreased progression of diabetic retinopathy.,Changes in the plasma level of glutathione as measured by ELISA technique,Changes in visual acuity as measured by electronic visual testing algorithm,2013-09,TERMINATED,INTERVENTIONAL,['NA']
3018,NCT05849428,Time-matched CGM-derived blood glucose differences between left arm and right arm in patients with Type 1 or Type 2 Diabetes below target range (<70 mg/dL).,Time-matched CGM-derived blood glucose differences between left arm and right arm in patients above target range (>180 mg/dL).,,2023-05,RECRUITING,INTERVENTIONAL,['NA']
3019,NCT00955201,Peroneal Nerve Conduction Velocity,Short Form-36V: Mental Component Score,Age,2010-01-14,COMPLETED,INTERVENTIONAL,['NA']
3020,NCT03690180,Decrease in serum magnesium,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
3021,NCT00548639,Morisky medication adherence scale,,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
3022,NCT01512680,Difference between HbA1c at Month 12 and Month 0 > 0.5%,"Better score at surveys of quality of life (SF-6D, DQOL) and auto-management",,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3023,NCT05422053,Other serious adverse events,Glucose < 70 mg/dL,CGM Metrics by Time of Day,2022-06-29,COMPLETED,INTERVENTIONAL,['NA']
3024,NCT01222078,Proportion of Anti-otelixizumab Neutralizing Antibodies,Terminal Phase Half-life (Thalf) of Otelixizumab,,2010-11-22,TERMINATED,INTERVENTIONAL,['PHASE2']
3025,NCT05054842,Changes in HbA1c relative to baseline,Evaluate the concentration of the main metabolite of SP2086 in Type 2 diabetes,,2021-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3026,NCT00388986,AUC0-tau of glyburide,"AEs, laboratory parameters.",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3027,NCT03207269,Fasting Plasma glucose,Fasting continuous glucose monitoring glucose,,2017-07-20,COMPLETED,INTERVENTIONAL,['NA']
3028,NCT02152371,Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c),Rate of Hypoglycemic Events up to 28 Weeks,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3029,NCT03033433,Stage 2: Number of Participants with Adverse events and Serious adverse events that are related to treatment,Stage2: Change from baseline in biomarker( serum fructosamine) testing results.,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3030,NCT05992350,Minutes of Sleep per Day,Change in how parents feel about episodes of hypoglycemia in their children,,2024-01-16,RECRUITING,OBSERVATIONAL,['NA']
3031,NCT05566977,Efficacy of the adoptive T regs transfer,Prevention or stop progression to organ failure,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3032,NCT04572009,percentage of time in glycemic target,changes in activity over time,,2021-01-12,COMPLETED,INTERVENTIONAL,['NA']
3033,NCT06107153,Change in hemoglobin A1c,Hypoglycemia,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
3034,NCT03362762,"Characteristic of type 2 diabetes patients, treated with insulin in Guadeloupe",Describe the relation between the rate of HbAC and the plan of insulinothérapie,,2013-12-16,COMPLETED,OBSERVATIONAL,['NA']
3035,NCT01113515,Safety outcome,Efficacy outcome,Pharmacokinetics,2014-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3036,NCT05636007,nocturnal hypoglycemia,,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
3037,NCT03481283,Blood vessel wall amylin deposition vs severity of peripheral neuropathy,Heat thermode test vs RBC amylin and blood vessel wall amylin deposition,,2018-02-05,RECRUITING,OBSERVATIONAL,['NA']
3038,NCT03739268,plasma glucose,Appetite measured by visual analog scale,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
3039,NCT06295900,Patient Introduction Form,Patient Follow-up Form,Visual Comparison Sleep Scale,2024-01-05,RECRUITING,INTERVENTIONAL,['NA']
3040,NCT01018017,Mean clinical chemistry parameters including serum creatinine,"Muscle histology and biomarkers of oxidative capacity-succinate dehydrogenase content Complex I, Complex II/III, complex IV.",,2010-03-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3041,NCT02505893,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),72-hour Continuous Glucose Monitoring,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3042,NCT02227875,Change in HbA1c From Baseline to 24 Weeks,Change in Cross-Reactive Insulin Antibody Percent Binding for Lantus Assay Over Time,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3043,NCT05549570,Area under the plasma concentration versus time curve (AUC) 0-t,"Number of participants with adverse events (AEs), abnormal clinical laboratory test results, physical examination findings and glycemia.",,2017-10-22,COMPLETED,INTERVENTIONAL,['PHASE1']
3044,NCT00888732,"Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between fast-acting human insulin vs. IAsp, BIAsp 50 and BIAsp 70, IAsp vs BIAsp 50 and BIAsp 70, BIAsp 50 vs. BIAsp 70.","Serum GH, total IGF-I, IGF-I bioactivity, IGFBP-1, IGFBP-2, binary complex of IGF-I, IGFBP-3 and the acid-labile subunit (ALS)",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3045,NCT04260100,Dietary Behaviour,Fasting Blood Glucose,,2020-02-17,COMPLETED,INTERVENTIONAL,['NA']
3046,NCT02010541,Glycaemic control,knowledge on diet and diabetes management,Quality of Life measures,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
3047,NCT01726413,Mean 24-hour average pain intensity (API) score.,Clinician Global Impression of Change,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3048,NCT00337298,Vessel diameter changes in arbitrary units as measured with the Retinal Vessel Analyzer,24 hour ambulatory blood pressure (mmHg),,2006-07,COMPLETED,INTERVENTIONAL,['NA']
3049,NCT02368600,Proportion of subjects developed GDM,Proportion of neonates born with macrosomia,,2015-04-21,COMPLETED,INTERVENTIONAL,['NA']
3050,NCT06041412,the presence of DPN,,,2012-02-01,RECRUITING,OBSERVATIONAL,['NA']
3051,NCT01871428,Change in HbA1c,Safety: Incidence of adverse events,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3052,NCT05203042,Timed Get Up and Go Test-Motor and Cognitive Task:,Biochemical Analysis,,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA']
3053,NCT06172166,Continuity of care,Diabetic Ketoacidosis,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3054,NCT01813799,Difference in average 24-h pain intensity (Likert scale) between before and after IP administration,Average daily dose of acetaminophen,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3055,NCT02373059,Patient Involvement Questionnaire,Patient Medication Adherence Questionnaire,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
3056,NCT02204527,Ambulatory Blood pressure monitoring,,,2015-10,TERMINATED,INTERVENTIONAL,['NA']
3057,NCT02081586,Computer System Usability Questionnaire (CSUQ),Body Mass Index Change,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3058,NCT05175677,Impact on diabetes control in the study population,Lifestyle modification for diabetic patients,,2022-03-10,COMPLETED,OBSERVATIONAL,['NA']
3059,NCT00069628,HbA1c value obtained 6 months after randomization,Diabetes Self Management Profile at 6 months,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3060,NCT01630512,change in severity of depressive symptoms,intersession changes in mood,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
3061,NCT00771576,Pancreas [11C] DTBZ binding,,,2006-09,COMPLETED,OBSERVATIONAL,['NA']
3062,NCT00155922,,,,2003-11,UNKNOWN,OBSERVATIONAL,['NA']
3063,NCT03534193,Effectiveness of tablet education in newly diagnosed type 1 diabetes,Improved subject compliance with glucose monitoring,,2017-04-17,SUSPENDED,INTERVENTIONAL,['NA']
3064,NCT02175121,Number of Participants With Electrocardiogram (ECG) Data Meeting Criteria of Potential Clinical Concern,Apparent Clearance (CL/F),,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3065,NCT01821846,The incidence of SADRs (Serious Adverse Drug Reactions),Number of SAEs/ ADRs (Serious Adverse Events/Adverse Drug Reactions),,2013-11-20,COMPLETED,OBSERVATIONAL,['NA']
3066,NCT00331448,,,,2000-06,UNKNOWN,OBSERVATIONAL,['NA']
3067,NCT05723445,Change in percent time in target range 70-180 mg/dL,Change in intestinal fatty acid binding protein (I-FABP),,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
3068,NCT02683902,Weight loss,"Weight, waist circumference and total body fat loss after 3 and 6 month of end of intervention",,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
3069,NCT05824286,Change in measured HbA1c from baseline to 24 weeks,The rate of severe hypoglycemic events and confirmed hypoglycemic events during the 24 weeks of the study,,2023-01-04,RECRUITING,INTERVENTIONAL,['NA']
3070,NCT01228500,Time to healing,,,2008-01,WITHDRAWN,INTERVENTIONAL,['NA']
3071,NCT05838222,Feasibility measure,Hypertension,,2023-05-08,COMPLETED,INTERVENTIONAL,['NA']
3072,NCT03717909,Visual acuity (VA),Pancreatic beta cell reserve - glycated haemoglobin or equivalent,PMBC - Biomarker 2,2018-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3073,NCT02649465,The improvement in histologic features of NAFLD,Epigenomic changes from baseline in genes of the liver and blood cells,,2015-11-11,COMPLETED,INTERVENTIONAL,['PHASE4']
3074,NCT01303900,Cardiovascular disease risk factors,Association between clotting factor concentrate administration and cardiovascular events,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
3075,NCT02264951,plasma GIP,plasma CCK,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
3076,NCT01968265,The effect of ISIS-GCCRRx on serum fructosamine,The tolerability of ISIS-GCCRRx,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3077,NCT02967211,Change in HbA1c (percentage %),Change in fasting plasma glucose,,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE4']
3078,NCT01041144,HbA1c,PP2hr Lipid profile,,na,COMPLETED,INTERVENTIONAL,['NA']
3079,NCT05347030,The change in the value of 2-hour blood glucose from baseline at the end of the 12-week treatment,The change from baseline of blood pressure,Incidence of Adverse Events,2022-10-06,RECRUITING,INTERVENTIONAL,['NA']
3080,NCT01760707,Exercise capacity,maximal oxygen pulse,,2002-11,COMPLETED,INTERVENTIONAL,['NA']
3081,NCT04822480,Medical expenditures,Coping self-efficacy,Implementation,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
3082,NCT03147274,Change from baseline self-care adherence at 12 months,Change from baseline hemoglobin A1c at 12 months,,2017-05-03,COMPLETED,INTERVENTIONAL,['NA']
3083,NCT00660907,Adjusted Mean Change in HbA1c Levels,Proportion of Participants With Body Weight Reduction of at Least 5%,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3084,NCT02152891,Change in rate of EMS Calls,,,2015-11-01,COMPLETED,INTERVENTIONAL,['NA']
3085,NCT02290925,Glycosylated Haemoglobin,Renal Adverse Effects - 2,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3086,NCT03663322,Fasting glucose,A1C,,2018-11-15,UNKNOWN,INTERVENTIONAL,['NA']
3087,NCT01107171,Hemoglobin A1c (HbA1c),"The rate of adverse events,the blood and urine and stool routine examination, electrocardiogram (ECG)and liver and kidney function tests",,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3088,NCT01686945,Number of treatment emergent adverse events (TEAEs) recorded,Change from baseline in glycosylated haemoglobin type A1c (HbA1c),,2012-09-19,COMPLETED,INTERVENTIONAL,['PHASE1']
3089,NCT01189422,Dose regimen,,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1']
3090,NCT02060357,Endothelial stent coverage,MACE,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
3091,NCT01697657,Incidence of total self-recorded hypoglycaemic episodes,Incidence of adverse events,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3092,NCT00655603,Glucose turn-over,"The inhibitory effect of GLP-1 on glucagon, and the role of this in its anti-diabetic potential, measured by looking at glucose turn-over.",,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
3093,NCT01739205,Weight loss,Inflammation,Other outcomes,2008-01,COMPLETED,INTERVENTIONAL,['NA']
3094,NCT05316662,Change in HbA1c,"DTSQs, change in absolute treatment satisfaction",,2022-04-06,RECRUITING,OBSERVATIONAL,['NA']
3095,NCT02558270,Change in endogenous glucose production,Changes in hormones involved in hypoglycemia counter regulation,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
3096,NCT03851666,Effect of the treatment on reduction of the HbA1c level (%),Effect of the treatment on evolution of the subject weight,,2018-08-09,COMPLETED,INTERVENTIONAL,['NA']
3097,NCT03549559,11C-Martinostat Binding,,,2018-09-07,UNKNOWN,INTERVENTIONAL,['NA']
3098,NCT03440203,Activities of daily living,,,2017-05-11,COMPLETED,OBSERVATIONAL,['NA']
3099,NCT05924724,Treatment Satisfaction,Activity in the last 7 days,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
3100,NCT01961401,insulin sensitivity,,,2013-01,TERMINATED,INTERVENTIONAL,['NA']
3101,NCT01475786,The Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up.,,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3102,NCT04240574,Subjects Feedback,,,2020-01-24,TERMINATED,INTERVENTIONAL,['NA']
3103,NCT05596760,EHR documentation of Goals of Care discussions,Anxiety and depression (HADS),,2023-09-11,RECRUITING,INTERVENTIONAL,['NA']
3104,NCT01807377,HDL cholesterol,,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3105,NCT04825795,Prevalence of obstructive coronary disease,Change in coronary calcium score,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
3106,NCT02426073,"Inflammatory markers (TNF-α, interleukin-1, interleukin-2, interleukin-6, RANKL, Myostatin and GDF11)",,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
3107,NCT01924312,Brain T2 hyperintensity volume on MRI,Total brain volume,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3108,NCT05442398,HbA1c,,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3109,NCT04161651,changes in quality of life evaluated questionnaires (DTSQ),Any adverse event related to study device,,2019-11,UNKNOWN,INTERVENTIONAL,['NA']
3110,NCT02227212,Ease-of-use / ease of learning questionnaire,Number of participants with site injection site reactions / hypersensitivity reactions,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3111,NCT02756832,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6,Percentage of Participants Who Used Healthcare Resources,,2016-09-20,COMPLETED,OBSERVATIONAL,['NA']
3112,NCT03774394,Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50%,Clopidogrel Active Metabolite Concentration,Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50%,2019-08-22,COMPLETED,INTERVENTIONAL,['PHASE4']
3113,NCT00394030,Pharmacokinetic measurements for different injection sites after one dose.,Pharmacodynamic measurements at three different times after one dose.,,2006-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
3114,NCT01582308,Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough,Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax),,2012-06-21,COMPLETED,INTERVENTIONAL,['PHASE1']
3115,NCT01964950,Number of Participants Reporting One or More Serious Adverse Drug Reaction,Change From Baseline in Fasting Insulin Level,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
3116,NCT00031213,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
3117,NCT01582282,Triglyceride Change From Baseline,,,1988-05,TERMINATED,INTERVENTIONAL,['PHASE4']
3118,NCT02312427,Serum BNP level with and without DPP-4 inhibitor use.,"Other neurohormonal factors (Changes in plasma renin, aldosterone, serum stromal cell-derived factor 1 alpha, serum active glucagon-like peptide-1, serum active glucose-dependent insulinotropic polypeptid)",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3119,NCT03235440,Change in Body Weight,Body Image Assessment of Children (BIA-C):,,2017-06-19,COMPLETED,INTERVENTIONAL,['NA']
3120,NCT00099515,Hypothesis that std training for HIIP system is noninferior to intensive training by 1.2 mmol/L with respect to overall 2-hr postprandial glucose excursion of (SMBG) in type 2 diabetes patients that have been on preprandial trmt with HIIP,Compare the test meal blood glucose profiles of preprandial HIIP administration with standard training and with intensive training,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3121,NCT00591227,Hospital Length of Stay,Frequency of Hypoglycemia During Emergency Room Therapy With Insulin,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
3122,NCT06287840,Bone Strength (Failure load),Alkaline phosphatase,,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
3123,NCT00184561,Change in HbA1c,after 24 weeks of treatment.,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3124,NCT01609088,Brachial artery flow mediated dilation,C-reactive protein,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
3125,NCT00519480,"Home diary of blood sugar results, adverse events and drug dosing.",fluid intake & output,,2007-09-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3126,NCT00990184,Acute Insulin Response (AIRg) to Intravenous Glucose,Glucose Disappearance Rate,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3127,NCT04799925,Effect of treatment of hyperuricemia on estimated Glomerular Filtration Rate by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.,,,2021-04-15,UNKNOWN,OBSERVATIONAL,['NA']
3128,NCT00488930,"Measure changes in dendritic cells at baseline, 6 months and 1 year following weight loss",,,2007-06,TERMINATED,OBSERVATIONAL,['NA']
3129,NCT03999853,Insulin sensitivity,Glucose Variability and Triglycerides,,2022-07-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3130,NCT04567563,Change in ulcer area and overall healing rate,tissue perfusion,,2020-11,UNKNOWN,INTERVENTIONAL,['NA']
3131,NCT00569595,"Serum glycosylated hemoglobin, heart rate recovery step test","Total Cholesterol, BMI, waist circumference, healthy eating, physical activity, perceived health status, patient satisfaction, mood",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3132,NCT01222429,"indices of renal function (serum creatinine, microalbumin)",,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
3133,NCT05579977,"Placebo-adjusted, percent change from baseline in body weight at Week 32 in Obesity",Assessment of mental health as determined by Columbia-Suicide Severity Rating Scale (C-SSRS) in Obesity,,2022-10-27,TERMINATED,INTERVENTIONAL,['PHASE2']
3134,NCT04757285,determine stress hormones in serum cortisol and copeptin,correlation of psychological stress with stress hormone copeptin,,2020-05-10,COMPLETED,OBSERVATIONAL,['NA']
3135,NCT05661799,Change in amount of physical activity assessed by the French Version of GPAQ,Progressive medical data assessed by a specific form for the study,,2021-09-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3136,NCT00873925,C-Peptide following the 1 year mixed meal tolerance test,Peripheral Blood T-cell assays,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3137,NCT03623139,Change in mean amplitude of glycaemic excursions (MAGE),Change in intake of dietary fibre,Change in urinary biomarkers of carbohydrate intake,2018-09-28,COMPLETED,INTERVENTIONAL,['NA']
3138,NCT01633086,Neuopathic Pain Scale,the likelihood of reusing the nitric oxide gel recorded,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3139,NCT00736099,Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol,Change in FPG From Baseline to Week 78,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3140,NCT00523042,"Changes in lung function, chest X-rays, or asthma exacerbation frequency",Preprandial insulin doses,,2007-08-30,TERMINATED,INTERVENTIONAL,['PHASE3']
3141,NCT06036004,Change in EmBody/EmFace to assess recognition of facial and body expressions,Change in Beck's Depression Inventory II (BDI-II) to assess depression,Change in Close third-person assessment,2024-01-08,RECRUITING,INTERVENTIONAL,['PHASE2']
3142,NCT03486964,Post-prandial plasma glucose,Cardiovascular death,,2018-03-27,COMPLETED,OBSERVATIONAL,['NA']
3143,NCT04664036,Association of NAFLD with microvascular and macrovascular complications in type 1 diabetes mellitus: odds ratio to develop in NAFLD and diabetes compared to diabetes without NAFLD in subjects with no prior complications,Natural history of NAFLD in type 1 diabetes,,2018-09-17,RECRUITING,OBSERVATIONAL,['NA']
3144,NCT05577650,Prevalence of chronic kidney disease,,,2023-01-09,COMPLETED,OBSERVATIONAL,['NA']
3145,NCT00726505,The change in urinary glucose excretion dynamics,Glucose effects on tubular markers,,2009-06,TERMINATED,INTERVENTIONAL,['PHASE1']
3146,NCT01002352,Improvement of comorbidities,"Mortality, weight loss, surgical complications",,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
3147,NCT01240980,"Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments",The single-dose pharmacokinetics parameter apparent clearance from plasma after extra-vascular administration (CLT/F) of BMS-903452 will be derived from the plasma concentration versus time data,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3148,NCT02307279,Co-Primary Outcome: Percentage of Subjects Who Achieve Body Weight Loss ≥ 5%,Change in Hemoglobin HbA1c in Subjects With Type 2 Diabetes at Baseline,Assess Safety and Tolerability of Administration of Gelesis100,2014-11,COMPLETED,INTERVENTIONAL,['NA']
3149,NCT04016155,Difference in time in hypoglycaemia,Fear of hypoglycaemia,,2019-07-17,UNKNOWN,INTERVENTIONAL,['NA']
3150,NCT03066284,Impact of IPT on QoL of children and adolescents from their perspective and their parents' perspective,,,2016-03-14,UNKNOWN,OBSERVATIONAL,['NA']
3151,NCT02555332,75g oral glucose tolerance test (OGTT) positive or not,,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
3152,NCT06005051,Changes in postprandial metabolites response as measured by micro-sampling,Changes in personal metabolic states through the day as measured in micro-sampling by Olink proteomics,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3153,NCT04370171,Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.,"Number of conventional hospitalizations, in intensive care and deaths.",,2020-05-04,COMPLETED,OBSERVATIONAL,['NA']
3154,NCT05286892,Perceived Competence Scale,,,2023-04-30,RECRUITING,INTERVENTIONAL,['NA']
3155,NCT06190717,Primary Effectiveness Endpoint,Freedom from Events through 30 and 90 Days,Intervention to Assist Maturation Rate,2024-02-21,RECRUITING,INTERVENTIONAL,['NA']
3156,NCT02837094,To examine the risk of C19A3 GNP administration in terms of general safety and induction of hypersensitivity.,To study the immune responses to C19A3 GNP generated in the draining (axillary) lymph node.,,2016-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
3157,NCT03207711,frequency of eating in response to cravings (primary mechanistic outcome),Perceived Stress (secondary mechanistic outcome),,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
3158,NCT02691247,Change From Baseline in 4-hour Mixed Meal Tolerance Test (MMTT)-Stimulated C-peptide Area Under the Curve (AUC) at Week 52,Change From Baseline in Mean Daily Dose of Insulin,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3159,NCT02684929,Change in glucose disposal,Change in gene expression in adipose tissue,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
3160,NCT06150209,Time Closure in Diabetic foot ulcers Managed with Vendaje,Reduction of wound volume in diabetic foot ulcers treated with Vendaje,,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3161,NCT01509742,Area under the Curve (AUC) glucagon,Adverse events,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3162,NCT00682903,"The HbA1c, the witness of the quality of the metabolic balance, in 6 and 12 months. We shall compare the deltae of HbA1c between the period of inclusion and 6 and 12 months following the training course in the ""fonctional"" insulin therapy",,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
3163,NCT05607576,Post radiation Dexcom G6 transmitter functional duration,,,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3164,NCT04061200,Albuminuria,Inflammatory and endothelial biomarkers,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3165,NCT03566810,Maximum Observed Plasma Concentration (Cmax) of Metformin,Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings,,2018-10-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3166,NCT00000620,First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.,First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3167,NCT03515421,Marketing Claims Evaluation questionnaire.,,,2018-04-09,COMPLETED,INTERVENTIONAL,['NA']
3168,NCT04696653,Change in self-efficacy as assessed by an adapted version of Compeau & Higgins' task-focused self-efficacy scale,Change in the percent of individuals diagnosed with dyslipidemia who received lifestyle counseling,,2021-02-24,COMPLETED,INTERVENTIONAL,['NA']
3169,NCT04229628,Proportion of community diabetes mellitus patients receiving treatment as Chinese guideline recommended,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
3170,NCT01293773,Target lesion failure,Effect of dual antiplatelet therapy on outcome,,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
3171,NCT01536626,HbA1c (glycosylated haemoglobin),Quality of Life (QoL) using the World Health Organization Wellbeing Index (WHO-5),,2006-06-09,COMPLETED,OBSERVATIONAL,['NA']
3172,NCT02456051,Pancreatic cancer diagnosis,Mortality,,2015-04,TERMINATED,OBSERVATIONAL,['NA']
3173,NCT02383537,miRNA profiling,,,2017-04,UNKNOWN,OBSERVATIONAL,['NA']
3174,NCT04440319,Statistical analyses for HbA1c and Fasting blood glucose,Statistical analyses for Waist Circumference,,2020-07-01,COMPLETED,INTERVENTIONAL,['NA']
3175,NCT01944618,Incidence rates of spontaneously reported hypoglycaemia in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice,Subgroup analyses may be conducted for selected safety parameters,,2013-10,TERMINATED,OBSERVATIONAL,['NA']
3176,NCT00127192,Change From Baseline in HbA1c at Week 12,Change From Baseline in Fasting Plasma Glucose at Week 12,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3177,NCT05368454,Change in HbA1c,Change in diabetes distress,,2022-05-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3178,NCT04388059,glycemic control in morbid obese diabetic adolescents.,weight loss in morbid obese diabetic adolescents.,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
3179,NCT01756105,Efficacy of metformin in treatment of gestational diabetes based on capillary glycaemia with an objective of less than 6 measures out of range,,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE2']
3180,NCT00674518,Improve physical activity and dietary behaviors among sedentary patients,"Improve biomarkers of obesity including glucose, lipid levels, CRP, leptin and insulin.",,2005-01,COMPLETED,INTERVENTIONAL,['NA']
3181,NCT00063232,Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category),"Change in Insulin Sensitivity (Glucose Tolerance, Homeostatic Model Assessment of Insulin Resistence (HOMA-IR)) From Baseline",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3182,NCT04696640,Change in hemoglobin A1c (HbA1c),Remote patient monitoring survey,,2021-06-03,COMPLETED,INTERVENTIONAL,['NA']
3183,NCT01571817,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3184,NCT02817217,The area under the plasma concentration-time curve (AUC) of Valsartan,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
3185,NCT03758430,Change from Baseline to Week 16 in Hemoglobin A1c (HbA1c),Change from Baseline to Week 16 in Post-Prandial Glucose Concentrations Following Commonly Eaten Meals,,2019-02-06,COMPLETED,OBSERVATIONAL,['NA']
3186,NCT01857973,Percentage of Time in Euglycemic Range - Phase 3 (Closed-loop Using the NGP Pump Platform),Percentage of Time in Euglycemic Range - Phase 7,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
3187,NCT05514184,Dietary adherence to PLAFOND vs. standard-of-care renal diet assessed by diet diaries,Glycemic status by continuous glucose monitoring (GCM),,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3188,NCT01004848,Change in Weight From Baseline to 6 Months,Knowledge & Attitudes About Diabetes Risk,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
3189,NCT04739215,"Main Structural Objective: Changes in serum levels of procollagen type I C-terminal propertied (PICP, ng/mL)",Changes in high sensitivity troponin T (pg/mL),,2021-01-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
3190,NCT02626832,AVP response to plasma osmolality as measured by slopes between the two variables,,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
3191,NCT00689377,"Prevalence of lower extremities peripheral arterial disease (PAD), in subjects with a moderate CVD risk, with no overt cardiovascular diseases nor diabetes mellitus","Determinants (i.e., subject and physician characteristics) for PAD underdiagnosis in the selected population",,2007-05,COMPLETED,OBSERVATIONAL,['NA']
3192,NCT01727349,Measure of risk of developing type 2 diabetes in at-risk families,,,2011-12-14,COMPLETED,INTERVENTIONAL,['NA']
3193,NCT02639988,Time to the addition of a new treatment for type 2 diabetes in months,Proportion of patients with increased HOMA-IR between 2 visits in %,,2016-04-13,SUSPENDED,OBSERVATIONAL,['NA']
3194,NCT00797134,Retinal thickness.,Choroidal Thickness,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
3195,NCT02740283,Rate of GDM diagnosed in 18-20 gestational week.,,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
3196,NCT04521634,Stroke Primary outcome - MRS,,,2020-09-30,COMPLETED,OBSERVATIONAL,['NA']
3197,NCT03023293,postpartum glucose metabolism,,,2017-03-10,UNKNOWN,OBSERVATIONAL,['NA']
3198,NCT04002557,Young people's beliefs about good health as assessed by interview with open questions,,,2019-05-31,COMPLETED,OBSERVATIONAL,['NA']
3199,NCT04909580,Decisional Conflict,Genetic Counselling Satisfaction Scale (modified version),,2013-09-05,COMPLETED,INTERVENTIONAL,['NA']
3200,NCT04253431,Volume (uL) of blood in the capillary tube,The intensity of pain perceived by the patient assessed with the use of the VAS (Visual Analog Scale).,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
3201,NCT06323538,Incidence of diabetes type 2,Intake of medication,Microbiome,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3202,NCT02775266,Serum Resistin Levels and HBAIC Levels,Clinical Attachment levels,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
3203,NCT02470637,Assessment of PD parameter: Area under the glucose infusion rate curve within 24 hours after administration of the investigational medicinal product or until administration of rescue insulin (GIR-AUC0-end),Number of patients with adverse events,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3204,NCT01538290,,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
3205,NCT00966368,Maximum observed Insulin Degludec concentration after single dose,Terminal half-life for Insulin Degludec,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3206,NCT00791479,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3207,NCT05349955,Primary Outcome of Phase 2: Composite of 3P MACE and hospitalization for heart failure.,Secondary Outcome of Phase 2: All-cause death,The time rate of glycemic target range,2022-11-21,RECRUITING,INTERVENTIONAL,['NA']
3208,NCT05755321,Characterization of neural progenitors cells,,,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3209,NCT01574157,Change in Urinary Transforming Growth Factor Beta 1 (TGF-b1),Change in Estimated Glomerular Filtration (eGFR),,2012-11-05,COMPLETED,INTERVENTIONAL,['NA']
3210,NCT03305367,Gastrointestinal tolerability,,,2017-02-06,COMPLETED,INTERVENTIONAL,['NA']
3211,NCT00810173,,,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
3212,NCT01521598,Relief of diabetic neuropathy pain,Average daily pain score,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3213,NCT02177786,Change in eGFR From Baseline at Week 48,Percentage of Participants Achieving at Least a 30% Reduction From Baseline in Albuminuria (As Measured by Urine Albumin to Creatinine Ratio) at Week 48,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3214,NCT02733211,Percentage of glucose sensor readings within 70 to 180 mg/dl (3.9 to 10 mmol/l) during the night (23:00-7:00 h),Percentage of sensor glucose readings >300 mg/dl,,2019-03,WITHDRAWN,INTERVENTIONAL,['NA']
3215,NCT05015946,Health related quality of life (HRQoL),Aerobic intensity and movement patterns,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
3216,NCT02224365,Blood Pressure,Body Composition,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3217,NCT03906513,changes in the characteristics of the subbasal corneal plexus at confocal,- changes in clinical signs and symptoms of ocular surface damage,,2017-05-03,COMPLETED,INTERVENTIONAL,['NA']
3218,NCT05055219,Progression of glucose tolerance,,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
3219,NCT03952728,Medicare Part D Prescription Drug Fill Count,Medicare Skilled Nursing Facility payments,Medicare Imaging + Test payments,2016-12-19,COMPLETED,OBSERVATIONAL,['NA']
3220,NCT02748980,The coronary microcirculation dysfunction is measured by index of microcirculatory resistance,,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
3221,NCT05758545,Complete wound healing,Quality of life survey,,2023-06-19,RECRUITING,INTERVENTIONAL,['NA']
3222,NCT05315973,Accuracy: glucose readings in mg/dL,"Acceptability: questionnaire ratings on a scale of 1-5, with 5 being the highest",,2022-06-01,WITHDRAWN,INTERVENTIONAL,['NA']
3223,NCT00957060,Fasting and postprandial glucose,,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3224,NCT00700362,Plasma glucose level.,laboratories for inflammation and oxidative stress.,,2011-12,WITHDRAWN,OBSERVATIONAL,['NA']
3225,NCT03660293,"The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.",Identification of risk factors for developing diabetic cardiac insult.,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
3226,NCT00104572,Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density,Effect of Testosterone Gel vs. Anastrozole on Prostate Volume/Prostate Specific Antigen Levels/Urinary Function,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3227,NCT04833569,Crestal bone loss,Interleukin-6,,2020-09-20,COMPLETED,INTERVENTIONAL,['PHASE1']
3228,NCT04845412,Rate of Hearing loss,,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
3229,NCT00763074,,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
3230,NCT05593575,Percentage change from baseline in UACR,The change trend of eGFR,,2023-03-22,RECRUITING,INTERVENTIONAL,['PHASE2']
3231,NCT00781950,"Number of Participants With All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions","Effects on Exercise Performance, Blood Pressure and Circulating Lipid Levels.",,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3232,NCT00552370,"To compare the frequency of severe hypoglycemia events for 5 dosing algorithms of Lantus®, each of varying intensity and defined by their end-of-study target for self monitored blood glucose (SMBG).",To compare the number of subjects whose final A1c is <7.0% at the end of the study for the 5 dosing algorithms.,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3233,NCT04834245,the percentage of a reduction rate of the diabetic foot ulcer after intervention,,,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
3234,NCT04894916,User Experience,Change in Medication Adherence,,2021-06-12,COMPLETED,INTERVENTIONAL,['NA']
3235,NCT01760356,Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.,Post transplant surgical complications,,2011-05-01,TERMINATED,OBSERVATIONAL,['NA']
3236,NCT04558775,Proportion of participants who have DFU wound recurrence by 16 weeks after complete wound healing,Clinician assessment of DFU wound recurrence,,2020-06-17,COMPLETED,OBSERVATIONAL,['NA']
3237,NCT03407196,Change in HbA1c(%),Discontinuation rates of dapagliflozin in the first 6 months of treatment,,2017-05-24,COMPLETED,OBSERVATIONAL,['NA']
3238,NCT03313024,T cell population content at the time of preeclampsia diagnosis compared to controls and verified by flow cytometry,,,2017-09-26,RECRUITING,OBSERVATIONAL,['NA']
3239,NCT04621656,Assessment of percent of total time monitored that blood glucose is in range 70-180 mg/dL,Assessment of change in sleep quality and pattern as measured by heart rate monitor coupled to participant logs.,,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA']
3240,NCT03516994,Proportion of Whites who complete advance care planning,Patient Quality of Life,,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3241,NCT06253429,Changes in urinary albumin excretion rate,,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
3242,NCT01989988,Remission of diabetes,weight loss and improvement in quality of life,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
3243,NCT04334499,Quantitation of mitochondrial DNA in vitreous humor and serum samples,Evaluation of mtDNA quantitation versus ocular comorbidities as described in electronic medical record.,,2020-02-21,WITHDRAWN,OBSERVATIONAL,['NA']
3244,NCT04573335,All-cause mortality,COVID-19 illness,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
3245,NCT01304615,consumption of Self-made Meals,Percent Body fat,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
3246,NCT00099944,Change from baseline in HbA1c after 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3247,NCT04076007,24 hour Ambulatory Blood Pressure monitoring after 2 weeks placebo juice,Insulin sensitivity,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
3248,NCT01498731,Rate of major adverse cardiac events (MACE) within 30 days Copeptin vs. Control arm.,Length of hospital stay,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
3249,NCT01973413,Percent Time Near Normoglycemia,Glycemic Events,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
3250,NCT02671331,Excess weight loss (EWL),Protein malnutrition,,2016-01,TERMINATED,OBSERVATIONAL,['NA']
3251,NCT00653341,Percentage of subjects reaching target HbA1c = or < 7% at endpoint and not experiencing symptomatic nocturnal hypoglycemia,"Safety data (Adverse events, vital signs, laboratory values, etc.)",,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3252,NCT00309712,percent of patients achieving study goal oftriglycerides <200 mg/dL,"Percent of patients achieving all study goals: LDL-C < 100 mg/dL, HDL-C:40 mg/dL, Triglycerides <200 mg/dL and the Percent of patients achieving non-HDL cholesterol <130 mg/dL",,2002-08,COMPLETED,INTERVENTIONAL,['NA']
3253,NCT00470795,GCSI score,SF-12 Health Survey Questionnaire; C-13 acetate breath test,,2009-06,SUSPENDED,INTERVENTIONAL,['PHASE3']
3254,NCT02553382,Change in HbA1c,Change in 24h ambulatory systolic blood pressure,Change in Hs-CRP,2015-11,COMPLETED,INTERVENTIONAL,['NA']
3255,NCT00362011,Hemoglobin A1c,"compliance (plasma fatty-acids, returned supplements, diet records, body weight).",,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3256,NCT04402710,"Acceptability as assessed by semi-structured exit interviews with participants which will include questions related to their thoughts and feelings about the study and whether they believed the study was acceptable (e.g. content, timing).",Change in Cognitive Emotion Regulation strategies from baseline to 6 weeks (intervention end),,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
3257,NCT01168765,Biomarkers,Quality adjusted life years,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
3258,NCT01089829,"The primary outcome of the study is to identify the neurovascular risk factors for foot ulceration as renal function declines, and to develop a suitable foot protection programme for CKD patients.",The secondary outcome measure is to identify whether dialysis modality choice influence foot ulcer development and should this be used to inform patient choice of dialysis.,,2010-04,UNKNOWN,OBSERVATIONAL,['NA']
3259,NCT01939470,Change from Baseline in Bone Mineral Density at Year 1 and Year 2,Change from Baseline in C-reactive Protein at Year 1 and Year 2,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
3260,NCT04648137,area under the concentration time curve in oxytocin level,Level of general physical & mental health using the short form health survey (SF-36),,2021-02-05,COMPLETED,INTERVENTIONAL,['NA']
3261,NCT05623189,Primary Endpoint,Endpoint 28,,2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE2']
3262,NCT02755064,Relationship between gastric emptying and glycemia,Number of subjects with delayed gastric emptying,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3263,NCT01728883,Test efficacy of the test algorithm improvements,Assess patient satisfaction with the test,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
3264,NCT01236794,Insulin Sensitivity,QOL,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3265,NCT03463564,Change in glucose variability,Diabetes treatment satisfaction,,2016-01,RECRUITING,INTERVENTIONAL,['PHASE4']
3266,NCT05961878,Handgrip test,Dietary lifestyle,health-related quality of life,2023-07-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3267,NCT02680457,Glycemic Variability: Mean Amplitude of Glucose Excursion (MAGE),Glycemic Variability: Area Under the Curve of Glucose,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
3268,NCT05458167,Time-in-range of Hedia Diabetes Assistant bolus calculator with physical activity module,Time-below-range of Hedia Diabetes Assistant bolus calculator with physical activity module,Usability of Hedia Diabetes Assistant bolus calculator with physical activity module,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
3269,NCT00770926,Body weight,diet,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
3270,NCT01769378,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks,Change From Baseline in Amylase,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3271,NCT05454891,Glucose Area Under Curve [AUC],Percentage of time between 70-140 mg/dL,,2022-07-15,RECRUITING,INTERVENTIONAL,['PHASE4']
3272,NCT01982435,Number of Participants With Severe Non-ocular Adverse Event,Number of Participants With Nonperfusion,,2014-06-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3273,NCT05089942,Efficacy of Recombinant Human Insulin Patch ZJSRM2021,Pain assessment of Recombinant Human Insulin Patch ZJSRM2021,,2021-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
3274,NCT04039945,presence of multiple islet autoantibodies,,,2015-02,RECRUITING,OBSERVATIONAL,['NA']
3275,NCT04342624,Mircobiome effects of cinnamon through stool sample collection,,,2021-04-14,COMPLETED,INTERVENTIONAL,['NA']
3276,NCT02910076,glucose level,,,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3277,NCT01790945,% change in Diabetic Retinopahy/Diabetic Macular Edema diagnosis with pre-screening system compared to post-screening system,Change in HgA1C from Primary Care Physician referral to post retinal specialist visit,Time from PCP referral for patient to see an ophthalmologist and appointment with retinal specialist,2013-02,UNKNOWN,OBSERVATIONAL,['NA']
3278,NCT03522311,Visual acuity measurement,Presence of postoperative vitreous hemorrhage,Presence of postoperative retinal detachment,2013-01,COMPLETED,OBSERVATIONAL,['NA']
3279,NCT01608620,Coronary heart disease (CHD) analysis,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
3280,NCT01589718,Tractional Retinal Detachment Repair,Visual Acuity,,2012-04,WITHDRAWN,INTERVENTIONAL,['PHASE3']
3281,NCT01282567,Dosage of plasma insulin concentration and blood glucose every 20 minutes during 6 hours and 40 minutes,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
3282,NCT01375270,Insulin Secretion,"Plasma Cytokines (IL-6, TNF, IL-1beta, IL-1ra)",,2011-04,COMPLETED,INTERVENTIONAL,['NA']
3283,NCT00013910,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
3284,NCT01047865,"Retrospective and prospective analysis of pancreas transplant recipients to determine frequency, and time course of autoantibody recurrence of disease. Prospective follow up to: monitor autoantibody levels, monitor and phenotype autoreactive T",Monitor autoantibody levels as well as phenotype autoreactive T cells in peripheral blood.,,2005-05,RECRUITING,OBSERVATIONAL,['NA']
3285,NCT03845114,Decrease in plasma glucose levels during exercise,Amount of carbohydrates needed to treat a hypoglycemic event,,2019-06-30,RECRUITING,INTERVENTIONAL,['NA']
3286,NCT04558827,Effectiveness of Intervention: Changes in Insulin Dosage,Feasibility: Percent of day compliant with Carbohydrate target,,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
3287,NCT02353923,Change in Electronic-ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity testing,Change in Blood levels of circulating endothelial progenitor cells (EPC),,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
3288,NCT00467285,Changes in BMD 0.33 Radius,Changes in CTx at Follow up,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
3289,NCT01546844,"Change in Hemoglobin A1c - In control, over time.",Disease Management,,2012-03,UNKNOWN,INTERVENTIONAL,['NA']
3290,NCT01794650,24 hour blood glucose area under the curve,Ketogenesis,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
3291,NCT00498537,reduction in proteinuria,Changes in GFR and incidence of hyperkalemia,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
3292,NCT01147250,"Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina",Percent Change From Baseline in the Urinary Albumin/Creatinine Ratio (UACR) at Week 108,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3293,NCT02389335,"Roles of interferon gamma, interleukin-2, tumor necrotizan factor alpha in the pathogenesis of type 1 diabetes",,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
3294,NCT01241253,Net blood glucose changes over time,,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3295,NCT00958997,PET-determined pancreatic islet beta-cell mass,Insulin secretion response following an acute arginine-stimulus test,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
3296,NCT00613782,Insulin Resistance,Bone microarchitecture,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3297,NCT01820377,Waist Circumference,Parent Lifestyle Behaviours Questionnaire,Social Determinants of Health,2010-10,COMPLETED,INTERVENTIONAL,['NA']
3298,NCT04958356,"Number of participants with confirmed positivity for at least one diabetes-associated autoantibody (insulin autoantibodies and antibodies to GAD65, islet antigen 2 and zinc transporter 8) or confirmed positivity for tissue transglutaminase antibodies",,,2018-11-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3299,NCT02858843,Change in units of insulin used over a period of 6 months to 1 year.,Pulmonary function test (PFT) forced expiratory volume at one second (FEV1) measurements,,2016-08-01,TERMINATED,INTERVENTIONAL,['NA']
3300,NCT04642755,"Prevalence of malnutrition, DM and helminth infections in LTBI individuals and their effects on biosignatures",,,2021-04-19,RECRUITING,OBSERVATIONAL,['NA']
3301,NCT04810507,Effect of Improving Glycemic Variability,Average nighttime (18:00~07:59) blood glucose change after 12 weeks compared to baseline,,2018-11-09,COMPLETED,INTERVENTIONAL,['PHASE4']
3302,NCT00916513,"Diabetes-related QoL and treatment satisfaction questionnaires: DTSQ, ADDQoL, HFSws and EQ5D","Health-economic variables: Use of healthcare resources Days off work (for either hypoglycaemias, acute or chronic complications)",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
3303,NCT02321904,The utility of corneal confocal microscopy to assess diabetic neuropathy in children.,Corneal nerve branching density (CBD) by CCM,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
3304,NCT00603590,Systolic Blood Pressure,LDL Cholesterol,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3305,NCT04038528,glycated hemoglobin (GlyH) level,Hyperglycemic events,,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA']
3306,NCT05679115,Change of long-term blood glucose concentration measured as glycated hemoglobin at 1 year,,,2023-01-10,RECRUITING,INTERVENTIONAL,['NA']
3307,NCT03332472,HbA1c,Standard deviation,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
3308,NCT01965665,Change in Sepsis Rate,,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
3309,NCT04643899,Carbohydrate balance,MES sessions check,,2021-03-29,COMPLETED,INTERVENTIONAL,['NA']
3310,NCT04304430,Combined categorized endpoint,Proportion of patients attaining blood pressure target,,2018-10-18,COMPLETED,OBSERVATIONAL,['NA']
3311,NCT04970810,A1c,Diabetes Self-Efficacy,,2021-07-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3312,NCT03272074,"Fasting blood glucose, insulin resistance, and insulin sensitivity",Lipid panel,ABCA1 Protein,2015-09-11,COMPLETED,INTERVENTIONAL,['NA']
3313,NCT06117436,Wound Healing size,Treatment-related side effects.,,2023-10-19,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3314,NCT02445833,Changes in blood pressure levels at 6 and 12 months,Satisfaction with treatment,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
3315,NCT04210089,Complete Healing Rates,Patient Complications,,2020-10-13,RECRUITING,INTERVENTIONAL,['NA']
3316,NCT02029833,Abdominal imaging of visceral and subcutaneous abdominal fat,Lipopolysaccharide (LPS),,2013-03,COMPLETED,INTERVENTIONAL,['NA']
3317,NCT02994316,Interest of copeptin dosage as a severity marker in children under the age of 16 with diabatic ketoacidosis,Correlation between plasma copeptin levels and other markers used in management of diabatic ketoacidosis in the first 36 hours after diagnosis- Plasma copeptin levels at diagnosis of diabate mellitus type 1 without ketoacidosis in children,,2016-10-03,COMPLETED,INTERVENTIONAL,['NA']
3318,NCT00458029,Fasting insulin (mU/mL),"Decisions, policies, and activities at the school, local, state, or federal level that influence the school environment for nutrition and physical activity",,2006-08,COMPLETED,INTERVENTIONAL,['NA']
3319,NCT03352674,Incidence of immune response,Adverse events,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3320,NCT00610038,assess continuously the capillary glycaemia for three consecutive days and evaluate the insulin secretion under insulin and sulfonylureas,To assess the kinetics of glibenclamide in children,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3321,NCT00608101,catecholamines,,,2010-09,WITHDRAWN,INTERVENTIONAL,['NA']
3322,NCT05606913,HbA1c change from baseline at week 28,To assess changes in PD parameters fasting C-peptide at different time points before and after administration.,,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3323,NCT05930561,Annualized number of aflibercept injections in the study eye,Percentage of subjects with a ≥2 and ≥3-Step Diabetic Retinopathy Severity (DRS) improvement from baseline on the ETDRS-DRSS,"Incidence and severity of treatment-emergent adverse events and serious adverse events, including clinically significant changes in safety parameters",2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE2']
3324,NCT05904769,Blood glucose level,,,2023-05-31,RECRUITING,INTERVENTIONAL,['NA']
3325,NCT01811485,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups,"Number of Patients With Adverse Events (Including Hypoglycemia), Serious Adverse Events and Death",,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3326,NCT05301413,DPP Class Attendance,Office/clinic visits,,2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2']
3327,NCT02432391,Change from baseline glycosylated hemoglobin at 6 months,,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3328,NCT02742662,Change in body weight in kg,Change in plasma triglycerides,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
3329,NCT03839641,Overnight Respiratory Exchange Ratio,Slope of Respiratory Exchange Ratio,,2019-01-14,COMPLETED,INTERVENTIONAL,['NA']
3330,NCT00374361,,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
3331,NCT02949037,Patient Activation Measure (PAM),Summary of Diabetes Self-Care Activities (SDSCA),,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
3332,NCT05576025,24-hour area under the curve (AUC) for glucose,,Sedentary time,2022-11-23,RECRUITING,INTERVENTIONAL,['NA']
3333,NCT01219582,Change in Hemoglobin A1c (HbA1c) levels,Percentage of patients with satisfaction of treatment,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
3334,NCT00516204,Cholesterol levels,,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
3335,NCT01152957,Glycemic Control,Cholesterol,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
3336,NCT03531905,Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C),Percent Change From Baseline to Week 12 in HbA1c,Number of Participants With Any Treatment-emergent Adverse Event (TEAE),2018-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3337,NCT01678469,link between plasma concentrations and dietary intakes of lipophilic micronutrients and risk of developing a Gestational diabetes mellitus,,,2011-11-28,COMPLETED,INTERVENTIONAL,['NA']
3338,NCT05799976,Care gap order rate,,Care gap completion rate,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3339,NCT03947879,Change in hemoglobin A1c,Change in waist circumference,,2019-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
3340,NCT02122666,Sarcoplasmic Reticulum Composition,Lean and Fat Body Mass,,2014-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3341,NCT00286598,Change in weight-bearing physical activity (steps/day),Foot-related self-care,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3342,NCT05933174,Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management,Diabetes Distress Scale,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
3343,NCT00481117,"Safety labs, ECGs, vital signs, adverse events.",Pharmacodynamics (lab samples) and Pharmacokinetics (lab samples),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3344,NCT00725127,"To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration in subjects with impaired fasting glucose or type 2 diabetes on primary prevention of cardiovascular, cerebrovascular and renal fatal, and non-fatal events.","To evaluate, for all previous objectives, potential differences in the benefits of low-dose ASA for primary prevention between subjects with and without metabolic syndrome.",,2008-10,RECRUITING,INTERVENTIONAL,['PHASE4']
3345,NCT00156078,Mean pain score,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3346,NCT03380416,Liver fat content,Biochemical parameters,,2017-04-04,COMPLETED,INTERVENTIONAL,['NA']
3347,NCT01519466,Time in Target Blood Glucose Range,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 60.,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
3348,NCT00782496,Average Number of Weekly Post-Prandial Blood Glucose Tests Performed by Subjects Using Either Basic or Advanced Meter Features,Percent of Level 2 Participants Who Rated Helpfulness of Advanced Meter Features as 1 or 2,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
3349,NCT03387657,Assessment of PK parameter: AUCtau,Assessment of PK parameter: tmax,,2018-01-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3350,NCT00005474,,,,1996-09,COMPLETED,OBSERVATIONAL,['NA']
3351,NCT04104321,Double Blind Part: To evaluate the effect of Aramchol compared to placebo on composite long-term outcome,,,2019-09-23,SUSPENDED,INTERVENTIONAL,['PHASE3']
3352,NCT01724502,Protein Concentration of Mitochondria,,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
3353,NCT04991142,Feasibility of measuring meal quantity and composition using CGMs,Feasibility of measuring impact of gut microbiota on estimations of meal composition using CGMs,,2021-09-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3354,NCT02617160,Percentage of glucose readings within range of 70-180 mg/dl,Percentage of glucose readings below 50 mg/dl,Device Satisfaction,2016-05,TERMINATED,INTERVENTIONAL,['NA']
3355,NCT04405895,Change in Clock Genes mRNA,Change in Overall Glycemia,,2020-05-31,UNKNOWN,INTERVENTIONAL,['NA']
3356,NCT02192255,120 day medication adherence,"Composite Control Level of Blood pressure, A1c and/or LDL",,2012-01,COMPLETED,INTERVENTIONAL,['NA']
3357,NCT04385888,Glycemic Variability,Inflammatory cytokines (e.g. IL-6),,2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3358,NCT02201199,Area under the serum insulin glargine (INS) concentration curve over the first 12 hours after dosing,"Safety and tolerability (Number of patients with adverse events, clinically significant changes in vital signs, laboratory parameters)",,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3359,NCT05701813,"Efficacy on insulin-resistance, measured with the HOMA-IR index","Improvements in triglycerides, total cholesterol and HDL cholesterol.",Effect on BMI (Body Mass Index),2023-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3360,NCT02597309,Reduction in insulin recuirement,,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
3361,NCT01480804,change in hemoglobin A1c,"Change in clinical, functional and psycho social tests and questionnaires",,2006-11,COMPLETED,INTERVENTIONAL,['NA']
3362,NCT04583800,Heart failure (≥ stade B).,Major cardio-neuro-vascular events,,2021-06-22,RECRUITING,OBSERVATIONAL,['NA']
3363,NCT04886388,The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups,The difference in the mean change from baseline in HbA1c at Day 180 between Intervention and Standard of Care groups,,2021-04-22,COMPLETED,INTERVENTIONAL,['PHASE3']
3364,NCT02334241,Favourable healing outcome (FHO),Number of local cares requiring instrumental debridement (surgical or sharp debridement).,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
3365,NCT01774565,Time spent in target glucose range (5.6-10.0mmol/l),"Pre-breakfast, pre-lunch, pre-dinner, and evening capillary glucose values",Total and endogenous insulin exposure within 1 hour postprandial period (Phase 4 only),2016-08,COMPLETED,INTERVENTIONAL,['NA']
3366,NCT01768559,Change in Body Weight From Baseline to Week 26,"Percentage of Participants Who Reached the Target of HbA1c <7%, Had no Weight Gain at Week 26, and Did Not Experience Documented (Plasma Glucose <60 mg/dL) Symptomatic Hypoglycemia During 26-Week Treatment Period",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3367,NCT03597412,Change from baseline to week 24 in LDL-C level,Occurrence of MACCE (Major Adverse Cardiovascular and Cerebrovascular Event),,2018-10-17,COMPLETED,INTERVENTIONAL,['PHASE4']
3368,NCT01681147,Barriers Associated With Poorer Adherence to Diabetes Screening Guidelines and Weight Loss Goals,Exercise Frequency in Women With Gestational Diabetes Post-Partum,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
3369,NCT00677664,Retinal function,Nerve fiber layer thickness,,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
3370,NCT02123628,Primary outcome measure was the proportion of patients of each group with remission of diabetic foot osteomyelitis at the end of follow-up.,tolerance to treatment in each group of patients,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3371,NCT01169818,Change (decrease) in mean hemoglobin glycosylated (HbA1c) level,PROMs (patient reported outcome measures) scores from the DTSQs/c (diabetes treatment satisfaction questionnaire status) and EQ-5D (European quality of life - 5 dimensions),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
3372,NCT00765063,Number of Trivial Hemorrhages,36-Item Short-Form Health Survey (SF-36) Score,,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3373,NCT02103595,Perception of pain during infusion set insertion assessed by means of a visual analogue scale (VAS),Insulin set replacement pattern,,2013-11-01,COMPLETED,INTERVENTIONAL,['NA']
3374,NCT01932476,Change in Markers of Autoimmunity,Gastrointestinal Symptoms,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
3375,NCT05524792,Other Diabetes mellitus,Taste disorders,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
3376,NCT02439684,The specificity of the use of HbA1c,DM risk,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
3377,NCT02528396,AUClispro 0-30min (timepoint 0 = time of dosing),Local tolerability injection site reactions,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3378,NCT04238949,Hemoglobin A1c,Healthcare costs,,2019-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3379,NCT01832077,cost-effectiveness,Cost-effectiveness of van,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
3380,NCT02509858,area under the glucose uptake versus time curve-AUC,Number of participants with adverse events,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
3381,NCT03426956,Difference in GLP-1 secretion (evaluated by iAUC).,Difference in bile acid responses (evaluated by iAUC) between the two test days.,,2018-02-08,UNKNOWN,INTERVENTIONAL,['NA']
3382,NCT01529541,The Change in HbA1c from baseline to week24.,change from baseline to week 24 in HOMA-IR,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3383,NCT01582451,Change From Baseline to 26-week Endpoint in Hemoglobin A1c (HbA1c),Number of Participants With Change in Anti-LY2605541 Antibodies,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3384,NCT01350284,The effect of 3grams cinnamon on gastric emptying half time,Food intake,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
3385,NCT03358745,Area under the curve of postprandial glycemia,"Area under the curve (AUC) of postprandial Glucagon-like peptide (GLP-1), Peptide YY (PYY) and glucose-dependent insulinotropic polypeptide (GIP)",,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
3386,NCT01451372,Daily Usage of Blood Glucose Test (BG Testing),Frequency of Sensor Usage Per Month,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
3387,NCT05147116,Mean AUC (Area Under the Curve) Plasma [Glucose],Sleep efficiency (time in bed + time asleep),,2022-02-17,COMPLETED,INTERVENTIONAL,['NA']
3388,NCT02105324,Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5,Percentage of Participants Using Pramlintide During the Usual Care Period,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3389,NCT03267758,change in baseline flow mediated dilation (FMD) at 6 weeks,,,2018-05-15,RECRUITING,INTERVENTIONAL,['NA']
3390,NCT02686177,Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group,Difference of Circulating soluble adhesion molecules as endothelial activation markers: ICAM-1 and VCAM-1 concentration at 4 weeks of treatment from baseline (Liraglutide versus control group),,2016-05-18,COMPLETED,INTERVENTIONAL,['PHASE4']
3391,NCT00558571,"Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG",HbA1c,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3392,NCT03115099,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics: Maximum Concentration (Cmax) of LY3325656,,2017-05-31,COMPLETED,INTERVENTIONAL,['PHASE1']
3393,NCT04427982,DES Score,,Glycated Hemoglobin (A1c),2020-09-03,COMPLETED,INTERVENTIONAL,['NA']
3394,NCT00690326,incremental physical activity,glycosylated hemoglobin,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
3395,NCT05725889,"Finger tap, visual and auditory reaction test data within 10 seconds",,,2021-07-15,COMPLETED,OBSERVATIONAL,['NA']
3396,NCT00230464,Rate of appearance of endogenous glucose,Rate of appearance of oral glucose,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3397,NCT00254254,Number of adverse events,,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3398,NCT03984058,Recruitment Yield as assessed by number of participants enrolled from electronic medical records (EMR),Adherence to Pap Therapy as assessed by the ResMed AirView Remote Monitoring system,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
3399,NCT01441518,Perinatal mortality and morbidity rates,Costs,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3400,NCT02601729,Evolution over time of HbA1c,Quality of life measured by the Diabetes Quality of Life for Youth for children,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
3401,NCT01653119,A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS,A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS,The proportion of any AST or ALT >3 x ULN or CK >5 x ULN,2012-04,UNKNOWN,INTERVENTIONAL,['NA']
3402,NCT00018486,,,,1999-04,COMPLETED,OBSERVATIONAL,['NA']
3403,NCT05088616,Change in A1c (from baseline to 90 days and 180 days),Change in identity and level of cultural connectedness (using part of Multigroup Ethnic Identity Measure survey questions) (from baseline to 90 days and 180 days),,2021-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3404,NCT05795439,HbA1C,Diet Acceptability,,2023-07-11,RECRUITING,INTERVENTIONAL,['NA']
3405,NCT03254381,Number of exercise classes attended at trial completion (6 months),Change in blood glucose levels as measured by finger prick glucose test,,2017-11-02,COMPLETED,INTERVENTIONAL,['NA']
3406,NCT05589155,Long term change in diabetes via fasting blood glucose,Quality of Life after using mHealth apps assessed by World Health Organization Quality of Life BREF questionnaire,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
3407,NCT01798030,Vitamin D,,PTH,2009-11,UNKNOWN,OBSERVATIONAL,['NA']
3408,NCT02312596,Percent of wounds healed,Quality of Life score,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
3409,NCT01011387,Mean Change in Wound Area.,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3410,NCT01307995,,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
3411,NCT05038020,To Investigate the Efficacy of AKST4290 Assessed by the Improvement in the DRSS Score From Baseline.,To Evaluate the Changes From Baseline in the Workplace Productivity and Activity Impairment General Health (WPAI-GH) Questionnaire.,,2021-08-17,TERMINATED,INTERVENTIONAL,['PHASE2']
3412,NCT05829642,Number of Participants with hospital readmission,Number of hypertension patients (all risk levels) with drug prescription appropriate,,2020-11-24,COMPLETED,OBSERVATIONAL,['NA']
3413,NCT02070510,Area under the lisinopril concentration-time curve,Maximum observed lisinopril plasma concentration,,2014-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
3414,NCT05409235,Proportion of participants who have improved by ≥ 2 steps from baseline in Diabetic Retinopathy Severity Scale (DRSS) scores,Time to administration of rescue therapy,,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE2']
3415,NCT01644500,Change From Baseline in HbA1c at 26 Weeks,Visual Analog Scale (VAS) Score at 26 Weeks,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3416,NCT03180710,Cmax_total,Number of hypoglycaemic events in each treatment arm,,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3417,NCT03794752,Response Speed to Visual-motor Skills to Identify Shapes and Objects With the Head-mounted Electronic Visual Enhancement Device,,,2015-02,TERMINATED,INTERVENTIONAL,['NA']
3418,NCT05769712,Elasticity of the supraspinatus tendon,Thickness of the supraspinatus tendon,Blood flow within the supraspinatus tendon,2021-03-01,RECRUITING,OBSERVATIONAL,['NA']
3419,NCT04135365,"Cognitive Function: Behavior Rating Inventory of Executive Function, Second Edition",Imaging,,2021-01-18,COMPLETED,OBSERVATIONAL,['NA']
3420,NCT04008147,insulin,alpha glycoprotein,,2019-07-03,RECRUITING,INTERVENTIONAL,['NA']
3421,NCT01930097,The positive incremental area under the curve of postprandial glucose excursions,Incremental area under the curve of the 4-hr postprandial glucose excursions but the reference glucose is set to 5.0 mmol/L if premeal glucose is less than 5.0 mmol/L.,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3422,NCT04421053,The incidence rate of infant outcomes,the value of gestational weight gain during third trimester,,2020-03-24,UNKNOWN,OBSERVATIONAL,['NA']
3423,NCT03498001,Change from Baseline Concentration of intramyocardial triglycerides at 6 months,,,2018-04-16,COMPLETED,INTERVENTIONAL,['NA']
3424,NCT03278236,Change in glycaemia,Change in food intake,,2017-09-21,TERMINATED,INTERVENTIONAL,['NA']
3425,NCT05733962,Percentage of time spent in 70 - 180 mg/dL glycemic range,Scoring of Diabetes Treatment Satisfaction (DTSQs) Questionnaire,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3426,NCT02106104,"Changes from baseline following 8-week treatment with linagliptin vs glimepiride on fasting and postprandial renal hemodynamics, measured as GFR / ERPF (determined by inulin/para-aminohippuric-acid clearance)",Blood Pressure and Heart Rate,DPP4- and ACE activity,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3427,NCT01940003,Glycemic control,Birth injury,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
3428,NCT05822232,Efficacy endpoint,,,2022-08-17,RECRUITING,INTERVENTIONAL,['NA']
3429,NCT03951805,Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring),"Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter)",,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3430,NCT00217061,Adherence to the decision to use or not to use statins,Trust in clinician,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3431,NCT05322213,Change in Vascular Endothelial Function,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3432,NCT03903042,Image Quality of Aurora camera,Outcome of artificial intelligence algorithm,,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA']
3433,NCT02501876,The rate of conversion to Alzheimer's disease (AD),The presence of common alleles for Alzheimer's disease (AD) and Diabetes mellitus type 2,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
3434,NCT01085292,Safety and tolerability of multiple intravenous doses of NOX-E36 in healthy subjects and patients with type II diabetes mellitus,Multiple dose pharmacokinetics and pharmacodynamics of NOX-E36 in healthy subjects and patients with type II diabetes mellitus,,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3435,NCT03861039,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Number of Participants With Anti-Tirzepatide Antibodies,,2019-03-30,COMPLETED,INTERVENTIONAL,['PHASE3']
3436,NCT03407833,Ability to establish organoid cultures,,,2018-02-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3437,NCT00883038,Insulin resistance,Visceral to subcutaneous fatty tissue ratio,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3438,NCT00261417,"Dose-response relationship of tesaglitazar in subjects with type 2 diabetes by the assessment of the effects of each of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) to placebo with respect to fasting plasma glucose",Assess the safety and tolerability of tesaglitazar compared to placebo,,2004-05,TERMINATED,INTERVENTIONAL,['PHASE2']
3439,NCT03978884,Proportion of Subjects achieving Target Blood Pressure,,,2019-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
3440,NCT00368095,,,,2006-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3441,NCT01779089,Change in 24 hour urine protein/creatinine ratio (average of 2 values) baseline compared to 6-months in placebo vs minocycline,Change in urine and blood biomarkers in minocycline vs placebo treated patients at baseline vs 6 mos,Safety,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
3442,NCT04482283,Proportion of patients diagnosed with symptomatic HF,,,2020-07-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3443,NCT01329016,Study drug dosage in pregnancy,Determine GLY and MET PK parameters,,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3444,NCT02183350,Assessment of tolerability by investigator on a 4-point scale,Change in plasma glucose levels,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3445,NCT02087293,Discontinuation of mediation,Adverse drug reaction awareness,Call metrics,2013-06,UNKNOWN,INTERVENTIONAL,['NA']
3446,NCT02657876,Number of participants with adverse events through study completion,,,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
3447,NCT06256614,"The Blood glucose of Time in Range (TIR, %) of type 1 diabetes mellitus.","The incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0",,2024-03-01,RECRUITING,OBSERVATIONAL,['NA']
3448,NCT02610036,presence of microangiopathy,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
3449,NCT04208295,Autonomic adrenergic measure,,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
3450,NCT00558909,Global tolerability - number of patients by category,PTF (peak trough fluctuation).,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3451,NCT05404295,The efficacy of UCB-PL in ulcer healing by assessing the change in ulcer size.,,,2019-06-10,COMPLETED,INTERVENTIONAL,['PHASE4']
3452,NCT02751398,subclinical diastolic dysfunction assessed by supine bicycle diastolic stress echocardiography,the impact of dapagliflozin on resting diastolic function,,2016-08-18,COMPLETED,INTERVENTIONAL,['PHASE4']
3453,NCT03255902,Effect of Intervention on Evening Glucose Control.,Difference Between Child's Pre-intervention and 3 Month Hemoglobin A1c Value,,2016-05-24,COMPLETED,INTERVENTIONAL,['NA']
3454,NCT01645891,Complete (100%) wound closure defined as complete re-epithelialization without drainage,Total Bates-Jensen Wound Assessment Tool Score,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
3455,NCT05146869,Change from baseline in active glucagon-like peptide1 concentration,Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point.,,2021-12-30,COMPLETED,INTERVENTIONAL,['PHASE1']
3456,NCT01069549,,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
3457,NCT05296759,Pittsburgh sleep quality index,,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3458,NCT00993603,To estimate the correlation between weight loss over 8 months achieved through a programme of intensive lifestyle management and changes in GLP-1 production over the same period in obese without presence of diabetes but with family history of diabetes.,"The secondary aim is to examine the changes in weight, cardiovascular risk factors and hormonal regulators of food intake and blood glucose metabolism.",,2010-09,COMPLETED,INTERVENTIONAL,['NA']
3459,NCT00861341,Percent Platelet Aggregation Induced by Collagen,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3460,NCT02316522,DNA methylation,Micro-RNAs,,2014-10-23,COMPLETED,OBSERVATIONAL,['NA']
3461,NCT00541697,Determine the additional LDL-C lowering achieved by switching to MK0653A as compared to Atorvastatin after 6 weeks of treatment,Determine the effect of MK0653A versus Atorvastatin on total cholesterol after 6 weeks of treatment,,2005-01-19,COMPLETED,INTERVENTIONAL,['PHASE3']
3462,NCT03906383,Diameter change of retinal vessels,,,2017-11-21,COMPLETED,INTERVENTIONAL,['NA']
3463,NCT03239366,Change in HbA1c levels from baseline,Evaluation of the safety profile of 2 capsules of Bio-K+50B® (dosage of 100 billions bacterias),,2017-09-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
3464,NCT00938405,To demonstrate a 10% LDL reduction in type 1 diabetic subjects with initial LDL > 100 after twelve weeks in the colesevelam group.,"In addition change in insulin dose at one, two and three months from baseline will be evaluated.",,2009-07,COMPLETED,INTERVENTIONAL,['NA']
3465,NCT02459496,change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter,"change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN, MSDD)",,2013-09,UNKNOWN,INTERVENTIONAL,['NA']
3466,NCT04533646,Time in Target,Hypoglycemia duration,,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
3467,NCT05809843,The measurements of retinal and choriocapillary vessel density in type 1 diabetic patients undergoing artificial pancreas device,,,2023-01-30,COMPLETED,OBSERVATIONAL,['NA']
3468,NCT04099550,Weight (Kg) change,lipid profile,,2019-12-06,UNKNOWN,INTERVENTIONAL,['NA']
3469,NCT06148649,Change from baseline of HbA1c at week 12,Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs),,2023-12-10,RECRUITING,INTERVENTIONAL,['PHASE2']
3470,NCT06222476,renal magnetic resonance imaging(MRI),HOMA2-IS,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3471,NCT02783066,Gait Speed Difference Between Pulseflow Offflaoding and Standard Offloading,Peak Forefoot Pressure,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3472,NCT01230749,Change From Baseline (Day -1) to Day 28 in Twenty-Four-Hour Weighted Average Glucose (24-Hour WAG),Change From Baseline to Day 29 in Body Weight,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3473,NCT05338125,Electrophysiological properties,Endocrine deficiencies,,2020-12-10,TERMINATED,INTERVENTIONAL,['NA']
3474,NCT06219590,Numerical rating pain scale,,,2023-10-28,RECRUITING,INTERVENTIONAL,['NA']
3475,NCT02510612,sedation level,noradrenaline measured by Biochemical test,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
3476,NCT00929539,Change in glycosylated hemoglobin (HbA1c) levels,Safety and tolerability data,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3477,NCT02312375,Insulinogenic index,"Urinary albumin creatinine ratio, urinary protein creatinine ratio",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3478,NCT04593693,"Goal of therapy: The wound bed is progressing acceptably towards a transition to another treatment modality such as Moist Wound Healing (MWH), surgical closure, or a flap or graft",Evaluate overall satisfaction from clinicians,Determine performance satisfaction of dressing components on periwound,2020-12-10,COMPLETED,INTERVENTIONAL,['NA']
3479,NCT02159378,Serum fructosamine rate,,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
3480,NCT01152242,"Part II: The within-subject coefficient of variation in time-action profile of glargine for AUC-GIR (AUC of glucose infusion rate), GIRmax (maximum level of glucose infusion rate), over the duration of action of glargine",Part II: The within-subject standard deviation in duration of action of glargine (the difference between onset of action and end of action),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3481,NCT01591525,,,,2012-06,UNKNOWN,OBSERVATIONAL,['NA']
3482,NCT02077686,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
3483,NCT01371747,Least Squares Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group,Proportions of Participants Achieving Serum Potassium Levels Within 3.8 to 5.0 mEq/L at Week 52 for Each Individual Starting Dose Group,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3484,NCT01375738,Blood sugar stabilization after gastrectomy,,,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
3485,NCT02671864,Prevalence of Severe DR at V1 (inclusion),Concentrations of blood circulating EPCs and PBMCs,,2016-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3486,NCT00000462,,,,1987-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3487,NCT04239521,Study 4: The incidence of a composite of viral infections in adult patients with Alopecia Areata,Study 4: The incidence of herpes simplex infection in adult patients with Alopecia Areata,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
3488,NCT04790175,Safety Information (Non-serious Adverse Events),,,2021-03-29,RECRUITING,OBSERVATIONAL,['NA']
3489,NCT00464854,Achievement of a fasting blood glucose of 130 mg/dl and a mean daily glucose level of 180 mg/dl during hospitalization,Hypoglycemia of < 60 mg% (symptomatic and asymptomatic),,2005-07,TERMINATED,INTERVENTIONAL,['NA']
3490,NCT04774822,To determine the sensitivity and specificity of RETINA-AI Galaxy to detect vision-threatening diabetic retinopathy in the primary care setting,,,2021-03-25,COMPLETED,OBSERVATIONAL,['NA']
3491,NCT05922033,Fasting glycemic control,Diabetes Distress Screening (DDS) Scale,,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE4']
3492,NCT01556152,Mean 24-hour average pain intensity (API) score,"Pharmacokinetics: Cmax, Tmax, AUC 0-tau, AUC0-24",,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3493,NCT00313547,Heart rate variability,Impact of selected pharmacogenetic polymorphisms,,2006-04,TERMINATED,INTERVENTIONAL,['PHASE4']
3494,NCT01939834,Time in range overnight,Time within target range,,2013-12,TERMINATED,INTERVENTIONAL,['NA']
3495,NCT01499472,healed ulcer,,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
3496,NCT04524949,Change in stimulated C-peptide response during the first two hours of a mixed meal tolerance test (MMTT) from baseline to 48 weeks between IMCY-0098 and placebo groups,To evaluate the safety features of IMCY-0098 on lymphocytes ratio,,2020-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3497,NCT04272099,"Glycemic control, health related quality of life and clinical phenotypes of PG1","Psychometric evaluation of the health literacy, health-related quality of life, self-esteem and self-efficacy questionnaires in PG1",,2017-06-20,RECRUITING,OBSERVATIONAL,['NA']
3498,NCT04634890,Total cholesterol,Subcutaneous adipose tissue transcriptome,,2016-08-11,UNKNOWN,INTERVENTIONAL,['NA']
3499,NCT00790556,Mean Change From Baseline in Hepatic Glucose Production (HGP) at Day 14,,Hepatic Glucose Production (HGP) at Baseline,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3500,NCT05123157,Mortality among patients with diabetic foot,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
3501,NCT02688075,Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at 6 and 12 Months,Number of Participants with Adverse Events (AEs) and Serious AEs,,2015-11-13,COMPLETED,OBSERVATIONAL,['NA']
3502,NCT01728714,"Number of people with type 2 diabetes treated with oral antidiabetics assessed as compliant with treatment after 1 year educational programme on diabetes, compared with normal clinical practice.","Measure level of satisfaction of the patient with treatment and medical care following 1 year educational programme on diabetes, compared with normal clinical practice.",,2014-05-19,COMPLETED,OBSERVATIONAL,['NA']
3503,NCT00652288,Maximum Glucose Infusion Rate (GIR) to maintain euglycemia,Time to Maximum Glucose Infusion Rate,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3504,NCT02798393,Decrease in Pain (MPI Pain Scale),Improvement in Sensation,Safety Assessment (incidence of treatment related AEs at each follow up visit),2016-06,TERMINATED,INTERVENTIONAL,['NA']
3505,NCT00256867,Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy,Number of of Participants With Laboratory Evaluations of Potential Clinical Concern at Any Time Post-baseline,,2005-08-18,COMPLETED,INTERVENTIONAL,['PHASE3']
3506,NCT02538055,Quality of Life (SF12),Diet - eating unhealthy foods because of pain in the past 7 days,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
3507,NCT00678704,The Erectile Function (EF) domain score of IIEF calculated as the sum of scores from Questions 1 to 5 and 15,Safety data,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3508,NCT04031300,Safety evaluation: paucity of adverse events,Device usability,,2019-06-01,WITHDRAWN,INTERVENTIONAL,['NA']
3509,NCT01411865,Death or non-fatal myocardial infarction,Prescription for nitrate,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
3510,NCT02891382,Change in Glycated Hemoglobin,Change in Weight,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
3511,NCT04094064,Mean Absolute Relative Difference (MARD) Between Continuous Glucose Monitor (CGM) Value and Venous Blood Glucose (vBGM),,,2020-02-19,COMPLETED,INTERVENTIONAL,['NA']
3512,NCT01265017,stimulated C-peptide response,Insulin requirement,,2012-07,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3513,NCT00885352,Change From Baseline in Hemoglobin A1c (A1C) at Week 26,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26,,2009-04-15,COMPLETED,INTERVENTIONAL,['PHASE3']
3514,NCT05541458,Body Weight - 12 month,,,2022-09-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3515,NCT02193984,Changes in HbA1c levels.,Changes in distress.,,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
3516,NCT03865394,Changes in wound size,Record of adverse events,,2019-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3517,NCT05666843,Cardiometabolic risk profile (DIAL risk score),Skeletal muscle fat infiltration,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
3518,NCT02607865,Change in HbA1c: Week 26,Change in CoEQ: Scores From the 4 Domains and the 19 Items,,2016-02-15,COMPLETED,INTERVENTIONAL,['PHASE3']
3519,NCT00961480,The area under the plasma concentration-time curve (AUC) after administration of sitagliptin/metformin (50/500; 50/850; 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets.,"Peak plasma concentration (Cmax) for metformin after administration of sitagliptin/metformin (50/500; 50/850, 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets.",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3520,NCT03226210,The primary endpoint was the between-group difference of MAGE,,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3521,NCT01097551,Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit),"Serum concentration of: CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin.",,2011-01,COMPLETED,OBSERVATIONAL,['NA']
3522,NCT06043245,Type 2 Diabetes (T2D) remission.,Epicardial fat,,2023-06-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
3523,NCT00976391,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26,"Change From Baseline in Body Weight at Weeks 36, 48 and 52",,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3524,NCT04594603,To record the vascular changes that may be present in the macular after uncomplicated phacoemulsification surgery by using OCTA,,,2021-04-13,RECRUITING,OBSERVATIONAL,['NA']
3525,NCT00784511,2-hr post load glucose,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3526,NCT05219942,Total crystalline insulin consumption,,,2020-12-01,RECRUITING,INTERVENTIONAL,['NA']
3527,NCT06078683,Changes in maximal exercise performance,Change in Cardiac function after acute ingestion of KE or placebo,Change in stiffness,2023-06-06,RECRUITING,INTERVENTIONAL,['NA']
3528,NCT00885118,Change From Baseline in 8-point Glucose,"CLR,ss",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3529,NCT02451137,Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia,"Percentage of Participants With at Least One Treatment-Emergent Hypoglycemia Event (Any Time of the Day, Nocturnal) Per Type of Hypoglycaemia During the Month 6 and Month 12 on Treatment Period",,2015-06-16,COMPLETED,INTERVENTIONAL,['PHASE4']
3530,NCT02475109,Number of Patients with Adverse Events,Time to first rescue treatment,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3531,NCT03526445,Hepatic lipid metabolism,Changes in appetite sensation,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
3532,NCT00784745,Incremental GLP-1 response during the mixed meal test. Assessed as AUC during the 4 hour test.,,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
3533,NCT04702477,Intervention Attendance,Program satisfaction and barriers for attending sessions,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
3534,NCT03557658,Urinary Glucose Excretion 0-48 Hours,,,2018-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
3535,NCT02734667,Time Spent in Hypoglycemia (< 70 mg/dL),C-peptide,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
3536,NCT04302012,Agreement between multiple EyeArt operations,,,2019-12-18,COMPLETED,OBSERVATIONAL,['NA']
3537,NCT06040567,Inflammatory Neuropathy Cause and Treatment (INCAT),Physical Activity Scale (PAS2),,2023-09-23,RECRUITING,OBSERVATIONAL,['NA']
3538,NCT04529317,Blood glucose fluctuations,Nutrient intake recorded,Serum albumin in g/dL,2016-05,COMPLETED,INTERVENTIONAL,['NA']
3539,NCT05856877,"Comparison of the blood-brain-barrier permeability in different age, weight, sex and metabolic risk groups",,,2023-05-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3540,NCT04303611,Weight Loss,,,2018-08-13,COMPLETED,OBSERVATIONAL,['NA']
3541,NCT03956914,Changes of blood glucose,Waist-hip ratio (WHR),,2016-06-02,COMPLETED,INTERVENTIONAL,['NA']
3542,NCT00400231,triglyceride levels,"HDL-C, Resistin, insulin resistance",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3543,NCT00917449,To evaluate the efficacy of long term (18 months) L-Arginine therapy in preventing or delaying clinical onset of type 2 diabetes mellitus in subjects with impaired glucose tolerance (IGT) and Metabolic Syndrome.,Define if the treatment with L-arginine can ameliorate insulin sensitivity and endothelial dysfunction and find new risk profiles and candidate genes able to characterize the sub-group of patients at higher risk to develop type 2 diabetes mellitus.,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3544,NCT01889784,Change in muscle oxygen uptake after phototherapy and placebo phototherapy with light emitting diode (LED) - 300J,Change in baroreflex sensitivity after phototherapy and placebo phototherapy with light emitting diode (LED) - 300J,Change in heart rate after phototherapy and placebo phototherapy with light emitting diode (LED) - 300J,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
3545,NCT05687812,Plasma c-peptide levels changes,Appetite regulation,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
3546,NCT00175266,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
3547,NCT02504086,Change in diabetes self-management behaviours as measured by Summary of Diabetes Self Care Activities (SDSCA; Toobert et al 2000),"Perceived usefulness and perceived ease of use of online support as measured by the Unified Theory of the Acceptance and Use of Technology (UTAUT) for telehealth (Kohnke et al., 2014 based on Venkatesh et al., 2003)",,2015-08,TERMINATED,INTERVENTIONAL,['NA']
3548,NCT00173641,,,,2005-09,UNKNOWN,OBSERVATIONAL,['NA']
3549,NCT02182830,Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks,Change From Baseline in Trough Seated DBP (mmHg) at Week 24,,2014-07-25,COMPLETED,INTERVENTIONAL,['PHASE3']
3550,NCT03191227,Metabolic syndrome,Anxiety,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
3551,NCT02692040,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability],Body Weight (Percentage Change From Baseline),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3552,NCT05294822,Changes in HbA1c values,Changes in glucagon,,2019-09-30,UNKNOWN,INTERVENTIONAL,['NA']
3553,NCT01592539,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
3554,NCT01046422,Fasting Plasma Glucose Improvement,Lipid profiles,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3555,NCT03911843,Number of Participants With Insulin Demand Adjusted for HbA1c %(IDAA1c) <9,,,2017-01-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3556,NCT04496817,Change in Retina Function,,,2022-07-11,RECRUITING,INTERVENTIONAL,['NA']
3557,NCT04040777,Mortality rate,,,2015-06,RECRUITING,OBSERVATIONAL,['NA']
3558,NCT05688332,Change in mean Glycated Hemoglobin (HbA1c) levels,Drug related AEs,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
3559,NCT01648244,Change in A1c,Demographic variables,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
3560,NCT02330276,Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites,Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3561,NCT05145998,Change in baseline blood glucose over 3 hours (glycemic response),Change in satiety sensation,,2018-05-23,COMPLETED,INTERVENTIONAL,['NA']
3562,NCT06126354,Relative change in serum C-peptide,Plasma glucose kinetics: endogenous glucose production,Serum cortisol level,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3563,NCT00964574,Mean change in Glycosylated haemoglobin (HbA1c),Mean change of Fasting Blood Glucose and Post Prandial Glycemia,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3564,NCT02776722,Chronic glycemic outcome - fasting insulin,,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
3565,NCT01689090,Diameter changes of retinal vessels,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
3566,NCT05446337,Facilitators and Barriers,Value-Based Healthcare,,2022-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3567,NCT03909269,HbA1c evaluated by the total mean glucose from continuous glucose monitoring,Hypoglycaemic events,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
3568,NCT03928249,Fasting glycemia,Rate of change in anthropometric parameters,,2019-12-01,COMPLETED,INTERVENTIONAL,['NA']
3569,NCT04012983,measurement of the level of FGF21 (pg/ml) in gingival crevicular fluid of healthy controls,measurement of the level of chemerin (ng/ml) in gingival crevicular fluid of healthy controls,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
3570,NCT04422821,Mean glycemia results (fasting and 1-h postprandial glucose concentrations),Neonatal glycemia,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
3571,NCT06094920,Treatment adherence,(Additive) treatment effects finerenone on fasting plasma glucose,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
3572,NCT00331162,Acute Rejection,Health Status and Quality of Life,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
3573,NCT00738114,assess impact of hyperglycemia and diabetes during the periop period on clinical outcome(mortality and morbidity)in patients undergoing general and non-cardiac surgery.,determine the scope of clinical inertia in patients with diabetes and untreated hyperglycemia in patients undergoing non-cardiac surgery,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
3574,NCT04269655,Percentage time in severe hyperglycemia of interstitial glucose values,Hospital readmission rate,CGM Satisfaction,2020-02-25,TERMINATED,INTERVENTIONAL,['NA']
3575,NCT04892771,Number of wound,Adequate footwear,,2021-05-20,COMPLETED,OBSERVATIONAL,['NA']
3576,NCT00949091,TAK-875 M-I renal clearance CLr,Absolute change from baseline to Day 14 in insulinogenic index,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3577,NCT01413542,"The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and Bradykinin (Group 1) or Glucagon Like Peptide-1 and Brain Naturetic Peptide (Group 2).",Effect of Treatment (DPP4 Inhibition vs. Placebo) on Venous GLP-1 Levels in Response to Arterial GLP-1 Infusion,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
3578,NCT01134107,Mean of Last Six 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Insulin Aspart 6D Pump Reservoir In-use,Number of Participants Who Achieve or Maintain a Glycated Hemoglobin A1c (HbA1c) Less Than or Equal to 6.5% and Less Than 7%,Change From Baseline to 12 Weeks Endpoint for Each Treatment in Blood Pressure,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3579,NCT01729130,Change in body fat distribution,,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
3580,NCT00791895,Percentage of subjects achieving HbA1c below 6.5%,,,2003-06-26,COMPLETED,INTERVENTIONAL,['PHASE4']
3581,NCT00493727,This research will test the possibility the Mucomyst given by mouth for a month will decrease oxidative stress and slow the disease.,Reduction of proteinuria,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
3582,NCT05141968,"Percent of HbA1c in children with T1DM for both intervention, and control groups.","Concentration of Vitamin D for both intervention, and control groups",,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
3583,NCT00263965,Whole-body insulin sensitivity by assessing the M value during high (80 mU/m2/min) insulin level euglycemic hyperinsulinemic clamp.,Safety and tolerability of tesaglitazar in patients with type 2 diabetes.,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2']
3584,NCT01925443,Muscle function,Quality of life,,2015-12,SUSPENDED,INTERVENTIONAL,['NA']
3585,NCT02147314,Accuracy of the Yofimeter as compared to the YSI 2300 Stat Plus Glucose Analyzer,Evaluate the usability of instructional materials.,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
3586,NCT01699763,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) in the High Glucose Range (>180 mg/dL),,2012-10,COMPLETED,INTERVENTIONAL,['NA']
3587,NCT01039532,Glycaemic control,Weight gain Hypoglycaemic episodes Adverse effects Cost effectiveness,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
3588,NCT03888872,Measuring Nerve Conduction Velocity,,,2019-03-12,COMPLETED,INTERVENTIONAL,['NA']
3589,NCT00940472,"Metabolic Control (Fasting glucose, postprandial glucose, HbA1C)",Adverse Events,,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3590,NCT00233142,hemoglobin A1C (indicator of blood glucose),quality of life,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3591,NCT04330079,Percent change in global myocardial perfusion reserve (MPR) index,"Change in blood pressure(systolic, diastolic both )",,2020-05-21,TERMINATED,INTERVENTIONAL,['PHASE4']
3592,NCT00753896,Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events,Change in Blood Pressure From Baseline to Week 52,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3593,NCT00289497,Intervention of device use decreases foot ulcers.,Comparison of foot ulceration from enhanced device group as opposed to control group.,,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3594,NCT04966754,Rate of mortality,Quality of life,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
3595,NCT01432405,Hepatic Fat,Plasma Adipocytokines,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3596,NCT01767688,Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞),Number of Participants Discontinued From Study Due to AEs,,2013-01-16,COMPLETED,INTERVENTIONAL,['PHASE1']
3597,NCT02765204,Change in plasma glucagon levels from baseline to 7 hours after single-dose administration of drug.,,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3598,NCT04392284,Treatment credibility,Changes in lipids,,2021-04-19,COMPLETED,INTERVENTIONAL,['NA']
3599,NCT00595504,Change in Abdominal Fat (DEXA).,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3600,NCT05481034,Percentage of time with sensor glucose measurements between 3.9 and 10.0 mmol/L,Proportion of participants with sensor glucose in the target range (3.9 - 10.0 mmol/L for >70% of the time.,Nature and severity of adverse events,2023-01-11,COMPLETED,INTERVENTIONAL,['NA']
3601,NCT00191581,"The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in IDDM patients treated BID with human insulin mix 50/50, vs the 2-hour PPBG excursion in patients treated BID with insulin lispro mix 50/50",Effects on fasting blood glucose values obtained throughout the study;,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3602,NCT00249314,,,,2005-11,UNKNOWN,OBSERVATIONAL,['NA']
3603,NCT04342455,"diagnosis accuracy (including sensitivity,specificity of the low-dose radiation and contrast agent exposure protocol for coronary CTA)",kidney function,,2018-10-07,UNKNOWN,INTERVENTIONAL,['NA']
3604,NCT01546558,"Area under the plasma concentration vs time curve over the dosing interval, at steady state (AUCtau) of metformin","Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
3605,NCT02980276,Insulin Initiation/Fasting Glucose,Gestational weight gain,Cost effectiveness and budget impact of metformin treatment in addition to standard care,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3606,NCT00815828,To compare the frequency of women who use insulin in the group who participate in the exercise program with the group that don't do the exercises,To verify the impact of the exercise program on the adequacy of capillary glycemic control of the pregnant women,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
3607,NCT04050553,Change in Mean Glucagon Concentration During Induced Hypoglycemia from Target Plasma Glucose (PG) Concentration of 100 Milligrams per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL,Mean Change in Heart Rate from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL,,2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1']
3608,NCT05197114,Feasibility and acceptability of the virtual summerlunch+At Home program,Changes in glycemic control as measured through HbA1C levels,,2022-01-25,UNKNOWN,INTERVENTIONAL,['NA']
3609,NCT00472888,,,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
3610,NCT04854187,Absolute change in fasting blood glucose for people with diabetes using air purifier and facemask,,,2021-03-25,RECRUITING,INTERVENTIONAL,['NA']
3611,NCT01636258,"Effect of ""FRESH"" Program on Weight Loss",Sleep,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
3612,NCT00097292,Development of type 1 diabetes,Metabolic and Autoantibody Assessments,,2004-02,RECRUITING,OBSERVATIONAL,['NA']
3613,NCT00430040,Brachial artery vascular reactivity at 6 months,"Oxidative stress in Mononuclear cells, serum and plasma at six months",,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4']
3614,NCT04530617,Rate of hospitalizations and oxygen use,,,2020-10-05,TERMINATED,INTERVENTIONAL,['PHASE2']
3615,NCT00681278,Attainment rate to the target blood pressure.,Change in DBP/SBP value during the follow-up period will be addressed. Change in the DBP/SBP value will be investigated according to the risk factors and concurrent disease.,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
3616,NCT02886884,Number of Treatment Emergent Serious Adverse Events (TE-SAEs),Tumor Necrosis Factor (TNF) Alpha Levels,,2017-10-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3617,NCT04671043,Hypoglycaemia,Area under the glucose curve post exercise,,2022-02-04,COMPLETED,INTERVENTIONAL,['NA']
3618,NCT04754334,Mean change in A1C,The mean change in fasting plasma glucose,,2021-03-16,TERMINATED,INTERVENTIONAL,['PHASE3']
3619,NCT04164602,incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes,Cost-benefit analysis,,2019-10-09,RECRUITING,OBSERVATIONAL,['NA']
3620,NCT01718925,Fatigue,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
3621,NCT01460459,HbA1c,quality of life,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
3622,NCT03830879,Fetal outcomes.,Neurodevelopment.,,2018-03-06,RECRUITING,OBSERVATIONAL,['NA']
3623,NCT05726461,Time in range(TIR),Frequency of serious adverse events about device,,2023-02-11,RECRUITING,INTERVENTIONAL,['NA']
3624,NCT02588950,Part B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R,Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R,,2016-01-12,TERMINATED,INTERVENTIONAL,['PHASE1']
3625,NCT01488734,25OH Vitamin D level,Markers of inflammation and metabolic control,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
3626,NCT01074268,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Extension Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3627,NCT03981627,ΔAUCPG(0-4h),Safety and tolerability (Adverse Events recording),,2019-06-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3628,NCT00633425,Change in interstitial glucose levels between the observation and maintenance phases.,HbA1c and fasting blood glucose levels.,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
3629,NCT06154135,Time in range,Reasons to stop using the DBLG-1 device,Patients who stop using the DBLG-1 system,2022-12-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3630,NCT00666458,Hemoglobin A1c (HbA1c) Change From Baseline to Week 18,Fasting Plasma Glucose Change From Baseline to Week 18 (mmol/L),,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3631,NCT03463941,Health Educators' Perceptions of Feasibility as Measured by Semi-structured Interviews,Goal Attainment as Measured by Days Per Week That Participants Exercised for 30 Minutes or More,,2019-01-05,COMPLETED,INTERVENTIONAL,['NA']
3632,NCT00814008,retinal blood flow after 1 hour of insulin clamp,"Mean blood velocities in ophthalmic artery, posterior ciliary arteries and central retinal artery after 1 hour of insulin clamp",,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3633,NCT00608049,"Systolic blood pressure (SBP), Low Density Lipoproteins (LDL) cholesterol, High Density Lipoproteins (HDL) cholesterol, triglycerides, and insulin sensitivity",Overall CVD risk using risk equations,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
3634,NCT02009527,Change in endothelial function,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3635,NCT01343589,fatty acid composition in plasma,phytanic acid,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3636,NCT03264976,exosomal miRNAs in serum samples,,,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA']
3637,NCT02788903,Number of Participants Diagnosed With COVID-19 Who Were Hospitalized,"Number of Patients With a COVID-19 Diagnosis and ICU Use, Ventilator Use, or Death",,2016-03,COMPLETED,OBSERVATIONAL,['NA']
3638,NCT01918865,Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy,"Change in FPG, weekly average SMPG, seven-point glucose profile, lipid profile, body weight, & BMI at Week 27 compared to Baseline as a measure of efficacy",,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3639,NCT01760746,The primary outcome will be the change in global levels of intraocular inflammatory cytokines in the aqueous humour of patients with Proliferative Diabetic Retinopathy.,Secondary outcome measure considers intraoperative complications during vitrectomy.,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
3640,NCT01181986,Reactive Hyperemia Index (RHI),Plasma Glucose,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
3641,NCT06035874,The change in liver fat content,Change between groups in HDL levels,,2023-10-15,RECRUITING,INTERVENTIONAL,['NA']
3642,NCT02925559,Glycemic Variability,Hypoglycemia,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
3643,NCT01316367,HbA1c level,Body Mass Index (BMI),,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
3644,NCT05597293,Number of participants with a change in HbA1c of 5.5 mmol/mol or more,Change in the Diabetes Quality of Life (DQOL) score,,2023-02-27,RECRUITING,INTERVENTIONAL,['NA']
3645,NCT00113620,Pain rating scale obtained from patient diaries,Additional diary rating scales and scores obtained from clinic visits,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3646,NCT01488877,Number of Participants With Confirmed and Severe Hyperkalemia,Change From Baseline in Sitting Pulse Rate at Day 15,,2012-01,TERMINATED,INTERVENTIONAL,['PHASE1']
3647,NCT00507494,proteinuria,"efficacy: filtration fraction, renal nitric oxide bioavailability, insulin resistance, platelet function safety: tolerability, plasma glucose, body weight, edema",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3648,NCT04409587,Percent time in euglycemia (BG 70 to 180 mg/dl) by CGM,Total daily insulin dosage,,2018-04-12,COMPLETED,INTERVENTIONAL,['PHASE4']
3649,NCT02683746,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26,Trough Plasma Concentration of Albiglutide Over Time,,2016-03-16,COMPLETED,INTERVENTIONAL,['PHASE3']
3650,NCT02811172,Collection of samples: mother's milk,Bioactive peptides,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
3651,NCT00839774,Postprandial dietary fatty acid oxidation,,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3652,NCT01713530,Change From Baseline in HbA1c (%),Incidence of Treatment Emergent Adverse Events (TEAE),,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3']
3653,NCT02912455,Change at Six Months Versus Baseline in Hemoglobin A1c Value (%),Change in Leg Bone Mineral Density,,2017-01-05,TERMINATED,INTERVENTIONAL,['PHASE4']
3654,NCT02920385,Area under the semaglutide plasma concentration-time curve during a dosing interval (0-24 hours) at steady state,Maximum observed SNAC plasma concentration during a dosing interval (0-24 hours) at steady state,,2016-10-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3655,NCT02629406,Endothelial precursor cell account (EPC),,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
3656,NCT00273286,treatment adherence,quality of life,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3657,NCT04783376,Capillary blood glucose levels six hours after the test meals.,assessment of serum triglyceride level three hours after the test meal following each intervention,,2021-04-12,COMPLETED,INTERVENTIONAL,['PHASE4']
3658,NCT04283201,New type 2 diabetes cases,,,2020-02-20,COMPLETED,INTERVENTIONAL,['PHASE2']
3659,NCT02866734,"The overall, & at different fee level, uptake (as a percentage of participants) of screening from those at-risk patients who attend private GP's","Prevalence of DR (overall, and for sight-threatening diabetic retinopathy) among diabetic patients in private primary care",,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
3660,NCT00502359,,,,2005-04,COMPLETED,OBSERVATIONAL,['NA']
3661,NCT03575988,"pulmonary function parameters(diffusing capacity for carbon monoxide of lung/unit volume,DLCO/VA,%)","Vascular endothelial function(endothelin-1,ET-1,μmol /L)","Serum lipid(Triglycerides,TG(mg/dl))",2018-07-03,UNKNOWN,OBSERVATIONAL,['NA']
3662,NCT03235050,Percent Change in Body Weight,Immunogenicity Endpoint: Median Titer of the Anti-Drug Antibodies (ADA) to MEDI0382 in the Positive Participants,,2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3663,NCT00044460,Change in HbA1c from baseline to Week 24.,Change in FPG (fasting plasma glucose) from baseline to Week 24; characterize the effects of rosiglitazone on the albumin-creatinine ratio at Week 24.,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4']
3664,NCT05149625,Hemoglobin A1c (HbA1c),"Fasting, postprandial plasma glucose",,2022-11-27,RECRUITING,INTERVENTIONAL,['NA']
3665,NCT00566475,hemoglobin A1c,"glucose levels, hypoglycemia, quality of life, satisfaction",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
3666,NCT03840343,Adverse Events,Kidney Function,,2019-10-23,TERMINATED,INTERVENTIONAL,['PHASE1']
3667,NCT02844660,Study Safety Measurement,Cost effectiveness of treatment,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
3668,NCT04769167,Maternal Immune Response,,,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3669,NCT01851694,Second-phase insulin response during GPA test,Change in insulin secretion among CF groups,,2013-05,RECRUITING,INTERVENTIONAL,['NA']
3670,NCT00713440,"Incretin effect before and after dysregulation of glucose homeostasis using high calorie diet, physical inactivity and administration of adrenocortical steroids.",GLP-1 and GIP response curves,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
3671,NCT01100892,"Change in lung function (FEV1, FVC)","Change in effort-dependent lung function: MIP, MEP, SnIP",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3672,NCT04207541,Proportion of insulin initiation,,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
3673,NCT00950898,plasma glucose levels,plasma insulin,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
3674,NCT05228340,Ulcer recurrence,Incremental cost-effectiveness in QALY's of flexor tenotomy after 2 years,,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
3675,NCT01241370,"Comparison of retinal microvascular endothelial function in obese insulin sensitive, insulin-resistant and type 2 diabetic subjects with retinal microvascular endothelial function in lean healthy control subjects.",Comparison of the Oral Glucose Tolerance Test (OGTT) in the different subject groups with skin and retinal endothelial function.,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
3676,NCT04193566,Change in Renal oxygenation,Change in baroreflex sensitivity,,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3677,NCT05941000,Change in Diabetes Distress,Change in Health-Related Problem-Solving,,2024-03-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3678,NCT01640834,Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose,Pharmacodynamics: Area Under the Glucose Concentration Curve After a Single Dose of Glucagon on Day 3,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3679,NCT00596297,Intra- and postoperative intra-ocular bleeding,Visual acuity,,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3680,NCT02017171,iGFR at the End of the Wash-out Period,Fatal or Non-fatal Cardiovascular Events,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3681,NCT02553408,Patient and Care provider satisfaction structured interview guide,,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
3682,NCT01084850,Corneal endothelium cell number,Corneal endothelium morphology,,2009-06,UNKNOWN,OBSERVATIONAL,['NA']
3683,NCT03885869,The Evaluation of Dual Task Performance,,,2019-03-25,COMPLETED,OBSERVATIONAL,['NA']
3684,NCT01101503,The metabolic memory effect of endothelium-dependent arterial dilation,,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3685,NCT03560505,Common fibular nerve fascicle properties,,,2018-05-16,COMPLETED,OBSERVATIONAL,['NA']
3686,NCT01275235,Risk of type 2 diabetes mellitus (T2DM),,,2012-12,TERMINATED,OBSERVATIONAL,['NA']
3687,NCT01054300,Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin,,,2010-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
3688,NCT02610738,Participant feedback on teaching,Change in perceived stress - parent participants,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
3689,NCT00320853,"OGIS Index, Total Insulin Secretion",ApoB,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
3690,NCT03094767,Change from baseline of Glycated Hemoglobin at 3 months,Change from baseline of the distance traveled at 3 months.,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
3691,NCT02255266,Frequency of patients achieving HbA1c reduction of at least 1%-point,Changes in blood pressure and lipid profile,,2015-03-26,COMPLETED,OBSERVATIONAL,['NA']
3692,NCT01512797,Change in Area Under the Curve (AUC) Glucose Levels After Mixed Meal Test,Active GLP-1,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
3693,NCT03700580,100% epithelization,80% epithelization,,2012-08-15,COMPLETED,INTERVENTIONAL,['PHASE2']
3694,NCT01919385,Evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting,Capturing the number of Adverse Events as a measure of assessing subject safety,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3695,NCT04124302,Postprandial glycemia,Hypoglycemia Episodes,,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
3696,NCT03401697,Number of Type 2 Diabetes patients that initiate HCV treatment,HCV cure rate,,2018-01-23,COMPLETED,OBSERVATIONAL,['NA']
3697,NCT02384447,ultrasonographic appearance,,,2014-06,WITHDRAWN,OBSERVATIONAL,['NA']
3698,NCT05493345,Feasibility and fidelity,Loneliness,,2022-08-05,RECRUITING,OBSERVATIONAL,['NA']
3699,NCT00596323,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
3700,NCT05564481,glycemic variability,Diabetes self-management,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3701,NCT02945540,Measuring patient satisfaction at childbirth by a questionnaire on satisfaction of hospital care,Neonatal blood glucose measurement,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
3702,NCT03406585,Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment,"Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372",,2017-11-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3703,NCT02763943,Patient reported survey results regarding psychosocial status from baseline to end of study,,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
3704,NCT05584085,Change from baseline HbA1c at 3 months post-intervention,Psychological flexibility,,2022-10-15,RECRUITING,INTERVENTIONAL,['NA']
3705,NCT02798757,Composite outcome measure. % change to the concentrations of specific metabolites.,,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3706,NCT04475861,PEDIS,,,2018-10-31,WITHDRAWN,INTERVENTIONAL,['NA']
3707,NCT00451321,Number of Participants With Positive Epstein Barr Virus (EBV) Viral Load,Change From Baseline in Percent Glycosylated Hemoglobin (HbA1c),,2006-07-31,TERMINATED,INTERVENTIONAL,['PHASE2']
3708,NCT05994755,"association between hypoglycemia, glycemic variability and cardiac arrhythmias","association between hypoglycemia, glycemic variability and heart failure",,2023-10-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3709,NCT02045199,Complete healing of target fissure on the heel,,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
3710,NCT01677611,Skeletal muscle sirtuin 1 (SIRT1) expression,Liver function,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3711,NCT04917471,Percentage recovery of left ventricular function,,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
3712,NCT06269120,Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%,Change in high sensitive C-reactive protein (hsCRP),,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3713,NCT05895552,Count of reported adverse events,,,2023-08-21,RECRUITING,INTERVENTIONAL,['PHASE2']
3714,NCT04062773,HbA1c,Inflammatory markers,,2019-07-10,UNKNOWN,INTERVENTIONAL,['NA']
3715,NCT02508844,Change in glucose levels (Oral glucose tolerance test),Change in HbA1c,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3716,NCT02156336,Fifty percent or greater reduction in the mean Numeric Rating Scale (11-point NRS 0-10) recorded in the subjects' diaries from ranolazine compared to placebo.,Occurrence of Serious Adverse Events after randomization,,2014-05,TERMINATED,INTERVENTIONAL,['PHASE4']
3717,NCT04306770,Diabetic control,Incidence of vascular complications,,2020-01-20,UNKNOWN,INTERVENTIONAL,['NA']
3718,NCT01106157,Change in Metabolic Function Baseline to 12 Months.,Change in White Blood Count (WBC) From Baseline to 12 Months,,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3719,NCT01144078,Feasibility of these exercise interventions in people with type 2 diabetes,Exercise Self-efficacy,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
3720,NCT04063930,Urinary albumin creatinine ratio (UACR),Urinary potassium,Safety outcome - Electrocardiogram,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
3721,NCT05965869,Evaluate the integration of the intervention,Provide acceptability data of the intervention,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
3722,NCT00515632,"HbA1c, fasting plasma glucose and 7-point plasma glucose profiles, weight gain, lower leg oedema and safety parameters.","Waist and hip circumferences, plasmaNT-proBNP, ECG, body composition as measured by DXA, blood lipid profiles, plasma insulin",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3723,NCT05290207,endocrine hormone changes,,,2022-01-06,COMPLETED,OBSERVATIONAL,['NA']
3724,NCT01498185,Mean Change From Baseline in 7-Point Glucose Monitoring (7-PGM) at Day 7,Pharmacokinetic Parameters on Day 7 - Ratio of Metabolite (RM) to Parent AUC[TAU],,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3725,NCT00486681,compare glycemic control of patients hospitalized in 3 departments,mean of % of glycemia for patients in warning phase with or without diabetologist intervention,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
3726,NCT04706481,"To discover the pathological mechanism of different acute and chronic diseases such as cancer, stroke, heart disease, dementia & diabetes",,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
3727,NCT03050619,Baseline Characteristics of Adults (as Measured by Concomitant Medications) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK,Baseline Characteristics (as Measured by Concomitant Medications) of Patients Starting Index Prescriptions Off-label,,2016-09-10,COMPLETED,OBSERVATIONAL,['NA']
3728,NCT00331487,Change in fasting triglyceride level,Apolipoprotein C-III.,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3729,NCT03522597,Breastmilk and infant microbiomes,Hormones and cytokines in infant serum,,2018-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3730,NCT01850615,Change From Baseline in HbA1c,Number of Adverse Events,,2013-09-23,COMPLETED,INTERVENTIONAL,['PHASE3']
3731,NCT01653392,Infant Outcomes,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
3732,NCT02605889,Improvement of blood postprandial glucose levels,Improvement of Nursing Diagnoses,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
3733,NCT05358080,Proportion of subjects maintained or improved in DRSS level,Proportion of subjects with CSME,,2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE4']
3734,NCT04804774,HbA1c,,,2021-03-23,COMPLETED,INTERVENTIONAL,['NA']
3735,NCT05256043,Length of hospital Stay,,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
3736,NCT04724330,Total gestational weight gain,Proportion of low birth weight infants,,2021-03-15,RECRUITING,INTERVENTIONAL,['NA']
3737,NCT01864460,Autonomic Function: heart rate variability,balance,Sweat gland nerve fiber density,2013-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3738,NCT02031341,"Fore-arm insulin uptake measured as ([A]-[V]) x F in pmol/min where A = arterial insulin concentrations, V= venous insulin concentrations, F = fore arm plasma flow;",,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
3739,NCT04143412,Urinary albumin/creatinin ratio (UACR),Serum K,,2019-02-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3740,NCT01055080,Beta-cell autoantibodies,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
3741,NCT00651105,GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjects,"Effects of LAF237 on prandial glucose profiles, prandial insulin, and gastric-emptying in patients with Type-2 diabetes and in matching healthy subjects.",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3742,NCT00780650,Change in level of catecholamines in blood from baseline,,,2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3743,NCT04092569,"Change from Baseline Blood Glycosylated haemoglobin, HbA1c at 9 months",The Chinese version of the Diabetes Empowerment Scale Questionnaire - Short Form,,2019-09-10,UNKNOWN,INTERVENTIONAL,['NA']
3744,NCT01702298,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C),,2012-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3745,NCT05935410,Glycemic Control (Hemoglobin A1C [HbA1C]),,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
3746,NCT05368402,"The proportion of responders at week 27/28 (visit 4), with responders defined as ""patients with an HbA1c reduction from baseline of ≥0.50% (absolute difference) without episodes of severe hypoglycemia",Incidence of Treatment Emergent Adverse Events (TEAEs) recorded from the beginning of study treatment to up to the end of study participation,,2022-07-27,TERMINATED,INTERVENTIONAL,['PHASE2']
3747,NCT06291129,Bleeding on probing,,,2022-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3748,NCT03223389,Within group difference in cholecystokinin (CCK) secretion (evaluated by AUC above basal).,Between group comparison of differences in CCK secretion (evaluated by AUC above basal).,,2017-08-07,UNKNOWN,INTERVENTIONAL,['NA']
3749,NCT03005288,Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48,Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial,,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3750,NCT00495469,Mean Change From Baseline in Hemoglobin A1c (Glycosylated Hemoglobin) (HbA1c) at Week 12,Number of Participants With Abnormal Hematology Value of PCI at Any Time on Therapy,,2007-08-17,COMPLETED,INTERVENTIONAL,['PHASE2']
3751,NCT04550520,Maximal increase in copeptin level,Maximal Change in oxytocin,,2020-09-28,COMPLETED,INTERVENTIONAL,['NA']
3752,NCT02529982,Change in pancreatic B-cell function,Waist circumference,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
3753,NCT00524875,early post-vitrectomy vitreous hemorrhage,Visual improvement,,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
3754,NCT04516200,sway index of sensory integration test,risk of fall index,,2020-08,UNKNOWN,INTERVENTIONAL,['NA']
3755,NCT05168657,"Percentage of individuals with mean CGM glucose <183 mg/dL (corresponding to an estimated HbA1c of <8.0%) on days 3-14, by group.","Percentage of individuals with mean CGM glucose <154 mg/dL (corresponding to an estimated HbA1c of <7.0%) on days 3-14, by group.",,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
3756,NCT02571738,"Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, by the End of Single-Blind Treatment Visit with follow-up confirmation of continued closure at 2 consecutive study visits 2 weeks apart","Percentage of patients who achieve complete wound closure, defined as 100% re-epithelialization as determined by the Investigator, who participate in the Open-Label Treatment Phase","Change in Quality of Life from Baseline, as determined by the Cardiff Wound Impact Schedule (CWIS)",2015-10,TERMINATED,INTERVENTIONAL,['PHASE3']
3757,NCT00543751,,,,2003-01,TERMINATED,INTERVENTIONAL,['PHASE3']
3758,NCT01337362,EEG,Cognitive function,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
3759,NCT03819335,Empowerment,Satisfaction with the app,,2019-04-09,COMPLETED,INTERVENTIONAL,['NA']
3760,NCT03938324,Change in Patient activation as measured by the Patient Activation Measure (PAM-13),Change in Emotional Health as measured by the Brief Symptom Inventory (BSI 18),,2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3761,NCT04667728,Change From Baseline in HbA1c at 3 Months,,Change From Baseline in daily fat intake at 3 Months,2017-05-30,COMPLETED,INTERVENTIONAL,['NA']
3762,NCT01199783,Clinical Response of the Infection at Test-of-cure (TOC) at Day 14 Post Therapy,Rate of Amputations Due to Infection,,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3']
3763,NCT00001612,,,,1997-05,COMPLETED,OBSERVATIONAL,['NA']
3764,NCT02898766,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
3765,NCT02916576,System accuracy criteria (see description),,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
3766,NCT06246799,Number of subjects failing to achieving HbA1c <6.5% Long-term,Change in body weight,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
3767,NCT05948592,3. Percentage of patients that achieve a 50% reduction in wound surface area by week 4,4. Percentage of patients with target strain not-susceptible to TP-102 for TP-102 versus Placebo at EOT;,,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
3768,NCT01966432,Treatment for Drug Use or Alcohol,,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
3769,NCT04603508,Percent change from baseline of LDL-c levels.,Incidence and severity of adverse events recorded during the study.,,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
3770,NCT01756703,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Plasma concentrations of MT-3995 and its major metabolite,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3771,NCT01086111,insulin sensitivity and beta cell function,changes in plasma levels of gut hormones and inflammation markers,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
3772,NCT05211479,Evaluation of the anxiety level of adolescents with type 1 diabetes,,,2021-12-20,COMPLETED,INTERVENTIONAL,['NA']
3773,NCT01194479,Norepinephrine (pg/mL),Blood Glucose Levels (Average),,2010-08,COMPLETED,INTERVENTIONAL,['NA']
3774,NCT02839226,"comparison of the formation of new granulation tissue according to a Granulation Score, between the AR/101 treated group and the placebo group, during the treatment phases",Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 2,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
3775,NCT00762671,Endothelium-dependent and endothelium-independent vasodilation of peripheral resistance and conduit vessels will be studied in diabetic (type 1 and 2) and healthy subjects two weeks following randomization to the ebselen or placebo.,,,1999-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3776,NCT04784637,Number of SAE or ADE Related to the Use of ATM / WST and BAM Modules.,INSPIRE Questionnaire,,2021-07-23,COMPLETED,INTERVENTIONAL,['NA']
3777,NCT02460081,Transcutaneous oxygen measurement (TCOM),Patient Global Impression of Change in Neuropathy (PGICN),,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3778,NCT02450500,Participants acceptability of intervention by focus group,"Health status, well being, food intake and exercise levels by questionnaires",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3779,NCT04454827,Fear of Hypoglycemia,HbA1c,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
3780,NCT01158131,Postpartum weight loss,,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3781,NCT05855863,Cognitive function testing,Attention assessment,Concentration of irisin,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
3782,NCT03896360,Proportion of participants achieving a normal 2-hour glucose (less than 140mg/dl) and/ or greater than or equal to 15% improvement in 2-hour glucose,,,2019-02-28,COMPLETED,INTERVENTIONAL,['NA']
3783,NCT05740254,Mean change in weight in excess of the 95th percentile at week 24 compared to baseline,Mean change in systolic and diastolic blood pressure at week 24 compared to baseline,,2023-03-27,RECRUITING,INTERVENTIONAL,['NA']
3784,NCT00432809,Success Rate of Biochemical Resolution of Diabetes at 12 Months as Measured by HbA1c ≤ 6% With no Diabetes Medications,Cardiovascular Medications - Anticoagulants,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
3785,NCT01123239,Hemoglobin A1c,Health-related quality of life,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
3786,NCT06246578,Difference between paired Dexcom and Libre glucose values,,,2024-01-19,RECRUITING,INTERVENTIONAL,['NA']
3787,NCT03092310,Percent time within the target glucose range of 70-180 mg/dl overall as assessed by continuous glucose monitoring (CGM).,Failure analysis of the devices/connectivity issues that may occur (# disconnects and device restarts).,,2017-03-20,COMPLETED,INTERVENTIONAL,['NA']
3788,NCT01580462,,,,2012-04,UNKNOWN,OBSERVATIONAL,['NA']
3789,NCT03514238,Insulin Sensitivity,,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
3790,NCT01106287,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3791,NCT06003751,Systemic Adverse events,,,2023-08-05,RECRUITING,INTERVENTIONAL,['PHASE2']
3792,NCT01722240,HbA1c (%),Body Weight,,2012-11-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3793,NCT00151021,Step-count bout ratio = 7 day average of steps taken during 10 minute bouts in one day divided by total steps taken during the same day,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
3794,NCT05279911,Osteoprotegrin (OPG) level,,,2021-03-03,COMPLETED,INTERVENTIONAL,['NA']
3795,NCT02681874,Increase in Healthy Food Dietary Patterns,Improvement in Parental Feeding Behaviors,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
3796,NCT02134860,Insulin resistance,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3797,NCT03324971,Change in Hemoglobin A1c,,,2017-06-02,COMPLETED,INTERVENTIONAL,['NA']
3798,NCT01136096,Exercise behavior,Exercise behavior,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
3799,NCT06048510,Incidence of GDM diagnosed during pregnancy.,Neonatal morbidity 4,,2023-12-18,RECRUITING,INTERVENTIONAL,['NA']
3800,NCT03192228,Success rate of the therapeutic education program,Long term success rate of the therapeutic education program,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
3801,NCT01519102,Incremental area under the curve of plasma glucose concentration as compared to pre-meal glucose value of the postprandial glucose excursions,Percentage of postprandial time of plasma glucose concentrations spent in the low range (below 4.0mmol/l),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3802,NCT02561377,glycemic control,Incidence rate of diabetes,,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
3803,NCT00829699,Percent change in flow mediated dilation of brachial artery,Change in Lipid measures,,2009-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3804,NCT00600730,fMRi scans,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
3805,NCT04369833,Number of Participants With Insulin Resistance,,,2020-05-11,COMPLETED,OBSERVATIONAL,['NA']
3806,NCT02600338,Mean arterial pressure,,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
3807,NCT02985866,Time Above 180 mg/dL,Coefficient of Variation,,2017-10-27,COMPLETED,INTERVENTIONAL,['NA']
3808,NCT01297387,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
3809,NCT04540536,Change in hemoglobin A1c after three-month follow-up visit after remote continuous glucose monitoring monitoring and secure text messaging.,,Average time spent by medical provider per participant per day.,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
3810,NCT02981069,Change in Endogenous Glucose Production (EGP) After 16 Weeks of Treatment With Each Study Drug.,Change in Plasma Insulin Concentration,,2017-12-15,COMPLETED,INTERVENTIONAL,['PHASE4']
3811,NCT02933424,Change in body composition,Meal challenge,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
3812,NCT00835861,Blood Glucose Measurements,Number of Babies With Adverse Neonatal Outcomes,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3813,NCT04127448,Change in Verbal fluency test (VFT) from baseline to 6th week,Change in Random Blood sugar (RBS) from baseline to 6th week,Change in respiratory rate in breaths/min from baseline to 6th week.,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
3814,NCT03495362,Changes in islet function,Changes in hepatorenal function,,2018-03-13,UNKNOWN,INTERVENTIONAL,['NA']
3815,NCT03199053,Change from baseline in HbA1c at Week 26,"Percentage of subjects with baseline HbA1c ≥ 7%, who achieve an HbA1c level < 7.0% at Week 26",Percentage of subjects with baseline HbA1c ≥ 7% who achieve an HbA1c level < 7.0% at Week 52,2017-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3816,NCT03102476,"Onset of action, time from trial product administration until the blood glucose concentration has decreased at least 0.3 mmol/L (5 mg/dL) from the baseline",Time to maximum glucose infusion rate curve,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
3817,NCT00773279,HbA1c (Glycosylated Haemoglobin) for Participants Treated With PDS290 and FlexPen®,"Hypoglycaemic Episodes, Number of Events Per Subject Day",,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3818,NCT05428943,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Serum samples collected to determine glucose levels (mmol/L) pre and post mixed meal tolerance test,,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE1']
3819,NCT06173934,Characteristics of gastric emptying(the gastric half-emptying time ) in patients with type 1 diabetes.,The blood glucose,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
3820,NCT01646047,Changes in visual function,Changes in retinal structure,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
3821,NCT05669547,Time in Range (TIR) at 12 months (measured with an independent FSL Pro IQ sensor),Percentage of time glucose control algorithm active DHFCL outcomes,Reasons for discontinuation of the DHFCL treatment.,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3822,NCT00408993,Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score,Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Uric Acid,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3823,NCT03061266,Glycated hemoglobin (HbA1c),quality of life using questionnaire,,2016-03-09,UNKNOWN,INTERVENTIONAL,['NA']
3824,NCT06059404,Mini Nutritional Assessment-Short Form,Falls efficacy scale,,2023-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3825,NCT05284344,Gastric-half emptying time of the 75 g glucose drink,Heart rate,,2021-01-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3826,NCT06223204,Change of the electrical impedance tomography (EIT) signal of the thoracic region across the glycemic trajectory.,"Performance of the machine learning model to predict glucose values from the above-mentioned signals (EIT, symptoms, voice, physiological signals) using the Clarke Error Grid.",,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3827,NCT03477786,development of microalbuminuria,development of cardiovascular events,,2013-10-28,UNKNOWN,INTERVENTIONAL,['NA']
3828,NCT01272583,Glucagon Response to Acute Hypoglycaemia,Symptomatic Hormone Responses to Acute Hypoglycaemia.,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
3829,NCT06115460,Percentage of Time in range,Level of Stromal cell-derived factor-1 (SDF-1),,2022-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3830,NCT01607450,Myocardial Glucose Uptake.,GLP-1 Concentrations,,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3831,NCT01201928,"Comparison of change from baseline to final treatment visit in pulmonary function (FEV1 FVC, TLC and DLco) between treatment Groups (TI vs comparator arms) using ANCOVA models.",,,2010-10,TERMINATED,OBSERVATIONAL,['NA']
3832,NCT03396146,Measurement of pancreatic polypeptide for calculating the area under the curve,Measurement of fecal elastase level,,2018-06-14,COMPLETED,INTERVENTIONAL,['NA']
3833,NCT05039645,Patient Adherence,DFU Incidence rates and severities,,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
3834,NCT03411395,Blood glucose response,Capillary blood glucose response,,2016-10-13,COMPLETED,INTERVENTIONAL,['NA']
3835,NCT02895750,Efficacy of once daily Metformin XR on 24-h blood glucose control,Tolerability of Metformin XR in mild to moderate (CKD) 2,,2017-08-30,COMPLETED,INTERVENTIONAL,['PHASE2']
3836,NCT01695629,changes between control and diabetic patients,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
3837,NCT00535535,"A comparison of the iAUC in VLDL TG palmitate 4 hours after F:G1:1, 1g/kg, vs. 1) fructose 0.5g/kg, and 2) F:G:1:1, 2g/kg.",Linear regression analysis of the relationship between the iAUC in VLDL TG palmitate after oral fructose and markers of carbohydrate and lipid flux,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3838,NCT03342274,Weight loss,Triglycerides,,2018-02-16,COMPLETED,INTERVENTIONAL,['NA']
3839,NCT05548218,Change in A1C level,,,2022-08-15,RECRUITING,INTERVENTIONAL,['NA']
3840,NCT02491814,Subjective Appetite,Food Intake,,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3841,NCT02027103,Serum concentrations of osteoprotegrin,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
3842,NCT04665102,Validation of Image classification by transfer learning algorithm,,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA']
3843,NCT00771901,Body Composition,VLDL-triglyceride (TG) Concentration,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
3844,NCT05694741,"Adverse Events (AEs), and Serious Adverse Events (SAEs)",Maximum observed concentration (Cmax),,2022-12-20,TERMINATED,INTERVENTIONAL,['PHASE1']
3845,NCT03302377,Feasibility of recruitment,Physical activity change,,2017-10-03,COMPLETED,INTERVENTIONAL,['NA']
3846,NCT01517919,"Changes in clinical, self-care and diabetes-related quality of life from baseline","Changes in clinical, self-care and diabetes-related quality of life from baseline",,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3847,NCT00918151,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
3848,NCT06334172,Insulin secretion - c-peptide,Procollagen type I N-terminal propeptide (P1NP),,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
3849,NCT00450489,,,,2008-06,WITHDRAWN,OBSERVATIONAL,['NA']
3850,NCT06146036,Incremental Area Under the Curve (AUC),Blood pressure,,2024-01-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3851,NCT04172337,Change in average calories per serving purchased per shopping trip,Calories per dollar spent per shopping trip,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
3852,NCT01483781,Change in hematology laboratory analytes,Change in percent Hemoglobin A1c (HbA1c),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3853,NCT06066528,Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76,Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L),,2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
3854,NCT00912002,Mean Percent of Dose Recovered in Urine and Feces Following a Single Oral Dose of [^14C]MK-0941 (160 µCi).,Number of Participants Who Discontinued the Study Due to An Adverse Event,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3855,NCT02523001,uAQP2,Cholesterolemia,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
3856,NCT01092663,Postprandial Glucose (AUC),Postprandial Glucagon (AUC),,2010-03,COMPLETED,INTERVENTIONAL,['NA']
3857,NCT00439985,quality of life,parent-child collaboration,,2006-09,TERMINATED,INTERVENTIONAL,['NA']
3858,NCT05505669,Changes in frequency of circulating biomarkers that correlate with beta cell death from type 1 diabetes patients compared to other cohorts,,,2022-03-29,RECRUITING,OBSERVATIONAL,['NA']
3859,NCT04702672,Postprandial glycemic response,Visual analogue scale (VAS),,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3860,NCT00795600,Absolute Change in Trunk Fat Mass,Number of Non-serious Adverse Events,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3861,NCT02059005,Change in Substance Use Rates From Baseline,Number of Hospitalizations and Use of Emergency Services,,2014-11-18,COMPLETED,INTERVENTIONAL,['NA']
3862,NCT01193218,Change From Baseline in HbA1c After 12 Weeks of Treatment.,Change From Baseline in FPG,Confirmed Hypoglycaemic Adverse Events,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3863,NCT01142908,Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent),HBA1C in Diabetic Patients,,2011-11-01,COMPLETED,INTERVENTIONAL,['NA']
3864,NCT02384226,Engagement with the Application,Acceptability of the Application,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
3865,NCT01937858,Correlation,,,2012-07,TERMINATED,OBSERVATIONAL,['NA']
3866,NCT04663282,Change in HbA1c,Serum INS068 concentration,,2021-02-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3867,NCT05023538,Global longitudinal strain (%),"Calf muscle oxygen saturation (haemoglobin variables: ΔHHb, ΔtHb, ΔHbO2 and ΔTSI%)",,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
3868,NCT00488423,To assess the effect of gastric by-pass surgery to decrease lipotoxicity.,To examine the effect of roux-en-Y compared to gastric banding on pancreatic B cell recovery or insulin secretion in response to oral and IV glucose.,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3869,NCT02272348,To assess the impact of therapeutic education by functional insulin therapy in patients with type 1 diabetes on their ability to disease self-management.,"To assess the validity, the concordance and the sensitivity to change of EAD questionnaire (specific for self-management of diabetes) in comparison with CIDS test",,2015-02-10,TERMINATED,INTERVENTIONAL,['NA']
3870,NCT01476345,Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus,Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3871,NCT06115616,g of glucose,,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3872,NCT02068027,Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score,Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3873,NCT00639613,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
3874,NCT02222623,Mean daily blood glucose,Hospital mortality,Length of hospital stay,2015-04,WITHDRAWN,INTERVENTIONAL,['NA']
3875,NCT02916706,Change in HbA1c From Baseline to Week 24,The Changes in Fasting Plasma Glucose (FPG) at Week 24,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3876,NCT05559892,Quality of Life as measured by SF-12,Self-Care,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
3877,NCT00224224,"To identify the differences between primary care and traditional medicine residents in clinical performance, continuity of care and utilization of resources.",,,1995-01,COMPLETED,OBSERVATIONAL,['NA']
3878,NCT02227485,Modified Gingival Index,Satisfaction of Patients,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
3879,NCT00932048,Vascular inflammation analyzed by PET: Define attenuation of plaque inflammation (plaque SUV or TBR) at 12 weeks,Change in carotid plaque thickness by ultrasound,,2011-08,WITHDRAWN,INTERVENTIONAL,['NA']
3880,NCT00988182,"Blood glucose, Insulin, Subjective appetite",Physical comfort,,na,COMPLETED,INTERVENTIONAL,['NA']
3881,NCT00434811,Proportion of participants with a HbA1c less than 7.0% AND free of severe hypoglycemic events,"Acute insulin response to glucose insulin sensitivity, and disposition index derived from the FSIGT test",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3882,NCT02344992,Area under the blood glucose time curve: AUCbg(0-2h),"Safety and tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3883,NCT03335930,exercise-induced glucose response,trend of post-exercise blood glucose,,2009-03-01,COMPLETED,INTERVENTIONAL,['NA']
3884,NCT01565096,Postprandial increase in intact proinsulin levels in patient treated with Vildagliptin and Metformin compared to intact proinsulin levels in patients treated with Glimepiride and Metformin (Area under the curve 0-300 min),Drug related adverse events,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
3885,NCT04816890,Body weight change from baseline to week 16 of treatment,Hypoglycaemic episodes,,2021-03-23,COMPLETED,INTERVENTIONAL,['PHASE2']
3886,NCT03221452,Change in Diabetes Self-Care Activities,Center for Epidemiologic Studies Depression Scale,,2016-09-02,UNKNOWN,INTERVENTIONAL,['NA']
3887,NCT02204397,Safety and tolerability,Composite C-Peptide efficacy according to specific parameters,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3888,NCT01831765,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change in PPG (Postprandial Glucose),,2013-08-26,COMPLETED,INTERVENTIONAL,['PHASE3']
3889,NCT00793884,Social and Demographic Characteristics,Change in Diastolic Blood Pressure,,2008-10,SUSPENDED,OBSERVATIONAL,['NA']
3890,NCT00628212,Change From Baseline in HbA1c at Week 12,Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3891,NCT01578096,Hemoglobin A1c,Diabetes specific distress,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
3892,NCT05492630,AUC0-∞,,,2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
3893,NCT05514925,Intraoperative bleeding,Visual acuity,,2017-11-21,RECRUITING,INTERVENTIONAL,['PHASE4']
3894,NCT02084004,Change in HbA1c from baseline to week 12,Adverse effects,,2015-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3895,NCT03889977,Changes in blood triglycerides,Changes in substances that react with thiobarbituric acid (TBARS),,2019-02-11,COMPLETED,INTERVENTIONAL,['NA']
3896,NCT01989975,Subject Experience After Using the Carelink Connect Device,Number of Participants With Investigational Device Deficiencies,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
3897,NCT01544881,"PK measures for RAA (8U) as measured by area under the concentration-time curve (AUC 0-360) - timepoints 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing","Area under serum glucose infusion rate (GIR AUC 0-360) for RAA (8U) as measured by: GIR AUC 0-360 timepoints: 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing",,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3898,NCT00347698,Score on a patient satisfaction scale at six months and one year,Complications associated to each treatment,,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3899,NCT03550976,Incidence of gestational diabetes,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
3900,NCT06070103,"Depression ,Anxiety and stress disorders among diabetic patients in Assuit University Hospitals.",,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3901,NCT04455867,Neuropsychological function,Cognitive Status,,2017-12-21,RECRUITING,OBSERVATIONAL,['NA']
3902,NCT06301022,serum potassium,,,2022-12-15,RECRUITING,OBSERVATIONAL,['NA']
3903,NCT02893891,SF-36 Questionnaire evaluation,Effectiveness evaluation,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
3904,NCT01943045,Fasting Plasma Glucose,Lipids,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3905,NCT02372578,Change from Baseline in mean 24-hour average pain intensity as reported on the NPRS,Clinical Global Impression of Change (CGIC),,2015-05-27,TERMINATED,INTERVENTIONAL,['PHASE2']
3906,NCT00139659,Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco),Severe Hypoglycemic Event Rates,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3907,NCT00685594,development of diabetes type 2,change in telomer length,Oral glucose tolerance response to vitamin D supplementation in relation to polymorphisms in the vitamin D system,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3908,NCT03728647,nursing hours,insulin performance rate,,2013-08-16,COMPLETED,INTERVENTIONAL,['NA']
3909,NCT03675269,Change in wound size,,,2018-09-05,WITHDRAWN,INTERVENTIONAL,['NA']
3910,NCT01699074,Effect of KWG on vascular and glycemic measures,Effect of KWG on vascular and glycemic measures,KWG and satiety,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1']
3911,NCT00330733,Change in Systemic Glucose Disposal- Glucose Infusion Rates,Plasma Adiponectin,,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3912,NCT03280524,Quality of Life Questionnaire SF-36,,Stanford Health Assessment Questionnaire,2016-01,COMPLETED,INTERVENTIONAL,['NA']
3913,NCT00371007,"HbA1c, safety and tolerability",Plasma glucose,,2004-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3914,NCT05604352,Assessing the safety of the DiaSole insole,acceptability of DiaSole to health care professionals (HCPs),,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3915,NCT04083820,Change in Glycated Haemoglobin A1c (HbA1c),Patient completed the study under treatment with semaglutide (yes/no),,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
3916,NCT01884363,Change in reactive hyperemia index occurring between baseline and 12 weeks (end of intervention),Change in blood levels of hormones produced by fat cells between baseline and 12 weeks (end of intervention),Change in heart rate variability between baseline and 12 weeks post-intervention,2013-06,COMPLETED,INTERVENTIONAL,['NA']
3917,NCT02346344,"Repeatability of the meal tolerance test and the arginine stimulation test, as indicated by the ICC (intraclass correlation coefficient)",,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
3918,NCT02749942,Peripheral tissue oxygen oxygenation of dorsal part of foot,Cardiovascular Autonomic neuropathy; Heart rate variability,"Assessment of quality of life and empowerment, 4",2016-05-11,COMPLETED,INTERVENTIONAL,['NA']
3919,NCT02022111,Percentage of Combined Improvement of Depressive Symptoms and CVD Risk Factors,Cost Utility in the Treatment Arm and Usual Care Arms,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
3920,NCT05769868,Ejection Intraventricular Pressure Difference (EIVPD) measure,Matrix metalloproteinase-1 (MMP-1),,2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE3']
3921,NCT05048719,Change From Baseline in HbA1c in LY3502970 as Compared to Placebo,Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970,,2021-09-15,COMPLETED,INTERVENTIONAL,['PHASE2']
3922,NCT05869734,Sleep efficiency,Self-management of urologic health,,2023-05-30,RECRUITING,INTERVENTIONAL,['NA']
3923,NCT03800901,Change in the percentage of evidence-based diagnostic and treatment decisions made in the simulations.,Impact of available CME and ABIM MOC on retention rate,,2019-01-11,COMPLETED,INTERVENTIONAL,['NA']
3924,NCT03119584,Improvement in frequency of bowel movements,,,2015-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
3925,NCT00918138,Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4,"Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning Meal",Participants With Reported Hypoglycemic Adverse Events During Treatment Period,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3926,NCT00194558,Hemoglobin A1c,Satisfaction with care,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
3927,NCT05918484,Specificity,Percentage of iCGM in MODY patients,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
3928,NCT00689546,Duration of icteric hepatitis.,Mortality,,2007-02,UNKNOWN,OBSERVATIONAL,['NA']
3929,NCT01447121,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15mg/dL (<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Study Staff Results Within +/- 15mg/dL (<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method When Testing Subject Blood Glucose (BG),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
3930,NCT05773209,Changes in subfoveal choroidal thickness,Changes in DR grading,,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3931,NCT01061060,Symptomatic improvement by Total Symptom Score (TSS),Change in mean rate of blood flow in the toes,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3932,NCT01935466,Bladder cancer rate,,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
3933,NCT00865033,Bioequivalence according to US FDA guidelines,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3934,NCT00806169,Best Corrected Visual Acuity,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3935,NCT01998269,Measure of Medication Self-Management (MeDS),,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
3936,NCT01810822,Albumin to Creatinine Ratio,,,1994-05,COMPLETED,OBSERVATIONAL,['NA']
3937,NCT00588380,Insulin Secretion at 150-180 Minutes.,Insulin Secretion at 210-240 Minutes,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
3938,NCT01804803,Changes in HbA1c from baseline value,"Subgroup analyses of changes in HbA1c from baseline according to patients' age (<45 yrs, >45yrs), type of diabetes (type 1, type 2), and diabetes duration (<5 yrs, >5 yrs)",,2013-09-09,COMPLETED,INTERVENTIONAL,['NA']
3939,NCT00655798,inflammation parameters,glucose and fat response,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
3940,NCT00535483,,,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
3941,NCT05630508,User friendliness,physical performance assessments - endurance,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
3942,NCT01397513,Fibrin network permeability,Platelet microparticles,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3943,NCT02691429,ocular inflammation,complications of the posterior segment,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
3944,NCT01769404,Concentration of Epinephrine,Concentration of Norepinephrine,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
3945,NCT04031417,Hypoxia and low humidity on the endothelial function in healthy volunteers and patients with type 2 diabetes using Wilcoxon signed rank test,,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
3946,NCT01114061,show no increase in hypoglycemia events when the InsuPatch device is used compared to the number of hypoglycemia events when the InsuPatch device is not used.,,,na,SUSPENDED,INTERVENTIONAL,['NA']
3947,NCT04521452,Change in aortic valve calcium volume at week 96 from baseline,Time of major cardiovascular event,,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
3948,NCT00251953,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3']
3949,NCT02202876,Acute oxidation,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
3950,NCT02287883,PHQ-4,,,2015-04,COMPLETED,OBSERVATIONAL,['NA']
3951,NCT06063109,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Pharmacokinetics - PTF,,2023-10-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3952,NCT02664207,Post-operative complications,,,2016-01-26,RECRUITING,INTERVENTIONAL,['NA']
3953,NCT01927562,Changed in Mixed Meal Tolerance From Baseline to 3 Months,,,2013-07-13,COMPLETED,INTERVENTIONAL,['NA']
3954,NCT05404061,Prospective assessment of gut hormone response pre and post-surgery: Change in Peak plasma level of gut hormones after meal ingestion.,Change in Genetic factors,,2018-08-01,RECRUITING,INTERVENTIONAL,['NA']
3955,NCT00407381,Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6,,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3956,NCT00132418,"Incidence of medically important infections, defined as infections that result in hospitalization or treatment with intravenous antibiotics","Infections associated with antimicrobial use; physical examination, vital signs, clinical laboratory assessments; symptom assessment, withdrawals, deaths, and serious adverse events",,2000-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3957,NCT00005479,,,,1996-09,COMPLETED,OBSERVATIONAL,['NA']
3958,NCT00491543,Pharmacokinetics,,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3959,NCT02252757,Measuring Cardiac Output for wireless transmission as per discharge guideline,,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
3960,NCT05394844,A1C,Self-Efficacy for Diabetes,,2022-11-11,RECRUITING,INTERVENTIONAL,['NA']
3961,NCT05144737,Change in body mass index over a 6-month period,Change in resting metabolism over a 12-month period,Change in pain severity over the 12-month period,2021-11-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3962,NCT00223340,Document changes made to study procedures to better implement this study's interventions that are designed to reduce risks of heart disease and stroke,Assessment of Chronic Illness Care (ACIC) Surveys,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
3963,NCT05489172,Sallis Self Efficacy for Physical Activity,Weight loss,HbA1C level,2020-02-01,COMPLETED,INTERVENTIONAL,['NA']
3964,NCT00954967,Smoking abstinence: Self reported abstinence (6 or more months without smoking) confirmed by an expired air carbon monoxide concentration of 6 parts per millions or less,Total time (minutes) spent in the intensive smoking cessation intervention,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
3965,NCT00690768,amount of intraoperative intra-ocular bleeding,,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3966,NCT05219526,Measurement performance: System accuracy,,,2022-01-03,COMPLETED,INTERVENTIONAL,['NA']
3967,NCT05353114,The primary outcome measure was the requirement of Therapeutic Footwear change after prescription because ill fitting.,Number of participants with an ulcer occurrence event,,2022-06-15,COMPLETED,INTERVENTIONAL,['NA']
3968,NCT00198497,Vitreous hemorrhage resolution,Visual Acuity,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3969,NCT03751813,lower blood stress markers via venous draw,,,2019-03-21,TERMINATED,INTERVENTIONAL,['NA']
3970,NCT00343980,Treatment difference in HbA1c,Hypoglycaemia,,2006-10-10,TERMINATED,INTERVENTIONAL,['PHASE3']
3971,NCT04885712,Changes in HbA1c,,,2021-05-28,COMPLETED,INTERVENTIONAL,['PHASE3']
3972,NCT00865124,Change in Coronary Flow Reserve From Baseline to 6 Months,Change in Renal Plasma Flow,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
3973,NCT00494884,Change from baseline in HbA1c,Change in systolic and diastolic blood pressure,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3974,NCT04161131,Hemoglobin A1c (HbA1c),Frequency of Blood Glucose Monitoring,,2019-12-09,COMPLETED,INTERVENTIONAL,['NA']
3975,NCT01023906,Sensory/hedonic rating,Genetic Variation,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
3976,NCT01179945,Blood glucose area under the curve (AUC),Metabolite Profiles,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
3977,NCT01076075,Number of Participants Discontinuing Study Drug Due to An Adverse Event,Change From Baseline in Fasting Plasma Glucose at Week 24,,2010-06-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3978,NCT05472883,Correlation between plasma levels of 9 target molecules and diabetes remission,The expression level of genes encoding 9 biomarkers in the adipocyte and the muscle cell,,2023-02-27,RECRUITING,INTERVENTIONAL,['NA']
3979,NCT03085524,Restenosis,,,2017-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3980,NCT04518813,Safety evaluation of the Investigational Medical Device by reporting of adverse events,Device function,,2020-09-24,COMPLETED,INTERVENTIONAL,['NA']
3981,NCT02429297,Change from baseline on self-care behaviors and health at 16 weeks (questionnaire),"Evaluate program feasibility (questionnaire, satisfaction, and usage rates)",,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3982,NCT02579837,Proportion of participants with Actionable Eye Disease (AED),Proportion of participants with Diabetic Maculopathy (DME),,2016-03,COMPLETED,INTERVENTIONAL,['NA']
3983,NCT05290506,change from baseline in insulin sensitivity/resistance index after 12-week treatment,change from baseline in beta-cell function after 12-week treatment,,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3984,NCT01832181,Adiposity in the offspring,adipocytokine profile in the offspring,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
3985,NCT05763069,Feasibility of Home monitoring of high-risk pregnancies,Placenta-associated biomarkers: improving CTG prediction of adverse outcomes?,,2022-11-21,RECRUITING,OBSERVATIONAL,['NA']
3986,NCT00668590,Hemoglobin A1c,Diabetes self-care behaviors,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
3987,NCT05166200,Glucose positive area under the curve (AUC),Glucose Concentrations,Sensory Questionnaire,2022-03-11,COMPLETED,INTERVENTIONAL,['NA']
3988,NCT06251466,Admission to the neonatal intensive care (NIC) in pregnancies with gestational diabetes mellitus in which telemonitoring was added to the standard care of gestational diabetes mellitus compared to the standard care without telemonitoring.,Reaction time from measuring abnormal glucose values to performing an intervention in pregnancies in which telemonitoring was added to the standard care of gestational diabetes mellitus compared to the standard care alone.,Satisfaction and usability of the modified care process through the administration of patient and staff questionnaires compared to the conventional follow-up approach.,2023-12-18,RECRUITING,INTERVENTIONAL,['NA']
3989,NCT03920085,Clinical Evaluation of Blood Glucose result (mg/dl) from LifeScan Blood Glucose Monitoring Systems by comparison of a blood glucose result (mg/dl) obtained from a reference instrument (YSI2900) to demonstrate accuracy (%).,,,2019-01-08,COMPLETED,INTERVENTIONAL,['NA']
3990,NCT00790153,Pharmacodynamic variables,"Safety Variables (AEs, BP, pulse, electrocardiogram (ECG), hypoglycaemic symptoms and laboratory variables)",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3991,NCT06203860,"Time to first occurrence of major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure (HF).",Cost-effectiveness ratio of implementing a Cardio-Metabolic Clinic,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
3992,NCT04187443,Treatment-emergent adverse events,Average mean change in best corrected visual acuity,,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE1']
3993,NCT02796534,"Prevalence of obstructive sleep apnea syndrome by oxymetry, confirmed by polysomnography",Incidence of new cardiovascular events and changes in microangiopathic complications of diabetes patients depending on the presence of sleep apnea syndrome and to the adherence to CPAP treatment in case of sleep apnea syndrome treated,,2016-07-28,COMPLETED,OBSERVATIONAL,['NA']
3994,NCT05869344,Glucose postprandial levels,,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
3995,NCT05711602,Mini Nutritional Assessment (MNA),,,2023-01-09,COMPLETED,INTERVENTIONAL,['NA']
3996,NCT03798054,Change in HbA1c,Immunogenicity (antibody variables),,2019-02-15,COMPLETED,INTERVENTIONAL,['PHASE3']
3997,NCT00005116,,,,na,COMPLETED,INTERVENTIONAL,['NA']
3998,NCT01536600,Change in HbA1c (glycosylated haemoglobin),Adverse drug reactions (ADR),,2004-09,COMPLETED,OBSERVATIONAL,['NA']
3999,NCT05709847,Verbal memory,Processing Speed,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
4000,NCT00921960,Prevalence and severity of LVD,,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
4001,NCT00412269,,,,1998-02,COMPLETED,OBSERVATIONAL,['NA']
4002,NCT05139472,Peak Pulmonary Capillary Wedge Pressure (PCWP),6 minute walk time,,2021-11-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4003,NCT02841969,Rate of complete wound healing,,,2017-02-28,SUSPENDED,INTERVENTIONAL,['NA']
4004,NCT03417466,Mean Percentage of Enlite Sensor Values That Are Within 20% Agreement of Gold Standard (Yellow Springs Instrument (YSI) YSI Plasma Glucose Values),Consensus Error Grid Analysis of Paired Sensor and YSI Plasma Glucose Values,,2018-06-28,COMPLETED,INTERVENTIONAL,['NA']
4005,NCT04621929,New kidney stone formation (mm2) as determined by non-contrast CT scan,Change in urinary uric acid parameters,,2021-03-31,RECRUITING,INTERVENTIONAL,['PHASE3']
4006,NCT00370565,"HbA1c is measured at Weeks -4, -1, 0, 6, and 12 of comparative treatment. The baseline value is the mean of the Week -1 and Week 0 values.","A patient satisfaction and preference questionnaire will be administered at screening, at baseline, during active therapy, and at the end of the study.",,1999-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4007,NCT03021837,The length of time that maternal glucose levels remain elevated after steroid administration.,,,2012-08-24,COMPLETED,OBSERVATIONAL,['NA']
4008,NCT00561158,"Fat intake (measured by Food Frequency Questionnaire) including: percent calories from fat, percent calories from saturated fat.",Cultural relevancy,,1994-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4009,NCT06188234,Change in HbA1c at 6 months of prescribing Tenero Tablet/Tenero Emextended Release Tablet compared to baseline,,,2022-12-27,RECRUITING,OBSERVATIONAL,['NA']
4010,NCT00732147,Endogenous glucose production,Endogenous VLDL-Triglyceride production,,2009-04,WITHDRAWN,INTERVENTIONAL,['NA']
4011,NCT00312156,HbA1c,Hypoglycaemia,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4012,NCT03016832,ACR,High sensitivity C,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
4013,NCT01631084,Incidence of all diabetes-related clinical endpoints,Proportions of patients with improved control of risk factors,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
4014,NCT00907374,Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio,Endothelial Dysfunction,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
4015,NCT03280758,Lipid profiles,Functional performance,,2017-10-01,UNKNOWN,INTERVENTIONAL,['NA']
4016,NCT00496405,Retinal thickness,Best corrected visual acuity,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4017,NCT00541879,Diabetes knowledge and prevention behaviors in elementary school children,"Parental diabetes knowledge, self-reported physical activity",,2001-08,COMPLETED,INTERVENTIONAL,['NA']
4018,NCT02427464,Number of Participants With Treatment-emergent Adverse Events.,Participants With at Least a 50 Percent Reduction in Average 24-hour Pain Score From Baseline to Day 180,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4019,NCT04004273,Change in liver saturated lipid index (%) determined by proton magnetic resonance spectroscopy (1H-MRS) using a 3T MRI scanner,Change in macronutrient intake,,2018-10-30,COMPLETED,INTERVENTIONAL,['NA']
4020,NCT00360815,,,,1983-08,COMPLETED,INTERVENTIONAL,['NA']
4021,NCT05666895,"Measure of inflammatory markers like (platelets-lymphocyte ratio, red blood cell distribution width) changes in DKA patients and affection of these changes on inflammation development and prognosis of DKA","Hematological parameters (RBC, Hct , Hb MCV, PLT ,WBC) which are used as an alternative approach to estimate the extent of dehydration in DKA patients",,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4022,NCT00709514,The incidence of complete ulcer closure,The time of healing rate and change in ulcer area,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4023,NCT05777330,Progression to persistent dysglycemia and stage 3 type 1 diabetes,,,2023-08-09,RECRUITING,INTERVENTIONAL,['NA']
4024,NCT00306072,The primary variable to be measured was positive AUC (0-180 minutes) for plasma glucose.,· Positive AUC 0-180 (0 to 120) minutes for serum insulin,,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4025,NCT00219440,glucose,blood pressure,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4026,NCT01062048,Mean change in 2hr-postprandial glucose (PPG),,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
4027,NCT05566912,Completing the surveys,,,2021-10-15,COMPLETED,OBSERVATIONAL,['NA']
4028,NCT01929863,Mean Change From Baseline in Overall Gastrointestinal Symptom Rating Scale (GSRS) Scores,Median Time to Observed Peak Plasma Concentration (Tmax) When Co-dosed With GSK2330672 or Placebo on Day 7,,2013-08-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4029,NCT00675220,Safety profile of Insulin Aspart among Filipino patients,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
4030,NCT05999110,Change in Respiratory Compensation Point (RCP - VO2),Change medical appointments number related with Knee Osteoarthritis,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
4031,NCT01110577,Intra-class correlation coefficient (ICC) for repeated hepatic fat fraction (HFF) measurements from the LIPOQuant method,ICC for repeated HFF measurements from the 3-point Dixon method,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
4032,NCT00977808,Occurrence of Hypoglycemic Episodes,,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
4033,NCT05609747,high sensitivity C- reactive protein- hsCRP.,Clinical and Radiographic success,,2021-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4034,NCT03552523,Average Time Spent With CGMG Less Than 54 mg/dl,,,2017-07-28,COMPLETED,INTERVENTIONAL,['NA']
4035,NCT01162694,The primary endpoint is the A1c level or the change in A1c level,A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,,2010-07,SUSPENDED,INTERVENTIONAL,['NA']
4036,NCT04203147,LDL-Cholesterol,Self-Care Behaviors,Resource Utilization and Cost,2020-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4037,NCT02959762,Change in beta-cell function,Change in endothelial function (flow-mediated dilation),,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
4038,NCT00136773,Change from baseline in the urine albumin/creatinine ratio after 52 weeks,Change from baseline in a marker of heart failure after 52 weeks,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4039,NCT04476472,Time in Range 70-180 mg/dL,Body Mass Index (BMI) (kg/m^2),,2020-09-08,COMPLETED,INTERVENTIONAL,['NA']
4040,NCT02649010,Enlite 3 Sensor inserted at Arm accuracy using a real time device: (640G pump) with the minimum calibration requirements (every 12 hours after the second calibration) will be evaluated.,,,2016-01,WITHDRAWN,INTERVENTIONAL,['NA']
4041,NCT01107431,Fasting Blood Glucose,Fasting Blood Insulin Levels,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
4042,NCT02925156,Difference in body weight index (BMI) between high and low activity energy expenditure (AEE) groups.,,,2008-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4043,NCT03766724,"Cmax,ss",,,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
4044,NCT00649909,The outcome measure is the laboratory Aspirin Resistance.,"To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors.",,2008-11,COMPLETED,OBSERVATIONAL,['NA']
4045,NCT04759495,Changes in glycated haemoglobin (HbA1c),"Incidence of skin reaction, infection or hematoma at the site of insertion of the sensor",,2019-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4046,NCT05737654,Change in quality of life,,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
4047,NCT01444248,compliance of patients treated with once-daily or twice-daily,other adverse events,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4048,NCT00661362,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients Achieving a Therapeutic Glycemic Response,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4049,NCT00141986,change in 25(OH)D from baseline,changes in urine calcium:creatinine ratio,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4050,NCT06032429,the self-management level assessed by the self-developed scale,the self-care level assessed by the self-developed scale,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
4051,NCT01552499,The proportion of completely healed ulcers in patients treated with amniotic membrane vs. standard of care,Mean time to complete healing,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
4052,NCT01412905,,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
4053,NCT05439226,HbA1C,Metabolomics,,2022-07-05,RECRUITING,INTERVENTIONAL,['NA']
4054,NCT00525577,Change from baseline in HbA1c to the 6-month time point is identical in the study groups (placebo and AGI-1067 treatment groups),• Change of HbA1c from baseline throughout the study • Change of FPG from baseline throughout the study•,,2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4055,NCT03063229,Total metabolic Rate (TMR),,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
4056,NCT05322746,Short Form McGill Pain Questionnaire,,,2022-04-28,COMPLETED,INTERVENTIONAL,['NA']
4057,NCT02821117,Change in Time in Range,,,2016-06-30,COMPLETED,INTERVENTIONAL,['NA']
4058,NCT05200390,Change in percent time in range of 70-180mg/dL (%TIR),Percentage of patients at goal % CV,,2022-01-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4059,NCT00824499,HBA1C,Influenza Vaccination Prescriptions,,2004-02,UNKNOWN,INTERVENTIONAL,['NA']
4060,NCT04129190,Oral Glucose Tolerance,,,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
4061,NCT00566124,"Area under GIR-curve, maximal glucose infusion rate, time to maximal glucose infusion rate.",,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4062,NCT02305355,The mean percent change of Triglyceride(TG),The mean percent change of apolipoprotein B,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4063,NCT00521027,"Reduction in the average skin-to-skin time of the first surgical debridement with VERSAJET™, compared to conventional debridement techniques.","Difference in outcomes of the procedure, according to the debridement technique in terms of; time to wound closure, number of subsequent debridements, number of serious adverse events",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4064,NCT05340868,Body composition - change in body weight (kg),Body composition - change in lean body mass content (kg),,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
4065,NCT01527747,Change in fasting and postprandial triglyceride concentrations,Changes in glycemia,,2012-01,SUSPENDED,INTERVENTIONAL,['PHASE4']
4066,NCT04998032,HbA1c,salvage treatment,,2021-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4067,NCT00198471,Vitreous detachment,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4068,NCT03398538,Percentage of index ulcers healed at 12 weeks,Difference in cellulitis and/or infection at 12 weeks,,2017-12-26,COMPLETED,INTERVENTIONAL,['NA']
4069,NCT05881447,Incidence of cardiovascular- and non-classic risk factors of CKD:,Assessment of Hypertension incidence,,2023-06-21,RECRUITING,OBSERVATIONAL,['NA']
4070,NCT02995629,Perceived patient pain assessment,Time of treatment,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
4071,NCT01176253,Use the assays to detect beta cell destruction throughout the early time-course of type 1 diabetes mellitus,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
4072,NCT03030209,Number of participants with new-onset diabetes mellitus as defined by American Diabetes Association,Number of participants with new-onset exocrine insufficiency,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
4073,NCT00394875,lipid profile,health care consumption and costs,,2002-03,COMPLETED,INTERVENTIONAL,['NA']
4074,NCT06324669,Rate of endogenous glucose production,Energy expenditure,,2024-03-16,RECRUITING,INTERVENTIONAL,['NA']
4075,NCT02216201,Identification of participants with abnormal SUDOSCAN electrochemical skin conductance scores,,,2014-12,WITHDRAWN,OBSERVATIONAL,['NA']
4076,NCT00230087,(2) HOMA model- determined by the OGTT method,"Change in serum levels of proinflammatory cytokines (ie IL-6, TnF-αR2)",,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4077,NCT01201785,Collagen Induced Aggregation,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4078,NCT01107886,"Participants With Any Event From the Composite of Cardiovascular Death (CV Death), Non-fatal Myocardial Infarction (MI), or Non-fatal Ischaemic Stroke",Participants With Event of Death,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4079,NCT04803708,3. Incidence and severity of treatment-emergent SAEs and relationship to IP from first administration until EOS.,"Changes in wound/ulcer healing from to baseline in terms of wound complete closure and partial closure (25%, 50% and 75%) at EOT.",,2021-03-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4080,NCT05034380,Change from baseline in skeletal muscle whole genome nucleosome maps,Cholesterol,,2014-09-14,COMPLETED,INTERVENTIONAL,['NA']
4081,NCT00411970,Subjective postoperative recovery,Intra- and postoperative complications,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4082,NCT03899623,"The diagnostic sensitivity, specificity and ROC curve of the artificial intelligence（AI） system compared with reference standard (ophthalmologist).",,,2018-04-23,UNKNOWN,OBSERVATIONAL,['NA']
4083,NCT01508949,Change in weight,Adverse events,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4084,NCT01301521,Water-soluble Cinnamon,,,2013-06-11,COMPLETED,INTERVENTIONAL,['NA']
4085,NCT02834689,Mean 24 hour glucose levels (mmol/l),Time spent above 10 mmol/l glucose,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
4086,NCT04959799,Retrospective description of the setting of dalbavancin treatment in diabetic patients.,Incidence of Adverse Events,,2022-01-02,COMPLETED,OBSERVATIONAL,['NA']
4087,NCT01165944,HgA1c,Continuous glucose monitoring,,2009-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4088,NCT00523393,Change of number of circulating EPC 4 weeks after start of therapy compared to baseline as detected by FACS analysis,Markers of inflammation and vascular risk in diabetes,,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
4089,NCT01093833,Blood Glucose,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4090,NCT03872089,Correlation with podologic grade,,,2019-04-08,TERMINATED,INTERVENTIONAL,['NA']
4091,NCT00807976,Prevalence of orthostatic hypotension,"Adverse events, Score risk profile questionnaire, Heart rate, Gender, Body mass index, Medication, Smoking, History of cardiovascular disease, Family history of cardiovascular disease, Duration of diabetes mellitus, Glycosylated haemoglobin, Insulin use",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
4092,NCT04597229,Change of fasting serum insulin,,,2020-09-28,COMPLETED,INTERVENTIONAL,['NA']
4093,NCT01940835,Mean Interleukin 15 (IL-15) Expression,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
4094,NCT05363774,Number of treatment emergent adverse events (TEAE) in T2D QW cohort,"Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period in the MAD QW s.c. cohort",,2022-04-20,RECRUITING,INTERVENTIONAL,['PHASE1']
4095,NCT06220968,Cavernosal blood glutathione level,,,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4096,NCT05616351,Compliance with the hospital in-house guidelines for diabetic foot infections with regard to antibiotic treatment,Relapse of diabetic foot infections (number),,2022-10-12,COMPLETED,OBSERVATIONAL,['NA']
4097,NCT03626623,Number of Wounds With Wound Closure,Indirect Diabetic Foot Ulcer (DFU) Product(s) Costs,,2019-05-21,TERMINATED,INTERVENTIONAL,['NA']
4098,NCT03665974,Pre-pregnancy BMI,,,2013-01-05,COMPLETED,OBSERVATIONAL,['NA']
4099,NCT05061030,Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.,Change in peak C-peptide,Peripheral blood mononuclear cells,2022-01-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4100,NCT05886088,Glycated hemoglobin (HbA1c),Blood pressure,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
4101,NCT04754464,BFM,HOMA-IR,WHtR,2020-05-13,COMPLETED,INTERVENTIONAL,['NA']
4102,NCT05065879,Neutralizing antibody level,Adverse events following vaccination,,2021-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4103,NCT01869959,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline to Day 28 in The Patient Health Questionnaire (PHQ-9) Score,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4104,NCT03441919,"Arterial wall inflammation, measured by 18F-FDG-PET/CT","Arterial wall inflammation, measured by 18F-FDG-PET/CT",,2018-01-18,COMPLETED,OBSERVATIONAL,['NA']
4105,NCT03189225,"Venous blood collected for impact assessment of Biochemistry parameters on 3 LifeScan Blood Glucose Monitoring Systems (OneTouch Ultra 2, OneTouch Verio, OneTouch SelectPlus).",,,2016-08-01,COMPLETED,INTERVENTIONAL,['NA']
4106,NCT05811078,Implementation of trainings containing peer interactive group support to adolescents and application of scales,Evaluation of Data,,2023-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4107,NCT06333132,Number of participants with incretin effect's restoration after achieving weightloss-induced diabetes remission,Rate of sustained weightloss-induced diabetes remission assessed by 2 consecutive HbA1c <48mmol/mol within 6 months,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4108,NCT03044860,Evaluation of differences in enteroendocrine cells (density and mRNA expression) along the intestinal tract of healthy individuals compared with type 2 diabetes patients.,,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
4109,NCT05135195,Average time it takes to understand how to interact with the system and run the simulation of the bus ride,,,2021-10-24,COMPLETED,INTERVENTIONAL,['NA']
4110,NCT03550066,Acceptance of Health Message,Diabetes Prevention Behavior: Intention,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
4111,NCT01142297,Implant Stability Quotient (ISQ),Clinical Success of Implants,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
4112,NCT01870934,Comparison of 3D image and normal assessment of wounds,Comparison of 3D and 2D image assessment of wounds,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
4113,NCT00771680,Serious adverse drug reactions including major hypoglycaemic events,Quality of Life (QoL) as assessed by patient questionnaire,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
4114,NCT00375960,11 point numerical pain rating scale (NPRS) daily diary,daily sleep interference score,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4115,NCT05337098,24-hour glycemic control,Monocyte chemoattractant protein-1,,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
4116,NCT05735873,Change from Baseline to 12 weeks in Numeric Pain Rating Scale,Change from Baseline to 12 weeks in diastolic blood pressure,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4117,NCT02887898,Change in HbA1c,Change in treatment satisfaction,Adherences to bolus calculator use,2016-09,COMPLETED,INTERVENTIONAL,['NA']
4118,NCT00772356,Comparison of glucose infusion rate necessary to keep blood glucose constant,Serum insulin and free fatty acid levels,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
4119,NCT01955746,Type 1 diabetes gene,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
4120,NCT06099067,3-point MACE,,,2020-05-15,COMPLETED,OBSERVATIONAL,['NA']
4121,NCT02436369,Change from baseline in values of HbA1c at 8 week,"Change from baseline in values of Lipid profile (Total cholesterol, triglyceride, LDL-C, HDL-C) at 8 week",,2014-09,COMPLETED,INTERVENTIONAL,['NA']
4122,NCT01627899,Change in A1C From Baseline to Week 24,Change in 30 Day Mean Glucose Comparing First Month to Last Month After 24 Weeks,,2012-10-01,TERMINATED,INTERVENTIONAL,['NA']
4123,NCT00468351,"Central Macular Thickness, Best Corrected Visual Acuity",Intraocular pressure; lens status,,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
4124,NCT01103609,To evaluate the pharmacokinetics of warfarin after a single dose when administered alone and in combination with AZD1656 at steady state by assessment of AUC and Cmax of both enantiomers of warfarin (S- and R-warfarin).,"To describe the pharmacokinetics of AZD1656 and its metabolite during concomitant warfarin administration by assessment of AUC0-24, Cmax, Ctrough, tmax, t1/2 and CL/F (AZD1656 only).",,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4125,NCT03962296,The change(Improvement)in the hard exduates,The change of total macular volum(TMV),,2012-11-21,COMPLETED,INTERVENTIONAL,['PHASE4']
4126,NCT02546063,Average of the postprandial area under the glucose curve (AUC) measured over three hours after each meal's start using Continuous Glucose Monitoring,User satisfaction,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
4127,NCT04051359,The rate of treatment failure defined as patients needing additional hypoglycemic therapy by long-insulin acting analogue detemir evaluated by capillary glucose levels,,,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA']
4128,NCT01062269,Patient Acceptability of Orange-flavored Generic Questran (Cholestyramine) vs. Tang (a Commercial Powdered Orange Drink) Via 2 Versions of a Bile Acid Sequestrant Acceptability (BASA) Scale.,Weighted vs. Unweighted BASA Scale,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4129,NCT02666924,Glycemic control,Albuminuria screen,Diabetes self knowledge assessment,2017-10-31,COMPLETED,INTERVENTIONAL,['NA']
4130,NCT03132571,BMI,Waist Circumference (Inches),,2017-06-01,TERMINATED,INTERVENTIONAL,['PHASE2']
4131,NCT02482662,proportion of OGTTs falsely negative,preference of participants regarding the two tests (OGTT vs. SMBG),,2014-11,COMPLETED,OBSERVATIONAL,['NA']
4132,NCT02994095,PACIC score,,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
4133,NCT04932213,Change from baseline in pupillary diameter,Change from baseline in central corneal thickness (CCT),,2021-07-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4134,NCT01423877,Insulin Resistance,Vitals status,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
4135,NCT01217463,"Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition",Relative Wound Area Regression of 40% or More at 6 Week,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4136,NCT00566566,,,,2008-01,UNKNOWN,OBSERVATIONAL,['NA']
4137,NCT05661474,the proportion of patients complete responders,,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4138,NCT01105858,Diabetes,,,2010-11-16,RECRUITING,OBSERVATIONAL,['NA']
4139,NCT03530930,Change From Baseline in Visual Analogue Scale for Pain,Patient global assessment of osteoarthritis,,2018-06-29,COMPLETED,INTERVENTIONAL,['PHASE4']
4140,NCT03863054,Percentage change in ulcer size,Pain at wound site,,2018-08-17,COMPLETED,OBSERVATIONAL,['NA']
4141,NCT06003400,Change in wound size between V1 and the last treatment,,,2023-03-29,RECRUITING,INTERVENTIONAL,['NA']
4142,NCT05263232,average 24h blood glucose levels,Culturing human primary myotubes to assess circadian reporter characteristics,mRNA in peripheral blood mononuclear cells (PBMC) of markers involved in the molecular clock,2022-03-16,COMPLETED,INTERVENTIONAL,['NA']
4143,NCT00790517,Cholesterol levels,Health/functional status,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4144,NCT05407207,Change in fear of falling,Change in depression,,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4145,NCT02117154,Area Under The Curve for Glucose excursion,"Measurement of HbA1c, fructosamine, Glycated albumin levels",,2013-06,COMPLETED,OBSERVATIONAL,['NA']
4146,NCT00548522,The documentation of Cpeptide in women with type 1 diabetes who are pregnant,,,2007-08,TERMINATED,OBSERVATIONAL,['NA']
4147,NCT04582448,"AUCIco,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose","tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose",,2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4148,NCT02829177,Improved Albuminuria,,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4149,NCT04190368,Number of Standard Care cohort participants completing appointments,PROMIS - Informational Support,Provider/Facilitator Session Feedback Form:,2021-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4150,NCT02835859,Measure in glucose concentrations,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
4151,NCT04150315,Major adverse coronary or cerebral event,,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
4152,NCT05736484,Change in mean daily step count from baseline to the end of the 26 week intervention period.,Participants' acute care utilization throughout the entire study (Baseline to end of study [52 weeks]).,,2023-09-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4153,NCT04014660,Autoimmunity,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
4154,NCT06218147,Percent of glucose time in range assessed by using continuous glucose monitor,Amount of fasting blood glucose,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA']
4155,NCT02737722,"Number of Participants With Normal and Abnormal Cultures at Visits 2, 3, 4, and 5",Mean Change From Baseline in the Percentage of Area Reduction for Ulcers in the Per-Protocol Population,,2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4156,NCT00464061,Efficacy (sub-study): change from baseline for glycemic measure HbA1c,Safety: adverse events and laboratory abnormalities,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3']
4157,NCT02819011,Center of Mass (COM) Sway Change Baseline to 6 Months,Stride Length,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4158,NCT01498913,Body weight,Adverse events,,2001-08-30,COMPLETED,OBSERVATIONAL,['NA']
4159,NCT01421225,Nocturnal Glycemic Control,Pre-lunch Blood Glucose Level,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
4160,NCT03006666,Patient Activation Measure (PAM) scores,,,2017-07-13,COMPLETED,INTERVENTIONAL,['NA']
4161,NCT01500798,Measured GFR assessed by plasma clearance of Tc99m-DTPA,Circulating endothelial cell assessments,,2012-01-31,TERMINATED,INTERVENTIONAL,['PHASE1']
4162,NCT00902616,Improvement in microcirculation,Effect of L-arginine on clinical parameters of neuropathy,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4163,NCT03882970,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia,,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4164,NCT02135952,Changes in number of sites with probing depth (PD) ≥5 mm post-treatment,Occurrence of adverse events,,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
4165,NCT05492916,Percentage Change in Body Weight,Change in San Francisco Chinese Food Security Module Score,,2023-06-27,RECRUITING,INTERVENTIONAL,['NA']
4166,NCT04454957,Healthcare expenditures,Patient Health Questionnaire,,2020-08-24,RECRUITING,INTERVENTIONAL,['NA']
4167,NCT03486535,Sensory block duration,Rescue analgesic consumption,,2018-02-20,COMPLETED,OBSERVATIONAL,['NA']
4168,NCT00760526,Number of Participants With a Decrease >=0.5% HbA1c With no Severe Hypoglycemic Events,Parental Quality of Life Measures: CGM Satisfaction Scale,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4169,NCT01709123,Blood Glucose Levels,Blood Levels of Cytokines/Inflammatory Biomarkers,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
4170,NCT01654172,Change in Fasting Brain Blood Flow,Change in diabetes control,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
4171,NCT02293135,Peripheral microcirculation measured using Laser Doppler flowmetry,Reactive Hyperemia Index (RHI),,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
4172,NCT01316107,change from baseline in hemoglobin A1c (HbA1c),"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2011-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
4173,NCT00229112,Clinical Cure/Improvement at discontinuation of IV antibiotic therapy.,Clinical Cure: 1. Day 5 of IV antibiotic therapy; 2.10 days after completion of all antibiotic therapy.,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4174,NCT01751399,Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541,,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4175,NCT02365129,Change from Baseline in BAT mass and activity evaluated with Positron emission tomography/computed tomography (PET/CT),Change from Baseline in Basal Heart Rate Variability: with a heart rate monitor,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
4176,NCT05201846,Time in range,Perceived stress scale of parents,,2022-01-18,UNKNOWN,INTERVENTIONAL,['NA']
4177,NCT05304975,Generation of variability data on the primary outcome measure (cognition) from baseline to 6 months on which to base a formal power calculation for a large-scale trial,,,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
4178,NCT01654380,Part B: Glycodynamics: Maximum Rate of Glucose Disposal,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4179,NCT02907684,Liver fat %,Plasma leptin,4 day food diaries,2017-03-29,COMPLETED,INTERVENTIONAL,['NA']
4180,NCT01715012,Safety,Scarring of skin graft donor site,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE2']
4181,NCT01919489,Glycemic Control at Hospital Discharge and 6 Months Follow up,Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4182,NCT03067662,Change in fasting plasma glucose levels (mg/dL),Length (cm) of child 3 months after delivery,,2012-09-27,UNKNOWN,INTERVENTIONAL,['NA']
4183,NCT05616273,A description of the strength and reproducibility of the relationship of post-Mixed Meal and Arginine stimulated glucagon with hypoglycaemia.,Home finger prick blood spot C-peptide measurement is a practical alternative to MMTT,,2023-03-23,RECRUITING,OBSERVATIONAL,['NA']
4184,NCT00998699,Change in beta-cell function as measured by change in C-peptide level during thd MMTT (Mixed meal tolerance test) at Day 112 compared to baseline (Day 0 pre-dose),Measurement of serum concentrations of XOMA 052,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4185,NCT01744132,All Aims: DFE follow-up adherence rate,Aim 3: Rates of ocular disease,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
4186,NCT02949193,HbA1c,HbA1c response rate,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4187,NCT01917669,Are peak (nM) calcium responses to bradykinin enhanced along the continuum of disease in skin fibroblasts from the 4 patient groups?,Are glucose utilization rates (a.u./min) measured in skin fibroblasts from the 4 patient groups different with disease progression?,"What component of peripheral metabolic dysregulation (HbA1c (%), adiponectin (ug/mL), cholesterol (mg/dL)) is associated with changes in calcium responses (nM) in skin fibroblasts?",2013-10,WITHDRAWN,OBSERVATIONAL,['NA']
4188,NCT03650088,Change in Weight,Change in Diabetes-related Quality of Life: The Diabetes Obstacles Questionnaire (DOQ-30),,2019-10-20,COMPLETED,INTERVENTIONAL,['NA']
4189,NCT06319300,time in target range (3.9-10.0 mmol/L ),Other/Serious Adverse Events,,2024-03-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4190,NCT05850611,Wound Size,Neutrophils count at baseline and after the intervention,,2023-04-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4191,NCT06099509,Completion of 75-gram oral glucose tolerance test,,Patient satisfaction,2023-11-02,RECRUITING,INTERVENTIONAL,['NA']
4192,NCT00704223,number of major and minor hypoglycaemic events and adverse events,FBG,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
4193,NCT00441077,Intentions to seek information about family history.,,,2007-02-19,COMPLETED,INTERVENTIONAL,['NA']
4194,NCT01214239,HbA1c Change From Baseline at Week 24,Number With HbA1c at Least Lowering 0.5%,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4195,NCT00116922,Development of diabetes based on 1 positive OGTT or 2 fasting glucose levels,"Lipids, CBC, CRP, homocysteine, adiponectin, insulin, proinsulin, and routine biochemistry will be done annually",,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4196,NCT01922791,Prevalence of allergy in child,Physical activity by questionnaires and activity monitor,"Body composition, growth, development and metabolic markers of the child",2013-10,COMPLETED,INTERVENTIONAL,['NA']
4197,NCT03922750,Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring),"Number of Hypoglycaemic Alert Episodes(Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by BG Meter)",,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4198,NCT01829256,Change in kidney function as measured by estimated glomerular filtration rate based on cystatin C(eGFRcys),"Change in blood pressure, glucose/HbA1c and urine albumin",,2014-05,COMPLETED,INTERVENTIONAL,['NA']
4199,NCT03758742,"Mean 24-hour glucose levels, peak glucose levels, and mean amplitude of glycemic excursions (MAGE), as measured using continuous glucose monitoring",Dosage of cardiovascular medications used,Intervention satisfaction and feedback,2019-09-10,COMPLETED,INTERVENTIONAL,['NA']
4200,NCT03416270,Proximal sodium reabsorption (FENa),Urinary adenosine,,2018-06-28,COMPLETED,INTERVENTIONAL,['PHASE2']
4201,NCT02784236,To analyze the metabolic impact measured through HbA1c of a telemedicine program by MenaDiab® online platform in the care of patients with DM1.,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
4202,NCT02287285,Beta Cell Sensitivity (BCS),Maximal Beta Cell Function,,2014-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4203,NCT01202266,Pharmacokinetic Endpoints: single dose and steady state pharmacokinetics of PF-05161704 and its metabolite PF-05200145. Urinary recovery will also be assessed for PF-05161704 and PF-05200145,Exploratory Parameters: absolute value and change from Day 0 baseline in concentrations of fasting serum lipids and body weight,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1']
4204,NCT05006872,Mean adherence to antidiabetic drugs (%),Self-efficacy to manage Diabetes (DSES-S),International Physical Activity Questionnaire (IPAQ),2021-10-06,UNKNOWN,INTERVENTIONAL,['NA']
4205,NCT03863431,Whole-body insulin sensitivity index,Subjective appetite ratings,,2019-05-22,UNKNOWN,INTERVENTIONAL,['NA']
4206,NCT04088461,Pancreatic beta cell function,,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4207,NCT00722631,Effect of treatment on the nominal change in FDG uptake of atherosclerotic plaque from baseline after 4 months of treatment as measured by FDG-PET/CT imaging.,All cardiovascular events and all cause death for 5 years,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
4208,NCT04866264,Subjective effectiveness questionnaire of eNutrition Optimizer,systolic and diastolic blood pressure,,2021-11-11,RECRUITING,INTERVENTIONAL,['NA']
4209,NCT03999268,Change from baseline in psychological insulin resistance at 6 months,Provider Satisfaction,Provider usability,2019-11-25,COMPLETED,INTERVENTIONAL,['NA']
4210,NCT01868555,Adverse events (AEs),Area under the serum insulin aspart concentration curve,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4211,NCT05762107,Incidence of nocturnal hypoglycemia,Incidence of hypoglycemia,Mean glucose concentration,2023-07-28,RECRUITING,INTERVENTIONAL,['PHASE2']
4212,NCT02952352,Weight,Stages of Change for weight loss,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
4213,NCT00162305,To assess the safety and tolerability of multiple oral doses of BMS-512148 administered alone or concomitantly with metformin in diabetic subjects,To identify potential biomarkers in both urine and blood,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4214,NCT00489879,"HbA1c, fasting blood glucose level, Weight change, Blood pressure level in the morning, lipid profiles","exercise time during one week, self reported change in dietary habit, fat consumption ratio",,2007-07,COMPLETED,INTERVENTIONAL,['NA']
4215,NCT00177398,Time to mean 24 hour plasma glucose < 180 mg/dl,Outpatient glycemic control and self management practices,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4216,NCT04786262,Proportion of Participants Free of Severe Hypoglycemic Events With Either a Glycosylated Hemoglobin (HbA1c) <7.0% or a ≥ 1% Reduction in HbA1c From Baseline,Changes in Stimulated C-peptide,,2021-03-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4217,NCT06287645,Finding inter-rater agreement among the graders,,,2022-05-12,RECRUITING,OBSERVATIONAL,['NA']
4218,NCT04977635,"Change in patient-reported outcomes between baseline and 2 year timepoint as measured by WHO-5, PAID-20 and WHOQOL surveys",,,2016-06-08,COMPLETED,OBSERVATIONAL,['NA']
4219,NCT05144802,Assess accuracy of interstitial glucose values measured respectively by FreeStyle® Libre and Dexcom® G6 compared to blood glucose values in standardized hypoxemia conditions in patients with diabetes and in healthy volunteers.,Tolerability of acute hypoxia,,2022-05-16,RECRUITING,INTERVENTIONAL,['NA']
4220,NCT02489968,Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment,,,2015-05-12,COMPLETED,INTERVENTIONAL,['PHASE3']
4221,NCT02068872,Safety of Sleeve Gastrectomy,Weight Loss,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4222,NCT03440502,the incidence of complete failure of spinal block.,determine the effect of DM on the other spinal block criteria,,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA']
4223,NCT01249677,Improvements in first and second phase insulin secretion,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4224,NCT00182286,,,,1999-09,COMPLETED,OBSERVATIONAL,['NA']
4225,NCT06254339,Dyslipidemia,The China-PAR project model,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
4226,NCT03308773,Time to development of type 2 diabetes,,,2009-01-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
4227,NCT02051959,Reduced phantom limb pain,Effects of treatment on the electrical activity of the brain,,2015-05,SUSPENDED,INTERVENTIONAL,['NA']
4228,NCT01242826,Area under the serum insulin aspart concentration-time curve from 0 to 24hours,Number of hypoglycaemic events,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4229,NCT02597049,Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand),Number of Participants With Adjudicated Cardiovascular (CV) Events,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4230,NCT05624853,Change from baseline to week 8 in Visual Analogue Scale(VAS),Number and proportion of subjects with adverse event,,2020-05-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4231,NCT01043029,Renal function: estimated glomerular filtration rate,Effect on blood hemoglobin,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4232,NCT05915884,Change in triglyceride index,,,2023-06-10,RECRUITING,OBSERVATIONAL,['NA']
4233,NCT03222180,Glycated hemoglobin (Hemoglobin A1c),Website utilization,,2018-02-15,COMPLETED,INTERVENTIONAL,['NA']
4234,NCT03883412,Microvascular Blood Volume - change from baseline,Insulin Sensitivity-Change from baseline,,2019-02-28,RECRUITING,INTERVENTIONAL,['PHASE4']
4235,NCT06188572,Ferrans&Powers Quality of Life Index Diabetes Version,,,2023-05-01,COMPLETED,OBSERVATIONAL,['NA']
4236,NCT05751720,Change in Liver fat quantification,Glycaemic control,,2023-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4237,NCT00423215,Measure of Glycolysated Haemoglobin (HbA1c) level reduction,Patient's satisfaction,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
4238,NCT03965975,Accuracy to compared device,,,2019-06-10,UNKNOWN,INTERVENTIONAL,['NA']
4239,NCT03221127,Death,Infectious disease,,1984-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4240,NCT02695433,Changes in insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI) in 12-week intervention of active treatment vs control treatment.,Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs control treatment.,Changes in blood MCP-1 in 12-week intervention of active treatment vs control treatment.,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
4241,NCT01894568,Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c),Percentage of Participants With Total and Nocturnal Hypoglycemic Events (HE),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4242,NCT02544347,omentin levels,clinical attachment level,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
4243,NCT03018938,Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c),Change From Baseline to Week 48 in Self-Efficacy About Insulin Therapy Questionnaire (SEITQ) Score,,2017-02-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4244,NCT03167996,Initial User Assessment,,,2016-06-23,COMPLETED,INTERVENTIONAL,['NA']
4245,NCT05904743,Change in HbA1c,CGM-measured hypoglycemia events (both a safety and efficacy endpoint),Patient-reported outcome (PRO) questionnaires,2023-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
4246,NCT00355537,"The effect of testosterone replacement on arterial stiffness measured by ultrasound derived index B of the femoral artery in men with a combination of DM, PVD and hypogonadism.","The effect of testosterone on markers of vascular risk; blood pressure, serum-lipid levels, weight, waist circumference, body fat percentage, urinary micro-albumin concentration and C reactive protein levels.",,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4247,NCT01902316,measurement of the amount of plasma peptides,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
4248,NCT01480791,The primary endpoint is baseline-adjusted change in media/lumen ratio in patients who were randomized to aliskiren (group 1) comparatively to those randomized to hydrochlorothiazide (group 2),Flow-mediated dilation in hypertensive diabetic patients randomized to aliskiren vs. hydrochlorothiazide,,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4249,NCT03638778,"AUC0-24h,sema,day10, area under the semaglutide plasma concentration time curve from 0 to 24 hours after the 10th dosing",Number of treatment emergent adverse events,,2018-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
4250,NCT04286529,C-Peptide Level,PROMIS 10 Questionnaire,,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE1']
4251,NCT00858273,Glutathione Concentration,Plasma Protein Bound 3-nitrotyrosine,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
4252,NCT04051229,Blood collection_insulin follow up 2,VO2 peak,,2019-10-29,TERMINATED,INTERVENTIONAL,['NA']
4253,NCT04031222,Inflammatory markers,,,2017-05-19,COMPLETED,OBSERVATIONAL,['NA']
4254,NCT05498974,PAID,Metabolomics,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
4255,NCT01960231,fasting and post glucose load glucose level,fasting and post glucose load c-peptide,glucose metabolism measured by CGMS,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
4256,NCT02228642,Prevalence of Hypoglycemia Associated Autonomic Failure in the inpatient setting as assessed by hypoglycemia symptom scores,Measures of cognitive function following a hypoglycemic event,Measure of cognitive function,2014-08,COMPLETED,OBSERVATIONAL,['NA']
4257,NCT03753568,Adherence to the medication,Variation of daily pill taking times,,2019-03-20,UNKNOWN,INTERVENTIONAL,['NA']
4258,NCT02464462,Serum calcidiol,Glycated Hemoglobin,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
4259,NCT05222477,"Sleep quality (0 is best, 3 is worst)",Abdominal and pelvic floor muscle electrical activity,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA']
4260,NCT03761797,Number of Participants With Adverse Drug Reactions (ADRs),,,2019-01-15,COMPLETED,OBSERVATIONAL,['NA']
4261,NCT06206005,Crestal bone loss around implants,Probing depth,,2023-12-04,RECRUITING,OBSERVATIONAL,['NA']
4262,NCT01465672,"diagnostic accuracy, i.e. difference of copeptin levels between patients without and patients with postoperative DI, of copeptin in the diagnosis of water disturbance in neurosurgical patients",,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
4263,NCT00818077,Glycemic Response to the Fixed Meal,,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
4264,NCT05492305,subjective effect of GLP1 receptor agonist on mental health,mean change in eating disorder examination questionnaire (EDE-Q) score with GLP1 receptor agonist over 12-16 weeks,,2022-09,RECRUITING,OBSERVATIONAL,['NA']
4265,NCT03427931,Percentage Time in Range 70-180 mg/dL by CGM,Percentage Time in Range <70 mg/dL by CGM,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
4266,NCT01340924,Glucose tolerance assessed using a 75g-Oral Glucose Tolerance Test (OGTT) in mothers,Physical activity,,2009-09,UNKNOWN,OBSERVATIONAL,['NA']
4267,NCT05091736,Analysis of system accuracy based on DIN EN ISO 15197,,,2021-10-18,COMPLETED,INTERVENTIONAL,['NA']
4268,NCT00935467,Evidence of steady-state pharmacokinetics (PK) of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects,To assess the safety and tolerability of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4269,NCT00800176,Absolute Change in HbA1c,Percentage of Participants With at Least One Adverse Event,,2009-01-22,COMPLETED,INTERVENTIONAL,['PHASE2']
4270,NCT04429737,Assessment of the change in Albumin (g/L) relative to baseline,,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
4271,NCT05684341,Change from baseline in HbA1c at Week 24,Number of participants with adverse events during the 24-week study period,,2023-02-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4272,NCT02560090,Change of Self-management Success Measured by Diabetes Self-Management Assessment Survey Tool from Baseline to Study Completion,Change of Diet Measured By a 24-item Introduction to the Lifestyle Survey from Baseline to Study Completion,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
4273,NCT05571306,Changes in Diabetes Distress levels,Changes in Blood lipds,Changes in Resilience measured using the Conner-Davidson Resilience Scale,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
4274,NCT01726621,User Acceptance of the New MiniMed 620G and 640G Insulin Pumps and Guardian Link Transmitter,,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
4275,NCT04073641,"Diabetes membership survey of health, access to care, support and services",,,2019-04-11,COMPLETED,OBSERVATIONAL,['NA']
4276,NCT02194517,HbA1c (glycated hemoglobin),Glucose Area Under the Curve (AUC),Treatment satisfaction,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4277,NCT02208115,Acute subjective appetite responses,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
4278,NCT02216552,Efficacy Outcome,Efficacy Outcome,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4279,NCT01588366,Change From Baseline to Day 28 in Hepatic Glycogen Content,Change From Baseline to Day 29 in Insulin Response to an Arginine Stimulation Test (AST) (Part A),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4280,NCT02723539,Proportion of participants who are clinically cured,Proportion of participants who are microbiologically cured,,2017-03-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4281,NCT04263675,Study the mechanisms linked to the effect of breastfeeding on the growth of children in women who have had GDM.,"Associate level of hormones related to satiety and energy metabolism (i.e. endocannabinoids, ghrelin, leptin) in the human milk of women with or without GDM and the growth of the child.",,2020-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4282,NCT05130593,Palatability of Bar,Measurement of Blood Levels of Serum Insulin Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.,,2021-10-25,COMPLETED,OBSERVATIONAL,['NA']
4283,NCT05523375,Body weight (Percent Change),Perceived Stress Scale-4 Questionnaire,,2022-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4284,NCT05214209,Acceptability of mobile app assessed by a semi-structured interview,Change in waist-to-hip ratio,,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4285,NCT02718638,Changes in cytokines plasma levels,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
4286,NCT06039293,Number of Steps,General Quality of Life,Aerobic Capacity,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4287,NCT05181254,Proportion of patients who change their risk profile,Blood pressure,,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
4288,NCT01001689,Maternal body composition,Proportion of newborns with birth weight over the 90th percentile for gestational age,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4289,NCT04857996,Ocular and systemic safety and tolerability of a single IVT injection of UBX1325 evaluated by incidence of treatment emergent adverse events (TEAEs),Proportion of patients without macular fluid as assessed by SD-OCT,,2021-06-25,COMPLETED,INTERVENTIONAL,['PHASE2']
4290,NCT00399997,Patient-reported health related quality of life at 4 and 10 months,Patient-reported compliance with national guidelines for physical activity at 4 and 10 months,,2005-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4291,NCT03430284,Control rate of diabetes and diabetic vascular complications,Stage of diabetic retinopathy evaluated by fundus photograph,,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
4292,NCT02627898,"Change from Baseline in Aortic Pulse Wave Velocity measured in meters / second, at 12 weeks",Change from Baseline in central systolic blood pressure measured in mm / Hg at 12 weeks,Change from Baseline in Body and visceral fat measured in centimeters ^ 2 at 12 weeks,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4293,NCT00021801,,,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE2']
4294,NCT03404895,Number of days to ulcer healing,Total number of subjects with minor and major amputations,,2018-04-13,RECRUITING,INTERVENTIONAL,['NA']
4295,NCT00561171,ABPM,sitting PB,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4296,NCT01051245,"Combined outcome assessing adequate control of hypertension, LDL-cholesterol and glycated hemoglobin",Quality of care process measures,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
4297,NCT05484427,metabolic control (HbA1c concentrations) at Month 9,Patient´s satisfaction of regular and telemedicine (email) visits.,,2021-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4298,NCT05330208,Incidence of reaction of the injection sites,Immunogenicity,,2022-04-30,UNKNOWN,INTERVENTIONAL,['PHASE1']
4299,NCT01536639,HbA1c (glycosylated haemoglobin),Adverse events,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
4300,NCT04660006,Change from baseline of retinal thickness up to 3 months post-cataract surgery.,Development of new cystoid macular edema,,2019-05-27,UNKNOWN,OBSERVATIONAL,['NA']
4301,NCT02480244,Change in BMI,Change in blood pressure,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
4302,NCT05202470,The Problem Areas in Diabetes Scale (PADS),,,2022-01-06,COMPLETED,INTERVENTIONAL,['NA']
4303,NCT02647346,Occurrence of Plantar Diabetic Foot Ulcer,Device-related Injuries,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
4304,NCT02460783,Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) P-pan-Tyrosine-IRS-1 (pY-IRS-1),Mean Change in Total Sedentary Bouts,,2015-06-22,COMPLETED,INTERVENTIONAL,['NA']
4305,NCT00944619,Percentage of plasma glucose values in target (3.9-8.0 mmol/L),Percentage of plasma glucose and CGM values below 3.0 mmol/L,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4306,NCT01620125,HOMA index,Changes in diabetes medication and hypoglycemia events,,2012-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4307,NCT00975533,"composite quantitative score calculate from the results of glycemic control, weight response and degree of hypoglycemia",differences in insulin requirement,,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
4308,NCT01941719,Patient Interpretation of Neuropathy (PIN) Questionnaire,Foot Complications,,2008-05-02,COMPLETED,INTERVENTIONAL,['NA']
4309,NCT05500937,Changes of HbA1c,Rate of MACE,,2021-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4310,NCT01391585,response rate to home monitoring prompts,response to barrier questions for non-adherence,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
4311,NCT04528212,Sirtuin1 (SIRT1) (ng/ml),Triglyceride (mg/dl),,2020-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4312,NCT04047537,Hemoglobin A1c,Change from baseline in Laboratory Complete Blood count Values,,2019-08-06,TERMINATED,INTERVENTIONAL,['NA']
4313,NCT00734448,Insulin sensitivity index (HOMA-IR) and continuous glucose monitoring profile,baby weight at delivery,,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
4314,NCT00527397,Self-Monitoring Blood Glucose Levels: Change From Baseline,Insulin Antibody Levels : Change From Baseline,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE3']
4315,NCT01189890,Number of Participants Discontinuing Study Treatment Due to An AE,LS Mean Change From Baseline in Participant Body Weight at Week 30,,2010-08-16,COMPLETED,INTERVENTIONAL,['PHASE3']
4316,NCT00549133,"Evaluation of the effect of irbesartan on nitric oxide (NO), which has key role in the endothelial dysfunction and the development of pressure vasomotor response, compared to standard therapy (atenolol)","Evaluation of the effect of irbesartan on chronic inflammatory process and tendency for procoagulation, associated with endothelial dysfunction, compared to atenolol.",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4317,NCT02080377,Number of women willing to be randomised,Clinical Outcome,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4318,NCT05038046,Change from Baseline in Nerve Conduction Velocity at 3 months,heart rate variability,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4319,NCT02950181,Observing Cerebral oximetry readings when patients present to the pediatric emergency department,,,2014-07-29,TERMINATED,INTERVENTIONAL,['NA']
4320,NCT06223490,Skin fold thickness and estimation of total body fat,,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
4321,NCT06132126,Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters,Part A and Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC),,2023-11-17,RECRUITING,INTERVENTIONAL,['PHASE1']
4322,NCT05649137,Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction greater than or equal to (>=) 5% (yes/no),Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes,,2023-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4323,NCT00469833,Insulin Concentration in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.,HbA1c Before and After 2 Months of Insulin Treatment to Improve Average Glycemia.,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
4324,NCT01512979,Change From Baseline in HbA1c After 24 Weeks,Change From Baseline in FPG by Visit Over Time,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4325,NCT05919927,Sum score of the Z-scores of the performed standardized neuropsychological tests,,,2018-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4326,NCT05243810,Incidence of intervention-related adverse events collected throughout the trial,Quantitative progression of local inflammatory biomarkers over the course of the intervention versus screening and baseline.,,2022-11-28,COMPLETED,INTERVENTIONAL,['NA']
4327,NCT01698697,Area under the glucose infusion rate curve,GIRmax: The maximal GIR (glucose infusion rate),,2002-09-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4328,NCT02501850,Change in blood levels of Lipoprotein (a) (Lp(a)),,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
4329,NCT00521690,"Incidence of serious adverse events, including major hypoglycaemic events",Incidence of hypoglycaemic episodes,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4330,NCT01388361,Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin),Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4331,NCT05407961,Part B: Change from Baseline in Total Clamp Disposition Index (cDI),Part A & B: Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT,,2022-06-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4332,NCT01572402,Postprandial plasma concentrations of gastrointestinal peptides,Postprandial plasma lipids,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
4333,NCT05452993,diabetic retinopathy screening rate,consistance between artificial intelligence and ophthalmologist re-read for doubtful images,,2022-09,UNKNOWN,INTERVENTIONAL,['NA']
4334,NCT06072287,Illness-related distress,Cognitive and Behavioural Responses to Symptoms,,2023-06-28,RECRUITING,OBSERVATIONAL,['NA']
4335,NCT01396837,Number of Participants Experiencing Adverse Events,Percent of Reduction in Wound Size Over 12 Weeks (ITT Population),,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4336,NCT02202161,Number of Participants With Fecal Occult Blood Monitoring for Symptomatic or Visible Gastrointestinal Bleeding or Asymptomatic Occult Bleeding,Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10),,2014-08-27,COMPLETED,INTERVENTIONAL,['PHASE2']
4337,NCT05109520,"Time in range (TIR, 70-180 mg/dL)","Treatment satisfaction measured by the Diabetes Treatment Satisfaction Questionnaire, status (DTSQs)",Hospitalization,2021-09-08,COMPLETED,OBSERVATIONAL,['NA']
4338,NCT01516242,Patient satisfaction with NovoPen® 4 insulin delivery system,Hypoglycaemia,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
4339,NCT04259047,Decline in Verbal Memory,,Dementia,2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
4340,NCT01347671,Change in mean daily pain intensity score,Plasma concentration,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4341,NCT02662400,Improvement in insulin sensitivity after stem cell transplantation,Improvement in β cell function after stem cell transplantation,,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4342,NCT03814512,Change in Total Sleep Time,,,2019-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4343,NCT00957268,AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alogliptin,Observed Effect at 24 Hours Post-dose (E24) of the Baseline-corrected Glucagon-like Peptide-1 (GLP-1) Concentration,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
4344,NCT04354142,Carbohydrate (CHO) Counting Efficiency (Time to count),Implementation outcomes: Acceptability,,2018-07-12,COMPLETED,INTERVENTIONAL,['NA']
4345,NCT02911311,The primary outcome is mean visual acuity change(BCVA),change of central retinal thickness,,2019-10-12,UNKNOWN,INTERVENTIONAL,['NA']
4346,NCT04361097,Creatinine Clearance,Lactate,,2018-08-07,COMPLETED,INTERVENTIONAL,['NA']
4347,NCT02274207,Days to patient discharge,Rate of adverse event,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
4348,NCT01452893,difference in cognitive function before and after physical stress,differences in counterregulatory hormonal response to physical stress,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
4349,NCT05760768,gestation weight gain（GWG）,diastasis recti abdominis（RDA）,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
4350,NCT02934893,Hemoglobin A1C,Patient satisfaction questionnaire,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
4351,NCT03161912,Mean change of visual acuity (VA) from baseline to 12 months as evaluated in routine clinical practice per cohort and per country.,"Mean change in VA by number of injections during the first 6 months, the first year, and the 2-year treatment period.",,2017-11-24,COMPLETED,OBSERVATIONAL,['NA']
4352,NCT03710928,Hemoglobin A1C change,Highly Processed Food Withdrawal Scale (ProWS),,2020-01-03,RECRUITING,INTERVENTIONAL,['NA']
4353,NCT00485758,Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo,Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4354,NCT01940965,"Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data",Absolute change in body weight,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4355,NCT01720446,"Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke",Change From Baseline to Last Assessment in the Trial in Other Treatment Outcomes: Vital Signs (Pulse Rate),,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3']
4356,NCT03066830,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With HbA1c <7.0% at Week 26,Percentage of Participants With Hypoglycemic Events,2017-02-24,COMPLETED,INTERVENTIONAL,['PHASE3']
4357,NCT00001859,,,,1999-06-04,COMPLETED,OBSERVATIONAL,['NA']
4358,NCT04965051,HbA1c,Insulin dose,,2021-08,UNKNOWN,INTERVENTIONAL,['NA']
4359,NCT02119689,The ACE/ACE2 ratio within EPC's,The balance of the RAS (renin-angiotensin system) within EPCs,Fluorescein angiogram findings,2011-10-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4360,NCT00425009,HbA1c at 13 weeks,Blood lipids at 13 weeks,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4361,NCT03512132,Anti-inflammatory effect,,,2018-04-24,RECRUITING,OBSERVATIONAL,['NA']
4362,NCT01278160,Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline,Number of Treatment Emergent Hypoglycaemic Episodes,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4363,NCT02662114,Change in HbA1c after switch to Tresiba®,"Reason(s) for discontinuing Tresiba®, if applicable and available",,2015-12-08,COMPLETED,OBSERVATIONAL,['NA']
4364,NCT00494013,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),Number of Injections of Basal Insulin Analog at Endpoint,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4365,NCT01893125,Pain Intensity Numerical Rating Scale,Neuropathic Pain Symptom Inventory,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4366,NCT04270942,Safety and tolerability of teplizumab treatment,Change in T-cell Subpopulations,,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4367,NCT05963022,Change from Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants Who Achieved Weight loss of ≥15%,,2023-08-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4368,NCT04620876,Visualization and image analysis of a structure of interest,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
4369,NCT00231530,The percent change in body weight and change in Hemoglobin A1c from enrollment to Week 60.,"Change from enrollment or baseline to Week 60 in BMI, waist circumference, glucose tolerance, lipid profile; safety measures, such as adverse events, throughout study.",,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4370,NCT05671250,Wound area regression rate,rate of partial wound closure of ≥ 50%,Adverse effects,2021-07-15,COMPLETED,INTERVENTIONAL,['PHASE2']
4371,NCT04087941,Change in 24-hour Morphine Milligram Equivalents (MME),Efficacy- Change in Average Pain Intensity,,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
4372,NCT01264809,Change in daily physical activity measured by SenseWear Pro3 Armband®. Participants were instructed to wear the monitor for seven days during all waking hours except bathing.,Benefits obtained after the physical activity counseling,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
4373,NCT05174507,Number of symptomatic hypoglycemia,Change in RNA sequencing (RNAseq) in peripheral PBMC,,2022-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4374,NCT03767790,Time in target glucose range,Unanticipated adverse device effects (UADE),Device Issues,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
4375,NCT00516074,Change in Mean 24-hour Heart Rate From Baseline to Endpoint,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4376,NCT03384758,rHb,,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
4377,NCT04467606,Rate of foot infection and readmission for foot ulcer,Self-efficacy regarding diabetes-related foot ulcer self-management,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
4378,NCT03078725,Failure rate,incidence of medication side effects,,2017-06-20,WITHDRAWN,INTERVENTIONAL,['PHASE4']
4379,NCT02692716,"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke",Change in Triglycerides - Ratio to Baseline,,2017-01-17,COMPLETED,INTERVENTIONAL,['PHASE3']
4380,NCT01997281,Area Under the Curve (AUC) of Plasma Total GLP-1 Levels After Intake of the Study Meal,AUC of Plasma Total GLP-1 Levels After Lunch,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
4381,NCT03394352,Continuous Glucose Monitor metrics,,,2018-01-17,COMPLETED,INTERVENTIONAL,['NA']
4382,NCT03008057,"serum Fasting blood suger,",serum YKL40,,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4383,NCT04876274,HbA1C,Score of Simplified True / False Version of Diabetes Knowledge Scale,Score of Newest Vital Sign,2020-07-14,COMPLETED,INTERVENTIONAL,['NA']
4384,NCT03757845,Quantity of ERBB receptors expressed on atrial endothelial cells,Quantity of specific lipids in plasma,,2018-12-15,TERMINATED,INTERVENTIONAL,['NA']
4385,NCT00269061,Changes in interstitial fluid volume in the lower extremities as measured by MRI.,"Assessments of other indicators of fluid volume changes, including labwork evaluation, fluid compartment volume measurement, direct measurement of the calf.",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4386,NCT00960453,"To evaluate the pharmacodynamics (activity of Dipeptidyl peptidase-IV enzyme) after repeated administrations of sitagliptin 25, 50 and 100 mg",,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4387,NCT00445627,evaluate phenotype of T2DM,,,2007-06-18,COMPLETED,OBSERVATIONAL,['NA']
4388,NCT05550480,Time spent with glucose value <3.0 mmol/l (level 2 hypoglycemia),Hypoglycemia awareness,,2022-09-08,RECRUITING,INTERVENTIONAL,['NA']
4389,NCT01462227,Glucose Infusion Rate (mg/kg.Min),Norepinephrine (pg/mL),,2011-08,COMPLETED,INTERVENTIONAL,['NA']
4390,NCT00925977,Treatment satisfaction,Hypoglycemic events,,2009-07,TERMINATED,INTERVENTIONAL,['NA']
4391,NCT01207934,Post-treatment Glucose Disposal. I.e. Glucose Disposal After Treatment With Leptin or Placebo.,Post-treatment Plasma Leptin Levels,,1998-08,COMPLETED,INTERVENTIONAL,['NA']
4392,NCT02463487,Number of Participants Who Achieved Complete Healing or Coverage of the Study Wound,Number of Participants With Wound Dehiscence After Hospital Discharge,,2015-06-02,COMPLETED,INTERVENTIONAL,['NA']
4393,NCT03597568,Vascular endothelial function,Oxidative stress,,2019-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4394,NCT04614038,Non-healing status based on change in wound area over 12 weeks,Effect of various patient biometry and wound conditions on non-healing status based on change in wound area over 12 weeks,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
4395,NCT01033773,Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit,Change in Hemoglobin A1C From Baseline to End of Intervention at 30 Days,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
4396,NCT02262806,Serum triglycerides,,,2014-10-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4397,NCT01703208,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change,Percentage of Participants Achieving a Target A1C <7.0 % (53 mmol/Mol) at Week 18 in a Sub-Study of Participants Taking Insulin,Number of Participants With an Event Per 100 Person-years of the Event of the First Hospitalization for Heart Failure (Exploratory),2012-10-05,TERMINATED,INTERVENTIONAL,['PHASE3']
4398,NCT02671136,Counts of Each Subgingival Bacterial Species,,,2016-08-18,TERMINATED,INTERVENTIONAL,['NA']
4399,NCT00641043,HbA1c Change From Baseline to Week 24,Percentage of Patients Who Have an HbA1c Lowering by 0.5% at Week 24,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4400,NCT01340664,Change in HbA1c From Baseline to Week 18,Percentage of Patients With HbA1c <7% at Week 18,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4401,NCT01726764,Change in Area Under Curve (AUC) 0-24h of metformin,Change in messenger RiboNucleic Acid (mRNA),Hypericin/hyperforin,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4402,NCT03859401,Number of hypoglycemic occurrences in relation to exercise activity,CGM-based High Blood Glucose Index,Total Amount of Rescue Carbohydrates,2019-04-12,COMPLETED,INTERVENTIONAL,['NA']
4403,NCT03014908,Metabolic phenotype of type 1 diabetes mellitus,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
4404,NCT00501709,lnsulin independence,,,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4405,NCT04362917,Measurement of beta cell function during the first phase of the first clamp procedure,Measurement of beta cell function during of Second Phase of the first clamp procedure,"Test-retest variability of the above mentioned variables (first phase, second phase, Unmethylated and methylated DNA, fasting PI:C",2017-11-14,COMPLETED,OBSERVATIONAL,['NA']
4406,NCT03281512,Diabetes,Overweight,,1989-01-01,COMPLETED,OBSERVATIONAL,['NA']
4407,NCT03238898,pain intensity on a 0-10 severity scale,the Cramp Threshold Frequency (CTF),,2014-09-27,COMPLETED,INTERVENTIONAL,['PHASE2']
4408,NCT00997711,"The composite of death, nonfatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR) at 12 months post procedure.",Stent thrombosis (ARC criteria),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4409,NCT05597943,Malama app as intervention,Postpartum hemoglobin A1c level,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
4410,NCT02186080,Difference between baseline and peak serum LPS,mRNA expression level of inflammatory markers in the adipose tissue,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
4411,NCT00776854,Decrease of Bioburden Effect In diabetic Foot Ulcer,,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE1']
4412,NCT00853801,Providers improve their ability to diagnose and treat metabolic syndrome/pre-diabetes.,Assess changes in insulin resistance using the HOMA-IR index and in vascular inflammation status using C-Reactive protein in the intervention and control groups.,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
4413,NCT01595594,Clinical Attachment Level,Microbial Load,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4414,NCT03152084,Change in 24-hour Sodium Excretion From Baseline to Start of Treatment,Number of Patients With AEs and SAEs,,2017-07-12,TERMINATED,INTERVENTIONAL,['PHASE4']
4415,NCT05983562,To determine the feasibility of conducting such an RCT: Retention as measured by the number of participants that complete the study,Overall acceptability,,2023-06-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4416,NCT01402232,contrast-induced nephropathy,Follow-up major adverse cardiovascular and clinical events,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
4417,NCT01517412,Change in HbA1c From Baseline to Week 24,Change in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 24,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4418,NCT04123067,Degree of Disability or Dependence in the Daily Activities,"Concentration of Stress Response Markers Including Cortisol, Norepinephrine and Epinephrine",,2020-09-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4419,NCT02294474,Change in HbA1c From Baseline to Week 26,Percentage of Participants With Treatment-Emergent Anti-insulin Antibodies (AIAs),Change in Daily Insulin Dose From Baseline to Week 26,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4420,NCT01370837,Induration Size as a Response to Intracutaneous Candida Albicans.,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4421,NCT02160184,Percentage of time in target range (3.9-8.0 mmol/l) YSI glucose during the in clinic overnight visit.,,,na,UNKNOWN,INTERVENTIONAL,['NA']
4422,NCT03400501,Lower beta hydroxybutyrate levels,Measure of beta hydroxybutyrate levels between the 2 groups.,,2017-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4423,NCT01228526,Percent of study ulcers healed,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
4424,NCT03648918,Autoantibody Measurement,,,2001-08,RECRUITING,OBSERVATIONAL,['NA']
4425,NCT03083899,Patient reported outcome,Diabetes Dependent quality of Life,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
4426,NCT02448498,Change in Hemoglobin A1c across study visits,"Change in Dietary Intake, as measured by Food Frequency Questionnaire",,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4427,NCT00501488,,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
4428,NCT05949957,Glucose Tolerance Changes,Social-emotional development (Children),Child's Sleep Habits,2023-10-20,RECRUITING,INTERVENTIONAL,['NA']
4429,NCT01748552,Number of Participants With 1 or More Serious Adverse Event(s) (SAEs),Change From Baseline in C-Peptide Area Under the Effective Concentration Curve From Time 0 to 6 h Postdose [AUEC(0-6)],,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4430,NCT03174821,The change of 8-hydroxy-deoxyguanosine (8-OHdG),The change of superoxide dismutase (SOD),,2010-10-20,COMPLETED,INTERVENTIONAL,['NA']
4431,NCT03247608,Re-admissions rate,Biometrics change,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
4432,NCT00306176,Cardiovascular risk factors alterations,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4433,NCT05840796,interleukin (IL)-6,lipid profile,,2014-04-01,COMPLETED,INTERVENTIONAL,['NA']
4434,NCT00843388,"albuminuria, expected decrease","plasma renin, angiotensin, aldosteron",,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
4435,NCT00264394,Reduction in total cholesterol in the entire SHCS population,"The reduction in total cholesterol, systolic and diastolic blood pressure, and Framingham 10-year CHD risk score in individuals with a greater than or equal to 10% 10 year risk of CHD (according to the Framingham risk profile)",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4436,NCT06007157,24-hour Blood Pressure,Hydration state,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
4437,NCT02313428,Wound Closure,Quality of Life for subjects- SF-36,,2020-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4438,NCT05651919,"Comparison of the inflammatory profile of PBMC from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF",,,2023-05-23,RECRUITING,OBSERVATIONAL,['NA']
4439,NCT00041405,,,,2001-07,COMPLETED,OBSERVATIONAL,['NA']
4440,NCT03997331,Change in HbA1c,Median Adherence to Metformin,,2020-05,UNKNOWN,INTERVENTIONAL,['NA']
4441,NCT00859599,Number of subjects who completely healed and time to 100% wound reduction.,"Time to 50% wound reduction, Subjects with increased ulcer and/or wound reduction less than 20%, Wound status, Elimination of gram-positive and anaerobic bacteria from the wound, Hospitalization caused of foot ulcer, Presence and level of amputation",,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
4442,NCT01868529,Area under the glucose infusion rate curve,Area under the serum insulin concentration curve at steady state,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4443,NCT01930188,Change in HbA1c (Glycosylated Haemoglobin) From Baseline,Subjects Who Achieved HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target (Yes/no),,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4444,NCT06085339,Feasibility: Retention Rate,Screen Time,,2023-10-23,RECRUITING,INTERVENTIONAL,['NA']
4445,NCT02616809,Evidence of change in blood glucose following changes in posture and increasing energy expenditure,,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4446,NCT03911323,Sensitivity and specificity,,,2018-10-01,UNKNOWN,OBSERVATIONAL,['NA']
4447,NCT01906086,high sensitive C reactive protein (mg/l),Adiponectin (ng/ml),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
4448,NCT05459701,VCAM-1 (ng/ml),,,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
4449,NCT00468754,Variability of blood glucose characterised by the standard deviation of the mean blood glucose,Daily insulin requirement,,2003-07,COMPLETED,INTERVENTIONAL,['NA']
4450,NCT01726829,The percentage of nights mean overnight sensor glucose levels was within90-140 mg/dl,Artificial Pancreas Satisfaction Questionnaire,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
4451,NCT00791128,% of Excess Weight Loss (EWL),HbA1c Values at 12 Months,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4452,NCT05248412,Health outcomes,Healthcare service utilization,Burden of diseases due to indirect effect of COVID-19,2021-06-21,RECRUITING,OBSERVATIONAL,['NA']
4453,NCT00570739,Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks,Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose >or= to 126 mg/dL or Plasma Glucose >or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4454,NCT02768220,Change in AGE levels,Change in weight,,2017-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
4455,NCT05594563,Number of participants with treatment-related adverse events as assessed by CTCAE v5,"Biomarkers of β cell stress at 3, 6, 9, and 12 months after treatment.",,2023-03-14,RECRUITING,INTERVENTIONAL,['PHASE2']
4456,NCT04522882,Glucose level modification,Medication intake,,2020-09-09,COMPLETED,INTERVENTIONAL,['NA']
4457,NCT04944264,Connor-Davidson Resilience Scale (CD-RISC),Implementation Facilitators,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
4458,NCT03144505,"Changes from baseline HbA1c at 3, 6, 9 and 12 months",Changes from baseline quality of Life at 12 months,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
4459,NCT04011228,Specifying the microRNAs in saliva in diabetic patients,Correlation of the percentage of the content of fat in the skeletal muscle with miRNA´s in diabetic patients.,,2016-02-29,UNKNOWN,OBSERVATIONAL,['NA']
4460,NCT02293577,Time with blood glucose >300 mg/dL,Physical Activity,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
4461,NCT03379792,Energy Expenditure,,,2018-03-08,COMPLETED,OBSERVATIONAL,['NA']
4462,NCT05111301,CGM Time Above 180 mg/dL,Coefficient of Variation (CV),Unanticipated Adverse Device Effects,2021-11-30,COMPLETED,INTERVENTIONAL,['NA']
4463,NCT04245267,Glycemic control after the program,"Health-related Quality of Life perception assessed by EQ-5D Indexed score (0-1, higher score means better Quality of life perception)",Blood pressure of the patients who attended the program compared with patients attended in primary care units (wait-list),2017-01-07,UNKNOWN,INTERVENTIONAL,['NA']
4464,NCT04600622,Average Feasibility Score,Change in Family and Friend Involvement in Diabetes score,,2021-06-17,COMPLETED,INTERVENTIONAL,['NA']
4465,NCT03664921,Numeric Pain Scale,Adverse Events,,2018-11-15,COMPLETED,INTERVENTIONAL,['PHASE2']
4466,NCT06206525,Clinical significant hypoglycemia,Clinical significant hyperglycemia,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4467,NCT00982371,"1 Tesla peripheral MRI assessment at non dominant distal radius: Trabecular bone micro-architecture parameters Tb.Th, Tb.Sp, Tb.N, BV/TV, bone CSA, marrow space","Calcium, vitamin D and vitamin K dietary intakes; TUG (sec); grip strength; DXA assessment of hip, lumbar spine, total body; physical activity",,2008-09,COMPLETED,OBSERVATIONAL,['NA']
4468,NCT00815178,Maximum inspiratory pressure,autonomic modulation assessed by heart rate variability,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
4469,NCT05353790,Changes in Kidney function markers,Changes in Cognitive Function-6,,2021-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4470,NCT01307410,Incidence of CVD events,Annual incidence of microvascular complications,,2011-03,UNKNOWN,OBSERVATIONAL,['NA']
4471,NCT05022875,Change in Hypoglycemic Events,Change in Diabetes Knowledge Questionnaire score over time,,2021-04-23,UNKNOWN,INTERVENTIONAL,['NA']
4472,NCT00412230,,,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
4473,NCT05068895,Metabolic profiles of lower extremity artery disease,Pathway analysis of differential metabolites,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
4474,NCT00005665,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2']
4475,NCT02076880,Change of area under the curve of post prandial glycemia,"Change in insulin sensitivity, Change in insulin secretion, Change in incretins",,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
4476,NCT00579436,Adipocyte Size After Fish Oil Treatment,Insulin Resistance After Fish Oil Regiment,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
4477,NCT06231771,Proportion of patients with complete healing/closure of the target ulcer at any time during the 6-weeks period.,The proportion of patients with at least 50% closure of target ulcer during the 6-weeks period,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4478,NCT01269996,To evaluate the treatment efficacy,proportion of patients with HbA1c <6.5% in 1 year,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4479,NCT00536549,"HbA1c, fasting blood glucose level, weight change, blood pressure in the morning, lipid profiles",three day diary meals and seven day physical activity diary,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
4480,NCT04115592,Postprandial glucose,Postprandial insulin,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
4481,NCT01596244,Weight (kg),Body Mass Index (kg/m2),,2008-04,COMPLETED,INTERVENTIONAL,['NA']
4482,NCT01195090,The Percentages of Patient Achieving an A1C <7%,Baseline High-density Lipoprotein Cholesterol (HDL-C),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4483,NCT05229445,time in range,,,2022-07-05,COMPLETED,INTERVENTIONAL,['NA']
4484,NCT05295706,Change in HbA1C,Change in the Behavioral Strategies - Engagement and Intentions score,,2022-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4485,NCT02236962,brown adipose tissue activity,,,2012-04,UNKNOWN,INTERVENTIONAL,['NA']
4486,NCT01983917,Change of diabetic retinopathy risk factors,Motivation for adhering to treatment recommendations and follow-up,,2012-09,WITHDRAWN,INTERVENTIONAL,['NA']
4487,NCT00964262,To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection,To examine the effect on glucose control and pharmacodynamic parameters of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
4488,NCT04872647,Change of HOMA2-IR,EVS,,2020-12-18,UNKNOWN,INTERVENTIONAL,['NA']
4489,NCT06275971,Time within the target range of 100-180 mg/dL,Mortality within 30 days of surgery,,2022-11-24,RECRUITING,INTERVENTIONAL,['NA']
4490,NCT05822609,Change in kidney cortical relaxation rates (R2*),Change in total daily insulin dose,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4491,NCT01099956,Increase of Interleukine 6 in group DTI versus control group,"Increase of others cytokines (IL1-beta, l'IL-4, l'IL-10 and TNF alpha) and increase of High sensitivity CRP in group DTI versus control group",,2010-04,COMPLETED,OBSERVATIONAL,['NA']
4492,NCT05070741,Change in intraepidermal nerve fibers (IENF),Utah Early Neuropathy Scale (UENS),,2020-07-27,TERMINATED,INTERVENTIONAL,['NA']
4493,NCT01778049,Change From Baseline of HbA1c After 24 Weeks of Treatment.,Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4494,NCT00360217,Lowering of triglyceride level,Alteration of LDL particle size,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
4495,NCT04769115,Predicting diabetic foot complications,,,2021-02-24,COMPLETED,INTERVENTIONAL,['NA']
4496,NCT01285934,C-peptide,Stimulated C-peptide levels during mixed meal tolerance test,,2009-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4497,NCT02813863,The area under the plasma concentration-time curve (AUC) of metformin,The number of volunteers with adverse events as a measure of safety and tolerability,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4498,NCT03563313,Time in Target Range,BMI,Any Adverse Event Rate Per 100 Person-years,2018-06-28,COMPLETED,INTERVENTIONAL,['NA']
4499,NCT01426685,sudden cardiac death,non-fatal cardiovascular event,,2007-08,UNKNOWN,OBSERVATIONAL,['NA']
4500,NCT05975242,Spanish-language Diabetes Self-Efficacy Scale (DSES-S),Weight,Mobile Device Proficiency Questionnaire (MDPQ),2023-04-04,RECRUITING,INTERVENTIONAL,['NA']
4501,NCT00942188,Change From Baseline in the Glycosylated Hemoglobin (HbA1c) at 12 Weeks,Pharmacokinetics Measured by Serum Concentration at End of Dosing (12 Weeks),,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4502,NCT03572699,Sensitivity and specificity of the AI in detecting any grade of diabetic retinopathy,Sensitivity and specificity of the AI in detecting sight threatening diabetic retinopathy (referable retinopathy defined as severe non proliferative retinopathy or greater),,2018-07-11,UNKNOWN,OBSERVATIONAL,['NA']
4503,NCT04474808,Feet Care Feelings,,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
4504,NCT05844748,"The Effect of Training Given by Motivational Interview Technique on Self-Efficacy Perception, Level of Adjustment to Disease and Metabolic Parameters in Type 2 Diabetes Patients",,,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
4505,NCT01121835,Percentage of patients with Glycosylated Haemoglobin (HbA1c) <7% with no documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) ≤ 56 mg/dL [3.1 mmol/L],Biochemistry and lipid profile,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4506,NCT00515099,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT),Hemoglobin A1c,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2']
4507,NCT01460446,Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 24,The Diabetes Treatment Satisfaction Questionnaire at Baseline (DTSQs) Score and the Diabetes Treatment Satisfaction Questionnaire for Change From Baseline (DTSQc) Score,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
4508,NCT01496430,Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure,Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT,,2012-01,TERMINATED,INTERVENTIONAL,['PHASE3']
4509,NCT05814406,HbA1C (24 Weeks) lowering effect,HbA1c lowering effect,,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE3']
4510,NCT01109043,Changes in systolic and diastolic BP,Assessment of quality of life (SQ-8 Short Form Health Survey),,2009-06,COMPLETED,OBSERVATIONAL,['NA']
4511,NCT00907075,"Average percent deviations from the assigned eating system score for full days, meals, and snacks for each group during each evaluation period throughout the intervention (days 23-28 and days 51-56).",Change in dietary macronutrient composition from baseline to end of treatment.,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
4512,NCT02713477,Measurement of plasma glucose concentrations,Measurement of anti-insulin antibodies,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4513,NCT03837262,Recruitment and retention,WPAI questionnaire,,2019-03-25,COMPLETED,INTERVENTIONAL,['NA']
4514,NCT01929512,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin Vd/F",,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4515,NCT02273180,Change in HbA1c From Baseline to Week 26,Percentage of Participants With Treatment Emergent Anti-insulin Antibodies (AIAs),Change in Daily Insulin Dose From Baseline to Week 26 and Week 52,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4516,NCT02289612,Satiety-producing effect for each pudding and control product,3-Day food records,Heart rate and blood pressure,2014-11,COMPLETED,INTERVENTIONAL,['NA']
4517,NCT01138488,Area under the serum insulin aspart concentration-time curve,Maximum observed insulin aspart concentration of NN5401 (insulin degludec/insulin aspart) observed,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4518,NCT04692220,Variables associated with the presence of an Adverse Drug Events or Drug-Related Problems,Number and type of Adverse Drug Events and Drug-Related Problems,,2011-11-01,COMPLETED,OBSERVATIONAL,['NA']
4519,NCT05561517,Plasma glucose,,,2023-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4520,NCT05236335,Cardiac Output (L/min),Exercise capacity (METs),,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
4521,NCT01487798,Frequency of hypoglycaemic episodes,Diabetes Treatment Satisfaction Questionaire,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4522,NCT01527643,"Cmax, maximum insulin aspart concentration",Incidence of hypoglycaemic events,,2003-11-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4523,NCT03466398,Hemoglobin A1c,DKA Admission Rates,,2018-04-11,WITHDRAWN,INTERVENTIONAL,['NA']
4524,NCT03632759,Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.,,,2018-08-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4525,NCT00639457,Insulin-stimulated Glucose Disposal Rate,Myocardial Contractility-DBP,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
4526,NCT06292624,Muscle oxygenation,Functional mobility,,2023-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4527,NCT06202950,Glycemic control form,,,2023-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4528,NCT02194595,"Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2)",Baseline-adjusted glycemic control at 8 weeks,Baseline-adjusted insulin sensitivity at 20 weeks,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4529,NCT03651466,"Incidence, nature and severity of Adverse events",Pharmacokinetics(PK) variables,,2017-08-31,COMPLETED,INTERVENTIONAL,['PHASE1']
4530,NCT02234973,mean HbA1C of patients with diabetes (A1C ≥ 8.0% at baseline),,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
4531,NCT00993096,Area (AUC) under the glucose infusion rate curve,Area (AUC) under the insulin aspart concentration time curve,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
4532,NCT00780715,HbA1c Change,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4533,NCT02896010,Yield of Recruitment,Adherence to physical activity goal,,2016-10-10,COMPLETED,INTERVENTIONAL,['NA']
4534,NCT01486940,HbA1c (glycosylated haemoglobin),Incidence of adverse events,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4535,NCT03274089,Hemoglobin A1c,Health-related quality of life questionnaire,,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA']
4536,NCT02890836,Early preterm delivery (Danish),Chronic hypertension,Body mass index (BMI),2016-02,COMPLETED,OBSERVATIONAL,['NA']
4537,NCT01871831,Influence of the blood sample's partial pressure on blood glucose measurement results,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
4538,NCT04264572,Change in hemoglobin A1C for patients with poorly controlled type 2 diabetes mellitus,Change in diabetes quality of life for patients with poorly controlled type 2 diabetes mellitus as measured by Diabetes Quality of Life (DQoL) instrument,,2020-01-21,RECRUITING,INTERVENTIONAL,['NA']
4539,NCT03956797,Incidence of Anesthesia-Related Adverse Events,Pain of Intravitreal Injection (Follow-Up): VAS,,2019-04-15,COMPLETED,INTERVENTIONAL,['NA']
4540,NCT04544527,all-cause mortality,chronic complications of diabetes,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
4541,NCT00063674,,,,2003-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4542,NCT02065674,,,,2014-02,AVAILABLE,EXPANDED_ACCESS,['NA']
4543,NCT00705536,Relative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone),Area Under the Glucose Infusion Rate Curve From 0 to 360 Minutes After Injection (AUC[GIR{0-360}]),,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4544,NCT01997021,Area under the insulin curve in response to meal tolerance test,24-hour Glycemic variability,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
4545,NCT00775333,"Sensory function (Semmens-Weinstein), motor function (Abductor Pollicis Brevis (APB)-strength, grip strength)","Pillar pain, cold intolerance, and patient satisfaction.",,2003-12,COMPLETED,OBSERVATIONAL,['NA']
4546,NCT03491241,left ventricle ejection fraction,,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
4547,NCT02666521,Frequency of mild hypoglycaemic episodes,Frequency of severe hypoglycaemic episodes,Incidence and severity of hypoglycaemic episodes,2012-07-20,COMPLETED,OBSERVATIONAL,['NA']
4548,NCT01545024,Glycemic control,autonomic nerve disturbance,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
4549,NCT02145572,"Differences in metabolite concentrations measured by mass spectrometry, comparing blood and urine samples from obese adolescents with type 2 diabetes, obese adolescents without diabetes, and age-matched healthy non-obese controls.",,Validation of presence of DENND1A isoform in the urine of adolescent females with polycystic ovarian syndrome,2014-05,COMPLETED,OBSERVATIONAL,['NA']
4550,NCT02868320,change in HbA1c,Rate of hospital/ER admissions,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
4551,NCT05407376,Change in HbA1c between baseline and 6 months,Analyze the difference in difference of patient-reported nutritional security between the intervention and control group.,,2021-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4552,NCT00545727,Blood glucose level,,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
4553,NCT00871312,Wound closure,The level of wound pain,,2007-05,TERMINATED,INTERVENTIONAL,['NA']
4554,NCT05953532,Measure of Engagement in Personal Healthcare,Glycemic control,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
4555,NCT06083675,Change in glycated haemoglobin (HbA1c),Change in AHA Life's Simple 7 summary score,,2024-01-26,WITHDRAWN,INTERVENTIONAL,['PHASE3']
4556,NCT03052283,"Development and evaluation of a diary for assessment and quantification of abdominal symptoms, a CF-specific PROM following FDA recommendations","Effects of a new therapy with CFTR-modulator on abdominal symtoms, quantified with the CFAbd-Score",,2017-01-26,RECRUITING,OBSERVATIONAL,['NA']
4557,NCT01591902,Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale.,Change from baseline in HbA1c by intensification of concomitant diabetic treatment,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE4']
4558,NCT04009642,The difference in myocardial FA extraction fraction (%) between T2D patients and non-diabetic controls at rest.,,,2018-03-05,COMPLETED,OBSERVATIONAL,['NA']
4559,NCT01120444,Blood Glucose,Insulin levels,,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4560,NCT01176656,prevalence of hypoglycemia and impact of hypoglycemia,"Treatment adherence and modification related to hypoglycemia, including health status, glycemic control and healthcare utilization",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
4561,NCT00670683,Incidence of adverse events,Clinical laboratory abnormality,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
4562,NCT01575301,Change in HbA1c between baseline and 6 months,,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
4563,NCT00993720,insulin-dose,"weight change from baseline, change in fructosamine from baseline",,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4564,NCT01482455,Blood flow,Interstitial insulin concentration,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
4565,NCT03761186,Change in insulin use,Time taken to complete the Trail making test A+B,Frequency of intake of different foods measured by a Food frequency questionnaire (FFQ),2018-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4566,NCT00494559,Comparison of pioglitazone and placebo on 8 months follow-up neointima volume by intravascular ultrasound (IVUS).,"Comparison of pioglitazone and placebo on the changes in the levels of inflammatory markers (hsCRP, IL-6, TNF-α, adiponectin).",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4567,NCT00768651,Weight Change From Baseline After 6 Months of Therapy,Blood Glucose Laboratory Value Before Mixed Meal Tolerance Test (MMTT) After the 3 Month Washout Period,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4568,NCT00740922,The primary objective of this study is to retrospectively evaluate the safety of sterile becaplermin gel vs. sterile placebo gel treatment 12 months or more after the last dose was administered.,The secondary objective of the trial was to evaluate recurrence of the Target Ulcer if it had healed in the previous trial.,,1999-07,COMPLETED,OBSERVATIONAL,['NA']
4569,NCT01192711,Blood levels of glycosylated hemoglobin,Frequency and times of hypoglycemic events with regard to occurrence during the day (24 hours) and total treatment duration (24 weeks),,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
4570,NCT03730727,Postprandial blood glucose concentrations.,Postprandial blood glucose control.,,2017-10-09,COMPLETED,INTERVENTIONAL,['NA']
4571,NCT00508430,Pain severity rating,Clinical's global impression of change,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
4572,NCT05727592,Fasting blood glucose,Renal profile,,2023-03-20,COMPLETED,INTERVENTIONAL,['NA']
4573,NCT04597697,"AUC,Ico,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose","tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose",,2020-12-22,COMPLETED,INTERVENTIONAL,['PHASE1']
4574,NCT05291975,Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS),Neuropathic Pain Symptom Inventory (NPSI),,2022-02-17,RECRUITING,INTERVENTIONAL,['NA']
4575,NCT01524770,Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide,Pharmacokinetics: Time to Maximum Concentration (Tmax) for Dulaglutide,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4576,NCT05074147,Percentage of treated patients achieving remission from the diabetic foot osteomyelitis at the end of follow-up,Rates of major amputation in each group of patients.,,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
4577,NCT01534013,Percentage Time in Euglycaemia,Insulin Requirement in Units/kg/hr,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
4578,NCT02835495,Adherence to the Lifestyle Weight Loss Intervention,,Cholesterol (Lipid Panel),2017-11-15,COMPLETED,INTERVENTIONAL,['NA']
4579,NCT02426606,Postprandial blood insulin,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
4580,NCT01785134,Insulin Sensitivity at 2 Years,Blood Lipids,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
4581,NCT00728377,Gestational diabetes diagnosis assessed through glucose tolerance test.,Adoption and maintenance of exercise during pregnancy,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
4582,NCT05795582,Comparison of the values of upstroke time (TMS) obtained by a new method of measurement by PPG (photoplethysmographic) technique and IPSo,,,2023-06-14,RECRUITING,INTERVENTIONAL,['NA']
4583,NCT00529048,Progress in Incretin effect in patients with T2DM compared with healthy subjects,GIP and GLP-1 responscurvs,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
4584,NCT05937984,Change in PROMIS-29 v2.0 Profile,Change in nerve conduction assessments,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4585,NCT02317172,Changes in subjective dry mouth score,Satisfaction of the edible gel-based artificial saliva,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
4586,NCT04177420,"Geriatric Depression Scale-15, GDS-15",,,2018-03-23,UNKNOWN,INTERVENTIONAL,['NA']
4587,NCT04621045,Acceptability of PATH intervention,Change from baseline in Barriers Exercise Self-efficacy (BARSE) scale at 12 weeks,,2020-10-27,COMPLETED,INTERVENTIONAL,['NA']
4588,NCT05933616,Correlation between blood glucose and patterns,"Association between the onset of change in glucose, vital signs and VOC spectra",,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4589,NCT01478776,postprandial ASP,gene expression of C5L2,,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
4590,NCT01960179,"Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data.",Absolute change in body weight,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4591,NCT02449213,Insulin resistance,glycated hemoglobin (HbA1c),,2016-03-11,COMPLETED,OBSERVATIONAL,['NA']
4592,NCT05224258,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]),,2022-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4593,NCT04712409,Change in GIP dynamic profile,Metabolic syndrome remission rates,Late morbidity,2020-08-16,RECRUITING,INTERVENTIONAL,['NA']
4594,NCT03478254,Adherence to Regional Guidelines for the Immunization of Adults With Type 1 Diabetes Mellitus (T1DM,Number of Participants Who Have Taken Related Sick Leaves,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
4595,NCT00592072,Telephone Search,,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
4596,NCT01186354,Accurate understanding of genetic risk information,Impact on behavior change,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
4597,NCT03556605,"Change in A1c from baseline at 12 weeks in intervention group compared to control group. At this point, control group subjects will cross-over to the same treatment as the intervention group for an additional 12 weeks.",,,2018-07-30,UNKNOWN,INTERVENTIONAL,['NA']
4598,NCT03136822,Recovery of the wound 100%,Recovery of the wound 80%,,2017-04-26,COMPLETED,INTERVENTIONAL,['NA']
4599,NCT02185963,Functional HDL-C,Patients with LDL-C < 70 mg/dl and HDL > 40 mg/dl in men; > 50 in women,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4600,NCT00634868,The wound healing process,,,2008-08,TERMINATED,INTERVENTIONAL,['NA']
4601,NCT00530023,Change in A1C From Baseline to Week 15,Hypoglycemia Fear Scale (HFS) Assessed at Baseline and Week 15,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4602,NCT04887077,Change in daily physical activity from baseline to 3 months,Change in weight bias internalisation from baseline to 9 months,Perceived exertion during the APA sessions,2021-06-10,UNKNOWN,INTERVENTIONAL,['NA']
4603,NCT01951287,plasma glucose levels,Plasma Insulin Levels,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
4604,NCT04311021,The main study parameter will be the current prevalence of IAH and exposure to SH in the past 12 months.,Answers to questionnaire,,2020-01-23,UNKNOWN,OBSERVATIONAL,['NA']
4605,NCT00311298,Weight gain,Mortality,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4606,NCT00274118,Change from baseline in glomerular filtration rate GFR after five years of treatment.,Resting 12-lead ECG,,1997-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4607,NCT00979628,"Mean Blood Glucose Levels (Measured in mg/dL) at Randomization Are Compared to Mean Blood Glucose Levels After First Day of Treatment Among Subjects Treated With Basal Plus, Basal -Bolus and SSRI Treatments","Number of Patients With Hypoglycemia Events (Blood Glucose Levels < 70 mg/dL) During Their Hospital Stay That Are Treated With Basal Plus, Basal-bolus and SSRI Treatments",,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4608,NCT03885362,MARD between Libre and YSI,Missing glucose data,,2019-12-11,COMPLETED,INTERVENTIONAL,['NA']
4609,NCT00266240,"HbA1c mean change from baseline, compared to placebo.",Pharmacokinetic and exposure-response relationship,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4610,NCT04815772,The advantages of including the effect of diabetes and smoking on periodontal disease in the 2018 classification compared to the 1999 classification,,,2020-11-01,COMPLETED,OBSERVATIONAL,['NA']
4611,NCT01981031,End of action of 0.8 U/kg BioChaperone® Combo (time from administration until blood glucose concentration is consistently above 8.3 mmol/L during the glucose clamp procedure),Number of Adverse Events,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4612,NCT01600534,Change in glycosylated hemoglobin,Change in weight after pregnancy,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4613,NCT00766441,Occurrence of hypoglycemia,"Body weight, fasting blood sugar, HbA1c, triglycerides, total cholesterol, LDL-C, HDL-C. CGMS to define glycaemic excursions",,2008-08,TERMINATED,INTERVENTIONAL,['PHASE4']
4614,NCT05411640,Australian type 2 diabetes risk assessment tool (AUSDRISK),Borg rating of perceived exertion (RPE),,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4615,NCT04440839,Specialty Consultation,Amputation,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
4616,NCT03941184,Incidence Rate of SCAD,SCAD recurrence,Odds of validated rheumatoid arthritis in SCAD cases compared to controls,1995-01-01,COMPLETED,OBSERVATIONAL,['NA']
4617,NCT00687284,Change in glycaemic control as measured by HbA1c.,Change in waist and hip perimeter,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
4618,NCT03588000,absolute change in % HbA1c from baseline to 12 months,change in blood glucose from baseline to 24 month,change in health economics indexes from baseline to 24 months,2018-11-23,COMPLETED,INTERVENTIONAL,['NA']
4619,NCT01835964,Change Between Pre and Post Challenge Glucose Variability,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4620,NCT03669770,Changes in Glycaemic control between baseline and follow-up,,Health-related quality of life,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
4621,NCT03597815,Apnea-Hypopnea Index,CPAP compliance,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
4622,NCT02162004,Percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00.,Positive Incremental Area Under the Curve,Mean absolute relative difference.,2014-06,TERMINATED,INTERVENTIONAL,['NA']
4623,NCT04403945,the comparison of the density of total length of the small perfusd vessels(PDV) in the acquisition window between the 3 groups,Correlation comparison: The correlation between SDF vascular parameters and the clinical data of the subjects was compared,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
4624,NCT03449433,Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm,Pharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT),,2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE1']
4625,NCT04383990,Hypoglycemia incidence,Acute diabetes complications,,2020-02-28,COMPLETED,INTERVENTIONAL,['NA']
4626,NCT00325364,To assess the change in baseline to endpoint in HbA1c in Type II diabetic patients comparing inhaled human insulin to injectable insulin,To assess the pharmacokinetics on inhaled human insulin in a subgroup of patients,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4627,NCT01353469,Change in HbA1c from baseline to the end of treatment,Change in fasting plasma glucose from baseline to the end of treatment,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4628,NCT00899483,The difference in the mean left ventricular end-systolic volume index (LVESVI) after CABG and the amount of new permanent injury detected in the late CMRI study,Glycaemic control will be assessed 2 hours pre-operatively and 72 hours post-operatively. Measurement timings will be standardized allowing comparison of glycaemic control during different time-periods.,,2009-07,UNKNOWN,INTERVENTIONAL,['NA']
4629,NCT02566317,Mean Change in Sitting Time at Work From Baseline to 12 Months,Clustered Metabolic Risk Score From Baseline to 12 Months,Dynamic Glucose Control,2016-01-15,COMPLETED,INTERVENTIONAL,['NA']
4630,NCT00739180,"Abdominal obesity, visceral fat","Insulin sensitivity and secretion, glucose tolerance",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
4631,NCT01951677,Safety,Efficacy,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4632,NCT05266963,Patient-reported change in pancreatic exocrine insufficiency (PEI) symptoms,,,2022-09-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1']
4633,NCT01744236,"Changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on pancreatic exocrine function, measured as fecal Elastase-1.",Changes from baseline following infusion of GLP-1RA (acute effects*) and changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following gastrointestinal parameters:,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4634,NCT02962921,Left ventricle ejection fraction (%),Time needed to exert insulin effect on myocardial function (hour),A' (centimeters),2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4635,NCT02521116,Difference of oxygen saturation of retinal vessels between DVA and Oxymap T1,Difference of retinal vessel diameter between DVA and Oxymap T1,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4636,NCT04832984,Change in body weight,Change in anthropometry measures,,2022-03-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4637,NCT02237352,House localization,Protein expression,Albuminuria,2014-09-15,UNKNOWN,OBSERVATIONAL,['NA']
4638,NCT03870997,Number of Participants With Self-reported Influenza Vaccination in People With Diabetes,,,2018-09-12,COMPLETED,INTERVENTIONAL,['NA']
4639,NCT03178773,Change in HBA1c From Baseline,Change in Partner Distress Scale From Baseline,,2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE2']
4640,NCT02847390,Hyperglycemia,,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
4641,NCT02711059,quality of life - self estimation protocol,cognition,,2015-10,WITHDRAWN,INTERVENTIONAL,['NA']
4642,NCT00461630,Major Vascular Event,Mortality,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4643,NCT05916131,The number of participants recruited to reach 20 participants that complete the intervention,Percentage of participants finding message content helpful (positive) at the end of the intervention,,2023-09-19,RECRUITING,INTERVENTIONAL,['NA']
4644,NCT03284996,Early detection of diabetic nephropathy in patients with type 2 diabetes mellitus by measuring changes in renal resistive index using Doppler ultrasonography,,,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA']
4645,NCT02326337,Wound closure within 12 weeks with the use of Topical Wound Oxygen Therapy (TWO2),Economic Analysis,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
4646,NCT03205150,Change From Baseline in Alanine Aminotransferase (ALT) at Week 12,Change From Baseline in Aspartate Aminotransferase (AST) at Week 12,,2017-10-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4647,NCT01978613,Number of treatment emergent adverse events recorded,Maximum observed NNC0113-0987 plasma concentration,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4648,NCT02373592,Foot ulceration,Glycosilated hemoglobin control targets,"Sub-group analyses, intervention group only",2015-09,COMPLETED,INTERVENTIONAL,['NA']
4649,NCT01238484,Range of Motion,Pain,,2010-08,TERMINATED,INTERVENTIONAL,['NA']
4650,NCT01880476,Changes from baseline in the Summary of Diabetes Self-Care Activities questionnaire,Changes from baseline in number of hypoglycemic events per week (blood glucose <4.0 mmol/L),Partnership and collaboration questionnaire,2013-06,COMPLETED,INTERVENTIONAL,['NA']
4651,NCT05903482,Gastric volume in pediatric patients on GLP-1 RA,,,2023-06-06,RECRUITING,OBSERVATIONAL,['NA']
4652,NCT02890693,Self-reported symptoms of depression (mother) measured by Edinburgh Postnatal Depression Scale,Laboratory (mother): miRNA,"Self-reported life events (mother, partner) measured by Life Events Questionnaire",2016-09,COMPLETED,INTERVENTIONAL,['NA']
4653,NCT02250066,Incidence of Diabetes in 322 Subjects with Prediabetes,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
4654,NCT02288585,Change in LDL-C,Change in blood lipids,Change in Advanced Glycation End products (AGEs),2014-10,COMPLETED,INTERVENTIONAL,['NA']
4655,NCT04198350,Safety of the procedure with regards to opthalmic complications,,,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4656,NCT01170442,Area under the curve of HA1C.,incidence of hypercalciuria,,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3']
4657,NCT02422420,Weight Change,,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
4658,NCT04651816,Subject Retention,Opinions about PSH DPP program,,2021-05-25,COMPLETED,INTERVENTIONAL,['NA']
4659,NCT03235492,Salivary glycated albumin vs. glycosylated hemoglobin (HbA1c),,,2017-08-24,WITHDRAWN,INTERVENTIONAL,['NA']
4660,NCT02227849,Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events),Change in Blood Pressure,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4661,NCT05967312,Proportion of patients with ACR test in the last 12 months,"Proportion of patients with newly diagnosed albuminuria (i.e., since randomisation)",,2022-11-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4662,NCT05990933,Monocyte count,Distribution of monocyte subset,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4663,NCT02836574,Change in Renal Function,Treatment emergent adverse events,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4664,NCT01302145,"Safety assessed by incidence of adverse events, vital signs, 12-lead ECG and glucose monitoring",Pharmacokinetics assessed by metformin plasma concentration change,,2009-02-25,COMPLETED,INTERVENTIONAL,['PHASE1']
4665,NCT02872922,Percentage of the endothelium-dependent vasodilation (%FMD),Percentage of the endothelium-independent vasodilation (%NMD),,2016-12-10,COMPLETED,INTERVENTIONAL,['NA']
4666,NCT04146155,Initial and absolute claudication distance,Changes from baseline in HbA1c,,2020-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
4667,NCT04430582,Assessment of working memory,Assessment of psychomotor speed,,2020-08-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4668,NCT00456963,new hypertension or initiation of any antihypertensive treatment during the treatment period of the trial.,variations of fasting blood glucose.,,2007-09,TERMINATED,INTERVENTIONAL,['PHASE4']
4669,NCT02499107,Food Intake,subjective appetite,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4670,NCT01572090,Change in body fat,Change in BMI,,2006-01,UNKNOWN,INTERVENTIONAL,['NA']
4671,NCT04952324,carriers of the MTHFR gene mutation have higher serum homocysteine concentrations in the blood,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
4672,NCT04672031,Difference in birth weight,IUFD or stillbirth,,2021-07-08,RECRUITING,INTERVENTIONAL,['NA']
4673,NCT00645840,Effect of Anakinra Treatment on PBMC Gene Expression for Patients,C-peptide Secretory Capacity,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4674,NCT02004886,Number of Participants Discontinuing Study Treatment Due to an AE,Change From Baseline in 3-hour Insulin Total AUC at Week 4,,2006-08-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4675,NCT00262197,LDL-cholesterol levels and test rates in the 12 months post-intervention.,Charlson comorbidity score,,2001-12,COMPLETED,INTERVENTIONAL,['NA']
4676,NCT00747149,Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy,Incidence of Adverse Events and Abnormal Laboratory Values After 12 Weeks of Therapy,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4677,NCT05066230,Proportion of eyes improving ≥2 steps on the ETDRS Diabetic Retinopathy Severity Scale (DRSS),Safety and Tolerability of KSI-301 5 mg compared to sham treatment,,2021-08-30,TERMINATED,INTERVENTIONAL,['PHASE3']
4678,NCT02026232,Effect of HCQ on Fasting Blood Glucose,Effect of HCQ on Fasting Low Density Lipoprotein,,2012-03,TERMINATED,INTERVENTIONAL,['NA']
4679,NCT05014789,Serious Adverse Events,CGM Metrics by time of day,,2021-08-19,COMPLETED,INTERVENTIONAL,['NA']
4680,NCT01489189,Mean Change in Visual Acuity From Baseline,Number of Eyes With Greater Than or Equal to 10 Letter Vision Loss,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4681,NCT00360698,Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%,Rate of Severe Symptomatic Hypoglycemia,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4682,NCT00319189,Insuline release,Plasma endothelin-1,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
4683,NCT06309654,Superoxide dismutases (SOD),,,2021-09-13,COMPLETED,INTERVENTIONAL,['NA']
4684,NCT01754142,"Effectiveness of Kombiglyze XR as assessed by change from baseline in Hemoglobin A1c (HbA1c), Fasting plasma glucose (FPG), and 2-hour post-prandial glucose (2-hr PPG)","Safety information related to overdose, drug-to-drug interaction and laboratory abnormalities based on incidence rates of AEs",,2012-11-24,COMPLETED,OBSERVATIONAL,['NA']
4685,NCT04283162,The rate of the progression of diabetic retinopathy,Changes in metabolic biomarkers such as HbA1c,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
4686,NCT02388100,HbA1c obtained from venous versus capillary measurements at one point in time for each participant.,,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
4687,NCT03092882,Change from Baseline in A1c at 6 months,,,2017-03-03,COMPLETED,INTERVENTIONAL,['NA']
4688,NCT03466567,"Cmax,SNAC,SD, maximum observed SNAC plasma concentration on the concentration-time curve after a single dose of oral semaglutide","Cmax,E1247,SD, maximum observed SNAC metabolite E1247 plasma concentration on the concentration-time curve after a single dose of oral semaglutide",,2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE1']
4689,NCT04304963,LIG optimum detection of hypoglycemia,Secondary outcome 10,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
4690,NCT02007278,Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE),"Number of Patients With Any Adverse Events, Serious Adverse Events and Death",,2014-01-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4691,NCT05577169,Acceptability of intervention in the study population.,"Hemoglobin A1c (HbA1c, %)",Child and Adolescent Social Support Scale (CASSS) questionnaire,2022-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4692,NCT05751525,IQ score,"Hyperactivity, emotional problems, conduct problems, peer relationships, prosocial behaviour.",,2016-07-01,RECRUITING,OBSERVATIONAL,['NA']
4693,NCT02843139,It is expected that the identification of circulating miRNAs as potential biomarkers may facilitate to the diagnosis of obese preschoolers at high risk for developing diabetes.,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
4694,NCT00639626,Blood Sugar,Lean Body Mass,,2008-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4695,NCT00348374,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at End of Treatment,Change From Baseline in Standard Deviation of 24-hour Glucose Values Measured by Continuous Glucose Monitoring System (CGMS),,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4696,NCT05794789,Change from baseline in children's moderate to vigorous physical activity to 6 months,Social Identity,,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
4697,NCT04803357,Health of baby using delivery and post delivery well baby assessments,,,2021-04-10,RECRUITING,INTERVENTIONAL,['NA']
4698,NCT04088552,Change in abdominal circumference,Change in knowledge regarding hypertension,,2020-03-07,COMPLETED,INTERVENTIONAL,['NA']
4699,NCT02947620,Change in LDL Cholesterol,"Change in Insulin, HOMA-β, HOMA-IR after 4, 8, 12, and 16 weeks of treatment with investigational products compared to baseline.",,2015-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4700,NCT00347100,A1c values,Adverse events including hypoglycemia,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4701,NCT04139369,"Overall mean methylation percentage (%) of CpGs cytosine-guanosine islands within the promoter regions of INS, PTPN-22,HLA-G genes between T1DM and healthy children and adolescents",,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
4702,NCT02065752,Plasma concentration of metformin following the single dose of drug administration,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4703,NCT04167410,Rates of hypoglycaemia development,,,2017-09-15,COMPLETED,INTERVENTIONAL,['NA']
4704,NCT01305434,change in 2 hour post prandial blood glucose,"number of subjects with adverse changes in creatinine, AST, ALT, and blood pressure due to intervention",,2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4705,NCT03453970,"Change from baseline diastolic blood pressure (DBP) at 6 months, change from baseline diastolic blood pressure at 12 months and change from baseline diastolic blood pressure at 18 months.","Change from the baseline level of adherence to the diet at 6 months, change from the baseline level of adherence to the diet at 12 months and change from the baseline level of adherence to the diet at 18 months.",Participation in the program,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA']
4706,NCT05552859,Difference in the mean change from baseline to Week 24 in HbA1c level (Gla-300 vs IDeg-100),"Number of participants with adverse events (AEs)) and serious adverse events (SAEs), including adverse events of special interest (AESIs)",,2022-12-05,TERMINATED,INTERVENTIONAL,['PHASE4']
4707,NCT05752591,Genetic predisposition,,,2018-05-25,COMPLETED,OBSERVATIONAL,['NA']
4708,NCT01013571,Percentage of subjects reaching target HbA1c <=7.0% without severe hypoglycemia,Adherence with the patient-managed monitoring algorithm,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4709,NCT01729403,Change in whole-body insulin sensitivity as assessed by M-value (Insulin-stimulated glucose disposal rate),Safety: Incidence of adverse events,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4710,NCT02897219,Change from baseline in HbA1c,Safety assessed by laboratory tests: Urinalysis,,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE3']
4711,NCT01425905,Insulin Resistance at 12 months in CB depression prevention versus HE control group.,"CB, depression, prevention, group, will, show, greater, improvements, in, mediators, (eating, behavior, fitness, and stress biomarkers) than the HE control group.",,2011-08-23,COMPLETED,INTERVENTIONAL,['PHASE2']
4712,NCT04759469,Exercise enjoyment and acceptability,Adherence rates,,2018-12-01,COMPLETED,INTERVENTIONAL,['NA']
4713,NCT06141967,patients real positive for each screening technique,Nurse's satisfaction with the use of Withings Sleep Analyzer,,2023-11-30,RECRUITING,INTERVENTIONAL,['NA']
4714,NCT02649374,Bacterial population diversity,,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4715,NCT03699709,change (from baseline) in healthy and unhealthy food purchases (measured using the Healthy/Unhealthy Food Acquisition Survey) at 6 months and 12 months,"Process evaluation: intervention dose received (i.e., number of lessons included in the curriculum completed by participants)",,2020-02-27,COMPLETED,INTERVENTIONAL,['NA']
4716,NCT03601884,"Difference in Diabetes Management Self-Efficacy Scale (DMSES) scores between OHP+TAU (experimental group) and TAU alone (control group), and within OHP plus TAU across time","Difference in HbA1c between OHP+TAU (experimental group) and TAU alone (control group), and within OHP plus TAU across time",,2018-10-05,COMPLETED,INTERVENTIONAL,['NA']
4717,NCT04446767,Wound assessment,,,2020-06-30,COMPLETED,INTERVENTIONAL,['NA']
4718,NCT05629403,HOMA-IR,,,2021-09-01,COMPLETED,OBSERVATIONAL,['NA']
4719,NCT01958671,Percentage of Participants Discontinuing Study Treatment Due to an AE,Change From Baseline in DBP at Week 26,,2013-10-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4720,NCT03020264,Number of confirmed or severe hypoglycemia,Number of death due to hypoglycemia,,2017-11-28,TERMINATED,INTERVENTIONAL,['NA']
4721,NCT02386982,24-hour glucose change,"Composite measure of adverse events monitoring, physical examinations,12 lead ECGs, vital sign,and safety laboratory measurement",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4722,NCT01983007,Arterial dilation,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
4723,NCT02517866,Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12,"Change From Baseline in DBP at Week 12 in ""Treatment-Naïve"" Participants",,2015-07-13,COMPLETED,INTERVENTIONAL,['PHASE4']
4724,NCT03557697,Change in Average Plasma Glucose Concentration measured by Hemoglobin A1c (HbA1c) Levels,Minutes of Sleep as Measured by ActiGraph Watch,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
4725,NCT00004360,,,,1995-09,COMPLETED,OBSERVATIONAL,['NA']
4726,NCT02386540,Number of emergency department visits,"Qualitative analysis of action plans (Health coach documentation notes will be analyzed, data will be coded to identify themes such as type of goals, barriers to care, and resources identified in the action plan)",,2015-02-06,COMPLETED,INTERVENTIONAL,['NA']
4727,NCT00395603,Percentage reduction in ldl-c at end-point after 6 weeks.,,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3']
4728,NCT00211471,tyo investigate the use of anecortave acetate in rubeosis iridis,mean change in VA(ETDRS) from baseline to 24 months,,2002-03,TERMINATED,INTERVENTIONAL,['PHASE2']
4729,NCT00039026,Change in HbA1c from Baseline to Week 30,Change in body weight from Baseline to each intermediate visit and Week 30,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4730,NCT02047643,Count of Participants Experiencing a Hypoglycemic Event During Scheduled Exercise,Count of Participants With Hypoglycemia in the Post Exercise Period,,2014-03-12,COMPLETED,INTERVENTIONAL,['NA']
4731,NCT02203240,Change in insulin sensitivity,Change in gut permeability,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
4732,NCT03705260,Hemoglobin A1C,Change in rate of symptomatic hypoglycemia requiring medical intervention,,2018-11-26,COMPLETED,INTERVENTIONAL,['NA']
4733,NCT03656341,Manchester Foot Pain and Disability INdex,Foot Health Score,,2018-09-27,COMPLETED,INTERVENTIONAL,['NA']
4734,NCT01953393,Beta-cell function,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
4735,NCT00998686,"To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG",To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE3']
4736,NCT05310526,food intake of 400g of vegetables per day,Professionals' perception regarding the incorporation of MAC guidelines into practice (implementation component),,2022-11-01,COMPLETED,INTERVENTIONAL,['NA']
4737,NCT04149548,The number of diabetic fetuses who will have undesirable effects,,,2019-11-05,UNKNOWN,OBSERVATIONAL,['NA']
4738,NCT02681185,HbA1c,Survey of Quality of Life,,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
4739,NCT05004948,Change in Glycated hemoglobin% (HbA1c%),The maximum oxygen uptake (VO2max),,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
4740,NCT03752840,Pinhole visual acuity (logMAR) in people aged 60 years and older,Cost-effectiveness of the screening intervention,"Bilateral presenting blindness in people aged 60 years and older, defined as presenting visual acuity worse than Snellen 20/400 (Metric Snellen worse than 6/120; logMAR worse than 1.3) in the better-seeing eye",2019-04-21,RECRUITING,INTERVENTIONAL,['NA']
4741,NCT03792399,Change of score for self efficacy,Change in exercise amount (time spent in sedentary behavior),,2016-03-07,COMPLETED,INTERVENTIONAL,['NA']
4742,NCT03242343,Occurrence of safety events,,,2017-11-29,COMPLETED,INTERVENTIONAL,['NA']
4743,NCT02681094,Change From Baseline in HbA1c at Week 24,Change in Total Body Weight at 24 Weeks,,2016-02-26,COMPLETED,INTERVENTIONAL,['PHASE3']
4744,NCT03983551,Change in urinary albumin-to-creatinine ratio,Change in systolic blood pressure,,2016-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4745,NCT02697201,Effects of lipid infusion on mitochondrial fission,Insulin sensitivity,,2016-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4746,NCT00737126,Change in albumin excretion rate,"Change in serum homocysteine, thrombomodulin and von Willebrand factor.",,2004-01,COMPLETED,INTERVENTIONAL,['NA']
4747,NCT05806723,change in testosterone level after atorvastatin treatment,change in DHEAS levels after atorvastatin treatment,change in vitamin D level after atorvastatin treatment,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4748,NCT04071626,"Peak VO2, ml/kg/Min, as Measured by Metabolic Gas Exchange",Serum Ketone Bodies (Betahydroxybutyrate),,2020-03-01,TERMINATED,INTERVENTIONAL,['PHASE4']
4749,NCT01770561,Performance longevity,Physical duration,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
4750,NCT01961466,Correlations between glycemic balance (HbA1c) and the score on the Bortner self-questionnaire,Scores on the scales,,2010-12-01,COMPLETED,OBSERVATIONAL,['NA']
4751,NCT00871507,Incremental glucose AUC after an oral glucose tolerance test (OGTT),Safety and Tolerability,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4752,NCT00106366,HbA1c,Glucose profiles,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4753,NCT04975230,Continuous Glucose Monitor (CGM) data downloaded directly from each participant's existing or provided blinded Dexcom G6 [trademark],Diabetes Symptom Checklist Revised (34-item),,2022-04-29,COMPLETED,INTERVENTIONAL,['NA']
4754,NCT01833988,Percentage of Time With a Low Plasma Glucose Reading (Less Than 70mg/dl) in the Bionic Pancreas Arm as Compared to Insulin Pump Arm,Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Carbohydrate Interventions for Hypoglycemia at Night,Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Mean Insulin Total Daily Dose,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4755,NCT02750098,Aqueous humor glucose concentration,Hemoglobin A1c,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
4756,NCT03329651,Difference in postprandial glycemic control as assessed by mean blood glucose concentration during a 4 hour mixed-meal tolerance test,Difference in peripheral glucose uptake as assessed by rate of glucose disappearance from blood,,2017-11-10,COMPLETED,INTERVENTIONAL,['NA']
4757,NCT00770575,Change in the intima-media thickness of the common carotid artery.,Change from Baseline in Pulse wave velocity.,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4758,NCT01263496,Number of Participants With Adverse Events.,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4759,NCT04449120,Change in fasting insulin level,Change in culinary habits measured by Culinary Habits Frequency Questionnaire (CHFC),,2020-06-01,COMPLETED,INTERVENTIONAL,['NA']
4760,NCT05929170,"Assessing the results of gastric sleeve surgery, by weight loss","Assessing the half and one-year results of gastric sleeve surgery, weight loss. (We try to find a confluence between the perioperative parameters and the expected outcome)",,2021-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4761,NCT01044602,"Resolution of obesity co-morbidities including hypertension, OSA, and hyperlipidemia",Identify predictors of success with regard to improved co-morbidities and velocity of weight loss,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
4762,NCT00071422,,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4763,NCT04253860,Pain perception,C Reactive Protein ultra-sensible,,2019-02-01,TERMINATED,INTERVENTIONAL,['PHASE3']
4764,NCT02001480,ECG surrogate markers compared to cardiac events,Continuous glucose monitoring is performed to identify episodes of hypoglycaemia,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
4765,NCT02703350,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part B),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) (Part B),,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4766,NCT00325624,A1c,,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4767,NCT03560375,Change in body weight,Change in frailty syndrome,,2018-05-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
4768,NCT03578991,Change of score obtained in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).,The Resource Utilization in Dementia (RUD).,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
4769,NCT05708859,Reduction of total non-calcified coronary plaque volume,Change in HgA1c lab values in the blood.,,2024-01-02,RECRUITING,INTERVENTIONAL,['PHASE4']
4770,NCT01253278,Number of Participants with Clinically Significant Effects,Change from baseline to day 14 in C-peptide,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4771,NCT00678522,"GFR, clearance of sodium and lithium, fractional excretion of sodium and lithium, U-AQP-2, total sodium excretion, albumin excretion rate and free water clearance.","AVP, Ang-II, Aldo, ANP, BNP, PRC, BP, HR.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4772,NCT04384471,Self-reported acute diabetes complication,"Impact on stress, anxiety and depression for children and adolescents",,2020-04-29,COMPLETED,OBSERVATIONAL,['NA']
4773,NCT04296825,"Changes in lipid profiles (total cholesterol, total triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in millimole per liter)","Changes in gut hormones (amylin, ghrelin, GLP-1, PP and PYY in petagram per milliliter)",,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4774,NCT00340639,,,,2003-01-28,COMPLETED,OBSERVATIONAL,['NA']
4775,NCT06264661,Insomnia,Gene expression analysis of PER2,,2022-08-08,COMPLETED,INTERVENTIONAL,['NA']
4776,NCT01823406,Difference in the levels of TCA cycle metabolites between groups during euglycemia and hyperglycemia,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4777,NCT01781754,Levels of gene expression for UCP2 (RQ),Improved metabolic state,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
4778,NCT05364190,The cumulative mean of daily diuresis,The progression of heart failure severity,,2022-06-04,RECRUITING,INTERVENTIONAL,['PHASE3']
4779,NCT00689026,The Percentage of Patients That Received a Quality of Colonoscopy Preparation Rating of <=2 on a 5 Point Likert Scale.,,,2008-05,TERMINATED,INTERVENTIONAL,['NA']
4780,NCT05770154,Peak torque,Dynamic balance,,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4781,NCT00797823,Effectiveness of Closed Loop Diabetes Control,Percent of Time Venous Blood Glucose <70 mg/dl,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4782,NCT05621551,Hs-Troponin-I,Hs-Troponin-I,Length of in-hospital time,2022-11-11,RECRUITING,INTERVENTIONAL,['PHASE4']
4783,NCT03726697,Admission to NICU for hypoglycemia,Pain scale,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
4784,NCT02273050,Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue,Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
4785,NCT04833660,Quality of life after intervention to be assessed with Short Form 36-Item Health Survey,,,2021-04-30,UNKNOWN,INTERVENTIONAL,['NA']
4786,NCT05510531,Change in outcome expectancy,Participants perspective of the intervention,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
4787,NCT03146208,Role of endothelial bio markers in patients with coronary artery disease,,,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA']
4788,NCT00994266,Difference of glucose concentrations (fasting and post-prandial) at week 24 and at the beginning of the study considering the adjusted insulin doses during treatment,Difference of triglycerides and cholesterol concentrations at week 24 and at the beginning of the study,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4789,NCT02361606,Youth satisfaction of the program. (Questionnaire regarding the degree that the session was helpful.),"Change in glycemic control. (HbaA1c levels, obtained from medical records)",Youth expectations of the program. (Questionnaire regarding the expectations of the possible benefits of the program.),2009-03,COMPLETED,INTERVENTIONAL,['NA']
4790,NCT03049228,Cellular respiration ex vivo,Basal energy metabolism,,2017-03-21,COMPLETED,OBSERVATIONAL,['NA']
4791,NCT03712501,Triacylglycerol,Superoxide dismutase 3,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
4792,NCT02480062,Glycated haemoglobin (HbA1c),Cost,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
4793,NCT01601574,Change in HbA1c,Secondary Endpoints,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4794,NCT03246997,Overall satisfaction score,Self Efficacy for Eating/Cooking Fruit and Vegetables by Condrasky,,2017-06-21,COMPLETED,INTERVENTIONAL,['NA']
4795,NCT02773381,Area under the serum glucose concentration-time curve,Area under the paracetamol plasma concentration-time curve,,2016-06-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4796,NCT01919788,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and mRNA expression of target genes in muscle- and fat-tissue.",Metabolism,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
4797,NCT01898026,Postprandial Glycemia,Satiety Score,Safety,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
4798,NCT01238276,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
4799,NCT00151749,addition of WelChol® to current antidiabetic therapy,other oral drugs,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4800,NCT05418179,Inflammatory parameters,Total Body lean mass Percentage (%),,2021-12-01,RECRUITING,INTERVENTIONAL,['NA']
4801,NCT01221545,"Primary Objective to assess the safety and tolerability of AZD1656, following oral administration of single ascending supratherapeutic doses of AZD1656 to patients with type 2 diabetes mellitus in a fasted state.",Secondary objective to evaluate glucose levels and insulin secretion in type 2 diabetes mellitus patients following oral administration of single ascending supratherapeutic doses of AZD1656,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4802,NCT03927859,Number of bookings made through the TOP program,Number of self-reported booking made outside of TOP,,2018-07-05,UNKNOWN,INTERVENTIONAL,['NA']
4803,NCT02700048,Within Person Difference in Peak Epinephrine During Hypoglycemia,Naloxone Pharmacokinetics,,2016-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4804,NCT01556880,incidence rate of DM,incidence of DM,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
4805,NCT04647773,Compare the change from baseline in Average Daily Pain Score （ADPS） between HSK16149 and placebo at week 13.,Pharmacokinetic (PK) characteristics of HSK16149 capsules in Chinese patients with diabetic peripheral neuropathic pain.,,2020-12-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4806,NCT00081328,Treatment Failure (Loss of Glycemic Control),Comorbidity -- Triglycerides Dyslipidemia,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4807,NCT00770302,Pharmacokinetic variables for saxagliptin after single and multiple oral doses of 5 mg saxagliptin,"Safety variables (adverse events reported, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests after single and multiple oral doses of 5 mg saxagliptin",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4808,NCT01390480,Increase and function of regulatory T-cells,Calcium levels,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
4809,NCT00999635,Reduction in peak pressure,Comparison of cost,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4810,NCT00695474,"Vitamin D status and its association with inflammation, glycemic control, lipids and blood pressure.","Lifestyle (exercise, sun exposure, food intake)",,2008-06,COMPLETED,OBSERVATIONAL,['NA']
4811,NCT03773185,Amyloid load,,,2018-12-15,WITHDRAWN,OBSERVATIONAL,['NA']
4812,NCT05852132,Incidence of proliferative diabetic retinopathy (PDR),,,2024-05-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4813,NCT05404711,Feasibility of CGM use to determine Type 2 Diabetes Risk,Acceptability of CGM use for at-home T2D risk evaluation in youth,,2022-10-11,COMPLETED,INTERVENTIONAL,['NA']
4814,NCT05678712,time below range (CGM),Sensitivity and specificity of algorithm,Diabetes-related quality of life,2022-03-09,COMPLETED,INTERVENTIONAL,['NA']
4815,NCT04904406,Changes in body weight of ≥2 kg,Cardiac biomarkers,Cardiac MRI substudy secondary outcome lipid,2020-10-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
4816,NCT03362983,Quality-of-care outcome measures (n=131),Interdisciplinary learning (n=20),,2016-01-01,COMPLETED,INTERVENTIONAL,['NA']
4817,NCT00106808,Change in HBA1c from baseline to Week 24,To assess safety and tolerability of both Muraglitazar regimens relative to pioglitazone regimen when administered for up to 24 weeks,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4818,NCT02161250,resistant starch effects,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
4819,NCT06129448,Effect of Tumor necrosis factor- α (TNF-α) on cardiac functions,,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4820,NCT03944616,HbA1c,Dietary Practices,,2019-06-06,COMPLETED,INTERVENTIONAL,['NA']
4821,NCT01002053,Interval worsening of the severity of neuropathy,New functional neuropathy defined as any new sensory or motor deficit compared to preoperatively.,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
4822,NCT03117998,Change in Average Daily Total Insulin Use,Continuous Glucose Monitoring (CGM) - Change in Percent Time Spent in Hypoglycemia (Blood Glucose Range <55 mg/dL) at Week 12,,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
4823,NCT03880760,Change in concentration of blood glucose (AC),Change in concentration of TGF-β1,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
4824,NCT01866137,Changes in copeptin levels after a psychological stress test in healthy volunteers,Changes in copeptin levels after a psychological stress test in patients with central diabetes insipidus,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
4825,NCT04043065,Beta-cell secretion,"Appetite, satiety, and general well-being",,2019-01-28,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4826,NCT02871180,Hypoglycemia,Blood glucose profile,,2003-03,COMPLETED,INTERVENTIONAL,['NA']
4827,NCT05025540,AUC,mPA,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
4828,NCT05793645,Assessment of adherence,Description of Adverse events,,2023-05-15,RECRUITING,INTERVENTIONAL,['NA']
4829,NCT05687656,Wound Healing area using digital image,Adverse events,Presence of protease levels,2022-10-06,RECRUITING,INTERVENTIONAL,['NA']
4830,NCT01467323,HbA1c (glycosylated haemoglobin A1c),Occurrence of adverse events,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4831,NCT00021918,,,,2001-04,COMPLETED,OBSERVATIONAL,['NA']
4832,NCT02341690,"Changes in Physical activity from baseline to 52 weeks, measured with accelerometrics","Body temperature, measured by an ear thermometer",Changes in physical activity habits and diabetic motivation from baseline to 52 weeks - patients will be asked to answer 4 questions regarding their physical activity habits,2015-01,COMPLETED,INTERVENTIONAL,['NA']
4833,NCT05214573,3-point MACE,Severe genitourinary tract infection,,2021-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4834,NCT05211869,Technology Use,Technology Use,Cost,2022-11-07,RECRUITING,INTERVENTIONAL,['NA']
4835,NCT00983775,(time to) maximal glucose infusion rate,(time to) maximal insulin concentration,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
4836,NCT03161964,Ratio of Self-reported Hypoglycemic Episodes to Total Hypoglycemic Episodes Determined by Continuous Glucose Monitoring (CGM),Mean Blood Glucose,,2017-10-19,TERMINATED,INTERVENTIONAL,['PHASE2']
4837,NCT05519163,New-onset diabetic foot,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
4838,NCT00450710,Evaluate safety and efficacy of the ileal interposition associated with a sleeve gastrectomy and the ileal interposition associated with a diverted sleeve gastrectomy.,Hormonal effect and effect of the operations on diabetes related and total mortality.,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4839,NCT05395377,Patient-Centered Outcomes,,,2017-12-18,COMPLETED,INTERVENTIONAL,['NA']
4840,NCT04722900,Body height,Magnetic resonance imaging,,2021-01-15,RECRUITING,OBSERVATIONAL,['NA']
4841,NCT00359801,Time to Persistent Decline in FEV1 Exceeding 20% From Baseline,Change in Glycosylated Hemoglobin (HbA1c) From Baseline,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4842,NCT02914886,Relative thickness as assessed by MRI,Side effects,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4843,NCT01972542,Changes of Triglyceride,Changes of incretin,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
4844,NCT05491421,To assess safety and tolerability of multiple escalation doses of ZT002 in healthy participants with a BMI range of 26 kg/m2 to 40 kg/m2 and a body weight of ≥80 kg through incidence severity of serious adverse events in MAD Cohorts.,The anti-drug antibody (ADA) response through testing serum or plasma of the participant post dosing in SAD and MAD cohorts.,,2022-09-02,RECRUITING,INTERVENTIONAL,['PHASE1']
4845,NCT04981613,"Urinary protein remission rate, %","Time of participants achieving end stage renal disease (ESRD) or requiring dialysis or kidney transplantation, or blood creatinine doubling, or renal death, or all-cause death, days","Number of participants with treatment-related adverse events as assessed by reproductive toxicity (menorrhea or amenorrhea or infertility), %",2021-07-28,RECRUITING,INTERVENTIONAL,['NA']
4846,NCT03089463,Perfusion measurement,Ulceration incident,,2017-11-27,SUSPENDED,OBSERVATIONAL,['NA']
4847,NCT01326533,Insulin Sensitivity,Beta Cell Function,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4848,NCT03419624,Change in HbA1c from baseline (week 0) to week 28,Proportion of patients achieving HbA1c of ≤ 7% at week 28 compared to baseline,,2018-02-19,TERMINATED,INTERVENTIONAL,['PHASE3']
4849,NCT03006952,N terminal brain natriuretic peptide (NT-pro BNP),serum creatinine concentrations,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4850,NCT03002246,Comparison Between 5D Limb Vol and 2D Birth weight Prediction,Birth weight Predictions in Suspected Growth Abnormalities,,2017-01-06,COMPLETED,OBSERVATIONAL,['NA']
4851,NCT01059825,Change From Baseline in HbA1c at Week 12,Number of Participants Who Discontinued Study Medication Due to an AE,,2010-02-24,COMPLETED,INTERVENTIONAL,['PHASE2']
4852,NCT06000813,IMB barrier sum score,Diabetes self-efficacy,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4853,NCT01318109,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).,,2008-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4854,NCT02672176,Diabetes Self-Efficacy Measured Using the Diabetes Empowerment Scale Short Form (DES-SF)- Scores at 9-months,Perceived Stress Measured by PSS,PROMIS Physical Function,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4855,NCT06300047,Lost to Followup,Clinical Outcome 6,,2024-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4856,NCT00551876,Percent change in fasting LDL-C from baseline to the average of the Week 6/Week 12 measurements,Well tolerated in patients in Diabetic patients,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3']
4857,NCT02517320,Change form baseline in UACR,Adverse events,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4858,NCT01692002,Study 3: Incremental area under the insulin profile,Insulin,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
4859,NCT05933356,The Positive and Negative Syndrome Scale (PANSS),,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
4860,NCT02159144,browning of subcutaneous white adipose,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
4861,NCT06115876,Conversion to Pre-Diabetes,,,2022-05-23,RECRUITING,OBSERVATIONAL,['NA']
4862,NCT04093856,"Volumetric bone mineral density (vBMD) at the spine, hip, radius and tibia",Health-related quality of life,,2020-01-14,COMPLETED,OBSERVATIONAL,['NA']
4863,NCT00788840,Weight change,Glycaemic control,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4864,NCT05580120,A Measure of Quality of Life in the Elderly,,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA']
4865,NCT02434315,Change from Baseline - time in glucose range - for penultimate sensor wear,,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
4866,NCT01041599,Correlation between albuminuria and arterial stiffness,,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
4867,NCT05528770,Difference in Daytime Time-in-range,Difference in Overall Time-below-range,,2022-10-20,COMPLETED,INTERVENTIONAL,['NA']
4868,NCT04608136,Change from baseline Insulin at 180 minutes,Changes in fat intake following dietary intervention,,2020-09-21,COMPLETED,INTERVENTIONAL,['NA']
4869,NCT00031239,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
4870,NCT00547872,Death and myocardial infarction,Symptomatic heart failure,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4871,NCT05067075,Average percentage time in target glucose range,neonatal hypoglycemia,postpartum 2 hour 75 gram OGTT results from mother,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
4872,NCT01094899,"evaluate the MicroScanner, alterations quantitative and qualitative bone in the foot in patients with type 1 diabetes 2 with or without neuropathy",correlation involving bone and extension of neuropathy Assessment criteria associated with biological abnormalities qualitative and quantitative bone in diabetic subjects,,2010-03-10,COMPLETED,INTERVENTIONAL,['NA']
4873,NCT02691481,Glucose area under the curve 0-240 minutes,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
4874,NCT00995345,Change in HbA1c From Baseline (Week 0) to Week 24,Percentage of Patients Requiring Rescue Therapy for Elevated Glucose,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4875,NCT05324462,Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c),Comparison between the daily dose of basal insulin and IDegLira,,2022-03-22,COMPLETED,OBSERVATIONAL,['NA']
4876,NCT00291590,Reduction in glycated hemoglobin levels,Improvement in health status and diabetes self-care practices,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4877,NCT05902156,The Metabolic Parameter Monitoring Form,,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4878,NCT00514618,The Primary Outcome Measure Will be the Time Interval From Start of Induction to Delivery.,"Other Outcome Measures Will be Number of Doses of Medication Required, Oxytocin Requirements, and Route of Delivery.",,2006-03,TERMINATED,INTERVENTIONAL,['NA']
4879,NCT05392452,The proportion of time spent in the target glucose range from 5.6 to 10.0 mmol/L,"Peri- and postoperative costs (perspectives: hospital, statutory health insurance system)",Number of clinically significant hyperglycaemic events (>20.0 mmol/L) with ketonaemia (beta-hydroxybutyrate >1.0 mmol/L),2022-08-09,COMPLETED,INTERVENTIONAL,['NA']
4880,NCT01630928,Change in blood pressure,Effect of RDN on subclinical organ injury: Impedance cardiography,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
4881,NCT01795144,Incretin Effect,,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4882,NCT02434744,"Number of Subjects Experiencing Adverse Events as a Measure of Safety, Tolerability, and Efficacy",Changes in Serum Levels of Non-Esterified Free Fatty Acids,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4883,NCT01394055,Pharmacodynamic (PD) effects of RM-131 on gastric emptying,Pharmacokinetics (PK) of RM-131,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4884,NCT04924400,Percentage of patients who complete the study,Total cost of care over 6 months.,,2022-03,UNKNOWN,INTERVENTIONAL,['NA']
4885,NCT03936049,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
4886,NCT05499702,Rate of leucine oxidation in response to rising glucagon concentrations,,,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2']
4887,NCT05336214,Change in practice-reported prescriptions of Continuous Glucose Monitors,Implementation and Maintenance,,2022-06-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4888,NCT00508599,Insulin resistance and orthostatic response,"Change in glucose, insulin, and orthostatic impairment.",,2003-01,COMPLETED,INTERVENTIONAL,['NA']
4889,NCT03888157,Change in HbA1c (mmol/mol),Changes in quality of life (EQ VAS),,2019-03-10,COMPLETED,OBSERVATIONAL,['NA']
4890,NCT01879917,Beta-cell function,Postprandial glucagon,Hypoglycemia,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4891,NCT00528879,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Percentage of Participants Achieving Hemoglobin A1c (HbA1C) ≤6.5% at Week 24 (Last Observation Carried Forward [LOCF]),Number of Participants With Orthostatic Hypotension,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4892,NCT01382121,Psychological: Self-Efficacy,Changes in variability (standard deviation),,2010-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4893,NCT06305351,Proportion of participants who discontinued study medication due to an AE,t1/2 of plasma K-833,,2023-12-07,RECRUITING,INTERVENTIONAL,['PHASE1']
4894,NCT01689129,Change from baseline in HbA1c,Number of Patients with various types of Hypoglycemia Events,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4895,NCT04249778,"Number of Participants With Hospital Admissions, Emergency Department Visits, Urgent Clinic Visits for Heart Failure (HF) and Death After Admission With Acute Decompensated Heart Failure (ADHF)",Number of Participants With Acute Kidney Injury,,2020-07-29,COMPLETED,INTERVENTIONAL,['PHASE4']
4896,NCT01919476,Change in markers for glucose intolerance.,Change in metabolic markers,Change in satiety markers,2011-09,COMPLETED,INTERVENTIONAL,['NA']
4897,NCT03597035,Left Ventricular Mass,,,2018-07-17,TERMINATED,INTERVENTIONAL,['PHASE4']
4898,NCT02791295,Weight change,Retention of weight change,,2016-10-04,COMPLETED,INTERVENTIONAL,['NA']
4899,NCT02584582,Glucagon concentration (postprandial),triacylglycerol (TAG),,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4900,NCT01475565,Change from Gestation Week 12-14 in Insulin Sensitivity at Gestation Week 32-34,Change from Gestation Week 12-14 in Physical Activity at Gestation Week 32-34,,2013-05,TERMINATED,OBSERVATIONAL,['NA']
4901,NCT04484259,P2Y12 reaction units (PRU),,,2021-03-31,RECRUITING,INTERVENTIONAL,['PHASE4']
4902,NCT03127696,Proportion of subjects with at least 20% lean-associated microbiota in recipients after FMT compared with subjects receiving lifestyle intervention alone up to week 24,Changes in liver stiffness to assess improvement of other metabolic disease weeks 24 compared with baseline,,2017-04-26,COMPLETED,INTERVENTIONAL,['NA']
4903,NCT00292890,"HbA1c levels, insulin doses and the number of experienced hypoglycaemic events",blood glucose measurements and the experiences of the patients,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
4904,NCT01190436,Percentage of Participants With Decrease in Heart Rate by at Least 10 Bpm at Week 12,Number of Participants With Adverse Events (AEs),,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4905,NCT03925064,ultrasonographic myocardial performance index values,,,2018-08-01,COMPLETED,OBSERVATIONAL,['NA']
4906,NCT00539435,"Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect progression of cardiac disease in diabetic patients. Monitor results of Cardiac tests,carotid ultrasounds and echocardiograms,cardiac QOL, labs, meds to analyze progress.",,,2007-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
4907,NCT01408277,Mean Percent Change in Wound Area,,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4908,NCT00014911,Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation.,Percent of Participants With Detectable Fasting Basal C-Peptide Levels,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4909,NCT00308256,Patient's acceptance of the disease evaluated by an analogical visual scale rating,Episodes number of severe hypoglycaemia having required an intervention of a third party or a hospitalization.,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
4910,NCT02532101,Blood glucose level,Beta Cell Function,,2014-12,TERMINATED,INTERVENTIONAL,['NA']
4911,NCT04335331,A1c order,Weight,,2020-02-27,COMPLETED,OBSERVATIONAL,['NA']
4912,NCT04582357,Physical activity program attendance,Security,,2020-12,WITHDRAWN,INTERVENTIONAL,['NA']
4913,NCT02772783,Nucleus Accumbens Blood Flow,"Functional Connectivity of Nucleus Accumbens, Hypothalamus and Other Brain Areas Involved in Intake Regulation",Metabolomics,2016-07,COMPLETED,INTERVENTIONAL,['NA']
4914,NCT00945204,"The percentage of participants reaching target control of HbA1c (7.0), and blood pressure (<140/80) and cholesterol (<4 mmol/l),",Control of risk factors in all patients with type 2 diabetes in participating practices using anonymised routine data,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
4915,NCT02901860,cardio-metabolic risk,Obesity,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
4916,NCT03791125,PK profile of Salvianolic acid A following administration of multiple doses assessed by time of occurrence of Cmax [tmax],,,2018-11-20,UNKNOWN,INTERVENTIONAL,['PHASE1']
4917,NCT00879203,,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
4918,NCT05352815,Change in glycated haemoglobin (HbA1c),"Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)",,2022-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4919,NCT04032561,Sleep Duration,HbA1c,,2019-01-08,COMPLETED,OBSERVATIONAL,['NA']
4920,NCT04259606,Brachial - ankle index,Lipid profile,,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA']
4921,NCT04210024,Change in Health Literacy,,,2019-05-03,COMPLETED,INTERVENTIONAL,['NA']
4922,NCT00231634,Percent change in body weight and change in Hemoglobin A1c (HbA1c) from baseline to Week 52.,"Change from baseline to Week 52 in BMI, FPG; safety evaluations (adverse events, hypoglycemic events) throughout study.",,2001-05,TERMINATED,INTERVENTIONAL,['PHASE3']
4923,NCT01144728,Evolution of Fasting Plasma Glucose (FPG),Change in Weight,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4924,NCT03928132,"Change from immediate clinical behavioural intention at 3 months, as measured by CPD-REACTION questionnaire",Acceptability Questionnaire,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
4925,NCT01694758,Percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1,The LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
4926,NCT02973412,HBA1C level (%) measured from a blood sample,Continuous Glucose Monitoring (CGM),,2016-12-07,RECRUITING,OBSERVATIONAL,['NA']
4927,NCT01486238,Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline.,Proportion of Subjects Requiring Macular Laser Treatment at Week 12 and Week 24.,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4928,NCT01767831,Ability of Behavioral Intervention to Improve Glycemic Outcome,Relationships Between Physiology and Behavior Transferred to In Silico Environment,,2013-03,TERMINATED,OBSERVATIONAL,['NA']
4929,NCT02057497,Association of defined G protein- and FTO-related genotypes with the presence of T2DM or T1DM from a blood sample; also other genes of potential relevance for the evolution of obesity and/or diabetes.,Association of defined G protein- and FTO-related genotypes with the T2DM risk of healthy volunteers from a blood sample.,,2017-10-09,WITHDRAWN,OBSERVATIONAL,['NA']
4930,NCT02082756,Change in 2-hour postprandial blood glucose between baseline to week 12,Adverse effects,,2015-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4931,NCT06150690,Glycated hemoglobin,Islet area,,2012-08-21,RECRUITING,OBSERVATIONAL,['NA']
4932,NCT01618552,Physician use of self-efficacy enhancing interviewing techniques,Healthcare Climate Questionnaire,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4933,NCT00837096,Number of Participants With 100% Wound Closure,,,2007-06,TERMINATED,INTERVENTIONAL,['NA']
4934,NCT01607944,Glucose turnover,Palmitate turnover and oxidation,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
4935,NCT01253304,Pharmacokinetics: Apparent Volume of Distribution (Vz/F),,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4936,NCT02689778,Effect of oral pirfenidone (1800 mg) in glomerular filtration rate,Number of patients with treatment related adverse events,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4937,NCT05674110,Change in Diabetes knowledge,Change in Hemoglobin A1c,,2023-01-09,RECRUITING,INTERVENTIONAL,['NA']
4938,NCT01926041,Number of Participants With New-onset Type 2 Diabetes Mellitus (DM),HbA1c Change Between Baseline and 6 Months,10-year Probability of Regression to Normoglycemia,2013-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4939,NCT06035536,Percentage of index ulcers healed at 12 weeks,Change in pain levels during the clinical investigation,"Cost to closure (both treatment groups; all wounds, and only closed wounds)",2023-06-08,RECRUITING,INTERVENTIONAL,['NA']
4940,NCT01467401,HbA1c (glycolated haemoglobin),Number and severity of hypoglycaemic episodes,,2002-08-19,COMPLETED,INTERVENTIONAL,['PHASE4']
4941,NCT04450407,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,,2020-07-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4942,NCT00803608,The first occurrence of a plantar ulcer or pre-ulcer in subjects who have had one previously healed plantar ulcer,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4943,NCT04614870,Positive predictive value of the device in the determination of infection in wounds with clinical signs of infection,Likelihood of infection,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
4944,NCT01529528,The Change in HbA1c from baseline to week24,change from baseline to week 24 in HOMA-IR,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4945,NCT01960205,oral glucose tolerance test,,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
4946,NCT03814395,Numbers of participants with adverse pregnancy outcomes,Fetal Humerus Length,,2018-06-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4947,NCT00012753,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
4948,NCT06319287,Primary endpoints,Secondary Endpoint,Tertiary Endpoints,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE2']
4949,NCT00709319,Change in Optical Coherence Tomography Central Subfield Thickness From Baseline to 6 Months,Surgical Complications From Baseline to Six Months,,2005-07,COMPLETED,OBSERVATIONAL,['NA']
4950,NCT04730882,Myocardial Microvascular Perfusion (measured by contrast-enhanced ultrasound),E-selectin,,2021-04-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4951,NCT04194515,bile acid profile,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
4952,NCT02488057,Beta Cell Function,Presence of genetic polymorphisms,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4953,NCT01128985,The concentration of canagliflozin and major metabolites (M5 and M7) in blood will be measured by protocol-specified pharmacokinetic parameters.,"The safety and tolerability of canagliflozin will be determined by monitoring adverse events and findings from laboratory evaluations, vital signs measurements, and ECG measurements reported.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4954,NCT04721847,Self-completed Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS),Diabetic peripheral neuropathic pain impact measure,,2020-08-13,COMPLETED,INTERVENTIONAL,['NA']
4955,NCT05804890,Comparing Activated Carbon Cloth Dressing and Silver-Based Dressing in a Diabetic Foot Ulcer Population.,,,2022-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
4956,NCT05497674,rongliflozin:Cmax ratios of geometric means of rongliflozin+probenecid relative to rongliflozin alone.,the number of participants with adverse events (AE) in Cohort B,,2022-02-21,COMPLETED,INTERVENTIONAL,['PHASE1']
4957,NCT00967798,Number of Participants With Conversion to Cystic Fibrosis Related Diabetes,Change in Percent Predicted FEV1,,2010-05,TERMINATED,INTERVENTIONAL,['PHASE3']
4958,NCT05138029,Review the patient's vision before surgery,Review the patient's vision for 6 months after surgery,,2021-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
4959,NCT00642434,Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4960,NCT04355832,Change in the level of catecholamines in plasma,,,2020-06-24,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4961,NCT01467375,Frequency of hypoglycaemic episodes,HbA1c (glycosylated haemoglobin),,2001-01-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4962,NCT05719181,Effect of Recombinant Human Bone Morphogenetic The Primary outcome will be measuring the effect of rhBMP- 2/ACS in improving the secondary stability of dental implant by using RFA in comparison to control group.,,,2021-12-06,RECRUITING,INTERVENTIONAL,['PHASE1']
4963,NCT03698708,Center for Epidemiologic Studies - Depression Scale Revised (CESD-R),Hemoglobin A1c (HbA1c),Treatment Satisfaction Survey,2019-01-20,COMPLETED,INTERVENTIONAL,['NA']
4964,NCT01472666,Postprandial triglyceride response,"Postprandial apolipoprotein-48 (apoB-48), 6 hour",,2011-10,COMPLETED,INTERVENTIONAL,['NA']
4965,NCT04857346,Clinical attachment level,Interleukin-6,,2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4966,NCT03933956,Change in amino acid metabolome signature,,,2020-01-09,TERMINATED,INTERVENTIONAL,['PHASE3']
4967,NCT00549757,Percentage of Participants With All Cause Mortality (Extension Phase),Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Extension Phase),Percentage of Participants With Angioedema/Angioedema-like Events or Colorectal Events (Extension Phase),2007-10,TERMINATED,INTERVENTIONAL,['PHASE3']
4968,NCT01525693,"The primary endpoint of this study is the overall proportion of patients whose HbA1c is less than 6.5%, measured at the end of one year follow up.",The clinical effectiveness of each regimen measured by the proportion of patients reaching the target glycemic control,,2012-04,UNKNOWN,OBSERVATIONAL,['NA']
4969,NCT04910178,"fatty liver staging (0, I, II, and III)",Changes in total protein and albumin,,2020-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4970,NCT05881213,Cmax of CKD-378,,,2023-06-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4971,NCT03064841,"Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and 2013 Chinese Diabetes Society (CDS) Guidelines.",Follow up Duration of Type 2 Diabetes Related Risk Factors in Clinical Practice,,2017-03-09,COMPLETED,OBSERVATIONAL,['NA']
4972,NCT00956800,"Columbus Research Foundation will take the objective data that constitutes the defined end-points of the study and enter it for each patient into an Access data base, using the established data base management system of Columbus Research Foundation.",,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4973,NCT03994536,Level of empowerment,Clinic attendance 2,,2019-08-15,RECRUITING,INTERVENTIONAL,['NA']
4974,NCT02767596,Change in body weight,,,2016-07-12,TERMINATED,INTERVENTIONAL,['PHASE4']
4975,NCT01631643,Change in A1C from baseline to week 24,Change in 30 day mean glucose comparing first month to last month after 24 weeks,,2012-12,WITHDRAWN,INTERVENTIONAL,['PHASE4']
4976,NCT00904176,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"To assess the safety and tolerability of the combination of dapagliflozin with warfarin, and the combination of dapagliflozin with digoxin in healthy subjects",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4977,NCT04532385,Change from baseline in TNF-α at week 12,Change from baseline in body water at week 12,,2018-06-12,COMPLETED,INTERVENTIONAL,['NA']
4978,NCT05067621,Change in Protein Density Fat Fraction (PDFF),Triglycerides,Changes in liver fibrosis,2023-07-17,RECRUITING,INTERVENTIONAL,['PHASE2']
4979,NCT00202670,,,,2004-01,TERMINATED,OBSERVATIONAL,['NA']
4980,NCT00685984,Post-occlusive hyperaemia endothelium-dependent brachial artery dilation,biologic markers of endothelial function,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
4981,NCT05112146,Post-prandial glucose,T max glucose,,2018-08-20,COMPLETED,INTERVENTIONAL,['NA']
4982,NCT01766778,Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12,"Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability",,2013-05-13,COMPLETED,INTERVENTIONAL,['PHASE4']
4983,NCT01648647,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
4984,NCT02805361,The mean change in HbAlc from mean baseline and at Month 12.,Changes from baseline in Diastolic Blood Pressures,Capture influence of the combined effect of fasting and hot climate on the level of total ketone bodies levels in T2DM subjects treated with Dapagliflozin,2016-08-21,COMPLETED,OBSERVATIONAL,['NA']
4985,NCT00789191,HbA1c (Glycosylated Haemoglobin A1c),Self-measured 9-point Plasma Glucose Profile,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4986,NCT02799121,Complete Wound Closure,Neuro-QoL,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4987,NCT06140537,Albuminuria,safety and tolerability,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
4988,NCT00160732,decrease in incidence of hypoglycemic events,absence of complications from the procedure and side effects of the medication,,2003-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4989,NCT00403091,Lipids,Smoking cessation advice,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
4990,NCT03121755,Total cellular cholesterol on leukocytes collected from the subjects,,,2015-01-21,COMPLETED,OBSERVATIONAL,['NA']
4991,NCT02505516,Number of diabetic patients on metformin therapy,,,2013-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4992,NCT01747356,12-month TVF occurrence,Patient related adverse events,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
4993,NCT02531776,Area under curve (AUC) of skin blood perfusion increase,"Skin reactions (bleeding, bruising, redness, swelling) on a scale from 0 to 4.",,2014-12,COMPLETED,INTERVENTIONAL,['NA']
4994,NCT00354939,Frequency of subjects with conventionally detected hypoglycemia,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4995,NCT02306005,Factors influencing relationship between insulin treatment and lipoproteins,Development of Diabetic kidney disease,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
4996,NCT02026817,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin AUCinf",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4997,NCT05477173,Measures frequency of psychiatric problems with diabetes mellitus type 1,,,2022-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4998,NCT04286464,Swabs during respiratory infection,Sputum,,2003-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
4999,NCT03103126,The effects of home-based combined exercise on insulin sensitivity compared to physical activity advice during the 6 week study period,Self-efficacy to regulate exercise scale,,2019-05-01,WITHDRAWN,INTERVENTIONAL,['NA']
5000,NCT00987363,AngioRNM and/or AngioTC changes,Clinically objective improvement in the ischemic limb,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5001,NCT06280053,Wound Healing,Incidence of Safety Events,,2016-03-02,COMPLETED,INTERVENTIONAL,['NA']
5002,NCT00825253,,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5003,NCT03095651,Maximal Glucose Infusion Rate,Apparent Terminal Half-life,,2017-04-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5004,NCT00239707,"GIP, glucose, insulin measured frequently during infusions","GLP-1, ghrelin measured frequently during infusions",,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5005,NCT00762112,Adverse event occurrence.,Change from baseline in inflammation marker C-reactive protein.,,2003-11,TERMINATED,INTERVENTIONAL,['PHASE3']
5006,NCT03842683,Optimal Time Shift of Continuous Glucose Monitoring Measurements,Area Under the Receiver Operating Characteristics Curve of the Hypoglycemia Prediction,,2016-06-06,COMPLETED,OBSERVATIONAL,['NA']
5007,NCT04255381,Safety: Number of Participants Who Experienced an Adverse Event,Percent Time AP System Active,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
5008,NCT04531631,first phase insulin response to glucose,Area under curve of GLP-1 levels,,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE2']
5009,NCT03577158,Number of hypoglycaemias,Rate-of-change of glucose during exercise (ROCe) and recovery (ROCr),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
5010,NCT00291356,"Safety and tolerability: side effects and relevant changes in blood pressure, heart rate and ECG measurements, blood and urine measurements, the amount of fluid taken in and excreted, and kidney function will be monitored over course of study.",Amount and percentage of glucose excreted in urine by kidneys. Effect of compounds on lipid metabolism analysed.,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5011,NCT02776696,Percentage of glucose sensor readings within 70 to 180 mg/dl,Closed-loop acceptance questionnaire,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
5012,NCT01308008,Six Minute Walk Distance,Physical Activity,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
5013,NCT01375166,Retinal blood flow velocities,,,2013-03-06,TERMINATED,OBSERVATIONAL,['NA']
5014,NCT03359837,Change in hemoglobin A1c (HbA1c),Subgroup analysis,,2018-01-20,COMPLETED,INTERVENTIONAL,['PHASE4']
5015,NCT01478672,SF-36,EQ-5D,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
5016,NCT05403437,Evaluation of PGP severity,Evaluation of Body Mass Index (BMI),,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5017,NCT05487755,change in 2- Hours Postprandial blood glucose,Change in serum malondialdehyde (MDA) .,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5018,NCT02443155,Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline,Cmax of Glucose at Week 80 Relative to Baseline,,2015-11-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5019,NCT04009239,Glucose control in response to mTRF,Difference in substrate oxidation rhythms between experimental conditions,,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
5020,NCT03605979,Glycemia measured by continuous glucose monitoring (CGM) and pump,,,2012-07-01,COMPLETED,OBSERVATIONAL,['NA']
5021,NCT04543630,Implant survival,Effect of implant placement and graft material on hematological and inflammatory parameters,,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5022,NCT04240964,Composition of the DFO Metagenome,,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
5023,NCT05605704,rate of fasting glycemia level reduction,,rate of H1B1C balance variation,2023-01-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5024,NCT05250999,Toronto Clinical Neuropathy scoring system,,,2021-07-15,COMPLETED,INTERVENTIONAL,['NA']
5025,NCT00153179,Difference in Insulin-mediated Skeletal Muscle Glucose Utilization Between Test Agent and Placebo,,,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5026,NCT03586830,Number of Participants With Treatment Emergent Adverse Events (TEAEs),Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 12,,2018-06-26,COMPLETED,INTERVENTIONAL,['PHASE2']
5027,NCT01214356,Change in Urinary Albumin:Creatinine Ratio (ACR),Decrease in Estimated Glomerular Filtration Rate (eGFR),,2010-08,COMPLETED,INTERVENTIONAL,['NA']
5028,NCT02120755,Reduction in Wound Size,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5029,NCT01856881,Subject incidence of anti-AMG 876 antibodies,Pharmacodynamic parameters,,2013-03,TERMINATED,INTERVENTIONAL,['PHASE1']
5030,NCT04038931,Evaluating autoimmune response to AIPs,,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA']
5031,NCT02211651,Quantity of macrophages,,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
5032,NCT01943357,Metabolic control HbA1C,Health care utilization,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
5033,NCT00686816,weight loss,Weight maintained,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5034,NCT03436992,Change in Flow-Mediated Dilation (FMD),,,2018-04-17,COMPLETED,INTERVENTIONAL,['NA']
5035,NCT01833403,Insulin Sensitivity,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
5036,NCT05995756,overall mean absolute relative difference (MARD),,,2021-12-20,COMPLETED,OBSERVATIONAL,['NA']
5037,NCT01486901,Maximum serum insulin concentration (Cmax),Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5038,NCT00228865,"Using repetitive respiratory quotients, we will assess the success of the reversal of the abnormal underlying metabolism in diabetic patients from primarily fat metabolism to carbohydrate metabolism.",,,2003-06,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5039,NCT00519623,Pharmacodynamics of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients (GIRmax),Skin Response to the Application of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients,,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5040,NCT06314061,Time in range (TIR) of CGM glucose levels,Complications,Staff experience,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5041,NCT01868230,Child Length,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
5042,NCT01496443,AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose Pharmacokinetic Parameter for TAK-875,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5043,NCT05462756,Change from Baseline in HbA1c,Treatment Experience for Diabetes Injection Device at Week 26 - Experience Questionnaire (DID-EQ),,2022-08-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5044,NCT02655666,Change in Glycosylated Hemoglobin (A1C),Percentage of Time in the Hyperglycemic Range,,2015-04,TERMINATED,OBSERVATIONAL,['NA']
5045,NCT02764905,change in A1C,change in indices will be collected before initiation of intervention and will be measured again after 3 months and 12 months,,2016-11,COMPLETED,OBSERVATIONAL,['NA']
5046,NCT00716092,GLP-1 (Glucagon Like Peptide 1) AUEC (0-2h) (Area Under Effect Curve) Change From Baseline at Day 28,Plasma Glucose Area Under Effect Curve (AUEC) (0-3h) Change From Baseline at Day 28,Exploratory Sensitivity Analysis of Plasma Glucose AUEC (0-3h) Change From Baseline at Day 28,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5047,NCT03222765,Sudomotor Index,depressive symptoms,,2015-03-15,UNKNOWN,INTERVENTIONAL,['NA']
5048,NCT05411458,Heart rates,Health Related Quality of Life,,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
5049,NCT05325892,IDH,,,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA']
5050,NCT01507038,Change from baseline in HbA1c at week 12,"Change from baseline in 1,5-anhydroglucitol at week 12",,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5051,NCT03215914,Endogenous Glucose Production,Endogenous Glucose Production,,2017-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5052,NCT00501202,The mean of the last 7 average daily DPN scores of the first treatment period on days when study drug is taken.,"The means of the last 7 average daily DPN pain scores with no use of rescue medication, the last 7 current daily DPN pain scores, the last 7 maximum daily DPN pain scores, and the last 7 daily sleep interference scores.",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5053,NCT04558645,General Quality of life,Dyspnea,,2020-09-18,COMPLETED,OBSERVATIONAL,['NA']
5054,NCT04372316,changes of inferior whorl length （IWL）from baseline at 8 weeks,changes of corneal nerve fibre tortuosity （CNFT) from baseline at 8 weeks,,2017-12-25,UNKNOWN,INTERVENTIONAL,['PHASE2']
5055,NCT05110365,sphygmomanometer,(EuroQoL five-dimensional instrument ),,2021-06-26,COMPLETED,INTERVENTIONAL,['NA']
5056,NCT00306098,a1c less than 6.5 without severe hypoglycemia,assessment of EXN to improve islet survival at time of islet transplantation - number of subjects achieving insulin independence with a single infusion,,2000-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5057,NCT00289848,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18,Change From Baseline in 2-hr Post-Meal Glucose (PMG) at Week 18,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5058,NCT00567775,Area under the serum insulin curve,Time to maximum serum insulin concentration,,2002-10-21,COMPLETED,INTERVENTIONAL,['PHASE2']
5059,NCT05395000,Success rate of glucagon administration,Preferences in relation to the teaching method of administering the two forms of glucagon,,2021-03-19,COMPLETED,INTERVENTIONAL,['NA']
5060,NCT00508937,LDL subclasses,Apolipoprotein A1,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
5061,NCT04145154,Changing the dimensions of the ulcer area,Change in pain intensity,,2018-06-05,COMPLETED,INTERVENTIONAL,['NA']
5062,NCT04263168,Changes in glycemic index prior and following bariatric surgery,,,2020-03-01,WITHDRAWN,INTERVENTIONAL,['NA']
5063,NCT03455257,Change in per capita food expeditures,Change in Grip Strength,,2017-04-25,UNKNOWN,INTERVENTIONAL,['NA']
5064,NCT02371876,Percent of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15mg/dL (<100mg/dL) and Within +/- 15% (>=100mg/dL) of Laboratory Glucose Method,Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements Regarding Views/Behaviors Related to Self-Monitoring Blood Glucose,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
5065,NCT04075032,Change (1 log units) of Bacteroidetes per gram of feces,"Evaluation of genotype frequencies for 60 single nucleotide polymorphisms (SNPs) related to the incidence of obesity, metabolism, diabetes and cardiovascular diseases",,2018-06-10,COMPLETED,INTERVENTIONAL,['NA']
5066,NCT03495089,Presence of diabetic neuropathy diagnosed by EMG,Utah Early Neuropathy Scale,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
5067,NCT05351476,Change from baseline whole-body lipolysis at 12 weeks,Change in adipogenesis,,2022-05-20,RECRUITING,INTERVENTIONAL,['NA']
5068,NCT03450200,"Change in signs of DPN after intervention, at follow-up",Change in walking speed,,2017-06-17,COMPLETED,INTERVENTIONAL,['NA']
5069,NCT04014192,Change from baseline to post-treatment in islet alpha cell secretory function.,"Change from baseline to post-treatment in urinary output of uric acid, sodium, calcium, and phosphorus.",,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
5070,NCT01213901,"Anatomic site, abdomen versus deltoid, that offers the most consistent(superior) absorption of insulin",Injection technique which allows the most comfortable method of inserting the needle subcutaneously,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5071,NCT02726490,efficacy of glyburide compared to glucovance,neonatal hypoglycemia,,2016-07,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
5072,NCT05479565,The values of highly sensitive CRP in pregnant women with gestational diabetes are higher compared to healthy pregnant women.,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
5073,NCT01703637,Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 12,The side effect of each drug.,change from baseline in content of NOS,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
5074,NCT01994291,Mean Letter Change From Baseline at Week 12 in Best Corrected Visual Acuity (BCVA),Plasma Concentration of PF-04634817 up to Week 12,Number of Participants With Change in Ophthalmoscopy Examination Results in Study Eye After Administration of Ranibizumab or Masked Sham Therapy at Week 8,2013-11,TERMINATED,INTERVENTIONAL,['PHASE2']
5075,NCT02165228,Metabolic Syndrome Extent,Mindfulness,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
5076,NCT01215435,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 11,Number of Treatment Emergent Hypoglycaemic Episodes,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5077,NCT01343446,Coping style of Patients with Diabetes suffer from Sleep Disorder,,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
5078,NCT00998595,the fraction of each group that participates in postpartum follow up and glucose tolerance testing 4-12 weeks post partum.,the fraction of women in each group that attends a referral visit,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
5079,NCT02630277,Assess ocular and non-ocular adverse events,,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5080,NCT02418637,Feasibility (Likert scale),,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
5081,NCT01459133,Efficacy of Inhaled Insulin versus Subcutaneous Insulin in a patient who receives inadequate response from subcutaneous alone.,,,2013-05,WITHDRAWN,INTERVENTIONAL,['NA']
5082,NCT03565666,Percentage of Time Where Glucose is Less Than 54 mg/dL,,Mean Absolute Relative Difference Between Senseonics Eversense CGM and Contour Next One Glucose Meter,2018-07-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5083,NCT04589351,Urinary albumin creatinine ratio (UACR),Magnetic resonans estimate of kidney parenchymal triglyceride fraction,Urine extracellular vesicles,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5084,NCT03511885,"Proportions of hospital coronary patients and high risk individuals in primary care achieving European lifestyle, risk factors and therapeutic targets for cardiovascular disease prevention",,,2016-08-23,COMPLETED,OBSERVATIONAL,['NA']
5085,NCT06129526,Number of participants who suffer from bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria during the entire follow-up period.,"Number of participants who suffer from the secondary safety end points which are Atrial fibrillation, Palpitations, Arrhythmias, Heart failure, Pneumonia, Peripheral edema, Diarrhea.",,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5086,NCT00663624,to determine whether initiation of hyperglycemia management in the ED with scheduled aspart insulin for patients versus usual care with type 2 diabetes will result in a decrease in subsequent hospital length of stay.,"to determine diff. in the mean BG during the ED stay, the mean BG achieved during hospital, frequency of hypoglycemia during the ED and hospital visits among those treated with the scheduled protocol insulin regimen vs. usual hyperglycemia mgmt",,na,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5087,NCT01091025,To identify if using the selective approach to screen for CFRD is as accurate as screening all patients with OGTT at annual review.,Which is the more cost effective way of screening all patients with OGTT?,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
5088,NCT02056366,Primary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy,Secondary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy,Number of Patients with Adverse events as a Measure of Safety,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5089,NCT02588859,Medication usage in enrolled subjects,Reduction in HbA1C,,2015-10-30,COMPLETED,OBSERVATIONAL,['NA']
5090,NCT01009580,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-11-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5091,NCT00709150,Reduction in symptoms of major depression,Quality of life,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5092,NCT03436628,Change in Hemoglobin A1c (HbA1c),Change in Parental Monitoring,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
5093,NCT00287651,Serial fundus photography,,,2005-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5094,NCT01728467,Change in plasma glucose following treatment with RVX000222 compared to placebo,Change in insulin secretion and insulin sensitivity following treatment with RVX000222 compared to placebo,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5095,NCT00448903,total healing with intact skin or a significant improvement defined as a reduction of ulcer area > or = 50% or one degree reduction on Wagner Classification.,incidence of major bleeding and the incidence of adverse events.,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5096,NCT02469207,Number of donors from which induced Pluripotent Stem Cells were generated,Levels of baseline and stimulated gut hormones detected,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
5097,NCT00540709,Primary efficacy data was HbA1c.,Secondary efficacy data included HbA1c.,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
5098,NCT01447251,Number of participants with a change in their seven serum biomarker panel results,Number of participants with increased Continuous Positive Airway Pressure (CPAP)Compliance,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
5099,NCT00865592,To demonstrate safety and tolerability of dutogliptin,To demonstrate maintenance or lowering of fasting blood glucose,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE3']
5100,NCT04930276,the glycemic qualification rate,pregnancy outcome,,2021-03-05,UNKNOWN,INTERVENTIONAL,['NA']
5101,NCT01883622,"Glucose variability indexes during first, second and third trimester of pregnancy","Association between HbA1c and glucose variability indicators in the three trimesters pf pregnancy, in the three groups of women",,2004-01,COMPLETED,OBSERVATIONAL,['NA']
5102,NCT00975065,Hemoglobin A1c at 24 weeks,"Hypoglycemic events, Gastro-Intestinal events, other adverse events at each visit",,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5103,NCT01400191,Endogenous glucose production,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5104,NCT02745821,"Prevalence of number of vessels fulfilling each of 4 permutations of fractional flow reserve (FFR) and coronary flow reserve (CFR) ie FFR ≤0.80 CFR ≥2.0, FFR ≤0.80 CFR <2.0, FFR >0.80 CFR ≥2.0 and FFR >0.80 CFR <2.0.",Change in index of microvascular resistance (IMR) in target vessel,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
5105,NCT02193113,Number of participants with Adverse Events as a measure of safety and tolerability,Best Corrected Visual Acuity as measured by ETDRS EVA,Change in retinal thickness from baseline,2014-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
5106,NCT05464186,Fat mass,Diastolic blood pressure,Food and beverage intake pattern,2022-12-28,RECRUITING,INTERVENTIONAL,['NA']
5107,NCT05998525,changes in cardiac epicardial fat volume quantified in cm3 and evaluated by simple cardiac tomography.,Mortality due to cardiovascular causes,,2021-06-21,COMPLETED,INTERVENTIONAL,['PHASE3']
5108,NCT01775579,"metformin, rosuvastatin AUC","Metformin, Rosuvastatin Vd/Fss",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5109,NCT03680482,glycemic response in blood,Insulin response in blood,Through food provided ad libitum (objective appetite),2016-01-11,COMPLETED,INTERVENTIONAL,['NA']
5110,NCT03167411,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion (UGE),,2017-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
5111,NCT02214329,Gait,Functional Performance,,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
5112,NCT00172536,Diastolic heart function,Blood test,,2004-10,COMPLETED,INTERVENTIONAL,['NA']
5113,NCT00576862,Evolution of efficacy parameters between first study visit (V1) and last study visit (V5),,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
5114,NCT00659646,Number of Participants With a Clinical Cure at Visit 3 (Day 7),Lipsky Wound Score,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5115,NCT02137031,HbA1c,Frequency of Diabetic Ketoacidosis,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
5116,NCT05123196,Change from baseline in the weekly mean 24-hour average NRS score at Week 12 in treatment period,Proportion of CGIC responder at each assessment point,,2021-11-16,COMPLETED,INTERVENTIONAL,['PHASE2']
5117,NCT02013843,Body mass index standard deviation score,Change in quality of life assessed by PedsQL,cost effectiveness,2013-03,COMPLETED,INTERVENTIONAL,['NA']
5118,NCT00460499,glycemic control,free fatty acid levels,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5119,NCT04841837,Time in range,Body composition (fat and muscle mass),,2021-04-15,RECRUITING,INTERVENTIONAL,['NA']
5120,NCT02690766,Change in Body Weight,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5121,NCT00661921,Change from baseline in HbA1c at week 14 (end of treatment),,,2008-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5122,NCT00184665,HbA1c,Hypoglycaemia,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5123,NCT01338870,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Percentage of Participants With Greater Than or Equal to (>=) 1% or >= 2% Loss in Body Weight From Baseline,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5124,NCT03891056,Number of participans with normal glycosylated hemoglobin levels,Comparison postoperative pain in sleeve and bypass with analogue assessment scale of postoperative pain.,,2019-01-15,UNKNOWN,INTERVENTIONAL,['NA']
5125,NCT01277614,decrease body mass index,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5126,NCT05661149,Percentage time spent in the euglycaemic range specific for pregnancy (63-140 mg/dL),,,2023-05-11,COMPLETED,OBSERVATIONAL,['NA']
5127,NCT00441363,Change in Baseline to End of Study in HbA1c,Number of Serious Adverse Events Experienced by the Subjects,,2005-02,TERMINATED,INTERVENTIONAL,['PHASE3']
5128,NCT01094769,Urine albumin/creatinine ratio (UACR),muscle sympathetic nerve activity (MSNA),,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5129,NCT04959552,Characterize the safety of the FreeStyle Libre 2 Flash Glucose Monitoring System when used to manage diabetes in pediatric and young adult patient populations,,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
5130,NCT05373004,estimated glomerular filtration rate,the change in Urine Albumin Creatinine Ratio (UACR),"the rates of clinical events (myocardial infarction, ESRD, congestive heart failure, and stroke)",2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5131,NCT05723185,Analyse and compare the function of the two outpatient clinic models,,,2023-02-13,RECRUITING,OBSERVATIONAL,['NA']
5132,NCT02816749,Wound healing time(days),Negative bacterial culture time (days),,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
5133,NCT03435198,Absolute and relative change in concentration of measured volatile organic compounds in human breath in subjects with type 1 diabetes during hypoglycemia compared to euglycemia measured by proton-transfer-reaction time-of-flight mass spectrometry.,Identify differences in patterns of exhaled VOCs in people who have hypoglycemia unawareness,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
5134,NCT05892861,The change of cognitive function from baseline at 3 and 6 months,The change of dietary control belief from baseline at 3 and 6 months,The change of health behavior frequency per week from baseline at 3 and 6 months,2021-06-03,COMPLETED,INTERVENTIONAL,['NA']
5135,NCT00882882,Bioequivalence based on AUC and Cmax,,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5136,NCT04583813,Maintenance of sinus rhythm after the blanking period,Safety endpoint: Incidence of adverse events,Changes in patient's functional capacity,2021-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
5137,NCT00091949,"Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction","Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure",,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5138,NCT05790785,Change in biomarkers of vascular health during the first 24 months of type 1 diabetes diagnosis,Smoking and substance use,,2023-12-01,RECRUITING,OBSERVATIONAL,['NA']
5139,NCT00254501,Change in Hemoglobin A-1C From Baseline,Change in Diabetes Knowledge and Empowerment (Patient Self-efficacy) From Baseline to 12 Months,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5140,NCT02233179,Daily Physical Activities,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
5141,NCT01831102,total adiponectin concentration,Insulin sensitivity,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
5142,NCT00710008,"ATP-Synthesis, liver lipid content, skeletal muscle lipid content",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
5143,NCT04006028,Non-diabetic renal disease,Patient survival,,2019-06-06,COMPLETED,OBSERVATIONAL,['NA']
5144,NCT06041971,Mean Sensor Glucose Value,,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
5145,NCT01547104,fasting oxidatively modified nucleosides 8-oxodG and 8-oxoGuo,Body Weight,,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
5146,NCT04154579,Change in Pulse Oximetry from Week 1 to Week 16,Weekly Post-Session Survey,HeRe We Ed Week 16 Survey,2019-07-01,TERMINATED,INTERVENTIONAL,['NA']
5147,NCT04219709,Glycemic threshold for hypothalamic activation,Blood glucose level at which participant reports symptoms of hypoglycemia.,,2020-01-03,RECRUITING,INTERVENTIONAL,['NA']
5148,NCT00538174,Urine safety markers,24h urine,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5149,NCT02345291,• Change from the baseline week to Week 3 in the weekly average daily pain intensity as measured on an 11-point numerical pain scale (NPS),Incidence of treatment-emergent AEs (TEAEs),,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5150,NCT00943371,15-Hour weighted mean plasma glucose (WMG) concentration,4-Hour weighted mean plasma glucose (WMG) concentration,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE1']
5151,NCT00542178,"Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy",Development or Progression of Macular Edema,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5152,NCT01601236,Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12,"Percent Change From Baseline of Serum Total Cholesterol, Triglycerides, LDL, HDL, Lp(a), Albumin, and Cortisol",Change in Mean HbA1c,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5153,NCT01515553,"Cmax, maximum concentration",Adverse events,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5154,NCT01070238,Lower postprandial glucose and insulin responses after isomaltulose ingestion than after sucrose,,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5155,NCT02488616,Percentage of time of glucose levels spent between 3.9 and 10.0 mmol/L,Number of days with hypoglycemic events less than 3.1 mmol/L,,2018-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5156,NCT03716401,Cross-sectional (multi-centre collaboration),Longitudinal (multi-centre collaboration),Exeter Microvasculature Assessment Cohort - Thickness of the sublingual glycocalyx,2018-09-01,RECRUITING,OBSERVATIONAL,['NA']
5157,NCT02404207,Change in lipid profile,Change in waist circumference,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5158,NCT00314717,Self-blood-glucose-monitoring results,perceptions of diet treatments,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5159,NCT05463874,Diabetes Distress as measured by the Problem Areas in Diabetes - Teen Version (PAID-T),Diabetes distress as measured by the Problem Areas in Diabetes - Teen version (PAID-T),Time in Range,2022-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5160,NCT06316115,Introductory Information Form,Meggit-Wagner classification of diabetic foot,State Anxiety scale (STAI),2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
5161,NCT02598986,AUC of serum glucose,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
5162,NCT01215097,HbA1c Change From Baseline at Week 24,Number With HbA1c at Least Lowering 0.5%,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5163,NCT02338921,Glycemic target goal achievement rate,Glycemic target goal achievement rate,body weight change,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5164,NCT06280703,Part C: PK: Concentration of LY3938577,Part C: PD: Glucose infusion rate (GIR) of LY3938577,,2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
5165,NCT01274715,Change in Hemoglobin A1C,,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
5166,NCT04051008,Change in Nutritional Quality of Purchases,Nutritional Quality of Foods Consumed,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
5167,NCT01192373,Exercise capacity and oxygen consumption,metabolic and hormonal profile,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5168,NCT00617565,2-hr postprandial plasma glucose (PPPG) excursion,Fasting plasma glucose,,2003-07-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5169,NCT04058730,Glycosylated Haemoglobin less than 6.5 mg/dl,,,2015-04-01,UNKNOWN,INTERVENTIONAL,['NA']
5170,NCT01857076,Diabetes remission evaluated by patients glycemic rates,Number of Late Adverse Events,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
5171,NCT04976361,Measurement of retinal thickness,,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
5172,NCT04255238,Chages from baseline HbA1c at Week24,,,2020-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
5173,NCT04497805,Proportions of subjects who achieved complete wound closure.,Durability of complete wound closure for the additional 24 weeks.,,2020-09-08,RECRUITING,INTERVENTIONAL,['PHASE2']
5174,NCT02366273,Evaluation of correlation between diabetes and psoriasis,,,2015-02-01,COMPLETED,OBSERVATIONAL,['NA']
5175,NCT06326489,Variations in HbA1c,changes in The Pediatric Quality of Life Inventory™ 4.0 Short Form 15 Generic Core Scales questionnaire scores,,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE4']
5176,NCT02320721,Change in HbA1c From Baseline to Week 26,Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment,"Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year During the 26 Weeks of Treatment",2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5177,NCT02887677,Ambulatory systolic aortic pressure,HbA1c,,2016-10,TERMINATED,INTERVENTIONAL,['PHASE4']
5178,NCT03356457,• Measurement of hormone changes during hypoglycemia,cognitive function,,2017-11-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5179,NCT02577003,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in Body Weight at Week 24,,2015-11-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5180,NCT05682495,Pharmacokinetics parameters of Metformin in the fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,,2023-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
5181,NCT01650259,Percentage of Participants With Adverse Drug Reactions (ADRs),Change From Baseline in HbA1c at the Last Observation During the Observation Period.,,2012-07-23,COMPLETED,OBSERVATIONAL,['NA']
5182,NCT05686421,Comfort Level Rating of Device C on 0-5 Scale,Time Duration to Adjust for Number of Motion Artifacts Present with Device C Imaging,,2023-03-30,COMPLETED,INTERVENTIONAL,['NA']
5183,NCT01973920,Adverse events and serious adverse events occurence,To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs routine use,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5184,NCT05720377,Body Mass Index,IL-6,,2024-02-01,WITHDRAWN,INTERVENTIONAL,['NA']
5185,NCT03968224,Change in Weight,Change in Triglycerides level,Change in Cytokines Level,2018-07-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5186,NCT02804750,Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events,Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5187,NCT02353416,Advanced glycation end products levels,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
5188,NCT02586545,"Change from baseline Hemoglobin A, Glycosylated (HbA1c) at 12, 24 and 36 months",The proportion of patients who meet national standard indicators reflecting quality of care,"Change from baseline diabetes symptoms at 12, 24 and 36 months",2015-08,COMPLETED,INTERVENTIONAL,['NA']
5189,NCT00065663,,,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5190,NCT00335465,adverse events,changes of myocardial structure and left ventricular systolic and diastolic function,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5191,NCT00415688,Hemoglobin A1c,Serum lipoproteins,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5192,NCT05888909,change in estimated glomerular filtration rate (eGFR) from baseline,,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA']
5193,NCT00772174,Increase in High-Density Lipoprotein cholesterol levels.,"The change from Baseline in Laboratory Parameters (hematology, chemistry and urinalysis).",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5194,NCT00658463,"Fractional Catabolic Rates (FCR)of VLDL1-apoB, VLDL2-apoB, IDL-apoB, LDL-apoB and HDL-apoA-I","Production Rates (PR) of VLDL1-apoB, VLDL2-apoB, IDL-apoB, LDL-apoB and HDL-apoA-I",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5195,NCT03388229,association between frequency of food group/item consumption and HbA1c among T2D patients,"To measure the percentage of frequency of consumption of food groups among T2D patients ,",,2017-08-08,COMPLETED,OBSERVATIONAL,['NA']
5196,NCT00182026,A1c,incremental cost/quality-adjusted life-year [QALY],,2005-06,UNKNOWN,INTERVENTIONAL,['NA']
5197,NCT01806194,Change in Hemoglobin A1c,Change in Weight,Blood Pressure,2012-01,COMPLETED,INTERVENTIONAL,['NA']
5198,NCT05561595,Internalized Health-Related Stigma Scale,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5199,NCT02384902,Serum creatinine (and blood urea nitrogen (BUN) (mg/dL) were measured by colorimetric method and enzymatic colorimetric method using commercial assay kit.,"Serum levels of high sensitive C- reactive protein (hs-CRP) (mg/L) were quantified by using an ultrasensitive latex-enhanced immunoturbidimetric assay (Randox Laboratory Ltd., Belfast, United Kingdom).",Fasting blood sugar (FBS) and lipid profile concentrations (mg/dl) were measured using commercially available enzymatic reagents adopted to an auto-analyzer system.,2014-05,COMPLETED,INTERVENTIONAL,['NA']
5200,NCT04008745,Change from Baseline of the Fuzzy classification of the diabetic neuropathy severity at 8-weeks,Change from Baseline Functional balance at 8-weeks,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
5201,NCT05104593,Change in healthcare appointments,Change in number of participants with advanced directives,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5202,NCT01433406,Adverse events,,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5203,NCT03849339,AUClast of Metformin,Vd/F of Metformin,,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE1']
5204,NCT04284722,Incidence of Perioperative Hyperglycemia,Mortality,,2020-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
5205,NCT05904847,Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes,Blood Glucose Level,,2023-06-16,COMPLETED,INTERVENTIONAL,['NA']
5206,NCT06256549,"Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks",The overall incidence of adverse events and the incidence of serious adverse events,,2023-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5207,NCT03950973,Change in HbA1c as measured by an HbA1c machine,Change in Unmet Social Risk Factors as measured by participant questionnaire,,2019-06-26,COMPLETED,INTERVENTIONAL,['NA']
5208,NCT02395315,Differences in alveolar bone vascularity among well-controlled and not well-controlled diabetic patients.,RANK-L to OPG ratio,Implant surgery-related complications,2015-12,COMPLETED,OBSERVATIONAL,['NA']
5209,NCT03614780,temperature,fasting glucose,,2017-07-11,COMPLETED,INTERVENTIONAL,['NA']
5210,NCT04631653,diagnostic accuracy,Referral rate of diabetic retinopathy,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
5211,NCT00950079,Incidence of contrast-induced nephropathy,myocardial infarction,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
5212,NCT01998113,insulin treatment,Neonatal Intensive Care Unit (NICU) admittance,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
5213,NCT02059161,Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24,Bolus Insulin Dose Per kg of Body Weight at Week 24,,2013-10-17,COMPLETED,INTERVENTIONAL,['PHASE3']
5214,NCT01220557,Changes in Glycemic Control Measured by A1c,Evaluation of the Diabetes Education Course,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5215,NCT00790309,Determine to what extent improvements in glycemic control can be attributed to caloric restriction after weight loss surgery,Determine changes in inflammatory markers after weight loss surgery,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
5216,NCT02598791,food intake,procollagen type 1 N-terminal propeptide (P1NP),,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
5217,NCT00057317,,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5218,NCT04698330,Change in HbA1c,Hypoglycemic events,,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5219,NCT00903851,Mean change from baseline to Week 3 in average pain intensity as measured from patient diaries using Brief Pain Inventory Question 5.,"Assessment of safety was based on AEs, skin assessment, physical examination, vital signs, clinical laboratory data, and plasma lidocaine levels",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5220,NCT03459573,Hemoglobin A1c,Self-Monitoring of Blood Glucose,Life Satisfaction,2018-02-23,UNKNOWN,INTERVENTIONAL,['NA']
5221,NCT00350064,Change in Abdominal Visceral Fat,Endothelial Function,,2004-04,UNKNOWN,INTERVENTIONAL,['NA']
5222,NCT01991769,endothelial function,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
5223,NCT02944110,PPG excursions measured as incremental area under curve (iAUC),Gastric inhibitory peptide (GIP) and Glucagon like peptide-1 (GLP-1) pmol/l,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
5224,NCT03604224,Change From Baseline in Mean Weight,,,2018-09-05,COMPLETED,OBSERVATIONAL,['NA']
5225,NCT04642313,"Effect of magnesium and/ or potassium on serum electrolytes (Mg, K) among insomnia patients with diabetes mellitus",Gender and age based response to magnesium and/ or potassium on insomnia patients with diabetes mellitus,Effect of magnesium and/ or potassium on quality liver function tests (LFTs) among insomnia patients with diabetes mellitus,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA']
5226,NCT00167570,Durability during household and community mobility.,"User perceptions of comfort, fit, and function.",,2003-04,COMPLETED,OBSERVATIONAL,['NA']
5227,NCT05862311,Evaluation of bone metabolism biomarkers in different periodontal conditions,Plaque index,,2020-03-12,COMPLETED,INTERVENTIONAL,['NA']
5228,NCT00569907,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
5229,NCT05535322,Major acute cardiovascular events,Therapeutic inertia,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
5230,NCT01129960,Change From Baseline to Endpoint in Mean Pain,,,2010-11,TERMINATED,INTERVENTIONAL,['PHASE3']
5231,NCT01393873,rapid changes in the level of retinopathy,,,2011-07,TERMINATED,OBSERVATIONAL,['NA']
5232,NCT01956929,Change in Glucagon-induced endogenous glucose production.,Change in glucagon-induced alterations in whole body protein metabolism and resting energy expenditure.,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5233,NCT01817595,Time required to teach meter/internet platform,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
5234,NCT05491954,Changes in glycemic control over late gestation as measured by A1c,The number of neonatal hypoglycemic episodes,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA']
5235,NCT04159766,Change in plasma glucagon,,,2019-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
5236,NCT02142309,"The primary outcome is maintenance of metabolic control (glycemic durability), defined as time to primary failure with a HbA1c value >7% on maximally tolerated doses of the assigned drug.",Continuous glucose monitoring for 72 consecutive hours at least once each year of follow-up,Changes of triglyceride level from baseline each year of follow up,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
5237,NCT03767543,Change in glycated hemoglobin (HbA1c)%,Annualized rate of hypoglycemia (<3.0 mmol/L) over 26 weeks,,2019-03-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5238,NCT02586831,Proportion of regulatory T cells,Incidence of immune response adverse events,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5239,NCT00551564,Insulin resistance,Body composition,,2007-07-31,COMPLETED,INTERVENTIONAL,['PHASE1']
5240,NCT00337610,Change From Baseline in A1C at Week 18,Change From Baseline in A1C at Week 30,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5241,NCT05928013,Vibration Perception Threshold (volts) as measured by person with diabetes,,,2023-04-19,RECRUITING,INTERVENTIONAL,['NA']
5242,NCT06085378,The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days,Changes of Montreal cognitive assessment (MoCA) from baseline to 90±7 days,"Incidence, severity, and causality of adverse events (AE) and serious adverse events (SAE) during the intervention",2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5243,NCT00804921,Intra-ocular pressure variation after intra-vitreous injection of bevacizumab,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
5244,NCT04684602,Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months.,,,2020-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5245,NCT02501343,Changes in venous blood pH,Changes in hunger and satiety scores,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5246,NCT05646147,Reliability of standard bedside tests and the maximal systolic acceleration (ACCmax),Wound healing and ACCmax,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5247,NCT01658501,Evaluation of dose response of Glymera as measured as the change from baseline in HbA1c after 20 weeks of dosing with Glymera compared to placebo and active comparator,Proportion of subjects reaching HbA1c targets (<7.0%) after 20 weeks of dosing,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5248,NCT03951298,Change in regional brain volumes over time,Change in disease severity score,,2018-08-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5249,NCT01657630,Study device acceptance,preprandial SMBG (self monitoring blood glucose),,2012-09,COMPLETED,OBSERVATIONAL,['NA']
5250,NCT01247363,Number of Participants With Clinically Significant Adverse Effects,Number of Hypoglycemic Events,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5251,NCT00511030,,,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
5252,NCT03560323,Cardiac Function,Myocardial energetics,,2019-01-07,RECRUITING,INTERVENTIONAL,['PHASE1']
5253,NCT01356381,"Measure: effect of treatment on insulin sensitivity, assessed as glucose Rd (rate of glucose disposal).",,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5254,NCT01651845,"Evaluate effectiveness of the UHN handheld PRODIGI™ imaging device for real-time and non-invasive detection and tracking of pathogenic bacterial presence, contamination and infectious status in complex wounds over time.",,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
5255,NCT03823664,Cardiorespiratory fitness,Pulmonary functions,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
5256,NCT02888769,Change in systolic blood pressure obtained in office during each interview,Change in proportion of non-smokers,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
5257,NCT00917553,The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group,Number of Participants Who Developed Vitreous or Preretinal Hemorrhage,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5258,NCT02183935,Change in BMI (BMI SDS),"Change in emotional and behaviour problems, body image and eating disorder symptoms",Safety profile of DJL in adolescents.,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5259,NCT06294704,time spent within glycemic target 70-180 mg/dL,Time spent in level 2 hypoglycemia (< 50 mg/gdl),,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5260,NCT01876992,% Cyclic Amine Mono Phosphate (cAMP) Response Element Binding Protein (CBP) White Blood Cell (WBC) Phosphorylation (Metformin Treated vs no Treatment),Fasting Blood Glucose.,Effect of Dose Escalation,2012-01,TERMINATED,INTERVENTIONAL,['NA']
5261,NCT03271580,macrophage phenotyping,,,2020-02-01,TERMINATED,OBSERVATIONAL,['NA']
5262,NCT04315909,Wound Size,Pro-Oxidant Antioxidant Balance at baseline and after the intervention,,2019-08-28,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5263,NCT05370612,Percentage of Time Where Blood Glucose is between 70-140 milligrams per deciliter (mg/dL),Qualitative Outcome: Interviews to understand Participant Sense of Control around Glucose Monitoring,,2022-08-08,RECRUITING,INTERVENTIONAL,['NA']
5264,NCT02232503,The prevalence of diabetic retinopathy as the proportion of patients with DR (any stage) in a given subgroup according to DM duration,Evaluate the impact of risk factors on the prevalence of Diabetic Retinopathy and Diabetic Macular Edema,Identification of patients with extreme phenotypes and family history of DM with eye complications,2015-02,COMPLETED,OBSERVATIONAL,['NA']
5265,NCT06089070,Feasibility of CGM use measured with Feasibility of Intervention Measure.,Problem Areas in Diabetes,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
5266,NCT05777317,Lower limb pain responder rate,Average change in body weight,,2023-04-24,RECRUITING,INTERVENTIONAL,['NA']
5267,NCT01352767,efficacy,Satisfaction,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5268,NCT05159089,Metabolic participants outcomes,Socioeconomic participant status,Medication patients intake,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
5269,NCT05575609,height anthropometric measurement,,,2022-11-01,COMPLETED,OBSERVATIONAL,['NA']
5270,NCT01175811,Change in Haemoglobin A1c (HbA1c) From Baseline to 24 Week Endpoint,Percentage of Participants Experiencing a Severe Hypoglycemic Episode,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5271,NCT03725657,Measure of sleep expenditure through wrist accelerometer,Measure of insulin dosage,,2018-10-29,COMPLETED,OBSERVATIONAL,['NA']
5272,NCT02569684,Changes in plasma GLP-1 in response to standardized test meal before and after six weeks of ingestion of prebiotic fibers or placebo,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
5273,NCT01645332,Reduction of A1c level,Adverse events,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5274,NCT06095492,Spot urine protein-creatinine ratio,Changes in HbA1c,,2023-10-30,RECRUITING,INTERVENTIONAL,['NA']
5275,NCT00351650,,,,2006-07-09,COMPLETED,OBSERVATIONAL,['NA']
5276,NCT04093635,Management of diabetic foot ulcers.,,,2019-11,UNKNOWN,OBSERVATIONAL,['NA']
5277,NCT04324736,Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19,describe the care management of hospitalized subjects with diabetes and COVID-19,,2020-03-10,COMPLETED,OBSERVATIONAL,['NA']
5278,NCT01255384,,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
5279,NCT01897532,"Time to the First Occurrence of Any of the Following Adjudication-confirmed Components of the Primary Composite Endpoint 3-point Major Adverse Cardiovascular (CV) Events (3-point MACE): CV Death, Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke.","Time to the First Occurrence of Any of the Following Adjudication-confirmed Components: Renal Death, Sustained End Stage Renal Disease (ESRD), or Sustained Decrease of 40% or More in Estimated Glomerular Filtration Rate (eGFR).",,2013-07-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5280,NCT04511468,Change the Risk of T2DM Progression,The assessment on the Safety of the ZCC Supplementation for the respondents,Change in Vitamin C Level (optional),2021-06-23,UNKNOWN,INTERVENTIONAL,['NA']
5281,NCT05662332,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Treatment Experience in Diabetes Injection Device Experience Questionnaire (DID-EQ) in Device Characteristics,,2023-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5282,NCT05521737,Nerve Conduction Velocity,Genetic expression,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
5283,NCT01468116,,,,2011-03,UNKNOWN,OBSERVATIONAL,['NA']
5284,NCT00551538,Combined morning and evening mean 2 hour postprandial plasma glucose during each 24 hour inpatient period.,Insulin dose and body weight,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5285,NCT01325987,HbA1C,AUC for c-peptide and glucose after MMTT,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
5286,NCT05993871,Demonstrate the findings of nerve ultrasound CSA of right ulnar nerve.,Diabetic neuropathy quality of life evaluation using Euro quality of life -5 dimensions -5 levels scale.,,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5287,NCT00409240,"Percent of Patients Achieving Hemoglobin A1C Goal, LDL Cholesterol Goal, and Systolic Blood Pressure Goal From the Enrollment Until the End of the Study",,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5288,NCT06227221,The primary endpoint of the study is the change from baseline of serum C-peptide area under the curve (AUC) over 2 hours following a mixed meal,"Drug safety: gastrointestinal symptoms, rashes, fatigue, bleeding, anemia, infections, cardiovascular events, etc.",,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5289,NCT02653027,Change in Fasting Glucose,Change in Fasting Insulin,,2018-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
5290,NCT03072563,Composite outcome,,,2017-03-07,UNKNOWN,OBSERVATIONAL,['NA']
5291,NCT02687152,Change in cutaneous microvascular endothelial function,,,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5292,NCT05180591,Change in HbA1c values,Change in adjusted HbA1c,Exploratory: Change in overall inflammation,2022-03-22,RECRUITING,INTERVENTIONAL,['PHASE2']
5293,NCT01416766,Change in blood pressure (BP),Satisfaction,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
5294,NCT02486484,vision before and after ziv-aflibercept,central macular thickness before and after ziv-aflibercept,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
5295,NCT01114542,Area under the glucose infusion rate curve during one dosing interval of Insulin Degludec at steady state,Area under the concentration-time curve during one dosing interval at steady state for insulin glargine,,2010-05-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5296,NCT01952145,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent Confirmed Hypoglycaemic Episodes,,2013-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
5297,NCT03821220,Physical activity level assessed through average weekly steps,Vitamin C intake 0<mg/day<2500,,2019-02-15,UNKNOWN,INTERVENTIONAL,['NA']
5298,NCT05199350,Determination of autonomic dysfunction by subject,Establish the absence of any relationship of autonomic dysfunction (AD) to any other vital signs parameters.,,2021-11-17,COMPLETED,OBSERVATIONAL,['NA']
5299,NCT03895229,Time to Maximum drug concentration in plasma (tmax),Half life( t½) of drug in plasma,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5300,NCT00325650,Time of progression to type 2 diabetes,Change from baseline in HDL-Cholesterol and triglycerides (TG),,2006-05,TERMINATED,INTERVENTIONAL,['PHASE3']
5301,NCT02860611,Difference in T helper cytokines between groups,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
5302,NCT00342927,Diabetes and diabetic kidney disease.,Blood pressure and serum lipids.,,2001-03-07,RECRUITING,OBSERVATIONAL,['NA']
5303,NCT00999050,Hemoglobin A1C changes,improvement in glycemic control,,2009-10,UNKNOWN,INTERVENTIONAL,['NA']
5304,NCT06176599,Effective rate,Urinary microalbumin/urinary creatinine,,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5305,NCT05035368,The mean difference in glucose infusion rate (GIR) from baseline,Change in average (previous 3 days) daily insulin requirements,,2021-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5306,NCT04457440,Changes in 2-hr oral glucose tolerance (mg/dl),Changes in dietary composition,,2020-07-01,SUSPENDED,INTERVENTIONAL,['NA']
5307,NCT04843592,the patient's compliance after using SOKARY mobile app,,,2019-08-30,COMPLETED,OBSERVATIONAL,['NA']
5308,NCT02154100,Arterial Stiffness,Body Composition,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5309,NCT02340507,Daily blood glucose profile (easured for each low and high GI treatment as the area under the curve over 24 hours using CGMS),Energy intake (The amount of food consumed at the ad libitum lunch is measured by weighed quantities (in grams converted to kilocalories) based on the difference of the weight of food before and after consumption),,2013-05,COMPLETED,INTERVENTIONAL,['NA']
5310,NCT02767440,change in parent weight over 6 months,change in home food environment over 6 months,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
5311,NCT00121966,HbA1c following two years of treatment,urine albumin/creatinine ratio,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5312,NCT02026843,Aqueous secretory angiogenic and anti-angiogenic protein concentration,,,2012-04,UNKNOWN,OBSERVATIONAL,['NA']
5313,NCT00566189,Improvement or reversal of type 2 diabetes mellitus,Retardation of progression or regression of albuminuria as detected by microalbuminuria assay in 24-h urine collection,,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5314,NCT02473081,Hemoglobin A1c,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
5315,NCT05537233,Proportion of adults with T1D achieving composite outcome (CGM-measured time in range (TIR)>70% with time below range (TBR) of <4% and reduction in body weight by 5%) at 26 weeks in the semaglutide group compared to placebo group,Change in NAFLD biomarkers,Change in ectopic fat volumes in the abdomen and around the heart,2023-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5316,NCT03558581,Glycemic control - HbA1< 7%,Improve Knowledge assessed by questionaries DKNA,Improve attitude and coping of Diabetes assessed by questionaries ATT-19,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
5317,NCT00235014,Phase A: microalbuminuria; Phase B: progression from microalbuminuria to macroalbuminuria.,"Course of albumin excretion over time, GFR, blood pressure (BP), incidence of major CV events, overall and CV mortality, HbA1c, progression of retinal changes.",,1997-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5318,NCT03934281,Epidermization rate at 6 months.,Epidermization rate at 2 months,,2018-06-27,COMPLETED,INTERVENTIONAL,['NA']
5319,NCT00212901,reducing proteinuria,"side-effects of hypotension, postural symptom",,2004-08,COMPLETED,INTERVENTIONAL,['NA']
5320,NCT02065050,Hemoglobin A1c,BMI,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
5321,NCT03289338,Time for resolution of active Charcot foot,Time for radiologic resolution/reduction on MRI,,2016-06-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5322,NCT00374595,Carotid Intima Media Thickness (CIMT),,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
5323,NCT02909894,Blood glucose Area Under the Curve (AUC),Cognitive function - Part 4 - Rapid Visual Information Processing Test,,2016-05-26,COMPLETED,INTERVENTIONAL,['NA']
5324,NCT00692237,"Left Ventricular Torsion Defined as Change in Ventricular Mid-wall Rotation (°) Measured by Cine-Cardiac Magnetic Resonance (CMR) Imaging With Tagging, Before and After Three Months of Treatment With Sildenafil and Placebo (100 mg/Day).",Ejection Fraction (EF) Defined as the Volume of Blood Ejected With Each Beat Was Measured on Cine-Cardiac Magnetic Resonance (CMR) Images Before and After Three Months Treatment With Sildenafil and Placebo (100 mg/Day).,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5325,NCT03150901,dIABETIC FOOT ULCERS INCIDENCE,,,2015-02-20,COMPLETED,OBSERVATIONAL,['NA']
5326,NCT04941794,Chronic Heart Failure,6 minutes walk test,HOMA-IR,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
5327,NCT00804414,Compare the proportion of patients in the two arms who have complete healing of target ulcer,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5328,NCT05268081,Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and cholesterol,Questionnaire for the assessment of practice staffs' confidence in managing type-2 diabetes and cholesterol at 12 and 24 month,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5329,NCT00795262,Comparison of relative change of systolic BP/diastolic BP and urinary albumin excretion from baseline in diabetic patients treated with quinapril plus lipoic acid versus quinapril and placebo.,"Comparison of patients treated with quinapril plus lipoic acid versus quinapril plus placebo in the following areas: a) Changes from baseline in high sensitivity C-reactive protein, adiponectin, and leptin",,2008-07,COMPLETED,INTERVENTIONAL,['NA']
5330,NCT02611232,FPIR (first phase insulin response),Serum C-peptide AUC,,2015-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
5331,NCT03880162,Change from baseline in intrahepatic triglyceride content,Change from baseline in insulin sensitivity,Length of hospital stay,2019-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5332,NCT01771185,Hb A1a,Lipidic control,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
5333,NCT00712478,Evaluate improvement of diabetes control with fasting glycemia and after diner glycemia measurements,Evaluate improvement of diabetes control with fasting glycemia and after diner glycemia measurements,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
5334,NCT03341026,Accuracy,Reliability,,2020-06,UNKNOWN,INTERVENTIONAL,['NA']
5335,NCT05552339,Number of patients with Urine albumin-creatinine ratio (UACR) values between 30 and 299 mg/g and above 300 mg/g,Location of HCP,,2023-08-18,RECRUITING,OBSERVATIONAL,['NA']
5336,NCT01063361,serum lipids,"creatine, urea, and c-peptides in 24 hour urine collection",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5337,NCT01437332,,,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
5338,NCT00592527,HbA1c,Incidence of adverse events,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5339,NCT03710083,Mean Absolute Relative Difference (MARD),,,2019-02-28,COMPLETED,INTERVENTIONAL,['NA']
5340,NCT05019807,Follow-up rate in patients with diabetic macular edema receiving education materials about diabetes and its complications.,,,2020-12-18,COMPLETED,INTERVENTIONAL,['NA']
5341,NCT05107063,Percentage Change Rate From Baseline in the Modification of Diet in Renal Disease(MDRD) Estimated Glomerular Filtration Rate (eGFR) at Week 24 After Routine Care of Pravastatin Administration,Number of Participants With Treatment-emergent Adverse Events After Routine Care of Prevastatin Administration,,2016-01-20,COMPLETED,OBSERVATIONAL,['NA']
5342,NCT06147232,Change in dynamic R2*-weighted signal (BOLD) as an indirect measure of renal blood oxygenation,Difference in Kidney Function after 12 weeks treatment with sotagliflozin vs placebo,Ethnicity,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5343,NCT00262548,"All participants will receive an intervention on diet and physical activity counseling, which will be carefully monitored.","Other variables will be: proinflammatory cytokines - tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), IL-12, Th2/Th3 cytokines -IL-4, IL-10 and transforming growth factor beta (TGF-beta)",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5344,NCT00443521,Vitreous haemorrhage,Safety and Tolerance of the treatment,,2005-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5345,NCT05336071,Area under the plasma concentration versus time curve (AUC0-inf ) of INS068 injection,Number of subjects with adverse events and the severity of adverse events,,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5346,NCT00255645,,,,2005-09,TERMINATED,OBSERVATIONAL,['NA']
5347,NCT00317954,Changes in blood pressure,Changes in glomerular filtration rate,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5348,NCT05806957,Specificity of the Ophthal-360 Software to detect diabetic retinopathy in fundus images,,,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5349,NCT01387165,The achievement of the planned completed number of questionnaires.,Assessment of fasting blood glucose,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
5350,NCT03710850,Glucose disposal,Suppression of lipolysis,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
5351,NCT00007098,,,,1995-05,COMPLETED,OBSERVATIONAL,['NA']
5352,NCT01557972,Death,Macrovascular complications,,1999-11,UNKNOWN,OBSERVATIONAL,['NA']
5353,NCT00094770,Change From Baseline in HbA1c at Week 52,Number of Participants With Drug-related LAEs at Week 104,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5354,NCT01833559,The incidence of GDM at the second gestational trimester,Gestational outcomes,Child growth measures,2012-06,UNKNOWN,INTERVENTIONAL,['NA']
5355,NCT04755946,Absolute change in Estimated glomerular filtration rate (eGFR),Change in serum irisin level,,2021-03-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
5356,NCT02440282,Heart rate,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
5357,NCT03809299,Insulin sensitivity,Autophagy level,,2019-06-20,COMPLETED,INTERVENTIONAL,['NA']
5358,NCT03484689,Dropout rate,The Audit of Diabetes-Dependent Quality of Life (ADDQOL),,2018-07-14,COMPLETED,INTERVENTIONAL,['NA']
5359,NCT05999656,Rate of wound area change,Change in Wagner scale,,2023-05-28,RECRUITING,INTERVENTIONAL,['NA']
5360,NCT02946541,HbA1c,HbA1c response rate,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5361,NCT06329674,Changes in HbA1c,,,2021-04-27,COMPLETED,INTERVENTIONAL,['PHASE3']
5362,NCT04192292,Difference in incretin effect between mixed meal tests,Variation in blood glucose during intervention blocks analysed by continuous glucose monitoring,,2019-10-08,COMPLETED,INTERVENTIONAL,['NA']
5363,NCT02455076,Change in HbA1c Concentration Inpatient,Change in Diastolic Blood Pressure,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5364,NCT04262661,Part 2: Number of treatment emergent adverse events,Maximum observed serum NNC0472-0147 concentration at steady state,,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5365,NCT04386187,gamma-glutamyltransferase (GGT),Triglycerides,Triglycerides,2020-07-28,COMPLETED,INTERVENTIONAL,['NA']
5366,NCT01109212,Urinary Albumin Excretion (µg/min) levels in the overnight urine specimen.,Albuminuria remission rates,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5367,NCT06187129,cross sectional area of peripheral nerves using nerve ultrasound,,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5368,NCT05793788,Opening link within SMS Text message,Completion rate of one screening/test,,2023-03-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
5369,NCT03387735,UCLA Loneliness Scale,Falls Requiring Medical Attention,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
5370,NCT02651480,Blood pressure,Quality of Life and Mood,,2016-02,SUSPENDED,INTERVENTIONAL,['NA']
5371,NCT00262704,lipid control,,,2001-12,COMPLETED,INTERVENTIONAL,['NA']
5372,NCT01336322,Beta-cell function,Glucose control,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5373,NCT00574834,Changes in Insulin Sensitivity,,,2007-03,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
5374,NCT02586519,Rate of Wound Resolution,Complication Rates,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
5375,NCT00972452,"The overall aim of the project is to determine whether or not acute exercise training influences postprandial metabolic, vascular or autonomic nervous system responses in individuals with insulin resistance or T2D.",,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5376,NCT00976261,"Part B: Safety, tolerability parameters: adverse events, gastro-intestinal side effects, subject reported outcomes, clinical laboratory results, ECGs and vital signs",Part B: 3-O-Methyl-Glucose Kinetics,,2009-10-17,COMPLETED,INTERVENTIONAL,['PHASE1']
5377,NCT01892280,Change in glycemic control from baseline to 1 year,Psychosocial factors (self-report surveys),,2013-11,COMPLETED,INTERVENTIONAL,['NA']
5378,NCT00935129,Treatment satisfaction,continuous glucose measurements,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5379,NCT03444064,Adverse Events,Stimulated C-peptide level,,2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5380,NCT01058889,"System availability, acceptance, transmission rate",HbA1c,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
5381,NCT01000519,"Hemoglobin A, Glycosylated (Hba1c). Measuring unit: percentage",Cholesterol,,2002-12,COMPLETED,INTERVENTIONAL,['NA']
5382,NCT02500706,Change From Baseline in HbA1c 26 Weeks After Randomisation,Change From Baseline in Body Mass Index 26 Weeks After Randomisation,,2016-05-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5383,NCT01099163,glycosylated hemoglobin,oxidative stress (MDA),,2009-01,COMPLETED,INTERVENTIONAL,['NA']
5384,NCT01666028,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring (CGM) adjusted for sensor error.,"Number of episodes of hypoglycaemia, severe hypoglycaemia as well as nature and severity of any other adverse events.",Duration of use of the closed-loop system at home.,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5385,NCT05700513,Fasting blood glucose,High-sensitivity C-reactive protein level,,2023-07-28,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5386,NCT03655535,2 hr PPG,Change in oral hypoglycemic medication,,2018-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
5387,NCT06098417,soluble biomarkers of liver fibrosis,Biobank,,2015-09-22,RECRUITING,OBSERVATIONAL,['NA']
5388,NCT01545791,"Number of serious adverse drug reactions (SADRs), including major hypoglycaemic events",Quality of Life as assessed by a treatment satisfaction questionnaire,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
5389,NCT03655223,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,Impact of Screening: Semi-structured parent interviews.,,2018-10-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5390,NCT05145374,Measurement of Glucose Concentration,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
5391,NCT05411952,Change in mean of HbA1c from baseline to 6 months,Change in mean of Mediterranean Diet Quality Index Scale (KIDMED) from baseline to 6 Months,,2020-08-13,COMPLETED,INTERVENTIONAL,['NA']
5392,NCT00209417,Assessment of the Incidence Rate of Contrast Medium-Induced Nephropathy (CIN) Between Iodixanol and Iopamidol in Patients With Impaired Renal Function.,Assessment of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Contrast-enhanced Multi-detector-row Helical Computed Tomography (MDCT) Examination.,,2005-06,TERMINATED,INTERVENTIONAL,['PHASE4']
5393,NCT01478737,Reoperation,Rebleeding,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5394,NCT02772926,Serum levels of Carboxymethyl-lysine,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
5395,NCT05836350,fasting plasma glucose levels,cardiac function: tricuspid regurgitation systolic jet velocity,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5396,NCT00424437,Primary outcome is 24 week change in baseline in HbA1c,Patient satisfaction and preference.,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5397,NCT04591704,Lung involvement,,,2020-03-20,UNKNOWN,OBSERVATIONAL,['NA']
5398,NCT05681286,C-reactive protein to serum albumin ratio in type 2diabetic patients with diabetic nephropathy,,,2023-08-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5399,NCT01621516,Change in the stimulated serum C-peptide leveS (mean area under the curve [AUC] after hypercemic clamp test,,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
5400,NCT00854035,Safety and Tolerability,Fasting plasma glucose,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5401,NCT02657083,"to evaluate the safety and efficacy of blood glucose control using the DreaMed MD-AID in children and adolescents with T1D during and after planned physical activity, in a controlled in-hospital environment.",to evaluate the physiologic responses and risk of hypoglycemia among children and adolescents with T1D after afternoon exercise during closed-loop control in a controlled in-hospital environment,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
5402,NCT02847091,Percent change from baseline in insulin dose,Safety assessed by biochemistry,,2016-07-29,COMPLETED,INTERVENTIONAL,['PHASE4']
5403,NCT03879642,Hypoglycemia Fear Survey,Child Hemoglobin A1c,,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
5404,NCT06242808,Adherence,Self-efficacy and knowledge around food procurement and healthy eating,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5405,NCT00897390,Metformin PK Parameter Tmax,"Electrocardiogram (ECG), Vital Sign, and Physical Finding Abnormalities",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5406,NCT01211847,Triglyceride-lowering efficacy of DCCR,Improvement in other lipid profiles with DCCR,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5407,NCT01536652,HbA1c (glycosylated haemoglobin),Incidence of hypoglycaemic episodes,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
5408,NCT04404699,Correlation of stimulation TcPO2 parameters with the type of peripheral arterial flow,Correlation of stimulation TcPO2 parameters with macrocirculation parameters,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
5409,NCT06048653,Executive function,,,2022-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5410,NCT01967186,C-peptide derived from the Mixed Meal Tolerance Test (MMTT),,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
5411,NCT02248454,"Predictors of fat ""sensitivity""",,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
5412,NCT03061227,Brain activity,Change in hormone levels,,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
5413,NCT02109835,Greater than 20% increase in plaque volume,Greater than 20% increase in coronary artery calcium score,"Incidence of major adverse cardiovascular events (MACE) during the 18-month follow-up period. MACE is defined as incidence of cardiac death, non-fatal myocardial infarction, STEMI and NSTEMI, unstable angina, late revascularization and onset of angina",2012-09,UNKNOWN,OBSERVATIONAL,['NA']
5414,NCT00551590,To asses the effect of sitagliptin compared to placebo and to coadministration of sitagliptin and the GLP-1 receptor antagonist exendin(9-39)NH2 on the incretin effect after an oral glucose challenge.,"Plasma glucagon, plasma GIP, plasma GLP-1, Insulin, C-peptide, plasma glucose profiles. 13CO2 exhalation kinetics assessing gastric emptying",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5415,NCT03561987,Evaluate the association of the cardiovascular benefit of the obese patient after bariatric surgery with the basic mechanisms of adipose tissue (metabolic profile),Determine the association of the cardiovascular prognosis modification (risk subgroups) with the basal metabolic profile.,,2013-11-06,UNKNOWN,OBSERVATIONAL,['NA']
5416,NCT04083339,Peak VO2 during cardio-pulmonary exercise test (CPET);,Changes in the modified Kansas City Cardiomyopathy Questionnaire (KCCQ) score,Changes in echocardiographic parameters,2019-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5417,NCT00351234,To see if the number of hypoglycemic events decreases with treatment of carnitine on type I diabetic patients. The measurements will be taken after the second 72-hour continuous glucose monitoring.,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
5418,NCT01322321,Measure: Change from baseline of stimulated C-peptide after a mixed meal tolerance test at 13 months,Measure: anti-ACZ885 antibodies,,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5419,NCT05857007,Comparison of CGM with fingerstick blood glucose values in critical care setting.,,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA']
5420,NCT01725412,Microabluminuria,Serum Thiamine Level,Inflammatory Markers,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
5421,NCT06080542,Interstitial glucose,Lactate,PHYSICAL ACTIVITY,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
5422,NCT01518101,Proportion of patients preferring each treatment regimen,Investigator preference and subjective reasons of preference to each treatment,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5423,NCT00223613,Development of clinical type 1 diabetes,Changes in serum metabolite patterns (metabolomics),,1997-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
5424,NCT04899271,Proportion of patients with HbA1c <7% and daily insulin requirement <0.50 IU/Kg/day,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),,2020-12-14,TERMINATED,INTERVENTIONAL,['PHASE2']
5425,NCT03042936,Change From Baseline Hemoglobin A1c,Change From Baseline Shuttle Run Speed,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5426,NCT05336929,HbA1c values,Diabetes Knowledge Level,Roy Adaptation Model Interview results,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
5427,NCT00825643,Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemia,Body weight and its change from trial start,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
5428,NCT04128995,Glycemic Control,Diabetic Kidney Disease,,2019-12-15,RECRUITING,INTERVENTIONAL,['PHASE4']
5429,NCT02133729,Metabolic index value,Prevalence of abnormal glucose tolerance in women with GDM,Adiponectin level,2011-06,COMPLETED,INTERVENTIONAL,['NA']
5430,NCT05974878,Functionality,Anxiety level,,2023-05-18,COMPLETED,INTERVENTIONAL,['NA']
5431,NCT02687256,Time to an infusion set failure due to an occlusion,signs of infection at insulin infusion site,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5432,NCT00906529,Length of Hospitalization Stay,Time to becoming medically stable for discharge,,2009-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5433,NCT05069727,Time in Range( 70-180 mg/dl),Severe Hypoglycemia,Total Daily Insulin,2021-11-21,COMPLETED,INTERVENTIONAL,['NA']
5434,NCT04375449,Glucose-iAUC(0-180min),GLP-1-iAUC(0-120min),,2020-05-04,COMPLETED,INTERVENTIONAL,['NA']
5435,NCT00886366,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables and ECG)","Pharmacodynamic variables (P-Glucose, S-Insulin and C-peptide)",,2009-04,TERMINATED,INTERVENTIONAL,['PHASE1']
5436,NCT01202461,Best-corrected visual acuity,Central subfield macular thickness,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5437,NCT02681887,change in beta-islet cell function,change in TNF-alpha,,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
5438,NCT05115682,Exercise-induced Changes in 24 Hour Interstitial Glucose Concentration,Metabolic Response to Exercise,,2021-11-10,UNKNOWN,INTERVENTIONAL,['NA']
5439,NCT02248272,Serum levels of glucose,Lipidemic profile,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
5440,NCT03083795,Self-reported social support,Weight,,2017-04,UNKNOWN,INTERVENTIONAL,['NA']
5441,NCT03087877,Interference Effect for the G6 CGM,Duration of interference effect for the G6 CGM,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
5442,NCT04129268,Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities,Lowering of serum insulin values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
5443,NCT05232071,Assessment of the effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on absolute change in HbA1c from baseline (Week 0) to Week 24,,,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5444,NCT03371082,Immunogenicity,Efficacy - The number and percentage of subjects who achieve a HbA1c of < 7.0%,,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE3']
5445,NCT06191614,Change in fasting plasma glucose (FPG) after 12 of DEXINEURO® tab administration compared to baseline,,,2022-05-19,COMPLETED,OBSERVATIONAL,['NA']
5446,NCT03502031,Combination Therapy - RAAS inhibition and Spironolactone to lower UP/Cr,Combination Therapy - RAAS inhibition and Spironolactone that develop hyperkalemia,,2018-10-01,RECRUITING,INTERVENTIONAL,['PHASE4']
5447,NCT02730377,Time to Inadequate Glycaemic Control,Change in Pulse,,2016-03-28,COMPLETED,INTERVENTIONAL,['PHASE4']
5448,NCT01855763,Neonatal morbidity,Maternal hypertensive complications,treatment acceptability and cost of drug,2008-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5449,NCT02411682,Postprandial Glucose,Postprandial Free Fatty Acids,,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
5450,NCT01868646,Changes in the Mean Value of HbA1c,Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data,,2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5451,NCT00131846,New onset type 2 diabetes (WHO criteria 1998),Gout (American College of Rheumatology 1997 criteria C),,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5452,NCT00222846,Dietary adherence,Waist circumference,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
5453,NCT01921881,Glucose area under curve (AUC) 0-2 hours,Other metabolic markers,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5454,NCT05161897,"Change in glucose tolerance [Time Frame: baseline, 10 days, 20 days, and 30 days]","Change in dietary intake [Time Frame: baseline, 10 days, 20 days, and 30 days]",,2022-04,UNKNOWN,INTERVENTIONAL,['NA']
5455,NCT05198674,Office Systolic Blood Pressure change at 6 months - Subgroup Diabetes (Type II),Evaluation of slope of eGFR,,2021-10-20,RECRUITING,INTERVENTIONAL,['NA']
5456,NCT01035281,To evaluate the efficacy of nabilone compared to placebo in the treatment of diabetic neuropathy-associated peripheral neuropathic pain (DPN).,To evaluate safety and tolerability of nabilone for the treatment of neuropathic pain in subjects with diabetic peripheral neuropathy.,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5457,NCT00116207,Global [11C]HED Retention Index (RI),Inflammation,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5458,NCT03926598,Participant Task Completion Rate for Usability Testing Session,,,2019-06-05,COMPLETED,OBSERVATIONAL,['NA']
5459,NCT05199077,percentage change,Changes of ECG examination results,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5460,NCT02487680,Area under the curve for Glucose after ingestion of a test meal,Area under the curve for insulin after ingestion of a test meal,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
5461,NCT01158417,NF-Kb,GLP-1,,2008-12,TERMINATED,INTERVENTIONAL,['NA']
5462,NCT02315092,Comparison of number/variety of bacteria obtained by fluorescence-guided sampling vs. standard practice,Assessment of the clinical functionality of the K2 Imaging Device,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
5463,NCT00266695,Sustained Moderate Visual Loss (SMVL),Number of Participants Receiving Treatment With Panretinal Photocoagulation,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5464,NCT05182359,The relation of prescription rates of cardioprotective medications (SGLT2i or GLP1 RA) to CVD-T2D test risk assessment in the Informed group vs. Uninformed group.,"Survey of healthcare providers on the impact of SomaLogic's CVD-T2D calculator on patient care, medication prescription, and risk perception.",The change in prescription rates of cardioprotective medications (SGLT2i or GLP1 RA) after revealing the Metabolic Factors test results at the end of the study in the Informed group.,2022-01-26,COMPLETED,INTERVENTIONAL,['NA']
5465,NCT04363710,Weight in kilogram and height in meters will be combined to report BMI in Kg/m^2,,,2017-05-31,COMPLETED,INTERVENTIONAL,['NA']
5466,NCT01456195,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Meal Tolerance Test (MTT),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5467,NCT04271631,Change from Baseline Hb1A1c at 3 months,Self-Monitoring Blood Glucose,,2019-06-12,UNKNOWN,INTERVENTIONAL,['NA']
5468,NCT02388958,Postpartum weight change measured in kilograms,Change in dietary choices during versus after pregnancy measured with the Personal Diabetes Questionnaire,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
5469,NCT00552903,For patients with diabetes: blood HbA1c at target level (7% or less),"Improvement in body mass index, health-related quality of life (15D instrument), amount of exercise, diet, smoking cessation; for patients with heart failure also use of emergency services and NYHA class",,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
5470,NCT05254496,Changes in HgbA1c,Changes in blood pressure,,2022-04-04,RECRUITING,INTERVENTIONAL,['NA']
5471,NCT03527667,Proportion of CO readings completed,Cigarettes per day,,2018-06-22,COMPLETED,INTERVENTIONAL,['NA']
5472,NCT01039116,2 year change in insulin resistance via HOMA-IR,"Change in dietary intakes of energy, fat, carbohydrate and selected essential nutrients. Change in minutes/day spend in moderate- and high-intensity physical activity. Improvement or stabilization of self-esteem.",,2005-03,COMPLETED,INTERVENTIONAL,['NA']
5473,NCT01351181,SPAQ score,,,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
5474,NCT01714895,Normalized current signal from the CGM devices,,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
5475,NCT03814434,Radiographic Bone height Gain,Periimplant Pocket probing depth,,2018-05-28,UNKNOWN,INTERVENTIONAL,['NA']
5476,NCT03224234,Number of Participants Experiencing Insulclock Device Malfunctions,Change in Diabetes Quality of Life Clinical Trial Questionnaire-Revised (DQLCTQ-R) Score,,2017-11-29,COMPLETED,INTERVENTIONAL,['NA']
5477,NCT01196728,Safety measurements,PK samples for CM3.1-AC100,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5478,NCT03609697,Percent weight change,Carotid artery intima-media thickness (cIMT),,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5479,NCT00449553,Change from baseline in glycosylated hemoglobin.,"Change from baseline in fasting lipoproteins (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein-cholesterol and triglycerides).",,2001-06,COMPLETED,OBSERVATIONAL,['NA']
5480,NCT00001733,,,,1998-03-06,COMPLETED,OBSERVATIONAL,['NA']
5481,NCT03091920,Change From Study Baseline Over Time in Estimated Glomerular Filtration Rate (eGFR),,,2017-02-28,COMPLETED,INTERVENTIONAL,['PHASE2']
5482,NCT04064437,Vertebral fracture detected with VFA,Osteocalcin,Microalbuminuria,2019-07-29,COMPLETED,OBSERVATIONAL,['NA']
5483,NCT03365531,Hepatic Triglyceride by MRS,Diet Tolerability,,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
5484,NCT00133718,Reduction in 10-year absolute CHD risk,Effects on health related quality of life,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5485,NCT02641184,Major adverse cardiovascular events (MACE),New-onset diabetes,,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
5486,NCT05797285,Wound Closure,Change in Quality of Life,Number of Adverse Events Observed,2023-02-28,COMPLETED,INTERVENTIONAL,['NA']
5487,NCT01190904,Composite outcome of all-cause mortality,MACCE,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
5488,NCT00660309,Change From Single Dose Peak to Steady State Peak in Renal Plasma Flow (RPF) After Aliskiren or Irbesartan,Change From Baseline in Retinal Blood Flow After Aliskiren or Irbesartan,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5489,NCT02113163,"AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and Vascepa",,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5490,NCT02420054,Change of insulin secretion,Insulin signalling cascade proteins,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
5491,NCT02282423,Transcription Factor Response to Exercise,,,2014-05,TERMINATED,INTERVENTIONAL,['NA']
5492,NCT05603793,Stunting,Bone age,Household Dietary Diversity Scale (HDDS),2022-09-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5493,NCT01724554,Mean Change in Capillary Non-Perfusion,,,2012-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5494,NCT01377844,Change From Baseline in Hemoglobin A1c at 24 Weeks,Percentage of Subjects Achieving HbA1c <7%,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5495,NCT00714441,"Distress. Patient distress will be assessed across several measures including: the 20-item CES-D, the 17-item DDS, the PHQ8, and screening items from the SCID to rule out psychosis.",Lipids,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
5496,NCT00418522,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population,"Change From Baseline in Diabetes Treatment Satisfaction Questionnaire-Status, Diabetes Treatment Satisfaction Questionnaire-Change, Diabetes-39, Mental Health Inventory-17, and SF-36 Vitality Domain Questionnaire",Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5497,NCT02516358,Change in glycaemic blood levels during ICU stay,Neuron Specific Enolase (NSE) blood levels and glycaemic disorders,,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
5498,NCT00820807,Mean changes in blood HbA1c values from baseline to end of study,"Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]",,2009-01,TERMINATED,INTERVENTIONAL,['NA']
5499,NCT01179672,Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score,Mean Change From Baseline at 12 Week Endpoint in the SDS Total Score,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5500,NCT01613807,Hemoglobin A1C,Birthweight of Infant,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5501,NCT01203774,HbA1c at Three Months of Each Period of Treatment,Compliance and Patient Satisfaction,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5502,NCT04417127,Viral Suppression,Change in glycated hemoglobin (HbA1c),,2020-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5503,NCT02061059,The cost-effectiveness of shoes produced with and without plantar pressure measurements.,Differences in plantar pressures between the two shoes produced.,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
5504,NCT04817514,Supraspinatus tendon thickness measurement,,,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA']
5505,NCT02248311,Subclinical Cardiovascular Diseases,Ischemic events,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
5506,NCT00231725,To collect complaint data on the Pre-filled Pen B when used by persons with type 2 diabetes to self-administer insulin in take-home situations for 2 months.,To assess overall patient perception of the device's performance through a patient questionnaire.,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5507,NCT02309138,Large for Gestational Age (LGA) Infant,Neonatal Composite Morbidity,,2015-08-11,COMPLETED,INTERVENTIONAL,['NA']
5508,NCT02467998,Healing,Side effects and adverse Events During Therapy,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
5509,NCT04101383,AUC(0-t),,,2017-10-16,COMPLETED,INTERVENTIONAL,['NA']
5510,NCT00442767,"Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone","Measure of Glucagon Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone.",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5511,NCT01301456,Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements,Number of Participant With Anti-Drug Antibodies (ADA): Stage 2,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5512,NCT06098625,Change in spot urine protein-creatinine ratio,Changes in HbA1c,,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5513,NCT04410419,Mean difference of preoperative glucose between the two groups,Rate of peri-operative insulin use,,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5514,NCT01153516,Response in Glucagon AUC at Baseline vs. Following Gastric Bypass,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
5515,NCT03845179,C-peptide,Lipids,heart rate,2019-05-29,COMPLETED,INTERVENTIONAL,['NA']
5516,NCT02643277,Comparison of the glycaemic outcome measured as improvement in HbA1c (≤ 7.0% (53mmol/mol)) in the intervention group in comparison with the conventional care.,Adherence to the prescription,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
5517,NCT02292810,Glucose level,Autonomic control,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
5518,NCT03188835,BAT triglyceride content,hormonal responses,,2017-05-23,COMPLETED,INTERVENTIONAL,['NA']
5519,NCT00510952,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),Total Daily Insulin Dose Per Body Weight (Units/Kilograms) at Endpoint,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5520,NCT03189732,Change in adipose tissue lipolysis in response to exercise,Change in lactate production in response to exercise,,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
5521,NCT04006392,Participants With a 30% or Greater Change in Visual Analog Scale (VAS) Pain Scores,,,2019-02-15,TERMINATED,INTERVENTIONAL,['NA']
5522,NCT01389505,Functional Macular Evaluation,Structural Macular Evaluation,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
5523,NCT02458027,Blood Pressure,Energy/Fatigue,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
5524,NCT01843959,"Percentage of the population in the U.A.E that are positive for adenovirus -36, specifically in children.",,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
5525,NCT00911833,,,,2009-05-19,COMPLETED,OBSERVATIONAL,['NA']
5526,NCT02115412,Adherence determinants,Medication usage,Adverse Events,2014-07,COMPLETED,OBSERVATIONAL,['NA']
5527,NCT01755416,"Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone",,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5528,NCT03006081,Improvement of retinal nonperfusion,Factors associated with the progression of retinal nonperfusion 3 (Anatomical),Safety outcome; Adverse effect of intravitreal aflibercept (Eylea) injection,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
5529,NCT00730275,Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin,Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo,,2008-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
5530,NCT00069576,Number of Children at the 5-10 Year Followup With BMI ≥ 95th Percentile for Age and Sex,Number of Children at 5-10 Year Follow-up With Impaired Fasting Glucose ≥100 mg/dL,Mean Gestational Age at Birth,2002-10,COMPLETED,INTERVENTIONAL,['NA']
5531,NCT05854251,Change in insulinogenic index (IGI) concentration following a standardized mixed-meal test,,,2023-06-15,RECRUITING,INTERVENTIONAL,['PHASE2']
5532,NCT03550443,Time to onset of a ≥ 30% decrease in eGFR from baseline or ESRD,Change in eGFR from baseline at each evaluation time point,,2018-05-30,TERMINATED,INTERVENTIONAL,['PHASE3']
5533,NCT01747083,Cmax,AUClast,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5534,NCT06124495,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2023-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
5535,NCT00228904,To evaluate objective testing performed including nerve conduction velocity in diabetic patients treated with pulsatile intravenous insulin therapy,"To obtain patient questionnaires and perform objective testing to analyze, compare and measure progress",,2005-02,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5536,NCT03034759,overall time in target (70-180mg/dl),corrective bolus after meal during intervention phase,,2019-10-01,WITHDRAWN,INTERVENTIONAL,['NA']
5537,NCT02662010,Change in Advanced Glycation Endproducts (AGE) Levels,Change in HbA1C Levels,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
5538,NCT04132128,HbA1c,HbA1C for measuring glucose control,,2015-11-25,COMPLETED,INTERVENTIONAL,['NA']
5539,NCT01581476,Albumin creatinine ratio,Quality of Life and Health Economics,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5540,NCT01499511,Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack),Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
5541,NCT01479075,Insulin sensitivity,Energy metabolism,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5542,NCT03009864,changes of albumin-to-creatinine ration,the rate of doubling the baseline with serum creatinine value,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
5543,NCT01038050,"Number of endothelial progenitor cells, endothelial function(FMD)",,,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
5544,NCT03258723,Change in Hemoglobin A1c (HbA1c),Change in Sugar-sweetened Beverage Intake (Teaspoons Per Day),,2018-07-30,TERMINATED,INTERVENTIONAL,['PHASE4']
5545,NCT01066715,Mean change from baseline (Day 0 pre-dose) in HbA1c at Day 182,Serum levels of XOMA 052 (select sites only),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5546,NCT05483816,Changes in brain activity and connectivity through functional Magnetic Resonance Imaging (fMRI) between somatotopic and non somatotopic stimulation at feet,changes in speed and cadence in the 10 meter and 6 min walk test,Changes in reflex,2022-06-30,RECRUITING,INTERVENTIONAL,['NA']
5547,NCT01043354,medication adherence,exercise adherence,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
5548,NCT01596504,Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours,Change From Baseline to Day 56 in the Cumulative Score Mean on the Appetite Perception Using a Visual Analogue Scale After Standardized Solid Breakfast,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5549,NCT00549887,"The estimation of the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and a short-acting human insulin therapy within the first year following the switch.","The estimation of the total costs (direct and indirect) associated with switching, in either direction, between rapid-acting analog and short-acting human insulin within the first year following the switch",,2007-09,COMPLETED,OBSERVATIONAL,['NA']
5550,NCT01711385,Occurrence of follow-up visit to physician regarding screening result,Improved periodontal measures,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
5551,NCT00035750,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
5552,NCT06159192,• Numerical Rating Pain Scale,,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
5553,NCT01023113,"Comparison of the two methods in relation to visual field loss in terms of MD,CPSD and each quadrants loss of fields",Effect on macular edema in terms of OCT thickness,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
5554,NCT02070835,healing rate,recurrent rate,complication rate,2014-04,COMPLETED,INTERVENTIONAL,['NA']
5555,NCT01520753,Fasting serum glucose,Incidence of adverse events,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5556,NCT00385671,"Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Pregabalin Compared With Duloxetine",Number of Patients With Treatment-Emergent Elevated Laboratory Analytes,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5557,NCT00135941,"To compare improvements from baseline in patient reported outcomes (quality of life, treatment satisfaction) when aggressively treated with insulin glargine plus rapid acting insulin glulisine vs treatment with Premix insulin","change in A1c (baseline to week 24), reported hypo events (throughout the trials), correlation between patient reported outcomes and glucose variability as measured by CGMS (baseline, week 8 and week 20).",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5558,NCT04817215,Mean change from baseline (Visit 1) in A1C at 26 weeks,Safety of repeat administration of ORMD-0801 in inadequately controlled T2DM subjects,Means and mean changes from baseline over time for C-peptide,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
5559,NCT05195333,World Health Organization Quality of life Short Form for measurement of quality of life,Body mass index (BMI) measurement,,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
5560,NCT01122446,Adverse Events,First-phase Insulin Response From IvGTT Over Time,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5561,NCT05786703,CHANGE IN BLOOD PRESSURE LEVEL,,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
5562,NCT01501201,overall mortality,"cost, cost-effectiveness and cost utility",,2011-08-08,RECRUITING,INTERVENTIONAL,['PHASE4']
5563,NCT02310932,cholesterol,medication adherence,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
5564,NCT06033508,inflammatory markers,,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5565,NCT02503943,"Lipid profile (triglyceride, total cholesterol, LDL-c; HDL-c; mmol/L) change","Insulin resistance assessed by fasting serum insulin and HOMA-IR, and control rate of diabetes.",,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
5566,NCT06111183,Incidence of Wound Closure,Incidence of target ulcer related hospital visits,,2023-07-21,RECRUITING,INTERVENTIONAL,['PHASE2']
5567,NCT00417950,Postprandial hyperglycemia,Postprandial oxidative stress,,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
5568,NCT01793350,Efficacy of BC-DN-01,Safety of BC-DN-01,,2013-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5569,NCT04295889,Cost-effectiveness of the screening.,Usability scores of the two screening methods.,Role of health literacy in albuminuria screening.,2019-11-14,UNKNOWN,INTERVENTIONAL,['NA']
5570,NCT05331339,HbA1c,Mean fasting glucose,,2022-11-02,COMPLETED,OBSERVATIONAL,['NA']
5571,NCT03349944,HbA1c,Oral glucose tolerance test,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
5572,NCT03374774,Proportion of patients who are using BIAsp 30 as their primary insulin,Diabetes Pen Experience Measure (DPEM) Scores (frequency of each item),,2017-11-13,COMPLETED,OBSERVATIONAL,['NA']
5573,NCT00821665,Hyperglycemia,Hyperglycemia,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
5574,NCT01303315,Decrees in HbA1c of at least 0.5 points and Weight loss of at least 3% of total body weight after 6 month of treatment,Glycemic and metabolic parameters,,2011-01,TERMINATED,INTERVENTIONAL,['NA']
5575,NCT00967642,"Reintervention, Myocardial Infarction, Cardiovascular Death",,,2006-08,TERMINATED,INTERVENTIONAL,['NA']
5576,NCT02650596,left ventricular ejection fraction measured by 3D echocardiography,differences in the incidences of treatment-emergent adverse events,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
5577,NCT02762695,Systolic and Diastolic Blood Pressure,Medication adherence,,2016-05-04,UNKNOWN,INTERVENTIONAL,['NA']
5578,NCT01977859,Difference in level of B-type Natriuretic Peptide (BNP),Difference in responses of lean and obese subjects,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5579,NCT01533142,weight loss,remission of diabetes mellitus type 2,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
5580,NCT02343354,Change in post 75 gram glucose load 2-hour glucose value in mothers and fathers,Change in diastolic blood pressure in mothers and fathers,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
5581,NCT03972215,Differences of serum C-peptide levels between BBR and placebo treatment groups during the 2-hour hyperglycemic clamp study.,Differences of blood glucose levels between BBR and placebo treatment groups during the 2-hour hyperglycemic clamp study.,Heart rate and QT-interval duration using electrocardiogram before and after drug treatment.,2019-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5582,NCT02655627,HbA1c,Euro Quality of Life-5 Dimension,cholesterol levels,2015-04,COMPLETED,INTERVENTIONAL,['NA']
5583,NCT01643382,Incidence of Poor Graft Function After Kidney Transplant,,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
5584,NCT03238963,Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period,Percentage of Participants With Adverse Events Other Than Ocular Adverse Events Over On-treatment Period,,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
5585,NCT01891474,Glucose Variability assessed by 3 day SMBG,Michigan Diabetes Knowledge Test,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
5586,NCT04277780,# od hospital re-admissions,Severity of first hypoglycemic event,,2018-10-31,TERMINATED,INTERVENTIONAL,['NA']
5587,NCT00576667,Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS),Change from baseline in hepatic transaminases (AST/ALT),,2008-01,TERMINATED,INTERVENTIONAL,['PHASE3']
5588,NCT04474535,Macrovascular complications,Association between c-peptide and complications,,2020-03-03,UNKNOWN,OBSERVATIONAL,['NA']
5589,NCT01868594,Changes in the Mean Value of HbA1c,Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data,,2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5590,NCT01339637,Validation of the SCOUT DS algorithm comparing it to Oral Glucose Tolerance Test in dark skinned individuals,Compare SCOUT DS and FPG to HbA1c,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
5591,NCT01710527,Apparent First-order Elimination or Terminal Rate Constant,Assessment of Subject Well-being Questionnaire,,2012-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5592,NCT04199676,Accuracy of immediate glucose tolerance testing,Transition to primary care,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
5593,NCT00316667,,,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
5594,NCT01638260,Change in weight from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks),Health-care related costs,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE4']
5595,NCT02849899,Diabetes event,The cost-effectiveness ratio,,2018-10-26,RECRUITING,INTERVENTIONAL,['PHASE3']
5596,NCT03313856,Modification in HbA1c in patients with type 2 diabetes after of administration of combination with Guazuma ulmifolia and Tecoma stans,"Renal safety of administration of guazuma, tecoma through the determination of serum creatinine",,2010-01-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5597,NCT01496820,Postprandial blood glucose(PPG),HDL-cholesterol,,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5598,NCT01142895,,,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
5599,NCT05492071,Brachial Artery Mean Flow Velocity,,Magnitude of Maximum Mean Flow Velocity Change,2022-08-08,COMPLETED,INTERVENTIONAL,['NA']
5600,NCT06191094,Rates of post-operative vitreous hemorrhage,Number of patients with intra-operative bleeding,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5601,NCT01824017,The consistency of an ELISA-based RLIP76 assay in the serum of human subjects with metabolic syndrome.,"Effect size of correlation of RLIP76 levels with treatment measures of metabolic syndrome such as hemoglobin A1c, LDL, and triglyceride levels.",,2012-12,COMPLETED,INTERVENTIONAL,['NA']
5602,NCT00999375,"Change in glycemic control, change in dietary intake","Change in social cognitive mediators of behavior; change in psychosocial status; change in body composition, lipids, oxidative stress, and inflammation",,2009-09-18,COMPLETED,INTERVENTIONAL,['PHASE2']
5603,NCT02206607,Change From Reference in Weighted-Mean-Daily-Glucose (WMDG) on Day 1,Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5604,NCT06037486,Analysis of system accuracy based on DIN EN ISO 15197,,,2022-10-17,COMPLETED,INTERVENTIONAL,['NA']
5605,NCT05392231,Early prediction of gestational diabetes,,,2022-02-10,COMPLETED,OBSERVATIONAL,['NA']
5606,NCT00804596,Percentage of Participants Rated as <=3 (Comprehension of Labeling),Number of Capillary Blood Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
5607,NCT05851820,overall length of hospital stay,,,2020-09-25,COMPLETED,OBSERVATIONAL,['NA']
5608,NCT02312063,Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction,Correlation of Estimated Seafood Intake With HbA1c Reduction,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5609,NCT02714660,Mean Score on Burden of Treatment Questionnaire,,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
5610,NCT01456806,HbA1c,Quality of Care Indicators,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
5611,NCT05230615,Change in HbA1c (Glycated haemoglobin),"DTSQs (Diabetes Treatment Satisfaction Questionnaire, status), change in absolute treatment satisfaction From baseline (week 0) to",,2021-11-21,COMPLETED,OBSERVATIONAL,['NA']
5612,NCT04267770,Change in Basal Insulin Rate,,,2018-04-10,COMPLETED,INTERVENTIONAL,['NA']
5613,NCT05565924,The functional balance,Fasting blood glucose level,,2022-01-02,COMPLETED,INTERVENTIONAL,['NA']
5614,NCT01353391,"A composite of: pregnancy loss, preterm birth, birth injury, moderate/severe respiratory distress, neonatal hypoglycemia, and NICU admission > 24 hours.",Shoulder dystocia,,2011-05-25,COMPLETED,INTERVENTIONAL,['PHASE3']
5615,NCT03123237,Renal Counts,,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
5616,NCT00767208,Apparition of exogenous glucose in plasma in the postprandial phase and its effect on carbohydrate and lipid metabolism,Carbohydrate and lipid oxidation,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
5617,NCT02204839,24 hour blood glucose area under the curve,Ketonaemia,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
5618,NCT01342484,Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment,Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5619,NCT04124484,HBA1c,body weight,,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE2']
5620,NCT04631913,Beta-cell function,,,2020-08-14,UNKNOWN,OBSERVATIONAL,['NA']
5621,NCT02631512,Performance of Woulgan Gel as primary dressing in diabetic foot ulcer in terms of reduced wound size in sqcm.,Useability of Woulgan as primary dressing in diabetic foot ulcer measured as degree of pain (100 mm VAS).,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5622,NCT02979860,Insulin Resistance,Metabolic Measures,Acceptability/Feasibility,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
5623,NCT00497003,Endothelial function and insulin stimulated endothelial function,Insulin stimulated glucose uptake,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5624,NCT06297850,Agreement between glucose,Agreement between glucose readings when at high glucose levels,Mortality,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5625,NCT03864432,Cmax of Gemigliptin,,,2019-07-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5626,NCT03359590,The Frequency of Hypoglycaemic Episodes With Sitagliptin vs Placebo Treatment.,,,2018-03-21,COMPLETED,INTERVENTIONAL,['PHASE2']
5627,NCT01038089,Brachial artery flow-mediated dilation,"Blood markers of inflammation, oxidative stress, insulin resistance",,2010-01,COMPLETED,INTERVENTIONAL,['NA']
5628,NCT03145649,Infant head circumference at day 90,,,2010-01-12,COMPLETED,OBSERVATIONAL,['NA']
5629,NCT03215043,Glucose,alanine aminotransferase,visceral fat area,2017-07-02,COMPLETED,INTERVENTIONAL,['NA']
5630,NCT04114903,Change in Plasma Insulin,Stanford Leisure-Time Activity Categorical Item (L-Cat),"Daily online survey of cannabis use, alcohol use, exercise and diet",2019-11-08,RECRUITING,OBSERVATIONAL,['NA']
5631,NCT04161170,Change of HbA1c (glycated hemoglobin) at 6months from baseline,time in range of >250 mg/dL by CGMS in interventional group C,,2019-11-20,UNKNOWN,INTERVENTIONAL,['NA']
5632,NCT05542537,Household Food Insecurity as assessed by the U.S. Department of Agriculture self-report food insecurity measure,Skin carotenoid level as assessed by The Veggie Meter,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5633,NCT04626089,Viral Load,Incidence of adverse event,,2021-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5634,NCT03870724,Type 2 diabetes,,,2019-08-27,COMPLETED,OBSERVATIONAL,['NA']
5635,NCT01105429,"Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments",Excretion of the investigational drug and metabolites from the body,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5636,NCT02645448,Concentration of glucose and hyperglycemia prevalence,Correlation between heart rate variability and glucose 24 hours,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
5637,NCT03782155,Wound healing:Number of cells per clauster in tissue sample of wound.,,Incidence of treatment- adverse events,2021-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
5638,NCT03890822,Minimal lumen area,Change in minimal lumen area,,2019-03-25,UNKNOWN,OBSERVATIONAL,['NA']
5639,NCT00205725,Effects of olanzapine/ziprasidone/haloperidol on glucose regulation,Explore treatment-related effects on glucose effectiveness,,2000-11,COMPLETED,INTERVENTIONAL,['NA']
5640,NCT00783744,Frequency of subjects with HbA1c ≤ 7.0 % and > 7.0 %,"Frequency of subjects with FBG ≤ 100 mg/dl (5.5 mmol/l), 100 mg/dl < FBG ≤ 120 mg/dl (5.5 mmol/l < FBG ≤ 6.6 mmol/l), 120 mg/dl < FBG ≤ 150 mg/dl (6.6 mmol/l < FBG ≤ 8.3 mmol/l) and > 150 mg/dl (> 8.3 mmol/l)",,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3']
5641,NCT02426294,Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 26 from baseline,Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 12 from baseline,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
5642,NCT01788241,Patient Perceived Health Status,Biochemical correlates,,2009-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5643,NCT00788853,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",,2008-11,COMPLETED,OBSERVATIONAL,['NA']
5644,NCT04585776,Percentage of Time With Sensor Glucose Values Between 70 and 180 Milligrams Per Deciliter (mg/dL) With Continuous Glucose Monitoring (CGM),Product of Insulin to Carbohydrate Ratio and Total Daily Dose (ICR×TDD),,2020-10-30,COMPLETED,INTERVENTIONAL,['PHASE2']
5645,NCT02211261,Number of Participants With Positive Anti-drug Antibody (ADA) Result,"Observed Accumulation Ratio Based on Cmax (Rac,Cmax) of PF-06293620 (MAD Cohorts)",,2014-09-15,COMPLETED,INTERVENTIONAL,['PHASE1']
5646,NCT05377268,Assessment of lipohypertrophy by US machine,,,2023-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5647,NCT00145392,,,,2002-09,COMPLETED,OBSERVATIONAL,['NA']
5648,NCT01649466,Rate of confirmed hypoglycemic events,Change from baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) at 24 week,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5649,NCT04156685,Part B : AUClast under fed condition,Part B : t1/2 under fed condition,,2019-08-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5650,NCT06258148,Changes in glycosylated hemoglobin (HbA1c) from baseline at 24 weeks of treatment,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb),,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
5651,NCT04955691,Time in the optimal glucose range,Time spent with hyperglycemia,Human Factors,2021-07-29,RECRUITING,INTERVENTIONAL,['NA']
5652,NCT01967030,Incident Type 2 Diabetes,Maternal waist circumference,Metabolite profiles,2008-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5653,NCT02326259,Progression of diabetic retinopathy,,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
5654,NCT03474393,Change in HbA1c,DTSQ,,2018-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5655,NCT03237767,Glycaemic control (measured using arm-mounted Freestyle Libre continuous glucose monitor),Physical activity,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
5656,NCT04170790,Heart Rate,,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA']
5657,NCT05880654,Effect of SRP on GCF levels of IL-39 & IL35,,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
5658,NCT00005487,CVD,,,1999-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5659,NCT04631965,Emergency admissions,Change in employment status,Adolescent-friendliness of healthcare services in pediatric and adult hospitals,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
5660,NCT04973644,HbA1c concentration,Diabetes Treatment Satisfaction Questionnaire,,2021-08-21,UNKNOWN,INTERVENTIONAL,['NA']
5661,NCT05099770,Primary Composite Endpoint,Secondary Composite Endpoint,,2022-01-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5662,NCT01515930,Diabetes Management Scale,Blood Glucose Testing Frequency,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
5663,NCT01969357,the change from baseline in HbA1c at 12 week,"Change From Baseline in Body Weight at Week 4,8,12",,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5664,NCT01055652,To evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessment of AUC and Cmax of dapagliflozin,"To evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessmentof AUC0-t, tmax, t1/2, CL/F.",,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5665,NCT04272840,Transfer/KM Level 3: Change in average dietary GI,"Maternal Weight, during pregnancy",,2019-10-24,UNKNOWN,INTERVENTIONAL,['NA']
5666,NCT03014479,Change From Baseline in Total Score for All Question Items in the Diabetes Therapy Related -QOL (DTR-QOL) Questionnaire at the End of Study,Number of Participants With Hospitalization for Type 2 Diabetes (Excluding Educational Hospitalization Without Worsening of Diabetes),,2017-02-18,COMPLETED,INTERVENTIONAL,['PHASE4']
5667,NCT01401790,Patients' health (reported number of hypoglycemias and nocturnal hypoglycemias),Family satisfaction with the software application,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
5668,NCT05590442,The rate of mild cognitive impairment occurrence,Montreal Cognitive Assessment (MoCA) score,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
5669,NCT04829045,Homeostasis model assessment- insulin resistance (HOMA-IR),Incident of treatment adverse events in terms of intensity (grades 1 - 5),,2021-05-27,COMPLETED,INTERVENTIONAL,['NA']
5670,NCT02957513,Diabetes Self-Care Activities,Average Blood Sugar (A1c),,2016-11-01,UNKNOWN,INTERVENTIONAL,['NA']
5671,NCT05516797,Difference in change in 14-day CGM-derived TIR,Difference in Change in HbA1c,"Difference in change in the CGM-derived metric, Mean amplitude of glucose excursion, from Baseline to 3-month Post-Dietary Change period",2022-09-22,COMPLETED,INTERVENTIONAL,['NA']
5672,NCT02971865,Consumer Assessment of Healthcare Providers and Systems (CAHPS),Patient Health Questionnaire-9 (PHQ-9,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
5673,NCT06260254,Matsuda insulin sensitivity index in the morning after exposure to high vibration,Evening neurobehavioural accuracy,,2024-02-05,RECRUITING,INTERVENTIONAL,['NA']
5674,NCT00926744,Objectively measured amount of physical activity,Incidence of musculoskeletal and joint pain,,2006-04,UNKNOWN,INTERVENTIONAL,['NA']
5675,NCT01002768,Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration,Hypoglycaemic symptoms score during recovery from hypoglycaemia,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5676,NCT00597233,Prandial blood glucose lowering profile,Serious adverse events,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5677,NCT03727035,Expression of CD163 gene,Quantify the levels of CD163,,2018-02-10,UNKNOWN,OBSERVATIONAL,['NA']
5678,NCT00843479,Distinctive Beta-cell Function From the Arginine Stimulation Test in Normoglycemic Subjects After Sixty-five Years Old in Comparison With Middle-age Normoglycemic Subjects.,GLP-1 Area Under the Curve (AUC),,2009-06,COMPLETED,OBSERVATIONAL,['NA']
5679,NCT04344301,Acceptability of Intervention Measure (AIM),,Stigma Scale for Chronic Illness (SSCI-8),2020-08-31,COMPLETED,INTERVENTIONAL,['NA']
5680,NCT01023698,Stabilization of proliferative diabetic retinopathy,,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
5681,NCT04091854,C peptide,8-iso PGF2α,,2018-12-12,UNKNOWN,OBSERVATIONAL,['NA']
5682,NCT02467972,Change in satiety,Change in biochemical parameters,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
5683,NCT03318913,High performance liquid chromatography,,,2017-10-23,COMPLETED,INTERVENTIONAL,['NA']
5684,NCT03468894,Change in Workplace sitting time,Change in perceived vigor,,2018-03-22,WITHDRAWN,INTERVENTIONAL,['NA']
5685,NCT04485871,Fasting white adipose tissue NLRP3 inflammasome activation,Physical activity,,2019-12-19,RECRUITING,INTERVENTIONAL,['NA']
5686,NCT05863884,Blood Glucose Level,Diabetes Self-Management Score,COVID-19 Vaccination Confidence and Uptake,2022-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5687,NCT00110864,Effect on change in average daily insulin dose,Effect on lipid levels,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5688,NCT01561508,change in stimulated c-peptide,change in total daily insulin dose per kilogram,,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5689,NCT03027726,microRNA expression in circulating exosomes and in blood peripheral mononuclear cells,Inflammation and biochemical cardiovascular disease risk factors,Confounding variable: Socio-demographic variables:,2017-03-07,COMPLETED,INTERVENTIONAL,['NA']
5690,NCT04257565,Wound Healing,Physical Function,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
5691,NCT05663931,Mean glucose levels,Infection,,2023-01-10,RECRUITING,INTERVENTIONAL,['NA']
5692,NCT05329415,Rifampicin/Isoniazid/Pyrazinamide Cmax 2 hours post-dose,Mean daily subcutaneous glucose measurement,,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5693,NCT00822198,intraepidermal nerve fiber density in ankle and thigh,clinical assessment of peripheral neuropathy,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
5694,NCT02001532,Agatston Score (CT),,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
5695,NCT02081599,Change From Baseline in HbA1c,Change From Baseline in 2-hour Postprandial Plasma Glucose,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5696,NCT03298542,Number of Participants With Treatment Related AEs and SAEs Reported From Week 52 to Week 78,Incidence of Antibodies to Golimumab,,2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
5697,NCT02903615,Glucose control,Follow-up of glycemic control and insulin secretion,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
5698,NCT05662930,Heart Rate,Health related Quality of life,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
5699,NCT04919954,Tebipenem Pivoxil Hydrobromide Tissue Penetration,Tebipenem Pivoxil Hydrobromide Area Under the Curve (AUC) in Tissue,,2021-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5700,NCT05120388,number of participants with insulin requirement,number of participants with diabetes at postpartum,,2022-01-11,RECRUITING,INTERVENTIONAL,['NA']
5701,NCT04212325,patient satisfaction: survey,,,2019-12-10,COMPLETED,INTERVENTIONAL,['NA']
5702,NCT05163054,Incidence of hypoglycemia,Life quality.,,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5703,NCT06252051,Immunogenicity,Inflammatory interleukin measurements,,2021-01-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5704,NCT02295085,Incident cancer during the period of cohort follow-up,Incident renal disease during the period of cohort follow-up,Other incident conditions during the period of cohort followup,1990-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5705,NCT03867773,Change from baseline to week 8 in body weight,"Change from baseline to week 8 in sex steroid levels (estrogen, androgens, sex hormone binding globulin)",,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
5706,NCT00108901,Cognition (Executive function),Academic achievement,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5707,NCT00468364,,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
5708,NCT04653220,Change in postprandial blood glucose over 240 minutes period,Change in postprandial plasma active GLP-1 over 240 minutes period,,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
5709,NCT01248481,Change in HbA1c,Postprandial Blood Glucose,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
5710,NCT01095965,HbA1c as a measure of glycemic control,Body mass index,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
5711,NCT00995540,Injection tolerability,C-peptide,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2']
5712,NCT02982798,Cmax of Metformin and rosuvastatin,,,2017-07-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5713,NCT00455598,Change and % change from baseline Adiponectin,concomitant medications,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5714,NCT01714102,Reduction in Insulin resistance,Changes in gene expression in stool,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
5715,NCT00971516,Healing profile of cytokines,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5716,NCT00018616,,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5717,NCT03550105,Glycemic Control,Carry Over Effect of Muscle Endurance,,2018-06-05,COMPLETED,INTERVENTIONAL,['NA']
5718,NCT03037970,Successful wound healing for at least two consecutive measurements. (Efficacy),Complication rate,,2017-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
5719,NCT02104804,Change in HbA1c From Baseline to Week 24,Analysis of Change in Mean Total Daily Dose of Insulin From Baseline to Week 24,,2014-05-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5720,NCT03708380,Continuation with the dietary intervention after initial period when study participants may choose to pay for meals developed on their own,Fourth Point-of-Care HbA1c Test,,2019-03-25,TERMINATED,INTERVENTIONAL,['NA']
5721,NCT04506151,Glycemic control,Mood,,2021-01-19,RECRUITING,INTERVENTIONAL,['NA']
5722,NCT04424537,Change in fasting blood glucose level,Change in Muscle function as measured by relative power of jump,,2024-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
5723,NCT01517321,"Incidences of adverse experiences and change in vital sign, safety lab etc. as parameters of safety and tolerability",Fasting plasma glucose,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
5724,NCT03343782,Adverse events,Hemoglobin A1c (HbA1c) level,,2017-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5725,NCT02200666,Adverse event incidence,,,2014-10-03,COMPLETED,OBSERVATIONAL,['NA']
5726,NCT02403427,postprandial glucose,Glucose variability parameters,Patients' acceptances to use VoiceDiab system,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
5727,NCT01215955,Change From Baseline to 24 Week Endpoint in Glycated Hemoglobin (HbA1c),Percentage of Participants With Severe Hypoglycemic Episodes,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
5728,NCT00684086,self-efficacy to manage diabetes,communication with physicians,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
5729,NCT05721599,Change from baseline calf circumference,,,2023-04-13,RECRUITING,INTERVENTIONAL,['NA']
5730,NCT00461331,Number of Participants With Glycemic Control (Glucose Levels Between 180-300 mg/dL) 24 to 100 Hours After Line Change,"Oxidative Stress Marker 48, 72 and 96 Hours After Keeping the Same Pump Infusion Line in Place",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5731,NCT05442918,Venous blood gas levels,,,2020-01-15,COMPLETED,OBSERVATIONAL,['NA']
5732,NCT00801892,"Physical Activity, Steps Walked",Fatigue/Inertia,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5733,NCT01477112,Changes in oxidative status,Serum and erythrocyte folates.,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
5734,NCT04709887,Healing rate of wound surface,Recurrence rate of foot ulcer,,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
5735,NCT05074667,Proportion of Participants with sustained CGM use,Mean change in BMI from baseline,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
5736,NCT00638716,Reduction of HbA1c From Baseline,Reduction in Fasting Body Weight From Baseline,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5737,NCT02586155,Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE,Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR <60 mL/Min/1.7m2),,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5738,NCT03969719,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 16,Change From Baseline in HbA1c at All Timepoints Other Than Week 16,,2019-07-18,COMPLETED,INTERVENTIONAL,['PHASE2']
5739,NCT05041244,Wound closure,Adverse events,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
5740,NCT00128336,Weight,Change in mood state,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5741,NCT03622957,Glomerular Filtration Rate [ml/min/1.73m2],CV Events (Yes/No),,2018-08-10,UNKNOWN,OBSERVATIONAL,['NA']
5742,NCT01089556,Change From Week 8 to Week 16 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form,Number of Participants Who Discontinued From Study Between Week 8 and Week 16 Endpoint,Number of Participants Who Discontinued From Study Between Baseline and Week 8 Endpoint,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5743,NCT01351675,Time-to-first event of the composite endpoint,"Frequency, intensity, and relationship to study drug of adverse events and serious adverse events, as well as clinical and laboratory test abnormalities.",,2011-06-30,TERMINATED,INTERVENTIONAL,['PHASE3']
5744,NCT05039034,Prevalence rate of dyslipidemia,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
5745,NCT02827266,Percentage of Participants With Hemoglobin Greater Than (>) 11 Grams per Deciliter (g/dL) After 8-Week Correction Phase,Number of Participants per Type of Diabetes,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5746,NCT01077323,"Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During ""Past Use"" Period) - Time on Drug Analysis","Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis Among Initiators of Exenatide, Diabetics Initiating Other Antidiabetic Drugs, and the Non-diabetes Cohort - Intent to Treat Analysis",,2004-09,COMPLETED,OBSERVATIONAL,['NA']
5747,NCT00551356,Change from baseline to endpoint in 2h postprandial blood glucose excursion after breakfast,Total Insulin Doses,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5748,NCT00351884,Change from baseline in HbA1c at 24 weeks,Change from baseline in body weight at 24 weeks,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5749,NCT05354297,Changes in A1c from screening to 3 and 6 months in each of the OneTouch Solutions programs,Change from baseline in medication adherence as assessed by a medication adherence survey after 3 and 6 months,Quantify the number of medical insurance claims made by subjects within each of the OneTouch Solutions programs using data harvested from a large medical insurance dataset,2022-07-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5750,NCT02384941,Change From Baseline in A1C at Week 24,Percent Change From Baseline in Body Weight at Week 24,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5751,NCT01254552,Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes Mellitus,Number of Patients With and Without Occult Myocardial Scar on Cardiac MRI According to the Degree of Stenosis,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5752,NCT00418366,Determination of the pharmacokinetics of MK0431 (sitagliptin phosphate) in patients with renal insufficiency compared to healthy volunteers,Safety and tolerability in patients with renal insufficiency,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5753,NCT01931280,Change in glycosylated hemoglobin,Change in weight after pregnancy,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
5754,NCT02898506,FPIR (1+3min serum insulin level after iv glucose infusion),Serum C-peptide AUC,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5755,NCT05686694,State Anxiety Scale,,,2023-11-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
5756,NCT00461617,Hemoglobin A1C (HbA1C),One-hour postprandial glucose level (PPG1),,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5757,NCT00382096,Change from baseline in HbA1c,Change from baseline in body weight,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5758,NCT00913562,Flicker induced vasodilatation,,,2009-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5759,NCT05998460,GGE adherence,Changes in the soluble receptor for advanced glycation end-products (sRAGE),,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5760,NCT00854594,Provider Abilities Scale - Subscale From the Midwest (MW) Clinicians' Network,Attitudes Toward Healthcare Teams Scale and Subscales,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5761,NCT06185491,Coefficient of variation of individual HGI distribution,"Glycation gap, determined from comparison between HbA1C measured and HbA1C derived from glycated albumin",,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5762,NCT03332771,Change From Baseline in Hemoglobin A1c at Week 52,Percentage of Participants With Adverse Events (AEs),Percentage of Participants With Hypoglycemic Events,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5763,NCT04927871,Change of weight in kilograms,Percentage of Completion of the program.,,2020-11-16,COMPLETED,INTERVENTIONAL,['NA']
5764,NCT04873050,Regression to normoglycemia,Change in body weight,,2022-01-13,RECRUITING,INTERVENTIONAL,['PHASE4']
5765,NCT00326573,"HbA1C at 6 months, end of intervention and one year follow up",quality of life at baseline and end of one year intervention,,2001-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5766,NCT03980808,Frequency of Engagement in Diabetes-Related Health Behaviors,,,2020-10-29,COMPLETED,INTERVENTIONAL,['NA']
5767,NCT00572650,Pharmacokinetic measures,Safety and tolerability measures,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5768,NCT04702490,Safety and tolerability of MET409 with or without empagliflozin (incidence of adverse events),Pharmacodynamic profile of MET409 alone or in combination with empagliflozin,,2020-12-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
5769,NCT05692518,Creation of a patent anastomosis,,,2022-12-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5770,NCT00501657,Gastric emptying rate,"Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5771,NCT00004364,,,,1995-12,UNKNOWN,OBSERVATIONAL,['NA']
5772,NCT00309192,Macular edema reduction or stabilization 6 months after treatment.,Tolerance of the treatment.,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5773,NCT05531877,No undersizing,Adequate Girth,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
5774,NCT00303394,HbA1c,Insulin signaling- and cytokine- gene expression profiles derived from muscle and fat biopsy samples.,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5775,NCT01297738,Cerebral binding of [123I]FP-CIT to serotonin- and dopamine transporters and correlation with changes in in vivo and ex vivo insulin sensitivity,Insulin signalling pathways,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
5776,NCT00869128,Sleep Efficiency,,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5777,NCT00434850,Proportion of Insulin-independent Subjects,"Acute Insulin Response to Glucose, Insulin Sensitivity, and Disposition Index (DI)",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5778,NCT05709938,Mid night blood glucose level,,,2019-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5779,NCT02287532,"Efficacy data: change in HbA1c, measured at 1 year minus the value baseline",,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
5780,NCT00815399,Circulating Endothelial microparticles,"Glucose profile, lipid profile, hemoglobin A1c, carotid intima-media thickness",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5781,NCT02205996,To examine the effect of hypoglycaemia on platelet surface expression of platelet activation markers P-selectin and fibrinogen binding.,To measure changes in markers of inflammation (high sensitivity C-reactive protein) and endothelial function using EndoPat 2000,To assess the effects of hypoglycaemia on participants scores on cognitive function tests,2011-11,COMPLETED,INTERVENTIONAL,['NA']
5782,NCT04733612,Change from Baseline Quality of Life Assessed by SF-36v2 at 6 months,Change from Baseline Energy Intake at 6 months,,2016-06-30,COMPLETED,INTERVENTIONAL,['NA']
5783,NCT05896319,Change in residual socket volume,Change in pain assessment,,2022-09-07,COMPLETED,INTERVENTIONAL,['NA']
5784,NCT06042517,Glucose metabolic clearance rate,High blood glucose index (HBGI),,2023-09-30,RECRUITING,INTERVENTIONAL,['NA']
5785,NCT02557620,Area under the semaglutide concentration-time curves,Area under the the single dose concentration-time curve,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5786,NCT03093636,% Time Within Target Range,,,2017-04-17,COMPLETED,INTERVENTIONAL,['NA']
5787,NCT02218619,C-peptide measurement as reflection of insulin secretion,liver function tests,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
5788,NCT01159249,"Measure AEs, vital signs, laboratory evaluations",HOMA-B,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5789,NCT02009670,"Fat oxidation, energy expenditure",Breath sampling 13CO2,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
5790,NCT01248143,Assess the effects of green tea and FPP on the levels of C-reactive proteins,Assess the effect of green tea and fermented papaya preparation on development of atheroma and drug therapy outcomes,,2010-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5791,NCT05717387,Change in percent of time in range (glucose between 3.9-7.8mmol/L) over 6 months measured with continuous glucose monitoring.,Change in quality of life,,2023-04-11,RECRUITING,INTERVENTIONAL,['NA']
5792,NCT05169034,System Performance,,,2021-12-14,TERMINATED,OBSERVATIONAL,['NA']
5793,NCT03282981,Measurement of timolol serum during the treatment phase,The time to wound closure between the two groups,,2018-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5794,NCT02839044,"Absolute change in ongoing calcium deposition quantified as volumetric bone metabolic rate (CSUVMEAN x cm3) in the femoral artery between baseline and 6 months after baseline, as determined by 18F-NaF PET/CT imaging.",,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
5795,NCT01845064,Determine the pharmacokinetic of DM199 after single and multiple doses,Determine changes in immune cell populations by FACS analysis.,,2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5796,NCT00282685,Improvement of neurological score: modified NIS(LL)+7,Heart rate variability,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5797,NCT03364387,"Composites of Myocardial Infarction, Hospitalization, Revascularization, Death",Heart failure,,2018-03-05,COMPLETED,OBSERVATIONAL,['NA']
5798,NCT04604093,Impact on time above 180 mg/dL in subjects with type 2 diabetes,,,2020-10-20,COMPLETED,OBSERVATIONAL,['NA']
5799,NCT03726762,Weight loss,HA1C,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
5800,NCT05713266,All cause higher level of care utilization,Highly likely+somewhat likely COVID-19 related healthcare utilization,,2022-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5801,NCT02002091,Number of Patients With Erectile Dysfunction,Number of Patients That Died From Cardio Vascular Cause,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
5802,NCT03324776,Percentage change from baseline HbA1c,Percent of time that Blood glucose (BG) is under 70 mg/dL on CGMS,,2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE3']
5803,NCT02505334,Change in Glycosylated Haemoglobin (HbA1c) (Week 26),Change in Calcitonin,,2015-07-21,COMPLETED,INTERVENTIONAL,['PHASE3']
5804,NCT03905863,Percentage Reduction in Ulcer Area (cm^2).,Number of Adverse Events,,2019-06-04,COMPLETED,INTERVENTIONAL,['NA']
5805,NCT03004664,Patients will improve their capacity for diabetes self-management: Measured through change in Patient Activation,Patients will successfully self-manage their diabetes as measured though change (reduction) in chronic stress levels,,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
5806,NCT00166673,Navigator Accuracy,Exploratory assessment of impact of Navigator on HbA1c,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5807,NCT00351936,Change From Baseline in Triglycerides,,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
5808,NCT03240432,Time spent with glucose level <70 mg/dL,Time spent with glucose level <54 mg/dL,Glycemic variability (coefficient of variation),2017-09-26,COMPLETED,INTERVENTIONAL,['NA']
5809,NCT00441844,Monocyte function,Plasma biomarkers,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5810,NCT03422263,Maximum oxygen uptake,Body constitution (Muscle mass predicted II),Echocardiographic parameters (E/e' avg),2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
5811,NCT04970719,Rescue treatment,Time to recovery,,2021-07-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
5812,NCT02983812,Hospital readmission within 30 days of discharge,Total health care cost utilization in 6 months after discharge,,2017-01-23,COMPLETED,OBSERVATIONAL,['NA']
5813,NCT00499356,Incident foot ulcers,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
5814,NCT00658957,The percentage of patients who remain free of signs and symptoms of infection until the end of the study,Treatment emergent Adverse Events,,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2']
5815,NCT06164535,serum amyloid-β,HOMA-IR,,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5816,NCT04261361,Glycemic control,DM-specific distress,,2018-12-12,COMPLETED,INTERVENTIONAL,['NA']
5817,NCT01200394,Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12,Plasma Concentration Versus Time Summary of PF-00489791,Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs),2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5818,NCT00913393,Measure: change from baseline in 24-hour urinary ACR for each arm compared with placebo,Measure: Change from baseline in serum creatinine for each FG-3019 arm compared with placebo,,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2']
5819,NCT01476449,Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision.,"Percentage of Patients Anatomically ""Dry.""",,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5820,NCT00062764,Number of Patients With Improvement in Liver Histology,Mean BMI Change,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5821,NCT00971997,Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Below 6.5% at Week 48 Endpoint,Number of Hypoglycemia Episodes Participants Experienced at Any Time From Baseline Through Week 48,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5822,NCT00555490,mortality or using dialysis,,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1']
5823,NCT01348685,subjective appetite and short term food intake,,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
5824,NCT05030844,The change in diabetes self managament of individuals with Type 2 diabetes at 3rd month and 6 rd month with the Diabetes Self-Management Scale,Metabolic control variables,,2021-07-14,COMPLETED,INTERVENTIONAL,['NA']
5825,NCT01120119,C peptide,Glycometabolic control,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
5826,NCT05447806,Average hospital length of stay (LOS),Hospital revenue,Provider's practice performance,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
5827,NCT04289818,Change from Baseline HbA1c at 6 months,Change of Body mass index at 6 months,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
5828,NCT02985099,Defect depth reduction (%),plaque index,,2015-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5829,NCT00977262,PBMC gene expression profiles,Endothelial function,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5830,NCT03506750,Changes of intraocular VEGF and PLGF of patients with proliferative diabetic retinopathy post-IVC (intravitreous injection of Conbercept).,Effect of IVC on postoperative complications,,2017-06-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
5831,NCT06247748,Baseline-corrected difference of Corrected QT interval after multiple subcutaneous injections of JY09 injection,Immunogenicity,Relative abundance,2023-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5832,NCT06022601,HbA1c,Systolic and Diastolic Blood pressure,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
5833,NCT01370005,Mean 24-hour Systolic Blood Pressure Change From Baseline,Orthostatic Blood Pressure,Confirmed Hypoglycaemic Adverse Events,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5834,NCT05765903,Number of moderate-high risk participants with 30-day post-discharge hospital readmission,90-day post-discharge emergency department usage,,2024-03-31,WITHDRAWN,INTERVENTIONAL,['NA']
5835,NCT05217953,Change in HbA1c,AUC of glucose below 3.5 mmol/l,,2022-06-30,RECRUITING,INTERVENTIONAL,['NA']
5836,NCT01910051,anthropometric measures and metabolic biomarkers indicative of prediabetes,intra-subject and inter-subject variability of analyzed biomarkers,"the correlation between anthropometric data, medical history, and biomarkers with regard to metabolic risk",2013-09-25,COMPLETED,OBSERVATIONAL,['NA']
5837,NCT03595267,Kidney Failure Risk,,,2019-10-01,RECRUITING,OBSERVATIONAL,['NA']
5838,NCT00925717,Investigate LDL-C goal achievement rate according to ADA recommendation,Investigate reduction of 10-year risk for CHD by using UKPDS risk engine,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
5839,NCT05094401,Mean change in HbA1c,Change in Medications,,2021-10-04,TERMINATED,INTERVENTIONAL,['PHASE3']
5840,NCT01099397,"Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose Tolerance Test [OGTT]), at Three Timepoints During Antihypertensive Treatment",,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
5841,NCT02749890,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,,2016-05-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5842,NCT02825251,Change in Glycosylated Haemoglobin (HbA1c),Number of Subjects With at Least One Non-routine Change-of-infusion-sets Categorised by Reasons for Change-of-infusion-sets,,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5843,NCT02071498,adherence,safety medication use,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
5844,NCT03455543,Change in Pain Intensity,Changes in Nerve Conduction Studies of Amplitude Between Baseline and End of Treatment at 4 Months.,Exploratory Endpoint: Changes in Intraepidermal Nerve Fiber Density (IENFD) at the Distal Thigh and Distal Leg - Part B,2018-03-26,COMPLETED,INTERVENTIONAL,['NA']
5845,NCT04383197,Insulin secretion,Body composition,,2019-12-10,UNKNOWN,INTERVENTIONAL,['NA']
5846,NCT05818995,albuminuria,,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5847,NCT03254979,Implementation of the recommended clinical intervention by health care porfessionals,Lifestyle change at patient level,,2017-03-15,COMPLETED,INTERVENTIONAL,['NA']
5848,NCT03648996,Carotid Femoral Pulse Wave Velocity (cfPWV),Insulin-stimulated Leg Blood Flow,,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5849,NCT04955834,Change value of glycosylated hemoglobin (HbA1c),Abnormal findings,,2021-07-27,RECRUITING,INTERVENTIONAL,['PHASE3']
5850,NCT02144909,Change from Baseline diabetes management functioning as measured by the Problem Areas in Diabetes questionnaire at 3 months and 6 months,Change from Baseline weight in kg at 3 months and 6 months,Change from Baseline dietary patterns as a questionnaire at 3 months and 6 months,2013-11,COMPLETED,INTERVENTIONAL,['NA']
5851,NCT00300105,"Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs (blood pressure and pulse), body weight","Central obesity (waist circumference, hip circumference and waist/hip ratio)",,2005-10,TERMINATED,INTERVENTIONAL,['PHASE3']
5852,NCT02024399,Improved body compositon (decrease in % fat; increase in % lean tissue) using DEXA,"Improved levels of fitness using ACSM guidelines / assessments to measure such constructs of fitness as flexibility, muscle strength, cardiovascular endurance and agility.",Quality of life as perceived by the children and the parents.,2004-08,COMPLETED,INTERVENTIONAL,['NA']
5853,NCT01984567,Plasma oxyphytosterol concentrations,Markers reflecting antioxidant capacity,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
5854,NCT00436176,Rate of HbA1c control (<7%),Rate of blood pressure control (< 140/90 mmHg),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5855,NCT01000688,Forearm vasodilator response to intra-arterial infusion of acetylcholine (endothelium-dependent) following treatment with vildagliptin and following active control with acarbose,Effect of vildagliptin on ex vivo mononuclear cell responses to various stimuli,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5856,NCT01050803,BMI,Audit of Diabetes-Dependent Quality of Life (ADDQOL),,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5857,NCT03335501,Change in plasma glucose levels 1 hour after the meal,Number of hypoglycemic events less than 3.3 mmol/L (>20 minutes).,,2018-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5858,NCT00695526,the change of total to HDL cholesterol ratio,the change of UAE,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5859,NCT01450592,Percentage of complex carbohydrate intake from total carbohydrate by Indian diabetic population,Percentage of diabetic population with glycaemic control,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
5860,NCT00437918,7 point SMBG (self monitoring of blood glucose),HOMA-beta for predicting the effectiveness of each agents,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5861,NCT05043636,Cardivascular Autonomic Neuropathy assesed by Vagus,Blood pressure in supine and standing position,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
5862,NCT04234581,Hemoglobin A1c,2-AAA,,2019-08-13,TERMINATED,INTERVENTIONAL,['NA']
5863,NCT00395746,Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Hypoglycaemic Episodes,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5864,NCT00894868,To evaluate the effect of vildagliptin on left ventricular function in patients with T2DM and CHF (NYHA class I-III) by showing that vildagliptin is at least not inferior to placebo with respect to change in left ventricular ejection fraction (LVEF).,To evaluate the efficacy of vildagliptin in patients with T2DM and CHF (NYHA class I-III) by assessing the HbA1c reduction with vildagliptin compared to placebo after 16 weeks of treatment.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5865,NCT00563004,Reduction in fasting plasma glucose of more than 20% in the treatment group compared to placebo,Reduction by half in the daily dose of oral hypoglycemic agents compared to baseline,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
5866,NCT05374343,Plasma concentrations of rongliflozin,Change from baseline in 24-hour urine glucose excretion in varying degrees of kidney function,,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE1']
5867,NCT01887964,Changes in metabolic syndrome risk components,Changes in blood glucose indices,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
5868,NCT00663000,To evaluate a correlation between IGF-I and glucose tolerance in patients with acromegaly.To evaluate changes of impaired glucose tolerance by different treatment options for acromegaly.,"Evaluate a correlation between body weight/BMI, age, family history of diabetes,duration of acromegaly and current medical treatment for acromegaly and glucose tolerance / insulin resistance",,2008-04,COMPLETED,OBSERVATIONAL,['NA']
5869,NCT05944029,Weight,,,2023-02-20,RECRUITING,INTERVENTIONAL,['NA']
5870,NCT00143338,"To assess in patients with type 2 diabetes mellitus the effects, if any, on lung lining fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.","(1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.",,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5871,NCT00695682,This is a pilot study to study the safety and tolerability of intravitreal Infliximab in patients with refractory diabetic macular edema and choroidal neovascularization (CNV),Incidence and severity of adverse events,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
5872,NCT01377558,Change in HbA1c-level (haemoglobin A1c),Follow up of all parameters mentioned above,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
5873,NCT01710371,Optimal PET-determined mean pancreatic Volume of Distribution (VT) of 18F-AV-133,,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5874,NCT02325960,Mean amplitude of glycemic excursions (MAGE) change from baseline by continuous glucose monitoring system (CGMS),body composition,Exploratory Objective assessed by the relationships between oxidative stress and inflammatory markers and MAGE,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5875,NCT02059187,Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24,Percentage of Participants With Hemoglobin A1C <6.5% at Week 24,,2014-02-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5876,NCT05713448,Prevalence of patients with type 1 diabetes and obesity,,,2021-02-24,RECRUITING,OBSERVATIONAL,['NA']
5877,NCT02838147,Neonatal hypoglycemia,Macrosomia,,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
5878,NCT00285844,Adipose Cell Size Distribution,Adipose Tissue Gene Expression,Insulin-Mediated Glucose Uptake,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5879,NCT01600924,Independent predictors of reduced muscle and bone strength,Relation of changes in predictors with reduced muscle and bone strength,,2016-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5880,NCT04910763,Changes in Hormonal Response to Feeding,Changes in Ad libitum Energy Intake - Free Living,,2019-06-12,TERMINATED,INTERVENTIONAL,['NA']
5881,NCT01899872,Circulating endothelial progenitor cells,Forearm vascular reactivity,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
5882,NCT01628627,"Change in Nerve Conduction Velocity of the Deep Peroneal, Tibial, or Sural Nerve",Number of patients with treatment-related adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5883,NCT04298229,"Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight",Hospital Readmission,,2020-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5884,NCT00363948,tolerability,Plasma glucose,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5885,NCT03974139,cerebrospinal fluid /plasma leptin ratio,Score of the Dutch Eating Behaviour Questionnaire (DEBQ),,2020-07-03,RECRUITING,INTERVENTIONAL,['PHASE2']
5886,NCT01020123,HbA1c: Change From Baseline to 4 Month,EC50 to Characterise the PD Properties of AZD1656.,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5887,NCT00675493,Change in HbA1c from baseline,Number of adverse drug reactions (ADR),,2008-05,COMPLETED,OBSERVATIONAL,['NA']
5888,NCT05802927,Postprandial blood glucose,Appetite,,2023-07-05,COMPLETED,INTERVENTIONAL,['NA']
5889,NCT05181917,TIme in range,Prediction capacity of the model of postprandial glucose values,Actions carried out by participants,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5890,NCT05670600,Change in pain level at 4th and 8th weeks compared to baseline.,Effect of neuropathic pain on quality of life at 4 and 8 weeks change from initial state,,2021-07-19,COMPLETED,INTERVENTIONAL,['NA']
5891,NCT01939496,Change From Baseline in the Mean 24-Hour Systolic Blood Pressure (SBP) to Week 6,"Change From Baseline in the Difference in Seated Heart Rate (HR) and Standing HR to Day 2, to Week 3, and to Week 6",,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5892,NCT06289387,"Role of the PNPLA3, TM6SF2, GCKR, MBOAT7 and HSD17B13 genetic variants in the development and progression of MASLD.",Correlation between serum creatinine levels (eGFR) and the genetic variants,,2024-01-20,RECRUITING,OBSERVATIONAL,['NA']
5893,NCT00839878,Percentage of diabetic patients having diabetic nephropathy,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",,2009-03,COMPLETED,OBSERVATIONAL,['NA']
5894,NCT01043965,"myocardial blood flow velocity, myocardial blood flow reserve",,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5895,NCT02709057,Incident diabetes,The change in insulin sensitivity during a 3 year follow-up,Incident cardiovascular disease,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
5896,NCT02746627,Glycemic Control (HbA1c),Coping,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
5897,NCT03865290,Change in effect of Gastrointestinal symptoms on Quality of Life,Severity of gastrointestinal symptoms - Nepean Dyspepsia index,,2019-04-02,RECRUITING,INTERVENTIONAL,['PHASE2']
5898,NCT01409889,Participant Weight,Minutes of Physical Activity,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
5899,NCT03537131,"Time to hypoglycaemia during the exercise challenge, before and after dapagliflozin treatment.","Concentration of plasma potassium, sodium, calcium and pH at each 10min interval during exercise challenge",,2018-06-02,TERMINATED,INTERVENTIONAL,['PHASE2']
5900,NCT02793505,Spontaneous abortion,Pregnancy complications,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
5901,NCT06320054,Clinical Outcomes,Patient Reported Outcomes,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5902,NCT01129232,Prevalence of virus infected islets in pancreatic biopsies,Glycosylated hemoglobin A1 (HbA1c),,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2']
5903,NCT00385528,"Psychological distress, quality of life",health care utilization,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
5904,NCT04529473,Glycated haemoglobin (HbA1c),Blood Pressure,Adverse Events (AE),2021-02-03,COMPLETED,INTERVENTIONAL,['NA']
5905,NCT03908021,profile the oral bacteria related to caries and periodontal disease of children with type 1 diabetes mellitus,,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
5906,NCT01932775,"Mean percentage of blood glucose measurements in the target range 70 to 140 mg/dl, as calculated by all premeal and bedtime glucose values measured ≥ 24 hours after start of therapy",Mean daily blood glucose as calculated by premeal and bedtime blood glucose values: Overall and per treatment day,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5907,NCT04854603,Insulin,Food pleasantness,,2021-09-02,COMPLETED,INTERVENTIONAL,['NA']
5908,NCT02348294,Increase in erythema index,,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
5909,NCT05619406,Primary Outcome,Secondary Outcome,,2022-08-20,RECRUITING,INTERVENTIONAL,['NA']
5910,NCT02581098,Wound macrophage isolation to determine miR-21,,,2019-08-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5911,NCT03987308,The percentage of patients with at least a 0.7% change in the absolute value of glycated hemoglobin,The percentages of subjects with greater than 3% weight loss,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
5912,NCT01732705,Insulin sensitivity,,Glycogen content in skeletal muscle,2012-09,COMPLETED,INTERVENTIONAL,['NA']
5913,NCT04857073,Birth weight,Number of NICU admission,,2021-04-10,COMPLETED,INTERVENTIONAL,['NA']
5914,NCT00862433,Measure Vitamin E Kinetics,,,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5915,NCT03316261,greater than 10% risk for multiple beta-cell autoantibodies/type 1 diabetes,,,2017-10-19,RECRUITING,OBSERVATIONAL,['NA']
5916,NCT03626909,Patients meeting their HgbA1c treatment goal,Community Health Worker adherence,,2018-01-14,COMPLETED,OBSERVATIONAL,['NA']
5917,NCT01416649,Sleep duration and sleep efficiency,,,2011-02-01,COMPLETED,OBSERVATIONAL,['NA']
5918,NCT05135039,The rate of progression from prediabetes to diabetes one year after the intervention in both groups of subjects.,Changes in the number of CD4 T cells after one year intervention in the two groups.,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
5919,NCT02722655,Intelligence quotient evaluation,Hypertension,,2008-03,RECRUITING,OBSERVATIONAL,['NA']
5920,NCT00789737,Percent Change in Hemoglobin A1c,"Change in Postprandial Plasma Glucose, 2 Hours After a Meal Tolerance Test",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5921,NCT00612950,2.phase insulin response measured as incremental area under the curve from 10-120 minutes,"2.phase insulin response measured as incremental area under the curve from 10-120 minutes, after 4 weeks of insulin treatment",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
5922,NCT01794091,"All cause mortality, cardiovascular death, myocardial infarction or stroke",,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
5923,NCT00969592,fractional and total glucose infusion rates,fractional and total insulin areas under the curve (AUC),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5924,NCT03821662,Change from Baseline Glycated hemoglobin (HbA1C),Change from Baseline Medication Adherence Assessment Scale,,2019-04-11,COMPLETED,INTERVENTIONAL,['NA']
5925,NCT00252837,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Audit of Diabetes Dependent Quality of Life (ADDQoL). ADDQoL will only be applied in Poland.,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE3']
5926,NCT05408234,Ankle Brachial Index,,,2022-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5927,NCT00740051,HbA1c Change From Baseline at Week 18 (Final Analysis),The Change in FPG From Baseline by Visit Over Time,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5928,NCT05140304,Mean area of FAZ in various stages of diabetic retinopathy and difference between these groups in superficial and deep capillary plexuses,,,2021-11-30,UNKNOWN,INTERVENTIONAL,['NA']
5929,NCT00542334,Frequency and magnitude of nocturnal hypoglycemia,Patient satisfaction with continuous glucose sensing,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
5930,NCT06215352,Gestational weight gain,,,2024-01-09,RECRUITING,OBSERVATIONAL,['NA']
5931,NCT02660242,Glycemic Response During Exercise and Early Recovery,CGM Metrics During Late Recovery - Time > 250 mg/dL,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5932,NCT01113216,Identification of Genes or other factors that influence the development of CFRD,,,2008-04,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5933,NCT05765214,CRC-KPSS change and screening uptake,,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
5934,NCT02028975,Plasma levels of biological markers of orosensorielle perception fatty acids,Measure the detection threshold for linoleic acid,,na,UNKNOWN,INTERVENTIONAL,['NA']
5935,NCT02057952,Change in Body Weight From Baseline to 6 Months.,Change in Diastolic Blood Pressure Baseline to 12 Months,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
5936,NCT02058147,Change in HbA1c From Baseline to Week 30,Percentage of Participants With Severe Symptomatic Hypoglycemia,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5937,NCT04019431,Body Mass Index change from baseline,Safety (subjective unit) change from baseline,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
5938,NCT05708040,Time in Range,Health-Related Quality of Life in Patients with Type 1 Diabetes,,2022-08-19,COMPLETED,INTERVENTIONAL,['NA']
5939,NCT04787978,"Change in cardiovascular health (a composite measure of blood pressure, cholesterol, glucose, physical activity, smoking status, and body mass index).",Change in Patient Activation,,2020-02-29,COMPLETED,INTERVENTIONAL,['NA']
5940,NCT01794143,"Time to HbA1c>=7%, while receiving metformin and the randomly assigned study medication","Time to HbA1c>7.5%, while receiving metformin and the randomly assigned study medication.","Time to HbA1c>7.5%, while receiving study medications and basal insulin",2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5941,NCT00495014,"Adverse reactions and changes in laboratory values, vital signs, and/or ECGs following each dose",Body weight following 14 days of repeat dosing with GSK376501.,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5942,NCT06108388,Hematopoietic colony formation in ALDHhiSSClow regenerative cell subsets,Frequency and absolute number of circulating ALDHhiSSClowCD133+ progenitor cells,,2023-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5943,NCT00476918,"Visual acuity, no of treatments, duration of efficacy","intraocular pressure, retinal thickness",,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
5944,NCT02695810,Mean amplitude of glycaemic excursions (MAGE) as assessed by continuous glucose monitoring,Responsiveness to interventions in individuals with different glucose tolerance status (impaired fasting glycaemia vs. impaired glucose tolerance),,2016-02-24,COMPLETED,INTERVENTIONAL,['PHASE2']
5945,NCT05067452,Change in food security severity from baseline to twelve weeks by study arm,Change in diabetes self-efficacy from baseline to twelve weeks by study arm,Change in health-related quality of life (healthy days) from twelve weeks to twenty-four weeks by study arm,2021-11-08,RECRUITING,INTERVENTIONAL,['NA']
5946,NCT04295031,metformin daily dose in diabetic outpatients type 2,renal filtration rate,,2019-10-09,UNKNOWN,OBSERVATIONAL,['NA']
5947,NCT05431660,Plantar pressure senses,Vibration sense,Individuals' information about diabetic foot,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5948,NCT01473329,HbA1c,Changes in Lipids,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
5949,NCT02410005,24h urine 24hr urine albuminuria,,Estimated glomuerula filtration rate (eGFR),2014-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5950,NCT01328821,To assess safety and tolerability of CTP-499,"To assess Pharmacokinetics, Pharmacodynamics and relative bioavailability",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5951,NCT02893072,intravenous glucose,,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
5952,NCT03028220,"% Time Spent in Hypoglycaemia (<3.3mmol/L, 60mg/dL)",Glucose Variability Measured by CONGA,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
5953,NCT05507697,Change of nerve conduction velocities in the lower extremity,Change of glycosylated hemoglobin (HbA1c),,2022-05-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5954,NCT03047200,Restoration of sustained euglycemia without exogenous insulin or with reduced insulin dosage in patients who underwent pancreatic islet cell after kidney transplantation,To assess total islet mass needed to achieve sustained euglycemia with or without exogenous insulin.,,2008-07,WITHDRAWN,INTERVENTIONAL,['PHASE1']
5955,NCT00709683,Incidence of major hypoglycaemic events reported as serious adverse drug reactions,"Average post-breakfast (90-120 mins), post-lunch (90-120 mins), post-dinner (90-120 mins) plasma glucose level",,2008-05,COMPLETED,OBSERVATIONAL,['NA']
5956,NCT05305326,Telocytes,,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
5957,NCT01989754,Progression of Albuminuria,Cardiovascular (CV) Death,,2014-01-16,COMPLETED,INTERVENTIONAL,['PHASE4']
5958,NCT01079195,Reduction in Systolic Blood Pressure and Diastolic Blood Pressure From Baseline to Study End,Evaluation of Adverse Events (AEs) Leading to Discontinuation of Tarka and a Summary of All AEs Possibly or Probably Related to Tarka by Frequency and Severity,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
5959,NCT06251323,Hemoglobin A1c,,,2025-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5960,NCT03256747,Glucose levels,Oxygenation tissue,,2017-09-15,COMPLETED,INTERVENTIONAL,['NA']
5961,NCT02285231,2-h oral glucose tolerance tests (OGTTs,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
5962,NCT04720170,Intra-epidermal Nerve Fiber Density,Patency of Lateral Plantar Artery,Medial Plantar Sural Nerve Action Potential Amplitude,2021-02-15,UNKNOWN,INTERVENTIONAL,['NA']
5963,NCT00348231,daily profile of blood glucose,QOL,,2004-11,UNKNOWN,INTERVENTIONAL,['NA']
5964,NCT04767672,Glycated hemoglobin,Fecal Short-Chain Fatty Acids (SCFA),Blood pressure,2021-05-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5965,NCT02776098,Compare change in mean lean body mass (LBM) from baseline to end of study,Compare Intramyocellular lipid (IMCL) accumulation from baseline to end of study,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
5966,NCT02129231,Total antioxidant capacity,nerve conduction studies,alanine aminotransferase,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5967,NCT05021705,renal biopsy,,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
5968,NCT05772169,Prevalence of Hypercortisolism,Effect of Treatment on Non-neoplastic Hypercortisolism,,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE4']
5969,NCT00754130,Number of Participants Who Discontinued Study Drug Due to an AE,"Plasma Pharmacokinetic Parameter: Day 5 to Day 1 Accumulation Ratio for AUC (0-24hr), Cmax, and C24hr",,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5970,NCT01676220,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5971,NCT05647824,Fingerstick Test: Obtain TV4 BGMS performance data in the hands of lay users with diabetes using fingerstick capillary blood obtained with Microlet NEXT® lancing device.,Subject Questionnaire on the Usability of TV4 BGMS,,2020-02-05,COMPLETED,OBSERVATIONAL,['NA']
5972,NCT05786521,6 minute walking distance,,,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
5973,NCT04769037,Persistent confirmed multiple beta-cell autoantibodies,Measurement of Safety parameters,Stool calprotectin,2021-04-22,RECRUITING,INTERVENTIONAL,['NA']
5974,NCT04506216,Eating disorders in men and women,Blood glucose monitoring,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
5975,NCT03290768,Program Completion Rate (%),Coaching Participation Rate,,2017-09-13,COMPLETED,INTERVENTIONAL,['NA']
5976,NCT01776528,Safety and tolerability,Pharmacodynamics,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5977,NCT03165110,Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Success in Interpreting the Expanded Graph and My Readings View in the Onyx App System,Average Change in Total Daily Insulin Dose From Study Start to End of Study,,2017-03-17,COMPLETED,INTERVENTIONAL,['NA']
5978,NCT05380544,Patient and clinician acceptability of the trial process and ESWT,"Validity, reliability and responsiveness of virtual follow-up for wound healing in research",,2022-04-13,RECRUITING,INTERVENTIONAL,['NA']
5979,NCT00231621,Percent change in body weight and the percent change in fasting serum triglycerides from baseline (Week 0) to Week 60.,"Absolute change in body weight, body mass index, triglycerides, and absolute and percentage changes in cholesterol measures from baseline to Week 60. Safety evaluations throughout study.",,2001-05,TERMINATED,INTERVENTIONAL,['PHASE3']
5980,NCT04437485,Hemoglobin A1c at 6 Months,Depressive Symptoms,,2020-10-14,COMPLETED,INTERVENTIONAL,['PHASE2']
5981,NCT01324921,Positive AUC for plasma glucose concentration,Positive AUC for serum insulin concentration,,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5982,NCT04380064,Postoperative ERM Development,Visual Acuity,,2020-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5983,NCT04417452,Maturation of the gonadal regulation,,,2019-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5984,NCT00836030,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
5985,NCT04795726,Proportion of participants with progression of non-proliferative diabetic retinopathy (NPDR),Change in severity of diabetic retinopathy (DR),,2021-03-10,COMPLETED,INTERVENTIONAL,['NA']
5986,NCT00351000,Change From Baseline on Fasting Insulin,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5987,NCT05706155,Change in Glycated Hemoglobin,Adherence to a plant-based diet,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
5988,NCT00800683,HbA1c Change From Baseline at Week 12,"Clinically Relevant Drug-related Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
5989,NCT00627471,Mean difference in HbA1c (efficacy),"Minor, severe and nocturnal Hypoglycaemic events (safety)",,2008-01,TERMINATED,INTERVENTIONAL,['PHASE4']
5990,NCT02812498,glycosylated hemoglobin HbA1c,Cost analysis by patient estimation through a questionnaire of the overall cost and time saved thanks to the service,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
5991,NCT01322035,Measure erythrocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic Gastric Bypass.,Measure hepatocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic gastric bypass.,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
5992,NCT00841087,Rate of Nocturnal Major and Minor Hypoglycaemic Episodes,Systolic Blood Pressure (BP),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5993,NCT00979368,Exposure to the investigational drug will be measured to assess safety and tolerability,To assess the single dose Pharmacokinetics of BMS-816336,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5994,NCT01718015,"Concentrations of IGF-I and II, sCD-163, VEGF, NGF and BDNF in cerebrospinal fluid and blood.","Nerve conduction studies: Nerve velocity, Amplitude, F-waves, Motor Unit Number Estimate (dominating arm and non-dominating leg)",Protein profile of the cerebrospinal fluid using mass spectrometry.,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
5995,NCT05210972,Coronary artery disease severity,Correlation of HbA1c to CAD severity,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
5996,NCT04848480,Change in Glycosylated Haemoglobin (HbA1c) at Week 26,Change in Body Weight,,2021-04-30,COMPLETED,INTERVENTIONAL,['PHASE3']
5997,NCT03893422,CRP,Hospital Anxiety and Depression Scale,,2017-10-22,COMPLETED,INTERVENTIONAL,['NA']
5998,NCT03044132,Time (days) required for wound bed preparation (granular bed after placement of DermACELL AWM).,"The number of adverse events after DermACELL AWM application including infection, hospitalization, and reoperation.",,2017-01-15,COMPLETED,INTERVENTIONAL,['NA']
5999,NCT02668328,Mean Amplitude of Glycemic Excursion (MAGE),,,2016-09,WITHDRAWN,INTERVENTIONAL,['NA']
6000,NCT00833677,Diabetes Self Efficacy,Diabetes Specific Conflict,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
6001,NCT01682759,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue,Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54,,2012-09-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6002,NCT00708175,Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA),Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA,Number of Participants With Fracture,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6003,NCT00570687,EGP AOC0-480 - Meal Challenge,,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6004,NCT03320031,glucose variability,hypoglycemia,,2017-06-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
6005,NCT03088670,Mean change of HbA1c,Adverse event,,2013-04-23,COMPLETED,INTERVENTIONAL,['PHASE3']
6006,NCT05843929,Diabetic foot exam: dermatologic examination,Diabetes Self-Care,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6007,NCT03893526,Blood Glucose,Plasma Concentrations of Amino Acids,,2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE4']
6008,NCT01376323,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12,Number of Participants With HbA1c < 7.0% and < 6.5%,,2011-07-13,COMPLETED,INTERVENTIONAL,['PHASE2']
6009,NCT04820556,"Significant (p<0,05) correlation (r>0,5) between abundance of Faecalibacterium genus and concentration of lipopolysaccharide",,,2021-04-12,COMPLETED,OBSERVATIONAL,['NA']
6010,NCT00714844,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
6011,NCT05544643,Percentage of sets that failed due to unexplained hyperglycemia,,,2022-08-04,COMPLETED,INTERVENTIONAL,['NA']
6012,NCT04855292,Safety and tolerability assessed by incidence and severity of adverse events,The occurrence of TG103 anti-drug antibodies (ADA),,2021-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6013,NCT05943626,Insulin sensitivity change from baseline,Average (per week) daytime alertness change from baseline,,2023-06-13,RECRUITING,INTERVENTIONAL,['NA']
6014,NCT00810290,HgbA1c,Change in quality of life.,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
6015,NCT04127994,Impact of 3 stroke diet in glycemic variability compared to a 6 stroke diet,Impact of 3 stroke diet in weight loss compared to a 6 stroke diet,,2018-08-17,RECRUITING,INTERVENTIONAL,['NA']
6016,NCT02793427,Serum AGEs,,,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
6017,NCT03895697,Time to plasma glucose recovery,Immunogenicity - Occurrence of anti-drug antibodies,,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE3']
6018,NCT01281228,Differences in neuronal activity in CNS reward and satiety circuits,Self-reported hunger,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
6019,NCT01001611,Change from baseline in Glycosylated Hemoglobin (HbA1c),"Change from baseline in glycemic parameters (Fasting Plasma Glucose, C-peptide, Homeostasis Model Assessment of Insulin Resistance(HOMA-IR), Homeostasis Model Assessment of β-cell function(HOMA-β), Quantitative Insulin Check Index(QUICKI))",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6020,NCT01717183,Percentage of complete wound closure,Change in wound surface area,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
6021,NCT02872402,Weight retention,Time physically active,,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6022,NCT00896610,Blood glucose level,,,2009-05-13,TERMINATED,OBSERVATIONAL,['NA']
6023,NCT03889210,Rate of change in plasma glucose concentration,Correlation with physical activity,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
6024,NCT00914524,The change in the urinary protein/creatinine ratio from baseline to the end of treatment.,The change of creatinine clearance,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6025,NCT04484987,Adipose tissue gene expression,Peripheral diurnal rhythmicity in in peripheral mononuclear blood cells,,2020-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6026,NCT03021187,Change in HbA1c (Week 26),Change in DTSQs: Individual Items and Treatment Satisfaction Score (6 of the 8 Items Summed),,2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6027,NCT03769948,Diabetic retinopathy indicator (yes/no),,,2022-02,UNKNOWN,OBSERVATIONAL,['NA']
6028,NCT02169531,Change from Baseline Hemoglobin A1c (HbA1c) at up to 27 weeks.,Change from Baseline Lipid Profile at up to 27 weeks.,Change from Baseline Symptoms at up to 27 weeks.,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6029,NCT06045221,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form Domain Summary Scores,,2023-09-22,RECRUITING,INTERVENTIONAL,['PHASE3']
6030,NCT04741568,"Change in Diabetes Eating Problem Survey Revised (Markowitz et al., 2010)",Change in Children's Eating Behaviour Questionnaire (Wardle et al. 2001),Feasibility Outcomes: Usability of Online Content (Google Analytics),2021-06-07,COMPLETED,INTERVENTIONAL,['NA']
6031,NCT03003806,Percentage of glucose readings below 54 mg/dl (3.3 mmol/l),Diabetes treatment satisfaction questionnaire,,2017-10-02,COMPLETED,INTERVENTIONAL,['NA']
6032,NCT01332071,Cmax of Metformin Hydrochloride,,,2009-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
6033,NCT05538819,Hospitalizations and emergency visits for heart failure,Hospitalizations for acute myocardial infarction or stroke,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
6034,NCT02555631,Change in Weight in Pounds,Number of Participants That Participated in Each Session,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
6035,NCT01251757,Adherence to Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs),Percentage With Good (<=100mg/dL) Low Density Lipoprotein (LDL) Control,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
6036,NCT04859348,APGAR Score,,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
6037,NCT05714761,Percentage of participants with at least 72 hours of CGM data downloaded.,Negative predictive value (NPV),,2023-02-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6038,NCT01096667,Change From Baseline on 24-hour Average SBP at Week 4,Number of Participants Who Discontinued Study Drug Due to an AE,,2010-05-17,COMPLETED,INTERVENTIONAL,['PHASE2']
6039,NCT00065793,apoB concentration of LDL with apoC-III,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
6040,NCT01680133,Change from baseline in insulin sensitivity of adipose tissue and skeletal muscle lipolysis,Baseline skeletal muscle lipid accumulation,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
6041,NCT00789308,Level of stimulated c-peptide at 90-minute derived from the mixed-meal tolerance test (MMTT),Incidence of immune sensitization defined by detecting anti-HLA antibodies not present prior to transplantation,,2008-07-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6042,NCT00135330,Change in ASIiAUC During a Hyperglycemic Clamp Test.,Pedal Edema Score,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6043,NCT04865770,"Change in kidney inflammation (medulla), T1 mapping (MRI)",Change in kidney function (creatinine clearance) (urinalysis,,2021-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6044,NCT01686828,Insulin Sensitivity Quantified by Matsuda Index,Changes in Adipose Tissue Gene Expression,,2013-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6045,NCT04332354,glycemic profile after bariatric surgery,identification of predictive factors for diabetes remission 1 year after surgery,,2016-03-30,COMPLETED,OBSERVATIONAL,['NA']
6046,NCT00746642,"Mellitor technology feasibility will be established by comparing Mellitor glucose measurements results to ""gold standard, Yellow Springs"" glucose analyzer, or a comparable. Interdevice variability should be within 10%.",,,2009-10,UNKNOWN,INTERVENTIONAL,['NA']
6047,NCT01790724,Physical Activity,Psychosocial outcomes,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
6048,NCT05098327,HOMA-IR,TLR-4,,2021-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6049,NCT05208424,Short-term outcome,,,2020-02-27,COMPLETED,OBSERVATIONAL,['NA']
6050,NCT00627380,The primary efficacy outcome is a metabolic parameter: insulin integrated area under the curve (AUC) during the oral glucose tolerance test.,Safety: CD4 count and plasma HIV RNA,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6051,NCT00095082,HbA1c,Insulin Treatment Satisfaction,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
6052,NCT03803072,Weekly adherence rates for time restricted eating (TRE),Change between baseline and post-intervention visceral fat area,,2019-01-18,COMPLETED,INTERVENTIONAL,['NA']
6053,NCT05358444,Survey Administration Feasibility as assessed by mean time for administration of surveys to participants,Change in caregiver attitudes regarding child health behaviors,,2022-07-08,COMPLETED,INTERVENTIONAL,['NA']
6054,NCT00771693,"Co- primary platelet response variables: U46619 stimulated platelet P- selectin activation, platelet-leukocyte aggregation, platelet-platelet aggregates and platelet-monocyte aggregates.",To elucidate if short-term lowering of blood glucose by insulin infusion (pretreatment standardization of blood glucose) reduces platelet activity in patients with T2DM.,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6055,NCT05370560,Type 2 diabetes mellitus,,,2010-12-01,COMPLETED,OBSERVATIONAL,['NA']
6056,NCT00109720,Blood glucose level,Diabetes Related Quality of life,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
6057,NCT05193929,Percentage of index ulcers healed,Changes in wound quality of life from screening visit to end of study ( per W-QoL),Cost to Closure,2021-12-15,RECRUITING,INTERVENTIONAL,['NA']
6058,NCT01528254,Time to Initial Treatment Failure,"Percentage of Participants With Adverse Events, Serious Adverse Events and Death",,2012-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
6059,NCT01201460,,,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
6060,NCT03580226,Uric Acid,,Management,2015-01,COMPLETED,OBSERVATIONAL,['NA']
6061,NCT01440140,Percentage of CGM (Continuous glucose monitoring) values in target (3.9 - 8.0 mmol/l).,Glycaemic control assessed by fructosamine and HbA1c,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6062,NCT00212914,The proportion of patients screened in each group,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
6063,NCT02112071,endothelial function measured by brachial artery flow mediated vasodilation,24-hour albuminuria,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
6064,NCT04030091,Endothelial function,Diabetes treatment satisfaction questionnaire,,2019-09-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6065,NCT05009602,Diagnostic accuracy,Inter- and intra-rater reliability,,2022-03-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6066,NCT04662164,AEs,fasting plasma glucose,,2025-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6067,NCT02301806,"Change in endothelial function during the OGTT evaluated by flow-mediated vasodilatation (FMD). The change is defined as below, assuming the peak value and changes of FMD will be observed at t=60 min.",Change in endothelial function during OGTT* evaluated by endo-PAT. Change in endothelial function after 12-week treatment at the fasting state evaluated by endo-PAT and FMD.,Change in the number of EPCs after 12-week treatment,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6068,NCT00370942,Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group,Long term safety variables,,2006-04-01,TERMINATED,INTERVENTIONAL,['PHASE2']
6069,NCT02038764,Number of Participants With Serum Anti-PF-06342674 Antibody Response Listed by Visit,Accumulation Ratio (Rac) on Day 71,,2014-06-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6070,NCT01796418,Brachial ankle pulse wave velocity (PWV),Blood pressure,,2013-03,UNKNOWN,INTERVENTIONAL,['NA']
6071,NCT00995787,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG","Pharmacodynamic variables: 24 h plasma glucose, Insulin",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6072,NCT03052400,Hemoglobin A1c,Basal Insulin Dose,,2017-02-03,TERMINATED,INTERVENTIONAL,['PHASE2']
6073,NCT01667783,Change in HbA1c from baseline to final data collection,Change in insulin secretion,,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6074,NCT04874415,Moderate to Vigorous Physical Activity (MVPA),Daily Step Count,,2021-11-16,RECRUITING,INTERVENTIONAL,['NA']
6075,NCT04247451,Efficiency of nutritional therapy: Dietary intake (food diary; in Kcal) compared to caloric need (indirect calorimetry; Kcal),"Evaluation of choice for oral nutritional supplements, enteral nutrition and parenteral nutrition (%)",,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
6076,NCT05024032,Percentage of Participants Who Achieve ≥5% Body Weight Reduction,Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg),,2021-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6077,NCT00797563,Number of Capillary and Venous Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method,Number of Partipants Who Gave These Ratings for Overall Testing Experience With This Meter,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
6078,NCT00211536,Incidence of Severe Hypoglycemia Events,Low Blood Glucose Index (LBGI);,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6079,NCT00933491,Radiographic Bone Level,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
6080,NCT04254029,Variation of mitral E' velocity,Variation of blood pressure.,,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6081,NCT03520608,prevalnce of irrational use of pain reliever drugs,Generalized Anxiety Disorder Screener (GAD-7),,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
6082,NCT04956094,Proportion of patients diagnosed with gestational diabetes mellitus,,,2021-06-21,RECRUITING,OBSERVATIONAL,['NA']
6083,NCT01713023,Compare the effects of fructose and glucose and TAS1R2 in postprandial metabolism of individuals with type 1 diabetes,Effect of fructose or glucose on leptin levels,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
6084,NCT01526941,"Steady state area under the glucose infusion rate profile, 6-12 hours",Adverse events,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6085,NCT02738996,Postprandial glucose excursions measured with Area under curve,"Qualitative exploration of the knowledge, beliefs and experiences of those with type 2 diabetes on the use of technology to decrease sedentary behaviour and improve glycaemic control",,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
6086,NCT05757258,"Association between incidence of MALE and IL-1, IL-6, TNF-alpha, C reactive protein, HMGB-1, osteoprotegerin, sortilin and omentin-1 serum levels","Association between incidence of cardiovascular death and IL-1, IL-6, TNF-alpha, C reactive protein, HMGB-1, osteoprotegerin, sortilin and omentin-1 serum levels",,2019-10-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6087,NCT01857167,insulin resistance,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
6088,NCT04626323,Mean differenceGlomerular filtration rate (GFR),Costs of care and health care utilization,,2021-05-25,RECRUITING,INTERVENTIONAL,['PHASE2']
6089,NCT00477191,Change in CRP Levels From Baseline to 6 Months of Treatment in Subjects With Psoriasis and Metabolic Syndrome,Change in the Safety and Tolerability of Etanercept in Patients With Psoriasis and Metabolic Syndrome Over a 6-month Period.,,2007-05,TERMINATED,INTERVENTIONAL,['NA']
6090,NCT01279317,Postprandial Glycemic Incremental Area Under the Curve,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
6091,NCT05443802,Metabolic complications,Episode of severe hypoglycaemia in patients suffering from first ketoacidosis episode,,2022-08-16,RECRUITING,INTERVENTIONAL,['NA']
6092,NCT05037526,Composite adverse pregnancy and neonatal outcome,Respiratory distress syndrome,,2021-09-24,RECRUITING,INTERVENTIONAL,['NA']
6093,NCT02927951,Decrease in fall risk associated with walking assessed with the Physiological Profile Assesment,Patient Global Impression of Change (PGIC),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6094,NCT00904592,"incidence rate of proliferative diabetic retinopathy, panretinal photocoagulation",Symptoms scores of TCM,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
6095,NCT06021158,Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L),"Area under the sensor glucose concentration-time curve (AUC) from 0-1 hours, 0-2 hours, 0-3 hours, 0-4 hours, and 0-5 hours after the end of announced exercise periods",,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE2']
6096,NCT01752127,in-segment late lumen loss (mm)at 12month,procedure success rate,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
6097,NCT04877366,Post-prandial glycemic excursion (ARMs A and B),Matsuda Index (ARMs A and B),Plasma IL-6 iAUC (ARMs A and B),2021-07-21,COMPLETED,INTERVENTIONAL,['NA']
6098,NCT00722371,Change From Baseline in A1C at Week 54,Change From Baseline in 2-Hour PMG at Week 54,,2008-09-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6099,NCT06249399,Bladder Sensation,Patient Information Form,,2023-05-03,COMPLETED,INTERVENTIONAL,['NA']
6100,NCT00507936,"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP",Clinician Global Impression: Severity (CGI-S) and Patient Global Impression: Change (PGI-C),,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6101,NCT00330330,To evaluate the pharmacologic activity of ISIS 113715,,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6102,NCT02366416,Change of bloodglucose,Change of musculoskeletal pain,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
6103,NCT00559884,Urine:,lab tests:,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6104,NCT05926947,Post prandial insulemia,Short Form 12 (SF-12) questionnaire,,2023-07-05,RECRUITING,INTERVENTIONAL,['NA']
6105,NCT03144869,Acceptability,Parental fear of hypoglycaemia,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
6106,NCT02660736,Peak plasma concentration (Cmax) for albiglutide in session 1 and 2,Composite of urinalysis parameters as a measure of safety,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6107,NCT06055582,Glycemic indices as per Continuous glucose monitoring system (CGMS) & HbA1c (%),,,2022-02-11,COMPLETED,INTERVENTIONAL,['NA']
6108,NCT03618628,Peak Plantar Pressure,,,2016-05-24,COMPLETED,INTERVENTIONAL,['NA']
6109,NCT00951912,Percentage Change in Low Density Lipoprotein Cholesterol,Total Energy Intake at Follow-up,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
6110,NCT01175824,Change in HbA1c From Baseline to 24 Weeks Endpoint (Intention-to-Treat Population),The Number of Participants With Severe Hypoglycemic Episodes,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
6111,NCT03243253,"association between densities of fast food (FFR) and full service restaurants (FSR) with mortality from CVD and stroke, and the prevalence of type 2 diabetes (T2D).",,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
6112,NCT00756613,The Long Term Effect of Intensive Glycemic Control in Type 2 Diabetes on Major Cardiovascular Complication.,Patients Reported Health Related Quality of Life,,2008-02-01,COMPLETED,OBSERVATIONAL,['NA']
6113,NCT06147466,Time in target range,Perceived social support,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
6114,NCT02963753,To determine serum glucose levels in both groups during 75 gram oral glucose tolerance test screening,,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
6115,NCT02639637,Forearm Blood Flow,Heart Rate,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6116,NCT01698775,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A: 24-week Placebo Controlled Period + Phase B: 30-week Active Controlled Period),Change From Baseline in eGFR at Week 54,,2012-10-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6117,NCT00095654,death,Renal Events,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6118,NCT02475499,Incident pancreatic cancer,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
6119,NCT00729196,Percent change in weight,Change in HbA1c,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
6120,NCT00941447,Blood Glucose,Quality of Life,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
6121,NCT06241638,HbA1c in the two groups,,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA']
6122,NCT04319003,Change in sugary beverage (coffee/tea) consumption using beverage frequency questionnaires,,,2018-08-03,COMPLETED,INTERVENTIONAL,['NA']
6123,NCT05830318,System Usability Scale,Cardiovascular events,,2023-08-23,RECRUITING,OBSERVATIONAL,['NA']
6124,NCT00147251,Changing LDL Cholesterol,Changing Blood Pressure,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6125,NCT03738865,Severe Hypoglycemia Rescue,Hypoglycemia Resolution,,2018-09-27,COMPLETED,INTERVENTIONAL,['PHASE3']
6126,NCT04861324,Maternal Lipids,Maternal serum carotenoids,,2021-04-28,COMPLETED,INTERVENTIONAL,['NA']
6127,NCT05029804,Pedometer,,,2021-09-30,UNKNOWN,INTERVENTIONAL,['NA']
6128,NCT00717483,,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
6129,NCT00449605,Change from baseline in glycemic measure HbA1c,Relative change from baseline in HDL-C,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE3']
6130,NCT05681884,Primary Objective,Mean change in CST,,2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2']
6131,NCT06206317,Static Two-Point Discrimination Test,,,2024-02-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6132,NCT04529278,Weight Loss at Week 26,Therapeutic monitoring,,2021-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6133,NCT01472809,Safety and tolerability,Pharmacodynamics,,2011-12,SUSPENDED,INTERVENTIONAL,['PHASE1']
6134,NCT04013594,Glycemic variability,hand grip strength,,2019-08-20,COMPLETED,INTERVENTIONAL,['NA']
6135,NCT06229795,Effect on,Effect on,,2023-11-07,RECRUITING,INTERVENTIONAL,['PHASE3']
6136,NCT02166294,Number of participants with adverse events,Time to Initial Wound Closure,,2014-06,TERMINATED,INTERVENTIONAL,['NA']
6137,NCT02955238,Change in Carotid Intimal Medial Thickness (CIMT) Measurement,Medication Adherence,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
6138,NCT00829062,The aim of this project is to present evidence based practice to Missouri Medicaid to expand coverage of continuous subcutaneous insulin infusion (CSII) in pediatric patients with diabetes. - Hemoglobin A1C,Glycemic variability as shown by continuous glucose recording,,2009-01,WITHDRAWN,INTERVENTIONAL,['NA']
6139,NCT02416193,Trail Making Test Part B,Semantic Fluency Test,,2015-09-23,TERMINATED,INTERVENTIONAL,['PHASE2']
6140,NCT03353818,Physical activity,Estimated VO2max,,2017-05-01,UNKNOWN,INTERVENTIONAL,['NA']
6141,NCT00846638,Drinking outcome,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6142,NCT04799327,Change from baseline in body weight,Concentration of SHR20004 in plasma at steady state,,2021-03-29,UNKNOWN,INTERVENTIONAL,['PHASE2']
6143,NCT01782105,Weight change during pregnancy,Optimize the intervention before measuring its impact on the prevention of gestational diabetes mellitus on a larger scale.,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
6144,NCT01546597,"Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of metformin","Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6145,NCT02433262,To measure the prevalence of GDM diagnosed using WHO versus IADPSG criteria,To measure the incidence of adverse neonatal outcomes in women diagnosed with GDM using either of the criteria (WHO or IADPSG),,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
6146,NCT06283277,Third trimester clavicle length measurement,Neonatal actual clavicle length,,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6147,NCT00694122,Blood Glucose,Growth Hormone,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6148,NCT00473330,Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24,Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6149,NCT02471794,Change in A1C using the A1C blood test,Change in low-density lipoprotein cholesterol (LDL) using LDL measurement,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
6150,NCT05738577,glycemic control according to apelin level,Detection of the relation of apelin and lipid profile in diabetic patients,,2023-02-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6151,NCT04133493,Wound Healing,Pain reduction: visual analogue scale (VAS),Histology assessment from biopsies,2019-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6152,NCT00131144,time to progression of diabetic retinopathy,time to moderate vision loss,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6153,NCT02934113,Change in Weight,,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
6154,NCT03202979,Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale,Frequency of treatment-related adverse events,,2017-05-16,COMPLETED,INTERVENTIONAL,['PHASE2']
6155,NCT04222231,Change in insulin sensitivity by blood-flow restriction or classical resistance training,Changes in skeletal muscle mass by blood-flow restriction or classical resistance training,Changes in skeletal muscle strength by blood-flow restriction or classical resistance training,2019-10-28,RECRUITING,INTERVENTIONAL,['NA']
6156,NCT03520660,Phase I - SVR 12,Phase II: Change in Ishak fibrosis score,,2018-10-19,RECRUITING,INTERVENTIONAL,['PHASE4']
6157,NCT03936634,Arm B - Auto-antibody positive first degree family members,Arm B - Auto-antibody positive first degree family members - Framework,,2016-11-14,UNKNOWN,OBSERVATIONAL,['NA']
6158,NCT00328848,Quality of medical management,Opportunity costs of caregiver time,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
6159,NCT05342545,Frequency of UACR testing order for CKD in patients with T2DM who have not had such testing within the past year,Frequency of new clinical diagnosis of CKD in patients with T2DM who have not had UACR assessment within the past year,Frequency of referral to a nephrologist,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
6160,NCT03610178,NR3C1,Methylation of candidate genes,,2015-08,UNKNOWN,INTERVENTIONAL,['NA']
6161,NCT01472328,Skeletal muscle insulin sensitivity,,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
6162,NCT01943214,Body constitution of type II diabetes mellitus patients,Diabetic neuropathy of type II diabetes mellitus patients,,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
6163,NCT00867425,Change in weight,Health Related Quality of Life,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
6164,NCT02050984,Reduction of hypertension medication prescription,Reduction of hypertension medication prescription,Adverse events,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
6165,NCT05551858,Adverse events,Change in Pain Measurements numeric score from baseline to end of treatment with proglumide compared to Placebo,,2022-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6166,NCT02274272,Change in blood fat,Change in the DM marker,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6167,NCT03405415,Assessment of glucose concentrations,,,2018-01-27,COMPLETED,INTERVENTIONAL,['NA']
6168,NCT06117449,HbA1C level,,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6169,NCT04015388,"Evaluate performance of glucose predictive models, clinical decision support algorithms, and performance measures in simulated real-time setting.","Further development of GlyCU system functionality (simulation, training, and clinical decision support capabilities) and identification of necessary steps for integration with the OSUWMC electronic health record database.",,2014-08-19,COMPLETED,OBSERVATIONAL,['NA']
6170,NCT02226003,Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach,Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach,,2014-09-23,COMPLETED,INTERVENTIONAL,['PHASE3']
6171,NCT06320600,The currency analysis of diabetes classification,To establish a model for predicting diabetic neuropathy,To establish a model for hypoglycemic therapy,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
6172,NCT02569151,Death,"new, worsened, or improved microvascular and macrovascular events",,2016-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6173,NCT00819741,Change in Glycosylated Haemoglobin A1c (HbA1c),Haematology: Haemoglobin,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
6174,NCT03556033,Symptom score in response to insulin-induced hypoglycaemia,Glucose variability as measured by glucose sensor monitoring,Inflammatory/atherogenic phenotype of circulating monocytes from the participating patients,2018-11-23,COMPLETED,INTERVENTIONAL,['PHASE2']
6175,NCT01663220,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
6176,NCT04058626,Diagnostic Accuracy,,,2019-03-04,COMPLETED,OBSERVATIONAL,['NA']
6177,NCT00675740,between-group difference in flow-mediated dilation of the brachial artery,relative effects of treatment on parameters of - glucose metabolism - inflammatory plasma markers - markers of endothelial function - cellular markers in muscle and fat biopsies,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6178,NCT04120259,Measurement of Fasting Blood Sugar,,,2019-04-22,COMPLETED,INTERVENTIONAL,['NA']
6179,NCT05388643,Gestational Diabetes Mellitus,Patient Satisfaction with Diabetes Screening Method,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6180,NCT01824407,Complete closure,Rate of amputation and other adverse events,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
6181,NCT03334643,Postprandial glycemic response,,,2018-06-04,COMPLETED,INTERVENTIONAL,['NA']
6182,NCT05252728,Differences of β diversity of gut microbiota between diabetic groups and healthy control.,,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
6183,NCT05176132,Prevalence of unrecognized obesity-related diseases,SDOI attitude to physical activity questionnaire,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
6184,NCT01068197,Change in BMI z-score between the two dietary groups,"Differences in subjective, hormonal, and metabolic between the two dietary arms",,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6185,NCT02759107,Number of Participants With One or More Serious Adverse Event(s) (SAEs),Pharmacodynamics (PD): Ratio of AUC of Glucose on Day 23 to Baseline (Part C),,2016-05-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6186,NCT01129557,Cumulative Incidence of Aldosterone Breakthrough in Subjects Who Completed the 9-month Study Protocol.,Pre- and Post-treatment Serum Aldosterone in Subjects With and Without Aldosterone Breakthrough.,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE4']
6187,NCT02036892,Hemoglobin A1c,Center for Epidemiological Studies Depression Scale,,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
6188,NCT00850096,Continuous Glucose Monitoring (CGM),Overall Glycemic Control,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6189,NCT01586442,PIIINP,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6190,NCT01068665,Change in Glycosylated Haemoglobin (HbA1c),Change in Fasting Plasma Glucose (FPG),,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6191,NCT04905680,"Behaviour, self-efficacy and attitudes",Systolic and Diastolic Blood pressure,,2021-05-04,UNKNOWN,INTERVENTIONAL,['NA']
6192,NCT04867707,Change in glycocalyx integrity,Change in Vascular function,,2021-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6193,NCT00996658,Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks,Change From Baseline in Fasting Plasma Glucose (FPG) After 18 Weeks,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6194,NCT06245252,fasting blood glucose levels,score of fatigue severity scale,,2024-02-10,RECRUITING,INTERVENTIONAL,['NA']
6195,NCT01749345,Quality of life,Low density lipoprotein (LDL) Cholesterol,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
6196,NCT01137695,Glucose control,adverse effects,,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
6197,NCT00110448,"Aortic and peripheral vascular events, which needs internal medicine and/or surgical medical treatment",,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6198,NCT04708145,DRSS Level Achievement in the VOYAGE study,Incidence of Adverse Events,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6199,NCT05078697,microbiota,,,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA']
6200,NCT00172406,,,,na,COMPLETED,OBSERVATIONAL,['NA']
6201,NCT04790526,HBA1c,Joint error position test,,2021-07-12,COMPLETED,INTERVENTIONAL,['NA']
6202,NCT06222086,Physical activity level assessment with multi-sensor activity tracking,Upper extremity functional exercise capacity (percentage of the expected value (%)),,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6203,NCT03195855,Change in maximum ankle range of dorsiflexion in stance phase when both feet are in contact with the ground (double support phase).,Change in functional reach test,To investigate the compliance/adherence rates of the home exercise programme,2018-05-11,COMPLETED,INTERVENTIONAL,['NA']
6204,NCT03811587,Dosage of antidiabetic medication used,,,2018-11-05,COMPLETED,INTERVENTIONAL,['NA']
6205,NCT04145804,The achievable percentage of time in range (TIR) 70 - 180 mg/dL for the whole study population after 3 months.,Percentage of time spend in Auto Mode,,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6206,NCT02217306,Contrast Sensitivity,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
6207,NCT00000159,,,,1983-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6208,NCT05207020,Collect glucose values (after a test meal),,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
6209,NCT03369145,Leukocyte cell-derived chemotaxin 2 (LECT2),Body fat percentage,,2017-12-11,COMPLETED,INTERVENTIONAL,['NA']
6210,NCT05134662,Changes from baseline in fasting serum glucose and insulin as measured by Homeostasis Model Assessment for Insulin Resistance 2 (HOMA-IR2),Change from baseline in hemoglobin A1c (HbA1c),Change from baseline metformin concentrations,2022-02-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6211,NCT00787670,To determine whether surgically induced weight loss decreases the risk of CVD in morbidly obese subjects with Type 2 Diabetes Mellitus (T2DM),To elucidate the mechanisms by which surgically induced weight loss reduces over time the risk of CVD in morbidly obese subjects with T2DM.,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
6212,NCT01279928,,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
6213,NCT04737499,Change of Concentration of HbA1c,Change of Score of Quality of life,,2016-07-05,COMPLETED,INTERVENTIONAL,['NA']
6214,NCT01471509,Change in blood glucose concentration,Change in serum insulin concentration,,1982-08,SUSPENDED,INTERVENTIONAL,['NA']
6215,NCT01966393,Percentage of time of glucose levels (as measured by continuous glucose sensor) spent in the hypoglycemic range.,Number of patients with at least one hypoglycemic event with or without symptoms below 3.0 mmol/L based on glucose sensor reading,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6216,NCT00511732,Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline),"Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations",,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6217,NCT01223339,Urinary Glucose Excretion over 24 hours for the Multiple Dose Cohort,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6218,NCT05453357,Overall Feasibility of Remote Glucose Monitoring,Changes in self-efficacy,,2024-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6219,NCT00841867,To determine differences in glucose metabolism between subjects who have had partial pancreatectomy due to a benign lesion and those who have not had such a surgery.,,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
6220,NCT02851849,Change from baseline in HbA1c,Change from baseline in body weight,"Exploratory Objective - Change from baseline from an Oral Glucose Tolerance Test (area under the curve for glucose, glucagon, insulin, C-peptide, and total and active GLP-1)",2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6221,NCT01527539,HbA1c,Occurence of hypoglycaemic episodes,,2001-11-23,COMPLETED,INTERVENTIONAL,['PHASE3']
6222,NCT06144788,Changes in HbA1c at the 12 week from the baseline,,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6223,NCT00810823,"What is the factor ""X"" that cause the remission of type 2 diabetes after gastric bypass",,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
6224,NCT04128150,Evolution of retina diseases,,,2018-01-17,UNKNOWN,OBSERVATIONAL,['NA']
6225,NCT02244879,C reactive protein (CRP),Metabolic and oxidative markers,body composition and bone mineral density,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6226,NCT05849753,Percent sensor glucose time-in-range,Technology Attitudes,,2023-07-26,RECRUITING,OBSERVATIONAL,['NA']
6227,NCT03398356,Serum Levels of DMA at Different Time Points,,,2017-10-20,COMPLETED,INTERVENTIONAL,['PHASE4']
6228,NCT03704103,Number of participants meeting HgbA1c <7%,Hypoglycemia,iSage Product Satisfaction Survey (iSage group only),2018-08-28,COMPLETED,INTERVENTIONAL,['NA']
6229,NCT02313805,The total number of educational points addressed for the safe and effective use of insulin (of the possible 21 specified),"The number of educational points addressed under each of the four educational domains: insulin side effects, recognition and treatment of hypoglycemia, administration of insulin, and drawing up insulin using the syringe method.",,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
6230,NCT00473525,Evaluation of Dose Response in HbA1c (%),Incidence of Adverse Events,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6231,NCT03559621,weight-loss goal,Sence of Coherence,,2019-04-14,COMPLETED,INTERVENTIONAL,['NA']
6232,NCT06136793,Participant Cardiometabolic Disease Markers: Waist circumference,Household Supports for cardiometabolic disease reduction measures: Family Collective-Efficacy,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6233,NCT05836194,The International Clinical Diabetic Retinopathy Disease Severity Scale within the 2-fields fundus photography and Ultra-Wide field scanning laser ophthalmoscopy (Optomap) imaging and statistical comparison,Number of predominantly peripheral lession(PPL) with Optomap imaging,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
6234,NCT00555854,HbA1c,"Lipids profile ,blood pressure, waist, BMI and medication Questionnaire: PAID PCD HCCQ TSRQ Health Care Behavioural a",,2005-12,COMPLETED,INTERVENTIONAL,['NA']
6235,NCT02475070,Glucagon Response to Meal,Incretin Hormones,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6236,NCT06050642,Change in the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care],E.2 Number and relevance of impact that can have an impact on diabetes [Comparison: Enhanced Care vs Standard Care],,2023-09-04,RECRUITING,INTERVENTIONAL,['NA']
6237,NCT00444483,The primary outcome measure regarding patients metabolic control was the improvement of quality of life six months after DTTP.,A secondary objective of the study was the comparison of QoL- subscale in patients already on insulin therapy with those newly on insulin therapy.,,na,COMPLETED,INTERVENTIONAL,['NA']
6238,NCT01816906,Postural Sway During Shod Standing,Ankle Strength Right 2,Vibration Perception Threshold,2012-04,COMPLETED,INTERVENTIONAL,['NA']
6239,NCT04092959,Change from Baseline Systolic Blood Pressure at 3 months,Time and Frequency of Adverse Reactions and Serious Adverse Events through the study completion,,2019-09-20,UNKNOWN,INTERVENTIONAL,['NA']
6240,NCT01010035,to identify the removal of the free and esterified cholesterol in type 2 diabetes patients,,,2006-09,COMPLETED,OBSERVATIONAL,['NA']
6241,NCT00817973,Triglyceride levels,Incretin levels,,na,COMPLETED,INTERVENTIONAL,['NA']
6242,NCT01300338,Mean Change in Diastolic Blood Pressure,,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
6243,NCT03500016,Cardiorespiratory fittness/maximal oxygen consumption,Plasma and tisue metabolomics,Lipid profile,2018-02-26,COMPLETED,INTERVENTIONAL,['NA']
6244,NCT05625321,Dietary Intake,Perceived Quality of Life,,2023-03-27,RECRUITING,INTERVENTIONAL,['NA']
6245,NCT01226966,Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%,Change in Body Weight at Month 24,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
6246,NCT01840085,The proportion of all subjects reporting Adverse Events and Serious Adverse Events related to study treatment,,Proportion of all subjects treated and terminating prematurely due to adverse events related to study treatment.,2015-12,TERMINATED,INTERVENTIONAL,['PHASE3']
6247,NCT04710940,Completion of diabetes self-management training (Aim 3),Hemoglobin A1C (HbA1C) (Aim 3),Predictors of guideline-concordant diabetes care (Clinical utilization) (Aim 1),2021-01-13,COMPLETED,INTERVENTIONAL,['NA']
6248,NCT00742547,HbA1c,incidence of diabetes-related complications,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
6249,NCT05789251,standardized breakfast test resuslt compare to oral induced hyperglycemia test,,,2023-06-19,RECRUITING,INTERVENTIONAL,['NA']
6250,NCT01948479,ulcer recurrence rates,peak pressure reduction with the addition of the intervention,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
6251,NCT01941199,"Cmax,ss of DA-1229 and metformin",,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6252,NCT04907721,Differences in the calculated GLUSENTIC index between individuals with or without MASLD without diabetes,"Simple linear regression between the variables, pancreatic steatosis and amino acid stimulated glucagon or insulin levels in individuals without diabetes.",Differences in fetuin-B,2021-05-27,COMPLETED,INTERVENTIONAL,['NA']
6253,NCT01693133,Percentage of subjects with complete closure of the study ulcer,Cost effectiveness of treatment,Safety,2012-07,COMPLETED,INTERVENTIONAL,['NA']
6254,NCT00859638,Physical Functioning Inventory (PFI),Eight Foot Walk Test,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
6255,NCT01375322,To compare the change from baseline in blood pressures (DBP/SBP) to 16-week regimen between Amtrel® and Co-Diovan®,To compare the response rate (defined as SBP < 130 mmHg and DBP < 80 mmHg) at the end of study,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6256,NCT01762657,Insulin Requirements Among Patients Treated with Oral Cyclosporine and Oral Lansoprazole,Glucagon C-peptide (under the curve) and Hemoglobin A1C levels among patients with existing type 1 diabetes treated with Cyclosporine and Lansoprazole,,2014-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6257,NCT05421715,Evolution of glycemic control hemoglobin (HbA1c) between inclusion and 6 months,Evolution of knowledge about diabetes and glycemic targets between inclusion and T6 months,,2023-04-11,RECRUITING,INTERVENTIONAL,['NA']
6258,NCT05724888,Retention for follow-up measurements,BREQ2 (Behavioral Regulation in Exercise Questionnaire-2) change,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6259,NCT01263483,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).,,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6260,NCT02339909,Number of Patients Attending Screening Appointment,Number of Patients Requiring Intervention After Sight Outcome From Diabetic Retinopathy Screening.,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
6261,NCT05686655,sleep problems as frequent awakening during the night,,,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6262,NCT04684030,The change of glycated hemoglobin (HbA1c) level,The number of participants with improved clinical glycometabolic parameters,,2020-08-28,UNKNOWN,INTERVENTIONAL,['NA']
6263,NCT02753400,"Change in Aqueous Humor Concentration of the Following Biomarkers:IL-6, IL-8, IP-10, PDGF-AA, TGFβ-1, MCP-1, IL-1β, and VEGF, to be Reported in pg/mL Values",,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6264,NCT05591391,Time in range,Treatment satisfaction questionnaire,,2022-09-28,RECRUITING,INTERVENTIONAL,['NA']
6265,NCT03257566,Screening the incidence of hypothyroidism in patients with type 1 diabetes,,,2017-11,UNKNOWN,OBSERVATIONAL,['NA']
6266,NCT05479591,Change in Glycated Haemoglobin A1c (HbA1c),Change in body weight,,2022-07-30,WITHDRAWN,OBSERVATIONAL,['NA']
6267,NCT01086189,Postprandial glucose and insulin,Postprandial satiety,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
6268,NCT02815943,lipid metabolism,physical activity,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
6269,NCT00240175,Quantitative measures of plantar pressure,,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
6270,NCT01113099,Statin prescription at hospital discharge,,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
6271,NCT02434094,Human factors feedback,,,2015-04,COMPLETED,OBSERVATIONAL,['NA']
6272,NCT01234155,Glycemic Control,Body Composition,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
6273,NCT05348551,Assessment of the proportion of pediatric patients with access to remote monitoring,Evaluation of patients' (and parents') perception of telemonitoring using a scale,,2022-05-20,UNKNOWN,OBSERVATIONAL,['NA']
6274,NCT01754467,Acceptability of NEAT!,Changes in Total Sedentary Time,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
6275,NCT02186353,Change from week 0 in peripheral insulin sensitivity (assessed by frequently-sampled oral glucose tolerance test) at week 12,Change from week 0 in physical activity (assessed by accelerometry) at week 12,,2014-09,WITHDRAWN,INTERVENTIONAL,['NA']
6276,NCT01416324,Adverse events relative to placebo,Measurement of the apparent volume of distribution (V/F) of the study drug,,2011-06-15,COMPLETED,INTERVENTIONAL,['PHASE1']
6277,NCT01070433,The incidence of complete healing of the target ulcer.,Absolute and percentage change in ulcer surface area from baseline to endpoint.,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6278,NCT04889053,The prevalence and incidence rate of CAC in T2DM,The effect of statins on the occurrence and development of CAC in patients with T2DM,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
6279,NCT05051436,Oral glucose tolerance test,Hemoglobin A1C,Muscle biopsy,2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE4']
6280,NCT00696982,"arterial stiffness, defined as change in augmentation index measured by means of a non-invasive technique using the commercially available SphygmoCor System, and the results of the 24 hour blood pressure monitoring","The secondary end results would be oxidative stress parameters, as evaluated by oxidized LDL and Isoprostanes, and markers of inflammatory status, including measurements of pro-inflammatory interleukins and performance of highly sensitive CRP test.",,2008-06,UNKNOWN,INTERVENTIONAL,['NA']
6281,NCT01168297,Diabetes,,,2010-07-06,COMPLETED,OBSERVATIONAL,['NA']
6282,NCT00604383,Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period,Change From Baseline up to 36 Months in Mental and Physical Components of the Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Questionnaire,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6283,NCT02389010,Number of closed skin ulcers within 4 weeks of treatment with cord blood platelet gel (CBPG) vs standard local medications,Cost of treatment,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6284,NCT05327595,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PD: Change from Baseline to Day 28 in Oral Glucose Tolerance (OGTT) 2 Hour Glucose,,2022-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6285,NCT04381429,Change of time in range of blood glucose variation (70-180 mg/dl) versus baseline at the end of each treatment period of 3 months (the last 2 weeks of the period of 3 months) is assessed.,Other CGM parameters: Time in range of blood glucose 70-140 mg/dl,,2020-08-17,RECRUITING,INTERVENTIONAL,['PHASE4']
6286,NCT03737799,Diabetes type defined by insulin requirement at 3 years,Wellbeing (SF12 questionnaire),,2016-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6287,NCT04339530,HOMA-IR (Homeostasis modelling assessment-Insulin resistance),Augmentation index,,2019-07-01,SUSPENDED,OBSERVATIONAL,['NA']
6288,NCT03399825,Evaluation of the sensitivity and specificity of OCTA,,,2018-01,WITHDRAWN,OBSERVATIONAL,['NA']
6289,NCT06028386,Days to complete wound closure,Changes in quality of life,,2023-08-15,RECRUITING,INTERVENTIONAL,['NA']
6290,NCT03414736,Frequency of GI AEs,Adverse events (AEs),,2018-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
6291,NCT02596581,gingival crevicular fluid chemerin level,clinical attachment level,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
6292,NCT00950209,"To determine whether an acute elevation of plasma insulin, secondarily to plasma insulin infusion, modulates the production and the clearance rates of intestinal TRL-apoB48 in type 2 diabetic patients in the fed state",To determine if this is a direct effect of insulin or an indirect effect due to the decrease of plasma FFA or the decrease of plasma glucose.,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6293,NCT00554281,Decrease in HYPO score,Number of patients who decide to continue using the device,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6294,NCT01937702,injection pain,variability of injection pain,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6295,NCT00329225,HbA1c at each visit,FPG at each visit C-peptide at each visit lipids at each visit BNP at each visit CRP at each visit PAI-1 at each visit MMP-9 at each visit,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6296,NCT01613937,HbA1c,hours of physical activity per week at all time points,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
6297,NCT05984979,VOC Patterns over time as boxplots,Correlation between VOCs and subgroups,,2023-08-07,RECRUITING,OBSERVATIONAL,['NA']
6298,NCT02672436,The ulcer closure rate,Adverse event incidence,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE2']
6299,NCT01917760,pharmacokinetic characteristics of γ-aminobutyric acid (GABA),serological characteristics,Exploratory measures,2013-07,COMPLETED,OBSERVATIONAL,['NA']
6300,NCT02200991,Change from baseline in postprandial plasma glucose at Day 29 after a standardized breakfast,Proportion of patients with adverse events,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6301,NCT04477694,Comparison of stomach ache and other effects in diabetic and non-diabetic patients in colonoscopy under sedoanalgesia,,,2020-12-27,RECRUITING,OBSERVATIONAL,['NA']
6302,NCT02277509,Percent Change in BMI,Sustained changes in HbA1c,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
6303,NCT01113801,Change in Log Transformed (In) Serum Creatinine From Baseline to 12 Month Endpoint,Estimated Glomerular Filtration Rate (eGFR) Slope of Change From Baseline Through 12 Months,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2']
6304,NCT02374879,System Accuracy (SA) evaluation,,,2015-02-01,COMPLETED,INTERVENTIONAL,['NA']
6305,NCT05040009,Screening for diabetic foot and diabetic complication in patients attending at Diabetic center,,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6306,NCT00940797,Insulin sensitivity,"Creatinine, Total Cholesterol, HDL, Triglycerides, Uric acid, AST, ALT, FA, DHL",,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6307,NCT04815278,Blood Pressure at Month 12,Medication Covariates,Scores on Effort-Reward Imbalance Scale,2021-09-17,RECRUITING,INTERVENTIONAL,['NA']
6308,NCT05281614,Adverse events of vedolizumab treatment as a measure of safety and tolerability,Change in T1D antibody titers,,2022-09-21,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6309,NCT03202875,Assessment of PD parameters: Area under the body weight standardized glucose infusion rate (GIR),Number of adverse events (AEs),,2012-11-14,COMPLETED,INTERVENTIONAL,['PHASE1']
6310,NCT03051243,Percentage of patient with mean blood glucose levels,TTD (total daily dose) of insulin,,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
6311,NCT05216796,Decrease in cerebral gluatamate,,,2022-05-18,RECRUITING,INTERVENTIONAL,['NA']
6312,NCT03059550,Percentage of OGTT performed after an acute coronary syndrome,Profile of the patients according to their glucose abnormalities,,2013-03-01,UNKNOWN,OBSERVATIONAL,['NA']
6313,NCT01622816,ETDRS Letter Score,ETDRS Letter Score Consistency,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
6314,NCT02012465,Incidence of hyperglycemia,Remission of primary oncologic diagnosis at one year,,2013-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6315,NCT04903756,Analysis of audio-recorded consultations between surgeons and patients.,Analysis of healthcare professional interviews,,2020-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6316,NCT01363609,food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%),GLP-1 analog treatment related changes in obese patients with type 2 diabetes in brain arterial blood flow.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
6317,NCT03982381,"Time to first occurence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer.",Health-related quality of life with respect to diabetes treatment satisfaction.,,2019-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6318,NCT01686620,Change in HbA1C,Daily blood glucose measures,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6319,NCT01710748,Neointimal hyperplasia volume obstruction,Target vessel failure,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
6320,NCT03638349,Scaled preference questionnaires on new blood glucose monitoring digital tool.,Preference questionnaires on new blood glucose monitoring digital tool based on insulin or non-insulin using subjects,,2018-07-17,COMPLETED,OBSERVATIONAL,['NA']
6321,NCT03907423,serum levels of Sortilin,,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
6322,NCT00901043,Brachial artery flow mediated dilation (FMD),"Change in weight, waist circumference, blood pressure, fasting lipids, fasting insulin, HBA1c and glucose levels",,2007-10,COMPLETED,INTERVENTIONAL,['NA']
6323,NCT00279305,Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year,,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6324,NCT03988413,Change of urinary routine,Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of SYHA1402,,2019-08-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6325,NCT01009528,Outcome and process measures from the danish diabetes guideline,Interview data concerning the impact of the electronic feedback system in the intervention clinics,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
6326,NCT05234281,Changes in level of patient activation,Changes in level of functioning,,2021-05-01,RECRUITING,INTERVENTIONAL,['NA']
6327,NCT04468243,Point of Care HbA1c Test,,,2021-04-01,TERMINATED,INTERVENTIONAL,['NA']
6328,NCT01898572,Carotid Intima Media Thickness (CIMT),CIMT,Diet intake,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
6329,NCT02713997,Maximal acute C-peptide response to glucose (ACRmax),Severe Adverse Events,,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6330,NCT04635280,"Description of Patient satisfaction and experience at Day 90 by the ""You and your management by your home healthcare provider"" questionnaire","Evolution of patients' clinical profile : Percentage of time spent over a 4-week period in glycemic target range, in hypoglycaemia and in hyperglycaemia",,2021-05-10,COMPLETED,INTERVENTIONAL,['NA']
6331,NCT02366767,Safety of Automatic Closed Loop Insulin Delivery System in Adolescents and Adults With Type 1 Diabetes,Efficacy of Hybrid Closed-loop System in Comparison With Control,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
6332,NCT02145611,Change from baseline in the central blood pressure after 12 weeks of vildagliptin x glibenclamide treatment,,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6333,NCT01536028,Area under the GIR (glucose infusion rate)-curves in the first two hours post-dosing,Hypoglycaemic episodes,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6334,NCT03358264,Vascular function,,,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6335,NCT04092140,Electromyogram,,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA']
6336,NCT03829046,Number of Adverse Events,Alpha5/Beta3 Activation Levels,,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6337,NCT04892069,Change in Glycated Haemoglobin (HbA1c),Change in the occurrence of severe hypoglycaemic events before and after initiation of treatment,,2021-05-27,COMPLETED,OBSERVATIONAL,['NA']
6338,NCT05574335,Acceptable T cell phenotype signature by the change from baseline in the CD4 Treg/Tem ratio,Insulin use (U/kg/day),,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6339,NCT00350701,Effect of Androgel Treatment on Relative Nuclear Factor kB Activity Compared to Placebo,Change in Inflammatory Mediator C-Reactive Protein (CRP) Following Treatment With Testosterone,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6340,NCT01864564,Number of Participants With a Composite Perinatal Outcome,Large for Gestational Age,,2013-06-18,COMPLETED,INTERVENTIONAL,['NA']
6341,NCT05369078,Collect and evaluate TEAEs (including clinical AEs and Lab AEs) of THR-1442 in healthy subjects during study,Select and evaluate pharmacokinetic characteristics(Cmax) of THR-1442 in healthy subjects during the study,,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
6342,NCT01906970,"Measurement accuracy, glucose control quality, safety, handling and functionality of ClampArt®",,,2013-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6343,NCT04195477,Change in BMI,Change in Physical Activity,,2020-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6344,NCT00948116,Development of contrast induced nephropathy (CIN) which will be defined as an increase in Cr of ≥ 44 μmol/l within 72 hours post-procedure.,,,2009-07,UNKNOWN,OBSERVATIONAL,['NA']
6345,NCT04961931,urine phosphorus concetration,,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6346,NCT01611168,"Lipids (LDLc, HDLc, cholesterol, and triglyceride)",,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
6347,NCT05481801,Vaccination adherence,Death,,2022-09-01,COMPLETED,OBSERVATIONAL,['NA']
6348,NCT00001346,,,,1992-11,COMPLETED,OBSERVATIONAL,['NA']
6349,NCT03071692,"Number of patients with first occurrence of nonfatal MI, nonfatal ischemic stroke, coronary revascularization, or CV death.",Nonfasting Remnant Cholesterol Endpoint,,2017-03-23,TERMINATED,INTERVENTIONAL,['PHASE3']
6350,NCT04315545,fasting and postprandial insulin,fasting and postprandial stable glucose isotopes,MP,2020-02-06,RECRUITING,OBSERVATIONAL,['NA']
6351,NCT01208701,Fractional excretion of sodium,Augmentations index,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6352,NCT01209416,Effects of ghrelin during basal and hyperinsulinemic conditions,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
6353,NCT04278742,Wound healing,Behaviour score assessed by questionnaire,,2018-12-03,UNKNOWN,INTERVENTIONAL,['NA']
6354,NCT01787669,Proportion of eyes that have central macular thickness <300 microns 6 months after switching,Mean change in central macular thickness (CMT) as measured by OCT.,Mean change in BCVA (best corrected visual acuity),2013-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6355,NCT03100383,Gestational Weight Gain (GWG).,Eating behavior,,2013-11-01,COMPLETED,OBSERVATIONAL,['NA']
6356,NCT02479399,Incidence of malignant tumor,Safety developed by adverse events and laboratory tests,,2014-07-17,COMPLETED,OBSERVATIONAL,['NA']
6357,NCT03877003,"Plasma lipids (total cholesterol, HDL cholesterol and triglycerides) in mg/dL",Analysis of microbiota diversity (expressed as concentrations of different microorganisms.,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
6358,NCT01085682,Incidence of Type 2 Diabetes Mellitus,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6359,NCT00228605,Safety and tolerability when used over a 12-month period for the management of breakthrough pain in opioid tolerant patients,Assess the patients' overall medication performance,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6360,NCT02400450,LDL-Cholesterol,Food Consumption Patterns,,2016-09,WITHDRAWN,INTERVENTIONAL,['NA']
6361,NCT06232746,Anastomosis Patency,,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6362,NCT04107207,Blood Sugar Levels,vulvovaginal health,,2019-11-11,COMPLETED,INTERVENTIONAL,['NA']
6363,NCT01189461,Mean Total Number of Injections,Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Week 48 (End of Treatment),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6364,NCT02629705,Insulin sensitivity assessed by hyperinsulinemic clamp: M-value,Glycemia during OGTT,"Markers of systemic inflammation including lymphocyte activation, cytokines and adipokines",2015-10,COMPLETED,INTERVENTIONAL,['NA']
6365,NCT00509262,Percentage of Participants With Hypoglycemic Events,Change From Baseline in Body Weight at Week 54,,2007-10-09,COMPLETED,INTERVENTIONAL,['PHASE3']
6366,NCT01334151,Speed of absorption,,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6367,NCT03652389,reduction in the levels of HbA1c,,,2018-12-18,COMPLETED,INTERVENTIONAL,['NA']
6368,NCT00057304,,,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6369,NCT05119179,Previously unidentified cis-eQTLs associated with change in gene expression due to GLP-1 challenge,Polygenic prediction model for GLP-1 therapy-associated outcomes,,2021-11-22,RECRUITING,INTERVENTIONAL,['PHASE4']
6370,NCT05873920,atrial fibrillation recurrence,,,2023-05-09,RECRUITING,OBSERVATIONAL,['NA']
6371,NCT00812539,Subject and provider satisfaction with the intervention.,Subject knowledge of diabetes and motivation,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
6372,NCT00748072,The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications.,,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6373,NCT02129595,"insulin sensitivity: overall, muscle- and liver specific",brown adipose tissue activity,Blood pressure,2014-04,COMPLETED,INTERVENTIONAL,['NA']
6374,NCT01183455,Mixed-Meal Tolerance Test (MMTT)-Stimulated 2-hour C-peptide Area Under the Curve (AUC),Pharmacokinetic Parameters of Aralast NP,,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6375,NCT00543959,Body fluid gain from baseline after 12 weeks,Fasting plasma glucose after 12 weeks,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE2']
6376,NCT04501341,Decreasing total daily dose of insulin (>= 30%),HbA1c,,2016-03-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6377,NCT05600179,Changes in epivascular glia after Dexamethasone implant in patients with diabetic retinopathy and inflammatory macular edema,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
6378,NCT04171648,Change from Baseline Blood Glucose Response (Glycemic Response),waist to hip ratio,,2020-03-02,TERMINATED,INTERVENTIONAL,['NA']
6379,NCT00196989,Percentage change from Baseline (Day 1) in glycated hemoglobin (HbA1c) levels at Week 16 as a measure of improvement in glucose control,Change from Baseline (Day 1) in QUICKI at Week 16,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6380,NCT01124617,Change From Baseline in Average Numerical Rating Scale (NRS) Score at Week 12,Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Scores at Week 12,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6381,NCT00518115,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6382,NCT05478070,Maternal outcomes,,,2022-05-15,RECRUITING,INTERVENTIONAL,['NA']
6383,NCT00529204,Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy,Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2']
6384,NCT01398995,Comparison of glucose excursion (change in blood glucose) between baseline and the end of exercise between the four conditions.,Ratio of respiratory quotient (RQ) at the beginning of exercise to RQ at the end of exercise compared between the four conditions.,,2011-05,TERMINATED,INTERVENTIONAL,['NA']
6385,NCT03794739,Altered TMEM219 expression in pancreatic islets/beta cells in diabetes.,Altered TMEM219-peripheral regulating factors in diabetes.,,2020-08-08,RECRUITING,OBSERVATIONAL,['NA']
6386,NCT05231031,Serum cortisol level,The perceived stress score (PSS),,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
6387,NCT03363464,All-cause mortality,"Acute kidney injury (Inpatient, any position)",,2017-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6388,NCT01498900,HbA1c (glycosylated haemoglobin),Adverse drug reactions (ADR),,2004-08,COMPLETED,OBSERVATIONAL,['NA']
6389,NCT01885260,The effect of ISIS-GCGRRx on serum fructosamine,The tolerability of ISIS-GCGRRx,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6390,NCT04789473,Polygenic Risk Score Prediction for Gestational Diabetes,Impact of Social Determinants of Health on Risk,,2021-06-24,UNKNOWN,OBSERVATIONAL,['NA']
6391,NCT00116831,Model Adjusted Change From Baseline in Percent Atheroma Volume (PAV) to Month 18,Number of Other Cardiovascular Events,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6392,NCT01605422,"Effect of pulse consumption on satiety in acute, single bolus controlled feeding trials.",,,2011-10,UNKNOWN,OBSERVATIONAL,['NA']
6393,NCT03760991,Change in glycated hemoglobin (HbA1c),Number of participants with health care utilization,,2018-12-18,COMPLETED,INTERVENTIONAL,['PHASE4']
6394,NCT01772251,Adverse events and serious adverse events occurence,• To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,• Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs. placebo,2013-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6395,NCT04512885,success rate,satisfaction measured by auto-questionnaire,,2020-07-16,COMPLETED,OBSERVATIONAL,['NA']
6396,NCT03657537,Cognitive composite score (global score),Symbol Digit Modalities Test (SDMT),,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1']
6397,NCT01431807,Adverse events,,,2011-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6398,NCT00344903,,,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
6399,NCT04822740,Glycemic variability by the coefficient of variation of blood glucose in percent,Patient satisfaction,,2022-12-07,TERMINATED,INTERVENTIONAL,['NA']
6400,NCT00910130,,,,2008-07,UNKNOWN,OBSERVATIONAL,['NA']
6401,NCT02660047,Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion),Brown adipose tissue,Hypoglycaemic episodes,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6402,NCT01973361,Change in wound surface area,Number of wounds healed,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
6403,NCT00004572,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
6404,NCT06005142,Fasting Glycemia,Microbiota composition by 16S rRNA gene sequencing,,2023-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6405,NCT03192410,Major cardiovascular events,Cognitive function,Circulating fatty acids,2002-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6406,NCT00821795,"For Transition From Inpatient to Outpatient Care, Evaluate Glycemic Control in Subjects Randomized to Receive 70/30 NPH/Regular Insulin or Aspart Analog 70/30 Mix Bid- Main Outcome Will be HbA1c During Transition Outpatient Therapy Phase.",Twice Daily Blood Glucose Monitoring Using Telehealth Transmitter,,2009-03-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6407,NCT03645109,Changes in the parameters that make up the glycemic profile,"Changes in calcium, phosphorus and vitamin D3",,2020-02-28,COMPLETED,INTERVENTIONAL,['NA']
6408,NCT03683888,Epicardial fat thickness (EAT),Hemoglobin A1c (HbA1c) percentage (%),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
6409,NCT01648153,Change from baseline in fasting plasma glucose and weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test (MMT),t1/2,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6410,NCT00713921,Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke. Develop pilot data of medical therapy (Toviaz) in diabetic and stroke bladder dysfunction.,,,2009-09-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
6411,NCT02373150,Safety and tolerability of imeglimin: laboratory assessments,,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6412,NCT01113671,Reverse Cholesterol transport of the HDL,Serum inflammatory markers,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6413,NCT01374568,Bone Turnover in Subjects Treated With Sitagliptin When Compared to Those Treated With Placebo,,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE4']
6414,NCT05926414,HbA1c (%) changes,,,2023-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6415,NCT03181737,Diabetes Self-Management Questionnaire (DSMQ-R),Subjective usefulness of the program,,2017-08-03,TERMINATED,INTERVENTIONAL,['NA']
6416,NCT03794336,Overall Gastrointestinal tolerability,Medication possession ratio (MPR),,2019-06-29,COMPLETED,INTERVENTIONAL,['PHASE4']
6417,NCT03544684,24 hour glycaemic profile,,,2015-03-09,COMPLETED,INTERVENTIONAL,['NA']
6418,NCT01559025,Beta cell function,Glycemic variability,,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
6419,NCT02769481,Change From Baseline in HbA1c at Week 60,Superiority of Bexagliflozin Over Glimepiride in HbA1c Reduction at Week 60.,,2016-08-15,COMPLETED,INTERVENTIONAL,['PHASE3']
6420,NCT04550585,Low-literacy based education on diabetes knowledge,,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
6421,NCT04627402,Macular thickness,Incidence of complications,,2020-11-12,UNKNOWN,INTERVENTIONAL,['NA']
6422,NCT01255254,Metabolic control,Inflammation,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
6423,NCT04916132,Prevalence,Death,,2021-08-10,RECRUITING,OBSERVATIONAL,['NA']
6424,NCT02587975,Serum concentration of C-terminal telopeptide after treatment in comparison with the baseline,,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
6425,NCT00449891,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
6426,NCT02097277,Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12,Percentage of Participants With ANTI-BMS-986036 Antibody Response,,2014-04-15,COMPLETED,INTERVENTIONAL,['PHASE2']
6427,NCT02210845,Three months average blood glucose (A1c),A1c,body mass index (BMI),2018-07,UNKNOWN,INTERVENTIONAL,['NA']
6428,NCT03694470,"The proportion of patients who were new users of SGLT-2 inhibitors in 2015, 2016, 2017",Number of participants with co-morbidities,,2018-04-15,COMPLETED,OBSERVATIONAL,['NA']
6429,NCT00872326,Angiographic evaluation of angiogenesis and vasculogenesis at target limb,Ankle-Brachial pressure index,,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6430,NCT00788879,Fruit and Vegetable Intake,Confirmed Awareness: Confirmation of recognition of messages,,2003-02,COMPLETED,INTERVENTIONAL,['NA']
6431,NCT03512236,AUCPram_0-8h,Safety and tolerability (Adverse Events recording),,2018-04-25,COMPLETED,INTERVENTIONAL,['PHASE1']
6432,NCT00206258,Area under the curve for glucose,Glucagon and gastric emptying,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6433,NCT02582840,24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set,Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6434,NCT01784471,Changes in total peripheral resistance as assessed by impedance cardiography (ICG) from baseline to day 30,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
6435,NCT00585936,,,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
6436,NCT00518882,Change in Glycosylated A1c (HbA1c) at Week 26,"Hypoglyceamic Episodes, Weeks 26-78",,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6437,NCT03578887,Weight Regain,,,2019-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6438,NCT02219269,Contraceptive method continuation and satisfaction,If Contraception is Accessed in post-partum or post-abortion setting,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
6439,NCT03668470,HbA1c level,coefficients of variation (CV),,2019-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
6440,NCT05823948,Change in glycated haemoglobin (HbA1c),,,2023-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6441,NCT00118963,Glycemic control (HbA1c).,"Markers of endothelial dysfunction, inflammation and fibrinolysis including Small-dense-LDL, Lp(a) and Apo B100, von Willebrand-factor, ICAM, VCAM, selectin, endothelin, Amadori-protein, CRP, fibrinogen, IL-6, TNF-alfa, ADMA, PAI- and t-PA-activity",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6442,NCT03874715,Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm),Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm),,2019-03-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6443,NCT04103671,progression rate of severe non proliferative diabetic retinopathy,The change of quality of life,,2019-12-04,RECRUITING,INTERVENTIONAL,['NA']
6444,NCT03388762,GlycoMark,Adverse events,,2017-12-05,COMPLETED,INTERVENTIONAL,['NA']
6445,NCT06156124,Clinical problems,Sociodemographic data,,2023-06-13,RECRUITING,OBSERVATIONAL,['NA']
6446,NCT04860336,Large for gestational age (LGA),Nutrition Substudy: large for gestational age birthweight,Nutrition Substudy: Maternal fasting free fatty acids,2021-04-01,RECRUITING,OBSERVATIONAL,['NA']
6447,NCT02845557,Area under the curve for incretin hormone,Incretin effect,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
6448,NCT06100796,Response Rate,,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
6449,NCT03162237,Blood glucose,Cytokine detection,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6450,NCT04683211,Iodine supplementation,,,2021-01-05,COMPLETED,OBSERVATIONAL,['NA']
6451,NCT02367690,Presence of Local Skin Reactions (LSR),Ulcer Closure,,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6452,NCT04083248,Acceptability of intervention: Semi-structured Diabetes Study Acceptability Interview Guide,,,2019-09-20,TERMINATED,INTERVENTIONAL,['NA']
6453,NCT01414556,"glucagon/insulin(c-peptide) absolute, incremental and area under curve values",plasma gut hormones and nutrients,,2011-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6454,NCT05094037,Number of foot ulcers,,,2023-12-04,RECRUITING,INTERVENTIONAL,['NA']
6455,NCT06288529,Development of post-contrast acute kidney injury,,,2023-07-15,COMPLETED,OBSERVATIONAL,['NA']
6456,NCT05641402,Experienced Acceptability of the text messages for people with type 2 diabetes,Rating of fidelity to intended behaviour change technique,,2022-07-14,RECRUITING,INTERVENTIONAL,['NA']
6457,NCT04070794,"AUC0-∞ of gemigliptin, LC 15-0636 and metformin",,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
6458,NCT05702931,Mean sensor glucose (mmol/L),Incidence of self-reported hypoglycaemic episodes,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
6459,NCT04439903,"Technology Expectation and Technology Acceptance Questionnaires: Perceived Ease of Use, Usefulness and Trustworthiness of the System at Baseline and Week 5 (Post-intervention)",Diabetes Distress Scale at Baseline and Week 5 (Post-intervention),Potential Correlation Between System Use and Changes in Perceived Emotional Burden at Baseline and Week 5 (Post-intervention),2020-10-12,COMPLETED,INTERVENTIONAL,['NA']
6460,NCT00608348,Muscle sympathetic nerve activity,,,2002-04,COMPLETED,INTERVENTIONAL,['NA']
6461,NCT02445911,Number of Participants With One or More Treatment-Emergent Adverse Events,Accumulation Index (AI),,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6462,NCT05934409,"Change in cardiac non-esterified fatty acid (NEFA) uptake, oxidation and esterification",Change in glycerol turnover,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
6463,NCT02027259,Change in 10-year UKPDS coronary event risk and PHQ-9 depression scores.,,,2012-01-19,COMPLETED,INTERVENTIONAL,['NA']
6464,NCT04883424,Diabetes Attitude Scale,,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
6465,NCT06334068,Number of days at home after surgery (DAH-30).,Quality of Recovery15 (QoR-15),Change in diabetic management at 30 days,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6466,NCT00956735,Lipids and lipoproteins,Mood and perceived stress,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
6467,NCT05579626,Number of Participants with death,All cause mortality,,2023-03-14,RECRUITING,INTERVENTIONAL,['NA']
6468,NCT01109316,Mean of Last Five 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Day 2 for Insulin Lispro 2D and Day 6 for Insulin Aspart 6D Pump Reservoir In-use,Change From Baseline to 8 Weeks Endpoint for Each Treatment in Blood Pressure,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6469,NCT01372163,Number of participants with Adverse Events as a measure of safety and tolerability.,"Urinary recovery and renal clearance of PF-05190457 will be estimated via comparison of the plasma AUC and urinary excretion to provide AE0-τ, AE0-τ%, and CLR as the data permit.",,2011-07,TERMINATED,INTERVENTIONAL,['PHASE1']
6470,NCT01832441,Abolition or reduction of insulin by >50 percentage,Improvement in HbA1C levels,,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6471,NCT01316835,,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
6472,NCT04387448,Percentage change in Urine Albumin-to-Creatinine Ratio (UACR),Plasma PK parameters: area under the plasma concentration-time curve (AUC),,2020-07-28,TERMINATED,INTERVENTIONAL,['PHASE2']
6473,NCT02758275,Changes of mean score adherence to treatment from baseline at 6 and 12 months,Changes of mean systolic blood pressure from baseline at 6 and 12 months,,2016-04-28,COMPLETED,INTERVENTIONAL,['NA']
6474,NCT03159546,System Related adverse device effects,,,2017-05-13,COMPLETED,OBSERVATIONAL,['NA']
6475,NCT04515992,Change from baseline of HbA1c,,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
6476,NCT03191201,"Change from baseline in glucose homeostasis status, assessed by a dynamic two-step hyperglycaemic clamp investigation.",Change from baseline in the Homeostasis Model Assessment (HOMA-2) index at 28 days,Change from baseline in circulating miRNAs,2017-06-21,TERMINATED,INTERVENTIONAL,['PHASE4']
6477,NCT01613105,Data collection on pre treatment concomitant diseases,Safety variables will be summarized using descriptive statistics based on adverse events collection,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
6478,NCT03159052,The number of volunteers with adverse events as a measure of safety,Adjusted Mean Change in Fasting Plasma Glucose,,2017-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
6479,NCT00326222,PAM - Patient activation measure,Triglyceride,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
6480,NCT04976517,readmission,,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
6481,NCT04926415,Change in Adiponectin Plasma Concentration induced by sham taVNS,Changes in Autonomic Function induced by sham taVNS,,2021-06-14,COMPLETED,INTERVENTIONAL,['NA']
6482,NCT01103414,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12.,Changes in LDL Particle Size Subfractions From Baseline to Week 12,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6483,NCT01901861,Release of incretins hormones,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6484,NCT03789695,Difference in annual eGFR decline (slopes) between dabigatran and warfarin patients,,,2018-11-14,UNKNOWN,INTERVENTIONAL,['PHASE4']
6485,NCT02683135,"Difference in glycemic control assessed by continuous glucose monitoring in low-carbohydrate, low-carbohydrate plus post-meal walking, and high-carbohydrate low-fat arm.",Change from baseline in flow mediated dilation of brachial artery after 4 days of intervention.,Change from baseline in body weight after a single meal and 4 days of intervention.,2015-11,COMPLETED,INTERVENTIONAL,['NA']
6486,NCT05181826,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,Ascertain Sample Stability,,2019-05-21,RECRUITING,OBSERVATIONAL,['NA']
6487,NCT03578094,Assessment of the anthropometric measurements of the infant according to the breastfeeding patterns,,,2015-12-01,COMPLETED,OBSERVATIONAL,['NA']
6488,NCT01514305,Absolute Relative Difference (%) to Reference Standard,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
6489,NCT02673138,Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal,Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
6490,NCT00859079,time to reach a plasma glucose below 115 mg/dl,number of hypoglycaemic episodes,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6491,NCT00097500,Beta-cell Function After 52 Weeks of Therapy,"M-value at Baseline, Week 52 and Week 56",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
6492,NCT04767880,Concentration differences in blood glucose following an OGTT,Continuous glucose measurements (CGM),,2021-04-26,COMPLETED,INTERVENTIONAL,['NA']
6493,NCT04504305,effect of investigational product on diabetic individual suffering from diabetic neuropathy assessed by 11 point numeric rating scale.,effect of investigational product on diabetic individual suffering from diabetic neuropathy assessed by Neuropathy total symptom score - 6 .,,2020-07-23,COMPLETED,INTERVENTIONAL,['NA']
6494,NCT05990595,Glycosylated hemoglobin (HbA1C),Small-dense LDL-cholesterol,"Center for Epidemiologic Studies Depression Scale (CES-D), NIMH",2023-07-07,RECRUITING,INTERVENTIONAL,['NA']
6495,NCT01091896,Recurrent vitreous hemorrhage incidence after vitrectomy,Visual outcome,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6496,NCT00723307,Difference in progression of carotid intima-media thickness (measured in millimetres) between groups treated with metformin and placebo,Difference in progression of carotid total plaque volume (measured in cubic millimetres) between groups treated with metformin and placebo,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
6497,NCT05847400,predictors of CKD among T2DM patients attending Assiut University Hospitals. To classify our patients into stages according to KDIGO guidelines,the possible risk factors contributing to progessing CKD in T2DM patients.,,2024-03-01,RECRUITING,OBSERVATIONAL,['NA']
6498,NCT03519529,sex hormone-binding globulin,SD,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
6499,NCT00842426,Body Mass Index,Patient and Physician Satisfaction,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6500,NCT02587936,"All Cause Hospitalizations for Patients With a Triad of Chronic Kidney Disease, Diabetes and Hypertension",30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization),,2016-07-18,COMPLETED,INTERVENTIONAL,['NA']
6501,NCT04385862,To assess the validity of the Dexcom G6 CGM system measurements in IV insulin therapy patients hospitalized in the intensive care unit of the CHUM compared to the blood glucose measurements made using the Accuchek Inform II glucometer,"Assess the obstacles to the integration of the use of the CGM in the intensive care unit, namely the technical problems encountered and remote data management.",,2020-07-27,WITHDRAWN,OBSERVATIONAL,['NA']
6502,NCT04094415,Change in HbA1c (measured in mmol/mol),Patient completed the study under treatment with semaglutide (yes/no),,2019-10-28,COMPLETED,OBSERVATIONAL,['NA']
6503,NCT02421055,Number of Participants With Complete Diabetes Remission at 3 Months,BMI Reduction,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
6504,NCT05596812,Feasibility of the novel risk stratification screening tool,Health service outcomes - Short-form Patient Satisfaction Questionnaire (PSQ-18),,2022-08-23,RECRUITING,INTERVENTIONAL,['NA']
6505,NCT00411411,Restoration of the Insulinotropic Effect of GIP,"Examination of GLP-2, Somatostatin, Glucagon, Peptide-YY and Two Glycaemic Control Parameters (HbA1c and Fasting Plasma Glucose)",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6506,NCT03519841,Generation and validation of predictive models by ISUP and MARD measures,Safety evaluation: paucity of adverse events,,2018-04-13,COMPLETED,INTERVENTIONAL,['NA']
6507,NCT04559191,the normalized absolute change in total atheroma volume on serial intravascular ultrasound imaging.,the frequency of hypoglycemia,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6508,NCT00763087,daily step count,skin breakdown,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
6509,NCT01585051,24 hour mean blood pressure,HOMA,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6510,NCT00160017,HbA1c,"These intermediate outcomes will be measured as well, in both the intervention and the control group.",,2005-01,COMPLETED,OBSERVATIONAL,['NA']
6511,NCT02673554,Insulin secretory response after GIP bolus or infusion.,,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6512,NCT00737074,Final opening or closure of macular hole,Post-operation best corrected visual acuity,,2002-01,COMPLETED,OBSERVATIONAL,['NA']
6513,NCT03324438,Pediatric Diabetes Quality of Life Scale - Change from baseline and every 12 weeks up to 72 weeks (18 mo),Biological Markers of T1D Complications - Change from baseline and every 24 weeks up to 72 weeks (18 mo),,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
6514,NCT05454059,HbA1c levels,Clinical attachment level (CAL),,2020-10-22,COMPLETED,INTERVENTIONAL,['NA']
6515,NCT04437641,Smoking prevalence,Parental smoking evolution,,2019-10-22,UNKNOWN,OBSERVATIONAL,['NA']
6516,NCT01192659,"To identify risk factors for lymphopenia, defined as an absolute lymphocyte count < 500 cells/μl, or investigator reported lymphopenia, in the SAVOR study population.",To evaluate whether risk factors for low lymphocyte counts or decreasing lymphocyte count differ between saxagliptin users and non-users.,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
6517,NCT02260609,100% granulation of wound as determined by the investigator,Closure of wound defined by 100% re-epithelialization,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6518,NCT06319560,To compare the shearwave elastography of the placenta between the two groups,Hospital admission,,2024-01-02,RECRUITING,INTERVENTIONAL,['NA']
6519,NCT02023489,change in myocardial glycogen content,change in myocardial lipid composition,differences in hepatic energy metabolism/ATP synthesis,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
6520,NCT03497260,Time (in minutes) to hypoglycaemia (plasma glucose <3.9mmol/l),Carbon dioxide production during exercise,,2019-01-04,COMPLETED,INTERVENTIONAL,['NA']
6521,NCT05581225,"Changes in geometric perfusion deficits (GPD) on the superficial and deep retinal vascular layers on SS-OCTA, considering macular region and midperiphery.","Changes in mean luminous sensitivity in dB, evaluated by Microperimetry.",,2022-12-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6522,NCT01043510,Area under the glucose infusion rate curve during one dosing interval at steady state,Area under the Insulin Degludec concentration-time curve during one dosing interval at steady state,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6523,NCT00473811,"Our outcomes are recruitment and retention rates, as well as physiological measures (HbA1c, blood pressure, and body mass index), dietary GI scores and acceptability of the intervention",,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6524,NCT00227383,Solid-phase gastric emptying time and score on Gastroparesis Cardinal Symptom Index(GCSI) at 2 weeks,,,na,UNKNOWN,INTERVENTIONAL,['PHASE3']
6525,NCT02251301,Change from baseline in glycemic control assessed by continuous glucose monitoring at end of week 12 of intervention,Change from baseline in peak oxygen uptake as a measure of aerobic fitness at end of week 12 of intervention.,Change from baseline in task switching capabilities at end of week 12 of intervention.,2015-01,COMPLETED,INTERVENTIONAL,['NA']
6526,NCT01755273,Resolution of diabetes,,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
6527,NCT03480022,Free Androgen Index (FAI),Diastolic Blood Pressure (BP),,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE3']
6528,NCT03100084,Rate of acute cesarean section (due to suspected fetal distress),Abnormal intrapartum CTG patterns,,2016-09-15,UNKNOWN,OBSERVATIONAL,['NA']
6529,NCT04039763,Change in glycated haeomglobin (HbA1c),,,2020-09-03,RECRUITING,INTERVENTIONAL,['NA']
6530,NCT01415271,HbA1c,unplanned hospitalizations,,2011-10,TERMINATED,INTERVENTIONAL,['NA']
6531,NCT03723486,Change in HOMA-IR,Gut Hormone,,2015-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6532,NCT03406377,Change in HbA1c in Subjects With Type 2 DM,Change From Baseline of Fasting Plasma Glucose (FPG).,,2018-04-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6533,NCT01829061,The objective is to conduct reproducibility testing using duplicates of each of 3 levels of HbA1C,Obtain CLIA Waiver Status for the Quo-Test,,2013-04,TERMINATED,OBSERVATIONAL,['NA']
6534,NCT02378259,Body Mass Index (kg/m2),Attention,Cancer or precancerous lesions,2014-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6535,NCT03574909,Perinatal mortality,Sepsis,,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
6536,NCT00614783,Produced SCOUT DS measurement algorithm.,Intra- and inter-day Scout test reproducibility.,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
6537,NCT04345107,GIP concentration changes before and after meal.,"Stable Valley concentration (ctrough, SS).",,2020-05-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6538,NCT00455403,Change in Carotid Intima-media Thickness From Baseline to Year 1,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
6539,NCT01162993,Pain intensity measured on a weighted NRS according to Jensen and a PGIC for pain measured on a 7-point Likert scale.,"Effect SCS on health related quality of life, quality of sleep, mood, blood glucose control, large/small nerve fibre functions, predictive factors success of SCS treatment, small fibre loss/regeneration, cost-utility and cost-effectiveness",,2010-04,UNKNOWN,INTERVENTIONAL,['NA']
6540,NCT01083433,Glycemic Control,Diabetes Knowledge,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
6541,NCT00972244,Adjusted Mean Change in HbA1c Levels,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6542,NCT00373178,Novel cardiovascular risk factors modification,Lipid and glucose regulation,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6543,NCT01402388,"Lifestyle impact on GLP-1, HbA1c and fasting glycaemia.",,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
6544,NCT02592616,Ad-libitum meal energy intake,Satiety,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
6545,NCT06278207,Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone.,"Proportion of participants who down-titrate from 20 mg daily dose to a 10 mg dose daily at the 1, 3, 6, and 12 months mark",,2024-02-15,RECRUITING,OBSERVATIONAL,['NA']
6546,NCT04587414,Change in total mean daily step count,"Changes in the mean daily number of moderate-to-vigorous PA bouts lasting at least 1, 5 and 10 minutes.",,2019-03-06,UNKNOWN,INTERVENTIONAL,['NA']
6547,NCT05009433,Childhood outcomes: changes in diastolic blood pressure,Covid-19 disease,The serotonin transporter (5-HTTLPR) polymorphism,2021-06-24,RECRUITING,INTERVENTIONAL,['NA']
6548,NCT05704491,SPEZ,,,2023-01-30,RECRUITING,OBSERVATIONAL,['NA']
6549,NCT05472142,Change in DSMES Referrals,Change in A1c Levels,,2023-05-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6550,NCT03030300,partial-remission rate,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6551,NCT04796428,Primary Objective,Secondary Objectives - biomarkers,Safety Objectives,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE4']
6552,NCT00652509,"Program satisfaction, behavioral and emotional outcomes.","Blood sugar level, blood pressure, lipids, cost, comorbidities.",,2008-05-01,COMPLETED,INTERVENTIONAL,['NA']
6553,NCT00905073,insulin dose,renal function,,1990-02,COMPLETED,INTERVENTIONAL,['NA']
6554,NCT02975297,Cue-induced Craving for Cigarettes Following Virtual Reality Exposure as Assessed by the Questionnaire of Smoking Urges,Post-quit Craving as Assessed by the Questionnaire of Smoking Urges,,2016-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6555,NCT00032474,,,,2001-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6556,NCT01112696,Glucose Sensor Accuracy When Compared to Laboratory Standard (YSI): Proportion of Glucose Sensor Readings That Met Accuracy Criteria,Device Related Moderate or Device Related Severe Adverse Events,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
6557,NCT01846312,Fluctuation in islet autoantibodies titers,Fluctuation in T-cell specificity profiling (mainly for CD8 (cluster of differentiation 8) T-cells),,2013-05,COMPLETED,OBSERVATIONAL,['NA']
6558,NCT01869621,Heritability,Single nucleotide polymorphisms (SNPs),,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6559,NCT06250192,Birthweight standard deviation score,Continuous glucose monitoring metrics 1 months post delivery,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
6560,NCT01837069,"Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism",Modified Composite of Cardiovascular Events,Each Individual Endpoint of the Composite of Cardiovascular Events,2014-02,TERMINATED,INTERVENTIONAL,['PHASE4']
6561,NCT03566524,Change in Arginine production,Change in Insulin secretion,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
6562,NCT01728116,Primary Safety Endpoint: Early Device Removal Due to Device-Related SAE,Percentage of Subjects Who Achieve % Total Body Weight Loss Greater Than or Equal to 5% at 12 Months,,2012-12,TERMINATED,INTERVENTIONAL,['NA']
6563,NCT01173315,Evidence of clinically neuropathy confirmed by nerve conduction velocities,nephropathy indices were determined by 3 times urine microalbumin concentration using Enzyme Immuno Assay commercial kit,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6564,NCT06229847,"mindful eating, its subgroups and diabetes control in patients with type 2 diabetes","mindful eating, its subgroups and the presence of obesity in patients with type 2 diabetes",,2019-07-01,COMPLETED,OBSERVATIONAL,['NA']
6565,NCT05570877,Time to complete healing,Safety of use,,2022-01-11,RECRUITING,INTERVENTIONAL,['NA']
6566,NCT00766298,"Effects of physical activity and weight loss, alone or in combination, on intramyocellular lipid, intermuscular adipose tissue and abdominal AT, oxidative capacity and insulin resistance.",Assess the mechanisms by which these interventions may prevent the development of diabetes,,2004-06,COMPLETED,INTERVENTIONAL,['NA']
6567,NCT03215498,"Continuous subcutaneous infusion related area under the insulin aspart curve, baseline corrected and based on concentrations from 0 to 30 min",Number of hypoglycaemic episodes,,2017-07-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6568,NCT05422235,Changes passive ankle stiffness compared with baseline and last measurement and Follow-up,Changes vibration test compared with baseline and last measurement and Follow-up,,2022-11-12,RECRUITING,INTERVENTIONAL,['NA']
6569,NCT05911659,Platelet Reactivity Index and maximum platelet aggregation,,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
6570,NCT02351323,Weight gain,Change in A1C,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6571,NCT04021199,Genetic diagnosis of atypical diabetes: More comprehensive genetic tests,,,2018-10-22,COMPLETED,INTERVENTIONAL,['NA']
6572,NCT05660538,Change from Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS),Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2022-12-20,COMPLETED,INTERVENTIONAL,['PHASE2']
6573,NCT00122421,Compliance with process measures at 30 days after the index primary care visit,Percentage of pharmacist recommendations accepted by primary care providers within 30 days after index visit,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
6574,NCT03370874,Proportions of subjects who achieved complete wound closure,Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations,,2018-06-27,COMPLETED,INTERVENTIONAL,['PHASE3']
6575,NCT02881060,Increase in plasma glucose,Difference in glucose sensor data between the study period with and without alcohol - Number of hypoglycaemia episodes (glucose sensor value < 4.0 mmol/l),,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6576,NCT03087032,"change in HbA1c level after 24 weeks,with a noninferiority margin of 0.3%",changes in serum lipid profile,,2019-01-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
6577,NCT00408824,,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
6578,NCT00395512,Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Mean HDL Particle Size,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6579,NCT04056208,Fasting plasma glucose concentration,Change in the composition of the gut microbiome,,2019-09-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6580,NCT04979312,Prevention of gestational diabetes mellitus and preeclampsia,Examine role of sleep as a potential mechanism in changing blood pressure in pregnancy,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6581,NCT01516255,Maximum time-matched mean difference between the baseline subtracted QTci intervals,Serial electrocardiography,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6582,NCT01492062,Test the feasibility of using MMPPC controller for closed loop insulin delivery in a monitored inpatient clinical research environment.,Efficacy,,2011-02,WITHDRAWN,INTERVENTIONAL,['NA']
6583,NCT02016911,Area under the semaglutide plasma concentration curve,Maximum observed SNAC plasma concentration,,2013-12-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6584,NCT01898286,Hypoglycemic Events,Change From Baseline in Glucagon-stimulated C-peptide AUC at Early Termination Visit,Glycemic Control (Change From Baseline in % HbA1c),2013-10,TERMINATED,INTERVENTIONAL,['PHASE3']
6585,NCT00488527,Number of severe hypoglycemia,- Change in body weight initial visit vs. final visit,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
6586,NCT02589873,Body weight lost,Stress and well-being,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
6587,NCT03708029,Complete Wound Closure,Percent(%) Healed,,2018-11-13,UNKNOWN,INTERVENTIONAL,['NA']
6588,NCT01017718,"How many children and adolescents suffering from diabetes mellitus type 1 (duration of disease > 1 year, age 8 to 18a, insulin requirement > 0.5 IU/kg/d) show pathological nerve conduction velocity?",Is there a correlation between nerve conduction velocity in our study patients and the Young Score?,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
6589,NCT01666223,Change in GLP-1,Change in bile acid composition,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
6590,NCT05599633,Change of high density lipoprotein cholesterol (HDL-C) level,Change of heart rate from baseline,,2022-01-10,RECRUITING,INTERVENTIONAL,['NA']
6591,NCT00518362,To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of diabetic nephropathy,To investigate the safety and tolerability of TW vs ARB. To access whether TW can delay the progression to ESRD or creatinine-doubling in diabetic nephropathy with heavy proteinuria.,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
6592,NCT00489229,Measuring arterial stiffness (pulse wave velocity and augmentation index),"Measuring fasting blood sugar and 2 hours post prandial sugars, fasting insulin level, HbA1c, and total cholesterol level.",,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6593,NCT01420016,Predicted Annual Rate of Change in 10-year Risk of Fatal or Nonfatal Heart Attack or Stroke,,,2012-08-20,COMPLETED,INTERVENTIONAL,['NA']
6594,NCT00777712,Determine molecular mechanisms underlying impaired wound healing in diabetes,Characterize mechanisms responsible for dysregulated wound inflammatory cell function in patients with diabetes,,2008-09-01,RECRUITING,OBSERVATIONAL,['NA']
6595,NCT04328363,Glucosa level,Reversion to normal glucose,,2020-10,UNKNOWN,INTERVENTIONAL,['NA']
6596,NCT04461405,Feasibility of the intervention,Patient Health Questionnaire-9,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
6597,NCT05329376,"Screening for depression, anxiety and common mental health disorders in elderly",Perception of stress:,,2023-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6598,NCT02694575,EPC,Renal function,,2015-03-01,COMPLETED,OBSERVATIONAL,['NA']
6599,NCT05749874,Time to first occurrence of composite endpoint of new-onset diabetes and major cardiovascular events.,Time to newly diagnosed cancer,Subgroup analysis 10 for primary outcome measure,2023-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
6600,NCT04670094,Mortality up to 3 months from admission,Correlation between admission to ICU and in-hospital mortality,,2020-12-30,COMPLETED,OBSERVATIONAL,['NA']
6601,NCT01770054,Prevalence of metabolic syndrome,Genetic testing,determination of the prevalence of hyperinsulinemia,2013-01,COMPLETED,OBSERVATIONAL,['NA']
6602,NCT02373332,inhibition of platelet activation,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
6603,NCT01706211,"To determine the effectiveness of BRL 49653C (2 mg bd) compared to placebo when added to sulphonylurea therapy, for 24 weeks in out-patients with NIDDM.","To assess the clinical safety of BRL 49653C (2 mg bd) compared to placebo when added to sulphonylurea therapy, for 24 weeks in out-patients with NIDOM.",,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6604,NCT05166785,Changes in HbA1c in participants in DPP-TOAT is similar to those in In-Person DPP,Adherence to the DPP-TOAT is greater than the in-person DPP,,2022-10-05,RECRUITING,INTERVENTIONAL,['NA']
6605,NCT04350879,Risk of unplanned pregnancy,,,2020-03-12,COMPLETED,OBSERVATIONAL,['NA']
6606,NCT00872560,Weighing of reflux of insulin,Reactions at injection sites,,1998-01-20,COMPLETED,INTERVENTIONAL,['PHASE3']
6607,NCT00804297,mean glucose level for the non-octreotide group is higher than the octreotide group,number of hypoglicemic events,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6608,NCT04232774,Incidence of Serious Device- and Procedure-Related Complications,Procedure Success,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA']
6609,NCT01945645,Modelled cardiovascular disease risk,Smoking,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
6610,NCT01147692,The effect of albiglutide on the pharmacokinetics of simvastatin,The pertinent plasma pharmacokinetic parameters of simvastatin with and without albiglutide,,2010-05-19,COMPLETED,INTERVENTIONAL,['PHASE1']
6611,NCT03258086,Assessment of vitamin D level (ng/ml),,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
6612,NCT01071850,Mean change from baseline in Hemoglobin A1c (HbA1c),Proportion of subjects achieving target goal of HbA1c <6.5%,,2010-03-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6613,NCT00655902,Change in Insulin sensitivity (ISI composite) from 3h OGTT,Changes in Metabolomic profile in blood and urine,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6614,NCT04545411,Change in Vascular Endothelial Function,,,2021-02-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6615,NCT06031428,Hemoglobin A1C,"Quality of Life (Short Form Health Survey, SF-12)",,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6616,NCT05788731,The proportion of patients integrating the common law system,Proportion of patients resorting to one or more consultations with a general practitioner.,,2023-01-18,COMPLETED,OBSERVATIONAL,['NA']
6617,NCT02020629,Glucagon response to hypoglycemia,Catecholamines,HbA1c,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6618,NCT01433393,HbA1c,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
6619,NCT01237509,Hypoglycaemia associated EEG changes during sleep,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
6620,NCT01068951,The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells,,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
6621,NCT05306028,Blood glucose control rate,HbA1C control rate,Overall survival，OS,2022-08-01,RECRUITING,INTERVENTIONAL,['NA']
6622,NCT02499185,"Number of participants diagnosed with AKI stage 2 or 3 using the updated rifle ""KDIGO"" guidelines",Number of participants who need renal replacement therapy,persistence of renal dysfunction at 30 days,2015-04-01,TERMINATED,INTERVENTIONAL,['PHASE4']
6623,NCT05591235,Insulin resistance,,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
6624,NCT00983021,"Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes",The area under the NN1250 concentration-time curve after single-dose,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
6625,NCT04963777,Change in frequency of hypoglycemia,Change in serum metabolite concentration,,2022-03-29,RECRUITING,INTERVENTIONAL,['NA']
6626,NCT04149262,1-hour glucose levels on Novorapid,Occlusion events in Novorapid,,2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
6627,NCT05968131,Change in Quality of Life,,,2021-10-27,COMPLETED,INTERVENTIONAL,['NA']
6628,NCT01075997,The primary endpoint will be improvement of glycemic control as measured by glycosylated hemoglobin (A1c).,"To compare mean blood glucose levels,the number of hypo- and hyperglycemic events,the duration of time spent in target blood glucose range,the perceived level of diabetes-related stress and the perceived effect of diabetes on quality of life.",,2007-11,UNKNOWN,INTERVENTIONAL,['NA']
6629,NCT04177303,Change in GLP-1 (glucagon like peptide) and GIP (gastric inhibitory peptide) postprandial secretion,Change in gut microbiome analysis,,2019-11-29,UNKNOWN,INTERVENTIONAL,['PHASE3']
6630,NCT02099110,Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach,Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach,,2014-04-22,COMPLETED,INTERVENTIONAL,['PHASE3']
6631,NCT00889486,change from baseline in gastric half-emptying time,change from baseline in gastroparesis symptoms and health-related quality of life,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6632,NCT01621308,glycaemic regulation,Macrovascular complications of diabetes,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
6633,NCT05592288,Blood Glucose Measurement,Brand Loyalty Scale,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6634,NCT00266253,HbA1c mean change from baseline compared with placebo.,Pharmacokinetic and exposure-response relationship,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
6635,NCT03662217,Evaluation of the total daily time of plasma glucose levels,Change in Fructosamin parameter,Patients Diet compliance evaluation,2018-10-28,UNKNOWN,INTERVENTIONAL,['NA']
6636,NCT00806572,4-hour C-peptide AUC,Insulin usage,,2002-05,TERMINATED,INTERVENTIONAL,['PHASE2']
6637,NCT00696722,Acetylcholine induced vasodilation,assessment of vascular inflammation by determination of adhesion molecule levels,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6638,NCT03592355,Days until third available appointment,Revenue from virtual or in-person visit,,2018-04-13,TERMINATED,INTERVENTIONAL,['NA']
6639,NCT00994513,Endothelial function,Pulse wave velocity,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6640,NCT00337142,,,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
6641,NCT05159856,Prevalence of cardivascular autonomic neuropathy assed by VagusDevice in children and adolescent with type 1 diabetes (T1D) > 12 months,The association between early markers of diabetic complications and glycemic control,,2022-05-03,RECRUITING,OBSERVATIONAL,['NA']
6642,NCT03717194,Global Longitudinal Strain (GLS),Body Fat Mass,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6643,NCT00324792,changes in urinary LTE4 excretion and HbA1c after 3-month intensive insulin therapy versus baseline,sICAM-1 plasma levels,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
6644,NCT01497522,Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups,"Number of patients with adverse events (including hypoglycemia), serious adverse events and death",,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
6645,NCT02775253,The changes of UCP-1 expression in subcutaneous white adipose before and after cold acclimation program,,,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
6646,NCT01903070,ΔAUCGLP-1-OGTT(0-240),,,2013-07-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6647,NCT03806920,hepatic insulin extraction,additional endocrine parameters,,2016-11-05,COMPLETED,INTERVENTIONAL,['NA']
6648,NCT04907214,Change in Liver Steatosis at 3 Months,Change in the Plasma Inflammatory Cytokine IL-6 After 3 Months,,2021-07-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6649,NCT02336945,"Glucose variability as measured by AGP Interquartile Range, (IQR) obtained via System-Pro Sensor.",Assessment of ambulatory glucose profiles (AGPs) generated by the Software,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
6650,NCT04841096,Mean difference change between groups in HbA1c concentration,Incidence of adverse events and reactions,,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE3']
6651,NCT06180109,Time of the maximum measured plasma concentration (Tmax),,,2023-07-30,COMPLETED,INTERVENTIONAL,['PHASE1']
6652,NCT01232608,Atherosclerosis,Visceral obesity,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
6653,NCT05265741,Number of Participants with Gestational Diabetes Mellitus (GDM) Week 8 to post-delivery throughout their entire pregnancy,Gestational age at Delivery,,2021-11-09,RECRUITING,OBSERVATIONAL,['NA']
6654,NCT00575874,Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo,Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6655,NCT04129424,The preprandial insulin dose of insulin pump at the end of the 6-day follow-up,The frequency of errors in patency of needle fixation,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6656,NCT06017349,The results were analyzed by consensus error grid (CEG),Accessibility evaluation Questionnaire for non-invasive glucose meter,,2022-09-21,COMPLETED,INTERVENTIONAL,['NA']
6657,NCT01684956,Aggregate mean difference in tmax between the delivery methods (the insulin and glucagon data will be evaluated separately),Difference in mean visual analog pain score between insulin and glucagon with intradermal injection,,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
6658,NCT05284071,"Diabetes Treatment Satisfaction Questionnaire (change, DTSQc), at 3 months","Summary of adherence in the population, from baseline to 3 months, from 3 months to end of investigation and from baseline to end of investigation.",,2022-03-14,COMPLETED,INTERVENTIONAL,['NA']
6659,NCT01228981,Phenotypes of Diabetic Retinopathy progression.,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
6660,NCT00974051,Blood Glucose Nadir,Percent of Nighttime Glucose Levels >250 mg/dl,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
6661,NCT00715585,A1C,dietary behavior,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
6662,NCT01434407,Urine AGE,Urine isoprostanes,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
6663,NCT03140865,Change in performance on cognitive measures.,Change in brain volumes on magnetic resonance imaging (MRI).,,2014-01,RECRUITING,OBSERVATIONAL,['NA']
6664,NCT03241706,Glucose Infusion Rate,Peripheral Glucose Uptake,,2018-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6665,NCT05951283,1. Change in Corneal nerve fibre density (CNFD),Quality of life questionnaire,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6666,NCT06186843,Weekly one day food recall,Triglycerides,"Urine electrolytes (Na, K, Cl, Ca, Phosphorous)",2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6667,NCT00253786,"Composite endpoint of time to first occurrence of (1) Doubling of serum creatinine, (2) Need for chronic dialysis or renal transplantation, or (3) Death in Protocol B",Urinary protein/creatinine ratio in Protocol B,,2005-11-11,COMPLETED,INTERVENTIONAL,['NA']
6668,NCT00516048,Incidence of Potentially Immune-related Treatment-emergent Adverse Events,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6669,NCT03089632,Changes in upper gastrointestinal symptoms assessed by the Gastroparesis Cardinal Symptoms Index (GCSI),Changes in glycemic control assessed by continuous glucose monitoring,,2017-12-15,UNKNOWN,INTERVENTIONAL,['NA']
6670,NCT01632163,Change in HbA1c,Anti-lixisenatide antibody assessment,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6671,NCT00170742,regression of neovascularization.,Determine tolerability and safety,,2003-12,TERMINATED,INTERVENTIONAL,['PHASE3']
6672,NCT03176056,The reduction of medication effect score (MES),The improvement of carotid intima-media thickness (IMT),,2016-02-02,COMPLETED,INTERVENTIONAL,['NA']
6673,NCT00311922,A1C,Patient satisfaction,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
6674,NCT04810260,Diabetes quality of life measured by the Diabetes Quality of Life instrument,Patient Health Questionnaire-9 for depression,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
6675,NCT04632849,Total Treatment Effect (TTE),Treatment Optimization Scale,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
6676,NCT00448344,The Impact of a Family-supported Intervention on Rates of Abstinence From Cigarettes Compared to a Standard Intervention,The Impact of a Family-supported Intervention on Abstinence at 12-month Follow-up,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
6677,NCT05992545,Changes in Diabetes Self-Management Behaviors for Older Koreans (DSMB-O) scores,"Change in lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (mg/dL)",Persistent changes in Diabetes Self-Management Behaviors for Older Koreans (DSMB-O) scores,2022-06-13,COMPLETED,INTERVENTIONAL,['NA']
6678,NCT02637154,Change in glycaemic variability,Influence of changes in marker of bone turnover: aminoterminal telopeptide of type I collagen (INTP - ng/ml),,2015-10-15,UNKNOWN,INTERVENTIONAL,['NA']
6679,NCT01564498,Blood cholesterol,circulating biomarkers of cardiovascular disease and type II diabetes risk,,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
6680,NCT00807092,Change in IAUC (Incremental Area Under the Curve) for Postprandial Glucose (0-4 Hours) Over 3 Main Meals,Hypoglycaemia Based on Self-reported Episodes,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6681,NCT04892680,Change in HbA1c at 6 months from baseline,Change in medication adherence at 6 months from baseline,Health care utilization at 6 and 12 months from baseline,2021-03-04,TERMINATED,INTERVENTIONAL,['NA']
6682,NCT02326129,"Compare 11β-HSD1 activity and 5α-reductase activity among obese adolescents with T2D, obese adolescents without T2D and normal weight controls",Metabolic signatures correlate with parameters of glucose tolerance,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
6683,NCT01466075,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
6684,NCT04251156,Subjects who achieve body weight reduction equal to or above 5% (yes/no),Change in calcitonin,,2020-12-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6685,NCT02205528,Change in HbA1c,Change in percent HbA1c,,2014-08-18,COMPLETED,INTERVENTIONAL,['PHASE2']
6686,NCT01562678,Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6687,NCT01798225,Periodontal Pocket Probing Depth (PD),,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6688,NCT00688701,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Percentage of Patients Requiring Rescue Therapy During the Double-Blind Treatment Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6689,NCT05377502,Serum glucose levels,,,2021-12-15,RECRUITING,OBSERVATIONAL,['NA']
6690,NCT02908555,Glycemic control,Executive functioning,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
6691,NCT01237314,4-hour glycemic response at 3 time points,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
6692,NCT05292495,Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf,ADA：anti-drug antibody,,2022-03-31,UNKNOWN,INTERVENTIONAL,['PHASE1']
6693,NCT04215536,"Composite outcome of Stroke, MI, and Mortality",,,2019-07-08,COMPLETED,OBSERVATIONAL,['NA']
6694,NCT05923632,Quality of Life Scale for Children with Type 1 Diabetes (PedsQL 3.0),Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6695,NCT05766488,Hemoglobin A1c,Perceived or experienced benefits and barriers to device use,,2023-07-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6696,NCT05162183,Relative Hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up),,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
6697,NCT04881799,Change in body mass index,,,2022-07-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6698,NCT00503152,Development of persistent microalbuminuria (i.e. urinary albumin excretion rate >20 µg/min in at least 2 of 3 consecutive overnight urine collections confirmed in two consecutive visits). Whenever a patient will be found to have 2 of 3 collections in the,Regression to low-normal albuminuria (i.e. urinary albumin excretion rate <7 µg/min in at least 2 of 3 consecutive overnight urine collections confirmed in two consecutive visits); Albuminuria (considered as a continuous variable); Serum creatinine (v,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6699,NCT00310297,"Time to GLUmax (Tmax, min)","Time to maximum concentration (Tmax, min)",,2004-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6700,NCT05574062,Continuation Phase Primary Endpoint: mean in HbA1c,Continuation Phase Secondary Endpoint 3- Time spent in target range (70 to 180 mg/dL [3.9-10.0 mmol/L]),,2023-03-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6701,NCT02874313,Change from baseline in of retinal microaneurysm or hard exudates,Change from baseline of intraocular pressure,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6702,NCT00763802,CSME needing Photocoagulation,Vision Loss,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
6703,NCT03510624,Area under the curve (AUC) blood glucose concentrations during an OGTT,"Concentration(t) (C(t))rebaudioside A, steviol and steviol glucuronide",,2018-11-09,COMPLETED,INTERVENTIONAL,['PHASE1']
6704,NCT06247514,Disordered Eating Behaviors (DEBs) - Change in Participant-Reported Outcomes (PROs),Change in participant's HbA1c,,2024-01-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6705,NCT01862939,incremental area under the curve (IAUC) blood glucose,determine blood concentrations of DS-7309,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6706,NCT04859205,To compare the level of confidence in treating individuals with type 1 diabetes measured at 3 months to the level of confidence measured at baseline.,Satisfaction of the platform.,,2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6707,NCT05642793,rate of postvitrectomy complication,postvitrectomy BCVA,,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6708,NCT05958927,Retinal nerve fiber thickness and macular thickness in pregnant women with impaired blood sugar and/or gestational DM,,,2023-04-13,RECRUITING,OBSERVATIONAL,['NA']
6709,NCT01478607,Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scale,Treatment satisfaction using the Self-Assessment of Treatment (SAT) questionnaire at week 12/End Of Study visit,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6710,NCT01692938,Repeatability of Microperimetry Tests in Normal and With Pathology Participants Based on 3 Microperimetry Tests Taken for Each Participant for a Given Operator-device Combination.,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
6711,NCT01359904,Hemoglobin A1c Levels,the Number of Infections Related to Vascular Access in Dialysis Among Those Who Receive a Higher Glucose Concentration in the Dialysate and Those Who Receive the Standard Concentration,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
6712,NCT02146651,Pharmacokinetic endpoint: Cmax(Lisp),"Safety and Tolerability: adverse events, local tolerability, vital signs variations, ECG, laboratory safety parameters.",,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6713,NCT00929812,"Changes in satiety scale, total and acylated ghrelin concentrations.","Changes in glucose, insulin and NEFA concentrations.",,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
6714,NCT00469092,Glycosylated Haemoglobin A1c (HbA1c),Number of Subjects Reporting Treatment Emergent Adverse Events,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6715,NCT01782092,Lowered A1C Levels,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
6716,NCT03426423,Continuous smoking abstinence,Continuous smoking abstinence,Exploratory microbiota outcome,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
6717,NCT04660630,change of triglyceride,Compliance rate of low density lipoprotein cholesterol,Health self assessment,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6718,NCT01283854,Diagnosis of gestational diabetes mellitus,"Obstetric outcomes (rates of medical intervention during labour, birth weight, newborn anthropometrics and incidence of newborn hypoglycemia)",,2011-06,COMPLETED,INTERVENTIONAL,['NA']
6719,NCT04423302,Fasting plasma glucose concentration at V3 with a 3 times a day regimen,Proportion of subjects having an improvement or a deterioration of their glycemic status from V1,,2020-07-08,COMPLETED,INTERVENTIONAL,['NA']
6720,NCT05446948,the efficiency of stripping membrane,best corrected visual acuity (BCVA),Post-operative complications,2022-07-11,COMPLETED,INTERVENTIONAL,['NA']
6721,NCT02261441,Cardiovascular risk factors,,,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
6722,NCT00935220,"DPP-4 Inhibition: E_24,ss",DPP-4 Inhibition: E_24,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6723,NCT01102946,Fluorescein leakage area (mm2),Rod pathway integrity and oscillatory potential amplitudes,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6724,NCT01183104,Number of Participants With Hypoglycaemia,Change From Baseline in Body Weight at 52 W,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
6725,NCT00673894,Postprandial Glucose Area Under the Curve (AUC),Fructosamine,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6726,NCT03181165,Proportion of participants not on glucose-lowering medications,Diastolic Blood Pressure,Intervention Satisfaction,2017-07-05,COMPLETED,INTERVENTIONAL,['NA']
6727,NCT01853072,Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0),Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6728,NCT02628106,the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI,,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6729,NCT01130480,Successful rate of blood glucose control (the proportion of patients with HbA1c <7%),To evaluate the change of quality of life in the 6 months by the health questionnaire SF-36,,2010-05-31,COMPLETED,INTERVENTIONAL,['NA']
6730,NCT02916667,Offspring of participants with GDM with higher Chrono Biological score will be reported with higher birth weight (+100 gr) compared to offspring of participants with GDM with lower Chrono Biological score.,Offspring of participants with GDM with higher Chrono Biological score will be reported with higher birth weight above the 90 percentile compared to offspring of participants with GDM with lower Chrono Biological score.,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
6731,NCT00777621,Glucoregulatory function,,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6732,NCT02790645,Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).,Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
6733,NCT01034618,Glucose and insulin homeostasis.,Plasma amino acid profiles,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
6734,NCT03695913,Participant Satisfaction With Continuous Glucose Monitoring,Utility of CGM Feedback for Changing Diet,,2018-10-16,COMPLETED,INTERVENTIONAL,['NA']
6735,NCT02137720,HbA1c,Cholesterol,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
6736,NCT04198857,Neonatal hypoglycemia,Glucose readings over glycemic target,,2021-10-18,RECRUITING,INTERVENTIONAL,['NA']
6737,NCT02212925,Assessment of tolerability by investigator on a 4-point scale,Area under the curve of plasma glucose,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1']
6738,NCT02568501,Change in HbA1c by 3 months,Glucose Monitoring Adherence by 6 months,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6739,NCT03489031,basal/total ratio,hypoglycemia,,2016-04-11,COMPLETED,OBSERVATIONAL,['NA']
6740,NCT03945903,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
6741,NCT02481479,The change in LVEF from baseline to 6 months,Change in log-scale in NT-pro BNP,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6742,NCT03503552,Bone mineral density,Urine Markers,,2015-02-13,COMPLETED,OBSERVATIONAL,['NA']
6743,NCT02512276,Medication Adherence,Healthcare Utilization - Hospitalizations,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
6744,NCT05564039,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score,,2022-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6745,NCT05369793,Change in HbA1c,Changes of Douleur Neuropathique-4 (DN4) questionnaire (DN4),Major adverse cardiovascular events (MACE),2022-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6746,NCT02703155,proportion of annual screening for Cystic Fibrosis Related Diabetes(CFRD) in children between 10years and 17 years with Cystic Fibrosis(CF) using the Home OGTT device.,Variability- timing of sample,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
6747,NCT00985101,endothelial damage,,,2010-04,UNKNOWN,OBSERVATIONAL,['NA']
6748,NCT04132934,Proportion of patients with at least one Hypoglycemia event,,,2019-03-11,COMPLETED,OBSERVATIONAL,['NA']
6749,NCT06119035,Glucose levels will be analyzed,Serum samples,,2023-11-06,COMPLETED,INTERVENTIONAL,['NA']
6750,NCT03997409,Change in HbA1c,Change in Diabetes Burden as Measured by the Problem Areas in Diabetes: Teen Version (PAID-T) Report,,2019-11-18,COMPLETED,INTERVENTIONAL,['NA']
6751,NCT03117829,Change in brain blood flow from baseline to 12 weeks,Change in brain blood flow from 12 weeks to 6 month post intervention,,2017-03-15,COMPLETED,INTERVENTIONAL,['NA']
6752,NCT02379299,Number of CHO interventions to treat hypoglycemia,,,na,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6753,NCT03262415,Mean absolute relative difference (MARD),,,2017-02-17,COMPLETED,OBSERVATIONAL,['NA']
6754,NCT02961192,Change in mean daily steps,Change in LDL-C levels,,2017-02-13,COMPLETED,INTERVENTIONAL,['NA']
6755,NCT01342042,To compare treatment arms in terms of change from baseline to endpoint in HbA1c,To compare treatment arms in terms of change from baseline to endpoint in body weight,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
6756,NCT05753696,proteinuria,urinary albumin/ creatine,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
6757,NCT00372086,HbA1c,adiponectin,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6758,NCT01793909,Change in Muscle Oxygen Saturation,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
6759,NCT05939869,Risk of CVD Event,,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
6760,NCT06038669,DBS kit assay performance,Interviews,,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6761,NCT05887791,Glucose iAUC,Satiety assessment,Amino acids,2023-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6762,NCT02224118,Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs),Number of Participants Exhibiting Anti-Drug Antibodies for CNTO 3649 at any Visit,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6763,NCT04696159,Change from Baseline in Glucose Levels measured by Continuous Glucose Monitor,Change from Baseline on Gastroparesis Cardinal Symptom Index,,2023-01-04,RECRUITING,INTERVENTIONAL,['NA']
6764,NCT03644004,Performing oral glucose tolerance test in order to detect type 2 diabetes,,,2018-10-30,COMPLETED,OBSERVATIONAL,['NA']
6765,NCT01318083,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).,,2008-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6766,NCT04649203,TSS (Total Symptom Score),,,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3']
6767,NCT05562492,Time spent in the target glucose range between 3.9 and 10.0 mmol/L based on CGM glucose levels,Percentage of time of CGM availability,Human Factors Evaluation - Questionnaires,2023-04-12,RECRUITING,INTERVENTIONAL,['NA']
6768,NCT01729117,Change in BMI,Severe Hypoglycemic Events,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
6769,NCT06025110,Change from baseline in beta-cell function as compared to placebo at week 52.,Assess the incidence and severity of adverse,,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2']
6770,NCT03088475,Self-efficacy: change is being assessed,Unplanned medical consultation,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6771,NCT03333044,Percent of patients that experience a reduction in HbA1c of >0.5%,Referral to community services,,2019-07-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6772,NCT05622123,Correlation between residual beta cell mass and function,Correlation with other parameters,,2023-02-23,RECRUITING,INTERVENTIONAL,['PHASE2']
6773,NCT03832907,Number of Severe Hyperglycemia (>240 mg/dl) Events by POC Reading Compared to CGM Reading,"Percentage of Dexcom G6 CGM Sensor Values Within 15/15%for Values > 180 mg/dl, Compared to the Standard-of-care POC BG",,2019-02-21,COMPLETED,INTERVENTIONAL,['NA']
6774,NCT02787551,Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period,Number of Documented Symptomatic Hypoglycemia Events Per Participant-Year: Single Arm Extension Period,,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6775,NCT04000867,Overall Pain reduction,Improved Activities of daily living,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
6776,NCT02026830,Causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
6777,NCT03483155,the incidence of Cardiovascular disease,,,2018-04-15,UNKNOWN,OBSERVATIONAL,['NA']
6778,NCT03850314,LDL Cholesterol levels,HbA1C levels,,2019-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6779,NCT00808535,,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA']
6780,NCT00789035,Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment,Trough Concentrations of Empagliflozin in Plasma,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6781,NCT00741702,systolic blood pressure,"Change in diastolic blood pressure, change in urine albumin status and incidence of adverse events",,2001-09,COMPLETED,INTERVENTIONAL,['NA']
6782,NCT05037591,"Blood Glucose ""change"" is being assessed",waist-to-hip ratio (WHR),,2021-08-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6783,NCT01686711,Glycosylated Hemoglobin (HbA1c),,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6784,NCT03967561,Glycated Hemoglobin levels (HbA1c),"Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Long Form.",,2019-06-10,UNKNOWN,INTERVENTIONAL,['NA']
6785,NCT01505803,"Inflammation & oxidative stress (CRP, TNF-α, IL-1, IL-2, IL-6, IL-10 F2 isoprostanes, NF-κB, MPO, other)",Plasma fatty acids,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6786,NCT02670915,Change in the Percentage of HbA1c,Change in Anti-insulin Aspart Antibody Development: Total,,2016-05-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6787,NCT04313803,Cost of care for fee-for-value patients (specifically PMPM savings),Evaluation of HEDIS performance for those using CGM compared to historical utilization and the broader T2DM cohort within Intermountain Healthcare.,,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
6788,NCT01387425,Success rates and safety at week 24 in the varenicline vs placebo. Success rates will be defined as the Continuous Quit Rate since last visit. Maintain abstinence during this period of time with end-expiratory exhaled CO measurements ≤ 10 ppm.,"""Change from Baseline in BMI""",,2011-06,COMPLETED,INTERVENTIONAL,['NA']
6789,NCT04812171,Influence of diabetes mellitus on apical periodontitis healing after non-surgical endodontic treatment,Association of glycated hemoglobin level (HbA1C) with apical periodontitis healing,,2021-04-01,COMPLETED,OBSERVATIONAL,['NA']
6790,NCT01488474,Minimal current threshold for distal motor response at needle tip nerve contact,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
6791,NCT05413928,Core body temperature response to meal consumption,Heart rate response to meal consumption,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6792,NCT02548650,Maximal Platelet Aggregation in DM,Maximal Platelet Aggregation in Non-DM,,2016-03-25,COMPLETED,INTERVENTIONAL,['PHASE4']
6793,NCT00812253,Hospital Length of Stay,Cardiac Output,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6794,NCT02098746,Frequency of Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin Level,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
6795,NCT04177147,Number of participants with hypoglycemia during the study period,"Number of participants with changes to prescriptions for diabetes or antibiotics: new, refilled, changed, or discontinued","Number of A1c, glucose, and creatinine blood tests",2016-01-14,COMPLETED,INTERVENTIONAL,['NA']
6796,NCT05743387,Mean HbA1c (in percent),Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs),Change in dosage of lipid-lowering medications prescribed by CC-VHWs or healthcare professionals,2023-05-13,RECRUITING,INTERVENTIONAL,['NA']
6797,NCT00025883,"Triglycerides at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin",,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6798,NCT02789800,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,,2016-04-22,COMPLETED,INTERVENTIONAL,['NA']
6799,NCT00005152,Coronary heart disease (CHD),,,1980-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6800,NCT05925556,change in Self-Care Inventory from baseline to 6 weeks; higher score = better self-care; range 1-5; also change over ecological momentary assessment period,change in Quality of Marriage Index and intimacy subscale from Personal Assessment of Intimacy in Relationships from baseline to 6 weeks; higher numbers = better; range = 1 to 7; also change over ecological momentary assessment period,change in self-efficacy subscale from Multidimensional Diabetes Questionnaire from baseline to 6 weeks; higher numbers = greater efficacy; range = 0 to 100%; also change over ecological momentary assessment period,2023-08-02,RECRUITING,INTERVENTIONAL,['NA']
6801,NCT03531177,Waist circumference,Physical activity,,2018-04-26,COMPLETED,INTERVENTIONAL,['NA']
6802,NCT02772263,Change in rate of EMS calls over 1 year,Change in Canadian Diabetes Risk (CANRISK) score over 1 year,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
6803,NCT02114476,Diabetes mellitus,metabolic syndrome,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
6804,NCT00793143,Excessive weight loss,QOL (15D and BAROS),,2008-04,COMPLETED,OBSERVATIONAL,['NA']
6805,NCT02375932,Glycemic Control (HbA1c control (% patients < 7.0% and mean HbA1c levels),Patient assessment of visit communication (measures of communication quality using validated instruments),,2015-03,COMPLETED,INTERVENTIONAL,['NA']
6806,NCT04761094,HbA1C,Hospital admission,,2021-09-01,COMPLETED,OBSERVATIONAL,['NA']
6807,NCT00108004,Understand management issues in subjects with type 1 and type 2 diabetes mellitus,,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6808,NCT01413126,Change from baseline in glucose homeostasis at eight hours,Change from baseline in appetitive sensations at twelve hours,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
6809,NCT04185844,Slope of the GFR,Slope of change in proteinuria over time,,2020-08-31,RECRUITING,OBSERVATIONAL,['NA']
6810,NCT00958061,Determine the prevalence of lifetime and current psychiatric conditions including PTSD among women who served during the Vietnam Era.,Characterize the level of current disability in women who served during the Vietnam Era.,,2010-03-01,COMPLETED,OBSERVATIONAL,['NA']
6811,NCT01681693,Plasma glucose,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6812,NCT01663519,In shoe plantar pressure measurement,Gait analysis,Cost and cost analysis,2008-01,COMPLETED,INTERVENTIONAL,['NA']
6813,NCT03993132,Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - ITT Analysis,Incidence Rate of Hospitalization for Heart Failure (HF) - ITT Analysis,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
6814,NCT02845466,Level of Applied Growth Factors in Chronic Wound Fluid,Levels of Healing Biomarkers in Chronic Wound Fluid,,2018-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
6815,NCT06173804,Acceptability,MoCA,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6816,NCT00745498,Recurrent VH Incidence (Early and Late),Postoperative Resolution of Neovascularization,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
6817,NCT03341013,Maximum observed plasma concentration of MEDI0382,Clinical laboratory assessments (urinalysis),,2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE1']
6818,NCT03355092,Mean reduction in HbA1c,,,2018-02-23,WITHDRAWN,INTERVENTIONAL,['NA']
6819,NCT02409329,Change in Glycemic Control as Indicated by Hemoglobin A1c (HbA1c),Change in Self-reported Medication Adherence,Change in Glycemic Control - REACH Only vs. Control & REACH+FAMS vs. Control,2016-05-23,COMPLETED,INTERVENTIONAL,['NA']
6820,NCT00832481,To investigate the effects of monotherapy of either repaglinide or metformin on glucose excursion after 3 months treatment in newly diagnosed type 2 diabetes patients in China,,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
6821,NCT00453934,,Number and type of adverse events.,,2007-05,TERMINATED,INTERVENTIONAL,['PHASE4']
6822,NCT01117584,Change from baseline in HbA1c at Week 12,Achievement of target goal (HbA1c <6.5%) at Week 12,,2010-04-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6823,NCT00351507,Effect on gastric emptying,"Effect on endogenous glucose appearance, glucose appearance and glucose disposal",,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6824,NCT03989232,Change in HbA1c,Change in Pulse Rate,,2019-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
6825,NCT01496625,"Interaction of key parameters of phenotype with genetic variants, and characterization of new experimental models of eye health and disease.",,,2012-06-18,RECRUITING,OBSERVATIONAL,['NA']
6826,NCT05443568,Change in HbA1c (Glycated haemoglobin),"DTSQs (Diabetes Treatment Satisfaction Questionnaire, status), change in absolute treatment satisfaction",,2023-03-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
6827,NCT03682640,Stimulated C-peptide during an MMTT,Change in stimulated C-peptide,,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
6828,NCT01934842,Non Inferiority of Analyte Levels,,,2013-09,WITHDRAWN,INTERVENTIONAL,['NA']
6829,NCT01373450,Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM,"Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM",,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6830,NCT00162799,Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).,Reduction antropometric measures associated with insulin resistance and arterial hypertension.,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6831,NCT01456026,Postprandial Change from Baseline in Flow Mediated Dilatation,Postprandial Change from Baseline in Microcirculation (Laser-Doppler measurements of reactive hyperemia at the hand),,2009-06,COMPLETED,INTERVENTIONAL,['NA']
6832,NCT05973422,Serious adverse device effects (SADE),System Usability Scale (SUS) at baseline and 15 days for the Pump Assembly,,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6833,NCT00508287,Safety: incidence of adverse events,"PD Measures: Fasting and postprandial serum glucose (AUC), serum insulin, and plasma glucagon concentrations. Acetaminophen plasma concentrations will be measured after a single dose of acetaminophen",,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
6834,NCT04624737,Progression to severe retinopathy,Comparison of algorithms prediction to human prediction.,,2020-12-21,RECRUITING,OBSERVATIONAL,['NA']
6835,NCT01994811,Prevalence of non-communicable diseases,,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
6836,NCT04874116,Change in Medication Adherence,Change in CollaboRATE,,2021-05-26,RECRUITING,INTERVENTIONAL,['NA']
6837,NCT02114814,Hemoglobin A1c,Health-related Quality of Life (SF-12),,2012-06,COMPLETED,INTERVENTIONAL,['NA']
6838,NCT03315052,Acute cellular rejection (ACR),Infection,,2019-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
6839,NCT01131676,"Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.",Percentage of Participants With the Composite Microvascular Outcome,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6840,NCT00717223,Literacy levels and HbA1c,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
6841,NCT00267839,"Bone parameters after 6, 12 and 18 months",Quality of live after 12 and 18 months,,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3']
6842,NCT01253694,Proportion of subjects with resolution of diabetic macular edema compared to baseline as determined by mean foveal thickness on Spectralis < 300 microns.,Evaluate the main change in BCVA (best corrected visual acuity) score over time,,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6843,NCT02940418,Safety of using allogenic ASC assessed by any adverse events,,,2017-02-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
6844,NCT05920096,Acceptability - nurses' (intervention providers) satisfaction with the intervention,Preliminary evidence of effectiveness - point prevalence smoking abstinence at follow-up,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
6845,NCT00661908,,,,2004-03,COMPLETED,OBSERVATIONAL,['NA']
6846,NCT01758016,vascular complications in pregnancy,,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
6847,NCT05641090,Trail Making Test-B and Stroop test,Nitric oxide,,2021-12-16,RECRUITING,INTERVENTIONAL,['NA']
6848,NCT05189470,Complete healing,Change in Wound-QoL global score from baseline to end of follow-up,One-year amputation rate,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
6849,NCT01098461,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6850,NCT00124397,Flow mediated vasodilatation (FMD) on atorvastatin,CV events,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6851,NCT00213070,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
6852,NCT00456898,the biotransformation of codeine to morphine and the safety and tolerability of DVS SR,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6853,NCT02514954,"Delta AUCBG,0-2h",Local tolerability,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6854,NCT02632032,Changes in HbA1c,Changes in weight,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6855,NCT04074603,The glucose fluctuation,Assessment of safety and tolerance,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
6856,NCT02411929,Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUC Last) (Dose Normalized to 1 mg) and Absolute Oral Bioavailability (F) (Period 1),Number of Participants Discontinuing Study Drug Due to Adverse Events (Periods 1 and 2),,2014-10-29,COMPLETED,INTERVENTIONAL,['PHASE1']
6857,NCT00320112,Change in Glycemic Control (HbA1c),Number of Participants With Insulin Starts at 6 Months,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6858,NCT00259896,Pharmacodynamic measurements during 7 days of dosing.,Pharmacokinetic measurements during 7 days of dosing.,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6859,NCT00543010,,,,2002-11,TERMINATED,INTERVENTIONAL,['PHASE3']
6860,NCT00303134,Insulin independence 12 months after final islet infusion,Mixed meal test,,2003-08-01,TERMINATED,INTERVENTIONAL,['PHASE1']
6861,NCT02460978,Adjusted Mean Change From Baseline in HbA1c at Week 24,Percentage of Subjects With HbA1c Reduction From Baseline to Week 24 Last Observation Carried Forward (LOCF) >= 0.5% and Without Severe Hypoglycemia Events at Week 24,,2015-07-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6862,NCT04897815,Changes of cerebral blood flow on fasting and 1 hour postprandial.,The relationship between the fluctuation of blood glucose and the change of cerebral blood flow.,,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA']
6863,NCT05666128,Change in HbA1c(%),,,2022-06-17,RECRUITING,INTERVENTIONAL,['PHASE2']
6864,NCT00858897,Glutathione Concentration,,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
6865,NCT06148259,Change in prostate symptoms,,,2021-03-12,COMPLETED,INTERVENTIONAL,['NA']
6866,NCT05029297,"To demonstrate the efficacy and the non-inferiority of a new formulation of the capsaicin topical solution in ""roll-on"" compared to capsaicin in cream.",Grade of compliance/complacency of treatment.,,2010-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6867,NCT04240171,HbA1c %,IL-34 (pg./ml),,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
6868,NCT02976012,• Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks:,Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy,,2016-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6869,NCT06037499,Blood glucose measurement using BGMS,,,2023-03-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6870,NCT04543032,Measurement of stride length,Assessment of Quality of life,,2021-01-05,COMPLETED,INTERVENTIONAL,['NA']
6871,NCT02999841,Change of the visceral fat area in square centimeter assessed by abdominal CT scans from baseline to 24 weeks.,Change of brain natriuretic peptide in nanograms per milliliter from baseline to 24 weeks.,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
6872,NCT05320510,Change of HbA1c concentration,Change of TC concentration,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6873,NCT03138356,PK assessment: Cmax (Maximum observed plasma concentration),"Laboratory assessments (hematology, clinical chemistry and urinalysis)",,2017-05-25,COMPLETED,INTERVENTIONAL,['PHASE1']
6874,NCT01255293,Retinal redetachment rate,Silicone oil emulsification rate,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
6875,NCT05321368,Blood Pressure Control as assessed by percentage of participants with controlled Blood Pressure,Change in Health-Related Quality of Life as assessed by the PROMIS 29,,2023-10-16,RECRUITING,INTERVENTIONAL,['NA']
6876,NCT01493934,Change of glycemia,insulin resistance,,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6877,NCT03246828,Change in plasma glucagon from baseline (0min),Continuous glucose monitor recordings,,2017-07-03,COMPLETED,INTERVENTIONAL,['NA']
6878,NCT02187913,resistant starch effects,,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
6879,NCT01907113,Cmax (Maximum Concentration of the Analyte in Plasma),Assessment of Tolerability by Investigator,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6880,NCT02377583,Depression (CDI) score,Hippocampal volume and mean diffusion,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
6881,NCT01697618,Area under the serum insulin curve,Serum glucose excursions (EXC),,1997-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6882,NCT05274295,Reduction rate of the wound size,Improvement Wound pain,,2022-02-28,UNKNOWN,INTERVENTIONAL,['NA']
6883,NCT05851469,Clinical performance,Adverse events,,2023-05-31,COMPLETED,INTERVENTIONAL,['NA']
6884,NCT05725330,self-management scale,anthropometric measurements (Body Mass Index),,2023-02-25,RECRUITING,INTERVENTIONAL,['NA']
6885,NCT01392898,Body weight change (measured body weight at 26 weeks minus baseline body weight),Measuring change in insulin dose (insulin dose at 26 weeks minus insulin dose at baseline),,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
6886,NCT04838431,LGA,,,2018-06-01,TERMINATED,OBSERVATIONAL,['NA']
6887,NCT05937152,Change in pain intensity,Pain relief at 24 weeks,,2024-04,RECRUITING,INTERVENTIONAL,['PHASE2']
6888,NCT03323996,Semi-Structured interviews,,,2017-07-26,UNKNOWN,OBSERVATIONAL,['NA']
6889,NCT06046833,Metrics of Glucose Variability,Hypoglycemia episodes,GIQLI questionnaire,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
6890,NCT04104451,SAE,Change in A1c,,2019-11-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6891,NCT05409131,Percent of time in range 70-180 mg/dL,Change in Diabetes Quality of Life (DQL)-brief total score,,2022-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6892,NCT00695565,Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation,Change in Blood Pressure From Baseline to Week 12,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6893,NCT00889785,Lipids,self-care behaviors,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
6894,NCT00569465,arterial blood pressure decrease,oxidative parameters decrease,,2005-01,TERMINATED,INTERVENTIONAL,['PHASE4']
6895,NCT04064203,p-glucagon,growth hormone,,2017-07-05,COMPLETED,INTERVENTIONAL,['NA']
6896,NCT00813930,Six-month United Kingdom Prospective Diabetes Study (UKPDS) risk engine score. The UKPDS risk engine is a validated scoring system that uses multiple clinical characteristics to predict new coronary heart disease risks in patients with type 2 diabetes.,"Six-month: HbA1c, seated systolic blood pressure, serum Total Cholesterol concentration, serum HDL-C concentration, Total/HDL-C ratio value, LDL-C concentration, self-reported smoking status, adherence to medications and lifestyle measures.",,2008-11,UNKNOWN,INTERVENTIONAL,['NA']
6897,NCT04524832,"Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (AUC0-24h,sema,SS)",Change in blood pressure,,2020-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
6898,NCT01381900,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <6.5% at Week 18,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6899,NCT03073551,Glucose levels,Maternal weight gain,,2010-07-27,UNKNOWN,INTERVENTIONAL,['NA']
6900,NCT06031987,63-140 mg/dL Time in Range,fetal:Meconium aspiration,,2022-01-26,RECRUITING,INTERVENTIONAL,['NA']
6901,NCT05925829,Safety of SVF and aaPRP in Type 2 Diabetes Patients,,,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6902,NCT06236256,Improvement of glucose measures in older individuals,Grip strength,WHO-5,2024-01-09,RECRUITING,INTERVENTIONAL,['NA']
6903,NCT01850199,Median blood glucose (Interquartile range),Time from glucose criteria for insulin prescription to actual insulin starting,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
6904,NCT00505375,Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 2 Year Visit,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6905,NCT01043445,"The effect of this newly discovered GPR 119 agonist on gut hormone responses, in particular GLP-1 in response of the different meals administered to the subjects","Glucose homeostasis, gall bladder contraction in response of the different meals administered to the subjects",,2009-09,COMPLETED,INTERVENTIONAL,['NA']
6906,NCT00044421,Reduction in the progression of DPN measured by composite score,"Vibration sensation;Electrophysiology of tibial, peroneal and sural nerves;Neurological signs;Neuropathic symptoms;Clinical global impression of change;Health outcome measures",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6907,NCT02815787,The area under the plasma concentration-time curve (AUC) of Glyburide,The number of volunteers with adverse events as a measure of safety and tolerability,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6908,NCT00888628,Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant.,Reduction of Insulin Requriements,,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6909,NCT05610124,Food Intake,Change in Fatigue Level,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
6910,NCT04293367,Change in Post-absorptive Lipid Oxidation,Glucose Disposal Rate (GDR) during the Hyperinsulinemic-Euglycemic Clamp,,2009-06-01,COMPLETED,INTERVENTIONAL,['NA']
6911,NCT06268990,Insulin sensitivity,Tolerability of repeated FMT,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
6912,NCT00642681,To measure Serum FDKP AUC,,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
6913,NCT00654121,body weight gain.,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6914,NCT01638429,Gastric Emptying,% Stool Dry Weight,,2012-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6915,NCT04247620,Glycemic Control (HbA1c),Social Vulnerability (CDC/ATSDR Social Vulnerability Index),,2020-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6916,NCT00959725,Best-corrected visual acuity,Macular thickness,,2009-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6917,NCT02128581,Calories consumed during buffet meal test,,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6918,NCT00371306,Maternal glucose at delivery,Infant complications,,2002-09,UNKNOWN,INTERVENTIONAL,['NA']
6919,NCT01280695,Change From Baseline in Fasting Plasma Glucose,Change From Baseline in High Molecular Weight Adiponectin,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6920,NCT01780272,The number of electroencephalogram (EEG) identified arousals,Total sleep time,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6921,NCT05537480,Obtain CGM data concomitant with OGTT to determine what CGM metrics obtained in pregnant women with and without a high risk of GDM correlate best with the diagnostic OGTT (obtained via the 2-step and 1-step approaches),Determine what CGM metrics obtained in pregnant women correlate best with the need for pharmacologic management of GDM,,2022-01-14,RECRUITING,INTERVENTIONAL,['NA']
6922,NCT01235819,change in insulin requirement,C peptide response,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6923,NCT03220919,Doses,Hypoglycemia,Adverse effects,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA']
6924,NCT03736083,Change in Diabetes Treatment Satisfaction Questionnaire- Parent version,Change in Glycemic control measured by A1c,Percentage of glucose sensor readings above 180 mg/dl,2019-09,WITHDRAWN,INTERVENTIONAL,['NA']
6925,NCT05685927,Changes in parameters defining sarcopenia in relation to weight-loss or glycemic improvement,"Correlation analyses of primary measures with metabolic parameters including insulin resistance, HbA1c, metabolic economy, bioenergetics, and low-grade systemic inflammation (hs-CRP)",EMG assessment of myopathic changes,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
6926,NCT00101751,HbA1c and Incidence of hypoglycemia,Postprandial glucose from 8-point SMBG spontaneously reported adverse events; any changes from baseline,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6927,NCT01624116,Change in body weight and fructosamine levels during Ramadan fasting.,Change in renal profile from baseline to end of Ramadan,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
6928,NCT00478322,"Assessment of ECGs, physical examinations and laboratory values for adverse events",,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6929,NCT01447992,estimation of the failure rates of system components,percent time of active CTR,,2011-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6930,NCT01739829,To establish the safety and efficacy of xenotransplantation of DIABECELL,,,2011-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6931,NCT04033042,Risk/benefit analysis,Number of encountered Device Deficiencies,,2019-09-18,COMPLETED,INTERVENTIONAL,['NA']
6932,NCT05299502,Fasting plasma glucose,Gestational Diabetes Mellitus diagnosis,,2022-06-30,RECRUITING,INTERVENTIONAL,['NA']
6933,NCT00877123,interleukin-10 level,hs-CRP level,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6934,NCT04503408,Time of activities of daily living test,,,2019-09-13,COMPLETED,OBSERVATIONAL,['NA']
6935,NCT01934686,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
6936,NCT00925119,Change in Free Fatty Acid Kinetics,Change in Insulin,,2009-12,TERMINATED,INTERVENTIONAL,['PHASE4']
6937,NCT05161793,CGM - Tele-monitoring effects on HbA1c,CGM-Tele-monitoring effects on protocol driven enhancement of therapy with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and sodium-glucose cotransporter -2 (SGLT-2) inhibitors,,2022-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6938,NCT00697580,insulin sensitivity,adiposity,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
6939,NCT05610111,CGM-measured percent time in range 70-180 mg/dL,CGM-measured coefficient of variation during the day,,2023-01-18,RECRUITING,INTERVENTIONAL,['NA']
6940,NCT00962065,Change From Baseline at Day 28 in 24-hour Urinary Glucose Excretion,Change From Baseline at Day 28 in Triglycerides,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6941,NCT06329544,Degree of fibrosis,,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6942,NCT01082445,Tissue oxygenation improvement,Oxidation status reduction,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6943,NCT05791955,MyChart letter opened,Completion rate of one screening/test,,2023-05-23,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6944,NCT01455883,Change in HbA1c,,,2013-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6945,NCT02282397,Phase 2 (T1DM),Phase 2 (T1DM) - Insulin Use Outcomes,Phase 1 (T2DM) - Post-Hoc A1C Outcome,2014-09,COMPLETED,INTERVENTIONAL,['NA']
6946,NCT01858545,Number of Participants With Complete Wound Closure,,,2013-05,TERMINATED,INTERVENTIONAL,['NA']
6947,NCT00664183,Ultrasound,"Ultrasound, OCT, Safety",,2008-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6948,NCT04510506,Combined Triple Label Surveillance and Randomized substudies: Change in insulin sensitivity (Si) over time,Both substudies: Change in percent time <70 mg/dL,,2020-11-19,RECRUITING,INTERVENTIONAL,['NA']
6949,NCT05230342,Evaluation of the total daily interstitial glucose over 140 mg/dl,16s ribosomal gene analysis,,2022-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6950,NCT00572052,HbA1c,Quality of Life,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6951,NCT03174340,Prescription of insulin during the follow-up,Compliance with the exercise (in the exercise group only),Dosage of short-acting insulin,2008-02-21,COMPLETED,INTERVENTIONAL,['NA']
6952,NCT01709851,Point Accuracy of the microdialysis signal,Rate accuracy of the microdialysis signal,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
6953,NCT02809963,Liver fat content,potassium,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6954,NCT01973972,Hemoglobin A1c,Estimated Costs of Intervention Strategies,,2014-12-12,COMPLETED,INTERVENTIONAL,['NA']
6955,NCT00639665,Hemodynamic Measurements,Blood Pressure,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
6956,NCT02370537,Part B: Baseline Corrected Cmax for Total EPA+DHA Following Administration of EPANOVA® and OMACOR®.,,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6957,NCT04101669,Change in HbA1c,Questionnaire,,2019-09-09,RECRUITING,INTERVENTIONAL,['NA']
6958,NCT00948324,beta cell function;fast blood glucose;,,,2008-06,SUSPENDED,INTERVENTIONAL,['PHASE4']
6959,NCT04113694,Novolog Subjects - Rate of Infusion Set Failure at the End of Day 6,Novolog Subjects - Rate of Infusion Set Failure at the End of Day 7.,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
6960,NCT01107015,HBA1c at One Year,,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
6961,NCT00646724,Glucose and C-peptide levels,Complete Blood Count,,2008-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6962,NCT05362578,Change in American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptoms Index-Daily Diary (ANMS GCSI-DD),Electrocardiogram (ECG),36-Item Short Form Survey Instrument (SF-36) to measure quality of life (QOL),2022-09-08,RECRUITING,INTERVENTIONAL,['NA']
6963,NCT03249610,Number of subjects with reduced Body Mass Index,Number of subjects with reduced Fasting Blood Glucose,,2014-03-11,COMPLETED,INTERVENTIONAL,['NA']
6964,NCT00324584,frequency of hypoglycemic episodes (<70 mg/dl),,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6965,NCT06118931,Average 24-hour glucose total area under the curve (AUC) over 7 days,TRE fasting window adherence,Safety and Adverse Events,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6966,NCT06176703,Glycemic control,Quality of life,,2023-11-22,RECRUITING,INTERVENTIONAL,['NA']
6967,NCT05174975,Change in Glycosylated hemoglobin(HbA1c) levels,Change in Diabetic Positive Characteristics,,2021-10-20,COMPLETED,INTERVENTIONAL,['NA']
6968,NCT00716170,Plasma glucagon responses,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
6969,NCT04656210,Atrophy difference based on two cerebral MRI volumetries,changes in amyloid biomarkers in blood at 4 years of inclusion,,2021-10-14,RECRUITING,OBSERVATIONAL,['NA']
6970,NCT01915849,Area Under the Postprandial Curve (AUC) for Rate of Appearance (Ra) of Exogenous Glucose,,,2013-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6971,NCT02797314,Trabecular Bone Score,,,2017-03-28,RECRUITING,INTERVENTIONAL,['NA']
6972,NCT01530048,"Cmax, maximum concentration",Adverse events,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6973,NCT02506582,Blood glucose level by 2-h oral glucose tolerance tests (OGTTs),,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
6974,NCT01874080,Point estimates and 90% CIs for the ratio of geometric means for AUC(INF) for Saxagliptin and Metformin in the 5/500 mg FDC XR (Mt. Vernon/Humacao) and 5/500 mg FDC XR (Mt. Vernon),"Safety assessments based on adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests",,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6975,NCT01208948,occurrence of clinically significant macular edema (CSME) within a follow-up period of 2 years,The time to CSME development,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6976,NCT03536910,Changes in copeptin levels after general or spinal anesthesia,,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
6977,NCT00614055,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6978,NCT00818935,Glycated Haemoglobin,"body weight, homocysteine, C-reactive protein, plasma lipids and lipoproteins, fasting body glucose, insulin, insulin resistance, serum urea, creatinine, C-peptide",,2004-06,COMPLETED,INTERVENTIONAL,['NA']
6979,NCT04940572,Preservation of auditory function.,Quality of sleep assessment on adult population - Qualitative questionnaire (no scale),,2021-11-26,RECRUITING,INTERVENTIONAL,['PHASE2']
6980,NCT03799185,Prevalence of dyslipidemia,Prevalence of cardiovascular associated risk factors,Dietary assessment,2016-01-04,COMPLETED,OBSERVATIONAL,['NA']
6981,NCT06025422,During the procedure difference in the mean in-shoe PPP by ROI associated with each toe gap standard,During the procedure PTSR associated with habitual footwear,,2023-03-13,RECRUITING,OBSERVATIONAL,['NA']
6982,NCT05795972,glycemic control,akkermania levels,,2020-06-01,RECRUITING,INTERVENTIONAL,['NA']
6983,NCT01826162,"Fat oxidation, energy expenditure",Appetite VAS scoring,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
6984,NCT06148376,Precentage of patients whose prandial insulin is wthdrawn,Diabetes treatment satisfaction,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6985,NCT03029390,Insulin sensitivity,Creatinine levels,,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6986,NCT03851978,Change in vaccination rates,Barriers to receiving vaccination,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
6987,NCT01893242,Time to the first occurrence of either component of the composite endpoint: end stage renal disease or cardiovascular death,Time to the first occurrence of any component of composite outcome of end-stage renal disease and all-cause mortality,,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6988,NCT03393338,Number of emergency room visits and hospitalizations over 12 months,Physician Trust,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
6989,NCT02739217,Description and number of abnormal laboratory values and adverse events that are related to treatment.,Change from baseline of antidiabetic treatment,Change from baseline in hyperinsulinaemic-euglycaemic clamp measurements.,2016-02-22,COMPLETED,INTERVENTIONAL,['PHASE2']
6990,NCT00651378,Percent change in LDL-C level from baseline to the study endpoint.,"Adverse events, laboratory test results, vital signs.",,2004-09-01,TERMINATED,INTERVENTIONAL,['PHASE4']
6991,NCT01961674,Temperature at supraclavicular region,Glycaemic response,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
6992,NCT02177747,Diabetic retinopathy grading,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
6993,NCT04354740,Major adverse cardiac events (MACEs),In hospital mortality,,2020-07,UNKNOWN,OBSERVATIONAL,['NA']
6994,NCT06283849,sedentary time,,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6995,NCT00504816,blood hormone levels,vital signs,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6996,NCT04259489,Glycemic achieving rate,The days of Hospitalization due to hypoglycemia,,2020-01-31,UNKNOWN,INTERVENTIONAL,['NA']
6997,NCT00919347,"The primary outcome will be to quantify, using the ANSR ANX 3.0 technology, the prevalence of cardiac autonomic neuropathy (CAN), diabetic autonomic neuropathy (DAN),referred to as advanced autonomic nervous system dysfunction in non-diabetic patients.",The strength of various comorbidities as predictors of autonomic dysfunction in both diabetics and non-diabetics will be evaluated. The differential effect of these various comorbidities in Type I versus Type II diabetes on ANS dysfunction and neuropathy,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
6998,NCT02449187,AUC(last),Vd/F,,2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6999,NCT04324424,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of CLr (if applicable),,2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7000,NCT05736536,Changes of readiness to change for weight loss (behaviour),Changes in body fat composition (anthropometric),,2023-04-01,COMPLETED,INTERVENTIONAL,['NA']
7001,NCT03883230,GLYWD test result,Clinician's wound characterization,,2017-07-27,COMPLETED,OBSERVATIONAL,['NA']
7002,NCT06032988,Effects of probiotics supplementation on glycemic control (HbA1c),Effects of probiotics supplementation on changes in gut microbiota diversity (alpha- and beta-diversity),,2023-08-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
7003,NCT00302042,Change in Weight,Change in Dietary Composition,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
7004,NCT02717078,Change in hemoglobin A1c from baseline to week 12,24-hour diet recall,,2017-06-19,COMPLETED,INTERVENTIONAL,['NA']
7005,NCT04771403,Percent of Time With Sensed Glucose <70 mg/dl,Mean Amount of Insulin Delivered Per Day (in Units/Day),,2021-02-23,COMPLETED,INTERVENTIONAL,['NA']
7006,NCT00300976,"The occurrence of myocardial infarction, coronary bypass surgery, percutaneous transluminal coronary angioplasty, stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, carotid artery stenting, or death",All-cause mortality (deaths due to any cause),Changes in QOL (EQ-5D),2006-05,UNKNOWN,INTERVENTIONAL,['NA']
7007,NCT05196958,Weight loss,Impact of aGLP1 on the treatment already in place to regulate blood glucose,,2022-01-25,RECRUITING,INTERVENTIONAL,['NA']
7008,NCT01334645,Copeptin value,"Troponin, Myoglobin and Creatin Kinase values. Clinicals and paraclinicals events .",,2011-03,COMPLETED,INTERVENTIONAL,['NA']
7009,NCT02587286,Change in HbA1c,Change in HbA1c,mHealth intervention satisfaction,2015-03,COMPLETED,INTERVENTIONAL,['NA']
7010,NCT05663515,Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population,,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7011,NCT01537497,Modulation of carbohydrate and lipid metabolism,Area under the curve (AUC) of PF-05175157 after single oral doses,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7012,NCT00947427,C-peptide Response to Mixed Meal Glucose Tolerance Test (MMTT) at One Year for Subjects Given Canakinumab Compared to Placebo,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7013,NCT00349128,Change in fasting triglycerides.,Assessment of lipid and glucose metabolisms.,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7014,NCT03037099,Dietary glycemic index,Systolic blood pressure,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
7015,NCT01199692,,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
7016,NCT05838209,clinical attachment level,clinical attachment levels,,2023-04-05,RECRUITING,INTERVENTIONAL,['NA']
7017,NCT04336800,To build a registry of diabetic volunteers by inviting them to get a LiverMultiScanand collecting their contact information to seek interest in participating in future studies.,To use multi-parametric MRI (LiverMultiScan) of the liver to assess liver health,,2020-04-01,COMPLETED,OBSERVATIONAL,['NA']
7018,NCT04474496,Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure,Sources of Stress During COVID-19,,2020-07-27,COMPLETED,OBSERVATIONAL,['NA']
7019,NCT01966978,Mean Change From Randomization in A1c at Week 26,Change in Short Form-36 (SF-36) Questionnaire Score,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4']
7020,NCT03912480,glucose-c peptide release test,Continuous dynamic blood glucose,,2019-01-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7021,NCT00272064,Changes of glycosilated haemoglobin (HbA1c),Hypoglycemic episodes,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7022,NCT02243176,Absolute Change From Baseline in HbA1c at Week 24 (DAO),Change From Baseline in Body Weight,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7023,NCT01885546,User's ability to obtain the enhanced meter feature,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
7024,NCT04498156,Preferences regarding chronic kidney disease in T2D,Time point of communicated CKD diagnosis,,2020-09-16,COMPLETED,OBSERVATIONAL,['NA']
7025,NCT02035059,Development of Gestational Diabetes in second/third trimester,,,2014-05-01,COMPLETED,OBSERVATIONAL,['NA']
7026,NCT02174146,leptin levels in gingival tissue,clinical attachment level,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
7027,NCT00989547,insulin production,"Insulin Dose, Autoantibody levels, T-cell functional response assays, Cytokine levels",glycated hemoglobin (HbA1c),2008-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
7028,NCT04164966,Characterization of circulating β cell-specific exosomes in children with T1D and healthy normal controls using baseline samples,,,2019-11-27,RECRUITING,OBSERVATIONAL,['NA']
7029,NCT01280682,Change of 3-hour Mean Area Under the Curve (AUC) of C-peptide,HbA1c Levels,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
7030,NCT00899470,Metformin T-half and T-max,Number of Participant With Clinically Relevant Physical Examination Abnormalities,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7031,NCT00949442,HbA1c,Need of additional prandial insulin,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
7032,NCT01333774,Change in HbA1c value between initial and final visit,Number of participants with adverse events in both study groups. The influence of different approaches to dietary advising on the appearance of adverse events.,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
7033,NCT01213563,efficacy and safety of an intensive glycaemic protocol after bariatric surgery,,,2009-01,TERMINATED,INTERVENTIONAL,['NA']
7034,NCT01865292,Area under the glucose infusion rate curve,Area under the insulin degludec/insulin glargine curve,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7035,NCT03312595,Percentage of Participants With Wound Closed,Time to Wound Closure,,2017-09-14,COMPLETED,INTERVENTIONAL,['NA']
7036,NCT02977039,Glycemic control,quality of life,,2019-11,WITHDRAWN,INTERVENTIONAL,['NA']
7037,NCT05256303,"Total cost, hospitalization",Percent of day lying down,Qualitative interviews,2022-02-16,COMPLETED,INTERVENTIONAL,['NA']
7038,NCT01588106,Reduction in HbA1c,,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
7039,NCT04907019,AUC0-∞,CLz/F,,2021-07-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7040,NCT03380988,Postprandial glucose response,,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7041,NCT04612595,increasing by 50% of the serum creatinine level from baseline,,,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA']
7042,NCT02085876,"To determine a correlation coefficient > 0.80, alpha 0.05 and beta 0.20 between the MRI markers relevant.",To determine the correlation between the unsaturated fat measurements and MRI Lipidomics Spectro analysis.,,na,UNKNOWN,OBSERVATIONAL,['NA']
7043,NCT02989649,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6,Time to Alogliptin or Alogliptin FDCs Dose Escalation or Dose Reduction,,2016-12-22,TERMINATED,OBSERVATIONAL,['NA']
7044,NCT01698008,Evidence for Improved Diabetic Care With Mobile Phone Application Use,,,2012-01-28,COMPLETED,INTERVENTIONAL,['NA']
7045,NCT01553266,Change from 12 months prior to intervention in HbA1c up to 12 months during the intervention,MDET educators' quarterly debriefing session group discussions regarding intervention issues,,2012-03-01,COMPLETED,OBSERVATIONAL,['NA']
7046,NCT01150292,Platelet function induced by collagen,Evaluation of cellular and plasmatic redox status,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
7047,NCT01084005,HbA1c Change From Baseline to Week 24,Number of Patients With Rescue Therapy,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7048,NCT01490879,Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment,Incidence of adverse events,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7049,NCT01232491,Change From Baseline in Body Weight,Rate of Nocturnal Treatment Emergent Hypoglycaemic Episodes,,2010-10-29,COMPLETED,INTERVENTIONAL,['PHASE4']
7050,NCT04627103,Weight Loss,Albumin - Nutritional Status,,2021-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7051,NCT01528059,Glycemic control,Nutritional status assessment,,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7052,NCT03889600,Feasibility - Implementation fidelity: percentage of indicated referrals that are made,Limited Efficacy - 30-Day readmission rate,Process Outcome- Referral Completion: percentage of patients who receive services post-referral,2021-03-02,WITHDRAWN,INTERVENTIONAL,['NA']
7053,NCT05104047,Gracely Pain Scale,Subjective Peripheral Neuropathy Screen (SPNS),Neurological Sensory Testing (NST),2019-07-29,COMPLETED,INTERVENTIONAL,['NA']
7054,NCT00986700,fasting glucose level,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
7055,NCT02626156,Time Spent in Minutes Engaging in Physical Activities,Knowledge Questionnaire of Study Instructions,,2015-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7056,NCT05878431,Neuropathic Pain Impact on Quality of Life Questionnaire (NePIQOL),,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
7057,NCT02577016,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in FPG at Week 24,,2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7058,NCT04372355,HbA1c change at Week 8 in comparison to Baseline,HbA1c change at Week 12 in comparison to Baseline,,2019-06-19,COMPLETED,INTERVENTIONAL,['PHASE2']
7059,NCT04934228,Adipose Tissue Sample: Efficacy of 4-week supply of Clonidine Compared VS 4-week supply of control condition using hydrochlorothiazide (HCTZ) and a separate placebo treatment,,,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE1']
7060,NCT04854512,Change in HbA1c,HbA1c response (Metformin DR vs. metformin IR),,2021-05-18,SUSPENDED,INTERVENTIONAL,['PHASE3']
7061,NCT04066400,Effect of ATI-free Nutrition on hepatic inflammation,Quality of Life using the chronic liver disease questionnaire (CLDQ),,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
7062,NCT05360537,Change from Baseline Reactive Hyperemia Index at 3 and 9 months,Change of intra and extra-hospital mortality,,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7063,NCT03078478,Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks),Change in Body Weight From Baseline to End of Treatment (up to 88 Weeks),,2017-03-13,COMPLETED,INTERVENTIONAL,['PHASE3']
7064,NCT00659711,"Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients",Change in Oxidative Stress From Baseline to 12 Weeks,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
7065,NCT04885153,Changes from Baseline Vascular Cell Adhesion Molecule-1 (VCAM -1) at 3 Months,,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
7066,NCT05037058,Proportion of patients receiving guidance on individualized physical activity,,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
7067,NCT04705558,change in glycated hemoglobin,change in Body composition,,2020-07-20,UNKNOWN,INTERVENTIONAL,['NA']
7068,NCT02859116,Tissue collection,,,2016-07-21,COMPLETED,OBSERVATIONAL,['NA']
7069,NCT04251559,Gestational diabetes mellitus risk faktors,,,2014-01-01,COMPLETED,INTERVENTIONAL,['NA']
7070,NCT01388192,Change of glucose metabolism after pancreaticoduodenectomy,,,2011-11,UNKNOWN,OBSERVATIONAL,['NA']
7071,NCT01264796,quality of life,,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
7072,NCT01931137,Area under the serum insulin 338 concentration-time curve,Number of treatment emergent adverse events,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7073,NCT02488213,Glicemic control,Adherence to nutritional counseling,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
7074,NCT04127084,changes of 8-OH-dG,Change in angiotensin,,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
7075,NCT01318135,Number of Participants With Adverse Events.,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7076,NCT02057172,Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks,Number of subjects attaining goal glycosylated haemoglobin (HbA1c) <7%,Assess the immunogenicity of HM11260C,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7077,NCT04583462,Change between below-knee arterial calcification score evaluated by CT-scan at T0 and T2years in type 1 diabetic patients treated or not with metformin.,Change between below- knee arterial calcification score progression between T0 and T2years with initial below-knee arterial calcification score ≤ and >400 (subgroup analysis),,2021-06-02,RECRUITING,INTERVENTIONAL,['PHASE3']
7078,NCT01422876,Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive Patients,Occurrence of Treat to Target Efficacy Response for Treatment Naive Patients,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7079,NCT01659294,diabetes distress (DDS),Depressive Symptoms Severity,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7080,NCT04655131,Number of positive events for each protein amount.,,,2018-06-18,COMPLETED,INTERVENTIONAL,['NA']
7081,NCT02478190,ED Length of Stay,Return ED visit for any reason,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
7082,NCT03460899,Changes in Platelet Activation Marker Adenosin Diphosphate (%),Changes in Coagulation Marker Fibrinogen (g/L),,2018-02-12,COMPLETED,INTERVENTIONAL,['NA']
7083,NCT03712046,Diagnostic accuracy of 18F-FDG PET-CT for the diagnosis of diabetic foot osteomyelitis,,,2019-01-15,TERMINATED,INTERVENTIONAL,['NA']
7084,NCT03804905,Lacking medication insurance,Time from allocation to use of Trillium Health Partners outpatient pharmacy,Health care costs,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7085,NCT02157350,Proliferative diabetic retinopathy progression/regression.,"Retinal vessel geometry (caliber, fractals and tortuosity)",Retinal areas of non-perfusion.,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7086,NCT03755479,Achieving glucose values more than 67% in Time in Range (70-180 mg/dl),Time spend in Auto Mode,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
7087,NCT00611988,Maximal treadmill walking distance,,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7088,NCT03985566,Change in insulin response,Change in glucose trajectories over 14 days of continous glucose monitoring,,2018-07-03,COMPLETED,INTERVENTIONAL,['NA']
7089,NCT03948347,Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic),Percentage of patients with the 90-day Modified Rankin Scale (mRS) ≤ 2,,2019-06-25,RECRUITING,INTERVENTIONAL,['NA']
7090,NCT03143816,Change in Time in Range (%) (70-180 mg/dl) With TI on CGM,Hypoglycemia Frequency (%) (Below the Target <70mg/dl) on CGM,,2017-09-30,COMPLETED,INTERVENTIONAL,['PHASE4']
7091,NCT00799643,"The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.","Response Rates in Patients Initially Treated With Lifestyle Modification, Insulin Secretagogue, Metformin or Combination Therapy",,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7092,NCT00366301,Percentage Reduction in C-reactive Protein (CRP),,,2006-08,TERMINATED,INTERVENTIONAL,['PHASE4']
7093,NCT00364988,Renal function,,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
7094,NCT04143802,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Mean Daily Plasma Glucose (PG),,2019-12-18,COMPLETED,INTERVENTIONAL,['PHASE1']
7095,NCT00159536,pre-eclampsia,Snoring and sleep quality,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7096,NCT04085926,Percentage of participants with healed foot ulcers at 12 weeks,"Sick-leave from work (number of days per participant) during treatment period (average 12 weeks) and during the period after treatment end up to 12 months later, assessed with study-specific questionnaire and Swedish Social Insurance Agency's system data",,2019-08-02,RECRUITING,INTERVENTIONAL,['NA']
7097,NCT01307137,Compare changes in weight and hemoglobin A1c between participants receiving peer-led care (with or without TAP intervention) and those receiving UC over 12 months.,"Compare changes in health care utilization (physician visits, emergency visits, and days in hospital) among treatment groups (UC, PC, and TAP).",,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
7098,NCT03009513,Area under the plasma concentration versus time curve (AUC),,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7099,NCT04246814,Change in complete ulcer healing,Short Form-36 Health Survey questionnaire,,2019-08-27,COMPLETED,INTERVENTIONAL,['NA']
7100,NCT05958264,Determination of DeBacker Score of sublingual microcirculation of children,Differences of DeBacker Score of sublingual microcirculation with parameters of healthy children in the same age categories,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
7101,NCT04371042,Registry creation,,,2019-09-01,RECRUITING,OBSERVATIONAL,['NA']
7102,NCT04400344,Current state of diabetic foot care education and knowledge base among diabetic educators,,,2020-06-13,UNKNOWN,OBSERVATIONAL,['NA']
7103,NCT04226378,Glycated hemoglobin (A1C),Annual incidence of severe hypoglycemia,A1C stratified by age cohort,2020-01-20,COMPLETED,OBSERVATIONAL,['NA']
7104,NCT01433380,Changes in carbohydrate and lipid metabolism,"Pharmacokinetics: 0.5, 1, 1.5, 2.5, 6.5, 10.5, 24 hrs after dosing, parameters: Cmax, Tmax and Area under the Curve (AUC)",,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7105,NCT04511715,Percentage of patients with equal or more than 2 stages of progression in diabetic retinopathy staging,Number of visits,,2020-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7106,NCT04493177,"Prevention of overweight/obesity mothers, determined by loss in body mass index (BMI)",Changes in blood concentration of lipids: intervention,,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7107,NCT03385265,Parent Diabetes Distress,Behavioral Pediatric Feeding Assessment Scale_Problem,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
7108,NCT01842282,Hepatic Steatosis by MRI,Weight,,2013-07-19,TERMINATED,INTERVENTIONAL,['PHASE2']
7109,NCT05427916,Number of Participants With Healing Complication,Patient Satisfaction,,2022-07-12,TERMINATED,INTERVENTIONAL,['NA']
7110,NCT05863611,Frailty has an effect on balance in patients with type 2 diabetes.,Frailty has an effect on the risk of falling in patients with type 2 diabetes.,,2023-05-20,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7111,NCT01497301,Change in Hemoglobin A1C,Change in LDL cholesterol,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
7112,NCT00379548,Insulin resistance assessed by HOMA,,,2005-11,COMPLETED,INTERVENTIONAL,['NA']
7113,NCT03655067,Center for Epidemiological Studies - Depression Scale (CES-D),Problem Areas in Diabetes - Teen version,,2020-12-15,COMPLETED,INTERVENTIONAL,['NA']
7114,NCT02676401,Adverse events,Change from baseline in Urine Albumin to Creatinine Ratio (UACR),,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7115,NCT00954343,Percentage decrease of ulcer size twelve weeks after treatment begin (i.e. first shock wave treatment) compared to the baseline (ulcer size at first treatment),Tissue oxygen concentration after shock wave treatment,,2009-08,WITHDRAWN,INTERVENTIONAL,['NA']
7116,NCT01000363,"Patients who participate in the diabetes group visits should achieve improvement in Clinical outcomes - better A1C levels, reduced blood pressure, reduced cholesterol levels",behavioral outcomes,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
7117,NCT01366287,"Safety: Safety labs, vital signs, ECGs, physical examinations and adverse event monitoring.",,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7118,NCT05505721,Body mass index (kg/m2),,,2021-03-16,COMPLETED,OBSERVATIONAL,['NA']
7119,NCT00018239,,,,1999-10,COMPLETED,INTERVENTIONAL,['NA']
7120,NCT01839071,Fat tissue biopsy,Blood collection,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
7121,NCT00202748,Change in self-reported activity,Quality of life,,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
7122,NCT00247455,Plasma GLP-1 concentration,C-peptide/insulin ratio as marker of hepatic insulin extraction,,2002-03,COMPLETED,INTERVENTIONAL,['NA']
7123,NCT02609243,change in hepatic fat content confirmed by proton magnetic resonance spectroscopy by 3 T MR imaging,change in distribution of body fat confirmed by MR-Imaging by 3 T whole body imager,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
7124,NCT04097483,Diabetes Distress Scale (DDS),Research nurse qualitative and quantitative evaluation about Treatment Adherence and diseases management.,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
7125,NCT00175253,,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7126,NCT01946451,Gene expression in patients with idiopathic and secondary epiretinal membranes in proliferative diabetic retinopathy.,,,2012-06,UNKNOWN,OBSERVATIONAL,['NA']
7127,NCT02155361,Pain Scores on the Neuropathic Pain Scale (NPS),Motor amplitude (microvolt) of tibial nerve,,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7128,NCT03516422,Wound healing,Reduction in bacterial colonization,,2018-11,UNKNOWN,INTERVENTIONAL,['NA']
7129,NCT01087502,HbA1c Change From Baseline to Week 12,Plasma Concentration of Linagliptin at Trough,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7130,NCT04473274,Adverse events attributable,A1c,,2020-05-21,COMPLETED,INTERVENTIONAL,['PHASE4']
7131,NCT05887635,Tolerability Endpoint:,Change in ALT and AST from baseline to 24 weeks post procedure.,,2023-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7132,NCT02856516,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
7133,NCT00767351,,,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
7134,NCT01003184,Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26),Hypoglycemia Rate Per Year,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7135,NCT00082381,Change in Glycosylated Hemoglobin (HbA1c),Change in Rate of Hypoglycemic Events,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7136,NCT03292185,Area under the plasma liraglutide concentration time curve,Local tolerability at the injection site,,2017-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
7137,NCT01593215,Insulin Secretion,Glucose,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7138,NCT02956811,Change in left ventricular (LV) Mass by Cardiac MRI at 52 weeks,Change in diastolic function and global longitudinal strain,,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
7139,NCT05459987,Feasibility of an intensive multidisciplinary program based on lifestyle changes in coronary heart disease patients recently diagnosed with prediabetes that are referred to the Centre EPIC.,"Evolution of the HOMA-IR between the start of the program, the end of intervention (3 months) and the follow-up visit (6 months).",,2022-03-15,COMPLETED,INTERVENTIONAL,['NA']
7140,NCT04106050,Change in Nerve Excitability from Baseline (Day 1) to Last Treatment Visit (Day 8) as Determined by Compound Muscle Action Potential Threshold Tracking (CMAP-TT) in the Median Nerve of Healthy Participants,Time to Reach Maximum Observed Concentration (Tmax),,2020-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7141,NCT01313156,"Metabolic Syndrome, Type 2 Diabetes",,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
7142,NCT01145066,Leptin,PBMC Leukotriene Stimulation,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7143,NCT02160717,Beta-Cell Function measured as Disposition Index,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
7144,NCT00923962,Coronary metabolite uptake,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
7145,NCT03380832,Vestibular threshold,,,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA']
7146,NCT00399347,,,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
7147,NCT02045758,Non-Inferiority of Analyte Levels,,,2014-12,UNKNOWN,INTERVENTIONAL,['NA']
7148,NCT03437135,presence or not of an ear wax cap,frequency selectivity of the patient,,2015-12-01,COMPLETED,OBSERVATIONAL,['NA']
7149,NCT02620787,Tedizolid Tissue Penetration,Tedizolid AUC in Plasma,,2016-02-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7150,NCT01301287,HbA1c,Insulin concentration during oral glucose tolerance test,,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
7151,NCT00493935,,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
7152,NCT00283049,Change in Hemoglobin A1c (HbA1c) From Baseline to Week 12,"Rate of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia and Serious Hypoglycemia",,2006-02,TERMINATED,INTERVENTIONAL,['PHASE4']
7153,NCT05141565,Mortality,,,2021-05-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7154,NCT01351922,"Percentage of patients having complications (dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications)",,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
7155,NCT01842620,Geometric Means for Maximum Plasma Concentration of the Study Drug (Oxemet) to the Reference Drug (Glafornail) From 0 to 36 h,Time to Reach Maximum Plasma Concentration (Tmax) of the Study Drug (Oxemet) and the Reference Drug (Glafornail) Over Period,,2013-03-13,COMPLETED,INTERVENTIONAL,['PHASE4']
7156,NCT02140983,OGTT,,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7157,NCT01868568,Area under the insulin aspart concentration curve,Area under the serum insulin 454 concentration curve,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7158,NCT04201938,insulin sensitivity (%S),cytokines levels,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
7159,NCT00535925,"""Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)""","""Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase""",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7160,NCT05794152,Adverse birth outcomes,Number of participants developing type 2 diabetes,,2023-03-21,RECRUITING,INTERVENTIONAL,['NA']
7161,NCT06067451,To determine the impact of SMART Goal setting on BMI z-scores To determine the impact of SMART Goal setting on BMI z-scores,Temporal changes in Lipids,,2023-12-10,RECRUITING,INTERVENTIONAL,['NA']
7162,NCT02148250,Duration (in Hours) of 20 % Dextrose Infusion Requirement,Total Glucose Required to Maintain Euglycaemia,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7163,NCT01282970,"Safety and tolerability of BI 135585 will be assessed in a descriptive way using physical examinations (occurence of findings), vital signs, electrocardiograms, laboratory tests, and incidence and severity of adverse events.",Exploratory evaluation of the pharmacodynamics of BI 135585 by measuring of cortisol and cortisone and their metabolites in urine,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7164,NCT03002155,Chair Stand Test (5x Sit-to-Stand) at 12-week Session,Adverse Events,Recruitment,2017-01,COMPLETED,INTERVENTIONAL,['NA']
7165,NCT01010594,Change in Hba1c,change in fruit intake,,2009-11,TERMINATED,INTERVENTIONAL,['NA']
7166,NCT01030926,Area under the NN1250 concentration-time curve after single dose,Time to maximum observed NN1250 concentration after single dose,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7167,NCT04688671,Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS),Change in the Daily Amount of Acetaminophen Use From Baseline to Week 4,,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7168,NCT00364767,"enzymes involved in fatty acid oxidation, oxidative phosphorylation and glycolysis in skeletal muscle","insulin sensitivity (oral glucose tolerance test) and related factors (adiponectin, HbA1c)",,2004-10,COMPLETED,INTERVENTIONAL,['NA']
7169,NCT00426413,,,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
7170,NCT05586542,Adverse events,Cost,,2022-10-03,RECRUITING,INTERVENTIONAL,['PHASE1']
7171,NCT01154374,The incidence of complete healing of the target ulcer.,Absolute and percentage change in ulcer surface area from baseline to endpoint.,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7172,NCT03368937,System Suitability,,,2017-12-08,COMPLETED,INTERVENTIONAL,['NA']
7173,NCT05086549,Rate of change in albuminuria (urine ACR),Rate of change in proteinuria (urine PCR),,2021-09-29,COMPLETED,OBSERVATIONAL,['NA']
7174,NCT05101135,Changes in HbA1c,,,2021-11-17,UNKNOWN,INTERVENTIONAL,['PHASE3']
7175,NCT03993990,Foot infection and recurrence of foot ulcer,Self-efficacy regarding diabetes-related foot ulcer self-management,,2019-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
7176,NCT02674828,number of consecutive weeks step goal met,Habitual Total Weekday Activity Score,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
7177,NCT01216618,Safety,Pharmacodynamic,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7178,NCT00457938,"Project specific: improvement in serum triglycerides, insulin resistance, liver triglyceride content, liver volume, Hgb A1c,",,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
7179,NCT00314379,Endothelial function by a non-invasive method of FMD,"Predefined in the protocol submitted to the EC approved prior to study beginning and the Inform Consent Form signed by all study participants prior to study related procedures, serum was preserved for the analysis of oxidative and inflammatory markers.",,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7180,NCT01647438,Change in Saturated Fat (% of Daily Kilo-calories From Fat) Intake,,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7181,NCT05928637,Cmax,,,2023-07-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7182,NCT05489536,Incidence of GDM,Physical Activity,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7183,NCT02015299,change from baseline carotid-(right) femoral arterial Pulse Wave Velocity (PWV) at 26 weeks,Subclinical vascular inflammation (FDG PET-CT),Lifestyle,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7184,NCT01619059,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7185,NCT03798717,Mean AUC (Area Under the Curve) Plasma [Glucose],Change in Inflammatory Status,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
7186,NCT05593874,Clinical failure,Time-to-additional-intervention,,2022-10-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7187,NCT00842361,Rate of Nocturnal Major and Minor Hypoglycaemic Episodes,Systolic BP (Blood Pressure),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7188,NCT04057339,Change in glycemic parameters,Change in hs-CRP,Change in mitochondrial structure and gene expression in skeletal muscle,2019-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7189,NCT03627455,MACE,,,2003-01-01,COMPLETED,OBSERVATIONAL,['NA']
7190,NCT04997460,Correlation of glycated hemoglobin and glycemic variability,Correlation of hypoglycemia and glycemic variability,C-peptide concentration in different pregnancy trimesters,2021-01-11,UNKNOWN,OBSERVATIONAL,['NA']
7191,NCT00036192,,,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7192,NCT02505308,Maximal Insulin Secretion (composite measure) following formal stimulation (GPAIS) test,Faecal elastase,,2015-03-04,COMPLETED,INTERVENTIONAL,['NA']
7193,NCT03451201,Endothelial Dependent Mediated Vascular Dilation,Endothelial independent vascular dilation,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
7194,NCT04682054,counts of each cell type,,,2021-01-15,UNKNOWN,INTERVENTIONAL,['NA']
7195,NCT04705506,Markers of vascular calcification,,,2017-02-05,COMPLETED,INTERVENTIONAL,['NA']
7196,NCT01344278,Primary outcome: meeting the postpartum weight goal,physical activity,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
7197,NCT03615755,Serum creatinine,,,2016-12-27,COMPLETED,INTERVENTIONAL,['NA']
7198,NCT00985842,Oxygen in tissue,,,2009-11-01,COMPLETED,INTERVENTIONAL,['NA']
7199,NCT02330939,postprandial incremental glucose AUC,,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
7200,NCT03332836,Number of participants with adverse events,AUC of HM12460A,,2017-10-25,TERMINATED,INTERVENTIONAL,['PHASE1']
7201,NCT05656924,Difference in step counts between the two groups,Difference in Prosthesis Evaluation Questionnaire (PEQ) scores in the two groups,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7202,NCT05555095,"Patient satisfaction, 1-item researcher generated question",,,2022-09-26,RECRUITING,OBSERVATIONAL,['NA']
7203,NCT00671424,Serum sodium and potassium concentrations:,weight:,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7204,NCT06017544,MACE,,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
7205,NCT03607799,Glucose area-under-the-curve (glucose AUC),Gestational diabetes mellitus,Maternal pregnancy complications,2020-11-26,RECRUITING,INTERVENTIONAL,['NA']
7206,NCT06035523,Percentage of index ulcers (the ulcers being treated in the study) healed at 12 weeks,Change in subjects reported pain levels (NPRS),Cost to closure,2021-12-29,RECRUITING,INTERVENTIONAL,['NA']
7207,NCT06254274,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Fasting Serum Glucose,,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE2']
7208,NCT00752180,Mean AUCins.0-12h and Cins.max,"PK endpoints: AUC0-4h, AUC0-6h, AUC6-12h,tmax, t½ and elimination rate constant.PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR6-12h, AUCGIR0-12h, GIRmax and tGIRmax .Safety endpoints: AEs, hematology, biochemistry, urinalyses, physical exam",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7209,NCT02923323,Association between interstitial glucose concentration and EEG power,Association between interstitial glucose concentration and neurocognitive functions,DTI assessment of brain MRI according to HbA1c,2016-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7210,NCT03855449,Task Analysis Wireframe Development part 2,,,2019-06-05,RECRUITING,INTERVENTIONAL,['NA']
7211,NCT02470039,Change in fasting plasma glucose (FPG),area under the serum insulin concentration-time curve,,2015-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7212,NCT05631119,collect biospecimen samples,,,2022-12-15,COMPLETED,OBSERVATIONAL,['NA']
7213,NCT02648204,Change in HbA1c,Change in Pulse Rate,,2016-01-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7214,NCT03794232,Incidence of blood sugar reversal to normal after intervention,Body weight,,2016-05-30,COMPLETED,INTERVENTIONAL,['NA']
7215,NCT01725126,Change From Baseline in Fasting Plasma Glucose (Safety Laboratory) Values During the Double-blind Treatment Period of Part B and C,Tmax of Metformin During the Double-blind Treatment Period of Part C,,2013-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7216,NCT03112005,Number of subject eyes whose EyeArt results match the reading center grading for identifying vision threatening diabetic eye disease (severe NPDR or PDR or surrogate markers for CSME).,,,2017-04-17,COMPLETED,OBSERVATIONAL,['NA']
7217,NCT01529918,Patient's uptake and preferences,"The comparison of yield of actual diabetes detected from those who have high risk at self risk-assessment, compared to the usual diabetes detection rate in a random sample from the practice within a one year period.",,2009-11,UNKNOWN,INTERVENTIONAL,['NA']
7218,NCT00438698,Change in Fasting Glucose,Urinary C-peptide,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
7219,NCT02811484,Change in HbA1c,Change in total dose insulin,,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7220,NCT04228003,Decreased Gastrointestinal Symptoms,Improvement in A1C,,2021-01-15,WITHDRAWN,INTERVENTIONAL,['NA']
7221,NCT01182493,Between Group Difference in HbA1c When Comparing CSII to MDI,Safety - Diabetic Ketoacidosis Incidence,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
7222,NCT02227862,Change in HbA1c From Baseline to 24 Weeks,Proportion of Patients With HbA1c < 7%,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7223,NCT05278806,Hypertension control,Breast cancer screening rates,,2022-03-24,COMPLETED,INTERVENTIONAL,['NA']
7224,NCT03595384,Participant Satisfaction With Overall Program,Waist Circumference,,2018-04-29,COMPLETED,INTERVENTIONAL,['NA']
7225,NCT01115088,"Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels.",Satiating effects by examining food consumption,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
7226,NCT02413567,Device or procedure related Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs),,,2015-03-23,COMPLETED,INTERVENTIONAL,['NA']
7227,NCT05579119,Change of the mean daily blood glucose levels during hospital,Mean length of stay in days in the hospital among different groups,,2022-07-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7228,NCT01177332,Intrahepatic lipid content (IHL) and hepatic ATP and PI concentrations,"Substrate oxidation and blood plasma levels of FFA, triglycerides, glucose and catecholamines",,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7229,NCT04824586,Intraoperative level of glucose,Insulin quantities,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7230,NCT03506776,change from baseline foot assessment as evidenced by a diabetic foot ulcer,change from baseline foot assessment evidenced by presence or absence of redness,,2017-08-21,COMPLETED,INTERVENTIONAL,['NA']
7231,NCT00879697,Total Walking Distance,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7232,NCT04662398,Erectile dysfunction,,,2020-12-05,COMPLETED,INTERVENTIONAL,['NA']
7233,NCT04029480,Number of Participants Who Discontinue Study Treatment Due to an AE over 54 weeks,Change from Baseline in FPG at 54 Weeks,,2019-10-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
7234,NCT00712673,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7235,NCT02798744,Change from baseline in Total PYY at 24 weeks,Change from baseline in liver functioning to 24 weeks,,2016-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7236,NCT00150423,Safety Efficacy,,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7237,NCT00322075,patients´satisfaction,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7238,NCT00747175,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables and ECG)",Pharmacodynamic variables,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7239,NCT03367806,All-cause mortality,Cancer mortality,,1999-01,COMPLETED,OBSERVATIONAL,['NA']
7240,NCT01503892,Increased intraepidermal nerve fiber density,Subjective improvement,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
7241,NCT00464594,FPG >= 140mg/dl and HbA1c >= 7.0%,,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
7242,NCT05443191,Change in Glycated haemoglobin (HbA1c ),"DTSQs, change in absolute treatment satisfaction",,2022-10-20,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7243,NCT00263393,The proportion of individuals with correct knowledge about the effects of behavioural determinants of the risk of cardiovascular disease,The risk factor levels of the population identified as high risk.,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7244,NCT00194909,"Our primary outcome will be a reduction in the weekly average 11 point Likert pain scale (0 - no pain, 10 - worst possible pain) at 8 weeks.","Secondary outcomes will include the Rand-36 quality of life scale, McGill visual analogue scale (VAS) and a sleep interference scale.",,2004-08,COMPLETED,INTERVENTIONAL,['PHASE4']
7245,NCT04492384,rate of letal outcomes depending on pre-existing disease,,,2020-06-29,COMPLETED,OBSERVATIONAL,['NA']
7246,NCT04891315,Correlation of sVAP-1 levels with Fetal outcomes: Miscarriage,Correlation of sVAP-1 levels with patient characteristics: Medications at time of booking,,2021-07-25,TERMINATED,OBSERVATIONAL,['NA']
7247,NCT03170752,Proportion of patients who are comprehensively screened to the number of eligible patients seen in the intervention group compared to the control group as assessed by the completeness of CV Screening Checklist data collection form.,The patient and NP factors that influence participation in the CASP as assessed by content analysis of patient and NP feedback questionnaires.,,2017-09-28,COMPLETED,INTERVENTIONAL,['NA']
7248,NCT02023411,SUV Max on PET/CT Scan at 12 Months,Clinical Events,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7249,NCT00382473,The degree of improvement in fat oxidation during submaximal exercise obtained by indirect calorimetry after subjects have completed an eight week aerobic exercise program.,Increase in fat oxidation from non-plasma sources after the eight week intervention.,,2006-09,TERMINATED,INTERVENTIONAL,['NA']
7250,NCT03053336,Change in physical activity level (counts/min from accelerometers),Blood pressure (mmHg),Social support for exercise assessed using a 6 item questionnaire,2017-02-21,COMPLETED,INTERVENTIONAL,['NA']
7251,NCT04237311,Semen quality assessment,Semen quality assessment,,2020-05-01,UNKNOWN,OBSERVATIONAL,['NA']
7252,NCT03170089,Patient awareness,Oral hygiene,,2017-06-30,UNKNOWN,INTERVENTIONAL,['NA']
7253,NCT01881919,Risk of getting hyperuricemia assessed by the measure of plasma uric acid.,Metabolomic and metabonomic profiling of blood plasma,Primary health assessment,2013-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7254,NCT00455325,Insulin Sensitivity,Triglycerides,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7255,NCT00712439,The primary study objective is to assess the relative efficacy of G-ER versus placebo in reducing the mean daily pain score from the baseline week to end of efficacy treatment period (Treatment Week 4) in patients with DPN.,"Secondary efficacy measures will include changes from baseline in average daily sleep interference scores, SF-MPQ, BPI,NPS, PGIC, and CGIC.",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7256,NCT05365152,Time required for blood sugar to reach target,,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
7257,NCT00434772,glucose,hospitalisation days,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7258,NCT03196024,Change in tobacco use,Support for healthy behaviors,,2017-10-05,COMPLETED,INTERVENTIONAL,['NA']
7259,NCT00005135,,,,1991-09,COMPLETED,OBSERVATIONAL,['NA']
7260,NCT00286624,• The proportion of recipients who develop alloantibodies directed at islet donor alloantigens during the first year after the first and any subsequent islet transplants.,• The impact of islet transplantation on the quality of life of transplant recipients.,,2003-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7261,NCT01306981,Best corrected visual acuity,Extent of retinal neovascularisation,,2011-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
7262,NCT06045598,Lumbal proprioception,Dynamic Balance,,2023-09-10,RECRUITING,OBSERVATIONAL,['NA']
7263,NCT03936023,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
7264,NCT02579395,Objective Physical Activity via accelerometer,Physical Activity Partner Investment Scale,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
7265,NCT01535677,Maximum concentration (Cmax),Safety profile description in term of Safety Labs,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7266,NCT05203471,Proportion of patients receiving guideline-concordant vascular and infectious disease care processes,Proportion of patients undergoing amputation,Patient retention rate,2023-02-16,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
7267,NCT02435199,"The efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN), as assessed by the difference in the weekly mean of the 24 hour average pain score, using an 11-point Numeric Rating Scale (NRS).",The safety and tolerability of EMA401 in patients with PDN as measured by number and severity of adverse events.,,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7268,NCT03602846,APGAR Score,Method of Delivery,Glycated Hemoglobin (HbA1c),2015-01,COMPLETED,OBSERVATIONAL,['NA']
7269,NCT01427257,Pharmacokinetics,Safety/Tolerability,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7270,NCT01032629,"Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke",Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment,,2009-12-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7271,NCT03473262,Changes in Fasting Plasma Glucose From Baseline to Week 24,Percentage of Patients With At Least 1 Episode of Genitourinary Tract Infections Between Baseline and Week 24,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
7272,NCT02042339,ICG (indocyanine green) video angiography,High performance 3D LifeViz™ system,Endothelial progenitor cells,2019-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
7273,NCT01726777,"Change in plasma glucose concentration 2 hours after consuming 75g oral glucose (2 hour PC glucose, or 2hrPC glucose)",Correlation between changes in serum 25-hydroxy-vitamin D concentration (25(OH)D) and changes in 2 hour PC glucose,Urinary calcium:creatinine ratio,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7274,NCT06060886,Number of patients with a therapeutic response to aripiprazole or paliperidone,Number of patients with side effects,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
7275,NCT01064687,Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7276,NCT02305381,Change in HbA1c (Glycosylated Haemoglobin),HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target,,2014-12-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7277,NCT00796744,The Primary Efficacy Parameter Will be the Proportion of Ulcers Healed by 12 Weeks as Defined as 100 % Epithelialized With no Drainage.,The Time to Re-epithelialization of the Ulcer Site.,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7278,NCT01181440,Proportion of patients with complete wound closure,Recurrence of the ulcer,,1994-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7279,NCT04938869,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) survey score,Incidence of adverse events,,2021-10-05,COMPLETED,INTERVENTIONAL,['NA']
7280,NCT05874635,App engagement,,,2023-05-11,RECRUITING,INTERVENTIONAL,['NA']
7281,NCT04849143,Wound size reduction,,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
7282,NCT02607345,the difference in glycemic index between 25gr. Zusto® and 25gr. Glucomedics®,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
7283,NCT03847779,Changes in average spectral amplitude of the entire frequency range between baseline and after stimulus,,,2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
7284,NCT01977560,Skeletal muscle insulin sensitivity,Skeletal muscle mitochondrial metabolites,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
7285,NCT04472962,The area over the curve (AOC).,Satiety (assessed by visual analog scale after pre-exercise meal) during the in-clinic period,,2020-08-14,COMPLETED,INTERVENTIONAL,['NA']
7286,NCT04495881,HbA1c change,Glycated Albumin（GSA）change,,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
7287,NCT00173940,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
7288,NCT01441921,Changes from baseline in circulating levels of glucose and insulin according to the intervention arm,Changes from baseline in telomeric length of leukocytes (LTL),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
7289,NCT06145360,Number of participants achieved HbA1c level i.e. <7%,systolic blood pressure and diastolic blood pressure,,2023-12-31,RECRUITING,INTERVENTIONAL,['PHASE4']
7290,NCT05870670,"AUC0-24h,0130, SS: Area Under the NNC0519-0130 Plasma Concentration-Time Curve After the Last Dose in Each Treatment Period",Number of Treatment Emergent Adverse Events (TEAEs),,2023-05-15,COMPLETED,INTERVENTIONAL,['PHASE1']
7291,NCT03544411,Change of malondialdehyde,Change of Glutahione,,2018-07-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7292,NCT03581266,Investigate glucose kinetics after ingestion of wheat and rye breads,,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
7293,NCT00470418,Safety Assessments: Number of Participants With Adverse Events,Changes From Baseline in Clinical Measures of Cognition at Terminal Visit,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7294,NCT05266261,Bone mineral density,Bone turnover markers,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
7295,NCT00747968,steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo.,,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7296,NCT01494298,ApoB Levels in African American Men With Diabetes and Those Without.,Lipoprotein a [Lp(a)] in African Americans With Diabetes and Without.,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
7297,NCT00322257,HbA1c,Fasting plasma glucose,,2006-05-01,TERMINATED,INTERVENTIONAL,['PHASE3']
7298,NCT03961347,Adverse Event and/or Serious Adverse Event,,,2020-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7299,NCT06188013,differential proteins of exosomes,,,2024-01-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7300,NCT00552734,Decrease in A1c of at least 0.4% in the insulin guidance software group as compared to the control group at 6 months and/or 1 year.,"Hypoglycemic episodes, weight gain, insulin dose, frequency of self monitoring of glucose",,2005-07,COMPLETED,OBSERVATIONAL,['NA']
7301,NCT03748810,Changes in fasting plasma glucose from baseline to week 156 (3-year),Percentage of patients with at least 1 episode of genitourinary tract infections between baseline and week 156 (3-year),,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
7302,NCT03660189,Time to anion gap closure in hours,Total volume of intravenous fluids administered,,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
7303,NCT01257451,To evaluate the proportion of vildagliptin treated patients achieving HbA1c reduction and/or proportion reaching investigator defined target HbA1c relative to placebo,To assess the responder rates of patients treated with vildagliptin as compared to placebo,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
7304,NCT05726409,Satisfaction with the mobile application,Change in nutrition knowledge,,2023-09,WITHDRAWN,INTERVENTIONAL,['NA']
7305,NCT01002807,Blood samples to measure the pharmacokinetic parameters Cmax and AUC for the combination products versus each investigational product alone,"Safety and tolerability measures (adverse events, physical exams, vital signs, ECGs, and clinical laboratory assessments)",,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7306,NCT02713555,Change from baseline diabetes status at 12 months after surgery,Assessment of changes in Glucagon levels from baseline,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
7307,NCT00102466,Change from baseline in HbA1c at 52 weeks,Patients with reduction in HbA1c >/= 0.5% after 52 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7308,NCT04079660,fasting capillary blood glucose level,LOS,,2021-02-01,COMPLETED,OBSERVATIONAL,['NA']
7309,NCT00212290,Beta-amyloid in spinal fluid (sub-study),"Blood levels of insulin, insulin degrading enzyme, cortisol and inflammatory markers",,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
7310,NCT00755846,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 85.,Mean Percent Incidence of Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg/dL).,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7311,NCT05399134,Postprandial glycemic response of novel staple foods in Type 2 diabetics,,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
7312,NCT02970357,The DIAPASON questionnaire,Psychological indicators,,2016-01-26,COMPLETED,INTERVENTIONAL,['NA']
7313,NCT01108120,The recurrence rate of diabetic foot ulcers,cardiovascular events during the follow up period,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7314,NCT04264793,Change in HbA1c,Change in Diabetes Treatment Satisfaction Score,,2011-11-20,COMPLETED,INTERVENTIONAL,['NA']
7315,NCT01635361,Operation of the NMS,Professional relationships,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7316,NCT03298295,Area of inflammation (mm2),Macrophage marker gene expression (fold change),,2018-02-01,RECRUITING,INTERVENTIONAL,['NA']
7317,NCT00131664,Mean Change From Baseline in A1C at Month 6,Mean Change From Baseline in Adiponectin at Month 12,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7318,NCT05772507,relative wound area reduction (RWAR),Nature and incidence of Treatment Adverse Effects as assessed in percentage for each dressing,,2023-08-22,RECRUITING,INTERVENTIONAL,['NA']
7319,NCT01564550,VLDL1 and VLDL2-triglyceride secretion rate (µmol/min),,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
7320,NCT01690572,MACE-rate,OCT-measurement,,2012-10,TERMINATED,INTERVENTIONAL,['NA']
7321,NCT00604669,Mortality,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
7322,NCT03572166,The primary outcome is the overall diagnostic accuracy - defined as the proportion of correct diagnoses - of each diagnostic procedure in differentiating patients with central diabetes insipidus from patients with primary polydipsia.,Frequency of test preference at follow up visit,,2018-09-03,COMPLETED,INTERVENTIONAL,['NA']
7323,NCT00856284,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104,Change From Baseline in Body Weight Over Time,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7324,NCT00001395,,,,1994-03,COMPLETED,OBSERVATIONAL,['NA']
7325,NCT04863313,Change of blood glycated hemoglobin (HbA1c) concentration from baseline to week 12.,Adherence to the intervention at week 12.,,2021-03-11,COMPLETED,INTERVENTIONAL,['NA']
7326,NCT04185558,Incidence of complete wound closure by 12 weeks,Number of patients showing a consistence wound closure post healing determination,,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7327,NCT03144271,Number of Adverse Events,Morning fasting glucagon,,2007-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7328,NCT00585494,Prevalence of Hyperglycemia in the Elective Orthopedic Population,Prevalence of Adverse Outcomes in the Hyperglycemic Elective Orthopedic Population.,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
7329,NCT01843127,Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT),"Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.",,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7330,NCT00231673,Change in peroneal nerve conduction velocity (NCV) from baseline to the end of the double-blind phase.,"Changes from baseline to the end of the double-blind phase in NCVs of the sural sensory nerve and ulnar (motor and sensory) nerve, and changes in amplitudes and latencies of the peroneal motor, sural sensory, and ulnar nerves. Adverse event reporting.",,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7331,NCT02607410,improvement in HbA1c levels,improvement on alpha cell function with a meal test,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7332,NCT04891575,Change in tobacco use,,,2021-09-11,RECRUITING,INTERVENTIONAL,['NA']
7333,NCT05177172,Glucose tolerance,Subjective appetite variables,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
7334,NCT05451147,OBJECTIVE PARAMETERS,SUBJECTIVE PARAMETERS,,2018-09-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7335,NCT03807596,Gain in clinical attachment level,,,2017-03-16,COMPLETED,INTERVENTIONAL,['NA']
7336,NCT01492959,Change in HbA1c (glycosylated haemoglobin),Adverse events: Serious and non-serious,,2004-03-23,COMPLETED,OBSERVATIONAL,['NA']
7337,NCT01924767,Assessment of Tolerability by Investigator,Serum Insulin,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7338,NCT05736263,Comparison of CGM-derived percentage time in range (TIR) when temporary target is enabled or disabled during exercise,CGM-derived percentage time below range (TBR < 54 mg/dl) during and after exercise trials,Associations between sleep quality and glycemic variations,2023-03-31,RECRUITING,INTERVENTIONAL,['NA']
7339,NCT01178723,blood glucose balance,lipid profile,,na,UNKNOWN,INTERVENTIONAL,['NA']
7340,NCT00397631,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,Change From Baseline in 2-hour PPG (Post-prandial Glucose) at Week 24,,2006-12-19,COMPLETED,INTERVENTIONAL,['PHASE3']
7341,NCT00831129,Change in High-sensitivity C-reactive Protein,Change in Body Mass Index,,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7342,NCT03155568,failure rate,Duration of motor blockade,,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA']
7343,NCT00867594,To determine the safety and tolerability of multi-doses of Oramed oral insulin in people with type 1 diabetes,To determine if oral insulin is likely to improve glycemic stability assessed by the reduction of the frequency and severity of hypoglycemic episodes in people with unstable type 1 diabetes,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7344,NCT03983499,HbA1c Blood Value,Generalized Anxiety Disorder 7-item (GAD-7),,2015-07-16,COMPLETED,INTERVENTIONAL,['NA']
7345,NCT03847701,MAGE comparison following 3 months of intake of a diet either high or low in SDS,Characterisation of the percent of compliance to H-SDS diet in free living conditions,,2019-06-25,UNKNOWN,INTERVENTIONAL,['NA']
7346,NCT01285245,insulin sensitivity as determined by euglycemic hyperinsulinemic clamp,insulin sensitivity as determined by euglycemic hyperinsulinemic clamp,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
7347,NCT04564872,HbA1c Change From Baseline at Week 24,Percentage of Patients Required Use of Rescue Therapy or Dropout due to Hyperglycemia and Week 52,,2020-11-13,COMPLETED,INTERVENTIONAL,['PHASE3']
7348,NCT04322032,Cmax,,,2020-04-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
7349,NCT01221519,"Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of tmax of AZD1656.","pharmacodynamics of AZD1656 following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-4) for insulin",,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7350,NCT02768987,Change from baseline in daily physical activity energy expenditure over 24 weeks,Change from baseline in push-up test over 24 weeks,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
7351,NCT05147896,Change in structural arterial wall characteristics,"Correlations between changes in rate of cIMT reduction, % of endothelial function improvement and rate of arterial stiffness reduction on one hand and changes in concentration of sdLDL, % of HbA1c and concentration of hsCRP on the other",,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
7352,NCT01008345,level of oxidized LDL cholesterol at end of study,small dense LDL level,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7353,NCT05263401,Postprandial P-glucose,Differences in circulating concentrations of gastrin,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
7354,NCT03940209,HbA1c,Health-related Quality of Life,,2019-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7355,NCT03197363,Death or the occurrence of diseases,,,2018-11-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7356,NCT03397147,Child Sleep Quality,Parental Diabetes Distress,,2018-07-05,COMPLETED,INTERVENTIONAL,['NA']
7357,NCT00296400,Urinary Protein/Creatinine Ratio at Week 52 [LOCF],Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7358,NCT04515849,To assess the effects of cotadutide at different dose levels compared to placebo on UACR after 14 weeks,To evaluate the safety and tolerability of cotadutide compared to placebo by assessment of changes in ECG,To assess the effects of cotadutide at different dose levels compared to placebo and semaglutide on rate pressure product,2020-08-31,COMPLETED,INTERVENTIONAL,['PHASE2']
7359,NCT00684658,Pediatric Quality of Life Inventory (PedsQL),Diabetes Conflict,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7360,NCT02737423,"Improvement in painful diabetic neuropathy by the use of vitamin D Injections (600,000 IU) assessed with the DN4 Neuropathic Pain Diagnostic Questionnaire","Improvement in painful diabetic neuropathy by the use of vitamin D Injections (600,000 IU) assessed with the SF-Mac Gill Pain Questionnaire.",,2012-06,COMPLETED,INTERVENTIONAL,['NA']
7361,NCT01052714,Beck Anxiety Inventory (BAI) Mean Total Score Change Per Week From Baseline to Termination,,,2010-09-01,COMPLETED,INTERVENTIONAL,['NA']
7362,NCT03607448,System Performance,System Related Adverse Device Effects,,2018-07-23,COMPLETED,OBSERVATIONAL,['NA']
7363,NCT01783327,Change from baseline quality of life over 12 months,Change from baseline quality adjusted life years over 12 months,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
7364,NCT00361608,,,,2008-07,WITHDRAWN,OBSERVATIONAL,['NA']
7365,NCT04303468,Postprandial glycaemic response during a 2 hour oral glucose tolerance test (OGTT),Plasma glutamate concentration,,2020-09-29,COMPLETED,INTERVENTIONAL,['NA']
7366,NCT00468039,glycosylated hemoglobin (HbA1c)at Baseline and week 24,"Safety assessed by monitoring and recording all adverse events, serious adverse events.",,2007-03-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7367,NCT04853615,SGLT2i proves protective effect,SGLT2i is non inferior to allopurinol,,2021-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7368,NCT01826409,Glucose profiles during meal tolerance test,Change in lipid profiles,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7369,NCT00728598,"Vitreous levels and serum levels of Fractalkine, VEGF, other growth factor.",,,1998-01,COMPLETED,OBSERVATIONAL,['NA']
7370,NCT00141076,Insulin sensitivity as measured by FS-IVGTT,Thermic effect of food,,2003-10,COMPLETED,INTERVENTIONAL,['NA']
7371,NCT03968380,Glucose Tolerance,Waist circumference,,2020-10-13,UNKNOWN,OBSERVATIONAL,['NA']
7372,NCT02859818,Self-efficacy evaluated with the 10 items-SEDM,"Outcome expectations, socio-structural factors and personal goals",,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
7373,NCT04618744,Number of treatment-related adverse events,Percent change in liver fat content,,2020-11-24,COMPLETED,INTERVENTIONAL,['PHASE2']
7374,NCT04764786,the between-group difference in postprandial glycemia changes after the dietary interventions,,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
7375,NCT02898155,Rate of potentially avoidable admissions,Standardized Rate of potentially avoidable admissions,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
7376,NCT00427154,Change in HbA1c,Change in body weight,,2007-01-10,TERMINATED,INTERVENTIONAL,['PHASE3']
7377,NCT06104358,Sleeping Metabolic Rate (SMR) change from Baseline to 6 Months (26 weeks),,,2023-11-17,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7378,NCT04267601,Change of HbA1C,,,2017-07-06,UNKNOWN,OBSERVATIONAL,['NA']
7379,NCT00728351,HbA1c reduction after 24 weeks of treatment in patients with T2DM inadequately controlled with metformin monotherapy,Changes in the fasting lipid profile,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7380,NCT04735042,Change from Baseline of total bacterial load,Triglycerides,,2020-10-07,UNKNOWN,OBSERVATIONAL,['NA']
7381,NCT05074732,Reduction in violence,Improving overall functioning level,,2019-12-01,RECRUITING,OBSERVATIONAL,['NA']
7382,NCT06007404,Monocyte /macrophage populations by flow cytometry,Triglycerides (MMTT),,2023-09-06,RECRUITING,OBSERVATIONAL,['NA']
7383,NCT03008395,Hemoglobin A1c,Diabetes Distress,,2017-10,WITHDRAWN,INTERVENTIONAL,['NA']
7384,NCT02615353,Insulin Sensitivity,Body Composition,,2016-05-13,COMPLETED,INTERVENTIONAL,['NA']
7385,NCT03753087,Change in 6-minute walking distance (6MWD),Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) score,,2019-01-16,COMPLETED,INTERVENTIONAL,['PHASE4']
7386,NCT00690755,Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles,,,2000-05,COMPLETED,OBSERVATIONAL,['NA']
7387,NCT06203067,HbA1c,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7388,NCT00340938,,,,2004-11-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7389,NCT02702011,Change From Baseline in 24 Hour UGE on Day 7,,,2016-03-20,COMPLETED,INTERVENTIONAL,['PHASE2']
7390,NCT02814838,Area Under the Curve (AUC)(0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Week 13,Proportion of Patients With HbA1c <7% and Absence of Episodes of Severe Hypoglycaemia From the Previous Visit in Patients With Screening C-peptide < Median Value,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7391,NCT02513888,fasting glucose (mg/dL),TC (mg/dL),,2013-02-01,COMPLETED,INTERVENTIONAL,['NA']
7392,NCT05144750,Change in Food Security,Self Reported Improved Health,,2021-12-06,COMPLETED,INTERVENTIONAL,['NA']
7393,NCT01858532,Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized),Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized),,2013-05-17,TERMINATED,INTERVENTIONAL,['PHASE3']
7394,NCT04227626,Average plasma glucose over the closed-loop control period,Dextrose dosing (g/kg),,2021-04,WITHDRAWN,INTERVENTIONAL,['NA']
7395,NCT02180152,Weight gain after postprandial walks in obese pregnant women.,,,2015-03,WITHDRAWN,INTERVENTIONAL,['NA']
7396,NCT02706977,Change in Visual Acuity assessed by the Standard Snellen Static Chart,,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7397,NCT01667016,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
7398,NCT00592241,Validate safety while using the ADI Insulin Pump by intended users. This objective will be assessed by independently and successfully carrying out a list of tasks.,Evaluate user's satisfaction.,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
7399,NCT02356848,Ulceration,step count,,2015-09-03,COMPLETED,INTERVENTIONAL,['NA']
7400,NCT05169359,Change from pre-visit diabetes distress score at 1 week post visit,Promis,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
7401,NCT02588729,"Oral glucose tolerance test (OGTT), fasting and 2 hours blood glucose level after intake up til 75gr glucose (1.75gr/kg body weight)",HbA1c,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
7402,NCT01476384,Glycocalyx permeability,Microvascular density,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
7403,NCT04430660,Change in percent 13C enrichment of bicarbonate measured via carbon-13 magnetic resonance spectroscopy (13C-MRS),,,2020-08-19,COMPLETED,INTERVENTIONAL,['NA']
7404,NCT02459691,Change in weight from baseline,Clinically significant weight loss,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
7405,NCT06189638,Clinical response,Wound infection Score and Total Wound Score,,2024-01-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7406,NCT01777893,Incidence of type 2 diabetes,In a sub-group: Insulin Growth factor 2 (IGF-II) and IGF-II receptor (IGF2R),Direct and indirect costs.,2013-06,COMPLETED,INTERVENTIONAL,['NA']
7407,NCT02536768,HIV viral supression using lab data,,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
7408,NCT02188823,Hemoglobin A1c,Body weight,,2014-07,TERMINATED,INTERVENTIONAL,['NA']
7409,NCT04107935,Change From Baseline in Glycemic Control,Change From Baseline in Medication Adherence Across 3 Month Intervals for 12 Months,,2020-02-04,TERMINATED,INTERVENTIONAL,['NA']
7410,NCT06135532,salivary IL-13 level (pg/ml),serum IL-13 level (pg/ml),,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
7411,NCT00470860,Knowledge related to blood pressure and lipid management for diabetes patients,,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
7412,NCT02423434,Comparison of Manual versus Automated Image analysis,Determination of the Factors associated with CCM Parameters and their Longitudinal Change,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
7413,NCT04282395,Change from baseline in depressive symptoms at 24 months,Change from baseline in social support at 12 months,,2020-01-25,RECRUITING,INTERVENTIONAL,['NA']
7414,NCT06279637,Glycemic Control (Hemoglobin A1C [HbA1C]),,,2024-03-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7415,NCT05029583,Prevalence of presumed advanced NASH based on biochemical and FibroScan results,Health-related quality of life by study arm,,2021-08-11,RECRUITING,INTERVENTIONAL,['NA']
7416,NCT02985853,Capillary Blood Glucose,,,2008-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7417,NCT01135446,Total 24-hour Urinary Glucose Excretion as a Measure of Pharmacodynamic Effect,Dapagliflozin and Dapagliflozin 3-O-glucuronide (Metabolite of Dapagliflozin) Concentrations to Characterize Dapagliflozin Pharmacokinetics,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
7418,NCT06112691,The accuracy,The percent of false positive detection of DR,,2022-02-01,RECRUITING,OBSERVATIONAL,['NA']
7419,NCT05410080,The diagnostic value of middle cerebral artery (MCA) Doppler indices in predicting adverse perinatal outcome among diabetic pregnant patients,The diagnostic value of ductus venosus Doppler indices in predicting adverse perinatal outcome among diabetic pregnant patients.,,2022-06-15,RECRUITING,OBSERVATIONAL,['NA']
7420,NCT02757937,Change in Diabetes Self-Efficacy Scale Score from Baseline to 4 Months,Change in glycated haemoglobin (HbA1c) from Baseline to 6 Months,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
7421,NCT03406923,Change in diabetes control,Experiences and perceptions of the intervention processes and outcomes,,2018-12-04,COMPLETED,INTERVENTIONAL,['NA']
7422,NCT00335712,Fasting Blood Glucose at week 8,"Other glycemic control parameters (e.g., HbA1c, glycoalbumin)",,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7423,NCT04035395,Rate of Change in Hemoglobin A1c,Rate of Change in Self-efficacy: Diabetes Self-Efficacy Scale,,2016-09-29,COMPLETED,INTERVENTIONAL,['NA']
7424,NCT01605773,Triglyceride levels post standardised fat tolerance test,Change in FPG (fasting plasma glucose),,2001-11-08,COMPLETED,INTERVENTIONAL,['PHASE4']
7425,NCT00690066,C-peptide area under the concentration curve (AUC) response (MMTT),Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies,,2008-06-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7426,NCT04540016,"Area under the concentration-time curve (AUC0-t, AUC0-∞)",,,2020-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
7427,NCT03374020,The level of agreement between NOTAL-OCT and commercial OCT in detecting fluid in the 10 central degrees of the macula.,,,2017-01-17,COMPLETED,OBSERVATIONAL,['NA']
7428,NCT02204280,"The urine UbA52 levels in 30 patients with type 2 diabetic mellitus,30 patients with diabetic nephropathy，30 patients with proteinuria due to nondiabetic renal disease and 30 healthy persons",,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
7429,NCT01597531,Type 2 diabetes remission,First Phase Insulin secretion,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE4']
7430,NCT04214600,Change of Glycated Hemoglobin A1c (Hb A1c) After the Cognitive Behavioral Therapy Sessions,Change of Depression Score on Beck's Depression Index,,2019-04-30,COMPLETED,INTERVENTIONAL,['NA']
7431,NCT00989976,diabetes risk as assessed by disposition index,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
7432,NCT03445377,Sensor Glucose readings within target range,Total daily insulin dose,,2018-07-16,COMPLETED,INTERVENTIONAL,['NA']
7433,NCT06290544,Prevalence of cardiovascular disease in type 1 diabetes patients,Stratify type 1 patient by glucose control using HbA1c and Ambulatory Glucose Profile metrics.,,2021-11-29,RECRUITING,INTERVENTIONAL,['NA']
7434,NCT01370707,Change from baseline in HbA1c at week 24,Glycemic variability,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7435,NCT04263376,Changes in human gut microbiota,,,2019-04-24,COMPLETED,OBSERVATIONAL,['NA']
7436,NCT05335863,Areas under the glucose metabolism curve for the determination of the glycemic index,,,2021-11-03,COMPLETED,INTERVENTIONAL,['NA']
7437,NCT04450563,Percentage of time of plasma glucose levels spent in target range (placebo vs empagliflozin 5 mg),Rise in ketone level between interventions,,2020-11-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7438,NCT01657318,,,,2012-09-01,TERMINATED,OBSERVATIONAL,['NA']
7439,NCT00806897,Change in HbA1c from baseline,Change in body weight,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
7440,NCT06005012,Change in fibrosis due to NAFLD,Change in ALT,,2023-07-25,RECRUITING,INTERVENTIONAL,['PHASE2']
7441,NCT03862547,intracavernous p75NTR,"clinical staging of ED and NGF,TrKa,p75NTR",,2019-01-30,UNKNOWN,INTERVENTIONAL,['NA']
7442,NCT02228252,Effect on apolipoprotein B48 of whey protein as pre-meal after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min).,Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -30/-15 - 360 min),Responses of satiety visual analog scale (VAS) measured as incremental Area Under the Curve (AUC -30/-15 - 360 min),2014-08,COMPLETED,INTERVENTIONAL,['NA']
7443,NCT01289990,Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment,Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7444,NCT04337723,ABI/WIFI adoption,ABI/WIFI sustainability,,2020-03-10,COMPLETED,INTERVENTIONAL,['NA']
7445,NCT02306122,Duration of Nonadherence Event,Probability of Pharmacist Action Triggered,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
7446,NCT05007197,Effectiveness of education,,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
7447,NCT00577590,Percent Change in Plasma Triglycerides,,,2003-10,COMPLETED,INTERVENTIONAL,['NA']
7448,NCT02967900,Correlation of OCT Measurement of blood vessel density with rate of wound healing,"Correlation of OCT Measurement of blood vessel density at baseline, with rate of wound healing",,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
7449,NCT02501161,Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification,Change in TRIM-D,,2016-01-31,COMPLETED,INTERVENTIONAL,['PHASE3']
7450,NCT01922492,Changes of insulin secretory function,Adverse effects,,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
7451,NCT02045290,Change in insulin resistance (IR) from baseline to 13 weeks,Change in Adipose IR from baseline to 13 weeks,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7452,NCT00869102,Insulin secretion,,,2009-05,WITHDRAWN,INTERVENTIONAL,['NA']
7453,NCT04944316,24-hour Carbohydrate to Insulin Ratio,Interleukin (IL) - 1 (IL-1) and interleukin-6 (IL-6),Diet Acceptability,2022-01-19,COMPLETED,INTERVENTIONAL,['NA']
7454,NCT03979768,Number of Participants with undiagnosed type 2 diabetes,Explore if there was any difference in the number of participants with a high risk of developing type 2 diabetes in the risk test only (RTO)- group and the group that also offered a HbA1c-measurement (HbA1c-group),,2016-09-15,COMPLETED,INTERVENTIONAL,['NA']
7455,NCT05767255,To compare the percentage of hypoglycemia,Evaluate associated adverse effects,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE3']
7456,NCT04631159,Change from baseline HbA1c through a mobile app.,The number of participants who have related every day steps as assessed by Mi Smart Band 4.,,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA']
7457,NCT04888390,Oxygen consumption (VO2),MEP (maximal exspiratory pressure),,2021-04-20,RECRUITING,INTERVENTIONAL,['NA']
7458,NCT01680211,Change in Blood Sugar and lipid profiles,Clinical laboratory evaluations,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
7459,NCT01535105,Frequency of Impaired Glucose Homeostasis among obese adolescents in high risk diabetes prone population,Description of the metabolic profile in obese adolescents,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
7460,NCT01945216,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Blood Glucose,,2010-07-08,COMPLETED,OBSERVATIONAL,['NA']
7461,NCT03563794,blood glucose,hypoglycemia,,2018-06-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
7462,NCT04869800,Cmax of CKD-398,Vd/F of CKD-398,,2021-05-27,COMPLETED,INTERVENTIONAL,['PHASE1']
7463,NCT05150041,Change in HbA1c(%),changes in patient satisfaction level,,2020-04-07,COMPLETED,INTERVENTIONAL,['NA']
7464,NCT03600116,Identification of Volatile Organic Chemical Indicators of Hypoglycemia,,,2018-05-24,COMPLETED,OBSERVATIONAL,['NA']
7465,NCT01785771,Change in HbA1c between Week 39 and Day 0,,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3']
7466,NCT03404037,Serum Endostatin Level as a Marker for Coronary Artery Calcification in Type 2 Diabetic Patients with Coronary Heart Disease,,,2017-03-02,COMPLETED,OBSERVATIONAL,['NA']
7467,NCT02305199,Postoperative glucose level,Postoperative Stress hormone level,,2015-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
7468,NCT05302050,Change in HbA1c,Significant change in HbA1c,,2022-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7469,NCT01475435,Evaluate level change of oxidative stress biomarkers in crevicular gingival fluid and whole saliva on diabetes type 2 individuals,,,2011-08,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7470,NCT01552811,Difference in pancreatic uptake of % injected dose (ID) [11]5-hydroxy tryptophan between healthy volunteers and patients with long-standing type 1 diabetes,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
7471,NCT00694278,,,,2008-06,UNKNOWN,OBSERVATIONAL,['NA']
7472,NCT01490658,NN4440 (2/500) Cmax (maximum plasma concentration) combination tablet,Vital signs,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7473,NCT00194896,Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months.,Patients Positive for T Cell Responses to Islet Proteins at 36 Months.,,2000-02,COMPLETED,INTERVENTIONAL,['NA']
7474,NCT03007186,Blood glucose measurements,Insulin level,Result of oral glucose tolerance test,2016-10,COMPLETED,OBSERVATIONAL,['NA']
7475,NCT00865683,Insulin sensitivity,Interleukin-6 (IL-6),,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
7476,NCT02686281,Number of Participants with Serious and Non-Serious Adverse Events,Area Under the Concentration-Time Curve,,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1']
7477,NCT03215069,Baseline-adjusted ISSI-2 at 48-weeks,Glucose tolerance status at 48-weeks,Quality of life at 48 weeks,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3']
7478,NCT01339390,Change in Weight (From Baseline),,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
7479,NCT04903496,"The proportion of non-diabetic patients with established cardiovascular disease, or chronic kidney disease, or at high cardiovascular risk among all non-diabetic patients","Serum creatine concentration (μmol/L) at the latest visit for all patients, as well as the trends for inpatients over time (2015, 2017, and 2019 respectively)",,2021-09-06,COMPLETED,OBSERVATIONAL,['NA']
7480,NCT01947569,The incidence of treatment-emergent adverse events.,2-hour area under the curve (AUC) average of C-peptide at 12 months after completion of administration of assigned therapy (Protocol Month 15).,,2013-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7481,NCT02212158,Change in Baseline HA1c at 12 months post baseline,Change from baseline in Children's Hope Scale at 60 weeks,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
7482,NCT04669912,Changes in percentage of time spent in range 70-180 mg/dL during second month of lockdown compared to before lockdown,Evolution of glucose sensor use compared to before lockdown.,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA']
7483,NCT03334370,Change of the proportion of patients who have achieved a HbA1c <7.5%.,"Service utilization outcomes measured by hospital attendance rates at baseline and 12, 24, 36 and 48 months after enrollment.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
7484,NCT02057848,Plasma glucose,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7485,NCT03332849,Number of participants with adverse events,AUC of HM12470,,2015-07-28,UNKNOWN,INTERVENTIONAL,['PHASE1']
7486,NCT01884714,Measure circulating inflammatory markers and fatty acids associated with obesity and diabetes.,Measure standard clinical and anthropometric parameters in obese and diabetic participants following a standardized meal.,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7487,NCT03787836,Exercise responders following additional exercise program,Body mass index,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
7488,NCT06037551,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7489,NCT02235584,The potentiating effects of GLP-1 on second phase insulin response when clamped at at bloodsugar of 7 mmol/l,Second phase insulin response to GIP infusion at 7mmol/l,Total insulin response to arginine infusion,2009-07,COMPLETED,INTERVENTIONAL,['NA']
7490,NCT04589533,Variation in fasting glycemia between the two groups of Centres during phase 3 of the study,Description of characteristics of patients with T2DM hospitalized in Internal Medicine,,2019-09-19,UNKNOWN,OBSERVATIONAL,['NA']
7491,NCT00368953,"""In-stent late lumen loss"" at follow-up-angiography (9 months)","Combined MACE (cardiac death, myocardial infarction, emergency bypass, stent thrombosis, target lesion revascularization)",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7492,NCT00875290,Reduce blood glucose variability among 0-3 year old children with type I diabetes.,Number of adverse events,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
7493,NCT00325117,Change from baseline to endpoint on HbA1c at 12 weeks,Adverse events profile after 12 weeks of treatment,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7494,NCT05243368,Ulcer evaluation,Concentration of stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor A (VEGFA),Hydration status,2023-10-20,RECRUITING,INTERVENTIONAL,['NA']
7495,NCT00326196,The Hypothesis Being Tested is That a Strategy of Initial Surgical Revascularization is Superior to Percutaneous Intervention in Preventing Death or Myocardial Infarction in Diabetics With Severe Ischemic Heart Disease Assessed up to 4 Years.,,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE4']
7496,NCT01420198,Caloric intake,Blood pressure,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
7497,NCT01837680,Glycemic Control,Neonatal Hypoglycemia,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
7498,NCT04625751,Change in blood levels of gastrointestinal hormones and markers of metabolism following meal test,,,2021-04-07,RECRUITING,OBSERVATIONAL,['NA']
7499,NCT06199505,Change in HbA1c,Change from baseline in ADA and Nab,Change from Baseline in Body Weight,2023-11-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
7500,NCT04971252,Estimate risk of thrombosis or bleeding for the 3 study groups by plateletcrit,,,2021-07-07,COMPLETED,OBSERVATIONAL,['NA']
7501,NCT05259644,Change in Body Weight,Change in fasting blood glucose,Change in the IWQOL (The Impact of Weight on Quality of Life) questionnaire,2022-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7502,NCT02744820,Number of Participants with Serious and Non-Serious Adverse Events,Time to reach steady state,Preliminary effect on %HbA1c (Cohort 4 only),2016-04,TERMINATED,INTERVENTIONAL,['PHASE1']
7503,NCT03141710,Change of oral glucose tolerance test (OGTT),Change of fermentation markers,,2017-05-10,UNKNOWN,INTERVENTIONAL,['NA']
7504,NCT03130894,type 2 diabetes,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
7505,NCT01142050,ITT; insulin dosage; Hemoglobin A1c; Fast blood glucose (FBG) and Postmeal blood glucose (PBG); C-peptide levels; Serum Insulin levels;,Serious adverse event frequency and severity,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
7506,NCT03973827,Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.,"Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.",,2019-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7507,NCT03769883,Pancreatic beta-cell function (Per protocol),Satiety,Fat tissue metabolic function,2018-12-12,UNKNOWN,INTERVENTIONAL,['NA']
7508,NCT04233034,C-peptide,DKA,,2020-07-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7509,NCT02711839,HbA1c After Intervention,Triglyceride After Intervention,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
7510,NCT02810613,"A collection of samples for the purpose of (bio)medical laboratory assays including immunological, metabolic, transcriptional or biological analyses.",,,2016-05-31,WITHDRAWN,OBSERVATIONAL,['NA']
7511,NCT00005184,,,,1985-12,COMPLETED,OBSERVATIONAL,['NA']
7512,NCT01892020,2-hour PPG (Postprandial Plasma Glucose) Increment Following a Standard Meal Test,Incidence of AEs (Adverse Event),,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7513,NCT01423266,"Change from Baseline in adiposity (and body composition; i.e., % body fat))",Change from Baseline in levels of quality of life,Change in Cardiac Function,2009-12,COMPLETED,INTERVENTIONAL,['NA']
7514,NCT03617757,Incidence of DM,Capacity of the studied population to join intensive lifestyle intervention,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
7515,NCT01030679,Change from baseline in fasting plasma glucose at 8 weeks,Adverse event profile after 8 weeks of treatment,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7516,NCT01758380,Percentage of patients experiencing at least one Hypoglycaemic Event (HE) during the Ramadan fasting period to test superiority,"Number of patients with treatment emergent adverse events (AEs), serious AEs, discontinuation due to AEs, deaths or laboratory abnormalities as assessment of safety and tolerability",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7517,NCT04023487,"Change in glycemic control, using Glycated Hemoglobin (HbA1C)",Change in cost to payor,Background Information,2019-10-22,COMPLETED,INTERVENTIONAL,['NA']
7518,NCT03823339,Change in laboratory measured glycosylated haemoglobin A1c (HbA1c),"Reason(s) for discontinuing treatment with Xultophy® during the treatment period, if applicable",,2019-01-29,COMPLETED,OBSERVATIONAL,['NA']
7519,NCT00001625,,,,1997-04-03,COMPLETED,OBSERVATIONAL,['NA']
7520,NCT00604344,HbA1c,Insulin antibodies,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7521,NCT04836221,Feasibility of an active management strategy for comorbidities,Provider perspectives on acceptability of active management of comorbidities,Preliminary changes in social support,2021-05-05,COMPLETED,INTERVENTIONAL,['NA']
7522,NCT00487162,Wound Infection,Hemodynamic Instability,,2007-06,TERMINATED,INTERVENTIONAL,['NA']
7523,NCT02229396,Change in HbA1c From Baseline to Week 28,Change in Systolic Blood Pressure From Baseline to Week 28,,2014-09-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7524,NCT01324505,Area under the levonorgestrel concentration-time curve,Percentage of subjects experiencing adverse events,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7525,NCT02091336,fetal growth,insulin requirements to achieve glucose targets,need of c section,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
7526,NCT03755960,Visual analogue Scale (VAS) general complaints and pain,neurophysiological assessment of Nervus Suralis height of amplitude of action potential,,2019-03-02,COMPLETED,INTERVENTIONAL,['NA']
7527,NCT05312450,The change of postprandial blood glucose,Serum metabolomics,,2022-03-10,RECRUITING,OBSERVATIONAL,['NA']
7528,NCT02413398,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.,,2015-06-15,COMPLETED,INTERVENTIONAL,['PHASE3']
7529,NCT01148680,ß score evaluation 6 months after first infusion (group 1 'immediate registration on infusion waiting list') or 6 months after inclusion (group 2: 'delayed registration on infusion waiting list'),Evaluation of side effects and iatrogenic effects,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7530,NCT05854979,Gastric Volume in RLD Position,Incidence of aspiration,,2023-08-09,RECRUITING,OBSERVATIONAL,['NA']
7531,NCT05517772,Semi-structured interviews,Patient reported outcomes,,2022-06-16,COMPLETED,OBSERVATIONAL,['NA']
7532,NCT01511835,OGTT,Number of newborn infants requiring Neonatal Intensive Care (NIC),,na,UNKNOWN,INTERVENTIONAL,['PHASE4']
7533,NCT01678820,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants With A1C Level <7% at Week 16,,2012-10-10,TERMINATED,INTERVENTIONAL,['PHASE3']
7534,NCT02875782,Self-reported 7-day point-prevalence smoking abstinence,Self-reported quit attempt numbers over the past 12 months.,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
7535,NCT02214017,Glycemia,Lipids,Blood Pressure,2011-10,COMPLETED,INTERVENTIONAL,['NA']
7536,NCT00372814,Metabolic Control: Hemoglobin A1c (HbA1c),"Regimen Adherence: Diabetes Management Scale (DMS), Twenty-Four Hour Recall Interview, Glucose Meter Downloads",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
7537,NCT04082884,Percentage of Time in Target Range of 70-180 mg/dL.,Average Sensor Glucose Level,,2020-06-25,COMPLETED,INTERVENTIONAL,['NA']
7538,NCT06120569,HbA1C less than 7%,ratio of albumin (mcg/L) to creatinine (mg/L)ratio,,2024-09-18,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7539,NCT00220207,Hemoglobin A1c,,,2003-09,COMPLETED,INTERVENTIONAL,['NA']
7540,NCT03645421,Number of Patients Who Experienced Adverse Events (AEs),Number of Patients With Antidrug Antibody (ADA) Response to MEDI0382,,2018-08-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7541,NCT05692934,Pharmacokinetics parameters of Metformin in the fast and fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,,2023-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
7542,NCT02128815,change from baseline A1C after one year,change from baseline in quality of life at 1 year,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
7543,NCT05156736,Burden of atherosclerotic plaque assessed via coronary computed tomography angiography,Incidence of hypertension in mm Hg measured by Omron digital BP apprataus,,2023-03-15,RECRUITING,OBSERVATIONAL,['NA']
7544,NCT03413215,Composite primary endpoint,Composite secondary endpoint,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
7545,NCT00427271,glomerular filtration rate,,,2003-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
7546,NCT00296374,Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.,Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7547,NCT04496921,Change in serum vitamin K levels from baseline at 6 months,Glycemic marker levels,,2020-08-10,WITHDRAWN,INTERVENTIONAL,['NA']
7548,NCT01439178,"intraocular VEGF levels (pg/ml) in both groups (measured in aqueous humor), using multiplex beads immunoassay",,,2011-08,UNKNOWN,INTERVENTIONAL,['NA']
7549,NCT01916265,AUCGlucose of different glucagon dosages given s.c.,,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7550,NCT03598621,"Cmax,sema,SD, the maximum plasma semaglutide concentration after a single dose subcutaneous semaglutide administration","Number of site-initiated technical complaints with or without co-reported adverse events: DV3372 device, 1.0 mg/mL versus PDS290 semaglutide pen-injector, 1.34 mg/mL",,2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7551,NCT03371108,Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint,Efficacy - HbA1c Control,,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE3']
7552,NCT01271777,Glucose Infusion Rate (GIR),Changes in HGP (Hepatic Glucose Production),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7553,NCT04035031,Area under the curve for glucagon-like peptide I in oral glucose tolerance test clamp,Area under the curve for somatostatin in oral glucose tolerance test clamp following dapagliflozin compared with placebo,,2020-01-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7554,NCT02949024,Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events,CLS-TA Injections,,2016-11-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7555,NCT01855321,Percentage of improvement in Glycemic control after Vitamin D therapy.,,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7556,NCT01382628,Structural and metabolic changes,Relationship between collagen changes and system changes,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
7557,NCT04256460,Change of BMI from baseline at 12 months,Change of Low density lipoprotein cholesterol from baseline at 12 months,Change of C-reaction protein from baseline at 12 months,2019-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7558,NCT02540993,"The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death","The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death",,2015-09-17,COMPLETED,INTERVENTIONAL,['PHASE3']
7559,NCT00602914,Blood samples for PK and PD will be collected,"Feedback from study participants and staff on their overall impression with the MicronJet device, using questionnaires",,2008-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7560,NCT01098994,Demonstrate the presence of HDL dysfunction among individuals with the Haptoglobin 2/1 and 2/2 compared to those with the Hp 1/1 phenotype and improvement in HDL dysfunction with natural d-α-tocopherol supplementation,Assessment of adherence to the clinical trial study protocol in a random sample of individuals with type 1 diabetes recruited from the ACR and CHP/EDC Diabetes Registries,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
7561,NCT02640118,PPG excursions measured as incremental area under curve (iAUC),"glucagon, gastrin, cholecystokinin, GIP, GLP-1, oxyntomodulin",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
7562,NCT03921593,Quantification of Quality of Life,Estimate cost-effectiveness of pancreas transplantation,,2018-11-04,UNKNOWN,OBSERVATIONAL,['NA']
7563,NCT02915250,Delta AUC BG 0-2h (area under the blood glucose concentration-time curve),Hypoglycaemic events,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7564,NCT00748137,24 hours BGL > 8.3mmol/l (CGMS),HbA1c,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
7565,NCT01435707,fasting blood glucose,visual analogue scale of subjective pain,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
7566,NCT02587104,"The proportion of product related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events",Cost effectiveness of treatment of dHACM,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
7567,NCT01798420,Hemoglobin A1C LEVEL,Glucose levels,Weight,2012-04,COMPLETED,OBSERVATIONAL,['NA']
7568,NCT00656864,Change in incretin-mediated insulin secretion and receptor regulation of glucose-dependent insulinotropic peptide (GIP) in patients with type 2 diabetes.,Change in adipocyte GIP receptor mRNA expression levels.,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7569,NCT05369052,Vital signs - heart rate,Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators,,2022-05-03,RECRUITING,INTERVENTIONAL,['PHASE3']
7570,NCT04457531,Mean maximal nerve conduction velocity,low density lipid Protein cholesterol (LDL-C).,"Amino acids, lipid metabolites, vitamins, neurotransmitters and other metabolites",2020-10-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7571,NCT00366132,Time to Complete Wound Healing,"o Durability of wound closure (i.e., status of wound at one week following determination of ""healed"")",,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
7572,NCT00963768,The number of patients with adverse events as a measure of safety and tolerability,Renal glucose threshold,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7573,NCT00994253,"The primary objective is to assess the effect of a multimodal drug therapy regimen including the renin inhibitor Tekturna (aliskiren), an ACE inhibitor, and a calcium channel blocker on coronary flow reserve (CFR) in hypertensive Type II diabetics.","Secondary measures include evaluation of serum and urine biomarkers related to endothelial function, the renin-angiotensin system, oxidative stress, and inflammation.",,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7574,NCT04677699,Diagnosis of Celiac Disease,Severity of disease at diagnosis,,2020-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7575,NCT06065852,Facilitate translational and epidemiological research,,,2009-11-06,RECRUITING,OBSERVATIONAL,['NA']
7576,NCT00106704,Change From Baseline in A1C at Week 24,Change From Baseline in FPG at Week 24,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7577,NCT00920582,Mean Change From Baseline in HbA1c Between Teplizumab and Placebo,Number of Participants With Serious Adverse Events,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3']
7578,NCT00751842,Meal Stimulated C-peptide (area under the curve),Insulin Dose,,2008-09,TERMINATED,INTERVENTIONAL,['PHASE3']
7579,NCT03262116,Percentage of Time Spent With CGM Glucose < 54 mg/dl,Total Daily Dose of Insulin,,2019-03-19,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7580,NCT02895867,Change in Hemoglobin A1C (A1C),Change in c-reactive protein level,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
7581,NCT01186965,Process data,Diabetes knowledge,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
7582,NCT02498990,Change from Baseline in HbA1c (mmol/mol) at 12 and 24 months,"Change from Baseline in 2-hour Glucose (mmol/l) and Insulin (mU/l) by Glucose tolerance test at 7 weeks, 6, 12 and 24 months",,2015-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
7583,NCT04978649,Composite of Major Renal Events,Cancer,,2021-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7584,NCT01184768,Number of subjects with new diagnosis of type 2 diabetes,Effect of vitamin D status on glucose tolerance,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
7585,NCT05943899,Association between SGLT2i intake and hepatic fibrosis,,,2020-02-01,COMPLETED,OBSERVATIONAL,['NA']
7586,NCT02317835,Detection of hot spots on a foot thermal map image,,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7587,NCT01046318,Clinical laboratory tests,Changes in fasting blood glucose (FBG) from baseline to each visit (OC) and Week 52 (LOCF),,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7588,NCT05674981,Change from baseline in Cys-C (Cystatin C) level at 6 months,Change from baseline in gut microbiota at 6 months,,2023-04-24,RECRUITING,INTERVENTIONAL,['NA']
7589,NCT00812578,Insulin secretion and insulin resistance,"Glycemic control, lipid status, inflammatory markers, BMD",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7590,NCT01058733,physicians' labour time and frequency of contact with the online communication system required for reviewing the patients' information and sending recommendations,,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
7591,NCT05654142,"Assess changes in weight at baseline 0, 6, 12,24 and 52",,,2023-04-17,RECRUITING,INTERVENTIONAL,['NA']
7592,NCT00308373,,,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
7593,NCT01984372,Incidence of AEs (Adverse Events) by preferred term,Incidence of severe hypoglycaemia,,2013-11-06,COMPLETED,OBSERVATIONAL,['NA']
7594,NCT01443741,Variation in HbA1c,Severe hypoglycemia over 6 months and quality of life,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7595,NCT01679899,Markers of bone remodeling,Calcitonin,Levels of aminotransferases,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7596,NCT03495908,Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Non-inferiority Hypothesis.,"Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Intent-to-treat Population Secondary Outcome, Non-inferiority Hypothesis.",Evaluate the Change in Glucose Patterns Between Groups Based on 7-point Glucose Profiles.,2018-04-09,COMPLETED,INTERVENTIONAL,['NA']
7597,NCT02685345,change in 24 hour weighted mean glucose,change in derived glucagon AUC,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7598,NCT04490941,Glycated haemoglobin (HbA1c),triglyceride concentration,,2020-07-22,RECRUITING,INTERVENTIONAL,['NA']
7599,NCT02121483,t1/2,Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7600,NCT05422807,Change in Body Mass Index (Weight Status) at 6 months and at 12 months,Waist circumference (weight status),Teen Quality of Life,2011-04,COMPLETED,INTERVENTIONAL,['NA']
7601,NCT02623998,Number of Participants With Severe Hypoglycemic Episodes,Change in Waist Circumference,,2016-07-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7602,NCT01575483,Adverse events occurrence,"Effectiveness of Onglyza® measured by Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and 2-hr post-prandial glucose (2-hr PPG) comparing baseline data",,2012-03-01,COMPLETED,OBSERVATIONAL,['NA']
7603,NCT01135901,Diabetes mellitus type 2,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7604,NCT02815722,The area under the plasma concentration-time curve (AUC) of Simvastatin,The number of volunteers with adverse events as a measure of safety and tolerability,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7605,NCT01863914,Primary patent rate of AV fistula,Composite outcome measurement of the overall shunt-related complication rate,Composite outcome measurement of systemic pro-inflammatory response,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7606,NCT04586907,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PK: Maximum Concentration (Cmax) of LY3537021,,2020-11-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7607,NCT04271709,Proportion of Subjects with Visual Acuity Worse than 20/40,,,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7608,NCT02222506,Safety and tolerability of the KLOX BioPhotonic System in patients with diabetic foot ulcers.,Wound volume reduction over time.,Impact of treatment on Health-related quality of life.,2013-04,COMPLETED,INTERVENTIONAL,['NA']
7609,NCT01304225,Incidence of severe visual loss after 1 year,Retinal sensitivity,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
7610,NCT03121027,Anemia,,,2011-05-11,COMPLETED,OBSERVATIONAL,['NA']
7611,NCT01009138,Depressive Symptoms (CES-D Score),Health-care Costs: Medication Intake,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
7612,NCT00865345,Glucose Sensor Accuracy When Compared to Laboratory Standard (YSI-Yellow Springs Instruments),Device Related Moderate or Device Related Severe Adverse Events,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
7613,NCT00683020,Changes in the Mental Component Summary of the SF-12 Health Survey,Changes in Diastolic Blood Pressure (DBP),,2009-04,COMPLETED,INTERVENTIONAL,['NA']
7614,NCT01862263,Percentage of patients with hyperglycemic events evaluated with CGM,"Number of patients with adverse events, serious adverse events and death as evaluation of safety and tolerability of coadministration of vildagliptin with insulin",,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4']
7615,NCT02813161,Death,Patient Reported Outcome,,2015-02,RECRUITING,OBSERVATIONAL,['NA']
7616,NCT01972724,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Fasting Plasma Glucose at Week 24,,2013-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
7617,NCT02405260,Change in HbA1c (Glycosylated haemoglobin),Pulse,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7618,NCT00928005,Cardiovascular structure and function,Body composition,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
7619,NCT04949152,MACE,,,2016-06-01,RECRUITING,OBSERVATIONAL,['NA']
7620,NCT01735123,"Intestinal permeability will be determined at the age of 3, 6, 9 and 12 months with the lactulose/mannitol test Intestinal permeability at the age of 9 months assessed with the lactulose/mannitol test",Serum metabolic profile,Intestinal microbiome,2013-01,COMPLETED,INTERVENTIONAL,['NA']
7621,NCT00564395,Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Either Insulin Detemir Mixed With Rapid Acting Insulin (RAI) or Insulin Detemir and RAI as Separate Subcutaneous Injections,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4']
7622,NCT05865353,Shear data,,,2023-02-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7623,NCT05670379,Adverse events,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
7624,NCT05814965,hs-CRP,,,2023-04-05,RECRUITING,INTERVENTIONAL,['NA']
7625,NCT02203084,Albumin/creatinine ratio,,,2014-09-01,COMPLETED,OBSERVATIONAL,['NA']
7626,NCT00008801,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7627,NCT04665284,Number of participants reported adverse events,Frequency of participants achieved FBS level within normal range,Mean score of diabetes mellitus quality of life,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7628,NCT05935514,Change in HbA1c% at 6 months,Percentage of patients achieving 10% weight loss at 12 months,Change in glucose variability (coefficient of variation) at 12 months,2023-08-22,RECRUITING,INTERVENTIONAL,['NA']
7629,NCT04516759,Clinical Improvement by Day 14,Intubation/Mechanical Ventilation,,2020-08-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7630,NCT03411460,Satisfaction of patient-determined hospital care at discharge in the two groups,Number of hypoglycmic events with the corresponding glucose level,,2017-04-19,TERMINATED,INTERVENTIONAL,['NA']
7631,NCT00553280,Summary of Adverse Events,Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7632,NCT05621811,Change in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index - Daily Diary total score from baseline to week 12,,,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7633,NCT03139019,Outcome measure: Measure of decrease in weight loss across 16 weeks,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
7634,NCT02437084,Insulin Secretion Rate Area Under the Curve (ISR-AUC),OGTT Insulin AUC,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7635,NCT00167115,Fasting plasma HDL cholesterol,Episodes of hypoglycemia,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
7636,NCT00519727,safety and tolerability,Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups.,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7637,NCT02648685,the proportion of basal/post-prandial blood glucose contributed to the overall glycaemia(HbA1c),,,2015-11-30,COMPLETED,OBSERVATIONAL,['NA']
7638,NCT00160485,Newborn birth weight,Incidence of neonatal metabolic derangement,,2004-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7639,NCT01275040,Between group differences in HbA1c categories,Between group differences in patients where LDL cholestrol and creatinine was measures,,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
7640,NCT00699426,insulin secretion,blood pressure,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7641,NCT01967589,Number of treatment emergent adverse events (TEAEs) recorded,Change in body weight,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7642,NCT03451838,the number of paticipants who will have babies with macrosomias,,,2018-03-03,UNKNOWN,OBSERVATIONAL,['NA']
7643,NCT04608058,Change in Self-management behavior,Change in Glycated hemoglobin A1c,,2019-07-30,COMPLETED,INTERVENTIONAL,['NA']
7644,NCT05144984,Change in HbA1c,Number of treatment-emergent adverse events (TEAEs),,2021-11-29,COMPLETED,INTERVENTIONAL,['PHASE2']
7645,NCT00339833,Change in the Average Serum Insulin Concentration During the Last 40 Min of Clamp,,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
7646,NCT02450097,Change from baseline in fasting serum insulin in 6 months.,,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
7647,NCT04557228,Change in Insulin-stimulated blood flow,Change in Vascular function,,2023-03-17,RECRUITING,INTERVENTIONAL,['NA']
7648,NCT02044718,The number of participants with preventable adverse events,Quality of the chart review,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
7649,NCT00783315,Weight,Lipid levels,,2008-02-01,COMPLETED,INTERVENTIONAL,['NA']
7650,NCT06185790,Faecal microbiome composition analyses via DNA isolation,Blood ketone concentration,,2024-01-05,RECRUITING,INTERVENTIONAL,['NA']
7651,NCT02072551,Mean insulin secretion output,glucago secretion output,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
7652,NCT03249506,Incidence Rate of the Composite of All-cause Mortality (ACM) or Hospitalization for Heart Failure (HF),Percentage of Participants With Below Knee Lower Extremity (BKLE) Amputation,,2016-05-12,COMPLETED,OBSERVATIONAL,['NA']
7653,NCT01974544,"Change in the microvascular complications of type 2 diabetes, specifically peripheral and sympathic neuropathy.",How many patients not requiring antidiabetic agents,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
7654,NCT05292066,Toronto clinical neuropathy score,,,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7655,NCT05764629,Hemoglobin A1c (HbA1c),Adverse events,,2021-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7656,NCT01827280,Change from Baseline in microcirculation function at 30 days,Change from Baseline in endothelial function at 30 days,Change from Baseline in incretins and inflammation markers at 30 days,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7657,NCT02500628,Heart Rate Variability (Frequency Domain),Number of Patients Reporting Side Effects From the Medication,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7658,NCT04477928,"Demonstrated feasibility of large-scale population screening, as evidenced by:",Assessment of costs associated with implementation of study compared to potential impacts on cost and quality of life.,,2020-07-17,RECRUITING,OBSERVATIONAL,['NA']
7659,NCT00461136,To evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.,To investigate whether there is a change on biomarkers of inflammation and cardiovascular risk.,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7660,NCT04662879,Earlier detection of pancreatic ductal adenocarcinoma (PDAC),Depression and Anxiety as early indicators,,2021-10-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
7661,NCT05345327,Rate of decline in eGFR,Quality of life measured by EQ-5D-5L,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
7662,NCT01273558,RTG values using the MMTT and the stepwise hyperglycemic clamp methods,Rate of Urinary glucose excretion (UGE) during the MMTT and the hyperglycemic clamp procedure,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7663,NCT02229097,postprandial glycaemia,fructosamine,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7664,NCT01093794,Cmax for Sitagliptin and Metformin,,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7665,NCT03301792,Effect of Diabetes Group Care on postpartum weight retention,Psychosocial Stress and Depression,,2017-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7666,NCT01231308,The primary end-point will be the control of hyperglycemia (HbA1c <6.5% + FG<126mg/dl).,"Short (2 yrs) and long term (5 yrs.) achievement of 'adequate"" glycemic control, mean change in HbA1c from baseline.",,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
7667,NCT04432337,Variation in the plasma concentration of cytokines IL-1β and IL18,Compare the plasma levels of IL-1β and IL18,Compare the plasma concentration of reactive protein C (CRP) the level of activation of the NLRP3 inflammasome in circulating blood monocytes.,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
7668,NCT01053793,Glycemic response,Bioavailability of polyphenols from potatoes,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
7669,NCT05368623,To determine the sensitivity and specificity of RETINA-AI Galaxy v2.0 for diabetic retinopathy screening in the primary care setting.,,,2022-11-03,COMPLETED,OBSERVATIONAL,['NA']
7670,NCT06191328,HbA1c,Serum lipid profile,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7671,NCT02032173,Number of Participants With a Stable BCVA in the Study Eye at 24 Months Compared With BCVA at 6 Months,Evaluation of the Spaced Out Follow-up on Visual Functions and Quality of Life,,2014-05-19,TERMINATED,INTERVENTIONAL,['PHASE3']
7672,NCT00690235,Weight Loss With Pramlintide in Persons With Schizophrenia Who Have Gained Weight Taking Olanzapine or Clozapine,,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
7673,NCT02854202,Plasma glucose,Change in body weight,,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
7674,NCT02579655,"Composite rate of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, need for coronary revascularization, hospitalizations for chronic disease-related ambulatory care sensitive conditions",Overall health care costs,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7675,NCT00494663,"1. The primary efficacy endpoint will be change from baseline to the end of treatment (Study Visit 6, Week 16) in HbA1c","1. Change from baseline to Week 8 in total and LDL-cholesterol (LDL-C) 2. Change from baseline to the end of treatment (Week 16) in the following : Seated blood pressure (systolic, diastolic and mean arterial pressure) Fasting blood glucose",,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
7676,NCT02097342,To study the effect of Linagliptin on insulin sensitivity by performing euglycemic hyperinsulinemic clamp in patients with type 2 diabetes mellitus.,To study the effects of Linagliptin on glycemic control and beta cell function in patients with type 2 diabetes mellitus 6 months,To study the effect of voglibose on glucagon like peptide1 (GLP1) secretion and insulin resistance in patients with type 2 diabetes mellitus 6 months,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
7677,NCT02628392,change in HbA1c,change in triglyceride,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7678,NCT03001583,Weight loss,Weight loss,,2019-10-30,WITHDRAWN,INTERVENTIONAL,['NA']
7679,NCT05640869,Change in A1c,Physical activity change,"Change in Processes of Change for Weight Loss including the following processes: emotional re-evaluation, weight consequences evaluation, supporting relationships, and weight management actions",2023-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7680,NCT03552757,Participants Who Achieve (Yes/no): Body Weight Reduction ≥5% - Semaglutide 2.4 mg Versus Placebo,Change in Calcitonin - Semaglutide 2.4 mg Versus Placebo,,2018-06-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7681,NCT00607347,Correlation of area under curve (AUC) up to 24 hour time point of atenolol plasma drug concentrations and glucose/insulin values obtained from OGTT and triglycerides,"HDL-cholesterol, fatty acids, total cholesterol",,2008-02,COMPLETED,INTERVENTIONAL,['NA']
7682,NCT04124211,Safety of FMT,Blood chemistry panel,,2019-08-25,UNKNOWN,INTERVENTIONAL,['NA']
7683,NCT03538743,Number of Participants With Abnormal Electrocardiogram (ECG) Interval,Renal Clearance (CLr) of PF-06882961 on Day 28,,2018-06-25,COMPLETED,INTERVENTIONAL,['PHASE1']
7684,NCT00339885,"T2D status, quantitative traits measurements",,,1996-06-01,COMPLETED,OBSERVATIONAL,['NA']
7685,NCT00445354,hemoglobin A1c,diabetes medications,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7686,NCT05294536,Area under the plasma concentration-time curve from time zero to time t (AUC0-t),"Adverse Event, Serious Adverse Event",,2020-06-22,COMPLETED,INTERVENTIONAL,['PHASE1']
7687,NCT05872711,Change of time in range (TIR) 70-180 mg/dl after following a LCD or a MD in adolescents with T1DM.,Change in LDL cholesterol,,2023-04-19,RECRUITING,INTERVENTIONAL,['NA']
7688,NCT01429467,Correlation of HbA1c and level of cortisol,Change in levels of cortisol following CGM,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7689,NCT01144975,"Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, daily fasting blood glucose measured by the subject using a glucose monitor, and treatment-emergent adverse events.","Anti-diabetic activity measured by HbA1c, FPG, OGTT, C-peptide, and insulin collected at time points specified in the protocol.",,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7690,NCT01920984,"Vitreous levels of Fractalkine, Cyr61, and VEGF of patients with proliferative diabetic retinopathy",,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
7691,NCT06305208,Change in the number and dose of anti-diabetic medications,Changes in health-related quality of life scores (EuroQol-5D-5L),,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
7692,NCT04864327,HbA1c,BP(systolic and diastolic blood pressure),,2011-05-05,COMPLETED,INTERVENTIONAL,['NA']
7693,NCT01065337,"The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred",Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7694,NCT01475461,Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12,Number of Participants With Abnormal Laboratory Values,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7695,NCT01285232,"To determine the effect of anakinra on insulin secretion, as derived from hyperglycemic clamps .",Effects of anakinra on fat cell morphology and gene expression,,2011-01,UNKNOWN,INTERVENTIONAL,['NA']
7696,NCT03309007,Change in Leucocyte LC3 Score,,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7697,NCT02101229,Time spent in blood glucose range [70-180 mg/dl],time spent below 70 mg/dl and above 180 mg/dl,,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7698,NCT04619836,Effects to quality of care with questionnaire,How to guide patients,,2020-06-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7699,NCT03042442,Rate of patients with loss of > 5% body weight,"Assessing the survival rate by phone-calls follow-up every 6 months, up to 2 years",,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
7700,NCT01792206,The change in brachial artery Flow Mediated Dilataion with paracalcitol (1mcg/day)compared with placebo for 3 months.,Biomarker Measurement,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
7701,NCT05789550,The prevelance of H PYLORI Infection in type 2 DM,,,2023-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7702,NCT00909480,Change in HbA1c From Baseline,"Number of Subjects Having the Adverse Event ""Incorrect Dose Administered""",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7703,NCT03311516,The ratio of normoglycemia values to total glucose values,Usability of the insulin pump,,2019-10-10,UNKNOWN,INTERVENTIONAL,['NA']
7704,NCT03010683,"Differences in Endothelial Glycocalyx Thickness at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.",Endothelial Glycocalyx and Coronary Flow Reserve.,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7705,NCT03315988,"Change from Baseline 3-hour post-challenge glucose levels at 1, 8 and 12 weeks.","Semi-structured interviews with the completers, at the end of the study, to investigate perception responses having been on a vegan diet.",,2017-10-04,COMPLETED,INTERVENTIONAL,['NA']
7706,NCT02868606,Transfer to intensive care unit (y/n),In-hospital death (y/n),,2015-07,COMPLETED,OBSERVATIONAL,['NA']
7707,NCT02077127,Genetic association,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
7708,NCT00703235,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7709,NCT03688919,Change From Baseline in Youth Future Orientation (Objective Measure) at 8 Weeks (Z-score),Change From Baseline in Self-Care Inventory Revised at 8 Weeks (Z-score),,2019-05-13,COMPLETED,INTERVENTIONAL,['NA']
7710,NCT01819922,Cardiopulmonary Exercise Test: Oxygen Uptake Efficiency Slope (OUES): 1 Hour 40 Minute Post-dose,Plasma Metabolomic Profiles Before and Immediately Following Steady State and Incremental Exercise,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7711,NCT04226027,Change in HbA1c value,PAID Score,,2020-01-17,UNKNOWN,INTERVENTIONAL,['NA']
7712,NCT01171703,Occlusion of the stent or bypass,Restenosis measured by Duplex Ultrasound or CTA,,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
7713,NCT03351478,Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26,Percentage of Participants With HbA1c <7.0% at Week 26,,2017-11-27,COMPLETED,INTERVENTIONAL,['PHASE3']
7714,NCT04256005,Area Under the Curve following second Carbohydrate load measured by continuous glucose monitoring,Mean Heart Rate (HR) during the exercise trials,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
7715,NCT03407599,"AUC(IAsp),0-12h, area under the serum insulin aspart concentration-time curve from 0 to 12 hours",Number of hypoglycaemic episodes,,2018-01-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7716,NCT04930679,Fasting blood glucose,,,2018-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
7717,NCT05508490,prevalence of acute kidney injury in diabetic ketoacidosis,,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7718,NCT05745090,Composite endpoint based on first occurrence of all-cause death or cardiovascular events,All-cause hospitalization,Proportion of study subjects with reduced left ventricular diastolic function,2022-11-10,RECRUITING,OBSERVATIONAL,['NA']
7719,NCT01567254,Blood glucose values before and after listening to the recording.,"The delta of HA1C between before and after three months of periodic listening to auditory guided imagery, compared to listening to music.",,2012-04,COMPLETED,INTERVENTIONAL,['NA']
7720,NCT01619592,Quality of Life (QoL),,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
7721,NCT01782547,Change in Hemoglobin A1c,Change in Diabetes Knowledge,Telehealth intervention satisfaction,2013-06,COMPLETED,INTERVENTIONAL,['NA']
7722,NCT00876980,HbA1C,Fasting glucose & fructosamine microalbuminuria blood pressure lipids endothelial function,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
7723,NCT01127308,Number of Participants Experiencing an Adverse Event (AE),,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7724,NCT01484262,Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life),Total cost of patient education,,2011-11-14,COMPLETED,OBSERVATIONAL,['NA']
7725,NCT00978796,The primary objective of this pilot study is to compare 24-hour blood glucose values (overnight and pre- and post- prandial glucoses) in adult subjects with type 1 diabetes receiving either sitagliptin or placebo,Time spent in hypoglycemic and hyperglycemic excursions recorded on the DexCom STS continuous glucose monitor (CGM) at 3 time periods throughout the study,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7726,NCT01983813,Adherence of medical regimen/treatment to all of the Guideline Advantage criteria that apply.,"Control of blood pressure, low density lipoprotein cholesterol and hemoglobin A1c.",,2014-03-19,COMPLETED,INTERVENTIONAL,['NA']
7727,NCT00155454,Recurrent vitreous hemorrhage rate,,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
7728,NCT03838783,Time in range within 6 hours,Change in TRIM-D Score,,2018-05-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
7729,NCT06286566,Number of complication,Valuation of patient satisfaction,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7730,NCT01923688,Incidence of Severe Hypoglycemia,,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
7731,NCT04755660,Physical activity,Hemoglobin A1c,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
7732,NCT00939276,Percentage of patients who develop macular edema within 90 days following cataract surgery,Mean change in best-corrected visual acuity (BCVA) from baseline to Day 90,,2009-08,TERMINATED,INTERVENTIONAL,['PHASE3']
7733,NCT05054712,To describe the prevalence of metabolic liver diseases (NAFLD and GH) by different diagnostic approaches in the population of patients with T1D.,To study the relationship between metabolic liver diseases in patients with T1D and the presence of microvascular and macrovascular complications.,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
7734,NCT00632008,,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7735,NCT04513587,Change in Waist circumference,Change in Sense of coherence,,2019-09-01,RECRUITING,INTERVENTIONAL,['NA']
7736,NCT05915338,Fırst follow - up survey,Last test survey,Durabılıty test for both groups,2022-10-01,COMPLETED,OBSERVATIONAL,['NA']
7737,NCT00163683,"The primary outcomes include: HBAIc and lipids (Cholesterol, HDL-cholesterol, Triglycerides) at study entry and 6 months after dietary intervention","Key secondary outcomes include: TNF-a, IL-6, High sensitivity CRP, plasma carotenoids and serum fatty acids.",,2003-01,COMPLETED,INTERVENTIONAL,['NA']
7738,NCT05834868,Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment,Change From Baseline in 2-hour Postprandial Glucose (PPG) Excursion at Week 26,,2022-05-06,RECRUITING,INTERVENTIONAL,['PHASE3']
7739,NCT04946799,Fasting insulin at follow-up,International Physical Activity Questionnaire - Short Form at baseline,,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
7740,NCT01387633,blood pressure,Self-monitoring of blood glucose,,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
7741,NCT00491023,,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
7742,NCT00994812,Miscarriage rates,Effects of metformin versus placebo on the rates of gestational diabetes during pregnancy,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7743,NCT04589325,Residual insulin secretion,HbA1c,Change in International Physical Activity Questionnaire (IPAQ) scores from baseline and week 52.,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2']
7744,NCT05331586,Excessive gestational weight gain,Pelvic Floor and sexual disorders during pregnancy,,2022-07,UNKNOWN,INTERVENTIONAL,['NA']
7745,NCT00673621,AUCF 0-360 min of serum insulin,,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
7746,NCT01541956,Change from baseline in hemoglobin A1c(HbA1C) after 24 weeks of treatment with vildagliptin,"Number of patients with adverse events, serious adverse events and death",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4']
7747,NCT04536480,Change in total body fat mass (kg),Change in BMI in excess of the 95th percentile (%BMIp95),Adult eating behavior Questionnaire,2023-04-15,RECRUITING,INTERVENTIONAL,['NA']
7748,NCT05353686,Primary endpoint,,,2019-02-25,COMPLETED,INTERVENTIONAL,['PHASE2']
7749,NCT06240403,SAT microvascular endothelial cell β-galactosidase,,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7750,NCT04639726,Post-prandial glycemic excursion.,Beta-cell function II,Plasma peptide,2020-09-28,COMPLETED,INTERVENTIONAL,['NA']
7751,NCT02551900,Change from baseline in cutaneous blood flow,Change from baseline in Peripheral arterial stiffness,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
7752,NCT03004612,Change from basal fasting and post2h OGTT glucose levels at 12 and 24 months,Incidence of type 2 diabetes,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7753,NCT00334711,HbA1c reduction,Incidence of Hypoglycemia,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
7754,NCT06068114,Pyloric distensibility,Autonomic function testing,,2022-10-05,RECRUITING,OBSERVATIONAL,['NA']
7755,NCT01045954,Determine the mean value for the slop between the variables of total daily dose versus total basal dose.,"Determine the slope between the other variables: weight, total daily dose, total basal dose, insulin correction carbohydrate rate, correction factor",,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
7756,NCT00133952,Percentage of Participants With Sustained Moderate Visual Loss (SMVL) Any Time Baseline Through Month 48,Number of Participants Requiring Repeat Focal Photocoagulation at Any Time From Baseline Though Month 24,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7757,NCT01193179,"Adverse events, clinical laboratory tests",Secondary Outcome HbA1c,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7758,NCT05442840,Change in Baseline Hemoglobin A1C (HbA1C) at 10 months,Modifiable Risk Factor - Blood Pressure,,2022-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7759,NCT00417924,Patient satisfaction post-examination,,,2004-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7760,NCT02991534,Referrals to Health Promotion and Disease Prevention Services,Depression screen (PHQ-4),,2016-11-15,COMPLETED,INTERVENTIONAL,['NA']
7761,NCT00639600,"Rate of insulin-independence at 6 and 12 months after transplantation, duration of insulin-independence, survival curves","Tolerance (Measurement of portal pressure during islet injection) Quality of life (Questionnaires SF-36 and DQOL at inclusion time, then every 6 months during their waiting period and then 6 months and 12 months after transplantation) Costs",,2008-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7762,NCT01395303,,,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
7763,NCT04595396,Weight Loss,Early complications,,2012-09-01,COMPLETED,OBSERVATIONAL,['NA']
7764,NCT00069537,Accuracy of the GlucoWatch G2 Biographer and CGMS,,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7765,NCT01991470,"Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With the Guardian Mobile System","Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD), With GST3C Transmitter, Using One Additional Calibration During FST",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
7766,NCT01119404,,,,2003-06,UNKNOWN,OBSERVATIONAL,['NA']
7767,NCT02790060,Fear of hypoglycemia score,Standard Deviation (SD) of recorded Home Monitoring of Blood Glucose (HMPG),,2015-06,COMPLETED,OBSERVATIONAL,['NA']
7768,NCT05308095,Diagnostic accuracy of the hypoglycaemia warning system using in-vehicle data to detect hypoglycaemia quantified as the area under the receiver operating characteristics curve (AUROC).,Technology acceptance of the hypoglycaemia warning system,,2022-04-13,COMPLETED,INTERVENTIONAL,['NA']
7769,NCT00406991,Retinal blood flow,Retinal arterial diameter,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7770,NCT00005205,,,,1987-08,COMPLETED,OBSERVATIONAL,['NA']
7771,NCT01195662,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants,"Proportion of Participants With Orthostatic Hypotension at Baseline and Week 12, Including Data After Rescue",,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7772,NCT06268392,Ultrasound fetal weight estimation,,,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7773,NCT02518581,Activity-induced energy expenditure,,,2015-08-12,COMPLETED,INTERVENTIONAL,['NA']
7774,NCT05096858,Insulin use,,,2020-06-01,RECRUITING,OBSERVATIONAL,['NA']
7775,NCT04521712,Pancreatic beta cell function,Maternal diabetes mellitus,,2021-09-17,RECRUITING,INTERVENTIONAL,['NA']
7776,NCT03008824,Differences in B12 levels between GDM and Controls,Predictors of abnormal post-natal OGTT in the first trimester,Validation of newborn adiposity measured by skin-fold thickness and objective measurement by PEAPOD,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
7777,NCT04192019,Time to hypoglycaemia,Any adverse events,,2023-04,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
7778,NCT00056290,Safety,,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7779,NCT03382873,Weight loss,Decreased Glycemia,,2018-02-08,UNKNOWN,INTERVENTIONAL,['NA']
7780,NCT01340768,Percentage of Participants With at Least One Symptomatic Hypoglycemic Event,Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event,,2010-06-22,COMPLETED,INTERVENTIONAL,['PHASE3']
7781,NCT01071772,Exercise capacity,Regional left ventricular function before and after maximum exercise(regional 2D tissue velocity and strain),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7782,NCT00739336,Body Weight,Questionnaires,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
7783,NCT01146886,Assessment of tolerability by the investigator,Total urinary corticosteroids (5α-THF + 5β-THF + THE + UFF + UFE) as an indicator of the activation of the HPA axis,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7784,NCT01945918,Change in body mass index (BMI) from baseline to 18 months,Evidence of documented self-management support for patients through medical record review,Change in patient-reported diabetes self-care rating from baseline to 18 months,2013-10,COMPLETED,INTERVENTIONAL,['NA']
7785,NCT02423798,Sensor Survival,,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
7786,NCT01460251,DiaPep277-specific antibodies,Daily insulin dose adjusted to body weight at study end,,2012-01,TERMINATED,INTERVENTIONAL,['PHASE3']
7787,NCT04451980,Adipose tissue T cell surface marker phenotype and antigen receptor sequence,Circulating T cell surface marker phenotype,,2017-08-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7788,NCT03648281,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2018-08-24,COMPLETED,OBSERVATIONAL,['NA']
7789,NCT03900286,A change from baseline in HbA1c,The Three Factor Eating Questionnaire,,2020-01-16,RECRUITING,INTERVENTIONAL,['NA']
7790,NCT03650712,age- and sex-based nomograms for OGIS (oral glucose insulin sensitivity),evaluate the relationships between age and sex-based quantiles for c-peptide and number of pulmonary exacerbations in the previous 12 months,Correlation between CGM standard deviation of sensor glucose values and b-cell glucose sensitivity,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
7791,NCT01971125,Prevalence of Left Ventricular Dysfunction in patients with type II diabetes,,,2006-07,COMPLETED,OBSERVATIONAL,['NA']
7792,NCT04939766,Change in burden of diabetes following activation of closed loop,Glycemic variability,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
7793,NCT05633784,Change in tolerance capacity,Assessment of physical activity.,,2022-08-18,RECRUITING,INTERVENTIONAL,['NA']
7794,NCT00677313,"To provide metreleptin, an investigational medication, under a treatment protocol to subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia","Information on the efficacy of metreleptin as assessed by its effects on fasting triglyceride concentrations, HbA1c, and fasting glucose concentrations in subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia",,2009-03,COMPLETED,INTERVENTIONAL,['NA']
7795,NCT03930004,Left atrial dysfunction,,,2018-07-06,COMPLETED,OBSERVATIONAL,['NA']
7796,NCT02223793,Change in ad Hoc Risk Score (Measure on a Scale From Min 4 to Max 14),8-week Change in Total Cholesterol,Effect of Heart Age and Tailord CVD Advice After 1 Year,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
7797,NCT04410055,Oxygen consumption,Attention levels,,2012-01-08,UNKNOWN,INTERVENTIONAL,['NA']
7798,NCT03829514,Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid Chromatography-mass Spectrometry,,,2019-02-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7799,NCT03024788,prevalence of retinopathy,incidence of retinopathy,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
7800,NCT04023734,Medication adherence,Patients' willingness to maintain the intervention,,2019-08-16,COMPLETED,INTERVENTIONAL,['NA']
7801,NCT06299098,Percent change in total fat mass,Severity of TEAEs,,2024-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7802,NCT00589459,Prevalence of undiagnosed pre-diabetes or undiagnosed diabetes,,,2001-10-01,COMPLETED,OBSERVATIONAL,['NA']
7803,NCT00851773,Adverse events,Antibody development against N9535,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7804,NCT05784220,Fasting blood glucose at final visit < 7 mmol/L measured by lab test,Change in blood pressure,Objective scoring of program coach audits,2019-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7805,NCT05066542,Percent Weight Loss Efficacy,% Fat,,2021-06-11,UNKNOWN,INTERVENTIONAL,['NA']
7806,NCT05953818,Brain magnetic resonance high-resolution structural imaging was performed to observe the changes of brain structure,The cognitive function of the two groups was evaluated and analyzed by the Chinese version of Montreal Cognitive Assessment Scale (MoCA),,2023-05-30,RECRUITING,OBSERVATIONAL,['NA']
7807,NCT04027530,Renal oxygenation measured by BOLD-MRI (R2*),Total insulin extraction,,2020-12-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7808,NCT04307511,changes of Maximum Amplitude (MA) detected by TEG,,,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE4']
7809,NCT01690962,Mood,Quality of life,Acceptability of vegan diet,2012-11,COMPLETED,INTERVENTIONAL,['NA']
7810,NCT00922402,Average time to glycemic target (90-130 mg/dL),Evaluation of organizational impact,,2009-06,WITHDRAWN,INTERVENTIONAL,['NA']
7811,NCT06007430,Body Mass Index (BMI),Rate Pressure Product,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7812,NCT03895437,Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC),Events of Special Interest,,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7813,NCT04203927,Myocardial microvascular perfusion,Pulse Wave Velocity ( PWV),,2020-02-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7814,NCT00906659,macular volume (measured in mm3),,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
7815,NCT03970161,GCL+ thickness in the macular region obtained using the 3D Macula (v) mode,,,2019-05-29,UNKNOWN,INTERVENTIONAL,['NA']
7816,NCT02863354,Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0,"Change in Area of Total Retinal Capillary Non-perfusion, as Assessed by the Central Reading Center",,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7817,NCT02066350,Endothelial function,Oral glucose tolerance test,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
7818,NCT01455870,Change in HbA1c between Week 52 and Day 0,,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7819,NCT06336122,Number of participants with change in A1c,Social Network Scale,,2024-02-21,RECRUITING,INTERVENTIONAL,['NA']
7820,NCT02707380,Paired T-test to compare test-retest Perceived dyspnea,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
7821,NCT04915014,The Excess Weight Loss percentage (EWL%),Change of physical activity assessed by the International Physical Activity Index (IPAQ) score.,,2021-07-23,RECRUITING,INTERVENTIONAL,['NA']
7822,NCT02549924,Mean amplitude of glucose excursions (MAGE),Body and visceral fat %,,2016-09,TERMINATED,INTERVENTIONAL,['PHASE2']
7823,NCT02803905,A1c </= 6.5% and no severe hypoglycemia,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2016-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7824,NCT05928572,Phase 1 CGM-derived time in range (TIR),Total healthy eating index (HEI) score,Phase 2 CGM-derived time in range (TIR),2023-07-25,RECRUITING,INTERVENTIONAL,['NA']
7825,NCT00699686,Change in endothelial progenitor cell count,Change in body weight,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7826,NCT03565770,Difference between the rate of glycosylated hemoglobin (HbA1c) before randomization (baseline) and the rate of glycosylated hemoglobin after 6 months coaching (measure M6).,Binary variable attendance = 80% honored appointments,,2018-09-29,UNKNOWN,INTERVENTIONAL,['NA']
7827,NCT02129985,remission rate of type 2 diabetes at a year.,the beta cell function change,number of hypoglycemia and severe hypoglycemia during the study,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
7828,NCT06066515,Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76,Relative change from baseline to Week 76 in liver fat content (%),,2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
7829,NCT01746017,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline in C-Peptide Area Under the Effective Concentration Curve From Time Zero to 6 Hours [AUEC(0-6)],,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7830,NCT01354925,Difference in mean 4-point SMBG during days 23-30 of treatment between the two groups.,,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7831,NCT03458286,Total wound healing,Diabetic foot ulcer reoccurrence rates,,2018-04,UNKNOWN,INTERVENTIONAL,['NA']
7832,NCT00310752,,,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7833,NCT04504396,Change in HbA1c,Change in Body Mass Index,,2020-06-23,COMPLETED,INTERVENTIONAL,['PHASE3']
7834,NCT02316054,"cardiac death,or Q-wave myocardial infarction (MI), or the need for myocardial revascularization > 3 months after SPECT",myocardial revascularization > 3 months after SPECT,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
7835,NCT04246190,"AUClast of CKD-501, D759 and CKD-396",,,2020-02-24,UNKNOWN,INTERVENTIONAL,['PHASE1']
7836,NCT00109369,Glycemic control,Functional status,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
7837,NCT02208206,Analysis of gene expression,,,2014-07,COMPLETED,OBSERVATIONAL,['NA']
7838,NCT05385211,Exocrine pancreatic insufficiency,,,2022-04-30,COMPLETED,OBSERVATIONAL,['NA']
7839,NCT02146079,Area under the plasma semaglutide concentration-time curve,Number of treatment emergent adverse events (TEAEs) from baseline to follow-up,,2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE1']
7840,NCT04061473,glucagon excursions measured as incremental area under the curve (iAUC),food intake,,2019-04-02,COMPLETED,INTERVENTIONAL,['NA']
7841,NCT01995656,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics: Area Under the Curve (AUC) of LY3108743,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7842,NCT00861042,Subject withdrawal due to adverse events,Quality of life assessments during specific site visits,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7843,NCT06194240,12-Item Short Form Health Survey,Generic Adherence Profile for Chronic Diseases,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
7844,NCT02691273,10 percentage improvement in the quality of life questionnaire,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
7845,NCT05896644,Change in number of ED Visits,Change in blood pressure,,2023-06-20,RECRUITING,INTERVENTIONAL,['NA']
7846,NCT03090464,Change from baseline to end of study (Month 6) in HbA1c levels,Proportion of patients in both cohorts who intensify antihyperglycemic treatment from Visit 1,Change in baseline to Month 6 in Morisky Medication Adherence Scale (8-item) (adherence),2017-05-08,COMPLETED,OBSERVATIONAL,['NA']
7847,NCT05147701,Safety (adverse events),,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE1']
7848,NCT01729156,Whole Body Glucose Rd,VLDL-TG Oxidation,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7849,NCT02331420,Cardiac autonomic function (heart rate variability measurements on 24-hour Holter ECG recordings),,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
7850,NCT04123054,Change in HbA1c levels,Mean sensor glucose level during:,Recurrent themes from semi-structured interviews,2020-03-05,RECRUITING,INTERVENTIONAL,['NA']
7851,NCT02249897,CML SERUM LEVELS,MULTIFOCAL ELECTRORETINOGRAPHY,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7852,NCT05975541,Fecal calprotectin levels identification,assessment of the circadian rhythm trough MEQ questionnaire,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
7853,NCT02675257,Improvement of glycaemic control as measured by the HbA1c,Improvement of quality of life as measured with the Short Form-36 Health Survey (SF-36),Inflammatory Marker: Adiponectin,2015-07-01,COMPLETED,INTERVENTIONAL,['NA']
7854,NCT02827669,HbA1c,,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
7855,NCT00109434,Hypoglycemia defined as <=70 mg/dL.,Changes in epinephrine and glucagon levels.,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
7856,NCT01301196,Sedentary behaviour,Psychosocial indicators,,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
7857,NCT03613857,Ischemic or hemorrhagic stroke,,,2017-04-15,COMPLETED,OBSERVATIONAL,['NA']
7858,NCT05319990,Insulin Sensitivity,Effective Renal Plasma Flow (ERPF),,2022-03-09,RECRUITING,OBSERVATIONAL,['NA']
7859,NCT02692313,Flow mediated dilation (FMD) of the brachial artery,,,2016-06,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7860,NCT00523913,"The safety profile (adverse events, laboratory parameters and other observations) of BRL49653C administered for 52 weeks will be evaluated.","The efficacy profile (HbA1c, FPG and Insulin) of BRL49653C administered for 52 weeks will be evaluated.",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7861,NCT00133692,First occurrence of death or nonfatal myocardial infarction (MI) or nonfatal stroke,Compliance,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7862,NCT05484817,Prevalence of impaired cardiac function in type 2 diabetes diagnosed by echocardiography,Biomarker measured by blood test,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
7863,NCT04601753,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2020-11-12,COMPLETED,OBSERVATIONAL,['NA']
7864,NCT04451915,The occurrence of materno-fetal complications,Number of complications in each subgroup of the late GDM management group,,2020-11-30,RECRUITING,INTERVENTIONAL,['NA']
7865,NCT04909632,The differentiation of tongue features mellitus and pre-diabetes,The tongue coating metabolic markers in patients with diabetes,,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA']
7866,NCT00791076,Total Amount of Insulin Administered While on Placebo/PP.,Frequency of Hypoglycemia Defined as < 60 mg/dl.,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2']
7867,NCT03299790,ECG (Electrocardiogram),Maximal oxygen uptake (ml/O2/kg/min),,2017-10-06,COMPLETED,INTERVENTIONAL,['NA']
7868,NCT00407641,"the composite event rate in death (any cause), myocardial infarction and stroke",Lipid profile,,2009-03,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7869,NCT05353699,"Implementation change: Change from Baseline Implementation at 3, 6,9 months",Qualitative assessment-maintenance:,,2022-05-01,UNKNOWN,INTERVENTIONAL,['NA']
7870,NCT05413369,Change in HbA1c from baseline to Week 24,Change in fasting C-peptide,,2022-07-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7871,NCT03174288,Augmentation Index-Change from baseline,Microvascular Blood Volume-Change from baseline,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
7872,NCT03508323,HbA1c,,,2018-04-03,COMPLETED,INTERVENTIONAL,['PHASE4']
7873,NCT02725502,Effect of Linagliptin on insulin requirement in T1DM patients,Effect of linagliptin on glucagon level during mixed meal test in T1DM patients,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
7874,NCT01066039,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Month 6,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7875,NCT02361489,A1C,Hypoglycemia,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
7876,NCT05581264,Difference in Glycated hemoglobin (HbA1c) level between experimental group and control group across time,Difference in health related quality of life HRQOL scale scores between experimental group and control group across time,,2021-09-28,COMPLETED,INTERVENTIONAL,['NA']
7877,NCT01023646,"Glucose, Insulin, Free Fatty Acids.","Fasting and non-fasting plasma lipids and lipoproteins, C reactive protein (CRP), HbAIc.",,2007-12,COMPLETED,INTERVENTIONAL,['NA']
7878,NCT04689074,Biological samples collection for establishment of the first National Microbiome Biobank,,,2021-02-03,COMPLETED,OBSERVATIONAL,['NA']
7879,NCT00850798,"The primary study outcomes are a composite of macrovascular events and a composite of microvascular events, considered both jointly and separately.","The secondary outcomes are death from any cause, disability from any cause, total coronary events, total cerebrovascular events, heart failure, peripheral vascular events, all cardiovascular events, and hospitalization for 24 hours or more.",,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
7880,NCT01618188,Area under the glucose infusion rate curve,Time to maximum glucose infusion rate,,2012-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7881,NCT04207099,Rate of change in wound area of diabetic foot ulcers in ARM 2 vs ARM 1,Wound Healing Rate,,2020-02-14,UNKNOWN,OBSERVATIONAL,['NA']
7882,NCT01419652,periprocedural glucose,,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
7883,NCT04884425,Change in the EQ-5D-5L tool score,,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
7884,NCT02715934,Provider referral,Patient participation,Summary of Diabetes Self-care Activities Measure (SDSCA),2016-04,COMPLETED,INTERVENTIONAL,['NA']
7885,NCT05852639,To evaluate the efficacy (sensitivity & specificity) of fetal cerebroplacental ratio at term in prediction of adverse neonatal outcome in pregnancies complicated by gestational diabetes,To evaluate the incidence of adverse neonatal outcome in both groups,,2022-11-30,RECRUITING,OBSERVATIONAL,['NA']
7886,NCT02733991,Mean Number of Sensor Glucose Hypoglycaemic Events Below or Equal to 55 mg/dL Per Patient/Week.,Mean Time Spent of Sensor Glucose Values Within Range and Including 70-180 mg/dL.,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
7887,NCT00970060,Dermal and epidermal nerve fiber densities,"Clinical assessments of neuropathy, pain, body mass index, muscle strength, and glycemic control (glycosylated hemoglobin or A1C)",,2008-06,COMPLETED,INTERVENTIONAL,['NA']
7888,NCT03167866,HbA1c levels at 6 months from beginning of messages,Diabetes Quality of Life questionnaire,,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA']
7889,NCT00220961,Prevention of Type 2 Diabetes,Change in Atherosclerosis,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7890,NCT00687453,Hemoglobin A1c Change From Baseline,Any Adverse Event Other Than Hypoglycemia,,2003-02,TERMINATED,INTERVENTIONAL,['PHASE4']
7891,NCT01170468,The incidence of DM,time to develop DM,,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3']
7892,NCT01504620,Accuracy of the blood glucose meter in comparison to a standard reference,Hematocrit Interference (Helios),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7893,NCT02347787,Short Form Health Survey (SF-12) Physical Component Score (PCS),Hospital Admission - Mean Length of Stay (Among Participants With Hospitalization),,2015-01-28,COMPLETED,INTERVENTIONAL,['NA']
7894,NCT03182582,Bacterial Load Pre- and Post-Sharp Debridement,Percent Change in Wound Size - 1 Week Post-debridement,,2017-01-05,COMPLETED,INTERVENTIONAL,['NA']
7895,NCT01771835,Quantification of retinal venous pressure (RVP),Quantification of ET-1 in correlation with RVP,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
7896,NCT00286572,Death and/or major adverse cardiac events,,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
7897,NCT01877590,Alpha-lipoic acid regress the left ventricular mass,The change of endothelial dysfunction before and after alpha-lipoic acid intervention.,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
7898,NCT02470156,Wellness Coaching Program Effectiveness on Goal Success,Economic Assessment of the Intervention,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
7899,NCT01309022,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
7900,NCT00184574,HbA1c,Other glycemic variables,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7901,NCT02077309,Effect of linagliptin on vascular inflammation of the carotic artery,Effect of linagliptin on biomarkers of vascular inflammation,,2014-08,TERMINATED,INTERVENTIONAL,['PHASE3']
7902,NCT05330390,Blood drug concentration,,,2022-04-04,UNKNOWN,OBSERVATIONAL,['NA']
7903,NCT02402374,Proportion of patients with complete wound closure,,,2018-04-12,UNKNOWN,INTERVENTIONAL,['NA']
7904,NCT01478841,Peripheral insulin-sensitivity,biochemical parameters,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
7905,NCT05304325,"Adipose tissue fibrosis using qRT-PCR, immunoblotting, histochemistry and immunohistochemistry","Inflammation in adipose tissue using qRT-PCR, immunoblotting and immunohistochemistry",,2012-04-25,UNKNOWN,OBSERVATIONAL,['NA']
7906,NCT00505960,HbA1c,BP control,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7907,NCT02154997,Post prandial blood glucose levels,,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
7908,NCT06138821,Change in Liver Fibrosis measurement at 12 months compared to baseline,Change in eating behaviors compared to baseline,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
7909,NCT02132338,Glycated hemoglobin level before and after intervention,body mass index,Loss of participants in the intervention by forfeit,2014-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7910,NCT01704417,"BGpre-exe - BGminimum,exe, difference between blood glucose concentration before exercise and the minimum blood glucose concentration observed during exercise","BGminimum,30-180min,post-exe, minimum blood glucose concentration",,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7911,NCT02911792,GFR (Glomerular Filtration Rate) Change After Treatment,,,2016-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
7912,NCT02136654,Change in A1C or blood pressure (systolic or diastolic blood pressure),change in health status,Procedure related outcomes,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
7913,NCT04099745,Accuracy of different blood glucose monitoring systems (CGM and FGM) with intravenous blood glucose level as the gold standard,forty-day blood glucose fluctuation of FGM,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
7914,NCT02009254,blood glucose,food intake,subjective appetite,na,COMPLETED,INTERVENTIONAL,['NA']
7915,NCT02053714,Changes in knowledge of diabetes self-management from baseline to six months as evidenced by scores on the Stanford Diabetes Self-Management Questionnaire.,Changes in diastolic and systolic blood pressure from baseline to six months.,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
7916,NCT01077505,AUC0-24 of norethindrone and ethinyl estradiol after OC alone in Period 1 and after OC with albiglutide in Period 2.,Predose serum levels of progesterone after OC alone and after OC with albiglutide.,,2010-03-15,COMPLETED,INTERVENTIONAL,['PHASE1']
7917,NCT04006938,Fasting blood sugar level,,,2019-07,UNKNOWN,INTERVENTIONAL,['NA']
7918,NCT00252694,Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale,Rate of Change in Urinary Albumin Excretion Rate (UAER).,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7919,NCT05899023,Percent of Patients who Complete at least One In-Person Follow-up Outpatient Visit,Percent of Patients who Start on Diabetes Medications within 6 Months of Diagnosis,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7920,NCT01028846,Endogenous Glucose Production (EGP),,,2011-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
7921,NCT00353691,Change in HbA1c from baseline to Week 24 or last evaluable ontreatment value.,Mean change in body mass index (BMI) from baseline to Wk 12 and Wk 24 or last evaluable on-treatment value,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7922,NCT00732862,HbA1c,Catecholamines,,1998-02,COMPLETED,INTERVENTIONAL,['NA']
7923,NCT00978835,Blood Pressure,Hemoglobin A1c,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
7924,NCT00162175,Compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + glyburide vs placebo + glyburide,"Change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24",,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7925,NCT05247034,Rate-dependent depression on the frequency of stimulation of the H reflex,Diabetes 39 Instrument,,2021-06-04,RECRUITING,INTERVENTIONAL,['NA']
7926,NCT03556631,hemoglobin A1c in percentage,weight in kilograms,,2020-09-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7927,NCT04499768,VD at 3 months postoperatively,BCVA at 3 months postoperatively,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
7928,NCT03179085,The Patient Activation Measure (PAM),Nutritional Measures,,2017-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7929,NCT03881995,Brain insulin sensitivity,Body weight,Hypoglycemia time of day,2019-03-18,TERMINATED,INTERVENTIONAL,['PHASE4']
7930,NCT03489967,Change in glucose levels 15 minutes after hypoglycemic treatment,Number of patients requiring a second treatment 15 minutes after the first hypoglycemic treatment,,2018-04-18,COMPLETED,INTERVENTIONAL,['NA']
7931,NCT00073281,,,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7932,NCT03195868,"total nerve fiber density,",NTSS- Nueropathy Total Symptom Score,,2019-09-30,COMPLETED,INTERVENTIONAL,['NA']
7933,NCT02056210,CD34+ stem cell mobilization in diabetic vs non diabetic subjects,EPC (endothelial progenitor cell) mobilization within diabetic patients,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
7934,NCT03790579,Dietary acid load,,,2014-01-05,COMPLETED,OBSERVATIONAL,['NA']
7935,NCT05071820,Percent weight lost at 12 months from baseline weight,change in hemoglobin A1c,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
7936,NCT03421379,Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia,PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM,,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE3']
7937,NCT00701181,Mean Change from Baseline in the Best Corrected Visual Acuity Score,Mean Changes in Macular Volume from Baseline,,2008-06,TERMINATED,INTERVENTIONAL,['PHASE2']
7938,NCT03890900,Change from baseline hemoglobin A1c to 3 and 6 months,Change from baseline LDL cholesterol to 3 months and 6 months,,2020-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7939,NCT03903016,Assessment of PK parameter :INS-AUClast -,Adverse Events,,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE1']
7940,NCT02830048,Decrease in fasting plasma glucagon concentration,Pre-dose plasma concentration of glibenclamide,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7941,NCT00849056,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Change From Baseline in Body Weight at Week 156,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7942,NCT00803660,The percentage of patients achieving the BP<130/80 mmHg,The number and percentage of patients with positive proteinuria by treatment groups,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
7943,NCT00886574,Maximal and mean intima media thickness (IMT) of both common carotid artery of the cilostazol group in comparison with the aspirin group,Events of hemorrhagic vascular complication,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
7944,NCT05383209,Percentage of subjects improving ≥2 steps in the Diabetic Retinopathy Severity Scale (DRSS) score each EYP-1901 dose level versus the sham IVT injection group.,Rates of ocular (study eye and fellow eye) and non-ocular Treatment-Emergent Adverse Events,,2022-08-31,RECRUITING,INTERVENTIONAL,['PHASE2']
7945,NCT05979246,marginal bone loss,Survival rate,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7946,NCT02502071,Change in Number of Participants With Urine Uric Acid Precipitation by Polarized Microscopy,,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7947,NCT00800085,The systematic and simultaneous determination of markers of functional beta cell mass and immune status allows stratification according to the stage of the pathogenic process rather than according to a late metabolic consequence of this process,,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7948,NCT02001805,Body Composition,Activity level and diet,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
7949,NCT05269589,Hemoglobin A1C (HbA1C),Blood pressure,,2022-02-18,RECRUITING,INTERVENTIONAL,['NA']
7950,NCT03285230,Health outcomes,,,1990-06-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7951,NCT01950806,Change in biomarkers of insulin resistance compared with control diet,Change in plasma lipid profile compared with control diet,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
7952,NCT00618007,HbA1c,Fasting Insulin,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7953,NCT01085773,Glycated hemoglobin (HbA1c).,"Adherence, Anthropometry,Blood pressure, Lipid profile, VO2max and quality of life.",,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7954,NCT04108299,Satisfaction Questionnaire Score,Change in International Physical Activity Questionnaire (IPAQ)-short version Score,,2021-04-21,COMPLETED,INTERVENTIONAL,['NA']
7955,NCT00616811,Safety and tolerability in patients with T2DM and severe renal insufficiency over 24 weeks of treatment,Efficacy of vildagliptin versus sitagliptin in patients with T2DM and severe renal insufficiency by assessing the hemoglobin A1c (HbA1c ) and fasting plasma glucose (FPG) reduction from baseline,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7956,NCT06171230,Pain intensity measured with the Numeric Rating Scale (NRS),Pain Disability Index (PDI) Limitations in daily activities,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
7957,NCT03095196,All cause deaths.,,,2012-09-01,COMPLETED,OBSERVATIONAL,['NA']
7958,NCT05915260,The association of pericardial- and epicardial fat with myocardial function and MACE after 5 year,"Characterization of the progression of diabetic cardiomyopathy over 5 years, including LV+RV function, the coronary microvascular function, the coronary macrovascular function, fibrosis, aortic stiffness, per and epicardial fat, perfusion of other organs",,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7959,NCT01710774,healing time for leg ulcer and/or diabetes related foot ulcer,"A new foot ulcer appears, the incidence of amputation and survival.",,2012-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7960,NCT00646542,To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment,To explore the efficacy of vildagliptin (50 mg qd) versus placebo in patients with T2DM and moderate or severe renal insufficiency.,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7961,NCT03263728,Prevalence of myocardial ischaemia,Major adverse cardiovascular events,,2017-08-10,COMPLETED,INTERVENTIONAL,['NA']
7962,NCT03511521,Glycemic Control,Percentage of Glucose Values Within the Hypoglycemic Range,,2018-03-27,TERMINATED,INTERVENTIONAL,['PHASE4']
7963,NCT01469312,Change in Blood Glucose,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7964,NCT02863419,Change in HbA1c (Week 26),Change in DTSQs: Individual Items and Total Treatment Satisfaction Score (6 of the 8 Items Summed),,2016-08-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7965,NCT00479258,To Assess Pulmonary Safety and Glycemic Control of Exubera Over a 12 Month Controlled Period,7 Point Home Glucose,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE3']
7966,NCT05819138,Change in Carotid and Radial Artery Pulse Wave Velocity (CR-PWV),Change in Renal Vascular Resistance (RVR),,2023-06-21,RECRUITING,INTERVENTIONAL,['PHASE3']
7967,NCT05475587,Body constitution of body constitution questionnaire (BCQ),,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
7968,NCT01331317,Change in plasma NT-proBNP,Change in Urinary Albumin Excretion Rate,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7969,NCT01879800,Mean Change in Participants World Health Organization Quality of Life Measure- Physical Score: Change From Baseline to 3 and 6 Month Follow-up.,Mean Change in Hamilton Anxiety Rating Scale (HAM-A) From Baseline to 3 and 6 Month Follow-up,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7970,NCT01151072,Area under the serum Insulin Degludec concentration-time curve (only for subcutaneous administration),Back-extrapolated initial serum Insulin Degludec concentration after single-dose (only for intravenous administration),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7971,NCT02124590,Change in Acylcarnitine/Carnitine ratio,Change in Mitochondrial Function,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
7972,NCT01387334,HbA1c,compliance of home-based resistive exercise training,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7973,NCT03980236,Change in A1c,,,2019-05-06,TERMINATED,INTERVENTIONAL,['NA']
7974,NCT00550329,,,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
7975,NCT05860842,Change in peak power output (PPO),,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7976,NCT05925933,Metabolomics profile,,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7977,NCT00568854,Kinetics of Mycobacterial-specific Immune Response After BCG Vaccination,,,2007-04,TERMINATED,INTERVENTIONAL,['NA']
7978,NCT05472272,Percent of participants achieving significant weight loss and diabetes remission,Metabolomic profiling performed by liquid chromatography mass spectrometry,,2022-08-03,RECRUITING,INTERVENTIONAL,['NA']
7979,NCT00513630,"Composite of cardiovascular events which were defined as death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization",new peripheral vascular events,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7980,NCT01773707,Change from Normal Glucose Tolerance to Abnormal Glucose Tolerance,Change in C-peptide response to Oral Glucose Tolerance Test (OGTT),,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7981,NCT05656963,Specific link between high incidence of thrombotic events in patients with membranous nephropathy and diabetic nephropathy,,,2021-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7982,NCT04233489,Change in Brief Infant Toddler Social Emotional Assessment (BITSEA) score,Change in M/CHAT R/F score,,2020-01-03,TERMINATED,INTERVENTIONAL,['NA']
7983,NCT01225081,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-09-15,COMPLETED,INTERVENTIONAL,['PHASE3']
7984,NCT01889914,changes from baseline in insulinoresistance measured by biological tests of hyperinsulinemic euglycemic clamp in the two groups of treatment 6 months after the start of the treatment.,"change from baseline in weight at three, six, nine and twelve months in the two groups.",,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
7985,NCT05163964,The change of baseline continuous glucose monitoring (CGM) profile among prediabetes adults at 6 months.,The change of chronotype among prediabetes adults at 6 months.,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
7986,NCT03159832,The maximum plasma concentration (Cmax) of SHR3824,The number of volunteers with adverse events as a measure of safety and tolerability,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
7987,NCT03460769,"Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",,,2017-11-01,RECRUITING,OBSERVATIONAL,['NA']
7988,NCT03771417,Skeletal Muscle Mass,Mitochondrial Function,,2019-01-16,COMPLETED,INTERVENTIONAL,['NA']
7989,NCT00585897,Hemoglobin A1c,Fasting glucose,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
7990,NCT05697484,diabetes control,Usability and satisfaction,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7991,NCT06239636,Safety as assessed by number of treatment related adverse events accoridng to CTCAE v 5.0,Score in diabetes treatment satisfaction questionnaire,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7992,NCT00358059,Treatment adherence,Diabetes-related quality of life,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7993,NCT03673969,Excess weight loss,Diarrhoea,,2019-02-01,WITHDRAWN,INTERVENTIONAL,['NA']
7994,NCT05160974,• Incidence (%) of SAEs in patients who are treated with Qtern,• Clinically significant results from urinalysis,,2021-12-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7995,NCT00549874,Myocardial blood flow regulation,biomarkers of oxidative/nitrosative stress,,2002-02,COMPLETED,INTERVENTIONAL,['NA']
7996,NCT02972528,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection,Assess the efficacy of allogenic Platelet Lysate injection by clinical examination,,2018-02-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7997,NCT03995498,Percentage of time of interstitial glucose concentrations spent between 4.0-10.0 mmol/L,Total number of confirmed hypoglycemia episodes requiring treatment,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
7998,NCT03314467,Presence of obstructive sleep apnea in diabetic patients is a predictive factor for diabetic retinopathy occurence,Correlation between severity of obstructive sleep apnea and presence of diabetic retinopathy,,2017-10-06,COMPLETED,OBSERVATIONAL,['NA']
7999,NCT03365349,Change from baseline IPQR (Illness Perception Questionnaire) score at 3 months,comparison of the two groups concerning answers to qualitative interviews at T 3 months after the intervention,,2012-02-01,COMPLETED,INTERVENTIONAL,['NA']
8000,NCT03664089,Weight loss,Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Lipid Panel,,2018-09-10,COMPLETED,INTERVENTIONAL,['NA']
8001,NCT06029517,Change in SSB intake for men affiliated with Native American athletic communities,Change in body weight,,2022-07-20,RECRUITING,INTERVENTIONAL,['NA']
8002,NCT01210664,Number of Participants Experiencing Severe or Life Threatening Laboratory Abnormalities,Hemoglobin A1c,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8003,NCT00540488,Adjusted area under the curve (adj-AUC) of glucose response,Adjusted peak for glucose and insulin response;peak time for glucose and insulin response; Adj-AUC for insulin response; change in glucose and insulin; subjective gastrointestinal tolerance,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8004,NCT01602718,change in short physical performance battery,change in inflammation,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
8005,NCT05033899,Quality of recovery after surgery (QoR40),serum markers of stress response: interleukin 6 ( IL-6),,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
8006,NCT02106039,Better diabetes control in diabetes patients with tuberculosis under treatment,Association between glycemic control and clinical-microbiological response to TB treatment,,2014-04-28,COMPLETED,INTERVENTIONAL,['NA']
8007,NCT03202680,Change in insulin sensitivity index (Si),Apo A1 measurements.,,2017-07-06,COMPLETED,INTERVENTIONAL,['NA']
8008,NCT00669630,Diet History Questionnaire; 7 - Day Physical Activity Recall,"Blood pressure; Total cholesterol, HDL, LDL, Triglycerides; Glucose level; Hemoglobin A1C (Diabetics only)",,2008-09,COMPLETED,INTERVENTIONAL,['NA']
8009,NCT04382521,Participant's mean ratings of message utility to measure acceptability of the text-message intervention,Change in physical function measured by 6-minute test,,2020-09-22,COMPLETED,INTERVENTIONAL,['NA']
8010,NCT00745914,Change in carotid plaque volume,"Change in inflammatory markers include C-reactive protein, interleukin-6, adiponectin, metalloproteinases",,2008-09,COMPLETED,INTERVENTIONAL,['NA']
8011,NCT01060605,"Evidence of insulin independence with adequate control of blood glucose (<140 mg/mL fasting; < 180 mg/mL post prandial, after the final infusion","renal and liver function, white blood cells count, total lymphocytes and lymphocytes subpopulations (CD24, CD19), hemoglobin, fibrinogen (FG), cross-linked fibrin degradation products, C-reactive protein (CRP)",,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3']
8012,NCT03547635,"The Number of Participants Meeting Criteria of Complete Wound Closure, as Assessed by the Investigator at or Before Week 12 of the Treatment Phase, Which is Confirmed Closed Two Weeks Later.",,,2018-05-03,COMPLETED,INTERVENTIONAL,['NA']
8013,NCT05527847,Change in blood glucose (hemoglobin A1C),Adherence to Refills and Medicines Scale for Diabetes (ARMS-D) Score,,2023-02-13,COMPLETED,INTERVENTIONAL,['NA']
8014,NCT01403025,The incidence of SADRs (Serious Adverse Drug Reactions),The incidence rate and type of ADRs (Adverse Drug Reactions),,2011-07-19,COMPLETED,OBSERVATIONAL,['NA']
8015,NCT04881123,A change of urine albumin-to-creatinine ratio (UACR) of > 30% from Baseline to Day 168,PK trough SER150 concentrations (pre-dose),,2021-08-18,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8016,NCT00497666,,,,2007-08,UNKNOWN,OBSERVATIONAL,['NA']
8017,NCT02037867,Liver and cardiovascular-related mortality,All-cause mortality,,2013-05,RECRUITING,OBSERVATIONAL,['NA']
8018,NCT02563457,Hemoglobin A1c blood level,,Quality of life,2009-02,COMPLETED,INTERVENTIONAL,['NA']
8019,NCT02826044,Cumulative excretion of SP2086,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
8020,NCT00504712,Change in Arterial Stiffness,Change in IMT,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8021,NCT00276367,,,,2006-10,WITHDRAWN,OBSERVATIONAL,['NA']
8022,NCT06270836,Proportion of eyes improving ≥2 steps on the ETDRS Diabetic Retinopathy Severity Scale (DRSS),Safety and Tolerability of KSI-301 5 mg compared to sham treatment,,2024-03-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8023,NCT02146404,Brain lactate concentration,Hormone response,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
8024,NCT03378908,Glycemic profile below pregnancy target capillary blood glucose concentration,Point-of-care glycated hemoglobin (HbA1c),,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
8025,NCT01717313,"Percentage of Participants Who Discontinued From the Study Drug Due to an Adverse Event (Phase A + Phase B, Excluding Data After Glycemic Rescue, Safety Population)","Change From Baseline in FPG at Week 54 (Phase A + Phase B, FAS Population)",,2012-12-05,COMPLETED,INTERVENTIONAL,['PHASE3']
8026,NCT02388113,glycosylated hemoglobin (HbA1c),,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
8027,NCT04943523,Grip strength,Erythrocyte fatty acid profile,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
8028,NCT05078658,Change in continuous glucose monitoring time in target range (3.9-10.0 mmol/l) during the LCD period compared to the RCD period,Differences in urine metabolome between the LCD and RCD periods,,2021-09-22,RECRUITING,INTERVENTIONAL,['NA']
8029,NCT03675074,Change in HbA1c,Change in weight,Improvement in metabolic comorbidities,2018-09-12,WITHDRAWN,INTERVENTIONAL,['NA']
8030,NCT02230618,Incidence of Adverse Events (AEs),The reason for initiating or intensifying treatment with Ryzodeg™,,2015-11-24,COMPLETED,OBSERVATIONAL,['NA']
8031,NCT00542399,Total daily basal and bolus insulin,documentation of hypoglycemic and hyperglycemic episodes,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8032,NCT05112445,OCTA metrics and predict progression to PDR and/ or CI- DME,,,2022-05-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8033,NCT04315519,Cardiorespiratory Fitness,The Strength of Hamstring Muscle,,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA']
8034,NCT03249896,Percentage of patients who have excessive gestational weight gain (EGWG),Neonatal intensive care unit admission,,2017-09-05,UNKNOWN,INTERVENTIONAL,['NA']
8035,NCT00598871,Number of Participants With Treatment Emergent Adverse Events (TEAEs) After Treatment With Thymosin Beta 4 in the Target Eye of Diabetic Patients During Vitrectomy,Number of Participants With Corneal Epithelial Wound Healing at Day 14 (End of Treatment),,2007-12,TERMINATED,INTERVENTIONAL,['PHASE2']
8036,NCT01052025,To examine the efficacy of curcumin on the delay of degenerative beta-cells in pancrease for protection of Type 2 Diabetes in patients with impaired glucose tolerance (Pre-diabetes),"To examine the efficacy of curcumin on the reduction of blood sugar level, lipid profile, insulin resistance status and oxidative stress status in Pre-diabetes patients",,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
8037,NCT05960604,"Difference of mean CCE, dP/dt, SVI, CPI, Ea at the 30th second of passive leg raising by hypertension and diabetes mellitus",Predictive factors of hypotension,Days out of hospital 30,2023-12-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8038,NCT02305784,Blood concentration of YKL-40 (ng/ml),Change of Blood concentration of YKL-40 (ng/ml) during an exacerbation,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
8039,NCT00704236,Glucose Disposal Rate,"Fasting Plasma Glucose,Postprandial Plasma Glucose,HbA1c,triglyceride,cholesterol,HDL-c and LDL-c,lipid levels ,body weight, blood pressure",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8040,NCT01238978,Percent of patients in each of the two treatment groups presenting no hypoglycemia (confirmed events with SMBG and severe episodes) after 24 wk of randomized therapy added to their ongoing metformin background therapy.,"Glycemic control assessed by A1C, and the mean of 6 Points self-monitoring of blood glucose (SMBG) at baseline and after 24 weeks.",,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8041,NCT04605497,Average time-in-range over a 24 hour period,Average time-in-range while asleep,,2021-02-11,RECRUITING,INTERVENTIONAL,['NA']
8042,NCT00119938,"Composite measure of diabetes self-care activities, developed from the Summary of Diabetes Self-Care Measure","Biological markers of diabetes care (hemoglobin A1c, blood pressure, LDL cholesterol)",,2004-09,COMPLETED,INTERVENTIONAL,['NA']
8043,NCT00506662,Change in Glycosylated Haemoglobin (HbA1c) at Month 7,"Mean Number of Total Hypoglycaemic Episodes, Months 5-7",,2007-07,TERMINATED,INTERVENTIONAL,['PHASE4']
8044,NCT02384148,Difference of period length,Difference of amplitude,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
8045,NCT05177250,Bisphenol A and paraben detection in urine samples of diabetic (n=50) and non diabetic persons (n=50),,,2022-02-20,RECRUITING,INTERVENTIONAL,['NA']
8046,NCT01652729,Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28,Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16 (Visit 8),,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8047,NCT01895569,Glycemic variability,Glyco-metabolic control,Insulin-resistance parameters,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
8048,NCT00395343,Change From Baseline in A1C at Week 24,Percent of Patients With A1C < 6.5% at Week 24,Change From Baseline in A1C at Week 24,2006-12-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8049,NCT02535299,physiological parameter:glycosylated hemoglobin A1c,physiological parameter:TNF-α,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
8050,NCT01724736,Change in the ratio of Bacteroidetes to Firmicuites ratio in the stool comparing the baseline value to the completion of study value.,Gastrointestinal Symptoms,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
8051,NCT04999124,Diabetes complications,haemoglobin A1c (%),,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
8052,NCT03925948,Change in Health literacy as assessed by the Newest Vital Sign,Change in Diabetes self-efficacy measured with Stanford Diabetes Self-Efficacy scale,Change in Quality of Life as assessed by the EuroQol Quality of Life scale,2015-05-06,COMPLETED,INTERVENTIONAL,['NA']
8053,NCT03723707,Percent of Patients Who Reach Consensus Target HBA1c,,,2018-12-03,COMPLETED,INTERVENTIONAL,['NA']
8054,NCT04928248,Change in hemoglobin A1c (HbA1c) levels,Change in body mass index (BMI) levels,Rate of use of the Disease Manager's diabetes module,2021-09-23,COMPLETED,INTERVENTIONAL,['NA']
8055,NCT05179954,Apolipoprotein C turnover rate,Apolipoprotein B-100 concentration,,2022-05-09,RECRUITING,INTERVENTIONAL,['NA']
8056,NCT02389114,Food intake,Physiological Outcomes,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
8057,NCT01714232,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) in the High Glucose Range (>180 mg/dL),,2012-10,COMPLETED,INTERVENTIONAL,['NA']
8058,NCT02342834,Plasma glucose response during the Oral Glucose Tolerance Test,Endothelial function assessed as the reactive hyperemia index by an EndoPAT device,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
8059,NCT01678183,Improvement in hemoglobin A1c,Improvement in blood pressure.,Lipid levels,2012-09,COMPLETED,INTERVENTIONAL,['NA']
8060,NCT00410436,Change in HbA1c,"serum C-reactive protein,",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8061,NCT03061851,The proportion of patients with HbA1c <7% after 48 weeks of maltose software intervention,The total score of Kessler's psychological distress scale after 48 weeks of intervention was higher than baseline.,,2017-01-25,UNKNOWN,INTERVENTIONAL,['NA']
8062,NCT03819153,"Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease",Number of severe hypoglycaemic episodes,,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8063,NCT02483949,Change from baseline to 6 months of moderate and vigorous physical activity (walking).,Change from baseline to 6 months in Low Glycemic Index foods.,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
8064,NCT01121471,change in plasma glucose AUC,change in body composition,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
8065,NCT01931644,Biospecimen & Clinical Data Collection,,,2013-07,RECRUITING,OBSERVATIONAL,['NA']
8066,NCT00596063,The primary objective is to test for bioequivalence based on AUC0-12h and Cmax between Wockhardt's Insulin Human Regular for injection and Novolin® R,"PK endpoints: AUC, tmax and t½ PD endpoints: AUC-GIR, GIRmax and tGIRmax Safety endpoints: AEs, haematology, biochemistry, urinalyses, physical examination, vital signs, ECGs, blood glucose and local tolerability.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8067,NCT01441986,Area under the blood glucose (BG) concentration-time profile,Adverse events,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8068,NCT02137174,HBA1C,Hypoglycemia rate,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8069,NCT01774942,Glycosylated hemoglobin (HbA1a),high-sensitivity C-reactive protein (hsCRP),Retention of implants,2008-06-01,COMPLETED,INTERVENTIONAL,['NA']
8070,NCT03056456,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Following Administration of Each Study Arm With a Standard Dual-wave Bolus,Glucodynamics (GD): Change From Baseline Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Glucose Relative to MMTT Following Administration of Each Study Arm With a Standard Dual-wave Bolus,,2017-02-23,COMPLETED,INTERVENTIONAL,['PHASE1']
8071,NCT01889810,Change in Insulin Resistance,Health Status,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
8072,NCT06177210,Establish a cohort of participants who achieved T2D remission through bariatric surgery,Qualitative interviews,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
8073,NCT01353833,Kinetic parameters of Treg proportions variation within CD4+ T cells in peripheral blood,Improvement of residual secretion of insulin assessed by the AUC of peptide C during a standardized test meal in IL-2 vs placebo treated patients,,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8074,NCT00001853,Diabetes and Heart Disease Risk,,,1998-10-21,RECRUITING,OBSERVATIONAL,['NA']
8075,NCT03903965,OCT Angiography parameters,aqueous humor cytokines levels,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
8076,NCT04800861,glycemic control,average per patient,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
8077,NCT01227473,"insulin resistance, as measured by the homeostatic model assessment-insulin resistance (HOMA-IR)",Insulin resistance as measured by the HOMA-IR,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8078,NCT02222350,change in 24-hour weighted mean blood glucose,change in postprandial plasma glucose level,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8079,NCT02914691,Change in Urinary Peptide Patterns (Proteomics),,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8080,NCT00960791,"Total recovery of radioactive dose, rate and routes of excretion of total radioactivity, metabolic pattern and metabolic profile, and PK variables of AZD1656 (AUC, Cmax, tmax, t1/2, Total Ae, CL/F and CLR)",Plasma Glucose,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8081,NCT05391659,AUC,false positives and false negatives,,2021-06-17,RECRUITING,INTERVENTIONAL,['NA']
8082,NCT00264901,Comparison of the change from baseline to end of treatment,Within-subject variation of before-breakfast SMPG values at Visit 2 and Visit 3,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8083,NCT04476693,Total trial area under the curve (AUC) for insulin.,Total trial area under the curve (AUC) for triaclyglycerol,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
8084,NCT01472588,Weight Loss,Physical Activity,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8085,NCT04383041,Summary of Diabetes Self-Care Activities for Diabetes and Kidney Disease (SDSCA) Score,DTSQ Participation rate,,2020-07-02,COMPLETED,OBSERVATIONAL,['NA']
8086,NCT01590836,Area under the glucose infusion rate curve during one dosing interval,Maximum observed serum insulin aspart concentration,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
8087,NCT05571800,Effect of mango consumption on glycemic control evaluated by HOMA-β,Effect of mango consumption on anthropometric measure WC/HC ratio,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
8088,NCT01691365,Oxidative damage,Antioxidant status,Infections,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8089,NCT03206294,Measurement of biological test glycosylated haemoglobin evolution between the entrance and discharge,,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
8090,NCT02490098,Mean day-and-night glucose levels,Total carbohydrate intake,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8091,NCT03404700,Difference of insulin levels compared between different test breakfasts,"Difference in total energy intake (kcal) compared between Remote Food Photography Method (RFPM), 7-day food record and 24-hour recall",,2018-05-22,COMPLETED,INTERVENTIONAL,['NA']
8092,NCT05059860,Time Control IQ system not in use,Hospital Anxiety and Depression questionnaire,Gold Hypoglycaemia questionnaire,2023-06-09,RECRUITING,OBSERVATIONAL,['NA']
8093,NCT00478972,Relative change from baseline in body weight,Safety: Overview of adverse events,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3']
8094,NCT00544921,A Dose-Ranging Study to Evaluate the Phamacokinetics and Safety of Six Single-Dose Levels of GLY-230 in Healthy Subjects,,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8095,NCT01067950,"The primary end-point is the 5-year evaluation of efficacy/failure rate, a composite end-point including: (i) patient mortality and (ii) renal function impairment",Secondary objectives are to evaluate and to compare the safety and the efficacy of the two treatments (IPT versus IIT).,,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
8096,NCT00953186,Ulcer healing,QoL,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8097,NCT01741480,ICU Transfer,Mortality,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
8098,NCT02949739,>7% reduction in weight,Reduction of ≥5 cm waist circumference,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
8099,NCT05733195,GDM（Pregnancies with gestational diabetes mellitus and no gestational diabetes）,,,2022-05-04,RECRUITING,OBSERVATIONAL,['NA']
8100,NCT01734785,HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment,Body Weight Change From Baseline After 24 Weeks of Double-blind Treatment,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8101,NCT02449460,all cause mortality,Cardiovascular mortality,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
8102,NCT00825383,glucose and lipid metabolism,"calcium isotope absorption in the gastrointestinal tract, stool mineral content, 24 h urinary mineral concentration, and serum chemistry including mineral concentration.",,1993-01,COMPLETED,INTERVENTIONAL,['NA']
8103,NCT02461511,glycated hemoglobin measure,hopitalization,,2015-03,WITHDRAWN,OBSERVATIONAL,['NA']
8104,NCT02550548,Beta cell sensitivity,,,2016-04-21,COMPLETED,INTERVENTIONAL,['PHASE1']
8105,NCT03702660,Glucagon,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
8106,NCT02402361,Risk factors and determinants for neuropathic pain,,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
8107,NCT02236481,Glycated Hemoglobin,Plasma levels of glucose,,2013-07,TERMINATED,INTERVENTIONAL,['PHASE4']
8108,NCT06287736,Change in PROMIS quality of life in relation to pain level,change in neuropathic symptoms using Michigan Neuropathy Screening instrument,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8109,NCT04168372,Rate of appearance of blood glucose from gluconeogenesis,Whole body fructose oxidation,,2019-09-15,RECRUITING,INTERVENTIONAL,['NA']
8110,NCT03241212,Change in knowledge about type 1 diabetes,Percent of text messages responded to in the study.,,2017-09-12,COMPLETED,INTERVENTIONAL,['NA']
8111,NCT01556594,Number of Participants With at Least One Adverse Event,Area Under the Curve (AUC0-last) of Baseline Adjusted Glucagon,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8112,NCT01677013,C-peptide,adverse event,,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8113,NCT00400283,To determine the safety and the tolerability of ascending multiple oral doses of NNC 55 0414 in patients with type 2 diabetes.,,,2001-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
8114,NCT05857943,Sensitivity and Specificity,,,2023-03-29,COMPLETED,INTERVENTIONAL,['NA']
8115,NCT04090840,Weight loss,Hemoglobin a1c,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
8116,NCT03908242,Plasma concentrations of salvianolic acid A,,,2019-04-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
8117,NCT01686139,Frequency of Adverse Events,,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
8118,NCT03840278,The Ratio of Cumulative Drug Doses Delivered to Cumulative Drug Doses Attempted for Insulin and Dasiglucagon,Mean Grams of Carbohydrate Per Day to Treat or Prevent Hypoglycemic Events (Reported Daily by Subjects),,2019-05-15,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8119,NCT01049412,Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles,Glycemic Variability in Fasting Blood Glucose (FBG) at Week 8 Endpoint,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8120,NCT05659537,Percentage of Participants with AEs and SAEs,Mean Change from Baseline in Hemoglobin A1c (HbA1c),,2022-12-29,COMPLETED,INTERVENTIONAL,['PHASE4']
8121,NCT00824603,We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program.,pre-CME training level of patient's A1c when starting insulin therapy compared to post-CME training level of patient's A1c when starting insulin therapy,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
8122,NCT02474381,Infrapopliteal arterial patency of the affected extremity,Amputation rate of the affected extremity,,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
8123,NCT00884819,Hepatic adiposity as assessed using MRI,"Reproductive parameters (androgens, hirsutism)",,2008-12,TERMINATED,INTERVENTIONAL,['NA']
8124,NCT04020445,"change in risk of hypoglycemia from baseline to 3, 6, 9 and 12 months",,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
8125,NCT03615807,Number of Participants Experiencing Clinical Failure,Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy,,2017-02-16,COMPLETED,INTERVENTIONAL,['NA']
8126,NCT04875858,Serotype-specific immunogenicity assessed by opsonophagocytic killing assay.,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2021-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8127,NCT00826904,Change in maternal postprandial lipemia,Correlation of neonatal adiposity and fetal growth,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
8128,NCT00629681,"Correlation between global status (as measured by the Clinical Global Impression of Change [CGIC] and the Patient Global Impression of Change [PGIC]) and changes in pain, anxiety, and sleep parameters",Course of mean pain score of patient's daily pain diary (NRS),,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8129,NCT01284608,Diabetes,Fracture Risk Assessment Tool (FRAx) assessment,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
8130,NCT01589029,Regression of retinal neovascularizations (NVE and NVD) in FA.,Change in HbA1c and inflammatory markers,,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1']
8131,NCT02827383,Continuous Glucose Monitor,Heart Rate,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
8132,NCT03479619,Volume (uL) of blood in the capillary tube,The intensity of pain perceived by the patient assessed with the use of the VAS (Visual Analog Scale).,,2018-03-06,COMPLETED,INTERVENTIONAL,['NA']
8133,NCT00871416,"Location of the injected sterile, atmospheric air",Cutis/subcutis thickness on 14 recommended injection sites,,1997-04-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8134,NCT05307237,Infection Rate,Electronic Medical Record (EMR) - Derived Outcome: fasting POC blood glucose,Process Indicators (Maintenance): Stakeholder and advisory board feedback,2022-04-19,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8135,NCT03068286,Anxiety (as measured by the 7 item Generalised Anxiety Disorder inventory),Patient Experience (As measured by the Patient Experience Questionnaire),,2017-01-01,TERMINATED,INTERVENTIONAL,['NA']
8136,NCT03002545,questionnaire SF-36,,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
8137,NCT00915954,Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml,"Median Bioactive IGF-1 Area Under the Curve in Response to Placebo, OGTT, and rhIGF1 Testing",,2008-12,COMPLETED,INTERVENTIONAL,['NA']
8138,NCT01697150,Percent time of active CTR,Frequency analysis of lost data caused by system components,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
8139,NCT05813496,To compare the relative change in NCS parameters between the study arms,To assess safety of Thiotacid® as per the nature and severity of the recorded adverse events.,,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4']
8140,NCT00754403,Change from randomization in Glycosylated Hemoglobin,Change from randomization in Creatine Phosphokinase,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
8141,NCT01828242,HbA1C,Fasting Blood Glucose,Iron status,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8142,NCT01779115,Prevalence rates of Diabetes,Number of visits to physician offices,,1998-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8143,NCT05560971,Insulin sensitivity M value change before and 8 weeks after POA vs placebo intake,"Serum; fasting glucose, insulin, LDL cholesterol, hsCRP, circulating inflammatory cytokines (TNF-a, IL-6), FABP4, glucagon",,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
8144,NCT03995238,Step Length Symmetry,World Health Organization Disability Assessment Scale 2.0,Socket Comfort Score,2019-10-09,RECRUITING,INTERVENTIONAL,['NA']
8145,NCT02197078,Number of Participants With Stroke,Number of Participants With Acute Renal Failure Requiring Dialysis,,2014-07-30,COMPLETED,OBSERVATIONAL,['NA']
8146,NCT02230891,Change in Cardiac Global Longitudinal Strain,Change in Troponin T Measured Using a High Sensitivity Assay,,2014-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8147,NCT06227819,Establish equivalence of BVA-200 to BVA-100,Usability,,2023-05-23,COMPLETED,OBSERVATIONAL,['NA']
8148,NCT01953757,Pain,Quality of life,Acceptability of vegan diet,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8149,NCT00312364,"Incidence of complete healing of target ulcer at endpoint or 90 days, whichever is earlier.","Incidence, intensity, and seriousness of adverse events. Changes in irritation scores.",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8150,NCT05464043,Retrospective study: characterization of hyperglycemia and diabetes after liver or kidney transplantation,Prospective: analysis of impaired glucose tolerance (prediabetes) and diabetes after liver or kidney transplantation,,2019-06-20,COMPLETED,INTERVENTIONAL,['NA']
8151,NCT02693938,Glucose Infusion Rate,,Glycemic variability,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
8152,NCT05251480,Impact of Treatment on Quality of Life (WoundQoL),Mean and median reduction in wound area at 12 weeks,,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8153,NCT03517527,Exercise Decisional Balance Scale,,,2015-10-25,COMPLETED,INTERVENTIONAL,['NA']
8154,NCT05451914,Change in Blood Glucose Control,Satisfaction/Usability of My Diabetes Care (for Intervention Group),,2023-07-06,RECRUITING,INTERVENTIONAL,['NA']
8155,NCT00367978,Time from baseline to the achievement of first treatment success (defined as achieving a blood pressure (BP) <130/80 mm Hg). The proportion and cumulative proportion of patients who achieved first treatment success were also determined.,change from baseline in estimated glomerular filtration rate (EGFR) at Week 24,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE4']
8156,NCT03505268,The impact of telehealthcare intervention on the change of the glycemic control in children with type 1 diabetes,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
8157,NCT03824379,Change of Human Serum Osteocalcin level,Quality of Life (QoL) Assessment: D-39 Questionnaire,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8158,NCT00681850,"HbA1c, LDL-cholesterol, Systolic Blood Pressure","Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice",,2008-03,COMPLETED,OBSERVATIONAL,['NA']
8159,NCT04839575,Symptom Severity Reduction,,,2021-04-06,TERMINATED,INTERVENTIONAL,['PHASE2']
8160,NCT01450943,Wound Closure by Week 15,Cost Effectiveness,,2011-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8161,NCT05478967,Incidence of VH,Changes of BCVA,,2019-08-08,COMPLETED,INTERVENTIONAL,['NA']
8162,NCT02921425,Systolic and Diastolic Blood Pressure,Change in Patient Activation,,2014-07-01,COMPLETED,INTERVENTIONAL,['NA']
8163,NCT04371978,Time to clinical change,"Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test.",,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE3']
8164,NCT02741050,Self-Report Changes in Physical Activity from Baseline to 6 Months,Self-Report Changes in Physical Activity from 6 Months to 12 Months,,2016-08,TERMINATED,INTERVENTIONAL,['NA']
8165,NCT06289933,Cmax,,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE1']
8166,NCT00642798,Pharmacokinetics of sitagliptin after administration of single and multiple 100-mg doses of sitagliptin to healthy chinese adult subjects.,,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8167,NCT04864860,postprandial blood insulin concentration,side effect of ecklonia cava,,2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8168,NCT06067139,2-hour post-load glucose (2hPG) (mg/dL),"Insulin resistance score (probability ranking, Calculated using the insulin and C-peptide concentrations converted to pmol/L)",,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
8169,NCT05276128,glucose tolerance,Appetite sensations,Cognitive test variable,2022-03-20,COMPLETED,INTERVENTIONAL,['NA']
8170,NCT02738151,Change From Baseline in HbA1c to Week 24,"Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period",Change From Baseline in Total Diabetes Treatment Satisfaction Questionnaire (DTSQ) Status at Week 12 and Week 24,2016-05-19,COMPLETED,INTERVENTIONAL,['PHASE4']
8171,NCT00844090,Change in HbA1c Over Baseline,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
8172,NCT04078308,Change from baseline number of hypoglycemic Unawareness episodes at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells,Changes from baseline serum cytokines levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells,,2015-07-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8173,NCT00135915,,,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
8174,NCT03098654,Retention in HIV care,Cost-effectiveness of integrating NCD screening and care with HIV screening and care,,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
8175,NCT00340093,,,,2002-08-23,COMPLETED,INTERVENTIONAL,['PHASE1']
8176,NCT06217302,eGFR at the end of the wash-out period following the treatment period,"Time to ≥40% eGFR decline from baseline, end-stage kidney disease, renal replacement therapy, or death from renal causes",Mean total daily insulin dose during the treatment period,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8177,NCT05377333,Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PK: Area Under the Concentration Versus Time Curve (AUC) of LY3457263,,2022-06-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8178,NCT04847856,"To compare the mean differences in the: Blood glucose level, BMI, Waist circumference between intervention and control groups","To compare the mean differences in the: HbA1C, Serum cholestrol, and blood pressure between intervention and control groups",To explore the knowlege and skills gained by nurse staff as a result of their participation in the trial intervention.,2020-03-30,COMPLETED,INTERVENTIONAL,['NA']
8179,NCT00251940,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"• Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3']
8180,NCT05573477,Hemoglobin A1c (HbA1c) (ATB-1011+ATB-1012 vs. ATB-1011),Changes in glycemic parameters,Extension period: Changes in MSDBP,2022-11-16,RECRUITING,INTERVENTIONAL,['PHASE3']
8181,NCT01366794,Release of gut hormones,Insulin secretion,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
8182,NCT00914706,Change in monitoring frequency,,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
8183,NCT02461914,Composite measure the plasma concentrations of warfarin,Incidence of adverse events and serious adverse events,,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8184,NCT03066089,Change in Postprandial sugar,"SGPT,SGOT,ALP,Creatinine,TLC,DLC & Hb",,2015-12-14,COMPLETED,INTERVENTIONAL,['PHASE4']
8185,NCT00885846,Fasting Blood Glucose,Fasting Cortisol,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
8186,NCT01772680,Oral glucose Tolerance Test,Fructosamine,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
8187,NCT03333525,Change Postprandial Glucose Concentrations,Postprandial insulin need,,2013-09-10,COMPLETED,INTERVENTIONAL,['NA']
8188,NCT04255264,Inflammatory status,,,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA']
8189,NCT01742741,Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.,Time spent in target range,Reliability of inter-device connections between DiAs and the CGM and between DiAs and the insulin pump.,2013-05,COMPLETED,INTERVENTIONAL,['NA']
8190,NCT03421301,intestinal microbiota,inflammatory profile,,2014-08-07,COMPLETED,INTERVENTIONAL,['NA']
8191,NCT00842192,HbA1c,Number of adverse drug reactions (ADR),,2009-04,COMPLETED,OBSERVATIONAL,['NA']
8192,NCT01106885,Participant cardiovascular risk index,Resource use,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
8193,NCT00578890,no osteomyelitis spreading and wound healing and no osteomyelitis relapse 12 months after wound healing,ulcer relapse 12 months after healing,,2008-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8194,NCT01067118,The primary endpoint for this third phase is daytime (6 am to midnight) average glucose values.is percent of CGMS glucose values in range (70-180 mg/dL) for the third week fo sensor data in each group.,,,2010-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8195,NCT01388153,Difference of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load without (Day 1) and with Glucobay (Day 2),Tmax of serum insulin following sucrose load without (Day 1) and with Glucobay (Day 2),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8196,NCT06313008,Troponin (ng/ml),FBG (mg/dl),,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
8197,NCT03001336,Diabetic retinopathy which is diagnosed by the measurement of fundus fluorescein angiography. (Diabetic retinopathy is clinically graded based on the international clinical diabetic retinopathy severity scales.),24h-albuminuria,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
8198,NCT01355536,The prevalence of Diabetes Mellitus,Serum levels of insulin,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
8199,NCT03652649,Type 2 diabetes remission,Hunger scale scores,,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA']
8200,NCT01629277,Primary efficacy outcome measure,Secondary efficacy outcome measure,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8201,NCT00229658,Annual Event Rate of Patient-Ascertained Severe Hypoglycemia (PASH) During the Adjustment Period,Change in Body Weight From Baseline at Month 6,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
8202,NCT01524705,Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline,Weight Change During Trial,HbA1C Levels,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8203,NCT03372005,Blood pressure,,,2017-09-12,UNKNOWN,INTERVENTIONAL,['NA']
8204,NCT03407118,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm,Glucodynamics (GD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp Following Administration of Each Treatment Arm,,2018-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8205,NCT05040087,β-CELL FUNCTION - PRIMARY OUTCOME #2c.,COST EFFECTIVENESS - to be explored only if additional (ancillary) funding can be obtained,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
8206,NCT00168519,glucose metabolism,,,2002-10,COMPLETED,INTERVENTIONAL,['NA']
8207,NCT05856149,Percent weight change three months post intervention,Program Evaluation - Program Satisfaction,,2023-04-19,RECRUITING,INTERVENTIONAL,['NA']
8208,NCT01002339,Primary Outcome Measure (Glucose Intolerance),Percentage of Patients Using Acetylsalicylic Acid (ASA),,2010-02,TERMINATED,INTERVENTIONAL,['PHASE4']
8209,NCT05333159,Major adverse cardiovascular and cerebrovascular events (MACCEs),Changes of plasma lipid parameters,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
8210,NCT01012037,HbA1c Change From Baseline at Week 12,The Occurrence of a Treat to Target Efficacy Response (HbA1c <6.5 %) After 12 Weeks of Treatment,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8211,NCT04159558,Satisfaction with the mobile application assessed by an ad hoc questionnaire,Treatment adherence assessed by Morisky Medication Adherence Scale (MMAS),Health goals compliance assessed by an ad hoc questionnaire,2018-04-24,UNKNOWN,INTERVENTIONAL,['NA']
8212,NCT04096313,Analytical verification of Allegro - Urine Albumin comparison,,,2020-03-25,COMPLETED,OBSERVATIONAL,['NA']
8213,NCT02198209,Liver glucokinase activity (chronic effect),Acute insulin response to glucose and the disposition index,,2019-12,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8214,NCT03936036,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
8215,NCT02804932,Change in skeletal muscle mitochondrial function,,,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
8216,NCT01068860,"Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.","Number of Participants Reporting Death, Serious Adverse Events (SAEs) and Adverse Events (AEs) Above 5% Frequency, From Baseline to 4 Weeks",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8217,NCT01159847,The effects of sitagliptin on β cell function and insulin sensitivity of LADA patients,The possible immunomodulatory effects of sitagliptin on LADA patients,,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8218,NCT06000371,"Dimensions of diabetic foot ulcer (manual measurement of length, width and depth of the ulcer by metal ruler).",,,2020-04-25,COMPLETED,OBSERVATIONAL,['NA']
8219,NCT04570527,Number of patient death during the follow up period,six-min walk distance (6MWD),,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
8220,NCT03751657,Change in HbA1c [Millimoles/Mole (mmol/Mol)],Change in Anti-insulin 287 Antibody Level,,2018-11-29,COMPLETED,INTERVENTIONAL,['PHASE2']
8221,NCT01986855,Percentage of Participants Who Discontinued Study Treatment Due to an AE,Percentage of Participants With A1C <7.0% (<53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to <60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach,,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8222,NCT04176731,Percentage of Time in Range 70-180 mg/dL During Overall (Days 1-14) and Standard Therapy Period (14 Days),"Total Daily Bolus Insulin (Units, Units/kg)",,2019-12-15,COMPLETED,INTERVENTIONAL,['NA']
8223,NCT00980941,Appetite,Palatability of treatments,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
8224,NCT03105011,Absolute change in laboratory-measured HgbA1C,,,2017-03-13,COMPLETED,INTERVENTIONAL,['NA']
8225,NCT03721991,insulin production,metabolic parameters quality of life,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
8226,NCT02356757,Ulcerative and non-ulcerative Foot lesions,Cost-effectiveness,,2015-08-24,COMPLETED,INTERVENTIONAL,['NA']
8227,NCT05734313,Depressive symptom severity,Hemoglobin A1c (HbA1c),Anxiety symptom severity,2023-10-31,RECRUITING,INTERVENTIONAL,['NA']
8228,NCT01108276,Overall decrease in wound size,,,2010-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8229,NCT00167778,Local Dynamic Stability (Ankle During Turning With the Prosthesis on the Outside of the Turn),How Bothersome Was Your Pain?,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
8230,NCT03970122,Urine PK parameters: CLR,,,2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE1']
8231,NCT05095610,HbA1c difference,Insulin dose,,2021-11-01,COMPLETED,OBSERVATIONAL,['NA']
8232,NCT04663061,Change in Body Weight,International Physical Activity Questionnaire (IPAC) short form: sitting time,,2021-06-09,RECRUITING,INTERVENTIONAL,['NA']
8233,NCT01328639,Change in Patient Health Questionnaire-9 items (PHQ-9) score,Change in Satisfaction with care,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
8234,NCT02320110,Correlation of irisin leves with risk factors for metabolic syndrome in Hispanic children,"Irisin plasma levels and adiponectin, leptin, insulin and resistin.",,2014-09,COMPLETED,OBSERVATIONAL,['NA']
8235,NCT05239572,"Uptake of health education (health promotion, awareness of risk factors)",Cost-effectiveness of NCD interventions,Impact of training of community health volunteers on their performance in NCD interventions.,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
8236,NCT02748018,SAP Cohort: Time in Hypoglycemic Range for subjects with baseline A1c ≤ 8%,SAP Cohort: Change in A1C for all subjects,,2017-05-25,RECRUITING,INTERVENTIONAL,['NA']
8237,NCT00231894,2 Hour Glucose From Glucose Tolerance Test US Sample,Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) China Site,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
8238,NCT04907760,Risk factors for type 2 diabetes in participants,program compliance,,2021-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8239,NCT03234946,Body Mass Index,Steps per day,,2017-06-19,UNKNOWN,INTERVENTIONAL,['NA']
8240,NCT00790257,Inflammatory/immunological reaction and insulin production,- Encapsulated human islets function and biocompatibility,,2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8241,NCT03977116,ventricular arrhythmias recurrence,hospitalization for heart failure worsening,,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8242,NCT01417845,Exercise Capacity,,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
8243,NCT03687827,"Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)",Mean Glucose Levels Using Flash Glucose Monitoring (FGM),,2018-10-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8244,NCT04181996,6 month change in FDG uptake TBR (Tissue to Blood Ratio) in the MDS (Maximum Disease Segment),Levels of Interleukin-6 (IL-6) (pg/ml) and its change.,Exploratory outcomes - the effect on quality of life outcomes,2020-08-01,RECRUITING,INTERVENTIONAL,['PHASE3']
8245,NCT05268393,Interventionist adherence to session manuals,Glycemic control,,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
8246,NCT00110240,Change from baseline in HbA1c at 24 weeks,Patients with endpoint HbA1c <7% after 24 weeks,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8247,NCT06246279,Reynolds Adjustment Screening Inventory for Adolescents,Glycemic Control - Hemoglobin A1C,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
8248,NCT01898702,Glycosylated hemoglobin A,Health services utilization,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
8249,NCT01660386,The acute phase and second phase of insulin secretion and C peptide secretion,"Alpha cell function,GLP-1 response",,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
8250,NCT00880139,Arteriolar to venous ratio,"Systolic/diastolic arterial blood pressure, pulse rate",,2009-06,TERMINATED,OBSERVATIONAL,['NA']
8251,NCT05965336,Biomechanical modulation of ankle stiffness,Changes induced by biofeedback in biomechanics during gait,,2024-05,RECRUITING,INTERVENTIONAL,['NA']
8252,NCT00005530,,,,1994-05,COMPLETED,OBSERVATIONAL,['NA']
8253,NCT04249102,To evaluate the change in baseline hypoglycemia after 8-week Continuous Glucose Monitoring system use,To evaluate the change in the quality of life of patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system.,,2020-03-12,UNKNOWN,INTERVENTIONAL,['NA']
8254,NCT01700868,hemoglobin A1C (diabetes management),24-Hour Multi-Pass Dietary Recalls,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
8255,NCT02283411,Safety of the Abbott Sensor Based Glucose Monitoring Systems Was Characterized by Adverse Device Effects and Serious Adverse Device Effects Experienced by Study Participants.,The Point Accuracy of the Device Performance Was Evaluated in Reference to Capillary Blood Glucose (BG).,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
8256,NCT02068885,"Total Energy Expenditure, Assessed by Indirect Calorimetry Using Stable Isotopes",Change in Self-reported Binge Eating Score,Effect Modification by Amylase Gene Copy Number,2014-08-17,COMPLETED,INTERVENTIONAL,['NA']
8257,NCT01005121,24 hr urine protein collection,,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
8258,NCT03566472,SDBG,,,2018-06-12,UNKNOWN,OBSERVATIONAL,['NA']
8259,NCT02352246,loss of abdominal fat mass (g),Change from baseline in food behavior after training (visual analog scale from Flint et al. 2000),,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
8260,NCT01934712,Area under the serum insulin aspart concentration-time curve,Area under the glucose infusion rate (GIR) curve,,2013-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
8261,NCT05275231,Acceptability: Changes in Satisfaction questionnaire,Changes in weight of participant's social contact,,2022-04-04,COMPLETED,INTERVENTIONAL,['NA']
8262,NCT00798785,Evidence of clinically relevant beta cell graft function,,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8263,NCT00231387,"The effect of 52 wks oral treatment with rosiglitazone in comparison to placebo on change from baseline of the plaque total wall volume in the carotid artery, in patients with type 2 dm and vascular disease/hypertension, using cardiac mri.","These include magnetic resonance endpoints related to plaque lipid content, volume, plaque size and fibrous cap thickness. Colour duplex measurements, laboratory assays for glycaemia and lipids.",,2002-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8264,NCT00301392,Cumulative incidence of diabetes based on 1 positive OGTT or fasting glucose levels,Number of adverse events,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8265,NCT02574195,Percentage of patients with diabetes mellitus type 1 and type 2diabetes mellitus complications,"Structure of antidiabetic therapy (% insulin, % OAD mono, % OAD dual, % OAD triple)",,2015-08,COMPLETED,OBSERVATIONAL,['NA']
8266,NCT00686283,exercise adherence,cardiorespiratory fitness,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8267,NCT00295828,Regression of iris neovascularization and prevention of development of neovascular glaucoma,Development of neovascular glaucoma.,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8268,NCT01123122,Islet cell function,,,2011-09,WITHDRAWN,INTERVENTIONAL,['NA']
8269,NCT04959487,Change in food insecurity severity from baseline to six months by study arm,Change in diabetes self-efficacy from baseline to six months by study arm,Durability in scores of food security from six to twelve months in the intervention arm.,2021-08-23,RECRUITING,INTERVENTIONAL,['NA']
8270,NCT04826159,Change in cardiac PCr/ATP ratio with dobutamine stress (Stage 1 only) measured by 31P-MRS at baseline and at EOT with 200 mg BID of IMB-1018972,"Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs",,2021-04-21,RECRUITING,INTERVENTIONAL,['PHASE2']
8271,NCT01013792,Percent Diabetic Foot Ulcer Area Reduction From Baseline to Last Treatment Visit,,,2009-11,TERMINATED,INTERVENTIONAL,['NA']
8272,NCT04030611,pulse examinatin,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
8273,NCT02522494,Resistance to Treatment Questionnaire (RTQ),Diabetes Self-Efficacy,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
8274,NCT01819129,Change From Baseline in HbA1c,Change From Baseline in Body Weight,,2013-09-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8275,NCT00145093,To determine the effect of Baker's yeast treatment on glycemicic control and insulin resistance when given in combination with oral blood glucose lowering therapy to patients with type 2 diabetes mellitus,"To determine the effect of Baker's yeast treatment on serum lipids, blood pressure, body fat percentage and BMI when given in combination with oral blood glucose lowering therapy to patients with type 2 diabetes mellitus",,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8276,NCT04373967,glycated hemoglobin (HbA1c),Percentage of participants with clinically significant change from baseline in laboratory parameters.,,2020-04-29,UNKNOWN,INTERVENTIONAL,['PHASE3']
8277,NCT05719740,"to test and evaluate the role of bone-derived factor (osteocrin) in glucose metabolism,in diabetic patients with risk of micro and macrovascular complications .","to identify bone-derived factor (osteocrin) may provide as new perspectives on the prediction, prevention, and treatment of diabetes mellitus",,2023-02,RECRUITING,OBSERVATIONAL,['NA']
8278,NCT05453344,Change in HbA1c,rtCGM measurements,,2022-08-10,RECRUITING,INTERVENTIONAL,['NA']
8279,NCT06117631,Determine how parent support coaching and other predictors relate to infant and toddler growth in Latino children in first 2 years of life.,,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
8280,NCT03641352,Change from baseline in Glycosylated Hemoglobin,Change from baseline in Apo-AⅠ,,2018-05-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
8281,NCT01029444,Evaluate the effectiveness of Pulsed IV Insulin Therapy on the stabilization of blood glucose levels on patients with brittle or uncontrolled diabetes,,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE3']
8282,NCT05225337,Change in percent body weight,Change in medication effect score (MES),,2022-02-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8283,NCT00044408,Reduction in neuropathic symptoms,"Vibration sensation;Neurological signs;Electrophysiology of peroneal, tibial and sural nerves;Relief of symptoms as measured by VAS;Composite scores of nerve function;Clinical global impression of change",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8284,NCT00222885,Triple tracer PET method development for in vivo imaging of skeletal muscle metabolism,Testing of mathematical modeling of PET data,,2002-12,COMPLETED,OBSERVATIONAL,['NA']
8285,NCT05105919,Incomplete platelet aggregation inhibition by aspirin at 7 days.,Platelet aggregation response to various agonists,,2021-08-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8286,NCT04419779,Demonstrate superiority of Revita DMR to sham in improving glycemic control,Demonstrate superiority of Revita DMR to sham in elimination of insulin use at 24 weeks,,2021-03-08,RECRUITING,INTERVENTIONAL,['NA']
8287,NCT04962399,rs1800796,,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
8288,NCT04322071,Thematic Analysis,,,2020-02-26,UNKNOWN,OBSERVATIONAL,['NA']
8289,NCT01964521,Changes in Signs and Symptoms of Local Infection,Levels of Pain in Connection to Dressing Changes.,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
8290,NCT00359996,hemoglobin A1c,Urine microalbumin levels,,2000-06,COMPLETED,INTERVENTIONAL,['NA']
8291,NCT06055036,Cardiovascular Health,"Identify the organizational context and resources necessary to align, coordinate, and sustain academic-community-government partnerships focused on advancing cardiovascular health equity.",,2023-08-24,RECRUITING,INTERVENTIONAL,['NA']
8292,NCT03207893,Medication changes,change in psychological functioning (attitude towards glucose monitoring questionnaire),,2018-07-19,COMPLETED,INTERVENTIONAL,['NA']
8293,NCT04203563,Change from Baseline in American Heart Association's Life's Simple 7 score at 12 Weeks,Change from Baseline Stress at 12 Weeks,,2019-08-20,COMPLETED,INTERVENTIONAL,['NA']
8294,NCT00626249,Differences in exposure to fumaryl diketopiperazine (FDKP),Additional safety parameters,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8295,NCT03920397,Glycemic control after an adipose tissue-derived stem/stromal cells,Oral cholecalciferol 2000UI/day supplementation,,2015-03-01,COMPLETED,INTERVENTIONAL,['NA']
8296,NCT04048642,Change in total daily insulin requirements,Change in urinary catecholamines,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
8297,NCT02371343,Birth size,Insulin like growth factor DNA methylation,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
8298,NCT00443755,Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR),Change From Baseline in the Inflammatory Biomarker Adiponectin,Change From Baseline in Fat-Free Mass (FFM),2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8299,NCT01600950,Pharmacodynamics: Duration of Action of LY2963016 and Lantus,Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2963016 and Lantus,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
8300,NCT05364476,Change of HbA1c after 16 weeks intervention,Change in EQ-5D-5L score,,2022-04-11,COMPLETED,INTERVENTIONAL,['NA']
8301,NCT02533453,Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs),"Evaluation of ""Subjective Improvement of Main Indication""",,2016-01-28,COMPLETED,INTERVENTIONAL,['PHASE4']
8302,NCT01809730,Transfusion within 48 hours post-op,,,2012-05,WITHDRAWN,OBSERVATIONAL,['NA']
8303,NCT02895113,Changes in renal function in diabetic patients treated with aspirin,Relationship between changes of Thromboxane B2 excretion and renal function in diabetic patients treated with aspirin,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
8304,NCT03976271,Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA,Oxidative stress responses using oxidative stress marker,,2019-08-12,COMPLETED,INTERVENTIONAL,['NA']
8305,NCT04853030,Time above range 180 mg/dl,Mean glucose,,2021-04-06,COMPLETED,INTERVENTIONAL,['NA']
8306,NCT02443532,HbA1c (between-group difference in variation from baseline),"Severe hypoglycemia (incidence of episodes of hypoglycemia requiring hospitalization and/or help from third parties, self-reported)",,2012-03,TERMINATED,INTERVENTIONAL,['NA']
8307,NCT01462266,Change From Baseline in Daily Insulin Dose at Week 24,Time to Achieve the Fasting Glucose Target,,2012-01-13,COMPLETED,INTERVENTIONAL,['PHASE3']
8308,NCT05357534,average running speed,,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8309,NCT04453605,Incidence of microvascular complication,Change of HbA1c through study completion (an average of 5 year),,2008-01-01,COMPLETED,OBSERVATIONAL,['NA']
8310,NCT00390975,Proportion of patients treated with tegaserod that improve gastric emptying at Week 2 as compared with baseline via a solid phase technetium gastric emptying time (GET),The safety and tolerability of tegaserod,,2007-01,TERMINATED,INTERVENTIONAL,['PHASE4']
8311,NCT00295334,"adherence, HbA1c, Glc","LDL, HDL, TG",,2006-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
8312,NCT02211235,The percentage of time spent > 140 mg/dl on CGM,The number of excursions > 200mg/dl in 24 hours for one week,Characterize the relationships between markers of glycemia,2014-08,COMPLETED,OBSERVATIONAL,['NA']
8313,NCT00388388,Effect of 6 months of losartan or hydrochlorothiazide on media/lumen ratio of gluteal subcutaneous resistance arteries in otherwise normal subjects who fulfill criteria for pre-hypertension and pre-diabetes,"Safety and tolerability of 6 month therapy with losartan or hydrochlorothiazide, and effect on media thickness, lumen diameter and vascular function of gluteal subcutaneous resistance arteries, and serum and tissue inflammatory markers in same subjects",,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2']
8314,NCT01415544,Calibrate near-infrared spectroscopy-based glucose meter,Compare Noninvasive to invasive techniques,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
8315,NCT00398619,"Assessment of ECGs, laboratory results and physical exams for adverse events",,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8316,NCT01450787,Conjunctival Staining Score,Tear Film Osmolarity,Corneal Staining,2012-01,TERMINATED,OBSERVATIONAL,['NA']
8317,NCT02460354,Change in mean urine osmolality,Change in mean urine volume,,2015-09,TERMINATED,INTERVENTIONAL,['PHASE1']
8318,NCT00456352,Treatment success based on patients' glycemic control.,"Physiologic measurements, Comorbidity improvement, Improvement in QOL.",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8319,NCT06107816,Evaluate the impact of a F&V Rx on DSME/S retention in low-income adults.,Evaluate the impact of a F&V Rx on Food insecurity,Assess program implementation outcomes - Clinic/providers/staff - Implementation Outcomes Questionnaire (IOQ),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8320,NCT02871882,Change in Postprandial Glucose,,,2016-09-15,COMPLETED,INTERVENTIONAL,['PHASE2']
8321,NCT02263352,Change in Serum MDA,Change in Clinical attachment level (CAL),,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8322,NCT05743244,The area under the stimulated C-peptide curve (Y_AUC),,,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
8323,NCT03865914,change in eGFR and urine protein from baseline,,,2017-11-30,RECRUITING,OBSERVATIONAL,['NA']
8324,NCT01413204,Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value),"Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events, Laboratory Tests, 12-lead ECG and Vital Signs",,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8325,NCT04417270,Comparison of values between two devices,,,2020-06-12,COMPLETED,INTERVENTIONAL,['NA']
8326,NCT03598855,Changes in vascular function,Change cerebrovascular function,Change in insulin sensitivity,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
8327,NCT02933788,platelet reactivity testing,"Observation of Clinical laboratory data(total cholesterol, HDL, LDL and triglyceride",,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
8328,NCT02231658,Change from baseline (week -1) in the number of reflux episodes,Change from baseline (week -1) in the time of pH < 4.0 in the lower third of the oesophagus,,2015-07-16,TERMINATED,INTERVENTIONAL,['PHASE1']
8329,NCT01359241,Percent of plasma glucose values within target range 3.9-8.0 mmol/l,Frequency of hyperglycaemia,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
8330,NCT03504605,Self-compassion items,,Pediatric Inventory for Parents,2018-08-15,COMPLETED,INTERVENTIONAL,['NA']
8331,NCT00838799,Change in mean daily pain rating,50% reduction in pain,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8332,NCT02377531,Composite Perinatal morbidity,Maternal weight gain,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
8333,NCT01531569,"Terminal phase half-life of secoisolariciresinol, enterodiol and enterolactone.",Inflammatory markers,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8334,NCT05263011,"Changes in plasma tumor necrosis factor (TNF)-alpha, concentration",,,2022-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8335,NCT05331469,Hba1c reduction,Weight changes after intervention,,2021-07-19,UNKNOWN,INTERVENTIONAL,['PHASE4']
8336,NCT02559128,Exercise capacity,Endothelial function,,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
8337,NCT00292994,Metabolic Syndrome Score,,,2004-04,UNKNOWN,INTERVENTIONAL,['NA']
8338,NCT00681161,"blood glucose level, composite autonomic system score (CASS), homeostasis assessment model (HOMA), insulin sensitivity index (ISI)",,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
8339,NCT06190158,The magnitude of non-suppressible and renin-independent aldosterone production.,,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8340,NCT02563522,Proportion of Subjects With a Target Wound Closure by the 4-month Follow-up Visit,,,2017-06-27,TERMINATED,INTERVENTIONAL,['PHASE3']
8341,NCT06069076,Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.,correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.,,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8342,NCT00973401,"Changes in amplitude/implicit times, retinal vessel diameter, dark adaptation and OCT",,,2009-09,UNKNOWN,OBSERVATIONAL,['NA']
8343,NCT06033664,Number of participants with a percentage change in Hemoglobin A1C (HbgA1C),Change in food insecurity,,2023-11-06,RECRUITING,INTERVENTIONAL,['NA']
8344,NCT02559843,total antioxidant capacity,fasting blood glucose,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8345,NCT01777282,Number of Participants With Any Hypoglycemic Event,Time to Study Withdrawal Due to Hyperglycemia,,2013-02-23,COMPLETED,INTERVENTIONAL,['PHASE3']
8346,NCT01492283,The Incretin effect,Plasma glucagon response,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
8347,NCT01635062,The Change in Circulating RAS Activity After Calcitriol/Placebo Therapy,Change in Urine Protein After Calcitriol/Placebo Therapy,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
8348,NCT05431686,"Perceived benefit of the SMA intervention content, as measured by user satisfaction surveys summary statistics (mean and standard deviation as well as percent answering a specific Likert level)",CGM Benefits and Burdens scale,,2022-02-16,RECRUITING,INTERVENTIONAL,['NA']
8349,NCT06290947,Improvement in Aerobic Capacity,Change in Body Mass Index (BMI),,2022-03-06,COMPLETED,INTERVENTIONAL,['NA']
8350,NCT03037255,Number of patients who died from any cause by the end of the study censoring period,Number of patients who received guideline recommended therapy during the study period,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
8351,NCT03208309,Cholesterol,,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8352,NCT00704197,To assess sex differences in adipose tissue gene expression in different fat depots,To assess sex differences in other characteristics of adipose tissue structure and function in different fat depots across sex including: preadipocyte kinetics; lipolysis and lipogenesis; macrophage content; and tissue oxygenation,,2007-08,TERMINATED,OBSERVATIONAL,['NA']
8353,NCT01785108,"Change in C-peptide (90 minute value and AUC mean 0-120 min) during a Mixed Meal Tolerance Test from baseline to month 6, 15 and 30","Fasting C-peptide, change between baseline and month 6, 15 and 30",,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8354,NCT04498819,Feasibility: Adherence,Participant Attitudes: Diabetes Emotional Distress,,2020-11-09,COMPLETED,INTERVENTIONAL,['NA']
8355,NCT00157482,"LDL-cholesterol, at 16 weeks of treatment. LDL-cholesterol is measured at -4, 0, 8, 12 and 16 weeks.","Urinary albumin excretion, at -4, 0, 8 and 16 weeks",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8356,NCT00625833,Change from baseline in weekly average pain score,Modified Brief Pain Inventory-Short Form,,2007-12,TERMINATED,INTERVENTIONAL,['PHASE2']
8357,NCT02839031,Glycated hemoglobin (HbA1c) level,,,2015-03-11,TERMINATED,INTERVENTIONAL,['NA']
8358,NCT00588172,Change in glucose area under the curve after a mixed meal in response to metformin,Change in glucose disappearance and suppression of endogenous glucose production in response to metformin,,2010-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8359,NCT03388723,Epigenetic signatures in the cord blood of the offspring of GDM mothers.,Qualitative and quantitative comparison of epigenetic signatures in the offspring of GDM mothers [Indian and Danish cohort].,,2014-09-02,COMPLETED,OBSERVATIONAL,['NA']
8360,NCT00448526,time to the doubling of sCr,% change of urinary albumin and protein excretion from baseline,,1997-12,TERMINATED,INTERVENTIONAL,['NA']
8361,NCT03954834,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide,,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8362,NCT02417935,Change From Baseline to 12 Weeks in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point Numeric Rating Scale (NRS),Number of Participants With a 30% and 50% Reduction in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point NRS at 12 Weeks,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8363,NCT00592904,Mean Change From Baseline in SF-MPQ Current Pain Intensity (CPI): From Baseline to Week 48,Mean Change From Baseline in Short Form 36 Item (SF-36) Health Survey: Physical and Mental Component Scores From Baseline to Week 48/EOT,,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8364,NCT03428295,Percentage of time in severe hyperglycemic range,,,2017-06-22,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8365,NCT01182480,Patient Engagement,Glycemic Control,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
8366,NCT00031226,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
8367,NCT05367063,Change in myocardial micro-perfusion,Change in resting mocardial blood flow,,2022-01-05,RECRUITING,INTERVENTIONAL,['PHASE4']
8368,NCT05960656,Ketone Body Turnover (ketogenesis) during Study 2,Plasma Free Fatty Acids (FFS) Study 2,,2023-10-05,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8369,NCT00147719,To assess the additional lowering of HbA1C achieved by addition of colesevelam hydrochloride to current antidiabetic therapy,To assess the safety and tolerability of colesevelam hydrochloride when added on to current therapy,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
8370,NCT02988427,Diabetes Self-efficacy,Clinical Outcomes,,2016-12,WITHDRAWN,OBSERVATIONAL,['NA']
8371,NCT04013919,Glucose levels,,,2019-09-20,UNKNOWN,OBSERVATIONAL,['NA']
8372,NCT00676208,Change in Confidence in Ability to Perform Teamwork,Change in Professionals' Attitudes About Diabetes,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
8373,NCT03090451,Non-insulin mediated glucose uptake (NIMGU),Time spent in hyperglycemia,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
8374,NCT06094491,A1c,Low density lipoproteins,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8375,NCT00511472,Number of Participants Who Experienced an Adverse Event During the Study,Number of Participants Who Experienced an Adverse Event During the Outpatient Treatment Period,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8376,NCT03602963,Accuracy of the Dexcom G5 mobile continuous glucose monitoring (CGM) system by comparison of sensor glucose measurements with capillary blood glucose determinations,Patients' and parents' satisfaction with the Dexcom G5 mobile CGM system will be evaluated by a standardized questionnaire,,2018-07-09,COMPLETED,OBSERVATIONAL,['NA']
8377,NCT01630369,Decrease of Hb A1c ≥ 1%,Assessment of efficacy of education courses in Diabetes Schools,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8378,NCT02214719,Glucose control - A1c,Long term use,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
8379,NCT01881009,Target Sensor Glucose 70-150 mg/dl,Target Sensor Glucose 70-180 mg/dl,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
8380,NCT06314048,Diabetes distress measured at baseline and 12 months post-diagnosis.,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8381,NCT02266576,Change From Baseline in the Quality of Life Short Form Survey (SF-12),Change in From Baseline in Empowerment,Lipid Bioassays,2015-06,COMPLETED,INTERVENTIONAL,['NA']
8382,NCT00233259,Hemoglobin A1c,Social support,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
8383,NCT05291013,Muscular insulin sensitivity,Metabolomics,,2022-07-01,UNKNOWN,INTERVENTIONAL,['NA']
8384,NCT03426345,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,,2018-02-16,TERMINATED,INTERVENTIONAL,['PHASE3']
8385,NCT01546766,Pupillary response,Pupillary response.,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
8386,NCT03934593,The change in HbA1c,Occupational physical activity,Spiritual coping,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
8387,NCT00730561,Change in nerve conduction velocity,,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
8388,NCT02245399,change in HbA1c,urinary analyses,Estradiol level,2014-10,COMPLETED,INTERVENTIONAL,['NA']
8389,NCT02704494,Serum creatinin,Number of patients with adverse events,,2016-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8390,NCT01422057,Major cardiovascular event,Total mortality,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
8391,NCT01834144,"Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.","Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.",,2013-05,TERMINATED,INTERVENTIONAL,['NA']
8392,NCT00663260,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF],Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF]),,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8393,NCT06114186,percentage of time with severe hyperglycemia,,,2024-01-16,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8394,NCT00481897,"Assignment to the diet intervention, decreases the prevalence of work absenteeism, as measured by the proportion of days that a participant is absent from work, compared with assignment to a control group.",Assignment to the diet intervention program promotes adherence and acceptability.,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
8395,NCT06035406,PK parameters：AUC0-∞；,Incidence and severity of adverse events (AEs),,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
8396,NCT02927678,"Rate of remission of osteomyelitis at one year after the cessation of antibiotic treatment, evaluated by white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography).",Negative predictive value of White Blood Cell SPECT/CT performed at the end of antibiotic treatment to predict the remission of osteomyelitis at one year.,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
8397,NCT00539890,Mean change in HbA1c from baseline to treatment week 24,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8398,NCT02197299,Skeletal muscle total carnitine content,,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
8399,NCT00808431,"Growth trajectories (using BMI, waist circumference), body composition","Physical activity accelerometry change over time, parental self-efficacy, child feeding questionnaire (parental food habits), identification of medical home",,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8400,NCT01940302,Metabolic Control,,,2013-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8401,NCT06011356,Step count,Patient Activation Measure (PAM),,2023-08-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8402,NCT02545049,"The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.","The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death",,2015-09-17,COMPLETED,INTERVENTIONAL,['PHASE3']
8403,NCT02100475,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment-emergent Confirmed Hypoglycaemic Episodes,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8404,NCT01455415,Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period),PGIC Score at the End of Period 1 (Week 6) - Categorized Scores,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8405,NCT04325347,Change in number of awakenings during the night between experimental and control intervention.,"Nature, severity and impact of insomnia",,2021-01-27,UNKNOWN,INTERVENTIONAL,['NA']
8406,NCT02665689,Difference of Best Corrected Visual Acuity Measured in ETDRS Letters Score Between Month 12 Baseline Visit,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,,2016-01-18,TERMINATED,INTERVENTIONAL,['PHASE4']
8407,NCT04084886,Number of patients with genotype TCF7L2 by PCR,,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
8408,NCT01527656,"Cmax, maximum insulin aspart concentration",Incidence of hypoglycaemic events,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8409,NCT00360061,HBA1c,Modified Health Care Climate Questionnaire (at baseline only).,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
8410,NCT01319331,To assess participant safety & feasibility of study drug administration,Assess the effects of AAT on glycemic variability and A1c.,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8411,NCT06066944,Measure the intensity of neuropathy induced pain,,,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8412,NCT03336528,Mean Daily Blood Glucose Concentration in Discharged Patients.,Number of Episodes of Severe Hyperglycemia in Discharged Patients,Number of Participants Experiencing Acute Kidney Injury in Discharged Patients,2018-01-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8413,NCT03651908,Radiographic parameters - Change in bone level,clinical parameters - Changes in relative clinical attachment level,,2017-09-05,COMPLETED,INTERVENTIONAL,['NA']
8414,NCT01215903,Plasma and serum inflammatory markers,Fatty acids of phospholipids in skeletal muscle,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8415,NCT04931537,Urinary Albumin Creatinine Ratio，UACR,,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
8416,NCT00141401,Safety Efficacy,,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8417,NCT02441504,Change in Cutaneous Capillary Density in twelve weeks of aerobic physical activity,,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8418,NCT01298518,Change From Baseline in Post-Prandial Glucose Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28,Area Under the Concentration-Time Curve AUC (0-24) of PF-04620110,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8419,NCT02545738,Change in albuminuria,24h heart rate,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8420,NCT03914183,The percentage of participants in the mCPN group who demonstrate an improvement (vs baseline performance) in the recommended site rotation techniques relative to the proportion of that in the control group.,the percentage of participating patients who decide to continue using mCPN upon study completion,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
8421,NCT06159543,8-iso-PGF2 alpha,Lean body mass,,2024-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8422,NCT01264523,Fat-free mass,Satiety assessment,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
8423,NCT01165268,The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin,"Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin",,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8424,NCT05829811,Detection of neurological disorders,Analysing of potential precipitating factors for DFU,,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8425,NCT00624767,To evaluate the effect on postprandial glycemic control of intranasal insulin compared to NovoLog,To evaluate the pharmacokinetics of intranasal insulin compared to NovoLog,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8426,NCT02360878,Change in postprandial glucagon-like peptide-1 (GLP-1) secretion from baseline 3 weeks after explantation,Change in postprandial glucosedependent insulinotropic peptide (GIP) from baseline 3 weeks after explantation,Change in caloric intake as measured by ad libitum meal test 3 weeks after explantation,2013-02,COMPLETED,OBSERVATIONAL,['NA']
8427,NCT05408936,NT-proBNP,,,2022-06-03,RECRUITING,OBSERVATIONAL,['NA']
8428,NCT02686996,Change in insulin sensitivity measured by euglycaemic glucose clamp,Change in Resting systolic and diastolic blood pressure,Change in Other Tissue Analyses,2017-02-13,UNKNOWN,INTERVENTIONAL,['NA']
8429,NCT00446277,central corneal thickness,intraocular pressure,,2007-01,SUSPENDED,OBSERVATIONAL,['NA']
8430,NCT04560062,Proportion of patients with access to health care of diabetes,Proportion of patients with at least one disease complication,,2020-10-13,UNKNOWN,OBSERVATIONAL,['NA']
8431,NCT02661581,Glycemic Control measured by HbA1c,"Weight measured on a high quality, calibrated digital scale, with the participant wearing clothes, but no shoes",,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
8432,NCT05491850,Effect of moderate physical activity on early symptoms of peripheral diabetic neuropathy in type-II diabetes,,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
8433,NCT01626469,Change in ophthalmic artery blood flow from baseline,Change in renal plasma flow (RPF) from baseline,,2012-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8434,NCT01518205,Proportion of subjects obtaining the ulcer healing (Class 0A according to TEXAS classification) after 12 month from the study starts.,proportion of subjects with major amputation (these are usually below the knee or above the knee)- in agreement with the approved amendment,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
8435,NCT00840541,CSME,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
8436,NCT00536250,hepatic fat content and abdominal fat ratio,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
8437,NCT00044668,"Change in concentrations of fasting plasma glucose and lipids from Baseline Visit 2 (Day 1) to Week 24, to Week 52, and to each intermediate visit",,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8438,NCT04492566,Time in Target Glucose Range,Mean CGM Glucose Level,Fetal Outcomes: Neonatal Intensive Care Unit Admission,2020-07-27,COMPLETED,INTERVENTIONAL,['NA']
8439,NCT04616014,Number of Participants With Treatment-related Adverse Events.,Change From Screening in Liver Steatosis,,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8440,NCT03045250,Normative values for corneal confocal microscopy (CCM),Serum biomarkers - fibrinogen,,2018-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
8441,NCT01006291,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8442,NCT00272090,severe nocturnal hypoglycemias will be measured throughout the study period.,severe hypoglycemias and nocturnal hypoglycemias will be measured throughout the study period.,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8443,NCT02175459,"Change from baseline in metabolic status (normal glucose tolerance, impaired glucose tolerance, diabetes)","islet cell areas (beta, Alpha and delta cell positive area)",change in gene expression analysis among different groups of baseline metabolic status,2010-08,RECRUITING,OBSERVATIONAL,['NA']
8444,NCT02606747,Foot sole tactile threshold,,,2015-03,UNKNOWN,OBSERVATIONAL,['NA']
8445,NCT00182494,3. Impact on incidence of diabetes,3. Sustained changes in eating & activity patterns,,2005-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
8446,NCT00356421,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Percent (%),Change in Fasting Lipids From Baseline,Subject Reported Quality of Life From Baseline as Determined From Phase V System Measurement,2006-11,TERMINATED,INTERVENTIONAL,['PHASE4']
8447,NCT01369069,Number of Participants With Severe Hypoglycemia (Blood Glucose < 40mg/dL),Stroke Specific Quality of Life (SSQOL),Death,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8448,NCT01863667,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in Body Weight at Week 54,,2013-07-08,TERMINATED,INTERVENTIONAL,['PHASE3']
8449,NCT00179127,Time of Acidosis Correction,Total Hospital Stay,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
8450,NCT02742233,Completely healing time of the participants'target ulcer during the treatment period.,Proportion of participants with complete healing during the treatment period.,New ulcers,2015-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
8451,NCT02798250,Percentage of time below 4.0 mmol/L,Total glucagon delivery,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8452,NCT05565651,Outcome percentage Phyla,,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
8453,NCT02875821,changes in visceral fat area,Changes in liver fat,,2016-04-26,COMPLETED,INTERVENTIONAL,['PHASE4']
8454,NCT02018809,Statin Adherence,Morisky Medication Adherence Scale (MMAS),,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8455,NCT02763267,Insulin secretory response,Change in insulin secretory response,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
8456,NCT05525117,HbA1c,Proportion of patients achieving a reduction in HbA1c,systolic blood pressure,2023-07-04,RECRUITING,INTERVENTIONAL,['NA']
8457,NCT04190251,Medication adherence (longitudinal data),Patients' satisfaction,,2016-04-14,COMPLETED,INTERVENTIONAL,['NA']
8458,NCT05695651,Investigate the association between TyG index and HOMA IR with the risk of macrovascular and microvascular complications of type 2 diabetes,Percentage of diabetic patients who developed vascular complications.,,2023-02-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8459,NCT01879137,Discriminative value of copeptin after arginine infusion in the differential diagnosis of polyuria-polydipsia syndrome.,,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
8460,NCT04328181,quality of the images,Statistical comparison between SPCCT and DECT,,2021-01-29,RECRUITING,INTERVENTIONAL,['NA']
8461,NCT06283394,Percentage of food purchasing expenditures spent on eligible healthy foods,Qualitative results,,2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8462,NCT01785043,Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin.,The evaluation of other emerging potential cardiovascular risk factors,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8463,NCT01736059,Incidence and severity of ocular adverse events,The number of stem cells isolated and injected into the study eye,Incidence and severity of systemic adverse events,2012-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8464,NCT02796170,Change in Blood Pressure From Baseline to 6 Weeks Measured by ABPM,Change in Urinary AGT Levels From Baseline to 6 Weeks,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8465,NCT02025673,"Serum levels of betatrophin in type 2 diabetes patients, gestational diabetes patients and pregnant women",Correlation of betatrophin concentration with other variables,,2013-08,UNKNOWN,OBSERVATIONAL,['NA']
8466,NCT06273761,Medication adherence,Beliefs in medicines,,2024-02-06,RECRUITING,INTERVENTIONAL,['NA']
8467,NCT01911104,Change in ATPmax,Change in in vivo and in vitro mitochondrial function,Promoter methylation,2013-10-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8468,NCT00781001,Spontaneous Pain Score,Adverse events,,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8469,NCT04818242,Time in Range (TIR) Between 70-180 mg/dL,Number of Participants With Problems With Sensor Insertion,,2021-04-19,COMPLETED,INTERVENTIONAL,['NA']
8470,NCT03566693,Phase 2: Change in CGM time in target range,Phase 2: Change in CGM time-hypoglycemic,Phase 1 and Phase 2: Safety Events - Other adverse events,2018-07-30,COMPLETED,INTERVENTIONAL,['NA']
8471,NCT01382303,Percentage Change in Proteinuia,Mean Change of TNF-a,,2010-10-25,COMPLETED,INTERVENTIONAL,['PHASE4']
8472,NCT00566215,Improvement or reversal of type 2 diabetes mellitus,Improvement of insulin sensitivity as measured by insulin tolerance test.,,2007-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8473,NCT00624013,HbA1C (%),Quality of Life,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8474,NCT02701894,HbA1c,HOMA- IR,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
8475,NCT03827434,Change in mortality among participants who are managed with Continuous Glucose Monitoring Devices and Clarity versus participants who are managed with Point of Care glucose testing (standard of care),,,2018-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
8476,NCT03297931,Food intake,,,2017-07-19,UNKNOWN,INTERVENTIONAL,['NA']
8477,NCT05483972,Change in Adult and Offspring Waist Measurements,,,2022-10-04,COMPLETED,INTERVENTIONAL,['NA']
8478,NCT04856670,Aqueous humor concentrations of inflammatory mediators at the onset of manual cataract surgery and following femtosecond laser treatment,Prevalence and severity of postoperative flare,,2021-05-25,UNKNOWN,OBSERVATIONAL,['NA']
8479,NCT03511898,Incidence of dose-limiting toxicities up to the Day 14 visit,Occurrence of laboratory abnormalities up to the end of the study,,2018-05-18,COMPLETED,INTERVENTIONAL,['PHASE1']
8480,NCT00116792,In-stent and In-segment late lumen loss,(There are 3 more secondary endpoints not listed here.),,2004-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8481,NCT06313138,Symptom burden,Health literacy,,2023-07-15,COMPLETED,INTERVENTIONAL,['NA']
8482,NCT03521934,"Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)",Change From Baseline in Estimated Glomerular Filtration Rate (eGFR),,2018-06-15,TERMINATED,INTERVENTIONAL,['PHASE3']
8483,NCT05867797,prognosis risk factors and outcomes of AKI in patients with DKA,,,2023-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8484,NCT04819815,Chronotropic index,Life Quality,,2020-01-20,COMPLETED,OBSERVATIONAL,['NA']
8485,NCT05025852,Body Mass Index (BMI) z-score,Neurocognitive development,,2022-05-11,RECRUITING,OBSERVATIONAL,['NA']
8486,NCT04856800,Maternal glycemic variability (GV),Weight of placenta,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
8487,NCT01944904,The Effects of Xyloologosarcharide (XOS) on colonic flora in volunteers with abnormal glucose levels,The Effects of Xyloologosarcharide (XOS) on glucose and insulin,The effects of Xylooligosaccharide (XOS) on body weight and body composition,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8488,NCT00209170,"Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week 24",,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4']
8489,NCT00330954,,,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
8490,NCT01712061,Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12,"Summary of Plasma PF-04634817 Pharmacokinetic (PK) Concentrations at Day 1 and Weeks 1, 4, 8 and 12",Number of Participants With Increased Fasting Blood Glucose,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8491,NCT00539175,pain intensity,"Semmes-Weinstein sensation, proprioception, quality of life",,2004-10,COMPLETED,INTERVENTIONAL,['NA']
8492,NCT01427920,Change in HbA1c (Glycosylated Haemoglobin) - PP,Patient Reported Outcomes Evaluated: Treatment-Related Impact Measures for Diabetes (TRIM-D) - Total Score,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8493,NCT04464694,Early postoperative vitreous haemorrhage,Mean Best-corrected visual acuity (BCVA) at Month 6,,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8494,NCT00945165,Hyperglycemia,Mean Blood Glucose,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
8495,NCT05707481,Change in Health related Quality of Life,"Change in Patients health related Knowledge, Attitude and Practice",,2023-08-22,RECRUITING,INTERVENTIONAL,['NA']
8496,NCT03109587,Change in microbiota composition,Change in inflammation in the gut,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
8497,NCT02006836,AUCs With/Without Pomelo,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
8498,NCT00253240,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
8499,NCT05917249,Change of the perfusion index at the end of the first session compared to baseline readings.,The total remission rate,,2023-06-07,COMPLETED,INTERVENTIONAL,['NA']
8500,NCT03184337,Change in body mass index,Change in self-assessed general health,,2017-04-24,COMPLETED,INTERVENTIONAL,['NA']
8501,NCT03956927,Organizational advantages and limitations,,,2019-05-24,COMPLETED,OBSERVATIONAL,['NA']
8502,NCT05326490,Change in HbA1c,,,2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8503,NCT01343056,"Hemoglobin A1C (HbA1C, %)",Systolic Blood Pressure,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
8504,NCT04917458,Evaluating the effects of cholecalciferol for depression symptoms with BDI II score,Evaluating the effects of cholecalciferol against C-Peptide,,2021-01-18,UNKNOWN,INTERVENTIONAL,['PHASE2']
8505,NCT04102202,To evaluate the effect of BOL-DP-o-05 on preservation of beta-cell function,To assess the percent of subjects who require a daily insulin dose < 0.5 IU/kg body weight,,2020-11-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8506,NCT03444363,Laboratory findings,Clinical findings,,2013-09-20,COMPLETED,INTERVENTIONAL,['NA']
8507,NCT03118050,Amino acid transporter expression,Muscle protein synthesis,,2017-05-28,COMPLETED,INTERVENTIONAL,['NA']
8508,NCT01504412,Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy,Mean Change in Short Form-McGill Pain Questionnaire From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8509,NCT00027456,,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8510,NCT01406496,Post-prandial blood glucose excursions following three different meals and three different timings of insulin bolus.,,,2011-08,UNKNOWN,INTERVENTIONAL,['NA']
8511,NCT02635243,Time to reach a smoothed blood glucose of 70 mg/dL after initial administration of investigational medicinal product,Time to reach a smoothed blood glucose of 90 mg/dL after initial administration of investigational medicinal product,,2016-04,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8512,NCT01671306,,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
8513,NCT04889183,Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR),high sensitivity C-reactive protein (CRP),,2022-03-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3']
8514,NCT02241889,Percent of Time With Sensed Glucose Between 70-180 mg/dl,Percent of Time of CBG>180 mg/dl,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
8515,NCT03884920,HB-A1c,Lipid Profile,Kidney Function,2019-03-20,COMPLETED,OBSERVATIONAL,['NA']
8516,NCT00697450,Weight effect,Improvement in HbA1c levels,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
8517,NCT04198935,Adherence to the the program,,,2020-05,UNKNOWN,INTERVENTIONAL,['NA']
8518,NCT03143803,Mean amplitude glycemic excursion,Number of hypoglycemia episodes,,2017-05-05,COMPLETED,INTERVENTIONAL,['NA']
8519,NCT00268645,"For efficacy: FBG (Fasting Blood Glucose), HbA1c",For safety: ICA (Insulin Cell Antibody),,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8520,NCT02290418,Composite measure of success of bariatric surgery as measured by Bariatric Analysis and Reporting Outcome System (BAROS),"Change in Quality of Life, as measured by Moorehead-Ardelt Questionnaire II","Change in Body Mass Index (BMI), measured in kg/m2",2012-01,UNKNOWN,INTERVENTIONAL,['NA']
8521,NCT00973726,"Changes in amplitude/implicit times, changes in dark adaptation, changes in vessel caliber, changes in Optical coherence tomography (OCT)",,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
8522,NCT00144144,Clinical laboratory data,Changes in BNP· Changes in hs-CRP· Medical cost-effectiveness,,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
8523,NCT02085681,Proportion of patients with confirmed Diabetic Retinopathy (DR) diagnosed at the eye hospital,Proportion of patients eligible for referral who had DR and who did not attend,Drivers of acceptance,2014-05,COMPLETED,INTERVENTIONAL,['NA']
8524,NCT01481675,Diabetes resolution at 12 months after surgery,Changes in PYY response to glucose,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
8525,NCT02590016,Neonatal hypoglycemia,Proportion of participants needing insulin-glucose-infusion in the observational arm,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
8526,NCT01128205,"The proportion adequate control of blood glucose, blood glucose and blood pressure or blood glucose and blood lipid, and blood glucose, blood pressure and blood lipid.",,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
8527,NCT01089569,HbA1c Change,Change From Baseline in Weight Changes,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
8528,NCT02266823,Primary outcome: Lipoproteins. We will evaluate the impact of the intervention on serum lipids obtained after a 12-hour fast,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
8529,NCT03138447,Basal Insulin Dose,Office Contacts,,2017-03-30,COMPLETED,INTERVENTIONAL,['NA']
8530,NCT03853941,Change in healthcare professionals' communication style,Fidelity of delivery,,2019-03-21,COMPLETED,INTERVENTIONAL,['NA']
8531,NCT05407467,HbA1c,Blood Pressure,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8532,NCT01880736,Change From Baseline in HbA1c (%) Glycosylated Haemoglobin),Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
8533,NCT03729323,Blood pressure,,,2018-04-11,COMPLETED,INTERVENTIONAL,['NA']
8534,NCT04005430,The primary outcome measure of the study is safety assessment.,Secondary outcome are assessment of anatomical changes in the macula as measured via optical coherence tomography (OCT).,,2019-04-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8535,NCT03693521,Change in physical activity level,Physical Activity on Prescription,,2019-10-07,COMPLETED,INTERVENTIONAL,['NA']
8536,NCT05496907,Effectiveness of Intervention using HbA1c levels,Mental Health Outcome,,2022-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8537,NCT04422145,All cause mortality at study endpoint with each participant having a minimum follow up of 12 months and the final analysis of data being done 58 months after the first participant was recruited (this is study endpoint.),Assessment of differences in mortality rate between type 1 and type 2 diabetes participants,,2013-02-01,COMPLETED,INTERVENTIONAL,['NA']
8538,NCT00302874,Mean blood glucose during hospitalization,"Disposition at discharge (home, nursing home)",,2003-02,COMPLETED,INTERVENTIONAL,['NA']
8539,NCT02292511,Global Cognitive Functioning,Antisaccade direction errors,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
8540,NCT00445913,The trial is designed to assure that the toxicity rate is acceptably low to warrant further study of the cell vaccine in efficacy trials.,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8541,NCT04285450,Homeostasis model assessment of insulin resistance (HOMA-IR),,,2019-10-27,COMPLETED,INTERVENTIONAL,['NA']
8542,NCT04016987,changes in serum hemoglobin A1c level,Adverse events,,2020-09-08,UNKNOWN,INTERVENTIONAL,['NA']
8543,NCT05102149,Change in HbA1c,,,2021-09-30,RECRUITING,INTERVENTIONAL,['PHASE3']
8544,NCT00802022,Pain intensity measured on a weighted NRS according to Jensen and a PGIC for pain measured on a 7-point Likert scale.,"The practical- and technical feasibility of the procedures, predicting successful pain relief by SCS by classifying patients according to the MDNS. Define possible other predictors for successful pain relief.",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
8545,NCT01554566,serum lipids,C-peptide,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8546,NCT04016584,"Success (evaluated by a Yes/No format) recruiting and completing a new targeted diabetes and insulin education program, Diabetes Pueblo, for Latino adults with type 2 diabetes.",Participant evaluation of Diabetes Pueblo evaluated by questionnaire,"Menopausal status, pregnancy status, and gestational diabetes history for women determined by questionnaire",2019-05-10,COMPLETED,INTERVENTIONAL,['NA']
8547,NCT02730078,Diabetes-related distress,LDL-cholesterol,Adverse event,2016-04,COMPLETED,INTERVENTIONAL,['NA']
8548,NCT02280564,Change from Baseline in HbA1c at 4 months,Change from Baseline in Quality of Life measures at 4 months,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
8549,NCT04157738,Caregiver Treatment Adherence at 1 Month and 4 Months Post-intervention,Glycemic Variability (GV) at 1 Month and 4 Months Post-intervention,,2019-11-27,COMPLETED,INTERVENTIONAL,['PHASE4']
8550,NCT06303453,PainDETECT Tool,,,2024-02-25,RECRUITING,INTERVENTIONAL,['NA']
8551,NCT04270578,Glucose tolerance during 75 g oral glucose tolerance test,blood sample,,2012-05-23,RECRUITING,OBSERVATIONAL,['NA']
8552,NCT04117269,Percentage of diabetic foot ulcers healed,Time to healing,,2019-11-15,RECRUITING,INTERVENTIONAL,['NA']
8553,NCT02060279,"β-carotene, FABP4 and C16:1n7 palmitolate levels",Macrophage expression of genes involved in lipid and lipoprotein metabolism and adipose deposition,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
8554,NCT05833958,Change in glycosylated haemoglobin (HbA1c),Medication tolerability,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8555,NCT03334175,Palatability of Supplement,Change in Low Density Lipoprotein Levels,Number of Participants Who Had Plasma Metabolomics Performed,2018-05-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8556,NCT01068678,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8557,NCT01823458,Attendance at exercise classes,LDL cholesterol,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
8558,NCT00231608,The mean change from baseline to Month 6 in abdominal visceral fat as assessed by computed tomography; the safety of Topiramate for up to 12 months of continued treatment in male subjects with abdominal obesity.,"Mean change and percent change in body weight, and mean change in total abdominal fat, subcutaneous abdominal fat, body composition, and body mass index from baseline to Month 6.",,1998-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8559,NCT00285233,"Monitor the incidence, timing, and severity of adverse events as well as their relationship to the islet transplant procedure and additional protocol-regulated treatment products during the first year after islet transplantation.","Assess, in a selected group of islet allotransplant recipients, the autoimmune and alloimmune responses to transplanted islets at intervals during the first year posttransplant.",,2000-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8560,NCT05118217,Dynamic Vessel Analysis,Body Mass Index,,2021-11-18,UNKNOWN,OBSERVATIONAL,['NA']
8561,NCT00737815,Fasting insulin,Gene Expression,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
8562,NCT04653779,The preference regarding convenience of medication,TSQM-9 scores,,2020-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
8563,NCT02998970,Left Ventricular (LV) mass Changes,Plasma catecholamine levels,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8564,NCT01699737,Change in glycosylated hemoglobin (HbA1c) after administration of JTT-851,Pharmacokinetics of JTT-851 and its metabolites,Relationship between dose and response of JTT-851,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8565,NCT04114682,Magnetic Resonance Imaging metrics for liver fibro-inflammation in patients with type 2 diabetes,longer term evaluation of clinical outcomes,,2020-01-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8566,NCT01181453,Complete wound closure,Percent of wound closure by study end,,1998-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8567,NCT04403841,Disease awareness,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
8568,NCT00306384,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),Percentage of Participants With a Clinical Response,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8569,NCT02763423,Changes from baseline exogenous insulin dose at different time points post treatment,titres of islet antigen antibodies,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8570,NCT05343624,Time in Range,Hypoglycemia,,2020-06-18,COMPLETED,INTERVENTIONAL,['NA']
8571,NCT01322789,Safety,Immunologic reconstitution parameters,,2008-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8572,NCT01987206,time spent in safe blood glucose range,glucose level extremes and need for outside intervention,,2014-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8573,NCT01022658,"Vago-sympathetic activity, arterial stiffness, endothelial function",,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
8574,NCT00683657,Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4,Change From Baseline in 2-Day Average Fasting Plasma Glucose (FPG) at Week 4,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8575,NCT04076995,Area Under the Curve for Plasma osmolality,Mood assessment with a questionnaire,,2019-09-18,COMPLETED,INTERVENTIONAL,['NA']
8576,NCT00546351,Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).,Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Last Visit.,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
8577,NCT02344602,The Change in Effective Renal Plasma Flow (ERPF) After an 8 week Treatment with Febuxostat,The Change in Skin Biopsy Measures of Neurohormonal Activation After an 8 week Treatment with Febuxostat,,2012-12-18,COMPLETED,INTERVENTIONAL,['PHASE4']
8578,NCT06001801,Change in weight,Change in reported diet quality,,2023-09-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8579,NCT00184821,,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
8580,NCT02948673,Insulin sensitivity,Mitochondrial reactive oxygen species production,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
8581,NCT05179135,Change in blood glucose during exercise,Plasma growth hormone area under the curve during exercise and in the recovery period after the exercise session.,,2022-01-19,COMPLETED,INTERVENTIONAL,['NA']
8582,NCT03949582,Blood insulin,Energy intake 72 hours post study visit,,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA']
8583,NCT02504762,Assessing conventional CABG vs HCR in diabetic patients with multivessel CAD,Number of patients we can enroll in 1 year,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
8584,NCT01065298,Reduction of insulin requirement by ≥ 50% by the end of 6 months of ABMSCT and Improvement in Glucagon stimulated C - peptide levels .,Any reduction in requirement of insulin dosage and any improvement of HbA1c levels as compared to controls.,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
8585,NCT01402037,evaluate the hyperglycemic clamp to measure the functional beta cell mass test,evaluate the continuous glucose monitoring to measure within- and between-day glycemic variability,,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
8586,NCT00641251,LDL cholesterol < 100 mg/dl,,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
8587,NCT01005420,Insulin Sensitivity,Cognitive Performance,,2007-02,WITHDRAWN,INTERVENTIONAL,['NA']
8588,NCT02854748,"Cmax,ss of Lobeglitazone",AUCinf of Lobeglitazone,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
8589,NCT02813421,Percentage Time Within Target Blood Glucose (Range: 70-180 mg/dL),Number of Participants With Satisfaction of Transition to Pump Therapy,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8590,NCT01055223,Number of Low Impact Fractures in Males and Females After 12 Months of Exposure to TZD,Number of Hip Fractures Combined in Males and Females After 12 Months of Exposure to TZD,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
8591,NCT00824668,,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8592,NCT01693406,Change in infant percent body fat from birth to 4 months,Change in Antioxidant capacity of human milk,Change in Human Milk Nutrient Composition,2012-08,COMPLETED,OBSERVATIONAL,['NA']
8593,NCT03573856,Change from 0 to 12 months in fasting insulin,Change from 0 to 12 months in fasting glucose,Potential for sustained delivery,2018-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8594,NCT04591782,Impact of gut microbiome in glycemic response to pom juice vs. sugar water,,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
8595,NCT03789578,"AUCSema,0-tz, area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation after a single dose",Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies cross reacting with endogenous GLP-1,,2019-01-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8596,NCT01195532,"AUC0-t, AUC0-∞, Cmax, Tmax, T1/2, and MRT in plasma will be determined with gliclazide concentrations by non-compartment methods.",,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
8597,NCT01768611,Plasmatic Creatinine,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
8598,NCT04907006,Cmax,CLz/F,,2021-08-31,COMPLETED,INTERVENTIONAL,['PHASE1']
8599,NCT03558867,"Mean change in glycated haemoglobin (HbA1C, %) from baseline",Liver fat,Gut microbiome (exploratory),2018-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8600,NCT01298245,The differences in the distribution of candidate genotypes and alleles between the study groups,the frequencies of haplotypes of different single nucleotide polymorphisms,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
8601,NCT01384045,Composite Measure of Guideline Concordance,Individual measures of guideline concordance,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
8602,NCT05938712,Proximal tubular natriuresis with monotherapy,Safety: The number of allergic reaction events.,,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2']
8603,NCT00965458,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT),Hemoglobin A1c,,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2']
8604,NCT05747352,Glucose time,Glucose time,,2023-06-05,COMPLETED,OBSERVATIONAL,['NA']
8605,NCT00622856,consumption of health services,Changes in the wellbeing of adolescents and their parents,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
8606,NCT02700503,Subject's BMI calculation Charted on CDC Stature for Age and Weight for Age Percentiles chart,Dietary records,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
8607,NCT04743856,Change from baseline in Step counts at 12 months,Triglycerides over all timepoints for 12 months,,2022-03-29,RECRUITING,INTERVENTIONAL,['NA']
8608,NCT06077461,State-Trait Anxiety Scale,,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
8609,NCT03206827,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification,Genotoxicity testing of human fecal water in 2D and 3D cell cultures,,2016-11-29,COMPLETED,INTERVENTIONAL,['NA']
8610,NCT01324739,glucose,"insulin, c-peptide",,2010-05,COMPLETED,INTERVENTIONAL,['NA']
8611,NCT01530347,correlation between the acetone values generated by study device and oxygen,Clarke Error Grid (segment 1 only),,2012-03,TERMINATED,INTERVENTIONAL,['PHASE1']
8612,NCT03907202,Safety laboratory parameter - urinalysis.,Fridericia's corrected QT interval (QTcF).,,2018-04-17,TERMINATED,INTERVENTIONAL,['PHASE1']
8613,NCT03939143,Maximum plasmaconcentration of drug in plasma(Cmax),Terminal elimination half-life(t1/2),,2019-02-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8614,NCT03313960,Hemoglobin A1c,Health-related Quality of Life,,2017-10-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
8615,NCT02059564,PK profile of acetaminophen,Safety and tolerability,,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
8616,NCT03314714,Assessment of intramyocellular lipid composition via mass spectrometry,,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
8617,NCT01978925,Medication Adherence,Quality of Life,Fasting plasma glucose for diabetic patients,2013-11,COMPLETED,INTERVENTIONAL,['NA']
8618,NCT01939366,Change in Average Pain Intensity.,,,2013-09-27,COMPLETED,INTERVENTIONAL,['PHASE2']
8619,NCT00830791,Plasma AUC (0-infinity) After Administration of a Single Oral Dose of 5 mg of MK-0941 Among Participants With Severe Renal Insufficiency vs Matched Controls,Plasma Glucose Concentration After Administration of a Single Oral Dose of 5 mg of MK-0941 to Participants With Severe Renal Insufficiency Versus Matched Controls,,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1']
8620,NCT05015738,"Instructional Materials Motivation Survey (IMMS), 10. week (after the course finished)","Opinion Form on Diabetes Education Program supported by digital tools, for only experimental group, 10. week (at the end of the course)",,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
8621,NCT01241474,Change in insulin sensitivity assessed by hyperinsulinemic-euglycemic-eu-aminoacidemic clamp,Change in plasma inflammatory markers,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
8622,NCT02206919,Popliteal FMD MRI technique correlates with albuminuria in those with early diabetic disease,Dietary risk factors related to chronic disease,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
8623,NCT05333718,clusters of type 2 diabetes,Metabolomics and genetic profile related to diabetes,,2022-03-08,RECRUITING,OBSERVATIONAL,['NA']
8624,NCT02299388,Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors.,"Change in Pulse Pressure, Mean Arterial, Diastolic and Nocturnal Blood Pressures.",Change in Urinary Sodium Excretion,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8625,NCT01753024,Screening and risk factors of exocrine pancreatic insufficiency in critically ill adult patients receiving enteral nutrition,Effects of pancreatic enzyme supplementation on nutritional status and clinical outcomes in critically ill patients with sepsis,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
8626,NCT05135676,Co-primary Outcome: CGM-measured percent time <54 mg/dL (non-inferiority),CGM Metrics by nighttime only (00:00 AM to 06:00 AM),Glucose Variability,2022-05-10,COMPLETED,INTERVENTIONAL,['NA']
8627,NCT05473286,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2022-09-30,WITHDRAWN,OBSERVATIONAL,['NA']
8628,NCT00379379,"Hypoglycemic activity, plasma insulin level, HOMA index","Triglyceride, cholesterol, free fatty acid",,2005-01,COMPLETED,INTERVENTIONAL,['NA']
8629,NCT00440375,"metabolic bone markers before and after the intervention,",association between the changes in bone turnover parameters and plasma cytokine levels,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8630,NCT02659748,Insulin sensitivity,Bacterial microbiota,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
8631,NCT03412006,Change in urinary albumin to creatinine ratio (UACR),Number of patients with serious adverse events,,2018-02-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8632,NCT06132477,Effect of GLP1-RA on Glycemic control,,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
8633,NCT03934944,Change in foot care behaviour as measured by the SDSCA,Proportion of participants who developed a new diabetic foot ulcer,,2019-02-10,UNKNOWN,INTERVENTIONAL,['NA']
8634,NCT02692547,Descriptive endpoints,Descriptive endpoints,,2016-02,WITHDRAWN,INTERVENTIONAL,['NA']
8635,NCT04910321,Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L,Change of body mass index,,2020-12-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8636,NCT04266379,Difference in percent of time spent with blood glucose level below 70 mg/dL,Weight and Body Mass Index (BMI),,2020-05-13,UNKNOWN,INTERVENTIONAL,['NA']
8637,NCT05994937,Percent Change in Concentration of Tumor Necrosis Factor-alpha (TNFα) Biomarkers,,,2023-12-26,RECRUITING,INTERVENTIONAL,['NA']
8638,NCT05198284,Referrals,,,2021-11-01,RECRUITING,OBSERVATIONAL,['NA']
8639,NCT02299479,Change From Baseline in Supplemental Carbohydrate Interventions up to 3 Months From Baseline.,Change From Baseline in Supplemental Carbohydrate Interventions up to 3 Months From Baseline in Subjects With Activity Effect.,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
8640,NCT00935051,"MMP-1/TIMP-1 ratio at Week 0 assessed by ELISA and percent change in wound area of diabetic foot ulcer between week 0, week 4 and week 12","Correlation between MMP9, MMP13, MMP9/TIMP1 and MMP13/ TIMP1 ratios and wound healing expressed by the percent change in wound area between week 0, week 4 and week 12.",,2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8641,NCT00564551,Weight loss,Inflammatory Markers,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
8642,NCT00206401,HbA1C,Glucose excursions,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8643,NCT05854797,Body Mass Index,,,2022-10-28,COMPLETED,INTERVENTIONAL,['NA']
8644,NCT03832933,Change in body weight by weight scale,Change in % FFM,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
8645,NCT00797186,change in microvascular perfusion,,,2008-11,UNKNOWN,INTERVENTIONAL,['NA']
8646,NCT03174548,Area under curve (AUC) of sotagliflozin,Number (%) of subjects with treatment emergent adverse events,,2017-06-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8647,NCT02027753,Response rate (percentage of patients who meet the target HbA1c ≤7%) at week 24 (6 months) after adding insulin therapy,Number of Patients with Adverse Events,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
8648,NCT04461821,Change in Concentration of exhaled metabolites of pharmacotherapy,"Change in clinical endpoint (blood pressure, mmHg) for correlation between clinical endpoint and the abundance of exhaled metabolites",,2020-09-11,RECRUITING,OBSERVATIONAL,['NA']
8649,NCT04837989,Social Comparison Scale,Brief Illness Perception Questionnaire,,2021-02-01,TERMINATED,INTERVENTIONAL,['NA']
8650,NCT03403686,Assessing CD34+ cells function,,,2018-01-11,RECRUITING,OBSERVATIONAL,['NA']
8651,NCT03866005,Required number of anti-VEGF injections,Need for adjunctive laser photocoagulation and/or use of intravitreal steroids,,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA']
8652,NCT00312130,Change from baseline in acute insulin response to an iv glucose load at 6 weeks,Change from baseline in acute insulin response to an iv glucose load at 8 weeks,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8653,NCT04351945,Endocrine changes and their correction in heart and lung tranplant donors,Evidence of clinically definite postoperative complications,,2020-05-20,UNKNOWN,OBSERVATIONAL,['NA']
8654,NCT05148390,"Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')",Incidence of device disintegration (removability in one piece),,2022-04-24,COMPLETED,OBSERVATIONAL,['NA']
8655,NCT02131896,lipid profile,Endothelial function,,2014-12-01,TERMINATED,INTERVENTIONAL,['NA']
8656,NCT03640988,"Skin perfusion, effect on oxygenation level, by visit","Wound healing, effect on wound closure, by visit",,2019-04-25,TERMINATED,INTERVENTIONAL,['NA']
8657,NCT02420470,"Functional and structural connectivity relationships of multiple brain regions and biomarkers of brain alterations, and the changes in relationships and biomarkers at 2.5 years.",Lifestyle and its changes at 2.5 years,,2015-04,RECRUITING,OBSERVATIONAL,['NA']
8658,NCT02164266,Incidence of adverse events (AEs),Fasting serum insulin (Part 2 only),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8659,NCT01733758,"Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24",Time to Study Withdrawal for Any Reason,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8660,NCT04699734,Indication of pain relieved extremity,Distribution of evoked pain,,2020-09-08,RECRUITING,INTERVENTIONAL,['NA']
8661,NCT03811548,Change in HbA1c From Baseline to Week 24,Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period),Population pharmacokinetics assessment,2019-05-23,UNKNOWN,INTERVENTIONAL,['PHASE3']
8662,NCT00428961,,,,2002-07,COMPLETED,OBSERVATIONAL,['NA']
8663,NCT02804165,Identification of gene-enterovirus interaction effect on T1D onset,"""Precipitating"" effect of enterovirus infection on T1D.",,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
8664,NCT04289753,Diabetes Overtreatment in the Elderly,Rate of Hypoglycemia Requiring Urgent Care Among Previously Tightly Controlled,Diabetes Overtreatment in the Elderly by Ethnicity,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
8665,NCT01523405,Diabetic Quality of Life using Modified 15 item DQoL (MDQoL) questionnaire,Disease modifying variables Body Mass Index (BMI) and Blood Pressure (BP),,2012-03,COMPLETED,OBSERVATIONAL,['NA']
8666,NCT01387984,,,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
8667,NCT01311401,New incidences of Type II Diabetes Mellitus in Circassians minority in Israel,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
8668,NCT01768403,"Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.","The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
8669,NCT00789750,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8670,NCT02703324,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT),,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8671,NCT00762190,Left ventricular mass index by body surface area measured by echocardiogram.,"Change from Baseline in apolipoproteins (AI, B).",,2003-11,TERMINATED,INTERVENTIONAL,['PHASE3']
8672,NCT00282659,"Blood pressure, cardiac output, systemic vascular resistance, thoracic fluid content, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and blood glucose",,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8673,NCT02010528,parental diabetes-related distress,psychosocial characteristics,objective measures,2013-12,COMPLETED,OBSERVATIONAL,['NA']
8674,NCT01044537,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf),Change From Baseline in Ratio of Insulin Area Under Curve (Insulin AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8675,NCT04831606,Percentage of healed lesions on the total lesions treated for each arm,Healing time,Evaluation of cost-effectiveness of using EmoLED for the treatment of ulcers,2021-07-31,RECRUITING,INTERVENTIONAL,['NA']
8676,NCT02438943,Proportion of persons attending health centers in the Southeast Health region with normal lipid values,Proportion of persons attending health centers in the Southeast Health region with normal blood pressure values,,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
8677,NCT02440555,Sensitivity of detection of type 2 diabetes,To evaluate the numbers of patients screened by self-administered questionnaire and diagnosed as diabetics using fasting glucose.,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
8678,NCT04773834,Body Mass Index (BMI) (kg/m2),dDPP platform meal log (food item and calories/day),,2021-02-01,RECRUITING,INTERVENTIONAL,['NA']
8679,NCT05717205,mucosal nerve length density (MNLD),Immunohistochemical differences,,2023-02-16,RECRUITING,INTERVENTIONAL,['NA']
8680,NCT00993824,Hypoglycemia Percentage of Time <70 mg/dL Average by Group,,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8681,NCT02128932,Change in HbA1c From Baseline,"Subjects Who Achieve HbA1c ≤6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists (AACE)",,2014-08-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8682,NCT05752279,Hospital free days (HFD) up to day-28 after study enrolment,Cumulative potassium replacement,Cost-effectiveness,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8683,NCT04736225,HbA1C,self-care behavior,,2010-06-01,COMPLETED,INTERVENTIONAL,['NA']
8684,NCT04534439,Mean change in urine albumin to creatinine ratio (UACR) in APX-115 group compared to placebo group,,,2020-08-24,COMPLETED,INTERVENTIONAL,['PHASE2']
8685,NCT01065402,The daily blood glucose level will be monitored by the continuous glucose monitoring system (CGMS) device Medtronic MiniMed.,,,2010-02,UNKNOWN,INTERVENTIONAL,['NA']
8686,NCT04215523,"Composite outcome of Stroke, MI, and Mortality",,,2019-07-08,COMPLETED,OBSERVATIONAL,['NA']
8687,NCT05278143,Severe hyperglycaemic events detection,Time in severe hyperglycaemia,,2021-04-12,UNKNOWN,OBSERVATIONAL,['NA']
8688,NCT04040634,"Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure",Time to All-Cause Probable Dementia,,2019-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8689,NCT00955669,Magnetic resonance angiography,,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8690,NCT06268808,HbA1c,Frequency of hypoglycaemia events,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8691,NCT03736785,Change From Baseline in HbA1c,Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,,2018-11-15,COMPLETED,INTERVENTIONAL,['PHASE2']
8692,NCT00741429,Change in FEV1 (L) from Baseline Visit in Parent Trial to Visit 2 of MKC-TI-126,Change in Hemoglobin Corrected DLco (mL/min/mmHg) from Final Assessment of Treatment Phase in Parent Trial to Visit 2 of MKC-TI-126,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
8693,NCT02682563,Effective Renal Plasma Flow (ERPF) in ml/Min,Kidney Injury Molecule-1 (KIM-1) in ng/mmol,Systolic Blood Pressure,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8694,NCT00511667,Participants Discontinued Because of Any Clinical Adverse Experience,Concentration of MK-0941 at 24 Hours (C24hr) After Multiple Doses of MK-0941,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
8695,NCT03158415,Lived experience,Diabetes Distress,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
8696,NCT04081766,Frequency of total episodes of hypoglycaemia,Time to the first hypoglycaemic attack,,2020-02-09,COMPLETED,INTERVENTIONAL,['NA']
8697,NCT03047486,Glucose Time below range (hypoglycemia < 70 mg/dl) from CGM recording,HbA1c,Medical time at each consultation,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
8698,NCT05717491,Fasting glucose value according to the level of precariousness,Risk (odds Ratio) of (pre) diabetes and accelerated aging for assessed exposures,,2021-12-14,RECRUITING,OBSERVATIONAL,['NA']
8699,NCT03294369,Prevalence of cardiovascular disease,,,2011-04-01,UNKNOWN,OBSERVATIONAL,['NA']
8700,NCT03986073,Glycosylated hemoglobin (HbA1c),GLP-1 (glucagon-like peptide-1),,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8701,NCT03234491,PostPrandial Blood Glucose,Venous Glucose Levels,,2017-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
8702,NCT03423355,Change in blood EPO levels,Change of diastolic function parameters,,2021-09,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8703,NCT00258804,"Patient satisfaction before, during and after Ramadan.",,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
8704,NCT00605449,drug plasma levels of GSK376501:,"GSK376501 Day 7 AUC(0-24), Cmax, tmax and t1/2.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8705,NCT01270542,"The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction Retinal Detachment Due to PDR",Improvement of Visual Outcomes in Patients Given Pre-operative Adjunctive Bevacizumab in Eyes Undergoing PDR Surgery.,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
8706,NCT01945996,Acceptability 2: Would Patients Recommend the Program to Family or Friends?,Change in Summary of Diabetes Self-care Activities - Carb Spacing Sub Score,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8707,NCT03312478,Odds of Type 1 Diabetes Mellitus child having a diabetic parent,Characterization of diabetes education,,2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE4']
8708,NCT03666923,Incidence of dose-limiting toxicities up to the Day 14 visit,Occurrence of laboratory abnormalities up to the end of the study,,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8709,NCT02971202,Whole-body Glucose Utilization (Rd),Adipose Tissue Insulin Sensitivity,,2016-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8710,NCT05979584,4-week wound healing rate,Infection evaluation,,2023-11-15,RECRUITING,INTERVENTIONAL,['NA']
8711,NCT00976326,Area under the NN1250 concentration-time curve after single-dose,Number of adverse events,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8712,NCT06319716,Hemoglobin A1c (HbA1c) Levels,International Physical Activity Questionnaire (IPAQ) Short-Version Score,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8713,NCT01743963,Delay Interval (Days From Randomization Until the Provider Signs the Order for a hgbA1C Level).,Feasibility/Reach/Adoption,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
8714,NCT03217630,Prevalence of full stomach,Mean gastric emptying time of clear liquid and light meal,Risk factors of delayed stomach empty in diabetic patients,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
8715,NCT05591690,Time spent with glucose levels above range,,,2020-11-01,COMPLETED,OBSERVATIONAL,['NA']
8716,NCT01087242,glycosylated hemoglobin,"fasting blood glucose,2-hour postprandial blood glucose,true insulin,TG,TG、LCL-C、HDL-C、BMI,waistline, hipline,TCM syndrome and sign",,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
8717,NCT04862923,Change in glycated haemoglobin (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2021-05-12,COMPLETED,OBSERVATIONAL,['NA']
8718,NCT01703286,Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28,Number of Patients With Adverse Events,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8719,NCT01648985,"Number of Stroke (fatal, non-fatal)",Number of patients with Diabetes,Number of patients with Small Vessel Disease SVD,2010-05,COMPLETED,OBSERVATIONAL,['NA']
8720,NCT03687580,Incidence of complete (100%) wound closure,Time to complete (100%) wound closure,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
8721,NCT05835037,Zinc-dependent effect on HbA1c at 1 year,Zinc-dependent effect on HbA1c at 6 months,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
8722,NCT00576784,The proportion of patients with an increase in HbA1c by 0.5 % after 6 months of treatment compared to baseline HbA1c value,Absolute change of HbA1c Insulin resistance according to minimal model and HOMA-S analysis change of insulin resistance according to minimal model and HOMA-S analysis to baseline first phase insulin response,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8723,NCT05715307,Glycated haemoglobin (HbA1c) control rate,Number of participants with abnormal Renal function,,2023-02-09,RECRUITING,INTERVENTIONAL,['NA']
8724,NCT04827615,Body weight,,,2019-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8725,NCT01772914,Changes in copeptin levels after intake of a oral glucose tolerance test- and a mixed meal tolerance test liquid,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
8726,NCT05142020,Significantly different proteins at 32-34 gestational weeks,,,2022-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8727,NCT02754219,Pharmacokinetic(Cmax of Evogliptin),,,2016-09-22,COMPLETED,INTERVENTIONAL,['PHASE1']
8728,NCT04998461,Comparison of gene expression in USC (Urinary Stem Cells),,,2021-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8729,NCT01474083,Pharmacokinetic parameters of GK1-399 from plasma concentrations,Pharmacodynamic parameters of plasma glucose,,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8730,NCT04014413,The efficacy of FMT in treating dysbiosis-associated disorder will be assessed by number of patients who have improvement in clinical symptoms (depends on each disease as stated in outcome),Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0,Any improvement or deterioration or recurrence of the underlying condition by clinical judgement of doctors,2019-07-15,RECRUITING,INTERVENTIONAL,['NA']
8731,NCT05501483,Changes in fat cell lipolysis after 6 months of treatment,Changes in fat cell heterogeneity after 6 months of treatment,Changes in tissue cellularity after 6 months of treatment (explorative outcome),2023-02-08,RECRUITING,INTERVENTIONAL,['NA']
8732,NCT01128621,Number of Participants With Relationship Between GSK1292263 Drug Exposures and Pharmacodynamic Parameters (Part B),,,2009-11-23,COMPLETED,INTERVENTIONAL,['PHASE2']
8733,NCT00377117,,,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
8734,NCT03230123,Percent reduction in glycated hemoglobin,Percent increase in GLP-1,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
8735,NCT05810311,Change in kidney oxygenation levels,Change in urinary reactive oxygen species (ROS),,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8736,NCT00739323,,,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
8737,NCT04972955,New diagnosis of maternal diabetes or prediabetes based on 75g OGTT,Cost component analysis of CGM vs. 75g OGTT,,2023-07-04,RECRUITING,OBSERVATIONAL,['NA']
8738,NCT04385758,Diabetes Distress (using DDS),Self-Reported Hypoglycemia and Hyperglycemia,,2020-07-13,COMPLETED,INTERVENTIONAL,['NA']
8739,NCT00600626,HbA1c,changes in body weight and vital signs,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8740,NCT01464099,Maximum plasma concentration (Cmax) of insulin aspart,AUC (area under the curve) of insulin aspart,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8741,NCT03261362,Clamp test,Mixed Meal Test,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8742,NCT01236846,serum 25-hydroxyvitamin D,Blood pressure,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
8743,NCT02033239,Area under the glucose infusion rate curve,Maximum observed serum insulin aspart concentration,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8744,NCT02705053,"Change in Hemoglobin A1c (HbA1c) (%) from baseline (week 2) to end of week 15 (end of study), with A1c measured at weeks 7 and 11 as well for repeated measures.","Time with glucose ≤ 70 mg/dL, overall",,2016-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8745,NCT02324569,Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) That Occurred Before Start of Treatment Period II,Change From Baseline in Self-Monitoring of Blood Glucose Before Breakfast,,2014-12-27,COMPLETED,INTERVENTIONAL,['PHASE3']
8746,NCT02151188,Glucose response of different treatments,Gastric emptying rate,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
8747,NCT04219514,"Risk scores for severe hypoglycemia, non-severe daytime hypoglycemia, non-severe nighttime hypoglycemia",Exploratory causal estimates of different treatment regimens and hypoglycemia rates,,2020-02-10,COMPLETED,OBSERVATIONAL,['NA']
8748,NCT00073034,,,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2']
8749,NCT01614327,Sensitivity and specificity of retinal screening for risk stratification of DR using digital fundus photographs with and without the assistance of the RiskAnalyzer.,Sensitivity and specificity of retinal screening for risk stratification of DR using digital fundus photographs and the RiskAnalyzer,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
8750,NCT00850824,glycosolated hemoglobin (HbA1c) levels,keeping specialty referral for medical exams,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
8751,NCT03037528,Glycemic Control,Depressive Symptoms,,2017-01-27,COMPLETED,INTERVENTIONAL,['NA']
8752,NCT02379078,Decisional Conflict in Patients With Diabetes,Intention to Engage in Shared Decision-making in Health Care Providers,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8753,NCT01035528,change from baseline to endpoint in myocardial diastolic velocity E',glucose control,,2005-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
8754,NCT00316082,Change From Baseline in Hemoglobin A1 (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
8755,NCT00537303,Glycosylated Haemoglobin A1c (HbA1c),Cardiovascular Risk Marker: High-sensitivity C-reactive Peptide,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8756,NCT04756141,Mean Absolute Relative Difference (MARD),Continuous Glucose Monitor (CGM) Calibrations,,2021-03-03,COMPLETED,INTERVENTIONAL,['NA']
8757,NCT02915029,Patient Activation Measure (PAM) Level Greater Than 2,8-Item Morisky Score,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
8758,NCT01781013,Change from baseline in depression outcome at 6-months,Change from baseline in diabetes self-care score in 6 months,Change from baseline to 6 months in percentage of patients satisfied with care received for depression,2010-06,COMPLETED,INTERVENTIONAL,['NA']
8759,NCT01870297,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8760,NCT02541838,Change in protective stepping as determined by the number of steps it take to recover from a balance perturbation from baseline to 3 months and baseline to 6 months,Change in mobility as measured by the modified physical performance test,,2016-05,TERMINATED,INTERVENTIONAL,['NA']
8761,NCT03061461,Wound size,Satisfaction,,2017-02-23,UNKNOWN,INTERVENTIONAL,['NA']
8762,NCT04620590,Change in 24-hr sodium excretion,,,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
8763,NCT00159211,Abdominal adipose tissue (on scan) variation at 6 month,inflammation gene expression in sub-cutaneous fat,,2005-05,TERMINATED,INTERVENTIONAL,['NA']
8764,NCT04630691,No difference,,,2012-12-01,COMPLETED,OBSERVATIONAL,['NA']
8765,NCT00600067,HbA1c Change From Baseline Week 0 to Week 56,Percent Weight Loss From Baseline to Week 56,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8766,NCT00990444,Identification of the lowest dose of oral insulin in dextran matrix that produces a significant lowering of post-prandial blood glucose.,To establish the dose(s) when administered in a multi-dose fashion that lowers plasma glucose levels versus placebo in patients with Type 2 diabetes,,2009-09,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8767,NCT05050500,The rate of heart failure occurrence,,,2023-05-08,RECRUITING,INTERVENTIONAL,['PHASE4']
8768,NCT00652405,Pancreatic Polypeptide (PP),Cytokines excreted from PBMCs after in vitro stimulation with LPS,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
8769,NCT00248157,long-term safety and tolerability,monitor long-term efficacy,,2005-11,TERMINATED,INTERVENTIONAL,['PHASE3']
8770,NCT05678543,Offspring birthweight,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
8771,NCT03535935,Change in spot urine albumin-to-creatinine ratio,Change in lipids,Change in biomarkers related to inflammation and fibrosis,2018-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8772,NCT01551667,Humoral immune response,Presence / absence of clonal complexes of the S. aureus strains,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
8773,NCT05089890,Bacterial and fungal species irreversibly bound to the dressing after 2 days (+ 1 day).,Wound fluid inflammatory biomarker levels at 14 days (±1 days) compared to baseline,,2021-10,UNKNOWN,INTERVENTIONAL,['NA']
8774,NCT06272695,Change in Time to glucagon treatment success at Week 6.,Change from baseline in hemoglobin A1c (HbA1c) at Week 6.,,2024-02-29,RECRUITING,INTERVENTIONAL,['PHASE1']
8775,NCT00128089,Diabetes medication reduction,Patient satisfaction,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE1']
8776,NCT00304603,Percent change in weight,Number of patients with adverse events,,2004-04,COMPLETED,OBSERVATIONAL,['NA']
8777,NCT01226043,Patient Overall Preference,Percentage of Patients Who Discontinued Investigational Product During the Observational Phase,Number of Patients With Hypoglycemic Events,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8778,NCT03149770,Change in Epinephrine Levels,,,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2']
8779,NCT00842894,Incidence of serious adverse drug reactions (SADRs),Change in body weight,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
8780,NCT02222376,Ulcer size,,Healing time,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
8781,NCT04221360,AUClast of D390 and CKD-375,CL/F of D390 and CKD-375,,2020-01-29,UNKNOWN,INTERVENTIONAL,['PHASE1']
8782,NCT02685475,Sensory block duration,Rescue analgesic consumption,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
8783,NCT03314246,Change in HbA1c,Change in diabetes treatment satisfaction,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
8784,NCT01823341,"Comparison of the Time Spent in Hypoglycemia (<70 mg/dl, 3.9 mmol/L) Overnight on Intervention Nights Versus Control Nights, Normalized to an 8-hour Period.",Percent of Mornings With Urine Ketones >/= 15 mg/dl,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8785,NCT04914910,Difference between treatment groups in change in TIR (3.9-10.0 mmol/l) from baseline to Week 14,Total daily carbohydrate intake,Difference in number of severe hypoglycaemia events (cognitive impairment requiring external assistance for recovery).,2021-06-08,COMPLETED,INTERVENTIONAL,['NA']
8786,NCT04016974,"AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0-24 hours) at steady state",Number of treatment-emergent hypoglycaemic episodes,,2019-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8787,NCT05498116,Change in Albuminuria,Change in Large Elastic Artery Stiffness,,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE4']
8788,NCT00463502,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
8789,NCT01201109,Patient self-reported outcome questionnaire,Nerve conduction study and vibrotactile sense,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
8790,NCT00676923,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
8791,NCT05786612,Percentage wound area reduction during the investigational test period of four weeks,Total treatment costs during the investigational test period based on the number of dressings used during the investigation and the unit price of the products,,2023-01-30,COMPLETED,INTERVENTIONAL,['NA']
8792,NCT04007809,Evaluation and follow-up of quality of life: DisabKids Questionnaires,Production of prediction model of β-cell mass evolution,,2019-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8793,NCT05583045,HbA1c,Creatinine,,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8794,NCT01341392,Amlodipine AUC,Amlodipine Tmax,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
8795,NCT01406665,oGTT (WHO criteria)-defined impaired glucose tolerance or diabetes,Findrisk diabetes questionnaire score,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
8796,NCT00371982,"adiposity (total fat mass, adipocyte morphology), atherogenic markers and insulin sensitivity",and the impact of fish oil on systemic inflammatory markers and adipose tissue inflammatory genes.,,2002-12,TERMINATED,INTERVENTIONAL,['NA']
8797,NCT04982380,Glycosylated albumin,Serum lipid spectrum,,2021-07-31,UNKNOWN,INTERVENTIONAL,['PHASE4']
8798,NCT05449821,Asprosin Levels,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
8799,NCT04016558,Hemoglobin A1c (HbA1c),Self-compassion - Diabetes (SCS-D),,2019-09-15,COMPLETED,INTERVENTIONAL,['NA']
8800,NCT05439473,Effect of treatment with Curalin on the change in plasma HbA1c,Safety of Curalin as assessed by adverse events,,2021-08-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8801,NCT02372149,Change in Overall Neuropathy Limitations Score (ONLS) after 3 months,Adverse Events,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
8802,NCT04887688,Laser Speckle imaging,Wound swabs,,2022-10-05,RECRUITING,INTERVENTIONAL,['NA']
8803,NCT00071409,"assess efficacy and safety based on arginine stimulated C peptide, fasting C peptide, average daily insulin dose, fasting glucose, glycosylated hemoglobin (Hb A1c), and AEs",,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8804,NCT01533428,Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8,"Safety Assessed Through Adverse Events (AE) and Serious Adverse Events (SAE), Vital Signs, and Laboratory Analyses From Baseline to Week 12",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8805,NCT00908778,"Ultrasound, OCT, and clinical exam","Ultrasound ,OCT ,Safety, and Clinical Exam",,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
8806,NCT00735501,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Weight changes,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
8807,NCT05710900,Type 2 diabetes remission,"Feedback of the intervention with participants, RDs and pharmacists",,2023-07-15,RECRUITING,INTERVENTIONAL,['NA']
8808,NCT01804881,The Change in EEQ (Emotional Eater Questionnaire) Score is the Primary Outcome Measure in This Study.,Change in Weight,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
8809,NCT00641407,Change in hemoglobin A1c (HbA1c) level from baseline to end point for each treatment group.,"Percentage of subjects achieving HbA1c ≤7%, incidence of self-reported hypoglycaemic episodes, comparison of SMPG values from 8-point profiles, insulin doses, and body weight.",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8810,NCT05856318,QRISK3,Diabetes Risk,,2023-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8811,NCT02620553,Evaluation of Blood Glucose Levels,T-cell responses related to potential immune response to Insulin,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8812,NCT03403231,Engagement in Recommended Behaviors to Prevent Type 2 Diabetes,Physical Activity,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
8813,NCT00998881,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8814,NCT05855980,Wound healed,Functional outcome: FHSQ,,2023-05-22,RECRUITING,INTERVENTIONAL,['NA']
8815,NCT02433678,Difference in the Percent Change in Fasting Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells Activation (DNA Binding Activity) in Mononuclear Cells Before and After Dapagliflozin Use,Changes in Expression of Inflammatory Mediators,Change in Hypertension Mediators,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8816,NCT03165227,Percentage of patients with drug related Adverse Events (AEs),Change from baseline in log transformed Urine albumin creatinine ratio (UACR) measured in 10-hour urine,,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8817,NCT04689425,Wound area reduction rate,Amputation rate at 8 weeks,,2021-03-30,RECRUITING,INTERVENTIONAL,['PHASE3']
8818,NCT00957762,"To compare different methods of body composition analyses with the gold standard 4-compartment monitoring to determine accuracy and validity of those alternative, but less labor-intensive techniques.",To cross-validate the derived regression equations against the gold standard 4-compartment model in an independent group of persons with SCI.,,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
8819,NCT01511393,"Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.","Environmental exposures (occupational history, radioiodine exposure, nuclear fallout)",,2012-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8820,NCT00328172,Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12,Percentage of Patients With Absolute Efficacy Response (HbA1c <= 7.0%) at 12 Weeks,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8821,NCT00419718,Area under the plasma insulin profile in the interval,Maximum plasma insulin concentration,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8822,NCT05783115,visual analogue scale,skin temperature,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
8823,NCT02671968,"Change in the total number of low glucose events (<55 mg/dl), between baseline and outcome phase (week 22-26) in CGM group and control group (change = subtracting number of follow up events from number of baseline events",,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
8824,NCT04323189,Dipeptidyl peptidase 4 (DPP4),Mean heart rate,,2020-08-26,RECRUITING,INTERVENTIONAL,['PHASE4']
8825,NCT04449198,Skeletal Muscle Mitochondrial Function,Change in Post Occlusive Reactive Hyperemia (PORH),,2020-10-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8826,NCT02353975,The accumulative excretion rate of SHR3824 and its metabolites in urine and feces,The number of volunteers with adverse events as a measure of safety and tolerability.,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1']
8827,NCT02315274,Glucose variability,Changes is severe hypoglycemia,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
8828,NCT02034695,The proportion of patients who have achieved a HbA1c level <7%.,"Service utilization outcomes measured by GOPC consultation, SOPC consultation, A&E and hospital attendance rates in the past 12 months.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
8829,NCT02104739,Monocyte NfkB Levels as Detected by Western Blotting,Peak Forearm Blood Flow,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8830,NCT04332003,Time to complete wound closure.,Change in oxygenation at the wound site,,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
8831,NCT05885906,Change in unstimulated Salivary flow rate,,,2023-07-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8832,NCT04616053,HbA1c,Lipids - triglycerides,,2021-09,UNKNOWN,INTERVENTIONAL,['NA']
8833,NCT05897528,Hospital Mortality,,,2021-10-14,COMPLETED,OBSERVATIONAL,['NA']
8834,NCT05936242,Postprandial glucose response,,,2021-05-18,RECRUITING,OBSERVATIONAL,['NA']
8835,NCT01251211,Average pain intensity on numerical scales in a self diary by the patient,Predictors of the response,Evaluate pain relief at 24 weeks,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8836,NCT06335771,Macrophage isolation in skeletal muscle tissue,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8837,NCT00063583,The primary endpoint will be the change in renal function from baseline to the end of the study period (12 months).,• Determine the relationship between % change in TGF-b1 levels and the change in GFR,,2003-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8838,NCT02139943,Percentage of Participants With Adverse Events,,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8839,NCT04893135,RANKL/OPG level,Sudoscan measurement,,2021-10-11,COMPLETED,INTERVENTIONAL,['NA']
8840,NCT05351359,step count,body mass index,,2022-04-25,RECRUITING,INTERVENTIONAL,['NA']
8841,NCT00137046,Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco),Insulin Antibodies,,2002-05,TERMINATED,INTERVENTIONAL,['PHASE3']
8842,NCT01298882,Total insulin secretion concentration,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
8843,NCT05794581,To assess area under the curve (AUC) in glucose metabolism during MMTT,Area under the acetaminophen concentration-time (AUC),,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE1']
8844,NCT00481598,"glycogen metabolism, gluconeogenesis, after 3 months of treatment;",,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
8845,NCT00065377,,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8846,NCT02024477,CD 34+ Cell Function,Arterial Stiffness,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8847,NCT00559767,,,,2006-06-30,COMPLETED,OBSERVATIONAL,['NA']
8848,NCT05486065,Change in Glycosylated Haemoglobin (HbA1c),Number of Treatment-emergent Severe Hypoglycaemic Episodes,,2022-08-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8849,NCT02999945,Fat Free Mass,macronutrients in breastmilk-protein,,2019-03,WITHDRAWN,INTERVENTIONAL,['NA']
8850,NCT02082704,HbA1c levels,Patient's perceptions of the optimal parameters for the SE game intervention.,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
8851,NCT05816941,HbA1c test,Sulcus bleeding index (SBI),,2016-01-03,COMPLETED,INTERVENTIONAL,['NA']
8852,NCT01514149,Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18,Time to Hyperglycemia Rescue,,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2']
8853,NCT03050827,Ocular Nerve Fiber Density,Autonomic Function Tests - Root Mean Square of the Successive Differences,,2014-05-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8854,NCT05806554,Accuracy,,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA']
8855,NCT01386645,Disposition Index,Glycemic Variability,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
8856,NCT06214520,HbA1c,Usability of the Empower+ app and Motivational Interviewing module,,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8857,NCT02383940,Change From Baseline in Hemoglobin A1C (A1C) at Week 12,Change From Baseline in Number of Hypoglycemic Events/Day (<=70 mg/dL) by Self-Monitored Blood Glucose (SMBG) at Week 12,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8858,NCT00506961,The percentage of patients achieving the combined treatment goal of LDL-C < 100mg/dl and non-HDL-C < 130 mg/dl at week 12 with rosuvastatin treatment compared with simvastatin treatment,Percentage of patients achieving the LDL-C goal of <70 mg/dL at Week;The mean percent change from baseline in lipid profile at week 4 and week 12;,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8859,NCT04575389,the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
8860,NCT00967837,To measure progress of wound healing in subjects that have failed conventional wound care healing treatments for 60 days,,,2006-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8861,NCT04026139,3-m timed up and go test [TUG],,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
8862,NCT05033054,Change in serum klotho levels at 12 week,Change in serum magnesium levels at 12 weeks,,2022-11-20,RECRUITING,OBSERVATIONAL,['NA']
8863,NCT04807959,Reduction of Visceral Adiposity,Increase of Intracellular Fluid,,2016-10-27,COMPLETED,OBSERVATIONAL,['NA']
8864,NCT01147861,Weighted mean AUC for glucose,"Weighted mean AUC for NEFA, glycerol, triglycerides, insulin, and C-peptide",,2010-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8865,NCT06318429,blood sugar,,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8866,NCT05487833,%triglyceride reduction,incidence of hypoglycemia,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
8867,NCT04313920,Plasma Glucose Concentration,Gastric Emptying,,2020-04-07,COMPLETED,INTERVENTIONAL,['NA']
8868,NCT02504658,Total Self-Efficacy Score on the Physical Activity and Healthy Food Efficacy Scale for Children,"Number of text message responses to Goal Setting Question, as a measure of Adherence",,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8869,NCT05092399,Effects of VLCD,Effects of VLCD and bariatric surgery,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
8870,NCT01718093,To determine the glucose lowering effect of metformin and sitagliptin alone and as combination therapy when used as adjuncts to insulin in adolescents with T1DM.,,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8871,NCT04930588,The receptor ErbB4 in saliva,Body Mass Index (BMI),,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
8872,NCT05752851,Fecal 16S rRNA gene sequencing,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
8873,NCT01745549,hematic fructosamine levels,patient's satisfaction,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
8874,NCT00253760,a global metabolic spectrum detectable by H-NMR,,,2004-02,COMPLETED,INTERVENTIONAL,['NA']
8875,NCT00336323,Percentage of Participants With <250 Microns or ≥ 50% Reduction in Retinal Thickening From Baseline Over All Study Visits,Distribution of Change in Visual Acuity Over All Study Visits,Change in Central Subfield Thickness From 3 to 6 Weeks Among Eyes That Received 2.5mg Bevacizumab at 6 Weeks and Had Within >11% Increase in Change of Central Subfield Thickness From 6 Weeks to 9 Weeks,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8876,NCT00988377,Blood glucose subjective appetite Food intake at 30 min,physical comfort palatability,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
8877,NCT00643760,Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data,Change From Baseline in Emotional Functioning as Assessed by the Profile of Mood States-Brief Form (POMS-B) at EOMT Using LOCF Data,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8878,NCT01704378,Occurrence of adverse events,7-point blood glucose profile,,2001-04-18,COMPLETED,INTERVENTIONAL,['PHASE4']
8879,NCT04745702,Oral Glucose Tolerance Test,TNF (Tumor Necrosis Factor - alpha),,2020-11-02,UNKNOWN,INTERVENTIONAL,['NA']
8880,NCT02176681,Mean glucose value of CGM [M] to be averaged from day 2 and day 3 of CGM,Mean HbA1C and Glycated albumin,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8881,NCT00665093,HbA1c,"FPG, PG profile, weight, % of subjects on target",,2007-05,COMPLETED,OBSERVATIONAL,['NA']
8882,NCT00815789,"Change in the outcome (SBP, Hb A1c, or LDL) from baseline to the 12 month evaluation.","Changes in CVD related health behaviors (e.g., aspirin use, medication adherence, exercise, and diet) as well as changes in stroke and CHD risk as assessed by the UPKDS risk engine",,2008-12,COMPLETED,INTERVENTIONAL,['NA']
8883,NCT02093221,Change From Baseline in Mixed Meal Tolerance Test (MMTMT) Stimulated C-peptide 2 Hour Area Under the Concentration-time Curve (AUC),Change From Baseline for Mean Daily Glucose Levels Prior to Meals and Bedtime,,2014-03,TERMINATED,INTERVENTIONAL,['PHASE2']
8884,NCT02265809,"Change from baseline of CD4 T regulatory cells, CD4 T effector cells and CD25 expression on T regulatory cells during treatment with ultra low dose IL-2",Safety and tolerability,Recruitment analysis,2014-10-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8885,NCT05465616,Insulin Resistance,Fasting glucose,,2022-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8886,NCT02925312,Percentage Change in Hemoglobin A1C From Baseline to 3 Months,Frequency of Eye Exams,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
8887,NCT02862730,Percent of Time With Sensed Glucose Between 3.9-10 mmol/L,Mean Amount of Glucagon Delivered,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
8888,NCT00119535,� Optimal timing of photocoagulation (prior to intervention and 12 months after interventions,� Meeting retinopathy screening and surveillance guidelines � Patient satisfaction with care � Resource utilization (during study and previous 12 months) � Intervention Costs (conclusion of study),,2004-08,COMPLETED,INTERVENTIONAL,['NA']
8889,NCT00068887,,,,1999-09,WITHDRAWN,OBSERVATIONAL,['NA']
8890,NCT03411213,Can diffuse optical tomography detect microvascular function?,Predicting coronary artery disease before angiography,,2016-01-11,COMPLETED,INTERVENTIONAL,['NA']
8891,NCT02082028,Change in HbA1c levels from baseline,Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS),,2012-06-27,COMPLETED,INTERVENTIONAL,['NA']
8892,NCT03414723,Assessment of PK parameter: AUCtau,Adverse events,,2018-01-15,COMPLETED,INTERVENTIONAL,['PHASE1']
8893,NCT05417152,Scanning session completion status,,,2022-06-29,COMPLETED,OBSERVATIONAL,['NA']
8894,NCT01511861,,,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
8895,NCT00937703,Comparison HbA1c means of the 2 groups profiting from a telemonitoring system compared to the reference group.,"Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician",,2008-12,COMPLETED,INTERVENTIONAL,['NA']
8896,NCT02524782,Part B: Change in LDL-C from baseline to Day 36,"Part B: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)",,2015-10-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8897,NCT02577159,Changes in fasting lipoprotein profiles,Changes in biomarkers for renal and hepatic function,,2015-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8898,NCT00437554,Efficacy : Change in HbA1c between baseline and endpoint,"Safety: episodes of hypoglycemia, adverse events, laboratory values including hematology, blood chemistry and urinalysis, vital sign and physical examination, Frequency with hypoglycemic episode",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8899,NCT03125694,Change from baseline in mean glycated hemoglobin (A1C) levels by sitagliptin vs. pioglitazone,,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8900,NCT02476409,Change in Body Weight at 48 Hours Stratified by Copeptin,Change in Body Weight at Day 8,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4']
8901,NCT04330911,Digital Spirometer,,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
8902,NCT00573456,The primary end point is to determine the therapeutic effects of far infrared radiation on all types of diabetes.,"The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of diabetes complications including blindness, heart and blood vessel disease and kidney failure.",,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
8903,NCT03920098,Pandemic Anxiety Scale,Offspring body fat,,2019-06-01,UNKNOWN,OBSERVATIONAL,['NA']
8904,NCT04210128,severe hyperglycemia,,,2019-12-20,COMPLETED,OBSERVATIONAL,['NA']
8905,NCT02802215,Number of participants with gestational diabetes by measuring plasma glucose levels ( mg / dl ).,Maternal adverse effects,,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8906,NCT00962806,Determine whether intensive exercise improves mitochondrial function by P31 MRS and mitochondrial number by peripheral blood analyses.,"Determine whether intensive exercise improves body composition, by DXA, and intramyocellular fat content, by 1H MRS.",,2009-08,UNKNOWN,INTERVENTIONAL,['NA']
8907,NCT04564742,"The hierarchical composite endpoint of Death (CV death followed by non-CV death), Hosp due to heart failure (adjudicated followed by investigator reported), Non-fatal MI, AF/flutter event, New onset of T2DM, last visit NYHA class, and weight loss ≥5%",Time to death of any cause,,2020-12-22,COMPLETED,INTERVENTIONAL,['PHASE3']
8908,NCT01878370,Proportion of patients with perfect composite high risk score,cholesterol (LDL),Each metric within the composite scores,2013-06,COMPLETED,INTERVENTIONAL,['NA']
8909,NCT05833100,Hematocrit Measurement,β-Ketone Testing of Subject Plasma Samples,,2022-08-15,TERMINATED,INTERVENTIONAL,['NA']
8910,NCT01069926,"Change-from-baseline variables will be calculated for the safety variables listed below, as the post-treatment value minus the value at baseline",To evaluate the safety of AZD1656 in T2DM patients with various degrees of renal impairment. To describe the pharmacodynamics of AZD1656 in T2DM patients with various degrees of renal impairment by assessment of 24-hours glucose profile,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8911,NCT04977011,Anxiety Visual Analog Scale.,Richards-Campbell Sleep Scale,,2019-01-02,COMPLETED,INTERVENTIONAL,['NA']
8912,NCT03961256,Progression From Prediabetes to Diabetes,Adverse Events for Exenatide SR Intervention,,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8913,NCT01909245,"Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < or = 6.5% at 5 years post-transplant",Proportion of subjects who are free of severe hypoglycemic episodes AND have a hemoglobin A1c < or = 7.0%,Incidence of Gastrin-17 use for treatment of islet graft dysfunction AND incidence of change or early discontinuation of Gastrin-17 treatment,2013-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8914,NCT00212303,Blood pressure at 6 months,Systemic inflammation at 6 months,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4']
8915,NCT02836873,Change From Baseline in HbA1c at 24 Weeks,Change From Baseline in HbA1c in Subjects With Stage 3b CKD (eGFR 30 to 44 mL/Min/1.73 m2) at Week 24,,2016-09-23,COMPLETED,INTERVENTIONAL,['PHASE3']
8916,NCT05095389,DFU Closure Rate,Percent Reduction of Wound Area,,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8917,NCT03491436,blood glucose 2 hours after meal 3,,,2017-05-01,WITHDRAWN,INTERVENTIONAL,['NA']
8918,NCT02445508,Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve,Appetite as assessed by Visual analog scale score,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
8919,NCT02637245,Changes in disease state characteristics in response to therapy,Changes in visual acuity using ETDRS visual acuity assessment,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
8920,NCT01739868,To identify new biomarkers,Number of patients with others cardiovascular risk factors,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
8921,NCT00480805,To determine the antihypertensive effectiveness of HYZAAR as compared to Ramipril as measure by SiSBP at Week 4,To determine the safety anf tolerability of HYZAAR as compared to Ramipril as seen in overall adverse experiences for the duration of the study,,2001-08-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8922,NCT01258075,Percent Change in Hemoglobin A1c (HbA1c) From Baseline to Month 6,Number of Participants Requiring Rescue Medication Who Initially Met Rescue Criteria,,2011-02-24,COMPLETED,INTERVENTIONAL,['PHASE4']
8923,NCT00505882,The change in weight (kg) will be compared between as well as within the placebo and the pramlintide treatment group from baseline to the end of the study.,mixed meal tolerance test-the C-peptide area under the curve The HOMA R and McAuley's index HbA1c The event rate of severe hypoglycemia Waist circumference Cardio C-reactive protein level DQOL Safety parameter,,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8924,NCT05939895,To diagnose missed cases of prediabetes.,,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
8925,NCT00469365,"The primary outcome was the number of days from the index date until the next date on which the patient filled a prescription for any qualified medication, or until the end of the study follow-up period.","Secondary outcomes included indicators for whether the patient filled any medication within 30 days for their chronic disease, and whether the patient filled any medication within 30 days.",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8926,NCT00433628,,,,2007-02-07,COMPLETED,OBSERVATIONAL,['NA']
8927,NCT05697991,Prevalence of hepatic steatosis in T2DM,Pathogenesis of progressive disease,,2015-03-23,RECRUITING,OBSERVATIONAL,['NA']
8928,NCT05267990,rate of major coronary heart disease,medical expenditure,,2022-03-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8929,NCT01901055,HbA1C Level,Vigilance,,2014-02-13,TERMINATED,INTERVENTIONAL,['NA']
8930,NCT02554877,Change From Baseline in Glycosylated Hemoglobin (HbA1c) (%) at Week 12 as Compared to Placebo,"Changes From Baseline in Body Weight at Weeks 2, 4, 8, and 12.",,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8931,NCT00005481,,,,1996-09,COMPLETED,OBSERVATIONAL,['NA']
8932,NCT00711152,Change in glycated hemoglobin level,Hospitalizations with total length of stay,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8933,NCT00845793,Changes in the results of the nutrition quality questionnaire,Changes in anthropometric measures Changes in physical activity levels,,2009-04,UNKNOWN,INTERVENTIONAL,['NA']
8934,NCT03338829,Frequency of glucose monitoring,,,2016-05-05,UNKNOWN,INTERVENTIONAL,['NA']
8935,NCT03549390,Insulin area under the curve (AUC),Physical fitness and suitability to exercise.,,2018-10-30,COMPLETED,INTERVENTIONAL,['NA']
8936,NCT03764410,blood test for glycated hemoglobin,,,2016-12-20,COMPLETED,INTERVENTIONAL,['NA']
8937,NCT00162357,Evaluate symptom-free heart blockages that develop following initial opening in patients with Type II diabetes mellitus based on Cardiolite imaging,Compare patient hospital and out-patient cost for cardiac care for each group of patients (MPI versus standard care).,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8938,NCT02467920,the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin.,The incidence and rate of hypoglycaemic events during the study,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8939,NCT00006426,,,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8940,NCT00213122,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
8941,NCT04153981,Number or Participants With Hypoglycemic Events,Change From Week 4 in Insulin Treatment Satisfaction Questionnaire (ITSQ),,2019-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
8942,NCT06141941,Glucose values,,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
8943,NCT03736486,"Success (evaluated by Yes/No format) recruiting and establishing a pilot cohort of 100 Latino adults with Type 2 Diabetes and creating data collection methods to describe genetics, biology, behavior, psychology, & environment in Type 2 Diabetes",Trust in physician measured by the Trust in Physician (TPS) questionnaire,"Success measured by the number of health care workers trained, upskilled, and employed to be community health care workers (Especialistas) and the number of participant encounters with a trained health care worker",2017-08-24,COMPLETED,OBSERVATIONAL,['NA']
8944,NCT00868790,Number of Participants Who Discontinued Study Treatment Due to an AE,Percentage Change From Baseline (BL) After 4-Week Treatment in Low-Density Lipoprotein C (LDL-C) Levels,,2009-03-24,TERMINATED,INTERVENTIONAL,['PHASE2']
8945,NCT01633684,Bone mineral Density,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
8946,NCT04661917,Change from baseline in urine albumin-to-creatinine ratio (UACR) to the end of treatment (Visit 6),Frequency of treatment-emergent adverse events (TEAEs),,2021-05-31,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8947,NCT01075347,Patients With Corneal Epithelial Healing Time Within 14 Days,"Patients With Corneal Complications Due to Delayed Surface Re-epithelization (e.g. Infectious Corneal Ulcer, Corneal Melting, Sterile Corneal Ulcer, Corneal Neovascularization)",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8948,NCT02036554,"Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months",Prevalence of NODAT at 12 month(V6),,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
8949,NCT06273215,Pharmacokinetics of study drug,Genotype of OATP and BCRP,,2023-03-05,RECRUITING,INTERVENTIONAL,['PHASE4']
8950,NCT05856578,"Concentration of MBG, TIR, TAR, TBR, MAGE, MBG and LAGE","Concentration of adiponectin, leptin,IL-1,IL-6 andTNF-α",Incidence of hypoglycemia,2022-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
8951,NCT02137057,"Change of Heart rate variability during spinal anesthesia : total power, power of LF and HF, and LF/HF ratio",,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
8952,NCT01660789,BMI,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
8953,NCT02651181,"Time in range of sensor glucose data between 70 mg/dL to 180 mg/dL,during day time (6am-12am)",Incidence of Severe Hypoglycemia,Total insulin dose,2016-06,COMPLETED,INTERVENTIONAL,['NA']
8954,NCT04003259,Change in systolic and diastolic blood pressure (mmHg),Fitness index,,2009-01-01,COMPLETED,INTERVENTIONAL,['NA']
8955,NCT03866343,Insulin sensitivity,Microvascular function,,2018-09-07,COMPLETED,INTERVENTIONAL,['NA']
8956,NCT04108065,Gallbladder emptying,GDF15,,2019-10-02,COMPLETED,OBSERVATIONAL,['NA']
8957,NCT05912218,Lower limb atheroma plaque inflammation,Lower limb atheroma plaque progression,,2023-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8958,NCT03380546,Composite endpoint: birth weight ≥ 90th percentile for gestational age (large for gestational age: LGA) and/or neonatal hypoglycemia and/or shoulder dystocia and/or birth injury.,Conservation of serum and plasma; cord fluid. The samples may be used for further analyses ancillary studies and which could be beneficial for GDM care based on evolution in scientific knowledge.,,2018-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8959,NCT02645383,Visual analog score for pain,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
8960,NCT02360254,Change in HbA1c,Glucose variability,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
8961,NCT03517111,Food Insecurity,Parent and Adolescent Diet - Refined Grains (oz),,2018-09-26,TERMINATED,INTERVENTIONAL,['NA']
8962,NCT01559896,"The change (baseline vs 2 hours, and baseline vs 2 days) in arterial stiffness measured as carotid-femoral pulse wave velocity","Changes in glucose and insulin concentrations and calculated HOMA-index, incretins, lipids, characteristics of the microcirculation, and non-invasively assessed upper-arm blood pressure and central aortic systolic blood pressure and heart rate changes",,2011-09,COMPLETED,INTERVENTIONAL,['NA']
8963,NCT01474538,Glycosylated Hemoglobin A1C (HbA1c) at Endpoint,Percentage of Participants With Hypoglycemic Events,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8964,NCT03286751,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Versus Time Curve (AUC),Glucodynamics: Total Amount of Glucose Infused (Gtot),,2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE1']
8965,NCT00622323,"To determine the proportion of patients experiencing an adverse event and a list of the experienced adverse events, that would occur among Filipino patients with type 2 diabetes and inadequate glycemic control treated with exenatide",To evaluate the change from baseline to endpoint in HbA1c and body weight of Filipino patients with type 2 diabetes mellitus treated with exenatide who are taking metformin and/or a sulfonylurea but have not achieved adequate glycemic control.,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
8966,NCT04529239,"Glucose biomarker data from the continuous glucose monitoring device, which will be analyzed as a function of different homeostasis responses from the 3 different cohorts of individuals (i.e., i) low to moderate risk; ii) high risk, iii) very high risk).",,,2020-08-31,COMPLETED,OBSERVATIONAL,['NA']
8967,NCT02033499,Mean Difference in Health-related Quality of Life Scores From Baseline to 52 Weeks,Number of Participants on Specified Diabetes Medications at Baseline and Follow-up,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8968,NCT06101368,Dynamometry lower limb,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8969,NCT04192409,Change in glucose level measured by HbA1C level,low density lipoprotein,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
8970,NCT00975169,we plan to conduct a case-control study to test the association between single nucleotide polymorphisms (SNPs) in certain candidate genes and TZDs related peripheral edema,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA']
8971,NCT05926388,Insulin Administration Observation Form 2,,,2022-01-10,COMPLETED,INTERVENTIONAL,['NA']
8972,NCT02459938,Percentage of subjects achieving normoglycemia,Area under the plasma concentration versus time curve (AUC),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8973,NCT01571232,The Change in Central Foveal Thickness (Microns on High Resolution OCT).,The Change in Mean Central Amplitude on Multi-focal ERG From Baseline.,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8974,NCT05640180,"Time to first occurrence of the composite endpoint of Cardiovascular (CV) death or non-fatal CV event (i.e. myocardial infarction, stroke, or hospitalization for heart failure)","Time to first occurrence of the following composite endpoint: onset of kidney failure, a sustained decrease in eGFR of ≥ 57% from baseline over at least 4 weeks or renal death",,2022-11-23,COMPLETED,OBSERVATIONAL,['NA']
8975,NCT03374176,Probing Depth,Total Count of All Teeth Lost Across All Participants,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8976,NCT05476276,Daily 0-10 pain NRS,Opioid Use Questionnaire (OUQ),Neuropathy Examination,2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
8977,NCT03782259,Global Myocardial Strain,T2 Relaxation Time,hsCRP,2019-02-26,COMPLETED,INTERVENTIONAL,['PHASE4']
8978,NCT00941954,Change in ambulatory activity (walking),Change in ambulatory activity (walking),,2009-09,COMPLETED,INTERVENTIONAL,['NA']
8979,NCT01487408,HbA1c (glycosylated haemoglobin),Adverse events,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
8980,NCT02734277,Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC),Severity of Grade 3 or Higher Adverse Events (AEs) of Interest,,2016-08-18,RECRUITING,OBSERVATIONAL,['NA']
8981,NCT01935804,"Change in mean percentage change in BMD at various sites by Dual energy X-ray absorptiometry(DXA) from baseline and at 6, 12 months in PIO versus MET treatment group.",Bone turnover Markers and other Biomarkers,Exploratory and safety outcomes,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8982,NCT02320344,Problem Areas in Diabetes,Triglycerides,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
8983,NCT01621776,The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch.,Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
8984,NCT03480945,Endothelial function,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
8985,NCT01398592,demonstrate that the FPG after 14 days of treatment with Vildagliptin is superior to the FPG after 14 days of treatment with Sitagliptin,To assess the difference in FPG between vildagliptin and sitagliptin in patients with type 2 diabetes mellitus on concomitant treatment with metformin,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8986,NCT06050577,Procollagen type 1 N-terminal propeptide (P1NP),Body mass index (BMI),Osteogenic potential,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8987,NCT00298129,,,,2004-02,COMPLETED,OBSERVATIONAL,['NA']
8988,NCT00696111,Sleep recording/polysomnography,24-hour hormonal profiles,,2007-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8989,NCT06009055,Heart rate variability（HRV）,,,2023-09-17,RECRUITING,INTERVENTIONAL,['NA']
8990,NCT00961909,Change in hemoglobin A1c (HbA1c),"Change in metabolic parameters: glucose, insulin, C-peptide",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8991,NCT00289614,Increase in serum creatinine (SCr) at 48-72 hours post dose,Decrease in estimated glomerular filtration rate (eGFR) at 48-72 hours post dose; occurrence of adverse events,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8992,NCT04270656,"Variation of hepatic steatosis, between the insulin pump therapy (CSII) vs Multi injection treatement (MDI) groups.","Calculation negative predictive values of the FLI for the detection of fatty liver in this population, by using the quantification of hepatic MRI as Gold Standard.",,2021-02-05,UNKNOWN,INTERVENTIONAL,['NA']
8993,NCT06235762,Heart Rate (HR) beats per minute (bpm),"Physical activity level (sedentary, moderate, advanced)",,2020-08-16,COMPLETED,INTERVENTIONAL,['NA']
8994,NCT01295177,% of Wound healing closing measured each week,Complete wound healing,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8995,NCT02503865,Systolic/ Diastolic Blood Pressures (mm Hg),Immunoassay Cortisole in Blood,,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8996,NCT03470454,affection of estimated glomerular filtration rate,change in serum uric acid,Affection of albumin creatinine ratio,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
8997,NCT00680706,Effect of Thiamine Supplementation on Dyspnea,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8998,NCT04437537,Wound Microbiome,Wound pH,,2022-05-15,UNKNOWN,OBSERVATIONAL,['NA']
8999,NCT03026218,Reduction in the number of individuals requiring pharmacotherapy for treatment of gestational diabetes,Reduction in the number of infants with neonatal hypoglycemia.,,2017-04-15,COMPLETED,INTERVENTIONAL,['NA']
9000,NCT00365495,Mitochondrial respiratory measurements. The investigations are carried out by two rounds - one before Christmas and one after.,mitochondrial production of free oxygen radicals,,2006-08,UNKNOWN,INTERVENTIONAL,['NA']
9001,NCT00151190,"HbA1c, Triglycerides, Cholesterol, Urine Microalbumin, Blood Pressure,","Patients' attitudes and knowledge about diabetes self-management, American Diabetes Association standards of care.",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9002,NCT01144520,Ex vivo leukocyte function by measuring ROS production,Ex vivo NADPH oxidase gene and protein expression,,2010-03,TERMINATED,OBSERVATIONAL,['NA']
9003,NCT03556098,plasma glucose concentration,Pulse,,2019-02-22,COMPLETED,INTERVENTIONAL,['NA']
9004,NCT03271879,"The primary endpoint is the burden of premature ventricular complexes, defined as the PVCs percentage of all beats in a pre-specified period captured on ICD or CRTD/P device",Left ventricular ejection fraction (EF),,2018-02-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
9005,NCT04596631,Change from baseline in glycosylated haemoglobin (HbA1c),SNAC plasma concentrations,,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE3']
9006,NCT00272077,SMBG values,results of CGMS,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9007,NCT05151276,The Turkish Multidimensional Diabetes Questionnaire,triglyceride,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
9008,NCT01240785,Birth Weight Per Arm,Child Outcome at 2 Years Per Arm,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9009,NCT00570141,Percent Wounds Closed,,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9010,NCT06066021,Change in the Diabetes Knowledge Questionnaire (DKQ - Portuguese version),Measure the change in BMI,,2023-10-13,RECRUITING,INTERVENTIONAL,['NA']
9011,NCT01821508,The primary endpoint will be the proportion of patients that present normalization of the albumin/creatinine ratio in isolated urine samples (normal value considered as an albumin/creatinine ratio of less than 30 μg/mg ).,Changes in hepatic fibrosis,,2013-04-18,COMPLETED,INTERVENTIONAL,['NA']
9012,NCT00764361,Number of Participants Without Adverse Events,Analyze the Molecular Changes in Pro-inflammatory Cytokine Levels That Occur in Diabetic Foot Ulcers as a Function of Healing Rate in the Presence /Absence of NanoDOX Hydrogel (1% Doxycycline Monohydrate Gel),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9013,NCT01191983,Percentage of Participants Maintaining Hb Concentration Within the Target Range (10-12 g/dL) During EEP,Short Form-36 Health Survey (SF-36) score,,2010-08-13,COMPLETED,INTERVENTIONAL,['PHASE4']
9014,NCT04276207,Time to Recovery From Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog) After Pump Suspension,Pharmacokinetics (PK): Time to Maximum Observed Insulin Lispro Concentration (Tmax) Following Administration of LY900014 and Insulin Lispro (Humalog),,2020-02-25,COMPLETED,INTERVENTIONAL,['PHASE1']
9015,NCT05144672,The relation between different stages of diabetic nephropathy and irisin level.,,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
9016,NCT00498147,Rates of cardiovascular events and other complications of diabetes compared to provincial and national rates,"The secondary outcomes will be total mortality, CV- related events, and other selected complications of diabetes.",,2007-07,UNKNOWN,OBSERVATIONAL,['NA']
9017,NCT01805297,Rate of Resolved Post-operative Vitreous Hemorrhage.,Changes in Mean Central Retinal Thickness.,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9018,NCT01966380,Absorption of Wound Exudates.,,,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2']
9019,NCT04726319,Changes in risk-appropriate screening based on family history,Attitudes towards the FHAMe intervention,,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9020,NCT00741026,Plasma Free Fatty Acid,Diastolic Blood Pressure,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
9021,NCT02815657,The area under the plasma concentration-time curve (AUC) of valsartan,The number of volunteers with adverse events as a measure of safety and tolerability,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9022,NCT02866565,Percentage of patients achieving 100% wound closure,change in quality of life assessed by the SF-36 QoL survey from baseline,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9023,NCT02489942,Number of Patients With Adverse Drug Reactions (ADRs),Change From Baseline in Fasting Plasma Glucose (FPG) at the Last- Observation During Observation Period,,2015-06-12,COMPLETED,OBSERVATIONAL,['NA']
9024,NCT05797051,Microhyperspectral image of urine specimen,,,2023-05-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9025,NCT03912909,Reduction in muscle sympathetic nerve activity,Change in glycemic control,,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9026,NCT02442921,Change of urinary protein excretion ( mg/24hrs) from baseline to 18 months.,,,2016-02-22,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9027,NCT04509193,Any major or clinically-relevant nonmajor bleed resulting in hospitalization,New-onset vascular dementia,,2020-08-21,COMPLETED,OBSERVATIONAL,['NA']
9028,NCT01691989,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9029,NCT05316298,Postoperative wound healing,Foot Function Index (FFI) scores,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
9030,NCT02414958,Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) ),Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26,,2015-06-30,COMPLETED,INTERVENTIONAL,['PHASE3']
9031,NCT02987556,Percentage of time spent in the tight glycemic control area 70-180 mg/dl continuously measured for 12 weeks,Percentage of time spent in blood glucose <70 mg/dl continuously measured for 12 weeks,,2017-03-30,COMPLETED,INTERVENTIONAL,['NA']
9032,NCT03859245,Hard Drusen in the Mid-periphery pathology,Triglycerides/HDL ratio,,2019-02-23,UNKNOWN,INTERVENTIONAL,['NA']
9033,NCT03467659,Appetitive behavior,,,2017-02-16,COMPLETED,INTERVENTIONAL,['NA']
9034,NCT01211717,"Measuring Pain, using the short form McGill pain questionnaire",Measuring Muscle strength of the studied muscle,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
9035,NCT00422357,Blood pressure every two weeks.,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9036,NCT01612468,Change in HbA1c,Quality of life,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9037,NCT03527537,Composite Neonatal Outcome,Preeclampsia,,2021-05-04,RECRUITING,INTERVENTIONAL,['PHASE4']
9038,NCT01542554,Change in blood HbA1c,Change in blood pressure,,2012-03,UNKNOWN,INTERVENTIONAL,['NA']
9039,NCT00613951,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9040,NCT04876079,Time spent of glucose levels < 4.0 mmol/L,Percentage of participants experiencing a rebound hyperglycemia (≥ 10.0 mmol/L) within the first hour following the first carbobydrates consumption,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
9041,NCT02017132,Changes in measurements of body mass indicators,Changes in blood pressure,Change in urinary cortisol-to-cortisone ratio,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
9042,NCT02551874,Mean Change From Baseline in HbA1c at Week 24,Change From Baseline in the Mean Value of 24-hour Glucose at Week 2,,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3']
9043,NCT03178253,percentage of hypothyroidism in patients of type 2 diabetes with diabetic nephropathy,,,2017-06-30,UNKNOWN,OBSERVATIONAL,['NA']
9044,NCT04488887,coefficient of variation (CV),,,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA']
9045,NCT06080451,Proportion of patient participants with subsequent follow-up visit within 3 months,Sustainability,,2023-10-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9046,NCT00432029,Forearm Blood Flow,,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
9047,NCT00280865,Absolute change from baseline to end of randomized treatment period in fasting plasma glucose (FPG),"To evaluate diabetes-specific instruments, Audit of Diabetes Dependent Quality of Life (ADDQoL) and The Diabetes Treatment Satisfaction Questionnaire (DTSQ) (s and c) in the study population and estimate the effect size of the instruments in patients r",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9048,NCT03804125,"the number and type of suspected adverse drug reactions, including serious and non-serious cases",,,2021-09-01,WITHDRAWN,OBSERVATIONAL,['NA']
9049,NCT04507438,Change in Hemoglobin A1C,Change in creatinine,Change in albumin,2019-07-12,TERMINATED,INTERVENTIONAL,['PHASE2']
9050,NCT01516476,Change in hemoglobin A1c (HA1c),Safety (incidence of adverse events),,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2']
9051,NCT05109949,Pulse wave velocity,Blood pressure,,2020-03-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
9052,NCT02064881,Change in postprandial lipemia at 4 months,Number of Participants with Serious and Non-Serious Adverse Events,,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9053,NCT02928666,Number of conflicting recommendations detected out of total number of conflicts,,,2018-10,UNKNOWN,INTERVENTIONAL,['NA']
9054,NCT02769377,HbA1c,Hypoglycemia,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
9055,NCT00101426,Efficacy,Safety,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9056,NCT05369871,Glycemic control evaluation for the 12-week main study,System satisfaction questionnaire evaluation,,2022-08-29,COMPLETED,INTERVENTIONAL,['NA']
9057,NCT05168605,Change in Blood pressure,,,2022-07-27,RECRUITING,INTERVENTIONAL,['NA']
9058,NCT04255004,probability of healing at 24 months,rest pain,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
9059,NCT00533494,"HbA1c, LDL, systolic blood pressure",,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9060,NCT03970044,MAGE,Blood Glucose Time In Range,,2019-07-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9061,NCT04978662,chronotype,treatment,,2021-07-06,UNKNOWN,OBSERVATIONAL,['NA']
9062,NCT05969015,Glycemic control,Diabetes Attitude Questionnaire (ATT-19),Adverse Events,2022-01-15,RECRUITING,INTERVENTIONAL,['NA']
9063,NCT02470455,Change in Glycosylated Hemoglobin (HbA1c) from baseline,Lipid profile,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
9064,NCT01355718,Incidence of serious Adverse Drug Reactions (SADRs) including major (serious) hypoglycaemic episodes,Change in HbA1c,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
9065,NCT01845857,"Change in Health Status (symptoms, activities limitations)",Change in Health Care Utilization,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
9066,NCT03663738,HbA1c,Quality of life related to health,,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
9067,NCT00571519,Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus,Number of Participants With Treatment-Emergent Adverse Events by System Organ Class and Preferred Term Following Rivoglitazone or Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus,,2007-11-14,TERMINATED,INTERVENTIONAL,['PHASE3']
9068,NCT01510093,Pharmacokinetic profiles of endogenous insulin and Insulin Aspart,Pharmacodynamic glucose profiles,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9069,NCT00344240,Physical activity,,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
9070,NCT01427998,Serum glucose,Plasma insulin,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9071,NCT05957224,Change in plasma glucose concentration post oral intake of shake,"Sensory analysis of taste, texture, smell and appearance of shakes",,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9072,NCT05668819,Change in PPG,Change in WHR,,2023-02-09,RECRUITING,INTERVENTIONAL,['NA']
9073,NCT03328546,Physical functioning,,,1989-01-01,COMPLETED,OBSERVATIONAL,['NA']
9074,NCT04663295,Change in Time in Target Range (% of Sensor Glucose (SG)): 70 mg/dL (3.9 mmol/L) ≤ SG ≤ 180 mg/dL (10 mmol/L),"Time in Specific Range Stratified by Baseline HbA1c Ranges (< 7%, 7 - < 7.5%, 7.5 - 8%, > 8%)",,2020-10-31,COMPLETED,INTERVENTIONAL,['NA']
9075,NCT02310009,Beta-cell function,Glucose disposition,,2014-12,WITHDRAWN,INTERVENTIONAL,['NA']
9076,NCT05989867,steamed bun meal test result 3,glycemic control,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
9077,NCT00961857,The area under the plasma concentration vs. time curve (AUC) after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets,Peak plasma concentration (Cmax) of sitagliptin and metformin after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets,,2005-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9078,NCT01224548,weight,hip circumference,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
9079,NCT02699736,"Incidence of long-term virological, immunological and morbidity and mortality outcomes across different regions in Europe; and demographic, clinical, therapeutic and viral factors associated with these outcomes",Incidence of toxicities related to direct acting antivirals by regions,,1994-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9080,NCT02946632,"Proportion of patients who met HbA1c < 6.5% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 104 weeks",Changes in fat and lean mass from baseline to at 104 weeks,AEs/SAEs,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
9081,NCT01180530,The incidence of technical complaints related to adverse reactions,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
9082,NCT04201171,HRQOL,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
9083,NCT01616472,"New diagnoses of diabetes, hypertension, cataracts, osteoporosis, or avascular necrosis",,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
9084,NCT01857375,Insulin Dosing Accuracy (in units),Patient satisfaction with method of insulin administration measured by questionnaire.,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
9085,NCT05877378,Health-related effects on quality of life.,,,2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9086,NCT03337412,Chronological evolution of the physical activity score of patients benefiting from the education program with intervention of the adapted physical activity educator,musculoskeletal disorders,,2017-11-13,COMPLETED,INTERVENTIONAL,['NA']
9087,NCT02685449,Postprandial glycemia,The difference between the maximum and baseline glucose level,,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
9088,NCT06051318,Postprandial subcutaneous interstitial fluid glucose measured by continuous glucose monitor (CGM),Participant's gut microbiome species richness,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9089,NCT05370339,Assessment of facilitators and barriers to good sleep quality and duration,Identification of common causes of sleep disruptors in adolescents with type 1 diabetes,,2022-06-15,COMPLETED,OBSERVATIONAL,['NA']
9090,NCT03818568,glomerular filtration,Mortality,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
9091,NCT03191331,gestational weight gain (GWG),Eating habits,,2017-06-06,COMPLETED,INTERVENTIONAL,['NA']
9092,NCT00424333,Primary outcome is 24 week change in baseline in HbA1c.,Patient satisfaction and preference.,,1999-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9093,NCT05389254,The CCU occupancy rate,Major adverse cardiovascular events after 3 months,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9094,NCT02943486,Wound size change,Presence of Exudate,,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9095,NCT01486875,Incidence of major hypoglycaemic events,Fasting Plasma Glucose (FPG),,2006-01,COMPLETED,OBSERVATIONAL,['NA']
9096,NCT02835989,Change in number of repeat EMS calls,Change in number of hospital admissions,,2018-10-25,COMPLETED,INTERVENTIONAL,['NA']
9097,NCT01835730,Incidence and severity of adverse events including hypoglycemia,Pharmacodynamic Response,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9098,NCT02325466,Mean Change in High Shear Blood Viscosity,Mean Change in Microvascular Blood Flow Composite Score,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9099,NCT05120219,Pharmacokinetics parameters of SHR3824 and Metformin after multiple dose: AUCss,The incidence and severity of adverse events/serious adverse events,,2021-10-13,UNKNOWN,INTERVENTIONAL,['PHASE1']
9100,NCT00615212,drug plasma levels flurbiprofen:,Daily predose trough GSK376501 plasma concentrations when administered alone for 7 days (Days 4-13).,,2008-01-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9101,NCT03669887,Proportion achieving body weight goal,% of achieving dietary intervention goal,,2018-09-12,COMPLETED,INTERVENTIONAL,['NA']
9102,NCT03243136,Type 2 diabetes,,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
9103,NCT03863561,Validity of the SCPI with HbA1c,Responsiveness of the total SCPI score to an intervention,,2017-10-11,COMPLETED,OBSERVATIONAL,['NA']
9104,NCT06167499,Rate of glycated hemoglobin HBA1c,Evaluation of long-term complications over 18 months,,2024-02-09,RECRUITING,INTERVENTIONAL,['NA']
9105,NCT04135287,HbA1c,Fasting Plasma Glucagon,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9106,NCT02109029,Part B: Pharmacokinetics: ISF-to-Serum Concentrations,,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9107,NCT03069729,Pattern of thermal recovery,Correlation of DPN severity levels and DR severity levels,,2017-03-08,COMPLETED,OBSERVATIONAL,['NA']
9108,NCT01902043,"Process of care indicators and the following outcomes of care: HbA1C, quality of life (QoL), Patient Assessment of Chronic Illness Care (PACIC)",,Knowledge of and participation in the activities/projects of the Programme cantonal Diabète (PcD),2011-09,UNKNOWN,OBSERVATIONAL,['NA']
9109,NCT00600366,HbA1c,Incidence of adverse events,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9110,NCT01503164,Insulin Sensitivity (SI),Area Under the Curve Assessed by Oral Glucose Tolerance Test (OGTT),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
9111,NCT06061510,Diastolic blood pressure,Rate of smoking among participants,,2019-06-08,COMPLETED,INTERVENTIONAL,['NA']
9112,NCT05456984,Empower up,Diabetes treatment,,2022-05-03,COMPLETED,OBSERVATIONAL,['NA']
9113,NCT06163248,Change in insulin resistance (M value),Change in lipid profile (mg/dl),Hunger and satiety (score),2024-01-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9114,NCT00565318,Change in urinary excretion of: - Kidney injury molecule-1 (KIM-1) - Albumin,"Change in urinary excretion of: β2 microglobulin, macrophage inhibiting factor (MIF), monocyte chemo-attractant protein-1 (MCP-1), and other advanced glycation end-products (AGEs).",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9115,NCT00290927,Safety of HMR1964,"change in HbA1C from baseline to week 16,consecutive change in HbA1C every 4 wks,plasma glucose parameters, symptomatic hypoglycemia (comparison of HMR1964 intensive therapy, mono-or OHA combination therapy, with OHA therapy).",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9116,NCT00461058,"Incidence of cardiovascular death, hospitalization or clinic visit for heart failure with i.v. administration of diuretics during 26 week treatment period.","Efficacy: Change from baseline to week 26 in Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), fasting plasma insulin (FPI) and lipid profile.",,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9117,NCT01752842,Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent,Change in C24:0/C16:0 Ceramide Ratio,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
9118,NCT02308735,Phosphatidylethanol Level,,,2014-03,TERMINATED,OBSERVATIONAL,['NA']
9119,NCT00537251,"Compare efficacy of insulin glargine & short acting insulin (Lispro), NPH insulin regime as basal insulin and regular insulin for meal insulin for metabolic control, evaluated by means of HbA1c .",,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9120,NCT04154020,Mean time to healing of ulcers(s) in treated limb,Incidence of new ulcers on feet,,2019-11-30,COMPLETED,INTERVENTIONAL,['NA']
9121,NCT03242109,Diabetes,,,2005-03-01,COMPLETED,OBSERVATIONAL,['NA']
9122,NCT00221156,Cardiovascular event free survival time,Change in lipid profile,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9123,NCT04018105,Area under the curve of D-Xylose,Area under the curve of GLP-1,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9124,NCT01874483,Occurrence of adverse events,"Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)",,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9125,NCT03376490,Muscle strength (Leg extension),Vitamin D deficiency,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
9126,NCT06083909,To explore the correlation of sarcopenia and obesity on insulin resistance,To explore the correlation of sarcopenic obesity and glucometabolic and cardiovascular risk.,,2022-04-06,COMPLETED,OBSERVATIONAL,['NA']
9127,NCT04357392,Number of patients with HbA1c <7% at 12 and 24 weeks,"Blood glucose fluctuation at 4, 12 and 24 weeks",,2020-05-20,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9128,NCT05672433,Area under the curve for glucose during mixed meal test (mmol/L*min),Food consumption in kilocalories (kcal),Fasting Homeostatic Model Assessment for Insulin Resistance by C-peptide (arbitrary unit).,2022-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9129,NCT05140551,To assess the implementation of COMPASS in terms of patient adherence to COMPASS online sessions and number and duration of therapist support calls attended.,,,2022-04-06,COMPLETED,INTERVENTIONAL,['NA']
9130,NCT03173391,Change from baseline in HbA1c,Incidence of Treatment-Emergent Adverse Events over time,,2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE3']
9131,NCT04233203,MAGE,TIR-TAR-TUR,Severe adverse effects,2020-01-31,COMPLETED,OBSERVATIONAL,['NA']
9132,NCT05223569,Changes in visual acuity,Changes in visual acuity after 48 weeks,,2022-03-03,RECRUITING,INTERVENTIONAL,['NA']
9133,NCT05799781,Percent of time with sensed glucose between 70-180 mg/dl,Mean amount of insulin delivered per day,,2023-03-13,RECRUITING,INTERVENTIONAL,['NA']
9134,NCT05071950,Postprandial glucose (mg/dl),side-effects of D-allulose,,2021-03-10,COMPLETED,INTERVENTIONAL,['NA']
9135,NCT02903264,Gestational diabetes mellitus diagnosed by an endocrinologist,Leukocytosis as an indicator of inflammation,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
9136,NCT00761852,To test the hypothesis that activation of protein kinase Cß (PKCß) impairs vascular reactivity in patients with diabetes mellitus,,,1999-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9137,NCT00298844,,,,2006-01,UNKNOWN,OBSERVATIONAL,['NA']
9138,NCT00437775,,,,2007-01,UNKNOWN,OBSERVATIONAL,['NA']
9139,NCT02520076,To demonstrate AAT efficacy in preventing non-immunologic loss of transplanted islet mass in a single-donor islet transplant.,To demonstrate AAT efficacy in the prevention of long-term metabolic burn-out.,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9140,NCT00255541,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2004-09,TERMINATED,INTERVENTIONAL,['PHASE3']
9141,NCT02582814,Vital Signs (Blood Pressure),Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg,,2015-10-26,COMPLETED,INTERVENTIONAL,['PHASE3']
9142,NCT04797442,Fasting plasma glucose levels,Fat mass,,2021-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9143,NCT00072904,The primary objective of this research is to determine whether treatment with either insulin or an oral diabetes agent that increases endogenous insulin secretion will improve BMI and pulmonary function in cystic fibrosis patients who have diabetes,,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9144,NCT06239506,alternative FRs,levels of FPG,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
9145,NCT01930448,Change in Incretin Effect,Change in Body Composition,,2008-09,WITHDRAWN,OBSERVATIONAL,['NA']
9146,NCT01068756,AUC (area under the concentration-time curve) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data,Tmax (time of maximum observed concentration) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data,,2010-03,TERMINATED,INTERVENTIONAL,['PHASE1']
9147,NCT04550468,Change from Baseline Hemoglobin A1c at 12 weeks,Continuous glucose monitoring,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
9148,NCT04950283,Insulin sensitivity,,,2021-07-07,RECRUITING,OBSERVATIONAL,['NA']
9149,NCT01110746,3 hour incremental area under the glucose curve after a standardized high glycemic index meal.,"Draize scores at insulin infusion site at 24 hour and 72 hour follow-up visits, frequency of discomfort with insulin infusion, and severity of discomfort with insulin infusion (ratings of mild, moderate, or severe).",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9150,NCT01220310,Self-Efficacy,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9151,NCT01283425,frequency of mild hypoglycemia events (Blood Glucose<60mg/dl) with InsuPatch and without.,Adverse events (AE's) count with InsuPatch and without.,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9152,NCT03811288,Participants with a history of established cardiovascular disease (CVD),Participants with high risk of CVD according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS),,2018-12-10,COMPLETED,OBSERVATIONAL,['NA']
9153,NCT02723266,Lifestyle Management,Number of subjects reporting an unplanned pregnancy,,2018-03-16,COMPLETED,INTERVENTIONAL,['NA']
9154,NCT00543816,,,,2003-08,TERMINATED,INTERVENTIONAL,['PHASE3']
9155,NCT01546181,photoreceptor density,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
9156,NCT03074630,Change in Plasma LDL Cholesterol,Urinary Sodium Excretion,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9157,NCT01705639,Glucose tolerance,Activity,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9158,NCT01834274,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Plasma Glucose (FPG),,2013-06,TERMINATED,INTERVENTIONAL,['PHASE3']
9159,NCT03324191,Effect of tea extract on serum triacylglycerol concentration following a high fat meal,Effect of tea extract on whole body lipid oxidation following a high fat meal,,2017-10-10,COMPLETED,INTERVENTIONAL,['NA']
9160,NCT00743327,Evaluation for the development of incident diabetes,"Evaluation for other cardiovascular risk factors, markers of inflammation and immunological changes",,2008-10,TERMINATED,OBSERVATIONAL,['NA']
9161,NCT01322711,Evaluation of effect of Atorvastatin Therapy in Hypercholesterolemic Patients (n=30) and Diabetic Patients (n=30),,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
9162,NCT05726006,To examine the prevalence of antibiotic resistance of invasive GBS isolates among non-pregnant people in Malaysia.,Detection of Sequence Type (ST),,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
9163,NCT03274362,Quality of life,Diabetes empowerment,,2017-09,UNKNOWN,INTERVENTIONAL,['NA']
9164,NCT04374578,Effect on glycemic variability,Effect on Glycemic Control,,2020-05-08,COMPLETED,OBSERVATIONAL,['NA']
9165,NCT00222781,"Compare triple tracer PET imaging of skeletal muscle in lean, obese and T2DM",Mathematical modeling of PET data.,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
9166,NCT04198441,Time to Maximum Wound Closure,,,2020-06-02,UNKNOWN,INTERVENTIONAL,['NA']
9167,NCT00229710,Body weight,"Central obesity (waist circumference, hip circumference, waist/hip ratio)",,2005-02,TERMINATED,INTERVENTIONAL,['PHASE3']
9168,NCT02914743,Dental care-seeking behavior,Change from baseline Hemoglobin A1c at 3 and 6 months,Clinician attitude towards the value of having a hygienist in the hospital setting,2016-11,COMPLETED,INTERVENTIONAL,['NA']
9169,NCT04286555,Systolic blood pressure (SBP),Symptoms experienced by participants as assessed by a questionnaire,,2021-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9170,NCT00937872,Define the intravenous pharmacokinetics of SRT2104.,Potential systemic metabolite burden of SRT2104 following administration.,,2008-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
9171,NCT03715010,Measure of glucose AUC during 2H OGTT (Frame: 10 weeks),Measure of body composition (Time Frame: 10 weeks),,2016-03-18,COMPLETED,INTERVENTIONAL,['NA']
9172,NCT02677779,Bacterial Load,Bleeding: Proportion of Patients With Bleeding Necessitating Haemostasis,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
9173,NCT00521378,Daily glucodynamic profile of Oral HDV-Insulin,,,2007-09-17,COMPLETED,OBSERVATIONAL,['NA']
9174,NCT01773798,Area under the glucose infusion rate curve,Area under the serum IAsp concentration-time curve,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9175,NCT00222508,,,,2001-04,COMPLETED,OBSERVATIONAL,['NA']
9176,NCT03875625,Anthropomorphic measurements using BP machine,,,2019-04-01,RECRUITING,INTERVENTIONAL,['NA']
9177,NCT00995930,Change From Baseline in Plaque Burden (Aortic Vessel Wall Area and Carotid Vessel Wall Area),Pharmacokinetics: ACZ885 Serum Concentrations,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9178,NCT02831075,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
9179,NCT00305344,Children With T1D Underwent a Single Autologous UCB Transfusion,,,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9180,NCT05556005,Change from baseline Left ventricular functions at 3 months,Change from baseline Transforming growth factor beta 1 at 3 months,,2022-09-18,RECRUITING,INTERVENTIONAL,['PHASE2']
9181,NCT04891627,"It was aimed to compare IL-34 levels by taking gingival crevicular fluid in systemic healthy, periodontitis and diabetic patients with periodontitis groups.","It was aimed to compare CSF-1 levels by taking gingival crevicular fluid in systemic healthy, periodontitis and diabetic patients with periodontitis groups.",,2021-01-06,COMPLETED,OBSERVATIONAL,['NA']
9182,NCT03790787,"AUCτ,ss",,,2019-04-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9183,NCT00248352,Change in 10 year cardiac risk as estimated by the UKPDS risk engine at 6 months post discharge compared to baseline measures obtained at time of discharge,Quality of life as assessed by questionnaire,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
9184,NCT00448032,Safety,Pharmacokinetics/Pharmacodynamics,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9185,NCT03353792,Brain Alternate Fuel Uptake,Change in Cognitive Function: Grooved Pegboard Test,,2017-11-01,TERMINATED,INTERVENTIONAL,['NA']
9186,NCT01859117,Adverse Events,Toe-brachial index (TBI),,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1']
9187,NCT03590041,Diabetes Distress - Change in Patient Reported Outcomes (PROs),Change in Patient HbA1c,,2019-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9188,NCT01223196,Whole Body Insulin Sensitivity During the Euglycemic Insulin Clamp,Effect of Pioglitazone on TNF (Tumor Necrosis Factor) Alpha Converting Enzyme (TACE) Activity in Skeletal Muscle.,Percentage (%) of Haemoglobin A1C,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9189,NCT04025996,"Cross-sectional analyses will be performed to look at the association between diabetic retinopathy with left ventricular diastolic function, coronary flow reserve and urinary albumin excretion.",,,2018-02-20,UNKNOWN,OBSERVATIONAL,['NA']
9190,NCT01127997,Area under the curve of plasma glucose after meal,the mechanism of second-meal phenomenon,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
9191,NCT02206074,Pulmonary gas exchange via MedGraphics CardiO2 Cardiopulmonary Diagnostic Systems,Functional capacity measured by 6-Minute Walking Test (6MWT),,2012-05,COMPLETED,INTERVENTIONAL,['NA']
9192,NCT05449496,Post-transplant complications rates,Dietary complications,,2022-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9193,NCT01288885,"Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests",Pharmacodynamics assessed by ASP1941 glucose concentration changes in blood and urine,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9194,NCT01252979,Heteroplasmy,,,2010-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9195,NCT06037369,DFU Quality of life,Diabetes-related foot self-care behavior,,2023-09-14,RECRUITING,INTERVENTIONAL,['NA']
9196,NCT04436822,Percentage of Readings Within 20% Agreement,,,2020-07-15,COMPLETED,INTERVENTIONAL,['NA']
9197,NCT01507311,Insulin secretory burst mass,Adverse events,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9198,NCT04088929,Impact of Pure Green CBD tablets on diabetic neuropathy pain using a daily self-reported pain scale score.,Impact on the use of sublingual tablets as the route of administration,,2019-09-30,COMPLETED,INTERVENTIONAL,['PHASE2']
9199,NCT02154074,level of blood insulin,vital signs,,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
9200,NCT04287387,Changes from baseline to post-treatment in composition in level of C-reative protein.,The linear relationship between gut microbiota and inflammation factors level.,,2020-03-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
9201,NCT04513197,Development of endocrine dysfunction (diabetes & prediabetes) after acute pancreatitis,2) To evaluate whether severity of acute pancreatitis have an impact on the development of endocrine dysfunction or not?,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
9202,NCT05918653,Biomedical profile of diabetic patients,,,2022-12-15,COMPLETED,OBSERVATIONAL,['NA']
9203,NCT02308683,Post treatment mean HsCRP,Post treatment mean hgba1c,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9204,NCT01029327,,,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
9205,NCT02021890,improved physical fitness (physical activity exceeding 10 MET-hour/week,10% increase in 6-min walk test,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
9206,NCT03703544,Daily blood glucose profile,,,2017-12-15,COMPLETED,INTERVENTIONAL,['NA']
9207,NCT05823142,Sleep Health: Timing*,Diabetes distress symptoms,,2023-12-20,RECRUITING,INTERVENTIONAL,['NA']
9208,NCT00363844,tolerability,Plasma glucose,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9209,NCT00740363,Insulin secretion,Cyclosporine/tacrolimus blood concentrations,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4']
9210,NCT04869917,Weight,Participant initiation of treatment to intensive lifestyle (ILI) or Metformin,,2022-03-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9211,NCT01034319,stage of change,program attendance,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
9212,NCT01387659,Tolerability of Myfortic in combination with Simulect and Tacrolimus without steroids,Biopsy proven rejection,,2011-03,TERMINATED,INTERVENTIONAL,['NA']
9213,NCT00375492,Change From Baseline in Body Weight,Rate of Hypoglycemic Events,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9214,NCT01918345,For the Effectiveness Phase: Change in baseline-adjusted weight,Feasibility,Behaviour change,2014-07,COMPLETED,INTERVENTIONAL,['NA']
9215,NCT05162690,Intraepithelial nerve fiber density,corneal nerve fiber density,,2022-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9216,NCT00141219,Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population),Duration Adjusted Average Change (DAAC) of (Unadjusted) Mean Pain Score,Daily Pain Rating Scale (DPRS)- Mean Pain Scores (Evaluable Population),2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9217,NCT03805802,Fasting glucose,Inflammation: hsCRP,Waist circumference,2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
9218,NCT02297620,Specify incidence rates of adverse drug reactions associated with a decrease in body fluids and their risk factors,Investigate the occurrence of adverse drug reactions other than the above,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
9219,NCT04353869,Compare the plasma concentrations of glutamine in patients with various levels of cardiovascular (CV) risk.,characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B and TET2 activity in blood monocytes from patients with various levels of CV risk,,2020-11-16,RECRUITING,OBSERVATIONAL,['NA']
9220,NCT03330366,Changes of blood glucose during OGTT,Changes of HbA1c,,2015-11-24,COMPLETED,INTERVENTIONAL,['NA']
9221,NCT04417725,Incidence and prevalence,Treatment patterns,,2008-04-01,COMPLETED,OBSERVATIONAL,['NA']
9222,NCT02403375,Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5%,"Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis)",,2015-05-17,COMPLETED,INTERVENTIONAL,['NA']
9223,NCT00422487,"Determine the effect of MBX-2044 after 14 days administration, on efficacy parameters",,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9224,NCT06190756,Echocardiography,,,2023-11-22,RECRUITING,INTERVENTIONAL,['NA']
9225,NCT03301545,Change in Glycosylated Hemoglobin (HbA1c),Change in Fasting Blood Lipids,,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA']
9226,NCT00621868,HbA1c level,Safety,,2008-03-26,COMPLETED,INTERVENTIONAL,['PHASE2']
9227,NCT03395509,Baseline prevalence of carotic plaques,The cost(-effectiveness) of the screening program,,2014-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9228,NCT00351546,Effect on insulin sensitivity at 6 weeks,Gluconeogenesis rate after 6 weeks of treatment,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9229,NCT05058807,5 times sit to stand test,Single leg stance test,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
9230,NCT02929654,A1c change from baseline after 12 weeks,,,2016-10-01,COMPLETED,INTERVENTIONAL,['NA']
9231,NCT00393705,Hemoglobin A1c (HbA1c) at 16 Week Endpoint,Total Daily Insulin Dose at 4 Weeks and 12 Weeks,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9232,NCT05007301,Frequency of device deficiencies,,,2022-04-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9233,NCT02259634,Quality of Life,Healthcare Utilization,,2014-06,TERMINATED,INTERVENTIONAL,['NA']
9234,NCT00749606,Weight,International Physical Activity Questionnaire,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
9235,NCT01440257,Subject incidence of adverse events,Change from baseline in hemoglobin A1c,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9236,NCT05929079,Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset,Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA2 Subset,,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE3']
9237,NCT04443205,Foetal macrosomia,,,2020-06,UNKNOWN,OBSERVATIONAL,['NA']
9238,NCT00370656,Whether there is a reduction in subjective pain as assessed by the Brief Pain Inventory.,"Whether there has been an improvement in sleep continuity and subjective sleep, morning after cognitive and psychomotor performance, and quality of life (QoL).",,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9239,NCT02950272,cardiovascular events,,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
9240,NCT03642717,Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug,Number of Participants Per Final Effectiveness Assessment Category at Last Visit,,2018-08-21,COMPLETED,OBSERVATIONAL,['NA']
9241,NCT00482443,The difference in HbA1c between the patient in the DID group and in the standard education group.,"The differences between the two groups in terms of, lipid profile, blood pressure, the number of hypoglycaemic episodes, daily blood sugar fluctuation, total insulin dose, weight changes and patients' satisfaction with the treatment.",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
9242,NCT03010397,Phenotypic classification of DR in a 5-year period,mfERG assessement,,2016-12,COMPLETED,OBSERVATIONAL,['NA']
9243,NCT02304081,Glucagon / insulin ratio during hyperglycaemic clamp phase (AUCGluc270-390min / AUCIns270-390min),"Blood Lipids (Triglycerides [mg/dl]; total, HDL, LDL cholesterol [mg/dl])",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9244,NCT05644717,Radiologic liver parameters,Frequency of adverse events in 6 months,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
9245,NCT00437398,Mean Number of Hypoglycemic Events After Transplant,Mean Glycated Hemoglobin (HbA1c) Since Transplant,,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9246,NCT02186483,"Cmax,ss, AUCτ",Vd/Fss,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9247,NCT06064721,peripheral circulation,,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9248,NCT02220920,Change in HbA1c From Baseline,"Percentage of Participants With ""Adverse Events"" and ""Hypoglycemia and Blood Glucose Decreased""",,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9249,NCT02088827,Blood Pressure,Blood glucose levels,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
9250,NCT00353990,To define the bioavailability of a solution of insulin Aspart infused in the Duodenum,Explore any influence of PH/ insulin concentration on PK /PD parameters,,2006-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9251,NCT05840250,Glycemic control,Satisfaction with CGM device,,2023-05-15,SUSPENDED,INTERVENTIONAL,['NA']
9252,NCT00376038,"Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine","Blood levels of drugs at Day 3 Evaluation of efficacy and safety markers on Days 1, 2, and 3.",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9253,NCT02014259,Area under the semaglutide plasma concentration time curve,Maximum observed SNAC plasma concentration,,2013-12-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9254,NCT03950713,HbA1c values,Depression and Anxiety Stress Scale (DASS-21),,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
9255,NCT02067013,Cytokine Levels,Serum Pharmacokinetics,,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
9256,NCT02386579,RANKL,P1NP,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
9257,NCT03310749,"Gemigliptin AUCτ,ss Geometric Mean Ratio (and 90%CI)",Tmax,Incidence of treatment-emergent adverse events,2016-01-15,COMPLETED,INTERVENTIONAL,['PHASE1']
9258,NCT00206297,Area under the curve for glucose,glucagon and gastric emptying,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9259,NCT01568125,HbA1c,Content of dietary intake,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
9260,NCT05553275,first neonatal blood glucose level measured in mg/dL,Number of neonates that have Macrosomia,,2022-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9261,NCT06291155,Glomerular basement membrane (GBM) width and mesangial expansion,Kidney Transcript Changes,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9262,NCT03616392,"(Part 2) Css,max of CKD-501","(Part 2) Swing[(Css,max-Css,min)/Css,min] of CKD-501",,2018-07-25,COMPLETED,INTERVENTIONAL,['PHASE1']
9263,NCT05176197,Change in HbA1c,Hedonic survey,Compliance - fatty acid profile,2022-02-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9264,NCT01518023,Fasting blood glucose,HbA1c,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
9265,NCT04492722,Change From Baseline in Reduction of Urine Albumin to Creatinine Ratio (ACR) to Week 20,Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) to Week 12,,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE2']
9266,NCT01030341,Hypoglycemic Episodes,Change in Gastroparesis Cardinal Symptom Index (GCSI) Total and Mean Score and Patient Assessed Gastro-Intestinal Quality of Life (PAGI-QOL) Score,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
9267,NCT04025775,Time in the target glucose range (5.6 to 10.0 mmol/l),AUC of glucose below 3.5 mmol/l,Average inter-dialytic weight gain,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
9268,NCT04660643,Percent Change from Randomization (Week 36) in Body Weight,Change from Baseline in IWQOL-Lite-CT Physical Function Composite Score,,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
9269,NCT02215252,Daily Pain Numeric Rating Scale (NRS),Plasma Concentration of PF-05089771,,2014-11-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9270,NCT01757587,Proportion of patients responding to treatment (HbA1c less than 7%),"Compare HbA1c and other clinical and laboratory parameters (fasting plasma glucose (FPG), fasting lipids, weight)",Evaluate more precisely the optimized glycemic control through a glycemic holter,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9271,NCT00884611,Percentage of Nights With CGM (Continuous Glucose Monitor) Sensor Values < 60 mg/dL,Mean Morning Blood Glucose (BG),,2007-05,COMPLETED,INTERVENTIONAL,['NA']
9272,NCT01569893,Glycated hemoglobin (HbA1c) levels,Number of visits with specialists in diabetic center,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
9273,NCT02190669,Document the glycemic response of individuals without diabetes and with type 1 or type 2 diabetes,,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
9274,NCT00568035,Determine the safety of a three times daily application of QR-333 as compared to placebo.,Determine the efficacy of QR-333 on symptoms of diabetic neuropathy and the impact of QR-333 on the daily activities (including pain and sleep disturbance) of subjects with symptomatic diabetic neuropathy as compared to placebo.,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9275,NCT03376802,Sleep energy expenditure,Pharmacokinetics,,2018-04-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9276,NCT01779375,M/I,Clamp Measure of Insulin Sensitivity,OGTT Measures of ß-cell Function and Glucose Tolerance,2013-06-16,COMPLETED,INTERVENTIONAL,['PHASE3']
9277,NCT01170208,Change in Weekly Mean Blood Glucose From Week 4 to Week 16,Incidence of Severe or Serious Hypoglycemia.,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
9278,NCT02770079,Change in insulin sensitivity,Changes in the microbiota,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
9279,NCT03185078,VAS,,,2019-01-25,COMPLETED,INTERVENTIONAL,['NA']
9280,NCT00609856,Effect of pioglitazone vs. insulin glargine on beta-cell function and insulin sensitivity,Effect of pioglitazone vs. insulin glargine on BNP,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9281,NCT00290394,Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.,,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9282,NCT05662462,The primary clinical outcome is the proportion of participants with an A1c <6.5% in the third trimester before delivery,Doctor-Patient Communication Scale,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9283,NCT00419835,effect of treatment on proteinuria after 8 months of follow-up,incidence of hyperkalemia,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9284,NCT05550688,Weight Change after smoking cessation on incident T2DM in NAFLD-free individuals,Mediation analysis of smoking relapse on incident T2DM,,2007-01-01,COMPLETED,OBSERVATIONAL,['NA']
9285,NCT02013557,Percentage of patients that receive the 2-hour 75-g oral glucose tolerance test,Percentage of patients that receive any type of postpartum diabetes screening,,2014-01,TERMINATED,INTERVENTIONAL,['NA']
9286,NCT00982644,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9287,NCT03122093,TTG-IgA Serology,Presence of Celiac Disease Complications,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
9288,NCT00231192,serum fructosamine,quality of life,,2005-10,WITHDRAWN,INTERVENTIONAL,['NA']
9289,NCT03429543,Percentage of Patients With Treatment Failure up to or at Week 26,Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks,,2018-03-20,COMPLETED,INTERVENTIONAL,['PHASE3']
9290,NCT00207207,Level of diabetic control as measured by 7-month HbA1c.,Number of hypoglycemic episodes.,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9291,NCT03819790,Time in range within 12-hours (6 AM -6 PM) at week 13,HCP treatment satisfaction score,,2018-10-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9292,NCT05623111,Changes in daily neuropathic pain scores,Sensory function,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
9293,NCT00497172,in-stent LL,Target lesion or target vessel revascularization,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9294,NCT00482079,To asses the effectiveness of MK0431 compared to placebo,To test the safety and tolerability of MK0431 in patients with type 2 diabetes,,2003-05-13,COMPLETED,INTERVENTIONAL,['PHASE2']
9295,NCT05804097,Major Amputations,"TcpO2 before, during and after HBOT",,2021-10-08,RECRUITING,INTERVENTIONAL,['PHASE4']
9296,NCT00541567,Absolute change from baseline in body weight (kg) and HbA1c (%),"Waist circumference, fasting glucose and insulin, HOMA analysis, blood lipids (triglycerides, total cholesterol, HDL-C, LDL-C, ApoB) and systolic/ diastolic blood pressure",,2008-03,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9297,NCT04978441,"correlation between baseline personality characteristics, changing emotions throughout the day, and glycemic levels in patients with T1DM",,,2020-02-17,COMPLETED,OBSERVATIONAL,['NA']
9298,NCT01517269,Change in baseline of Diabetes Knowledge,Change in Baseline of Parent anxiety,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9299,NCT02201602,Mean blood glucose level,Glycemic variability,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9300,NCT02199470,We aimed to evaluate the extent of β-cell function by determining fasting levels of C-peptide and those after meal stimulus.,,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
9301,NCT04706377,serum vitamin B12 levels,Adverse events,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
9302,NCT05268250,youth time in range,Brief Resilience Scale,,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
9303,NCT03310502,Skeletal muscle insulin sensitivity,Coronary flow reserve,,2002-04-17,RECRUITING,OBSERVATIONAL,['NA']
9304,NCT03861052,Change From Baseline in Hemoglobin A1c (HbA1c),Number of Participants With Anti-Tirzepatide Antibodies,,2019-05-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9305,NCT00767000,Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event,Percentage of Participants Achieving an HbA1c of <7.0% at Week 54 Who Maintain an HbA1c of <7.0%,,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2']
9306,NCT02806700,Patient Activation,HbA1c,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
9307,NCT03387787,Random blood glucose <9.9 mmol/l in percent,"Time of glucose measurements derived from CGM in the following ranges: 0-<2.2 mmol/l, 2.201-<3.9 mmol/l, 3.901-<5.5 mmol/l, 5.501-<7.8 mmol/l, 7.801-<9.9 mmol/l, 9.901-<16.6 mmol/l, ≥16.601 mmol/l",,2018-01-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9308,NCT01715649,Hemoglobin A1c,Knowledge,Participant engagement with telehealth technology,2012-11,COMPLETED,INTERVENTIONAL,['NA']
9309,NCT00722241,SEVEN.2 System accuracy as compared to Yellow Springs Instrument (YSI) venous blood glucose measurements,,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
9310,NCT02713568,Area Under the Receiver Operating Curve (AUROC) for prediction of macrosomia (≥ P95),Comparative prediction rate for neonatal hyperbilirubinaemia,,2016-03-08,COMPLETED,INTERVENTIONAL,['NA']
9311,NCT04564131,life quality,,,2021-04-01,UNKNOWN,INTERVENTIONAL,['NA']
9312,NCT01499524,To establish whether raised serum bile acids are associated with abnormalities in cholesterol and triglycerides in the mother and fetus mother and fetus.,"To establish the relationship between raised serum bile acids in the mother and fetus and abnormalities in: Glucose homeostasis, gut liver signaling hormones related to FGF 19 and C4 levels, Gut hormone secretion",,2011-11,COMPLETED,OBSERVATIONAL,['NA']
9313,NCT00597350,Area under the curve for insulin and glucose,Any adverse event experienced by the subjects,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
9314,NCT05776563,Change in magnetic resonance spectroscopy (MRS) to assess brain glucose changes,,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
9315,NCT05966272,Change From Baseline in HbA1c after 20 weeks of treatment,Number of AEs During the Trial,,2023-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9316,NCT02627690,Modification of Diet in Renal Disease (MDRD),number of deaths,,2014-11-03,COMPLETED,OBSERVATIONAL,['NA']
9317,NCT01185561,Center for Epidemiologic Studies Depression (CES-D) Score,State-Trait Anger Expression Inventory (STAXI) Anger Expression Sub-test Score,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
9318,NCT02462057,Enrollment in 10% Level of Benefit,,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
9319,NCT00896077,"Safety (based on AEs, vital signs assessments, resting 12-lead ECG evaluations, physical examination findings and clinical laboratory test results)","Pharmacodynamic (PD) assessments (blood will be collected for determination of serum cytokine, chemokine, insulin and FFA levels at time points noted previously)",,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9320,NCT04276051,Number of Adverse Events Related to the Cryoablation,Fasting Insulin Level,,2020-10-23,COMPLETED,INTERVENTIONAL,['NA']
9321,NCT05626712,Number of Participants with Adverse Events,C-peptide during a 4-hour MMTT,,2023-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9322,NCT00757276,Diagnosis of diabetes insipidus(DI) centralis versus psychogenic DI,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
9323,NCT00749047,Reduction in proteinuria,Reduction in non-fasting plasma glucose concentration,,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
9324,NCT02437747,Clinical parameter of probing pocket depth,Clinical parameter of relative attachment level,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9325,NCT02284815,Insulin per kg from baseline to 12 months follow-up,Immune system (Th1 and Th2 cytokines) change from baseline to 12 months follow-up,,2012-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9326,NCT04010344,Change in Blood Pressure control by poverty status from Baseline,Change in the acceptability and usability of the Akoma pa app score as assessed by the Marshfield System Usability Survey,,2019-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9327,NCT00437489,Change in HbA1c From Baseline,Hypoglycemia Event Rate Per Month,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE4']
9328,NCT02898714,Quality of life,Work and school absenteeism,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
9329,NCT01386671,Glycosylated hemoglobin (HbA1c),Dismutase superoxide,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9330,NCT02897557,Percentage of time in severe hyperglycemic range (defined as >/=250 mg/dL),Standard deviation and coefficient of variation of CGM values,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
9331,NCT02800668,weight loss in kg,effect on blood pressure measured in mmHg,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
9332,NCT00110500,To determine the maximum tolerated dose (MTD) of a single treatment by intramuscular injection by SB-509.,"To evaluate the lower extremity clinical effects of SB-509 treatment on lower limb diabetic neuropathy by symptoms, neurological examination, and lower extremity electrophysiological testing.",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9333,NCT01762826,OGTT result,Adverse obstetric outcome,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
9334,NCT01089179,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
9335,NCT04236206,Glycemic Control,Medication Adherence,Diabetes-related Knowledge,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
9336,NCT05237219,Change in hemoglobin A1c level,Change in 24-hour blood pressure,,2022-05-01,WITHDRAWN,INTERVENTIONAL,['NA']
9337,NCT00354237,"improvement of peak VO2,",improvement of ventilatory threshold,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
9338,NCT00383877,HbA1c,Within-subject variation of self measured blood glucose (SMBG) before breakfast during the trial at the end of the trial,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9339,NCT04838392,RIGHTEST Continuous Glucose Monitoring System Performance,RIGHTEST Glucose Monitoring System Related Adverse Device Effects,,2021-07,UNKNOWN,INTERVENTIONAL,['NA']
9340,NCT00315588,Insulin Independence.,"Reduction in Severe Hypoglycemia, Improvement in Hypoglycemia Awareness",,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9341,NCT05593926,HbA1c levels,To investigate usability,,2022-11-16,COMPLETED,INTERVENTIONAL,['NA']
9342,NCT05730998,urinalysis,urine culture,,2022-09-01,COMPLETED,INTERVENTIONAL,['NA']
9343,NCT01080157,"Validation of SCOUT DS algorithm, ROC performance equivalency to FPG and A1c for detection of abnormal glucose tolerance.","Receiver operator characteristic area under the curve, sensitivity, specificity, and postive & negative predictive values of the SCOUT DS, FPG, and A1C tests for detection of abnormal glucose tolerance, and the intra- & inter-day SCOUT DS test",,2010-03,COMPLETED,OBSERVATIONAL,['NA']
9344,NCT00344370,NCEP LDL-C Target Attainment,Percent Change From Baseline in LDL-C,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9345,NCT00558883,effect of treatment of leucocyte count before and after test meal,"identification of gene arrays are registered of relevant pharmacodynamic structures and metabolism ways. Histological examinations of bioptats; Blood: hsCRP, PAI1; Lymphocyte subpopulations; blood lipids, plasma glucose fasting and postprandial",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9346,NCT06302127,CVD 10-year risk,total cholesterol,,2024-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9347,NCT03259217,complete healing,rate of ulcer recurrence,,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
9348,NCT00760955,Change from Baseline for a composite measure of Maximal Nerve Conduction Velocity of the Peroneal and Median Motor Nerves and the Median and Sural Sensory Nerves.,Change in Fasting C-peptide.,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9349,NCT02796456,Biological measure : Maternal apelinemia (Plasma Concentration),Placenta weight,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
9350,NCT01552018,Inflammatory biomarkers,Gene expression of DPP-4 in adipose tissue and leukocytes,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9351,NCT04809220,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Change From Baseline in Body Weight,,2021-04-13,COMPLETED,INTERVENTIONAL,['PHASE3']
9352,NCT01865474,Fibrinogen level reduction,Change of Thromboxane-B2 level,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9353,NCT01671293,Change From Baseline in Weight Parameter,Change of Baseline in Waist Circumference,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
9354,NCT06174129,Factors associated with atrial fibrillation,,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
9355,NCT05172089,Aim 4,,,2021-01-31,TERMINATED,OBSERVATIONAL,['NA']
9356,NCT03544645,compare the impact of audiovisual educational materials verses printed educational materials,,,2017-07-16,COMPLETED,INTERVENTIONAL,['NA']
9357,NCT05144971,Nova StatStrip A Glucose/Creatinine Meter System,,,2021-10-28,COMPLETED,OBSERVATIONAL,['NA']
9358,NCT02456636,Mean Weight Change Over 24 Months; Adjusted,Mean Change in Stress Measured by PSS; Unadjusted Except for Affiliation,,2016-02-15,COMPLETED,INTERVENTIONAL,['NA']
9359,NCT04845685,CGM accuracy,CGM recorded hyperglycemia episodes,,2024-06-01,SUSPENDED,INTERVENTIONAL,['NA']
9360,NCT05008276,Glomerular Filtration Rate (GFR),Renal oxygenation,,2021-09-27,RECRUITING,OBSERVATIONAL,['NA']
9361,NCT02491528,The change of relative baseline HbA1c,,,2015-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
9362,NCT03291249,Abnormal physical findings,change in HOMA/HOMA-IR scores,Mean serum concentrations of adiponectin,2017-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9363,NCT03126981,Insulin sensitivity index (SI),Interleukin-6 (IL-6),,2017-04-20,COMPLETED,INTERVENTIONAL,['NA']
9364,NCT02940873,Difference in severe hypoglycaemia between study arms,Quality of Life - general,Changes in treatment modality,2017-03-09,COMPLETED,INTERVENTIONAL,['NA']
9365,NCT03239717,Reduction of BCAA intake,Glucose tolerance,,2017-11-28,COMPLETED,INTERVENTIONAL,['NA']
9366,NCT00328601,,,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9367,NCT02879383,"Change From Baseline at 12 Weeks in MR-PDFF, DMR vs Sham",,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
9368,NCT03112382,serum zinc,change from baseline in total serum Calcium at three months,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
9369,NCT02466880,Change in Hemoglobin A1c,Change in Cholesterol,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
9370,NCT04879251,Number of patients with diabetes who have a higher BP (blood pressure) value (Change from baseline after 1 and 2 year of COVID 19 pandemic),,,2021-04-26,COMPLETED,OBSERVATIONAL,['NA']
9371,NCT05667220,Fasting blood glucose change,Fecal DPP4 activity change,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9372,NCT02039544,Change in Scores of TCM clinical symptom and the clinical scoring system of Toronto (TCSS),Change in Nerve conduction velocity,Number of participants with adverse events,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
9373,NCT05947916,The difference of Time in Range (TIR),"Number of newborns with neonatal birth injury, shoulder dystocia, neonatal jaundice, neonatal respiratory distress syndrome (RDS)",Adverse event record,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
9374,NCT02940379,Assessment of metoprolol PK parameter: AUC,Assessment of PK parameter: t1/2z,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9375,NCT02750280,Incidence of wound healing,Incidence of ulcer recurrence,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
9376,NCT00861809,Safety and tolerability of GSK962040 (Change from baseline in clinical chemistry and hematology parameters),Food intake,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9377,NCT00665145,Stem cells circulating in peripheral blood,Safety and Efficacy of SB-509,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9378,NCT05396443,"Change in diet quality of adolescent participants, as measured by the Healthy Eating Index Scores",Change in high blood pressure status,,2022-08-15,RECRUITING,INTERVENTIONAL,['NA']
9379,NCT06061172,Time spent in hospital during the preceding six months,Patient satisfaction with clinical performance as assessed by the European Task Force on Patient Evaluation of General Practice Care questionnaire,,2023-10-02,RECRUITING,INTERVENTIONAL,['NA']
9380,NCT00786500,HbA1c (glycosylated hemoglobin),"Body weight (BMI, hip-waist ratio)",,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9381,NCT02261168,Day-night rhythm in skeletal muscle mitochondrial respiration,Change in liver volume and liver lipid concentration during the day,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
9382,NCT04572945,Percentage of foot abnormalities in diabetic CKD patient,,,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA']
9383,NCT05295160,Concentration of fasting blood glucose < 126 mg/deciliter,Composition of the microbiome,,2020-09-25,COMPLETED,INTERVENTIONAL,['NA']
9384,NCT04750577,Change from baseline in log transformed Urine Albumin Creatinine Ratio (UACR) measured in 10-hour urine after 20 weeks of trial treatment,Number of patients achieving UACR decreases in First Morning Void urine of at least 20% from baseline after 20 weeks of trial treatment,,2021-04-27,COMPLETED,INTERVENTIONAL,['PHASE2']
9385,NCT04636411,Inflammation,Total or ionized Mg,,2020-11-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9386,NCT01152385,Change in Haemoglobin A1c (HbA1c),Change in High-sensitivity C-reactive Protein (Hs-CRP),,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9387,NCT03668301,Central venous oxygen saturation,,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
9388,NCT00034255,,,,2001-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9389,NCT00902161,Recovery Time (Rt[65] From Insulin-induced Hypoglycemia,Number of Participants Who Discontinued Study Treatment Due To AEs,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
9390,NCT02136199,Frequency of use of decision aids in clinical encounters by weekly reports,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
9391,NCT00484198,Change in Hemoglobin A1c From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,Drug-Related Treatment-Emergent Adverse Events Reported by ≥1% Participants Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,,2007-04-23,COMPLETED,INTERVENTIONAL,['PHASE3']
9392,NCT05127291,Dual-task effect,,,2023-05-20,COMPLETED,INTERVENTIONAL,['NA']
9393,NCT00612794,To assess the safety and tolerability of exenatide administered once weekly by subcutaneous (SC) injection in subjects with type 2 diabetes mellitus.,To explore the pharmacodynamics of exenatide administered once weekly by SC injection in subjects with type 2 diabetes mellitus regarding the following: *fasting and postprandial glucose concentrations; *HbA1c; *Body weight.,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9394,NCT02083133,Hypoglycemia,,,2013-10-01,COMPLETED,OBSERVATIONAL,['NA']
9395,NCT00467688,Daily time spent in the hypoglycemic glucose range during continuous glucose measurement with and without real time access to glucose values and glucose alarms,Time spent in euglycemic and hyperglycemic glucose range Satisfaction with CGMS Diabetes related distress Treatment satisfaction Anxiety and depressive symptoms,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
9396,NCT02918175,Change in mean weekly step count,Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score,Change in plasma metabolic profile,2017-08-02,COMPLETED,INTERVENTIONAL,['NA']
9397,NCT02627911,"Percentage of time spent in the tight glycemic control area 80-140 mg / dl during the night, continuously measured for 3 days with CGM","Measurement of AUC during physical activity , the two hours, then to lunch time , during dinner and throughout the night",,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9398,NCT03581968,Percentage of time of sensor glucose levels spent in target range,Number of participants experiencing hypoglycemia requiring oral treatment during:,,2018-07-02,COMPLETED,INTERVENTIONAL,['NA']
9399,NCT03811561,Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.,"Change in Lipids: Total-cholesterol, High density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides.",,2019-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9400,NCT01440439,"Glucose excursion (which, as defined below, is the change in blood glucose between the start and finish of one hour of exercise)",Blood glucose,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
9401,NCT06046976,MicroRNA 21 (Mir-21) expression,Superoxide Dismutase(SOD) enzyme activity (%),,2022-06-13,COMPLETED,INTERVENTIONAL,['NA']
9402,NCT05844644,The change in glycemic control as measured by change in weight (percentage of total weight) from baseline at Days 90 and 180 following the G4LP and supplementation with Release.,The change in quality of life from baseline at days 90 and 180 following the G4LP and supplementation with Release.,Clinically relevant changes in red cell distribution width (RDW) after 180 days.,2023-04-20,RECRUITING,INTERVENTIONAL,['PHASE2']
9403,NCT06325202,Towler questionnaire,all-cause mortality,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9404,NCT02561338,"After 12-week Treatment, the Change From Baseline in HbA1c",Change From Baseline in FPG,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9405,NCT00877864,The primary outcome will be A1c at the end of 6 months supervised exercise period.,,,2010-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9406,NCT00765830,To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment,To explore the efficacy of vildagliptin (50 mg qd) versus placebo in patients with T2DM and moderate or severe renal insufficiency,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9407,NCT05808972,Number of participants with composite endpoint achievement,Total insulin dose received,,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9408,NCT02122731,average daytime systolic and diastolic blood pressure,urine plasminogen and plasmin,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
9409,NCT03732209,Change in delay discounting,Change in waist and hip circumference,Perceived treatment effectiveness and ease of use,2019-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9410,NCT00005441,,,,1993-04,COMPLETED,OBSERVATIONAL,['NA']
9411,NCT00605475,Mean Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 - 4 Hours Following Oral Glucose Tolerance Test (OGTT ),"Number of Participants Reporting Death, Serious Adverse Events (SAEs), Adverse Events (AE) Above 5% Frequency",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9412,NCT04169243,Time in Target at gestational week 32,Diet quality measuremen¨t,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
9413,NCT01050205,Changes in Weight Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.,Changes in Diastolic Blood Pressure (BP) Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
9414,NCT01265563,Change From Baseline in Urinary Albumin Excretion,"Urinary Alpha-1 Microglobulin, Inflammatory Cytokines and C-C Chemokines",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9415,NCT04882293,Describe the proportion of subjects who reduced levels of LDL cholesterol,Events and adverse reactions presented.,,2022-02-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
9416,NCT06135935,The primary outcome will be area under curve for the plasma glucose response over 120 minutes after consumption of the ice creams.,CGM monitor readouts over 24 hours after consumption of the ice creams.,,2023-11-12,RECRUITING,INTERVENTIONAL,['NA']
9417,NCT06186063,Relative changes in the plasma levels of N-terminal propeptide of type I procollagen (P1NP),Changes in plasma concentrations of osteocalcin,,2024-02-12,RECRUITING,INTERVENTIONAL,['NA']
9418,NCT01600664,Quality of life,Hyperglycemia events,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
9419,NCT02306343,assessment of skin irritation,area under the curve,,2011-11,UNKNOWN,INTERVENTIONAL,['NA']
9420,NCT06141590,Cmax,,,2023-03-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9421,NCT02787785,All-Cause Mortality,Sudden Death in various subgroups,S-ICD device complications,2017-04-17,COMPLETED,INTERVENTIONAL,['NA']
9422,NCT02032459,Maternal Vitamin D Status,Vitamin D Status in relations to pregnancy complications,"Relationship of Vitamin D to maternal diet, etc.",2007-04,COMPLETED,OBSERVATIONAL,['NA']
9423,NCT05514548,Change in UACR from baseline to W16,Change in eGFR using cystatin C and the CKD-EPI formula from baseline to W16,,2022-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
9424,NCT02589756,persistent organic pollutants,Triglycerides,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9425,NCT01984489,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 12,Change From Baseline in Body Weight at Week 12,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9426,NCT01216865,Angiographic evaluation of angiogenesis at ischemic limb,Rate and extent of amputations,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9427,NCT00000532,,,,1992-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9428,NCT03792607,RNA sequencing analysis both in CD4+ and CD8+ cells,ROC curves to evaluate putative DNA methylation/microRNA interactions as prognostic biomarkers of cardiovascular dysfunction in T2D patients,,2019-02-14,UNKNOWN,OBSERVATIONAL,['NA']
9429,NCT00947557,Hemoglobin A1c (HbA1c),Fasting Plasma Glucose (FPG),,2009-07,TERMINATED,INTERVENTIONAL,['PHASE3']
9430,NCT00311870,change in glomerular filtration rate from study start to study end,change in urinary albumin excretion rate,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9431,NCT02220257,Development of chronic complication of diabetes (retinopathy or neuropathy or nephropathy),,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
9432,NCT03867656,P1NP,Heart rate,,2019-02-26,COMPLETED,INTERVENTIONAL,['NA']
9433,NCT03353350,Change in Glycated Hemoglobin (HbA1c) (%),Treatment Emergent Adverse Events (TEAEs),,2017-12-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9434,NCT06109597,Complications associated with gestational diabetes mellitus,,,2022-05-23,COMPLETED,OBSERVATIONAL,['NA']
9435,NCT04699864,Manual Analysis of Retinal Images - Severity of Diabetic Macular Edema (DME),Performance of NeoRetina Algorithm - Diabetic Macular Edema (DME),,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9436,NCT04854330,Cardiac output,VEGF,,2021-04-26,UNKNOWN,INTERVENTIONAL,['NA']
9437,NCT04218305,1- Study of human serum fetuin-A and whether it is involved in insulin resistance,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
9438,NCT01267591,RHPAT,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
9439,NCT05593133,Dynamic Gait index,,,2021-01-05,COMPLETED,INTERVENTIONAL,['NA']
9440,NCT02416440,prevalence of diabetes mellitus and associated cardiometabolic and infectious risk factors using the oral glucose tolerance test,"inform health policy and public health programmes aimed at addressing the rise in NCDs in South Africa, which may also shape public health strategies in other African countries",,2014-01,COMPLETED,OBSERVATIONAL,['NA']
9441,NCT03437018,classification of diabetic retinopathy (DR),medical time necessary for examination and analyse,,2019-10-10,COMPLETED,OBSERVATIONAL,['NA']
9442,NCT04511416,changes in executive function Z-score,"changes in biomarkers, including fasting glucose (mmol/L) and insulin (mIU/L), insulin resistance (HOMA-IR index)",,2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE3']
9443,NCT01438632,BG-AUC0-2h (mmol•min-1•l-1): area under the baseline-subtracted plasma glucose concentration time-curve from time 0 to 2 h after insulin injection and meal ingestion.,BG-AUC0-1h,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
9444,NCT04813146,Serum HbA1c concentration,,,2021-02-05,UNKNOWN,INTERVENTIONAL,['NA']
9445,NCT00873821,Change From Baseline to Day 13 in Weighted Mean Plasma Glucose Concentration,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
9446,NCT02280733,death,Wound related quality of life,,2005-01,RECRUITING,OBSERVATIONAL,['NA']
9447,NCT01634997,Hemoglobin A1c,,,2012-06,UNKNOWN,OBSERVATIONAL,['NA']
9448,NCT03345901,Diabetic Retinopathy Worsening or Diabetic Macular Edema (DME) Development (Composite Outcome),,,2018-01-15,TERMINATED,INTERVENTIONAL,['PHASE3']
9449,NCT04694326,Diabetes Unawaraness Prevalance,,,2017-04-20,COMPLETED,OBSERVATIONAL,['NA']
9450,NCT03208465,Percent change in global myocardial perfusion reserve (MPR) index,Absolute change in global MPR index,,2017-08-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9451,NCT03046498,Measure change in number of program offerings implemented in the community,,,2017-02-02,COMPLETED,INTERVENTIONAL,['NA']
9452,NCT01714505,"Safety, Frequency of Hypoglycemia","Efficacy, Time Spent in Target Range",,2012-10,COMPLETED,INTERVENTIONAL,['NA']
9453,NCT04823312,Number of subjects with Duo Extended set failures due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 7.,"Number of subjects with a rate of infusion set survival of 7 days or greater, excluding those that kinked on insertion or accidentally pulled out.",,2021-03-18,UNKNOWN,INTERVENTIONAL,['NA']
9454,NCT01143727,Wound Appearance,Percent Change in Wound Area,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9455,NCT00951899,Total Disposition Index,Lipid Values,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9456,NCT04229667,Proportion of patients demonstrating a change in self-reported medication adherence actions (30-day),"Proportion of patients demonstrating a change in disease control (defined as random blood sugar <200 mg/dL mmHg), among patients with diabetes at intake (defined as random blood sugar >=200 mg/dL at intake)",,2020-01-31,TERMINATED,OBSERVATIONAL,['NA']
9457,NCT02294123,Insulinemic index,,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
9458,NCT01989962,"Cultural safety, bias and discrimination--change is being assessed",Patient experiences of healthcare service (Canadian Institute of Health Information (CIHI) Patient Experience Survey)--change is being assessed,Referrals (to whom and date)--change is being assessed,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
9459,NCT00011531,,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9460,NCT01766752,The primary endpoint is the percentage of actions the system supports either to capture BG values or provide insulin dose suggestions according to the REACTION algorithm.,,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9461,NCT05533632,Number of Adverse Events,Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment,,2022-03-29,COMPLETED,INTERVENTIONAL,['PHASE4']
9462,NCT01040676,Hemoglobin A1c,Waist Circumference,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
9463,NCT04952779,Incidence of Adverse Events (AEs) by preferred term,Change in Post Prandial Blood/Plasma Glucose (PPBG/PPPG),,2021-06-02,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9464,NCT05397028,Efficacy of plant-based meal replacement system on A1-C levels,Efficacy of plant-based meal replacement system on insulin levels,,2022-12-08,TERMINATED,INTERVENTIONAL,['NA']
9465,NCT05779644,Abdominal fat distribution,,,2023-02-23,RECRUITING,INTERVENTIONAL,['NA']
9466,NCT03786978,Short term readmission rate,Economic evaluation,,2015-09-09,COMPLETED,INTERVENTIONAL,['NA']
9467,NCT00572689,"glycemic control through insulin, glucose, c-peptide and glucagon assays",Exenatide Pharmacodynamics and Pharmacokinetics,,2013-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
9468,NCT00984750,Arterial blood pressure and dyslipidemia,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9469,NCT04376112,Medication adherence,,,2020-10,WITHDRAWN,INTERVENTIONAL,['NA']
9470,NCT01497587,Area under the insulin detemir concentration curve,Insulin detemir half-life,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9471,NCT04142710,Change in yearly health and care cost per person from baseline at 12 months,Mean change in the patients' duration of municipal emergency day care unit visits from baseline at 18 months,,2019-02-09,COMPLETED,INTERVENTIONAL,['NA']
9472,NCT00698802,HbA1c,Total daily insulin dosages,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9473,NCT00506194,Short-term intensive insulin therapy can decrease the insulin resistance and improve the Beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia.,Improve long term glycemic control,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
9474,NCT03983200,Nerve conduction velocity examination,Glycosylated serum albumin,,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA']
9475,NCT06142006,SGLT2i and/or GLP-1 agonist use after DSS EHR template use,GFR,,2023-09-01,RECRUITING,OBSERVATIONAL,['NA']
9476,NCT00143156,The primary efficacy parameter is the endpoint End of Week 12 weekly mean pain score derived from the pain diary.,"End of Week 12 responder rates, Brief Pain Inventory - short form, sleep interference scores, Medical Outcome Study - Sleep Scale, Hospital Anxiety and Depression Scale, Patient Global Impression of Change, Neuropathic Pain Inventory Symptom Inventory.",,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9477,NCT03724383,Changes in Quality of Life on SF36,Left Atrial Pressure,,2018-09-06,UNKNOWN,INTERVENTIONAL,['NA']
9478,NCT04462081,Percentage of Liver Fat as Measured by MRI-PDFF,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
9479,NCT02839512,Change in glycosylated hemoglobin A1c,Weight loss (%TBWL),,2014-10,COMPLETED,INTERVENTIONAL,['NA']
9480,NCT02562573,Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment,Change from baseline on fasting plasma glucose,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9481,NCT00078052,cardiovascular disease,,,2003-09,COMPLETED,OBSERVATIONAL,['NA']
9482,NCT03956290,Percentage of patients who reduced eating duration by 4 hours,% of participants who achieve ≥ 5% weight loss,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
9483,NCT05173675,Hemoglobin A1C (HbA1c),Diabetes distress measured by the 2-item Diabetes Distress Screening Scale,,2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9484,NCT04473209,serum resistin,clinical attachment loss,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
9485,NCT01349387,Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
9486,NCT05648383,Change from Baseline in glycated hemoglobin [HbA1c] at 24 months (2nd follow-up),Change from Baseline in waist circumference [WC] at 24 months (2nd follow-up),Change form Baseline in the BMI z-score of children at 24 months (2nd follow-up),2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
9487,NCT05161429,3-point major adverse cardiac events (MACE),Non-cardiovascular outcomes,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
9488,NCT01179165,Prevalence of cardiac abnormalities/disease according to different examination modalities,"Feasibility of transthoracic coronary Doppler examination/Coronary Flow Reserve, and diagnostic yield related to MRI",,2011-01,COMPLETED,OBSERVATIONAL,['NA']
9489,NCT03482674,Body weight reduction,Quality of life,,2018-01-02,UNKNOWN,INTERVENTIONAL,['NA']
9490,NCT01263470,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9491,NCT00871572,Mean Change in Glycosylated Hemoglobin A1c (HbA1c),Change From Baseline to Endpoint for Total Cholesterol,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9492,NCT01204216,Specific Aim 1: To Determine the Stability of MRBC (Mean RBC Age)Over Time at Stable Glycemia. The Hypothesis is MRBC Will be Stable in Subjects Without Diabetes and in Subjects With Diabetes at Stable Glycemic Control.,Specific Aim 2: To Determine the Impact of Glycemic Control on MRBC.,,2010-09-01,TERMINATED,INTERVENTIONAL,['NA']
9493,NCT03251755,PSQI,ABI,,2017-05-24,COMPLETED,INTERVENTIONAL,['NA']
9494,NCT00947635,Cholesterol and fatty acid synthesis,Blood lipid levels,,2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9495,NCT02526069,Acceptability and feasibility of using SweetSpot,Well-being,Change in Valued Living (BEVS),2015-05,TERMINATED,INTERVENTIONAL,['NA']
9496,NCT06308549,Diabetes Distress,Events of ketoacidosis/severe hypoglycaemia,MyDiaMate usage data,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9497,NCT00475345,"Incidence of nocturnal hypoglycemia (< 4mmol/L) occurring between 11pm and 7am, as determined with the Continuous Glucose Monitoring System (CGMS) and hemoglobin A1c","Nadir nocturnal BG, timing and duration of nocturnal hypoglycemia, fasting BG, lipid profile, psychosocial factors, total insulin dose, insulin sensitivity and body composition (weight, BMI, % fat, waist circumference).",,2000-08,COMPLETED,INTERVENTIONAL,['NA']
9498,NCT05759468,The primary endpoint is the change from baseline in UACR over the 6-month intervention period.,Assess the change in measure of fasting glucose as a measure of glycemic control over the 6 months intervention period.,,2023-04-13,RECRUITING,INTERVENTIONAL,['PHASE2']
9499,NCT01041859,Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12,Change From Baseline in the EuroQoL-5 Dimension (EQ-5D) Health Status Index at the Week 12 Endpoint,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9500,NCT04018482,"Comfort of Povidone Iodine vs Avenova 1-2 hours post treatment based on an 11-point numerical scale (0-10, with 0 being no pain, and 10 being extreme pain)",Change in colony forming unit (CFU) growth pre- and post-treatment with Povidone Iodine or Avenova to determine if Avenova is non-inferior to Povidone Iodine for ocular disinfection.,,2019-07-16,COMPLETED,INTERVENTIONAL,['PHASE4']
9501,NCT04093752,Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia,,2019-12-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9502,NCT00499148,positive AUC for plasma glucose,positive AUC for serum insulin; adjusted peak values for plasma glucose and serum insulin; baseline plasma glucose and serum insulin concentrations; adjusted values for plasma glucose and serum insulin at individual postprandial time points.,,2006-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9503,NCT01968876,Change from baseline in number of pills taken over number of pills prescribed at 12 weeks,,,2013-10-30,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
9504,NCT01963156,Medication adherence,Full adherence to medications for the treatment of diabetes or cardiovascular disease,Rates of de-synchronization,2013-11,TERMINATED,INTERVENTIONAL,['NA']
9505,NCT04819256,HbA1c,Implementation of care model,,2020-12-07,TERMINATED,INTERVENTIONAL,['NA']
9506,NCT03790839,12-lead ECG,iAUC0-4h of GLP-1,,2019-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
9507,NCT04983277,UK Prospective Diabetes Study risk score,,,2021-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9508,NCT04544553,Attendance rates in patients with diabetic macular edema receiving short messaging services,,,2019-01-24,COMPLETED,INTERVENTIONAL,['NA']
9509,NCT01476475,Change in HbA1c From Baseline to Week 24,Percentage of Participants With Documented Symptomatic and Severe Symptomatic Hypoglycemia,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9510,NCT04963998,Incidence of Treatment-Emergent Adverse Events,Rate of change in percent of fibrin tissue,,2019-10-02,COMPLETED,INTERVENTIONAL,['NA']
9511,NCT00432965,Incidence of Complete Ulcer Closure Closure.,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
9512,NCT01119846,Part C: Summary of Change From Baseline in Fasted Insulin,"Part C: Summary of AUC0-24, AUC0-t of GSK1292263 and Sitagliptin When Co-administered",,2009-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9513,NCT03487692,Hemoglobin A1C,CAHPS Provider Communication,Health center provider/staff satisfaction,2018-10-18,COMPLETED,INTERVENTIONAL,['NA']
9514,NCT03598738,HbA1c change,,,2015-12-01,COMPLETED,INTERVENTIONAL,['NA']
9515,NCT04320719,number of patients with treatment,biological characteristics of patients,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
9516,NCT00682916,"without any altering of dietary habits or exercise routine, individuals shall lose or maintain body weight during the active phase as compared to the placebo phase.",blood lipid levels during the active phase will be improved relative to the placebo phase.,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
9517,NCT06049225,Self-efficacy,Glycemic Management,Health Dashboard Usability,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9518,NCT00596427,Rate of Appearance of Exogenous Glucose (Glucose Absorption),Glucagon AUC,Glucose AUC,2007-11,COMPLETED,INTERVENTIONAL,['NA']
9519,NCT00325611,Quality and cost of care,Lower total costs 6 months past hospitalization,,2002-04,COMPLETED,INTERVENTIONAL,['NA']
9520,NCT01159938,Postprandial Pulse Wave Velocity (PWV) in Type 2 Diabetes Mellitus (T2DM) Participants at 240 Minutes (Mins) Post-Breakfast,Change in Postprandial Pulse Wave Velocity (PWV),,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9521,NCT04706286,Cmax of CKD-393,,,2021-02-18,UNKNOWN,INTERVENTIONAL,['PHASE1']
9522,NCT00468403,Proportion of subjects with insulin independence,"Lipid profiles (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol)",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9523,NCT00548158,ETDRS visual acuity,retinal thickness measured by OCT,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
9524,NCT04742829,number of patients with improved/worsened macular edema,number of patients with improved/worsened blood parameters related to diabetes,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA']
9525,NCT00001344,,,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9526,NCT03352518,Generation and validation of predictive calibration models,Safety assessment of the intervention by the paucity of adverse events,,2017-12-28,COMPLETED,INTERVENTIONAL,['NA']
9527,NCT03325114,Hyperglycemia,,,2019-06-28,TERMINATED,INTERVENTIONAL,['PHASE2']
9528,NCT01472341,Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) According to Quartiles of Proinsulin/Insulin (PI/I) Ratio,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
9529,NCT02493374,Mitigation of Type 2 Diabetes,,,2016-05,WITHDRAWN,OBSERVATIONAL,['NA']
9530,NCT02316483,HBA1C >8.5% on total and gene-specific methylation.,,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
9531,NCT00099151,,,,2002-03,COMPLETED,INTERVENTIONAL,['NA']
9532,NCT03443986,Peripheral circulation,Plantar pressure distribution,,2018-02-26,UNKNOWN,INTERVENTIONAL,['NA']
9533,NCT05342740,Basic clinical and demographic information of participants in groups,,,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9534,NCT01947699,Glucose levels throughout the day,,,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE4']
9535,NCT03358394,Mindfulness,,,2017-10-26,UNKNOWN,INTERVENTIONAL,['NA']
9536,NCT01822431,number of participants with abnormal results,,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
9537,NCT00405418,Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.,Physical examination,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
9538,NCT00728143,Glycemic Index,Palatability,,1989-08,COMPLETED,INTERVENTIONAL,['NA']
9539,NCT00266643,Subscale of the UKU side effect rating scale to be measured during the switch period. The weeks during which the switch occurs are blinded.,"Weekly: Leeds Sleep Evaluation Questionnaire, Brief Profile of Mood States, Clinical Global Impression of Severity. Visits 2, 7, 11: Treatment Satisfaction Questionnaire for Medic",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9540,NCT00590044,Number of Hypoglycemia Episodes After the Transition Period From Intravenous Insulin to Subcutaneous Insulin Between 2 Treatment Groups,Difference in Time in Hours to Resolution of DKA Between the 2 Groups,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9541,NCT00361946,,,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
9542,NCT04974528,Change in HbA1c,Change in HbA1c,Change in percent predicted Forced Expiratory Volume in 1 Second (FEV1),2021-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9543,NCT02200627,Adverse event incidence,,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
9544,NCT05386186,Reduction of hemoglobin A1c from baseline at the end of the trial.,The level of weight gain,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9545,NCT01460095,one year change in glycated haemoglobin (HbA1c),One-year change in urinary albumin excretion,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
9546,NCT06297239,prevalence of high level of Lp(a),,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
9547,NCT00290940,Mean change from baseline in HbA1C after 12 weeks compared to placebo,Proportion of subjects discontinuing or requiring rescue for continued or worsening hyperglycemia,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9548,NCT01888133,Change in steps/day,Change in A1c,,2013-04,TERMINATED,INTERVENTIONAL,['NA']
9549,NCT02166372,Evaluate the natural course of the diabetes of obese patients over a period of 10 years,,,2014-03,RECRUITING,OBSERVATIONAL,['NA']
9550,NCT05183685,"HbA1c, defined as the amount of blood sugar attached to hemoglobin.","Number of attendances at a general practitioners' office, emergency department, hospital, and general out-patient clinic",Maintenance. It measures the sustained effect of the program. Cost-effectiveness will be measured by calculating the cost used in both groups.,2022-12-10,RECRUITING,INTERVENTIONAL,['NA']
9551,NCT02752113,Effect of empagliflozin plus linagliptin vs metformin plus insulin glargine on basal NO activity of renal vasculature (response of RPF (renal plasma flow) to L-NMMA (NG-monomethyl-L-arginine) infusion),"changes in albuminuria (urinary albumin to creatinine ratio [UACR]), assessed in the 24-hour urine",,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9552,NCT03635970,TcPO2,,,2018-05-18,COMPLETED,INTERVENTIONAL,['NA']
9553,NCT03159221,Change in Body Mass Index (weight status) at 6 months and at 12 months,Teen Quality of Life,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
9554,NCT00758927,Percentage change of plasma small dense LDL measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis,The percentage change of plasma HDL sub-fraction measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis,,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
9555,NCT00465478,Exogenous insulin requirement; Hemoglobin A1C; Glucose and C-peptide level;,"lipid profile, autoantibody， Quality of life",,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9556,NCT03071432,Change from baseline in dynamic cerebral autoregulation after induction of anesthesia,Clinical outcome,,2016-08-30,COMPLETED,INTERVENTIONAL,['NA']
9557,NCT02898428,Hypoglycemia,,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
9558,NCT01674049,Blood Glucose,Serum insulin,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
9559,NCT02012478,hemoglobin A1C,PAM scale,Summary of Diabetes Self-Care Activities,2014-02,COMPLETED,INTERVENTIONAL,['NA']
9560,NCT00124553,All measures to be compared at end of study (6 months),All measures to be compared at end of study (6 months),,2006-08,UNKNOWN,INTERVENTIONAL,['NA']
9561,NCT03010956,"Differences in flow mediated dilation (FMD) at baseline and 3, 6 and 12 months after the modification of the antidiabetic medication.",Endothelial glycocalyx and coronary flow reserve.,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
9562,NCT04190849,Survival,Asymptomatic progression of liver disease,,2017-11-14,RECRUITING,OBSERVATIONAL,['NA']
9563,NCT03925805,Self-perceived health status (SF-12),Illness perception (IPQ-B),,2019-11-12,COMPLETED,OBSERVATIONAL,['NA']
9564,NCT05159622,Change in Water Consumption for Parents,Parent 100% Fruit Juice Consumption,Hip Circumference for Parents,2019-05-07,COMPLETED,INTERVENTIONAL,['NA']
9565,NCT00685698,Clinical Success (in ITT Population),"Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9566,NCT01498614,Prevalence of depression,Level of A1C,,2009-03,TERMINATED,INTERVENTIONAL,['NA']
9567,NCT04519853,"Patient reported tolerability of dietary intervention, Likert scale",Change in intestinal fatty acid binding protein (I-FABP),,2021-10-25,COMPLETED,INTERVENTIONAL,['NA']
9568,NCT02044848,Stimulated C-peptide in Response to a Standard Mixed Meal Tolerance Test,,,2014-02,TERMINATED,INTERVENTIONAL,['PHASE2']
9569,NCT00782639,Baseline and Change From Baseline Measurements for the One Participant With Contrast-Induced Nephropathy (CIN) at the 48 to 72 Hours After Injection of Contrast Media Visit,Number of Participants Who Died From Acute Renal Failure,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE4']
9570,NCT02049034,Postprandial glucose kinetics,Postprandial and intestinal triglyceride-rich lipoproteins (TRL) kinetics,Post heparin lipoprotein lipase activity,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9571,NCT00276393,Mean fasting glucose,Continuos glucose monitoring,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9572,NCT00265473,Serious Adverse Events Related to Immunosuppressive Therapy.,Insulin Independent Multiple-donor Subjects.,,2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9573,NCT02065544,Hemoglobin A1c,Aerobic Fitness,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
9574,NCT04986345,Change in ambulatory systolic and diastolic blood pressure,Change in plasma C-peptide,,2021-10-04,RECRUITING,INTERVENTIONAL,['NA']
9575,NCT05962983,change in hemoglobin A1c% (HbA1c%),change in waist circumference (inches),eating motives,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9576,NCT00776243,Difference of incretin secretion before and after intensive insulin therapy,Factors affecting incretin secretion,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
9577,NCT02129868,Time spent with plasma glucose concentration in the target glucose range from 3.9 to 8.0 mmol/l.,Absolute relative difference between matched pairs of subcutaneous glucose sensor and reference plasma glucose.,nature and severity of any other adverse events,2014-04,COMPLETED,INTERVENTIONAL,['NA']
9578,NCT03076697,Disease diagnosis based on photography,Automated disease diagnosis,,2015-04-16,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9579,NCT00995995,Cost-effectiveness of rosiglitazone,,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
9580,NCT04591639,Rate of change in myocardial T1 values with manganese enhanced cardiac MRI,Measures of glucose control like glycated haemoglobin (HbA1c) in millimoles per mole,,2020-08-19,RECRUITING,INTERVENTIONAL,['NA']
9581,NCT04916470,Change in body weight,Number of treatment emergent severe or clinically significant hypoglycaemia episodes,,2021-06-15,COMPLETED,INTERVENTIONAL,['PHASE3']
9582,NCT00279318,"Appearance of one or more islet cell autoantibodies: GADA, IAA, or IA-2A confirmed at two consecutive visits.",Development of T1DM,,2004-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9583,NCT03477838,Change in A1c,Glycemic Variability,,2018-04-26,COMPLETED,INTERVENTIONAL,['NA']
9584,NCT02674893,Modifications in wanting,Anthropometric modifications,,2014-02-04,TERMINATED,INTERVENTIONAL,['PHASE4']
9585,NCT02402517,Exercise intensity,Substrate Oxidation,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9586,NCT01660009,Flow induced Dilation of the Brachial Artery (FMD%),Mitochondrial superoxide production,,2012-06,TERMINATED,INTERVENTIONAL,['NA']
9587,NCT03068065,Intrahepatic fat,WC,"Number of Participants with gliclazide, liraglutide or metformin adverse events as a measure of safety and tolerability",2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9588,NCT05026528,HbA1c,,Patient-reported outcome and experience measures,2021-11-30,RECRUITING,INTERVENTIONAL,['NA']
9589,NCT01684917,Metabolomic Biomarker Discovery - Changes in Blood Plasma Cholesterol,Body Weight,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
9590,NCT01608776,Wound Reduction,,,2012-05,TERMINATED,INTERVENTIONAL,['PHASE4']
9591,NCT02005848,Beta cell function,Safety parameters,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9592,NCT02018627,Tmax,Dermal Response (Draize Scale Grade for Edema Formation),,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9593,NCT00593567,"Number of Participants With a Clinical Outcome of ""Clinical Cure""",Time to Positive Clinical Response,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9594,NCT03104543,"Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c >=5.7% or Fasting Glucose >=100; if Diabetes, Hemoglobin A1c >=7%)",Primary Care Provider Attitudes,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
9595,NCT05883267,Anxiety assessment - trait anxiety,VR Satisfaction and effectiveness assessment,,2023-05-10,RECRUITING,INTERVENTIONAL,['NA']
9596,NCT05498610,"Cmax,NNC0480-0389,SD Maximum plasma concentration of NNC0480-0389 after a single dose","Cmax,sema,SD The maximum plasma concentration of semaglutide after a single dose",,2022-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9597,NCT06095622,Improvement in blood glucose levels,,,2023-03-15,COMPLETED,INTERVENTIONAL,['NA']
9598,NCT01930136,The percent change in glomerular filtration rate (GFR) at month 6 versus baseline and the rate of GFR decline from month 6 to study end,,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
9599,NCT04592263,Patient Reported Outcome,,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
9600,NCT03042520,Number of participants with hepatocellular carcinoma (HCC) development during 5-year follow-up period after sofosbuvir-based treatment,Renal disease,,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
9601,NCT03056014,Change from baseline in level of oxidative stress with varying doses of omega 6 fish oil(PUFA) at 2 weeks.,,,2018-11-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
9602,NCT00035568,,,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9603,NCT03407222,change in daily step count after 12 weeks of intervention,low-density lipoprotein cholesterol,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
9604,NCT04152408,Incidence of (Serious) Adverse Events,User satisfaction assessed by the Likert scale,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
9605,NCT05106231,laboratory-analysed HbA1C improvement (HbA1c level below 42mmol/mol or 6.5%),Diabetes knowledge improvement (scores in percentage),,2023-05-01,COMPLETED,INTERVENTIONAL,['NA']
9606,NCT01649297,HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16,Fasting Plasma Glucose (FPG) Change From Baseline at Week 16,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9607,NCT04824209,Variation in pro-diabetes inflammation markers over time upon endodontic intervention.,,,2021-02-09,COMPLETED,OBSERVATIONAL,['NA']
9608,NCT02672839,Pharmacokinetics Analysis- Maximum Concentration (Cmax),Severity of all Adverse Events graded according to the Common Terminology Criteria for Adverse Events (CTCAE),,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9609,NCT00069368,Urinary Outcomes,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
9610,NCT01593605,Glucose Control,Metabolic Markers,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
9611,NCT03543449,Operative mortality,Perioperative time-weighted average glucose,,2018-04-23,UNKNOWN,OBSERVATIONAL,['NA']
9612,NCT02175537,Waist circumference,Health Profile Survey,Social Network Relationships,2014-06,COMPLETED,INTERVENTIONAL,['NA']
9613,NCT00605111,HbA1c,FPG,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9614,NCT00386100,Change From Baseline in HbA1c at Week 80,"Percent Change From Baseline in Bone Alkaline Phosphatase (BSAP) at Weeks 20, 56, and 80",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9615,NCT02184676,Autoreactive T lymphocytes,Incidence of autoantibodies,,2015-05-28,COMPLETED,INTERVENTIONAL,['NA']
9616,NCT01452178,Cardiovascular events - longitudinal outcome measure.,,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
9617,NCT03324451,Change in Glycosylated Hemoglobin (HbA1c) Levels,Change in Body Mass Index,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
9618,NCT00100178,Mean Stimulated C-peptide Area Under the Curve,,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9619,NCT01789957,Change in body weight from Day 1 of Protocol 2993-112 to Week 52 (or termination),,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9620,NCT00258674,"Change Score for ""Blood Pressure (b.p.) <130/80 mmHg""","Change Score for ""Semiannual HbA1c Assessment"" (as Determined From Medicare Claims Data)",,2000-01,COMPLETED,INTERVENTIONAL,['NA']
9621,NCT01507116,Self-reported health and Quality of Life (QoL) (measured by the study questionnaire),Patient-centred diabetes care reported by people with diabetes and health care professionals measured by the study questionnaire,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
9622,NCT02919059,Effect of dapagliflozin relative to glimepiride at 24 weeks of treatment period regarding central systolic blood pressure,Effect of dapagliflozin relative to glimepiride at 24 weeks with inadequate glycemic control regarding augmentation index,,2016-12-13,UNKNOWN,INTERVENTIONAL,['PHASE4']
9623,NCT06024928,Percent Time in Range,Mean glucose reading measured by Continuous Glucose Monitor (CGM),,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
9624,NCT04797416,Difference value,,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
9625,NCT04443842,Glycemic control,Change in physical activity level,Change in health service utilisation,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
9626,NCT01719003,HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24,Body Weight Change From Baseline at Week 24,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9627,NCT05473806,Changes in Liver Stiffness Measurement at 24 weeks compared to baseline.,Analysis of predictors of HbA1c improvement after 24 weeks compared to baseline.,,2020-09-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9628,NCT02122835,exercise capacity,nitrite flux during exercise,,2012-02,WITHDRAWN,INTERVENTIONAL,['NA']
9629,NCT05343767,To compare the hypoglycemic effect of two doses of a herbal medicinal product (NW Low-Glu) to that of Metformin as measured by the mean change in HbA1c levels in patients newly diagnosed with type II diabetes mellitus.,To compare the mean change in the 2h-post prandial glucose levels between each experimental arm and active-control arm (efficacy),To investigate the effect of NW Low-Glu on weight.,2018-09-12,COMPLETED,INTERVENTIONAL,['NA']
9630,NCT02760303,Metabolic Control,Diabetes Quality of Life,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9631,NCT05981547,Glucose variability,A analysis of CGM glucose data for progression of glycaemia in a sub group,,2023-11-22,RECRUITING,OBSERVATIONAL,['NA']
9632,NCT01021865,To determine whether hyperglycemia alters myocardial perfusion in subjects with type 2 diabetes,To determine whether GLP-1 modulates myocardial perfusion in subjects with type 2 diabetes.,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
9633,NCT05572502,Glycated hemoglobin,medication usage,,2023-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9634,NCT00337324,"Daytime and night-time pain scores assessed at baseline, after FREMS/placebo, and 4 month follow-up",Partial tissue tension of oxygen and carbon dioxide by oxymetry,,2002-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9635,NCT04650945,"Glucose time in range (3,9-10 mmol/l) (% pr day)",Time with active isCGM,,2021-01-04,TERMINATED,INTERVENTIONAL,['NA']
9636,NCT00788827,Number of Participants Who Experienced Adverse Events,Serum Creatinine,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9637,NCT01440660,Multimodal testing/imaging procedures - Brain Imaging,Multimodal testing/ imaging modalities (raw data),,2012-01,COMPLETED,OBSERVATIONAL,['NA']
9638,NCT04315857,Time spent with an interstitial blood glucose level below 0.70 g/l and above 2.5 g/l,,,2020-06-09,COMPLETED,OBSERVATIONAL,['NA']
9639,NCT01034111,Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment,Change From Baseline in Fasting Plasma Glucose at Week 4,,2010-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9640,NCT03340467,Survival rate,Attachment site reactions,,2018-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
9641,NCT06096311,Qualitative Results from Interviews,,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA']
9642,NCT05687968,Fasting glucose,Triglyceride (TG),,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
9643,NCT04016415,Change in Hemoglobin A1c from Baseline to 6 months,Change in Perceived Stress Scale-10 from Baseline to 6 months,,2020-07-28,RECRUITING,INTERVENTIONAL,['NA']
9644,NCT01970462,Difference in Fasting Glucose,,Hypoglycemia,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4']
9645,NCT04982640,Acceptability as indicated by participant satisfaction ratings,Body Mass Index,,2022-10-24,RECRUITING,INTERVENTIONAL,['NA']
9646,NCT00286429,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9647,NCT05759676,Target lesion failure(Device-oriented composite endpoints),Procedural success rate,,2023-03-09,RECRUITING,OBSERVATIONAL,['NA']
9648,NCT02974491,Evaluating adequacy of the dialysis treatment,,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9649,NCT03229161,Compliance to the prescribed IWT-intervention,Physical fitness,BMI,2017-01-03,COMPLETED,INTERVENTIONAL,['NA']
9650,NCT02585674,Percentage of patients reaching fasting SMPG target range 90-130 mg/dL (5.0-7.2 mmol/L) at Week 16 (mean of the last 5 readings recorded over the last 2 weeks) without a severe hypoglycemic episode during the 16-week on-treatment period,Assessment of device Ease of Use using Ease of Use questionnaire,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9651,NCT04927702,"For Participants With Venous Leg Ulcers, number of participants with 100 Percent Epithelialization (Closure) of Wound",Number of Product Applications,Number of participants with coverage of product by payor (insurance),2021-07-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9652,NCT05026775,Rate of Initiation,Reduction of Cardiovascular Risk,Rate of Mortality,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9653,NCT00543361,This study will assess the lipid lowering effectiveness of MK0767 compared to metformin over the course of 52 weeks.,MK0767 will be safe and well tolerated.,,2003-05,TERMINATED,INTERVENTIONAL,['PHASE3']
9654,NCT01934673,Proportion of patients having HbA1c ((glycosylated haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
9655,NCT01095666,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9656,NCT01793974,Identify variations in the human genome associated with LADA by genotyping cases and comparing allele frequencies to an existing control database,Identify associations between genetic variants with certain measurable risk profiles that can be used to judge the health status or well being of a LADA case.,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
9657,NCT03344341,Absolute change from baseline in HbA1c at Week 24,Percentage of patients with reduction of SBP ≥3 mmHg,The difference of the number between tablets taken and tablets prescribed,2017-12-15,TERMINATED,INTERVENTIONAL,['PHASE4']
9658,NCT05866380,Major adverse cardiovascular events,,,2022-03-23,RECRUITING,OBSERVATIONAL,['NA']
9659,NCT00594399,12 Month Fasting Glucose,"Physical Activity, Endurance",,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9660,NCT01515579,"Cmax, maximum concentration",Adverse events,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9661,NCT01277965,Number of episodes of symptomatic or non-symptomatic hypoglycaemia,Duration of hypoglycaemia,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
9662,NCT00222807,,,,2003-08,COMPLETED,OBSERVATIONAL,['NA']
9663,NCT06317454,Identification of genetic factors affecting T1DM metabolic control,,,2021-11-11,RECRUITING,OBSERVATIONAL,['NA']
9664,NCT03686423,Apparent Diffusion Coefficient (ADC) in the Tibial Nerve,,,2018-11-28,COMPLETED,INTERVENTIONAL,['NA']
9665,NCT03234387,Maximal oxygen uptake (aerobic fitness),Insulin concentration,,2017-11-17,TERMINATED,OBSERVATIONAL,['NA']
9666,NCT04733690,Satiety,,,2021-02-04,UNKNOWN,OBSERVATIONAL,['NA']
9667,NCT03627039,"Cardiovascular composite (stroke, myocardial infarction, heart failure)",Costs,Tracer outcomes,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA']
9668,NCT02091778,Change in Peri-wound Skin,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
9669,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator,Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year,Major Ocular Adverse Events During First Year of Follow-Up,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9670,NCT01951859,Decrease in area or closure of wounds/fissures due to Homeopathic Anti-inflammatory Topical Cream,,,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
9671,NCT05844137,Acceptability of intervention by participants,Change in medication adherence,,2023-09-18,COMPLETED,INTERVENTIONAL,['NA']
9672,NCT05190198,Modified Toronto Clinical Neuropathy Score (mTCNS),,,2022-01-15,COMPLETED,INTERVENTIONAL,['NA']
9673,NCT01671189,Glycemic Control (hemoglobin A1c),Appointment Adherence Rate,,2012-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9674,NCT04161937,HbA1C,,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
9675,NCT05979142,Composite standard,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
9676,NCT02033876,Change in Area Above Basal (AAB) for Glucose,Change in FGF-19,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9677,NCT05951946,"Cmax,ss",,,2023-07-22,COMPLETED,INTERVENTIONAL,['PHASE1']
9678,NCT03374098,Changes in HbA1C values,Physical Activity,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
9679,NCT04280549,Protease Activated Receptor-1 Activation,,,2018-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9680,NCT04979559,Oral glucose tolerance test mean change from baseline,Likelihood ratio of screening instrument compared to American Diabetes Association criteria,Participant's acceptance of mobile health application,2021-05-25,UNKNOWN,INTERVENTIONAL,['NA']
9681,NCT04908904,Area under the curve for glucose,Area under the curve for GIP,,2021-05-27,COMPLETED,INTERVENTIONAL,['NA']
9682,NCT00903799,clinical efficacy,medico-economic evaluation of ENTERRA therapy,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
9683,NCT01513525,Area under the Curve (AUC) of liraglutide for each injection site,Adverse events,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9684,NCT02956759,Proportion of eyes progressing to any degree of PDR,Sensitivity & specificity of the diagnosis of any degree of PDR among study ophthalmologists,Patient vision-related quality of life (VRQOL); composite and individual domain scores of the NEI VFQ25 questionnaire.,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
9685,NCT02843399,Diabetes-related HCRU/costs,Medical Hypoglycemic events,Composite of A1C <7%/no weight gain/no hypoglycemia,2016-08-15,COMPLETED,OBSERVATIONAL,['NA']
9686,NCT01202526,Change in insulin sensitivity after RYGB,Change in insulin secretion in response to oral glucose after RYGB,Change in insulin secretion after iv glucose-glucagon after RYGB,2010-09,COMPLETED,OBSERVATIONAL,['NA']
9687,NCT05457088,Dietary intake of macro- and micro-nutrients,Protein carbonyls in plasma,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
9688,NCT05076292,Incidence rate of hypoglycemia (PG < 3.9 mmol/l),Point accuracy with the Clarke Error Grid Analysis (CEGA) (using SMBG and YSI as the reference value),,2021-11-23,COMPLETED,INTERVENTIONAL,['NA']
9689,NCT00935922,Improved lipid profile,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
9690,NCT03179137,Myocardial production of reactive oxygen species,Anti-cardiolipin antibodies in the blood of patients with symptoms of cardiac ischemia,,2016-10-01,UNKNOWN,OBSERVATIONAL,['NA']
9691,NCT05182970,Time to major CV event,Diabetes diagnosis,Hypoglycaemia,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE3']
9692,NCT01776788,the glycemic remission rate in different groups,the time of glycemic remission in different groups,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9693,NCT00862589,glucagon suppression,,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
9694,NCT04234763,Postprandial 1H-NMR metabolites,Dietary Glycemic load(GL),,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
9695,NCT03629301,Change in body weight,Number of participants achieving 5% of weight loss,,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
9696,NCT03622762,Soluble RAGE concentration,Aspartate aminotransferase,Weight and visceral fat %,2018-07-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
9697,NCT02213146,Area under the curve (AUCins(0-1h)),Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 2 hours,,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9698,NCT01589653,Change in HbA1c From Baseline,Change in Patient Reported Outcomes: Treatment-Related Impact Measures for Diabetes (TRIM-D)-Treatment Burden,,2012-05-26,COMPLETED,INTERVENTIONAL,['PHASE4']
9699,NCT04078854,Change in hemoglobin A1c (HbA1c) levels,Number of patients with mobility problems,,2020-07-08,TERMINATED,INTERVENTIONAL,['NA']
9700,NCT06065540,CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Relative change in body weight,"CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of severe hypoglycaemic episodes (level 3)",,2023-09-27,RECRUITING,INTERVENTIONAL,['PHASE3']
9701,NCT01706133,Change in hand grip strength (HS) as a physical performance test,Evaluation of individual and institutional impact,Quantify hospital readmissions,2013-06,COMPLETED,INTERVENTIONAL,['NA']
9702,NCT00793481,Changes in Microvascular,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
9703,NCT02906709,Percentage of Participants Who Discontinued Study Drug Due to an AE Including Data After Glycemic Rescue (Omarigliptin [Phase A+B]; Placebo→Omarigliptin [Phase B Only]),Percentage of Participants Achieving Hemoglobin A1c Goals (<6.5%) at Week 52 (Phase A+B),,2016-10-17,COMPLETED,INTERVENTIONAL,['PHASE4']
9704,NCT01016457,HbA1C,Mean glucose level,,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
9705,NCT06042153,Change in TIR (70-180 mg/dl),Total score of Kidney disease QoL short form,,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE4']
9706,NCT02472951,Insulin sensitivity,,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9707,NCT03049592,Utilization of LARC,Acceptability of contraceptive counseling intervention by patients and clinicians,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
9708,NCT05976191,Blood Glucose Measurement Patient Satisfaction Form,,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
9709,NCT04678284,Acceptability of Intervention,Diabetes Medication Adherence,,2021-03-24,COMPLETED,INTERVENTIONAL,['NA']
9710,NCT00595569,"Metabolic control (HbA1c, severe hypoglycemic events), psychological effects, diabetes knowledge","Changes in insulin doses, changes in weight",,2002-04,COMPLETED,OBSERVATIONAL,['NA']
9711,NCT02458495,Glycemic control (Change in participant's HbA1c level),"Time spent on website, 3 month assessment",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9712,NCT01651065,Weight,"Hemoglobin A1c (%, HbA1c)",Temporally investigate the causal induction of cascading changes in body weight between follow-ups on subsequent weight changes in other participants.,2011-06,COMPLETED,INTERVENTIONAL,['NA']
9713,NCT03676309,colesterol,Endothelial function,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9714,NCT03550378,Percent Change From Baseline in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4 Hrs) as Measured by Mixed-meal Tolerance Test (MMTT) to Day 32,Number of Participants With Positive Anti-drug Antibodies (ADA) Titre to MEDI0382,,2018-06-29,COMPLETED,INTERVENTIONAL,['PHASE2']
9715,NCT01006603,Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia.,Change From Baseline to Week 52 in β-cell Function (as Measured by Homeostasis Model Assessment-β [HOMA-β],,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9716,NCT00306644,Change from baseline of the composite intima-media thickness (IMT) in the carotid artery following 52 weeks of treatment.,Plaque occurrence & stenosis within the right carotid artery.,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9717,NCT02180620,glucose concentrations,triglyceride concentrations,GLP-1 concentrations,2013-09,COMPLETED,INTERVENTIONAL,['NA']
9718,NCT05065372,Glomerular filtration rate,Insulin sensitivity,,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE1']
9719,NCT05472597,Incidence of metabolic syndrome,,,2022-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9720,NCT01167881,The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.,The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9721,NCT00518427,Glycaemic controll will be asessed by HbA1c values,Incidence of symptomatic hypoglycemia and severe hypoglycemia,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9722,NCT01923181,Change in HbA1c (Glycosylated Haemoglobin),Number of Confirmed Hypoglycaemic Episodes Recorded,,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9723,NCT03715582,peak values of troponin and CKMB after PCI,occurrence of death,,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
9724,NCT03243903,glycosylated hemoglobin (HbA1c),Self-monitoring of blood glucose(SMBG),Subject Satisfaction,2017-08-18,COMPLETED,INTERVENTIONAL,['NA']
9725,NCT01690169,Number of treatment emergent adverse events (TEAEs),"tmax, the time to maximum plasma concentration of NNC0113-0987",,2012-09-14,COMPLETED,INTERVENTIONAL,['PHASE1']
9726,NCT00479986,"Short-term effect of Pioglitazone on Markers of vascular risk (MMP-9, hsCRP, monocyte activation)","Metabolic control (HbA1c, Glucose)",,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9727,NCT00304733,wound surface area reduction,time to wound healing (days),,2001-08,UNKNOWN,INTERVENTIONAL,['NA']
9728,NCT01522157,P-Triglycerides,P-HDL-Cholesterol,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
9729,NCT00943501,Number and type of adverse events,Pharmacodynamics: Fasting Plasma Glucose (FPG) and insulin,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9730,NCT01448070,"Area under the curve (glucose infusion rate (GIR)), 0-8h",Physical examinations and vital signs,,2002-10-15,COMPLETED,INTERVENTIONAL,['PHASE1']
9731,NCT06214780,Change in time in range,Change in Percentage of time of varibles modes of automatization,,2024-01-22,RECRUITING,OBSERVATIONAL,['NA']
9732,NCT02518503,Number of participants with Incident type 2 diabetes,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
9733,NCT06003530,Treatment related adverse events,Wound healing,,2022-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9734,NCT04605900,Change the 6 minutes walk test performance,Satisfaction with devices,,2017-03-13,COMPLETED,INTERVENTIONAL,['NA']
9735,NCT05386160,capillary non-perfusion zone of non-proliferative diabetic retinopathy,Determination of inflammatory factors in anterior aqueous humor,,2022-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9736,NCT04854135,To Determine the Feasibility of Initiating a Continuous Glucose Monitoring in Patients With Diabetes at Hospital Discharge,Mean Change in Self-efficacy at 3 Months,,2021-04-13,TERMINATED,INTERVENTIONAL,['NA']
9737,NCT03014011,Psychomotor Speed,,,2017-06-13,COMPLETED,INTERVENTIONAL,['NA']
9738,NCT01245270,Plasma Insulin iAUC (Incremental Area Under the Curve; ng/ml*Min),Bioavailability in Urine,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
9739,NCT05917587,blood flow response to insulin,Percentage of nitric oxide-dependent dilation,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
9740,NCT03156361,Glucose area under the curve,total units Insulin,,2017-05-18,COMPLETED,INTERVENTIONAL,['PHASE2']
9741,NCT03616171,Number of Participants Enrolled in the Intervention Arm Who Complete the Study,Number of Participants Extending Sleep,,2017-08-30,COMPLETED,INTERVENTIONAL,['NA']
9742,NCT01455727,Hgb A1c change,Taiwan Geriatric Depression Scale(GDS) Score change,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
9743,NCT01316094,changes in Hemoglobin A1c (HbA1c),"safety assessed by the incidence of adverse events, vital signs, laboratory tests and 12-lead ECGs",,2011-01-18,COMPLETED,INTERVENTIONAL,['PHASE3']
9744,NCT01177813,Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks,Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP),Confirmed Hypoglycaemic Adverse Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9745,NCT02759055,Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke,,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
9746,NCT03697369,Discontinuation rate differences,Glycemic control and metabolic parameters differences:BMI SDS,,2015-05-31,COMPLETED,OBSERVATIONAL,['NA']
9747,NCT06272851,comparison between choroidal thickness,,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9748,NCT04291313,The prevalence of gestational diabetes (GDM),Prevalence of post partum hemorrhage > 500 ml,,2020-06-08,UNKNOWN,INTERVENTIONAL,['NA']
9749,NCT05962710,System Performance,,,2023-01-27,TERMINATED,OBSERVATIONAL,['NA']
9750,NCT01240837,Blood glucose concentrations,,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
9751,NCT02604524,Time in range when using closed-loop compared with SAP.,Reduction of hypoglycemia episodes when using closed-loop,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
9752,NCT05205928,Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo),"Glucagon, C-peptide, Paracetamol absorption after mixed meal tolerance test (in first 15 participants)",,2022-10-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9753,NCT05112588,Diabetes mellitus type 2,Glucose tolerance,,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9754,NCT03394157,excess weight loss,Resolution of diabetes,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
9755,NCT03745300,change in defect depth,change in modified Sulcus Bleding Index (mSBI),,2017-03-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9756,NCT01520818,HbA1c (glycosylated haemoglobin A1c),Quality of Life (QoL) assessed via Diabetes Health Profile (DHP-2),,2000-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9757,NCT06157736,Describe evolution of the microbiome and metabolome during the early stages of new onset T1D,,,2023-10-06,RECRUITING,OBSERVATIONAL,['NA']
9758,NCT01951339,Changes From Baseline in 31P Measurement: pH,Change in (Non-invasively Measured) Deoxygenated Hemoglobin Concentration in the Vastus Lateralis During Exercise,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
9759,NCT03723772,"AUCI287,τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state",Positive cross-reactive anti-human insulin antibodies,,2018-11-29,COMPLETED,INTERVENTIONAL,['PHASE1']
9760,NCT03103867,Time in glucose target,hypoglycaemia fear in patients and caregivers,,2017-02-23,COMPLETED,INTERVENTIONAL,['NA']
9761,NCT01035801,AUC (Insulin and Blood Glucose),Frequency of Adverse Events,,2010-08-21,TERMINATED,INTERVENTIONAL,['PHASE1']
9762,NCT04626531,The Diabetes Quality of Life Scale,Website Analysis and Measurement Inventory,,2016-01-10,COMPLETED,INTERVENTIONAL,['NA']
9763,NCT00127634,To assess change in baseline to endpoint in HbA1c in type 1 diabetic patients.,To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to glycemic control as assessed by the 8-point self-monitored blood glucose profiles,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9764,NCT01680328,Injection Pain (VAS mm),Estimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9765,NCT00212641,Fasting Blood Glucose at 8 weeks,Pharmacodynamic parameters at all time points,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9766,NCT05512624,Pill Count Medication Adherence,,Incidence of seizure,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
9767,NCT01519674,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Patient Reported Outcome by Use of the Treatment Related Impact Measure - Diabetes.,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9768,NCT02789033,Biopsies,,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9769,NCT03814915,Glycemic deterioration,,,2012-10-15,COMPLETED,OBSERVATIONAL,['NA']
9770,NCT04733508,Gene expression,,,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA']
9771,NCT03734107,Diabetes-related hospitalizations,,,2018-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9772,NCT05762744,Exenatide effect on glucose disappearance rate,,,2016-06-01,TERMINATED,INTERVENTIONAL,['PHASE1']
9773,NCT00442858,,,,1999-01,COMPLETED,OBSERVATIONAL,['NA']
9774,NCT00006192,,,,2000-08,COMPLETED,OBSERVATIONAL,['NA']
9775,NCT02239354,Change in C-peptide,,,2014-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9776,NCT00717977,Glucose Variability Measure: Amplitude of Glycemic Excursions by Time of Day,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9777,NCT03772964,"Ex Vivo Cytokine Response of Peripheral Blood Mononucleocytes (PBMC) to Inflammatory Stimuli Compared to Baseline, Throughout Exposure, and Following Exposure to Metformin.",Measure Biogenesis of PBMCs.,,2019-01-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9778,NCT01490619,Change in Depressive symptoms from baseline to post intervention and change in Depressive symptoms over the two year study period.,Change in Glycemic Control from baseline to post-intervention and change in Glycemic Control over time during the two year study period.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
9779,NCT02380521,Subclinical atherosclerosis (as measured by cIMT) in patients with T2DM treated with exenatide once weekly,Endothelial dysfunction (as measured by flow mediated dilation of brachial artery) in patients with T2DM treated with exenatide once weekly,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9780,NCT02479022,Number of treatment-emergent adverse events,Area under the glucose infusion rate-time curve,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9781,NCT02827630,Week 4 Change in Systolic Blood Pressure,Number of Treatment-Related Adverse Events,Provider Reported Outcomes: Results from a provider satisfaction [to DH] questionnaire administered at the end of using DH.,2015-05,COMPLETED,INTERVENTIONAL,['NA']
9782,NCT06296550,HbA1c,Diabetes Distress Scale,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9783,NCT00979225,Rates of aggregate adherence by study group to all applicable pharmacotherapy rules during the study period.,Inpatient hospitalization rates.,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
9784,NCT02712632,HbA1c reduction.,,,2016-06-20,COMPLETED,OBSERVATIONAL,['NA']
9785,NCT00637338,"To describe the safety and tolerability of escalating, multiple, subcutaneously injected doses of PF-04603629 administered to subjects with T2DM.","To evaluate the effect of multiple, escalating, subcutaneously injected doses of PF-04603926 on additional exploratory efficacy biomarkers related to this drug's target in subjects with T2DM.",,2008-04,TERMINATED,INTERVENTIONAL,['PHASE1']
9786,NCT05977218,HbA1c (mmol/mol),Self-reported quality of life,24-hour dietary recall,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9787,NCT00804232,Primary Outcome Measure: the child's metabolic control as shown in HbA1C,"Quality of life, Satisfaction with care, Family impact and family climate, psychological variables, parental absenteeism from work; time use which is conditional on the child's diabetes etc), formal health care utilisation",,2008-01,UNKNOWN,INTERVENTIONAL,['NA']
9788,NCT01487369,Antibody titre findings,HbA1c (glycosylated haemoglobin),,2002-04,COMPLETED,OBSERVATIONAL,['NA']
9789,NCT01548885,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Low Glucose Range (<70mg/dL),,2012-03,COMPLETED,INTERVENTIONAL,['NA']
9790,NCT04230694,Number of Hypoglycemia Events during hospitalization,Number of Hyperglycemia Events during hospitalization,,2021-09-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9791,NCT00996294,"Diabetes control, define by FSG and HbA1c",Diabetes control defined by FSG and HbA1c,,2007-11,UNKNOWN,INTERVENTIONAL,['NA']
9792,NCT03287297,Blood Glucose Level,,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
9793,NCT00367055,Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment,Mean Change From Baseline in Insulin Sensitivity Index at Months 18 and 36,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9794,NCT01620437,"Cmax, maximum insulin aspart concentration",Adverse events,,2003-11-29,COMPLETED,INTERVENTIONAL,['PHASE1']
9795,NCT01410292,glycemic control,measures of satiety and appetite,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
9796,NCT01508481,Incidence of diabetes,Insulin resistance,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
9797,NCT02620774,Tazobactam Tissue Penetration,Number of Participants With Adverse Events,,2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1']
9798,NCT02198846,change of HbA1c,Percent of patients who reach target goal of HbA1c (<7.0%),,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
9799,NCT03899883,Albumin Excretion Rate (AER),Change in serum uric acid (sUA),,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
9800,NCT05694351,"Contextual appropriateness (questionnaire, 5-items Likert scale, higher score is best)",Well-being,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
9801,NCT04307797,Part B - Changes in absolute concentrations of PCr and ATP defined by AHA 17- segment territory as a measure of cardiac energy status (determined by 31P-MRS),Part A/B - gastric inhibitory polypeptide,,2022-01-18,UNKNOWN,INTERVENTIONAL,['PHASE4']
9802,NCT05572814,"Adoption of evidence-based CV-risk reduction and disease management therapies for HF, AF, and T2D/ASCVD. This data will be found in the patient's medical record.",Quality of Life Outcome-PAM,,2022-09-30,RECRUITING,INTERVENTIONAL,['NA']
9803,NCT03627377,Hemoglobin A1c or HbA1c,Smoking - Change in Smoking through Recall,,2018-12-28,UNKNOWN,INTERVENTIONAL,['NA']
9804,NCT03880838,Diastolic Blood Pressure From One Year Before to One Year After Intervention,Five Years Before to Two Years After Intervention in Depressed Mood and Anhedonia as Assessed by the Patient Health Questionnaire-2 (PHQ-2) (Extended Time Frame),,2019-06-20,COMPLETED,INTERVENTIONAL,['NA']
9805,NCT03301519,Pancreatic Beta Cell Compensation for Insulin Resistance,Circulating adipokine levels,,2001-07-01,COMPLETED,OBSERVATIONAL,['NA']
9806,NCT00709475,"Incidence of serious adverse drug reactions, evaluated via number of major hypoglycaemic events",Fasting glucose level control compared to baseline as measured by FBG,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
9807,NCT05035966,Prediabetes,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
9808,NCT01215331,Glycemic control,Acceptability of the treatment,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9809,NCT02130804,Change in plasma C-peptide levels over a 2-hour oral glucose tolerance test,Change in physical activity,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9810,NCT00156364,Structural-functional relationships in diabetic nephropathy through detailed quantitative studies of Podocytes.,We will continue our study the natural history of diabetic nephropathy.,We have compared the development of calcineurin lesions in the native kidneys of 14 tacrolimus- and 12 calcineurin-treated pancreas transplant alone recipients cured of type 1 diabetes.,1981-01,COMPLETED,OBSERVATIONAL,['NA']
9811,NCT01769183,Proportion with complete regression of neovascularization on fundus photography at one month,Mean Change in Visual Acuity from Baseline to 5 Months,Proportion with partial regression of neovascularization on fundus photography,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9812,NCT01889095,Number Of Hypoglycemic events,,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9813,NCT00592397,"Changes in microarray gene expression profiles in blood and subcutaneous abdominal fat tissue from healthy obese men, as a consequence of changes in dietary macro nutrient composition.",Time to stabilization of gene expression changes due to dietary intervention.,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
9814,NCT00664027,To determine the effects of RTA 402 on glomerular filtration rate (as estimated by the MDRD formula) when administered for 28 days at dose of 25 mg followed by a dose of 75 mg for another 28 days in patients with diabetic nephropathy (stratum 2).,To determine the safety and tolerability of RTA 402 when the dose is escalated after 28 days in patients with diabetic nephropathy from 25 mg to 75 mg and continued for another 28 consecutive days.,,2008-04-30,COMPLETED,INTERVENTIONAL,['PHASE2']
9815,NCT05473078,Evaluate the attitudes by general practitioners towards pre-diabetes,,,2021-10-21,COMPLETED,OBSERVATIONAL,['NA']
9816,NCT03871660,Hyperglycaemia,,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
9817,NCT00686712,Hemoglobin A1c Change From Baseline,Any Adverse Event Other Than Hypoglycemia,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9818,NCT03419195,Change in muscular mitochondrial function,,,2018-02-07,COMPLETED,INTERVENTIONAL,['NA']
9819,NCT01141192,"Fasting glucose level before, mid-way through, and after the vitamin D3 supplement or placebo trial.",Serum 25-OH D levels in response to vitamin D3 supplement or placebo across a range of adiposity,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
9820,NCT03011008,Mean amplitude of glycemic excursions (MAGE),Life quality evaluation,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9821,NCT01213212,"Glomerular Filtration Rate (GFR), absolute and percent change, at 6 months vs baseline.",Metabolic and inflammatory parameters.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9822,NCT01357304,Physical activity level,"Quality of life, measured using the EQ-5D questionnaire",,2011-03,COMPLETED,INTERVENTIONAL,['NA']
9823,NCT06288555,The accuracy of the Ipswich touch test,,,2023-12-21,COMPLETED,OBSERVATIONAL,['NA']
9824,NCT05791968,Continuous glucose monitoring,Body composition (weight and body fat),,2023-09,RECRUITING,INTERVENTIONAL,['NA']
9825,NCT04658693,Functional Gait Assessment (FGA),Neuropathic Pain Syndrome Inventory (NPSI),,2021-03-02,RECRUITING,INTERVENTIONAL,['NA']
9826,NCT05235672,GADA in serum of subjects with T2D,,,2021-01-30,COMPLETED,OBSERVATIONAL,['NA']
9827,NCT04109547,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Participants With Anti-semaglutide Binding Antibodies Cross Reacting With Native GLP-1,,2019-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9828,NCT01017523,Blood glucose control (hemoglobin AIc),Diabetes-related quality of life outcome (distress),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9829,NCT00643851,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF]),,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9830,NCT04416204,Hepatic Glycogen Content and Rates of Gluconeogenesis in Subjects With Type 2 Diabetes,Rates of Gluconeogenesis in Healthy Subjects,,2020-08-21,COMPLETED,INTERVENTIONAL,['NA']
9831,NCT04347291,Change in Psychosocial Well-being (Patient Participants) Sustained Post-intervention Effect,Change in Support Burden (Support Person Participants) Sustained Post-intervention Effect,Change in Support Person Involvement Alignment (Support Person Participants - Outcome & Mediator),2020-04-28,COMPLETED,INTERVENTIONAL,['NA']
9832,NCT03050645,Type 2 diabetes,"Questionnaires, physical activity (PAS 2), physical activity score",,2011-06,COMPLETED,OBSERVATIONAL,['NA']
9833,NCT04880005,"Change in a binary indicator, composed by a composite endpoint of HbA1c, systolic blood pressure, low-density lipoprotein cholesterol, no smoking, and normal albuminuria",Change in quality of life measured by European Quality of life - EQ VAS,,2021-05-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9834,NCT05643521,The primary outcome is the 1H-Magnetic Resonance Spectroscopy (MRS) determined liver TG content.,"Secondary outcomes are fasting and postprandial plasma glucose, insulin, and plasma TG concentrations after 2 days VLCD or LC compared with 2 days of eucaloric conventional diet.",Explorative outcomes,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9835,NCT02229240,Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26,"Assessment of clinical laboratory tests, lipids, vital signs, ECGs and physical examinations",,2015-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
9836,NCT05676593,Rate of change in glycated hemoglobine at 3 months,Eating behavior questionnaire,,2023-05-03,RECRUITING,INTERVENTIONAL,['NA']
9837,NCT05838872,Accuracy Evaluation: The Degree of Agreement (%) of the Minuteful - Kidney Urine Analysis Test System as Compared to the Comparator Device,Usability Evaluation: User Performance Analysis,,2021-12-09,COMPLETED,INTERVENTIONAL,['NA']
9838,NCT04485351,Compare glycated hemoglobin levels of patients with diabetes from the University Hospital of Nancy between the period preceding and following the lockdown related to the COVID-19 pandemic.,"Describe the proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19.",,2020-07,UNKNOWN,OBSERVATIONAL,['NA']
9839,NCT00505284,Mean Change in Average Pain Scores From Baseline at Each Study Week,Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period,,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9840,NCT02632383,Glycemic control measured by HbA1c,Health Care Climate measured by HCCQ-questionnaire,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
9841,NCT02669693,Post-prandial blood glucose concentration,,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
9842,NCT03138616,Change in glucose metabolism,change in metabolism of calcium and phosphorus,,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9843,NCT04398030,"The Primary Endpoint is the Rate of Decline (s) Over Wear Time (DOI, Day 3, Day 5, Day 7) of the Natural Logarithm of the Area Under the Glucose Infusion Rate Curve [ln (AUC0-300(GIR))].",Mean Differences (Within Treatments Over Time Between Day 0 and Day 7) in Time-to-50% (Late) Maximum Insulin Concentration [t50%(Late)],,2020-07-17,COMPLETED,INTERVENTIONAL,['NA']
9844,NCT02844153,Percentage of patients receiving metformin,occurrence of lactic acidosis,,2014-03,UNKNOWN,OBSERVATIONAL,['NA']
9845,NCT00542113,Diabetes knowledge and prevention of parents of elementary school children,Self-reported parental physical activity,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
9846,NCT00856908,Clinically Relevant Change of Laboratory Variables,"S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9847,NCT01719406,"Achieving 30 minutes of daily exercise, four or more times each week",Eating 5 or more servings of vegetables and/or fruits each day,HemoglobinA1C,2012-11,COMPLETED,INTERVENTIONAL,['NA']
9848,NCT03531021,Adolescent Food Habits Checklist,Change in weight,,2018-05-03,COMPLETED,INTERVENTIONAL,['NA']
9849,NCT05694169,Primary Endpoints is as follows:,Second Secondary Endpoint,,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1']
9850,NCT03129581,Weight,Body composition,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
9851,NCT01957592,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2014-10,WITHDRAWN,OBSERVATIONAL,['NA']
9852,NCT04053621,hemoglobin A1c,arterial elasticity,,2021-01,UNKNOWN,INTERVENTIONAL,['NA']
9853,NCT03188263,Change in Glucose Levels (Area-under-the-curve) Measured by Performance on Oral Glucose Tolerance Test (OGTT),Changes in Circadian Phase Measured by Dim Light Melatonin Onset (DLMO),,2017-09-05,COMPLETED,INTERVENTIONAL,['NA']
9854,NCT03447925,Measures of the sites with plantar keratosis,,,2017-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9855,NCT02082132,Frequency of MODY,Comparison of clinical and biochemical characteristics of other subtypes of diabetes,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
9856,NCT01923350,"In testing group, the number of women receiving a diabetes test per ADA Guidelines in the 6-month post-intervention period",Weight change from 6 to 9 months,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
9857,NCT01055093,Change of insulin sensitivity (M-Value),Incidence of any diabetic complication,,2005-09,RECRUITING,OBSERVATIONAL,['NA']
9858,NCT00502710,Absolute change in hemoglobin A1c (HbA1c),"Adverse events (AEs), vital signs, laboratory parameters.",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9859,NCT05463237,24-28. Visceral Adipokine Levels in Pregnant Women with Gestational Diabetes Between Weeks,,,2022-10-31,COMPLETED,OBSERVATIONAL,['NA']
9860,NCT02060916,To evaluate the efficacy of the food supplement PAZ320 on post-prandial glucose excursion,Number of Subjects with Adverse Events as a Measure of Safety and Tolerability,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9861,NCT03673111,Incidence of Treatment-Emergent Adverse Events (safety and tolerability),Body weight,,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9862,NCT01718457,percent change in BMI,percent in Triglycerides levels,change in C-peptide levels,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
9863,NCT03509870,serious adverse events attributable to intervention,healing,,2018-06-01,TERMINATED,INTERVENTIONAL,['PHASE1']
9864,NCT02375139,Maximum of concentration (Cmax) of Evogliptin and Metformin,Area Under Curve(AUC)inf of Evogliptin and Metformin,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9865,NCT00320060,,,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9866,NCT03571659,1. Decrease in number of leaking Mas on FFA 2. Decrease in diffuse leakage on FFA,,,2014-12-22,COMPLETED,OBSERVATIONAL,['NA']
9867,NCT02219750,HbA1c,total insulin dose,C peptide,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9868,NCT03031886,energy expenditure,,Nitrogen production,2016-01-20,COMPLETED,INTERVENTIONAL,['NA']
9869,NCT00214565,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) (US only).,,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3']
9870,NCT01373814,cardiac function,lipidomics,,2010-09-03,COMPLETED,OBSERVATIONAL,['NA']
9871,NCT00762138,Assess the incidence of hematological immunologic other ae's association with the application of AutoloGel on exuding wounds such as leg ulcers pressure ulcers and diabetics ulcers and during the management of mechanically or surgically debrided wounds,Absence of coagulopathies caused by inhibitors to coagulation Factor V as determined by a significant prolongation of the (PT) time. Depletion of Factor V activity with a positive Bethesda Assay,,2008-09,TERMINATED,INTERVENTIONAL,['NA']
9872,NCT05878587,Numeric Pain Rating Scale,Ankle Brachial Index,Goniometer,2023-03-31,COMPLETED,INTERVENTIONAL,['NA']
9873,NCT04585191,Patient-Reported Outcome: Number of Participants with Self-Reported Hypoglycemia,Patient-Centered Outcome: Number of Participants with improved scores on Perceived Efficacy in Patient - Physician Interactions,"HbA1c Change from baseline to study completion, an average of 1 year",2020-11-02,RECRUITING,INTERVENTIONAL,['NA']
9874,NCT05711043,Proportion of subjects with a clinically relevant reduction of insulin dose after 12 months,Cost-effectiveness,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9875,NCT02513277,Plasma glucose,Depression,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
9876,NCT01654341,Changes in summary ordinal score on the Short Physical Performance Battery test,Mortality,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
9877,NCT03936829,Average daily insulin dosage,HbA1c level,,2019-04-28,RECRUITING,INTERVENTIONAL,['NA']
9878,NCT05913726,Clinician preparation time,Clinician learning,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
9879,NCT05800509,Number and percentage of participants with interventional health education as accessed by the medical record of their infants' body weight in kilograms.,,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9880,NCT05171998,To determine whether SARS-CoV-2-specific T-cells cross-react with insulin producing cells in the pancreas of people with Type 1 diabetes.,To determine if expression of HLA A*02 and/or HLA A*24 is more common in Type 1 diabetes patients with SARS-CoV-2 cross-reactive T cells,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
9881,NCT04303754,Postprandial blood glucose,Appetite,,2020-06-24,COMPLETED,INTERVENTIONAL,['NA']
9882,NCT00657995,the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas,the total amount of insulin required for glycemic control after pancreatic resection,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
9883,NCT01460368,Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (LY2409021),Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (Moxifloxacin),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9884,NCT00860613,metabolic control,cost effectiveness,,2004-02,COMPLETED,INTERVENTIONAL,['NA']
9885,NCT00423488,"Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment",,,2005-07-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9886,NCT03003507,Glycemic Variability,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9887,NCT01771614,Pancreatic endocrine function,Oxidative stress,,2016-08,WITHDRAWN,INTERVENTIONAL,['NA']
9888,NCT01173939,"MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic event",Frequency and type of adverse events,,2010-07,TERMINATED,INTERVENTIONAL,['NA']
9889,NCT01907516,Compliance With Home Blood Glucose Reporting,Subject Satisfaction,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
9890,NCT01495975,Glycemic Control,Unplanned Readmission or ED Visit,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
9891,NCT02155855,hemoglobin A1c,Frequency of contact with diabetes care team,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
9892,NCT01204580,Adiponectin and Asymmetric Dimethylarginine (ADMA) plasma level changes,Change of Tumor Necrosis Factor- Alfa (TNF-Alfa),,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9893,NCT02917031,Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) Index Measured by Magnetic Resonance Imaging (MRI) at 24 Weeks,Number of Participants With Adverse Events,,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9894,NCT04235829,Correlation between early % total weight loss and % total weight loss 7 years following surgery.,Reduction or cessation in the treatment for either type 2 diabetes mellitus and hypertension 7 years following surgery..,,2012-04-01,COMPLETED,OBSERVATIONAL,['NA']
9895,NCT00287820,c-peptide,TD Scores,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9896,NCT02490553,airway obstruction,diabetes mellitus,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
9897,NCT06139133,Gestational diabetes mellitus with 75g OGTT,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9898,NCT01785524,Change in Exercise Capacity - Claudication Onset Time (COT),Change In Vascular Function,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9899,NCT00320021,Change in Serum Creatinine from baseline to week 26,,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9900,NCT00097279,HbA1c,8-point plasma glucose profiles,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9901,NCT02647736,Half life of Copeptin,,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
9902,NCT01025999,Determine if the improvements in glycemic control occurring early after RYGB can be reversibly inactivated and activated through delivery or exclusion of nutrients in the bypassed proximal small intestine.,"To evaluate whether improvements in glucose control occurring early after RYGB are related to altered insulin secretion, insulin sensitivity, or both.",,2010-01,COMPLETED,OBSERVATIONAL,['NA']
9903,NCT05945862,Triglycerides,Lifestyle,,2023-07-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9904,NCT00201227,practice adherence to diabetes guidelines,practice adherence to tobacco history taking guidelines,,2002-09,COMPLETED,INTERVENTIONAL,['NA']
9905,NCT05400694,Insulin,Food pleasantness,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
9906,NCT04125160,HbA1c evaluated by the total mean glucose from continuous glucose monitoring,Hypoglycaemic events,,2019-11-12,COMPLETED,OBSERVATIONAL,['NA']
9907,NCT00308737,FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care,Change in Weight From Baseline at Month 24,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9908,NCT03799796,Time-in-Range,Online peer support engagement,,2019-01-06,COMPLETED,INTERVENTIONAL,['NA']
9909,NCT02120794,Overall Mean Change in A1C,"Mean Change in A1C From Baseline to 1 Year, Stratified by Different A1c Subgroups",,2014-06,COMPLETED,INTERVENTIONAL,['NA']
9910,NCT00950963,Number of Patients With a Low Density Lipid (LDL) Value Less Than 100 mg/dL,Number of Patients With Hgb A1c Less Than 7 Percent at the End of the Study,Number of Total Emergency Department (ED) Visits and Hospital Admissions During the Follow up Period.,2005-09,COMPLETED,INTERVENTIONAL,['NA']
9911,NCT00642616,Change in Post-bronchodilator FEV1 From Baseline to Week 52,Change in HbA1C From Baseline to Week 52,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE3']
9912,NCT05905575,Change in health-related quality of life,Change in blood pressure control,,2023-06-09,RECRUITING,INTERVENTIONAL,['NA']
9913,NCT01233063,Change in added sugar,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
9914,NCT04256720,Clustering of common lifestyle behaviours,Examine associations socio-demographic factors and lifestyle behaviours,,2018-12-10,RECRUITING,OBSERVATIONAL,['NA']
9915,NCT02528162,Scale (1-4) with questionnaire on anxiety (six-item short form STAI),The frequency of an HbA1c ≥6.5%,,2015-10,COMPLETED,OBSERVATIONAL,['NA']
9916,NCT00659451,"Left ventricular mass, intraventricular septal thickness, fractional shortening; myocardial qualitative and diastolic function alteration; aortic strain and distensibility.",Heterogeneity of myocardial tissue; epicardial adipose tissue measurement,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
9917,NCT04190693,Serious Adverse Events,,,2019-02-14,COMPLETED,INTERVENTIONAL,['PHASE1']
9918,NCT04037436,Feasibility - Adherence,Resource use,,2019-09-24,COMPLETED,INTERVENTIONAL,['NA']
9919,NCT02356224,SHR3824 and its metabolites of concentrations to characterize SHR3824 harmacokinetics.,The number of patients with adverse events as a measure of safety and tolerability,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9920,NCT05804513,Growth hormone area under the curve.,Aldosterone peak,Heart rate,2023-04-17,RECRUITING,INTERVENTIONAL,['PHASE4']
9921,NCT05375630,Grip Strength,Vitamin K status,,2022-03-21,RECRUITING,INTERVENTIONAL,['NA']
9922,NCT00793741,Brain glucose concentration as measured by NMR spectroscopy,,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
9923,NCT02233140,Change in dynamic peak plantar pressure (sub-metatarsal 2) in barefoot walking from baseline to 4 weeks.,Change in dynamic peak plantar pressure (sub-metatarsal 2) in barefoot walking from 1 month to 3 months.,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
9924,NCT01469715,Absolute Relative Difference (ARD),,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9925,NCT06311799,Difference in WIC enrollment,RDN visit adherence,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9926,NCT00572806,Blood glucose value,Hypoglycaemic episodes,,2003-02-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9927,NCT03191435,Glycated hemoglobin in 12 weeks,Lung functions,,2017-07-11,UNKNOWN,INTERVENTIONAL,['NA']
9928,NCT02346669,40% decrease in insulin resistance compared to baseline,Maintenance of altered of enteric microbiota in the three diet groups,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
9929,NCT00596687,Mean Blood Glucose Concentration,# Participants With Hypoglycemic Events,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9930,NCT03129165,Primary adherence at baseline screening,Global change in estimated risk at 12th months,,2015-05-11,UNKNOWN,INTERVENTIONAL,['NA']
9931,NCT03829982,Postprandial glucose (mg/dL),Core body temperature (CBT) and skin temperature,,2018-07-13,COMPLETED,INTERVENTIONAL,['NA']
9932,NCT04667182,Change from Baseline in Area Under the Curve (AUC) of CGM,Time Below Range (TBR) <70 mg/dL,,2021-01-25,WITHDRAWN,OBSERVATIONAL,['NA']
9933,NCT01870141,Change from baseline glycosylated haemoglobin (HbA1c) at 26th and 38th weeks [mmol/mol],Change from baseline Binge-Eating Disorders at 26th and 38th weeks (BES score),,2012-10,SUSPENDED,INTERVENTIONAL,['NA']
9934,NCT03871049,blood sugar,,,2020-01-10,COMPLETED,INTERVENTIONAL,['NA']
9935,NCT03590262,Change of hemoglobin A1c in percentage,Change of weight in kilograms,,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9936,NCT00993525,central macular thickness,,,2008-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9937,NCT04505566,Severity of Diabetic Retinopathy (DR),Progression of Diabetic Macular Edema,,2020-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
9938,NCT02817152,"Probing depth change from baseline to 30, 90, and 180 days through periodontal probing","Plaque index change from baseline to 30, 90, and 180 days through periodontal probing",Glycated hemoglobin,2014-02,COMPLETED,INTERVENTIONAL,['NA']
9939,NCT01278823,Test the effect of gastric bypass surgery on glycemic control in obese type 2 DM patients,Determine the effects of gastric bypass surgery on pancreatic beta cell function and incretin hormone secretion in obese type 2 dm patients,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
9940,NCT00000466,,,,1987-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9941,NCT05601310,There are differences in the metabolic profile of diabetic patients with or without combined acute myocardial infarction,,,2017-05-23,COMPLETED,OBSERVATIONAL,['NA']
9942,NCT02283632,Assess change in glycosylated hemoglobin A1c,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
9943,NCT04125082,Hypoglycemia,Quality of Life Questionnaires,,2019-02-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
9944,NCT02099123,Major cardiovascular events,Revascularisation procedure,New onset diabetes,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9945,NCT00948311,,,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
9946,NCT01131052,Mean of Weekly Fasting Blood Glucose Concentration,Mean of Glycosylated Hemoglobin (hbA1c),,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9947,NCT02834078,Change in Glycated hemoglobin,Change in Body Mass Index,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9948,NCT03844646,Amount of Weight Lost (kg),Number of Participants Reporting at Least 5 Days of Moderate Physical Activity of 30 Minutes or More,,2019-08-01,TERMINATED,INTERVENTIONAL,['NA']
9949,NCT00058981,,,,2002-10,TERMINATED,INTERVENTIONAL,['PHASE2']
9950,NCT02541734,Renal uptake as measured by uptake of 111In-exendin-4 on SPECT images and without co-infusion of Gelofusine.,Pancreas uptake as measured by uptake of 111In-exendin-4 on SPECT images,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9951,NCT01087203,Change From Baseline in Average Diabetic Peripheral Neuropathy (DPN) Pain Score at Week 16,Serum Nerve Growth Factor (NGF),Number of Participants With Subcutaneous Doses of Study Medication,2010-03-30,TERMINATED,INTERVENTIONAL,['PHASE2']
9952,NCT04915716,blood glucose concentration,blood glucose concentration,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
9953,NCT05280925,Change in body mass index from baseline (Week 0) to Week 24,"Ease of Use and Treatment Effectiveness Questionnaire, Likert scale",Change in delay discounting from baseline (Week 0) to Week 24,2022-07-20,RECRUITING,INTERVENTIONAL,['NA']
9954,NCT04539288,T2DM,IGT,,2013-05-01,COMPLETED,OBSERVATIONAL,['NA']
9955,NCT03756688,Penile Length Change Between Baseline and Month 6,Erectile Function Among Groups - Evaluating Change From Baseline to 6 Months.,,2018-11-07,COMPLETED,INTERVENTIONAL,['NA']
9956,NCT01336673,Proportion of patients who experience at least one gastrointestinal side effect,Change of Hemoglobin A1c level from baseline after at least 12 weeks of Glucophage XR® therapy,,2011-06,TERMINATED,OBSERVATIONAL,['NA']
9957,NCT03594565,Difference in skin irritation before and after regular application of nsFP according to the modified Draize scale.,Change in glycated hemoglobin 6 months after nsFP use,,2016-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9958,NCT02444845,Number of patients with anemia secondary to CKD,Use of treatment modalities for the management of anemia secondary to CKD,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
9959,NCT01517373,Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12,Number of Participants With Abnormal Laboratory Values,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9960,NCT05923827,Change in HbA1c,Percentage of time <54 mg/dL,,2023-09-11,RECRUITING,INTERVENTIONAL,['NA']
9961,NCT04894344,blood pressure,Physical activity,,2020-10-28,COMPLETED,INTERVENTIONAL,['NA']
9962,NCT03110796,"% of Wound Area Regression (WAR), as a measure of efficacy",,,2017-07-31,UNKNOWN,INTERVENTIONAL,['NA']
9963,NCT03777956,Pain intensity,Use of escape medicine (paracetamol) during treatment period.,,2019-01-15,TERMINATED,INTERVENTIONAL,['PHASE2']
9964,NCT03405532,Renal O2 extraction,Renal blood flow,,2018-01-11,SUSPENDED,OBSERVATIONAL,['NA']
9965,NCT02516150,AOCGIR (Area Over the Curve for Glucose Infusion Rate),Maximum Change in GIR (Glucose Infusion Rate) From Baseline,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9966,NCT02087995,"The Percentage of Agreement of the Continuous Glucose Monitoring System Glucose Values Comparing to a Laboratory Reference, Yellow Sprint Instrument (YSI) Measurement.",,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
9967,NCT04907110,Ex vivo muscle mitochondrial function,Exercise efficiency,,2021-08-10,COMPLETED,INTERVENTIONAL,['NA']
9968,NCT05714683,Number (Incidence) of adverse events (AEs),Dose of Rybelsus,,2024-12-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9969,NCT02365740,gastric emptying measure,postprandial glucose variability after double-wave insulin bolus,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
9970,NCT00387582,Prevention of vision loss at one year as evidenced by ETDRS visual acuity.,Reduction in retinal thickening based on Optical Coherence Tomography.,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9971,NCT03447964,Comparison of plasma total ceramides concentration in type 2 diabetic patients versus type 1 diabetic patients.,- Correlation between sphingolipids species concentrations and macrovascular complications (cardiovascular disease history),,2017-04-04,COMPLETED,OBSERVATIONAL,['NA']
9972,NCT02310555,Remission diabetes mellitus type II,Adverse effects in the long term,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
9973,NCT04877119,Predictive SFLT-1 / PLGF ratio cat-off point for preeclampsia,Correlation between SFLT-1 / PLGF ratio and placental histopathology,,2019-10-14,UNKNOWN,OBSERVATIONAL,['NA']
9974,NCT01220479,Bone mineral density and content,Body composition,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
9975,NCT01092390,urine protein excretion,Biomarkers of oxidation and inflammation,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9976,NCT01368081,Number of Patients With Drug Related Adverse Events,Change From Baseline in HbA1c,Confirmed Hypoglycaemic Adverse Events,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9977,NCT02769091,Percentage of Participants with Adverse Events,Change from baseline in liver fibrosis measured using transient elastography (with Fibroscan),,2016-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9978,NCT00960765,,,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
9979,NCT04431687,"AUCtau,ss of CKD-501, D759, D150","Vd,ss/F of CKD-501, D759, D150",,2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1']
9980,NCT02462863,Improvement of type 2 diabetes,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
9981,NCT01612520,the absolute change in HbA1c,,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
9982,NCT03675919,remission rate,outpatient costs,,2018-09-15,COMPLETED,INTERVENTIONAL,['NA']
9983,NCT04658082,difference between core lab and non invasive glucose measurements,,,2020-10-07,COMPLETED,INTERVENTIONAL,['NA']
9984,NCT00407108,Facility of surgical maneuvers,,,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
9985,NCT00153023,"Change from baseline (Visit 6) in 24 hour proteinuria, after one year of treatment (study end) with telmisartan 80 mg versus valsartan 160 mg.","Change from baseline in BP endpoints (SBP, DBP and pulse pressure)",,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9986,NCT04562025,Adverse Events,Change in HbA1c,,2020-09-25,UNKNOWN,INTERVENTIONAL,['NA']
9987,NCT00401089,SANS,BMI Body Mass index,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9988,NCT04570111,Adherence to the study diet,Infant weight,,2021-01-22,TERMINATED,INTERVENTIONAL,['NA']
9989,NCT00638313,"To evaluate the safety and tolerability of escalating, single subcutaneous doses of PF-04603629 administered to adult subjects with T2DM.",No secondary outcomes listed in the protocol.,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9990,NCT00283842,Change in Mean Pain Severity Score From Baseline to 13 Weeks,Number of Patients With ≥50% Reduction in Mean Pain Severity Score.,,2006-03,TERMINATED,INTERVENTIONAL,['PHASE3']
9991,NCT05134480,Graft failure,Endothelial cell density,,2022-01-21,RECRUITING,INTERVENTIONAL,['PHASE3']
9992,NCT02735031,Symptom score in response to insulin-induced hypoglycaemia,Glucose variability as measured by glucose sensor monitoring,Gastrointestinal side effects,2017-02-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9993,NCT04841304,Clinically significant arrhythmias,All-cause mortality,"Correlation between heart rate variability, daytime and nighttime heart rate, physical activity, and risk of arrhythmias",2021-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9994,NCT02500329,endothelial function (reactive hyperemic index),Glycated albumin,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
9995,NCT05944432,HbA1c,Frequency of hypoglycaemia events,,2023-07-14,RECRUITING,INTERVENTIONAL,['NA']
9996,NCT01771887,adhesion,Self-management behaviors,self-efficacy,2013-02,COMPLETED,INTERVENTIONAL,['NA']
9997,NCT01292798,Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline,Qualitative Assessment of Diabetic Macular Edema (DME),,2011-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9998,NCT02509065,Number of Subjects Discordant for Reaching a BG < 60 mg/dl for > 2 Consecutive Plasma Glucose Measurements During Inpatient Exercise Visit,Total Glucagon Dosing by the Bihormonal Bionic Pancreas From the Start of Exercise Until the End of the Visit,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9999,NCT01598610,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
10000,NCT00565162,"Superiority is based on observing clinically significant difference in glycaemic control (> than or = to 0,5 % HbA1c). Programs are defined as equally successful if the HbA1c differs less than 0,5 %.",,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10001,NCT02881528,Between group difference in reduction in beta cell demand as measured by serum glucose (mmol/L) and C-peptide (ng/mL),Feasibility of a randomized controlled trial in children who are at high risk of T1D as measured by attrition rates (%),Between group difference in Immunological t-cell response to diabetes,2016-03-30,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10002,NCT00256646,"The primary outcome measure is to define these unique processes and to elucidate underlying biochemical, metabolic, and genetic determinants of vascular disease complications in diabetes.",,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
10003,NCT00855166,Adjusted Mean Change in Total Body Weight,Proportion of Participants With Body Weight Decrease ≥5%,Adjusted Percent Change in Bone Mineral Density (BMD) at Total Hip,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10004,NCT05174728,Placental mitochondrial function at delivery,Placental lipid metabolism,,2017-07-20,SUSPENDED,OBSERVATIONAL,['NA']
10005,NCT01963728,Change in Hemoglobin A1C (Glycosylated Hemoglobin),Mean Blood Glucose Values,,2013-11-27,TERMINATED,INTERVENTIONAL,['PHASE4']
10006,NCT06054035,Change in albuminuria,Numbers of patients showing resolution of chronic kidney disease (CKD),Interaction between diabetes risk cluster and intervention for change in albuminuria,2023-10-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10007,NCT01224054,Food tolerance in patients submitted to bariatric surgery,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
10008,NCT04840446,Adhesiveness and survivability of the adhesives,Assess user preference or acceptance of the adhesives worn during the study,,2021-02-08,COMPLETED,OBSERVATIONAL,['NA']
10009,NCT00814476,HbA1c,7 points glucose profile,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10010,NCT01300260,Insulin Area Under the Curve (AUC) - Second Phase Response,Insulin Maximum Concentration (Cmax),Area Under the Insulin Concentration-time Curve (AUC),2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10011,NCT04469790,Continuous glucose monitor measures,Cardiac autonomic nervous system measures,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
10012,NCT02835183,Compare mean postprandial glucose level,Hyperglycemia events,,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
10013,NCT03455816,Quality of life assessment: Diabetes Quality of Life (DQoL) questionnaire.,Scale of adherence to treatment in patients with diabetes type 1,,2017-07-07,UNKNOWN,INTERVENTIONAL,['NA']
10014,NCT01262898,Gastric Half Emptying Time (GEt1/2),"Change From Baseline in Whole Bowel Transit Time, 100 % Gastric Emptying Time (Truncated at 240 Minutes), Small Bowel Transit Time, Colonic Transit Time as Determined by Wireless Motility Capsule (WMC)",,2011-05-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10015,NCT05813249,NAFLD regression,Fibrosis regression,,2023-02-15,COMPLETED,INTERVENTIONAL,['PHASE4']
10016,NCT03490318,"Sensitivity of the new pathway (ophthalmic grader pathway) in detecting active DMO/PDR, using the standard care pathway as the reference standard.","Proportions of patients unable to undergo imaging, with inadequate quality images or indeterminate findings.",,2017-10-26,COMPLETED,OBSERVATIONAL,['NA']
10017,NCT01584856,,,,2006-05,UNKNOWN,OBSERVATIONAL,['NA']
10018,NCT05248841,Maximum GIR (GIRmax),Number of subjects with adverse events (AEs),,2022-03-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10019,NCT06197412,2-week reduction rate of wound area,Mortality,,2024-01-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10020,NCT06220773,The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
10021,NCT01848379,Change from Baseline in Clinical Attachment Level (CAL) at 6 and 12 Months,Glycated Hemoglobin (HbA1c),Cellular Immune responses,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
10022,NCT02055547,Average Concentration (Cave) of MK-8521 Corresponding to Slope of Insulin Secretion Rate/Glucose (ISR/G) During Graded Glucose Infusion (GGI) at Tmax After a Single Dose of MK-8521 (Part 3),Apparent Terminal Half-life (t1/2) for Plasma Concentration of Participants Treated With a Single Dose of MK-8521 (Part 3),,2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10023,NCT03794973,Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC),Immunologic,,2019-12-14,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10024,NCT03240978,change of fasting glucose,rate of non-responsiveness in the alleviation of insulin resistance to exercise intervention,,2016-09,SUSPENDED,INTERVENTIONAL,['NA']
10025,NCT04621890,Change in A1C (ΔA1C90-day) from baseline visit (visit 1) to 90-day visit (visit 2),Change in health-related empowerment from baseline visit (visit 1) to 90-day visit (visit 2) and to 180-day visit (visit 3).,,2022-02-14,RECRUITING,INTERVENTIONAL,['NA']
10026,NCT04802395,SGLT2/ GLP1,,,2021-03-02,RECRUITING,OBSERVATIONAL,['NA']
10027,NCT03669536,Short Portable Mental Status Questionnaire (SPMSQ),,Anemia,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA']
10028,NCT00236600,The percent change in body weight from the enrollment visit to week 60.,"Change from baseline to week 60 in absolute change in body weight, body mass index, waist circumference, fasting lipid profile; safety evaluations over study.",,2000-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10029,NCT03771781,Peak Plasma Concentration (Cmax),Area under the plasma concentration versus time curves (AUC),,2018-04-16,COMPLETED,INTERVENTIONAL,['NA']
10030,NCT06185296,CGM time in range,Change in perceived competence in Diabetes,Insulin dosing time,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10031,NCT01822717,Days per week participants performed foot inspection,Number of foot problems discovered,Acceptability,2010-09,COMPLETED,INTERVENTIONAL,['NA']
10032,NCT02910271,Prevalence of PAD in asymptomatic patients with T1DM assessed by ankle-branchial index.,Prevalence of asymptomatic atherosclerotic carotid disease in patients with asymptomatic PAD.,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
10033,NCT05728567,Inflammatory factors,,,2017-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10034,NCT00368368,"Vital signs, adverse events, laboratory parameters.","AUC, Tmax, Cmax, T1/2, CL/F, CLR for GK Activator (2) and metabolite. Glucose Cmax and Cmin, and percentage decrease in glucose from baseline.",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10035,NCT05373212,CmaxTOTAL,Local tolerability,,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10036,NCT05737771,Cmax of DWC202213,,,2023-01-25,RECRUITING,INTERVENTIONAL,['PHASE1']
10037,NCT00541229,24-hour Weighted Mean Glucose (WMG),,,2007-08-24,COMPLETED,INTERVENTIONAL,['PHASE1']
10038,NCT00848315,The primary outcome is improvement in metabolic control (HbA1c).,Efficacy of the intervention,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10039,NCT00893685,"Health related quality of life as assessed by the SF-36 questionnaire, at the beginning, at midterm and at the end of the trial period",Number of permanent transfers to elderly homes,,2009-05,UNKNOWN,INTERVENTIONAL,['NA']
10040,NCT05729776,"TIR, TBR and TAR evaluation(glucose metrics by glucose sensor) after the consumption of pizza meal vs control meal","TIR, TBR and TAR evaluation(glucose metrics by glucose sensor) after ""Medtronic pizza management"" and""Tandem T slim pizza management""",,2022-12-01,COMPLETED,OBSERVATIONAL,['NA']
10041,NCT00985712,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Endpoint,30-Day Adjusted Rates of Self-Reported Hyperglycemic Episodes at Any Time From Baseline Through Week 24,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10042,NCT04783441,Time in Range (70-180 mg/dl),Incidence of post-transplant infections during study period,safety endpoint Hypoglycemia,2021-06-29,RECRUITING,INTERVENTIONAL,['NA']
10043,NCT01554644,Relative (%) area wound size change versus baseline in respondents to treatment following a 12-week treatment period,Change of clinical wound infection during treatment period,,2012-03,WITHDRAWN,INTERVENTIONAL,['NA']
10044,NCT01188200,The primary variable is glucose concentration,Additional measures of glucose concentration,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10045,NCT06192108,Change from Baseline in Hemoglobin A1c: (HbA1c),Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Change (DTSQc) Scores,,2024-01-10,RECRUITING,INTERVENTIONAL,['PHASE3']
10046,NCT00596505,The changes of visual acuity,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
10047,NCT04632823,Change from Baseline Body Mass Index at 6 months,Change from Baseline Homeostasis ModelAssessment of Insulin Resistance at 6 months (HOMA-IR),,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
10048,NCT03796975,Change of liver enzyme after 24 weeks treatment as assessed by blood test,Change of weight and waistline after 24 weeks treatment as assessed by standard measurement,,2018-06-28,COMPLETED,INTERVENTIONAL,['PHASE4']
10049,NCT03816605,Expression of IRS-1 and GLUT-1 in different group,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
10050,NCT01399138,Change from Baseline in Systolic and Diastolic Blood Pressure at 6 weeks,Change from Baseline in insulin sensitivity at 6 weeks,,2010-07,WITHDRAWN,INTERVENTIONAL,['NA']
10051,NCT01759121,the probability of vitreous haemorrhage,change of ischemia area,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
10052,NCT01569841,Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL),Number of Treatment Emergent Confirmed Hypoglycaemic Episodes,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10053,NCT04466618,"Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39",,,2021-04-15,COMPLETED,INTERVENTIONAL,['PHASE3']
10054,NCT01722513,Primary Outcome,Secondary Outcome,,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
10055,NCT00111540,Change in lipids from Visit 1 to each protocol visit,,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10056,NCT02370927,Insulin concentrations,Lactate concentration,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
10057,NCT00715351,Body weight change,Changes in daily blood glucose values,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
10058,NCT00447213,Change in HbA1c from baseline,Preference for the study therapies,,2007-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10059,NCT06176443,Metabolic improvements of type 2 diabetes,Change of body mass index,,2020-01-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10060,NCT06256497,Clinical effectiveness,,,2023-06-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10061,NCT01323322,"To disentangle the relationship between race, SES, and health outcomes.",,,2009-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10062,NCT02916589,"Changes in the extent of gingivitis, as determined by the severity of gingival bleeding, Before and after study procedures.","Change in levels of proinflammatory cytokines in serum and gingival fluid in relation to ginigival bleeding, Before and after study procedures.",,2016-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10063,NCT00415428,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
10064,NCT01947595,postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT)),distribution of body fat confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager,"metabolic and genetic characterization to determine the non-response to lifestyle intervention confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires,BIA, ergospirometry",2012-03,COMPLETED,INTERVENTIONAL,['NA']
10065,NCT01822548,Absolute Change in the Endothelial Progenitor Cell (EPC) Number,Absolute Change in HbA1C Compared to Baseline,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10066,NCT01179048,"Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",Time From Randomisation to Each Individual Component of the Composite Microvascular Outcome and to the Retinopathy and Nephropathy Composite Outcomes Separately.,,2010-08-31,COMPLETED,INTERVENTIONAL,['PHASE3']
10067,NCT03540758,Endogenous glucose production (EGP),,,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
10068,NCT03538015,Change in Hypoglycemia Symptom Score,Frequency of CGM-Determined Hypoglycemic Episodes,,2019-04-22,TERMINATED,INTERVENTIONAL,['PHASE2']
10069,NCT02063048,Absolute weight loss in pounds,Patient Engagement Measures,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
10070,NCT01425424,"Prediabetes, Prehypertension and Vitamin D supplementation- A practice based clinical intervention",,,2012-04,TERMINATED,INTERVENTIONAL,['NA']
10071,NCT01597713,Number of adverse events,Area under the serum insulin concentration-time curve (Trial part 2),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10072,NCT02863523,Change From Baseline in Glycosylated Hemoglobin (%),Change From Baseline in Diabetes Regimen-Related Distress,Change in Depressive Symptoms,2014-09,COMPLETED,INTERVENTIONAL,['NA']
10073,NCT00547482,Glycemic control as measured by HbA1c: Difference in mean reduction between Control and Treatment Groups will be evaluated.,Device/procedure-related adverse events;hypoglycemic events; Proportion of subjects with HbA1c less than 7.0;reduction of weight for both groups;improvement of glycemic control as measured by HbA1c,,2007-09,TERMINATED,INTERVENTIONAL,['NA']
10074,NCT03349489,Decrease in glucose levels,Total amount of carbohydrates needed to treat hypoglycemic events,,2018-05-18,UNKNOWN,INTERVENTIONAL,['NA']
10075,NCT02636491,normal glucose level,glucose sensor readings,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
10076,NCT01394952,"Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)",Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina,,2011-07-22,COMPLETED,INTERVENTIONAL,['PHASE3']
10077,NCT01068041,Urinary Albumin/Creatinine Ratio (UACR),Urine Albumin Serum Creatinine and the estimated GFR (glomerular filtration rate) HbA1c,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10078,NCT00905203,skeletal muscle oxygenation response,,,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
10079,NCT04623151,5-item Foot Care Detection Behaviour Scale,,,2017-08-16,COMPLETED,INTERVENTIONAL,['NA']
10080,NCT01804842,Rmax (0-24) of Plasma Glucose,,,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10081,NCT03216460,Percentage of time in hyperglycemic range (defined as ≥ 250 mg/dL),Coefficient of variation,,2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
10082,NCT03197870,Percentage of Subjects With an Improvement in Study Eye Severity of Diabetic Retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 Steps,Summary of Subjects Developing Center-involved DME or PDR or Worsening of >=2 Steps DRSS at Week 48 Based on Central Image Reading Center Evaluation,,2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10083,NCT03675165,Diabetes Symptomatology (assessed using the Diabetes Symptoms Checklist - Revised),,Diabetes Risk (calculated using the Canadian Diabetes Risk Questionnaire),2018-08-28,COMPLETED,INTERVENTIONAL,['NA']
10084,NCT05759442,Fasting Blood Sugar,,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
10085,NCT05566028,Change from baseline in HbA1c,Change from baseline in Fasting plasma glucose,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10086,NCT00222924,To measure the functional capacity of mitochondria in skeletal muscle of those with T2DM and those at increased risk of developing T2DM,To assess whether exercise and diet can improve mitochondrial function and morphology.,,2003-12,COMPLETED,INTERVENTIONAL,['NA']
10087,NCT02220751,clinical attachment level,Salivary proteins levels,Density loss,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10088,NCT01422018,Changes in best-corrected visual acuity (BCVA),macular edema detected by optical coherent tomography,,2011-08,UNKNOWN,INTERVENTIONAL,['NA']
10089,NCT03070704,Incidence of treatment emergent Adverse Events (AEs),Number of patients withdrawn due to ineffective therapy,,2017-08-16,WITHDRAWN,OBSERVATIONAL,['NA']
10090,NCT03330951,Glycemic Control markers in pregnancy,Admission to neonatal intensive care unit,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
10091,NCT00708266,Concentrations of IL-6 measured in effluent samples from subcutaneous tissue.,Cytokine concentrations measured in serum samples.,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
10092,NCT00670722,HbA1c after switch from human insulin to modern insulin treatment,Number of adverse drug reactions (ADR),,2008-01,COMPLETED,OBSERVATIONAL,['NA']
10093,NCT00638573,,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
10094,NCT01181830,Blood pressure,Inflammation,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10095,NCT02285985,Change from baseline in the secretion of cytokines/adipokines by adipose tissue,change in reactive hyperemic index,change in percent arteriole dilation,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10096,NCT01771445,IL6,Copeptin,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
10097,NCT02091596,Clinical Response,,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10098,NCT03390959,Gait,Plantar Sensitivity,,2017-05-10,UNKNOWN,INTERVENTIONAL,['NA']
10099,NCT02607306,Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira,Plasma Concentrations of Liraglutide,,2015-11-18,COMPLETED,INTERVENTIONAL,['PHASE3']
10100,NCT02294110,sensorial loss with pin prick test,,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
10101,NCT05504096,Risk prediction model of diabetes using PPG features on the wearables,Validate that in-ear and wrist-worn wearables both provide relative accurate heart rate and heart rate interval measurements.,,2021-10-08,COMPLETED,INTERVENTIONAL,['NA']
10102,NCT06056687,Matrix metalloproteinase 2 (MMP-2),,,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
10103,NCT00969956,Time to retinopathy,Waistlines,,2012-04,TERMINATED,OBSERVATIONAL,['NA']
10104,NCT03236415,Percentage of uncovered struts at time of follow-up optical coherence tomography,Major adverse cardiac events,Subgroup analysis between 4 and 6 weeks,2017-08,WITHDRAWN,INTERVENTIONAL,['NA']
10105,NCT03893266,Collection of the needs of type 1 diabetic patients in therapeutic education in order to reconcile diabetes and work.,,,2019-04-26,COMPLETED,OBSERVATIONAL,['NA']
10106,NCT01184703,HbA1c,LDL-cholesterol,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10107,NCT05579743,Proportion of participants who successfully complete a weekly wound scan,,,2023-01-06,RECRUITING,INTERVENTIONAL,['NA']
10108,NCT04008121,Binary assessment by the Principal Investigator of the feasibility of MB-102 imaging as compared to fluorescein dye,Number of participants with adverse events,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10109,NCT01040468,The primary objective of this study is to compare the rates of diabetes remission over one year.,"To examine the attitudes that patients, health care professionals, and insurance providers have toward the use of bariatric surgery to treat type 2 diabetes.",,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10110,NCT03458494,Glucose,CRP,,2018-02-15,UNKNOWN,INTERVENTIONAL,['NA']
10111,NCT02075567,Number of Participants with no Adverse Events as a Measure of Safety and Tolerability,Hormonal Response,Blood Lactate Concentration,2014-01,COMPLETED,INTERVENTIONAL,['NA']
10112,NCT00886821,Stage 2: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 22,Stage 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC[0 - Inf]) of PF-04856883 on Day 1,Stage 2: Number of Participants With Anti-Drug Antibodies,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10113,NCT00910507,Stage of Exercise Behavior,,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
10114,NCT04142944,Time in hypo glycaemia,,,2019-12-11,COMPLETED,INTERVENTIONAL,['NA']
10115,NCT02700555,Incidence of newly developed diabetes mellitus,3-year recurrence-free survival & 5-year recurrence-free survival,,2016-02,TERMINATED,OBSERVATIONAL,['NA']
10116,NCT00548782,decreased insulin secretion,,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
10117,NCT00174993,"Time to the Composite of All Cause Mortality, Non-Fatal Myocardial Infarction, Stroke, Acute Coronary Syndrome, Major Leg Amputation, Cardiac Intervention, Bypass Surgery or Leg Revascularization.",Time to Cardiovascular Mortality.,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10118,NCT04766008,Increase in lactate of 20%,Metformin associated lactic acidosis,Death,2020-01-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
10119,NCT03952130,Change From Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants With HbA1c <7% and ≤6.5%,,2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE3']
10120,NCT01807221,Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90,Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits,Change From Baseline in Heart Rate at Specified Visits,2013-06-17,COMPLETED,INTERVENTIONAL,['PHASE2']
10121,NCT05704309,Cognitive Diagnoses,White matter microstructure,,2022-11-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10122,NCT04964921,Determination of autonomic dysfunction by subject,Establish the absence of any relationship of autonomic dysfunction (AD) to any other vital signs parameters.,,2021-12,UNKNOWN,OBSERVATIONAL,['NA']
10123,NCT05960019,Change in HbA1c,Change in FBG,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2024-01-17,RECRUITING,INTERVENTIONAL,['NA']
10124,NCT00333853,Hemoglobin A1c (HbA1c),Measured hypoglycemia,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
10125,NCT04864639,Emergency Department (ED) Visits Within 30 Days Post Discharge,Unplanned Readmissions to the Hospital Within 30 Days Post Discharge,,2021-08-04,COMPLETED,INTERVENTIONAL,['NA']
10126,NCT03459638,Risk of obstructive sleep apnea syndrome (OSAS),,,2018-03-09,COMPLETED,OBSERVATIONAL,['NA']
10127,NCT05854875,Change in glucagon levels,,,2019-09-22,COMPLETED,INTERVENTIONAL,['NA']
10128,NCT06130865,Fullerton Advanced Balance Scale (FAB),,,2023-11-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10129,NCT05866406,Insulin sensitivity,Adipose tissue gene expression,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
10130,NCT04592055,A1c,,,2020-03-20,UNKNOWN,OBSERVATIONAL,['NA']
10131,NCT03681704,ACR,,,2018-11-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10132,NCT03010241,"The clinical symptoms and signs of patients were recorded by Michigan Diabetic Neuropathy Score(MDNS), and the changes of Michigan Diabetic Neuropathy Score(MDNS) were compared between the two groups before and after medication",Clinical symptoms and signs change The clinical symptoms and signs of the patients were compared before and after taking the medicine.,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
10133,NCT03408678,Insulin sensitivity and secretion,Body fat distribution,,2017-01-23,COMPLETED,OBSERVATIONAL,['NA']
10134,NCT04180332,Catalase estimation,Antioxidant estimation,,2017-08-10,COMPLETED,INTERVENTIONAL,['NA']
10135,NCT03730168,concentration of serum intereukin6,concentration of serum tumour necrosis factor,,2018-05-13,COMPLETED,INTERVENTIONAL,['NA']
10136,NCT03867500,Difference in incorporation of 13-palmitate and D9-palmitate into intramyocellular lipid intermediates between overnight saline control study and overnight/insulin clamp niacin infusion study.,Effects of niacin on adipocyte lipolysis proteins,,2018-11-01,SUSPENDED,INTERVENTIONAL,['EARLY_PHASE1']
10137,NCT05940376,time to epithelial healing,any adverse effect of topical insulin or need for amniotic membrane transplantation,,2023-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10138,NCT04792268,Number of wards and clinician end-users recruited to the study,Rates of communication with GP/CMHT regarding diabetes or dysglycaemia follow up,Assessment of the implementation of the eCDSS on inpatient ward settings,2022-05-01,COMPLETED,INTERVENTIONAL,['NA']
10139,NCT05159843,Knowledge in diabetes management,Mood of patient,,2022-01-10,UNKNOWN,INTERVENTIONAL,['NA']
10140,NCT02019264,Time From Randomization to First Occurrence of MACE+,Change From Baseline in Echocardiographically-Determined Pulmonary Arterial Systolic Pressure,,2014-01-24,COMPLETED,INTERVENTIONAL,['PHASE4']
10141,NCT04876053,HbA1c,,,2021-10-22,RECRUITING,INTERVENTIONAL,['NA']
10142,NCT00930865,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"Explore potential pharmacodynamic (serum/urine electrolytes) effects of bumetanide + dapagliflozin following multiple doses of 1 mg bumetanide + 10 mg dapagliflozin, administered together, either simultaneously or after adaptation to either agent alone",,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10143,NCT01845870,determination of urinary albumin,determination of serum vitamin D metabolites,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
10144,NCT00851019,Hemoglobin A1c change from baseline,All adverse events,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10145,NCT00984841,Diabetes summary quality measure,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
10146,NCT05344768,β-cell function analysis,,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10147,NCT01571609,insulin secretion,Indirect calorimetry,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
10148,NCT00143247,Change in Carbon Monoxide Diffusing Capacity (mL/Min/mm Hg) by Time on Exubera Treatment,Number of Decliners in Carbon Monoxide Diffusing Capacity (ml/Min/mm Hg) by Duration of Exubera Treatment,,2003-03,TERMINATED,INTERVENTIONAL,['PHASE2']
10149,NCT01798914,,,,2008-10,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
10150,NCT02182895,Mean Daily Blood Glucose Levels During Hospital,Patient Satisfaction,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10151,NCT05344196,C-peptide,Health behavior,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
10152,NCT01957930,Ischemic Foot Ulcer,,Microvascular Endothelial Function,1984-01,COMPLETED,INTERVENTIONAL,['NA']
10153,NCT04467268,Total sleep time (TST),Multidimensional Assessment of Fatigue,,2017-04-15,COMPLETED,INTERVENTIONAL,['NA']
10154,NCT04303819,Plasma total bile acids in fasting state,Body mess index,,2020-01-05,COMPLETED,OBSERVATIONAL,['NA']
10155,NCT01762059,Percentage of Time Blood Glucose Values Less Than 70 mg/dl (Co-primary Outcome),Difference of Outcome Measures on Day 1 vs. Remaining Days (Days 2-5) During the Closed-loop Period.,Mean Blood Sugar as Measured by Continuous Glucose Monitor (CGM) Readings,2013-01,COMPLETED,INTERVENTIONAL,['NA']
10156,NCT02108197,glucose tolerance,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
10157,NCT03473704,Depression symptoms,Another disease,,2017-01-19,UNKNOWN,INTERVENTIONAL,['NA']
10158,NCT00847730,Ease of Use Assessment,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10159,NCT02346175,Plasma glucose concentration of SHR3824,The number and type of adverse events reported,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10160,NCT01637935,Incident Diagnosis of Bladder Cancer (10-year Analysis),Stage of Bladder Cancer (10 Year Analysis),,2004-07,COMPLETED,OBSERVATIONAL,['NA']
10161,NCT03448380,Safety of the FreeStyle Libre Flash Glucose Monitoring System,,,2018-02-27,COMPLETED,OBSERVATIONAL,['NA']
10162,NCT03658564,VAS,HOMA,,2018-09-30,UNKNOWN,INTERVENTIONAL,['NA']
10163,NCT00035711,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
10164,NCT00409786,Change in Weight,Physical Activity,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
10165,NCT01369823,The levels of HbA1c will be investigated on patients combining the pump therapy with continuous glucose monitoring over a period of three months.,To evaluate the % sensor usage,,2009-06,UNKNOWN,OBSERVATIONAL,['NA']
10166,NCT02102048,Homeostatis Model Assessment-Insulin Resistance (HOMA-IR) value,insulinemia,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
10167,NCT00371800,HbA1c,Compliance,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10168,NCT06053177,"The prevalence of undiagnosed fatty liver disease with evidence of fibrosis, obstructive sleep apnoea and heart failure in people with type 2 diabetes and prediabetes",Multi-morbidity screening,,2023-01-25,RECRUITING,OBSERVATIONAL,['NA']
10169,NCT03914547,Parents Hypoglycemia Fear,,,2019-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10170,NCT01140893,Change from baseline to 6 months of centrally measured HbA1c,Change from baseline in mean blood glucose value,,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10171,NCT05469659,Urine albumin-to-creatinine ratio (UACR),Albuminuria class,,2021-09-22,RECRUITING,INTERVENTIONAL,['PHASE2']
10172,NCT00416741,,,,2005-02,COMPLETED,OBSERVATIONAL,['NA']
10173,NCT05666570,The reduction in wound size of the target wound between baseline and end of study,Rate of Device Related Adverse Events,,2022-05-18,TERMINATED,OBSERVATIONAL,['NA']
10174,NCT05565248,Assess the clinical efficacy of VCTX211 units via evaluation of C-peptide increase from the baseline.,The percentage of graft cells per unit that have differentiated into endocrine/beta cells as determined by immunohistochemical staining.,,2023-01-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10175,NCT05464784,Mean change from baseline in fasting serum triglyceride levels at Week 24,Mean change from baseline in lipids,,2022-08-22,RECRUITING,INTERVENTIONAL,['PHASE2']
10176,NCT01950650,Reasons for insulin omission/non-adherence reported by patient and physician,Impact of insulin treatment on life domains (patient survey),,2010-03,COMPLETED,OBSERVATIONAL,['NA']
10177,NCT00108485,Change in Proteinuria,,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE3']
10178,NCT01156246,To assess the effect of food on the pharmacokinetics of dapagliflozin and metformin.,To examine the safety and tolerability of the fixed-dose combination tablet of dapagliflozin and metformin.,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10179,NCT05424107,HbA1c levels,Decalogue of healthy eating,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA']
10180,NCT05090202,Heart failure hospitalization.,,,2022-12-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10181,NCT02324218,"Occurrence of new HepB diagnosis among non-DM patients between 0-80 years of age, in the UK CPRD or HES.","New-onset or prevalent HepB diagnosis among new-onset or prevalent DM and DM-free (non-DM) patients between 0-80 years of age, in the UK, regardless of the onset of HepB in relation to the diagnosis of DM.",,2014-10,COMPLETED,OBSERVATIONAL,['NA']
10182,NCT00318422,HbA1c,"Glycemic control parameters (fasting plasma glucose, -glucose profiles)",,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10183,NCT00922376,Blood sugar levels (HbA1c),Self management,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
10184,NCT00436475,"Chang in Disposition Index, a Measure of Beta Cell Function",Change in Hemoglobin A1c,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10185,NCT04949867,Percentage of time with glucose values < 3.9 mmol/l as measured by the continuous glucose monitor,Sleep efficiency measured by ActiGraph GT9X Link,,2021-05-20,COMPLETED,INTERVENTIONAL,['PHASE4']
10186,NCT00118560,maximal exercise times on treadmill and calf ergometer,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
10187,NCT05350514,"Standardized uptake value ratio for cerebral to cerebellar comparison in young adults with Type 1 diabetes, Type 2 diabetes, and young adults without diabetes","Atlas based region of interest fractional anisotropy in young adults with Type 1 diabetes, Type 2 diabetes, and young adults without diabetes",,2022-07-19,COMPLETED,OBSERVATIONAL,['NA']
10188,NCT02940158,Postprandial Blood Insulin,,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
10189,NCT03330054,Frequency Of Eye problems In Type 2 Diabetes with Chronic Kidney Disease,,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10190,NCT05305287,Effect of pioglitazone on hepatic mitochondrial TCA cycle fluxes,Effect of pioglitazone on hepatic gene regulatory networks,,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10191,NCT05266625,Adverse Events,Adverse Events,,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10192,NCT05488119,Tracking people who complete the study,Changes in diabetes technology usage,,2025-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10193,NCT05420051,Change from Baseline Moderate to Vigorous Physical Activity (MVPA) at 16 weeks,Change from Baseline in positive affect (Positive and Negative Affect Schedule [PANAS] positive affect items) at 16 weeks,Change in triglycerides (milligrams per deciliter),2022-10-12,RECRUITING,INTERVENTIONAL,['NA']
10194,NCT02721602,Acceptability of the intervention measured via family feedback indicating at least 90% approve of the sessions on post-intervention surveys.,Blood glucose control in parent with Type 2 diabetes,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
10195,NCT03246295,Urinary samples were analyzed,Urinary samples were analyzed,,2015-10-20,UNKNOWN,OBSERVATIONAL,['NA']
10196,NCT00248131,long-term safety and tolerability,monitor long-term efficacy,,2005-11,TERMINATED,INTERVENTIONAL,['PHASE3']
10197,NCT04120974,Change in Glycemic Control,Change in Blood Glucose Levels,Effect on Behaviour: Injection in Lipohypertrophy Areas,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
10198,NCT03971955,Blood collection,,,2019-07-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10199,NCT05229640,Assess CFLD via abdominal imaging,,,2022-03-31,WITHDRAWN,INTERVENTIONAL,['NA']
10200,NCT05528393,PRL,OGTT,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
10201,NCT05628259,Diabetes Self-Management Scale,Triglyceride,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
10202,NCT02020343,Meal triglyceride (TG) absorption,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
10203,NCT01950637,"Level of patient dosing irregularity: missed, mistimed and reduced dose (HCP questionnaire)",Frequency of self-treated hypoglycaemia,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
10204,NCT03564431,the neuroimaging of Type 2 Diabetes and Depression,,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10205,NCT00101673,Change from baseline in HbA1c at 12 weeks,Change from baseline in body weight at 12 weeks,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10206,NCT04533945,Change in Hemoglobin A1C (HbA1C),Duration of CGM use,,2020-03-25,COMPLETED,INTERVENTIONAL,['NA']
10207,NCT02971241,Young students survey,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10208,NCT03642470,HbA1c,psychological health (Child Behavior),,2018-06-05,COMPLETED,OBSERVATIONAL,['NA']
10209,NCT00884013,percent of patients eligible for quality measures (ABCS),use of EHR clinical reminders,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
10210,NCT01171976,Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12,EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10211,NCT00458016,Fasting Plasma Glucose Concentration,"Fasting serum triglycerides and free fatty acids, fasting serum insulin.",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10212,NCT04324684,rate of recovery,organ failure,,2020-03-31,COMPLETED,OBSERVATIONAL,['NA']
10213,NCT02462421,Change in Fractional Excretion of Uric Acid (the Difference Between Data After Administration of Canagliflozin Minus Data Before Administration of Canagliflozin),Canagliflozin-induced Change in Fasting Plasma Glucose,,2015-06-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10214,NCT04906226,Peripheral skin temperature will be measured with a skin thermometer,,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
10215,NCT03978715,number of lower limb complications,,,2021-04-14,COMPLETED,OBSERVATIONAL,['NA']
10216,NCT01760447,Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54,Percentage of Participants Initiating Insulin Glargine During Weeks 20-54,Baseline A1C,2011-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10217,NCT01201161,amount of intraoperative intra-ocular bleeding,visual acuity,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10218,NCT02298803,Change in Corrected QT Interval During Day Time Hypoglycaemia,deltaQTc,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10219,NCT03713684,Change From Baseline to Week 30 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,,2018-11-09,TERMINATED,INTERVENTIONAL,['PHASE3']
10220,NCT02137512,"Time Spent <70 mg/dL - Main Phase, Night Only","Time Spent >300 mg/dL - Main Phase, Day Only",Reported Serious Adverse Events - Extension Phase,2014-08,COMPLETED,INTERVENTIONAL,['NA']
10221,NCT03864549,Mean value of the mean daily glucose charts after 2 weeks of treatment with the study products.,Duration of time until pharmacotherapy for glycemic control is indicated,,2020-01-08,COMPLETED,INTERVENTIONAL,['NA']
10222,NCT01453413,Percent of Subjects Outside Specified Blood Glucose (BG) Range -Estimated Versus Measured Blood Glucose,Percent of Subjects Outside a Second Specified Blood Glucose (BG) Range -Estimated Versus Measured Blood Glucose,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
10223,NCT02861144,Change of HbA1c,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
10224,NCT06309082,H-CEUS score,,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10225,NCT04690907,Gestational weight gain (GWG),Eating habits III,,2020-12-03,COMPLETED,INTERVENTIONAL,['NA']
10226,NCT05148130,blood biochemistry indices,,,2018-09-11,UNKNOWN,OBSERVATIONAL,['NA']
10227,NCT05473364,Preservation of Serum Potassium,,,2023-03-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10228,NCT02785445,Exact and ±1 agreement to compared device,User performance,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10229,NCT02077946,Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction,Change in creatinine,,2014-02-10,COMPLETED,OBSERVATIONAL,['NA']
10230,NCT01549600,fasting serum glucose,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
10231,NCT01620424,The maximum insulin aspart concentration,Adverse events,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10232,NCT01269606,Area under the curve (AUC) for IM treatment group,Adverse Events (AEs),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10233,NCT01383356,Area Under the Curve 0 to Last Measurable Value (AUC0-t),Area Under the Curve 0 to Inf (AUC0-inf),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10234,NCT06312553,Acceptability,,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10235,NCT00212004,The time till the first cardiovascular composite endpoint,worsening of renal function,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE4']
10236,NCT02629497,platelet reactivity,Oxylipin production,,2015-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10237,NCT02906891,Reduction in the aggregate rate of nocturnal hypoglycemia in the Vigilant period versus the Baseline period as measured by meter or logged blood glucose values (mg/dL).,Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).,"Average ratings of ""acceptable"" or better from self-reported survey clinician feedback on the utility of Vigilant in managing patients.",2016-05,TERMINATED,INTERVENTIONAL,['NA']
10238,NCT04481243,Immunoglobulin G (IgG) Antibodies,,,2021-04-30,COMPLETED,INTERVENTIONAL,['PHASE4']
10239,NCT01990469,Change of HbAlc from baseline at Week 24,,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10240,NCT03950219,HbA1c,,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
10241,NCT00157339,"To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c.",To explore the impact of Human Insulin Inhalation Powder on peak flow and peak flow variability in the study with asthma patients.,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10242,NCT03674957,Bone mineral density,"Early life health conditions from linked administrative health records, from the Manitoba Population Healthy Research Data Repository",,2016-03,TERMINATED,OBSERVATIONAL,['NA']
10243,NCT05939921,To assess the effect of metformin on Pancreatic fat and hepatic fat in T2DM patients.,,,2022-05-01,COMPLETED,INTERVENTIONAL,['NA']
10244,NCT01581658,Maximum Concentration,,,2012-04-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10245,NCT01286350,Hemoglobin A1c,Health-related quality of life,Cost of intervention delivery,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10246,NCT03123809,Changes of total gastroparesis symptom scores (TSS),Percentage of changes of gastric emptying retention of the radiolabeled meal (%) at 2-4 hrs,,2017-01-10,RECRUITING,INTERVENTIONAL,['NA']
10247,NCT06269107,Change in glycated haemoglobin (HbA1c),Number of severe hypoglycaemic episodes (level 3),,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE3']
10248,NCT06072326,change from baseline in Urine Albumin-Creatinine Ratio (UACR),Change from baseline blood pressure,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10249,NCT02407626,Biomarker NT-proBNP,"Expression of TNF/IL1beta and microRNA (miR144, miR125b, miR208a)",,2015-09,TERMINATED,INTERVENTIONAL,['NA']
10250,NCT03514420,Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27),Number of Participants With Treatment-emergent Adverse Events (TEAEs),,2018-06-15,COMPLETED,INTERVENTIONAL,['PHASE2']
10251,NCT00490854,Mean change in Hemoglobin A1c (HbA1c) from baseline to the end of each treatment period of Primary Phase,Patient-reported outcomes questionnaires.,,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10252,NCT02348801,Change in hemoglobin A1c,Change in composite cognitive score,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10253,NCT05174052,The effect of Dapagliflozin on change in burden of atrial fibrillation,Effect of Dapagliflozin on change in AF Effect on Quality of Life Survey,Effect of Dapagliflozin on change in Validated Echocardiographic Indices & Biomarkers of Atrial Myopathy,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10254,NCT01653210,High Blood Glucose Index (HBGI),Glycemic Changes During Luteal Phase,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
10255,NCT02092896,Change from baseline in gastric emptying rate,Change from baseline in hypoglycemic symptom score,Frequency of Hypoglycemic episodes,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10256,NCT02954016,The proportion of subjects affected by serious adverse device effects (SADEs) as defined by International Standards Organization (ISO) standard 14155:2011.,12 Month Weight Loss in Kilograms,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
10257,NCT00924573,Changes in HbA1c from baseline,Change in the ratio patients with < 7.0% of HbA1c,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10258,NCT01568242,Vitreous temperature,,,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
10259,NCT02793154,Part B: Assessment of Nausea by VAS Score,Part B: Number of Par. With Nausea AEs Presenting Outside the Timing of the WLT and GCSI-DD,,2016-09-26,TERMINATED,INTERVENTIONAL,['PHASE4']
10260,NCT02698618,Delta IMR pre-PCI,Severe microcirculatory impairment,Severe microcirculatory impairment in subject with BMI = or > 30,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
10261,NCT02580877,Change in mIAA Autoantibody Titer From Baseline,,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10262,NCT06312579,Gait speed,Community mobility,,2024-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10263,NCT02180191,The comparison of the gut microbiota composition,The relationship between metabolic parameters and the gut microbiota composition,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
10264,NCT01638351,Maximal muscle strength,Muscle oxygenation,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
10265,NCT04287179,Change in glycosylated haemoglobin (HbA1c),Number of treatment emergent adverse events (TEAEs),,2020-03-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
10266,NCT05752955,Decrease anaemia prevalence in women,Dysglycaemia after a pregnancy affected by GDM,Cost of care,2022-06-06,RECRUITING,INTERVENTIONAL,['NA']
10267,NCT01155518,Insulin Resistance,,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE2']
10268,NCT04278417,Change from Baseline in BCVA,Proportion of subjects with center-involved DME up to Week 96,,2020-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10269,NCT05457192,Glycosylated Hemoglobin (HbA1c) level,Spatiotemporal gait parameters,,2022-07,RECRUITING,OBSERVATIONAL,['NA']
10270,NCT04203823,Percentage of Time in Euglycemia - Cohort C,,,2020-07-20,COMPLETED,INTERVENTIONAL,['NA']
10271,NCT00567398,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10272,NCT03165643,DNA methylation level in macrosomia,,,2014-03-06,COMPLETED,OBSERVATIONAL,['NA']
10273,NCT02689765,Change in fasting glucose and HbA1C,Calculated pancreatic β-cell function and insulin resistance,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10274,NCT01424306,Fasting Plasma Interleukin-6 on Day 9 of Each Diet Period,Adipose Tissue Inflammation - Tissue Expression of IFN-gamma mRNA,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
10275,NCT05199714,Each participant's percentage of time glucose levels spent in the target range,Total bolus insulin delivery for each participant,Safety Endpoints,2022-02-21,COMPLETED,INTERVENTIONAL,['NA']
10276,NCT02123732,Change in HbA1C concentrations and fasting glucose levels,,,2014-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10277,NCT00774124,maternal blood glucose control,infant birthweight,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
10278,NCT03361098,Differences in neuronal activity in the central reward and satiety circuits in response to food-related stimuli by BOLD fMRI signal,Laboratory parameters,Exploratory: Microbiome,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE4']
10279,NCT00005193,,,,1986-09,COMPLETED,OBSERVATIONAL,['NA']
10280,NCT04054804,The questionnaire Orthotic and Prosthetic Users Survey (OPUS) will be used.,System Usability Scale (SUS). The score range from 0-100 and a SUS score above a 68 would be considered above average and anything below 68 is below average.,,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
10281,NCT00522470,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
10282,NCT03047278,Pharmacokinetic parameter (AUC),Pharmacokinetic parameter (Elimination half-life),,2015-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10283,NCT02305862,To evaluate whether 26 weeks of treatment with 5/20mg rosuvastatin results in regression of carotid atherosclerotic plaques as measured by CE-MRI,To evaluate the change from baseline in creatine kinase at 26 weeks,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
10284,NCT06287437,Percent Change in Body Weight from 24 weeks,Energy intake at 24 weeks,Change of body weight at 24 weeksl from baseline,2024-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10285,NCT03341299,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC),Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve,,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1']
10286,NCT05905588,Change in glycosylated hemoglobin (HbA1c),Number of participants with adverse events as a measure of safety and tolerability,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
10287,NCT02794155,Change in HbA1c,Mean Mixed Meal Tolerance Test,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10288,NCT02950142,Appropriateness,Laboratory test volume,Downstream or cascade clinical activities,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
10289,NCT02279407,Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo),Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10290,NCT03270956,Procedure and/or product related adverse events,Renal specific adverse events,,2018-04-25,COMPLETED,INTERVENTIONAL,['PHASE2']
10291,NCT01889446,Post prandial insulin levels,,,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
10292,NCT04746781,4 weeks of engagement in the Diabetes prevention program,Changes in Risk perceptions,,2021-02-17,COMPLETED,INTERVENTIONAL,['NA']
10293,NCT05317845,Proportion of patients with Established Atherosclerotic Cardiovascular Disease (eASCVD) pooled across all countries and separately for each country in scope,Proportion of T2D patients with high risk of Atherosclerotic cardiovascular disease (ASCVD) and without eASCVD,,2022-04-21,COMPLETED,OBSERVATIONAL,['NA']
10294,NCT00005134,,,,1988-09,COMPLETED,OBSERVATIONAL,['NA']
10295,NCT00138593,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10296,NCT01536613,Change in body weight,Occurrence of adverse events (non-serious and serious),,2004-09,COMPLETED,OBSERVATIONAL,['NA']
10297,NCT05094505,Changes from pre- to pos intervention on glycated haemoglobin,Changes from pre- to pos intervention in angiogenesis,Changes from pre- to pos intervention on lipid profile,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
10298,NCT00666172,"Measure endothelial function determined by brachial artery reactivity to stress, at baseline/following 6m program participation comparison of change between subj randomized to exercise with weight-loss intervention vs. those randomized to exerci...",,,2008-04-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10299,NCT01813773,Incidence and severity of adverse events of intravitreal aflibercept injection in the treatment of PDR.,Proportion of subjects with avoidance of vitrectomy,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10300,NCT05713058,Glycemic control,Body weight loss,Beta cell function,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
10301,NCT05767372,Evaluation of oxygen saturation (SPO2) and heart rate (HR),Evaluation of forced expiratory volume at one second (FEV1) and maximum voluntary ventilation (MVV),,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
10302,NCT00069056,,,,2003-09-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10303,NCT01042106,"Safety assessments include physical examination, laboratory variables and ECG.",Pharmacodynamics of DSP-8658 (how DSP-8658 acts in the body to affect glucose and lipid control): glucose and lipid levels will be measured at various time points throughout the study.,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10304,NCT00658866,Pharmacokinetics in tissue,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10305,NCT01353118,"Composite of Fasting Glucose, Glycosylated Haemoglobin c and Rates of Type 2 Diabetes Mellitus Remission.",A Composite of Microvascular Complications,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
10306,NCT00513214,Safety assessed by treatment-emergent adverse events.,,,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10307,NCT02611596,hsCRP,prevalence of hs cTnT > 99th percentile,,2016-11,WITHDRAWN,INTERVENTIONAL,['NA']
10308,NCT00006159,,,,1994-03,COMPLETED,INTERVENTIONAL,['NA']
10309,NCT04388228,percentage registered diagnoses of DM 2 in the EHR,percentage registered diagnoses of heart failure,Diabetes follow-up quality indicator,2022-01-30,WITHDRAWN,INTERVENTIONAL,['NA']
10310,NCT04245982,histological tissue evaluation,,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
10311,NCT01364350,effects of TODAY treatment assignment on long-term glycemic control,microvascular complications,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
10312,NCT02676609,2-hour postmeal blood glucose values between 80 and 180 mg/dl,Mean 2-hour postmeal blood glucose level,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
10313,NCT00006432,,,,2000-01,COMPLETED,INTERVENTIONAL,['NA']
10314,NCT00784433,Glycemic control,CVD status,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10315,NCT02753803,AUC,,,2016-07-27,COMPLETED,INTERVENTIONAL,['PHASE1']
10316,NCT04031599,Relative decrease in glucose levels during exercise compared to pre-breakfast levels (sub-study),Mean time (minutes) to the first hypoglycemic event (sub-study),,2020-07-10,COMPLETED,INTERVENTIONAL,['NA']
10317,NCT02348099,Presence of Subclinical Lipohypertrophy,,,2015-03,UNKNOWN,OBSERVATIONAL,['NA']
10318,NCT02501772,urinary spot albumin creatine excretion ratio (UACR) change,,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
10319,NCT03312764,HbA1c reduction,Decreased cardiovascular risk,Implementation Context,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
10320,NCT02412774,Weight loss,HA1C,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
10321,NCT00758069,Change From Baseline in 24-hour Weighted Mean Plasma Glucose,Change From Baseline in Plasma Glucose,,2005-07-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10322,NCT00151762,To evaluate safety and tolerability of colesevelam hydrochloride as add-on therapy,To assess effects on lipids and lipoproteins,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10323,NCT01454700,difference in change in urine albumine excretion from baseline to end of study (12 months),difference in carotid intima media thickness (CIMT),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10324,NCT01664650,homeostasis model assessment for insulin resistance (HOMA-IR),Adverse events,,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10325,NCT04639492,Post-treatment changes of intestinal flora,Incidence of treatment-emergent adverse events(TEAE),,2020-11-02,COMPLETED,INTERVENTIONAL,['NA']
10326,NCT02286128,Correlation between NF-кB dependent-proinflammation markers and osteoblast-specific gene expression in the MSC to measure the effects of NF-кB dependent-proinflammation on differentiation potential toward osteoblast in type 2 diabetes.,Correlation between NF-кB dependent-proinflammation markers and the expression of RAGE and its downstream signals in the MSC to measure effects of NF-кB dependent-proinflammation on cellular RAGE activation in type 2 diabetes.,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
10327,NCT01305005,,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
10328,NCT03422471,Modified Oxford Method Assessment of Baroreflex Function,,,2017-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10329,NCT02783807,Clinical Evaluation of Retina Camera Images from both Healthy and Diseased Subjects,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10330,NCT03977662,Incidence of Insulin independence,Beta cell function as assessed by Insulin-Modified Frequently-Sampled Intravenous Glucose ToleranceTest (FSIGT),,2019-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10331,NCT01097681,Plasma concentration of ASP1941,"Safety assessed by adverse events, vital signs, laboratory tests and 12-lead ECGs",,2010-02-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10332,NCT05417880,Triglycerides,Satisfaction with treatment and life,,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
10333,NCT05477511,Rate of DM in the young adult offspring,"Rate of impaired glucose regulation, obesity and adiposity, hypertension and various insulin indices",,2020-08-28,RECRUITING,OBSERVATIONAL,['NA']
10334,NCT00714129,Stable isotopic and magnetic resonance measures to determine the changes in lipid and carbohydrate metabolism after dietary intervention,"DEXA, insulin sensitivity and energy expenditure changes due to dietary intervention",,2007-09,COMPLETED,INTERVENTIONAL,['NA']
10335,NCT00210262,rate of ACE inhibitor use in index patients,Rate of retinopathy screening in all patients,,2002-10,COMPLETED,INTERVENTIONAL,['NA']
10336,NCT05057403,3-point MACE incidence rate,Non-alcoholic fatty liver disease prevalence,,2022-05-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10337,NCT04217369,Time in Range,Laboratory HbA1c,,2020-05-04,UNKNOWN,INTERVENTIONAL,['NA']
10338,NCT03403582,Postprandial blood lipids,Postprandial inflammation,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
10339,NCT05162014,Incidence Rate of Acute Pancreatitis,,,2021-12-20,COMPLETED,OBSERVATIONAL,['NA']
10340,NCT01799850,change in muscle glucose transporter expression,,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE4']
10341,NCT01117311,Disposition Index,Gastric Emptying Half-time,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
10342,NCT05946798,microvascular insulin-mediated dilation,endothelial cell NADPH oxidase expression,,2023-08-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10343,NCT01224886,Oxidative capacity,Physical fitness,,2010-10,RECRUITING,INTERVENTIONAL,['NA']
10344,NCT04881383,The sensitivity of the risk prediction function in detecting DM and pre-DM in primary care,Negative predictive value (NPV) of the risk prediction function in detecting DM and pre-DM in primary care,,2020-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10345,NCT00669864,Change in HbA1c (Glycosylated Haemoglobin A1c),"Hypoglycaemic Episodes, Diurnal/Nocturnal",,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10346,NCT04257409,Fitness - senior fitness,Metabolism - myokines,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
10347,NCT00571506,determine if treatment with rosiglitazone or pioglitazone affects platelet function as assessed by spontaneous and agonist-induced platelet aggregation,"adipocytokine concentrations (adiponectin, leptin), hemostatic parameters (fibrinogen, plasminogen activator inhibitor-1), high-sensitivity C-reactive protein",,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10348,NCT06292468,Spatiotemporal gait parameters,,,2023-07-07,COMPLETED,INTERVENTIONAL,['NA']
10349,NCT03594240,Change in plasma homocysteine,Change in HbA1c level,,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10350,NCT00360984,prevention of severe hypoglycemia,Diabetes Quality Of Life of questionnaires.,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10351,NCT00760344,Change from baseline in glycosylated hemoglobin,Body weight.,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10352,NCT03720912,Change in HbA1c Level,FoH-C Frequency of Help,,2018-10-22,COMPLETED,INTERVENTIONAL,['NA']
10353,NCT04390711,Carbamylated-HDL levels alteration between the control and the T2DM patients with and without concomitant CAD.,,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
10354,NCT00811460,Incremental area under insulin concentration time curve relative to basal insulin concentration,"Adverse events, laboratory parameters",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10355,NCT03698786,Plasma Acylated ghrelin concentration,Plasma Leptin concentration,,2017-05-24,COMPLETED,OBSERVATIONAL,['NA']
10356,NCT04157673,Prospective memory,Working Memory,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
10357,NCT02299791,Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
10358,NCT03151837,Oral Glucose Tolerance Test,Hemoglobin(Hb),,2017-05-10,COMPLETED,INTERVENTIONAL,['NA']
10359,NCT02974816,Change in HbA1c from baseline,Number of hospitalizations(Change from baseline),,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
10360,NCT00910923,To assess the safety and tolerability of JNJ-38431055,"To assess the pharmacodynamic effects of JNJ-38431055 on plasma glucose and insulin, during a Meal Tolerance Test (MTT)",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10361,NCT06324604,"Safety of multiple, ascending dose levels of MTX-101",anti-drug antibody (ADA) formation,Receptor occupancy of MTX-101,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
10362,NCT00362128,Number of Participants With Hypertension,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
10363,NCT01095991,To evaluate the effect of AZD1656 on the steady-state PK of sitagliptin and vice versa by assessment of AUC0-24 and Cmax,"To evaluate the safety of AZD1656 with and without sitagliptin by assessment of adverse events (AEs), physical examination, electrocardiogram (ECG), pulse, blood pressure (BP), weight and FPG.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10364,NCT02183558,Gestational Diabetes Mellitus,Anthropometric measures in offspring,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
10365,NCT02211963,Assessment of tolerability by investigator on a 4-point scale,Amount of glucose excreted in urine,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10366,NCT00044707,To determine the effect of pramlintide on the PK of an oral medication,safety and tolerability as measured by analysis of laboratory values and adverse events,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10367,NCT03113006,Sensitivity and specificity of OCT angiography as an expression of disease activity in PDR,Change in quality of life between the groups,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
10368,NCT03917758,Long term changes from baseline of renin-angiotensin-aldosterone system parameters,Changes in long term glicemic control,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
10369,NCT02144948,Decrease in HbA1c levels,change in gastrointestinal condition,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10370,NCT01268345,blood glucose value,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
10371,NCT04841668,Semantic verbal fluency,The percentage of time in glucose range (glucose level between 140-199 mg/dl),Number time awake,2021-04-10,RECRUITING,OBSERVATIONAL,['NA']
10372,NCT00699322,Glucose variability,"oxidative stress markers (oxidized LDL, N-carboxymethyl-lysine(CML), nitrotyrosine, 8-iso-prostaglandinF2α, 8-OhDG)",,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
10373,NCT00859898,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants,"Number of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10374,NCT02929901,Hepatic steatosis,gut microbiota,,2016-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10375,NCT06000735,Blood glucose time-in-range (TIR),,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10376,NCT06272136,Glucose changes will be measured noninvasively and transcutaneously in dynamic states of glycaemia,,,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
10377,NCT00867555,postprandial fat oxidation,,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
10378,NCT02875275,Change in postprandial plasma triglyceride over 360 minutes period,Change in postprandial plasma insulin over 360 minutes period,,2016-01-12,COMPLETED,INTERVENTIONAL,['NA']
10379,NCT03106870,Number of Participants With Glycemic Control Over Period From 20 Weeks to 36 Weeks Gestation,Number of Participants With Neonates Who Were Hypoglycemic,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
10380,NCT03228459,Assessment of the impact of arterial ultrasound on cardiovascular events and mortality in a low/moderate cardiovascular risk population.,Association of spirometry alterations and cardiovascular events in a low/moderate cardiovascular risk population,,2015-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10381,NCT05626725,Change in blood glucose levels from start of exercise to nadir during or up to 30 min post exercise.,Total insulin delivery during (at least 15-min) of habitual PA and 30-min after,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
10382,NCT00521105,"Medical outcomes: HbA1c, rates of severe hypoglycemia, rates of DKA","Associated costs to the family (time away from school and work, travel, etc)",,2005-08,COMPLETED,INTERVENTIONAL,['NA']
10383,NCT02300181,Difference in plasma glucose profile including AUC and Cmax after taking 50 g carbohidrate.,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
10384,NCT04904718,Change in glucose control with the use of DreaMed,,,2021-12,WITHDRAWN,INTERVENTIONAL,['NA']
10385,NCT05831085,The event rate of major adverse cardiac or cerebrovascular events,The number of anti-anginal medications used,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10386,NCT05914857,2h plasma glucose on an oral glucose tolerance test (OGTT),"Creatinine, calculated eGFR, and Albumin/Creatinine Ratio (ACR)",,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10387,NCT01638299,Evaluation of the performance of the HHM system response to meal insulin while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.,Number of Safety Events and any additional information that can be used for product development,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10388,NCT01487421,HbA1c (glycosylated haemoglobin),Adverse Drug Reactions (ADRs) including Serious Adverse Drug Reactions (SADRs),,2003-07,COMPLETED,OBSERVATIONAL,['NA']
10389,NCT02181244,glycosylated hemoglobin,plasma LDL cholesterol,tumor necrosis factor alpha,2013-05,COMPLETED,INTERVENTIONAL,['NA']
10390,NCT02809365,Improvement of diabetes treatment satisfaction measured by the 'Diabetes Treatment Satisfaction Questionnaire' (DTSQ),Reduction in hypoglycemic events <70 mg%,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
10391,NCT00446459,The Number of Subjects With a 10% Decrease in PRA Level at Month 8.,The Number of Transplants With a Negative Crossmatch at Transplant.,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10392,NCT01368549,To determine if Metanx® improves neuropathic symptoms as evaluated by the Neuropathy Total Symptom Score-6 (NTSS-6),To determine overall patient satisfaction with Metanx® using a 10-point satisfaction scale,,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
10393,NCT03951753,Change From Baseline in Total Clamp Disposition Index (cDI),Change From Baseline in Food Intake During Ad Libitum Meal,,2019-06-28,COMPLETED,INTERVENTIONAL,['PHASE1']
10394,NCT01611935,Number of Blood Products Transfused,Total Number of Complications,,2013-05-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10395,NCT01082120,To evaluate the effect of AZD1656 on the steady state pharmacokinetics of Pioglitazone and vice versa by assessment of AUC (0-24) and Cmax.,"To evaluate the pharmacokinetics of the Pioglitazone metabolite hydroxyl pioglitazone, when pioglitazone is administered with and without AZD1656, by assessment of AUC(0-24), Cmax and tmax.",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10396,NCT00010751,,,,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10397,NCT00600236,,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10398,NCT02111967,Measurements of serum vitamin B12 and serum holotranscobalamin concentrations,Questionnaire results,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
10399,NCT05184322,Number of treatment emergent adverse events (TEAEs),Incidence of anti-XW004 antibodies at end of study,,2022-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10400,NCT01907854,Change in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent Adverse Events (TEAEs),,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10401,NCT02667769,Plasma glucose day- and night profiles,,,2014-08,UNKNOWN,INTERVENTIONAL,['NA']
10402,NCT01671514,"Change from baseline in pre-specified biomarker levels in blood, skeletal muscle, and urine",,"Change from baseline in quality of life, health, and nutrition questionnaires",2012-07,COMPLETED,INTERVENTIONAL,['NA']
10403,NCT03066440,Length of acidosis,Length of stay in the hospital,,2018-09-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10404,NCT00950313,Increase in response rates to invitation to 2nd stage blood test,Increase in yield of OGTT positive results through filtering of high risk participants that pass 1st and 2nd stage screens,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
10405,NCT01871207,Ocular concentration of Erythropoietin and VEGF.,,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
10406,NCT01200849,Understanding of prescription medication,Change in HbA1c or blood pressure readings,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
10407,NCT00849537,Macula diameter,Diabetic retinopathy,,2008-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10408,NCT05702073,Change in HbA1c,Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs),,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE3']
10409,NCT01034826,"fasting serum glucose, fasting plasma insulin,post prandial serum glucose, post prandial plasma insulin, hbA1c",,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
10410,NCT02243098,Area under the digoxin plasma concentration-time curve,Number of treatment emergent AEs (TEAEs),,2014-09-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10411,NCT00573950,The effect on pulse wave velocity (PWV),"the effect on atherosclerotic and inflammatory markers such as adiponectin, hsCRP",,2007-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
10412,NCT01855386,Percentage of patients with NAFLD and gestational diabetes.,"Insulin sensitivity expressed as the Matsuda Index, measured during an oral glucose tolerance test (OGTT).",,2013-01,TERMINATED,OBSERVATIONAL,['NA']
10413,NCT05550870,Cholesterol in mg/dl,,,2022-01-24,COMPLETED,INTERVENTIONAL,['NA']
10414,NCT00686634,Hemoglobin A1c (HbA1c) Change From Baseline,Number of Adverse Events,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10415,NCT04948918,Change in estimated glomerular filtration rate renal function (eGFR),Change in peak linear blood flow velocity in the trunk and in segmental renal arteries,,2020-09-20,COMPLETED,INTERVENTIONAL,['NA']
10416,NCT00744367,Absolute change from baseline in HbA1c,"Safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies.",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10417,NCT00519142,change from baseline in HbA1c,change from baseline in fasting plasma glucose,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10418,NCT04976881,Knowledge of reproductive risks,Folic acid use,,2022-05-06,RECRUITING,INTERVENTIONAL,['NA']
10419,NCT04690309,Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.,Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.,,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
10420,NCT05070949,Self-compassion,Stress and depressive symptoms,,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10421,NCT01275027,HgA1c reduction,Diabetes medication,,2011-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10422,NCT05130463,Change from baseline in HbA1c after 24 weeks of treatment,Number of Participants with Final effectiveness evaluation,,2022-03-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10423,NCT00934570,Reduction in BMI,Improvement in physical activity,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10424,NCT06292000,Peripheral insulin sensitivity,Sleep outcomes,,2024-02-01,RECRUITING,INTERVENTIONAL,['NA']
10425,NCT00366249,Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.,Number of Patients With Microbiologic Response of Eradication.,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10426,NCT05548205,Percentage Change in Hemoglobin A1c (HbA1c),Number of Hypoglycemic Events,,2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10427,NCT01477034,Tumor Necrosis Factor alpha expression in adipose tissue,Fasting plasma lipopolysaccharide binding protein (LBP),,2011-11,COMPLETED,INTERVENTIONAL,['NA']
10428,NCT05303051,Assess the performance of the DNN score in different ethnicity and skin tones,Retrain the DNN algorithm,,2023-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10429,NCT00046150,Frequency of catheter occlusions,"Unexplained hyperglycemia, parameters of glycemic control",,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10430,NCT00363519,tolerability,Plasma glucose,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10431,NCT01289119,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Percentage of Participants With a Decrease in HbA1c ≥2.0%,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10432,NCT03877406,HbA1c,Insulin resistance,,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10433,NCT00875394,Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24,,,2007-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10434,NCT04392570,To compare the serum osmolarities of patients with type 2 diabetes who are fasting for 17 hours and who are not fasting.,,,2019-05-15,COMPLETED,OBSERVATIONAL,['NA']
10435,NCT00420901,Endothelial function responders - Improvement in endothelial function,Changes in vascular inflammatory markers,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10436,NCT04007003,Change in Insulin Use,Change in Needle Re-Use,,2018-06-26,TERMINATED,INTERVENTIONAL,['NA']
10437,NCT02117622,Incidence of adverse events (AEs) by preferred term,Incidence of confirmed hypoglycaemia,,2015-07-24,COMPLETED,OBSERVATIONAL,['NA']
10438,NCT01072578,Calculation of derivation of pharmacokinetic variables,To examine the safety and tolerability of the combination of dapagliflozin and metformin,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10439,NCT03716141,Wound Healing,,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
10440,NCT06068309,Proportion of days covered (PDC),Perception & Satisfaction Questionnaire (PSQ),,2022-07-01,RECRUITING,INTERVENTIONAL,['NA']
10441,NCT05459519,Changes in rate of platelet aggregation,Number of Participants with safety endpoint,,2022-07-20,RECRUITING,INTERVENTIONAL,['NA']
10442,NCT01154244,insulin resistance assessed using HOMA-IR,proportion of obesity in patients,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
10443,NCT00807651,Exogenous insulin dose,HbA1c level,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10444,NCT01317459,Change in HbA1c,DDS scales,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
10445,NCT01880242,Target Lesion Failure,Clinical Procedure Success,,2014-05-13,COMPLETED,OBSERVATIONAL,['NA']
10446,NCT01044368,The primary endpoint is the A1c level or the change in A1c level,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours",,2010-01,SUSPENDED,INTERVENTIONAL,['NA']
10447,NCT05063734,"Change From Baseline in BCVA ETDRS Letter Score, at Month 3, in Treatment-naïve Subjects in Part B of the Study",Incidence of Ocular and Non-ocular Adverse Events (AEs) and Serious Adverse Events (SAEs),,2021-08-27,TERMINATED,INTERVENTIONAL,['PHASE2']
10448,NCT00642915,Estimate the efficacy of combination therapy with Lantus plus Amarylin controlling blood glucose in Japanese patients with type 2 diabetes having failed oral antidiabetic drug therapy,Document the ability to preserve the endocrine pancreatic function with Lantus plus Amaryl combination therapy,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10449,NCT05225467,Blood ketone difference,Difference in ketone development between patient with and without diabetes mellitus.,Other,2022-03-15,COMPLETED,OBSERVATIONAL,['NA']
10450,NCT05596383,Homeostatic Model Assessment for Insulin Resistance (HOMA-IR),fasting insulin,,2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10451,NCT01847313,MCP-1:Creatinine Ratio in Urine,sCD163:Creatinine Ratio in Urine,Safety in All Participants as Measured by Adverse Event Rate,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10452,NCT01088711,Number of Participants Withdrawing From Study Therapy Due to an AE,Plasma Glucose Concentration,,2010-03-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10453,NCT00877851,Between Group Differences in Goal Setting,Between Group Differences in Self-Efficacy and Barriers to Management of Diabetes,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
10454,NCT02479516,Elevated HBA1c,Blood Pressure,Health Behaviour questionnaire,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10455,NCT04242511,TB medication levels,,,2021-05,UNKNOWN,OBSERVATIONAL,['NA']
10456,NCT00101803,Change from baseline in HbA1c at 24 weeks,Patients with reduction in HbA1c >/= to 0.7% after 24 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10457,NCT00936663,Fasting Blood Glucose,Hypoglycemia,AUC for C Peptide,2009-07-06,TERMINATED,INTERVENTIONAL,['PHASE4']
10458,NCT01194245,Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period,Mean Daily Postprandial Glucose (PPG) Excursions,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10459,NCT00327054,The primary end point for the trial is serum low-density lipoprotein (LDL) cholesterol concentration measured at six weeks after intervention.,Changes in serum creatinine after six weeks intervention,,2006-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10460,NCT01971554,Number of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in 24-Hour Weighted Mean Glucose (24h-WMG) at Day 15,,2013-10-14,COMPLETED,INTERVENTIONAL,['PHASE1']
10461,NCT05766657,Body mass index (BMI),Metabolomic analysis,,2022-12-23,RECRUITING,INTERVENTIONAL,['NA']
10462,NCT03621384,Association between BsmI Polymorphisms in Vitamin D Receptor Gene and Diabetic Kidney Disease,,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
10463,NCT00214591,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3']
10464,NCT05382533,"Fasting glucose, mmol/l (group C, D)",Zinc (µmol/l),Zinc (µmol/24 h),2022-05-30,COMPLETED,INTERVENTIONAL,['NA']
10465,NCT04326192,SUVmax,Ipsi- and contralateral BAT during SCS-activation,,2021-02-19,RECRUITING,INTERVENTIONAL,['NA']
10466,NCT02402439,Insulin independence,Incidence of adverse events,,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
10467,NCT06068439,decline of renal function,Change of renal function class,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10468,NCT05504005,Consensus Error Grid (CEG) for venous plasma glucose and glucose values measured by mμSORS at each time point of OGTT.,Incidence of Treatment-Emergent Adverse Events,,2022-08-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10469,NCT00806936,Percentage of patients achieving HbA1c below 7.0%,Comparison of scores of Insulin Treatment Appraisal Scale (ITAS),,2008-12,COMPLETED,OBSERVATIONAL,['NA']
10470,NCT05099198,Time until failure to maintain metabolic control,HbA1C change from baseline,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
10471,NCT02021591,Change in Score on the Summary of Diabetes Self-Care Activities Questionnaire (SDSCA),Change in Low-Density Lipoprotein,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
10472,NCT00778622,Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS),Mean Change From Baseline at Week 16 (95% Confidence Interval) in Adiponectin - Full Analysis Set,Number of Participants Who Had a Normal Electrocardiogram (ECG) at Baseline and an ECG at Week 16 (or Termination Visit) Which Was Considered to be Abnormal With Clinical Significance - Safety Population,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10473,NCT00953498,Action of glitazone on the endothelium-dependent vasodilatory effects of HDL lipoproteins,Look for possible differences between pioglitazone and rosiglitazone for their effects on HDL lipoproteins and phospholipase A2,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10474,NCT04705779,Change in Veggie Meter Score,Change in Glycosylated Hemoglobin,,2021-05-20,RECRUITING,INTERVENTIONAL,['NA']
10475,NCT00292357,Healing velocity,,,na,UNKNOWN,INTERVENTIONAL,['PHASE1']
10476,NCT00500370,Change in Body Weight,Change in Glycosylated Hemoglobin (HbA1c),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10477,NCT00252772,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Patient-reported outcomes: Well-Being Questionnaire (W BQ12),,2004-09,TERMINATED,INTERVENTIONAL,['PHASE3']
10478,NCT06134934,Experiences with and acceptability of intervention design(s),Costs,,2024-01-09,RECRUITING,INTERVENTIONAL,['NA']
10479,NCT00509925,"Total Energy Expenditure, Dietary Record Method","Hypoglycaemic Episodes, Diurnal/Nocturnal",,2007-07,TERMINATED,INTERVENTIONAL,['PHASE4']
10480,NCT04271189,Assess the T2DM remission rate in patients with newly diagnosed T2DM treated with either POLYCHEM or with SDC for 16 weeks.,Quantify the effects of either POLYCHEM or SDC on the main determinants of glucose regulation,,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10481,NCT03781232,Generation and validation of predictive models by Mean Absolute Relative Difference (MARD) measures,,,2018-11-22,COMPLETED,INTERVENTIONAL,['NA']
10482,NCT02054897,Change in HbA1c (Glycosylated Haemoglobin),Subjects Who Achieve (Yes/no):HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists Target,,2014-02-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10483,NCT02278913,Glycemic control,Mortality,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10484,NCT01484353,HBAIC before and after intervention,Blood pressure,,na,WITHDRAWN,INTERVENTIONAL,['NA']
10485,NCT04508751,Fetal Liver PDFF,Maternal Hepatic Fat PDFF,,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
10486,NCT04089280,Adverse gastrointestinal symptoms related to metformin treatment,Oxidative stress markers - TAS,,2018-10-16,COMPLETED,INTERVENTIONAL,['NA']
10487,NCT02088203,Levels of bioactive components from the Russian Tarragon Nutrasorb in the blood and urine,Glucose tolerance measured with an OGTT,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10488,NCT04335396,presence of incresed non-HDL cholesterol level of the sera,Prevalence of polyneuropathy,,2018-05-28,UNKNOWN,OBSERVATIONAL,['NA']
10489,NCT05267457,Gestational diabetes mellitus,,,2012-08-01,COMPLETED,OBSERVATIONAL,['NA']
10490,NCT03706378,Insulin,,,2017-08-18,COMPLETED,INTERVENTIONAL,['NA']
10491,NCT05167513,Diabetes Quality of Life assessment using DQOL-13 questionnaire,Change from baseline in HbA1c % and fasting blood sugar FBS (mg/dl) to the last-observation on treatment,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10492,NCT01128153,"Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF)","Proportion of Participants Achieving a Therapeutic Response: HbA1c Less Than 7% at Week 24, Last Observation Carried Forward (LOCF)",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10493,NCT01015937,,,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
10494,NCT05918523,Primary Endpoint: Long-term safety of REACT,Third Secondary Endpoint: Time from first injection to renal transplant.,,2023-12-11,RECRUITING,OBSERVATIONAL,['NA']
10495,NCT02885909,Glucose target,Orexin-A,,2016-09,RECRUITING,INTERVENTIONAL,['PHASE4']
10496,NCT00728403,"HbA1c levels and insulin sensitivity index using 3 different indices: ISI, HOMA, QUICKI","Cholesterol, triglycerides, fasting & post-prandial blood glucose and insulin, C-reactive protein, lipid peroxidation, blood pressure, endothelial function, body fat composition",,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
10497,NCT03012074,Number of participants with type II diabetes who adhere to using mobile technologies to self-monitor multiple types of diabetes-related data,Medication adherence Survey,"Explore health care providers' perspectives on using real-time data, by conducting one-time, individual interviews over a 2 month period.",2017-03-02,COMPLETED,INTERVENTIONAL,['NA']
10498,NCT02718703,System Use Evaluation - HCP ( HealthCare Professional) questionnaire,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
10499,NCT02269098,Medication Adherence,Hypoglycemia,ED Visits and Hospitalizations,2012-02,COMPLETED,INTERVENTIONAL,['NA']
10500,NCT00353834,The Primary Endpoint Was the Change in FMD at the End of the Study Compared to Baseline Measurements in Subjects Treated With Exenatide Compared to Subjects Treated With Lantus.,"Fourth Will be Changes in Insulin, Glucose, C-peptide, Lipids, and FFA Responses Following the MTT in Subjects Treated With Exenatide Compared With Subjects Treated With Lantus at the End of the Study Compared to Baseline Measurement",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
10501,NCT00296296,Estimated Glomerular Filtration Rate (eGFR) 1 Year Following Transplantation,Count of Participants With Biopsy Proven Acute Rejection at One Year Post Transplantation,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10502,NCT02234440,Reduction of portal pressure,Safety profile of the drugs like Random Blood Sugar (RBS) and serum lactate monitoring regularly.,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
10503,NCT01964612,self-monitoring and self-control scale,health anxiety scale,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
10504,NCT00097084,HbA1c,Insulin Treatment Satisfaction,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10505,NCT01163006,fat oxidation,24h glucose pattern,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
10506,NCT00651014,Percentage of patients reaching LDL-C goal of < 2.5 mmol/L (97 mg/dL) at endpoint.,"Safety/tolerability: adverse events, laboratory test results, vital signs.",,2004-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10507,NCT00706680,"Percentage of patients developing New Onset Diabetes post transplant, as identified by an oral glucose tolerance test",Incidence of acute rejection,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
10508,NCT04007107,Intensity of Injection Site Pain,,,2019-06-27,COMPLETED,INTERVENTIONAL,['PHASE2']
10509,NCT01804777,Blood Pressure,Hypertension,,2013-03,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
10510,NCT05995262,HbA1c levels,,,2023-04-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10511,NCT02015910,Percent Wounds Healed,,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10512,NCT04505618,Correlation of Imaging,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
10513,NCT00977483,"Primary efficacy variable: Absolute change in the neuropathy impairment score lower limbs enlarged by 7 objective items (NISLL+7) between baseline (mean of Visit 0.3 and 0.4 or last available value before randomisation, respectively) and endpoint","NIS, NSC, TSS, LLF, QST, VDT, CDT and HP, QAE by means of the HRDB, amplitude CMAP, DL and MNCV on peroneal and tibial nerves, amplitude SNAP and latency on sural nerve, foot inspection, efficacy.",,1998-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10514,NCT06213896,To determine the accuracy of diagnosis with artificial intelligence algorithm,To determine the sensitivity and specificity of EyeCheckup v2.0 to detect retinal and optic disc diseases,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
10515,NCT04638556,Nerve conduction velocity,,,2019-09-03,UNKNOWN,OBSERVATIONAL,['NA']
10516,NCT03552562,Total retinal blood flow (DVA and FDOCT),,Autonomic and sensomotoric neuropathy measurements,2018-11-21,UNKNOWN,INTERVENTIONAL,['NA']
10517,NCT02529969,Triglyceride,C-Reactive Protein,,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10518,NCT05803473,Time in range,Recurrent hypoglycemic events,Questionnaires,2023-04-11,RECRUITING,INTERVENTIONAL,['NA']
10519,NCT05272839,Decrease of ≥ 0.5 points of percentage of HbA1c,Blood pressure,,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10520,NCT01778751,Diabetes Control,Depressive Symptoms,,2013-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10521,NCT06321029,Feasibility of intervention and delivery modality,Diabetes Therapy-Related Quality of Life Questionnaire,,2023-10-19,RECRUITING,INTERVENTIONAL,['NA']
10522,NCT05766735,Change in Metformin at 13.5-months of follow-up,,,2023-08-08,RECRUITING,INTERVENTIONAL,['NA']
10523,NCT04243629,Time in target range,Number of hypoglycemia events,,2021-11-12,RECRUITING,INTERVENTIONAL,['NA']
10524,NCT00362323,TG / HDL-C ratio,Lipid and glycemic parameters,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10525,NCT00563628,Retinal thickness after treatment,,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
10526,NCT02689479,The relationship between β cell mass calculated from the 11C-5-HTP PET scans and the MMTT C-peptide at 90 minutes,The incidence and severity of adverse events related to the PET investigation including allergic reactions,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
10527,NCT00737633,Change in HbA1c From Baseline to Week 72,Percent Weight Change From Baseline to Week 72,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2']
10528,NCT00921882,Oral glucose tolerance test,Acceptability of screening test,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
10529,NCT00877968,Post-prandial glycemic response,"Appearance, taste, texture, smell and overall acceptability",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10530,NCT03026426,Proportion of participants with a reduction of 50% or more in the Patient Health Questionnaire (PHQ-9) score at the 3-month assessment,Proportion of participants who improve level of activity at the 3- and 6-month assessments,,2017-01-24,COMPLETED,INTERVENTIONAL,['PHASE3']
10531,NCT05608187,Compare incidence of serious adverse events (SAEs) between treatment groups,Presence of viable L. reuteri containing the pSIP_CXCL12 plasmid in wounds,"Analysis of L. reuteri containing the pSIP_CXCL12 plasmid in blood, feces, and perilesional skin",2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE2']
10532,NCT01049750,Evaluation of diabetic neuropathy in patients with erectile dysfunction,Glycemic control,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
10533,NCT04460612,Change in oxygenation of feet and lower legs,,,2021-05-26,COMPLETED,INTERVENTIONAL,['NA']
10534,NCT01964703,serum glucose (fasting and post 75g oral glucose tolerance test),serum insulin,"HOMA IR, QUICKI, HOMA beta, lipid profile, inflammatory markers",2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10535,NCT03635437,Adverse events possibly or probably related to GABA treatment,Change in diabetes treatment satisfaction questionnaire,,2018-09-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10536,NCT02750527,number of familial hypercholesterolemia or pre-type-1-diabetes,,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
10537,NCT05107154,Pediatric Quality of Life (PedsQL),Glycemic Control,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10538,NCT05764200,24 hour intestinal gas concentrations,Urine metabolites,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10539,NCT00262145,glucose and lipid uptake,lipid metabolism,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10540,NCT02144337,Feasibility: Number of Participants With Adverse Events,Change in Parental Hypoglycaemia Fear Using the Hypoglycaemia Fear Survey (HFS-Parent),,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10541,NCT03311802,fasting plasma glucose,,,2015-03-11,COMPLETED,OBSERVATIONAL,['NA']
10542,NCT01324557,Glycosylated hemoglobin (HbA1c) measurement,The frequency of hypoglycemic episodes,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
10543,NCT06065930,Fasting Neuropilin-1 concentration in subcutaneous interstitial fluid,Metabolites in urine including acylcarnitines measured by Mass Spectrometry,,2023-05-05,RECRUITING,OBSERVATIONAL,['NA']
10544,NCT01159353,Area under the plasma glucose concentration curve (AUC) between 0 and 1 hour after insulin injection AUC(0-1h),Hypoglycaemia and adverse events,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10545,NCT05093517,Muscle Insulin sensitivity,,,2021-11-10,SUSPENDED,INTERVENTIONAL,['EARLY_PHASE1']
10546,NCT04836546,Incidence of moderate and severe hypoglycemic and diabetic ketoacidosis events,,,2021-04-13,RECRUITING,INTERVENTIONAL,['NA']
10547,NCT00701935,Percentage Change in Abdominal Visceral Fat From Baseline to 6 Months,Assessment of Event Rate of Treatment- Emergent Hypoglycemic Event,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2']
10548,NCT00495885,change from baseline to 12 weeks for Sleep Maintenance Insomnia using patient reported Wake After Sleep Onset (pr-WASO),"Change from baseline to 12-week of ""General Productivity"" domain from Functional Outcomes of Sleep Questionnaire (FOSQ).",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10549,NCT06108076,Cardiac Efficiency after chronic dosing (Left-ventricular function),Patient Reported Outcomes Measure Information System (PROMIS) - Physical Function,,2024-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10550,NCT02694289,Units of Insulin used,"pro-BNP levels, pg/mL",,2016-11,WITHDRAWN,INTERVENTIONAL,['NA']
10551,NCT01585454,Gestational Weight Gain,Complications of Pregnancy and Delivery,,2012-03-27,WITHDRAWN,OBSERVATIONAL,['NA']
10552,NCT02073227,Plasma concentration of metformin following administration of a single dose of study drug,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10553,NCT04288063,Change in muscle mass as measured by D3 creatinine dilution method,Muscle Strength,,2020-09-18,COMPLETED,OBSERVATIONAL,['NA']
10554,NCT03904056,Fluorescein leakage area of active new vessels (FLA),Electroretinography,,2014-01-01,COMPLETED,INTERVENTIONAL,['NA']
10555,NCT03725917,Change in the integrity of the skin (Ulceration),Changes in the integral pressure-time,,2019-03-25,UNKNOWN,INTERVENTIONAL,['NA']
10556,NCT02250794,mean blood glucose for the duration of the hospital stay,frequency of hypoglycemia,Acute kidney injury,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10557,NCT00147836,"glycemic control, the improvement of β-cell l function and the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients","the effects of different interventions (oral anti-hyperglycemic agents, multiple daily injections and continuous subcutaneous insulin infusion) on glycemic control, β-cell function and the remission rate in newly-diagnosed type 2 diabetic patients",,2004-09,COMPLETED,INTERVENTIONAL,['NA']
10558,NCT04381598,Bio-marker (Ghrelin) levels in Gingival crevicular fluid.,Probing depth,,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
10559,NCT03254095,Percentage of patients developing a foot ulcer,Time to ulceration,Body mass index,2016-09-01,COMPLETED,OBSERVATIONAL,['NA']
10560,NCT04663685,Participant experience,Number of adverse events,,2020-10-05,UNKNOWN,INTERVENTIONAL,['NA']
10561,NCT00399425,Stage in Wagner's classification,Quality of life,,2001-06,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10562,NCT02877680,Acceptability - Number of Participants That Felt The Intervention Was Well-Received,"Parent-Adolescent Relationship Intervention Process Measure, Adolescent Report",,2017-07-31,COMPLETED,INTERVENTIONAL,['NA']
10563,NCT01489644,Fasting repaglinide and metformin Cmax (maximum drug concentration) following individual administration,Vital signs,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10564,NCT02304588,Frequency of Adverse Events,Relative Wound Area Regression of 40% or More at 6 Week,Reduced pain,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10565,NCT05301816,Global impression of change in health status,,Device Safety,2022-07-05,RECRUITING,INTERVENTIONAL,['NA']
10566,NCT04185662,HbA1c,,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA']
10567,NCT05787067,Evaluation of Participants' Insulin Injection Administration Skill Levels,,,2021-12-30,COMPLETED,INTERVENTIONAL,['NA']
10568,NCT00575588,Hemoglobin A1c (HbA1c) Change From Baseline to Week 52,Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c,Mean Slope of the Regressions of Change From Week 24 to Week 104 in HbA1c,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10569,NCT04126759,Validation of predictive algorithms for determining blood glucose levels,Number of encountered Device Deficiencies,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
10570,NCT06095544,Hospital costs (US dollar),Perioperative complications,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
10571,NCT01859494,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL (<75mg/dL) or Within +/-20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
10572,NCT04857398,Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state,Terminal half-life for insulin icodec at steady state,,2021-04-28,COMPLETED,INTERVENTIONAL,['PHASE1']
10573,NCT02248779,insulin sensitivity,,,2014-09-22,COMPLETED,OBSERVATIONAL,['NA']
10574,NCT05860413,Adherence to diet protocols,Insulin sensitivity,,2023-01-24,RECRUITING,INTERVENTIONAL,['NA']
10575,NCT01581073,"Composite renal outcome of chronic dialysis, kidney transplantation, eGFR 6 mL/min/1.73m2 or less, or eGFR less than 50% of initial value.",Number of Participants with Adverse Events baseline,,2012-02-16,COMPLETED,INTERVENTIONAL,['PHASE3']
10576,NCT00111670,Absolute change from baseline in HbAlc\n\n,"AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n",,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10577,NCT01961388,The mean change in post-meal glucose levels from baseline at the end of observation period of up to 16 weeks,Incidence rate of adverse drug reactions in acarbose and metformin treated groups during 16 weeks observation period,,2015-08,WITHDRAWN,OBSERVATIONAL,['NA']
10578,NCT00384488,Weight loss,Reduction in progression to type 2 DM,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
10579,NCT05207995,Adverse effects associated with the therapy,,,2022-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10580,NCT04980027,Percentage of participants with Treatment Emergent Adverse Events (TEAEs),Change in DTSQs scores from Baseline to Week 12 and Week 24,,2021-06-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10581,NCT00786175,,,,2008-10,WITHDRAWN,OBSERVATIONAL,['NA']
10582,NCT02663544,Change in glucose tolerance,Change in pancreatic beta-cell function: glucose sensitivity,Change in the homeostasis model assessment (HOMA) insulin resistance index,2016-01,COMPLETED,INTERVENTIONAL,['NA']
10583,NCT01197092,HbA1c Test (Glycated hemoglobin),"Vitamins B1,B2,B6,B 12, Vitamin D",,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
10584,NCT03293914,"Difference in the daily rate of change of Glycated hemoglobin (HbA1C) during the year prior to baseline, compared to the period from baseline to post-intervention",Timeliness,,2017-09-18,COMPLETED,INTERVENTIONAL,['NA']
10585,NCT03455985,Change in HbA1c From Baseline to 24 Weeks,Fasting Glucose,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
10586,NCT01307566,Change in Hemoglobine A1C from baseline,Change in ratio albumine to creatinine from baseline,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
10587,NCT00811317,Average Blood Glucose Over the Closed-loop Control Period,Insulin and Glucagon Levels During Closed Loop and Open Loop Admissions of Diabetic Subjects Compared to the Comparable 24 Hour Period During the Admission of Non-diabetic Subject,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
10588,NCT02138045,Evoked brain potentials (using standard electroencephalographic brain imaging).,OCT,Weight/body mass index,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10589,NCT04164030,Change in diabetes distress measured using the Diabetes Distress Scale,,,2019-08-26,UNKNOWN,INTERVENTIONAL,['NA']
10590,NCT03422185,"What is the true burden of hypertension, diabetes, and hyperlipidaemia?","Is infection, notably HIV infection or its therapy, associated with increased risk of NCDs?",,2013-05,COMPLETED,OBSERVATIONAL,['NA']
10591,NCT02192853,Correlation between the total and intact GLP-1 hormone during different doses of sitagliptin measured as total area under the curve (tAUC),Differences in Insulin measured as total Area under the curve (tAUC),,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10592,NCT03414320,Accepting mathematical model,,,2018-01-11,COMPLETED,INTERVENTIONAL,['NA']
10593,NCT04626570,Percentage of patients without food addiction,Evolution of quality of life,,2021-01-20,RECRUITING,INTERVENTIONAL,['NA']
10594,NCT00190502,C-peptide production,Insulin dose,,2000-11,UNKNOWN,INTERVENTIONAL,['NA']
10595,NCT04516694,HbA1c,Time in Range,,2020-09-10,COMPLETED,INTERVENTIONAL,['NA']
10596,NCT02868177,Changes in fasting glycemia,Changes in WHR (waist to hip ratio),Changes in physical activity score,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10597,NCT02817243,The area under the plasma concentration-time curve (AUC) of Simvastatin,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
10598,NCT02528019,Effects of treatment on the nominal change in arterial stiffness from baseline after 6 months of treatment as measured by cardio-ankle vascular index,Change from baseline in circulating inflammatory markers,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
10599,NCT04844164,Change in 25(OH)D3 level,Serum vitamin D-binding protein,,2019-04-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10600,NCT01684943,For Continuous Insulin Monitoring: Time to Maximum Plasma Insulin and Time to Maximum Continuous Insulin Monitoring Insulin,Multiplex PK: Average Number of Hypoglycemia Events Over the Last Month at Baseline Categorized According to Baseline Use of Insulin Analog Found to Have the Most Favorable PK Profile for Each Individual,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
10601,NCT06014437,"Incidence of complete wound closure during treatment and follow-up (12 weeks). (Outpatient follow-up 2-3 times per week, standardized photographs and measurement of wound size)",,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10602,NCT03361709,Mean change in corneal endothelial cell density before and after phacoemulsification,Intraocular pressure,,2018-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10603,NCT01589445,Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin,Comparison of Changes in Lipid Profiles With Pioglitazone and Metformin,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10604,NCT04791449,wound healing time,,,2021-10-10,RECRUITING,INTERVENTIONAL,['NA']
10605,NCT04238494,Fat involution and trophicity in rectus femoris,measure the serum interleukin IL-1b and IL-18 rate,,2019-10-18,UNKNOWN,INTERVENTIONAL,['NA']
10606,NCT00721552,Glucose tolerance as assessed by the area under the curve for glucose (AUCgluc) during a standardized meal test.,Beta-cell function as determined by hyperglycemic clamp tests and modeling analysis from mixed-meal tests.,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
10607,NCT02933853,Area under the serum insulin aspart concentration-time curve,Maximum glucose infusion rate,,2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE1']
10608,NCT00676260,Capillary filtration capacity.,Vascular Endothelium Growth Factor.,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10609,NCT00722397,Blood draw to be processed and analyzed to yield genetic data.,Laboratory values.,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
10610,NCT00787306,mean systolic blood pressure,Proportion of adults with 3 cardiovascular risk factors under optimal control,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10611,NCT05585502,Muscle and tendon stiffness differences between T2D patients and controls,Correlation between tissue glycation indicators (RAGE) and muscle-tendon stiffness in T2D patients and controls,,2022-12-10,RECRUITING,INTERVENTIONAL,['NA']
10612,NCT00394303,"Perioperative cerebrovascular event defined as any new, temporary or permanent, focal or global neurological deficit.",Re-hospitalizations,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4']
10613,NCT01474317,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL (<100mg/dL) or Within +/- 5to15% (>=100mg/dL) of Laboratory Glucose Method,Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
10614,NCT00120341,"changes in sensation using, vibration perception threshold testing, monofilament testing, and the Michigan Neuropathy Screening Instrument",,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10615,NCT06127823,Percentage of insulin-treated,Admission to neonatal intensive care unit (NICU),Total net costs,2024-01-03,RECRUITING,INTERVENTIONAL,['NA']
10616,NCT03299153,total cholesterol,Diastolic BP,,2016-12-21,COMPLETED,INTERVENTIONAL,['PHASE4']
10617,NCT00837590,Vascular Function,,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE1']
10618,NCT01512030,What is the long term development of diabetic neuropathy? Is there a significant deterioration or improvement in nerve conduction during the follow up period?,Nephropathy,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
10619,NCT04476108,Change From Baseline in Average Pain Intensity as Measured by the NRS,Change From Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L) (United States),,2020-07-15,COMPLETED,INTERVENTIONAL,['PHASE2']
10620,NCT01161030,,,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
10621,NCT01399580,Change from baseline to each post-baseline visit up to Week 8 in log-transformed Urinary Albumin to Creatinine Ratio (UACR),The change from baseline to each post-baseline assessment of thoracic bioimpedance,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10622,NCT02398383,Glucagon levels,Glucagon levels,,2015-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10623,NCT02794792,Change from baseline in HbA1c with ipragliflozin once daily added on to metformin compared to placebo added on to metformin,Percentage of patients with AEs of special interest,,2016-05-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10624,NCT01694940,There is no primary outcome measure for this study,,,2010-12,RECRUITING,OBSERVATIONAL,['NA']
10625,NCT00605007,The primary outcome of the study is to determine the mortality rate of COPD patients with corticosteroid-induce hyperglycemia.,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
10626,NCT01701570,Rating of perceived exercise effort (RPE) during exercise (Borg RPE scale),Serum lactate during exercise,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
10627,NCT00671346,Possible effects of B-vitamin treatment on risk of developing cancer during the trial periods (completed by 2004 and 2005) and during post-trial follow-up.,"The possible effects of B-vitamin treatment on major cardiovascular events, all cause mortality and cause specific death during the trial periods (completed by 2004 and 2005) and during post-trial follow-up.",,1998-12,UNKNOWN,OBSERVATIONAL,['NA']
10628,NCT00214214,to determine if Campath-1H can be used in patients recently diagnosed with type I DM,to determine if Campath-1H can eliminate or lower insulin requirements,,2005-10,WITHDRAWN,INTERVENTIONAL,['PHASE1']
10629,NCT05318326,HbA1c change from baseline at week 24,Fasting lipids From Baseline at Week 24 and Week 52,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10630,NCT05514535,Change in Glycated Haemoglobin (HbA1c),Change in Score of Short Form 36 Version 2 (SF-36 v2),,2022-08-29,RECRUITING,INTERVENTIONAL,['PHASE3']
10631,NCT04154904,Comparison of the Mean Relative Difference When Including Patterns in Hypoglycemia Prediction.,,,2020-08-11,COMPLETED,INTERVENTIONAL,['NA']
10632,NCT04313829,Measurement of Quality of Life (QoL) using the Euro Quality of Life 5 Dimension 5 Level (EQ-5D-5L) questionnaire,Measurement of HbA1c,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
10633,NCT06174779,The proportion of subjects achieving body weight loss ≥ 5% from baseline,Change of IWQoL-Lite-CT(Physical function domain) from baseline,,2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
10634,NCT02953262,Any My HealtheVet Patient Portal Use,Use of Secure Messaging,,2019-07-22,COMPLETED,INTERVENTIONAL,['NA']
10635,NCT01984606,The change from baseline in HbA1c after 52 weeks of treatment.,The change in Diastolic Blood Pressure (DBP) from baseline after 52 weeks of treatment,,2015-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
10636,NCT01693302,Blood glucose area under the curve,Glucose values two hours after the beginning of the meal,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
10637,NCT05389566,Co-existence of peripheral neuropathy and impaired dynamic postural control in people with diabetes,The impact of peripheral neuropathy on postural control (In quite stance),Muscle strength and peripheral neuropathy,2022-05-06,RECRUITING,OBSERVATIONAL,['NA']
10638,NCT03953963,Lack of serious adverse events (SAEs),Reduction in body weight,,2019-10-18,UNKNOWN,INTERVENTIONAL,['NA']
10639,NCT00126126,Amputee Mobility Predictor,Six-minute Walk Test,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
10640,NCT05455242,Change in Behavior Automaticity,,,2021-01-16,COMPLETED,INTERVENTIONAL,['NA']
10641,NCT04732780,Hypoglycaemia Fear Survey 2 - Worry Subscale,,,2021-03-02,COMPLETED,OBSERVATIONAL,['NA']
10642,NCT01836523,Change From Baseline in Total Daily Insulin Dose,Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10643,NCT05780905,bloodbrain barrier Ktrans,Inflammatory markers,,2023-04-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10644,NCT02302612,Composite CVD Goal,Patient Activation Measure (PAM) - 13 items,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10645,NCT00135226,Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only),Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only),Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only),2005-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
10646,NCT00067951,Hemoglobin A1c (HbA1c) reduction after 24 weeks of treatment.,"Change in FPG, insulin,C-peptide, insulin sensitivity,beta cell function, free fatty acids, lipids. Change in weight, vital signs, clinical laboratory tests, and adverse experiences.",,2003-10-17,COMPLETED,INTERVENTIONAL,['PHASE3']
10647,NCT00744926,Absolute change from baseline in HbA1c,"Responder rates for HbA1c (target <=7.0%, <=6.5%); relative change in glucose, insulin, C-peptide and glucagon during a meal tolerance test; beta cell function.",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10648,NCT00763451,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10649,NCT04682457,Change in C-peptide over a year,Change in dried blood spot C-peptide,,2019-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10650,NCT01874392,Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) Setting.,Test the Benefits of the AP Device Combined With the Technosphere® Insulin Powder System,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
10651,NCT01153243,Levels of inflammatory markers,"Levels of Vitamin D, PTH and Calcium",,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
10652,NCT04653532,The number and percentage of participants retained at 12-months.,Patient rapport with counsellor,Determine healthcare usage,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA']
10653,NCT00682240,Retinal morphological changes with time secondary to laser treatment as assessed with optical coherence tomography (OCT).,"changes in retinal function as an effect of treatment, documented by visual acuity testing and microperimetry. The change in vascular leakage will be assessed by performing fluorescein angiography, flare counts will be performed monthly.",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10654,NCT00857623,Change in Mean Numerical Rating Scale (NRS) Score From Baseline to Last 5 Days of Treatment,Change in Brief Pain Inventory-Short Form (BPI-SF) Pain Interference From Baseline to Day 28.,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10655,NCT03130699,Systolic blood pressure (SBP); mmHg units,Adherence to Refills and Medications Scale (ARMS) - patient-reported outcome,Pay for Performance (P4P) Clinical Metrics,2017-06-22,COMPLETED,INTERVENTIONAL,['NA']
10656,NCT01952535,"Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.","Pharmacodynamic variables will include maximum change (%) in fasting plasma glucose level, AUC0-4 of fasting plasma glucose , AUC of percent reduction in fasting plasma glucose from baseline versus time curve, time of minimum glucose level",,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10657,NCT00594152,Rate of loss of creatinine clearance,Change in cardiac function,,1993-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10658,NCT02192424,"Baseline-adjusted beta-cell function at 2 years, measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2).",Baseline-adjusted glycemic control at 2-years.,insulin sensitivity,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10659,NCT01694173,"• Increment in glucagon stimulated C - peptide levels at the end of 6 months of ABMSCT, as compared to baseline",• Any reduction in requirement of insulin dosage measured as a percentage decrease from baseline • Improvement of HbA1c levels as compared to baseline,,2010-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10660,NCT00242645,To test the effect of receiving computer tailored information about diabetes care before doctor visits and the differential effect of varying types of information,"Patient exit interviews after doctor visits about what happened during the visits, such as what was discussed, what tests and consults were ordered and what medications were added or changed.",,2004-06,TERMINATED,INTERVENTIONAL,['PHASE1']
10661,NCT04411342,Prevalence of Normoalbuminuric chronic kidney disease,,,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10662,NCT00274274,HbA1c,Duration of education,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10663,NCT03820050,System Performance,,,2019-01-29,COMPLETED,OBSERVATIONAL,['NA']
10664,NCT02506647,Pharmacokinetic effects,Safety assessment as measured by incidence and severity of adverse events,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10665,NCT03802942,Total number of patients with at least 1 documented low (equal or below 70 mg/dL) glucose levels,30-day readmission rate,,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10666,NCT01424891,NF-kappa B binding activity,Inflammatory markers,,2004-04,COMPLETED,INTERVENTIONAL,['NA']
10667,NCT03908281,Liver fat (%),Continuous glucose monitoring,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
10668,NCT00938275,Characterize and compare the pharmacokinetic profile of a single 500 mg dose of SRT2104 administered as an oral suspension and as a capsule formulation.,Assess the safety and tolerance of SRT2104.,,2009-01-20,COMPLETED,INTERVENTIONAL,['PHASE1']
10669,NCT06127355,Maternal fasting glucose concentration at 36 weeks,Infant birth weight,,2021-03-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10670,NCT02002143,Patients' control (decreased levels) of HemoglobinA1C (clinical),Patient Self-Management,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
10671,NCT00920725,Hours to achieve blood glucose less than 200mg/dl,,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
10672,NCT02098980,Insulin Resistance,,,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
10673,NCT05438251,Time to the ulcer grade down,Percentage of ulcer improvement,,2022-08-04,RECRUITING,INTERVENTIONAL,['PHASE4']
10674,NCT00451334,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
10675,NCT00696163,Change in Quality of Life from baseline (using QoLD questionnaire),Efficacy,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
10676,NCT01490918,The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment,"Changes in Glucagon During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),","Changes in MAGE of Glucose During CGMS Between 2 Group(Group 1 vs Group 2),",2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10677,NCT03146845,Change in the Cardiff Wound Impact Schedule-Physical Symptoms of Daily Living (CWIS-PSDL) Scale Score From Baseline to the Week 6 Visit,Healthcare Resource Use - Number of Dressing Changes Required for Each Type of Wound Debridement,,2017-06-15,COMPLETED,INTERVENTIONAL,['NA']
10678,NCT03711682,Change in HbA1c,Change in Systolic Pressure,Change in Theoretical HbA1c,2018-03-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10679,NCT03848637,Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration,Apparent volume of distribution of Metformin,,2019-04-14,UNKNOWN,INTERVENTIONAL,['PHASE1']
10680,NCT04039503,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Percentage of Participants Achieving an HbA1c Target Value of <5.7%,,2019-08-30,COMPLETED,INTERVENTIONAL,['PHASE3']
10681,NCT04666818,MODD= Adimensional coefficient calculated as mean of the daily serum glucose difference.,Cesarean section,,2020-11-26,COMPLETED,OBSERVATIONAL,['NA']
10682,NCT03125772,Composite safety endpoint of Target Vessel Failure (TVF) rate at 12 months post-index procedure: • Cardiac Death related to target vessel • Target Vessel Myocardial Infarction (TV-MI) • Target Vessel Revascularization (TVR),Stent Thrombosis Rate,Procedural complication rate,2011-06,COMPLETED,INTERVENTIONAL,['NA']
10683,NCT02105103,The primary objective is to evaluate the Accu-Chek Insight Insulin Pump and associated pump devices in routine practice. This will be expressed by the rate of error messages per 100 patient years (confirmed by pump uploads).,"Evaluate type and frequency of pump signals, i.e. reminders, errors, warnings, alarms, maintenance messages",,2013-10,COMPLETED,INTERVENTIONAL,['NA']
10684,NCT03827382,metabolic control,Quality of life by SF-36 Questionnaire,,2019-02-01,RECRUITING,INTERVENTIONAL,['NA']
10685,NCT01554631,Ratio of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load with Glucobay (Day 1) and without Glucobay (Day 0),Safety parameters,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10686,NCT00006163,,,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10687,NCT00417716,Optical Coherence Tomography,,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
10688,NCT04206748,# of Neonates with hyperbilirubinemia-requiring therapy.,Effect of SMBG checks on pregnancy,,2019-11-12,RECRUITING,INTERVENTIONAL,['NA']
10689,NCT01135433,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-05-15,COMPLETED,INTERVENTIONAL,['PHASE3']
10690,NCT01766362,Macular thickness,,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10691,NCT01011868,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment,"The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 18, 54, and 78 Weeks of Treatment",Confirmed Hypoglycemic Events,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
10692,NCT04591626,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Daily Mean Insulin Glargine Doses,,2020-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10693,NCT02221323,AUCINS.0-4h and AUCGIR.0-4h,,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10694,NCT03305822,Pharmacokinetics (PK): Insulin Lispro Area Under the Plasma Concentration Curve Zero to 10 Hours (AUC[0-10) Following Each Treatment Arm,Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm,,2017-10-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10695,NCT01364337,blood pressure,"Urinary magnesium, potassium, sodium and creatinine",,2010-11,UNKNOWN,INTERVENTIONAL,['NA']
10696,NCT00481663,Number of participants Who Discontinued Study Treatment Due to An AE up to Week 158,Change From Baseline in Daily Seven-Point Fingerstick Glucose Average at Week 52,,2003-08-19,COMPLETED,INTERVENTIONAL,['PHASE2']
10697,NCT01510847,The Effect of 90-day Oral Testosterone Therapy in Chinese Males with Type 2 Diabetes (T2DM): OTeST,The Effect of 90-day Oral Testosterone Therapy in Chinese Males with Type 2 Diabetes (T2DM): OTeST,,2011-10,TERMINATED,INTERVENTIONAL,['PHASE4']
10698,NCT00607646,Change in level of catecholamines in blood from baseline,,,2010-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10699,NCT00455858,Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20,Occurence of Hypoglycaemic Episodes,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10700,NCT01645696,Number of participants with adverse events,antibodies against the glucose binding protein,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
10701,NCT00543491,,,,2003-05,TERMINATED,INTERVENTIONAL,['PHASE3']
10702,NCT00320086,"Number of Subjects With Normal Urinary Protein Excretion in Healthy and Diabetic Children, Assessed Over 1 Day.",,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
10703,NCT06141434,Islet autoimmunity in the offspring,,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
10704,NCT04484883,Resting Energy Expenditure (REE),,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
10705,NCT02009878,Time of Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.,"Change From Baseline in Cumulative Urine Volume at 0-6 Hours, 0-12 Hours and 0-24 Hours.",,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10706,NCT03182296,Pancreatic uptake of 68Ga-NODAGA-exendin-4,"C-peptide, HbA1c",,2016-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10707,NCT02612805,Changes in levels of glycated hemoglobin,"Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Short Form.",,2015-11,COMPLETED,INTERVENTIONAL,['NA']
10708,NCT03792321,Effects of testosterone replacement therapy on vascular morphology - intima-media thickness (IMT),Effects of testosterone replacement on hematocrit,,2014-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10709,NCT01294553,Number of Participants With an Adverse Event,Number of Participants With the Indicated Unexpected Adverse Events,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
10710,NCT04341935,Changes in Glucose Llevels,Changes in chest structures,,2021-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10711,NCT02695173,Incidence of urinary tract infections (UTI) complications,Incidence of pyelonephritis,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
10712,NCT03607201,Mortality,,TIMI Score,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
10713,NCT02384018,C-peptide level after mixed meal tolerance test,The absence of severe hypoglycemic episodes,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10714,NCT01678742,Difference in the incremental area under the curve (iAUC) for peptide YY (PYY) after food ingestion between high-protein and standard diet groups,Difference in the iAUC for glucose-dependent insulinotropic polypeptide (GIP) after food ingestion between high-protein and standard diet groups,Difference in the iAUC for glucagon after food ingestion between high-protein and standard diet groups,2012-08,COMPLETED,INTERVENTIONAL,['NA']
10715,NCT01055951,Device-related adverse outcome,Mechanical dysfunction and diabetes-related adverse outcome,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10716,NCT03990857,Change is being assessed in Weigh,Use of services in the last year,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
10717,NCT03172494,Change in HbA1c,Plasma Concentration of Liraglutide,,2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE3']
10718,NCT05139914,Insulin-mediated endothelial nitric oxide synthase (eNOS) phosphorylation measured in endothelial cells (ECs) at 14 weeks,Circulating C-reactive protein (CRP) biomarkers of vascular health at 14 weeks,,2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE4']
10719,NCT04479826,Time in ranges,,,2020-07-16,COMPLETED,INTERVENTIONAL,['NA']
10720,NCT00625859,Blood samples and urine samples,Hunger and craving will be assessed using two assessment tools: (1) a questionnaire to assess hunger and craving; and (2) a Visual Analogue Scale (VAS) to assess hunger.,,2008-01-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10721,NCT03084965,Change in HbA1c,,,2017-05-12,COMPLETED,OBSERVATIONAL,['NA']
10722,NCT01623375,Area under the serum insulin degludec concentration-of i.v. administration,"Volume of distribution of insulin degludec, estimated during the terminal phase",,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10723,NCT00676338,Percentage of Patients Achieving HbA1c <=7% at Week 26,Change in Diastolic Blood Pressure From Baseline to Week 26.,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10724,NCT00887445,"Safety and tolerability parameters: adverse event, vital signs, 12-Lead ECG, continuous lead II ECG monitoring, laboratory safety variables and physical examination.",Interaction with Midazolam,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE1']
10725,NCT05172947,Serum neopterin levels,"Measurement of serum level of LDL, cholesterol, HDL, Triglyceride",,2021-12-05,COMPLETED,INTERVENTIONAL,['NA']
10726,NCT01806506,Excess Weight Loss From Baseline,LDH Level,Pulmonary Function Changes at 12 Months,2008-11,COMPLETED,INTERVENTIONAL,['NA']
10727,NCT01862029,Change in Insulin Sensitivity - Post-roflumilast,,,2013-05-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10728,NCT00311324,Mean Hemoglobin A1c,Median number of minutes per day engaged in physical activity,,2001-02,COMPLETED,INTERVENTIONAL,['NA']
10729,NCT04143269,Subjective gastrointestinal symptoms,Nerve conduction study - amplitudes,,2020-01-20,COMPLETED,INTERVENTIONAL,['NA']
10730,NCT03596203,Pain level,Changes in pain medication,,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10731,NCT00313183,To assess the safety and tolerability of Symlin in adolescent subjects with type 1 diabetes,To evaluate the effects of Symlin compared to placebo in adolescent subjects with type 1 diabetes on various pharmacodynamic endpoints,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10732,NCT05866900,Coefficient of variation (%),Height Z-score,,2023-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10733,NCT01835379,Percentage of Wounds Closed,Time to Wound Closure,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10734,NCT03504683,Peak glucose and mean amplitude of glycemic excursions (MAGE) glucose values,Inflammatory biomarkers,Sleep Quality,2020-08-17,RECRUITING,INTERVENTIONAL,['NA']
10735,NCT01954771,Evaluation of Peak and Nadir Glucose Profiles From Continuous Glucose Monitoring System (CGMS),HbA1c(%) at Endpoint,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
10736,NCT01354977,Peripheral Insulin Sensitivity (RD) Measured by the Change in Glucose Rates of Disappearance With Resveratrol or Placebo at Baseline and at 4 Weeks.,Muscle Mitochondrial Area,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10737,NCT05418465,Rate of change in Estimated Glomerular Filtration Rate (eGFR) compared to baseline,Change in 24-hour urine protein ration from baseline.,Incidence of adverse reactions,2022-01-26,RECRUITING,INTERVENTIONAL,['NA']
10738,NCT05000463,Pain Assessment,,,2022-02-25,UNKNOWN,INTERVENTIONAL,['NA']
10739,NCT01295788,Adherence to CGM (hours per week),Perception of Barriers/Facilitators to RT-CGM Use,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
10740,NCT04154046,New ulcers incurred,Incidence of new ulcers on feet,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
10741,NCT01296516,Incidence of glucose intolerance,Weight loss,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
10742,NCT06255288,Procedural uncertainties - Number of patients willing to participate.,Drop out rates,,2024-01-23,RECRUITING,INTERVENTIONAL,['NA']
10743,NCT02776397,Oxidative Stress,Non HDL-Cholesterol,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
10744,NCT04464213,Rate of adverse event,Rate of cure rate,,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10745,NCT05035849,Glycemic variations,Glycemic variations,,2020-01-30,COMPLETED,INTERVENTIONAL,['NA']
10746,NCT01527565,"Cmax, maximum insulin aspart concentration",Adverse events,,2003-01-20,COMPLETED,INTERVENTIONAL,['PHASE1']
10747,NCT02814123,Percentage of time of plasma glucose levels spent in target range. Target range is defined to be between 3.9 and 10.0 mmol/L of regular insulin-plus-pramlintide closed-loop delivery vs. fast-acting insulin-alone closed-loop delivery.,"Gastrointestinal symptoms during the treatment optimization (i.e., the minimum 10 days prior to the 24-hour closed-loop visits) and during the 24-hour closed-loop visits.",,2017-01-13,COMPLETED,INTERVENTIONAL,['PHASE2']
10748,NCT00860288,To evaluate the efficacy of vildagliptin as add-on therapy to metformin in patients with T2DM by assessing changes in HbA1c with vildagliptin added to metformin to that of placebo added to metformin after 24 weeks of treatment,To evaluate the long-term efficacy of vildagliptin compared to sitagliptin over the entire study duration as add-on therapy to metformin in patients with T2DM.,,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10749,NCT02906579,Change From Time-Matched Baseline (Placebo Cycle) in Platelet Function Assessments: Collagen/Epinephrine Time to Aggregation,,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10750,NCT00456885,Change in Body Mass Index,REE,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10751,NCT05227196,"Cmax,0-24h.semaglutide,SS Maximum semaglutide plasma concentration at steady state","Ctau,24h,semaglutide,SS Semaglutide plasma concentration 24 hours after last dose at steady state",,2022-02-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10752,NCT02262611,Change in diastolic blood pressure,Global assessment of tolerability by investigator on a 4-point scale,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
10753,NCT02033889,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach),Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach),,2013-12-13,COMPLETED,INTERVENTIONAL,['PHASE3']
10754,NCT01675310,Gestational diabetes mellitus,insulin resistance,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10755,NCT02088294,Change in Physical activity,Change in Dietary intake,Change in Intuitive eating,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10756,NCT01296438,Area under the serum insulin aspart concentration-time curve,Area under the serum insulin aspart concentration-time curve,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10757,NCT00210275,Change in Behavioral intention related to referring patient for retinopathy screening,Change in Perceived Behavourial Control (Theory of Planned Behaviour),,2005-07,UNKNOWN,INTERVENTIONAL,['NA']
10758,NCT03214380,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Number of Participants With HbA1c <7%,,2017-07-14,COMPLETED,INTERVENTIONAL,['PHASE3']
10759,NCT00351832,Change from baseline on HbA1c at 12 weeks,Change from baseline on fasting lipids at 12 weeks,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10760,NCT01044875,Visual acuity measurement by logarithm of the minimum angle of resolution (logMAR),Patient pain score during laser procedure,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
10761,NCT02886208,BMI,,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
10762,NCT04949022,Time in range (glucose between 3.9-10 mmol/l) before and during hybrid close loop insulin pump treatment,HbA1c before and during hybrid close loop insulin pump treatment,Sensor glucose coefficient of variation before and during hybrid close loop insulin pump,2021-08-23,UNKNOWN,INTERVENTIONAL,['NA']
10763,NCT03764631,Number of Participants With Dehydration,Number of Participants With Dehydration During Ramadan Periods,,2018-09-26,COMPLETED,OBSERVATIONAL,['NA']
10764,NCT01581099,Improvement in Metabolic Profile,,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
10765,NCT04926740,Time to DKA resolution (efficacy outcome),Major adverse kidney events,,2021-10-12,COMPLETED,INTERVENTIONAL,['NA']
10766,NCT03808090,Urinary oxalate excretion,,,2013-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10767,NCT05478707,Microvascular blood volume (MBV),"Skeletal muscle oxygenation, deoxyhemoglobin (HHb)",,2023-10-05,RECRUITING,INTERVENTIONAL,['PHASE2']
10768,NCT00562250,Maximum plasma concentration and exposure to glimepiride and dapagliflozin when administered alone and administered together,Recorded adverse events,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10769,NCT02092597,Exocrine pancreas function,,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10770,NCT02209051,Proportion of patients with complete wound closure (i.e. complete skin re-epithelialization without drainage or dressing requirements) at 6 weeks after initiation of study treatment,Changes in Quality of Life assessment,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
10771,NCT01733901,All-cause mortality,Medication adherence,,2012-11,UNKNOWN,INTERVENTIONAL,['NA']
10772,NCT00282971,Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in FEV1 at Week 24 LOCF,,2006-03-06,TERMINATED,INTERVENTIONAL,['PHASE3']
10773,NCT01521962,Change in glycosylated hemoglobin (HbA1c; Japan Diabetes Society value),,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10774,NCT03370237,Diabetic foot ulcer risk score,Raters' level of confidence,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
10775,NCT04564443,Proportion of wounds completely healed at or before 16 weeks,Kent Imaging - Snapshot camera,,2020-09-11,RECRUITING,INTERVENTIONAL,['NA']
10776,NCT03251846,HbA1c,Hypoglycemia,,2017-07-17,UNKNOWN,INTERVENTIONAL,['NA']
10777,NCT05633628,HbA1c,The Patient Preferences for Patient Participation (4Ps),,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
10778,NCT05275608,Change in metabolic control,Change in inflammatory status,,2022-11-07,RECRUITING,INTERVENTIONAL,['NA']
10779,NCT02159846,Allergy or hypersensitivity to preparation,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
10780,NCT00006505,Insulin independence,change in lipid profiles,,2000-11-16,COMPLETED,INTERVENTIONAL,['PHASE2']
10781,NCT01364402,Incidence of Contrast Induced Nephropathy(CIN),Hospital mortality,,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
10782,NCT01889667,Evaluate the Safety and Tolerability of ORMD-0801.,The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10783,NCT04014569,Percentage of sensor glucose readings within range of 70-180 mg/dl,Number of Diabetic Ketoacidosis events,Number of physician override advisor recommendations,2018-05-02,TERMINATED,INTERVENTIONAL,['NA']
10784,NCT02077218,"Feasibility, defined by the percentage of patients that enroll onto the study, successful completion of all study measurements, ability of studies to be interpreted, and achievement of the recruitment goal",,Expression of Lp-PLA2,2014-02,COMPLETED,INTERVENTIONAL,['NA']
10785,NCT03525899,Time to macular hole closure,Best corrected visual acuity,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
10786,NCT04794907,Risk Stratification,,,2022-12-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10787,NCT03685357,"RBDSQ (""Rapid eye movement Sleep"" Behavior Disorder Screening Questionnaire)",,,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA']
10788,NCT04178603,Muscle glucose uptake during exercise and enhanced insulin sensitivity in recovery from exercise.,Posttranslational modification of proteins in muscle biopsies.,Changes in gene-expression in muscle as a result of exercise and during subsequent insulin stimulation.,2018-07-05,COMPLETED,INTERVENTIONAL,['NA']
10789,NCT00643474,Change from baseline in HbAlc level; percentage of subjects reaching or maintaining the risk target (represented by a combination of LBGI<=2.5 together with HBGI<=5).,"Changes in HBGI & LBGI; blood glucose test frequency, blood glucose profile, diabetes therapy, urinary 8-isoPGF2alpha, blood pressure, creatinine clearance, lipid profile & BMI; QoL & Locus of Control analysis; hypoglycemic episodes; study-related SAEs.",,2008-03,COMPLETED,INTERVENTIONAL,['NA']
10790,NCT01072331,"Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 to 2h (Breakfast, Lunch and Dinner)",Change From Baseline in Fasting Plasma Glucose,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10791,NCT05475431,The eradication rate by the per-protocol analysis,,,2020-05-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10792,NCT00046267,,,,na,COMPLETED,INTERVENTIONAL,['NA']
10793,NCT03209466,Ulcerated area,,,2017-05-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
10794,NCT00827710,Percent of patients with BP < 130/80,Percent of patients with BP checked in past year,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
10795,NCT03970720,Change in Hypoglycemia Symptom Recognition,Ratio of Self-Reported Hypoglycemic Episodes to Total Hypoglycemic Episodes,,2019-05-28,RECRUITING,INTERVENTIONAL,['PHASE2']
10796,NCT05979519,Percentage Change in fasting blood glucose,Change in blood pressure,,2023-09-26,RECRUITING,INTERVENTIONAL,['NA']
10797,NCT03060538,Percentage of Participants with Adverse Events (AE),Change from Baseline in Percentage of Participants with Anti-Therapeutic Antibodies (ATAs),,2017-03-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10798,NCT01203111,Change in HbA1c level for patients with addition of glulisine at week 12,"Hypoglycemia (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe)",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10799,NCT04642261,Change in liver fat content,Changes of diastolic blood pressure,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10800,NCT05429554,improve the neurodegeneration and cardiovascular effect in diabetic patients,,,2022-06,RECRUITING,OBSERVATIONAL,['NA']
10801,NCT00469105,A1C,Patient satisfaction,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10802,NCT02663388,"Evaluation of folate mediated one-carbon metabolic pathway parameters (Folates, Vitamin B12, Methionine, Homocysteine) on severe obesity-related complications before and after bariatric surgery",Evaluation of DNA Methylation on severe obesity-related complications before and after bariatric surgery,,2016-01,RECRUITING,OBSERVATIONAL,['NA']
10803,NCT01240200,Diabetes Treatment Satisfaction Questionnaire: Change (DTSQc) Score,Number of Hypoglycemic Events,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10804,NCT04565756,The primary objective of the study is to evaluate the ocular safety and tolerability (by incidence of ocular adverse events) of EXN407 ophthalmic solution in Dose Expansion phase.,To evaluate the percentage (%) of changes in ocular structural measures as assessed using ophthalmoscopy.,,2020-11-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10805,NCT04203173,Resource Utilization and Cost,Self-Care Behavior Brooks Medication Adherence Scale (BMAS),,2019-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10806,NCT02786134,Change in Global Myocardial Blood Flow in Response to Vasodilator,,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
10807,NCT03446261,Change from baseline to week 8 in ApoB/ApoA1 ratio,Change from baseline to week 8 in FPG,,2018-02-23,COMPLETED,INTERVENTIONAL,['PHASE4']
10808,NCT03099928,Qualitative data,Change in optimism,,2015-03-01,COMPLETED,OBSERVATIONAL,['NA']
10809,NCT04406792,Participants with gestational diabetes that complete the recommended screening for Type 2 Diabetes Mellitus (T2DM),Participants with gestational diabetes who develop T2DM,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10810,NCT01770964,change in pain severity rating,,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
10811,NCT03670797,Oral mucosal alterations,Salivary glands function,,2018-12-25,COMPLETED,OBSERVATIONAL,['NA']
10812,NCT05393843,plasmatic glycated haemoglobin,therapy for diabetes,,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10813,NCT00637546,Gait parameter: comfortable speed,Fear of falling (Falls efficacy scale),,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10814,NCT04100070,Impact on glycaemic control all along the study,Impact on glycaemic control upon age classes,,2019-09-02,UNKNOWN,INTERVENTIONAL,['NA']
10815,NCT05521256,Number of adverse events,"For i.v. cohort and oral cohort- AUC0-∞,6856,SD/dose: Area under the NNC0113-6856 plasma concentration-time curve from 0 to infinity after a single dose divided by the dose administered",,2022-08-26,COMPLETED,INTERVENTIONAL,['PHASE1']
10816,NCT01134458,Cardiovascular Disease (CVD) Risk Knowledge Assessment,,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
10817,NCT02662569,Percent Change From Baseline in LDL-C at Week 12,Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12,,2016-04-14,COMPLETED,INTERVENTIONAL,['PHASE3']
10818,NCT00795704,Hemoglobin A1C,Change From Baseline in Self-Monitoring Blood Glucose (SMBG) Averages,,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10819,NCT00866801,Coronary flow reserve,Diabetic autonomic neuropathy,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
10820,NCT03617081,Number of treatment emergent adverse events (TEAEs),"Cmax,SNAC,SD; the maximum plasma concentration of SNAC in plasma after a single dose of oral NNC0113-2023",,2018-08-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10821,NCT03195140,Hypoglycemia < 70 mg/dL,High Blood Glucose Index (HBGI),,2017-08-11,COMPLETED,INTERVENTIONAL,['NA']
10822,NCT03437902,"Lipid profile in diabetic patients (TC,TG,HDL-c,LDL-c).",Quality of life of diabetic patients and this will be evaluated by using Quality of Life Questionnaire (Short Form 36 questions (SF-36)) .,,2018-02-24,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10823,NCT01665716,OVADIA 2: Age at menopause,,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
10824,NCT01697592,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,,2012-10-24,COMPLETED,INTERVENTIONAL,['PHASE3']
10825,NCT05176210,Incidence of dose-limiting toxicity (DLT) during the DLT observation period,Pharmacokinetics of PS1 - CL/F,,2023-12,RECRUITING,INTERVENTIONAL,['PHASE1']
10826,NCT01038102,Hepatic steatosis by MRT,Changes in adipose tissue gene expression and lipogenic enzyme activity,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10827,NCT00390962,,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
10828,NCT01865318,Area under the glucose infusion rate curve,Area under the serum insulin degludec curve,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10829,NCT03211858,Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26,"Percentage of Participants With Treatment-Induced, Treatment-Boosted and Treatment-Emergent Anti-insulin Aspart Antibodies (AIAs)","Change in Daily Insulin Dose From Baseline to Day 1, Week 26 and Week 52",2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10830,NCT04943861,Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) scores,,,2023-11-14,RECRUITING,INTERVENTIONAL,['NA']
10831,NCT03005600,Development and validation of composite risk score for GDM with the risk factors of interest and/or point-of-care HbA1c,Identification and the impact of other novel risk factors on the diagnosis of GDM and other adverse maternal outcomes,,2016-02,UNKNOWN,OBSERVATIONAL,['NA']
10832,NCT01074489,Blood glucose levels,,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
10833,NCT02461641,Mean adjusted heal rate,Length of time to 100% healing of foot ulcer,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
10834,NCT00141492,,,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10835,NCT04178525,Difference in proportions of ulcers completely healed for experimental group compared to control group.,To track diabetic ulcer recurrence for experimental group compared to control group in patients whose wound completely healed.,,2018-08-02,TERMINATED,INTERVENTIONAL,['NA']
10836,NCT01910441,Mean Amplitude of Glycemic Excursions (MAGE),,,2013-07,TERMINATED,INTERVENTIONAL,['PHASE4']
10837,NCT02388984,"The total effective rate of Fundus changes, the severity of diabetic retinopathy change from baseline at the end of week 24 compared to placebo",The severity of macular edema change from baseline at the end of week 24 compared to placebo,,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
10838,NCT05950659,Plantar ulcer recurrence,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10839,NCT00886340,Number of Participants Who Met Weight Loss Goal of 5% Weight Loss,Quality of Life,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10840,NCT02561546,glycosylated hemoglobin (A1C),postprandial glucose (PPG),,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
10841,NCT05229705,Trail Making Test,Timed Up and Go Test,,2022-09-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10842,NCT05280496,HbA1C,Weight,,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10843,NCT02680873,resolution of diabetes,,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
10844,NCT01089855,The decrease of neuropathic pain in diabetic patients using Brief Pain Inventory scale (BPI),Evaluate the quality of life,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10845,NCT04790617,Acute care service use,Medication adherence,,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10846,NCT05710913,Diabetes mellitus type II remission rate postoperatively,,,2023-01-05,RECRUITING,OBSERVATIONAL,['NA']
10847,NCT04118153,Change in frequency of TfH within total CD4 T cells (%),,,2021-03-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
10848,NCT02342535,Change in Physical Activity (Minutes/Week),,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
10849,NCT03943979,Stability of changes in food intake,Change in neuropsychological test:Symbol digit modalities test (SDMT; Smith A. 1982).,,2016-02-25,COMPLETED,INTERVENTIONAL,['PHASE2']
10850,NCT02121340,Hemoglobin A1c,,Diabetes self management,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10851,NCT01807351,Number of subjects develope Diabetes Mellitus,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
10852,NCT01714011,Tapering off of previous psychoactive medication.,The proportion of reversed metabolic syndrome components among schizophrenia patients after treated with either aripiprazole or ziprasidone,Total cholesterol and LDL cholesterol among schizophrenia patients after treated with either aripiprazole or ziprasidone.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10853,NCT05908513,Change of body weight over time points,,,2021-10-15,WITHDRAWN,INTERVENTIONAL,['PHASE1']
10854,NCT05274880,Cmax of CKD-393,,,2022-06-21,COMPLETED,INTERVENTIONAL,['PHASE1']
10855,NCT00563394,Reduction in clinical signs and symptoms of the infection,Wound Depth,,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10856,NCT01434901,The effects of Bethanechol on insulin secretion rates,,,2011-08-15,COMPLETED,INTERVENTIONAL,['PHASE1']
10857,NCT05286632,Evaluation of changes in Perceived Stress,,,2022-07-18,RECRUITING,INTERVENTIONAL,['NA']
10858,NCT03011021,Adverse effects,Life quality evaluation,,2017-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10859,NCT04874532,Diabetes Self-Management,Qualitative experience with hypoglycemia and its prevention,,2021-06-04,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10860,NCT03344692,Total area under the post-prandial triglycerides concentration-time curve from meal-time until 8h (AUC0-8h) after standardized high fat meal.,Effect of treatment with alirocumab versus placebo on fasting and post-prandial and glucose homeostasis following a standardized high-fat meal,,2019-02-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10861,NCT01843855,Change in Total Disposition Index from Study 1 (pre-RYGB) to Study 2 (post-RYGB),,,2011-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10862,NCT03596177,Percent Change in Body Weight From Baseline to Day 59,Number of Participants With Positive Anti-drug Antibodies (ADAs) to MEDI0382,,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE2']
10863,NCT01125956,Hemoglobin A1c,Experience of peer counseling,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
10864,NCT03523403,Gut microbiota profile,Plasma insulin levels,,2017-10-12,COMPLETED,INTERVENTIONAL,['NA']
10865,NCT02733185,"A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina",,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10866,NCT03157960,Changes in uric acid (µmol/L),,,2012-02-01,COMPLETED,INTERVENTIONAL,['NA']
10867,NCT02846662,Number of participants with 50% reduction in PHQ-9 score a 3-month assessment,"Proportion of participants who improve level of activity, as evaluated by the short form of the Behavioral Activation for Depression Scale (BADS)",,2016-09-19,COMPLETED,INTERVENTIONAL,['PHASE3']
10868,NCT00728286,Thrombus area,Factors affecting thrombus area,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
10869,NCT01421459,Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c),Rate Per 30 Days of Hypoglycemic Events,Percentage of Participants With Treatment Emergent Antibody Response (TEAR),2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10870,NCT01212328,Multiple CVD risk factor control targets,Prescriber and patient acceptability of the Digital Support software and care coordinator with management guidelines.,,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
10871,NCT02276131,Successful completion of frequent and risk-related tasks (Measure: Percent of tasks successfully completed),,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10872,NCT04568486,Hemoglobin A1c,Health-related quality of life measures,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
10873,NCT01311076,TGIRmax: Time to Reach the Maximum Glucose Infusion Rate (GIRmax) Pharmacodynamic Parameter.,Incidence of Hypoglycemia.,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10874,NCT04054076,Pressure time integral,Relation of different types of insoles and risk factors to pressure time integral,Costs for the assistive devices,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
10875,NCT04155645,Laboratory assessments: Clinical urinalysis,PD analysis: Levels of dyslipidemia related biomarkers.,,2019-11-21,COMPLETED,INTERVENTIONAL,['PHASE1']
10876,NCT02979756,Macrosomia,Lifestyle impact of GDM,,2016-11-14,COMPLETED,INTERVENTIONAL,['NA']
10877,NCT05348733,Descriptive summary of secondary therapies used in participants with CKD and T2D.,Occurrence of hyperkalemia,Occurrence of newly diagnosed diabetic retinopathy or progression of existing disease at treatment initiation,2022-06-13,RECRUITING,OBSERVATIONAL,['NA']
10878,NCT05595681,Time to complete ulcer healing,Amount of index ulcers completely healed,Other endpoints,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE1']
10879,NCT01787318,Peak Post-Prandial Glucose Excursions,Area Under Curve meal-related insulin excursion following meals,,2013-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10880,NCT00673465,Pharmacodynamic: Change From Baseline in 24-hour Plasma Glucose (AUC/Duration) at Week 4 (Part 2 - India),Pharmacokinetic: Mean Plasma Tmax (Part 2 - India),,2008-04-17,COMPLETED,INTERVENTIONAL,['PHASE1']
10881,NCT00501683,Urine & Fecal collection at Day -1 & days 1-5.,"Adverse events (AEs), vital signs, ECGs and clinical laboratory assessments at each day for up to 10 days",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10882,NCT03874754,Change in Mental Well Being,Change in Brain-Derived Neurotrophic Factor Level (in Sweat),,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
10883,NCT05164562,musculoskeletal disorders of upper limb,,,2022-01-07,UNKNOWN,OBSERVATIONAL,['NA']
10884,NCT02248714,Change From Baseline in Glucose Coefficient of Variation(CV),Change From Baseline in HOMA-IR,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
10885,NCT01098357,Incidence of complete wound closure,Safety Safety Measures,,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10886,NCT04831060,Characterization of a panel of cytokines in gingival fluid of patients with periodontitis versus without periodontitis,Characterization of proteases (MMP) present in gingival fluid and unstimulated saliva,,2023-02-15,RECRUITING,OBSERVATIONAL,['NA']
10887,NCT01257815,The change in mean Best Corrected Visual Acuity (BCVA),Proportion of patients with 10 and 15 letter improvement or loss in BCVA,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10888,NCT05527574,Changes in frailty status in response to the exercise intervention,Changes in cognitive health,,2019-11-30,RECRUITING,INTERVENTIONAL,['NA']
10889,NCT02447601,Plasma concentrations of simvastatin and simvastatin acid.,Incidence of adverse events and serious adverse events,,2015-03-30,COMPLETED,INTERVENTIONAL,['PHASE1']
10890,NCT04791371,Change in insulin sensitivity,,,2022-06-17,RECRUITING,INTERVENTIONAL,['NA']
10891,NCT05081583,Metformin area under the concentration vs. time curve (AUC) ratio (exposure/baseline),Midazolam half-life ratio (exposure/baseline),,2021-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10892,NCT01340079,Change from Baseline in hemoglobin a1c at 8 weeks after completion of the intervention.,Change from Baseline in physical activity at 8 weeks after completion of the intervention.,,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10893,NCT00890331,Parental involvement and Disease care behaviors,"Glycohemoglobin levels, Adverse effects and Blood glucose variability",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10894,NCT01792284,Hemoglobin A1c (HbA1c) at 12 Weeks,Percentage of Participants With HbA1c <7.0% and ≤6.5% at 12 Weeks,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10895,NCT01476995,Agreement of ClearView Scan versus Active Diagnosis,Sensitivity and Specificity of ClearView Scan versus Active Diagnosis,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
10896,NCT04698486,Fatty acid oxidation in Heart (µmol/min),VLDL-triglyceride uptake in adipose tissue (percent),,2020-07-03,COMPLETED,INTERVENTIONAL,['NA']
10897,NCT03173963,Effect of empagliflozin on change in cortical interstitial fractional volume [Vv(Int/cortex) over the 3-year study period.,Effect of empagliflozin on development or progression of diabetic retinopathy determined by changes from baseline to 3 years of at least 2 Early Treatment of Diabetic Retinopathy Study levels in grading of standardized retinal photographs.,,2017-05-27,WITHDRAWN,INTERVENTIONAL,['PHASE3']
10898,NCT03263351,Insulin secretion,Daily cortisol output,,2017-10-01,RECRUITING,INTERVENTIONAL,['NA']
10899,NCT05041491,Glycemia,Skeletal muscle content of COX4,,2021-11-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10900,NCT01193296,Glycemic variability assessed by MAGE (Mean Amplitude of Glycemic Excursion),"Unrecognized hypoglycemic periods recorded by CSGM, frequency and duration",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10901,NCT06147323,Changes in quality of life,,,2023-11-13,RECRUITING,INTERVENTIONAL,['NA']
10902,NCT01557504,Number of Participants Who Discontinued Study Drug Due to an AE,,,2012-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
10903,NCT03675464,Number of participants with Hypertension,Genetic variations linked to lipolysis,,2018-09-20,UNKNOWN,OBSERVATIONAL,['NA']
10904,NCT02050399,Cardiovascular responses during isometric exercise,,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
10905,NCT00285896,"Area under curve (AUC)for plasma glucose, insulin, insulin secretion velocity and glucagon for the periods 0-48 hours(day 1-2) and 0-180 min (day 3). And also the lowest plasma glucose during the period 0-180 min day 3 and mean blood pressure",,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
10906,NCT00712842,Pattern ERG,Blood glucose,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
10907,NCT04155619,Insulin secretion,"Glycemic (""Peripheral"") Rhythm Phase",,2021-04-26,RECRUITING,INTERVENTIONAL,['NA']
10908,NCT04419467,Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR),Percentage of Subjects Positive for Anti-drug Antibodies,,2020-09-14,COMPLETED,INTERVENTIONAL,['PHASE2']
10909,NCT02394158,Development of Gestational Diabetes at any point during the course of pregnancy,Cost effectiveness of the intervention,Fetal hyperinsulinaemia,2015-01-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
10910,NCT02888691,Percentage of Time Spent in Euglycemia,TNF-alpha,Ketones,2016-08,COMPLETED,INTERVENTIONAL,['NA']
10911,NCT02091323,fasting plasma glucose(FPG),hemoglobin A1c (HbA1c),weight loss,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
10912,NCT00482950,HbA1c,,,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
10913,NCT01293578,Patient Satisfaction and knowledge,Physician adoption and satisfaction with the decision aid.,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
10914,NCT01864603,HIV Incidence,Total Costs of Programming (ART),,2013-04,COMPLETED,INTERVENTIONAL,['NA']
10915,NCT05296642,Change in Pain Pressure Threshold (PPT),Change in Heat Pain Threshold (HPT),,2022-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
10916,NCT03313752,Effect of dapagliflozin on myocardial insulin sensitivity,Gut microbiota composition change from baseline,,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10917,NCT00229931,"Main Outcome Measures Will be Quantitative Changes in OCT Central Thickness, Visual Acuity, and Number of Snellen Acuity Lines Gained/Lost.","Rate of Elevated Intraocular Pressures, Retinal Detachment, Infection, and Vitreous Hemorrhage.",,2005-11,COMPLETED,INTERVENTIONAL,['NA']
10918,NCT00984867,Adjusted Mean Change in HbA1c Levels,Proportion of Participants Achieving a Therapeutic Glycemic Response Defined as a Reduction in HbA1c of ≥0.7% Compared to Baseline,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10919,NCT01525225,"Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death",Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities,,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1']
10920,NCT05400863,change in BMI z-score between the two groups at 12 weeks,improvement of A1C due to metformin between the 2 groups at 12 weeks,metformin-induced rise in GDF15 in both groups at 12 weeks,2022-04-21,RECRUITING,INTERVENTIONAL,['NA']
10921,NCT03363100,A1c,,,2017-12-05,COMPLETED,INTERVENTIONAL,['NA']
10922,NCT00836329,Proportion of participants with new neuropsychological deficits (20% decline on two or more neuropsychological tests),"Neuropsychological deficits (i.e., predictive utility of neuropsychological performance on presence, number, and volume of lesions)",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10923,NCT03440736,Percentage of patients achieving Psoriasis Area and Severity Index (PASI) Score of 90 at week 28,"Percentage change from Baseline in Participant's self-assessed pain, itching and scaling",,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
10924,NCT05752292,Completion of recommended postpartum diabetes screening.,Uptake of a lifestyle program for diabetes prevention.,,2023-04-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10925,NCT03260998,corrected QT dispersion,,,2017-08,UNKNOWN,OBSERVATIONAL,['NA']
10926,NCT05226182,Usability and acceptance of the application in patients and healthcare professionals,"Possible change,impact on personal clinical parameters: bodyweight",,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA']
10927,NCT01280188,Change from Baseline in 24-hour Urine Volume,Participants with Adverse Events Summarized by Incidence and Severity,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10928,NCT03516864,Tissue oxygenation is detected on both the MIMOSA Imager and Kent camera.,,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
10929,NCT02373865,Number of Hypoglycemic Episodes (HE) Under Treatment With Sitagliptin Compared to Glimepiride,Glycemic Variability (Profile) of Sitagliptin Compared to Glimepiride,,2015-09,TERMINATED,INTERVENTIONAL,['PHASE4']
10930,NCT02774733,The correlation between the pulmonary function parameters and the retrobulbar circulation parameters in 48 T2DM patients,"HbA1c, FPG, 2hPG, WC,BMI, DBP, SBP, and blood-fat in 48 T2DM patients",,2015-08,COMPLETED,OBSERVATIONAL,['NA']
10931,NCT01542775,change from baseline in soluble receptor for advanced glycation endproducts (sRAGE) after 12 weeks of aerobic exercise,energy expenditure,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
10932,NCT00960973,AIRg (acute insulin response to glucose) using FSIGT (frequently sampled intravenous glucose tolerance test),insulin sensitivity (FSIGT),,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10933,NCT03886974,Needs assessment for transition of care,,,2018-09-07,COMPLETED,OBSERVATIONAL,['NA']
10934,NCT01023165,Researchers will assess whether restoring metabolic integrity to diabetic patients improves quality of life and complications associated with diabetes,,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
10935,NCT00633282,"Improved metabolic parameters(glucose, lipid, liver enzymes, etc.)",the ratio of withdrawing because of inefficiency,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10936,NCT00737347,change in body weight,change in body composition,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10937,NCT02641548,Time to healing of deep heel fissures,Number of participants with complications,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
10938,NCT05676619,Interrater reliability (Intraclass Correlation Coefficient) of 3D foot scans repeated at baseline (change),,,2023-02-16,RECRUITING,INTERVENTIONAL,['NA']
10939,NCT02605200,Change in the Pediatric Quality of Life Inventory Transplant Module (PedsQL),Change in the Behavior Assessment System for Children (BASC) Score,,2016-07-07,COMPLETED,INTERVENTIONAL,['NA']
10940,NCT03047447,Hemoglobin A1c,Ketones (Blood),,2016-02-25,COMPLETED,INTERVENTIONAL,['NA']
10941,NCT04527965,Between-group changes in liver fat content between baseline and month 12,Between-group changes in FIB-4 between baseline and month 12,Between-group changes in plasma lipids (ceramides) using a targeted lipidomic approach between baseline and month 12,2020-08-11,COMPLETED,INTERVENTIONAL,['NA']
10942,NCT05593549,Autophagic Flux Protein Expression,Blood Pressure,,2023-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10943,NCT06267391,HbA1c,Incidence of adverse events,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10944,NCT05205876,Feasibility of the Eddii App as measured by frequency of use,User Engagement measured through app analytics,,2021-01-02,COMPLETED,INTERVENTIONAL,['NA']
10945,NCT01055808,Changes in Health Related Quality of Life (ITR-QOL) in insulin treated type 2 diabetes at baseline and 12 weeks after a significant change in insulin treatment regimen,Change from baseline in use of concomitant oral hypoglycemic drugs,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
10946,NCT01537016,"To identify EPA wounds using WOUNDCHEK™ Protease Status diagnostic test, and to compare the healing outcomes of two treatment regimes (PROMOGRAN®, a protease modulating therapy and current standard of care) on chronic wounds with EPA.",Reduction in wound area and cost effectiveness,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
10947,NCT05099900,Experiences and technology usage among women,,,2021-11-08,UNKNOWN,OBSERVATIONAL,['NA']
10948,NCT03507829,incidence of NODAT,"Mental component summary (MCS) and physical component summary (PCS) derived from the Kidney Disease Quality of Life Short Form (KDQoL-SFTM) at 6, 12 and 24 months after kidney transplantation",,2012-11-21,COMPLETED,INTERVENTIONAL,['PHASE3']
10949,NCT02716064,"The experience of patients, family members, primary health care providers, volunteers and community organizations with the TAPESTRY-CM program",Developmental decision evaluation - I,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
10950,NCT03010215,Score change of the AOFAS Hallux metatarsophalangeal interphalangeal scale,Change in clinical evaluation with VAS,,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
10951,NCT01480895,Change in HOMA.,BMI changes after delivery.,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
10952,NCT04209348,Change in Physical Activity Assessed by ActiGraph Monitoring Device From Baseline to Follow-up,Birthweight-for-gestational-age Z-score,,2020-08-21,COMPLETED,INTERVENTIONAL,['NA']
10953,NCT00561704,"GFR, HbA1c and the adiponectin concentration.",,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
10954,NCT00495794,Change in Systolic Blood Pressure,LDL Control,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
10955,NCT02935712,Safety of AZD8601 by assessing number of subjects with clinically significant urinalysis (Part B),,,2016-12-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10956,NCT00924430,"Simvastatin and simvastatin acid: Cmax, tmax, AUC0-t, AUC, lz, and t1/2, as well as CL/F and Vz/F for simvastatin only","Safety and tolerability assessments including adverse events, clinical laboratory tests, electrocardiogram (ECG) and vital signs",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10957,NCT01906294,"routine treatment data (composite of e.g. diagnostics, kind and dosage of pharmacological diabetes treatment)",,,2013-08,TERMINATED,OBSERVATIONAL,['NA']
10958,NCT01120899,Number of Study Eyes Demonstrating an Increase or Decrease in Best-corrected Visual Acuity (BCVA) of 15 or More Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 6 Months Compared to Baseline,"Number of Fellow Eyes Demonstrating a Decrease in the Area of Late Leakage, as Measured by Fluorescein Angiography (FA), at 24 Months Compared to Baseline",,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10959,NCT02616263,Change in metatarsal phalangeal joint angle (degrees) in people with diabetes from baseline and at a 3-year period,,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
10960,NCT04222738,Variation of mitral E' velocity,Variation of lipid profile.,,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10961,NCT00873639,Change in HbA1c,Number of adverse drug reactions (ADR),,2009-04,COMPLETED,OBSERVATIONAL,['NA']
10962,NCT03363360,HDL-C,blood pressure,,2016-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10963,NCT02065895,Glucose Area Under the Curve (AUC) Breakfast,Peak and Nadir Postprandial Glucose Concentration,Nighttime Time-in-target 5.0-8.33mmol/l (Controller Set-point Plus and Minus 15 mg/dL),2013-12,COMPLETED,INTERVENTIONAL,['NA']
10964,NCT03917576,Maximum heart rate,Heart rate post each HIIT-interval,,2018-01-04,COMPLETED,INTERVENTIONAL,['NA']
10965,NCT00672451,Albumin Concentration in Urine,Rate of Decline of GFR,,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2']
10966,NCT02111096,Change From Baseline to 6 Months in Hepatic Fat Fraction,Number of Participants With Hypoglycemic Events,,2014-04,TERMINATED,INTERVENTIONAL,['PHASE2']
10967,NCT01316068,Change from Baseline in urine albumin/creatinine ratio,Change from Baseline in urine albumin/creatinine ratio and serum creatinine,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
10968,NCT00029848,Change in body weight,Metabolic parameters,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10969,NCT03113110,OGTT-derived 2-hour blood glucose level,,,2017-01-15,COMPLETED,INTERVENTIONAL,['PHASE2']
10970,NCT05262257,Mini-Mental State Examination(MMSE),glycated hemoglobin(HbA1c、GHb),,2022-04-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
10971,NCT02648217,Change in HbA1c (%) (Glycosylated Haemoglobin),Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes,,2016-01-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10972,NCT00365170,Relative risk of major maternal hypoglycaemia,Other Adverse Events,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10973,NCT05612269,Reducing the risk of cancer among Diabetics with SGLT2 inhibitors,measurement of inflammatory factors like interleukin-6,,2022-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10974,NCT04709549,Ideal Cardiovascular Health,Binge Eating,,2021-02-10,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10975,NCT02808351,Contrast-induced nephropathy,Major adverse renal events,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10976,NCT00205660,Change in Whole Body Sensitivity (mg/kg/Min),,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10977,NCT03166423,Incidence rate of healing until 60 days or less,Incidence of treatment-emergent adverse events (Safety and Tolerability) of a formulation of snail slime and natural extracts in ulcer wounds in diabetics foot,,2015-11-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10978,NCT00391196,Percent change in body weight from baseline.,Change from baseline HbA1c to 1 year;,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3']
10979,NCT05875519,Glycemic level recorded before local anesthesia administration and 30 minutes following local anesthesia injection using glucometer,Healing score of the extraction socket,,2023-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10980,NCT04024306,Number of patients who developed Steroid-induced diabetes mellitus,Number of patients who didn't develop steroid-induced diabetes mellitus,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
10981,NCT01103245,Plasma Glucose,,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10982,NCT05619237,Quality Improvement,Patient satisfaction - overall satisfaction,,2022-12-06,COMPLETED,INTERVENTIONAL,['NA']
10983,NCT02048189,Mixed measurement of insulin secretion and insulin resistance,Decrease in the time spent in baseline and prandial hyperglycemia,,2012-03-08,TERMINATED,INTERVENTIONAL,['PHASE4']
10984,NCT01652716,Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28,Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10985,NCT01106131,Change from baseline in Glycosylated Hemoglobin (HbA1c),"Evaluate safety of CKD-501 from physical exam, vital sign, laboratory test, adverse events",,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10986,NCT00834496,The primary objective is that acute cellular rejection following a switch to sirolimus will be comparable to the historical rate at our center under calcineurin inhibitors of around 5% for post liver transplant recipients.,,,2009-01,WITHDRAWN,OBSERVATIONAL,['NA']
10987,NCT00542724,Change in HbA1c,,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10988,NCT02848053,Incidence of diabetes,Number of participants with abnormal blood glucose values (in mmol/L),,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
10989,NCT01628445,Change in A1c,Postprandial glucose reduction through measurement of 7 point glucose profile,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE3']
10990,NCT03481374,VO2 max,,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
10991,NCT00869908,Number of serious adverse drug reactions and major hypoglycaemic events reported as serious adverse drug reactions,Change in PPG (postprandial glucose),,2008-11,COMPLETED,OBSERVATIONAL,['NA']
10992,NCT04552002,Waist circumference,Microbiome sequencing,,2020-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
10993,NCT04919603,Change in liver steatosis quantified by MRI-PDFF (percentage),Cardiovascular risk,,2021-06-15,UNKNOWN,INTERVENTIONAL,['NA']
10994,NCT00525330,The primary objective of this trial is to demonstrate the hemoglobin A1c (HbA1c)-lowering effects of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone.,To assess the safety and tolerability of KRP-104;,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10995,NCT02294370,glucose levels in tissue fluid,capillary glucose,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
10996,NCT06273631,Change of time in range (TIR),Change in autoimmunity from baseline,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10997,NCT05865717,Physical activity which will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University,Prevalence of Chronic Diseases according to each profession and BMI,,2023-02-15,COMPLETED,OBSERVATIONAL,['NA']
10998,NCT01910805,Change in Diabetes Risk Awareness from baseline to 12 months postpartum,Change in physical activity levels from baseline to 12 months postpartum,Change in physical activity levels from baseline to 6 months postpartum,2014-08,COMPLETED,INTERVENTIONAL,['NA']
10999,NCT01477853,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16,,2011-10-24,TERMINATED,INTERVENTIONAL,['PHASE3']
11000,NCT04428658,Glycemic control,Patient-reported outcomes,,2022-09-15,RECRUITING,INTERVENTIONAL,['NA']
11001,NCT05506800,Incidence and mortality rate of cancer,Reproductive health,,2016-03-03,SUSPENDED,OBSERVATIONAL,['NA']
11002,NCT03803345,Maternal meal and snack distribution,Dietary data from food record app.,Birth head circumference,2019-03-28,COMPLETED,OBSERVATIONAL,['NA']
11003,NCT00834938,"Describe the endogenous response of incretins, orexins and anorexins to a mixed meal test in obese patients with DM2, in patients with DM2 undergoing RYGB with remission of DM2 and in patients without remission.",,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
11004,NCT00021788,,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11005,NCT01767012,Amount of aqueous flare measured with a Laser flare meter,Anterior capsule opacification (measured as brightness of anterior capsular reflect on slitlamp photographs),IOL tilt measured with a Purkinje-meter,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11006,NCT04343872,Change in Glycosylated Hemoglobin (HbA1c),,,2020-12-10,COMPLETED,INTERVENTIONAL,['NA']
11007,NCT01204593,Change in hemoglobin A1c (HbA1c) values (following the reference of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)),Symptomatic hypoglycemias,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11008,NCT01790438,Change From Baseline to 26 Weeks in Hemoglobin A1c (HbA1c),Change From Baseline to 26 Weeks in European Quality of Life (EQ-5D-3L) - Visual Analog Scales (VAS) Scores,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11009,NCT03658031,Incidence rate of T2DM,,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11010,NCT04026750,Change From Baseline in Peak Glucagon Response to Hypoglycemia,Number of Patients Returning to Blood Glucose =>70 mg/dL,,2019-09-15,TERMINATED,INTERVENTIONAL,['PHASE1']
11011,NCT02967354,[11C]5-hydroxy-tryptophan Uptake in the Pancreas,Hepatic Fat Content,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
11012,NCT06051565,Degree of vascular stenosis,Serum transferrin saturation,,2021-11-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11013,NCT03338855,Corrected Glucose Disposal Rate (cGDR) Measured as Change in Rate of Disposal (Delta RD) Basal vs High Insulin After 5 Weeks of Treatment,,Fibroblast Growth Factor 21 (FGF21) Area Under the Curve (AUC) in Plasma After 5 Weeks of Treatment,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11014,NCT00384215,To determine whether glycemic control as measured by HbA1c is different between insulin glargine [rDNA Origin] injection and pioglitazone when added to subjects who fail monotherapy with SU or metformin.,Compare cost of therapy for hyperglycemia treatment,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11015,NCT05007262,diabetic retinopathy(DR)progression rate,Efficacy of traditional Chinese medicine syndrome.,,2021-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11016,NCT05243628,Change in HbA1c,Change in Coefficient of variation (CV),Change in Percent Predicted Forced Expiratory Volume in 1 Second,2022-03-31,COMPLETED,INTERVENTIONAL,['PHASE4']
11017,NCT02329366,"To identify objective, quantitative biological and molecular markers that correlate with healing outcomes for diabetic foot ulcers (DFUs) using debrided tissue of patients with wounds",,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
11018,NCT04312802,Anaerobic threshold (AT) measurement correlation with cardiac perfusion,,,2018-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11019,NCT03751839,failure load in kN,measurement of serum periostin in ng/ml,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
11020,NCT05838755,"Change from baseline in the weekly average of average daily pain intensity at Week 12, assessed on the Numeric Rating Scale (NRS)","Number of participants with greater than or equal to ≥ 50 % reduction from baseline in the weekly average of average daily pain intensity at Week 12, assessed on the NRS",,2023-09-20,RECRUITING,INTERVENTIONAL,['PHASE2']
11021,NCT01816997,Glucose homeostasis,Chronic complications of diabetes,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11022,NCT04418869,Change in plasma glucose during exercise and recovery,Change in cardiac output.,,2014-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11023,NCT03861546,SMA program retention rate,Change in diet,,2019-03-03,COMPLETED,INTERVENTIONAL,['NA']
11024,NCT02759484,Blood Pressure Control,Intermediate Behavior: Medication Adherence,Intervention Costs,2015-03,COMPLETED,INTERVENTIONAL,['NA']
11025,NCT01349166,supervised physical training on cardiometabolic and inflammatory biomarkers,relationships between cortisol secretion and the postprandial inflammatory responses depending on the level of glucose tolerance,,2008-02,UNKNOWN,INTERVENTIONAL,['NA']
11026,NCT01703234,Flow Mediated Dilatation,FGF-23,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11027,NCT01281098,Regression of retinal neovascularization,Need for vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11028,NCT03914924,Disease-related knowledge,Cardiometabolic Health Parameter: cardiac autonomic control,Morbidity associated with diabetes,2020-01-20,RECRUITING,INTERVENTIONAL,['NA']
11029,NCT04525573,Fat Reduction,General Health Improvement,,2020-08-07,WITHDRAWN,OBSERVATIONAL,['NA']
11030,NCT00619034,Diameter of retinal blood vessels,Influence on retinal blood flow in diabetes,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
11031,NCT02045563,Determination of the existence of liver steatosis measured by magnetic resonance spectroscopy spectrometry,Measurement of monocyte expression of LDL receptors,,2007-10-15,COMPLETED,OBSERVATIONAL,['NA']
11032,NCT02554643,Attenuation of expression of proinflammatory genes verified by qPCR-array technique ranging from at least 5% in pre and post-intervention measurements,Enhance physical performance verified by oxygen consumption measurement on treadmill,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
11033,NCT01255163,Number of Participants With Incidence of Nausea,Body Mass Index (BMI),,2010-11-21,TERMINATED,INTERVENTIONAL,['PHASE2']
11034,NCT02083991,Cumulative incidence of New Onset of Diabetes After Transplantation(NODAT),Cumulative frequency of infections,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11035,NCT03954418,Amniotic fluid,,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
11036,NCT00754143,Safety and tolerability of FG-3019,Change from baseline in first morning urinary albumin creatinine ratio (ACR),,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11037,NCT01730014,Incidence of adverse events (AE),The maximal GIR (glucose infusion rate) observed,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11038,NCT05822648,Change over time in HbA1c,Change over time in self-reported caloric intake,,2023-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11039,NCT05293015,EFFICACY: TIR（Time in Range）,QUALITY OF LIFE:living quality,,2022-04-01,UNKNOWN,INTERVENTIONAL,['NA']
11040,NCT02181127,Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl,Episodes of Nausea Per Day on Glucagon vs Placebo,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11041,NCT04493814,Association between quantity of Visceral adipose Tissu and Liver Stiffness,Build an algorithm with Visceral adipose Tissue mesured and biological markers to predict fibrosis.,,2020-07,UNKNOWN,OBSERVATIONAL,['NA']
11042,NCT02294643,late lumen loss measured by quantitative coronary angiography,renal impairments as measured by increased microalbuminuria or decreased creatinine clearance,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11043,NCT05874141,Number of participants with Cancer,Correlate the presence of each co-morbidity with the extent of diabetes control,,2023-11-15,RECRUITING,INTERVENTIONAL,['NA']
11044,NCT00393510,Number of Participants With Limb Salvage,Time of Ulcer Healing,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11045,NCT01784965,Change in Weight Reported at 14 Weeks,Insulin Resistance in the Liraglutide vs.Placebo Group After Calorie Restriction,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11046,NCT00886665,Short-form (sf)- McGill pain questionnaire (SF-MPQ),Nerve conduction study,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
11047,NCT01030770,Number of patients requiring pars plana vitrectomy at week 7.,Grading of lens clarity using LOCS II (lens opacities classification system version II),,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11048,NCT05648903,Intervention primary outcome- Change in Hba1c (mmol/l),Intervention secondary outcomes- diabetes remission,Other study outcomes- engagement with the programme,2022-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11049,NCT00175734,To determine what hemoglobin level is best for diabetic dialysis patients. Specific parameters: endothelial cell function and related expansile capacity of blood vessels. *Assessed through labs and pulse wave velocity test,"Pulse rate, BP, respiratory rate, peripheral oxygen saturation, ECG during 6-min walk-test and Health Related Quality of Life Assessment as measured by questionnaires",,2005-08,UNKNOWN,INTERVENTIONAL,['NA']
11050,NCT02620072,Dysglycemia or diabetes,Progression to diabetes,Adverse events,2015-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11051,NCT03727854,Change in HbA1c From Baseline,Change in Homeostatic Model Assessment of β-cell Function (HOMA-beta) From Baseline,,2018-08-27,COMPLETED,INTERVENTIONAL,['NA']
11052,NCT05055804,"Standard OTC Glucose, A1C & Laboratory Results in Comparison to ELG Device During Non-Fasting Event",,,2021-08-11,UNKNOWN,INTERVENTIONAL,['NA']
11053,NCT03932630,Percentage of time in target glucose range (3.9 - 10.0 mmol/L),Percentage of time when pump was in Auto-mode,,2019-12,WITHDRAWN,INTERVENTIONAL,['NA']
11054,NCT01087645,Number and severity of adverse events (AEs) recorded,The uptake in blood of oral NN9925,,2010-03-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11055,NCT00641953,"Change from Baseline to endpoint (Day 29) in the average of neuropathic foot daily pain ""24 - Hour Average Pain"" scores",Change in weekly average sleep disturbance,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11056,NCT01929798,time spent in safe blood glucose range,glucose level extremes and need for outside intervention,,2013-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11057,NCT01910194,AUCISEC(0-10min),,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11058,NCT02036619,The glucose tolerance status 3 months postpartum in women with recent GDM.,The prevalence of women with a fasting plasma glucose ≥ 92-99mg/dl in early pregnancy to have a normal 75g OGTT between 26-28 weeks of pregnancy.,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
11059,NCT00187564,4. Trolox equivalent antioxidant capacity (TEAC) (measurement of total antioxidant status),2. Urine albumin/creatinine ratio,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
11060,NCT00601250,HbA1c Change From Baseline at Week 24,2 Hour Post-Prandial Glucose (PPG) Increment Over Fasting Plasma Glucose (FPG) at Week 24,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11061,NCT04473430,"Differences in mean percentage time-in-hypoglycemia (< 70 mg/dL) during the intervention phase, compared to control in both phases (i.e. intervention-control vs. control-intervention).",Number of hospitalization or emergency room visits for diabetes ketoacidosis,,2020-11-05,COMPLETED,INTERVENTIONAL,['NA']
11062,NCT00552175,Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg),Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score at Week 12,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11063,NCT00505947,improvement in best corrected visual acuity,anatomical improvement of diabetic macular edema and improvement in diabetic retinopathy,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE3']
11064,NCT01180283,Evidence that lodenafil carbonate improves erectile function in patients with diabetes type 2.,Adverse events in type 2 diabetes patients taking lodenafil carbonate and laboratory tests changes after this treatment.,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11065,NCT05259475,Change in liver fat content.,Change in the composition of gut microbiota from baseline due to the diet intervention.,,2021-08-20,COMPLETED,INTERVENTIONAL,['NA']
11066,NCT03331861,Change in Minute Ventilation to Carbon Dioxide Production (VE/VCO2) Slope,Heart Failure Hospitalizations,Fasting Sugar,2019-02-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11067,NCT00503464,,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
11068,NCT02620644,Retinal Ganglion Cell Complex in microns by Optical Coherence Tomography measurements,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
11069,NCT05359341,Proportion of cured patients in the sitagliptin group versus the proportion of cured patients in the empagliflozin group,The change in lipid profile in patients in sitagliptin group versus empagliflozin group,Percentage of adverse effects appeared in patients in sitagliptin group versus percentage of adverse effects appear in patients in the empagliflozin group.,2020-09-20,COMPLETED,INTERVENTIONAL,['NA']
11070,NCT00334399,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
11071,NCT03159559,myocardial perfusion reserve index (MPRI),,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11072,NCT05287906,Gastric inhibitory polypeptide,,,2022-04-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11073,NCT05510518,Number of obese women that will be diagnosed with late GDM diagnosis by the OGTT,neonatal hospitalization in intensive care rate,,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11074,NCT04279184,Psychometric validation of ICIQ-UI SF (questionnaire used to assess urinary incontinence),Objective characterization of urinary incontinence in women with and without diabetes,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
11075,NCT00954447,Change From Baseline in HbA1c After 24 Weeks,Change From Baseline in Incremental Post-prandial Glucose (iPPG) After 24 Weeks of Treatment,Number of Patients With HbA1c < 6.5 Percent,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11076,NCT02010827,Differences in Endogenous glucose production during the three days measured as total Area under the curve (tAUC),"differences in appetite, hunger, satiety between the three days",,2013-11,COMPLETED,OBSERVATIONAL,['NA']
11077,NCT02896140,Change in Hemoglobin A1C (A1C),Change in c-reactive protein level,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
11078,NCT03141073,Change from baseline in HbA1c,Incidence of Treatment-Emergent Adverse Events over time,,2017-10-15,COMPLETED,INTERVENTIONAL,['PHASE3']
11079,NCT05132660,Electroretinogram,HbA1c,,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1']
11080,NCT02053116,Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo,Change from baseline in very low density lipoprotein (VLDL),,2014-03,TERMINATED,INTERVENTIONAL,['PHASE2']
11081,NCT06030544,HbA1c,Presence of sediment in urine,,2022-02-25,RECRUITING,INTERVENTIONAL,['PHASE2']
11082,NCT00167934,Effects of Medication on Insulin Secretion at Skeletal Muscle (Glucose Disposal),,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
11083,NCT01218256,Muscle strength,Glycemic control,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11084,NCT04821921,Hemoglobin A1c (HbA1c),,,2021-04-09,COMPLETED,OBSERVATIONAL,['NA']
11085,NCT01260376,Effects of exercise and antilipolysis on FFA and VLDL-TG kinetics,,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
11086,NCT03047668,change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter,change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN),,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
11087,NCT00752440,Inspiratory muscle strength,Variability of heart rate,,2006-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
11088,NCT04807348,percentage of HbA1c change from baseline,number of participants with lab abnormality,,2021-05-17,UNKNOWN,INTERVENTIONAL,['PHASE3']
11089,NCT01060540,Weight,Moderate Intensity Physical Activity,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
11090,NCT00590434,"proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group",Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs),,2006-08,COMPLETED,OBSERVATIONAL,['NA']
11091,NCT00618995,Urinary 11-Dehydrothromboxane B2 (11-dTxB2),Prostaglandin I Metabolite (PGI-M),,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11092,NCT02608905,Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%),Arterial Flow Mediated Dilatation (%),,2015-11,TERMINATED,INTERVENTIONAL,['PHASE4']
11093,NCT02538705,Area of diabetic foot ulcers,Transcutaneous oxygen pressure,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
11094,NCT04409795,Glycated hemoglobin (HbA1c),Area under the plasma concentration versus time curve (AUC) of C-peptide,,2021-08-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11095,NCT03675360,Change in Hemoglobin A1c,Change in Body Weight,Change in Estimated Atherosclerotic Cardiovascular Disease Risk,2018-09-25,COMPLETED,INTERVENTIONAL,['NA']
11096,NCT00317707,cardiovascular deaths and hospitalization for cardiovascular causes,,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11097,NCT00939289,CGM System(s) performance (relative to YSI and/or SMBG) evaluated by standard accuracy metrics,"Documentation of all reported Adverse Device Effects, Serious Adverse Device Events, and Unanticipated Adverse Device Effects",,2008-07,COMPLETED,OBSERVATIONAL,['NA']
11098,NCT04937348,"Anthropometrics: body weight [kg], length [cm], head circumference [cm].",Impact of maternal adipokines on breast milk composition.,,2019-12-13,COMPLETED,OBSERVATIONAL,['NA']
11099,NCT03315598,Change from baseline Numeric rating scale pain score (0-10) at 8 weeks,5-pointed patient satisfaction scale,,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
11100,NCT00638209,Insulin effect on cortical function (spectral analysis),,,2008-02,UNKNOWN,INTERVENTIONAL,['NA']
11101,NCT02389127,Level of HbA1c in T2DM and cirrhosis,,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
11102,NCT03407508,HbA1c,Gingivitis,,2018-10-17,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11103,NCT02077452,"Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.","Insulin, C-peptide, glucagon and glucagon-like peptide 1 up to 6hr post-dose following single dose and steady state (fasting and postprandial)",,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11104,NCT03279263,Changes in HbA1c between active treatment groups and placebo at Week 12,Changes in Body Weight,,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11105,NCT00315016,blood pressure by home measurements,plasma angiotensins and bradykinins,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11106,NCT01738802,Change in the markers of oxidative stress and inflammation,Hemoglobin A1c,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
11107,NCT01500928,Device-related adverse outcome,Product quality (MTBF),,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
11108,NCT05232305,Anthropometric Measurements - Hip Circumference,Anthropometric Measurements - Hip Circumference,,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA']
11109,NCT04642911,Overall survival of subject with diabetes 2 type with gene therapy drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study,,,2020-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11110,NCT00219102,Change from baseline in diastolic blood pressure after 12 weeks,Achieve mean sitting blood pressure control target of < 130/80 mmHg after 12 weeks,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11111,NCT02317003,Change in total energy expenditure by accelerometry at 3 months compared to baseline,Adherence of doctors and patients to the suggested strategy,,2015-03-16,COMPLETED,INTERVENTIONAL,['NA']
11112,NCT02209662,Complete wound closure within 12 weeks,Improvement in wound healing for the patient to return to function over the 12 weeks,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
11113,NCT03076112,Glycated hemoglobin,25-hydroxyvitamin D,,2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE3']
11114,NCT06127433,Intergroup remission rate at 24 week,,,2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE4']
11115,NCT01323348,Change in HbA1c,Body Mass Index,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11116,NCT04275804,Ulcer size,Foot function,,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11117,NCT00950716,Lipid levels,"Cognitive-psychological-behavioral assessments: a) Depression Anxiety and Stress Scale (DASS21). b) Diabetes Empowerment Scale (C-DES). c) Summary of Diabetes Self Care Activities (SDSCA, Chinese version).",,2009-09,COMPLETED,INTERVENTIONAL,['NA']
11118,NCT04905823,Adverse events,Values of continuous glucose monitoring,,2021-03-31,COMPLETED,OBSERVATIONAL,['NA']
11119,NCT02783612,Assessing the compliance of the research group compared to the control group.,,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
11120,NCT01176578,Skeletal muscle capillarization,Cardiorespiratory Fitness,,2011-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11121,NCT02224417,HbA1c levels,Glucose testing within range,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
11122,NCT01773473,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,"Change From Baseline in 1,5-Anhydroglucitol (1,5-AG) at Week 26",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11123,NCT03428932,Changes in Gray Matter Volume in the Brain,Changes in WASI-II Perceptual Reasoning Index (PRI),,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
11124,NCT05000021,Diabetes Distress Levels,Coefficient of Variation (CV) calculated from Continuous Glucose Monitoring (CGM),Hemoglobin A1c,2022-06-27,RECRUITING,INTERVENTIONAL,['NA']
11125,NCT01286090,The change from baseline in Gastroparesis Cardinal Symptoms Index (GCSI) score,The type of adverse events reported,,2003-07,TERMINATED,INTERVENTIONAL,['PHASE4']
11126,NCT04979377,Prevalence of hyperandrogenic PCOS in T1DM,Influence of hyperandrogenism on chronic complications,,2020-03-09,RECRUITING,OBSERVATIONAL,['NA']
11127,NCT01145547,Mean Area Under the Curve for Rise in Breakfast Post-prandial.,,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
11128,NCT01536431,Safety,T cell (immune) response to islet cell antigens,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11129,NCT00318461,Change in Glycosylated A1c (HbA1c) at Week 104,Hypoglycaemic Episodes at Week 104,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11130,NCT01599338,"Change in appetite, desire to eat, pleasure in eating","Change in plasma ghrelin, leptin, and HbA1c levels",,2011-01,COMPLETED,INTERVENTIONAL,['NA']
11131,NCT05729282,Continuous glucose monitoring (CGM) profile,Fasting serum/plasma apolipoprotein B (ApoB) (relative/change),Deuterium tracer enrichment in body water (measured in saliva),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
11132,NCT00545337,Change of HbA1c,"Blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and basal insulins",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11133,NCT00933972,Creatinine clearance; Pk parameters; adverse events,Blood glucose; meal tolerance test,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11134,NCT02004678,time to reach maximum plasma concentration (Tmax),number of patients experiencing laboratory adverse events,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11135,NCT00333151,HbA1c,Glycaemic control,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11136,NCT00095030,Change in baseline HbA1c after 52 weeks,Change in lipids after 52 weeks; safety and efficacy when administered with metformin after 52 weeks,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11137,NCT01526733,Early Insulin Exposure (%AUC[0-60]),Duration of Insulin Action (AUMC[0-360]/AUC[0-360]),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11138,NCT01714674,Cardiac troponin T,Blood pressure,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
11139,NCT02194790,The difference of rate of estimated glomerular filtration(eGFR) decline,Change from baseline in Hemoglobin A1C,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
11140,NCT00870194,Change in HbA1c (Percent),Incidence of Confirmed Hypoglycemia(Overall),,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11141,NCT00108615,Effects of pioglitazone and metformin on ectopic lipid accumulation,Effects of pioglitazone and metformin on beta cell responsiveness,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11142,NCT04572802,Gensini score,,,2020-10-10,COMPLETED,OBSERVATIONAL,['NA']
11143,NCT02207374,Number of Treatment Emergent Adverse Events (TEAEs),Change in Glycosylated Haemoglobin A1c (HbA1c),,2014-08-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11144,NCT02739971,"Change from baseline in AGEs markers in serum (carboxymethyl lysine, CML and Methylglyoxal ,MG ) at 6 months",retention rate to the diet,Change in microbial diversity and composition of fecal microbiome following AGE reduction in diet,2016-06,COMPLETED,INTERVENTIONAL,['NA']
11145,NCT05098600,Measurement of Vitamin D levels,Identification and prevalence of possible exacerbating factors in patients with Alopecia Areata,,2021-10-15,COMPLETED,OBSERVATIONAL,['NA']
11146,NCT01648582,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,Change From Baseline in EQ-5D Visual Analog Scale Score,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11147,NCT00334581,The difference of urinary albumin excretion rate change,Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11148,NCT02597257,11-point Numeric Rating Scale,11-point Numeric Rating Scale,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
11149,NCT00012623,,,,na,COMPLETED,OBSERVATIONAL,['NA']
11150,NCT02385890,Subjective Appetite,Energy/fatigue measured by VAS questionnaire,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
11151,NCT03775057,Percentage of patients reaching fasting SMPG target without a severe hypoglycemic episode during the 16-week on-treatment period,Assessment of emotional well-being using WHO-5 well-being index,,2018-08-22,UNKNOWN,INTERVENTIONAL,['NA']
11152,NCT04823442,BAT glucose uptake,Changes in pancreatic and gut hormones,,2021-01-21,COMPLETED,INTERVENTIONAL,['NA']
11153,NCT05642143,"Evaluation of differences in bone turnover markers between T2D patients with and without previous fractures by biochemical analysis of different bone markers (CTX, P1NP, osteocalcin (OC), ucOC, sclerostin, osteoglycin and osteopontin).",Compare muscle mass and strength in T2D patients with and without neuropathy,The correlation between levels of Advanced Glycation End Products (AGEs) (assessed by skin autofluorescence) and bone material strength (assessed by microindentation).,2023-02-24,RECRUITING,OBSERVATIONAL,['NA']
11154,NCT03288233,Average end expiratory alveolar concentration of CO (ppm) 5 hours after lunch,,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
11155,NCT02631083,Substrate oxidation,,,2014-11-14,COMPLETED,INTERVENTIONAL,['NA']
11156,NCT05212519,Whether suffering from gestational diabetes,,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
11157,NCT03745937,Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs Through the End of the Follow-up Period,Percentage of Participants Achieving Greater Than 5% Body Weight Loss From Baseline to the End of the Treatment Extension Period,,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11158,NCT01697228,Hemoglobin A1c,Baseline differences between vitamin D deficient & sufficient subjects,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11159,NCT01076088,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2010-11-15,COMPLETED,INTERVENTIONAL,['PHASE3']
11160,NCT02544321,Hyperemia Peripheral Arterial Tonometry (RH-PAT): Reactive Hyperemia Index (RHI),Metabolic Markers - Insulin,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11161,NCT04510493,unmatched win ratio after treatment with canakinumab compared to Placebo (composite endpoint),Number of antidiabetic treatment at three months,,2020-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
11162,NCT01663298,FGF2 methylation level,Wound healing indices (WHI),,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11163,NCT02989831,Difference in center of pressure displacement (balance) between the two conditions.,Difference in anteroposterior velocity of the centre of pressure displacements between the two conditions (insoles 'on' or 'off'),,2014-04,COMPLETED,INTERVENTIONAL,['NA']
11164,NCT00862251,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).,Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11165,NCT03478969,"Treatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score","Amount of Waste, Inferred by Total Material Consumption",,2018-05-17,COMPLETED,INTERVENTIONAL,['NA']
11166,NCT04018365,HbA1c change at Week 24 of the treatment from baseline,Postprandial glucose for 2 hours over time,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11167,NCT06141980,Efficacy outcome_Proportion of subjects achieving HbA1c target of < 7.0 %,,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11168,NCT04965506,The change in HbA1c from baseline to 20 weeks,Number of participants with treatment-related adverse events,,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11169,NCT03855514,Length of time that a wound achieves complete wound closure (CWC),Time to complete wound closure (CWC) by or on 24 weeks,,2019-02-08,UNKNOWN,INTERVENTIONAL,['NA']
11170,NCT01447147,Subject incidence of adverse events,Change from baseline in first morning urinary albumin:creatinine ratio (ACR),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11171,NCT02966626,Change in HbA1c,Change in body mass index,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
11172,NCT00236626,Mean change in insulin sensitivity from baseline to Month 9.,"Mean change, baseline to Month 9, in body weight and composition, Body Mass Index (BMI), lipid profile, fasting glucose; blood pressure; safety evaluations (adverse events) during study.",,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11173,NCT01740921,change of baseline skin maximum hyperaemia at 4 months,change of baseline capillary density at 4 months,change of baseline adipose tissue inflammation at 4 months,2011-01,COMPLETED,INTERVENTIONAL,['NA']
11174,NCT01128829,The Effect of Sucralose on Insulin Concentration (Area Under the Curve; AUC),,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
11175,NCT01542463,Fasting plasma glucose (FBG),Hypoglycaemic episodes,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
11176,NCT00224796,To determine the effect of V.A.C. ® Therapy on the incidence of complete wound closure.,To determine the effect of V.A.C. ® Therapy on the quality of life,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11177,NCT02937987,Change of Weight,,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
11178,NCT02740829,Endogenous glucose production following intranasal glucagon compared to placebo,,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11179,NCT00543738,,,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE3']
11180,NCT01736228,to establish the efficacy and safety of DIABECELL,Improvement in the quality-of-life of xenotransplant recipients,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11181,NCT03304938,Pittsburgh Insomnia Rating Scale,Diastolic Blood Pressure,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
11182,NCT04200586,Change in myocardial perfusion reserve index,,,2020-04-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11183,NCT01434186,Mean Change in HbA1c From Baseline to Week 16,,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11184,NCT03741972,Change in cardiac biomarkers,Improve in the 6-minute walk,,2018-12-21,COMPLETED,OBSERVATIONAL,['NA']
11185,NCT05189938,Establish a relationship between laboratory-derived HbA1c and average glucose levels,,,2021-12-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11186,NCT00005262,,,,1990-07,COMPLETED,OBSERVATIONAL,['NA']
11187,NCT03631121,Change of glycemic variation,,,2018-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
11188,NCT04208282,Primary,Exploratory outcomes,Adverse Events,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
11189,NCT02769585,Change in weight (BMI),Degree of weight loss in obese versus overweight,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
11190,NCT03132181,Mode of action,Metabolism,,2017-04-24,COMPLETED,INTERVENTIONAL,['PHASE2']
11191,NCT03230786,Change from baseline in blood HbA1c at 12 weeks versus placebo.,Proportion of subjects reaching a level of HbA1c below 7.0% (53 mmol/mol) at 12 weeks versus placebo,,2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE2']
11192,NCT01874366,Food Effect,Time to peak plasma concentration (t-max),,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
11193,NCT04191525,HOMA-IR,Waist perimeter,Mediterranean diet adherence score,2018-09-10,COMPLETED,INTERVENTIONAL,['NA']
11194,NCT05980455,Scoring Change in Nausea Severity by GCSI-DD,Mean Change from Baseline in Quality of Sleep Scores,,2023-07-10,RECRUITING,INTERVENTIONAL,['NA']
11195,NCT05506215,Percentage of ulcer closed at 12 weeks,The type and number of serious adverse events experienced,,2022-07-10,TERMINATED,INTERVENTIONAL,['NA']
11196,NCT01735253,Hemoglobin A1C,oral glucose tolerance test,insulin level,2009-12,COMPLETED,INTERVENTIONAL,['NA']
11197,NCT02189135,Number of patients with hypoglycaemia in usual care versus telemedicine during Ramadan,Glycaemic control of patients measured with HbA1c in patients under usual care versus telemedicine from baseline to end of treatment,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11198,NCT02308059,Pain scores on the visual analog scale,Neuropathic pain scores on the Leeds Assessment of Neuropathic Symptoms and Signs pain scale,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
11199,NCT03443635,High or Medium (Versus Low) Mediterranean Diet Adherence,Food Costs,,2018-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11200,NCT00607230,concentration of autoreactive t-cells,"Concentration of TNF, TNF-receptors, other cytokines, and c-peptide levels",,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11201,NCT04465877,"Change From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo on Days 1, 14 and 28",,,2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1']
11202,NCT01317576,Blood sampling to determine the concentration of cardiovascular risk factors in the blood before and after exercise,"Muscle biopsy to measure muscle mitochondrial density, muscle mitochondrial function and muscle lipid metabolism",,2011-03,COMPLETED,INTERVENTIONAL,['NA']
11203,NCT02092220,Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 11,Number of Participants With Skin Rash,CGM Mean Absolute Relative Differences (MARD) Versus Time-stamped Blood Glucose (BG) Values From Meter Downloads,2014-04,COMPLETED,INTERVENTIONAL,['NA']
11204,NCT04074317,Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL,Insulin Area Under the Concentration (AUC) Curve,,2019-08-22,COMPLETED,INTERVENTIONAL,['PHASE2']
11205,NCT03031834,Changes in blood pressure response to standing,,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11206,NCT02259088,Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12,Mean Number of Ranibizumab Re-treatments Received in the Study Eye From Month 3 Onward,,2014-11-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11207,NCT05747872,Change in ulcer surface area,,,2022-03-10,COMPLETED,INTERVENTIONAL,['NA']
11208,NCT02011633,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin AUCinf",,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11209,NCT03591458,Ratio of Self-Reported Hypoglycemic Episodes to Total Hypoglycemic Episodes,Hypoglycemia Fear Survey Score,,2018-08-01,TERMINATED,INTERVENTIONAL,['PHASE2']
11210,NCT05921097,Comparison of axon-reflex flare responses with QST,Comparison of axon-reflex flare responses with NC-Stat DPNCheck,DPN severity and pain,2023-06-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11211,NCT01507272,AUC (area under the curve),"t½, terminal half-life",,1999-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11212,NCT05606471,Muscle protein breakdown rate,Right vastus lateralis muscle fibre pennation angle,,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE4']
11213,NCT03417076,absolute bioavailability (Fp.o.) of bexagliflozin tablets,adverse events,,2018-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11214,NCT00929838,Hemoglobin A1c (HbA1c) at 12 Months Post Randomization,,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
11215,NCT04088851,"The gluconeogenic flux rates from pyruvate (lactate, alanine) and glycerol are higher in patients with T2D compared to the healthy control group.",,,2019-09-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11216,NCT00225277,Nominal Change From Baseline in Percent Atheroma Volume,Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events,Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11217,NCT02258945,Eating behaviours of adult patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy measured using food diaries and food surveys.,Cardiometabolic risks of adult patients with Type 1 diabetes who are using insulin pump therapy.,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
11218,NCT00403884,Visual acuity,reduction of retinal edema,,2004-10,UNKNOWN,INTERVENTIONAL,['NA']
11219,NCT02759289,Change in platelet activity in response to arsenic exposure measured by Regression models,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
11220,NCT03622424,weight loss of >5.0% in at least 35% of prediabetic subjects or in at least 25% of diabetic subjects on Gelesis200.,"improvement in FPG status, post-OGTT plasma glucose status, or post-OGTT plasma glucose AUC in ≥50% of subjects on Gelesis200.",Number of TEAE for Gelesis200 similar to placebo or clinically acceptable.,2017-08-22,COMPLETED,INTERVENTIONAL,['NA']
11221,NCT00434499,Improvement in insulin resistance,Improvement in endothelial dysfunction,,2007-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11222,NCT01829477,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3']
11223,NCT05838586,iAUC of SBP,Net iAUC of HR,,2023-07-31,RECRUITING,INTERVENTIONAL,['NA']
11224,NCT01774058,"The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration.",,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
11225,NCT01855490,Effect of exenatide on metabolic responses to an oral (as a mixed meal) or intravenous glucose challenge in subjects with established T1D with or without residual insulin production.,"Effect of exenatide on insulin secretion, glucagon secretion, GLP-1 and GIP levels, and gastric emptying in these patients with T1D. - effect of exenatide on residual insulin production",,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11226,NCT02632747,Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.,"Filtration Status (Glomerular Filtration Rate (GFR) < 120 mL/Min/1.73m², Yes/no) After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril",,2016-05-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11227,NCT01492153,Change in body weight,Adverse events (AEs) including hypoglycaemic episodes,,2003-02-11,COMPLETED,OBSERVATIONAL,['NA']
11228,NCT04175496,Postprandial insulin response,,,2019-12-01,COMPLETED,INTERVENTIONAL,['NA']
11229,NCT01108978,Evaluation absolute and percentage reductions in low-density lipoprotein cholesterol (LDL-C) by fasting biochemistry examination,"Evaluation of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides by fasting biochemistry examination",,2010-05,TERMINATED,INTERVENTIONAL,['PHASE4']
11230,NCT02008851,Number of adverse events related to study procedures or investigational product,Number of renal-specific adverse events,Changes in renal function over time,2013-12,TERMINATED,INTERVENTIONAL,['PHASE1']
11231,NCT01746563,Macular Evaluation,Structural Macular Evaluation,,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11232,NCT01087073,"Lipids (HDL, LDL, total cholesterol, triglycerides)",Processes of care,,2009-01-01,COMPLETED,INTERVENTIONAL,['NA']
11233,NCT02452086,"The blood serum level of VEGF(pg/ml), VEGFR-2(pg/ml), HIF-1α(pg/ml) and NO (pg/ml)",Ankle Brachial Index(ABI),,2013-06,COMPLETED,INTERVENTIONAL,['NA']
11234,NCT00839527,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Change From Baseline in Body Weight at Week 104 and Week 156,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11235,NCT02246712,"Kinetic parameters (AUC, Cmax, Tmax, apparent total clearance, and apparent volume of distribution) of tramadol enantiomers were estimated.",Pain scores on the visual analog scale,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11236,NCT02490124,Contrast Enhanced Ultrasound,,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
11237,NCT03776448,Fasting venous blood glucose,Gastrointestinal symptoms,,2019-01,UNKNOWN,INTERVENTIONAL,['NA']
11238,NCT03785379,Change from baseline Glycated Hemoglobin (HbA1c) at 6 months,Change from baseline Glycated Hemoglobin (HbA1c) at 12 months,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
11239,NCT02799953,changes in systolic and diastolic blood pressure,changes in answering hypertension knowledge questions,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
11240,NCT01691287,Metabolic Control measured as HbA1c level,Number of Diabetic Keto Acidosis events,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11241,NCT04142424,Number of subjects experiencing adverse events and serious adverse events,Fraction of dose excreted unchanged into the urine from time t1 to t2 [fe(t1-t2)],,2019-10-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11242,NCT05701254,"Compare cortical bone tissue levels of pentosidine (AGE), pyridinoline (normal enzymatic collagen crosslinks), and matrix-bound water between T1DM and controls.",Compare cortical bone tissue heterogeneity in nanoindentation measures of modulus and hardness between T1DM and controls.,,2019-06-18,RECRUITING,OBSERVATIONAL,['NA']
11243,NCT04379427,Performance and accuracy of heart rate,,,2019-03-25,COMPLETED,INTERVENTIONAL,['NA']
11244,NCT00368693,Complete ulcer closure will be defined as complete re-epithelialization without the presence of any callus and/or exudate.,,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE3']
11245,NCT04317430,Estimated glomerular filtration rate (eGFR),Change of Urinary podocalyxin level,Change of Urinary 8-hydroxy-2' -deoxyguanosine (8-OHdG) level,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11246,NCT05993741,Plaque Control Record (PCR),Oral Health Related Quality of Life(OHRQoL),,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
11247,NCT04029298,Change in hemoglobin A1c,Adherence to treatment,,2023-03-01,WITHDRAWN,INTERVENTIONAL,['NA']
11248,NCT04190511,Weight change during pregnancy,,,2019-12-10,COMPLETED,INTERVENTIONAL,['NA']
11249,NCT05949008,Change in total body weight from baseline,Percent change in % body fat from baseline,,2023-11-22,RECRUITING,INTERVENTIONAL,['PHASE4']
11250,NCT00018122,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
11251,NCT05195502,Evaluation of metabolic profile,Colonic biofilm,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11252,NCT03270592,"Health related quality of life, EQ-5D",EQ-VAS,,2009-09-17,COMPLETED,INTERVENTIONAL,['NA']
11253,NCT00212329,,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
11254,NCT04213547,Qualitative data from focus group,BMI,,2020-09-16,RECRUITING,INTERVENTIONAL,['NA']
11255,NCT05925010,postprandial blood glucose,difference between fasting blood glucose value and postprandial blood glucose value,,2023-01-02,RECRUITING,INTERVENTIONAL,['NA']
11256,NCT06021119,peak postprandial plasma glucose (PPG) level in mg/dl,Time in range %,,2023-03-23,COMPLETED,INTERVENTIONAL,['PHASE3']
11257,NCT05603273,wound size and depth,blood flow,,2023-12-13,RECRUITING,INTERVENTIONAL,['NA']
11258,NCT05370014,Change in patient-reported outcomes measurement information system (PROMIS) Global Health Scale,Change in Modified Medical Outcomes Study Social Support Survey Instrument (mMOS-SS),,2023-01-03,RECRUITING,INTERVENTIONAL,['NA']
11259,NCT01091909,postoperative complications,Delayed wound healing,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
11260,NCT05314036,Establishment of proposed Wellness Transformation Network clinical trial procedures.,Time course and curve analysis of Meal Induced Glycemia (MIG) scores response after the test meal administration.,,2022-01-17,COMPLETED,INTERVENTIONAL,['NA']
11261,NCT00412347,,,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
11262,NCT01143168,Rate of reducing exogenous insulin requirement; Hemoglobin A1c; Fast blood glucose (FBG) and postmeal blood glucose (PBG); C-peptide levels.,Serious adverse event frequency and severity,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
11263,NCT04098575,Percentage of Participants With Antidiabetic and Cardiovascular Co-medication,Fasting Plasma Glucose (FPG),,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
11264,NCT05505565,Progression of prediabetes,Glycemic metrics,,2023-06-05,RECRUITING,INTERVENTIONAL,['NA']
11265,NCT01027585,,,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
11266,NCT01698528,Glycemic Control as Determined by the Change in Absolute HbA1c Level,Time Health Care Providers and Subjects Spend on Managing the Insulin Titration,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11267,NCT01130012,Number of at risk participants developing GDM during pregnancy,The effect of intervention on fetal growth,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
11268,NCT04085705,Presence of contact allergy for wound dressings,Presence of eczema,Past ulcers,2019-09-17,UNKNOWN,OBSERVATIONAL,['NA']
11269,NCT00650806,Percent Change in Body Weight From Baseline to Week 12,Change in Waist/Hip Ratio From Baseline to Week 12,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11270,NCT00538642,Insulin Sensitivity,LDL Cholesterol,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
11271,NCT04420650,Change in subjective feeling of hunger and food craving,Diffusion-weighted imaging,,2020-05-26,COMPLETED,INTERVENTIONAL,['NA']
11272,NCT01814787,Number of Children With Documented Risk Factors for Type 2 Diabetes,,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
11273,NCT05028140,Glycated hemoglobin,Adverse events,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11274,NCT04093284,Blood glucose profile,Sensitivity Questionnaire of Patients,,2019-09-12,UNKNOWN,INTERVENTIONAL,['NA']
11275,NCT03053518,Observed Incremental Area Under the Curve (iAUCobs),,,2017-06-30,TERMINATED,INTERVENTIONAL,['NA']
11276,NCT03445247,changes of proteinuria,changes of systolic and diastolic blood pressure,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
11277,NCT01830348,The proportion of subjects with a target ulcer which achieves complete wound closure (skin re-epithelialization without drainage or dressing requirements) up to 10 weeks (confirmed at a study visit 2 weeks later).,Time to the visit where the target ulcer achieves confirmed complete wound closure,"Incidence of target ulcer recurrence, time to ulcer recurrence, and number of days target ulcer remains closed after confirmed complete wound closure has been established.",2013-02,TERMINATED,INTERVENTIONAL,['PHASE3']
11278,NCT05099939,Change in lung function,CFRD diagnosis,,2021-11-25,RECRUITING,OBSERVATIONAL,['NA']
11279,NCT00644241,"Increment in glucagon stimulated C - peptide levels at the end of 6 months of ABMSCT, as compared to baseline",Improvement of HbA1c levels as compared to baseline,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11280,NCT01313949,To assess the effectiveness of the training program in improving glycemic parameters in diabetic patients before and after the training.,"To assess the efficacy of the training in improving the participants' knowledge of diabetes, as compared to the control patients.",,2009-02,COMPLETED,INTERVENTIONAL,['NA']
11281,NCT00131755,Glycemic control (measured by blood glucose),Side effects,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
11282,NCT03286816,the effect of exogenous lactate on brain lactate concentrations during euglycemia and hypoglycemia between T1DM patients with normal awareness of hypoglycemia and T1DM patients with impaired awareness of hypoglycemia,Changes in immune cell cytokine production capacity in response to hypoglycemia compared to euglycemia and in response to lactate infusion compared to placebo,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
11283,NCT02734745,accuracy of freestyle Libre flash monitoring,Evaluate the accuracy of the Free Style Libre for each day of use and during hyperglicemia ( >180 mg / dl ),,2016-04-01,UNKNOWN,INTERVENTIONAL,['NA']
11284,NCT01664637,Change from baseline in symptoms associated with diabetic gastroparesis,"Adverse events (AEs), vital signs, ECGs, clinical laboratory parameters",,2012-08,TERMINATED,INTERVENTIONAL,['PHASE2']
11285,NCT02345967,Number of Adverse Events,,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11286,NCT00466518,Changes in pharmacokinetics,Determine tolerability of sitagliptin therapy in post-kidney transplant patients.,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
11287,NCT00263861,Glycemic control as measured by Glycosylated Hemoglobin Assay,,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
11288,NCT01634282,Incidence and severity of adverse events,,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11289,NCT02883842,Change in glucose level measured by HbA1C level,Change in low-density lipoprotein cholesterol (LDL-C) level,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
11290,NCT04670666,Change from baseline in glycated hemoglobin (HbA1c) levels.,Incidence and severity of adverse events recorded during the study.,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11291,NCT01608932,Number of emergency hospitalisations,"Anxiety and depression status as measured by Hospital Anxiety and Depression Scale, HADS.",,2012-04,COMPLETED,INTERVENTIONAL,['NA']
11292,NCT06283264,1-Prevalence of coeliac disease among diabetic type 2 patient 2-its effect on glycemic control,,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11293,NCT00117780,Mean HbA1c,Hypoglycaemia,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11294,NCT00368394,"Outcome:In T1DM, glulisine, like RHI, displays dose proportionality in exposure over the dose range 0.075 to 0.3 U/kg, which partly only translates into dose proportionality in glucodynamics.",,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11295,NCT04112875,Changes in Endothelium-dependent and endothelium-independent vasodilation,Body composition by DXA,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
11296,NCT01106651,Change in HbA1c From Baseline to Week 26,Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11297,NCT01414920,Change from Baseline in Glycosylated Hemoglobin (HbA1c),Change from Baseline in Fasting Plasma Glucose,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11298,NCT00130312,Safety and tolerance of sulodexide therapy long-term,Change in urinary protein/albumin excretion,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE4']
11299,NCT01250106,Insulin resistance,body weight,,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11300,NCT02845024,Periodontal pocket depth,glycated hemoglobin (HbA1c),,2014-09,COMPLETED,INTERVENTIONAL,['NA']
11301,NCT04523454,Questionnaire - Number of women who have had the importance of a planned pregnancy explained to them,,,2020-10-02,COMPLETED,OBSERVATIONAL,['NA']
11302,NCT02928952,Problem Areas in Diabetes Scale (PAID) -(Measures Diabetes Distress),Summary of Diabetes Self-Care Activities (SDSCA)- - Medication Adherence,Insomnia Severity Index (ISI),2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
11303,NCT03909841,Cognition,Quality of Life: The Chinese (Hong Kong) 12-item Short-Form Health Survey version 2,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
11304,NCT05692778,Experiences of using an eHealth tool supporting the foot assessment,Long term effect,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
11305,NCT06125119,Diabetyping,Diabetyping,Self-reported experiences with capillary blood sampling in an at home setting,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11306,NCT04856683,Prediction of frailty,Inappropriate therapeutic regimen,,2020-08-10,RECRUITING,OBSERVATIONAL,['NA']
11307,NCT00221715,"Bypass permeability 5 years after surgery, assessed trough Doppler ultrasonography",leg salvage,,2002-07,COMPLETED,INTERVENTIONAL,['NA']
11308,NCT02019446,Side effects from laser treatment,Quality of Life,,2018-07,UNKNOWN,INTERVENTIONAL,['NA']
11309,NCT05577390,The Impact of INF® Therapy and Standard Physical Therapy on Heart Rate Variability,The impact of INF® Therapy and Standard Physical Therapy on inflammation,,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
11310,NCT04416269,Mean daily BG concentration,Patient antihyperglycemic drug preference survey,,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE4']
11311,NCT01049152,-Hemodialysis tolerability -Hypoglycemia numbers -Hyperglycemia numbers -Inflammation markers,variations of glycemia during the night; insulin-sensitivity,,2009-07-31,COMPLETED,OBSERVATIONAL,['NA']
11312,NCT04614168,The change in plasma glucagon levels (pmol/L) measured during normoglycaemic and hypoglycaemia,Four Choice Reaction Time Test,,2021-07-26,UNKNOWN,INTERVENTIONAL,['NA']
11313,NCT02153879,HDL particles size and number assessed by nuclear magnetic resonance (NMR) and reported as nm and micromol/L,"Apolipoprotein A1 (Apo A1), apolipoprotein A2 (Apo A2), paraoxonase (PON) HDL concentration (g/l - mg/l)",Lecithin-cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activity (AU - pmol/h*μl) and mass (microg/ml),2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
11314,NCT00626080,"Cerebral blood flow, in brain regions associated with appetite control, as determined by H2O-PET",Weight change,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
11315,NCT00719108,The area under the GIR-time curve at steady state from 240 to 300 minutes (AUCGIR-SS),"PD Endpoints: Area under the GIR-time curve from 0 to 7 hours, GlR at steady state. PK Endpoints: AUCINS-SS, AUCINS0-7h, CLtot, VSS, t1/2 ,Terminal rate constant Safety Endpoints: AE, Lab assessments, Vital signs, Phy Exam, ECG & Hypoglycemia.",,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11316,NCT02370680,change in platelet aggregation,Safety as measured by the number and system class of adverse events reported in each treatment arm,urinary metabolites of prostacyclin and thromboxane,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11317,NCT05738655,Hormone analysis,,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
11318,NCT02077348,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.",Ghrelin,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
11319,NCT02678390,Plasma Ketone Concentrations,Plasma Insulin Concentrations,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
11320,NCT04171557,All-cause Mortality,Cause specific mortality: Cardiovascular,All-cause Mortality,2019-11-20,UNKNOWN,OBSERVATIONAL,['NA']
11321,NCT04081064,Insulin sensitivity,Fasting Plasma glucose,Heart rate during exercise sessions,2019-01-15,UNKNOWN,INTERVENTIONAL,['NA']
11322,NCT01753921,Unique signal measured in Hertz,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
11323,NCT05080530,Change from baseline in serum vitamin D.,,,2021-10-29,RECRUITING,INTERVENTIONAL,['NA']
11324,NCT04270097,Genetic risk variants associated with increased risk of T2D in Emiratis,,,2016-03-23,UNKNOWN,OBSERVATIONAL,['NA']
11325,NCT00672204,The Proportion of Insulin-independent Subjects With Full Islet Graft Function,,,2007-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11326,NCT02327286,Incident diabetes mellitus,Weight at one year post randomization,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11327,NCT04708574,Change in nutrition assessment from baseline to post intervention,Change in steps per day from baseline to post intervention,,2006-03-08,COMPLETED,INTERVENTIONAL,['NA']
11328,NCT01713348,Time in Range,HbA1c,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11329,NCT01586481,Healing duration of the diabetic foot ulcer,Compliance of patients to footwear,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11330,NCT03211182,blood sugar,Metabolic syndrome,,2012-03-07,UNKNOWN,INTERVENTIONAL,['NA']
11331,NCT05497232,Patient survival & pancreas graft survival & renal graft survival,,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
11332,NCT00311818,"Frequency of subjects with HbA1c: ≤ 6.5 %, 6.5 %< HbA1c ≤ 7.0 %, 7.0 %<HbA1c ≤ 8.0 % and HbA1c > 8.0 %","Frequency of subjects with hypoglycemic events (overall, severe, nocturnal, symptomatic)",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11333,NCT00631774,The primary objective of this study is to evaluate the effect of a diet program including Glucerna SR as a meal replacement on postprandial glucose response after using Glucerna SR for 24 weeks in obese Asian subjects with type 2 diabetes,"evaluate the efficacy and safety of a meal replacement program with Glucerna SR vs. an EDP based on the nutrition therapy recommendations from the ADA on anthropometric measurements, lipid profile, meal-related metabolic changes and quality of life",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
11334,NCT03768973,Changes in intrapulmonary shunt fraction,,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
11335,NCT00442156,OCT-measured retinal thickness and visual acuity,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
11336,NCT05984238,Percentage of patients off insulin at 24 weeks [efficacy],Secondary efficay endpoint 1 - HbA1c 48 weeks,,2023-08-03,RECRUITING,INTERVENTIONAL,['NA']
11337,NCT02801942,"Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN",Number of Participants Who Appreciated Receiving Study Feedback,,2016-07-25,COMPLETED,INTERVENTIONAL,['NA']
11338,NCT00013117,,,,na,COMPLETED,INTERVENTIONAL,['NA']
11339,NCT02465515,Time to First Occurrence of Major Adverse Cardiovascular Events (MACE) During Cardiovascular (CV) Follow-up Time Period,Change From Baseline in Heart Rate,,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11340,NCT01680185,Glycosylated hemoglobin (HbA1c),Serum creatinine,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11341,NCT05543564,BCVA,,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
11342,NCT00541983,Glycated hemoglobin (HbA1c) at Days 0 and 28.,Assessment of inflammatory markers CRP and ESR collected at time points specified in the protocol.,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11343,NCT05362058,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L),,2022-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
11344,NCT05984771,Measurement of electrochemical skin conductance,vitamin B12 levels,,2021-01-10,COMPLETED,INTERVENTIONAL,['NA']
11345,NCT01647776,Efficacy of sDNA testing for the detection of advanced adenomas,"To investigate the association of activated (phosphorylated) IRS1, AKT and mTOR with colon adenomas.",,2012-04-01,COMPLETED,OBSERVATIONAL,['NA']
11346,NCT01153438,change in glucose tolerance after surgery (measured by glucose area under the curve),change in glucose tolerance before and after a GLP-1 receptor blocker is administered,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
11347,NCT01805830,HbA1c,HOMA-IR,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11348,NCT01283113,Visceral fat level,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11349,NCT04011020,Incidence of Treatment Adverse Events in T1D Subjects,Efficacy of SCE therapy in immune modulation,,2022-09-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11350,NCT01922817,Magnitude of epinephrine release at 2.5mmol/L,,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11351,NCT06275412,Glycemic Control,Diabetes-Specific Family Support,Intervention Satisfaction,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11352,NCT04416503,HbA1c levels (%),,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
11353,NCT05781334,Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors),,Number of participants with heart failure readmission,2023-06-09,RECRUITING,INTERVENTIONAL,['NA']
11354,NCT03320993,Plasma Glucose,AUC-PG,Hormones and metabolites,2018-10-25,COMPLETED,INTERVENTIONAL,['NA']
11355,NCT02024516,adiponectin change,Body Mass Index change,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
11356,NCT03433248,GFR,Blood Pressure (Dinamap®),Glucagon (mg/L),2017-11-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11357,NCT02081326,Change in HbA1c values in juvenile onset type 1 diabetics,Autoimmunity in juvenile onset type 1 diabetes (AOO<21 years),COVID-19 and BCG Adaptive Study: Reported Rates of Infectious Diseases,2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11358,NCT03538106,Risk factors associated with a cesarean delivery in patients with diabetes type 1,Risk factors associated with an emergency cesarean delivery in patients with diabetes type 1,,2016-11,COMPLETED,OBSERVATIONAL,['NA']
11359,NCT01172093,presence of OSA,glycemic control,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
11360,NCT01227538,Assessment of whether two-hour urinary C-peptide response to mixed-meal (measured as area under the curve on the graph) can be used assess residual beta-cell function in the first 5 years after diagnosis of Type 1 diabetes.,To assess whether urinary C-peptide response to mixed-meal is reproducible in non-observed setting.,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
11361,NCT01248364,"Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 28","Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 28",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11362,NCT03834207,Acceptability & usefulness of the C3-Cloud system,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
11363,NCT00380380,Evaluate the effects of acute effects of vildagliptin on gastric emptying,Effect on satiety,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11364,NCT05874726,Tissue sample repository,,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA']
11365,NCT00605787,Plasma lipids,Safety blood parameters,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11366,NCT02540733,Barthel index,,,2012-01-01,UNKNOWN,OBSERVATIONAL,['NA']
11367,NCT02727348,Blood pressure or heart rate changes more than 30% of baseline after spinal or block is considered significant,S-LANSS score in who receive FSNB versus SAB.,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
11368,NCT05343494,Fidelity - sessions attended,Intervention acceptability,Qualitative interviews,2022-04-04,COMPLETED,INTERVENTIONAL,['NA']
11369,NCT00763412,CRP,C-Peptide,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
11370,NCT01144065,Comparison of hair cortisol and testosterone levels between the patients with acute MI and the 2 control groups,Correlation of hair cortisol and testosterone with the burden of coronary atherosclerosis in the MI group,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11371,NCT05199090,Change-from-baseline in weight,,,2022-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11372,NCT00754988,Mean changes in HbA1c,"Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies.",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11373,NCT05597605,"Primary Initial Performance Objectives: Confirm the ability to (c) recharge the SENSOR, ED and CHARGER.",Secondary Performance Objective: Assessment of procedural success for the implantation and explantation procedure,Exploratory Analysis: Histopathology analysis of the biopsy,2022-09-21,COMPLETED,INTERVENTIONAL,['NA']
11374,NCT00487526,control of type 2 diabetes in non obese adults,"CCK FFA,Cholesterol,Ghrelin,C-peptide,HbA1c,Gastrin,GIP,Triglycerides,Insulin",,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
11375,NCT03315728,Understand the influence of community context on the implementation of the QI Strategy as assessed by the Consolidated Framework for Implementation Research,Glycated hemoglobin (A1C),,2017-10-26,COMPLETED,OBSERVATIONAL,['NA']
11376,NCT01703611,HbAIc decrease,Weight change,Blood pressure,2012-12,COMPLETED,INTERVENTIONAL,['NA']
11377,NCT02460718,patient activation,composite measure of healthcare utilization,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
11378,NCT00256633,The primary outcome measure will be to determine if DNA characteristics are associated with CV risk in type 2 diabetes mellitus.,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
11379,NCT01443156,Work Schedule,Preventive care habits,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
11380,NCT02290301,Time-to-event for the primary composite MACE(Major Adverse Cardiovascular Events) endpoint,,,2013-06-28,COMPLETED,OBSERVATIONAL,['NA']
11381,NCT01881828,"Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.",Change in Blood Pressure,Change in Vascular Dysfunction,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11382,NCT00612144,Adjusted mean changes in HbA1c from baseline to the last visit,Abnormal change from baseline in clinical laboratory,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11383,NCT01928420,Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score,APO-E genotyping,Pharmacokinetic analysis,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11384,NCT05562206,Accuracy,Visual Analog Scale (VAS) for site discomfort,,2022-08-30,RECRUITING,INTERVENTIONAL,['NA']
11385,NCT01839448,Presence/absence of abnormal glucose metabolism,Oral glucose tolerance test results if necessary,Number of pregnancies,2014-03-27,COMPLETED,OBSERVATIONAL,['NA']
11386,NCT05422846,ulcer depth (mm),sleep quality score,kinesiophobia score,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
11387,NCT03534687,Quantify the change in basal circulating sRAGE after 12-weeks of supervised aerobic exercise training.,Quantify the change in insulin sensitivity after 12-weeks of supervised aerobic exercise training.,,2018-12-20,COMPLETED,INTERVENTIONAL,['NA']
11388,NCT01962506,Non-inferiority of a single-sampling strategy of hs-cTn and copeptin compared with the dual hs-cTn sampling for the early diagnosis of NSTE-ACS in a selected cohort of consecutive patients admitted at the Emergency Department.,,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
11389,NCT03940300,Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by hemoglobin A1c.,Improve glycemic control measured by continuous glucose monitoring (CGM),Participant experience with the program evaluated by questionnaire,2019-01-28,TERMINATED,INTERVENTIONAL,['NA']
11390,NCT05046873,"AUC0-∞,NNC0480-0389,SD: Area under the NNC0480-0389 plasma concentration-time curve after a single dose","Cmax,NNC0480-0389,SD: Maximum plasma concentration of NNC0480-0389 after a single dose",,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11391,NCT05456906,preventable hospitalizations and/or preventable emergency department visits,,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
11392,NCT00762957,Change from baseline in glycosylated hemoglobin.,Change from baseline in urinary albumin to creatinine ratio.,,2004-11,TERMINATED,INTERVENTIONAL,['PHASE3']
11393,NCT05569876,Diagnostic accuracy of the HypoVoice approach to detect hypoglycemia based on voice data quantified as area under the receiver operating characteristic curve (AUROC),Physiological parameters indicative of hypoglycemia,Change in cognitive performance across the glycemic trajectory.,2022-11-11,COMPLETED,INTERVENTIONAL,['NA']
11394,NCT05018585,Change in hemoglobin A1c (HbA1c).,Number of episodes per patient of diabetic ketoacidosis between baseline and Month 24.,,2022-05-19,RECRUITING,INTERVENTIONAL,['PHASE3']
11395,NCT01823510,Thrombus Formation,Platelet Reactivity Index (PRI),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11396,NCT02413762,Macrovascular complication of diabetes mellitus - prevalence and incidence,Progression to NAFLD or NASH,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
11397,NCT02855645,Plasma Blood Sugar,,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11398,NCT02923453,HbA1c,serum creatinine,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11399,NCT04535830,the between-group difference in mean HbA1c,"the between-group difference in mean time in other biochemical indexes,such as LDL-C,TC,TG and so on",,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11400,NCT02644759,Exogenous insulin dose,HbA1c level,,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11401,NCT02446054,the change of glycosylated hemoglobin (HbA1c),the patients' compliance questionnaire,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
11402,NCT00372463,Self-efficacy,,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11403,NCT04807218,Change in hemoglobin A1c (Percent),Change in number and/or doses of anti-hyperglycemic medications • doses of anti-hyperglycemic medications,Acceptability of referral over time,2021-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11404,NCT05129891,"AUC0-24h,API,day10; area under the API plasma concentration-time curve from 0 to 24 hours after the 10th dose","tmax, API,day10; time from the 10th dose to maximal observed plasma concentration of API",,2021-11-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11405,NCT00970424,Hemoglobin A1c Level (HbA1c),Fasting Plasma Glucose Level (FPG),,2009-08,TERMINATED,INTERVENTIONAL,['PHASE3']
11406,NCT00391040,"HbA1c decrease, reduction of hypoglycemia, acute complications","treatment satisfaction, ability for diabetes management, diabetes knowledge",,2003-11,COMPLETED,INTERVENTIONAL,['NA']
11407,NCT02078635,Change from baseline of the maximum vessel wall volume of the carotid arteries,initiation of statin therapy,Palatability of the test / control diets,na,WITHDRAWN,INTERVENTIONAL,['NA']
11408,NCT00801164,"The primary study endpoints are periodontal evaluation including clinical attachment level, pocket depth, plaque index, suppuration and gingival index score.","Secondary endpoints include glycated hemoglobin A1c (HbA1c) and systemic biomarkers (LPS, TNF-a, CRP, IL-6, serum insulin and glucose). Tertiary outcome measures include staining, calculus, opportunistic Candida infection, and patient satisfaction.",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11409,NCT00772265,Mean AUC0-24h and Cmax,"PK endpts: AUC0-4h, AUC0-6h, AUC0-12h, AUC6-12h, AUC6-24h,tmax,and elimination rate constant. PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR0-12h,AUCGIR0-24h, AUCGIR6-12h, AUCGIR6-24h, GIRmax and tGIRmax Safety : AEs,haematology,biochem,phy exam.",,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11410,NCT01779362,"Insulin Sensitivity, M/I",ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11411,NCT03386344,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With Adverse Events (AEs),,2018-02-19,TERMINATED,INTERVENTIONAL,['PHASE3']
11412,NCT05862818,Difference in plasma triglyceride level between Meal Conditions and Shift Work,Difference in plasma free fatty acids level between Meal Conditions and Shift Work,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11413,NCT04931836,Chain in Serum Short Chain Fatty Acids (SCFA),Body Composition,,2021-07-29,RECRUITING,INTERVENTIONAL,['NA']
11414,NCT01848990,Change From Baseline to 12 Months in HbA1c,Mean Times Per Week Participants Said They Were Eating to Avoid Going Low Due to Late Insulin Action,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11415,NCT04668703,change in diabetic retinopathy severity score (DRSS),"change in the aqueous concentrations of VEGF, PIGF, interleukin- (IL-) 2, IL-5, IL-6, and IL-8",,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
11416,NCT03821961,Change in Uptake value of 18F-FDOPA PET/CT from baseline,Change in MAQOL scores of questionnaire from baseline,,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA']
11417,NCT00359762,Time to Treatment Failure,Hypoglycemia Rate Per Year in Period III,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11418,NCT02263677,Change in Liver steatosis,,,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE4']
11419,NCT03868683,Glucose [,Insulin,,2018-08-20,COMPLETED,INTERVENTIONAL,['NA']
11420,NCT03649243,allergenic to propolis analysis,obtaining biopses,,2015-10,COMPLETED,OBSERVATIONAL,['NA']
11421,NCT01050218,Change From Baseline in Mean Pain Score on the Numeric Rating Scale (NRS).,,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE3']
11422,NCT03903757,RNA sequencing analysisin adipose tissues,Linear regression to correlate epigenetic biomarkers with HOMA index,,2019-12,UNKNOWN,OBSERVATIONAL,['NA']
11423,NCT03859817,Variations in ketone levels,Changes in glycated hemoglobin (HbA1c),,2019-04-16,UNKNOWN,OBSERVATIONAL,['NA']
11424,NCT03194945,proportion of subjects with optimal glycemic control,Incidence of adverse events,,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11425,NCT02768948,number of differentiation marker,,,2017-05-05,COMPLETED,INTERVENTIONAL,['NA']
11426,NCT04797429,HbA1c [%] (change over a period of 7 months intervention and 7 months follow-up with 4 measurement dates),Biochemical parameters,,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11427,NCT00959595,Touch thresholds in the sole of the foot (Semmes-Weinstein monofilaments),fMRI,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11428,NCT01743599,Retrograde ejaculation (a minimum of a total of 1 million sperm in postejaculatory urine),Erectile dysfunction,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
11429,NCT00237237,Change from baseline in HbA1c at 52 weeks,Patients with reduction in HbA1c >/= to 7% after 52 weeks,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11430,NCT02610088,Vascular function assessed by Flow-mediated vasodilation (FMD),Carotid intima-media thickness (cIMT) assessed by ultrasound,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11431,NCT02273193,Fasting Glucose will be obtained during the first trimester of pregnancy,Hemoglobin A1c will be obtained during the second trimester of pregnancy (between 24-28 weeks),,2014-10-14,COMPLETED,OBSERVATIONAL,['NA']
11432,NCT04098679,IQ,Adiposity,,2019-09-30,RECRUITING,OBSERVATIONAL,['NA']
11433,NCT00916292,Safety and tolerability of a single dose of FGF-1 topically administered in normal volunteers given an artificial dermal wound,Serum levels of FGF-1 after topical administration,,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE1']
11434,NCT00031200,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
11435,NCT02858076,E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline),Retinal Neovascularization on Clinical Exam,,2016-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11436,NCT03991299,Change in Body Weight at 1 Month,,,2021-04-29,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11437,NCT01586780,"Blood glucose, insulin, amino acids, ghrelin and incretins",Subjective satiety,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
11438,NCT00542698,increased physical activity,"BP, BMI, & HgA1c (a long term measure of blood glucose)",,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11439,NCT02910141,HbA1c,Weight or BMI,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
11440,NCT01852214,P2Y12 Reaction Units,Platelet Reactivity Index,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
11441,NCT01570751,Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period,Number of Adverse Events (AEs),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11442,NCT06073457,Anastomosis Patency,,,2023-11-06,RECRUITING,INTERVENTIONAL,['NA']
11443,NCT00753766,Percent of Screened Participants That Are Eligible and Choose Participation,Percentage of Participants Who Need to Return to the Operating Room,,2005-10,TERMINATED,INTERVENTIONAL,['NA']
11444,NCT02282254,Percentage of time of plasma glucose levels spent below 4 mmol/L,Total number of hypoglycemic events requiring treatment,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11445,NCT00842010,Inpatient Mortality,Frequency of steroid use,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
11446,NCT01527552,"Cmax, maximum insulin aspart concentration",Adverse events,,2002-11-05,COMPLETED,INTERVENTIONAL,['PHASE1']
11447,NCT02251834,Blood Pressure,A1C,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11448,NCT03253237,Glycemic variability in individuals with type 2 diabetes mellitus in primary care measured by continuous glucose monitor device,,,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA']
11449,NCT04340908,Difference in NTproBNP between the treatment and control study arms,Post operative atrial fibrillation,,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11450,NCT01339143,Glycemic Variability,hypoglycemia,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
11451,NCT01302743,Decrease in LDL Cholesterol,,,2010-11,TERMINATED,INTERVENTIONAL,['NA']
11452,NCT01192152,Metformin Cmax,"Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities",,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11453,NCT03458338,Point prevalence of chronic kidney disease measured by lab values,Risk factors for chronic kidney disease measured by lab values and questionnaire,,2010-12-08,COMPLETED,OBSERVATIONAL,['NA']
11454,NCT04725799,Measurement of Glucose Concentration,,,2018-05-24,COMPLETED,OBSERVATIONAL,['NA']
11455,NCT03165786,Hypoglycemia Fear Scale Score (HFS_2),Glycemic variability,,2016-10-26,COMPLETED,INTERVENTIONAL,['NA']
11456,NCT04584242,Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days),Prognostic factor of the Improvement of HbA1 between baseline and week 24 (±7days) within and between arms,,2020-09-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
11457,NCT03792685,"The change and differences in postprandial substrates (carbohydrate, fat and protein) utilization levels associated with investigated single nucleotide polymorphisms.",The change and differences in postprandial plasma metabolites profiles associated with investigated single nucleotide polymorphisms.,,2009-09-24,COMPLETED,INTERVENTIONAL,['NA']
11458,NCT01553968,Exercise-induced changes in acetylcarnitine concentrations and dynamics of acetylcarnitine restoration after exercise,Blood plasma glucose,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
11459,NCT02663245,Glycaemic control measured by HbA1c,evaluation of quality of life using spanish version of diabetes quality of life questionnaire (EsDQOL),,2015-12,COMPLETED,INTERVENTIONAL,['NA']
11460,NCT05487079,Number of distinct phenotypes of type 2 diabetes within this population,Rate of progression of vascular disease within this population,,2022-01-17,RECRUITING,OBSERVATIONAL,['NA']
11461,NCT04917393,Rate of SADEs,Change in Glycemic control - fasting glucose,,2021-09-13,RECRUITING,INTERVENTIONAL,['NA']
11462,NCT01248442,Increase and function of peripheral regulatory T-cells,calcium levels,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11463,NCT01988987,Result of an early postpartum 75-gram oral glucose tolerance test (GTT) result,Result of a postpartum 75-gram oral glucose tolerance test (GTT),,2013-02-22,COMPLETED,OBSERVATIONAL,['NA']
11464,NCT01801254,postprandial blood glucose and triglycerides,,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11465,NCT05904262,Foot Sole Sensation Evaluation,Muscle strength,,2023-06-06,COMPLETED,OBSERVATIONAL,['NA']
11466,NCT02149992,overall mean glucose,metabolic differences,steady state,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
11467,NCT02589210,"The proportion of product related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events",Cost effectiveness of treatment,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
11468,NCT04757519,Change in Weight at 6 Months,Impact of Weight on Quality of Life,,2021-02-18,RECRUITING,INTERVENTIONAL,['NA']
11469,NCT01261052,Measurement of the Effectiveness of APD and FMPD/APD Intervention in Adapting to Reduced Insulin Sensitivity,Measurement of APD and FMPD/APD Interventions in Controlling Post-prandial Blood Glucose With Reduced Insulin Sensitivity.,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11470,NCT00631345,Fasting Glucose,Physical Activity,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
11471,NCT05688631,Dietary antioxidant capacity,Total body water,,2021-01-03,COMPLETED,OBSERVATIONAL,['NA']
11472,NCT05628532,Percentage of time spent in 70 - 180 mg/dL glycemic range,Scoring of Diabetes Distress Scale (DDS),,2023-02-03,RECRUITING,INTERVENTIONAL,['NA']
11473,NCT02282046,implant complications,resonance frequency analysis,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
11474,NCT01788527,Glycemic Control in pregnant group,Study Contacts,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
11475,NCT04407182,Symptom resolution,Time to return to normal activity,Change in myocardial enzymes,2020-05-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11476,NCT03334214,"Percentage of Participants With Adverse Events, Graded by Severity, That Were Related to Treatment With IONIS DGAT2Rx",Absolute Change in Hemoglobin A1C (HbA1C),,2017-11-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11477,NCT03038373,Evidence of clinically definition of remission of type 2 diabetes by by fasting blood glucose level < 7.0 mmol and HbA1c <6.5%,,,2012-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11478,NCT00482183,"The primary angiographic end point is in-stent luminal late loss, as determined by quantitative angiography.","Secondary end points include the percentage of in-stent stenosis of luminal diameter, the rate of restenosis.",,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11479,NCT01293461,"To assess the safety and tolerability of CBX129801 when administered SC by adverse events, injection site assessments, clinical laboratory tests, vital signs, physical examinations, and electrocardiograms.",To evaluate the technique of vibration perception threshold (VPT) in patients with type 1 diabetes (Part 2 only),,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11480,NCT00204009,,,,1992-07,COMPLETED,OBSERVATIONAL,['NA']
11481,NCT00629707,Cerebral Edema Measured by MR Imaging (Apparent Diffusion Coefficient),"Brain NAA/Creatine Ratio & Brain Lactate Measured by MR Spectroscopy, Cerebral Blood Flow & Oxygen Saturation Measured by MR Perfusion Weighted Imaging & Near Infrared Spectroscopy, Mental Status Evaluated by Glasgow Coma Scale Scores.",,2008-06,COMPLETED,INTERVENTIONAL,['NA']
11482,NCT02806830,Comparison of the overall scores of the ocular discomfort questionnaire after the 2 first intravitreal injection in naïve patients,,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
11483,NCT00142922,fitness,Diabetes Related emaitonal distress,,2002-10,COMPLETED,INTERVENTIONAL,['NA']
11484,NCT00214474,Changes in Minutes of Vigorous Exercise,Changes in Body Mass Index (BMI),,2002-11,COMPLETED,INTERVENTIONAL,['NA']
11485,NCT03091517,Change in HbA1c levels (Effectiveness),Degree of user satisfaction with the GlycoLeap program (Maintenance),,2017-06-22,COMPLETED,INTERVENTIONAL,['NA']
11486,NCT02700334,Glycosylated Hemoglobin,Diastolic Blood Pressure,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11487,NCT01111370,the Proportion of G4 CGM System in Agreement With the Reference Standard,,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
11488,NCT01978405,The changes of endothelium-dependent arterial dilation before and after contrast administrated,,,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
11489,NCT01051830,Quality of life,Activities of Daily life,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
11490,NCT00647439,,,,2008-03-27,COMPLETED,OBSERVATIONAL,['NA']
11491,NCT03570632,Rate of hypertensive disorders of pregnancy,Neonatal morbidity,Neonatal body composition,2019-07-08,RECRUITING,INTERVENTIONAL,['PHASE4']
11492,NCT02473926,Change From Baseline in Objective Physical Activity at 4 Months,Change From Baseline in Physical Function at 4 Months,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
11493,NCT05163587,lipid profile,body composition,,2021-03-26,COMPLETED,INTERVENTIONAL,['NA']
11494,NCT04239586,Metabolic control of diabetes measured by HbA1c in mmol/mol,"Effect on secretion of incretin hormones, assessed by oral glucose tolerance tests",,2017-04-18,UNKNOWN,INTERVENTIONAL,['PHASE4']
11495,NCT00246844,,,,2005-10-26,COMPLETED,OBSERVATIONAL,['NA']
11496,NCT01447524,Change from baseline in insulin secretion at 7 days.,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
11497,NCT01130727,flow-mediated dilation (FMD),plasma levels of flavonols,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
11498,NCT00334113,7-Day Physical Activity Recall (PAR),,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
11499,NCT06153537,Change in glycated haemoglobin (HbA1c),Change in laboratory measured FPG,,2023-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11500,NCT03092960,Number and Percentage of Men Achieving 5% Weight Loss or More,Change in Psychosocial Well-being: Number and Percentage of Participants Who Had no Problems With Anxiety and Depression Domain in Utility-based Quality of Life Measured by EuroQol EQ-5D,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
11501,NCT03262363,Change from Renal Function at 6 months,,,2018-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11502,NCT01103817,Change in Endothelial Function after Treatment with Vitamin D,Comparison of Urinary Albumin/Creatinine Ratio,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11503,NCT00473382,Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24,Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11504,NCT00385333,Fluorescence anisotropy,The difference in fluorescence anisotropy values within subjects under room air and 100% oxygen exposure (one minute exposure time).,,2006-09-29,COMPLETED,INTERVENTIONAL,['PHASE2']
11505,NCT04343131,Percentage of time spent with glucose levels between 70-140 mg/dl,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11506,NCT02341261,Change in Quality of Life (NQOL-DN) Questionnaire Results,,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
11507,NCT00005131,,,,1985-07,COMPLETED,OBSERVATIONAL,['NA']
11508,NCT05593081,Change in serum hemoglobin A1c level,The incidence of chronic complications of diabetes mellitus,,2022-05-20,RECRUITING,OBSERVATIONAL,['NA']
11509,NCT01755156,Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B),Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 104 (Phase A+B),,2013-01-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11510,NCT05910840,Change from Baseline Hemaglobin A1c (HbA1c) at 18 months,Cost effectiveness (QOL),"Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider",2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11511,NCT00575172,"Cardiovascular events 1)Sudden death 2)New development or recurrence of apoplexy or TIA 3)New development or recurrence of AMI or and angina pectoris 4)Newly developed ASO, amputation of leg due to ASO","1)Total mortality 2)Changes in the mean IMT of common carotid arteries 3)Changes in the pulse wave velocity (PWV) (rt & 1t baPWV), ABI",,2003-03,COMPLETED,OBSERVATIONAL,['NA']
11512,NCT04672655,Change in Hemoglobin A1c (HbA1c) over time,Change in Glucose Monitoring System Satisfaction Survey - Version: Type 1 Diabetes (GMSS-T1D),,2021-02-17,RECRUITING,INTERVENTIONAL,['NA']
11513,NCT05357742,Hemoglobin A1c (HbA1c),Self-Care Behavior,,2022-08-01,RECRUITING,INTERVENTIONAL,['NA']
11514,NCT01554618,Percentage of Patients Positive for Anti-Drug Antibodies (ADAs) to Exenatide up to Week 24,Plasma Exenatide Concentrations to Week 52 Among Patients Who Received Open-Label Exenatide (Treatment Period),,2011-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11515,NCT01469468,"If the data permit, terminal elimination half-life of simvastatin and simvastatin acid",,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11516,NCT02632877,assessing change of ulcerated area,mRNA levels of Matrix metalloproteinase-1 (MMP-1),,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11517,NCT01351857,The proportion of subjects who fail to attend at least one outpatient adult endocrinology visit during the second year after transition to adult diabetes care.,In the 2 year transfer to adult care-Frequency of A1C (glycated hemoglobin test),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11518,NCT01068743,Metformin PK Parameter Cmax,"Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities",Metformin PK Parameter Tmax,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11519,NCT06334042,Serum Chromium Level,Lipid Profile,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
11520,NCT03167684,Glycemic control (mean 24-hour and nocturnal glucose),Systemic inflammation,Subjective sleep quality,2017-05-01,UNKNOWN,INTERVENTIONAL,['NA']
11521,NCT03708419,Disposition index,DNA analysis,,2018-06-04,COMPLETED,INTERVENTIONAL,['NA']
11522,NCT05205005,Glygocalyx integrity - perfused boundary region,Popliteal artery flow mediated dilation,,2022-05-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11523,NCT06236607,Glucose time-in-range (TIR) of 70-180 mg/dL,Diabetic Ketoacidosis events,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11524,NCT00339781,,,,2005-02,COMPLETED,OBSERVATIONAL,['NA']
11525,NCT03922087,Number of participant with gestational complications.,Number of participant with postnatal depression.,,2018-11-20,COMPLETED,OBSERVATIONAL,['NA']
11526,NCT00971815,Changes in the 24-hour AUC of free plasma cortisol,Plasma-Inflammation markers,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
11527,NCT05983289,Number of Participants With Treatment-Emergent Adverse Events (TEAEs),Inhibition Rate of Dipeptidyl Peptidase 4 (DPP4) Activities following single dose administration,,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11528,NCT05548699,Daily stress levels over time,Alcohol misuse over time,Stressful life events,2023-05-02,RECRUITING,OBSERVATIONAL,['NA']
11529,NCT02030249,Bone mass,Muscle (handgrip) strength,Urinary N-terminal telopeptide,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
11530,NCT06184815,Changes in Glycemic Control Measured by A1c,Changes in Glycemic Control Measured by severe hypoglycemia,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11531,NCT03882463,Time spent hypoglycemia,Number of hypoglycemia,,2019-04-30,COMPLETED,INTERVENTIONAL,['NA']
11532,NCT02548702,Change from baseline in number of participants reporting one or more sessions of sport per week measured by the UK Single Item Questionnaire,Change from baseline in control of blood glucose concentration as measured by HPA1c (mmol/mol),,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
11533,NCT00565799,"1) insulin sensitivity, 2) beta cell function and 3) plasma markers of inflammation",Identify genes and proteins in adipocytes from obese patients that affect clinical presentation versus those that are affected by obesity for future study.,,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2']
11534,NCT02081352,Incidence of wound closure,Quality of wound healing,Rate of wound healing in crossover arm,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
11535,NCT02316821,"Change in glomerular filtration rate (GFR) measured by inulin clearance after 16 weeks of study drug administration, compared to baseline GFR",Profiles of pharmacokinetics of plasma RTA 402 concentration: Trough (Pre-dose) and peak (2-4 hours post dose) concentrations of study drug at steady state,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11536,NCT00542620,Glycosylated Haemoglobin A1c (HbA1c),"Percentage of Children Assessing Insulin Therapy Injection Pain as ""Very Happy Face""",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
11537,NCT05124834,Analysis of system accuracy based on DIN EN ISO 15197,,,2022-01-15,COMPLETED,INTERVENTIONAL,['NA']
11538,NCT00280046,HbA1c,Quality of Life,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11539,NCT02928016,Capillary blood glucose,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
11540,NCT03837405,diet adherence between intervention arms as measured by 24- hour diet recall--dichotomous,Weight change,Mindfulness,2018-12-12,COMPLETED,INTERVENTIONAL,['NA']
11541,NCT00271700,- Lab glucose values (percent of routine glucose readings between 60 and 180 mg/dL),- Quality of insulin orders using explicit criteria,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
11542,NCT01296633,Medication regimen knowledge,Patient-provider communication assessment,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
11543,NCT03428308,Number of follow-up visits,Change in blood cholesterol (blood test),Success of intersectoral cooperation,2018-04,UNKNOWN,INTERVENTIONAL,['NA']
11544,NCT04582435,"AUCIco,τ,SS, Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state","t½,Ico,SS, Terminal half-life for insulin icodec at steady state",,2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
11545,NCT01826370,Frequency of Adverse Events and Serious Adverse Events,Change From Baseline to Week 24 of Fasting Blood Sugar,,2012-05,TERMINATED,OBSERVATIONAL,['NA']
11546,NCT00362778,Glycemic control,High-sensitivity C-reactive protein levels,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11547,NCT03368807,Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM,Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM,,2017-12-11,COMPLETED,OBSERVATIONAL,['NA']
11548,NCT04137705,Assessment of repeatability (precision under the same conditions in the same subjects: 2 separate MRI acquisitions on the same scanner) of body composition and multiple organ metrics.,Assessment of the reproducibility (precision under different measurement conditions: same participants scanned on separate MRI scanners at both 1.5T and 3T) of multiparametric MRI for the assessment of body composition and multiple organ metrics.,Assessment of the mean differences in body composition and multiple organ metrics between healthy participants and those with type 2 diabetes acquired with multiparametric MRI.,2019-11-04,RECRUITING,OBSERVATIONAL,['NA']
11549,NCT01786941,Changes in Branched-chain Amino Acid Metabolism in Pre-Diabetes at Baseline and post-intervention,Changes in Insulin Sensitivity at Baseline and post-intervention,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
11550,NCT01651117,Change in Glucose Control (Stage 2: Non-mentors v. Mentors),Change in Depression Symptoms (Stage 2: Non-mentors v. Mentors),,2012-09-01,COMPLETED,INTERVENTIONAL,['NA']
11551,NCT02459353,Glycemic Variability (Standard Deviation),blood pressure DBP,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11552,NCT00962962,Fasting Plasma Glucose,Measures of Glucose control,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
11553,NCT04305431,Facilitators and Barriers,Second Phase Secondary Outcome,,2021-02-25,RECRUITING,INTERVENTIONAL,['NA']
11554,NCT02274103,HbA1c,"Adherence to diabetes treatment using the Diabetes Self Management Profile (DSMP) (Harris et al, 2001).",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11555,NCT02864914,Incidence of diabetic ketoacidosis (DKA),Incidence of severe genital infections,,2016-03-15,COMPLETED,OBSERVATIONAL,['NA']
11556,NCT02051504,Maximal oxygen uptake,Prefrontal cortex oxygenation during exercise,Body composition,2010-03,COMPLETED,OBSERVATIONAL,['NA']
11557,NCT05847413,Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL at 12 weeks.,,,2020-05-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11558,NCT05125445,change in margianl bone level,,,2021-02-11,COMPLETED,INTERVENTIONAL,['NA']
11559,NCT01365416,,,,2011-12-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11560,NCT02137863,"Changes in glomerular renal function after percutaneous coronary angiography as measured by neutrophil gelatinase-associated lipocalin, cystatin c, blood urea nitrogen, creatinin",complete blood count,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11561,NCT00257257,Absolute change in HbA1C from baseline to Month 6.,"Fasting glucose, fasting insulin, C-peptide, HOMA analysis, body weight, HDL-cholesterol, triglycerides, blood pressure, safety (physical examination, vital signs, laboratory tests, adverse events).",,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11562,NCT02856633,Successful diagnosis of patient's condition by Vitaliti software as compared to patient's Medical Record,,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
11563,NCT05130385,Evaluation of the sensitivity and specificity of High-Res-OCT for retinal fluid,Evaluation of the segmentation quality of the retinal layers using High-Res-OCT,Correlation of pathological changes with fundus color photographs,2021-11-30,RECRUITING,OBSERVATIONAL,['NA']
11564,NCT00257218,Incidence of diabetes mellitus,insulin sensitivity,,2006-01,UNKNOWN,INTERVENTIONAL,['NA']
11565,NCT04054284,Number of patients with adverse event,Fasting Glucose,Waist Circumference,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
11566,NCT00467376,Adverse events,"blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and Lantus.",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11567,NCT01637350,,,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
11568,NCT03070678,Area under the concentration-time curve from 0 to infinity (AUC0 ∞),Total 24-hour UGE (urinary glucose excretion) after each dose with sotagliflozin,,2017-03-14,COMPLETED,INTERVENTIONAL,['PHASE1']
11569,NCT03892265,"Prevalence of CVD risk factors and diseases and their association with social and environmental determinants in an established longitudinal cohort of ~3,000 Haitian adults",Incidence of CVD risk factors and CVD during ~7 years of follow-up and their association with social and environmental determinants,,2019-03-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11570,NCT00943917,Mean Change in HbA1c (ITT),,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11571,NCT03682250,QT intervals corrected for heart rate,Percentage of time below 3.5 mmol/L,,2018-09-17,UNKNOWN,OBSERVATIONAL,['NA']
11572,NCT03237975,Short form of the sense of coherence questionnaire (SOC-13),Diabetes Self-Efficacy Scale (DSES),,2017-03-27,UNKNOWN,INTERVENTIONAL,['NA']
11573,NCT05932953,"Prevalence of children,with current skin intolerance (eczema symptoms measured by questionnaire) to an insulin pump and/or blood glucose sensor assessed by an autoquestionnary.",Search for risk factors associated with skin side effect,,2022-05-15,RECRUITING,OBSERVATIONAL,['NA']
11574,NCT03916016,Blood Pressure,Blood glucose concentration,,2015-12-09,COMPLETED,INTERVENTIONAL,['NA']
11575,NCT01628341,Percentage of insulin-treated patients experiencing at least one hypoglycaemia (severe/non-severe),"Change in planned daily activities; work: effectiveness, missing hours or days for sick leave",,2012-05,COMPLETED,OBSERVATIONAL,['NA']
11576,NCT02543684,serum insulin changes over time,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
11577,NCT03303196,Mean Plasma Glucose Level.,,,2018-04-09,COMPLETED,INTERVENTIONAL,['NA']
11578,NCT05952219,Cmax,,,2023-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
11579,NCT04163874,Mean score of the Emotional Burden section of the Diabetes Distress Scale,Each participant's total insulin delivery,,2020-02-14,COMPLETED,INTERVENTIONAL,['NA']
11580,NCT03821636,Rate of type 2 diabetes remission,change in prealbumin levels,,2019-06-16,RECRUITING,INTERVENTIONAL,['NA']
11581,NCT06147518,Percentage of patients with glycemic control at 24 weeks (HBA1c <7.0 %),Number of patients with Mortality/ Liver transplantation in both groups,,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11582,NCT01116531,Concentration of O-desmethyltramadol,Concentration of O-desmethyltramadol,,2010-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
11583,NCT00607087,Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion,Total Daily Bolus Insulin Dose,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11584,NCT04215445,Comparison of change in retinal and choroidal vascular perfusion density in proteinuric and non-proteinuric chronic kidney disease patients treated with SGLT2-inhibitor,,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11585,NCT03542682,Time to Maximum Glucose Infusion Rate,Area Under the Curve for the Glucose Infusion Rate,,2018-05-30,COMPLETED,INTERVENTIONAL,['NA']
11586,NCT04439630,postprandial insulin concentrations,subjective appetite variables,,2020-07-01,COMPLETED,INTERVENTIONAL,['NA']
11587,NCT05764811,measure the severity of fatty liver via MRI,measure the body mass index (BMI) before and after the treatment,,2020-03-06,COMPLETED,INTERVENTIONAL,['NA']
11588,NCT02251431,ACR,,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11589,NCT01875341,Primary end-point: change in daytime and night-time mean systolic blood pressure,plasma renin and aldosterone,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11590,NCT03553030,Major Adverse Cardiac Events (MACE).,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
11591,NCT03898076,The difference of Predictive A1c level from CGM data with Real A1c level from EMR,,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
11592,NCT04451837,Hba1c,,,2020-09-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11593,NCT00634998,Changes in aldose reductase enzyme levels,Changes in Neuropathic Pain Scale (NPS) measurement and quantitative sensory testing in the lower extremities via touch discrimination with Semmes-Weinstein monofilaments and vibratory sensation testing,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11594,NCT05170880,HbA1c levels,,,2019-02-11,COMPLETED,INTERVENTIONAL,['NA']
11595,NCT04345016,rate of diabetic foot ulcer recurrence in after phase of trial,rate of lower extremity amputations in after phase of trial,,2017-04-13,COMPLETED,INTERVENTIONAL,['NA']
11596,NCT01326442,body weight,Glucose homeostasis,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11597,NCT05477030,Glycated Hemoglobin (HbA1c),Endothelial disfunction,,2022-02-23,RECRUITING,INTERVENTIONAL,['NA']
11598,NCT00883259,Incidence of gestational DM in high-risk patients,Intrauterine deaths,,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11599,NCT02074384,Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports,,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
11600,NCT01978886,prevalence of known and unknown diabetes diabetes,diabetes influence on the prognosis of frozen shoulder,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
11601,NCT03878290,Resilience,Inflammatory burden,,2017-08-03,COMPLETED,INTERVENTIONAL,['NA']
11602,NCT05798442,Reduced BMI and visceral obesity,Reduced alcohol consumption and tobacco smoking,,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11603,NCT01986881,Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study),Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study),,2013-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11604,NCT02536859,Area under the glucose infusion rate curve,Area under the glucose infusion rate curve,,2015-08-31,COMPLETED,INTERVENTIONAL,['PHASE1']
11605,NCT01627340,Number of Subjects Seroprotected for Anti- Hepatitis B Surface Antigen (Anti-HBs) Antibodies,Number of Subjects Reporting Any Serious Adverse Events (SAEs),,2012-07-24,COMPLETED,INTERVENTIONAL,['PHASE4']
11606,NCT02614768,Percentage of Test-to-Reference Measurement Pairs With an Absolute Relative Difference (ARD) ≤15%,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11607,NCT01630850,HbAlc <7.0% and an absence of severe hypoglycemic events,,,2012-05,RECRUITING,INTERVENTIONAL,['NA']
11608,NCT00476437,Incidence of hypoglycaemic episodes,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11609,NCT02228629,Comparison of peak pressure sub-metatarsal 2 and hallux in usual house shoes versus the CrocsRx clogs,,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
11610,NCT05347459,Prevention of decline in cognitive function associated with type 2 diabetes,Better cognitive performance in the intervention group at baseline,Reduced serum inflammatory markers in intervention group,2022-03-02,RECRUITING,OBSERVATIONAL,['NA']
11611,NCT01288729,Length of Wear of Infusion Site,,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
11612,NCT02932436,difference in E/E' ratio between 12 weeks after baseline and at baseline,difference in E/E' ratio (change from baseline (V1) to 12 weeks follow-up) in the subgroup of patients with HbA1c 6.5%-6.9%,association analysis for selected SNPs,2016-10-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11613,NCT02217943,Composite Measure of Glycemic Control - Recurrence,Assess the changes in SF-36 Health Survey,,2014-07-01,COMPLETED,INTERVENTIONAL,['NA']
11614,NCT05549583,Area under the plasma concentration versus time curve (AUC) 0-t,"Number of participants with adverse events (AEs), abnormal clinical laboratory test results, physical examination findings and glycemia.",,2018-04-15,COMPLETED,INTERVENTIONAL,['PHASE1']
11615,NCT00568620,Insulin sensitivity,Incretin effect,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
11616,NCT05325710,FINDRISC score,,,2022-03-20,RECRUITING,INTERVENTIONAL,['NA']
11617,NCT00638560,PGC-1alpha mRNA expression in skeletal muscle PPARgamma mRNA expression in skeletal muscle Serum malondialdehyde concentration,body weight glucose infusion rate during the steady state of an euglycemic-hyperinsulinemic clamp VO2max,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11618,NCT02757183,Usage and Adoption of the smart phone based mobile health application,Adherence to Prescribed Medication,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
11619,NCT03106727,Antenatal Care,CHW Retention,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
11620,NCT02502929,Biological risk for type 2 diabetes,,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
11621,NCT05414396,Changes in biomarkers,,,2018-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11622,NCT04221399,Concentration of serum glucose,,,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
11623,NCT03626324,Successful Home-use Performance,,,2018-07-25,COMPLETED,INTERVENTIONAL,['NA']
11624,NCT02834663,Central Macular Thickness(CMT),Safety Parameters,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11625,NCT01862237,Left Ventricular Mass measured by echocardiography,Magnetic Resonance Imaging (MRI) parameters.,,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
11626,NCT01869101,Diabetes prevention treatment decisions by physician,Subject initiation and persistence with diabetes prevention interventions,BMI,2013-06,UNKNOWN,OBSERVATIONAL,['NA']
11627,NCT01273311,,,,2010-12-22,COMPLETED,OBSERVATIONAL,['NA']
11628,NCT03534544,Youth and parent preferences for automated insulin delivery systems,Quality of life,,2018-08-23,COMPLETED,OBSERVATIONAL,['NA']
11629,NCT01923597,Effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.,Effect of green tea (epigallocatechin gallate) on plasma lipids in patients with diabetic nephropathy.,Effect of Green Tea (epigallocatechin gallate) in the glomerular filtration rate in patients with diabetic nephropathy.,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11630,NCT02422043,self-efficacy (Self-efficacy of Diabetes Management),socio-cognitive profile,,2015-01-28,COMPLETED,INTERVENTIONAL,['NA']
11631,NCT00564018,C-peptide Area Under the Curve,Glycemic Control as Determined by HgbA1c Values at 6 Months After Diagnosis,,2006-09,TERMINATED,INTERVENTIONAL,['NA']
11632,NCT00328302,Mesangial expansion,24 hour ambulatory blood pressure,,2000-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11633,NCT00323349,Scores on motivation to change behavior scale after the intervention,Scores on scales of perceived barriers to healthy lifestyle choices,,2003-04,COMPLETED,INTERVENTIONAL,['NA']
11634,NCT02374788,HbA1c (mmol/mol),Change in Smoking and snuffing habits,Hospital Anxiety and Depression Scale (HADS),2013-11,COMPLETED,INTERVENTIONAL,['NA']
11635,NCT04119167,Level of fasting blood sugar,,,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA']
11636,NCT03105219,Urinary albumin excretion,Retinol binding protein,,2017-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
11637,NCT01515592,Antibody against liraglutide,24-hour profiles of serum insulin,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11638,NCT02179788,Peak Change in Milk Output,,,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11639,NCT06184373,Comparative experience of OGTT and CGM,Medical care,Infant outcomes,2024-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11640,NCT05719155,AUClast,,,2023-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
11641,NCT05414149,CRT,postoperative fibrovascular proliferation progression,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
11642,NCT04700254,DASS (Anxiety),Eating Attitudes Test (EAT-26),,2020-12-28,COMPLETED,OBSERVATIONAL,['NA']
11643,NCT00493051,Effect of GAM501 on the incidence of complete ulcer closure,Safety and tolerance,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11644,NCT03889236,Percentage change from baseline in the Microvascular Health Index in the fasting mimicking diet or food supplement group compared to the placebo group,Percentage change from baseline in specific urinary heparan sulfate domains in the fasting mimicking diet or food supplement group compared to the placebo,,2018-05-03,COMPLETED,INTERVENTIONAL,['NA']
11645,NCT00055042,,,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11646,NCT02821585,Change in Waist Circumference,Glycemic variability,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
11647,NCT05131451,Number of Participants Who Get Screened With a Diabetic Eye Exam,Follow-up Rates With an Eye Care Provider,,2021-11-24,COMPLETED,INTERVENTIONAL,['NA']
11648,NCT02631928,"PK: Cins.max, maximum observed insulin concentration",Changes in Electrocardiogram recordings,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11649,NCT04383639,Postprandial insulin,"Satiety measured by a Visual Analogue Scale (see ""Description"" for details)",,2021-05-03,COMPLETED,INTERVENTIONAL,['NA']
11650,NCT02771093,Changes From Baseline in the Standard Deviation (SD) of 24-hour Blood Glucose Values,Number of Participants Reporting One or More Treatment-emergent Adverse Events,,2016-09-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11651,NCT00086502,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11652,NCT00682149,Amelioration of antioxidative capacity in diabetic patients by polyphenol containig antioxidants,treatment of type 2 diabetes by polyphenol containing antioxidants,,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
11653,NCT00976924,blood glucose value,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
11654,NCT02552277,"Percent change in the epidermal nerve fiber density (ENFD) at 6 months, compared to baseline",Adverse Events (AEs),,2015-10-27,COMPLETED,INTERVENTIONAL,['PHASE2']
11655,NCT03474939,Change in copeptin concentration,,,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11656,NCT01997411,Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes,Time to Achieving ≥25 mg/dL Rise in Plasma Glucose Above Nadir Level Within 30 Minutes,Percentage of Participants With >= 25 mg/dL Rise in Plasma Glucose Within 30 Minutes,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11657,NCT01218061,The main objective of the study is to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in this population,"Relation between ""working hours and conditions"" and metabolic disease",,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
11658,NCT00967993,The Primary Outcome of This Trial Will be the Change in Serum Phosphorus From Baseline to End of Treatment After a Four Week Treatment Period.,"The Incidence of Treatment-emergent Adverse Events (New or Worsened From Study Drug Initiation) Will be Summarized by Body System, Severity, Type of Adverse Event, and Presumed Relationship to the Study Drug.",,2010-01,COMPLETED,OBSERVATIONAL,['NA']
11659,NCT02048839,Type 2 Diabetes,Metabolic syndrome and cardiovascular morbidity,Obesity,2014-01,COMPLETED,OBSERVATIONAL,['NA']
11660,NCT01946347,Changes of endothelial function (measured by EndoPat),Insulin sensitivity measured as glucose disposal during clamp,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
11661,NCT01305551,"Evidence of BE on single-dose pharmacokinetic parameters half-life (T-HALF) derived from Saxagliptin, 5-Hydroxy Saxagliptin and Metformin plasma concentration versus time data.","Active metabolite of Saxagliptin, 5-Hydroxy Saxagliptin, from 5 mg Saxagliptin/500 mg Metformin XR FDC tablet & from 5 mg Onglyza administered together with 500 mg Glifage® XR in single-dose fed & fasted state pharmacokinetics in healthy subjects",,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11662,NCT00283751,HbA1c,Change in body weight,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11663,NCT03785301,HbA1c,FGM accuracy,,2018-12-20,UNKNOWN,INTERVENTIONAL,['NA']
11664,NCT01336777,Adipose Cell Size,Gene Expression,,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
11665,NCT04073576,Performance of the AHCL system,Safety of the AHCL system,,2019-05-20,UNKNOWN,INTERVENTIONAL,['NA']
11666,NCT04326569,Copeptin dosage,,,2020-06,UNKNOWN,INTERVENTIONAL,['NA']
11667,NCT00931125,Efficacy of preoperative intravitreal ranibizumab,Retinal circulation integrity.,,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
11668,NCT03340831,Change in hypoglycemic events,Change in Hypoglycemia Confidence PRO scores,,2017-10-20,UNKNOWN,OBSERVATIONAL,['NA']
11669,NCT00964964,Total number of periods where carbohydrate supplementation is needed during the treatment,Number of periods with low blood sugar during treatment,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11670,NCT04261738,Hba1c,Glucagon,,2022-09-02,RECRUITING,INTERVENTIONAL,['NA']
11671,NCT00654745,Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment,Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11672,NCT02297399,Tolerability of the bowel preparation (analogue visual scale),Adverse events,,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11673,NCT02206568,Pharmacokinetics of URAL,Number of subjects with adverse events,,2014-06,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11674,NCT00842075,HbA1c Value After 28 Days,Weight Change After 28 Days Intervention Period,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
11675,NCT01497574,Area under the insulin concentration curve (AUC),Adverse events,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1']
11676,NCT02175732,HbA1c,Depression,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
11677,NCT04090580,Impact of dapagliflozin in glycemic variability,Impact of dapagliflozin in waist circumference,,2019-08-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
11678,NCT00949416,,,,2009-06,UNKNOWN,OBSERVATIONAL,['NA']
11679,NCT04665128,Reducing the glucose levels of hyperglycemic patients in the emergency department may improve clinical outcomes and have a positive effect on post-discharge prognosis.,,,2020-12-15,UNKNOWN,OBSERVATIONAL,['NA']
11680,NCT00085800,,,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
11681,NCT00351585,Durability of this effect after a 2-week washout,Chance from baseline in glucagon secretion at 12 weeks,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11682,NCT02135068,Nadir blood glucose levels during exercise,Mean daytime and nighttime glucose values,,2015-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11683,NCT01356953,Blood Pressure - Ambulatory blood pressure monitoring (ABPM),,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
11684,NCT00790660,Evaluation of safety through clinical safety labs and adverse events,Evaluation of routine PK and PD parameters,,2008-10-23,COMPLETED,INTERVENTIONAL,['PHASE2']
11685,NCT03588234,Food literacy level,Fast food consumption,,2018-06-28,COMPLETED,OBSERVATIONAL,['NA']
11686,NCT05006508,Change of long-term blood glucose concentration measured as glycated hemoglobin at end of follow-up,Change of Patient Health Questionnaire 9-item scale,,2021-08-16,RECRUITING,INTERVENTIONAL,['NA']
11687,NCT06329882,Change in glycemic profile,,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11688,NCT01673191,Mean Change in Intraocular Pressure,,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11689,NCT05445284,Retention feasibility,Diabetes-related emergency department visits,,2023-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11690,NCT02102737,Correlation between measure of insulin resistance measurement by scintigraphy and hyperinsulinemic euglycemic clamp,strain by speckle tracking echocardiography,,2014-05-13,COMPLETED,INTERVENTIONAL,['PHASE2']
11691,NCT00388050,"Treatment Action, adherence",Acceptability,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
11692,NCT03304158,Mean fasting blood glucose level,,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
11693,NCT01892124,Change in Body Mass Index,Changes in Blood Pressure,Changes in Food Habits,2013-11,COMPLETED,INTERVENTIONAL,['NA']
11694,NCT03106480,Prevalence of hypertension,Prevalence of sub-clinical atherosclerosis,,2016-10-06,UNKNOWN,OBSERVATIONAL,['NA']
11695,NCT01369082,Duration of sustained islet allograft function,Donor-specific alloantibodies,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
11696,NCT00240383,"To compare, after 24 weeks of oral administration of double-blind treatment, the change from baseline in hemoglobin A1c (HbA1c) achieved with the highest dose and subsequent doses of BMS-298585 versus the lowest dose of BMS-298585 in subjects with Type 2","To assess, after 12 and 24 weeks of oral administration of double-blind therapy, the percent change from baseline in fasting lipids (total cholesterol,low density lipoprotein cholesterol,HDL-C, TG, non-HDL chol",,2002-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11697,NCT01608724,Absolute Change From Baseline in Haemoglobin A1c (HbA1c),Change From Baseline in 2-hour Postprandial Plasma Glucose (2h-PPG),,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11698,NCT04016662,CGM Measured Time <70 mg/dL,Hypoglycemia Unawareness,Patient Reported Questionnaires,2020-09-28,COMPLETED,INTERVENTIONAL,['PHASE4']
11699,NCT00862849,Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T]),Number of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11700,NCT02211495,Number of Day Until 50% Healing of Leg Ulcer,"Quality of Life (PAID, EQ5D, VAS, SF-12)",,2014-07,COMPLETED,INTERVENTIONAL,['NA']
11701,NCT01649167,,,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
11702,NCT02622113,Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events),Percentage Change in Body Weight,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11703,NCT01318564,Patients' Adherence to Unit Dose Packaging Devices,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
11704,NCT04222686,Variation of exercise-induced urinary albumin excretion,Change in uricemia concentration,,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
11705,NCT03433677,Rate of Infusion Set Failures,Number of Participants With Severe Hypoglycemic Events,,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE3']
11706,NCT00213213,"- Infant pain score during the newborn screening test, assessed by the Premature Infant Pain Profile (PIPP), or individual parameters of PIPP (facial grimace, heart rate, oxygen saturation)",- Serum Glucose concentrations in infants of diabetic mothers,,2003-07,UNKNOWN,INTERVENTIONAL,['NA']
11707,NCT04025281,Endothelial Function (EF) Assessment,Office Blood Pressure,,2019-07-09,COMPLETED,INTERVENTIONAL,['NA']
11708,NCT04161859,Prevalence of the use of nutraceutical in clinical practice,,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
11709,NCT05067231,Genetic Variants in the NPPA and NPPB gene of the Natriuretic Peptide family associated with the Cardiovascular and Metabolic Diseases,,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
11710,NCT02251418,Ulcer area,Ulcer area,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
11711,NCT01436201,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin,,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11712,NCT05264727,Change in Glucagon Suppression (G50) caused by amino acids vs. saline,glucagon suppression (G50) is greater in obese compared to lean people without T2DM,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE4']
11713,NCT01146678,Lixisenatide maximum plasma/serum peak concentration (LIX-Cmax),Time to GIRmax (GIR-Tmax),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11714,NCT01408628,Frequency of Hypoglycemia,Severity of Self-reported Hypoglycemia,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
11715,NCT01784211,Part A: Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Glargine: Intra-Participant Variability,Part B: Pharmacokinetics: Cmax of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11716,NCT02419859,Glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood),Hypoglycemic events,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
11717,NCT01019486,Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects.,Myocardial Perfusion Index,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11718,NCT01578837,Change in Mean 24 hour Systolic Ambulatory Blood Pressure at 12 weeks,Change in lipids at 12 weeks,,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11719,NCT03697109,"In all patients, assessment of safety based on treatment-emergent adverse events (TEAEs) as graded by CTCAE v5.0.",In patients with uncontrolled hypertension the mean change in SBP or DBP from Baseline to visit OL22/ET,,2018-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
11720,NCT03077997,Diabetes Distress (As measured by the Diabetes Distress Scale),EuroQol 5D5L,,2017-03-15,TERMINATED,INTERVENTIONAL,['NA']
11721,NCT00012649,,,,na,COMPLETED,OBSERVATIONAL,['NA']
11722,NCT05092477,Illness Perceptions Questionnaire (IPQ scores),Beliefs about Medicines Questionnaire (BMQ scores),,2022-01-27,COMPLETED,INTERVENTIONAL,['NA']
11723,NCT00527995,Improvement of flow mediated dilatation of the brachial artery following a single dose of 100mg Sildenafil.,Change in hemodynamics and cardiovascular parasympathetic and sympathetic nerve function using time domain and frequency domain indexes of heart rate variability (HRV) and baroreflex sensitivity (BRS) following a single dose of 100mg Sildenafil.,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11724,NCT06075121,Blood sugar,,,2023-06-12,RECRUITING,INTERVENTIONAL,['NA']
11725,NCT00194298,SUV measurement from PET scan,,,2002-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11726,NCT01623648,Plasma glucose,Change in body weight,,2013-02,UNKNOWN,INTERVENTIONAL,['NA']
11727,NCT04530383,Change in BK channel gene expression,Pharmacokinetics of metformin,,2022-02-14,RECRUITING,INTERVENTIONAL,['PHASE2']
11728,NCT02790892,Decrease diabetes related distress,Increase emotional,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
11729,NCT05275803,Microorganism,IL-1β、IL-6、TNF-α,,2023-06-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11730,NCT00063128,test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c,assess the impact of practice inhalations on inspiratory flow parameters (peak inspiratory flow rate [IFR] and total inspired volume [TIV]) achieved by patients using the insulin inhaler following training with the DFU,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11731,NCT04871958,Blood glucose Time-In-Range (TIR) during hospital stay,Accesses to the isolation room,,2021-03-19,TERMINATED,INTERVENTIONAL,['NA']
11732,NCT02871089,Area under the meal stimulated C-peptide curve (AUC) during a mixed meal tolerance test (MMTT),Lipid profile,Qualitative Human Factor Assessment,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11733,NCT02666430,Change in Hemoglobin A1c (HbA1c) From Baseline,Change From Baseline in Cross-Reactive Insulin Antibody - Lantus Assay,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11734,NCT05298163,Albuminuria,Calcium level,,2022-04,UNKNOWN,INTERVENTIONAL,['NA']
11735,NCT01019642,"Insulin resistance, measured by HOMA-IR index",Serum 25-OH-vitamin D3 levels,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11736,NCT04027023,impact of a temporary personalized poly-pharmaceutical treatment on the disease stage in patients with type 2 diabetes,Electrolytic balance,,2019-10-30,UNKNOWN,INTERVENTIONAL,['PHASE4']
11737,NCT05180604,The Patient Health Engagement score after intervention at 6 months,"The change Trajectory of Cholesterol level from baseline to after the intervention at 3, 6 and 12 months",,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
11738,NCT02705274,Proportion of visual acuity improvement using Snellen chart or equivalent from baseline and 1 year,Proportion of eyes Need for Vitrectomy,,2016-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11739,NCT00099320,Change from Baseline to Week 16 in fasting serum glucose (FSG) and glucose,Changes in lipids between Baseline and Week 16,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11740,NCT02681718,Difference in Hemoglobin A1C (Text Message vs. Control),Percentage of participants who visited a physician due to a diabetes related follow-up,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
11741,NCT05969106,Incremental Cost Efficiency Rate (ICER),,Glucose control at start of the study,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
11742,NCT00981448,Change in acute insulin response from IVGTT.,change in urinary zinc,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
11743,NCT05846191,Mean different in concentration of serum pentraxin-3 and high sensitive CRP levels in study groups.,,,2023-12-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11744,NCT02914821,Sugar-Sweetened Beverages Sold by Universal Product Code (UPC),Changes in types of beverages purchased,,2016-09-01,TERMINATED,INTERVENTIONAL,['NA']
11745,NCT00980356,To assess whether monotherapy with Vildagliptin improve glycemic control in kidney transplanted patients with newly diagnosed NODAT as judged in OGTT 3 months after treatment start compared to placebo.,To assess differences in the change in HbA1c and fasting plasma glucose after 3 months after treatment start and to assess the safety and efficacy of Vildagliptin in renal transplanted patients.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11746,NCT01121289,Area under the serum NN1218 concentration-time curve,Area under the serum NN1218 concentration-time curve,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
11747,NCT02694263,HbA1c + weight loss,Flash Glucose Monitoring - MAGE,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11748,NCT04226846,Comparison between Bios device readings and glucose values,,,2019-12-09,UNKNOWN,OBSERVATIONAL,['NA']
11749,NCT01730885,"Mean absolute relative deviation (MARD) from paired reference values of BGStar®, iBGStar® and comparator BG meter measurements at stable hypoglycaemic, euglycaemic and hyperglycaemic levels and overal",,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11750,NCT00380913,The Average Pain Score at target site.,Safety will be assessed through the collection of AEs and vital signs.,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
11751,NCT00299871,HbA1c levels at baseline and endpoint (at 13 weeks).,"Fructosamine, fasting plasma glucose, fasting serum insulin, proinsulin, C-peptide, glucagon.",,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11752,NCT03257228,Insulin like growth factors in patients with OLP and diabetes mellitus,,,2014-11-01,COMPLETED,OBSERVATIONAL,['NA']
11753,NCT04331444,"Difference between change in TIR (3.9-10 mmol/l) in percent, assessed via blinded CGM device, between CGM group (A) and SMBG group (C)",Difference between number of participants using CGM vs. not using CGM increasing 5 % or more in TIR,Evaluating which blood glucose measured by SMBG best reflect TIR,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
11754,NCT02220907,Number of Participants With Adverse Events,Percentage Change in Body Weight From Baseline,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11755,NCT04011397,Change in enjoyment,Change in systolic and diastolic blood pressure,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
11756,NCT04515745,Ever applied for public disability program benefits (Social Security Disability Insurance (SSDI) or disability-related Supplemental Security Income (SSI)),Application for Social Security Disability Insurance (SSDI) or disability-related Supplemental Security Income (SSI) benefits.,Ever participated in labor force conditional on enrollment in disability programs.,2016-12-19,COMPLETED,OBSERVATIONAL,['NA']
11757,NCT03146156,Neonatal adiposity comparison between intervention and usual care group,Maternal metabolic status,,2017-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11758,NCT01104168,prevalence of diabetes,evaluate the impact of quality of care and glycemic control on clinical outcome in elderly subjects,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
11759,NCT05812547,To evaluate the average change in blood glucose levels with the use the Lumen device,To evaluate the change in need for neonatal intensive care unit (NICU) admission,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11760,NCT05770076,Changes in fasting plasma glucose (FPG) level,body mass index (BMI),,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
11761,NCT03784612,Change in dietary intake,Blood pressure,Change in perceived social support from family and friends for healthy eating habits,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
11762,NCT00411554,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2 Hour Postprandial Glucose at Week 12,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11763,NCT04068285,walking speed,,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA']
11764,NCT05920434,Pain severity,Vibration sense,The quality of life,2020-07-19,COMPLETED,INTERVENTIONAL,['NA']
11765,NCT00361023,,,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
11766,NCT05525572,Changes in Endothelial Progenitor Cell Colony Forming Units (EPC-CFUs),Incidence of Serious Adverse Events (SAEs),,2024-06-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11767,NCT05890807,Parodontitis based on clinical observation of the patient's oral cavity (direct method),D. Visible clinical signs associated with periodontitis on the photos taken. Plaque,Charlson score,2023-03-20,RECRUITING,INTERVENTIONAL,['NA']
11768,NCT02938806,Analysis of gut microbial composition and diversity by 16S rRNA sequencing,Analysis of urine metabolite concentrations measured by mass spectrometry,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
11769,NCT01601990,Change of HbAlc,HbA1c Responder Rate,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11770,NCT00355823,,,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
11771,NCT03430141,Nutrition Intervention,Chronic disease prevalence,,2016-10-31,COMPLETED,INTERVENTIONAL,['NA']
11772,NCT04277117,Change in Hemoglobin A1C (HbA1c),Medication underuse due to cost (2 items),,2022-12-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11773,NCT01346527,Left ventricular strain,Maternal palmitate rate of appearance during hyperinsulinemia,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
11774,NCT01973231,Change in Glycosylated Haemoglobin (HbA1c) From Baseline,Number of Treatment Emergent Adverse Events (TEAEs),,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11775,NCT05110703,Examination of the effect of daily use of a prebiotic fiber meal replacement (PFMR) shake on quality of life [Time Frame: Baseline to 12 weeks],Changes from baseline on short-chain fatty acid synthesis from baseline after daily use of PFMR shakes. [Time Frame: Baseline to 12 weeks],,2021-10-11,COMPLETED,INTERVENTIONAL,['NA']
11776,NCT00790439,Level of Stimulated C-peptide at 90-minutes in Response to a Mixed-Meal Tolerance Test (MMTT),Incidence of Worsening Retinopathy,,2008-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11777,NCT04450394,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,,2020-07-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11778,NCT00742976,change in weight; change in extracellular volume,"sodium excretion in urine, 24 hour blood pressure, body composition change,urine osmolality, urine albumin excretion, GFR, HbA1c, Blood lipid profile, NT-proBNP, plasma Albumin, Plasma metanephrines, aldosterone, active renin, angiotensin II",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11779,NCT04449692,Difference between study visits in time (min) in hypoglycemia (plasma glucose < 3.9 mmol/l) from 0-180 minutes post-intervention,Difference between study visits in incidence rate of vomiting from 0-180 minutes post-intervention,,2020-07-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11780,NCT02915263,Change in Neuropathic Pain Severity as Measured by the Pain Visual Analogue Scores (VAS).,Change in Autonomic Neuropathy as Measured by Standardized Autonomic Nervous System Testing.,,2017-09-11,TERMINATED,INTERVENTIONAL,['PHASE2']
11781,NCT05252793,Healthy Lifestyle Behaviors Scale II Score Change,Self-Efficacy Questionnaire,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
11782,NCT02689570,coronary artery calcifications,diastolic dysfunction,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
11783,NCT04962048,Change of toleration / wellbeeing due to intervention of PSNP with Numeric Rating Scale,Change of microcirculation with thermal imaging (TH),,2021-05-28,TERMINATED,INTERVENTIONAL,['NA']
11784,NCT02723019,Number of Patients With at Least 1 Hospital Readmission Within 180 Days After Enrollment,Number of Outpatient Visits Over the Past 6 Months - Patient-reported,,2016-07-14,COMPLETED,INTERVENTIONAL,['NA']
11785,NCT02905487,Blood levels of C- Reactive Protein in mother and her child,Blood level of C-peptide in mother,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
11786,NCT00888719,Change in HbA1c before and after treatment,"Triglyceride, LDL-cholesterol and HDL-cholesterol change",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11787,NCT00374907,Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12,Insulin Secretion Rate AUC During IV Hyperglycemic Clamp - Percent Change From Baseline at Week 12,Marked Laboratory Abnormalities - During ST + LT Treatment Period,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11788,NCT06227247,Receipt of intervention (Exercise Session Completion),,,2024-02-01,RECRUITING,INTERVENTIONAL,['NA']
11789,NCT01522807,The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameter of Elimination of half-life (t ½ ) as data permit.,Changes in plasma glucose and insulin due to single doses of three formulations of PF-05190457 will be estimated.,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11790,NCT03370484,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Subjective ratings of appetite (au),,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
11791,NCT05193578,HbA1c (mmol/mol),Absolute change in systolic and diastolic blood pressure (mmHg),,2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE2']
11792,NCT05998837,Biopsy changes in the expression and location of senescence markers by immunohistochemistry,Outcomes of blood presssure control,,2021-04-13,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11793,NCT01682954,Body Weight,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
11794,NCT05510245,Fraction of unbound drug in plasma; Cu/C where Cu represents unbound concentration and C represents total concentration,Number of Participants With Treatment emergent Clinically Significant Abnormal ECG,,2022-08-29,TERMINATED,INTERVENTIONAL,['PHASE1']
11795,NCT05253521,The change in the frequency / absolute number of circulating ALDHhiSSChi granulocyte precursor cells between individuals of South Asian origins and White individuals of European origin,The change in the frequency / absolute number of circulating ALDHhiSSClo cells with primitive provascular progenitor cell phenotype between individuals of South Asian origins and White individuals of European origin,Changes in the concentration of serum inflammatory markers individuals of South Asian origins and White individuals of European origins,2022-01-08,COMPLETED,OBSERVATIONAL,['NA']
11796,NCT03183804,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,,2015-12-29,COMPLETED,OBSERVATIONAL,['NA']
11797,NCT01654120,Change from baseline in HbA1c at six months,GlycoMark,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11798,NCT00220337,"Number of Subjects With Urine Protein Status 'Positive +++' at Baseline, Categorized by Urine Protein Status at Last Visit",Change in Quality of Life From Visit 2 (Baseline) to Termination Visit,,2004-12-21,COMPLETED,INTERVENTIONAL,['PHASE3']
11799,NCT03178591,The average of systolic blood pressure at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group.,,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11800,NCT03531944,Change in HbA1c level,Cost effectiveness analysis,,2018-06-06,COMPLETED,INTERVENTIONAL,['NA']
11801,NCT06083116,"Steady-state pharmacokinetics parameters of Hydrochlorothiazide: Css, max",Adverse events,,2019-08-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11802,NCT03616275,Changes from Baseline Autonomic function (Heart rate variability) at 3 and 6 months,Changes from Baseline salivary cortisol at 3 and 6 months,,2017-10-17,COMPLETED,INTERVENTIONAL,['NA']
11803,NCT02881164,Satiety,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11804,NCT05766215,Body Mass Index,Adherence to diabetes treatment,Demographical information,2023-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11805,NCT00160056,,,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
11806,NCT05319496,Change in HbA1c,Hospital admissions,,2022-10-05,COMPLETED,INTERVENTIONAL,['NA']
11807,NCT01410097,Short Physical Performance Battery (SPPB) Score,Modified Mini-Mental Status Exam (3MS),,2009-09,COMPLETED,INTERVENTIONAL,['NA']
11808,NCT01464073,body fat mass reduction,biological parameter,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
11809,NCT03111433,change in soluble interacellular adhesion molecule level,,,2017-03-19,COMPLETED,INTERVENTIONAL,['PHASE2']
11810,NCT02343146,Glycemic Control/HbA1c,Child eating as measured by Remote Food Photography by the parent,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
11811,NCT00437008,A high-AGE meal causes a more pronounced postprandial endothelial dysfunction comparing to a low-AGE meal in people with type 2 diabetes mellitus.,To investigate whether treatment with Benfotiamine 1050mg/day for 3 days has a protective effect on endothelial function after a high-AGE meal,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11812,NCT03646812,Insulin,,,2018-08-10,COMPLETED,INTERVENTIONAL,['NA']
11813,NCT01175473,Change From Baseline in Area Under the Plasma Glucose Concentration Curve From Time 0.5 Hours to 4.5 Hours (GLU-AUC0:30-4:30h) at Day 28,Percentages of Patients by Ranges of Oxyntomodulin Levels,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11814,NCT03470415,epicardial fat thickness measurement,Electrocardiogram,,2018-05,UNKNOWN,OBSERVATIONAL,['NA']
11815,NCT01231178,Body weight,Body composition,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
11816,NCT03073577,Serious adverse event morbidity,Beta-2 score,,2017-02-17,RECRUITING,INTERVENTIONAL,['PHASE1']
11817,NCT01841229,Glycated hemoglobin (HbA1c),Homeostasis model assessment of insulin resistance (HOMA-IR),,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
11818,NCT05631431,primary objective,,,2021-10-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11819,NCT00297063,HbA1c change from baseline at Week 28.,"Efficacy variables (changes from baseline in FPG, fasting insulin, HOMA-IR and HOMA-beta) at stipulated date in each treatment group.",,2006-01-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11820,NCT03909802,Wound size,,,2019-07-06,COMPLETED,INTERVENTIONAL,['NA']
11821,NCT05234086,Proportion of patients with completely closed ulcers,,,2020-01-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
11822,NCT02391558,"Comparison between examination techniques on the detection of morphological changes in the retina (such as vessels morphology, vascular ischemia, retinal neovascularization, choroidal neovascularization, and other vascular abnormalities).",,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
11823,NCT03987633,Ethnic disparities in treatment failure,Identification of candidate genetic variants associated with observed disparities in treatment failure.,,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
11824,NCT03746093,Changes in HbA1c levels from baseline to visit 2 and 3,Changes in fasting serum triglycerides from baseline to visit 2 and 3,,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA']
11825,NCT03182842,Time within 3.9 and 10 mmol/l,,,2017-06-17,COMPLETED,INTERVENTIONAL,['NA']
11826,NCT01447940,HbA1c measured at 12 months in Meos ePoral group versus conventional care group. Non-inferiority level is defined at a 0.15% threshold for an expected HbA1c of 8.5% at 12 months,"Qualitative analysis by semi-structured interviews, then quantitative survey by questionnaire",,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11827,NCT05845190,homocystiene,cholestrol,,2022-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11828,NCT02057211,∆-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment.,,,2014-04,TERMINATED,INTERVENTIONAL,['PHASE2']
11829,NCT01483352,Percentage of Participants Categorized by Ability of the Port to Deliver Insulin Intraperitonally,Design Validation Participant Questionnaire - Percentage of Participants With a Positive Response,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
11830,NCT04620265,Change from baseline spatial and temporal gait parameters at 3 months,,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
11831,NCT03617146,Diabetes distress score,"Self-care behaviors (medication adherence, dietary practices, and physical activity behaviors)",,2018-06-15,TERMINATED,INTERVENTIONAL,['NA']
11832,NCT02626936,Percentage of time below 4.0 mmol/L,Total glucagon delivery,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11833,NCT01026103,Proportion of Patients With an Uneventful Creation of a Functional Staple Line,Incidence of Serosal Tearing,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
11834,NCT00219089,Change from baseline in mean sitting diastolic blood pressure after 8 weeks,Diastolic blood pressure less than 90 mmHg or reduction of 10 mmHg or greater from baseline after 8 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11835,NCT05197829,Problem Areas in Diabetes,Number of Sensor Checks per Day,,2022-01-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11836,NCT03960424,Hemoglobin A1C,Diabetes Quality of life,,2019-09-30,COMPLETED,INTERVENTIONAL,['NA']
11837,NCT03054454,Nights spent in hospital with a diabetes-related foot problem.,number of below knee amputations attributed to diabetic foot disease,,2017-04,UNKNOWN,INTERVENTIONAL,['NA']
11838,NCT05592860,HbA1c,Change in blood pressure,,2021-07-10,COMPLETED,INTERVENTIONAL,['NA']
11839,NCT00762242,change from baseline (pre-forearm ischemia) in circulating metabolites compared with post-ischemic forearm measurements,,,2007-05,TERMINATED,OBSERVATIONAL,['NA']
11840,NCT00394407,blood glucose control,inflammatory markers,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
11841,NCT01632007,Glycosylated hemoglobin (HbA1c),,,2012-05-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11842,NCT04150107,Average Exogenous Total Insulin Compared to Baseline,Daytime Low Blood Glucose Index (LBGI) Compared to Baseline,,2019-10-17,COMPLETED,INTERVENTIONAL,['PHASE2']
11843,NCT05342012,Pixel wise quantification of fat fraction will be performed from fat and water maps.,Biomarkers - cGMP,,2022-06-30,COMPLETED,INTERVENTIONAL,['NA']
11844,NCT02028078,Tracer to Tracee Ratio (the absolute relative difference ARDi ),Tracer to tracee Ratio,Time to reach each hypoglycaemic level,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11845,NCT00614939,Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 12 Last Observation Carried Forward (LOCF),Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - Moderate Renal Impairment Subgroup,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11846,NCT03659461,change in blood insulin response to sitagliptin,,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
11847,NCT02411006,Medication refills,LDL cholesterol,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11848,NCT01551446,Change in renal perfusion,Change in total body water,,2012-04-30,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11849,NCT02630706,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation),Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation),,2015-12-16,COMPLETED,INTERVENTIONAL,['PHASE3']
11850,NCT02231684,Area under the semaglutide plasma concentration curve,Number of treatment emergent adverse events (TEAEs),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11851,NCT02211742,postprandial glucose homeostasis,,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11852,NCT06311019,Change in Haemoglobin A1c,Fraction of patients with increased number of bolus insulin per day,Diabetes Treatment Satisfaction Questionnaire (DTSQ),2024-02-27,RECRUITING,INTERVENTIONAL,['NA']
11853,NCT06235086,Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb).,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11854,NCT01970033,Change From Baseline in HbA1c (Hemoglobin A1C) at Week24,"Change From Baseline in Body Weight at Week 4,8,12、24、38、52",,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
11855,NCT04276428,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose,,2020-02-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11856,NCT05033275,Babies with sacral agenesis identified with screening of asymptomatic babies with a spinal ultrasound,,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
11857,NCT02888951,Volume of Gastric Contents,"Episodes of intra-operative regurgitation, vomiting or aspiration",,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
11858,NCT04419337,HbA1C,insulin resistance,,2019-09-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11859,NCT02210871,Area under the semaglutide plasma concentration-time curve,Number of treatment emergent adverse events (TEAEs),,2014-08-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11860,NCT02791204,Assessment of lower extremity skeletal muscle perfusion in healthy control subjects compared to patients with peripheral arterial disease and diabetes using quantitative SPECT/CT imaging.,,,2016-05,RECRUITING,OBSERVATIONAL,['NA']
11861,NCT04298424,HbA1C,Self-Efficacy Score,,2020-02-14,UNKNOWN,INTERVENTIONAL,['NA']
11862,NCT00726674,Decrease in HbA1c level,Safety measures,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
11863,NCT01369277,Renal clearance (CLr),,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11864,NCT06051058,To determine the effect of the Care Transitions App on post-discharge adverse events,To determine the effect of the Care Transitions App on the 30-day readmission rate,,2024-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11865,NCT00950599,Change From Baseline in A1C at Week 12 in the 0-40 mg Cohort,"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0 & 100 mg Cohort",,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11866,NCT00391027,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Urinary Free 8-iso Prostaglandin F2-alpha (α) in a Subset of Subjects,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11867,NCT04375943,"E velocity, A velocity,E' velocity",,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
11868,NCT04399434,glucolipid metabolism and insulin sensitivity in pregnant women,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
11869,NCT05773183,To compare differences in steroid metabolomics in men with prostate cancer pre- and post-androgen deprivation therapy (ADT),To compare differences in metabolic phenotype in (i) hypogonadal men compared to healthy men (ii) hypogonadal men pre and post testosterone replacement therapy (iii) men with prostate cancer post initiation of Androgen Deprivation Therapy,,2023-03-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11870,NCT04018326,Final UCVA,,,2013-05-01,COMPLETED,OBSERVATIONAL,['NA']
11871,NCT01453842,Plasma GLP-1,Plasma paracetamol,,2011-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11872,NCT00654056,Insulin sensitivity,Changes in insulin signaling proteins?,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
11873,NCT00680849,"Food Frequency Questionnaire for Fruits, Vegetables and percent calories from fat (FFQ) by Kristal and colleagues","Lipids, weight loss",,2003-12,COMPLETED,OBSERVATIONAL,['NA']
11874,NCT06187285,Mean blood glucose concentration,Glycated hemoglobin,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
11875,NCT00488033,"Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina",Number of Participants With Limb Amputation or Peripheral Vascular Revascularization Procedure,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
11876,NCT01147627,the Comparison Between Treatment Groups of the Changes From Baseline in HbA1c at 48 Weeks,Safety and Tolerability in Different Groups,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
11877,NCT04745572,Changes in QUICKI index,Diet Intake and Physical Activity Monitoring,,2021-05-14,COMPLETED,INTERVENTIONAL,['NA']
11878,NCT05243589,"WHO Quality of Life Scale (WHOQOL BREF)( assessing change in quality of life at baseline, 4th and 6th week of intervention.",,,2021-02-26,COMPLETED,INTERVENTIONAL,['NA']
11879,NCT01481779,Hemoglobin A1c (HbA1c) at 26 Weeks,Rapid Assessment of Physical Activity (RAPA),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11880,NCT04790760,Difference in time-matched glucose levels between the right arm and the left arm,Difference in time below range between the right arm and the left arm,Change in bone mass,2021-03,UNKNOWN,INTERVENTIONAL,['NA']
11881,NCT01338922,Diabetes burden (main carer),Diabetes treatment satisfaction,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
11882,NCT01847937,Increase in magnetic resonance signal intensity of segmented nerves,Correlation of magnetic resoance signal intensity value and nerve conduction thresholds,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
11883,NCT01871415,Change in HbA1c,Safety: Incidence of adverse events,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11884,NCT05857319,Effectiveness of the national RNPC weight reduction program on the change of treatments (drug or instrumental treatments) or in the comorbidities of overweight/obesity.,Dropout rate,,2023-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11885,NCT02854111,The correct diagnosis of diabetes mellitus,The correct diagnosis of impaired glucose tolerance,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
11886,NCT05611112,Mental health - Depression,Health literacy,,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11887,NCT02508779,"Reduced consequences of extreme BG (e.g., diabetic ketoacidosis, SH)",Improved internal locus of control (as confirmed by the Perceived Competence for Diabetes Scale and the Treatment Self-Regulation Questionnaire),,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11888,NCT03120871,Insulin sensitivity (Si),Urinary follicle stimulating hormone (FSH),,2017-05-12,COMPLETED,OBSERVATIONAL,['NA']
11889,NCT01011062,insulin sensitivity measured as glucose disposal during clamp,plasma adipokines and their expressions in SAT,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
11890,NCT01105884,complete healing of the wound,,,2009-10,WITHDRAWN,INTERVENTIONAL,['NA']
11891,NCT00543556,,,,2001-10,TERMINATED,INTERVENTIONAL,['PHASE2']
11892,NCT01474161,"Safety parameters (Study Parts II, III and IV)","Pharmacokinetics parameters (Study Parts II, III and IV)",,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11893,NCT04843527,Impact on time above 180 mg/dL,,,2021-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11894,NCT00641056,Change in HbA1c From Baseline to Week 26,Assessment on Event Rate of Treatment-emergent Hypoglycemic Episodes,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11895,NCT02378675,Difference of adipocytokines between women with GDM and women with normal glucose tolerance.,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
11896,NCT01724814,Incidence and severity of treatment emergent adverse events,Peak Plasma Concentration(Cmax) of HM12460A following a single dose in Parts 1-3,,2012-12-20,COMPLETED,INTERVENTIONAL,['PHASE1']
11897,NCT01086293,Number of participants hospitalized with a diagnosis of acute liver failure,Hospitalizations with acute liver injury,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
11898,NCT06257082,Change in Eye Health Literacy as measured by Compliance with Annual Diabetic Eye Exams Survey (CADEES),Change in Trust in Healthcare as measured by Trust in the Health Care Team (T-HCT) scale score,,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11899,NCT02196571,"Number of pregnant women with complications during pregnancy, labour and delivery",Weight gain in pregnancy,Physical Activity in Pregnancy,2014-07,COMPLETED,INTERVENTIONAL,['NA']
11900,NCT02344186,Changes in unfolded protein response markers,Beta cell function,,2014-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
11901,NCT01001962,New onset of hypertension,Mortality cardiovascular,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11902,NCT06053047,Relative risk reduction in the incidence of new Diabetic Foot Ulcers (DFUs),Relative risk reduction in resource utilization,Healthcare Provider acceptance of Bluedrop Monitoring System (BMS),2024-01-22,RECRUITING,INTERVENTIONAL,['NA']
11903,NCT05413239,Time in Range (TIR),Attitudes toward diabetes device use,Diabetes incorporation/identity,2022-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11904,NCT02244164,Volumetric measurement of the pancreas,Quantitative response to secretin,Lipasemia,2014-10,TERMINATED,INTERVENTIONAL,['NA']
11905,NCT02607280,Change From Baseline in Average Daily Pain Score (ADPS) at Each Week,,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11906,NCT01506310,Serum fasting glucose values.,The mean birth-weight of newborns,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11907,NCT00423059,Factor VIII,complication rate,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
11908,NCT01264016,Percent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension),,2010-11,COMPLETED,INTERVENTIONAL,['NA']
11909,NCT00432887,glucose tolerance,plasma caffeine concentration,,2004-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11910,NCT04221152,"Adverse events, Adverse drug reactions, and Presence/absence of the use of rescue treatment drugs",Postprandial glucose for 2 hours over time,,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11911,NCT03059056,Area under the curve,,,2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11912,NCT00612599,Area under the serum glucose concentration profile during 24 hours,Hypoglycaemic episodes,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11913,NCT01105455,Serum glucose concentration 1hr after glucose challenge test,Acceptability of study foods,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
11914,NCT05917808,Change in 2 hour glucose in OGTT,Change in homeostasis model assessment (HOMA) Index between 1st and second OGTT,,2023-05-29,RECRUITING,INTERVENTIONAL,['NA']
11915,NCT05806294,Blood pressure,Changes in resting energy expenditure,Changes in hospital admissions rates for ischemic stroke events,2022-11-17,RECRUITING,INTERVENTIONAL,['NA']
11916,NCT02667652,body mass idex,blood fat,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
11917,NCT05713396,AV,TPF/FT,,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11918,NCT04838600,"Incidence of clean wound bed at End of Treatment, as assessed by investigator","Relative change in devitalized tissue and wound size at End of Treatment, compared to Baseline, assessed by planimetry",,2021-06-07,TERMINATED,OBSERVATIONAL,['NA']
11919,NCT00870402,Reduction of albuminuria,Reduction of diastolic disfunction,,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
11920,NCT04805996,HbA1c,Diabetes complications follow up,,2021-03-23,COMPLETED,INTERVENTIONAL,['NA']
11921,NCT00500097,"Sensitivity, specificity, kappa coefficient",,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
11922,NCT03997032,Plasma homocysteine level,Retinal vessel diameters,Intraocular pressure,2017-07-31,COMPLETED,INTERVENTIONAL,['NA']
11923,NCT02386943,β-cell function (measurement of insulin and c-peptide during the clamp study),Incretin effect (measurement of active GLP-1 during the clamp study),,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
11924,NCT01221207,Number of Participants Who Achieve Full Wound Healing.,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
11925,NCT00801450,central subfield macular thickness,Intraocular pressure,,2007-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11926,NCT03182231,Pancreatic uptake of 68Ga-NODAGA-exendin-4,Beta cell function,,2016-10-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11927,NCT04126603,Gene Expression of CD34+ Endothelial Progenitor Cell number,Biochemistry: LDL over HDl Ratio,,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11928,NCT03285750,GPR120 expression in adipose tissue,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
11929,NCT03078101,The difference of Ang 1-7 increase from baseline between a 3-month treatment with empagliflozin on top of ACEi treatment compared to ACEi treatment alone,Mean changes in salt sensitivity after 3 months of empagliflozin treatment,Number of hospitalizations during the study.,2017-04-15,COMPLETED,INTERVENTIONAL,['PHASE2']
11930,NCT02414217,Change in Objective Diabetes Numeracy from Baseline to ≈6 weeks,Change in Glycemic Control from Baseline to ≈3 months,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11931,NCT01181882,Platelet function,Lysophospholipids,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11932,NCT00402012,Change in skeletal muscle mitochondrial number (electron microscopy + qPCR of mtDNA) and mitochondrial gene expression in T2DM patients treated with pioglitazone (vs. placebo),intra hepatic and intra myocellular lipid by MRS; mitochondrial content by MRS (ATP max) post weight loss period,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11933,NCT05724134,Serum C-peptide (relative/change) (units: fold difference and/or ∆ µIU/mL relative to previous time points),Plasma glucose kinetics: endogenous glucose production (units: mg/kg/min),Serum or plasma growth hormone (relative/change) (units: fold difference and/or ∆ng/mL relative to previous time points),2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE1']
11934,NCT00875108,The frequency of occurrence of hypoglycemia measured quarterly over one year.,"Changes in total daily:Prandial insulin dose, insulin dose, body weight, insulin antibody titers, the effects of insulin antibodies on glycemic control, individual and group mean %HbA1C measured quarterly and over one year.",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11935,NCT02660593,Blood Sugar level,,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
11936,NCT02548585,Change From Baseline in Body Weight to the EOT (Cohort 4),"Percent Change From Baseline in Incretin AUC0-4h After MMT to EOT (Cohorts 1, 2, 3, and 4)",,2015-12-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11937,NCT02589028,Area under the curve (AUC) of plasma glucose level after breakfast,Area under the curve of plasma glucagon level after breakfast,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
11938,NCT02828995,Diabetes Medication Adherence,Diabetes Patient Weight (in Pounds),,2016-07-08,COMPLETED,OBSERVATIONAL,['NA']
11939,NCT00525629,Insulin Resistance,,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
11940,NCT05648721,Patient compliance,Patients' satisfaction from the monitoring protocol,,2023-05-18,RECRUITING,INTERVENTIONAL,['NA']
11941,NCT01469143,Area under the serum insulin aspart concentration-time curve,Time to maximum observed serum insulin aspart concentration,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11942,NCT03041844,Change in wound size,Microcirculatory blood flow index change,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
11943,NCT00237952,"The primary end point is an increase in serum creatinine to 1.5 times the base-line value, measured on two occasions one month apart, or the need for hemodialysis during the longitudinal observation period.",A secondary end point is a temporal change in the creatinine clearance or glomerular filtration rate during the follow-up period.,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
11944,NCT05380817,Percentage of underrepresented minority participants enrolled,Number of patient reported device related issues,,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11945,NCT00147342,,,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
11946,NCT01615978,Adverse events,24-hour profiles of plasma glucose,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11947,NCT03154060,Mean Absolute Relative Difference,Precision Absolute Relative Deviation,,2017-05-19,COMPLETED,INTERVENTIONAL,['NA']
11948,NCT03950505,A degree of liver fibrosis,Clinical glucometabolic parameters :Anthropometric parameters,,2020-05-29,UNKNOWN,INTERVENTIONAL,['PHASE4']
11949,NCT02337218,Gait Test (LegSys System),,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11950,NCT00571818,Evaluate insulin sensitivity/glucose effectiveness,,,2000-11-01,COMPLETED,INTERVENTIONAL,['NA']
11951,NCT02989740,The per patient incidence of the target lesion(s) related composite MACE,"The incidence of MACE (Cardiac death, MI, any clinically driven-revascularization or hospitalization due to unstable or progressive angina)",,2015-03-26,COMPLETED,OBSERVATIONAL,['NA']
11952,NCT05657769,HbA1C Changes,Lab outcome VI (triglyceride),,2022-11-12,RECRUITING,INTERVENTIONAL,['NA']
11953,NCT03625856,HbA1c changes,Depression score changes,,2018-11-30,COMPLETED,INTERVENTIONAL,['NA']
11954,NCT01925989,Sleep Respiratory Quotient (RQ) in Type 1 Diabetes Mellitus (T1DM),"Change in RQ, Pre-breakfast to Post-breakfast Meal, in T1DM",,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11955,NCT01065909,,,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
11956,NCT01483560,Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT),Change in Endothelial Function,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11957,NCT02080741,Telomere length,Level of expression of candidate genes,Analysis of the specific psychological interview EMIC,2014-09-23,TERMINATED,INTERVENTIONAL,['NA']
11958,NCT01038518,"5-year change in prevalence of biomarkers of chronic diseases (e.g. diabetes, asthma, allergy) and micronutrient status (e.g. vitamin D status).",significant interaction (on a additive scale) between Vitamin D status and genetic variants in the Vitamin D receptor in relation to selected chronic disease biomarkers,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
11959,NCT04581447,Proportion of patients with partial or complete T2D remission criteria,Level of glicentin,,2021-01-07,RECRUITING,INTERVENTIONAL,['PHASE3']
11960,NCT04722354,Insulin sensitivity,,,2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2']
11961,NCT02352974,Number of Subjects With Injection Site Reactions Month 32,"Mean IDAA1c Values, Month 43",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11962,NCT06243536,Eating Attitude Test (EAT-26) questionnaire score,"Concentration of incretin hormones (GLP-1, GIP)",,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
11963,NCT02371239,Mean 24 hour glucose concentration,Homeostatic model assessment 2 (HOMA2),,2015-02,COMPLETED,INTERVENTIONAL,['NA']
11964,NCT05662657,To evaluate the prevalence of post-traumatic stress disorder (PTSD) in adult with Type 1 Diabetes,To evaluate whether there is a correlation between PTSD and the patient participation to a therapeutic education program,,2022-11-30,RECRUITING,OBSERVATIONAL,['NA']
11965,NCT02968628,Lower Margin Amplitude on aEEG,Bandwidth on aEEG,,2016-09-01,COMPLETED,OBSERVATIONAL,['NA']
11966,NCT03521362,Change from Baseline HbA1c at 6 months and 12 months,"Unified theory of acceptance and use of technology (UTAUT) Vantakesh, Morris, et al., 2003",,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
11967,NCT01725672,AUC(0-t) and AUC(0-inf) for metformin and glimepiride,Number of subjects with adverse events (AE)s,,2012-09-27,TERMINATED,INTERVENTIONAL,['PHASE1']
11968,NCT00856882,,,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
11969,NCT02304627,Area under the serum insulin 338 concentration-time curve,Maximum observed plasma capric acid concentration,,2014-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
11970,NCT05649553,Change in HbA1c,Changes in quality of life,,2022-09-15,COMPLETED,INTERVENTIONAL,['NA']
11971,NCT04369313,Number of infants with neonatal hyperbilirubinemia,neonatal initial blood glucose levels,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
11972,NCT05098470,Contribution of gluconeogenesis (GNG) to endogenous glucose production (EGP),Glucokinase activity,,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE3']
11973,NCT03938233,Total cardiovascular risk,Body mass index (BMI),Smoking,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA']
11974,NCT01255085,Energy Intake,Subjective Appetite,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
11975,NCT00024583,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
11976,NCT03406663,Proportion of patients achieving fasting SMPG ≤ 5.6 mmol/L without hypoglycemia at 12 weeks,Health care professionals' satisfaction to the insulin titration methods (evaluated by prespecirfied questionnaire: health care provider treatment satisfaction questionnaire),,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
11977,NCT00377442,AUC0-6h of plasma glucose from pre-dose to 6h post-dose.,"AEs, laboratory parameters.",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11978,NCT02076555,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
11979,NCT01135914,Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12,Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11980,NCT01441323,insulin sensitivity,adiposity,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
11981,NCT02739984,Percent Change From Baseline in LDL-C at Week 12,Percent Change From Baseline in VLDL-C at Week 12,,2016-05-17,COMPLETED,INTERVENTIONAL,['PHASE3']
11982,NCT01276743,• Difference of distribution of PTPN22 C1858T alleles between patients and controls of Greek origin,• The association between the PTPN22 C1858T polymorphism among patients and presence of autoantibodies,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
11983,NCT01595789,LVEF,Diastolic heart function (E/E*),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11984,NCT04261933,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2020-02-13,COMPLETED,OBSERVATIONAL,['NA']
11985,NCT01125969,Hemoglobin A1c,Cost-effectiveness of change in Hemoglobin A1c,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
11986,NCT05485961,Time to first occurrence of CV death or MI (Phase 3),Total number of hospitalizations (Phase 3),,2022-10-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11987,NCT03957811,Effect of whole body vibration on TcPO2 levels,,,2017-04-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
11988,NCT01348672,"Topographic distribution of retinal / ON oxygen saturation disturbance, vascular dysfunction and change in morphometric parameters",,,2012-03,UNKNOWN,OBSERVATIONAL,['NA']
11989,NCT00315133,C-peptide levels,Quality of Life,,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11990,NCT00989534,,,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
11991,NCT04314622,Immunogenicity Tests,PK: Tmax of Supaglutide,,2020-04-14,COMPLETED,INTERVENTIONAL,['PHASE2']
11992,NCT02526615,insulin sensitivity in skeletal muscle,insulin stimulated intestinal glucose uptake,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11993,NCT03168295,Change in Endogenous Glucose Production (EGP),Change in Fasting Plasma Insulin,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11994,NCT01535612,"Patients ability to successfully assemble, fill, prime, apply and use the PaQ™ device",Dermal Irritation,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
11995,NCT06068686,NT-proBNP Concentration (pg/ml),Fasting blood glucose (mg/dl),,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
11996,NCT06203275,Change in HOMA-IR .,The secondary outcome is the change in expression of GRK2,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11997,NCT05570734,Psychological Distress - Anxiety,,,2023-02-27,RECRUITING,INTERVENTIONAL,['NA']
11998,NCT00366379,Percentage of patients at each dose who achieve FPG <100mg/dL.,"AEs, laboratory parameters.",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11999,NCT02039986,Change from baseline in insulin secretion capacity at 16 weeks,Composite change from baseline in relationships of insulin secretion and protein and interleukin levels at 16 weeks,,2014-01-06,COMPLETED,OBSERVATIONAL,['NA']
12000,NCT00630825,Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus,Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC),,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12001,NCT00737880,Pancreas graft survival,Exogenous insulin requirement,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12002,NCT01399489,Change from Baseline in Arterial stiffness (pulse wave velocity),Change in Resting blood pressure after 16 weeks of training,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
12003,NCT00402909,Change from baseline in hemoglobin (Hb)_A1c,Proportion of patients achieving reduction in HbA1c of 0.5%,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12004,NCT04909983,Response rate of active treatment versus standard of care,Time to resolution of Irritative contact dermatitis,,2021-05-19,TERMINATED,INTERVENTIONAL,['NA']
12005,NCT01056367,Pulse wave velocity,Pulse wave analysis,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
12006,NCT05958706,Substrate-specific JVO2 of ventricular myocardial mitochondrial oxidative capacity,Longitudinal Substrate-specific JVO2,,2021-12-01,RECRUITING,OBSERVATIONAL,['NA']
12007,NCT00699413,Body Mass Index,Hunger,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE4']
12008,NCT01069341,Adverse Event (AE),Mean Change in Intraocular Pressure (IOP),,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
12009,NCT04065724,Ulcer area,Participant satisfaction measured by Numeric Rating Scale(NRS),,2013-02,COMPLETED,INTERVENTIONAL,['NA']
12010,NCT00968812,Change in HbA1c From Baseline to Week 52,Change in HbA1c From Baseline to Week 104,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12011,NCT03478202,Change from baseline in weight,Change from baseline in fasting Insulin level,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
12012,NCT00991575,Fatal and non fatal cardiovascular disease (CVD) and stroke,Vessel area stenosis,,2009-04-01,COMPLETED,OBSERVATIONAL,['NA']
12013,NCT00554697,Diabetes Mellitus Type II and Tissue Oxygenation,,,2007-11,TERMINATED,OBSERVATIONAL,['NA']
12014,NCT05453838,Blood glucose - Product A versus Product B,GL new product,,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12015,NCT00826774,Weight,Homeostasis model assessment of insulin resistance (HOMA-IR),,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12016,NCT02846571,HbA1C ≤ 7% or a ≥ 2.5 decrease from baseline (before transplant),,,2019-12-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12017,NCT04254380,Treatment developed AIAs or important increase in AIA titers,Percentage of subjects who achieve an HbA1c of ≤ 7.0% at visit Week 26,,2019-12-04,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12018,NCT00411892,HbA1c change from baseline,Change in body weight,,2006-11-29,TERMINATED,INTERVENTIONAL,['PHASE3']
12019,NCT01970566,"Compare the rate of change in fat mass in intense exercise/moderate diet restriction, topiramate-phentermine and cognitive behavior therapy","Compare the change in quality-of-life in response to intense exercise/moderate diet restriction, topiramate-phentermine and cognitive behavioral therapy",,2013-11,WITHDRAWN,INTERVENTIONAL,['NA']
12020,NCT02095418,To evaluate incidence of NODAT in patients of two arms,"To evaluate patient overall survial, OS",,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
12021,NCT02417012,Change in Hba1c,Change in glucose lowering medication,Change in low grade inflammation,2015-04,COMPLETED,INTERVENTIONAL,['NA']
12022,NCT01519505,Incident cases of type 2 diabetes,Cost-effectiveness,,2005-03,UNKNOWN,INTERVENTIONAL,['NA']
12023,NCT06147310,Ridge horizontal width,Inflammatory proliferative remodelling,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12024,NCT01049633,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
12025,NCT04077216,trans-meal blood glucose,,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
12026,NCT02375737,Adherence to the program's intervention,Clinical effectiveness/impact on cholesterol,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
12027,NCT02294526,Change from baseline in fasting insulin at 6 months,Change from baseline in blood pressure at 6 months,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
12028,NCT06326047,Change in Glycated haemoglobin (HbA1c),Number of adverse events,,2024-03-18,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12029,NCT04476433,Change of Perceived level of disease threat (Baseline-Pre-Post),Change Psychological well-being (Baseline-Pre-Post),Exocrine pancreatic test ( Baseline-Pre-Post),2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
12030,NCT03133819,Peripheral arterial occlusive disease,"Major cardiac events ( myocardial infarction, strokes and cardiac related death)",,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
12031,NCT05952999,Patient Perception of Digital Care at discharge,Number of participants with Hospital Acquired Infections,Clinical Sustainability Assessment Tool,2023-08-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12032,NCT04610749,Retinal metabolism,Depressive symptoms,,2020-11-25,COMPLETED,OBSERVATIONAL,['NA']
12033,NCT03152552,Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 12,Change From Baseline in Bone Mineral Density (BMD) at Weeks 12 and 36,,2017-07-25,TERMINATED,INTERVENTIONAL,['PHASE2']
12034,NCT03344549,Know the renal function,Adherence to treatment,,2017-12-28,COMPLETED,INTERVENTIONAL,['NA']
12035,NCT04295005,Indirect healthcare cost,,,2020-11-16,COMPLETED,OBSERVATIONAL,['NA']
12036,NCT01661192,Safety and tolerability of the AAT in terms of laboratory values,Daily insulin dose adjusted to body weight,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12037,NCT05454709,Time in range,AP related parameters - algorithm,,2023-12-29,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12038,NCT01640210,weight of the insulin pump (JewelPUMP and usual pump),acceptability,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12039,NCT01156116,Change From Baseline in Area Under the Curve (AUC) Glucose at Week 2,Change From Baseline in 24-hr Diastolic Blood Pressure (mmHg) at Week 2,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12040,NCT03731533,Weight,Minutes per day of exercise,,2018-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
12041,NCT05270148,Body composition: Fatmass and Fat-free mass.,Self-reported quality of life,,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
12042,NCT05875259,"Cmax,ss",,,2023-05-13,COMPLETED,INTERVENTIONAL,['PHASE1']
12043,NCT01980017,Percentage of Participants Who Self Report of Not Smoking (Even a Puff) in the Last 7 Days + CO <10ppm,Cost-effectiveness of Smoking Cessation Interventions.,Implementation Costs - Clinic,2013-07,COMPLETED,INTERVENTIONAL,['NA']
12044,NCT05449678,Time in range (TIR),Adherence,,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12045,NCT03223129,Glucose kinetics,Metabolomics,,2018-01-09,COMPLETED,INTERVENTIONAL,['NA']
12046,NCT05683106,Change from Baseline Pre-ulcerative lesions and ulcers at 12 and 24 weeks,Change from Baseline Comfort at 12 weeks,,2023-09-06,RECRUITING,INTERVENTIONAL,['NA']
12047,NCT01557634,Time in target,Glucose variability,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
12048,NCT00005462,,,,1991-09,COMPLETED,OBSERVATIONAL,['NA']
12049,NCT03029546,Concentration of advanced glycation end products in maternal serum following the glucose load,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
12050,NCT01545401,Change in the proportion of patients achieving glycaemic and BP control,Other secondary outcome measures,,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12051,NCT00574639,Change in Epinephrine Levels,,,2007-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12052,NCT04857957,CNTX-6016 Pharmacokinetics - tmax,,CNTX-6016 Efficacy - PDN Cohort,2021-04-14,COMPLETED,INTERVENTIONAL,['PHASE1']
12053,NCT01972893,To evaluate Safety and tolerability of ZYD1,Pharmacokinetics (PK) and Pharmacodynamic (PD) effect after single and multiple subcutaneous dose administrations in healthy adult male volunteers Gender effect study.,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12054,NCT00270855,Glucose Effectiveness (Sg) Between Groups,Ratio of Total Cholesterol to High Density Lipoprotein Cholesterol (TC:HDL) Between Groups,Resting Metabolic Rate Between Groups,2008-05,COMPLETED,INTERVENTIONAL,['NA']
12055,NCT02812303,Difference in differences in Blood pressure (BP) goal achievement over the follow-up period comparing PHC and non-PHC practices,Difference in differences in proportion of patients completing colorectal cancer screening over the follow-up period comparing PHC and non-PHC practices,,2014-07,COMPLETED,OBSERVATIONAL,['NA']
12056,NCT03465878,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part,Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part,,2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE1']
12057,NCT01571661,urine glucose concentrations in subjects with type 2 diabetes mellitus following a 50g oral glucose challenge.,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12058,NCT02429258,Change in 24-hour Mean Weighted Glucose (MWG) From Baseline to End of Treatment (Week 4) Using the Continuous Glucose Monitoring (CGM) System,Change in Static Insulin Secretion Rate (10^-9 Min^-1) From Baseline to Week 4 - ITT Population,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12059,NCT00909597,Absolute change from baseline in HbA1c,Adverse events; laboratory parameters; cardiovascular events,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
12060,NCT05553509,Clinical Outcomes Following Surgical Debridement of Diabetic Foot Infection With Borderline Vascularity,Clinical Outcomes Following Surgical Debridement of Diabetic Foot Infection With Borderline Vascularity,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
12061,NCT01365793,the Number of Participants With Glasgow Coma Score (GCS) < 14 Within the First 24 Hours of Treatment for Diabetic Ketoacidosis (DKA),Intelligence Quotient (IQ) Testing,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12062,NCT02763150,Incidence of Gestational Diabetes Mellitus,Minutes per week of moderate physical activity,,2017-12-15,COMPLETED,INTERVENTIONAL,['NA']
12063,NCT02974244,Changes from baseline in weight (kg),Frequency of diarrhea and constipation,,2014-10-28,COMPLETED,OBSERVATIONAL,['NA']
12064,NCT03481829,Infant BMI,Child BMI,,2022-04-14,RECRUITING,OBSERVATIONAL,['NA']
12065,NCT03329118,The number of volunteers with adverse events as a measure of safety and tolerability.,,,2017-11-24,UNKNOWN,INTERVENTIONAL,['PHASE1']
12066,NCT01307072,Preoperative status,Postoperative status,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
12067,NCT01824277,Change in A1C over the study period.,Changes in the patient perioperative outcomes,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
12068,NCT03467932,Change From Baseline of HbA1C (Glycated Hemoglobin),Change Over Time in Hb1Ac,,2018-05-29,COMPLETED,INTERVENTIONAL,['PHASE2']
12069,NCT03203694,Plasma insulin,,,2017-12-04,COMPLETED,INTERVENTIONAL,['NA']
12070,NCT04226105,Immunogenicity,Achievement of Glycated Hemoglobin < 7%,,2020-01-20,UNKNOWN,INTERVENTIONAL,['PHASE3']
12071,NCT01453049,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Electrocardiogram (ECG) Data at Week 24/EW,,2010-04,TERMINATED,INTERVENTIONAL,['PHASE3']
12072,NCT02914496,HbA1c,The Summary of Self-Care Activities,,2016-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12073,NCT01657227,Change in Glycosylated hemoglobin (HbA1c),Change in Morisky Compliance Scale,Resource utilization and costs,2013-01,COMPLETED,INTERVENTIONAL,['NA']
12074,NCT01473654,Physical Activity,hemoglobin a1c,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12075,NCT04162067,HbA1c,Clinical outcomes stratified by age group,"HbA1c in the subgroup of patients using CSII therapy, stratified by patients considered ""atypical"" for pumping by Canadian regulatory authorities",2020-01-06,COMPLETED,OBSERVATIONAL,['NA']
12076,NCT05215730,Change in wound size,Physiological parameter - Average time to wound closure,,2021-07-07,COMPLETED,INTERVENTIONAL,['NA']
12077,NCT03330301,Bone facture,Mental diseases,Congenital disorders,2012-04-01,COMPLETED,OBSERVATIONAL,['NA']
12078,NCT05741489,Nocturnal Hypoglycemia Event Rate,Comorbidities,,2022-08-10,COMPLETED,INTERVENTIONAL,['NA']
12079,NCT03222726,kidney endpoint,Retinal progression,,2021-04-06,UNKNOWN,INTERVENTIONAL,['NA']
12080,NCT00795275,Change in Insulin Secretion,"Baseline and Change in Hormones, Substrates and Insulin Action: Glycerol",,2008-01,COMPLETED,INTERVENTIONAL,['NA']
12081,NCT01627210,Evaluate the Dexcom G4 system utility and usability during home use.,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
12082,NCT00493012,Change in Body Weight From Baseline to 12 Months,Change in Hb A1c From Baseline to 12 Months,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
12083,NCT05669560,Change of HbA1C measured in percentage.,Change in Clinical attachment levels(mm).,,2023-01-20,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
12084,NCT05319600,Change from Baseline in Physical Activity,Change in insulin requirements,,2022-03-23,COMPLETED,INTERVENTIONAL,['NA']
12085,NCT01490099,"Cmax, maximum serum insulin detemir concentration",Adverse events,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12086,NCT01590771,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone,,2012-07-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12087,NCT03215173,Change in postpartum weight retention,Change in Readiness to Change,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
12088,NCT00275223,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
12089,NCT01107132,,,,2010-05,UNKNOWN,OBSERVATIONAL,['NA']
12090,NCT05958368,Fasting Blood Glucose,Glycated Albumin,Insulin,2023-10-10,RECRUITING,INTERVENTIONAL,['NA']
12091,NCT01717911,The primary outcome was the comparison of A1C change.,Beta-cell function and insulin sensitivity and the proportion of subjects who reached the treatment target (A1C <7.0% or <6.5% at 6 months).,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
12092,NCT03851549,System Use Evaluation,,,2019-03-12,UNKNOWN,INTERVENTIONAL,['NA']
12093,NCT02125682,effect on HDL function,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12094,NCT04108884,Prevalence of Atrial Fibrillation,Compliance of patients using the app,,2019-10-22,RECRUITING,INTERVENTIONAL,['NA']
12095,NCT04115657,Postprandial insulin,Appetite control,,2019-05-02,COMPLETED,INTERVENTIONAL,['NA']
12096,NCT04623320,Correlation of the 13C breath test with the golden standard,,,2020-10-27,UNKNOWN,OBSERVATIONAL,['NA']
12097,NCT03526237,Change in BMI,Change in Diet and exercise Behaviors,,2015-04-24,COMPLETED,INTERVENTIONAL,['NA']
12098,NCT05203640,Blood glucose,carbohydrate supplementation,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
12099,NCT04791618,Life Simple 7(LS7 the metrics for defining ideal cardiovascular health) score at 6-month follow-up,Change in Tobacco Use,Change in Carotid Intima Media Thickness (CIMT),2017-05-01,UNKNOWN,INTERVENTIONAL,['NA']
12100,NCT03682237,Time in normoglycemia,Urinary albumin/excretion rate,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
12101,NCT04911582,Area under the curve for glucose,Area under the curve for GIP (Glucose-dependent insulinotropic polypeptide),,2021-05-25,COMPLETED,INTERVENTIONAL,['NA']
12102,NCT00950534,The percentage of patients achieving glycosylated haemoglobin (HbA1c) levels < or = 7.0%,Mean change in body weight,,2009-07,TERMINATED,INTERVENTIONAL,['PHASE4']
12103,NCT04187521,Peak blood glucose following test meal (CGM),Total caloric intake on the days of test meals,,2020-02-10,RECRUITING,INTERVENTIONAL,['NA']
12104,NCT04228341,Glucose,Insulin,,2019-02-13,COMPLETED,INTERVENTIONAL,['NA']
12105,NCT04782999,Insulin secretion during iv stimulation,Alpha cell function,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
12106,NCT06211270,Integration,Body Mass Index,,2023-11-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12107,NCT00949286,Death from any cause,Myocardial infarction (non-fatal and fatal),,2010-01,COMPLETED,OBSERVATIONAL,['NA']
12108,NCT04722289,"Change from baseline, use of healthcare services (diabetes controls at the ophthalmologist )",,,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
12109,NCT00878293,Average daily pain intensity,"Quality of life Neuropathic pain scale Amount and first time of Rescue medication Adverse events, ECG, Laboratory values",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12110,NCT01627509,,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
12111,NCT00134160,All cause mortality,Serious adverse events other than primary outcome events,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12112,NCT04126551,Mitochondrial DNA methylation,Mitochondrial Function,,2019-07-23,RECRUITING,OBSERVATIONAL,['NA']
12113,NCT05319301,Change in oxytocin concentration,Alexithymia assessment,,2022-04-01,UNKNOWN,INTERVENTIONAL,['NA']
12114,NCT00885378,Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12,Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C <= 6.5%) at Week 12,Participants Experiencing Changes From Baseline in Urinalysis Parameters That Met the Marked Abnormality Criteria,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
12115,NCT01629251,Primary efficacy endpoint,Secondary efficacy endpoints,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12116,NCT04183543,Change in baseline fasting blood glucose level at 17 weeks.,Change in baseline blood pressure at 17 weeks.,,2020-01-30,UNKNOWN,INTERVENTIONAL,['NA']
12117,NCT04097691,Injection of subcutaneous glucose 10% in small shots is effective in improving neuropathic signs using the Michigan Neuropathy Screening Instrument (MNSI),,,2019-07-14,COMPLETED,OBSERVATIONAL,['NA']
12118,NCT02438189,Comparison of percent time in range overnight between the two treatment arms,Change in HbA1c from clinical baseline to study completion,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12119,NCT04991350,Change in vascular density of the deep retinal capillary plexus,Change of severity of diabetic retinopathy,,2021-11-26,TERMINATED,INTERVENTIONAL,['PHASE4']
12120,NCT06326034,Quality of Life Assessment tool,,,2022-05-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12121,NCT00491322,Fibroblast Growth Factor 23 (FGF23) After 12 Weeks of Weekly Ergocalciferol 50000 Units,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
12122,NCT01638585,Duration of survival without major amputation in urokinase group compared to group with standard therapy,new lesions on the contralateral leg,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12123,NCT01170832,Heart rate (HR) Variability Studies,Positron Emission Tomography (PET) scan,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
12124,NCT01376557,Change From Baseline in HbA1c to Week 12,Change From Baseline in Triglycerides at Week 12,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12125,NCT00709917,HbA1C,FBG,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
12126,NCT00320879,urinary albumin excretion rate,genotypes with possible implications for the risk of cardiovascular disease,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12127,NCT00965315,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
12128,NCT03146975,"Changes in beta defensins 1, 2 and 3",Changes in percentage of diseased sites,,2014-03-02,COMPLETED,INTERVENTIONAL,['NA']
12129,NCT00840164,,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA']
12130,NCT06181721,Percentage of time in hyperglycemic range (defined as > 13.9 mmol/L (>250 mg/dL)),Average number of hypoglycemic treatments when CGM is less than 3.9mmol/L,,2023-09-05,COMPLETED,INTERVENTIONAL,['NA']
12131,NCT00412178,HbA1c,Compliance,,2004-12,TERMINATED,INTERVENTIONAL,['NA']
12132,NCT04164641,Number of re-ulceration occurrences,Percentage of patients who do not experience re-ulceration after custom orthosis,,2019-12-09,RECRUITING,INTERVENTIONAL,['NA']
12133,NCT02026310,"24 weeks after treatment, HbA1c values' change compared with baseline",hypoglycemia events,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12134,NCT01681290,Bilateral change in sensory nerve conduction velocity,Quality of life questionnaire,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12135,NCT01773668,Performance data,Physical duration,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
12136,NCT00647595,Central adiposity,neonatal adiposity,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12137,NCT00324675,Proteinuria,HbA1c,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
12138,NCT02496780,post-prandial protein turnover,,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12139,NCT01677936,Postprandial Glucose Levels,Systolic Blood Pressure,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12140,NCT03953092,Adverse events will be evaluated,maximum plasma concentration (Cmax),,2019-05-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12141,NCT00497133,,,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
12142,NCT02006342,Time to Anion Gap Closure,Number of Participants Who Developed Hypoglycemia,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
12143,NCT02082301,Primary outcome: sensitivity of immediate post partum screen,Secondary outcome: physiology,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
12144,NCT00938158,"The primary objective is to characterize the PK of albiglutide in subjects with type 2 diabetes and varying degrees of renal impairment, including subjects requiring hemodialysis, and in age, gender and BMI-matched subjects.","To assess the safety and tolerability of a single dose of albiglutide in subjects with varying degrees of renal impairment and in age, gender and BMI-matched subjects with normal renal function",,2009-08-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12145,NCT01324388,"Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol","Pharmacokinetics, Maximum Concentration (Cmax) of Metoprolol When Administered With LY2189265",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12146,NCT03606694,First phase of insulin secretion,Blood pressure,,2019-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12147,NCT05689684,change in levels of postprandial blood glucose,body weight,,2022-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12148,NCT00325910,Combined endpoint of all cause mortality and all cause hospitalization at 6 months,Development of Lactic Acidosis,,2006-05,TERMINATED,INTERVENTIONAL,['PHASE3']
12149,NCT03130101,Time in interstitial glucose target range (CGM analysis),,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
12150,NCT03036254,Change in Cognitive outcome,IADL questionnaire,,2017-10-08,RECRUITING,INTERVENTIONAL,['NA']
12151,NCT00263276,Mean change from baseline in HbA1c compared to placebo.,"Mean change from baseline in fasting plasma glucose, evaluate proportion of subjects who achieve a therapeutic response (HbA1c <7%); change from baseline in urinary glucose excretion",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12152,NCT02727231,Time spent in the target glucose range (3.9 to 10.0 mmol/l) based on subcutaneous glucose monitoring,Utility Evaluation,Accuracy of CGM,2016-03,COMPLETED,INTERVENTIONAL,['NA']
12153,NCT01617603,Difference in Insulin Resistance (HOMA) Between Treatments After 12 Weeks of Product Intake,Oxidative Stress After 12 Weeks of Product Intake,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
12154,NCT03546972,Feasibility of adding hunger training (HT) to Diabetes Prevention Program (DPP) as assessed by completion rates,Changes in proposed behavioral mediators through survey,,2017-12-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12155,NCT00605774,catecholamine levels,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
12156,NCT03793023,Change in HbA1c,Safety Outcome,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
12157,NCT05421845,incidence of gestational diabetes mellitus,maternal physical activity information,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12158,NCT01315171,Cognitive function tests,Brain activity,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
12159,NCT01881724,Change in HbA1c from baseline,sleep duration,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
12160,NCT05347836,To compare the levels of monocyte soluble activation markers among children with T1DM and healthy controls,,,2022-07-01,UNKNOWN,OBSERVATIONAL,['NA']
12161,NCT06273059,The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia.,To describe genetic variation in young-onset DM with diabetic complications in various systems:,,2022-09-12,RECRUITING,OBSERVATIONAL,['NA']
12162,NCT05717608,fructose on glucose metabolism,changes in (postprandial )plasma metabolites,,2023-02-05,RECRUITING,INTERVENTIONAL,['NA']
12163,NCT02925676,Number of adverse events,User experience in an everyday context based on interview,,2016-10-05,TERMINATED,INTERVENTIONAL,['NA']
12164,NCT03278483,Toxicity (liver function),,,2019-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
12165,NCT01196104,Change in HbA1c (%) From Baseline to Week 16,Week 20 (Follow-up) Change From Baseline in Forced Vital Capacity,,2010-09,TERMINATED,INTERVENTIONAL,['PHASE3']
12166,NCT02964585,Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Proliferation),eGFR,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12167,NCT03895515,Change in percentage of time spent in glycaemic target range (TIR),Change in Glycated Haemoglobin A1c (HbA1c),,2020-01-03,COMPLETED,OBSERVATIONAL,['NA']
12168,NCT04630925,"Glucose time in range (3,9-10 mmol/l) (% pr day)",Time with active isCGM,,2021-01-04,TERMINATED,INTERVENTIONAL,['NA']
12169,NCT03553862,Incidence of hypoglycaemia,"Work Productivity and Activity Impairment questionnaire, General Health version (WPAI-GH)",,2018-05-11,COMPLETED,INTERVENTIONAL,['NA']
12170,NCT02931292,Percent excess body mass index loss (%EBMIL),percent of complications,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
12171,NCT00853151,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 6-Month Endpoint,Change From Baseline in Homeostatic Model Assessment (HOMA) at 3-Week and 6-Month Endpoints,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12172,NCT04431141,"AUCτ,ss of teneligliptin and empagliflozin",t1/2β of teneligliptin and empagliflozin,,2020-09-15,COMPLETED,INTERVENTIONAL,['PHASE1']
12173,NCT03895996,"The incidence and severity of local i.v.-site reactions,",Changes from baseline in HbA1c,,2019-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12174,NCT00099333,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16,,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12175,NCT06080425,body weight measured at the five post-baseline follow-up points,Diabetes Distress,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
12176,NCT02714972,Comparison of percent time in range overnight between the two treatment arms,"Amount of total (manual, automatic, combined) and insulin boluses",,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12177,NCT00036504,,,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12178,NCT01456130,Number of Participants With Treatment Emergent Adverse Events (TEAEs),Change From Baseline in Fasting Glucose,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12179,NCT02954822,"AUCτ,ss for Evogliptin and Glimepiride",,,2016-11-14,COMPLETED,INTERVENTIONAL,['PHASE1']
12180,NCT03294265,Glycated hemoglobin,Foot care,,2016-08-01,UNKNOWN,INTERVENTIONAL,['NA']
12181,NCT00971048,Adequate Management of the Wound Assessed by a Left Movement (Improvement) in the Modified Bates Jensen Wound Assessment Tool.,Moist Wound Environment as Per the Bates-Jensen Wound Assessment Tool (BWAT),,2009-09,COMPLETED,INTERVENTIONAL,['NA']
12182,NCT03604198,Long-term safety of relacorilant,,Long-term benefit of relacorilant,2018-05-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
12183,NCT05645068,coefficient of variation of the superficial retinal capillary plexus,,,2023-02-28,RECRUITING,INTERVENTIONAL,['NA']
12184,NCT02606617,Change of control rate of blood glucose(%),Change of clinic blood pressure and 24h mean blood pressure(mmHg).,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
12185,NCT03766802,Glycated Hemoglobin (HbA1c),Accelerometer,Triglyceride,2018-02-05,UNKNOWN,INTERVENTIONAL,['NA']
12186,NCT04145479,postprandial triglyceride,,,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA']
12187,NCT03754036,Insulin sensitivity,Physical activity level,,2019-01-05,COMPLETED,INTERVENTIONAL,['NA']
12188,NCT01319240,The area under liraglutide concentration-time curve,Number of hypoglycaemic episodes,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12189,NCT02109315,Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.,Oxidative stress markers,,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE1']
12190,NCT03608163,Difference in peak epinephrine levels between first and third hypoglycemic episodes,Symptoms of low blood sugar (hypoglycemia),,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
12191,NCT04835194,The correlation between clinical phenotypes and combined endpoint,"Time to first cardiovascular mortality in patients with heart failure with preserved ejection fraction and concurrent hypertension, diabetes.","The correlation between simultaneous risk factor control (HbA1c (%), and LDL-c (mmol/L), and blood pressure (mmHg)) and mortality in patients with diabetes, hypertension and heart failure with preserved ejection fraction",2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
12192,NCT02349516,To explore the effect of Squalamine Lactate eye drops on Best Corrected Visual Acuity in subjects with diabetic macular edema,"To assess the safety and tolerability of Squalamine Eye Drops, measured by ophthalmic examination, the recording and evaluation of clinical AEs",,2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12193,NCT00155142,,,,2004-09,UNKNOWN,OBSERVATIONAL,['NA']
12194,NCT03333772,Acceptability,Change from baseline in Glycated hemoglobin (HbA1C) at post-intervention,,2017-11-15,COMPLETED,INTERVENTIONAL,['NA']
12195,NCT03087253,Prevalence of diabetes mellitus,Incidence of severe morbidities and causes of mortality,,2018-02-27,RECRUITING,OBSERVATIONAL,['NA']
12196,NCT01945138,Study Period: Serum BG Standard Deviation,Day 28 Follow-Up: C-Peptide,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
12197,NCT06152588,Change in HbA1c (mmol/mol),Use of antidiabetic medication,Dietary fibers (gram),2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12198,NCT02983214,Number of participants who suffer from bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria during the entire follow-up period.,"Number of participants who suffer from the secondary safety end points which are palpitations, tachycardia, headache, diarrhea, urticaria, neoplasms, blood disorders, drug interruption.",,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12199,NCT04136951,To learn if using PREVENT tool results in high nurses' system usability perception measured by the System Usability Scale (SUS).,,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
12200,NCT05314140,Proportions of diabetic patients with high coronary artery calcium score,Description of adverse events regarding to the coronary artery calcium score,,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12201,NCT00887302,Metabolics of RYGB with Gastrostomy - Glucose,,,2009-03-25,COMPLETED,OBSERVATIONAL,['NA']
12202,NCT02064335,Physical fitness,,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
12203,NCT01465620,Change from Baseline in NTSS6 score at 3 months,change from baseline of thermal and vibration thresholds,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12204,NCT01238406,Sleep efficacy,Total wake up time per night,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
12205,NCT01680653,Duration of Nocturnal Hypoglycemia,Duration of Glucose Readings <70 mg/dl,Prolonged Episodes of Hypoglycemic Events,2012-05,COMPLETED,INTERVENTIONAL,['NA']
12206,NCT01251497,,,,2009-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12207,NCT03628963,Patient Activation,Acceptability,,2018-09,UNKNOWN,INTERVENTIONAL,['NA']
12208,NCT04835636,HbA1c,Weight change,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
12209,NCT03172598,Efficacy as measured by reduction in pain using a numerical rating scale.,Plasma concentration of MT-8554,,2017-07-25,COMPLETED,INTERVENTIONAL,['PHASE2']
12210,NCT01278485,Number of Participants With Hemoglobin A1c <7.0% at the Time of Enrollment,Number of Participants Reporting Body Weight Fears in the 12 Months Prior to Enrollment,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
12211,NCT01480934,Development of Posterior capsule opacification.,"duration of diabetes, stage of diabetic retinopathy",,2005-06,COMPLETED,OBSERVATIONAL,['NA']
12212,NCT00378508,C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at Baseline,Baseline Hemoglobin A1c,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12213,NCT03363386,Change in fasting blood glucose level,,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
12214,NCT00600483,Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 90,Rehospitalization for Sternal Wound Infection,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12215,NCT06173765,Change in primary clinical marker of inflammation IL-6,Change in fasting Lipids,,2022-08-31,RECRUITING,INTERVENTIONAL,['NA']
12216,NCT04723628,Glycemic Control,Perceived Diabetes Self-Management Scale (PDSMS),,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
12217,NCT02862860,Amplitude of glycemic variations,,,2012-05-29,COMPLETED,INTERVENTIONAL,['NA']
12218,NCT04208230,Association between Type 2 diabetes status and marrow fat at the distal tibia,,,2017-01-03,COMPLETED,OBSERVATIONAL,['NA']
12219,NCT00110370,(A1C less than 7%) with once-daily insulin glargine in combination with OADs.,"body weight, SAE's and study drug related AEs.",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12220,NCT01289145,Self-reported physical activity frequency and duration,Social Cognition,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
12221,NCT01441232,Change from baseline in gut hormones,Change from baseline in urinary glucose excretion,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12222,NCT05482321,Primary outcome 4,Secondary outcome 6,,2023-02-27,RECRUITING,OBSERVATIONAL,['NA']
12223,NCT04545151,Area under the stimulated C-peptide response curve,Continous glucose monitoring (CGM),Quality of life: HypoFear questionnaire,2021-02-08,RECRUITING,INTERVENTIONAL,['PHASE2']
12224,NCT05851651,Infant Feeding pattern,Women's prevalence of Impaired Glucose Tolerance,"Women's experience, perception, and attitude for AME practices",2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
12225,NCT01275131,"Early Exposure to Insulin (%AUC[0-60]), Stage 3","Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 3",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12226,NCT04702048,Mean change in photoreceptor cell spacing,Proportion of participants who receive intravitreal aflibercept,,2021-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12227,NCT01990300,Changes From Baseline in Glycosylated Hemoglobin (HbA1c),Changes From Baseline in Fasting Blood Glucose (FBG),,2011-11-28,COMPLETED,OBSERVATIONAL,['NA']
12228,NCT02076945,Duration of analgesia,,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
12229,NCT02844517,The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.,,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
12230,NCT02961179,Change from baseline to 6 weeks in insulin sensitivity between high dairy and dietary counselling phases,Change from baseline to 6 weeks in metabolomics profiles between high dairy and dietary counselling phases,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
12231,NCT02967237,Mean change from baseline in HbA1c,Number of adverse events,,2016-01-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12232,NCT03012113,The effect of Mirabegron treatment on BAT activity measured by MRI in South Asians compared with white Caucasians.,The effect of Mirabegron treatment on sympathetic output in South Asian and white Caucasian individuals.,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
12233,NCT00420511,Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR,Proportion of Patients Achieving Sustained Normoglycemia Off Medication at 1-week Post-insulin Therapy,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12234,NCT03881657,Blood pressure,Life functioning,,2015-11-24,COMPLETED,INTERVENTIONAL,['NA']
12235,NCT05568134,"Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose",Perceived benefits and burdens of CGM use,,2023-07-17,RECRUITING,OBSERVATIONAL,['NA']
12236,NCT01226537,Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin 7) Eye test,,,2012-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12237,NCT05227677,The achievement rate of HbA1c (≤7%),The extent of change of HbA1c,,2022-08-15,RECRUITING,INTERVENTIONAL,['NA']
12238,NCT04964752,the percentage of MARD (Mean Absolute Relative Difference),Sensor Stability,,2021-07-30,UNKNOWN,INTERVENTIONAL,['NA']
12239,NCT01262586,Change in Glycemic profiles between vildagliptin and glimepiride,Glucose Fluctuation before and during treatment,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12240,NCT02526524,Change in HbA1c (%) at 16 Weeks,,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12241,NCT05826054,Maximum tolerated dose (MTD),,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE1']
12242,NCT00334503,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
12243,NCT01102699,CPC mobilization after a single G-CSF dose,,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12244,NCT02145988,Resting ankle-brachial index (ABI),Adverse events,,2015-06-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12245,NCT00975052,Weighted average active GLP-1 (glucagonlike peptide-1) concentrations,,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12246,NCT00954694,"The primary endpoint of the study is the qualitative measurement, by use of a questionnaire, of attitude and interest toward exercise in participants by assessing if they choose to seek and perform other modes of exercise.","Secondary endpoints are the quantitative measurement of the change in weight, waist-to-hip ratio, heart rate, blood pressure, 6-minute walk test, and A1C levels.",,2009-08,UNKNOWN,INTERVENTIONAL,['NA']
12247,NCT01182948,Change in haemoglobin A1c (HbA1c) levels,"Changes in expression in the muscle of some genes involved in ATP production, mitochondrial biogenesis and substrate utilization",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
12248,NCT06225154,Serum and saliva IL-1β levels (pg/ml),HbA1c ( %),Clinical Attachment Level (mm),2015-02,COMPLETED,INTERVENTIONAL,['NA']
12249,NCT05666791,Self-efficacy,,,2022-12-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12250,NCT00997152,Change in Fasting Plasma Glucose (FPG) levels,"Safety (biochemistry, hematology, urinalysis and adrenal-related markers) and tolerability (adverse events)",,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12251,NCT02681809,Number of Subjects With Total PVD by the Month 3 Visit,Number of Subjects With Ocular Treatment-emergent Adverse Events in the Study Eye,,2015-12,TERMINATED,INTERVENTIONAL,['PHASE2']
12252,NCT01337947,arterial vascular stiffness,nitric oxide dependent vasodilation,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
12253,NCT03210896,"Chemical components in breath will be captured into absorbent tubes followed by GCMS analysis, to determine if there are potential biomarkers in exhaled breath that can be directly correlated with blood glucose concentration.",Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition.,,2017-07-10,COMPLETED,INTERVENTIONAL,['NA']
12254,NCT04281186,Retinal sensitivity,Diabetes Specific Dementia Risk Score.,,2020-11-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12255,NCT01908816,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Ranibizumab Injection,,2013-09-26,COMPLETED,INTERVENTIONAL,['PHASE3']
12256,NCT00979719,physical activity,"social-cognitive predictors of behavior (self-efficacy, action control etc.)",,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12257,NCT02622295,Post-training Bone Turnover: Osteocalcin,Post-training Subject-report Measures: EQ-5D,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
12258,NCT02730754,Depressive symptoms measured with Patient Health Questionnaire-9,Diabetes distress measured with Problem Areas in Diabetes Scale (PAID-5),Health care utilisation/hospitalisation,2016-04,COMPLETED,OBSERVATIONAL,['NA']
12259,NCT01586065,Number of High Glucose Correction Doses Administered.,Pre- and Post-meal (2-3 Hour) Glucose Levels,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
12260,NCT00447629,Safety,Pharmacokinetics,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12261,NCT02924311,Mean change in Best Corrected Visual Acuity from baseline to month 12 in treatment naïve patients and previously treated patients,Number of participants with ocular and non-ocular safety events,Number of patients with prior intraocular steroids (DME Monitoring),2016-09-21,COMPLETED,OBSERVATIONAL,['NA']
12262,NCT02936115,Proportion of Patients that achieve a 50% or greater reduction in wound size by 8 weeks,Number of patients with worsening of index wound defined by ≥ 50% increase in wound size,,2016-07,TERMINATED,INTERVENTIONAL,['PHASE4']
12263,NCT03670043,Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire,,,2019-03-19,COMPLETED,INTERVENTIONAL,['PHASE4']
12264,NCT00674050,PK parameters of serum insulin,,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12265,NCT02386930,HbA1c%,physical exercise in minutes per day,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
12266,NCT00120536,Change from baseline in HbA1c at 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12267,NCT02230631,The percentage of patients experiencing at least 1 hypoglycaemic event,Difference in the reported incidence rates of hypoglycaemia,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
12268,NCT04953442,Percentage of participants that are satisfied with participation in the study,Average of minutes of sleep per night,Autonomous motivation for physical activity as assessed using Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2),2021-04-15,RECRUITING,INTERVENTIONAL,['NA']
12269,NCT02459899,Change From Baseline in Hemoglobin A1C (A1C) at Week 12,Change From Baseline to Week 12 in Fasting Plasma Glucose,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12270,NCT05780151,Query rate,,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE4']
12271,NCT01945242,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
12272,NCT02999386,All cause Mortality,Hospital length of stay,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
12273,NCT01718080,Overweight and Lean Children Sugar Metabolism Before and During Puberty,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
12274,NCT00270439,Insulin sensitivity as measured by the minimal model and HOMA score,Decreased use of oral hypoglycemics,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12275,NCT02934425,Net incremental area under the curve (AUC) appetite VAS ratings,Composite daily hunger and fullness VAS ratings,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
12276,NCT02663713,platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods (pre-crossover and post-crossover).,"• VerifyNow P2Y12 assay % inhibition, using the TRAP-induced (BASE channel) response at the end of the 2 study periods",,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12277,NCT00107107,To examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight,To examine the effects of long term pramlintide treatment on HbA1c in subjects with type 1 diabetes completing protocol 137-150.,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12278,NCT00603239,Change in Glycosylated Hemoglobin (HbA1c),Change in Euroqol - 5 Domain Quality of Life (EQ-5D) Score,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12279,NCT01161862,Mean Plasma Blood Glucose Achieved by the Bionic Pancreas (mg/dl),Nadir Blood Glucose in Each Arm,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
12280,NCT04550403,prevalence of intensive care unit admission and/or in-hospital mortality among COVID-19 inpatients,number of days of hospitalization in patients with and without diabetes,,2020-07-30,COMPLETED,OBSERVATIONAL,['NA']
12281,NCT04744636,Guanylate triphosphate cyclohydrolase (GTP-CH) investigations,Blood pressure supine,,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12282,NCT00476788,Mean Glycated Hemoglobin (A1c),Number of Reported Adverse Events,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
12283,NCT00021879,,,,2001-03,COMPLETED,OBSERVATIONAL,['NA']
12284,NCT00004647,,,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12285,NCT02737891,Effects of Co-administration of Tesofensine/Metoprolol Treatment vs. Placebo on 24-hour Mean Heart Rate,Change From Baseline to End of Treatment in Body Weight,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12286,NCT01545388,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG),,2012-02-23,COMPLETED,INTERVENTIONAL,['PHASE3']
12287,NCT01730196,Weight change,hemoglobin A1C,waist circumference,2009-09,COMPLETED,INTERVENTIONAL,['NA']
12288,NCT00580294,Brief Pain Inventory,,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
12289,NCT00407680,HbA1c,Serum angiotensinogen,,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
12290,NCT02123251,Changes in HDL From Baseline to the End of Intervention (December 2015),Change From Baseline to End of Intervention (December 2015) in Physical Component Summary Measure of the Short Form (SF-36v2) Health Survey,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
12291,NCT01435980,Clinical events,Blood testing,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
12292,NCT02659007,change in 10 meter walk,,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12293,NCT03544242,96 Hours Post Operative Blood Samples Serum Glucose Levels,,,2017-05-07,TERMINATED,INTERVENTIONAL,['PHASE2']
12294,NCT02806349,HbA1c,fasting insulin,ALT,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12295,NCT01102530,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
12296,NCT00477022,"Foot ulcer surface area was estimated stereologically, based on Cavalieri's principle before and after intervention, at pre treatment and post treatment",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
12297,NCT02313363,change of HbA1c,change of the scores of Summary of Diabetes Self-Care Activities (SDSCA),number of events of hypoglycemia,2013-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12298,NCT01272193,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12299,NCT05115175,Feasibility of the Scaled Mindfulness-Based Intervention as Assessed by Participant Feedback,,,2019-07-14,COMPLETED,INTERVENTIONAL,['NA']
12300,NCT05013346,Islet auto-antibody titre and positivity proportions,Type 1 diabetes genetic risk score,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
12301,NCT01619345,Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE),Time to CTE,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12302,NCT00607945,Difference in change in body weight of the intervention groups,Nutrition knowledge,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12303,NCT00472342,Improvements of adipokine levels,Prevention of diabetes,,2007-03,UNKNOWN,INTERVENTIONAL,['NA']
12304,NCT06227520,Wound Healing,Ulcer Reoccurrence,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12305,NCT02726425,Change in disease control (HbA1c),Health Service Utilization,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
12306,NCT01334203,The primary efficacy endpoint is the change from baseline in exercise treadmill duration in the peak ETT at week 12 or last visit.,Change from baseline in exercise treadmill duration in the trough ETT at week 12,,2011-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12307,NCT05147818,Identify risk factors for Acute kidney injury in diabetic patients,,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
12308,NCT00479973,"The primary objective measures will consist of fasting blood glucose, insulin and HA1C.","Total-C, TG, HDL, LDL, BP, weight, BMI, waist/hip ratio, self-monitoring blood glucose, HOMA-IR, AST, ALT, total protein, albumin, alk phos, total/direct bilirubin, creatinine, BUN, PT, PTT, fibrinogen, adverse effects, Diabetes-39, SF-36",,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
12309,NCT02313090,HbA1c,low density lipoprotein cholesterol,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12310,NCT00683878,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Total Body Weight (kg) Among Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF]),,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12311,NCT03664414,Change in the glomerular filtration rate,Change in health-related quality of life,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12312,NCT06140303,Incidence of index ulcers closed,Time to closure,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
12313,NCT00435565,,,,na,COMPLETED,OBSERVATIONAL,['NA']
12314,NCT04547348,Time until remission,Incidence of Adverse Events and Serious Adverse Events,,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3']
12315,NCT04235439,GIRmax,Safety and Local Tolerability,,2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE1']
12316,NCT05816733,Rate of atrial fibrillation recurrence,Cardiovascular complex adverse events,,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
12317,NCT00552942,diabetic indices,"interleukin and cytokine levels, weight loss",,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
12318,NCT02744976,Percentage plaque volume change over 24 months,Plaque volume change in metformin vs non-metformin treated patients over 24 months,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12319,NCT05677334,Time percentage (% TIR) in the range of 3.9~10.0 mmol/L blood glucose,time above range (TAR),,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE4']
12320,NCT00837941,analgesic efficacy measured by patients self reported pain level after single dose administration,The onset of analgesic efficacy following single dose of pregabalin and duloxetine hydrochloride versus placebo,,2009-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12321,NCT02928250,effect on on urinary albumin excretion (UAE),"total antioxidant capacity (TAC), malondialdhyde (MDA).",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
12322,NCT01307514,,,,2008-11,UNKNOWN,OBSERVATIONAL,['NA']
12323,NCT03987412,The risk of gestational diabetes mellitus (GDM),Satisfaction of prenatal medical care; questionnaires,,2019-08-16,UNKNOWN,INTERVENTIONAL,['NA']
12324,NCT06136013,"Changes in 24-hour area under cover (AUC) glucose from baseline to 1, 2, and 3 months",Quantify the differences in the number of responders and low-responders for glycemic control and other health-related outcomes for individuals with T2DM and age-matched overweight/obese older adults.,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12325,NCT01492205,Overall acceptance of the NovoLet® system among healthcare professionals (nurses and doctors),Incidence of adverse drug reactions,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
12326,NCT02755831,Number of Participants With Adverse Pregnancy Outcomes,Hospital Costs at Time of Delivery,,2017-02-20,COMPLETED,INTERVENTIONAL,['NA']
12327,NCT01370681,Geometric mean AUCt,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12328,NCT04559815,Change in Glycated haemoglobin (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2020-11-08,COMPLETED,OBSERVATIONAL,['NA']
12329,NCT04225507,Change from baseline 2-hour glucose levels at 6 months,Change from baseline morning blood pressure at 6 months,,2021-04-13,RECRUITING,INTERVENTIONAL,['NA']
12330,NCT03802825,Percent of Participants With A1C < 8%,Mean A1C Change,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
12331,NCT01298375,Euglycemic-hyperinsulinemic clamp for measurement of insulin sensitivity and metabolic flexibility,Evaluating mitochondrial function through measurement of phosphocreatine (PCr) recovery by phosphorus magnetic resonance spectroscopy (31P-MRS) within the skeletal muscle,,2011-03,RECRUITING,OBSERVATIONAL,['NA']
12332,NCT02645799,%NIH volume,Definite or probable ARC defined stent thrombosis,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
12333,NCT01330563,CKD-501 AUC,CKD-501 Tmax,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12334,NCT01086306,To compare the incidence of hospitalizations with infections associated with T Lymphocyte dysfunction,Inpatient diagnoses of respiratory tract infections,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
12335,NCT04041167,Number of participants with functional independence,Number of participants with recurrence,,2018-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12336,NCT04230889,Interstitial Glucose Response,Postprandial Glucose,Medications,2017-02-06,COMPLETED,INTERVENTIONAL,['NA']
12337,NCT00106457,,,,2005-02,COMPLETED,OBSERVATIONAL,['NA']
12338,NCT06323174,Change in glycated haemoglobin (HbA1c),"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2024-03-19,RECRUITING,INTERVENTIONAL,['PHASE3']
12339,NCT00286455,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Glucagon (Week 26).,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12340,NCT03069196,"Progression of Micro-vascular, Macro-Vascular and Pulmonary Complications.",Association of Risk factors with prevalence of complications.,,2016-06-10,UNKNOWN,OBSERVATIONAL,['NA']
12341,NCT01499082,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12,Change in HbA1c From Month 6 to Month 9,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12342,NCT03749889,Birth Outcome Questionnaire,,,2018-09-04,TERMINATED,INTERVENTIONAL,['NA']
12343,NCT03203278,Glycaemic control,Glycaemic control,,2017-11-06,COMPLETED,INTERVENTIONAL,['NA']
12344,NCT02383784,Body fat content determined by tetrapolar bioelectrical impedance .,,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
12345,NCT05967923,Range of motion of the shoulder,Shoulder and hand disability,,2023-07-05,RECRUITING,INTERVENTIONAL,['NA']
12346,NCT00577824,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24,"Change in 1,5-anhydroglucitol",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12347,NCT00789945,To determine the changes in A1C.,To determine changes in postprandial glucose excursion during the meal's 5 hour postprandial period.,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
12348,NCT01164501,HbA1c Change From Baseline in Patients With Moderate Renal Impairment,,Hypoglycaemic Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12349,NCT04739124,"Correlation between appropriation factors, intention to use, Freestyle Libre use and glycemic control",,,2021-06-10,COMPLETED,OBSERVATIONAL,['NA']
12350,NCT01999322,Number of Microscopically Confirmed Episodes of Infusion Set Occlusions,Number of Premature Infusion Set Changes,,2013-11-19,COMPLETED,INTERVENTIONAL,['PHASE3']
12351,NCT00174668,Total daily insulin dose,Physical examination,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12352,NCT00704795,"Glucagon responses (as assessed by area under curve (AUC)) during 50-g oral glucose tolerance test (OGTT) and isoglycemic iv glucose infusion, respectively.",GI-mediated glucose tolerance as assessed by the amount of glucose ingested as compared to the amount of glucose needed to mimic the OGTT curve during the iv glucose infusion.,,2008-06,UNKNOWN,OBSERVATIONAL,['NA']
12353,NCT05530369,Neuropathy,Mean glucose (mg/dl),,2014-09-01,COMPLETED,OBSERVATIONAL,['NA']
12354,NCT03650023,Glucose levels,The areas under the curve (AUC) of glucose,,2018-05-09,COMPLETED,INTERVENTIONAL,['NA']
12355,NCT01891955,Fasting glucagon,Fasting HbA1c,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
12356,NCT00453375,"The primary endpoint in this study is safety.Safety parameters include: stimulated C-peptide response levels, opthalmologic examination, laboratory assessments, 24-hr urine protein, allergic reactions and adverse events including hypoglycemia.","The secondary endpoints are pharmacodynamic parameters. Parameters include plasmid levels and insulin mRNA levels in blood and urine, Stimulated C-peptide response and Immunological response.",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12357,NCT02548767,Change of de novo lipogenesis: palmitate tracer-to-tracee ratios by gas chromatography-mass spectrometry.,Change of Very low density lipoprotein (VLDL)-triglyceride (TG) kinetics,Change of blood levels of uric acid,2016-02,COMPLETED,INTERVENTIONAL,['NA']
12358,NCT00530881,postprandial blood glucose,"fasting blood glucose, HbA1c, safety",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12359,NCT04602039,This project aimed to examine changes in insulin resistance in participants using dairy colostrum as a food supplement,This project aimed to examine changes in inflammatory markers in participants using dairy colostrum as a food supplement,,2016-07-21,COMPLETED,INTERVENTIONAL,['NA']
12360,NCT01116180,Cognitive function and brain cortical activity assessed by EEG,Cardiac conduction evaluated by a three channel digital Holter Monitor.,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
12361,NCT02595606,ocular surface disease index,corneal fluorescein staining assessment,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
12362,NCT06333080,Time-in-Range (TIR),Treatment-Related Impact Measure for Diabetes (TRIM-D),,2024-05-01,RECRUITING,OBSERVATIONAL,['NA']
12363,NCT02100488,Intra-subject postprandial glycemic variability,CV_AUC-PG_3-8h,Time into range,2014-03,COMPLETED,INTERVENTIONAL,['NA']
12364,NCT00553488,"Area Under Curve (AUC) of the blood glucose (BG) profile after the meal, with and without baseline correction.",Time to BGmax (tBGmax),,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12365,NCT00138554,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12366,NCT02210000,Percentage of Responders Based on the Fullness/Early Satiety Subscale (Responders) as Assessed by Gastrointestinal Cardinal Symptom Index-Daily Diary (GCSI-DD) at Week 12,Trough Plasma Concentration of Camicinal on Day 28 and Day 84,,2014-08-27,COMPLETED,INTERVENTIONAL,['PHASE2']
12367,NCT05145140,Diabetic Foot Ulcer relapse rate,C-reactive protein(CRP),,2022-01-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
12368,NCT05461716,Detection of hypoglycaemic events,Registry of hypoglycaemia events in patients with T2DM treated with insulin and insulin secretagogues,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
12369,NCT03624803,"To describe baseline characteristics of patients starting Dapagliflozin together with other anti-diabetic medications , alone or in combination. And to describe if Dapagliflozin was given as 2nd line , 3rd line or later in combination therapy.",To record the change in blood pressure (mmHg) from baseline.,,2019-03-09,COMPLETED,OBSERVATIONAL,['NA']
12370,NCT03452085,xerostomia,patients preference for treatment AS or TT,,2017-09-23,COMPLETED,INTERVENTIONAL,['NA']
12371,NCT03784443,Number of Lucentis Injections received in the study eye,Number of focal laser treatments,,2019-09-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12372,NCT05553093,Brain function,"Inflammation factors, including adiponectin,leptin,IL-1,IL-6,IL-18,TNF-α,ghrelin,asprosin.",,2022-03-15,RECRUITING,INTERVENTIONAL,['PHASE4']
12373,NCT05320276,Frequency of patients with chronic diseases seen in the emergency department who have not been offered an educational program,Identification of reasons for refusal to participate,,2022-02-28,COMPLETED,OBSERVATIONAL,['NA']
12374,NCT03061981,"[Safety and Tolerability] 12-lead ECGs, Vital signs. Physical examinations, Clinical laboratory testing and Adverse event assessments",Renal clearance (CLR),Key metabolites of DA-1241 in Cohort 6,2017-03-29,COMPLETED,INTERVENTIONAL,['PHASE1']
12375,NCT05495451,Feasibility of an intensive multidisciplinary program based on lifestyle changes in patients diagnosed with type 2 diabetes.,"Evolution of the HOMA-IR between the start of the program, the middle of the intervention (3 months) and the end of the intervention (6 months).",,2022-01-21,COMPLETED,INTERVENTIONAL,['NA']
12376,NCT04607096,Change in first phase insulin secretion.,Change in subcutaneous adipose tissue.,Change in insuin clearance.,2021-04-08,UNKNOWN,INTERVENTIONAL,['NA']
12377,NCT01724060,Change in Energy Intake From Baseline,Change in Macronutrient Composition From Baseline,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
12378,NCT03877068,Number of Clinically Significant Hypoglycemia Events While Hospitalized,Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE) After Discharge,,2019-06-26,COMPLETED,INTERVENTIONAL,['NA']
12379,NCT02822534,The steady-state urine concentration (Css) of SP2086 acid,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
12380,NCT01822925,Change in Clinic Visit Pain Score at the 12 Week Visit Compared to Baseline as Assessed by the 11-point Likert Numerical Rating Scale (NRS),Average Weekly Rescue Medication Use,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12381,NCT03153007,"Assessment of signs and symptoms, impacts on functioning and HRQoL among subjects with DFU",,,2017-08-11,COMPLETED,OBSERVATIONAL,['NA']
12382,NCT03443713,Percent of Time With Sensed Glucose Less Than 70 mg/dl,Mean Sensed Glucose,,2018-07-18,COMPLETED,INTERVENTIONAL,['NA']
12383,NCT06234787,To determine the cumulative incidence or risk of potential hypoglycemia during ICU admission,"To describe the theoretical cumulative incidence of potential hypoglycemia with alternative thresholds of 70, 75, 85, or 90 mg/dL",,2023-11-30,RECRUITING,OBSERVATIONAL,['NA']
12384,NCT06321302,Occurrence of a ≥2-step improvement compared with baseline in Diabetic Retinopathy Severity Scale (DRSS) level in the study eye at Week 52,Occurrence of ocular AEs of special interest in the study eye between baseline and EOS,,2024-05-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12385,NCT01179555,Pt. 1 Dilated Fundus Exam (DFE),Pt. 2 Appointment Adherence Characteristics,Pt. 2 Cost-effectiveness,2010-10,COMPLETED,INTERVENTIONAL,['NA']
12386,NCT00086515,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24,,2004-06-30,COMPLETED,INTERVENTIONAL,['PHASE3']
12387,NCT02795910,Systolic blood pressure,Ischemic heart disease treatment,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA']
12388,NCT05642377,Pharmacokinetic Assessment by Apparent Volume of Distribution of HGR4113,Pharmacodynamic Assessment by Change in Plasma C-peptide,,2022-11-22,RECRUITING,INTERVENTIONAL,['PHASE1']
12389,NCT02463682,"Safety and efficacy of the system, as assessed by the composite outcome of time in range for glucose levels of 70-180 mg/dL and time < 70 mg/dL.",Failure analysis of the devices/connectivity issues that may occur.,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
12390,NCT00740012,Glucose (continuous glucose monitoring),"Hormones (norepinephrine, cortisol, glucagon, growth hormone, prolactin), Pulse, Blood glucose",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
12391,NCT03452605,BOLD fmri response,,,2015-11-20,COMPLETED,INTERVENTIONAL,['NA']
12392,NCT02235298,Epicardial Fat Thickness,Left Ventricular Mass (LVM),,2015-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12393,NCT02372955,arterial stiffness,composite intravascular volume status,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
12394,NCT02453711,Relative Change in Body Weight (%),Anti-semaglutide Antibodies During and After Treatment,,2015-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12395,NCT02545842,Percentage of patients with HbA1c <7% achievement,Percentage of patients experienced hypoglycemic events,,2015-09-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12396,NCT05076656,Changes in HOMA-IR,Changes in glucose metabolism,,2019-06-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12397,NCT01430221,Severity of depressive symptoms,Changes in inflammation,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
12398,NCT06202742,Subjective Sleep Quality,Objective sleep parameters,,2024-03-08,RECRUITING,INTERVENTIONAL,['NA']
12399,NCT01268995,90 days OGTT,Hypoglycemia,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12400,NCT05717933,thyroid abnormalities among children and adolescents with type 1 diabetes mellitus when its first detected and its relationship with disease-related variables.,,,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12401,NCT05885659,Variability of glycemic levels,Anthropometric data,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
12402,NCT01790412,prevention gestational diabetes,Maternal weight gain,Other pregnancy outcomes,2009-02,COMPLETED,INTERVENTIONAL,['NA']
12403,NCT03156179,fractional calcium absorption,Estimated calcium retention,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
12404,NCT02733315,Weekly self-monitoring of blood glucose times as determined by medical chart review,fasting plasma glucose as determined by medical chart review,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12405,NCT00700908,Change in HbA1c,Change in adherence to SMBG frequency,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
12406,NCT02027571,The primary outcome measure is restoration of normal glucose regulation,Glucose normalization,Incident prediabetes in observational cohort,2013-10,COMPLETED,INTERVENTIONAL,['NA']
12407,NCT06185192,Fasting Insulin levels,"Species prevalence in stool, blood, and saliva",,2023-12-13,RECRUITING,INTERVENTIONAL,['NA']
12408,NCT01326117,improvement in Gastric Emptying Study residual tracer amount,,,2011-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12409,NCT03269058,Change from baseline the Fractional Catabolic Rate of HDL 'Apo A1,,,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
12410,NCT05994586,Discomfort related to metformin side effects,HbA1c level,,2023-05-25,RECRUITING,INTERVENTIONAL,['NA']
12411,NCT05700877,Rates of a composite cardiovascular endpoint,Cost-effectiveness,Cardiovascular risk markers 4,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE4']
12412,NCT04890886,Assessment of the distribution of adipose tissue,Thermal assessment,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
12413,NCT04880850,Change in Glycated haemoglobin (HbA1c),Change in body weight,,2021-05-14,COMPLETED,INTERVENTIONAL,['PHASE3']
12414,NCT02148978,glucose tolerance after treatment with Saxagliptin,,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
12415,NCT01636349,muscular adaptations,glycaemic control,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12416,NCT00672919,Change from Baseline in Triglyceride Levels,Change from Baseline in C-reactive Protein,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12417,NCT04185454,Osteocalcin ratio,Lipid profil 2,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
12418,NCT01347814,Gastric emptying half time,Appetite sensations,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
12419,NCT02960373,Glycemic index (GI),,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
12420,NCT04463082,Change in collapsibility index pre- and post-hydration,Correlation to body surface area,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
12421,NCT03554486,Percentage of Time in Range: Sensor Glucose Readings <70 mg/dl,Mean Sensor Glucose in mg/dl,,2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE4']
12422,NCT05047237,Point estimates of Feasibility Measures: Time,Implementation Metric- Value,,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12423,NCT02359214,Pulsewave Velocity,Systolic Blood Pressure,Plasma Angiotensin II,2014-04,COMPLETED,INTERVENTIONAL,['NA']
12424,NCT00822471,"Improvement in the percent of subjects correctly identifying guideline-recommended treatment targets for the ""ABC's of Diabetes"", where A = A1C < 7%; B = BP <130/80mmHg and; and C = LDL-C < 100mg/dl.",Decrease the percentage of participants with self-reported ED visits and hospitalizations for severe hypoglycemia and hyperglycemia.,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
12425,NCT00737022,Macular appearance,Post-operation best-corrected visual acuity,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
12426,NCT04604223,Difference in the incidence at 4 weeks of a composite outcome comprised of:,Incidence at 4 weeks of a composite of extrapulmonary disease comprised of :,,2021-01-18,UNKNOWN,INTERVENTIONAL,['PHASE4']
12427,NCT02647905,CGM Relative Difference to Laboratory Reference Reported as MARD,,CGM System Agreement With Reference Control,2016-01,COMPLETED,INTERVENTIONAL,['NA']
12428,NCT03627715,The Change in Albumin/Creatinine Ratio with Adjunct use of Propagermanium Compared to Placebo in Participants with DKD who are Receiving Irbesartan,The Effect of Treatment with Propagermanium on Measures of Proteinuria as measured by ACR,,2018-11-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12429,NCT00621140,HbA1c Change From Baseline at Week 24,Adjusted Means for 2h Post Prandial Blood Glucose (PPG) Change From Baseline at Week 24,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12430,NCT00437970,Medication side effects,Endothelial dysfunction.,,2008-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12431,NCT06057805,CGM metric of mean glucose compared to OGTT result,CGM variability measure MAGE will be compared to fructosamine test,Tolerability to dexcom adhesive,2024-02-06,RECRUITING,INTERVENTIONAL,['NA']
12432,NCT02641743,plasma glucose concentration,plasma free fatty acid concentration,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
12433,NCT05968924,Adherence to use of SmartMat,Use of health care facilities,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12434,NCT05951569,Measure of Loop Safety by Self-Report of Hospitalization Events,,HbA1c,2023-06-20,COMPLETED,OBSERVATIONAL,['NA']
12435,NCT03369834,strength capacities,blood flow,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
12436,NCT02486172,Glycaemic control,Body weight,Sustainability of the program,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
12437,NCT00271284,Efficacy data : fasting blood glucose concentration,Tolerance data : undesirable events including episodes of hypoglycaemia,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12438,NCT05521893,Average postprandial glucose concentration,Incidence of caesarean section,,2020-03-12,COMPLETED,INTERVENTIONAL,['NA']
12439,NCT02985242,"Microaneurysm formation rate over 12 months, i.e. number of newly developed microaneurysms within 12 months",Change in ambulatory blood pressure,,2017-06-12,TERMINATED,INTERVENTIONAL,['PHASE4']
12440,NCT04370600,Bicarbonate concentration,,,2020-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
12441,NCT06296485,Hypoglycemia aggregate outcome,Hypoglycemia Distress,Caregiver Action,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12442,NCT02245633,ADAMTS13 levels in diabetic hemodialysis patients,VWF levels in diabetic hemodialysis patients,miRNA expression in plasma from diabetic hemodialysis patients,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
12443,NCT04442451,Capillary density,,,2024-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12444,NCT05072990,"Changes from Baseline Body Mass Index at 3 months, 6 months",Changes from Diastolic Blood Pressure at 6 months,,2021-10-27,COMPLETED,OBSERVATIONAL,['NA']
12445,NCT02811289,whole body organ glucose partitioning,Electrocardiogram,,2016-08-05,COMPLETED,INTERVENTIONAL,['NA']
12446,NCT01341067,Change in HgbA1c,Change in Basal Insulin Dose From Baseline Values,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
12447,NCT01726114,Performance of the test device in comparison to the reference device,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
12448,NCT01180972,"Assess the built environment for energy requirements of movement, nutrition options, suitability for outdoor physical activity, and for children's actual physical activity and energy expenditure within those environments.",Assess the impact of children's social environment on movement and nutrition choices within the built environment.,"Conduct a quantitative assessment of children's fitness, obesity, and indicators of metabolic health.",2010-08,COMPLETED,OBSERVATIONAL,['NA']
12449,NCT04219085,Composite Primary Outcome,hypertensive disorders of pregnancy.,,2020-09-01,RECRUITING,INTERVENTIONAL,['NA']
12450,NCT01461616,Growth Hormone(ng/ml),"insulin concentration (mmol/L) after a single injection of either NPH insulin, insulin Detemir or insulin glargine",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12451,NCT00393718,Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Hypoglycaemic Episodes,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12452,NCT00813410,glucose concentration at the subcutaneous insulin delivery site,,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
12453,NCT00543595,,,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2']
12454,NCT00770640,Change of total daily Insulin Dose.,Change from Baseline in intact Parathyroid Hormone.,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
12455,NCT02231736,The quality of HbA1c influences micronuclei formation in binucleated cells,Type 2 diabetes duration of the subjects influences chromosomal damage,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
12456,NCT00744458,Percentage of patients with regular follow-up one year after the treatment was started,Treatment response of patients with arterial hypertension (blood pressure),,2008-08,COMPLETED,INTERVENTIONAL,['NA']
12457,NCT02655757,Changes in late lumen loss of target lesion,Incidence rate of MACE,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
12458,NCT05689372,Number (incidence) of adverse events (AEs),Dose of Ozempic,,2024-06-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12459,NCT03654586,Total calories purchased in last two weeks of study,Newest vital sign measure,,2018-07-30,TERMINATED,INTERVENTIONAL,['NA']
12460,NCT00770939,Percentage of patients with a 50% reduction of wound area after 4 and 8 weeks,Granulation rate,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12461,NCT01006889,Hepatic Steatosis,Change in Anthropometric Variables (BMI).,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12462,NCT06296836,Mean glucose levels,Mortality,Mean glucose levels while receiving metformin in the continuation arm and while not receiving metformin in the discontinuation arm,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
12463,NCT02380339,Reduction of fear of hypoglycemia in type 1 diabetic patients as measured by reduction of 2 point on the HFS-W). pre-treatment and after two months post completion of treatment.,,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
12464,NCT05830994,Changes in gastric emptying,Incidence of Treatment-Emergent Adverse Events rated by the ASGE lexicon for adverse events,,2023-04-12,RECRUITING,INTERVENTIONAL,['NA']
12465,NCT01578460,Offspring Birth Weight,Shoulder Dystocia (neonatal),,2012-05,COMPLETED,INTERVENTIONAL,['NA']
12466,NCT00111800,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Descriptive Statistics of Dipeptidyl Peptidase-IV (DPP-IV) Inhibition Performed as Part of the Population PK,,2005-04-28,COMPLETED,INTERVENTIONAL,['PHASE2']
12467,NCT04923386,Change in AUC glucose level above expected baseline,Change in fasting blood glucose levels above expected baseline,,2021-06-15,COMPLETED,OBSERVATIONAL,['NA']
12468,NCT00781495,To detect an association between insulin-induced weight gain and physical activity levels,To assess the relationship between insulin-induced weight gain and cardiovascular risk profile,,2008-12,UNKNOWN,OBSERVATIONAL,['NA']
12469,NCT03242252,Change From Baseline in HbA1c at Week 26,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),Percentage of Participants With Hypoglycemic Events,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE3']
12470,NCT05326204,Fetal weight,perinatal complications,,2021-12-30,RECRUITING,OBSERVATIONAL,['NA']
12471,NCT01472640,"Change in Left ventricular function from visit 1 to week 24, measured by Ecco",left ventricular diastolic function,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12472,NCT03218735,Number of children with birthweight above 4500 grams,Number of children admitted to NICU,,2017-07-12,WITHDRAWN,INTERVENTIONAL,['NA']
12473,NCT01068717,"Time to Achieve the Observed Maximum Plasma Concentration (Tmax) for Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States","Number of Participants With Clinically Significant Abnormalities in Body Temperature, Blood Pressure, or Heart Rate",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12474,NCT02709577,Change in HbA1c Values From Baseline Measurement,Absolute Weight Change,,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12475,NCT01384058,"Change of the concentration of apolipoprotein B (ApoB) in dense Low Densitiy Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs",Change of the concentrations of triglycerides,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12476,NCT04136730,Glycated Haemoglobin concentration (mmol/mol),Short performance physical battery test,Quality of life score,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
12477,NCT05893576,Calculate the ratio of bioavailability between the new formulation and original formulation of HRS9531 according to the equation F (relative bioavailability) =AUCT·DR/AUCR·DT×100%,Incidence and severity of adverse events,,2023-05-15,COMPLETED,INTERVENTIONAL,['PHASE1']
12478,NCT04213651,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,,,2020-03-02,UNKNOWN,OBSERVATIONAL,['NA']
12479,NCT01526980,Glucose average in 24-hour blood glucose profiles,Adverse events,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12480,NCT05632601,Satisfaction Questionnaire,,,2023-04-26,RECRUITING,INTERVENTIONAL,['NA']
12481,NCT04758858,Percentage of time-in-target (range of 4-10 mmol/L),Self-reported symptoms,,2021-03,WITHDRAWN,INTERVENTIONAL,['NA']
12482,NCT01162876,Pharmacodynamics,Safety issues,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12483,NCT01821053,preeclampsia,light for gestational age,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
12484,NCT02266758,Number of Cesarean Section Deliveries,Number of Infant Bone Fractures or Nerve Palsies associated with delivery,Number of pregnant women with anxiety or depression,2014-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12485,NCT01868191,Change from baseline in intraepidermal nerve fiber density,Change in neuropathic deficits,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
12486,NCT03112343,the proportion of patients who reach his/her optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits.,the number of self-monitoring blood glucose measurements,,2017-09-26,COMPLETED,INTERVENTIONAL,['NA']
12487,NCT03529123,Change in HbA1c,Change in SMPG profiles,,2018-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
12488,NCT03166852,Frequency of training,Interview,,2016-04-27,COMPLETED,INTERVENTIONAL,['NA']
12489,NCT00246987,Change in HbA1c from baseline to Week 24,Changes achieved from baseline in FPG after 24 weeks. Changes achieved from baseline in 3 hour post-prandial AUC for glucose and insulin levels after 24 weeks vs. placebo.,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12490,NCT02864160,Change in Patient Hemoglobin A1C from Baseline to 6 Months,Change in Health Coach Interpersonal Communication from Baseline to 6 Months as Assessed by the RIAS,Change in Program Reach to End of Year 5,2014-09,COMPLETED,INTERVENTIONAL,['NA']
12491,NCT02719132,Composite endpoint including quality of life score,Proportion of patients,laboratory values changes,2016-07,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12492,NCT01628289,Retinopathy profile in the two groups,Subjects' attendance of the screening,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
12493,NCT00541437,,,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
12494,NCT04833062,Addition of the UAPI to the CPR,,,2022-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12495,NCT00848757,Change in Blood Pressure,Physical Activity Levels (Self-reported),,2009-03,COMPLETED,INTERVENTIONAL,['NA']
12496,NCT02932826,Number of Participants with Adverse events as a Measure of Safety and Tolerability,Autoimmune Status,,2016-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12497,NCT00420095,Glycosylated Hemoglobin (HbA1c) Value at 12 Week Endpoint,Hypoglycemia Rate Per Participant Per 30 Days,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12498,NCT04511325,The effects of daily white potato versus white rice consumption for 12 weeks (each intervention for 12 weeks with a 2-week washout period) on pulse wave velocity (PWV) in individuals with type 2 diabetes mellitus.,The effects of daily white potato versus white rice consumption for 12 weeks (each intervention for 12 weeks with a 2-week washout period) on waist-to-hip ratio in individuals with type 2 diabetes mellitus.,,2019-04-27,COMPLETED,INTERVENTIONAL,['NA']
12499,NCT05743907,HbA1c(%),,,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE4']
12500,NCT00432276,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Mean HDL Particle Size,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12501,NCT02427802,Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection),Ulcer Closure (Percent of Patients With Target Ulcer Closure),,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3']
12502,NCT02844803,Change of serum glucose level after 8 weeks from baseline,,,2016-07,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12503,NCT00869609,Change in Weight,Change in Waist Circumference,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
12504,NCT04599738,Change in insulin response from baseline for 180 minutes,Satiety by visual analogue scale for 4 hours,,2017-03-06,COMPLETED,INTERVENTIONAL,['NA']
12505,NCT05884957,ِAssessments of endothelial nitric oxide synthase In diabetes mellitus,Tadalafil 5milligram (tablets) therapy in diabetic patients,,2023-06-01,COMPLETED,INTERVENTIONAL,['NA']
12506,NCT06278181,asymptomatic malaria,symptomatic malaria,strongyloides infection,2023-09-21,RECRUITING,OBSERVATIONAL,['NA']
12507,NCT03851627,Liver fat,diabetes management satisfaction questionnaire,amount of pancreatic fat,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE4']
12508,NCT00959348,To investigate the ICS effect on the risk of DM/IGT/insulin resistance,To study the dose response relationship and effect modifying factors if risk is present,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
12509,NCT04392557,side effects,lipid metabolism/atheroscelorisis,,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12510,NCT00191464,HbA1C,Apolipoproteins [substudy],,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
12511,NCT01304537,Safety and Tolerability,Efficacy,,2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12512,NCT03504059,Changes in the composite ICH score of adolescents from baseline to year 2 and 4,Changes in the composite ICH score of adolescents from baseline to adulthood,,2017-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12513,NCT04786418,"Changes in liver fat >5 percent, determined by MRI, from baseline to after 12 months of intervention.","Multi organs pancreas, spleen and kidney fat content",,2021-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12514,NCT03182426,Rate of Serious Adverse Event/Medical Event of Special Interest,T-cell phenotyping,,2017-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12515,NCT01292590,Change in insulin requirements,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
12516,NCT04069611,Probing Pocket Depth (PPD),Patient Satisfaction,,2020-01-30,RECRUITING,INTERVENTIONAL,['NA']
12517,NCT01396564,Short-term comparison of metformin and pioglitazone in pediatric patients with T2D,Comparison of long-term effects of metformin vs pioglitazone,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12518,NCT04726163,Percentage of time spent in the range 70-180 mg / dl (TIR),Time spent bellow glycaemia < 70mg/dl,,2021-01-29,TERMINATED,INTERVENTIONAL,['NA']
12519,NCT01374178,Pharmacokinetics: Area Under the Concentration-Time Curve (AUC),Number of Participants With Clinically Significant Effects,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12520,NCT04466007,Complication rate after treatment administration,% amputations,VascuQol-6 questionnaire,2021-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12521,NCT05097534,Change from baseline HbA1c,Change from baseline medication Adherence,,2021-12-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12522,NCT03557138,Kinetic behavior of glucose reabsorption,positron emission tomography (PET),,2017-02-22,UNKNOWN,INTERVENTIONAL,['NA']
12523,NCT00662519,Number of participants with adverse events,Increase T regulatory cells (Treg) from the bone marrow,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12524,NCT02053077,"Efficacy: Blood Glucose During Hospital Stay, an Expected Average of 1 Week",Usability: Coverage of the GlucoTab,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
12525,NCT00005760,,,,2000-05,COMPLETED,OBSERVATIONAL,['NA']
12526,NCT02737657,Percentage of Participants With at Least one Episode of Hypoglycaemia,Relationship of Volume Depletion Events With Number of Fasting Days,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
12527,NCT05140564,HbA1c,,,2022-01-18,COMPLETED,INTERVENTIONAL,['NA']
12528,NCT05470842,"Proportion of participants with captured hypoglycaemia; within that group, the time spent in the hypoglycaemic range","Emergency department re-attendances and/or hospital re-admissions for falls, fractures, heart attacks, ischaemic strokes and death within 30 days",,2023-06-06,COMPLETED,INTERVENTIONAL,['NA']
12529,NCT01288326,Percentage of participants reaching the treatment target of a HbA1c (glycosylated haemoglobin A1c) decrease of at least 1%,Frequency of hypoglycaemic episodes (frequency of episodes with low blood sugar),,2011-02,COMPLETED,OBSERVATIONAL,['NA']
12530,NCT04632862,HbA1c level at Week 24 after administration of the IP,"HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP",,2020-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12531,NCT04160078,Number of Participants With PSS Score Indicating High Stress,Blood Pressure,,2019-12-18,COMPLETED,INTERVENTIONAL,['NA']
12532,NCT02029846,Time to Achieve Glycemic Target (HbA1c <7.5%).,Overall Hypoglycemia Measured by Glucose Meter,Diabetes Quality of Life,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4']
12533,NCT01270191,The time of monotherapy failure and monotherapy failure rate,"Comparison of A1C change, the proportion of subjects who reached the treatment target",,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12534,NCT04864483,Incidence of early day hypoglycemia,Patient satisfaction and preference,,2021-03-21,COMPLETED,INTERVENTIONAL,['NA']
12535,NCT05005741,haemoglobin A1c(HbA1c),Homeostasis model assessment for β cell(HOMA-β),,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
12536,NCT05359796,the development or progression of diabetic retinopathy,the changes of carotid intima-media thickness(IMT),,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
12537,NCT00446251,The Number of Subjects Who Experience a Decrease in Their Panel of Reactive Antibodies (PRA) at 6 Months Post Rituximab Infusion.,The Number of Subjects With a Negative Crossmatch at the Time of Transplant.,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12538,NCT00707460,Pilot Study: no formal primary outcome measure. There is no noted safety issue for this study; although adverse/side effects and/or symptoms will be closely monitored by the RPN and community research staff.,"Future dietary intervention feasibility will be assessed by 24-hour recalls/ diet records, appointment attendance, participant and community staff feedback, and questionnaire completion.",,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12539,NCT03137966,Healing,Improvement of ulcer,,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12540,NCT03966911,Percentage of Readings Within 20% Agreement,,,2019-06-14,COMPLETED,INTERVENTIONAL,['NA']
12541,NCT00486187,Change in adiponectin level in the rosiglitazone vs. metformin/sulfonylurea arms,"Secondary end-points include changes in leptin, resistin, hs-CRP, IL-6, MMP-9, ICAM-1, insulin sensitivity (as estimated by the HOMA technique), HbA1c, and lipid levels in the rosiglitazone vs. metformin/sulfonylurea arms",,2006-04,COMPLETED,INTERVENTIONAL,['NA']
12542,NCT01469481,radioactivity t1/2,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12543,NCT02232971,Maximum plasma glucose response,Duration of hyperglycemic effect of glucagon,Plasma triglycerides,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
12544,NCT04450810,Clinical attachment level,,,2014-06-01,COMPLETED,OBSERVATIONAL,['NA']
12545,NCT03938441,Number of hypoglycemic events,,,2019-07-31,TERMINATED,INTERVENTIONAL,['NA']
12546,NCT06305377,Glucometric data,,,2024-03-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12547,NCT05105321,Rate of composite cardiometabolic endpoints,Changes of body mass index,,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
12548,NCT00929201,Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin,Peak Plasma Concentration (Cmax) of Metformin,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12549,NCT03543644,75g OGTT derived plasma glucose iAUC,75g OGTT derived Matsuda whole body insulin sensitivity index [Matsuda ISI OGTT],Urinary and blood proteomic panel,2018-05-31,COMPLETED,INTERVENTIONAL,['NA']
12550,NCT03490253,Physical Activity,Patient Health Questionnaire-8 (PHQ-8),,2020-02-05,COMPLETED,INTERVENTIONAL,['NA']
12551,NCT01618162,Change in Glycosylated Haemoglobin (HbA1c),Number of Adverse Events (AEs),,2012-08-29,COMPLETED,INTERVENTIONAL,['PHASE3']
12552,NCT03701087,incidence of gestational diabetes recurrence,,,2018-08-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12553,NCT02782195,To measure the rate of glucose absorption after a standard evening meal,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
12554,NCT00808795,"Incidence of CIN, defined as increase in serum creatinine concentration>=0.5mg/dL(44.2micromol/L) or >=25% above baseline.",Change in Glomerular filtration rate(GFR),,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12555,NCT03293082,Glucose variability,HbA1c,,2017-09-30,COMPLETED,OBSERVATIONAL,['NA']
12556,NCT04972539,Cmax,,,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12557,NCT05816759,AUCt of CKD-383,,,2023-05-26,COMPLETED,INTERVENTIONAL,['PHASE1']
12558,NCT02362607,Blood Glucose Control Status Measured by HbA1c,Patient Satisfaction Measured by Questionnaire,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
12559,NCT03818581,Subjective Total Sleep Time,Insomnia Severity Index,,2019-03-15,COMPLETED,INTERVENTIONAL,['PHASE4']
12560,NCT04656236,Differences in lipolysis rate,"Differences in circulating concentrations of 3-hydroxybutyrate, glucose, free fatty acids, insulin, glucagon and C-peptide",,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
12561,NCT01017302,Safety and Tolerability of various doses of RO5095932,"Pharmacodynamics: glucose, insulin, C-peptide",,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12562,NCT03666546,Capillary blood glucose levels as baseline corrected AUC: AUCbaseline_c (0-180 minutes) [Baseline corrected area under curve from 0 to 180 minutes for blood glucose concentration (= Area under curve from 0 to 180 minutes minus baseline*180 minutes)],"Incremental area under curve from 0 to 180 minutes for blood glucose concentration, i.e., above baseline levels for blood glucose concentration after oral intake of Laevolac crystals/liquid or control products (iAUC(0-180min))",Blood glucose concentration at 240 minutes - only when blood glucose is >10 mmol/L (>180 mg/dL) at 180 minutes,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE4']
12563,NCT00160927,,,,2003-01,UNKNOWN,OBSERVATIONAL,['NA']
12564,NCT02702375,Gout,,,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
12565,NCT04214704,Percentage reduction in HbA1c,Subjective assessment of probability of using Genteel for SMBG,,2020-02-04,COMPLETED,INTERVENTIONAL,['NA']
12566,NCT05544214,"Cmax of CKD-371, D745+D759",,,2022-10-21,COMPLETED,INTERVENTIONAL,['PHASE1']
12567,NCT00421850,Metabolic Outcomes (Systolic Blood Pressure),Satisfaction (Provider and Health Team),,2001-07,COMPLETED,INTERVENTIONAL,['NA']
12568,NCT01357889,Maximum Observed Plasma Concentration (Cmax) of Albiglutide in the BE Phase,Number of Participants With a Change From Baseline of Clinical Concern in Electrocardiogram (ECG) Values by Any On-therapy Visit,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12569,NCT03984929,Patient Activation,,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
12570,NCT05988346,normalization of LV diastolic dysfunction,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
12571,NCT06082973,Number of Level 1 (<70 mg/dL) and Level 2 (<54 mg/dL) hypoglycemic events,Total number of carbohydrates ingested,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12572,NCT04049110,Mean Amplitude of Glucose Excursions (MAGE) after physical exercise,"Area under the curve for glucagon before, during and after physical exercise","Area under the curve for somatostatin before, during and after physical exercise",2020-08-25,COMPLETED,INTERVENTIONAL,['PHASE3']
12573,NCT00338923,Safety,Time to Heal & Rate of Healing,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12574,NCT02608177,Glucose Time in Range,Biomarkers of Albuminuria,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
12575,NCT02097069,Insulin resistance level evaluated by homeostasis model assessment of insulin resistance (HOMA-IR),insulin therapy requirements,,2014-04,UNKNOWN,INTERVENTIONAL,['NA']
12576,NCT02982408,Adipose tissue expandability,Epigenetics,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
12577,NCT06238778,hypoglycemia percentage of time,blood chemistry values,,2024-01-23,RECRUITING,INTERVENTIONAL,['PHASE2']
12578,NCT03703440,Hemaglobin A1c (HbA1c),Cost effectiveness (self-efficacy),,2019-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12579,NCT02778269,Number of power-line interference on the ECG,"Number of congruences concerning identified arrhythmias of this validation study and the previous study ""Predicting Hypoglycaemia and Arrhythmias in the vulnerable Patient with Diabetes and Chronic Kidney Disease"".",,2016-06,COMPLETED,INTERVENTIONAL,['NA']
12580,NCT06150495,"Retinal vessel density (VD, %)",,,2019-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12581,NCT03906201,Changes in glycosylated hemoglobin (A1C) after 90 days of intervention with betaecdysterone and placebo,Blood pressure,,2019-02-06,UNKNOWN,INTERVENTIONAL,['NA']
12582,NCT00604253,HbA1c,Insulin antibodies,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12583,NCT02592421,Change in Endogenous Glucose Production (EGP),Change in Glucagon During EGP Measurement,,2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
12584,NCT00813020,"AUC0-8 (NN9535), the area under the plasma NN9535 plasma-concentration-time curve in the interval 0-8 after investigational medicinal product administration",Cmax of the plasma NN9535 curve,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12585,NCT05626842,Primary study objective- HbA1c,Secondary study objective- participant experience,,2021-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12586,NCT03574558,Number of hypoglycemic below 54 mg/dl,,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
12587,NCT02390973,Type 2 diabetes remission rate,Dislipidemia remission,Long-term complications,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
12588,NCT04022499,Weight loss,Attendance,,2019-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12589,NCT00761540,AUC 0-24h (last dosing day): Area under the plasma liraglutide curve from 0 to 24 hours after last dosing.,Hypoglycaemic events,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12590,NCT02688920,"Thickness of the duodenal mucosa using OCT, and EUS if possible","Thickness of the duodenal submucosa using OCT if possible, and EUS","Thickness of the duodenal muscularis using OCT if possible, and EUS",2016-03,COMPLETED,OBSERVATIONAL,['NA']
12591,NCT02299960,Test-retest-reliability EndoPAT,Clinical feasibility of circulating endothelial cells and EndoPAT,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
12592,NCT05421390,Change in whole-body insulin sensitivity,Change in C-reactive protein,Change in subcutaneous adipose tissue gene expression signature,2022-06-10,RECRUITING,INTERVENTIONAL,['NA']
12593,NCT03288571,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Evaluation of the preliminary efficacy of the injection on kidney's protein to creatinine ratio,,2019-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12594,NCT03708887,Change in blood lipids from baseline,Change in gut microbiota from baseline,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
12595,NCT01572610,Adverse Event collection and assessment,,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2']
12596,NCT00475202,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
12597,NCT06229379,Students' scores in the medical history acquisition exam,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
12598,NCT02957721,Change in A1C,Blood Pressure (BP),,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
12599,NCT00644748,Change from baseline Mean Pain Score,Global Change Impression from the Physician's Point of View,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12600,NCT05794009,Glycated Hemoglobin (HbA1C),Depression,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
12601,NCT04691973,Change of long-term blood glucose concentration measured as glycated hemoglobin at one year,Insulin secretion,"Change of long-term blood glucose concentration measured as glycated hemoglobin in participants with and without Mild Obesity-related Diabetes, respectively.",2017-01-01,UNKNOWN,OBSERVATIONAL,['NA']
12602,NCT02423993,HbA1c,Quality of Life (SF36 Questionnaire),,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12603,NCT01419535,Change in Insulin Sensitivity Index,Adipose-tissue Insulin Sensitivity Index (Adipo-SI),,2011-11-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12604,NCT02419612,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52,Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.,,2015-08-14,COMPLETED,INTERVENTIONAL,['PHASE3']
12605,NCT05360147,Changes in cognitive function from baseline to 12 weeks,Changes of metabolic parameters from baseline to 12 weeks,,2021-01-20,COMPLETED,INTERVENTIONAL,['PHASE3']
12606,NCT01208012,The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells,Safety evaluation,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12607,NCT04776811,Mean absolute relative difference (MARD),"Correlation between CGM metrics, HbA1c and fructosamine",,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
12608,NCT01875224,Decreased insulin resistance,,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
12609,NCT05279729,Long term diabetes improvement via A1c,mhealthy app preference assessed by questionnaire,,2022-08-01,RECRUITING,INTERVENTIONAL,['NA']
12610,NCT01972412,Telephone Support for self-monitoring of persons with diabetes mellitus using the Chronic Care Model,,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
12611,NCT01398670,Change in HbA1c,Correlation of the immunogenicity with hypoglycemia,,2012-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12612,NCT04127383,Perceived quality of care (PACIC): Patient Assessment of Chronic Illness Care,Productivity losses,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
12613,NCT04456192,C-reactive protein concentration (CRP) [mg/l],"Resting SBP [mmHg], Resting DBP [mmHg], Exercise SBP [mmHg], Exercise DBP [mmHg]",,2013-01-01,COMPLETED,INTERVENTIONAL,['NA']
12614,NCT01798706,Absolute Change in HbA1c From Baseline to Week 24,Percentage of Participants With Gastrointestinal Disorders,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12615,NCT03845465,Glycemic Control (HbA1c),Diabetes-Related Quality of Life,,2019-12-17,COMPLETED,INTERVENTIONAL,['NA']
12616,NCT05658770,MAGE,quality of life (self-reported questionnaire),,2023-09-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12617,NCT01536808,Telomere shortening,Cardiovascular events,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
12618,NCT03285386,Time constant for muscle deoxygenation kinetics (assessed by near-infrared spectroscopy),Time constant for heart rate kinetics,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
12619,NCT01033500,Achieve and consistently maintain insulin independence in simultaneous islet-kidney transplant recipients for one year.,,,2010-07,WITHDRAWN,INTERVENTIONAL,['NA']
12620,NCT04148482,Hunger perception before and after test meals consumption using visual analogue scales,Appetite satiety hormones levels by immunoassay kits,,2021-06-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12621,NCT05262595,"AUC (NNC0471-0119,0-30min,basal-corrected)/AUC (NNC0471-0119,0-t,basal-corrected)","GIRmax,basal-corrected: Maximum observed basal-corrected GIR",,2022-03-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12622,NCT02545140,Chronic disease risk factor - Body mass index (BMI),Chronic disease risk factor - total cholesterol,Risk tool refinement,2015-10,COMPLETED,OBSERVATIONAL,['NA']
12623,NCT02215200,Change in Area Under the Stimulated C-peptide Curve From Baseline to 12 Months.,,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12624,NCT01681550,Death,Macrovasular complications,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
12625,NCT02682056,Glucose Level,Pain Level Assessed by Pain Visual Analog Scale (VAS),,2017-12-21,COMPLETED,INTERVENTIONAL,['NA']
12626,NCT00235469,"To investigate the efficacy of 200, 400, and 600 mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.","To investigate the effect of lacosamide on subjects' perception of pain, sleep, activity, quality of life, as well as to investigate the pharmacokinetics and safety of lacosamide.",,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12627,NCT04590872,Number of successful manufactured products,Change in blood glucose levels,,2022-06-16,RECRUITING,INTERVENTIONAL,['PHASE1']
12628,NCT03020069,Change in Score of Diabetes Empowerment Scale Short Form (DES-SF) From Baseline to 3 Months,,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
12629,NCT00130845,time to progression of diabetic retinopathy,time to moderate vision loss,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12630,NCT01758757,Incidence of retinal breaks,Incidence of neovascular glaucoma,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
12631,NCT00297401,Change in the renal and peripheral pressor response to Angiotensin II pre and post-treatment with ruboxistaurin.,Secondary analyses will consist of the change in endothelial function and vascular compliance pre- and post-treatment with ruboxistaurin.,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12632,NCT00324363,To test the hypothesis that exenatide (before morning and evening meals) produces a greater decrease in HbA1c than placebo in patients with type 2 diabetes and inadequate glycemic control taking metformin alone or metformin and sulfonylureas.,To compare exenatide and placebo groups with respect to: *safety and tolerability; *proportion of patients achieving HbA1c<=7%; *body weight; *incidence and rate of hypoglycemic events; *glucose measurements,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12633,NCT02969954,Self-efficacy for diabetes management,,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
12634,NCT00991055,The change from baseline in HbA1Cand FPG,Insulin resistance (HOMA-IR index),,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
12635,NCT00108459,,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12636,NCT04769687,inflammation,fragility,,2020-11-21,RECRUITING,INTERVENTIONAL,['PHASE2']
12637,NCT00924599,Gestational diabetes not present in pregnancy,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
12638,NCT00751114,HbA1c: Change From Baseline to Study Endpoint,Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12639,NCT05029271,Endpoints are exploratory and descriptive related to time in glycemic range.,,,2023-04-17,COMPLETED,INTERVENTIONAL,['NA']
12640,NCT00935064,Expiration/Inspiration Ratio Before and After Treatment,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
12641,NCT05906199,Changes in carotid IMT,,,2021-07-28,RECRUITING,INTERVENTIONAL,['PHASE4']
12642,NCT04315688,Change in laboratory measured HbA1c (mmol/mol),"Reason(s) for discontinuing treatment with Tresiba® during the treatment period, if applicable (according to pre-specified response options)",,2020-03-30,COMPLETED,OBSERVATIONAL,['NA']
12643,NCT02713321,Diabetes-related preventable hospitalizations,Number of months of Medicaid coverage,,2017-01-24,COMPLETED,OBSERVATIONAL,['NA']
12644,NCT05893784,Fatigue Severity Scale,,,2022-01-20,COMPLETED,INTERVENTIONAL,['NA']
12645,NCT01436916,Change in insulin sensitivity using OGIS (oral glucose insulin sensitivity index),Change in fasting and post prandial blood glucose,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12646,NCT03542929,Changes in lactate levels,Borg's Rating of Perceived Exertion Scale (RPE) or Modified Borg Scale,,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
12647,NCT02637609,Measuring patients' priorities for barriers and facilitators for diabetes self-management using Best-Worst Scaling,,Self-reported difficulty in understanding and answering the survey questions,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
12648,NCT03430856,Change From Baseline in HbA1c at 24 Weeks (Part 1),CGM,Participants Achieving HbA1c < 7% Without Reported Clinically Significant or Severe Hypoglycemic Event Between End of Week 8 and Week 24,2017-12-26,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12649,NCT06062576,2-week reduction rate of wound area,,,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
12650,NCT00328965,To investigate the clinical effectiveness of lacidipine on elevated systolic blood pressure (SBP) in Korean patients aged 35 to 75 years.,To investigate the clinical effectiveness of lacidipine on elevated diastolic blood pressure and endothelial function by flow-medicated vasodilation and measurement of markers of inflammation in Korean patients aged 35 to 75 years with type 2 diabetes.,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12651,NCT01879501,Vision-related quality of life,"Perceived self-efficacy, emotional well being, and vision-specific distress",,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
12652,NCT04161976,PK: Maximum Observed Insulin Lispro Concentration (Cmax),Duration Until Catheter Failure,,2019-12-27,COMPLETED,INTERVENTIONAL,['PHASE1']
12653,NCT03426566,Abnormal Plantar Pressure Distribution,BMI,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
12654,NCT05011292,Percentage of parents who report that they do not give their young children fruit juice,Percentage of parents who viewed an intervention video report that they enjoyed it or learned something from it,,2021-08-10,COMPLETED,INTERVENTIONAL,['NA']
12655,NCT06289920,Cmax,,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE1']
12656,NCT04115579,Postprandial glucose,Postprandial insulin,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
12657,NCT03003793,Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
12658,NCT03221205,Strain,Mean value of arterial pressure,,2014-10-15,COMPLETED,INTERVENTIONAL,['NA']
12659,NCT04336176,Pressure Time Integral,Modified Monitoring Orthopaedic Shoes questionnaire,,2018-03-22,COMPLETED,INTERVENTIONAL,['NA']
12660,NCT06296992,Retention for follow-up measurements,Quality of Life (PedsQL 4.0),Motivation for Physical Activity (EMI-2),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12661,NCT03693560,Change in Adiponectin level.,Percent Change in (total cholesterol / High-density lipoprotein (HDL) cholesterol) for each patient before and after 3 months combination treatment for each group .,,2018-10-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12662,NCT06071559,"Blood tests for extracellular vesicles comparing two years after surgery with baseline (below referred to as ""changes in"").",,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
12663,NCT00403026,"Electrophysiological changes (ERG, VEP)","Ocular side effects (infection, RD, IOP rise, cataract)",,2006-08,UNKNOWN,INTERVENTIONAL,['NA']
12664,NCT01382459,,,,2011-07,UNKNOWN,OBSERVATIONAL,['NA']
12665,NCT02330549,Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR ) Index,Number of Participants With Abnormal Physical Examination Findings,,2015-07-17,COMPLETED,INTERVENTIONAL,['PHASE2']
12666,NCT05708820,HbA1c,Awareness of hypoglycemia,,2022-12-14,RECRUITING,INTERVENTIONAL,['NA']
12667,NCT02707406,Incidence of adverse events collected throughout the trial compared between the two groups,Difference in score of quality of life assessment determined by Cardiff Wound Impact Schedule (CWIS),,2016-02,COMPLETED,INTERVENTIONAL,['NA']
12668,NCT03012529,Amputation-Free Survival,First occurrence of ipsilateral amputation related to index osteomyelitis,,2018-01-22,RECRUITING,INTERVENTIONAL,['PHASE4']
12669,NCT06315361,Prevalence of significant fibrosis by non invasive tests,Identification of MACE,,2019-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12670,NCT02156843,Time to composite endpoint of >=50% SCr increase from baseline or ESRD,Time to the composite endpoint >=100% SCr increase or ESRD,Change in SCr,2014-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12671,NCT01407315,Accuracy of the GlucoMenDay,Safety of the GlucoMenDay System,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12672,NCT01117103,Proportion of subjects who discontinue Glucophage XR treatment prematurely (< 12 weeks) due to side effects,Change in glycosylated haemoglobin (HbA1c) levels from baseline after 12 weeks,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
12673,NCT05754008,Differences between study arms in HbA1c change 6-months following enrollment,Participant-reported measures: Diabetes stigma,,2023-03-31,RECRUITING,INTERVENTIONAL,['NA']
12674,NCT06260722,Change from Baseline in Hemoglobin A1c (HbA1c) (%),Change from Baseline in Systolic Blood Pressure (SBP),,2024-02-21,RECRUITING,INTERVENTIONAL,['PHASE3']
12675,NCT05273840,the proportions of participants regressing back to normal glucose level,body weight,changes in triglyceride level (blood lipids),2021-06-11,RECRUITING,INTERVENTIONAL,['NA']
12676,NCT00655200,Safety profile of Insulin Detemir among Filipino patients,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
12677,NCT01481623,"Identification and genetic, clinical and metabolic characterization of monogenic diabetes forms",Clinical and biological characterization of total or partial deficiency of the genes responsible for monogenic diabetes,,2012-09,UNKNOWN,INTERVENTIONAL,['NA']
12678,NCT01136902,Vessel caliber,Blood glucose level,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
12679,NCT04725890,Device- or Procedure-related SAE Rate,Changes in blood pressure,Procedure time,2021-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12680,NCT03410537,Ankle-brachial index,Fasting serum insulin,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
12681,NCT01647308,Total apoC-III,Insulin Sensitivity,,2012-07,TERMINATED,INTERVENTIONAL,['PHASE2']
12682,NCT03576300,Tear cytokines levels,Clinical correlations of the tear cytokines,,2018-02-01,COMPLETED,OBSERVATIONAL,['NA']
12683,NCT03909451,Adverse events (AEs),Assessment of PD parameter: urinary glucose excretion (UGE),,2019-04-28,COMPLETED,INTERVENTIONAL,['PHASE1']
12684,NCT05494450,evaluate the safety and performance of Exufiber Ag+ in medium to high exuding chronic wounds,,,2022-01-01,TERMINATED,INTERVENTIONAL,['NA']
12685,NCT00384085,Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis),Adjusted Hypoglycemic Event Rates (Event/Patient-year),,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12686,NCT01885234,glycated hemoglobin,HOMA,First ventilatory threshold,2011-12,COMPLETED,INTERVENTIONAL,['NA']
12687,NCT02668601,hypothalamic CBF,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
12688,NCT02175784,Change in HbA1C from baseline,"Safety assessed by the adverse events, vital signs. and laboratory tests",,2014-03-31,COMPLETED,INTERVENTIONAL,['PHASE4']
12689,NCT02284269,Incidence of adverse events,The change from baseline in Fasting Plasma Glucose,,2014-10,UNKNOWN,OBSERVATIONAL,['NA']
12690,NCT01988246,Number of Participants With Ocular and Non-Ocular Adverse Events,Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score,Change From Baseline in Retinal Thickness,2013-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12691,NCT00605592,A decrease in the average daily insulin requirement post-islet cell transplantation.,,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
12692,NCT04992325,"The measurements of corneal features in patients with type 2 diabetes mellitus, using anterior segment-optical coherence tomography",,,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
12693,NCT02428998,All adverse events occurring up to 24 weeks time after taking the Investigational product,Baseline by 24 weeks after the change in quality of life measures ingestion of Investigational product,variation of biological age,2014-09,COMPLETED,INTERVENTIONAL,['NA']
12694,NCT01238380,Identification of patients with monogenic diabetes,To develop a health economic model of the care pathway leading to testing of monogenic diabetes.,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
12695,NCT01809184,Number of adverse events (AEs),Area under the glucose infusion rate (GIR)-time curve,,2013-03-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12696,NCT05395806,Change in fatigue level,Change in cardiovascular risk level,,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12697,NCT01875783,Rates of Retina Care Referral for Patients With Diabetic Macular Edema,Rates of Retinal Treatment Over 1 Year for Patients With DME,,2014-03-17,COMPLETED,INTERVENTIONAL,['NA']
12698,NCT01028404,Number and severity of adverse events for trial part 2,Area under the glucose infusion rate-time curve after a single dose,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12699,NCT00544206,mean glucose level,"fasting capillary blood glucose level;percentage change from baseline in the dose and amount of antihyperglycemic medication(s), including insulin",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12700,NCT03592667,Ambulatory arterial stiffness index,Glomerular filtration rate,,2019-02-14,UNKNOWN,INTERVENTIONAL,['PHASE4']
12701,NCT01274663,Single dose pharmacokinetics of PF-05175157,Exploratory pharmacodynamic biomarkers,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12702,NCT02960295,Compliance With Requirements for Frequency of Glucose Measures,Glucose Concentrations,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
12703,NCT05117424,Coronary lesion severity,Cardiovascular events,Lipoprotein function assessment,2018-11-01,RECRUITING,OBSERVATIONAL,['NA']
12704,NCT04121572,To utilize capnography as a noninvasive tool for the detection and monitoring of DKA,To find the ability of EtCO2 in ruling in or out DKA,To evaluate the different severity grades of DKA using EtCO2 Monitoring,2019-10-10,RECRUITING,OBSERVATIONAL,['NA']
12705,NCT02199769,Resulted Diabetes Screening Test,Diabetes Diagnosis,,2014-07-01,COMPLETED,INTERVENTIONAL,['NA']
12706,NCT01399892,incidence of hypoglycemia after fiber supplementation,,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
12707,NCT02172313,Area under the semaglutide plasma concentration time curve,Area under the SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) plasma concentration time curve,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12708,NCT02356835,Percent change in total wound size,Wound pain,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
12709,NCT00012662,,,,na,COMPLETED,INTERVENTIONAL,['NA']
12710,NCT00734669,Number of hypoglycemic events,"Secretion of hormones increasing blood glucose, effect of exercise on hypoglycemic events, postprandial glucose excursions, heart rate and forearm blood flow at hypoglycemia",,2008-07,COMPLETED,OBSERVATIONAL,['NA']
12711,NCT00341614,Total kcal and fat kcal at 3 months,Bone-mineral density at 3 months,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12712,NCT03760640,Percentage of Time With Sensor Glucose Values Between 70 and 180 Milligrams Per Deciliter (mg/dL) (24-Hour),Total Daily Insulin Dose,,2019-02-18,COMPLETED,INTERVENTIONAL,['PHASE2']
12713,NCT00336310,Change of postprandial plasma glucose (PPG) at 12 weeks,change of liver and renal function test,,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
12714,NCT02624804,Treatment related adverse events,Number of patients unable to complete therapy,,2017-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12715,NCT04146740,Blood glucose level,Edinburgh Post Natal Depression scale (Punjabi version),,2019-03-12,COMPLETED,INTERVENTIONAL,['NA']
12716,NCT00380822,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
12717,NCT05760677,The recovery of menstrual cycle,The changes in body weight,,2022-10-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1']
12718,NCT02139878,Blood Pressure,Glucose,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
12719,NCT03789526,changes in ultrasound images of the Tenoasynovitis.,,,2018-12-11,COMPLETED,INTERVENTIONAL,['NA']
12720,NCT00662714,HbA1c,,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12721,NCT02138331,Total daily insulin dose,Pancreatic β-cell Mass,Hemoglobin A1c,2014-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12722,NCT00391209,Demonstrate that a simple approach for adding AIR® Inhaled Insulin to oral antihyperglycemic medication can achieve glycemic control similar to a more aggressive approach.,"Patient reported outcome from ""Expectations About Insulin Therapy Questionnaire""",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12723,NCT03420781,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results,,2018-01-24,TERMINATED,INTERVENTIONAL,['PHASE3']
12724,NCT00706017,Incidence of SADR (serious adverse drug reactions ) incl major hypo (hypoglycaemic events),Weight,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
12725,NCT00273572,Parameters of the metabolic syndrome,Attainment of weight reduction and physical activity targets,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
12726,NCT02897349,Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Percentage of Participants With Any Severe Hypoglycaemic AE,,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE3']
12727,NCT05571865,Primary Outcome Measure-II,Secondary Outcome Measure-I,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12728,NCT00313937,Difference of change of blood glucose between patients on Insulin glargine and NPH insulin.,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12729,NCT05494775,Visual acuity,Central subfield thickness,,2019-02-01,RECRUITING,INTERVENTIONAL,['NA']
12730,NCT00086450,"5-year Composite Endpoint of All-cause Mortality, Non-fatal Myocardial Infarction, and Stroke",Rates of Individual MACCE Endpoints,,2004-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
12731,NCT02444364,Change in Bone Turnover,,,2015-05,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
12732,NCT01207284,Peak pressure at lateral forefoot,Activities-Specific Balance Confidence Scale (ABC),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12733,NCT01538511,Area under the plasma insulin concentration curve from 0 to 24 hours,Frequency of adverse events,,2006-06-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12734,NCT00472875,Glucose threshold for development of symptoms and cognitive impairment due to hypoglycaemia,Improvement in counter regulatory hormone response to hypoglycaemia,,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
12735,NCT01308164,Time spent in the normal range,Number of recommendations for changes in setting per patient and per iPRO wear,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
12736,NCT00877526,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
12737,NCT00962026,Incidence and severity of infection in study participants,"Changes in participants' HbA1c levels, insulin doses, and beta cell preservation",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12738,NCT03462940,Change in vascular function,Change in lipid levels,,2018-04-02,TERMINATED,INTERVENTIONAL,['NA']
12739,NCT04957589,Muscle Protein Breakdown (MPB) (3MH),Skeletal Muscle & Creatine Pool Assessment (D3-C),,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
12740,NCT02384109,Uptake of evidence-based diabetes prevention (lifestyle change or metformin),Change in systolic blood pressure,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
12741,NCT00865397,Change in HbA1c,Change in waist and hip circumference,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
12742,NCT01022411,fasting glucose,HbA1c,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12743,NCT00973960,The primary efficacy endpoint is an assessment of glycemic control at week 24 or last assessment measured via HbA1c.,The safety endpoint will be the incidence and severity of anticipated and unanticipated adverse events (device and non-device related).,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
12744,NCT01474473,Kinetics of Evolution of wound size within 60 days,Pain experienced during time,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
12745,NCT01415726,Inflammation control,Metabolic control,,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12746,NCT00820313,Biomarkers of Cardiovascular Disease,Dietary Intake,,2006-10,UNKNOWN,INTERVENTIONAL,['NA']
12747,NCT01121315,"Composite end-point consisting of Cardiovascular Disease, elective coronary revascularisation and mortality",Number of consultations in primary care. Number of hospitalisations,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
12748,NCT00400036,Insulin signaling in skeletal muscle at 4 weeks,glucose tolerance at 4 weeks,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12749,NCT00283777,"Insulin Senstivity, glycated hemoglobin","weight, body composition",,1998-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12750,NCT02061579,Changes in Self-Reported Physical Activity Level Across Study Visits,Changes in Patient Satisfaction During Intervention Period,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
12751,NCT03644134,Change in HbA1c,,,2013-09-26,COMPLETED,INTERVENTIONAL,['NA']
12752,NCT05754281,Mean absolute relative difference (MARD),,,2023-02-03,RECRUITING,OBSERVATIONAL,['NA']
12753,NCT02694172,Fecal microbiota profile,Plasma HDL cholesterol,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
12754,NCT04440449,Frailty Scale Using Fried's Phenotype Method Based on Five Frailty Characteristics,SPPB Chair Stands,,2019-07-15,COMPLETED,INTERVENTIONAL,['NA']
12755,NCT00836940,Change from baseline in HbA1c compared with placebo at the end of 12 week treatment period,Waist circumference,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
12756,NCT04794478,Dexcom Continuous Glucose Monitoring System Performance,System Related Adverse Device Effects,,2021-02-19,COMPLETED,INTERVENTIONAL,['NA']
12757,NCT04994288,HbA1c,salvage treatment,,2021-09-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12758,NCT02167620,"Improvement in HbA1C derived from Oral glucose tolerance test (Matsuda, index of insulin sensitivity; area under glucose curve; insulin secretion sensitivity index-2 (ISSI-2))",Improvements in hippocampal volume,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12759,NCT04271228,HbA1c,Total daily consumed carbohydrates,"Time required to review insulin pump and sensor data, make and send recommendations or length of visit",2020-02-15,COMPLETED,INTERVENTIONAL,['NA']
12760,NCT00866658,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12761,NCT03941652,Basic version of the eMOM GDM application has developed,Usability of professional eMOM GDM application,Nutrition dataset,2019-05-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12762,NCT01050465,seeking information using MedlinePlus,,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
12763,NCT02870816,The number of participants out of 60 with complete healing of their diabetic foot ulcers as measured by complete epithialization of the foot wound comparing the two active treatment groups,Cost effectiveness of each treatment modality.,,2016-08-31,COMPLETED,INTERVENTIONAL,['NA']
12764,NCT03214107,Percentage of time of capillary glucose levels spent between 4-10 mmol/L,Mean glucose levels,,2017-08-03,COMPLETED,INTERVENTIONAL,['NA']
12765,NCT02231021,Change in glycohemoglobin(HbA1c) from baseline,The number of subject with any change of findings in electrocardiogram from baseline,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12766,NCT04902235,Change in oxytocin concentration,Alexithymia assessment,,2021-07-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12767,NCT04970108,Systolic blood pressure (SBP),Adverse events,,2023-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12768,NCT00005485,Cardiovascular Disease,Mortality,,2000-09-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12769,NCT04488848,Interleukin-6,,,2019-04-11,UNKNOWN,INTERVENTIONAL,['NA']
12770,NCT01991197,The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.,The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.,The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12771,NCT02680054,Time of Peak Glucose Level Following Test Meal,Number of Participants With Hypoglycaemia Events Following the Insulin Dosing,Acceptability of Giving Insulin at Different Times Related to Test Meal,2016-02,TERMINATED,INTERVENTIONAL,['PHASE4']
12772,NCT04562714,Time in Range (TIR),Mean number of glucose checks,Exploratory analysis 4: Frequency of glucose testing,2020-09-08,COMPLETED,INTERVENTIONAL,['NA']
12773,NCT03918525,Type 2 diabetes,Dyslipidemia,,2017-02-20,COMPLETED,OBSERVATIONAL,['NA']
12774,NCT03323788,Response of muscle mRNA to acute exercise,,,2016-11,UNKNOWN,OBSERVATIONAL,['NA']
12775,NCT01951768,Clinical Cure,Pathogen Eradication,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12776,NCT00954109,Blood Flow in Response to Oral Glucose Tolerance Tests,,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
12777,NCT04433598,Glycemic control,Health literacy (HL),,2019-06-09,COMPLETED,INTERVENTIONAL,['NA']
12778,NCT00358124,"Other efficacy variables were the change from baseline in FPG, serum lipids and weight.",Health-related quality of life was compared between the baseline visit and the follow-up assessments,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12779,NCT00190320,reduction of neonatal traumatism risk,reduction of maternal morbidity and caesarean,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12780,NCT02794506,Change of glycosylated hemoglobin (HbA1c),Change of serum N- epsilon (carboxymethyl) lysine level,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12781,NCT01204775,Mean Change in HbA1c From Baseline to Week 16,,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12782,NCT00989924,The smooth index of corrected QT interval (SIQTC) measured by MCG,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
12783,NCT05639088,Attendance at clinic visits,Change in Quality of Life,Transition Status,2023-08-24,RECRUITING,INTERVENTIONAL,['NA']
12784,NCT02838693,Changes in insulin sensitivity in Asian populations with normal glucose tolerance and prediabetes over 3 years. Data will be presented at the end of 5.5years.,To discover and/or validate biomarkers that predict which subjects will progress from NGT to prediabetes and/or from prediabetes to diabetes. Data will be presented at the end of 5.5years.,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
12785,NCT00119054,Blood Pressure and Hemaglobin A1c,Knowledge Compliance Self-efficacy Quality of life Satisfaction with care,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
12786,NCT02439177,User Performance of blood glucose monitoring system indicated by patient,,,2015-05,TERMINATED,INTERVENTIONAL,['NA']
12787,NCT02559180,Mean Absolute Change on Central Foveal Thickness,Mean Change on Visual Acuity Score,Number of Participants That Gained or Lost Letters of Visual Acuity.,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
12788,NCT06117098,Change and ceiling and floor effect in outcomes,Antropometric measures,,2023-05-02,RECRUITING,INTERVENTIONAL,['NA']
12789,NCT04149951,Glycated Hemoglobin (HbA1c),Fullness,Dose response analysis,2020-06-03,COMPLETED,INTERVENTIONAL,['NA']
12790,NCT02090673,The proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients who are treated with Exenatide for type 2 diabetes mellitus,Change from baseline to endpoint in subjective measures include improvement of main indication,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
12791,NCT01726075,"Changes in the Implicit Time assessed by mfERG (IT-mfERG) at month 6, 12, 18 and 24",DR severity assessed by ETDRS scale CFP - 30º/35º-7 fields at month 24,"ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 24",2013-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12792,NCT00944697,Short Form McGill Pain Score.,,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12793,NCT06278571,Number of participants with body mass index profile in control target,The proportion of patients with adequate knowledge of diabetes,,2023-01-30,RECRUITING,INTERVENTIONAL,['NA']
12794,NCT01965639,Mortality,Change in patient-reported outcomes,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
12795,NCT01299012,Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
12796,NCT04224428,Percent change in urinary albumin creatinine ratio (UACR),Urinary monocyte chemoattractant protein-1 (MCP-1),,2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12797,NCT03771053,Change from Baseline coronary plaque volume percentage(PAV) at 12 months,Inflammation marker,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
12798,NCT02291666,Metabolic ratio,Renal clearance,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12799,NCT01876485,Change in Diabetes Specific Quality of Life,,,2015-07-13,COMPLETED,INTERVENTIONAL,['NA']
12800,NCT00004984,Rate of Type 1 Diabetes Per Year,,,1994-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12801,NCT01870557,Bone Mineral Density (t-score),Lifestyle and Medical history,urine creatinine albumin ratio,2013-03,COMPLETED,OBSERVATIONAL,['NA']
12802,NCT00774800,Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60),Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG]),,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12803,NCT00123604,Flow Mediated Dilation,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12804,NCT05932251,glucose-disposition-index,Neonatal body length,,2023-06-19,RECRUITING,OBSERVATIONAL,['NA']
12805,NCT00982254,Glucose Infusion Rate (GIR),Adverse Events,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12806,NCT00425490,C-peptide total and incremental area under the curve.,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12807,NCT05333835,Mean Change From Baseline in HbA1c at Week 26,Number of Hypoglycaemic Episodes at Week 26,,2022-07-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
12808,NCT02091362,Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure,Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12809,NCT04629586,Gather longitudinal data from individuals living with type 1 diabetes.,,,2018-12-13,RECRUITING,OBSERVATIONAL,['NA']
12810,NCT06196996,insulin,Dose of exogenous insulin,,2021-09-14,RECRUITING,INTERVENTIONAL,['NA']
12811,NCT01792518,HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment,The Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12812,NCT03503370,Time to new foot complication among all randomized participants,Susceptibility to chlorhexidine among bacterial pathogens on the feet,Time to new foot complication among participants with a healed foot complication at randomization.,2019-01-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12813,NCT05797935,To assess and estimate the difference in pancreatic fat content in the patients of Type 2 Diabetes Mellitus at baseline and after taking dapagliflozin for 24 weeks,To estimate the correlation between two advanced MR techniques commonly used for quantification of pancreatic fat(PDFF and MR Spectroscopy),,2021-08-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12814,NCT04361799,The proportion of time spent in the target glucose range from 5.6 to 10.0 mmol/L based on sensor glucose levels during the time from hospital admission for elective surgery until discharge.,Total daily insulin requirements,Proportion when closed-loop was active,2020-09-25,COMPLETED,INTERVENTIONAL,['NA']
12815,NCT00674271,Plaque burden in carotid arteries,Genotyping genes for pattern recognition molecules,,2008-05,UNKNOWN,OBSERVATIONAL,['NA']
12816,NCT01770483,"Sustained Viral Response,",Normalization of Alanine Transferase Test,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12817,NCT02612402,increase in daily physical activity,glycemic control,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
12818,NCT00290043,"Outcome measures: Post-prandial glucose and insulin concentrations. Outcome: In T1DM, insulin glulisine provides a better mimic of the physiological postprandial glucose disposal than RHI.",,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12819,NCT03321032,Target lesion failure at 2-years follow-up,Non-target lesion revascularization,,2017-12-19,UNKNOWN,INTERVENTIONAL,['PHASE4']
12820,NCT05214235,Visual Analogue Scale (VAS) at 1 Year after Surgery,Number of Participants with Spinal Fusion at 1 Year after Surgery,,2022-02-07,RECRUITING,OBSERVATIONAL,['NA']
12821,NCT04096794,changes in serum hemoglobin A1c level,Adverse effects,,2016-09,RECRUITING,OBSERVATIONAL,['NA']
12822,NCT00464880,To investigate whether renin-inhibition using aliskiren 300 mg daily could be a treatment alternative to the angiotensin II receptor antagonist irbesartan 300 mg with an equivalent potential for reno-protection,"To investigate whether aliskiren, irbesartan or the combination reduce biomarkers of inflammation and cardiovascular risk",,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12823,NCT02426541,Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake,Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8,,2015-03-23,COMPLETED,INTERVENTIONAL,['PHASE4']
12824,NCT04042207,"Percentage of CGM time in glucose range 70-180 mg/dl, during 24 hours periods for the third and fourth week for each treatment period","Percentage of CGM time in glucose range 70-180 mg/dl, during 24 hours periods",,2019-09-03,COMPLETED,INTERVENTIONAL,['NA']
12825,NCT04617795,Hypoglycemia,Change in Hemoglobin A1c (HbA1c),,2020-11-23,COMPLETED,INTERVENTIONAL,['NA']
12826,NCT00818779,Plasminogen Activator Inhibitor 1,Serum Level of Nitric Oxide,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12827,NCT05742685,Diabetes medication adherence,Glycemic control,,2023-08-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12828,NCT05174806,Proportion of patients with adverse events,Proportion of subjects undergoing lower-extremity amputation,,2022-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12829,NCT06118008,Temperature,Pharmacodynamics (PD): HbA1c,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2']
12830,NCT00826007,Hypoglycemia Incidence,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
12831,NCT04217902,Description of individual experiences of patients and health care professionals in diabetes care.,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
12832,NCT00138580,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12833,NCT03531294,Incidence of Adverse Events for diabetic retinopathy subjects who receive intravitreal Aflibercept,Cytokine Levels,,2018-05-23,COMPLETED,INTERVENTIONAL,['PHASE2']
12834,NCT01490372,Metabolic syndrome,Inflammatory markers,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
12835,NCT00178633,Change in Weight,Change in Left Ventricular Mass,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
12836,NCT05670769,Diabetes Self-Care Activities Questionnaire,,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12837,NCT02328326,"Change in Cardiac Event 5-year Risk Score, as Measured by UKPDS Risk Engine",Change in Diabetes Self-Management Behavior - Check Feet,Change in Supporter Distress About Patient Participant's Diabetes,2016-11-16,COMPLETED,INTERVENTIONAL,['NA']
12838,NCT00482768,glycosylated hemoglobin,Change in risk of coronary heart disease,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
12839,NCT04587297,number of meals,,,2020-12-08,COMPLETED,OBSERVATIONAL,['NA']
12840,NCT06115304,Appetite regulating hormones measured by specific immunoassays,,Peptidomicsmeasured in blood and cerebrospinalfluid using mass spectrometry,2023-10-05,RECRUITING,INTERVENTIONAL,['NA']
12841,NCT04141111,Glycemic control,Therapeutic changes,,2015-03-22,COMPLETED,INTERVENTIONAL,['NA']
12842,NCT05147259,Onset of appearance,Assessment of development of Anti-drug Antibodies (ADAs),,2021-11-29,UNKNOWN,INTERVENTIONAL,['PHASE1']
12843,NCT01073566,Mean Daily Blood Glucose,Self-reported Hypoglycemic Episodes,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12844,NCT03754465,Proportions of subjects who achieved complete wound closure,Durability of complete wound closure,,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12845,NCT03576430,Change in Hemoglobin A1C,Diabetes treatment satisfaction questionnaire (DTSQ),resting pulse rate,2018-05-31,UNKNOWN,INTERVENTIONAL,['NA']
12846,NCT05279326,"Change in glycaemic management, to be assessed by blood analysis","Change in the participants' satisfaction, to be assessed by questionnaire",,2023-12,RECRUITING,INTERVENTIONAL,['NA']
12847,NCT01801150,Glycemic control,To determine additional effects of CPAP on insulin resistance in patients with type 2 diabetes and SAHS.,Influence of body distribution and activity on metabolic control,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
12848,NCT03913962,Maximal lipid oxidation rate during submaximal incremental exercise,Blood sample calprotectin,,2019-05-02,RECRUITING,INTERVENTIONAL,['NA']
12849,NCT02335931,Disease progression in the previously affected foot,Altered levels of bone resorption markers,Diabetes regulation,2014-09,COMPLETED,OBSERVATIONAL,['NA']
12850,NCT00808860,HbA1C (glycosylated hemoglobin),"body weight (BMI, hip-weight ratio)",,2008-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12851,NCT02981121,Cumulative incidence of Diabetes Mellitus after randomization,Change on HOMA2%B,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12852,NCT05848180,The Falls Efficacy Scale International (FES-I),,,2023-05-05,COMPLETED,INTERVENTIONAL,['NA']
12853,NCT02482675,Vascular Endothelial Function,Arachidonic Acid,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
12854,NCT05081765,correlation between glucose level and C through.olaparib in the blood of the patients with ovarian cancer,,,2021-09-20,UNKNOWN,OBSERVATIONAL,['NA']
12855,NCT01477567,Number of Participants With One or More Drug-related Adverse Events (AEs) or Any Serious AEs,Number of Participants Forming Antibody to LY3009385,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12856,NCT05624034,EGG findings,Factors affecting the condition,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
12857,NCT04981847,Hemoglobin A1c,Blood pressure,,2021-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12858,NCT05219994,Insulin change in response to OGTT,,,2020-09-09,COMPLETED,INTERVENTIONAL,['NA']
12859,NCT01282060,Link between HbA1c level and the overall mortality rate at 5 years.,Role of other cardiovascular risk factors,,2009-03,UNKNOWN,OBSERVATIONAL,['NA']
12860,NCT06124443,Assesment of prevalence of congenital heart defects among infants of diabetic mother compared to that in infants of non-diabetic mothers.,,,2024-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12861,NCT00846898,HbA1c,"Plasma glucose concentration Plasma lipid profiles (HDL, LDL, Triglycerides and total cholesterol) systolic and diastolic blood pressures. Body Mass Index. Waist circumference. Total calorie intake.",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12862,NCT00845858,The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score.,,The Pre-specified Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score by Gender.,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12863,NCT06049550,renal failure,,,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12864,NCT05435157,Residual gastric volume,Antral cross-sectional area,,2022-03-09,RECRUITING,OBSERVATIONAL,['NA']
12865,NCT06094231,Changes in HbA1c,Time in range,,2023-09-25,RECRUITING,INTERVENTIONAL,['NA']
12866,NCT05545722,diabetes self-management skill scale,Diabetes strengthening scale,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA']
12867,NCT06228911,low blood glucose,,,2020-01-15,COMPLETED,INTERVENTIONAL,['NA']
12868,NCT02135328,"Acceptability and effectiveness of radio stories, a health communication intervention that addresses family eating behaviors and physical activity among immigrant Somali, Latino, and Hmong families",,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
12869,NCT04094649,"Change in blood glucose Area Under the Curve (AUC, mg/dL ● hours) from baseline to 3 hours after an Oral Glucose Tolerance Test (OGTT) with Ultrasonic Vagus Nervous Stimulation (uVNS).hyperglycemia",Change in whole blood lipospolysaccharide-induced TNF-Alpha (pg/mL) production from base line to 4 hours post stimulation.,,2019-08-01,SUSPENDED,INTERVENTIONAL,['NA']
12870,NCT01565824,Well-Being Questionnaire (W-BQ12),,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12871,NCT02595580,difference between Glucopred and the reference method,,,2016-01,TERMINATED,INTERVENTIONAL,['NA']
12872,NCT02547935,Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24,Adjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24,,2015-09-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12873,NCT02852759,Change of Glucose Tolerance measured by OGTT,Change of glucose infusion rate by hyperinsulinemic euglycemic clamp,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
12874,NCT05317130,Incidence of sports injuries and illnesses 4 years following study start,Health literacy 12 months following study start.,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12875,NCT03849755,Change in the percentage of time in glucose target range (glucose levels 3.9-10 mmol/l or 70 - 180 mg/dl),Evaluation of usability of PEPPER system by conducting the usability test,,2018-11-15,COMPLETED,INTERVENTIONAL,['NA']
12876,NCT03182322,The activation of an immune response (antibody or CD4+ T cell) against insulin.,,Transcriptome of peripheral blood cell populations,2018-05-25,COMPLETED,INTERVENTIONAL,['PHASE2']
12877,NCT04936633,Changes in glycemic control measured by HbA1c,Changes in anxiety assessed by questionnaires,,2021-06-30,COMPLETED,INTERVENTIONAL,['NA']
12878,NCT06245369,Change in Healthy Eating Index,Change in Body weight,,2024-04-01,RECRUITING,INTERVENTIONAL,['NA']
12879,NCT02113332,Change in HbA1c from baseline to week 24.,Change in blood lipid levels from baseline to week 24,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12880,NCT02921906,Insulin levels,Paracetamol levels,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
12881,NCT04256304,The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus,,Health Literacy Scale for Turkish Diabetic Patients,2018-12-28,COMPLETED,INTERVENTIONAL,['NA']
12882,NCT00004407,,,,1998-02,TERMINATED,INTERVENTIONAL,['NA']
12883,NCT05695417,Safety and Tolerability,Diabetic Retinopathy Severity Scale (DRSS) changes,,2023-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12884,NCT00729456,Ulcer recurrence.,Amputation. Quality of life. Mood. Well-being. Compliance.,,2003-04,COMPLETED,INTERVENTIONAL,['NA']
12885,NCT03389490,Glycemic variability,Heart rate variability,,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12886,NCT06021691,delayed language development in children,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
12887,NCT04463160,"The impact of the ""Say No to Diabetes"" intervention on the incidence of type 2 diabetes",HbA1c assay for the diagnosis of glucose intolerance and prediabetes compared to HGPO,,2019-07-18,RECRUITING,INTERVENTIONAL,['NA']
12888,NCT01507285,Area under the Curve,Adverse events,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12889,NCT05372471,HbA1c change,Hypoglycemia level 1 and 2,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
12890,NCT04436666,pain relief,,,2020-07-15,COMPLETED,INTERVENTIONAL,['NA']
12891,NCT05000840,HcA1c at 6 months for participants with HbA1c < 7.5%,Changes in HbA1c over time- Patient-Reported Variable #4,,2021-10-20,RECRUITING,OBSERVATIONAL,['NA']
12892,NCT02575001,Significant between group differences in metabolic control,Significant differences in psychological scores between groups,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
12893,NCT06292871,Satisfaction levels,Proportion of participants with optimal blood glucose control,Proportion of participants delivering healthy live birth,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12894,NCT04499846,Compliance rate to the statin treatment,Compliance rate to the statin treatment according to treatment duration.,,2020-06-11,COMPLETED,OBSERVATIONAL,['NA']
12895,NCT01296308,Neuropathy-related Quality of Life (QOL-DN),Waist-to-Hip Ratio (WHR) and Body Mass Index (BMI),,2011-03,COMPLETED,OBSERVATIONAL,['NA']
12896,NCT02908152,Hepatic steatosis,AST,,2017-02-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12897,NCT03351530,"The change of hs-CRP between diabetes mellitus patients, periodontal disease patients and healthy people after receiving periodontal therapy and using mouthwash",,,2017-05-18,UNKNOWN,OBSERVATIONAL,['NA']
12898,NCT01022645,Glucose tolerance at 12 months postpartum.,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
12899,NCT00646438,The purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year.,Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.,,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
12900,NCT02009813,Insulin sensitivity,Hypoxia and inflammatory markers,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
12901,NCT04055090,Long-term Safety for Engensis Versus Placebo,Subgroup Analysis of the Change in the Average 24-hour Pain Score From Baseline (Day 0 of Study VMDN-003) to Day 365 for Engensis Versus Placebo for Subjects Without Gabapentin and/or Pregabalin Use at Baseline,,2019-02-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12902,NCT00841048,"Safety and Tolerability (Adverse events, vital signs, ECGs, physical examination, laboratory variables",Pharmacodynamic measurements allowing to assess AZD4017 effect in different tissues,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12903,NCT02636192,Number of Participants with a recorded diagnosis of Diabetic Ketoacidosis (DKA),,,2015-07-31,COMPLETED,OBSERVATIONAL,['NA']
12904,NCT05040412,Intubation time,Intubation difficulty,,2020-01-25,COMPLETED,INTERVENTIONAL,['NA']
12905,NCT05294458,"Relative bioavailability of a high concentration cotadutide SC formulation in comparison to low concentration formulation, in the fasted state",Evaluate immunogenicity for cotadutide administered as low and high concentration SC formulations and an IV formulation,Temperature needed at the injection site to homogenize at the point of injection,2022-03-28,COMPLETED,INTERVENTIONAL,['PHASE1']
12906,NCT02387164,Type 1 Diabetes Status Overall,Change From Baseline in GADA Month 24,,2015-03-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12907,NCT01323114,Hemoglobin A1C,,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
12908,NCT00763022,Change in Baseline in Glycosylated hemoglobin.,Urinary albumin/creatinine ratio.,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12909,NCT03786718,User Experience - Qualitative,Change in Patient Activation,,2018-12-27,COMPLETED,INTERVENTIONAL,['NA']
12910,NCT00691249,Post-Prandial metabolism,Satiety,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
12911,NCT02622282,Change in Physical Activity,Change in Quality of Life,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
12912,NCT02151461,Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr,Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12913,NCT00711503,Δ 2-h AUC C-peptide response,"Incremental and/or peak C-peptide response, Time to peak C-peptide, insulin requirement per kg body weight per day,frequency of insulin free state with maintenance of HbA1c <7.5%, HbA1c, Means of fasting glucose values, circulating IL-6 and CRP",,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12914,NCT00789282,A higher proportion of patients with type 2 diabetes enrolled in the 'enhanced care' arm compared with the patients enrolled 'usual' care' arm will achieve an absolute reduction in their HbaA1c of 1.0% or greater during the study period.,A higher proportion of patients with type 2 diabetes in the 'enhanced care' arm compared with the patients enrolled in 'usual care' arm will achieve a 10% or greater reduction in HbA1c values during the study period.,,2008-02,TERMINATED,INTERVENTIONAL,['NA']
12915,NCT03457818,Change in Cortical Porosity (Ct.Po) (%) by High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging From Baseline to 6 and 12 Months.,"Change in Dual-energy X-ray Absorptiometry (DXA) (gm/cm2) at Lumbar Spine, Femoral Neck, Total Hip and Radius From Baseline to 6 and 12 Months.",Change in Skin Autofluorescence (SAF) (Unitless) From Baseline to 6 and 12 Months.,2018-11-07,TERMINATED,INTERVENTIONAL,['PHASE2']
12916,NCT05352230,Compliance,Time in Range (TIR) of 70 to 180 mg/dL,,2023-04-15,RECRUITING,INTERVENTIONAL,['PHASE1']
12917,NCT03847753,Risk of Cancers,,,2000-01-01,COMPLETED,OBSERVATIONAL,['NA']
12918,NCT03278704,Change in fibre-type specific satellite cell content,Change in glycaemic control,,2017-12-06,TERMINATED,INTERVENTIONAL,['NA']
12919,NCT03739099,Percent of time spent in the 70-180 mg/dl glucose range assessed on daily CGM data,Score of the Artificial Pancreas Acceptance Questionnaire,,2018-11-05,UNKNOWN,INTERVENTIONAL,['NA']
12920,NCT04921306,insulin-stimulated fluorodeoxyglucose (18F-FDG) uptake in quadriceps muscle.,insulin-stimulated 18F-FDG uptake in BAT,skeletal muscle GLUT4 translocation,2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12921,NCT05598203,Change in diabetic retinopathy and baseline diabetic kidney disease at 12 months,Change in baseline blood pressure at 12 months,Change in baseline adherence to recommendations at 12 months,2022-09-06,RECRUITING,INTERVENTIONAL,['NA']
12922,NCT00614120,Change in Glycosylated Haemoglobin A1c (HbA1c),Hypoglycaemic Episodes,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12923,NCT00221234,Physical Activity Behaviour,"HbA1c, CRP, lipid concentrations, fasting blood glucose, insulin, health related quality of life, psychosocial predictors of physical activity.",,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12924,NCT00895986,Improved frequency of recommended self-care behaviors (Self-Care Inventory-R),"Major mediating/moderating variables include Problem Areas in Diabetes, Brief Symptom Inventory, Coping Styles, and Confidence in Diabetes",,2008-12,COMPLETED,INTERVENTIONAL,['NA']
12925,NCT00286442,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12926,NCT00106561,percent reduction in 24 hour urine protein excretion,,,2002-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12927,NCT02731859,Weight reduction,Reduction of daily caloric intake,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
12928,NCT03912766,change of serum sodium after surgery,,,2016-02-01,COMPLETED,OBSERVATIONAL,['NA']
12929,NCT00799448,HbA1c,Adverse events,,2003-09-16,TERMINATED,INTERVENTIONAL,['PHASE4']
12930,NCT00782847,deterioration of kidney function in diabetic nephropathy,HbA1c,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12931,NCT03659799,Decrease in plasma glucose levels during exercise,Total amount of carbohydrates needed to treat hypoglycemic events,,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE4']
12932,NCT03372018,Body Weight,Beck Depression Inventory,,2018-08-07,COMPLETED,INTERVENTIONAL,['NA']
12933,NCT05083559,Percent of Time With Sensed Glucose Between 70-180 mg/dl,Mean Amount of Insulin Delivered Per Day (in Units),,2021-12-08,COMPLETED,INTERVENTIONAL,['NA']
12934,NCT05579314,"Mean change from baseline in clinical laboratory values, vital signs, clinical findings from physical exam and ECG abnormalities",,,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE1']
12935,NCT03650127,Coronary heart disease/Type 2 diabetes/Venous thromboembolism diagnosis,,,2018-02-02,UNKNOWN,OBSERVATIONAL,['NA']
12936,NCT03492580,Number of Participants with Below Knee Lower Extremity Amputation Events,,,2018-02-22,COMPLETED,OBSERVATIONAL,['NA']
12937,NCT04053959,Proportion of time in target range,Total insulin dose,,2019-09-27,COMPLETED,INTERVENTIONAL,['PHASE4']
12938,NCT00813228,Changes in plasma TGF-Beta 1 levels.,"Changes in plasma or stimulated PBMC cytokines levels, changes in stimulated PBMC proliferation, changes in peripheral blood gene expression and changes in immune phenotyping.",,2009-01-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12939,NCT06261944,Dichotomised diabetes risk status,Sensitivity and specificity,,2024-03-13,RECRUITING,INTERVENTIONAL,['NA']
12940,NCT02424500,Reduction in HbA1C,Comparison Percent Reduction HbA1c w/out Hypoglycemia,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
12941,NCT03259789,Change From Baseline in HbA1c at Week 24 for High Glycemic Group,Change in HbA1c Over Time Among Subjects Who Have Baseline HbA1c of > 10.5% and ≤ 12.0%,,2017-11-28,COMPLETED,INTERVENTIONAL,['PHASE3']
12942,NCT03124043,Change in HbA1c,Change in Treatment Satisfaction,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
12943,NCT02034266,Change in corneal nerve fibre length,R-R interval,Serum fatty acid profile,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12944,NCT01400971,Number of Participants With Insulin-Related Treatment Change From Initial Insulin Therapy,Number of Participants Who Achieved Their Personalized HbA1c Target by the End of the Study,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
12945,NCT01382498,high sensitivity CRP and Endothelin-1 serum levels,,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12946,NCT04579341,glycemic control,,,2018-01-21,UNKNOWN,INTERVENTIONAL,['NA']
12947,NCT04598893,"Incidence of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs), including infections and malignancies",HbA1c,,2020-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12948,NCT00005489,,,,1998-01,COMPLETED,OBSERVATIONAL,['NA']
12949,NCT02004327,Maximum Concentration of DW1029M in plasma,Apparent volume of distribution of DW1029M in Plasma,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12950,NCT04656106,Change in HbA1c (Glycosylated Hemoglobin),Change in body weight,,2021-04-27,COMPLETED,OBSERVATIONAL,['NA']
12951,NCT05717127,Pancreatic beta-cell function,Fasting glucose,Satiety,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
12952,NCT04789798,BMI,The number of patients who added insulin to their oral antidiabetic medication or switched to oral antidiabetic medication by discontinuing insulin,Urine microalbuminurea,2013-10-21,COMPLETED,INTERVENTIONAL,['NA']
12953,NCT05483803,Sub-study 2: Changes on caregiver's positive mood,Behavioral outcome: Usability,,2022-10-01,COMPLETED,INTERVENTIONAL,['NA']
12954,NCT06325917,glycemic control,diabetes self management behaviors,,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12955,NCT03281486,Relief from drymouth using VAS scoring,,,2018-01-28,COMPLETED,INTERVENTIONAL,['NA']
12956,NCT00869362,Hemoglobin A1c,Average Intervention Effect Over 12 Months After Hospital Discharge,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
12957,NCT00831194,"Self reported stress, weight loss, and salivary alpha amylase.","Positive correlation between levels of salivary alpha amylase (sAA) and weight loss, BMI and levels of sAA, levels of sAA and maladaptive coping.",,2009-03,COMPLETED,INTERVENTIONAL,['NA']
12958,NCT05208164,Sleep Impairment,Inflammatory Markers,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA']
12959,NCT04943614,Functional reach test,,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
12960,NCT00848822,This study could help find if there are particular times of day or times during sleep that change glucose the most.,This study may help make recommendations about the best time to test glucose values and better help children with Type 1 Diabetes Mellitus control their glucose levels.,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
12961,NCT01937845,Weight loss of 7% body weight,,,2006-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12962,NCT01554358,cardimetablic risk,approximately 40 SNPs,,2009-08,UNKNOWN,INTERVENTIONAL,['NA']
12963,NCT02789319,Analytical accuracy and clinical performance criteria,Device issues,Results,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12964,NCT03660345,BCVA,,,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12965,NCT02284009,Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52,Population Estimates of PK Parameters: First-order Absorption Rate Constant [Ka],,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12966,NCT01582230,"Change from baseline in glycosylated hemoglobin (HbA1c) at study endpoint, assessed in Chinese study population",Percentage of patients meeting responder criteria after 24 weeks treatment on Chinese population,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12967,NCT05650229,Change in 30 Second Site-to-Stand Test.,Change from baseline in Glycated haemoglobin (HbA1c) for subjects with diabetes,,2022-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12968,NCT00143949,"To obtain two percutaneous renal biopsies from each patient, five years apart.",To evaluate retinal lesions in RASS cohort to determine relationship to the histologic changes of DN and the effects of RAS inhibition and/or systemic blood pressure.,,1997-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12969,NCT01921491,Proportion of ulcers achieving 100% epithelialization in the dHACM group vs other commercially available product and control.,Cost effectiveness of each treatment modality.,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
12970,NCT03973515,Area under the plasma concentration versus time curve (AUC),The change for plasma insulin,,2019-08-27,COMPLETED,INTERVENTIONAL,['PHASE1']
12971,NCT01303302,Comparison of the differences in HbA1c levels,Improvement in weigth and metabolic parameters,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
12972,NCT01616784,The change in HbA1c after 2 years in those participants whose baseline HbA1c was at or above 7.5% (58mmol/mol).,Quality of adjusted life years,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12973,NCT03485586,the visual quality of the eye after surgery,,,2018-04-03,UNKNOWN,OBSERVATIONAL,['NA']
12974,NCT02366377,The number of volunteers with adverse events as a measure of safety and tolerability,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
12975,NCT02039258,Plasma concentration of metformin following the single dose of CANA/MET XR FDC after fed and fasted conditions,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12976,NCT05703880,Descriptive summary of comedications of patients who initiate finerenone and have CKD and T2D in the US.,Incidence rate of proliferative diabetic retinopathy in patients who initiate finerenone with prior non-proliferative diabetic retinopathy,,2023-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12977,NCT05680155,Change from baseline in HbA1c,Pharmacokinetics: plasma trough level of XW003,,2022-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
12978,NCT04092738,Change in Waist circumference,Change in subjective occupational physical activity,"Sociodemographic variables (age, gender, socio economic status)",2019-03-04,UNKNOWN,INTERVENTIONAL,['NA']
12979,NCT02372630,JNK-1 Protein in MNC,Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp,,2014-05-23,COMPLETED,INTERVENTIONAL,['PHASE4']
12980,NCT03326206,Change in hemoglobin A1c,Change in counseling / behavioral services,Change in self-report coping,2013-11-01,COMPLETED,OBSERVATIONAL,['NA']
12981,NCT00813657,,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12982,NCT01588093,Difference in MD (microdialysate) IGF-1 over time (expressed as AUC or peak microdialysate IGF-I) between saline and IGF-I injection.,,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
12983,NCT02008682,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Confirmed Hypoglycaemic Episodes,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
12984,NCT03049839,Reduction of body weight average at year-end structured intervention compared with the baseline.,Reduced of waist circumference average at year-end structured intervention program compared with baseline.,,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA']
12985,NCT00157638,"Symptom improvement (constipation, pain)",Health services utilization,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12986,NCT02025907,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Systolic Blood Pressure (SBP) at Week 26,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12987,NCT05902468,Glycemic control,Serum asprosin,,2023-06-28,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12988,NCT04767750,"Measurement of the gene expression levels of LncRNA H19 & IGF-1R mRNA, normalized to the housekeeping gene GAPDH expression level, in HCC and T2DM in comparison with healthy controls using Real-Time Quantitative PCR (by the 2^-ΔΔCT method).",,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
12989,NCT03448029,Outcome Quality after Revascularization: Re-Intervention,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
12990,NCT00460304,The mean ICR from Vist 3a-e and 4a-e will be compared. Percentage reduction of ICR will be calculated. From these the mean ICR will be calculated.,The mean post-meal glucose from the four hour period after beginning a meal will be averaged for each bolus wave form. Then the three wave form mean glucose results will be compared.,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
12991,NCT03839667,change in HbA1C level (%),cardiovascular risk,,2019-01-07,COMPLETED,INTERVENTIONAL,['NA']
12992,NCT02929953,prematurity prevalence among T1D patients,Medications exposure in premature who developed T1DM compared with prematures who did not develop diabetes,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
12993,NCT05301855,The fifth part of the questionnaire is the Beliefs about medicine which is assessed using the Arabic version of the Beliefs about Medicines Questionnaire Specific (BMQ-Specific).,,,2022-03,RECRUITING,OBSERVATIONAL,['NA']
12994,NCT02540642,To compare the change in HbA1c levels (%) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients,To compare the change in serum homocysteine level (micromol/L) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
12995,NCT00952198,Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.,Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12996,NCT04520971,time in range,number with composite neonatal outcome,,2021-01-15,COMPLETED,INTERVENTIONAL,['NA']
12997,NCT05477134,The difference in arginine availability,The difference in insulin sensitivity and the effect of intravenous arginine bolus on insulin sensitivity,,2023-02-06,RECRUITING,INTERVENTIONAL,['NA']
12998,NCT00552409,Change in Urine Albumin Excretion,,,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12999,NCT00471549,Relative reduction in circulating osteoprotegerin levels,Relative reduction in adhesion molecules (ICAM and VCAM),,1991-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13000,NCT04993326,Type 2 Glycemic Control - HbA1c of 7% or less,"Understand of COVID-19 Risks, Protection and Prevention",,2022-01-10,WITHDRAWN,INTERVENTIONAL,['NA']
13001,NCT02146157,Change from Baseline in fasting blood glucose,Change from Baseline in waist-to-hip ratio,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
13002,NCT05339841,Long-term CV clinical outcome at 7 years follow-up,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - history of vaccination (questionnaire),Ancillary study of UO-14 (IRCCS San Raffaele Roma): mean corpuscular hemoglobin (MCH) in the CV-PREVITAL Exercise sub-study cohort,2022-06-10,RECRUITING,INTERVENTIONAL,['NA']
13003,NCT00399620,,,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
13004,NCT05179798,Percentage of postprandial capillary glucose values above target (>7.0 mmol/L),Patient satisfaction evaluated through a questionnaire,,2022-01-12,RECRUITING,INTERVENTIONAL,['NA']
13005,NCT00099918,Change from baseline in HbA1c at 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13006,NCT03177096,Evolution of Peds QL questionnaire results,Evolution of WHO-5 and felt questionnaire,,2016-09-20,COMPLETED,INTERVENTIONAL,['NA']
13007,NCT02284230,Plasma glucose during oral glucose tolerance test at week 26,Plasma liraglutide,,2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13008,NCT03710811,Circulating immunity cell profiles,skeletal muscle parameter,fasting blood glucose,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
13009,NCT03516474,Lower rates of DFU recurrence in patients monitored using mHealth,,,2018-05-15,UNKNOWN,OBSERVATIONAL,['NA']
13010,NCT04687215,Vascular improvement on lower extremities with the Doppler Flowmetry,Vascular improvement on lower extremities by performing the flow mediated arterial dilation test,,2022-01-27,RECRUITING,OBSERVATIONAL,['NA']
13011,NCT03889522,Examine the relationship between artificial sweeteners and hemoglobin A1c,,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
13012,NCT04205617,Change in Hemoglobin A1c,Change in diastolic blood pressure,,2019-12-14,COMPLETED,INTERVENTIONAL,['NA']
13013,NCT00094796,Peak VO(2) after 3 months of rosiglitazone therapy compared with baseline VO(2) max.,,,2004-10-20,COMPLETED,INTERVENTIONAL,['PHASE2']
13014,NCT03654651,Fasting Plasma Glucose,Microbiota Alpha-diversity,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13015,NCT04918004,Hba1c mmol/mol,,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
13016,NCT00464555,Proportion of participants with insulin independence,Quality of life measures,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13017,NCT04416737,Glucagon response to induced hypoglycemia,Glucose Values,,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
13018,NCT05073692,Incidence of 3-point Major Adverse Cardiovascular Events (MACE),,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
13019,NCT01375686,"Validation of SCOUT DS algorithm, ROC performance equivalent to FPG, A1c for detection abnormal glucose tolerance.",,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
13020,NCT01459120,Absolute number of clients newly tested HIV-positive who enrolled into HIV/AIDS care,Absolute number of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
13021,NCT02846831,Percentage of time of glucose levels spent between 3.9 and 10 mmol/L.,Number of patients calling for technical issues related to the closed-loop system,,2019-01-24,COMPLETED,INTERVENTIONAL,['PHASE2']
13022,NCT05355038,effect of lifestyle modification among GDM on pregnancy outcome,,,2020-11-11,COMPLETED,INTERVENTIONAL,['NA']
13023,NCT05787873,Cmax of SIPS-2209-1,Vd/F of SIPS-2209-1,,2022-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
13024,NCT04211220,Percentage of time spent in 70-180mg/dl (time in range) in the last month of each period of the study (without and then with IRTA©),Type of advice given by the IRTA system that is more often asked,,2020-01-09,COMPLETED,INTERVENTIONAL,['NA']
13025,NCT00876928,Percent of Subjects Who Develop Diabetes,Disposition Index,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
13026,NCT03336411,"Body weight, percent change",Weight regain,Self-efficacy,2017-12-12,COMPLETED,INTERVENTIONAL,['NA']
13027,NCT00136916,Summary of ≥ 20 % Decliners in DLco,Insulin Antibodies,,2002-06,TERMINATED,INTERVENTIONAL,['PHASE3']
13028,NCT00138619,Change from baseline in HbA1c at 104 weeks,Change in HOMA B between 24 weeks and 104 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13029,NCT01014949,Coronary Flow Reserve and Index of Microvascular Resistance values,,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
13030,NCT01620463,Adverse events,24-hour glucagon profile in plasma,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13031,NCT00978263,Change From Baseline in Glycosylated Hemoglobin at month 6,Change From Baseline in Body Weight (month 12),,2009-02,COMPLETED,INTERVENTIONAL,['NA']
13032,NCT06120322,"To identify the factors contributing to chronic inflammation within the intestine and in peripheral organs, in particular focusing on biopsies markers","Taking advantage of the measurements collected in Outcome 1, the investigators will use a machine learning-based multi-omics approach to easily recognize patient differences, stratification and characterization",,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13033,NCT03345667,Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema,Frame between the injections,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
13034,NCT05172622,The evaluation of the number of adverse events and the number and percentage of subjects,,,2020-11-24,UNKNOWN,INTERVENTIONAL,['PHASE1']
13035,NCT05974020,Plantar Pressure Distribution,Foot Posture,,2023-08-04,COMPLETED,INTERVENTIONAL,['NA']
13036,NCT05120544,Change in HbA1c,Change in hypertension knowledge,,2022-04-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13037,NCT04838145,Insulin secretion,Presence of enterovirus,,2018-08-30,COMPLETED,INTERVENTIONAL,['PHASE2']
13038,NCT03058926,"Protocol and Regulatory Compliance for Consortium Studies for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",,,2017-01-19,UNKNOWN,OBSERVATIONAL,['NA']
13039,NCT02074423,"Blood glucose incremental Area Under the Curve between 0 and 120 minutes after consumption of a standard meal, compared between MealShape and the placebo",Insulin incremental Area under the Curve between 0 and 60 minutes compared between MealShape and Placebo after consumption of a standard meal,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13040,NCT01743781,The acceptance rate of comprehensive eye examination in both groups,knowledges of eye disease and attitude of eye examination,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
13041,NCT03423862,Predicting the honeymoon period,Establishing the relationship between baseline inflammation and other measures,,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
13042,NCT01017965,HbA1c in %,Quality of life assessed through questionnaire,,2009-11,TERMINATED,OBSERVATIONAL,['NA']
13043,NCT02872974,Carotid intima-media thickness,Cardiovascular risk factors,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
13044,NCT02173834,Difference in sympathetic stimulation to BAT between lean and obese individuals,Difference in correlation between sympathetic stimulation of BAT as assessed with 123I-MIBG SPECT scans and metabolic BAT activity as assessed with 18F-Fluorodeoxyglucose(FDG)- positron emission tomography(PET)-CT scan in lean and obese individuals,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13045,NCT01557907,Insulin levels,Number of participants with adverse events,,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13046,NCT01488136,Adrenaline response(pmol/L) at 2.5mmol/L of glucose,"Glucose Thresholds (calculated when counter-regulatory hormone release is greater than 2SD of hormone level at euglycaemia 4.0mmol/L blood sugar) of each of the counter-regulatory hormones (adrenaline, noradrenalin, glucagon)",Symptom scores and Cognitive function scores at 2.5mmol/L,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13047,NCT02024542,Tensile Strength of White Adipose Tissue,,,2011-02,RECRUITING,OBSERVATIONAL,['NA']
13048,NCT03918148,Urinary albumin to creatinine ratio excretion,estimated Glomerular filtration rate (eGFR),Lipid profile,2018-01-15,RECRUITING,OBSERVATIONAL,['NA']
13049,NCT03091712,Change in HbA1c,Proportion of accepted MIDS recommended insulin degludec doses,,2017-05-05,COMPLETED,INTERVENTIONAL,['NA']
13050,NCT02359461,Changes from Baseline in endothelial function of the large vessels by FMD (Flow Mediated Dilatation),Assessment of microalbuminuria levels of 24 hours,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
13051,NCT00724087,Total energy expenditure,Glycerol turnover and free fatty acid concentration,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
13052,NCT02011529,Hemoglobin A1c,LDL cholesterol,Brief Psychiatric Rating Scale (BPRS),2013-11,COMPLETED,INTERVENTIONAL,['NA']
13053,NCT04866212,academic achievement,,,2020-04-30,UNKNOWN,OBSERVATIONAL,['NA']
13054,NCT01471808,the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients,the effects of different interventions on the remission rate in newly-diagnosed type 2 diabetic patients,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
13055,NCT02236364,Photographic Images of the eye,,,2014-08,TERMINATED,INTERVENTIONAL,['NA']
13056,NCT06025721,Treatment Engagement Measured by Sessions Attended,Cardiovascular health (AHA Life's Essential 8),,2024-01-05,RECRUITING,INTERVENTIONAL,['NA']
13057,NCT02004561,Change in Glucose Tolerance,Changes in nutritional health,Fat distribution,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13058,NCT01206322,Perfusion Outcome: Right Insular Cortex Perfusion (ml/100g/Min/mmHg),,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13059,NCT02290860,abnormal glucose tolerance,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
13060,NCT05785832,HbA1c,Coefficient of variation,Other device malfunctions/device issues,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
13061,NCT00516620,Body Weight,"Biomarkers of diet and obesity-related chronic diseases (serum lipids, homocysteine and C-reactive protein) and genotypes",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13062,NCT04497792,HbA1C level,,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13063,NCT03890003,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2019-03-28,COMPLETED,INTERVENTIONAL,['NA']
13064,NCT02736084,Intervention Acceptability,Changes in MOS SAS Scores,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
13065,NCT03536377,change in Hba1C,change in blood pressure medication,,2019-02-11,UNKNOWN,INTERVENTIONAL,['NA']
13066,NCT00737152,To determine cardiovascular side effects such as coronary artery disease (CAD) and congestive heart failure (CHF) in patients treated with RAS 130 along with diet and exercise.,To determine the effect of RAS 130 on reduction of blood glucose level with or without diet and exercise,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
13067,NCT03096002,independent bouts of physical activity,independent bouts of physical activity,dietary adherence,2017-06-12,UNKNOWN,OBSERVATIONAL,['NA']
13068,NCT00246623,Proportion of patients with type 2 diabetes (A1C 7.5-10% on >= 2 oral agents) in each study arm (Exubera dosage adjusted 'once weekly' or 'twice weekly') that attain an A1C of <=7% with forced dose titration of Exubera at 6 months.,"Secondary endpoints include change in A1C, fasting and 2 hr PP glucose, 24-hr mean glucose measured by continuous glucose monitoring, weight, lipids, and markers of oxidative stress. Hypoglycemia will also be assessed.",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13069,NCT04560296,Change in Self-care ability of Chronic disease,HbA1c,,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA']
13070,NCT02221284,Percentage of Participants Who Had One or More Adverse Reactions,Change From Baseline in Laboratory Test Values (Homeostasis Model Assessment of Beta-cell Function [HOMA-β]),,2014-06-30,COMPLETED,OBSERVATIONAL,['NA']
13071,NCT00575783,,,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
13072,NCT03378895,Individualized Prevention Program participation rate,Variation of the risk score in at least one of the three behavioral domains; The risk score will be calculated from the results reported on a self-administered questionnaire,,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
13073,NCT03503942,Diabetes incidence,Metformin adherence,,2017-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13074,NCT04283994,EHR documentation of Goals of Care discussions,Goal concordance,Key Implementation Factors,2021-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13075,NCT00469586,HbA1c change from baseline,Hypoglycaemia,,2007-04-26,TERMINATED,INTERVENTIONAL,['PHASE3']
13076,NCT00331370,"Primary outcome would be abnormal retinal geometry defined as the composite outcome of a) abnormal arteriolar length: diameter, b) narrowed branching angles, or c) disturbed junction exponents.",,,2006-05,UNKNOWN,INTERVENTIONAL,['NA']
13077,NCT01722682,Insulin secretion under stimulation,Islet function,,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13078,NCT00638131,change from baseline to week 16 in renal inflammation. The following urinary inflammatory/oxidative stress parameters will be measured: - TNF,change from baseline to week 16 in renal functioning. The following renal function parameter will be measured: - 24h UAE;,,2009-01,TERMINATED,INTERVENTIONAL,['PHASE3']
13079,NCT00065676,Does quercetin effect glucose absorption,,,2010-04-30,COMPLETED,INTERVENTIONAL,['PHASE2']
13080,NCT03940937,Oxygen consumption (VO2; mL/kg/min),,,2019-05,UNKNOWN,OBSERVATIONAL,['NA']
13081,NCT02459834,Plasma glucose iAUC,Mean plasma glucose and insulin responses,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
13082,NCT01928550,Total retinal blood flow & visual acuity,"Macular ischemic areas and microaneurysms, as identified by FA vs. OCT",,2013-08,COMPLETED,OBSERVATIONAL,['NA']
13083,NCT01855282,Change in BMI,Change in Waist Circumference,Change in fasting blood glucose,2010-04,COMPLETED,INTERVENTIONAL,['NA']
13084,NCT05168488,Capillary glucose (change during exercise),percent time in hypoglycemia,,2021-11-16,COMPLETED,INTERVENTIONAL,['NA']
13085,NCT02244385,Blood Pressure,Uteroplacental assessment,Urinary podocyte markers,2011-07,COMPLETED,OBSERVATIONAL,['NA']
13086,NCT01901952,Hemoglobin A1c,Medications,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
13087,NCT00333554,"At least a 20% reduction in the level of the major inflammatory cytokine, IL1-beta, achieved in the plasma of the treatment group",95% of families will continue to attend follow-up visits,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
13088,NCT00688363,Haemoglobin A1c after one year,the number of serious hypoglycaemic episodes (hypoglycaemic episodes when the patient needs help from other people),,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13089,NCT04082351,HbA1c,,,2016-07-03,COMPLETED,INTERVENTIONAL,['NA']
13090,NCT05237895,Detection of diagnostic value of serum endocan levels in patient with gestational diabetes,,,2022-03-03,COMPLETED,INTERVENTIONAL,['NA']
13091,NCT03225209,Change in Glycemic control,Change in Physical activity,,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
13092,NCT02032108,between groups difference in glycated haemoglobin (HbA1c),endpoint versus baseline differences in glycated hemoglobin,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13093,NCT02288351,Elevated Glut-1 gene and protein expression levels,Glut-1 level change in fasting glucose,,2014-11,WITHDRAWN,INTERVENTIONAL,['NA']
13094,NCT03397225,Hemoglobin A1c,,,2013-11-15,COMPLETED,INTERVENTIONAL,['NA']
13095,NCT03768245,Mean Change From Baseline In Power At 12 Weeks,,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
13096,NCT05007990,Natural History,,,2022-09-08,RECRUITING,OBSERVATIONAL,['NA']
13097,NCT01206725,Early diastolic tissue velocity (e'),Early diastolic tissue velocity (e'),,2010-09,COMPLETED,INTERVENTIONAL,['NA']
13098,NCT00971139,Impacts of the OPPC service on organizational processes/organizational change such as care processes,"Characteristics of high/low volume users, patient-caregiver communication and use patterns",,2009-11,COMPLETED,INTERVENTIONAL,['NA']
13099,NCT02302716,Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c),Percentage of Participants With Hypoglycemic Events,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13100,NCT04216485,Gestational weight gain,Incidence of Gestational Diabetes Mellitus,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
13101,NCT02172716,Change from baseline in the expression on mDCs,"periodontal probing depth, periodontal attachment level, bleeding on probing, visible plaque and gingival bleeding.",,2014-05,COMPLETED,INTERVENTIONAL,['NA']
13102,NCT02130401,Measurement of glycosylated hemoglobin (A1c),Feasibility and acceptability of the device as an intervention for the diabetes population,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
13103,NCT05951660,Changes from baseline to follow up in the total score of Changes in Sexual Function Questionnaire-14 (CSFQ-14),Changes from baseline to follow up in shared decision making,,2023-08-24,RECRUITING,INTERVENTIONAL,['NA']
13104,NCT04152811,Change in Hemoglobin A1c over 4.5 months,Change in Health Related Quality of Life over 4.5 months using SF-12 Survey,,2019-07-05,COMPLETED,INTERVENTIONAL,['NA']
13105,NCT04116203,Plasma Triglycerides and apoB-lipoprotein remnants in non-fasting and fasted state,"Plasma hormones, testosterone, SHBG, Estrogen",,2016-06-30,SUSPENDED,INTERVENTIONAL,['PHASE1']
13106,NCT05570357,HbA1C,Lipid profile,,2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13107,NCT03582878,Pancreas graft survival,Kidney graft survival,,2004-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13108,NCT04635670,Change in albuminuria based on urinary albumin-creatinine ratio (UACR),Change in autonomous neuropathy evaluated by VagusTM,Change in Gut microbiome characterization assessed by 16S RNA sequencing,2020-06-29,COMPLETED,INTERVENTIONAL,['NA']
13109,NCT02641522,Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12,,Adverse Event Monitoring,2016-03-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13110,NCT02949687,"glycated hemoglobin(HbA1c) level of 6.0% or less, without the use of diabetes medications",,,2016-09-20,WITHDRAWN,INTERVENTIONAL,['NA']
13111,NCT02843503,Mean Absolute Relative Difference (MARD),Glucose content (mg/dL) of capillary reference samples.,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
13112,NCT00467168,Lipids including triglyceride and cholesterol in four subfractions of ppTRLs.,Lipids lipoproteins in the postprandial plasma,,1998-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13113,NCT03248466,hospital stay,Transcutaneous oxygen partial pressure,,2017-08-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
13114,NCT02179385,Clinical composite,Change in Self Efficacy Score,Change in Quality of life score,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
13115,NCT05663736,HbA1c,CK-MB,,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
13116,NCT03285308,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,,2017-09-29,TERMINATED,INTERVENTIONAL,['PHASE3']
13117,NCT05108350,Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,,2021-11-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
13118,NCT04568382,Pilot acceptability),Anxiety Symptoms,,2020-10-12,COMPLETED,INTERVENTIONAL,['NA']
13119,NCT02043054,Change in peak early diastolic strain rate measured by cardiac MRI,Composite 7 point glucose profile,,2013-12-16,COMPLETED,INTERVENTIONAL,['PHASE3']
13120,NCT01106573,,,,2010-06,UNKNOWN,OBSERVATIONAL,['NA']
13121,NCT04445714,To assess the safety of fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients,To assess the efficacy of fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients,,2021-04-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13122,NCT00861445,The primary objective of this trial is to evaluate the efficacy of SPM 927 in reducing pain in subjects with diabetic distal sensory polyneuropathy,Examine the pharmacokinetics of SPM927 (assessment at all site visits during entire trial participation),,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13123,NCT02168348,Percentage of healed lesions,Number of malnourished patients according to HAS 2003 and 2007 criteria,Number of malnourished patients at 12 and 24 weeks,2013-11-26,COMPLETED,OBSERVATIONAL,['NA']
13124,NCT04977908,Time in target glucose range,"Total, basal, and bolus insulin dose",Human Factor assessment,2021-08-31,COMPLETED,INTERVENTIONAL,['NA']
13125,NCT03152994,fasting blood glucose(FBG),Exercise capacity (composite outcome measure),Symptom Evaluation(composite outcome measure),2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
13126,NCT01843114,Total retinal blood flow,Retinal blood velocities,,2015-01-12,COMPLETED,INTERVENTIONAL,['NA']
13127,NCT00816218,Vascular Endothelial Function,Insulin Resistance,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13128,NCT01879579,Percentage of Subjects Who Reach Optimal Long-acting Insulin Dose,Incidence of Hypoglycemia,Qualitative Patient Satisfaction Interview,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13129,NCT03653091,Change in Hemoglobin A1c (HbA1c),,,2018-09-28,COMPLETED,INTERVENTIONAL,['NA']
13130,NCT01071967,All-cause mortality,Weight control,,2002-04,UNKNOWN,INTERVENTIONAL,['NA']
13131,NCT03050229,Reduction of nocturnal blood pressure measured by ABPM,The correlation between blood pressure and body weight,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13132,NCT03057470,Reduction In Plasma Glucose (YSI),"Investigate Glycemic Response of a 0%, 50%, 100% and 150% Bolus Insulin Correction of Post-exercise Hyperglycemia Compared to no Bolus Insulin Correction",,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
13133,NCT02858648,Change in Glycemic control as assessed by HbA1c levels,Change in Self-efficacy for diabetes as assessed by the Self-efficacy for diabetes measure,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13134,NCT01310556,Frequency of unknown glucose metabolism disorders in patients with coronary artery disease,Fasting and 120 minute glucose levels have relation with vessels' stenosis.,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
13135,NCT01062763,Change of Diastolic Blood Pressure,Adverse Effects,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13136,NCT01476501,Change in serum vitamin D from baseline to 3 and 6 months,Change in bone health from baseline to 3 and 6 months,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13137,NCT00490165,,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
13138,NCT01889628,Glycaemic response,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13139,NCT03860558,Spermatozoa concentration,RNA Sequencing,,2018-05-01,RECRUITING,INTERVENTIONAL,['NA']
13140,NCT00668239,diffuse macular oedema,morphofunctional assessment of retina,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
13141,NCT02500979,Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM),Pharmacokinetics of Insulin as Demonstrated by the Time to the Maximum Plasma Insulin Concentration,,2015-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
13142,NCT02221466,Peripheral arterial tonometry (PAT),Nitric oxide and cytokine expression,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
13143,NCT04285554,Rate of Serious Adverse Device Effects,Adverse Event rate 365 days,,2020-07-28,COMPLETED,INTERVENTIONAL,['NA']
13144,NCT01424319,The change from baseline to each post-baseline visit in log-transformed UACR (urinary albumin to creatinine ratio),The proportion of subjects who achieve various percent of reduction in UACR (Urinary Albumin to Creatinine Ratio) from baseline to final,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13145,NCT03877523,Change in macrophages activation after 30-days Cocarnit administration,,,2018-10-03,COMPLETED,INTERVENTIONAL,['NA']
13146,NCT04927377,Glycemic Management,Health Technology Usability,,2022-10-31,RECRUITING,INTERVENTIONAL,['NA']
13147,NCT00005133,,,,1988-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13148,NCT00792935,Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic),,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13149,NCT06217614,Changes in subjective dry mouth score,Salivary Nitric oxide levels,,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
13150,NCT00755833,Change in HbA1c,Number of ADRs (adverse drug reaction),,2008-09,COMPLETED,OBSERVATIONAL,['NA']
13151,NCT02606838,Number of Subjects With Numeric Meter Results When Users Obtain Fingerstick Capillary Blood Using the Styx Lancing Device ( 28 Gauge Lancets),Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements Regarding the Styx Lancing Device,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
13152,NCT01588795,proteinuria/creatininuria ratio,Evaluate the outcome of specific kidney injury markers,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13153,NCT02384356,"Health Status using general health-related quality of life, perceived health, and PHQ8","Demographics, use of formal care and access, substance use, NCD diagnoses, self-care behavior, knowledge/perceptions, and anthropometric measures",,2014-06,COMPLETED,OBSERVATIONAL,['NA']
13154,NCT01906333,Change in IntraMyoCellularLipid (IMCL)content,Change in substrate metabolism,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
13155,NCT03665090,Prevalence and incidence rate of diabetic eye disease,Visual impairment,,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA']
13156,NCT05003154,Concentration of glycosylated hemoglobin A1c,Proportion of patients with abnormal resulets of postnatal oral glucose tolerance test,,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13157,NCT01269047,"Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus.",Difference in HbA1C Between the Treatment and the Control Groups,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13158,NCT06097689,Changes in spectral fingerprints measured by the Lab Demo 1.0 at fluctuations of venous blood glucose levels,Oxygen saturation,,2023-11-24,RECRUITING,INTERVENTIONAL,['NA']
13159,NCT03063138,Wound volume,,,2015-08-01,COMPLETED,OBSERVATIONAL,['NA']
13160,NCT02514850,Area under the glucose infusion rate curve (AUCGIR) 12-30h (mg/kg),Local tolerability,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13161,NCT00643435,"Resident physician use of self-efficacy enhancing patient interviewing techniques, assessment via coding of audio recordings from standardized patient encounters",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
13162,NCT00341406,adipose cell size distribution,,,2003-09-04,COMPLETED,OBSERVATIONAL,['NA']
13163,NCT00250731,diabetes regimen adherence,diabetes self-efficacy,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13164,NCT00818571,Measure: pharmacokinetics of vildagliptin and its metabolites,"Measure: safety assessments will include vital signs, electrocardiograms and adverse events",,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13165,NCT02399423,Change in adipose cell function after gaining 7% body weight and after losing 7% body weight,Change in cognition after gaining 7% body weight and after losing 7% of body weight,,2015-03-11,COMPLETED,INTERVENTIONAL,['NA']
13166,NCT01982019,Serum 26RFa levels,score of satiety,,2014-02-04,UNKNOWN,INTERVENTIONAL,['NA']
13167,NCT04515576,Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD):Change from baseline to Day 29 in Fasting Glucose (FG),,2020-08-25,COMPLETED,INTERVENTIONAL,['PHASE1']
13168,NCT05083767,Fasting Blood Sugar,,,2019-04-03,COMPLETED,INTERVENTIONAL,['NA']
13169,NCT01883024,"Patient agreement with the IPRA© advices: global rate of agreement, according to advice subtypes, according to blood glucose levels, according to the situations (pre or post-meal, bedtime)",Assessment of patient satisfaction,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13170,NCT02598544,Adipose tissue inflammation,Concomitant medication,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
13171,NCT01179815,Mortality,Diabetes related influence on quality of Life,,2010-01,RECRUITING,OBSERVATIONAL,['NA']
13172,NCT00171574,Change from baseline in urine protein excretion after 20 weeks,Change from baseline in diastolic blood pressure after 20 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13173,NCT01793168,"To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.",,,2010-07,RECRUITING,OBSERVATIONAL,['NA']
13174,NCT00005137,,,,1992-07,COMPLETED,INTERVENTIONAL,['NA']
13175,NCT04167553,adverse events (AEs):,,,2019-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
13176,NCT04897945,Weight change,Health-related quality of life,,2021-10-12,RECRUITING,INTERVENTIONAL,['NA']
13177,NCT01941277,A decrease in Insulin Resistance (IR) as measured by a change in IR.,,,2014-08,TERMINATED,INTERVENTIONAL,['NA']
13178,NCT03216226,Percentage of Patients With ADA,Pharmacodynamics - An Increase in the Plasma Glucose Concentration of ≥20 mg/dL Within 30 Minutes After Treatment,,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE3']
13179,NCT02675608,Change in HAI titer from day 0 to day 30 (+/- 4 days),Inflammatory Soluble Factor and Cellular Analysis additional measurements,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
13180,NCT03277742,Blood glucose control,,,2017-09-20,WITHDRAWN,INTERVENTIONAL,['NA']
13181,NCT05553912,HbA1c at Month 6,Quality of communication assessed using 3 questions from the CAHPS Clinician and Group survey,Clinician satisfaction survey,2022-11-02,RECRUITING,INTERVENTIONAL,['NA']
13182,NCT00110851,Effect on HbA1c levels,Effect on lipid levels,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13183,NCT01659697,occurence of diabetes,change in Body Mass index and Physical activity,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
13184,NCT05950516,Change in HbA1c,Percentage of Participants That Achieved Body Weight Loss ≥5%,,2023-07-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
13185,NCT04161846,Post Training Presentation Delivery Skills,Change in Physical Activity,Adherence,2019-08-08,COMPLETED,INTERVENTIONAL,['NA']
13186,NCT03554200,effect of Empagliflozin 10mg qd versus placebo on cardiac output in patients with acute heart failure,Effect of Empagliflozin 10 mg daily on Left ventricular diastolic function,,2018-06-11,TERMINATED,INTERVENTIONAL,['PHASE2']
13187,NCT00920881,,,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
13188,NCT01123980,Change in Glycosylated Haemoglobin (HbA1c),Number of Hypoglycaemic Episodes,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13189,NCT00566358,"Changes in the secretion pattern of incretins, insulin and glucagon after intervention, as measured by standardized mixed meal tolerance test",Regression of carotid intima-media thickness,,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13190,NCT02938572,The ratio of suppression of endogenous glucose production relative to total glucose lowering effect,Number of treatment emergent adverse events,,2016-10-19,COMPLETED,INTERVENTIONAL,['PHASE1']
13191,NCT01407276,Apparent Terminal Half-life (t1/2) of Omarigliptin,Number of Participants Withdrawn From Study,,2011-08-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13192,NCT00289237,Incidence of CHD and other lifestyle related diseases after ten years,"Changes in lifestyle and biological markers after one, three and five years",,1999-03,COMPLETED,INTERVENTIONAL,['NA']
13193,NCT04723160,consistent rate of diagnoses,full coincidence rate of software's diagnoses,,2020-08-10,COMPLETED,OBSERVATIONAL,['NA']
13194,NCT04496401,To characterise the bioavailability of Envarsus® and compare it to the bioavailability of tacrolimus,Assessment of biological and clinical tolerance/ safety: Incidence of serious adverse events,,2020-09-28,COMPLETED,INTERVENTIONAL,['PHASE4']
13195,NCT00005539,,,,1999-02,COMPLETED,OBSERVATIONAL,['NA']
13196,NCT01280929,Regression of neovascularization,Need for vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment relative to the three treatment arms.,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13197,NCT00397553,HbA1c,Post-prandial glycemia (2 hour after breakfast),,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13198,NCT05917093,Change in Blood Glucose,Adherence to Refills and Medicines Scale for Diabetes (ARMS-D) Score,Patient's Perceived Involvement in Care Scale (PICS),2024-03,RECRUITING,INTERVENTIONAL,['NA']
13199,NCT01176097,To investigate the safety and tolerability of AZD5658 following oral administration of single ascending doses and to estimate the maximum tolerated dose (MTD).,Effect of fasting on the pharmacokinetics and explore the pharmacodynamics of AZD5658.,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13200,NCT02940275,Perfused small vessel density of sublingual small vessels measured by Cytocam,Total small vessel density of sublingual small vessels measured by Cytocam,,2016-10-17,COMPLETED,OBSERVATIONAL,['NA']
13201,NCT02343926,Change from baseline in HbA1c,Number of serious adverse events,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13202,NCT01553526,Target Lesion Failure (TLF),Clinical Procedural Success,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
13203,NCT05919706,SF-36,,,2022-10-06,COMPLETED,INTERVENTIONAL,['NA']
13204,NCT01298726,GLYCATED HEMOGLOBIN (A1C) LEVELS,DIASTOLIC BLOOD PRESSURE LEVELS,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
13205,NCT03170518,Percentage of Participants with Adverse Events as a Measure of Safety and Tolerability,Percent Change in Body Weight From Baseline at Week 26 and Week 52,Change in Urinary Albumin/Creatinine Ratio (ACR) From Baseline at Week 26 and Week 52,2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE3']
13206,NCT04238936,Interleukin-1 (IL-1) receptor antagonist,,,2020-01-20,COMPLETED,OBSERVATIONAL,['NA']
13207,NCT02132637,Percentage of Participants With Clinically Significant Hypoglycemia,Beta Cell Function,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13208,NCT00390728,"Sub-study: The fear of hypoglycaemia as measured by the Hypoglycaemia Fear Survey questionnaire (HFS-98) assessed at baseline, 3 months and study end point or upon withdrawal of the subject from the study.",Proportion of patients reaching HbA1c target as per participation with the Prescription Plan,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13209,NCT02904512,Number of Participants With Hypoglycemic Events (< 70mg/dL),,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
13210,NCT04406402,High asymmetric dimethylarginine (ADMA) change,Glycated hemoglobin (HbA1c) change,,2006-12-05,COMPLETED,INTERVENTIONAL,['NA']
13211,NCT02984605,glycated hemoglobin,,,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
13212,NCT04569214,Assess the PAZ320 effect on postprandial blood glucose levels in type II diabetic patients.,Number of Subjects with Adverse Events as a Measure of Safety and Tolerability,,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13213,NCT01361971,Insulin sensitivity,Hypoxia and inflammatory markers,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
13214,NCT02868983,PROMIS-29 v2,Asthma Symptom Utility Index,Covid-19 patient measures,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
13215,NCT00057499,"Clinical endpoints including adverse events, local reactions, routine physical exams, insulin dose, and laboratory tests",T cells' secretion of IL-4 and Interferon (IFN)-gamma,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13216,NCT04443153,Glycemic Outcomes,High Blood Glucose Index,,2020-09-04,RECRUITING,INTERVENTIONAL,['NA']
13217,NCT02956044,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion up to 0-72 hr,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13218,NCT01672255,Change in Catecholamines,,,2012-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13219,NCT02264288,"Safety (adverse events [type, frequency, and severity of AEs, and relationship of AEs to study drug], laboratory abnormalities, and hospitalizations",Leg rest pain score,,2014-10-23,TERMINATED,INTERVENTIONAL,['PHASE2']
13220,NCT02735369,The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by regression of total area of neovascularization (NVD+NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.,Number of patients requiring pars plana vitrectomy surgery due to traction retinal detachment at the end of the study.,Evaluation of systemic exposure as measured by bioanalytic methods.,2014-12,TERMINATED,INTERVENTIONAL,['PHASE2']
13221,NCT04141423,Anti-insulin Tregopil antibodies,PD Endpoints - CGM profile,,2019-10-28,TERMINATED,INTERVENTIONAL,['PHASE1']
13222,NCT01451918,Examine the effect of resveratrol on ApoB 100 and ApoB 48 production in humans,Assess the change in insulin sensitivity with resveratrol treatment,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13223,NCT01719029,Glucose area-under-the-curve,Infant Adiposity,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
13224,NCT06074913,Temperature of the back of the hand,2-hour postprandial blood glucose (2hPG),,2023-07-07,RECRUITING,INTERVENTIONAL,['NA']
13225,NCT02857764,Incidence of Below-Knee Lower Extremity Amputation in Canagliflozin New Users Versus non-SGLT2i Aha New Users,,,2016-02-15,COMPLETED,OBSERVATIONAL,['NA']
13226,NCT00362193,Glycemic relapse: increase in HbA1c by 1% over baseline and >8%,Fasting Lipid Panel,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13227,NCT04767789,Glycated Hemoglobin A1c (HbA1c),Gastrointestinal Symptoms,Fecal calprotectin,2021-05-12,COMPLETED,INTERVENTIONAL,['NA']
13228,NCT00192803,ACE and ACE2 activities in monocytes,,,na,UNKNOWN,INTERVENTIONAL,['PHASE4']
13229,NCT04645875,Glycaemia,,,2020-11-19,UNKNOWN,INTERVENTIONAL,['NA']
13230,NCT04189848,Intensity of Injection Site Pain,,,2019-12-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13231,NCT01130207,Changes in microflora after bariatric surgery,,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
13232,NCT00805506,To collect sufficient glucose data by means of continuous glucose monitoring for the purpose of detecting clinically relevant alterations in blood glucose throughout a typical or modal day.,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
13233,NCT00231647,Percent change in body weight from baseline to Week 16.,"Changes in body weight, body mass index,anthropometric measurements (waste and hip circumference and their ratio),fasting blood glucose and lipid profile from baseline to Week 16; safety evaluations including incidence of adverse events during the study.",,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13234,NCT05037045,Change from baseline serum lipids at 6 month,incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment,,2019-01-10,RECRUITING,INTERVENTIONAL,['NA']
13235,NCT02330042,Number of participants with measureable macular edema by OCT imaging,,,2014-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13236,NCT05847907,Complications,Implant stability quotient (ISQ),,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13237,NCT01346254,Oral glucose tolerance test (OGTT),Lipid profiles,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13238,NCT03864510,Genetic factors associated with advanced liver disease (fibrosis >2),Number of patients that develop symptoms of end-stage liver disease,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
13239,NCT05323162,Preservation of residual beta cell insulin secretion capacity,Dietary intake,,2022-04,UNKNOWN,INTERVENTIONAL,['NA']
13240,NCT05789810,Fear Severity,,,2022-09-10,COMPLETED,INTERVENTIONAL,['NA']
13241,NCT02682901,Change in Hands ESC From Baseline to Endpoint After 24 Weeks of Intervention With Bromocriptine QR vs Placebo,,,2015-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13242,NCT04457752,Complete Wound Closure,Changes in bacterial Load,,2020-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
13243,NCT01053234,Prothrombin fragment 1+2,C-reactive protein,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
13244,NCT02003898,Mean Change in A1C From Baseline to 1 Year,"Mean Change in A1C From Baseline to 1 Year, Baseline A1c > 9%",,2013-11-26,COMPLETED,INTERVENTIONAL,['NA']
13245,NCT05986097,HbA1c change,Change in insulin resistance,,2023-08-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13246,NCT05214547,Change from 4 weeks Shoulder Pain at 6 weeks,Change from 4 weeks Shoulder Function at 6 weeks,Change from baseline Shoulder Muscle Tone at 6 weeks,2022-02-25,UNKNOWN,INTERVENTIONAL,['NA']
13247,NCT00836225,To evaluate the safety and tolerability of single and multiple doses of ISIS-SGLT2Rx administered subcutaneously,Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13248,NCT01195454,The area under the body weight standardized glucose infusion rate curve (GIR) within 36 hours (GIR-AUC0-36),"Maximum insulin concentration INS-Cmax, and time to Cmax (INS-Tmax)",,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13249,NCT02565862,Area Under the Curve (AUC),adverse events,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13250,NCT01881347,Change from baseline in Brachial artery flow mediated dilation,Change from Baseline in Reactive hyperemia,Change from Baseline in Endothelial cell protein expression,2013-01-01,COMPLETED,INTERVENTIONAL,['NA']
13251,NCT01610674,Barrier analysis,feasibility study,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
13252,NCT04829084,Increased number of DR patients at REMEH for eye screening,,,2021-02-26,COMPLETED,INTERVENTIONAL,['NA']
13253,NCT00383578,Change from baseline in HbA1c,Change from baseline in body weight,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13254,NCT01238224,"Capillary recruitment, muscle glucose uptake and circulating glucose levels following a meal",Vascular function and circulating biomarkers.,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE1']
13255,NCT04599075,Neonatal Hypoglycemia,Umbilical Cord Blood Level of Insulin,,2021-03-15,COMPLETED,INTERVENTIONAL,['PHASE4']
13256,NCT05054283,Prolonged Length of hospital,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
13257,NCT01021930,Comparison of the surface coverage between DM and Non-DM at 6 months after Cypher and YINYI stent implantation using OCT.,MACE,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
13258,NCT01572415,Comparison of SCOUT DS to Random Capillary Glucose,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
13259,NCT00311077,To evaluate the serum insulin glulisine concentration and insulin lispro concentration,Adverse events collection,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
13260,NCT00863967,Cardiovascular events,Disease activity score,,2003-10,UNKNOWN,OBSERVATIONAL,['NA']
13261,NCT01595269,Changes in A1C,Changes in Diabetes self-care activities,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
13262,NCT05402358,The RAND 36-item Health Survey 1.0,Focus group and individual interviews with health professional participants,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
13263,NCT03434860,HOMA-IR,cytokines levels,,2016-01-15,COMPLETED,INTERVENTIONAL,['NA']
13264,NCT01269008,Better meal and post meal sugars on the closed loop device using the study medications.,,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13265,NCT01583790,Weightloss of patients,Improvement of co-morbidities after surgery,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
13266,NCT04805541,Number of subject eyes whose EyeCheckup results match the reading center grading for identifying vision threatening diabetic eye disease (severe NPDR or PDR or surrogate markers for CSME).,,,2022-02-01,RECRUITING,OBSERVATIONAL,['NA']
13267,NCT02922179,serious hypoglycemic events,Serious cardiac events,A1C control,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
13268,NCT03631134,Changes of glycemic variation,Change of insulin dose,,2018-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
13269,NCT05526430,Dose Limiting Toxicity (DLT),Visual Analog Scale (VAS),,2022-09-13,COMPLETED,INTERVENTIONAL,['PHASE1']
13270,NCT01272232,Proportion of Subjects Losing More Than 10% of Baseline Body Weight,Incidence of Hypoglycaemic Episodes,,2011-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13271,NCT06137963,Change in percent of body weight before and after a 6 month intervention period.,Postoperative length of stay,,2024-01-24,WITHDRAWN,INTERVENTIONAL,['NA']
13272,NCT00677937,Reduction in incidence of diabetes at 3 years,"change in hba1c, fasting and post glucose levels, cardiovascular risk (framingham), presence of MetS (NCEP ATP III)",,2009-05,COMPLETED,INTERVENTIONAL,['NA']
13273,NCT01209312,Blood glucose area under the curve,,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
13274,NCT04595968,Frequency of all device related Serious Adverse Events,Frequency of hypoglycemic episodes,,2021-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13275,NCT03315143,"Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)","Total Number of Occurrences of CV Death, Non-fatal Myocardial Infarction and Non-fatal Stroke",,2017-12-19,TERMINATED,INTERVENTIONAL,['PHASE3']
13276,NCT02258373,"Percentage of Time in Range of 70 to 180 mg/dl, Measured With CGM",Number of Participants With >=1 Serious Adverse Event Other Than SH,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
13277,NCT04801121,Placental pathology,,,2020-11-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
13278,NCT03772600,Difference in time in range (70-180 mg/dL) between the control and experimental group,Between group difference in number of patients having allergic reactions to the sensors,Number of patients who stop using the Dexcom G6® CGM and the reason to stop,2019-01-29,COMPLETED,INTERVENTIONAL,['NA']
13279,NCT01247649,Correlation between continuous glucose measurements using study device and YSI(yellow springs instrument),,,2010-11,TERMINATED,INTERVENTIONAL,['NA']
13280,NCT01301092,Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV),)Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC),,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13281,NCT00901979,Effect of LCQ on measures of glucose control,Safety and tolerability,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13282,NCT04796649,Incidence of complete (100%) wound closure,Time to complete (100%) wound closure,,2022-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13283,NCT00841503,determine glucose-lowering potential of the buckwheat bioactive compound during acute phase testing in volunteers with Type 2 diabetes,determine bioavailability of buckwheat bioactive compounds,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
13284,NCT00680745,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Fasting Plasma Glucose (FPG),,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13285,NCT04646408,Educational,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
13286,NCT03447301,HbA1c (glycated hemoglobin),Weight,,2018-02-25,UNKNOWN,INTERVENTIONAL,['NA']
13287,NCT02533648,muscle oxidative stress in diabetic patients,Tolerance of the treatment measured by any adverse events during treatment and between each visit.,,2011-09-16,COMPLETED,INTERVENTIONAL,['PHASE3']
13288,NCT04129021,Visualization of a structure of interest and measuring the short-term and long-term reproducibility of the data collected compared to routine systems,,,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA']
13289,NCT05190744,Change in urine osmolality,Change in urine output,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13290,NCT00486109,Glycosylated albumin levels,"Participants' satisfaction evaluated with standard quality of life questionnaires and adverse events related to the study device including incidents of erythema > 2cm diameter, incidence of induration > 1cm dimater and incidence of suppuration.",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
13291,NCT01393275,alteration of HbA1c-level (haemoglobin A1c),follow up of all parameters mentioned above,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
13292,NCT02857491,perioperative hemorrhage of the surgical eye,best-corrected visual acuity,grade of surgical difficulty,2014-07,COMPLETED,INTERVENTIONAL,['NA']
13293,NCT00961974,"Glycemic control, assessed by hemoglobin A1c","Frequency of hospitalizations, emergency department visits, and episodes of severe hypoglycemia",,2002-04,COMPLETED,INTERVENTIONAL,['NA']
13294,NCT00924534,Change from baseline in Creatinine kinase level to Day 35,Change from baseline in High density lipoprotein cholesterol level to Day 28,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13295,NCT04814849,number of participants reporting financial burden,number of participants reporting emotional and/or psychosocial burden,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
13296,NCT01196325,Quantitative inner retinal blood flow,Mean angle opening distance and trabecular-iris spur area,,2009-07,UNKNOWN,OBSERVATIONAL,['NA']
13297,NCT03406975,Percentage of Excess Weight Loss (EWL),Change in Eating Behaviors,,2017-12-20,COMPLETED,INTERVENTIONAL,['NA']
13298,NCT02285218,new hepatokines,,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
13299,NCT06011798,Mean change from baseline in BCVA by ETDRS letter,Assess safety outcome - TEAE,,2023-08-23,RECRUITING,INTERVENTIONAL,['PHASE2']
13300,NCT03451630,Change in Hospital Readmission Rate,Gaps in care,,2018-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13301,NCT04118257,Change in glucose iAUC,Change in serum fructosamine,,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
13302,NCT01069393,Improvement in HbA1c (glycosylated haemoglobin),Qualitative evaluation via in-depth interviews to assess patients' experiences of the intervention,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
13303,NCT05464524,"Established the role of tested environmental factors and lifestyle choices on the incidence, recurrence, and severity of diabetic foot ulcers in adults living with diabetes in England.",Established changes to DFU status and quality of life over the 12 week follow up period.,,2023-10-19,RECRUITING,OBSERVATIONAL,['NA']
13304,NCT03073330,Incidence of gestational diabetes diagnosed on each screening test of each arm.,Apgar score,,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
13305,NCT03258268,HbA1c,Hypoglycemia,,2017-08-07,COMPLETED,INTERVENTIONAL,['NA']
13306,NCT05328726,Dose limiting toxicity,Glycosylated Hemoglobin,,2022-03-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13307,NCT02727790,"Number of participants with hypoglycemia, and/ or adverse events that are related to treatment",Changes in mean interstitial glucose levels measured by CGM,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
13308,NCT01323075,The duration of sensory block in minutes.,"Occurrence of neurological complications, yes/no",,2011-05,COMPLETED,OBSERVATIONAL,['NA']
13309,NCT00885638,Glucagon-like Peptide-1 Secretion After Meal Ingestion,Insulin Secretion After Ingestion of Meal,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13310,NCT06265935,SF-36 Quality of Life Scale:,Visual Similarity Scale for Fatigue,,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13311,NCT06327737,Prediction of cerebral edema with Integrated Pulmonary Index,,,2020-12-15,COMPLETED,OBSERVATIONAL,['NA']
13312,NCT05108987,Body Weight,Flow-mediated dilation,,2021-09-25,RECRUITING,INTERVENTIONAL,['NA']
13313,NCT05530486,Change in complete ulcer healing,,,2023-06-30,RECRUITING,INTERVENTIONAL,['NA']
13314,NCT03233178,"Change in ALT in patients with T2DM initiating SGLT2 inhibitors, Liraglutide or Sitagliptin compared to control",Change in triglycerides from baseline to follow-up,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
13315,NCT00753181,Average daily blood glucose level,"Percentage of time in specified glucose ranges; Glycemic excursions; Change in plasma glucose, insulin, free fatty acids, triglycerides, 1,5-anhydroglucitol, and fructosamine; Dietary intake variables",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13316,NCT02055755,Questionnaire relevant to wound healing,Develop new parameters for clinical decision support based on data collected in this study.,,2013-04,WITHDRAWN,OBSERVATIONAL,['NA']
13317,NCT03113916,Waist Circumference in Centimeters,Number of Vegetable Servings Per Day (Transformed Using the Natural Log),Recruit Participants for Sustainability Phase,2014-06-23,COMPLETED,INTERVENTIONAL,['NA']
13318,NCT00315991,Accuracy of blood glucose level estimation,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
13319,NCT02171130,Percentage of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration,Percentage of Participants With Adverse Events (AEs) Reported Through the Nasal Score Questionnaire,Number of Participants With Treatment-Emergent Glucagon Anti-Drug Antibodies (ADA),2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13320,NCT02627027,Cmax of Lobeglitazone Metformin,Vd/F of Metformin,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13321,NCT01114750,Pharmacokinetic variable: insulin,,,2010-04,SUSPENDED,INTERVENTIONAL,['PHASE1']
13322,NCT01785667,Incidence of diabetic retinopathy and proliferative diabetic retinopathy,Vessel diameters as a predictor of diabetic retinopathy and proliferative diabetic retinopathy,Fractal dimensions as a predictor of diabetic retinopathy and proliferative diabetic retinopathy,2011-01,COMPLETED,OBSERVATIONAL,['NA']
13323,NCT05892848,"level of serum ostecalcin, sclerostin in patients with type 1 diabetes ann d their age and sex matched control",,,2023-06-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13324,NCT00330473,To assess blood sugar control as measured by HbA1c,To assess patient-reported outcomes based on the DTSQ Questionnaire,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13325,NCT01791465,Serum Interleukin 6 (IL-6) at Levels at Baseline and 16 Weeks,Waist to Hip Ratio at Baseline and 16 Weeks,"Peripheral Endothelial Tonography, as Measured by the Non-invasive EndoPAT System Using the LnRHI (Natural Log of Reactive Hyperemia Index), at Baseline and 16 Weeks",2013-03,TERMINATED,INTERVENTIONAL,['PHASE4']
13326,NCT04937816,Incidence Rate of Lower Limb Amputation (LLA),Incidence Rate of Adverse Events Related to Amputation,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
13327,NCT02314637,Number of Participants With Adverse Events,Change From Baseline in Fasting Plasma Glucose at Week 52,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13328,NCT04917965,Coagulation Index,,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
13329,NCT01790711,The Efficiency of FMT on T2DM,Durability,,2012-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13330,NCT03680794,sCD160 concentration in the aqueous humor,Stromal cell-derived factor 1 (SDF-1),,2018-06-27,RECRUITING,INTERVENTIONAL,['NA']
13331,NCT00463671,The aim of the present study was to investigate whether changes in oxidative stress and NO bioavailability are responsible for the different effects of HBOT on tissue oxygenation in diabetic patients suffering from foot ulcers.,,,2003-12,COMPLETED,INTERVENTIONAL,['NA']
13332,NCT00318032,"To contribute to the ADDITION-Europe study, to assess screening and intensive treatment on 5 year cardiovascular outcomes",To assess the economic and psychological cost of screening,,2004-08,UNKNOWN,INTERVENTIONAL,['NA']
13333,NCT00462046,LDL-c,Blood pressure,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13334,NCT05096078,Blood count test 8,WMS Number Range Test,,2020-10-16,UNKNOWN,INTERVENTIONAL,['NA']
13335,NCT02120976,Plasma glucose,,,2014-04,TERMINATED,INTERVENTIONAL,['PHASE1']
13336,NCT05634174,Free Fatty Acid measured Catecholamine Sensitivity,IL-6 Adipokine Gene Expression,ADRB3 Signaling Pathway,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
13337,NCT03945656,Clinically significant hypoglycaemia (Double dose): Clinically significant hypoglycaemia (Plasma glucose [PG] less than 3.0 mmol/L [54 mg/dL]) after 2 times the individualised optimal basal dose of insulin,"Clinically significant hypoglycaemia (Triple dose) - Clinically significant hypoglycaemia [PG less than 3.0 mmol/L (54 mg/dL)], after 3 times the individualised optimal basal dose of insulin",,2019-05-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13338,NCT00690287,Pharmacodynamic variables,Pharmacokinetic variables,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13339,NCT04368741,Glycated albumin level,,,2019-10-15,UNKNOWN,INTERVENTIONAL,['NA']
13340,NCT00099853,Change from baseline in HbA1c after 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs low baseline HbA1c,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13341,NCT04436796,Non-inferiority for CGM Time <54 mg/dL,Basal: Bolus Insulin Ratio,Any Adverse Event Rate Per 100 Person-years,2020-08-05,COMPLETED,INTERVENTIONAL,['NA']
13342,NCT04817644,"Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)","Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)",,2021-09-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13343,NCT05029076,"Adverse Event, Serious Adverse Event and Drug Combination",The Number of participants with abnormal laboratory examinations,,2019-05-21,COMPLETED,INTERVENTIONAL,['PHASE1']
13344,NCT01162772,catecholamine,Homeostasis model assessment-estimated insulin resistance,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
13345,NCT04395521,The efficacy of the study intervention on participants' foot self-care adherence.,The efficacy of the study intervention on participants' quality of life.,,2021-02-16,COMPLETED,INTERVENTIONAL,['NA']
13346,NCT01550328,Determine Device Bias,,,2012-04,TERMINATED,OBSERVATIONAL,['NA']
13347,NCT00831389,Incidence of Nocturnal Hypoglycemia Following Exercise,Percentage of Time Plasma Glucose (PG) is Below the Euglycemic Range.,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
13348,NCT03696797,Change in FSIGTT DI (Frequently sampled intravenous glucose tolerance test),Number of participants that converted from pre-diabetes to normal glucose tolerance,,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13349,NCT05491746,Visual acuity at distance,Contrast sensitivity,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA']
13350,NCT04328233,Change in fasting glucose concentration,Duration of eating period,,2019-10-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13351,NCT01169779,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13352,NCT03305939,"Proportion of women with a change of glycaemic category, at or prior to final visit",Change in dietary habits as assessed by Intake 24 (a 24-hour recall questionnaire),,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13353,NCT06114134,Hemoglobin A1C (HbA1C),Antropometric Indices,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13354,NCT04001725,Metformin in preventing precocious (14 days) dexamethasone-induced diabetes,Amino acid profile,,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
13355,NCT00065130,Postprandial glycemic control,Adverse events,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13356,NCT01437072,HbA1c (Glycosylated Haemoglobin) level,The presence of retinopathy,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
13357,NCT02756442,Respiratory Disturbance Index,Air flow debit associated to micro awaking during sleep,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
13358,NCT04656093,Beliefs about Medicines Questionnaire (BMQ scores),Illness Perceptions Questionnaire (IPQ scores),,2021-01-15,COMPLETED,INTERVENTIONAL,['NA']
13359,NCT02092870,Percent change in wound size from baseline at 12 weeks,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13360,NCT02062047,Changes in clinical attachment level (CAL) in sites with initial PD ≥7mm from baseline to 12 months.,Changes in the levels of osteoprotegerin (OPG) in gingival crevicular fluid,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
13361,NCT05417646,Urinary glucose excretion,Renal threshold of glucose excretion,,2022-06-22,COMPLETED,INTERVENTIONAL,['NA']
13362,NCT02826655,Peripheral Retina Structure Differences between Healthy Controls and participants with diabetic retinopathy.,,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
13363,NCT01308437,Change in HbAlc from baseline to 6 months of treatment between Wosulin arm and Novolin arm(as surrogate indicator of change in insulin antibodies titers between the two treatment arms).,"Correlation of the immunogenicity with hypoglycemia, local allergic reactions and systemic allergic reactions will be evaluated.",,2011-03,TERMINATED,INTERVENTIONAL,['PHASE3']
13364,NCT04254016,Variation of mitral E' velocity,Variation of lipid profile.,,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13365,NCT00100204,,,,2004-12-21,COMPLETED,OBSERVATIONAL,['NA']
13366,NCT04834648,Primary Outcome,,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
13367,NCT05854862,TIR,Incidence of hypoglycemia,,2013-08-01,RECRUITING,OBSERVATIONAL,['NA']
13368,NCT02690168,Percent Enrichment of Bicarbonate as Measured by Magnetic Resonance Spectroscopy (MRS),Change in Leptin Levels,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
13369,NCT02405949,"Predictive value of the genetic test in identifying individuals who will have a good response to bariatric surgery, in terms of type 2 diabetes remission after the surgery.",,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
13370,NCT06098040,time in range,PAT plasma antioxidant capacity,,2023-09-22,RECRUITING,INTERVENTIONAL,['NA']
13371,NCT01420497,"glycemic values,",urinary excretion rate,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
13372,NCT05161741,Change from baseline in fasting plasma glucose to the last- observation on treatment,,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13373,NCT01970163,Effect of DermACELL on the proportion of chronic wounds of the lower extremity that have healed.,Proportion of wounds closed at 12 weeks and weekly thereafter for up to 24 weeks,"Incidence of treatment-emergent adverse events (AE), changes in vital signs, ankle-brachial index (ABI) and physical examination findings.",2013-10,COMPLETED,INTERVENTIONAL,['NA']
13374,NCT03369626,Level of engagement with the assigned mobile app,Change in self-reported diabetes medication type or dose,,2017-07-26,COMPLETED,INTERVENTIONAL,['NA']
13375,NCT05314855,Amplitude of SCN activity rhythm (peak-trough change in SCN activity),,,2023-01-04,RECRUITING,OBSERVATIONAL,['NA']
13376,NCT02798198,The correlation between the pulmonary function and the renal hemodynamics in 37 T2DM patients without DKD,"The albumin excrete rate (AER), urinary albumin/creatinine ratio (UACR)in the healthy people and T2DM patients and comparing the differences between the two groups",,2015-09,COMPLETED,OBSERVATIONAL,['NA']
13377,NCT02247635,"Reduction in the prevalence of metabolic syndrome (obesity, diabetes, hypertension, dyslipidemia)",Reduction of hypercholesterolemia,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
13378,NCT00368134,Change in HbA1c after 12 weeks,Safety Profile after 12 weeks treatment,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13379,NCT03545802,Compliance over the course of the training programme,change in glycaemic control,,2017-05-20,COMPLETED,INTERVENTIONAL,['NA']
13380,NCT04081792,Number of Participants with a clinical and microbiological remission of treated infection at 2 months,Statistical evaluation of risk factors for failure of remission,,2019-09-04,RECRUITING,INTERVENTIONAL,['NA']
13381,NCT03844789,Continuous Glucose Monitor (CGM)-Measured Percent Time in Range 70-180mg/dL Over 16 Week Trial Period,Continuous Glucose Monitor (CGM)-Measured Glucose Variability Percentage Measured With the Coefficient of Variation (CV) Over 12 Week Trial Extension Period,Body Mass Index (BMI) at Conclusion of 12 Week Trial Extension Period,2019-06-06,COMPLETED,INTERVENTIONAL,['NA']
13382,NCT00554450,Iohexol PK blood & urine samples for GFR assessment,"The following urine/serum safety parameters will be assessed: sodium, potassium, magnesium, phosphorus, calcium, and total protein (urine only)",,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13383,NCT03804983,change between Percent Time in Range at home pre/post intervention at home,Change in Total amount of carbohydrates corresponding to hypoglycemia treatment at camp,,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
13384,NCT00704132,Change From Baseline in Glucose 5-Hour Incremental AUC at Week 6,,,2007-02-14,COMPLETED,INTERVENTIONAL,['PHASE1']
13385,NCT04578431,Blood from mother,,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
13386,NCT04352907,Continous Glucose Sensor values (CGM),Vasopressor Use,,2020-11-06,RECRUITING,OBSERVATIONAL,['NA']
13387,NCT01310491,HbA1c change over time (participants with T2DM only),Satisfaction and usability of the technology and equipments.,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
13388,NCT02926950,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With HbA1c <7.0% at Week 26,Percentage of Participants With Hypoglycemic Events,2016-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13389,NCT04227769,Change in insulin concentration in blood during the cephalic phase of insulin secretion in obese patients with type 2 diabetes,Change in autonomic function,,2020-01-13,RECRUITING,INTERVENTIONAL,['PHASE2']
13390,NCT04173117,Recruitment and retention rates,The number of participants who experience any Major Adverse Cardiovascular Events (MACE),,2020-02-28,TERMINATED,INTERVENTIONAL,['NA']
13391,NCT02695095,incidence of acute liver injury,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
13392,NCT00174681,Percentage of subjects achieving HbA1c < 7% at the end of the study.,,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13393,NCT01400295,Contrast-Induced Nephropathy,An early abnormal increase in serum cystatin C,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
13394,NCT05832996,The efficacy of cooled versus room temperature artificial tears in reducing post intravitreal injection ocular discomfort as measured by pain scale survey.,,,2022-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13395,NCT02014207,blood glucose,food intake,subjective appetite,na,COMPLETED,INTERVENTIONAL,['NA']
13396,NCT03252132,Muscle strength (isokinetic strength),,,2017-08-10,COMPLETED,INTERVENTIONAL,['NA']
13397,NCT02487888,Glucose levels for patients being treated for T2DM,Urine drug screen results,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
13398,NCT02669732,First-phase and Second-phase secretion C-peptide,plasma concentration of DS-8500a,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
13399,NCT03391349,"mRNA expression of L-plastin,lipocalin and adiponection","Quantify the levels of L-plastin, lipocalin and adiponectin",,2016-10-20,COMPLETED,OBSERVATIONAL,['NA']
13400,NCT01432275,Overall User Preference for the FreeStyle InsuLinx System Compared to Current Method.,Preference Questionnaire (Insulin Calculator Not Activated),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
13401,NCT02330406,Change in glycated hemoglobin,Change in fatty acid fraction,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13402,NCT03111238,Complete relief of ischemic rest pain without developing ischemic lesions on the index leg.,,,2017-04-05,TERMINATED,INTERVENTIONAL,['PHASE3']
13403,NCT00512707,Change From Baseline in Erectile Function Domain Score of the International Index of Erectile Function (IIEF),Change From Baseline in Positive Affects Ratio (PAR) of Derogatis Affects Balance Scale (DABS),Change From Baseline in Sex Hormone Binding Globulin (SHBG),2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13404,NCT04424888,2-hour Interstitial Glucose Area Under the Curve (AUC),CGM-Smartphone Usability Feedback,,2018-03-15,COMPLETED,INTERVENTIONAL,['NA']
13405,NCT03207841,"Change in HDL, LDL, total cholesterol and triglycerides",Change in Spinal Cord Injury-Quality of Life (SCI-QOL) Score,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
13406,NCT02854696,Incremental cost- utility ratio at 1 year,Assessment of total cost of islet cell transplantation,,2016-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13407,NCT05165615,Percentage of time in target ranges,The 5-item World Health Organization well-being index (WHO-5 index),,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
13408,NCT02204657,Glycemic Control by Measurement of HbA1c,Hypoglycemia,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
13409,NCT02365363,Exercise intensity,Substrate Oxidation,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
13410,NCT01076218,,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
13411,NCT04455880,Prediction and differentiation of GDM and prognosis with Shear wave elastography velocity cut-offs,,,2019-05-15,COMPLETED,INTERVENTIONAL,['NA']
13412,NCT02623452,(Part B) PK: AUC of Insulin Lispro,(Part B) PD: AUC of Glucose Following a Meal,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13413,NCT00435240,"waist circumference at baseline, 3 months and 6 months","C-reactive protein at baseline, 3 months and 6 months",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13414,NCT01928381,"Brief Pain Index - Item 5, Average Daily Pain Score (Range 0-10) Higher Values Indicate Worse Pain",,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13415,NCT00964418,Area under the glucose infusion rate curve during one dosing interval at steady state (for NN1250),Area under the NN1250 concentration-time curve during one dosing interval at steady state,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13416,NCT00642278,Change in HbA1c From Baseline to Week 12,Percent Change in Body Weight From Baseline to Week 12,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13417,NCT03982693,Prevention of major cardiovascular endpoints,Changes in PAD Quality of Life,,2019-03-19,RECRUITING,INTERVENTIONAL,['PHASE3']
13418,NCT00024518,C-Peptide Level,Hemoglobin A1C,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13419,NCT00947024,Bioequivalence based on AUC and Cmax,,,1993-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13420,NCT03732690,Post meal tolerance test glycemic excursion (area under the curve),Adipose tissue gene expression modifications,,2018-12-05,COMPLETED,INTERVENTIONAL,['NA']
13421,NCT04809285,Percentage of Time in Range,,,2021-04-06,COMPLETED,INTERVENTIONAL,['NA']
13422,NCT02599805,Comparative change in ulcer surface area,,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
13423,NCT01640223,Percentage of data collected,,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
13424,NCT00097955,Change from baseline in urinary albumin creatinine ratio after 24 weeks,Change from baseline in urinary albumin excretion rate after 24 weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13425,NCT01497912,Fibrin network permeability,skin microvascular reactivity,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13426,NCT00495235,Prevalence Rate of Insulin Resistance,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
13427,NCT04149392,Frequency of diabetes medication changes that take place at the follow up visit,Mortality rate,,2019-12-16,WITHDRAWN,INTERVENTIONAL,['NA']
13428,NCT01475422,HbA1c,Diabetes Attitude Questionnaire - ATT-19,,2011-09,UNKNOWN,INTERVENTIONAL,['NA']
13429,NCT03777722,Change in depression,Light exposure using the Daysimeter,,2018-11-01,RECRUITING,INTERVENTIONAL,['NA']
13430,NCT02114008,Residual gastric volume (RGV) in morbidly obese diabetics. A comparison of 3 hour versus 8 hour fasting,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
13431,NCT04340648,Performance and accuracy in pulse monitoring,,,2019-06-03,COMPLETED,INTERVENTIONAL,['NA']
13432,NCT05922852,urinary protein changes,,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
13433,NCT04364685,HbA1c,Quality of life-39,,2017-01-25,COMPLETED,INTERVENTIONAL,['NA']
13434,NCT02834858,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
13435,NCT05514080,Glucose outcomes: percentage of time spent in specific glucose ranges (ex: 3.9-10.0 mmol/L),,,2019-12-06,COMPLETED,INTERVENTIONAL,['NA']
13436,NCT02354027,The area under the plasma concentration-time curve (AUC) of metformin,The number of volunteers with adverse events as a measure of safety and tolerability.,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13437,NCT05188014,Blood glucose,percent of time in hyperglycemia,Carbohydrate supplementation,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
13438,NCT01513746,Blood Glucose Values,Ecological Momentary Assessment of Emotional and Behavioral Outcomes,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
13439,NCT00286962,incidence of hypoglycemia; data taken from patient diaries during either study arm.,"daily glucose excursions; measured with continuous glucose monitoring system (CGMS) at baseline, halfway through and at the end of both study arms",,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13440,NCT02426138,Healthy Eating Index 2010 Score,Diabetes Distress Scale,Total Cholesterol,2015-04-01,COMPLETED,INTERVENTIONAL,['NA']
13441,NCT00233649,,,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
13442,NCT03607617,SDH data adoption,DM Key tests,,2018-09-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13443,NCT05391854,Glycated haemoglobin (HbA1c),SF-12 (Short-fom 12),,2022-06-21,COMPLETED,INTERVENTIONAL,['NA']
13444,NCT03941132,"Rate, frequency and severity of all adverse events including; hypoglycemic episodes; injection reactions; hypersensitivity reactions; evidence of infection and posterior leukoencephalopathy syndrome.",Glycaemic variability in continuous glucose monitoring and hypoglycaemia rates.,,2021-01-04,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13445,NCT00850135,Correlation Between Glucose AUC and Birth Weight.,"Pregnancy and Delivery Characteristics for Participants With AUC-130 <= 22,000 and AUC-130 > 22,000",,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13446,NCT01053026,1. Vascular function testing,"Circulating biomarkers including hs-CRP, adiponectin, myostatin, MMP, etc",,2009-12,COMPLETED,OBSERVATIONAL,['NA']
13447,NCT01160887,glucose,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
13448,NCT04632277,Serum Cholesterol,Serum Creatinine.,Body mass index,2020-08-25,COMPLETED,INTERVENTIONAL,['NA']
13449,NCT02525263,"Serial Estimation of Glomerular Filtration Rate (GFR) Through 6 Months Following the Final Cell Implantation, as Measured by Serial Serum Creatinine.",Renal-specific Laboratory Assessments Through 12 Months Following the Last NKA Implantation Under This Protocol.,Evaluation of Renal Structure Over Time as Measured by Imaging Modalities.,2016-07,TERMINATED,INTERVENTIONAL,['PHASE2']
13450,NCT01220856,The Percentage of Insulin-independent Patients Following Single Infusion Islet Cell Transplantation at Day 75 +/- 5,,Change From Pre-transplant in Cytokine Levels - IL-6,2010-07-28,COMPLETED,INTERVENTIONAL,['PHASE2']
13451,NCT05482958,Glycemic control amongst people with established T2DM.,Change in glycemic control.,,2022-07-29,RECRUITING,OBSERVATIONAL,['NA']
13452,NCT04317404,Post-injection glucose levels,KOOS Knee survey,,2020-11-01,COMPLETED,OBSERVATIONAL,['NA']
13453,NCT01582243,Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,The Percentage of Patients Achieving the Two Glycemic Goals After 12- and 24-week Treatment,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13454,NCT06143449,Provide data on disease management.,,,2015-10-01,RECRUITING,OBSERVATIONAL,['NA']
13455,NCT05788965,"Feasibility, safety, tolerability",,,2023-04-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13456,NCT04554810,Knowledge about chronic medications scores,,,2015-05-10,COMPLETED,INTERVENTIONAL,['NA']
13457,NCT02813759,Satiety,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
13458,NCT06143267,Total glucagon response,Food intake,,2022-12-06,RECRUITING,INTERVENTIONAL,['NA']
13459,NCT00767260,area under the curve of c-peptide,area under the curve of serum insulin,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13460,NCT04051866,Glycated Hemoglobin A (HbA1c),Gingival Probing bleeding,,2022-12-02,WITHDRAWN,INTERVENTIONAL,['NA']
13461,NCT00978627,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13462,NCT00325559,Paired difference in the time to complete a time trial corresponding to 5 km cycling between euglycaemia and hyperglycaemia,Pretest diary data,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
13463,NCT00464776,Investigate the antiproteinuric effect of increasing doses of Aliskiren compared to matching placebo.,To investigate whether there is a change in biomarkers of inflammation and cardiovascular risk.,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13464,NCT05027334,Fasting blood glucose (FBG),Weight,,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
13465,NCT05136287,Weight loss,Number of participants experiencing adverse events,,2022-02-01,COMPLETED,OBSERVATIONAL,['NA']
13466,NCT00205738,Effects of olanzapine/risperidone/haloperidol on glucose regulation.,Explore Treatment-related effects on glucose effectiveness.,,2000-07,COMPLETED,INTERVENTIONAL,['NA']
13467,NCT01529216,HbA1c,HbA1c,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
13468,NCT00873223,Insulin detemir pharmacokinetics with and without liraglutide administration,Pharmacokinetics of liraglutide with and without insulin detemir,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13469,NCT02327039,"Change from baseline in reverse cholesterol transport, measured as cholesterol efflux capacity of patient's plasma",Safety as measured by monitoring of adverse events,Exploratory analyses - changes from baseline in impedance cardiography analysis,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13470,NCT01363336,General evaluation of patient concerning efficacy of AdalatCR treatment in real practice,Overall evaluation,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
13471,NCT04040595,Mean adipocyte size (µm2) assessed using Image J software.,"Adipose tissue expression of genes that are determinants of adipose inflammation (IL-1beta, IL-6, and 8, TNFalpha, MCP-1/CCL2).",,2019-03-07,COMPLETED,INTERVENTIONAL,['NA']
13472,NCT02449330,Change of the ratio of peak velocity of early transmitral diastolic filling by echocardiography (E) to early diastolic mitral annular velocity by tissue Doppler echocardiography (E/e'),Change of plasma levels of NT-proBNP,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
13473,NCT01976689,Left ventricular hypertrophy,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
13474,NCT02417090,Metabolic late effects,,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
13475,NCT01929018,Timed Up-and-Go Test,World Health Organization Disability Assessment Scale,,2013-10-09,COMPLETED,INTERVENTIONAL,['NA']
13476,NCT05015504,estimated hemoglobin A1c levels,body weight,,2022-02-10,RECRUITING,INTERVENTIONAL,['NA']
13477,NCT01762046,Metformin response,Vitamin D,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
13478,NCT04097600,"AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state","t½,sema,SS; terminal half-life of semaglutide at steady state",,2019-09-30,COMPLETED,INTERVENTIONAL,['PHASE1']
13479,NCT00705952,"Whether weight loss achieved through a programme of intensive lifestyle management can result in enhanced production of Glucagon-Like Peptide-1 together with improvements in glycaemic control, in patients with new onset type 2 diabetes.","To examine the changes in hormonal regulators of energy homeostasis (leptin, adiponectin, ghrelin) and cardiovascular risk factors occurring with this intervention.",,2008-01,COMPLETED,INTERVENTIONAL,['NA']
13480,NCT03162926,Incidence of all adverse events reported for subjects,,,2017-07-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13481,NCT02265276,Change in the NAFLD fibrosis score,Change in HbA1c,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
13482,NCT04439474,HBA1C,,,2018-10-10,COMPLETED,INTERVENTIONAL,['NA']
13483,NCT00214253,post-transplant islet function,Suitability of cadaver donor pancreases for islet transplantation,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13484,NCT00159679,Nerve conduction measurements; Pain scores from patient diaries,Proportion of patients with at least a 50% reduction in pain scores; Short-Form McGill Pain Questionnaire; Sleep interference scores from patient diaries; Clinical Global Impression of Change; Patient Global Impression of Change,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13485,NCT05980754,biochemical parameters including level of insulin,pancreatic fat content,,2024-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13486,NCT04407650,Glycaemic control,Biomedical neonatal outcomes,,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13487,NCT03685773,Endogenous glucose production (EGP),Change in Arterial Spin Labeling (ASL) signal,,2019-04-21,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13488,NCT00660790,Change of Intima Media Thickness (IMT),,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
13489,NCT01108263,Overall Decrease in Wound Size,Decreased Peak Plantar Pressures in Both the Static and Dynamic Phases of Gait as Compared to Pre-operative Pressure Values.,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE4']
13490,NCT04486547,Change from baseline social motivation level of adolescents at 6 months,,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
13491,NCT04336969,Change in rise of HbA1c,Change in education exposure to safe exercise strategies,"T1D Patients receiving 4T education and care monitored on a step-down cadence in study 2, will achieve an HBA1c non-inferior to weekly review",2020-06-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
13492,NCT00233298,"Differences in response among healthy, healthy obese, pre-diabetic or 3 diabetes",,,2005-05-26,COMPLETED,OBSERVATIONAL,['NA']
13493,NCT00605280,Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 Year,Number of Participants Requiring Focal or Grid Laser Treatment During Year 2,,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13494,NCT05188586,Specificity,Stage Shift,,2022-12-06,RECRUITING,INTERVENTIONAL,['NA']
13495,NCT03962010,Change in HbA1c,,,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13496,NCT04234334,Plasma Zeaxanthin,Plasma glucose,,2020-01-13,COMPLETED,INTERVENTIONAL,['NA']
13497,NCT05039307,Change from baseline in the adherence to a healthy lifestyle score at 12 months,Change from baseline in systolic and diastolic blood pressure at 12 months,,2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13498,NCT00179400,Whole body in vivo glucose turnover,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE4']
13499,NCT04547439,Melatonin and Cortisol Rhythm,,,2021-02-03,RECRUITING,INTERVENTIONAL,['PHASE2']
13500,NCT05443204,MFG discharge - hypoglycaemic events,Postprandial glucose intersticial monitoringdiabetes specific supplement,,2022-07-07,RECRUITING,INTERVENTIONAL,['NA']
13501,NCT03084900,HbA1c value,DKA,,2017-07-27,COMPLETED,INTERVENTIONAL,['NA']
13502,NCT00641719,Number of Participants Who Experienced an Adverse Event (AE),Change From Baseline to One Year Endpoint in Beck Depression Inventory-II (BDI-II) Total Score,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13503,NCT00726713,Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks,(Exploratory) Change From Baseline in Levels Potential Antioxidant (PAO) at Week 24,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13504,NCT04182451,Efficacy of Meso Wound Matrix,Health Economics,,2019-12-05,COMPLETED,INTERVENTIONAL,['NA']
13505,NCT03383627,Mean HbA1c,Determination of Serum Fructosamine,,2017-11-30,COMPLETED,INTERVENTIONAL,['NA']
13506,NCT01729299,post-prandial insulin secretion,gastric emptying,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
13507,NCT01890226,Change in Composite Quality Score,Change in Health-related Quality of Life,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
13508,NCT03513055,the relationship between SDBG and injection score,the relation between insulin antibodies and glucose excursions,,2018-05-07,UNKNOWN,INTERVENTIONAL,['NA']
13509,NCT05950477,"In 100 subjects with type 1 diabetes it will be evaluated the relationship between time in range, assessed though continuous glucose monitoring, and the score of the depression questionnaire CES-D",,,2023-06-12,RECRUITING,OBSERVATIONAL,['NA']
13510,NCT00173134,,,,2005-05,UNKNOWN,OBSERVATIONAL,['NA']
13511,NCT01514292,CGM Relative Differences to Laboratory Reference,,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
13512,NCT01079234,Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13513,NCT01590797,Number of Participants Discontinuing Study Medication Due to an AE,Change From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin,,2012-07-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13514,NCT05759897,Mean Change From Baseline in HbA1c at Week 16,"A summary of adverse events, including serious adverse events (SAEs), and Hypoglycemic Event[",,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13515,NCT00693537,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
13516,NCT00049907,,,,2002-09,COMPLETED,OBSERVATIONAL,['NA']
13517,NCT01431430,Patient death,Renal lithiasis,,2012-01-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13518,NCT02321878,Number of AEs (adverse events),Change in HbA1c (glycosylated haemoglobin),,2014-12-15,COMPLETED,OBSERVATIONAL,['NA']
13519,NCT05541484,Ketone levels measured in blood and breath in persons with T1D in persons with T1D,Ketone levels in persons with T1D during usual care versus usual care plus SGLT2i treatment,Ketone levels in persons with T1D undergoing insulin withdrawal,2022-10-14,RECRUITING,INTERVENTIONAL,['PHASE4']
13520,NCT01765517,effects of probiotics on endotoxin levels in patients with T2DM,effects of probiotics on gut microflora,Effects of probiotics on insulin resistance,2013-10,COMPLETED,INTERVENTIONAL,['NA']
13521,NCT01221194,Number of Participants Who Developed Foot Ulcer During Study Time Frame,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
13522,NCT03312582,Peri-implant prpbing depth,,,2015-03-15,COMPLETED,INTERVENTIONAL,['PHASE4']
13523,NCT05705271,Number of participants with hyperkalemia events,Change in urine albumin-to-creatinine ratio (UACR) from baseline to 4 months,,2023-02-08,RECRUITING,INTERVENTIONAL,['PHASE4']
13524,NCT05095922,Blood pressure,,,2023-03-28,RECRUITING,INTERVENTIONAL,['PHASE4']
13525,NCT03797885,"Proportion of type 2 diabetes mellitus (T2DM) patients with cardiovascular risk factors (CVRFs) and/or established cardiovascular disease (CVD), regardless the date of diagnosis",Type of pharmacological treatment,,2019-01-15,COMPLETED,OBSERVATIONAL,['NA']
13526,NCT00518167,Diabetes incidence,CVD incidence,,1993-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13527,NCT00873405,"Weight loss, BMI reduction and waist circumference reduction","Glucose homeostasis, metabolic control.",,2006-06,UNKNOWN,INTERVENTIONAL,['NA']
13528,NCT01565317,Change in Sural nerve conduction velocity,Change in Sural Nerve Amplitude potential,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
13529,NCT03634098,"To study in type 2 diabetic participants with liver biopsy, the performance of a composite biomarker (3rd generation test) for the diagnosis of NASH",Constitution of a bio-collection,,2018-10-25,COMPLETED,INTERVENTIONAL,['NA']
13530,NCT00237094,,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
13531,NCT00633763,Difference in fallypride binding in the pancreas of long-standing T1DM patients versus healthy controls,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
13532,NCT00839865,The primary objective is to determine the effect of this ointment on the incidence of complete wound closure.,"Secondary objectives include: evaluating the acceleration of ulcer closure or facilitation of surgical closure, reduction of ulcer surface area over time, reduction in complications, the quality of life and it's safety.",,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
13533,NCT00005146,,,,1979-05,COMPLETED,OBSERVATIONAL,['NA']
13534,NCT01823367,Changes in weight,Changes in diet,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
13535,NCT01572649,GLU-AUC 0:30-4:30h: area under the plasma glucose concentration time profile from time of the standardized breakfast start (30 min after IMP injection and pre-meal plasma glucose) until 4 hours later subtracting the pre-meal value,"Area under the concentration time profile from time of standardized breakfast start (30 min after IMP injection) until 4 hours later for insulin, C-peptide and glucagon",,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13536,NCT00431977,Cardiac death,All-caused death,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
13537,NCT03536364,Effect of food order on postprandial glucose excursions as measured by incremental area under the curve (iAUC) for glucose ((mg/dl)*180) in the setting of 3 commonly followed meal patterns in overweight/obese patients with pre-diabetes,Effect of food order on satiety as measured by a visual analog scale (cm) in the setting of 3 commonly followed meal patterns in overweight/obese patients with pre-diabetes,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
13538,NCT03815955,Positive and Negative Affect,,,2019-03-14,COMPLETED,INTERVENTIONAL,['NA']
13539,NCT04678557,Cohort 2: The Change in AUC (Area Under Curve) From Baseline to Week 26 in C-peptide During 4-hour MMTT,,,2019-06-25,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13540,NCT01020955,Insulin sensitivity,body composition,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13541,NCT01125553,Maximum observed serum insulin aspart concentration,Time to maximum observed serum insulin aspart concentration,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13542,NCT02362737,Change help-seeking behaviors (Medication adherence and doctor/ER visits).,Change HbA1c.,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
13543,NCT05597202,Difference in coronary 68Ga-Dotatate uptake after treatment.,Difference in bone marrow aspirates after treatment.,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
13544,NCT01886989,Blood pressure (mm Hg),Inflammation,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
13545,NCT05756829,Change from Baseline HbA1c at 6 months,,,2023-05-10,RECRUITING,INTERVENTIONAL,['NA']
13546,NCT00874159,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",,2009-04,COMPLETED,OBSERVATIONAL,['NA']
13547,NCT01045005,Doppler Blood flow velocity waveforms measured at rest and after administration of oxygen and carbon dioxide,Radial Artery pressure waveforms,,2006-01,WITHDRAWN,INTERVENTIONAL,['NA']
13548,NCT01965496,To assess HbA1C levels after 14 weeks continuous treatment,To assess Fasting blood glucose levels,To assess the body weights after the treatment,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13549,NCT03782649,Generation and validation of prediction models - Consensus Error Grid,Safety evaluation: paucity of adverse events,,2018-11-29,COMPLETED,INTERVENTIONAL,['NA']
13550,NCT05536804,Change from Baseline in Kidney Oxygenation in Participants With or Without T2D,Percent Change from Baseline in Urine Albumin-to-Creatine Ratio (UACR),,2023-02-08,RECRUITING,INTERVENTIONAL,['PHASE2']
13551,NCT03015220,Number of Treatment-emergent Adverse Events (TEAEs),Diabetes Therapy-Related Quality of Life (DTR-QoL): Total Score and Scores for the 4 Domains,,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13552,NCT05073302,Rate of inflammation in the DL implant site,Cellular composition demonstrated by immunohistochemistry,,2022-03-22,RECRUITING,INTERVENTIONAL,['PHASE1']
13553,NCT06241664,Sensitivity and Specificity,,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA']
13554,NCT02963766,Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26,PK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss],,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE3']
13555,NCT02036515,Percentage of Participants Discontinuing Study Treatment Due to an AE,Change From Baseline in EQ-5D-3L Score at Week 52,,2014-03-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13556,NCT02470806,Percentage Change in Ulcer Area From Baseline to the End of the Treatment Period,Percentage Change in Target Ulcer Depth and Volume Following Treatment With Either PICO or tNPWT From Baseline Over the 12-week Treatment Period,,2015-07-02,COMPLETED,INTERVENTIONAL,['NA']
13557,NCT01845831,Change in HbA1C,Hospital Mortality Rate,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13558,NCT05498688,Plasma fatty acid composition,Subjective appetite,,2022-08-25,RECRUITING,INTERVENTIONAL,['NA']
13559,NCT04977583,Connection to New Resources,Hemoglobin A1c (HbA1c),,2022-05-02,COMPLETED,INTERVENTIONAL,['NA']
13560,NCT02118714,Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26,Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Inhibin B,,2015-04-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13561,NCT04143737,Change in average daily steps- measured by Pedometer,Change in Leadership self-efficacy scale,,2016-03-07,COMPLETED,INTERVENTIONAL,['NA']
13562,NCT00687063,Weight change from baseline,Insulin dose and frequency at the end of the study,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
13563,NCT03101865,Time in target (3.9 to 10.0mmol/l) (70 to 180 mg/dl),AUC of glucose below 3.5mmol/l (63mg/dl),Percentage of time of CGM availability,2017-08-08,COMPLETED,INTERVENTIONAL,['NA']
13564,NCT01511692,The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10,Adverse events,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13565,NCT04090008,Percent reduction in the ulcer size,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13566,NCT02072902,Hazard ratios for all-site and site specific cancer,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
13567,NCT01869881,ACR(Urine Albumin/Creatinine ratio),PCR(Protein to Creatinine ratio in Urine),,2013-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13568,NCT00508014,"Mean change in blood pressure, glycated hemoglobin, and LDL-cholesterol between baseline and follow-up","Use of aspirin, ACE inhibiters/ARBs (diabetic patients), pneumonia vaccine updated, diabetic foot exam, diabetic microalbumuria check, retinal exam, smoking cessation counseling, dental visit, and self management goal",,2006-12,COMPLETED,INTERVENTIONAL,['NA']
13569,NCT06111508,Change in Time in Range,Frequency of Dose Changes,,2023-11-29,RECRUITING,INTERVENTIONAL,['NA']
13570,NCT02377362,Number of Participants With One or More Treatment Emergent Adverse Events (Parts B),Change From Baseline in Hip Circumference (Part B),,2015-03,TERMINATED,INTERVENTIONAL,['PHASE1']
13571,NCT00171561,Blood measures of hypertension after 24 weeks,Change in serum markers of endothelial function and oxidative stress after 24 weeks,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13572,NCT00324350,Number of Participants With at Least One Fall,Number of Participants With > 2 cm of Height Loss,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13573,NCT01246687,Change from Baseline in Dietary KAB Score at 12 months,Change from Baseline in blood biomarkers at 12 months,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
13574,NCT03364868,The development of diabetes,Abnormal glucose tolerance (AGT) defined by dysglycemia or diabetes.,,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13575,NCT01963546,Stress Indicators,Vital Signs,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
13576,NCT02206152,Difference in Epinephrine Secretion During the Morning Episodes of Hypoglycemia on Days One and Two Under the Two Treatment Conditions,,,2015-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13577,NCT03235908,Copeptin level,operational function (functioning) after 12 months compared to baseline assessed by questionnaire,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
13578,NCT05411965,Pharmacokinetic variables - Cmax,Pharmacokinetic variables - t1/2 of Pioglitazone M-IV,,2022-04-28,COMPLETED,INTERVENTIONAL,['PHASE1']
13579,NCT04501107,AUCLIS.0-1h,AUCGIR.4-8h,,2020-08-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13580,NCT03858062,Time in target,Glucose measurement performance,Glucagon dose,2019-03-10,COMPLETED,INTERVENTIONAL,['NA']
13581,NCT05319275,mTCNS total score change from baseline at week 24,Changes in Nerve Conduction Amplitude from baseline at week 24,,2020-07-23,COMPLETED,INTERVENTIONAL,['PHASE3']
13582,NCT01792635,Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B,Ra in Part B in PF-05175157 200 mg BID Group,,2012-12,TERMINATED,INTERVENTIONAL,['PHASE2']
13583,NCT03036774,Number of patients with full stomach,Intraoperative hypoxemia,,2017-02-14,COMPLETED,INTERVENTIONAL,['NA']
13584,NCT02665455,Point Accuracy Determined as % Within Consensus Error Grid Zone A,,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
13585,NCT06236581,Change from baseline on percent time in range from continuous glucose monitor at post-intervention,,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13586,NCT01580813,Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Peak VO2,Triglycerides,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
13587,NCT03476876,Wound Saturation of Oxygen at 16 Weeks,Number of Participants With Wound Complications at 16 Weeks,,2018-04-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13588,NCT04657939,Change in myocardial perfusion after treatment,Peripheral endothelial function,,2020-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13589,NCT03684642,Change From Baseline to Week 56 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,,2018-09-26,TERMINATED,INTERVENTIONAL,['PHASE3']
13590,NCT03360604,Change in cognitive performance on a Letter Memory Task,Fullness,,2018-04-04,COMPLETED,INTERVENTIONAL,['NA']
13591,NCT03060577,Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm),"Number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)",,2017-04-27,COMPLETED,INTERVENTIONAL,['PHASE2']
13592,NCT01167959,Changes in gut hormones,,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
13593,NCT00547027,weekly physical activity,physical activity stage of change,,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13594,NCT03849261,AUClast of Metformin,CL/F of Metformin,,2019-01-14,UNKNOWN,INTERVENTIONAL,['PHASE1']
13595,NCT02353273,"Pharmacokinetic parameters of Salvigenin and Asiaticoside A as listed below. (AUC0-∞, AUC0-t, Cmax)(Cmax,ss, AUC0-τ)","Pharmacokinetic parameters of Salvigenin and Asiaticoside A as listed below, if appropriate. (Tmax,ss)",,2015-07-22,COMPLETED,INTERVENTIONAL,['PHASE1']
13596,NCT00954577,"Reduction in diabetes risk factors including insulin secretory capacity, insulin sensitivity, body fat content, dyslipidemia, and circulating concentrations of pro-inflammatory cytokines.",Improvement in self-esteem and in health-related behaviors.,,2006-07,UNKNOWN,OBSERVATIONAL,['NA']
13597,NCT02935868,"Salivary peroxidase - collection of stimulated saliva in 10 minutes, measurement by a spectrophotometer.","Plaque index - measured by visual observation and classification in scores (1 for presence, 0 for absence)",,2013-11,COMPLETED,OBSERVATIONAL,['NA']
13598,NCT02052037,Glycemic Index,Physical Activity,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
13599,NCT00957957,Change from baseline in PYY (Peptide YY) measured by ELISA 4 weeks after RYGBP,Change from baseline in PYY measured by dMS 4 weeks after RYGBP,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
13600,NCT03076424,Intestinal Microbiome Composition,Hemoglobin A1-c,,2017-03-08,COMPLETED,OBSERVATIONAL,['NA']
13601,NCT02382536,In-line fluid pressure,Leakage,Number of subjects with adverse events,2014-08,COMPLETED,OBSERVATIONAL,['NA']
13602,NCT04023344,Antibody Response,Treatment Satisfaction,,2018-03-14,COMPLETED,INTERVENTIONAL,['PHASE3']
13603,NCT02917057,Changes from baseline in weight (kg),Frequency of Vomiting,,2015-08-01,COMPLETED,OBSERVATIONAL,['NA']
13604,NCT05369585,Evolution of energy metabolism (energy expenditure),"Evolution of metabolomics (amino acids, fatty acids and acylcarnitine species)",,2022-04-25,COMPLETED,INTERVENTIONAL,['NA']
13605,NCT06228313,VivaChek Ino glucose concentration,,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
13606,NCT02311504,presence of diabetic retinopathy,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
13607,NCT00449839,Absorbed Insulin Aspart,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13608,NCT01318070,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).,,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13609,NCT05335083,Mean 24 hour glucose difference between the CPAP on and CPAP off conditions,Insulin sensitivity,,2023-01-31,RECRUITING,INTERVENTIONAL,['NA']
13610,NCT04272359,Long-term diabetes complications,Insulin parameters after shift to new-generation hypoglycaemic therapeutic regimens,,2019-05-06,UNKNOWN,OBSERVATIONAL,['NA']
13611,NCT01067092,% of persons with blood pressure less than 130/80,Summary of Diabetes Self-Care Activities,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
13612,NCT03058029,Percent change in body weight,Change in HbA1c,Proportion of subjects with weight loss ≥7.5%,2017-02-22,UNKNOWN,INTERVENTIONAL,['NA']
13613,NCT01053936,To assess a trend in mean change from baseline to Day 29 in eGFR (as estimated by the 4-component MDRD formula) with increasing doses of bardoxolone methyl (amorphous dispersion) in patients with Type 2 diabetes and CKD (eGFR 15-45 mL/min/1.73m2).,To assess a trend in mean change from baseline to Day 85 in eGFR (as estimated by the 4-component MDRD formula with increasing doses of bardoxolone methyl (amorphous dispersion) in patients with Type 2 diabetes and CKD (eGFR 15-45 mL/min/1.73m2),,2010-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
13614,NCT02025751,"Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure",,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13615,NCT01171456,Effect of metformin versus placebo on the development of GDM,Effects on maternal and fetal pregnancy outcomes of pre-conception metabolic intervention with metformin.,,2010-04,WITHDRAWN,INTERVENTIONAL,['NA']
13616,NCT01911663,change from baseline in glucose,change from baseline in C-peptide,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13617,NCT00355849,"To compare in patients who at study entry have type 2 diabetes not optimally controlled by one or more oral antihyperglycemic medications plus once daily insulin glargine, a regimen that may include mealtime AIR Insulin.",To assess rate and incidence of hypoglycemia,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13618,NCT00935532,Change in HbA1c From Baseline to Endpoint (Week 26),Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13619,NCT00398060,Weight,"Blood pressure (diastolic, systolic)",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13620,NCT04922294,Implementation preferences,,,2020-07-20,COMPLETED,OBSERVATIONAL,['NA']
13621,NCT01956773,Number of Participants With Uptake of Genetic Counseling for Those at Risk of Hereditary Conditions at 1 Year,Number of Providers Who Were Successfully Using MeTree in Their Clinical Work Flow,,2014-04-11,COMPLETED,INTERVENTIONAL,['NA']
13622,NCT02687893,Mean duration of time with sensed glucose less than 70 mg/dl post-exercise,Mean duration of time with capillary blood glucose > 180 mg/dl,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
13623,NCT04984044,Change from baseline Michigan Neuropathy Screening Instrument (MNSI) scores at 8 weeks.,Change from baseline Serum 25(OH) D level at 8 weeks.,,2020-11-07,COMPLETED,INTERVENTIONAL,['NA']
13624,NCT01618045,Monocyte Function,Lipid Profile,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
13625,NCT04266054,Glycemic control as measured by hemoglobin A1c. Hemoglobin A1c will be measured from whole blood samples obtained and analyzed in a blinded fashion.,triglycerides will be measured from the same blood sample used to derive the outcome measure.,,2019-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13626,NCT02181621,Within-patient Change From Baseline in Log^10 Biofilm-protected Bacteria Count (Colony Forming Units [Cfu]/Gram[g]),Presence of Biofilm by Clinical Judgment Versus Presence of Biofilm by Laboratory Test,,2014-08,TERMINATED,INTERVENTIONAL,['NA']
13627,NCT00179374,Metabolic control (measured by HbA1c),Cost evaluations,,2003-07,COMPLETED,INTERVENTIONAL,['NA']
13628,NCT04706637,Change of 24 hour urine creatinine,Adverse events,,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13629,NCT01138124,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
13630,NCT03164187,Percentage of patients achieving HbA1c level ≤ 7 %,Mean daily dosage of Diabeton MR,,2016-09-01,COMPLETED,OBSERVATIONAL,['NA']
13631,NCT01912092,"Clinical signs of local infection (Presence of erythema, pain, tenderness, warmth or induration)",Wound surface area,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
13632,NCT05477368,To determine the feasibility of conducting such an RCT: Retention as measured by the number of participants that complete the study,Self-reported blood pressure (systolic and diastolic),Viability of methods,2022-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13633,NCT01123083,Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12,"Composite Rank Sum: C-Peptide AUC, HbA1c and Exogenous Insulin Use at 6 and 12 Months",,2010-05-17,COMPLETED,INTERVENTIONAL,['PHASE3']
13634,NCT01507389,Area under the Curve (0-infinity),Adverse events,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13635,NCT05393284,Improvement in Diabetic Retinopathy Severity Scale (DRSS) score,Safety and tolerability,,2022-08-16,RECRUITING,INTERVENTIONAL,['PHASE2']
13636,NCT00513201,Glycemic control in lyspro vs regular insulin in cirrhotic patients,Tolerance to treatment and reduced postprandial hypoglycemia episodes,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
13637,NCT01107717,Difference in HbA1c level,hypoglycemic events,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13638,NCT05260021,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline PedsQL (3.2) Diabetic Module,,2022-04-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13639,NCT04731142,Number of Participants With Hospital Admissions,Change in Systolic Blood Pressure,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
13640,NCT04018833,Functional change,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
13641,NCT01497535,Maximum glucose infusion rate (GIRmax),Adverse events,,2004-05-27,COMPLETED,INTERVENTIONAL,['PHASE1']
13642,NCT03062475,GDM,pre-eclampsia,,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA']
13643,NCT04051294,Insulin level,Blood pressure,,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
13644,NCT02594397,the score of GCSI,motilin concentrations,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
13645,NCT05026723,Bodyweight at Month 6,Diabetes Distress Score as assessed by PAID-11 at Month 18,C-Reactive Protein (CRP) at Month 6,2021-10-04,RECRUITING,INTERVENTIONAL,['NA']
13646,NCT05508061,Percentage of time the glucose level is above 10 mmol/l for the study participants,AP-related parameters: algorithm activity,,2022-10-19,COMPLETED,INTERVENTIONAL,['NA']
13647,NCT06091501,The between group differences for change in Perceived competence in Diabetes (PCS-5),The between group differences for change in physical activity,,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13648,NCT04746599,Pain reduction,Limb salvage,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
13649,NCT01778738,Beta-cell function,Vitamin and mineral deficiencies,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13650,NCT00823381,global skeletal muscle gene expression profile,safety and tolerability,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
13651,NCT00668850,"To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy","To evaluate the safety, tolerability, and satisfaction with Generex Oral-lyn™ therapy when administered by the RapidMist™ Diabetes Management System",,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
13652,NCT03945747,Change in estimated insulin sensitivity,Change in DXA scan,,2019-08-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13653,NCT01412554,Exploring Insulin Sensitivity After 10-20 Years of Follow-up,Ultrasound Abdomen,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
13654,NCT03844217,"Change in Copeptin value (pmol/l), after intake of Macimorelin of 0.5mg/kg body weight",Change in Follicle-stimulating hormone value(FSH) (IU/mL),,2019-03-07,COMPLETED,INTERVENTIONAL,['NA']
13655,NCT02762578,Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin),Device Specific Questionnaires II (Would You Recommend the Pen?),,2016-05-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13656,NCT04789148,Dot-probe task - anxious behavior between low dose oxytocin and placebo,Socioemotional functioning - Emotion recognition task between all three interventions,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
13657,NCT04627636,- Visual analogue scale for pain (VAS-P) for pain assessment,,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
13658,NCT04621396,Type 2 Diabetes,,,2013-09,RECRUITING,OBSERVATIONAL,['NA']
13659,NCT01301339,Do Air Force personnel who fail the Air Force physical fitness test have a higher incidence of pre-diabetes than those who pass the test?,"And for those who fail, do they have higher cardiovascular risks as correlated with fasting lipid panel.",,2011-07,COMPLETED,OBSERVATIONAL,['NA']
13660,NCT00144937,Lowering of LDL cholesterol concentrations and blood pressure levels (at 12 months). Increase in use of antiplatelet agents (at 12 months),All the above-mentioned primary and secondary outcomes will be evaluated at 12 months,,2003-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
13661,NCT03528174,Mean Absolute Relative Difference of Sensed Glucose Values,Mean Draize Scale for Erythema for the Right Sensing Cannula at End of Study for All Subjects,,2018-04-16,COMPLETED,INTERVENTIONAL,['NA']
13662,NCT03724981,Participant Preference Between 2 Injection Devices Based on Global Preference Item,Participant Preference Between 2 Injection Devices Based on Ease of Use,,2018-10-18,COMPLETED,INTERVENTIONAL,['PHASE4']
13663,NCT03482596,Glucose incremental Area Under the Curve (iAUC),Intervention perception,,2018-02-21,COMPLETED,INTERVENTIONAL,['NA']
13664,NCT05765097,TIR,mean BG,,2022-09-28,COMPLETED,INTERVENTIONAL,['NA']
13665,NCT02062034,Oxidative Stress markers,Progression and regression of non-proliferative diabetic retinopathy,Security profile,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13666,NCT03300934,Time spent in glucose target (%) (3.9 - 10 mmol/l),User experience after the 4 week treatment,,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
13667,NCT00501397,"urine collections for volume, glucose, & creatinine at Day 1 Session 1, Days 5 & 6 Session 3.","Vitals: Screening,Days -1 & 1 Session 1,Days 1-4 Session 2,Days 5-6 Session 3,followup",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13668,NCT00403195,,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
13669,NCT03240874,Number of Participants Who Used the SweetMama Application,Difference in Hemoglobin A1c From Enrollment to Delivery,Clinical Outcomes of Pregnancy - Number of Babies With Neonatal Intensive Care Unit Admission,2017-08-02,COMPLETED,INTERVENTIONAL,['NA']
13670,NCT01234727,,,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
13671,NCT05104333,Neutralizing antibody level,Adverse events following vaccination,,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
13672,NCT03931759,The measurement of heart rate variability in laparoscopic surgeries,,,2019-06,UNKNOWN,INTERVENTIONAL,['NA']
13673,NCT01845324,width of fetal interventricula heart septum,glucose control in patients with normal and abnormal interventricular septal width,,2013-05,UNKNOWN,OBSERVATIONAL,['NA']
13674,NCT04653207,Change in postprandial blood glucose over 180 minutes period,Change in postprandial plasma insulin over 180 minutes period,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
13675,NCT00940082,"the gender, height, weight, blood pressure, course of the disease of each patient was recorded","Left ventricular mass index (LVMI), relative wall thickness (RWT) were calculated and High-sensitive C-reactive protein (HsCRP), homocysteine and TNF-α were detected",,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
13676,NCT00704574,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Variability in FPG (Fasting Plasma Glucose),,2008-01,COMPLETED,OBSERVATIONAL,['NA']
13677,NCT05977205,Glycemic control,Fear of COVID-19 infection,,2020-05-02,COMPLETED,OBSERVATIONAL,['NA']
13678,NCT01336023,Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.,Mean Actual Daily Insulin Dose,,2011-05-23,COMPLETED,INTERVENTIONAL,['PHASE3']
13679,NCT00674466,Reduction of HbA1c From Baseline,Reduction in Fasting Body Weight From Baseline,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
13680,NCT01030471,Diabetes-Related Family Conflict Scale (DFCS)-Measure of family conflict around diabetes-specific tasks,Hemoglobin A1c value,,2009-09,WITHDRAWN,INTERVENTIONAL,['NA']
13681,NCT05390307,Weight,Weight change,,2023-04-01,COMPLETED,INTERVENTIONAL,['NA']
13682,NCT01563120,glycemic control,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13683,NCT04811989,General foot health,Representations about diabetic foot,Sociodemographic data,2021-03-08,COMPLETED,INTERVENTIONAL,['NA']
13684,NCT04860908,Presence of anti COVID 19 antibodies in maternal and cord blood,,,2021-04-26,UNKNOWN,OBSERVATIONAL,['NA']
13685,NCT01529385,Microcirculation for Dorsum of Foot,Physical Activity Level,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
13686,NCT01758471,euglycemia,,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
13687,NCT03396484,DQ8 Antigen Presentation,,,2020-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13688,NCT05166512,Change from baseline in body weight (kilograms (kg) and percent of baseline bodyweight),Change from baseline in food security status over the past 30 days using the 10-item United States Department of Agriculture (USDA) adult food security survey module,Program satisfaction among DPP Cooks participants (qualitative),2022-02-02,COMPLETED,INTERVENTIONAL,['NA']
13689,NCT03258281,Change From Baseline in Adenosine Diphosphate (ADP) Stimulated P-selectin Expression,Change in ADP-stimulated Cluster of Differentiation (CD)-147 MFI,,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
13690,NCT03367390,Number of Participants Who Show a Resumption of Auto Mode Following Restored Continuous Glucose Monitoring (CGM) Connectivity,,,2017-11-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13691,NCT06066801,the remission of DFO,Incremental cost effectiveness ratio,,2024-03-14,RECRUITING,INTERVENTIONAL,['NA']
13692,NCT02473809,Change in collagen I cross-linked C-terminal telopeptide measured in serum,Change in procollagen type I N-terminal propeptide measured in serum,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13693,NCT00043797,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2']
13694,NCT02068443,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) National Glycohemoglobin Standardization Program (NGSP) at the End of Treatment (EOT) Period,Number of Participants Who Had Clinically Relevant Changes in 12-Lead Electrocardiogram (ECG) Findings,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13695,NCT02554851,The proportion of participants with 100% healing at the end of follow-up,,,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13696,NCT05730634,DOTATATE coronary arteries,Change in splenic/bone marrow DOTATATE signal,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
13697,NCT03523143,TESGO composite outcome,The growth and development of the offspring,,2018-06-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13698,NCT00264914,"Safety : Physical examination, vital signs, adverse events, electrocardiogram, hematology, serum chemistry",Serum sodium,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13699,NCT01876849,"Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.",,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13700,NCT03078049,Total costs,Index medication dose increase,,2017-03-31,COMPLETED,OBSERVATIONAL,['NA']
13701,NCT00985257,Percent of Blood Glucose (BG) Results Within +/-15mg/dL or +/-20% of Laboratory Glucose Method,,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
13702,NCT04120571,Blood glucose (CGM),Blood glucose (OGTT),,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
13703,NCT05403853,Performance of the LumiraDx POC HbA1c assay when compared to a current CE marked reference method in patients being assessed for diagnosis or monitored for diabetes.,,,2022-04-19,COMPLETED,INTERVENTIONAL,['NA']
13704,NCT00687479,Insulin action measures,infant gestational age,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
13705,NCT00353561,Mycological cure on the 15th day of therapy and defined as the absence of Candida growth on fungal culture of high vaginal swab,"Relief in clinical symptoms and signs of vulvovaginal candidiasis including vaginal discharge, pruritus, burning sensation and vaginal congestion",,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13706,NCT01977417,Aim 1: Vascular Endothelial Function in Obese Prediabetic Adults Before and After 1 Month of Salsalate or Placebo.,,,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2']
13707,NCT00829569,insulin sensitivity,oxidative stress,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
13708,NCT01836796,HbA1c,Urine albumine excretion rate,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
13709,NCT00805922,Mean blood glucose parameters of diabetic patients,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2008-12,COMPLETED,OBSERVATIONAL,['NA']
13710,NCT06055829,Glucose level,,,2022-10-24,COMPLETED,OBSERVATIONAL,['NA']
13711,NCT05168306,Difference in bodyweight from the control arm at 6 months,,,2021-12-05,TERMINATED,INTERVENTIONAL,['NA']
13712,NCT04387045,Salivary Tumor Necrosis Factor alpha,Depression,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
13713,NCT03958539,The incidence of new ulcer in patients with high-risk diabetic feet is our primary outcome measure,Need for debridement of callus,,2019-08-05,UNKNOWN,INTERVENTIONAL,['NA']
13714,NCT05719961,Time to maximum concentration （Part II）,Incidence and severity of adverse events (AEs)（Part II）,,2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE1']
13715,NCT01999218,Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104,Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach,,2013-12-16,COMPLETED,INTERVENTIONAL,['PHASE3']
13716,NCT01090752,Effects of Pioglitazone on 24h Blood Pressure Control,Effects of Pioglitazone on Salt Sensitivity,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
13717,NCT00599040,Insulin Sensitivity,,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13718,NCT05244200,Fasting plasma glucose (FPG),Body Weight.,,2022-01-20,UNKNOWN,INTERVENTIONAL,['NA']
13719,NCT01511185,AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval,Adverse events,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13720,NCT05232708,"Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of s.c. semaglutide 0.5 mg administration",,,2022-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
13721,NCT01858597,The Concentration of Serum FGF19,Expression of FGF19 in Term Placenta,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13722,NCT03814694,Change in glycated hemoglobin (HbA1c) during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.,Change in fasting plasma triglycerides during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.,Change in health-related quality of life (HRQoL) after 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.,2019-01-29,COMPLETED,INTERVENTIONAL,['NA']
13723,NCT02806973,PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax),,PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Glucagon,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13724,NCT01229891,Serum 25-hydroxyvitamin D,Serum High Density Lipoprotein (HDL),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13725,NCT00245206,"Change in LDL cholesterol, HDL cholesterol, and triglycerides",,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13726,NCT05712720,Change in Central Subfield Thickness,Repeat-dose AUC of RZ402,,2023-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13727,NCT02984709,Glycemic Control (A1C),Self Care Inventory,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
13728,NCT02447185,intraoperative bleeding,the change of inflammatory factors in vitreous body,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
13729,NCT01396772,Average number of vegetable and fruit servings consumed per day,average number of physical activity minutes per day,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
13730,NCT06188481,Change from baseline in HbA1c in %,Change from baseline in well-being,,2024-01-23,RECRUITING,INTERVENTIONAL,['NA']
13731,NCT02630524,Adherence to prescribed macronutrient composition as measured by multiple pass 24 hour dietary recall,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
13732,NCT02914730,Number of Missed Insulin Doses,,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
13733,NCT03554590,glycemic control,glucose variability: incidence of hypoglycaemia,,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
13734,NCT03284216,Exercise-induced change in blood glucose control.,Hyperglycemia-induced change in cognitive function.,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13735,NCT01452815,Change from baseline in symptoms associated with diabetic gastroparesis,Clinical Chemistry and Hematology Parameters,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13736,NCT04374864,Area under the curve,,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13737,NCT02830113,Insulin sensitivity,Inflammation,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
13738,NCT06019624,Change in Food Security,Change in Emergency Room Utilization,,2023-09-13,RECRUITING,INTERVENTIONAL,['NA']
13739,NCT01322256,The difference between AUCs for PET/CT scan and scintigraphy,,,2012-10,TERMINATED,INTERVENTIONAL,['NA']
13740,NCT05761301,Part B: Frequency of Adverse Events,Part B: Plasma Concentrations of ALN-KHK and Potential Major Metabolite(s),,2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13741,NCT00194805,glycosylated hemoglobin (A1C) levels.,"Study participants who receive the web-based telehealth intervention will have fewer depression symptoms and higher quality of life, social support, at the 12 month (long-term) follow-up than participants in the control group.",,2003-09,COMPLETED,INTERVENTIONAL,['NA']
13742,NCT05261841,Change from Baseline HbA1c at 6 and 12 months,,,2021-06-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13743,NCT04862858,"Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, excluding combination products, based on administrative claims data","Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, including combination products, based on administrative claims data",,2021-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13744,NCT00400491,glycated hemoglobin,insulin sensitivity,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13745,NCT06010433,Primary Outcomes,Secondary Outcome,,2023-09-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13746,NCT04511312,Days at Home at 30 Days after surgery (DAH-30),Quality of Recovery QoR-15 measuring quality of recovery on Day 1 only,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
13747,NCT04057248,HbA1C Value at 3 Months From Subject Start of Study Compared to Baseline,Triglycerides Value at 3 Months From Subject Start of Study,,2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
13748,NCT04523064,Acute kidney injury,Myocardial Infarction Type 5,,2020-09-22,RECRUITING,INTERVENTIONAL,['PHASE4']
13749,NCT03188757,prolonged reaction time,,,2017-07-13,COMPLETED,INTERVENTIONAL,['NA']
13750,NCT03340311,Glucose log completeness,Patient satisfaction,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
13751,NCT04831723,Normal range of capillary blood glucose in newborns at day 5 of life,Validation of laboratory procedures,,2021-07-09,COMPLETED,OBSERVATIONAL,['NA']
13752,NCT06124560,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2022-10-28,COMPLETED,INTERVENTIONAL,['PHASE1']
13753,NCT05949320,Eating Behaviour Questionnaire from the EatSmart Restaurant Star+ Campaign,,,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
13754,NCT00756041,Weight.,"Change from Baseline in quality of life index as assessed by the Short-Form, 36-Item Health Survey.",,2005-09,TERMINATED,INTERVENTIONAL,['PHASE2']
13755,NCT01865305,Maximum glucose infusion rate divided by the average glucose infusion rate (for subjects with type 2 diabetes),Area under the serum insulin degludec concentration curve,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13756,NCT02407899,Absolute changes from baseline in Fasting C-peptide levels at week 104.,"Absolute changes of body weight and BMI level from baseline and at week 26, 52, 78 and 104.",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13757,NCT01788033,C-peptide level,Number of Adverse Events,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13758,NCT04533152,DFU risk score,Survival without major microvascular events (MICE),,2021-11-24,RECRUITING,OBSERVATIONAL,['NA']
13759,NCT03022344,Progression of contrast enhanced cardiac CT in relation to baseline and follow-up cardiovascular risk factors and biomarkers.,Blood pressure (mmHg),,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
13760,NCT05355285,Change in anterior cingulate cortex glutamate concentration from Baseline Euglycemia to Hyperglycemia,Change in plasma insulin concentration from Baseline Euglycemia to Hyperinsulinemic Euglycemia,Self Referential Emotional Task (SRET) response time,2011-01,COMPLETED,INTERVENTIONAL,['NA']
13761,NCT01365013,Incidence of Diabetes,Implementation of the program,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13762,NCT01297049,Blood glucose control with changes in Glycated hemoglobin (HbA1c) values,Audit of Diabetes Dependence Quality of Life (ADDQoL-19),,2010-04,COMPLETED,INTERVENTIONAL,['NA']
13763,NCT00564070,Depression on the CGI at Acute Outcome,Glucose Control,Glucose Control Over Follow up,2007-06,COMPLETED,INTERVENTIONAL,['NA']
13764,NCT03925714,Number of patients with improved insulin resistance,,,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3']
13765,NCT06033872,a. To compare the first incidence rate of hypoglycemia or severe hypoglycemia between intervention and control groups in Ramadan,"Healthcare utilizations costs - Medical services, drugs and devices utilized, outpatient and inpatient visits, cost of intervention sessions, telemonitoring and equipment, indirect costs related to health care utilisation, and caregiver costs.",,2021-01-25,COMPLETED,INTERVENTIONAL,['NA']
13766,NCT05092945,Brown Adipose Tissue (BAT) Glucose uptake,Changes in insulin level and secretion,,2021-05-18,RECRUITING,INTERVENTIONAL,['NA']
13767,NCT03553524,Compare the efficacy of the morning and afternoon HIIT in lowering blood glucose values in participants with type 2 diabetes.,Respiratory exchange ratio (RER),,2021-10-30,WITHDRAWN,INTERVENTIONAL,['NA']
13768,NCT03878277,Renal Perfusion,Tubular Injury Markers,,2019-07-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13769,NCT01693510,Gestational weight gain within IOM guidelines,Bone outcomes,,2012-11-12,COMPLETED,INTERVENTIONAL,['NA']
13770,NCT05261867,"Composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE).",Any coronary revascularization,,2017-01,RECRUITING,OBSERVATIONAL,['NA']
13771,NCT00426920,AUC,AUC,,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
13772,NCT01521624,Serum concentrations of various markers of oxidative stress,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
13773,NCT02571608,Recruitment rate,Length of Hospital Stay,,2022-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
13774,NCT01143714,Change in Wound Area,Number of Sharp Debridements Performed During the 4-week Treatment Phase and the 8-week Follow-up Period (12 Weeks Total),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13775,NCT05874323,correlation of RAGE gene polymorphism rs1800625 with the incidence of type I diabetes,"the relation between MiRNA-34, MiRNA-146, to TID severity and activity.",,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
13776,NCT00837122,A,,,2009-02-03,RECRUITING,OBSERVATIONAL,['NA']
13777,NCT02131961,Proportion of contact cast systems intact by day 14,,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13778,NCT01270633,Percent of study ulcers healed,Cost of Treatment,,2010-12,TERMINATED,INTERVENTIONAL,['NA']
13779,NCT02036528,Complete wound clearing of infection,DFU Area % Change,,2014-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13780,NCT05628168,Effect of Neurodynamic Mobilization Techniques in Patients With Diabetic Neuropathy,,,2021-12-05,COMPLETED,INTERVENTIONAL,['NA']
13781,NCT02194608,Change from baseline in body mass index,Number of severe/symptomatic hypoglycemic episodes,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
13782,NCT02786823,HbA1c,Serum C reactive protein (CRP),,2017-05-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13783,NCT01914146,1. Presence or absence of orthostatic hypotension,3. The nadir of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during tilt table test.,,2015-04,WITHDRAWN,INTERVENTIONAL,['NA']
13784,NCT00497198,Change From Baseline in Hemoglobin A1c(HbA1c) at Week 12,Change From Baseline in Low Density Lipoprotein Cholesterol(LDL-c) at Week 12,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13785,NCT03154398,the percentage of patients progress to advanced diabetic nephropathy,,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
13786,NCT05086445,Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Body Weight,,2021-11-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13787,NCT05540704,Feasibility as measured by participant attrition less than 20%,Change in NIH PROMIS Scale - Anxiety,,2023-04-04,RECRUITING,INTERVENTIONAL,['NA']
13788,NCT01625507,Change in Nutrient Intake,Change in Waist Circumference,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13789,NCT05766449,"Risk factors of chronic hepatitis B patients with non-alcoholic fatty liver disease progressing to cirrhosis, liver cancer or liver failure","Incidence of cirrhosis, cancer and liver failure in patients with chronic hepatitis B and non-alcoholic fatty liver disease",,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
13790,NCT01159600,HbA1c Change From Baseline,Mean Daily Plasma Glucose (MDG) Change From Baseline,Confirmed Hypoglycaemic Adverse Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13791,NCT02371759,Electrocardiogram at 20 Minutes,Local Postoperative Complications,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13792,NCT03175315,Changes in Glycemic Control Measured by A1c,Depressive symptoms,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
13793,NCT01062529,Plasma levels of glucose,Serum levels of free fatty acids (FFA),,2009-10,COMPLETED,INTERVENTIONAL,['NA']
13794,NCT04624672,RATE OF PARTIAL REMISSION OF DIABETES,RATE OF COMPLETE REMISSION OF DIABETES,,2021-08-25,TERMINATED,INTERVENTIONAL,['PHASE4']
13795,NCT01933672,Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 14,Plasma PF-04937319 Time for Cmax (Tmax) on Day 14,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13796,NCT05272670,Foot Care Self-Efficacy Scale,Health promotion satisfaction,,2022-02-15,RECRUITING,INTERVENTIONAL,['NA']
13797,NCT02720393,Change in hemoglobin A1c,Change in insulin signaling pathway,Change in fecal calprotectin,2016-02,COMPLETED,INTERVENTIONAL,['NA']
13798,NCT00207389,GIP area under the curve after OGTT,Other GI peptides and hormones after OGTT,,2004-03,TERMINATED,OBSERVATIONAL,['NA']
13799,NCT02612493,Insulin dosage,Change in lipids,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
13800,NCT00330265,Percent of subjects achieving complete or (100%) study wound closure by week 12 after initial treatment,,,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13801,NCT01143870,Change in Percent of Glycosylated Hemoglobin 6 Months Following Enrollment,Change in Hemoglobin A1C Over 12 Months From Enrollment,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
13802,NCT03157414,Weighted mean glucose,Renal function,Urinary glucose excretion,2016-11-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13803,NCT01474525,"Mean blood glucose, based on the highest post-prandial blood glucose reading for each day, by trimester","Provider usage: number of logins onto the system, average amount of time spent on the system per week",,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
13804,NCT03071068,"Incidence of acute (up to the 7-day follow-up visit) ocular (serious) adverse events ([S]AEs) in the study eye, after each injection and across injections per subject","Mean change from baseline in CST, by study visit, based on spectral domain optical coherence tomography (SD-OCT), as assessed by the central reading centre (CRC)",,2016-12-22,COMPLETED,INTERVENTIONAL,['PHASE2']
13805,NCT00972322,Number of Participants Discontinuing Study Drug Due to an AE,,,2009-08-24,COMPLETED,INTERVENTIONAL,['PHASE1']
13806,NCT01869348,Change in Physical Activity From Baseline to 12 Weeks,Change in Weight From Baseline to 12 Weeks,Acceptability,2014-06,COMPLETED,INTERVENTIONAL,['NA']
13807,NCT03671161,Number of ketoacidosis episodes,Any changes in Weight,,2016-01-01,COMPLETED,INTERVENTIONAL,['NA']
13808,NCT00467246,Reduction of recurrence of ketoacidosis and hyperglycaemia.,To investigate time to treatment in patients presenting with a hyperglycaemic emergency,,na,WITHDRAWN,INTERVENTIONAL,['NA']
13809,NCT00627146,"The difference in change in daily insulin need between baseline and month 48, between placebo and ChAgly CD3 treated patients",,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13810,NCT01608607,Body weight,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
13811,NCT02345239,Mean post-prandial glucose excursion,Postprandial glucose excursion,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
13812,NCT03936010,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
13813,NCT01513798,Fat mass,Substrate utilization during submaximal exercise,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
13814,NCT05488197,Uterine artery Doppler ultrasonography in gestational diabetes mellitus,Prediction of GDM with uterine artery pulsatility index cut-offs,,2021-06-10,COMPLETED,OBSERVATIONAL,['NA']
13815,NCT03424044,Percent of Time With Sensed Glucose < 70 mg/dl,Mean Amount of Glucagon Delivered in One Day,,2018-03-29,COMPLETED,INTERVENTIONAL,['PHASE1']
13816,NCT02151695,Percentage of patients with regression of retinal neovascularization between baseline and 12th month.,,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13817,NCT02620332,Assessment of MultiPepT1De safety profile,Assessment of T lymphocyte immune response to islet cell antigens,,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE1']
13818,NCT03665870,Fear of Hypoglycemia,Knowledge of Diabetes,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
13819,NCT00787475,HgA1C level,Measurement of systolic blood pressure,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
13820,NCT05204706,Number of women withdrawn or loss to follow up,Number of women randomised,Length of stay at the hospital ward,2022-01-24,RECRUITING,INTERVENTIONAL,['NA']
13821,NCT01511172,Fasting plasma/serum glucose,Other adverse events,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13822,NCT04474795,Staff - Self-efficacy to Provide Diabetes Education Questionnaire (Newly Developed),Staff - Intention to Recommend Diabetes Prevention Activities Questionnaire (Newly Developed),Staff-Provider Teaching Motivation Questionnaire Intrinsic Motivation Subscale,2020-06-18,COMPLETED,INTERVENTIONAL,['NA']
13823,NCT04858854,Fasting serum glucose,Fasting insulin,,2021-10-10,COMPLETED,INTERVENTIONAL,['NA']
13824,NCT00563043,changes in ERG implicit time,,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
13825,NCT01364675,Cardiovascular Events,Incidence of Individual Cardiovascular Disease,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
13826,NCT00615121,Discover novel gene expression pattern in peripheral arterial disease,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
13827,NCT05226897,HbA1c,C-peptide,,2021-07-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13828,NCT03438617,Change from Baseline HbA1c at 12 and 18 months,Change from Baseline Depression at 12 and 18 months,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
13829,NCT04452331,Contextualization of Care,hospital admission rate,,2021-10-05,RECRUITING,INTERVENTIONAL,['NA']
13830,NCT03182712,Changes on hs-CRP (High-sensitivity C reactive protein),Changes on Total Antioxidant activity,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
13831,NCT00614341,Pain reduction in diabetic patients with chronic diabetic neuropathy,Improvement in sensation and overall foot condition,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13832,NCT06240910,Berge balance scale,Functional reach test,Michigan neuropathy screening instrument questionnaire,2023-07-17,RECRUITING,INTERVENTIONAL,['NA']
13833,NCT01157611,change of the blood glucose,satisfaction score,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
13834,NCT00982228,Extension Trial (Primary Endpoint): Cross-reacting Antibodies to Human Insulin,Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52,,2009-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13835,NCT01970046,Change From Baseline in HbA1c (Hemoglobin A1C) at Week24,"Change From Baseline in Body Weight at Week 4,8,12、24、38、52",,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
13836,NCT00993018,Average pain intensity,Number of patients with adverse events,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2']
13837,NCT03403283,Increase in acid sphingomyelinase (ASM) expression and activity in bone marrow-derived endothelial progenitor cells (EPCs),,,2014-01,RECRUITING,OBSERVATIONAL,['NA']
13838,NCT05110846,Change in hemoglobin A1c (HbA1c),Fasting plasma glucose,,2022-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
13839,NCT04509245,Change in insulin sensitivity,Change in öiver fat,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
13840,NCT00574808,Quality of care process index = ∑ of recommended services received by patient/ ∑ of the recommended services for which the patient was eligible,Quality of care outcome index = ∑ of recommended targets reached / ∑ of the number of targets for which the patient is eligible based on the number of conditions suffered by the patient,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
13841,NCT00792662,Hemoglobin A1C as a Marker for Glycemic Control,Instrumental Activities of Daily Living (IADL) Scale,,2008-11-18,WITHDRAWN,INTERVENTIONAL,['PHASE4']
13842,NCT00910780,Changes in per cent of body fat,Psychiatric safety and tolerability,,2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13843,NCT05095038,Fasting blood glucose,Change in subjective assessment of investigational product,,2022-02-10,TERMINATED,INTERVENTIONAL,['NA']
13844,NCT06060483,major adverse cardiovascular events,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13845,NCT00965549,Glycosylated Haemoglobin (HbA1c),"Hypoglycaemia (total, severe and nocturnal)",,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13846,NCT00958711,Bacterial Burden,Ease of Dressing Use,,2009-01,TERMINATED,INTERVENTIONAL,['NA']
13847,NCT00381186,insulin resistance,exercise change,,1999-02,COMPLETED,INTERVENTIONAL,['NA']
13848,NCT03202563,Changes from baseline MAGE(Mean amplitude of glycemic excursion) at week 12,Changes from baseline Nitrotyrosine at week 12,Changes of baseline Body weight at week 13,2017-08-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13849,NCT03228732,Change in the level of catecholamines in plasma,,,2017-12-19,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13850,NCT03782805,Change from Baseline TNF-alpha at 6 months,Change from Baseline Parathyroid hormone (PTH) at 6 months,,2018-05-09,COMPLETED,INTERVENTIONAL,['NA']
13851,NCT04550806,Area under the curve of GA combined with body composition for GDM diagnosis,GDM prediction model establishment,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
13852,NCT02322554,Healing,,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
13853,NCT00099957,Postprandial serum total triglycerides at 4 weeks,Postprandial apo B-48 and apo B-100 in the two lipoprotein fractions - chylomicrons and VLDL1+VLDL2+IDL (VLDL/IDL) at 4 weeks,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13854,NCT00849849,Determine best way to assess glucose disorder prevalence in women with prior GDM,"Investigate if cardiometabolic markers-lipid profile and blood pressure anthropometric markers such as BMI [BMI, absolute body weight]; visceral adiposity as assessed by abdominal girth are associated with an increased diabetes risk",,2011-07,COMPLETED,OBSERVATIONAL,['NA']
13855,NCT03563638,Serum PTX3 levels in early pregnancy,,,2015-10-01,COMPLETED,OBSERVATIONAL,['NA']
13856,NCT04258904,Incidence of dermatological complications,Trans Epidermal Water Loss (TEWL):,,2020-03-10,COMPLETED,INTERVENTIONAL,['NA']
13857,NCT02478554,Detection of fetal growth abnormalities,,,2015-08,WITHDRAWN,INTERVENTIONAL,['NA']
13858,NCT01889277,Plasma concentrations of MT-3995 and its major metabolite,Change from baseline in Urine albumin-to-creatinine ratio (UACR) and blood pressure,,2013-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13859,NCT05539066,Compliance rate of BMI (Body Mass Index),Incidence of hypoglycemia,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13860,NCT05132725,TTG-IgA,BMI,,2021-11-15,UNKNOWN,INTERVENTIONAL,['NA']
13861,NCT04192422,Neonatal sensor glucose time in target,,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
13862,NCT03025607,Change in Autonomous Motivation to Prevent T2DM,Change in psychosocial measures,,2017-05-03,COMPLETED,INTERVENTIONAL,['NA']
13863,NCT01349855,"Safety in terms of adverse and serious adverse events, vital signs, ECG, safety laboratory",Pharmacokinetic parameter : AUC,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13864,NCT00786487,Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
13865,NCT03371355,Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point,Number of Participants With Treatment-emergent Adverse Events (TEAEs),,2017-12-21,COMPLETED,INTERVENTIONAL,['PHASE2']
13866,NCT01947036,Identify shared defects in T and B cell function by disease classification,,,2014-01,TERMINATED,OBSERVATIONAL,['NA']
13867,NCT01768208,The primary objective of the study is to evaluate the changes in the metabolomic parameters before and after Saxagliptin treatment in type 2 diabetic patients.,,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
13868,NCT02019186,endothelial function,Endothelial progenitor cells,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
13869,NCT00406458,"Visual analog scale for pain intensity (VASPI), Nerve Conduction Velocity (NCV), Total Neuropathy Score (TNS), Epidermal Nerve Fiber Density (ENFD) & Epidermal Nerve Fiber Density Regeneration (ENFDR)",Safety,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13870,NCT00328536,"Postprandial (2, 4 and 6 hours) flow-mediated vasodilation after a 6-week treatment with Omacor",Baseline flow-mediated vasodilation after a 6-week treatment with Omacor,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13871,NCT00886392,"Thickening measured by optical coherence tomography in 3 zones: central subfield (when field 1 was thickened), inner ring (when any of fields 2, 3, 4 or 5 was thickened), and inner ring or outer ring (when any of fields 6, 7, 8, or 9 was thickened)","Severity level: adaptation of International clinical diabetic macular edema severity scale to fields of the OCT; mild if thickening exclusively involved outer-ring, moderate if was in inner-ring without involvement field 1, and severe if was in field 1",,2006-06,COMPLETED,OBSERVATIONAL,['NA']
13872,NCT01813929,Flow-mediated Brachial Artery Dilation,Cardiac Function,Mitochondrial Oxidant Generation,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13873,NCT00965510,"Scores on PHQ9, PAM and health indicators",Satisfaction with care coordination model.,,2009-09,TERMINATED,INTERVENTIONAL,['NA']
13874,NCT00961207,Reduction in albuminuria/proteinuria,"Safety of Triple RAAS inhibition with ACE-I, ARB and DRI",,2009-08,TERMINATED,INTERVENTIONAL,['PHASE4']
13875,NCT03504566,Strongest albuminuria-lowering effect.,Effect on glycocalyx.,,2017-11-15,WITHDRAWN,INTERVENTIONAL,['PHASE4']
13876,NCT06097351,Statistical analysis and target gene prediction of misexpressed mirnas and enrichment pathway analysis,,,2020-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13877,NCT06089655,The change of blood glucose level from diet consulting,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
13878,NCT01153048,"compare the improvement of HbA1c 1 year after an intervention led by peer educators, versus a conventional care in health centre","Study the evolution of bio clinical parameters: fasting glucose, weight, BMI, blood pressure, waist size",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13879,NCT04184440,changes of OGTT,changes of short chain fatty acids,,2020-03,UNKNOWN,INTERVENTIONAL,['NA']
13880,NCT04712266,hyperglycemic excursions,,,2020-09-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13881,NCT02488733,Rate of patients achieving diabetes resolution,"Renal (onset of nephropathy or microalbuminuria), cardiovascular (defined as the occurrence of myocardial infarction, congestive heart failure or stroke), and ocular damage (development of diabetic retinopathy), and diabetes-related peripheral neuropathy",,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13882,NCT01889355,Enhanced Meter Feature Usability,,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
13883,NCT04812782,Change of Endothelial function from pre meal to post meal period,Gastric emptying rate,,2018-02-12,COMPLETED,INTERVENTIONAL,['NA']
13884,NCT00011141,,,,na,COMPLETED,INTERVENTIONAL,['NA']
13885,NCT01120912,Adverse events occurrence,Evaluate the glucose lowering effect of Oshadi Oral Insulin,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13886,NCT03081676,Insulin secretion,Amount glucose used to maintain the glucose clamp,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
13887,NCT03998267,Difference in mean HbA1c,Lipids,Exploratory outcome,2019-08-22,UNKNOWN,INTERVENTIONAL,['NA']
13888,NCT04074668,Mitochondrial Function,Kidney Injury Biomarkers,Epigenetic profiling,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
13889,NCT03784027,Time in target (3.9 to 10.0 mmol/l) (70 to 180 mg/dl),Percentage of time of CGM availability,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
13890,NCT02463084,Change in cerebrospinal fluid levels of Alzheimer's disease biomarkers (CSF beta-amyloid 42),Change in brain perfusion,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13891,NCT00568984,HbA1c,Adverse events,,2002-11-21,COMPLETED,INTERVENTIONAL,['PHASE4']
13892,NCT01600690,Change in EPC levels,Change in hsCRP,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13893,NCT01432509,Type 2 Diabetes occurrence,Others cardiovascular risk factors,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
13894,NCT06241976,Postprandial glycaemic response,Knowledge and perception of vitamin D,C-reactive protein (CRP),2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
13895,NCT00444392,Brachial artery flow mediated dilation,Inflammatory Markers,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13896,NCT02919345,Change in flow mediated dilation (FMD) and its related endpoint (FMD post reperfusion lesion),Change in body composition (% of fat mass and % free fat mass),Change in Waist Circumference,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13897,NCT01737957,Macular thickness change,Adverse events,"Regression of neovessels, change over time",2012-11,UNKNOWN,INTERVENTIONAL,['NA']
13898,NCT04377399,Microcirculation,Neuropathic symptom score,,2018-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
13899,NCT00817622,Changes in leptin and adiponectin after 12 Weeks,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13900,NCT01959334,Number of Participants With At Least One Adverse Event,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13901,NCT03228004,Frequency of data upload,,,2017-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
13902,NCT05305352,Asses change in NFk,,,2024-01,SUSPENDED,INTERVENTIONAL,['NA']
13903,NCT04503174,Percent of Boluses Using the Auto Population Feature Resulting in Fewer Readings Less Than 70 mg/dL Than Those Not Using the Feature,"Diabetes Impact and Satisfaction Scale (DIDS), Impact Score",,2020-08-04,COMPLETED,OBSERVATIONAL,['NA']
13904,NCT00339482,To investigate the determinants of type 2 diabetes and its complications.,,,1976-09-03,COMPLETED,OBSERVATIONAL,['NA']
13905,NCT04352738,Intrahepatic free glucose concentration,First-pass hepatic extraction of glucose,Changes in intrahepatocellular lipid (IHCL),2021-04-15,COMPLETED,OBSERVATIONAL,['NA']
13906,NCT02591849,Concentration of glucagon during fasting glycemia and during hyperglycemic conditions measured in picomoles per liter,Insulin sensitivity index,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
13907,NCT02864654,Serious adverse reactions,Quality of life monitoring - 2,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13908,NCT02909829,AUCinc: The incremental area under the curve (as compared to pre-meal glucose value) of the postprandial glucose excursions for the lunch meal.,1. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal,,2017-10-31,COMPLETED,INTERVENTIONAL,['NA']
13909,NCT00348712,Treatment difference in HbA1c,Hypoglycaemia,,2006-10-30,TERMINATED,INTERVENTIONAL,['PHASE3']
13910,NCT00402727,Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population,Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13911,NCT03328975,Can diabetic patients maintain their blood glucose in a normal range after receiving a corticosteroid injection?,,,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
13912,NCT05491577,Results of the FAAM-F questionnaire at Month 24,K. Sanders Classification of the Charcot Foot,Front view X-ray of the ankle(s) under loading,2023-01-23,RECRUITING,OBSERVATIONAL,['NA']
13913,NCT00001310,,,,1992-03-05,TERMINATED,OBSERVATIONAL,['NA']
13914,NCT02577120,Ceramiseal and EpiCeram restore barrier function to wounds in patients,,,2019-01-09,RECRUITING,INTERVENTIONAL,['PHASE4']
13915,NCT03591354,Time in Target Range,BMI,Any Adverse Event Rate Per 100 Person-years From Months 4-12,2019-01-17,COMPLETED,INTERVENTIONAL,['NA']
13916,NCT01350388,Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks,Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
13917,NCT02070926,Time to major adverse events,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
13918,NCT01478763,,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
13919,NCT02605772,redunction of Hemoglobin A1c (HbA1c) Levels (%) in two groups respectively after three months intervention,Difference of Homeostasis model assessment of insulin resistance (HOMA-IR) and Homeostasis model assessment beta cell function index (HOMA-β) between two groups after three months intervention,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
13920,NCT00549536,To evaluate the difference in 24h blood pressure measurement and insulin sensitivity between the treatment and the control group.,To evaluate differences in the transmembrane sodium/hydrogen exchanger activity between the active treatment and the control group.,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13921,NCT03091673,Change in Plasma Glucose,Plasma Glucagon Tmax,,2017-03-27,COMPLETED,INTERVENTIONAL,['PHASE3']
13922,NCT03509532,MACE,,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
13923,NCT04268212,incremental area under the curve,,,2016-04-15,COMPLETED,INTERVENTIONAL,['NA']
13924,NCT00853424,"Composite outcome consisting of progression of DR, development of significant ME, or moderate visual loss in patients who have significant ME at randomization.",,,2009-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
13925,NCT05074342,The provision of a DRS status list to primary health care settings will increase the rate of annual DR screening in patients with type 1 or type 2 diabetes who have attended the centres.,,,2022-02-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
13926,NCT02004964,eligibility for islet transplantation,,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
13927,NCT05238987,Change in insulinogenic index,Change in insulin clearance rate,,2020-10-10,COMPLETED,INTERVENTIONAL,['NA']
13928,NCT05729334,Repeatability of Clinicgram Euclides in the automatic calculation of skin lesion areas between two measurements performed by the same investigator.,Usability of the investigational software Clinicgram Euclides.,,2022-11-28,COMPLETED,INTERVENTIONAL,['NA']
13929,NCT05402579,Identification of genomic variants associated with an increased risk of SGLT2 inhibitor-associated DKA,,,2022-07-29,RECRUITING,OBSERVATIONAL,['NA']
13930,NCT00242372,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),To validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI-Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) in patients with type 2 diabetes and to explore the effects of tesaglitazar (0.5 mg) on pati,,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3']
13931,NCT00264940,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
13932,NCT05348863,HbA1c,Physical activity using accelerometry,,2022-10-28,RECRUITING,INTERVENTIONAL,['NA']
13933,NCT04729296,The primary outcome is the elapsed time from random treatment assignment to the development of diabetes (T1D) or time of last contact among those randomized,,,2021-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13934,NCT00428571,Diabetic control as assessed by HbA1c,Utilization of resources and productivity losses,,2007-05,TERMINATED,INTERVENTIONAL,['NA']
13935,NCT05933460,Diastolic Blood pressure,Continuous glucose monitoring statistic data,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
13936,NCT05003908,Safety (adverse events),Efficacy: Insulin dose reduction,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE1']
13937,NCT05613985,To assess the ulcer after 2 weeks of study treatment by evaluation of the following primary endpoint:,The key secondary objective is to evaluate the ulcer after 4 weeks of study treatment by evaluation of the following endpoint:,,2021-09-14,RECRUITING,INTERVENTIONAL,['NA']
13938,NCT05527535,Efficiency of AI in diabetic retinopathy screening,Satisfaction of patients and health care personnel in AI-based screening,,2022-10-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13939,NCT00284609,Change in HgbA1c (Glycemic control),Body mass index,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
13940,NCT00454597,"To compare the Blood levels of of glucose, curve of tolerance wing glucose, hemoglobin glycosylated, insulin, triglyceride, cholesterol, HDL, LDL, leptin and Adiponectin before and after the procedure","To evaluate the metabolic conditions of the subjects of both groups to the 15 days and the month, 6, 12 and 24 months later to the procedure",,2007-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13941,NCT02956577,Changes in Global Longitudinal Strain (GLS) stratified by Coronary Artery Calcium Score (CAC) in patients with diabetes during one year of follow-up,Changes in GLS in patients with long-term diabetes and no macrovascular disease,LA function stratified by micro- and macrovascular status,2016-03-16,COMPLETED,OBSERVATIONAL,['NA']
13942,NCT02218931,"Composite fetal outcomes: stillbirth, small for gestational age or admission to neonatal intensive care unit",Development of a cohort for medium and long term follow up of mothers and babies after birth through applications to other grant giving bodies.,,2014-09-12,COMPLETED,INTERVENTIONAL,['NA']
13943,NCT00334841,,,,2006-07,UNKNOWN,OBSERVATIONAL,['NA']
13944,NCT04743479,Hazard ratio (HR),Diagnostic yield,,2020-12-01,RECRUITING,OBSERVATIONAL,['NA']
13945,NCT01879228,Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13946,NCT01013766,"Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F",Relationship between pharmacokinetic and pharmacodynamic parameters,,2009-08-13,COMPLETED,INTERVENTIONAL,['PHASE1']
13947,NCT05146401,Gestational diabetes mellitus,,,2012-08-01,COMPLETED,OBSERVATIONAL,['NA']
13948,NCT05937321,Time in Range,Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes,World Health Organisation-Five Well-Being Index,2023-11-02,RECRUITING,INTERVENTIONAL,['NA']
13949,NCT03594591,Changes in arterial wall microcirculation (vasa-vasorum density),Changes in retinal microcirculation (Foveal Avascular Area),,2018-01-02,UNKNOWN,OBSERVATIONAL,['NA']
13950,NCT00115973,HbA1c,Frequency of hypoglycemic events,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13951,NCT04800471,Change in hyperglycemia,Change in Glucose Variability,,2021-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13952,NCT05698875,Mean glucose (mmol/l),"Range times (Time in range, time above range, time below range)",,2023-02-14,COMPLETED,INTERVENTIONAL,['NA']
13953,NCT05329610,Adherence to the intervention,Blinding to the intervention,Fractional shortening (%),2022-04-05,COMPLETED,INTERVENTIONAL,['NA']
13954,NCT02068300,"The correlation between 1,5-anhydro-D-glucitol and Modified Hypoglycemic score","The relation between glycemic variability indices such as MAGE of continuous glucose monitoring system and 1,5-AG in insulin using patients.","The plasma 1,5-anhydro-D-glucitol level may be a useful marker of daily glucose excursion in diabetes patients",2013-10,COMPLETED,OBSERVATIONAL,['NA']
13955,NCT00780195,catecholamines,,,1998-07,COMPLETED,INTERVENTIONAL,['NA']
13956,NCT01242202,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-10-21,COMPLETED,INTERVENTIONAL,['PHASE3']
13957,NCT04485845,estimation of metabolic syndrome deterioration,reduce nephropathic impairement,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13958,NCT02153190,Percent time spent in target range (3.9-10.0 mmol/L or 70-180 mg/dL) during each study period,Low Blood Glucose Index (LBGI),,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13959,NCT01917227,HbA1c,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
13960,NCT04759144,Time in target (3.9 to 10.0mmol/L) (70 to 180 mg/dL),Human factors assessment,,2021-03-12,COMPLETED,INTERVENTIONAL,['NA']
13961,NCT00499954,,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
13962,NCT01876914,Total retinal blood flow & visual acuity,The degree of parafoveal ischemia as identified by OCT and visual acuity,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
13963,NCT01979081,Physical Functioning Inventory,Patient Specific Functional Scale (PSFS),Brief Pain Inventory,2013-01,COMPLETED,OBSERVATIONAL,['NA']
13964,NCT05208827,Gestational diabetes,Weight gain during pregnancy,,2022-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13965,NCT04101045,Fractional hepatic DNL,,,2019-11-21,TERMINATED,INTERVENTIONAL,['NA']
13966,NCT01727817,Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.,Time spent in target range,Reliability of inter-device connections between DiAs and the CGM and between DiAs and the insulin pump.,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13967,NCT04495231,Presence of metabolic syndrome,"Cardiovascular risk as estimated by Progetto Cuore Score (english translation: ""Heart Project Score"")",,2007-09-01,COMPLETED,OBSERVATIONAL,['NA']
13968,NCT03393208,Maximum Observed Plasma Concentration (Cmax) of Metformin (GIR Tablet Active Ingredient),"Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters, Physical Examination Findings and 12-lead Electrocardiogram (ECG) Findings",,2018-01-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13969,NCT06323161,Change in Glycated Haemoglobin (HbA1c),Number of Clinically Significant Hypoglycaemic Episodes (level 3),,2024-03-26,RECRUITING,INTERVENTIONAL,['PHASE3']
13970,NCT03017482,percent of time patients are on the closed loop system,Percent time in range,Diabetic Ketoacidosis,2017-07-15,COMPLETED,OBSERVATIONAL,['NA']
13971,NCT00552227,The primary efficacy measure is the ratio of urinary isoprostane to creatinine as measured by gas chromatography/mass spectrometry (GC/MS) in the two consecutive 12-hour urine samples obtained prior to both Visit 2 (baseline) and Visit 3 (endpoint).,The ratio of urinary albumin to creatinine,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13972,NCT05843175,Percentage of time spent in the euglycemic range for the 24 hours after each experimental condition,Placenta efficiency,Sleep quality (questionnaire),2023-06-22,RECRUITING,INTERVENTIONAL,['NA']
13973,NCT02438670,Time spent in safe blood glucose range,Glucose level extremes and need for outside intervention,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
13974,NCT05089617,Adverse events will be evaluated,maximum plasma concentration (Cmax),,2022-01-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13975,NCT02318797,Change in Health Status ( SF-12v2™): Mental Health Sub-scale,Change in Lab Monitoring - EKG,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
13976,NCT02137070,Change in BOLD fMRI signal,,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
13977,NCT01234649,Insulin Secretion-Sensitivity Index (IS-SI),Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio,,2011-08-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13978,NCT00701051,Skeletal Muscle Capillarization (Pre/Post Intervention),Body Composition (%Fat),,2006-10,COMPLETED,INTERVENTIONAL,['NA']
13979,NCT03835208,mean amplitude of glucose excursions (MAGE),C-peptide,3-hydroxy-butyrate,2019-02-25,UNKNOWN,INTERVENTIONAL,['NA']
13980,NCT04233658,Change of HbA1c-level from baseline to week 12,,,2020-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
13981,NCT03018665,Time of Maintaining Diabetes Remission,The Incidence of Diabetic Nephropathy,,2017-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
13982,NCT01371955,comparison of prevalence of homozygous polymorphism between the DN-group and the non-DN group,delay between diabetes diagnosis and ND onset by genetic polymorphism,HbA1c,2011-01,COMPLETED,OBSERVATIONAL,['NA']
13983,NCT02235194,Area under the curve for Glucose,Gut peptide hormones,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
13984,NCT00732407,arterial stiffness and platelet function,"oxidative stress parameters (oxidized LDL and Isoprostanes), markers of inflammatory status (highly sensitive CRP test) and 24 hours blood pressure monitoring",,2008-09,UNKNOWN,INTERVENTIONAL,['NA']
13985,NCT04012775,Antibody Response,Change in total basal insulin dose (U) from baseline,,2017-04-20,COMPLETED,INTERVENTIONAL,['PHASE3']
13986,NCT03094910,Heart rate variability (HRV),,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
13987,NCT03585738,Weight gain in pregnancy,,,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13988,NCT03849495,Cmax of Empagliflozin,Vd/F of Empagliflozin,,2019-02-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
13989,NCT02118376,Dual energy X-ray absorptiometry,lab testing,lab testing,2014-08,UNKNOWN,INTERVENTIONAL,['NA']
13990,NCT04682977,Executive functioning using the Executive Function Performance Test,Participation in life activities and roles using the Late Life Functioning and Disability Index,,2021-08-11,UNKNOWN,INTERVENTIONAL,['NA']
13991,NCT04915339,Episodic memory performances,Client satisfaction questionnaire,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
13992,NCT00282360,silent ischemia,symptomatic myocardial ischemia,,1999-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13993,NCT02539355,Change in adipose tissue macrophage cell surface expression of metabolic activation marker ABCA1 as measured by relative mean fluorescence intensity (rMFI),Change in fasting plasma total adiponectin assessed by ELISA,Changes in gut microbiota assessed by stool sample analysis,2015-08,COMPLETED,INTERVENTIONAL,['NA']
13994,NCT04988321,Change in bodily and emotional perception of pain (BEEP) score,Change in corticospinal excitability (CE),,2021-09-03,COMPLETED,INTERVENTIONAL,['NA']
13995,NCT03362112,Lipoprotein-associated Phospholipase A2,C Peptide,,2015-01-30,COMPLETED,OBSERVATIONAL,['NA']
13996,NCT03936660,Implementing a clinic-level multifaceted intervention,Measurement of average time from baseline to patient event.,,2019-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13997,NCT04588896,1-hour glucose from OGTT,Socio-cognitive measures,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
13998,NCT00952445,,,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13999,NCT03910361,Changes from baseline intrahepatic fat (%),,,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE4']
14000,NCT03738852,Brain glucose levels,,,2018-11-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14001,NCT01527981,Changes in depression severity,Changes in glucose levels,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14002,NCT00311064,too large infants (> 2 standard deviation [SD]),induction of labour,,2006-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14003,NCT03555591,Number of Participants Who Had One or More Adverse Drug Reactions,Percentage of Participants Achieving Good Glycemic Control (Reduction in HbA1c Values < 6.0 Percent),,2016-05-01,COMPLETED,OBSERVATIONAL,['NA']
14004,NCT05790421,Toe Strength Dynamometer,,,2022-04-02,COMPLETED,INTERVENTIONAL,['NA']
14005,NCT00675857,Change from baseline to Week 26 in HbA1c levels,Change in fasting serum glucose levels,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14006,NCT04735835,Glucose and HbA1c,Covid-19 symptom assessment,Hip Circumference (in sub-cohort),2020-07-20,RECRUITING,INTERVENTIONAL,['NA']
14007,NCT04654390,Change from Visit 2(Randomization) in HbA1c level at Week 24 after administation of the IP,"Proportions of subjects who achieved HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP",,2020-12-30,COMPLETED,INTERVENTIONAL,['PHASE3']
14008,NCT04231838,Change in Metabolic Syndrome Prevalence,Change in Waist Circumference,,2021-09-27,RECRUITING,INTERVENTIONAL,['NA']
14009,NCT02122874,Serum glucose levels (mg/dl),Homeostasis model assessment (HOMA),,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14010,NCT05248334,Visual acuity,The number of pars plana vitrectomy,,2022-04-10,RECRUITING,INTERVENTIONAL,['PHASE1']
14011,NCT04349696,Blood glucose concentration change from baseline at 2 hours after drug administration,,,2014-02-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14012,NCT02232126,30-day Hospital Readmission,30-day Readmission Among Intervention Participants,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
14013,NCT03787563,Number of Subject with adverse events,Flash Glucose Measurements,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
14014,NCT00299169,mean LDL levels,the proportions of participants taking statins at the end of the trial,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE4']
14015,NCT03102801,"Measurement of endothelial microparticles (composite number of CD105, CD106, CD142, CD54, CD62 & CD31) following hypoglycemic event",,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
14016,NCT00707629,Ease of Injections versus Insulin pump Therapy,,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
14017,NCT04634838,Percent reduction of wound size,Number of infectious episodes,,2021-02-02,TERMINATED,INTERVENTIONAL,['NA']
14018,NCT02379468,Time to complete wound healing within 12 weeks before the end of treatment duration.,To identify adverse events associated with the application of Pedyphar® ointment.,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14019,NCT03501511,Hypoglycemia,Number of successful fasting days,,2018-04-07,COMPLETED,INTERVENTIONAL,['NA']
14020,NCT00134550,Recurrence rate of foot ulcers (during 26 weeks of study),Cost of DFU treatment from debut to healing (IDUS substudy),,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14021,NCT01941329,Regression of neovascularization,Adverse events related to the treatments,,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14022,NCT01597882,Grip strength,Sickness behaviour scale,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
14023,NCT00315718,HbA1c values,Blood pressure (systolic/diastolic),,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14024,NCT03457012,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2018-03-29,COMPLETED,OBSERVATIONAL,['NA']
14025,NCT00494767,Body fat and fat-free mass as determined by a new investigational MR technique compared to 4C Model methodologies.,"Drug levels in blood over time (Day 42 PK parameters are AUC, Cmax, tmax)",,2006-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
14026,NCT03745885,Pharmacokinetic: t½ of Supaglutide,,,2018-12-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14027,NCT00235443,Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator.,Change From Baseline in Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS),,2004-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14028,NCT03598400,Severe hypoglycaemia,area under the curve of episodes of hypoglycaemia and hyperglycaemia,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
14029,NCT01796366,Number of treatment emergent adverse events,Area under the glucose infusion rate-time curve,,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE1']
14030,NCT01708083,Difference in polymorphids and/or mRNA expression in different types of fat tissue in patients with normal weight or obesity with or without diabetes type 2,,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
14031,NCT02303405,Hemoglobin A1c,Adverse Events,,2014-11,TERMINATED,INTERVENTIONAL,['PHASE2']
14032,NCT03871621,Left ventricular mass index,Plasma biomarker: fatty acid binding protein 4 (FABP-4),,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14033,NCT00970294,"Recruitment, Retention, Adherence",Glycemic Control,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
14034,NCT05767450,Glycemic control by Time-in-Range (TIR) monitoring,Measurement by flow cytometry of differences in the percentages of innate lymphoid cells,,2022-12-16,RECRUITING,INTERVENTIONAL,['NA']
14035,NCT00824330,Arterial baroreflex sensitivity,Increase in Gosling's pulsatility index,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
14036,NCT01668485,Whole body glucose counterregulation,Gluconeogenesis from lactate,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14037,NCT03642184,eGFR,Adverse events,,2018-07-14,TERMINATED,INTERVENTIONAL,['PHASE4']
14038,NCT02486237,Number of patients with microvascular and cardiovascular complications,Number of patients with microvascular and cardiovascular complications stratified by diabetes pharmacologic treatment,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
14039,NCT01976858,To determine serum concentrations of PEX168,To determin HbA1c levels of PEX168,To assess number of participants with Adverse Events as a Measure of Safety and To assess number of participants with Adverse Events as a Measure of Safety and Tolerability,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14040,NCT05662267,"Graft failure defined by death-uncensored graft survival, i.e. the return to dialysis or death",Death-censored graft survival,,2020-03-10,RECRUITING,OBSERVATIONAL,['NA']
14041,NCT00147745,Acute Effect of a Single Dose of Colesevelam on Oral Glucose Absorption From Baseline to First Dose,Change in Hemoglobin A1C Due to Effect of Colesevelam From Baseline to 12 Weeks,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14042,NCT05540197,Early islet graft function,Insulin concentration,,2022-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14043,NCT04429503,Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48,Safety Assessed by Serious Adverse Events (SAEs) Through Week 156,,2020-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14044,NCT05759884,central macular thickness (CMT),nonperfusion (NP),,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
14045,NCT04429958,BMI in offspring,Adiposity offsping skin folds,,2021-01-25,COMPLETED,OBSERVATIONAL,['NA']
14046,NCT05270343,Residual β-Cell function (RBCF),Daily Insulin Dosage,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14047,NCT05944731,Impact of continuous and intermittent CGM used on blood glucose levels in comparison to standard of care in people living with type 1 diabetes,Cost of continuous and intermittent CGM from a user and provider perspective,,2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14048,NCT05258240,Single leg standing test,,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
14049,NCT03983733,Hunger and appetite assessment,Covid-19 symptom assessment,Gut microbiome species richness,2019-06-10,COMPLETED,INTERVENTIONAL,['NA']
14050,NCT02143440,When the glucose level decreased to about 10 mmol/L,,,2012-03,UNKNOWN,INTERVENTIONAL,['NA']
14051,NCT03260452,Number of pro-inflammatory macrophages derived from human adipose tissue in mice transplanted with adipose tissue-hematopoietic stem cells .,Comparison of the metabolic profile of the transplanted mice evaluated by the grafted mice's oral glucose tolerance test.,,2018-06-28,COMPLETED,INTERVENTIONAL,['NA']
14052,NCT03811132,HbA1c,Marker of inflammation #4: interleukin-1 receptor antagonist (IL-1Ra),Fear of diabetes complications,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
14053,NCT06005987,Compliance,Percentage of in-range blood glucose levels,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14054,NCT01211197,Metformin: Maximum Measured Concentration (Cmax),"Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.",,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14055,NCT02610179,The serum glucose levels will be measured in response to oral glucose challenge and compared between Twizzlers and glucola beverage.,Cost-effectiveness,,2015-04,RECRUITING,INTERVENTIONAL,['NA']
14056,NCT04403789,Change from Baseline Fasting Plasma Glucose (mmol/L) at 12 Weeks,Change from Baseline Physical Activity (AX3 Device) at 12 Weeks and 16 weeks,,2021-03-28,COMPLETED,INTERVENTIONAL,['NA']
14057,NCT01540396,Diagnosis of gestational diabetes,Maternal birth trauma,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
14058,NCT04807452,Toronto Clinical Neuropathy Scoring System,,Berg Balance Scale,2020-03-30,COMPLETED,INTERVENTIONAL,['NA']
14059,NCT03290144,Change in FEV1,Change in Body Mass Index (BMI),,2015-02-02,UNKNOWN,OBSERVATIONAL,['NA']
14060,NCT01541735,Total Insulin Secretion,Glycated Hemoglobin A1C,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14061,NCT04065581,AUC (plasma metformin),Frequency of TEAE (treatment-emergent adverse event）,,2019-10-14,COMPLETED,INTERVENTIONAL,['PHASE1']
14062,NCT03990844,Change in insulin response,Change in satiety rating,,2019-01-12,COMPLETED,INTERVENTIONAL,['NA']
14063,NCT03376698,Change in serum high-sensitivity CRP (mg/dl),Change in plasma myeloperoxidase level (ng/ml),Concentration of colhicine in white blood cell (ng/1*10^9 cells),2017-06-15,COMPLETED,INTERVENTIONAL,['PHASE2']
14064,NCT03917238,Pancreatic uptake of gallium-68-NODAGA-exendin-4,,,2019-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14065,NCT04082091,Early Impact Measure of Intervention for Detection,Change in Physiological Characteristics of Intervention Participants - Physical Activity,,2019-09,UNKNOWN,OBSERVATIONAL,['NA']
14066,NCT03734367,Change in the emotional skills of adolescents with type 1 diabetes that will be related to a glycosylated index between normal values,,,2019-01,UNKNOWN,INTERVENTIONAL,['NA']
14067,NCT05603130,Effectiveness of patients with COVID-19 who have developed de novo diabetes.,Demographic characteristics of diabetic patients,,2022-03-23,COMPLETED,OBSERVATIONAL,['NA']
14068,NCT00900146,Change From Baseline in Dynamic Phase Secreted Insulin Per Unit of Glucose Concentration (Φd) Over 4 Months (Period III),Percentage Change From Baseline in Fasting Lipids Profile at Month 4 (Period II),,2009-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14069,NCT00698789,"Safety and tolerability as determined by monitoring of AEs, vital signs, ECGs, physical examinations, and clinical laboratory blood and urine parameters.",Change from Baseline in fasting plasma glucose and population pharmacokinetics of INCB019602 in type 2 diabetic patients.,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2']
14070,NCT04196231,Proportions of patients with significant HbA1c change,Diabetes treatment satisfaction,,2019-11-27,COMPLETED,INTERVENTIONAL,['PHASE4']
14071,NCT05189015,angiotensin(1-7),LDL,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14072,NCT00331851,HbA1c,Glycaemic control,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14073,NCT00830011,Pain intensity score (NRS),pain-related disability (MPI) and emotional functioning,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
14074,NCT01375660,Oral Glucose Insulin Sensitivity (OGIS),Incident Diabetes,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
14075,NCT06115213,Emergency room visits,New diagnosis of peripheral artery disease,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
14076,NCT00476281,nutritional and respiratory parameters,abnormal glucose tolerance,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
14077,NCT03830281,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 16,Percentage of Participants With at Least 1 Event of Unexplained Hyperglycemia >300 mg/dL Confirmed by SMBG That Leads to an Unplanned Infusion Set Change,,2019-02-14,COMPLETED,INTERVENTIONAL,['PHASE3']
14078,NCT01236053,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
14079,NCT00887094,Reduction of the prevalence of hyperglycemic peaks during a 24-h period after a bout of aerobic or aerobic/resistance exercise in type 2 diabetes patients on metformin/diet therapy.,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
14080,NCT03561571,after breakfast thromboxane B2 concentration,post prandial lipidomic composition of triglyceride rich lipoproteins,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
14081,NCT01182935,Number of subjects with type 2 diabetes diagnosed with oral glucose tolerance test (OGTT),The relation between serum 25(OH)D levels and blood glucose levels at OGTT,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
14082,NCT00591903,,,,2007-12-14,COMPLETED,OBSERVATIONAL,['NA']
14083,NCT06212778,Fatigue,,,2023-09-26,RECRUITING,OBSERVATIONAL,['NA']
14084,NCT05404789,Time of data entry completion during Emergency Scenario,,,2021-09-27,COMPLETED,INTERVENTIONAL,['NA']
14085,NCT02152384,"Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro",Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14086,NCT05129345,Aim 3: Number of strategies modified in the self-management support and education,,,2022-06-07,RECRUITING,OBSERVATIONAL,['NA']
14087,NCT03273738,metabolic changes in type 2 diabetes,,,2018-10-02,UNKNOWN,OBSERVATIONAL,['NA']
14088,NCT01587638,Rate of New Onset Diabetes (NOD),,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
14089,NCT00071448,HbA1c (glycosylated haemoglobin A1c),FPG (fasting plasma glucose),,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14090,NCT00937222,The primary outcome measure is HDL-C,"Serum lipids, glucose, HbA1c, anthropometrics and blood pressure",,2009-06,COMPLETED,INTERVENTIONAL,['NA']
14091,NCT02684331,On CMR; passive atrial emptying fraction (%) as a measure for cardiac diastolic function,Echocardiography,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
14092,NCT05364723,distribution of diabetic retinopathy in eastern morocco,,,2022-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14093,NCT05220917,Hospitalization for Heart Failure (HHF) Hospitalization for Heart Failure (HHF),Coronary revascularization,Switching patterns,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14094,NCT06147752,Change of homeostasis model assessment-insulin resistance（HOMA-IR）,Change of hepatic steatosis value,,2023-03-28,RECRUITING,INTERVENTIONAL,['NA']
14095,NCT00797771,"User satisfaction regarding the ""Adi"" pump functioning will be evaluated by questionnaire. The questionnaire will be administrated during the last study visit",Number of severe hypoglycemic events,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
14096,NCT00309608,HbA1c Change From Baseline at Week 12,Fasting Blood Plasma Glucose Level (FPG) Change From Baseline at Week 12,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14097,NCT00534547,Treatment success based on patients' glycemic control,"Physiologic Measurements, Comorbidity improvement, Improvement in QOL",,na,WITHDRAWN,INTERVENTIONAL,['NA']
14098,NCT03503747,Quantification of the number of participants with high-risk genetic markers for the development of type 1 diabetes.,,,2018-04-25,COMPLETED,OBSERVATIONAL,['NA']
14099,NCT00410722,Fasting insulin,Cancer cell proliferation,,2006-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
14100,NCT02154126,Accuracy (mean absolute relative difference) compared to be reference device should be less than 20%,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
14101,NCT00501020,The primary efficacy variable was HbA1c change from baseline (visit 3) after 24 weeks of treatment with either RSG+MET combination therapy or Metformin monotherapy.,"Secondary efficacy variables included: the change from baseline (visit 3) at week 24 (visit) in FPG, immunoreactive insulin, HbA1c and FPG responders, Questionnaire-Tolerability of GI side-effects, and Questionnaire - Quality of Life.",,2001-06-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14102,NCT02923063,Quadriceps muscle work efficiency,Perceived Stress (NIH),Walking economy during 6 minute walk,2020-01-16,RECRUITING,INTERVENTIONAL,['PHASE2']
14103,NCT05973734,Number of patients who receive Treg infusions (Arm1) or Donor Derived Vertebral Bone Marrow (Arm2) and islet transplantation (feasibility),Quality of life (QOL) assessment,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
14104,NCT06143566,Oxygen uptake during peak exercise (Peak VO2),Urine albumin to creatinine ratio,Medication Adherence,2024-03-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14105,NCT01942694,Time to Development of Diabetes,Identification of Characteristics Associated With the Variability in Achieved 25OHD Concentration.,Quality of Life and Mood Scores in Pre-diabetes Population Using a Validated Instrument (PROMIS-29 Profile v2.0 and a General Question on Perception of Overall Health From the PROMIS Scale 1.2).,2013-10,COMPLETED,INTERVENTIONAL,['NA']
14106,NCT05638880,Reduction of albuminuria,,,2022-12-20,RECRUITING,INTERVENTIONAL,['PHASE2']
14107,NCT06248190,Improved control of at least one condition that was not optimally controlled at baseline,Heathcare utilisation and cost,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
14108,NCT05260983,Phenomenological Body Shame Scale - Revised,Short-form State-Trait Anxiety Inventory,1-item Expected Diabetes Prevention Self-Efficacy Scale,2021-08-28,COMPLETED,INTERVENTIONAL,['NA']
14109,NCT01252082,Metabolic control,periodontal improvement after scaling and rootplaning,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14110,NCT00530309,Plasma concentrations and PD parameters over time and at the end of study,Other metabolic parameters at the end of study,,2007-08-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14111,NCT00413335,Mean Percent Change From Baseline in Hepatic Fat Fraction (HFF),Mean Percent Change From Baseline in Adiponectin,,2005-11,COMPLETED,INTERVENTIONAL,['NA']
14112,NCT00422630,Change in insulin sensitivity over time,Diet satisfaction,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
14113,NCT04637217,Correlation between neurodegeneration and retinal vessels characteristics,Correlation between choroidal parameters and diabetes control,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
14114,NCT02064023,Composite obstetrical/perinatal endpoint consisting of specific elements (see description),Mean maternal HbA1c during pregnancy,Number of episodes of severe hypoglycemia,2014-04,TERMINATED,INTERVENTIONAL,['NA']
14115,NCT02348190,protein kinase C enzyme activity in tissue samples,protein kinase C enzyme activity in T cells,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
14116,NCT04378972,pro-inflammatory cytokines analysis,,,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
14117,NCT00536796,Cholesterol levels,,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
14118,NCT05695573,Determine the urinary exosomal UMODmRNA gene expression,,,2019-07-05,COMPLETED,OBSERVATIONAL,['NA']
14119,NCT05974566,Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP),Change in renal function level,,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14120,NCT03332927,Insulin sensitivity index (IV-SI) from short (40 min) IVGTT.,Vertical Auto-Profile (VAP) analysis of cholesterol carried by lipoproteins and lipoprotein subfractions.,,2017-10-25,COMPLETED,INTERVENTIONAL,['NA']
14121,NCT06329375,Food insecurity at 30-days post initial discharge,Hospitalization,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14122,NCT03608358,Mean change from baseline in HbA1c at Week 24,Percent of subjects achieving a therapeutic glycaemic response of HbA1c <7.0% at Week 24,,2019-02-27,TERMINATED,INTERVENTIONAL,['PHASE3']
14123,NCT06208189,Prevalence of hypoglycemia,Session rating of perceived exertion,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14124,NCT01407003,"Safety and tolerability of single and multiple dose(s) of LIK066: number of patients with adverse events and changes from baseline in vital signs, ECG and clinical labs (blood chemistry, hematology and urinalysis).",Change in fasting and post-challenge plasma glucose after a single dose and 2 weeks of treatment,,2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14125,NCT04113239,Genotypes of participants,Food frequency questionnaire,,2019-11-27,COMPLETED,OBSERVATIONAL,['NA']
14126,NCT02742987,Flow-mediated Dilation of the Brachial Artery,Number of Patients With Platelet Reactivity >256 P2Y12 Reaction Units,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14127,NCT03032991,Electroencephalography (EEG),Metabolomic,Physical Activity,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
14128,NCT03958760,Triglyceride (TG) (mmol/L),The proportion of re-hospitalization,,2021-02-28,COMPLETED,OBSERVATIONAL,['NA']
14129,NCT00099931,Change from baseline in HbA1c at 24 weeks,Patients with endpoint <7% after 24 weeks,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14130,NCT02088268,effect of PRP on diabete wound closure,,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
14131,NCT02596932,Mean neonatal blood glucose levels,Maternal hypoglycemia,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
14132,NCT02817360,Number of patients with an unplanned cardiac hospitalization or death due to a cardiac event,,Change of kidney function,2016-02,RECRUITING,INTERVENTIONAL,['PHASE4']
14133,NCT01593137,"assess the effect of treatment with liraglutide compared to glimepiride, as add-on to metformin, for one year on circulating levels of EPCs in patients with type 2 diabetes poorly controlled.","Safety parameters of glycaemic control: HbA1c, FPG",,2012-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14134,NCT00171600,"Change from baseline in urine albumin excretion rate from collected urine samples, after 16 and 20 weeks",Change from baseline in kidney function after 16 and 20 weeks,,2005-07,TERMINATED,INTERVENTIONAL,['PHASE4']
14135,NCT01178957,Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) secretion,,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
14136,NCT01652911,To assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.,To obtain preliminary data on the efficacy of the Cell Pouch™.,,2012-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14137,NCT02201004,Change in HbA1c from baseline,Number of subjects with adverse events,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14138,NCT00545584,Hemoglobin A1c Measurement,Fasting Plasma Glucose (FPG) Measurement,,2007-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14139,NCT03260868,Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24,"Number of Participants With At Least One Hypoglycemic Events (Any, Severe Documented Symptomatic, Probable Symptomatic, Asymptomatic, Pseudo-hypoglycemia: Any Time of the Day) During 24 Week Treatment Period",,2017-09-19,TERMINATED,INTERVENTIONAL,['PHASE4']
14140,NCT03529188,HFS-Parent score,HbA1C,,2018-08-03,UNKNOWN,OBSERVATIONAL,['NA']
14141,NCT02131766,USS Virginia Time Within Target,Morning Glucose Levels,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
14142,NCT04057417,Major adverse cardiovascular events,Cardiovascular disease-related risk factors,Trail counts,2018-01-05,UNKNOWN,INTERVENTIONAL,['NA']
14143,NCT04038125,Evaluate re perfusion following Ozurdex use.,,,2019-08-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
14144,NCT02337972,Change of conjunctival flora and bacterial resistance,,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
14145,NCT04201496,CGM-measured time in the target range 70-180mg/dl (TIR) during the day,Number of hyperglycemic episodes as defined by contiguous CGM above 300 mg/dL,,2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1']
14146,NCT00672386,Mean change in HbA1c from baseline to week 12,Changes in insulin sensitivity and beta cell function (homeostatic model assessment 2 - HOMA-2 and MMTT); Changes in GLP-1 (glucagon-like peptide 1) and PYY (peptide tyrosine tyrozine) levels in the MMTT; Changes in insulin and glucagon,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14147,NCT06161844,Change from baseline to week 32 in glycosylated haemoglobin (HbA1c),Incidence and severity of adverse events,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14148,NCT03065140,Non-invasive 1H Magnetic Resonance Spectroscopy of vastus lateralis,Saturated and unsaturated lipid pool turnover examined by stable isotopes,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
14149,NCT01385865,Blood glucose change with meal tolerance test,"Lipid profile (triglyceride, total cholesterol, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, high-density lipoprotein cholesterol)",,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14150,NCT02726256,"HOMA-IR, HOMA-β",,,2007-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14151,NCT00961324,Area under the glucose infusion rate curve during one dosing interval at steady state,Area under the NN1250 concentration-time curve during one dosing interval at steady state,,2009-07-27,COMPLETED,INTERVENTIONAL,['PHASE1']
14152,NCT02328911,Change in self-reported pain.,Change in quality of life.,,2015-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14153,NCT02225691,Baseline change in HbA1c at month 3 and 6 between paired testing and control arms for each of the 3 patient segments.,Proportion of patients who achieve good glycemic control (HbA1c≤7%),Baseline change in self-care scores (based on Diabetes Self-Efficacy Scale Questionnaire),2014-12,UNKNOWN,INTERVENTIONAL,['NA']
14154,NCT03952819,change from levels of serum sclerostin of control group,,,2017-09-14,COMPLETED,OBSERVATIONAL,['NA']
14155,NCT06183476,Sleep,Glucose levels,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14156,NCT05956743,Pittsburgh Sleep Quality Index,,,2023-06-01,COMPLETED,INTERVENTIONAL,['NA']
14157,NCT05143411,Change in glucose levels,Change in glycemic variability,,2021-10-08,COMPLETED,INTERVENTIONAL,['NA']
14158,NCT04905589,Diurnal glucose Incremental area under curve (iAUC) concentrations,Peptide tyrosine tyrosine (PYY) Incremental area under curve (iAUC),,2021-04-30,COMPLETED,INTERVENTIONAL,['NA']
14159,NCT01031680,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14160,NCT01655810,Change from baseline in carotid intima-medial thickness,Urinary Calcium,,2012-08-13,COMPLETED,INTERVENTIONAL,['NA']
14161,NCT02009488,"Change from baseline in beta-cell glucose sensitivity, determined as a slope of ISR vs. plasma glucose concentration during MMTT","Change from baseline in renal threshold for glucose (RTG), estimated using an MMTT-based method",,2014-09-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14162,NCT06025292,Whole Body Protein Balance,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14163,NCT00044447,Change in HbA1C from baseline to Week 26.,Incidence of hypoglycemia.,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14164,NCT05343962,PROMIS Scale v1.2 - Global Health9. Spanish version,PROMIS-10_Q01. Spanish version.,,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA']
14165,NCT04007926,Whole-body Insulin sensitivity,Waist circumference,,2021-08,SUSPENDED,INTERVENTIONAL,['NA']
14166,NCT00845130,Quantify the Effect of Chronic Hyperglycemia on Cellular Uptake of Vitamin C Across the Blood-brain Barrier,,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
14167,NCT00774553,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG)",Pharmacodynamic variables,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14168,NCT06124573,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2022-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14169,NCT05492890,Maternal outcome,Neonatal outcomes,,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14170,NCT05219409,Rate of new diagnoses of Type 1 Diabetes Mellitus per year,Number of participants with adverse effects on Sitagliptin,Monitor Stage 2 patients with a CGM system (continuous blood glucose detection),2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14171,NCT03196154,HbA1C,Cardiovascular risk estimation,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
14172,NCT04585139,HbA1c,,,2020-10-06,COMPLETED,INTERVENTIONAL,['NA']
14173,NCT02109094,Plasma Leptin Level,,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
14174,NCT05285085,Statin use on primary prevention,High dose statin use on patients with unknown diagnosis,,2021-11-19,COMPLETED,OBSERVATIONAL,['NA']
14175,NCT05169502,Genome wide expression profile of circulating cells in blood samples from each cohort group,,,2021-12-08,RECRUITING,OBSERVATIONAL,['NA']
14176,NCT01916174,Maximum observed plasma liraglutide concentration after single dose,Terminal elimination half-life of liraglutide after single dose,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14177,NCT05298111,Changes in fasting and postprandial blood glucose,Changes in food intake,Habitual physical activity,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
14178,NCT00706420,Percent of subjects who have achieved insulin independence post transplant.,HgAlc</= 6.5%,,2004-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14179,NCT01791114,Insulin Sensitivity,Metabolic profile,Thermoregulation,2012-01,COMPLETED,INTERVENTIONAL,['NA']
14180,NCT03434119,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26,"Percentage of Participants With Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Hypoglycemia) During the On-Treatment Period",,2018-02-20,TERMINATED,INTERVENTIONAL,['PHASE3']
14181,NCT04424706,total MMP-9 levels,,,2020-06-30,UNKNOWN,OBSERVATIONAL,['NA']
14182,NCT01363141,Change in Blood Glucose and Insulin levels in 1 year as compared to baseline,Change in markers of cardiovascular disease in 1 year as compared to baseline,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
14183,NCT00706511,Polysomnography - Sleep Efficiency,IVGTT (Intravenous Tolerance Test) - Disposition Index (DI),,2007-12,COMPLETED,INTERVENTIONAL,['NA']
14184,NCT01059669,Peak enzyme Concentration IE,peak amylase,Rosemont score US,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
14185,NCT04851223,Changes in BCAA and its derivatives,,,2021-03-22,RECRUITING,OBSERVATIONAL,['NA']
14186,NCT05685810,Kidney disease,Insulin resistance,,2018-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14187,NCT02910674,"Percent of Participants Responding 'YES' on the Question ""Did You Successfully Obtain Measurement Result Using the Dario™ BGMS?""",,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
14188,NCT00428207,Glycemic Stability,Frequency of Catheter Change,,2007-02,TERMINATED,INTERVENTIONAL,['NA']
14189,NCT05016375,Explore bathing and spa behaviour by applying the social-ecological model to interpretivist thematic analysis.,Explore how passive heating might impact physical activity by applying the social-ecological model to interpretivist thematic analysis.,,2022-06-28,COMPLETED,OBSERVATIONAL,['NA']
14190,NCT01622777,Nerve growth factor,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14191,NCT06264258,Change in glucose average and variability,Change in game play patterns over time,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
14192,NCT04945551,Gene expression will be quantitatively determined at cellular resolution using single nuclei sequencing,Cardiorespiratory fitness,,2021-02-20,UNKNOWN,INTERVENTIONAL,['NA']
14193,NCT05286450,Distribution of Participants Responses as Regards DSMQ Health Care Use Domain,,,2022-03-15,COMPLETED,OBSERVATIONAL,['NA']
14194,NCT01341899,Changes in C-peptide levels during standard-meal tolerance test from baseline to different time points after transplantation,mortality and dysfunction of other endocrine glands,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14195,NCT05197920,diabetes mellitus (DM) following a qualifying episode of acute pancreatitis (AP),Fecal Elastase,,2022-01-14,RECRUITING,OBSERVATIONAL,['NA']
14196,NCT02054650,Change in low back pain severity,Change in biomarker concentrations,,2014-05,TERMINATED,INTERVENTIONAL,['NA']
14197,NCT02243072,Metabolic Control: Hemoglobin A1c (HbA1c),"Regimen Adherence: Diabetes Management Scale (DMS), Glucose Meter Downloads",,2014-12,COMPLETED,INTERVENTIONAL,['NA']
14198,NCT03815305,Change in SRRC,,,2018-07-30,UNKNOWN,INTERVENTIONAL,['PHASE4']
14199,NCT00794430,Investigate the safety and tolerability of V3381 in patients with diabetic neuropathic pain at doses of up to 400 mg bid,Determine the efficacy of V3381 in the treatment of diabetic peripheral neuropathic pain at does of up to 400 mg bid,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14200,NCT02964104,Number of treatment emergent adverse events (TEAE),"AUCGIR,0-24h,SS, area under the glucose infusion rate-time curve at steady state",,2016-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14201,NCT03728296,Occurrence of treatment related adverse events as assessed by CTCAE v4.0,,,2019-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14202,NCT03960333,circulating CD4+T cells in Type 2 Diabetic pre/post Metformin,,,2019-04-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14203,NCT05341063,Health Literacy Scale,,,2021-10-10,COMPLETED,INTERVENTIONAL,['NA']
14204,NCT04507867,Overall Mortality at Day 40,Number of Participants With Distension on Day 3,Number of Deceased Participants Stratified by Urea Level,2020-09-07,COMPLETED,INTERVENTIONAL,['NA']
14205,NCT02745470,Whole brain connectivity,intake of food in the buffet,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
14206,NCT02313220,Body weight (kg),Body weight (%),"Adverse events /serious adverse events, vital signs and collection of clinical chemistry/haematology parameters.",2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14207,NCT01267175,Usability of the X54 Insulin Pump Meets Expectations,Usability of the Training Material Meets Expectations,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14208,NCT01602003,Change of HbAlc,HbA1c Responder Rate,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14209,NCT03611322,"Cmax,sema,Week5: the maximum plasma semaglutide concentration after first maintenance dose of subcutaneous semaglutide 1 mg administration following a four week escalation period",Number of site-initiated technical complaints with or without co-reported adverse events,,2018-08-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14210,NCT02441023,Metabolic control,Body mass index (BMI),,2013-03,COMPLETED,INTERVENTIONAL,['NA']
14211,NCT02505321,Level of Circulatory Lipids following Triglyceride stimulation test (OTTT) (mmol/L),Incremental Area under the Curve NEFA levels (µmol/L),,2015-05-29,COMPLETED,INTERVENTIONAL,['NA']
14212,NCT04645641,System Performance,System Related Adverse Device Effects,,2020-10-12,UNKNOWN,INTERVENTIONAL,['NA']
14213,NCT03809858,Number of missed meal boluses,Diabetes Distress Scale (DDS) Scores,,2019-05-29,COMPLETED,INTERVENTIONAL,['NA']
14214,NCT04161430,Change from baseline in HbA1c (%) compared to placebo comparator at week 24,"Change from baseline in fasting plasma glucose/2-hour postprandial plasma glucose/body weight at week 12,week 24",,2020-01-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14215,NCT01831921,Hemoglobin A1c,Triglycerides,Homeostasis Model of Insulin Resistance (HOMA IR),2014-01,COMPLETED,INTERVENTIONAL,['NA']
14216,NCT00007696,,,,1998-04,COMPLETED,OBSERVATIONAL,['NA']
14217,NCT04088201,Interstitial fluid glucose readings,Acceptablility of sensor,,2019-09-26,UNKNOWN,INTERVENTIONAL,['NA']
14218,NCT00324207,,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
14219,NCT00363233,Total cholesterol at 3 months,LDL and triglycerides at 3 months; Blood glucose and HbA1C at 3 months,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14220,NCT02490969,All-cause mortality,,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
14221,NCT01836172,Flow-mediated dilation (FMD),Systolic and Diastolic Blood Pressure,"Serum Lipids (LDL, HDL and TG)",2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
14222,NCT06069258,Movement behaviour,Adverse events,,2023-10-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14223,NCT03042325,Percentage of Participants with Glycosylated Hemoglobin < 7.0%,,,2017-07-30,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14224,NCT02432859,"The wound fluid level of VEGF, VEGFR-2, HIF-1α and NO (pg/ml)",Wound surface area(cm2),,2013-11,COMPLETED,INTERVENTIONAL,['NA']
14225,NCT05188027,Blood glucose,carbohydrate supplementation,,2021-11-16,RECRUITING,INTERVENTIONAL,['NA']
14226,NCT03118739,Urinary Albumin to Creatinine Ratio (UACR),MRI Variables - LV Mass,Baseline Flow Mediated Dilatation (Reactive Hyperemia),2017-05-18,COMPLETED,INTERVENTIONAL,['PHASE2']
14227,NCT00989339,endothelial function,carbohydrate metabolism,,2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14228,NCT02578563,Change from baseline in the HbA1c level after 1 year,Change from baseline in Waist circumference at 12 months,,2016-02-12,COMPLETED,OBSERVATIONAL,['NA']
14229,NCT02196272,Medication adherence,Contacts with health services,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
14230,NCT06028399,Quality of life for disease-specific patient reported outcomes,,,2023-07-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14231,NCT03365180,Accuracy of estimate 2,Time spent in normoglycemia,,2018-01-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14232,NCT01040819,Plasma 15-epi-lipoxin A4,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14233,NCT02324036,Attainment of concrete behavioral goal (assessed in a two-week follow-up phone call to the patient),"Improvement in ""red flag"" outcome (assessed from the patient's medical record as the change in the measured value of the outcome measure identified as a high priority outcome)",,2014-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14234,NCT05222815,Change in Diabetes Distress,,,2022-08-29,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14235,NCT02637037,Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State,Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F],,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE1']
14236,NCT01772173,Area under the Curve of algorithm,,,2013-02-01,COMPLETED,OBSERVATIONAL,['NA']
14237,NCT02147925,Intrahepatic lipids (IHL),Change in hemoglobin A1c(HbA1c),,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14238,NCT05181449,To compare the percentage of patients in the TPT and Usual Care groups who have a HbA1c less than 6.5 and are not on any glucose lowering medications (excluding Metformin up to 2000 mg/day) at 12 months (360 days).,To compare the percentage of patients in the TPT and Usual Care groups who have a HbA1c less than at 6.5 and are not on any glucose lowering medications at 12 months (360 days).,,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14239,NCT02011620,Improvement in endothelial function as measured by laser doppler imaging.,Improvement in bone metabolism,,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14240,NCT00005248,,,,1989-08,COMPLETED,OBSERVATIONAL,['NA']
14241,NCT01291160,Number of 100% Wound Closure,,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14242,NCT02539160,Platelet Reactivity Measured by Vasodilator Stimulated Phosphoprotein (VASP) Platelet Reactivity Index (PRI %),Platelet Reactivity Measured by VerifyNow P2Y12,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14243,NCT01124656,Incidence of Adverse Events.,Change from Baseline for Glycosylated Hemoglobin.,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3']
14244,NCT01345227,Adverse events related to the procedure of intra bone marrow islet infusion,Beta-cell function,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
14245,NCT03842267,Changes from baseline HbA1c at week 24,,,2019-05-13,COMPLETED,INTERVENTIONAL,['PHASE3']
14246,NCT03018444,Postprandial GLP-1 secretion,Resting Energy Expenditure,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
14247,NCT06071325,Types and Amount of Diabetes Waste,,,2023-09-19,RECRUITING,OBSERVATIONAL,['NA']
14248,NCT05769335,Glucose area under curve (AUC) after 3 meals,Change in fat mass,,2023-03-15,RECRUITING,INTERVENTIONAL,['NA']
14249,NCT01514487,"Cmax, maximum concentration",Adverse events,,2005-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
14250,NCT00515723,Clamp Derived Insulin Sensitivity (mg/kg/Min),,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
14251,NCT04181853,genetic molecules,,,2020-02-05,COMPLETED,INTERVENTIONAL,['NA']
14252,NCT04938388,HbA1c < 7.0%,Number of participants with treatment-related adverse events assessed by research physician classified according to Good Clinical Practice guidelines,,2022-01-29,TERMINATED,INTERVENTIONAL,['PHASE4']
14253,NCT02308293,"Plasma level of adrenaline in response to hypoglycemia (Adrenaline, measured in arterial plasma)",Brain lactate accumulation measured with 1H-MRS,"Plasma insulin concentration (Insulin levels, measured in arterial plasma)",2015-01,COMPLETED,INTERVENTIONAL,['NA']
14254,NCT02965443,Percentage of subjects achieving a HbA1c ≤ 7.5% and having a reversal from a BBIT to a BOT regimen,changes in fear of hypoglycemia between groups,changes in clinical chemistry/haematology parameters between groups,2018-02-02,TERMINATED,INTERVENTIONAL,['PHASE4']
14255,NCT01590433,Change in Body Weight,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14256,NCT04349670,Complications,Correlation of symptoms,,2020-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14257,NCT03502083,Forearm bloodflow ratio with GLP-1,,,2015-12-01,COMPLETED,INTERVENTIONAL,['NA']
14258,NCT00265746,Incidence of type 2 diabetes mellitus.,Incidence of IGT,,2005-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14259,NCT01719640,microvascular complications,The incidence and severity of adverse events related to the stem cell infusion procedure,,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14260,NCT04426422,gut micribiota,glycemic control,,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14261,NCT00173628,,,,1990-01,UNKNOWN,OBSERVATIONAL,['NA']
14262,NCT01418703,Hypoglycemic Events,Mean Glucose,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
14263,NCT00612014,Change from baseline in the mean Gastroparesis Cardinal Symptom Index score (24 hour recall version) across the four days of dosing. Baseline is the average of the scores collected across the 4 days just prior to admission for dosing.,Cumulative GSA score after each dosing event and after all dosing events,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14264,NCT05426525,Insulin-stimulated glucose disposal,Skeletal muscle energetic stress,,2022-10-13,RECRUITING,INTERVENTIONAL,['PHASE4']
14265,NCT04813133,Serum High Density Lipoproteins (HDL),,,2021-02-05,UNKNOWN,INTERVENTIONAL,['NA']
14266,NCT00952991,Gastrointestinal Symptoms,Glucagon Secretion,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14267,NCT02038517,Relationship of insulin secretion and sensitivity with the development of abnormalities of glucose metabolism after OLT,Relationship of insulin secretion and sensitivity with the development of the metabolic syndrome after OLT,Morbidity and mortality after OLT,2013-06,RECRUITING,OBSERVATIONAL,['NA']
14268,NCT03820349,MRI outcome,Cognitive function,,2018-05-07,COMPLETED,OBSERVATIONAL,['NA']
14269,NCT01079325,To compare the effect of SB-509 versus placebo in subjects with moderately severe diabetic neuropathy (DN) on sural Nerve Conduction Velocity (NCV) at six-months,To evaluate the safety of SB-509 in subjects with moderately severe diabetic neuropathy,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
14270,NCT02673866,Change in weekly Average Daily Pain Score (ADPS),Rescue medication usage,,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14271,NCT04583839,Postpartum weight retention,Diabetes risk perception,Participant adherence with navigation,2020-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14272,NCT03361631,To evaluate the occurrence of clinical adverse event (tolerance) to intracavernous injection of autologous MSC in patients 18 to 50 years of age with complicated type 1 diabetes mellitus with erectile dysfunction refractory to oral treatment.,Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the Injection rate actually achieved,,2018-06-30,UNKNOWN,INTERVENTIONAL,['PHASE1']
14273,NCT04942119,Lifestyle adherence,Side effects or complications,,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
14274,NCT02791035,Correlation between change of HbA1c and urinary glucose excretion,Percentage of subjects achieving the target HbA1c(<6.5%),,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14275,NCT04630795,Plantar skin perfusion before and after use.,Plantar Pressure during walking,,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14276,NCT03439072,Number of Subjects With a Positive Glucose Response,Glucagon Preparation and Administration Time,,2018-01-23,COMPLETED,INTERVENTIONAL,['PHASE3']
14277,NCT03912623,HbA1c evolution,Subgroup analysis,,2019-09-13,UNKNOWN,INTERVENTIONAL,['NA']
14278,NCT01454973,,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
14279,NCT00924053,Vz/F,,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14280,NCT00879125,glycemic control,Correction of lipid profiles,,1999-11,COMPLETED,OBSERVATIONAL,['NA']
14281,NCT06327503,opiorphin levels in saliva,unstimulated saliva flow,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14282,NCT03104738,"Pre-operative Fasting Blood Glucose, as Measured by Standardized Point of Care Capillary Blood Glucose (CBG) Device in the Pre-op Holding Area.",Mean 24-hour Glucose Postoperatively,,2013-11-20,COMPLETED,INTERVENTIONAL,['NA']
14283,NCT02043886,Catecholamines,,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14284,NCT05210517,Fractional uric acid excretion,urinary glucose levels,,2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14285,NCT03912961,Number of subjects where the image readout by retina specialists match the readouts by EyeStar AI system for identifying diabetic eye disease,Number of subjects with ocular diseases other than diabetic retinopathy between the readout by the EyeStar AI system and those by the retina specialists,,2019-01-21,COMPLETED,OBSERVATIONAL,['NA']
14286,NCT03671915,"The time spent of the glucose level drop in below 70 mg/dl over the 72-h, as recorded by continuous subcutaneous glucose monitoring (CGM).","Subject's perception in terms of life-style change, satisfaction and diabetes management",,2019-05-06,COMPLETED,INTERVENTIONAL,['NA']
14287,NCT06251635,Resting State Functional Connectivity (assessed through Functional MRI),Processing Speed,,2024-02-28,RECRUITING,INTERVENTIONAL,['NA']
14288,NCT00138515,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
14289,NCT01715428,carotid intima-media thickness,changes in atherogenic lipoproteins,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
14290,NCT02715193,"Changes from baseline in 24-hour insulin requirements on Day 1 relative to the two 24 hour periods post-treatment on Days 3 and 4, between the REMD-477 and placebo treated subjects, needed to maintain targeted glycemic control.",Changes from baseline over time of lipase,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14291,NCT04878406,Number of treatment emergent adverse events (TEAEs),"Cmax,semaglutide,SD: Maximum plasma concentration of semaglutide upon a single-dose",,2021-05-18,COMPLETED,INTERVENTIONAL,['PHASE1']
14292,NCT04308590,Rate of safety based TEAEs,Proportion of patients with normalization of the mean SBP,,2020-07-27,RECRUITING,INTERVENTIONAL,['PHASE3']
14293,NCT03829891,Changes of blood sugar variation .,Inflammatory factors (hs-CRP) change,Safety Outcome Measure: Serious adverse event,2018-08-07,COMPLETED,INTERVENTIONAL,['NA']
14294,NCT06192693,Hba1c change from baseline to 6 months post randomization,Evaluate quality of life,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14295,NCT03713268,Estimate of subretinal fluid volume before and after surgery for retinal detachment based on surgical view versus based on OCT output,,,2018-09-30,RECRUITING,OBSERVATIONAL,['NA']
14296,NCT04903743,duration of postoperative analgesia,,,2021-01-10,UNKNOWN,INTERVENTIONAL,['NA']
14297,NCT01386099,Beta-cell function,Body weight,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14298,NCT00128154,Increase in insulin sensitivity,weight and/or body composition,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
14299,NCT01396161,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Urinary Recovery,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14300,NCT00707590,"AEs, vital signs, ECG and clinical laboratory test results",DPP-4 inhibition and incretin response,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE1']
14301,NCT00605839,Quality of Parent-child Relationship,,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
14302,NCT06072573,"Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)","Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11 and ≤14",Number and severity of adverse events (AE),2023-11-02,RECRUITING,INTERVENTIONAL,['PHASE3']
14303,NCT01572740,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16,Number of Confirmed Hypoglycaemic Episodes,,2012-04-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14304,NCT04742751,Drug adherence/Pill Counts,Glycemic Control,,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE2']
14305,NCT03989063,Change in balance performance,Change in patient's self-reported outcomes,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
14306,NCT02854423,major cardiac adverse events,Rate of target-vessel revascularization (TVR) in all participants,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
14307,NCT01212198,Incidence of diabetes in patients with high risk for diabetes and gestational diabetes in Koreans,,,2005-05,UNKNOWN,OBSERVATIONAL,['NA']
14308,NCT03963219,"% Time blood glucose in target, day time assess by device",,,2019-08-22,UNKNOWN,INTERVENTIONAL,['NA']
14309,NCT02404870,AUC of FGF23,"1, 25 vitamin D",,2014-09-16,COMPLETED,INTERVENTIONAL,['PHASE1']
14310,NCT05344066,Number of stillbirths,The acceptability of the dietary interventions will be explored qualitatively,Mode of delivery,2022-11-24,RECRUITING,INTERVENTIONAL,['NA']
14311,NCT01506869,number of participants who develop cancer during follow-up,,,2011-05,UNKNOWN,OBSERVATIONAL,['NA']
14312,NCT02620917,Number of Patients With Glycated Hemoglobin on Target,"Number of Patients With HbA1c on Target Using Advanced Pump's Functions, CGM and CHO Counting",,2015-11-01,COMPLETED,OBSERVATIONAL,['NA']
14313,NCT05018416,Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.,,,2021-07-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14314,NCT04283617,Intracerebral concentrations of glucose between T2DM patients,Multitasking Test (MTT),,2021-10-12,WITHDRAWN,INTERVENTIONAL,['NA']
14315,NCT02126358,LDL-C change rate,LDL-C change rate,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14316,NCT06239129,Effect of medications or conditions on kidney function decline,Adverse health events associated to laboratory abnormalities,,2006-01-01,COMPLETED,OBSERVATIONAL,['NA']
14317,NCT02223065,Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]),,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14318,NCT02526810,mean amplitude of glycemic excursions( MAGE),the level of blood 8-hydroxy-2-deoxyguanosine(8-OHdG),the incidence of severe hypoglycemia,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
14319,NCT05974592,Foot Care Behavior Scale (USAS),Diabetic Foot Evaluation Form (DADF),,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
14320,NCT04689984,Improvement in Brief Pain inventory at week 8,,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14321,NCT04620668,Changes in stress as measured by the Perceived Stress Scale (PSS-10),Changes in life satisfaction as measured by the Satisfaction with Life Scale,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
14322,NCT01198678,Evaluate capability to follow glucose concentration changes over 15 consecutive days,,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14323,NCT01868581,Maximum serum insulin degludec concentration (Cmax) (for IDegAsp),,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14324,NCT03613805,device accuracy,changes in fear of hypoglycaemia,,2018-03-14,COMPLETED,INTERVENTIONAL,['NA']
14325,NCT04283318,change of 2h glucose levels,Changes in body composition,,2018-06-13,COMPLETED,INTERVENTIONAL,['NA']
14326,NCT04622722,2-hour postprandial glucose,Gastrointestinal tolerance,,2018-08-22,COMPLETED,INTERVENTIONAL,['NA']
14327,NCT03937050,Mean fasting blood sugar (women with GDM),Adverse perinatal outcomes (composite measure),,2021-05-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14328,NCT03324737,Weight at 4 months post-delivery,Breastfeeding Status,,2017-11-16,COMPLETED,INTERVENTIONAL,['NA']
14329,NCT00437164,changes in fluid related parameters as measured by hematocrit and hemoglobin levels and body weight,"safety/tolerability, as measured by adverse events, clinical laboratory, edema & glycemic measures, ophthalmic assessments; & changes in weight, waist & hip circumference",,2006-09,TERMINATED,INTERVENTIONAL,['PHASE2']
14330,NCT01742624,"Incidence of efficacy failure (treated-BCAR, biopsy-confirmed acute rejection, graft loss rate, death, or follow-up failure)","Safety assessed by the incidence of adverse events, physical exam, and labo-tests",,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
14331,NCT05116410,"Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug",Weight change,,2021-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
14332,NCT02003274,1. Composite plasma glucose and hormone responses to a mixed meal; 2. Glucose control coefficients,Composite plasma free fatty and amino acid responses to a mixed meal,,2013-10,UNKNOWN,INTERVENTIONAL,['NA']
14333,NCT01627184,Glycemic Control during Exercise,System Utility and Usability,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
14334,NCT02710799,Number of consultations authorized,Usage of TelessaúdeRS teleconsultations,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
14335,NCT03399565,HDL-C,,,2016-01-18,UNKNOWN,OBSERVATIONAL,['NA']
14336,NCT05583877,Process Evaluation,Change in HbA1c Percentage,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14337,NCT01076647,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14338,NCT00272012,Change in HbA1c.,Adverse events.,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
14339,NCT02848261,Pediatric Quality of Life Inventory,General and diabetes-specific technology use,,2016-08-15,COMPLETED,INTERVENTIONAL,['NA']
14340,NCT05714852,Change in blood glucose,Change in waist circumference,,2023-02-15,RECRUITING,INTERVENTIONAL,['NA']
14341,NCT05452551,Logarithmic decrement,,,2021-07-06,COMPLETED,OBSERVATIONAL,['NA']
14342,NCT01168258,Genotype frequency of SNP in the study genes of DME participants and control participants.,"Secondary outcomes are ophthalmic measurements, including visual acuity, FA and OCT data, to investigate associations between detected genetic polymorphisms and response to conventional diabetic retinopathy treatment.",,2010-07-07,TERMINATED,OBSERVATIONAL,['NA']
14343,NCT05635266,Biospecimen & Clinical Data Collection,,,2021-10-26,RECRUITING,OBSERVATIONAL,['NA']
14344,NCT01606371,Number of participants with one or more drug related adverse events (AEs) or any serious AEs,Glucose excursion after meals,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14345,NCT02352298,Dario Blood Glucose Monitoring System Accuracy at High Altitude (ISO 15197:2003),,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
14346,NCT01913145,Usability and HbA1c Method Comparison Study Using Lay-Person Micro-Blood Specimens,,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14347,NCT01472406,% of time within zone [80-140] mg/dL except 5 hours post-prandial and during exercise and 3 hours post-exercise,% of time within zone [70-150] mg/dL during the 3 hours following exercise,,2011-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14348,NCT05262946,Cumulative Somatosensory Impairment Index,Validated Spanish version of Short-Form Late-Life Function and Disability Instrument,,2016-01-01,COMPLETED,INTERVENTIONAL,['NA']
14349,NCT03806166,Definitive treatment failure (infection recurrence),Quality of life measured by EuroQol 5 Dimensions 5 Levels Score and EuroQol Visual Analogue Score,,2019-02-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14350,NCT00254085,Blood glucose fluctuations,number of hypoglycemia,,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
14351,NCT01774474,Change in central subfield mean macular thickness as a measurement of efficacy,No. of subjects developing clinically significant macular edema as a measurement of efficacy,Change in central subfield mean macular thickness as a measurement of efficacy,2013-07-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14352,NCT03605810,Performance of classification to predict eGFR,,,2018-07-15,COMPLETED,OBSERVATIONAL,['NA']
14353,NCT01177384,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2011-01-25,COMPLETED,INTERVENTIONAL,['PHASE3']
14354,NCT05670548,Serum metabolomics,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
14355,NCT03725709,Exam metabolic profiles of CSF and plasma in diabetes. (Metabolites analysis of CSF and plasma),,,2016-08-01,COMPLETED,OBSERVATIONAL,['NA']
14356,NCT00569556,"Combined outcome of BP<130/80 mmHG, HgbA1C<8%, and LDL<100mg/dl at 1 year; the primary analysis will compare the intervention to usual care with respect to the percentage of diabetic individuals achieving all three therapeutic goals",Safety of the intervention (occurence of adverse events over the course of the trial),,2006-09,COMPLETED,INTERVENTIONAL,['NA']
14357,NCT01720290,Change in HbA1c (glycosylated haemoglobin A1c),Incidence of hypoglycemic episodes,,2002-07-25,COMPLETED,INTERVENTIONAL,['PHASE4']
14358,NCT03912012,"Glomerular hyper filtration (Glomerular filtration > 135 mL/min/1,73 m2)",trabecular microarchitecture,,2019-07-09,COMPLETED,INTERVENTIONAL,['NA']
14359,NCT02542735,Metabolic syndrome incidence,Risk of metabolic syndrome according to each of the measured SNP,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
14360,NCT00813280,glucose levels,type of insulin treatment,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
14361,NCT04481997,Reasons for prolonging DAPT over 1 year,Diabetes control (HbA1c values),,2021-01-11,UNKNOWN,OBSERVATIONAL,['NA']
14362,NCT05128097,Retrospective study of the management of the main geriatric risks in the University HÔptaux de Strasbourg,,,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA']
14363,NCT00576368,"Glycemic status (Fasting Blood Glucose, Fasting Plasma Glucose, and HbA1C as done in routine medical practice)",,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14364,NCT03998475,Program acceptability - provider,Change in transition readiness,Change in problem solving,2019-07-11,COMPLETED,INTERVENTIONAL,['NA']
14365,NCT03723785,"AUCI287,0-840h,SD: Area under the serum insulin 287 concentration-time curve after a single dose",Positive cross-reactive anti-human insulin antibodies,,2018-11-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14366,NCT01756274,Percent of Blood Glucose Results Within +/-15 mg/dL(<75 mg/dL) and Within +/-20% (>=75 mg/dL) of the Reference Instrument BG Value,Percent of BG Results (Per Population) Within +/-15 mg/dL (<100 mg/dL)and Within +/-15% (>=100 mg/dL) of the Reference Instrument BG Value,"Number of Blood Samples From Babies in the Neonatal Intensive Care Unit (NICU) That Produced Meter Results Beyond What Random Chance Would Predict (i.e., Outside 95% Limits for Studentized Residuals)",2012-12,COMPLETED,INTERVENTIONAL,['NA']
14367,NCT05224986,Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose,"Endothelial cell oxidative stress (sub-set, n≤10)",,2022-01-19,RECRUITING,INTERVENTIONAL,['NA']
14368,NCT05908812,Differences in glycated hemoglobin and/or insulin resistance in diabetic patients with non-sarcopenic obesity vs patients with sarcopenic obesity,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
14369,NCT02317484,HbA1c change level,Body composition and visceral fat change levels,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
14370,NCT00607906,vital signs assessments:,Correlation between drug concentrations & blood sugar levels:,,2007-11-16,COMPLETED,INTERVENTIONAL,['PHASE1']
14371,NCT02631902,Health-Related Quality of Life,Body Mass Index,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
14372,NCT01920256,Change in baseline A1C (glycated hemoglobin) at 12 months,Change in baseline insulin satisfaction at 12 months,Cost,2013-08,COMPLETED,INTERVENTIONAL,['NA']
14373,NCT06111833,Genetic testing for evaluate the different types of MODY,Sudomotor function,,2023-05-22,RECRUITING,OBSERVATIONAL,['NA']
14374,NCT02025296,proportion of patients achieving the target of HbA1c <7% without hypoglycemia,Lifestyle,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
14375,NCT01699932,Change in HbA1c,Hypoglycemia,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
14376,NCT02540486,Percentage of subjects reaching fasting plasma glucose (FPG) target,Serious adverse events,List of concomitant medications initiated after randomization,2013-12,COMPLETED,INTERVENTIONAL,['NA']
14377,NCT03696368,GDM Diagnosis,,,2019-01-04,RECRUITING,OBSERVATIONAL,['NA']
14378,NCT02170870,Mean Intestinal Chemosensitivity to Lipids Perfusion,Rate of Gastric Emptying (GE t 1/2) in Patients With Diabetes Mellitus (DM) or Non-ulcer Dyspepsia (NUD) Compared to Placebo,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14379,NCT00690456,Change from baseline in HbA1c,Percent change from baseline in HDL-C and Triglycerides,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3']
14380,NCT02178176,Adherence to oral hypoglycemic agents: Medication Event Monitoring System,,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
14381,NCT00509236,Number of Participants With Clinical Adverse Events,Change From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment,,2007-10-19,COMPLETED,INTERVENTIONAL,['PHASE3']
14382,NCT01906099,Fasting blood glucose (mg/dl),Triglyceride (mg/dl),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
14383,NCT01354990,Number of Participants With Concomitant Conditions,,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
14384,NCT04100473,Primary Pharmacodynamic Endpoint - PD 2,Secondary Pharmacodynamic Endpoint - PD3,,2018-04-23,COMPLETED,INTERVENTIONAL,['PHASE2']
14385,NCT02796079,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
14386,NCT02532829,Plasma GLP-1 and P-YY measurements by ELISA in participants treated by different bariatric and metabolic surgical techniques.,Plasma insulin levels in participants treated by different bariatric and metabolic surgical techniques.,"Plasma Liver Function Tests (SGOT, SGPT and GGT levels) in participants treated by different bariatric and metabolic surgical techniques.",2015-09,UNKNOWN,OBSERVATIONAL,['NA']
14387,NCT05731544,Change in HbA1c,To assess the effect on HbA1c,,2022-08-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14388,NCT05662475,Sirtuin 1 concentration in GCF,,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA']
14389,NCT01006018,Insulin Secretion,,,2011-07,TERMINATED,INTERVENTIONAL,['NA']
14390,NCT06195488,determine stomach fullness,Incidence of risk factors,,2022-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14391,NCT02673762,A multi marker test score based on a pre-specified model is measured in each patient. The test score is on a scale of 0 to 1.0 and relates to the probability of disease.,Housekeeping gene Ct values on PCR analysis will be measured in individual patients,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
14392,NCT05165758,Compare the levels of quality of life in diabetic subjects with and without foot ulcer,"Compare the quality of life levels according to the type of antidiabetic treatment, in diabetic subjects with and without foot ulcer",,2022-01-21,COMPLETED,OBSERVATIONAL,['NA']
14393,NCT06263348,Incidences of ADRs and SAEs,Response rate,,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE4']
14394,NCT00609154,Insulin Biosynthesis Rate,,,2010-08-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14395,NCT05899166,Decline in Beta-cell Function,"Qualitative patient perspectives, interview - child",Study termination for dyslipidemia,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14396,NCT00817271,P-Glucose levels,"Pharmacodynamics (P-Glucose, S-Insulin and S-C-peptide)",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
14397,NCT03409523,Compliance with Choosing Wisely guidelines measured by number of reductions of medications,Usability measured by module user testing with direct observation and semi structured interviews,,2018-01-08,COMPLETED,OBSERVATIONAL,['NA']
14398,NCT02898493,Internal Consistency (IC) assessed as Cronbach's Alpha Value,Test-retest Reliability,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
14399,NCT04180813,Proportion of T2DM patients with high medication adherence at Week 24,Patient satisfaction by Diabetes Treatment Satisfaction Questionnaire (DTSQ) among linagliptin and acarbose initiators. The DTSQ would be completed at routine physician visits since initiation of the drug,,2020-03-04,TERMINATED,OBSERVATIONAL,['NA']
14400,NCT00490178,,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14401,NCT00566592,Rate of glucose recovery from hypoglycemia.,Hormone and substrate concentrations,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
14402,NCT01241864,HbAlc <6.5% and an absence of severe hypoglycemic events,HbAlc < 6.5% and an absence of severe hypoglycemic events measured after last transplant,,2010-12,RECRUITING,INTERVENTIONAL,['PHASE2']
14403,NCT02274844,Change in Low-Density Lipoprotein (LDL) Cholesterol,Change in Diabetes Medication Counts,Change in Medication Beliefs- Concerns (Concerns About the Negative Effects of Medications),2016-04,COMPLETED,INTERVENTIONAL,['NA']
14404,NCT04593992,Neuropathy symptom score,,,2020-10-20,COMPLETED,INTERVENTIONAL,['NA']
14405,NCT06305416,Changes in Central Subfield Thickness (CST) from Baseline,Evaluation and comparison of safety between reference vs. test drug.,,2024-03-20,RECRUITING,INTERVENTIONAL,['PHASE3']
14406,NCT01926938,"markers of endothelial activation, coagulation and inflammation",,,2003-05,COMPLETED,OBSERVATIONAL,['NA']
14407,NCT05071235,Quality of life (QoL) follow up,Change in visual analogue scale (VAS),,2019-08-27,COMPLETED,INTERVENTIONAL,['NA']
14408,NCT05107388,Incidence rate of hyperglycemia,,,2021-12,UNKNOWN,INTERVENTIONAL,['NA']
14409,NCT04847414,change in BMI,HOMA-IR,,2021-04-10,UNKNOWN,OBSERVATIONAL,['NA']
14410,NCT05202067,Medication adherence,,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
14411,NCT02001337,To create a prospective cohort of subjects with increased probability of being diagnosed with pancreatic cancer and identify pancreatic cancer in this cohort.,,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
14412,NCT05944640,TIR,Mean sensor glucose concentration,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA']
14413,NCT01702051,Beta cell function,Incidence of complications after pancreatic surgery,Incidence of each individual postoperative complication,2012-02,RECRUITING,OBSERVATIONAL,['NA']
14414,NCT04182503,Incidence of gestational hypertension,,,2019-08-12,UNKNOWN,OBSERVATIONAL,['NA']
14415,NCT02785198,Wound healing change quantified by digital photo planimetry,"The biochemical changes during wound healing, is assessed by biochemical markers in peripheral venous blood samples.",,2016-04,TERMINATED,INTERVENTIONAL,['NA']
14416,NCT01176149,Improvement of metabolic control,Percentage of patients reaching target HbA1c (i.e. <7.0%),,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14417,NCT02803918,Number of patients with anti-lixisenatide antibodies,Assessment of pharmacodynamic parameter: plasma glucose AUC-0-4.5 hours,,2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE1']
14418,NCT05887817,Change in CAVI,Change in urinary L-FABP,,2023-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
14419,NCT03291171,Change in self-reported sedentary behaviour,change in coping planning,,2017-10-15,COMPLETED,INTERVENTIONAL,['NA']
14420,NCT01398267,"Glomerular filtration rate (mGFR), measured as iohexol clearance",High density lipoprotein-cholesterol (HDL-C) blood levels,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14421,NCT01350219,Autoimmune control,Analysis of islet beta cell function,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
14422,NCT02563834,Myocardial Fatty Acid Uptake Rate,Myocardial Perfusion Rate,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
14423,NCT01061216,Insulin measurements will be used to compute PK model parameters: absorption rate(s) and elimination rate using an appropriate transport model.,Feasibility of RCS for longer-term ID infusion,,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14424,NCT02138188,"Change from baseline glycosylated haemoglobin (HbA1c) at 6th, 12th and 24th months after transition to CSII.",Measures of Coping Strategies at Baseline,,2013-09,UNKNOWN,OBSERVATIONAL,['NA']
14425,NCT00651196,histomorphometry measurements,Bone mineral density,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
14426,NCT06014684,Peripheral Insulin sensitivity,24h substrate metabolism,Blood glucose levels measured continuously over 7 days.,2023-07-13,RECRUITING,INTERVENTIONAL,['NA']
14427,NCT00832624,Change From Baseline in HbA1c (Hemoglobin A1c) at Week 18,,,2008-11-26,TERMINATED,INTERVENTIONAL,['PHASE4']
14428,NCT00729040,Total steps,content of posts (qualitative),,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14429,NCT05551988,Predictors of amputation in diabetic foot ulcer patient,Antibiotic resistance level,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
14430,NCT05362071,Glycaemic control,Subjective perception of well-being,,2022-05-02,COMPLETED,INTERVENTIONAL,['NA']
14431,NCT00663949,decreasing urinary protein,,,2006-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14432,NCT02172092,Extracellular volume,Distribution of strong and weak acids,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
14433,NCT02343107,dietary score (International Diet Quality Index),Blood pressure,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
14434,NCT05435196,The glycosylated hemoglobin A1c,The Visual Analog Scale,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
14435,NCT03991026,Change in Body mass index (kg/m^2),Change in Blood pressure (mmHg),,2019-06-18,COMPLETED,INTERVENTIONAL,['NA']
14436,NCT01702311,Mean Fasting Blood Glucose,Number of Subjects With BG > 300 mg/dL,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14437,NCT00123227,Plaque volume change over 12 months as assessed by cardiovascular magnetic resonance (CMR),Change in plaque gadolinium enhancement as a measure of fibrous cap inflammation and plaque neovascularisation,,2002-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
14438,NCT00738023,Changes in Systolic Blood Pressure During Initial Intralipid Infusion,Changes in Systolic Blood Pressure During Intralipid Infusion Post-rosiglitazone Intervention,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14439,NCT02496156,Continuous Glucose Monitor Use Profile or Insulin Pump Use Profile,SURE Test,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
14440,NCT00819884,"24-hr glucose (Calculated plasma glucose AUC0-24, change in fasting plasma glucose)",Pharmacodynamics (S-Insulin AUC0-24 and C-peptide AUC0-24),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14441,NCT04913909,Change in blood fructosamine levels in Type 2 diabetic patients an Oral probiotic use,,,2015-09-10,COMPLETED,INTERVENTIONAL,['NA']
14442,NCT03285594,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18,Percentage of Participants With Adverse Events (AEs),Percentage of Participants With Hypoglycemic Events,2017-09-15,COMPLETED,INTERVENTIONAL,['PHASE3']
14443,NCT06092476,Efficacy endpoint 2,Mechanistic: Change in Cystatin Value,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14444,NCT00455988,,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
14445,NCT02084498,Change in HbA1c,Frequency of serious hypoglycemic events,Treatment Satisfaction,2012-09,COMPLETED,INTERVENTIONAL,['NA']
14446,NCT00295659,,,,2001-01,COMPLETED,OBSERVATIONAL,['NA']
14447,NCT00138671,Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco),Severe Hypoglcyemic Event Rates,,2003-01,TERMINATED,INTERVENTIONAL,['PHASE3']
14448,NCT05461495,BMI,,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
14449,NCT00501462,drug & metabolite plasma levels,"Safety and tolerability parameters, including AEs and clinically relevant changes in vital signs (heart rate and blood pressure), ECGs, urine electrolytes, and clinical laboratory assessments (clinical chemistry, hematology, and urinalysis).",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14450,NCT04517201,Fasting plasma glucose of T2D patients,Total insulin dose,,2020-11-04,UNKNOWN,INTERVENTIONAL,['NA']
14451,NCT00461006,Relative change from baseline in glomerular filtration rate,"Adverse events (AEs), laboratory parameters.",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14452,NCT05881200,Change in insulin resistance,,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
14453,NCT01835678,effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature,determine the relationship between changes of renal endothelial function with metabolic changes and changes of isoprostanes,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14454,NCT04636307,Presence of ischemia,,,2021-09-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14455,NCT03317028,The HbA1c treatment effect among CS02 groups and the Placebo group,,,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14456,NCT01153100,Reduction in rebound hyperglycemia (blood glucose levels over 180 mg/dl),Reduction in time to get back to control of glycemia (140-180 mg/dl) if rebound hyperglycemia occurs,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14457,NCT00433758,Clarke Error Grid,,,2006-12,UNKNOWN,INTERVENTIONAL,['NA']
14458,NCT03025399,"the changes of degree of retinal microvascular lesions before and after treatment (no, mild non proliferative phase, moderate non proliferative phase, severe non proliferative phase, proliferative phase)",Change of Vision (analysis of visual acuity before and after medication using EDTRS international visual acuity chart),,2017-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14459,NCT00359112,Change in HbA1c level from baseline following 52 weeks of treatment.,Diabetes treatment satisfaction.,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14460,NCT02568514,Change in inpatient mortality,Change in Hospital Consumer Assessment of Healthcare Providers and Systems (HCAPs) scores,,2016-08,WITHDRAWN,INTERVENTIONAL,['NA']
14461,NCT04341571,First phase of insuline secretion,Incidence of treatment-Emergent Adverse Events,,2019-10-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14462,NCT00831519,oxidative stress,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
14463,NCT03172260,HbA1c,Kidney function,,2017-02-08,COMPLETED,OBSERVATIONAL,['NA']
14464,NCT01866462,Metformin Tolerance,Weight Loss,,2013-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14465,NCT00811889,To determine the safety and tolerability of bardoxolone methyl when administered for 12 months (52 weeks)following randomization to type 2 diabetic patients with CKD (eGFR 20 - 45 mL/min/1.73m2).,To determine the change in eGFR from baseline in patients with type 2 diabetes and CKD (baseline eGFR = 20 - 45 mL/min/1.73m2) after receiving bardoxolone methyl for 12 months (52 weeks) following randomization.,,2009-04-30,COMPLETED,INTERVENTIONAL,['PHASE2']
14466,NCT02409511,Complementary markers for improving the performance of MA,To test whether the enhancement of this specific marker of kidney injury is able to identify those patients in which MA really means diabetic nephropathy.,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
14467,NCT04838561,"INsulin delivery Systems: Perceptions, Ideas, Reflections and Expectations Questionnaire Post Intervention (Youth and Parent Versions)",Estimated HbA1c (%),"INsulin delivery Systems: Perceptions, Ideas, Reflections and Expectations Questionnaire (Baseline and Post Intervention)",2021-03-15,COMPLETED,OBSERVATIONAL,['NA']
14468,NCT05177094,Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm),,2022-01-26,COMPLETED,INTERVENTIONAL,['PHASE2']
14469,NCT05228067,Change in dopamine-dependent cognitive function,Food choice,,2021-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14470,NCT03195257,C-terminal telopeptide of type I collagen (CTX).,N-terminal propeptide of type 1 procollagen (P1NP).,,2012-11-17,COMPLETED,INTERVENTIONAL,['NA']
14471,NCT03782441,Safety evaluation: paucity of adverse events,Device usability,,2019-11-05,COMPLETED,INTERVENTIONAL,['NA']
14472,NCT03326232,Mean blood glucose (mg/dL),Respiratory distress syndrome,,2017-11-13,UNKNOWN,INTERVENTIONAL,['NA']
14473,NCT06304844,Determine the number of participant with eGFR<60 ml/min/1.73 m2 or albuminuria (urinary albumin-to-creatinine ratio (ACR) ⩾3 mg/mmol) in patients with type 2 DM and MAFLD,,,2024-04-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14474,NCT00543517,,,,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3']
14475,NCT01328717,Percent of Fingerstick Blood Glucose (BG) Results Within +/-20%(>=75 mg/dL) and Within +/- 15mg/dL (<75 mg/dL) of Laboratory Glucose Method,Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Evaluation),,2010-12,COMPLETED,INTERVENTIONAL,['NA']
14476,NCT02312050,The change in eGFR from Screening to measurements taken at Week 26,Incidence of major cardiac events,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
14477,NCT02867436,Change in C-peptide area under the curve measured by mixed-meal tolerance test (MMTT) between group on GFD and standard gluten-containing diet.,Differences in fecal microbiome between children on normal diet and children on gluten-free diet over the first year of diabetes duration;,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
14478,NCT00489645,• To examine the influence of acute glycaemia (normoglycaemia and hyperglycaemia) on gastric emptying kinetics in patients with type 1 diabetes and non diabetic subjects when treated with subcutaneous (SC) injections of pramlintide.,"• Gastric peristalsis derived from high-resolution scintigraphy by means of Fast Fourier Transform (FFT) analysis. • Effects on gastric emptying and on the rate of appearance of ingested glucose appearance, postprandial glucose sequestration, endoge",,2005-01,COMPLETED,INTERVENTIONAL,['NA']
14479,NCT04894461,Pain assessment measured with the Neuropathy Pain Scale (NPS),Serum Albumin levels,,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA']
14480,NCT01285076,Number of Participants With Hypoglycemic Episodes,Self-reported Barrier Questionnaire,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
14481,NCT04595474,Proportion of subjects with advanced fibrosis,Lipid profile,,2021-01-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14482,NCT00813475,All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital,Total # of in-hospital days during 1 year follow-up.The rate of any major clinical events during 1 year follow-up. Hypoglycemic events during index hospital stay,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
14483,NCT01606085,Diabetes health related quality of life measures,Diabetes (DM) self efficacy,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
14484,NCT00419302,Glycemic response to a meal challenge,Safety variables,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14485,NCT03151343,Invasive hemodynamics,Daily activity,,2017-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
14486,NCT01275794,To assess frequency of target levels of HbA1c ≤ 7% in patients with T2D during OAD monotherapy,To compare the results of OAD monotherapy in different groups of patients,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
14487,NCT02451631,Change in HbA1c (%),Change in FBG(Fasting Blood Glucose),,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
14488,NCT06330727,Fasting triglycerides (mmol/L),Standard deviation of heart rate variability (SDNN),,2024-02-05,RECRUITING,INTERVENTIONAL,['NA']
14489,NCT01411930,Insulin sensitivity,Hepatic glucose production,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14490,NCT02859779,Needs and expectations of adolescents with type 1 diabetes for skills to be developed during the educational sessions,Needs and expectations of parents of adolescents with type 1 diabetes for skills to be developed during the educational sessions,,2017-02-04,COMPLETED,INTERVENTIONAL,['NA']
14491,NCT00118950,HaemoglobinA1c,"Adverse events and safety variables (e.g. hypoglycaemia, haemoglobin, white blood cell count, cobalamine and folate).",,2001-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14492,NCT03676595,Change of Berg Balance Scale (BBS) score,Change of Unipedal Stance Test (UST) time,,2013-11-20,COMPLETED,INTERVENTIONAL,['NA']
14493,NCT02059538,Look for differences in gut microbiota signatures using metagenomic approach in the 8 different groups,Establish differences in fecal metabolomic signatures using 1H nuclear magnetic resonance (NMR) spectroscopy and Ultra-high Performance Liquid Chromatography Mass Spectrometry ((UPLC-MS) on fecal samples) in the 8 different groups (cf above mentioned),Look for statistical association between gut derived signatures and lifestyle factors such as environment and diet (using data obtained from environment questionnaires and the results of both FFQ and Three day 24h diet recall),2013-06,UNKNOWN,INTERVENTIONAL,['NA']
14494,NCT05465317,"Composite outcome including: 40% decline in estimated glomerular filtration rate (eGFR), incident end-stage kidney disease (ESKD), all-cause mortality",Genital Mycotic infection,,2022-08-08,COMPLETED,OBSERVATIONAL,['NA']
14495,NCT00938119,"MACE (clinically driven TLR, cardiac death, MI, ST) at 12 months","ARC (probable + definite) ST at 1-day, and 1 and 12 months",,2009-08,TERMINATED,OBSERVATIONAL,['NA']
14496,NCT06046417,Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L).,Thematic interview analysis,Safety Endpoints,2023-11-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14497,NCT00700960,HbA1c,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
14498,NCT01345435,Changes in Hemoglobin A1c,Medication compliance,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14499,NCT02846779,Insulin Persistence,Number of Hospitalizations,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
14500,NCT02906917,Change in HbA1c (%) - Week 26,Incidence of TEAEs,,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
14501,NCT01685879,Blood Glucose response,Appetite Response,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
14502,NCT00273104,Improvement of co-morbidities,Safety issues,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
14503,NCT04695158,Physical Activity Level for Group III,The levels of Routine Blood Samples for Group III,,2021-01-06,UNKNOWN,OBSERVATIONAL,['NA']
14504,NCT05769439,evidence-based DhMRs concerning incident obesity,,,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14505,NCT00832741,blood glucose,gastric emptying,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
14506,NCT03196336,hospitalization,"severe evolving complication (ischemic or proliferative retinopathy, severe renal insufficiency, severe hypoglycemia, coronaropathy or evolving foot lesion)",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
14507,NCT01438814,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment,Change From Baseline in HbA1c Over Time,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14508,NCT00674596,,,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14509,NCT00570466,Dietary intake of servings of fruit and vegetables as measured by three 24-hour dietary recalls; and minutes of moderate to vigorous physical activity as measured by 5 days of accelerometry.,"Height, weight, waist circumference, propylthiouracil (PROP) sensitivity status and nutrition and physical activity psychosocial questionnaires.",,2008-01,COMPLETED,INTERVENTIONAL,['NA']
14510,NCT04403217,Changes in fasting insulin (μU/mL) levels from baseline to visit 2 and 3,Changes in waist perimeter (cm) from baseline to visit 2 and 3,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
14511,NCT04662866,Endogenous glucose production during fasting,,Intraabdominal fat,2021-02-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
14512,NCT02324309,Post-breakfast glucose exposure (AUC),Injection site toleration (VAS and severity scales),,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14513,NCT04529824,Diabetes Status,Fitbit-derived sedentary time,Healthcare medical costs,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
14514,NCT04678895,Change in Numeric Rating Scale for Pain,Ratio of Pre-treatment Expectations Compared to Change in Numeric Rating Scale,,2020-12-22,RECRUITING,INTERVENTIONAL,['PHASE2']
14515,NCT00323414,Number of Participants With Improvement of >= 2 Points in NAFLD Activity Score (NAS),HbA1C Levels,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14516,NCT00941161,"fasting glucose, HbA1c","total cholesterol, C-LDL, C-HDL, triglycerides, VLDL, insulin",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14517,NCT04412798,Capillary glycaemic responses,Systolic/diastolic blood pressure,,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA']
14518,NCT03890172,Change of ulcer size,time of wound healing,,2019-07-30,UNKNOWN,OBSERVATIONAL,['NA']
14519,NCT00946517,Parenting styles,Adherence to therapy,,2009-07,TERMINATED,OBSERVATIONAL,['NA']
14520,NCT01040104,Time to wound healing / Scar maturation,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
14521,NCT01420692,"The Changes in the Peripheral Blood Levels of TNF-α, IL-6, MCP-1, sICAM-1, sVCAM-1, vWF, E-selectin, P-selectin, Endothelin-1, PAI-1, tPA and HMW Adiponectin at 12th and 24th weeks compared to the baseline level, as Measures of Inflam. and Coagulation","Calculation of Body-mass Index, Body Fat Mass, Level of Insulin Resistance and the Insulin Secretion Capacity of Pancreatic Beta Islet Cells as Measures to Identify the Effects of Gliclazide and Insulin Detemir Treatments on Diabetes Progression",,2010-06,COMPLETED,INTERVENTIONAL,['NA']
14522,NCT01452451,Number of subjects with adverse events as a measure of safety and tolerability,The pharmacodynamics in repeat-dose,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14523,NCT00399711,HbA1c,Percentage of subjects achieving sudden levels of HbA1c,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
14524,NCT00534183,Study of metabolic profile,Study of obesity and diabetes,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
14525,NCT05031572,To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of insulin after crossing arm),variability on biliary acids (BA) after weight loss,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
14526,NCT02583061,Glucose tolerance status,,,2003-09,RECRUITING,OBSERVATIONAL,['NA']
14527,NCT00154401,HbA1c,Safety and tolerability,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14528,NCT02863887,Percent weight loss,Change in Pulse,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
14529,NCT01373346,Operation Related Mortality,Albumin : Good Response Group,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
14530,NCT04551625,"High amplitude, antegrade contractions assessed with HRCM",Distance of capsule movement.,,2020-10-15,UNKNOWN,OBSERVATIONAL,['NA']
14531,NCT00770367,Asymmetric Dimethylarginine (ADMA) Level,NOx f2-isoprostanes,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
14532,NCT00065650,HbA1C,Lipids,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
14533,NCT03794960,Treatment Effect,Immunologic,,2019-12-14,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14534,NCT01586897,"Medication Safety Monitoring - ACE/ARB, Thiazide",,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14535,NCT05176847,Change in body weight,Change in minutes a week of moderate to vigorous physical activity (MVPA),,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14536,NCT00590876,fMRI,,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
14537,NCT05570435,3h-iAUC of PPGR,iCmax of PPIR,additional endpoints slopes derived from PPGR,2022-11-16,COMPLETED,INTERVENTIONAL,['NA']
14538,NCT00267683,HbA1c,Percentage of subjects achieving the treatment target of HbA1c value < 6.5%,,2005-12,TERMINATED,INTERVENTIONAL,['PHASE3']
14539,NCT01377688,Blood pressure and /or Estimated Glomerular Filtration Rate (eGFR),,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
14540,NCT00678080,The Number of Participants Who Achieved a Hemoglobin A1C <7%,Number of Participants With Newborns Who Needed Neonatal Dextrose,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
14541,NCT05268926,urinary albumin/creatinine ratio,number of SAE's and AE's,,2022-02-03,TERMINATED,INTERVENTIONAL,['PHASE2']
14542,NCT01862120,Treg response following the induction cure period,Treg response during the maintenance period compare to the baseline,,2013-06-27,COMPLETED,INTERVENTIONAL,['PHASE2']
14543,NCT03949504,Concentration of glucose in plasma,,,2019-01-09,COMPLETED,OBSERVATIONAL,['NA']
14544,NCT01028963,Subject incidence of adverse events,Effect on fasting plasma glucose concentration,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14545,NCT02094521,Area under the NNC0113-0987 plasma concentration time curve,Maximum observed NNC0113-0987 plasma concentration,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14546,NCT00665106,Ocular safety,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14547,NCT02293720,Measure the incidence of device related serious adverse events requiring an early removal,,,2015-04,WITHDRAWN,INTERVENTIONAL,['NA']
14548,NCT06037512,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-04-13,COMPLETED,INTERVENTIONAL,['NA']
14549,NCT01964976,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin Level,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
14550,NCT00302224,"To evaluate the safety and tolerability of 14 daily doses; To determine the pharmacokinetic (PK) profile in plasma of DIO-902 after a single dose, and after fourteen daily doses; To evaluate the pharmacodynamic effects of fourteen daily doses","To explore the impact of treatment with the enantiomer of ketoconazole on markers of inflammation and coagulation as well as on lipomic profiles, pre- and post-treatment",,2005-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14551,NCT03791567,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
14552,NCT01136512,Vitamin B12 level,methylmalonic acid,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
14553,NCT02640768,Composite performance score computed as the sum of the performance scores of all 5 domains of appropriateness and efficacy in both the intervention and the control wards,discharge condition in the intervention and control wards,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
14554,NCT00035542,,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14555,NCT00744965,Mean Fetal Weight at Birth,Need for Insulin Therapy,,2008-09-16,COMPLETED,INTERVENTIONAL,['PHASE4']
14556,NCT04118374,Change in endothelial function - diet 2,,,2019-03-29,RECRUITING,INTERVENTIONAL,['NA']
14557,NCT02963662,The levels of adipokines and inflammatory cytokines in the fasting state at preoperation in patients with BMI ≥35 kg/m2 or BMI ≥28 kg/m2 and T2D or metabolic syndrome.,"The adipokines and inflammatory cytokines levels in the fasting state at 1 month, 3 months, 6 months and 12 months after surgery",,2015-10,COMPLETED,INTERVENTIONAL,['NA']
14558,NCT02750410,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Daily Total Insulin Dose,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14559,NCT00605020,HbA1c,Change in weight,,2003-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14560,NCT05809817,Metabolic control,,,2023-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14561,NCT01425645,Proportion of study subjects achieving a 7% weight loss,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
14562,NCT02605564,Area Under the Curve (AUC) of C-peptide on mixed meal tolerance test,,,2016-01-19,TERMINATED,INTERVENTIONAL,['NA']
14563,NCT03073070,Measurement of RBC survival in diabetic children using biotin-labeled RBCs,,,2017-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14564,NCT03653533,Occurrence of hypoglycemia between a phase with no SmartGuard® function and a phase with SmartGuard® function,,,2019-01-07,TERMINATED,INTERVENTIONAL,['NA']
14565,NCT03919617,Rate of Resting Energy Expenditure (REE),,,2019-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14566,NCT01353495,Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
14567,NCT01579292,Body mass index,Fasting plasma glucose,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14568,NCT03208010,Change from baseline in body mass index (BMI) at 36 months,Text Messages Intervention - Follow-up Phone Call Interview,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
14569,NCT00457470,Change of retinal thickness at Day 15 or Day 25 depending on dosing regimen,; Proportion of eyes experiencing an improvement in the degree of retinopathy at Day 28,,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14570,NCT01917656,Change in Fructosamine From Start of Ramadan to End of Ramadan,"Number of Treatment Emergent Adverse Events (TEAEs) During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.",,2014-01-09,COMPLETED,INTERVENTIONAL,['PHASE4']
14571,NCT02421510,Change From Baseline in A1C at Week 24,Percent Change From Baseline in Body Weight at Week 24,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14572,NCT04265469,Foot Self-care Behavior,,,2016-02-10,COMPLETED,INTERVENTIONAL,['NA']
14573,NCT00208637,Dietary intake as measured by 3-day weight diet records,All measures to be compared at end of study (6 months),,2002-08,COMPLETED,INTERVENTIONAL,['NA']
14574,NCT02773368,Change in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Treatment Related Impact Measure for Diabetes (TRIM-D),,2016-05-23,COMPLETED,INTERVENTIONAL,['PHASE3']
14575,NCT03232437,Precision (as measured by %CV) of HbA1c measurements,,,2017-06-14,COMPLETED,OBSERVATIONAL,['NA']
14576,NCT00501930,"Clinical laboratory tests, ECGs, adverse events",clinical lab tests,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14577,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions",Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14578,NCT00629213,Incidence of newly diagnosed type 2 diabetes,newly diagnosed hypertension,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
14579,NCT00354536,blood plasma levels of GSK716155,blood plasma levels of GSK716155,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14580,NCT02023918,Insulin Sensitivity,Lipolysis,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14581,NCT05915949,HbA1c,Fib-4,Adverse events,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
14582,NCT02064309,"Safety of device, as evaluated by incidence of adverse events or serious adverse events judged probable or highly probable related to the device","8. Number of patients with non-fasting c-peptide concentrations >0.003 nmol/l at 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 and 26 weeks post-transplantation; i.e. Kaplan-Meier analysis of survival time for islet grafts.",7. Score in diabetes treatment satisfaction questionnaire in transplanted patients at 12 and 26 weeks post-transplantation when compared to before transplantation and 6 months after explantation.,2014-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14583,NCT02849288,Assessment of safety outcomes and serious adverse events and device related adverse effects.,System functionality as evidenced by the availability of CGM data,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14584,NCT04061746,12 month Change in C-peptide area under the curve after a 2-hour MMTT,Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements,Changes in serum cytokine levels after treatment,2020-02-27,RECRUITING,INTERVENTIONAL,['PHASE1']
14585,NCT02503527,Blood glucose variability (within patient standard deviation of blood glucose values per day),"Gastro-intestinal intolerance (AEs, complications)",,2015-08,TERMINATED,INTERVENTIONAL,['NA']
14586,NCT04119947,The Safety and tolerance of SY-009，Collecting Number of subjects with adverse events as assessed by CTCAE V5.0,C-peptide secretion following single dose of SY-009,,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14587,NCT05293587,Participant satisfaction,Change in Aerobic Fitness from Baseline at 8 weeks,Structured Assessment of FEeasibility,2021-09-13,COMPLETED,INTERVENTIONAL,['NA']
14588,NCT01106690,Change in HbA1c From Baseline to Week 26,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14589,NCT05325294,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),,2022-05-05,COMPLETED,INTERVENTIONAL,['NA']
14590,NCT04569396,Fatty Liver Index,,,2016-01-12,COMPLETED,OBSERVATIONAL,['NA']
14591,NCT02227745,efficiency in visual function with dorzolamide after photocoagulation,,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
14592,NCT02809911,Lower Extremity - Pain Sensitivity to Various Experimentally Induced Pain Stimuli,,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
14593,NCT04226820,exercise test wilt hand held dynamometer,Blood pressure analysis,,2020-02-01,RECRUITING,INTERVENTIONAL,['NA']
14594,NCT00803296,Incretin effect,Insulin resistance,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
14595,NCT04089202,Glycemic control based on A1c,Cost effectiveness analysis (CEA),,2020-02-03,TERMINATED,INTERVENTIONAL,['NA']
14596,NCT05454176,Cost analysis of CGM,,,2022-08-15,RECRUITING,INTERVENTIONAL,['PHASE4']
14597,NCT03067012,"micronutrients' deficiency (iron, folate, vitamin B12)",Remission rates of co-morbidities,,2015-09-01,COMPLETED,INTERVENTIONAL,['NA']
14598,NCT01023919,To investigate the difference of surface coverage pattern between diabetic patients and non-diabetic patients after DES (Cypher stent or YINYI stent)implantation,To investigate the differences of surface coverage pattern，malapposition and the incidence of thrombosis between Cypher stent and YINYI in non-diabetic patients,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
14599,NCT04311164,Glycated Hemoglobin A1c (HbA1c),"Educational, time and risk preferences",,2020-05-15,COMPLETED,OBSERVATIONAL,['NA']
14600,NCT05152277,Number of Adverse Events,Glucose concentration,,2021-12-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14601,NCT03339336,Change from Randomization in Weekly Mean ADP Score,Maximum Observed Concentration (Cmax) at Steady State,,2018-05-31,TERMINATED,INTERVENTIONAL,['PHASE2']
14602,NCT05069545,Change in time in range (3.9-10 mmol/L),DHSS-HCP(Health Care Professional),,2021-10-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14603,NCT02245659,Average nightly hours of CPAP use,Maternal glucose levels,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
14604,NCT03972904,Insulin resistance index changes,Glycated albumin changes,BMI changes,2019-06-20,UNKNOWN,INTERVENTIONAL,['NA']
14605,NCT05439928,Time to Resolution of Metabolic Acidosis,Cost savings,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14606,NCT04243200,Repeat ambulance calls and attendances for hypoglycaemia within 14 days.,"To assess whether the ""Hypos can strike twice"" intervention can reduce repeat ambulance calls and attendance for hypoglycaemia within 30 and 90 days.",,2020-09-14,COMPLETED,OBSERVATIONAL,['NA']
14607,NCT01570660,whole body insulin sensitivity,intrahepatocellular lipid content,,2002-02,COMPLETED,INTERVENTIONAL,['NA']
14608,NCT04017832,Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%),Number of Participants With Treatment-emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes During Exposure to Trial Product,,2019-07-29,COMPLETED,INTERVENTIONAL,['PHASE3']
14609,NCT00276250,The Number of Insulin-independent Subjects at Day 75 (± 5 Days) Following the First Islet Cell Transplantation,"Number of Subjects With Normal Renal Function, as Measured by Serum Creatinine Levels",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14610,NCT01986231,Assess Difference in Hepatic Glycogen Measured in the Fasting State Before vs. After Repeated Glucagon Administration,Assess Difference in Hepatic Glycogen Measured in the Fed State Before vs. After Repeated Glucagon Administration,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14611,NCT05542420,The proportion of patients prescribed cardiovascular disease (CVD) medications,,,2022-10-19,COMPLETED,OBSERVATIONAL,['NA']
14612,NCT03221868,Change in HbA1c,Change in QoL,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
14613,NCT04026165,eGFRcr Slope,eGFRcys Slope,,2019-07-24,COMPLETED,INTERVENTIONAL,['PHASE2']
14614,NCT04238208,Outcome 2 Patient Global Impression of Change score,,,2019-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
14615,NCT05641753,Change in Light Transmission Aggregation (LTA) from Baseline,Percent Change in CD8 Cell Population from Baseline,,2022-12-06,RECRUITING,INTERVENTIONAL,['PHASE4']
14616,NCT03222791,Mean change in Glucose Tolerance Test from the baseline level,Change in HOMA-IR from baseline,Patients compliance evaluation using a compliance questionnaire,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
14617,NCT06273657,HbA1c,Diabetes Treatment Satisfaction,,2024-02-07,RECRUITING,INTERVENTIONAL,['NA']
14618,NCT04467255,Six-minute walk test,Surface multichannel electromyographic variables.,,2018-05-03,RECRUITING,INTERVENTIONAL,['NA']
14619,NCT01603329,Medication Adherence,Demographic Controls for Patients,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
14620,NCT01319487,change from baseline of central retinal thickness as determined by logOCT,Change in macular volume and retinal thickness from baseline to Week 12 and Week 24,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14621,NCT00194506,Hemoglobin A1c,Utilization,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
14622,NCT05659043,Qualitative and Quantitative Mapping ApoA-I Glycation Modification Profiles,Individual ApoA-I Glycation Profiles Variability and Cardiovascular Events,,2017-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14623,NCT01409213,Change From Baseline for Mean Fasting Blood Glucose (FBG),,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
14624,NCT01858896,Change in Flow mediated dilation (FMD),,,2013-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
14625,NCT01404676,Change in mean amplitude of glycemic excursion(MAGE) for 12 weeks(12weeks - 0 week).,Change from baseline in oxidative stress markers and inflammatory markers at 12 weeks. Change from baseline in endothelial cell function at 12 weeks.,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14626,NCT03041571,Patient provider orientation scale score (PPOS),Medical honors students focus group,,2017-03-01,WITHDRAWN,OBSERVATIONAL,['NA']
14627,NCT01005264,Decrease in ulcer size,Complete healing rate at the end of the study,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14628,NCT02919839,blood glucose,,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
14629,NCT03322631,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose,,2017-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14630,NCT02538120,Neurovascular microcirculatory response,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14631,NCT04304560,Diastolic Function,Galectin -3,,2020-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
14632,NCT06059287,Extra-cellular volume fraction,Native T2 mapping,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14633,NCT05992415,Adherence to Follow-up Eye Care,,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14634,NCT04523363,Birth Weight,Placental Pathology,,2025-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
14635,NCT02050191,attitudes and perceptions re: feasibility of web portal,,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
14636,NCT01468987,Change From Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks,Rapid Assessment of Physical Activity (RAPA) at 26 Weeks,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14637,NCT00346996,Severe hypoglycaemia,hypoglycaemia during daytime,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14638,NCT04060745,Changes in glucose metabolism between non-activated and cold-activated BAT,Changes in metabolic profiles in cold versus thermoneutral conditions,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
14639,NCT04242758,Urinary Phthalates concentration,Albumin excretion,,2019-06-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
14640,NCT00627783,"Death from all causes, non-fatal myocardial infarction, non-fatal stroke, or heart failure requiring hospitalization or emergency service intervention, measured after a minimum follow-up of 2 years",Unstable angina requiring hospitalization Coronary events Coronary revascularization,,2000-12,TERMINATED,INTERVENTIONAL,['NA']
14641,NCT00262977,Patient reported aspirin use daily or every other day.,,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
14642,NCT00811044,Genes affecting the development of Type 2 diabetes will be identified,Any differences between genetic groups in the metabolism of glucose/sugar will be studied to the extent that the data allow,,2000-10,WITHDRAWN,OBSERVATIONAL,['NA']
14643,NCT06243939,Quality of Life Scale,,,2023-06-06,RECRUITING,INTERVENTIONAL,['NA']
14644,NCT02328508,wound healing,glycemic control,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14645,NCT03971838,Enrollment and participation rates in a diabetes prevention intervention,BMI,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
14646,NCT02251067,Change from baseline in albuminuria,Change from baseline in eGFR,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14647,NCT04232631,Evaluating the effectiveness of 3 devices to measure perfusion to predict wound healing,,,2021-04-28,RECRUITING,OBSERVATIONAL,['NA']
14648,NCT01620450,Maximum insulin aspart concentration (Cmax IAsp),Adverse events,,2004-11-20,COMPLETED,INTERVENTIONAL,['PHASE1']
14649,NCT01215994,,,,2009-03,UNKNOWN,OBSERVATIONAL,['NA']
14650,NCT01666938,level of physical activity,Metabolic Control,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
14651,NCT01884792,Blood sugar area under the curve,Accelerometer counts,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
14652,NCT02051842,Oxidative stress,,Oxidative stress,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14653,NCT01270789,Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2),Glycemic Control,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14654,NCT03881956,Pre-test and post-test scores,Postpartum characteristics of neonates,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
14655,NCT00617916,,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
14656,NCT01812590,Pancreatic endocrine function,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
14657,NCT05754567,Childhood executive function,Significant associations between maternal pre-existing diabetes and ADHD (Attention Deficit Hyperactivity Disorder),Maternal CGM (Continuous Glucose Monitor) percentage time in target,2023-09-07,RECRUITING,OBSERVATIONAL,['NA']
14658,NCT04420936,Change in body weight,Change in blood pressure,,2021-09-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14659,NCT02673203,Glucose Nadir,Nutirion Intake: Protein,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
14660,NCT04616027,Fraction of unbound drug in plasma [fu],Incidence of treatment emergent Electrocardiogram [ECG] abnormalities,,2021-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
14661,NCT02908087,Serum C-peptide AUC,Insulin dose,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14662,NCT05166525,90-day hospitalization for any cause,"90-day composite of hospitalization for any cause, emergency department visit for any cause or all-cause death",,2020-04-27,COMPLETED,INTERVENTIONAL,['NA']
14663,NCT01087541,Glycosylated Haemoglobin A1c at 6 Months,Systolic and Diastolic Blood Pressure,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
14664,NCT05037695,NGAL values in pre-specified periods,Death,,2021-07-21,UNKNOWN,INTERVENTIONAL,['PHASE4']
14665,NCT04806685,Hemoglobin A1c,Insomnia Severity Index,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
14666,NCT00058968,Reduction in average pain severity as measured by an 11-point Likert scale.,Dynamic Allodynia measure to elicit the pain severity to a normally non-painful stimulus.,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14667,NCT01401127,Glucose excursion,Comparison between the two groups of levels of cortisol,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
14668,NCT01512940,Percent excess weight loss,Resolution of comorbidities,,2011-10,UNKNOWN,INTERVENTIONAL,['NA']
14669,NCT04637880,25- Hydroxyvitamin D and relation to development of preeclampsia,25 Hydroxyvitamin D in newborn,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
14670,NCT05588583,Wound progress of the total effect of treatment using Mepilex Up,Evaluation of all reported adverse events and device deficiencies,,2022-10-31,RECRUITING,INTERVENTIONAL,['NA']
14671,NCT01326299,Positive AUC from 0 to 240 minutes for plasma glucose.,Plasma glucose concentrations,,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14672,NCT01233622,HbA1c Reduction,Responder Rate,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14673,NCT04132089,20 participants baseline diabetes self-management score will be measured at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.,Participants who receive a Spark trigger message will login and use capABILITY quicker (time measured in seconds) than those participants who receive Facilitator trigger message.,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
14674,NCT02620592,"Safety and tolerability assessed by monitoring adverse events, clinical, laboratory, electrocardiogram, and vital signs examinations.",Glucagon,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14675,NCT00834262,Number of all hypoglycaemic episodes,"Average post-breakfast (2h), post-lunch (2h), post-dinner (2h) blood glucose level",,2009-04,COMPLETED,OBSERVATIONAL,['NA']
14676,NCT02215642,Disease-specific survival,Overall survival,Disease-free survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
14677,NCT00143013,,,,2004-10,UNKNOWN,OBSERVATIONAL,['NA']
14678,NCT00175721,Health care utilization and patient/provider satisfaction (5 years),Patient outcomes (5 years),,2005-12,COMPLETED,INTERVENTIONAL,['NA']
14679,NCT03832725,Remission of Type 2 Diabetes,Metabolom Markers,,2018-03-01,RECRUITING,INTERVENTIONAL,['NA']
14680,NCT02229175,Retinal thickness,Number of injections of bevacizumab needed,,2021-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14681,NCT02547311,Cost effectiveness,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
14682,NCT01135771,demonstrate the accuracy of the OptiScanner in measuring blood glucose levels in otherwise healthy diabetic subjects when compared to blood glucose levels simultaneously measured on the YSI,The secondary objective of the study is to demonstrate a blood glucose measurement range of 60 to 500 mg/dL at the hematocrit levels referenced as normal,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14683,NCT02862067,SGLT2 inhibition effects on cardiorespiratory fitness (CRF).,,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
14684,NCT00221208,Muscular strength,"Fasting blood glucose, insulin, lipid concentrations, C-reactive protein, body composition (DEXA), exercise adherence, behaviour change, psychosocial predictors of resistance training, quality of life.",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14685,NCT00529165,HbA1c,Quality of Life,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
14686,NCT01560676,BMI,Physical activity,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14687,NCT01970319,Left ventricle mass,RAAS activity,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
14688,NCT05593653,Insomnia Severity Index Score,Fasting Plasma Glucose,,2023-01-06,RECRUITING,INTERVENTIONAL,['PHASE4']
14689,NCT02435277,Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations,Change in Fasting Plasma Glucose,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14690,NCT03490773,Difference in immune function in Cpeptide negative and positive,Difference in HLA type in Cpeptide negative and positive groups,,2014-11-01,COMPLETED,OBSERVATIONAL,['NA']
14691,NCT03772067,Clock genes mRNA expression,Body Weight,,2018-12-28,UNKNOWN,INTERVENTIONAL,['NA']
14692,NCT02365233,Change in Hepatic Lipid Content From Baseline Visit to Six Month Follow up Visit,,,2013-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
14693,NCT00389636,Time to complete wound healing within 12 weeks,Excess pain,,2006-09,UNKNOWN,INTERVENTIONAL,['NA']
14694,NCT01464346,"Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With Minimum Calibration, Combined Abdomen and Buttock Insertion Sites","Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With 3-4 Calibrations Per Day, Combined Abdomen and Buttock Insertion","Mean Absolute Relative Difference (MARD) Between Sensor and YSI for Buttock Insertion Site, With Calibration Every 12 Hours",2011-11,COMPLETED,INTERVENTIONAL,['NA']
14695,NCT01199848,Postprandial Insulin Levels for 6 Hours,Strawberry Dose-response Effect on Postprandial Oxidative Stress (Ox-LDL) in Insulin-resistant Men and Women in an Acute Postprandial Paradigm,,2010-09-15,COMPLETED,INTERVENTIONAL,['NA']
14696,NCT05547594,Changes in Short Physical Performance Battery (SPPB) at different time points from baseline to 1 year after surgery,Changes in Patient Health Questionnaire-9 (PHQ-9) at different time points from baseline to 1 year after surgery,Postsurgical complications,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14697,NCT00760448,"Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration based on the Edinburgh Hypoglycaemia Scale: autonomic symptoms, neuroglycopenic symptoms and general malaise",,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14698,NCT00513643,AUC GIR 360-720 min,"PD endpoints like GIR max, t max/GIR, AUC GIR 0-120 min, AUC GIR 0-720 min, t >2/GIR, early and late t 50%/GIR",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14699,NCT02653209,On treatment HbA1c in patients with an eGFR <90 mls/min/1.73m2 compared to patients with an eGFR >90 mls/min/1.73m2.,HbA1c on therapy against predefined test of gender heterogeneity,,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14700,NCT03883503,Difference in copeptin levels between the interventions,Difference in Response to lottery Experiment before and after the intervention,,2019-02-25,COMPLETED,INTERVENTIONAL,['NA']
14701,NCT04726631,the percentage of maternal glycosylated Hemoglobin,,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
14702,NCT05221580,Change in Glycosylated Haemoglobin (HbA1c),Treatment satisfaction questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQ)),,2022-03-18,COMPLETED,OBSERVATIONAL,['NA']
14703,NCT01461434,Time to first diagnosis of atrial fibrillation,Stroke,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
14704,NCT02786953,Sleep Duration: 3 Months,Adherence (Self Care Inventory) Teen,,2017-10-19,COMPLETED,INTERVENTIONAL,['NA']
14705,NCT00698269,Change in HbA1c,Number of adverse drug reactions (ADR),,2008-02,COMPLETED,OBSERVATIONAL,['NA']
14706,NCT02577874,Blood sugar response measured by 7 finger prick blood samples,,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
14707,NCT00858676,"sudden cardiac death, fatal or non-fatal myocardial infarction, coronary revascularization, admission due to heart failure, fatal or non-fatal stroke",,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
14708,NCT06295289,TIR,MBG,postoperative infection,2023-10-16,RECRUITING,INTERVENTIONAL,['NA']
14709,NCT01611363,"Part B: Assessment of the relationship between the exposure to ipragliflozin in plasma, urinary glucose excretion and plasma glucose levels in subjects with T2DM","Part B: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia",,2011-10-27,COMPLETED,INTERVENTIONAL,['PHASE1']
14710,NCT04310137,Change in walking behavior (step timing),Waist circumference,,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
14711,NCT01197963,Serial Postoperative HgA1c levels,Serial Postoperative Lipid Profiles levels,,2010-09,TERMINATED,INTERVENTIONAL,['NA']
14712,NCT05387434,Change in Body Weight From 0-6 Months,Average Program Attendance,,2021-03-03,COMPLETED,INTERVENTIONAL,['NA']
14713,NCT03840161,CoG accuracy in monitoring glucose levels (invasively) during a standardized meal experiment.,Treatment satisfaction questionnaire,,2018-07-16,COMPLETED,OBSERVATIONAL,['NA']
14714,NCT01726816,A/C ratio,P/C ratio,c-peptide,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14715,NCT04339283,Change form Baseline Pulse on the 28th day,Change from Baseline Body Mass Index on the 28th day,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
14716,NCT00942318,HbA1c,"self monitoring blood glucose measurements (frequency, mean and standard deviation, number of hypoglycaemic and hyperglycaemic events)",,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14717,NCT04984421,Change in fidelity (R) assessed by questionnaire to parents,Change in parents' risk of type 2 diabetes assessed by FINDRISC questionnaire,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
14718,NCT03182569,Comfort measured by a visual analogue scale for pain,Metabolic stability according to lab determinations,,2016-12-11,COMPLETED,INTERVENTIONAL,['NA']
14719,NCT00132132,Percentage of Participants With BMI Reduction,,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
14720,NCT02887625,HbA1c,change in body weight,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
14721,NCT06117137,Number of participants with tight controlled diabetes melitus,Number of participant with changing in inflammatory biomarkers,,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14722,NCT04750837,size of the ulcer reduce to zero cm,,,2020-01-16,COMPLETED,INTERVENTIONAL,['PHASE2']
14723,NCT02743598,Neurocognitive performance- change in domain averages on a standard neuropsychological profile,Change from baseline serum LDL,,2016-09,TERMINATED,INTERVENTIONAL,['PHASE4']
14724,NCT00946504,Bioequivalence based on AUC and Cmax,,,1992-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14725,NCT02325531,"Rate Ratio of the Percent of the Clinics' Patients ""Indicated"" for ACE/ARB With Guideline-appropriate Prescription for ACE/ARBs",Rate Ratio of the Change in the Percent of the Clinic's 'Indicated' Patients With Correct Intensity Statin Prescribing,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
14726,NCT01800851,Energy expenditure,Insulin resistance,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
14727,NCT04885621,hemoglobin A1C levels,Weight/BMI,,2021-05-01,COMPLETED,OBSERVATIONAL,['NA']
14728,NCT01681160,change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 3days and change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 6 days,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
14729,NCT01571297,Effect of RM-131 on gastric emptying time,Safety and tolerability of RM-131,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14730,NCT01076829,The protocol is designed to study the effect of spice on MDA production in hamburg meat,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
14731,NCT00718198,Mean Inpatient Glucose,Percent of patient-days with severe hypoglycemia,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
14732,NCT06180811,Emergency Room Visit,Cost-Related Medication Underuse,,2024-01,RECRUITING,INTERVENTIONAL,['NA']
14733,NCT00553787,Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF,,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
14734,NCT00541606,"Primary outcomes included the achievement of targets for A1c (< or = 7%), LDL cholesterol (< or = 100 mg/dL) and blood pressure (< or = 130/80), changes in quality of life as measured by the SF-36 Health Survey, and patient satisfaction.",Secondary outcomes included diabetes-related hospitalizations and acute care visits during the study period for both the intervention and control groups.,,2000-09,COMPLETED,INTERVENTIONAL,['NA']
14735,NCT01891786,Coronary heart disease 10 year risk,Impact of receiving genetic results,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
14736,NCT03513874,Change in C-peptide,Adverse effects,,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14737,NCT01564459,Percentage of Participants Who Were Discontinued Form the Study Due to an AE,Change in Pain Intensity Scores - All Responders,,2012-03-26,COMPLETED,INTERVENTIONAL,['PHASE2']
14738,NCT03380338,Change in capillary recruitment,Changes in continous cardiovascular monitoring,,2016-05-11,COMPLETED,INTERVENTIONAL,['NA']
14739,NCT04678661,Change From Baseline in Glycemic Control at 3 Months,Number of Participants Who Experienced Severe Hypoglycemic Events.,Type of Escalation of Care,2021-02-15,TERMINATED,INTERVENTIONAL,['NA']
14740,NCT05566197,Body Fat Percentage,,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
14741,NCT00895427,,,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
14742,NCT00110435,Percent reduction in LDL-C from baseline after 6 weeks of treatment,Percent of patients attaining LDL-C <70 mg/dl after 6 weeks of treatment,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14743,NCT01073137,Otoacoustic emissions change with blood sugar levels,,,2006-06,UNKNOWN,OBSERVATIONAL,['NA']
14744,NCT06131918,Objective improvement in Diabetic Neuropathy,Levels of Superoxide dismutase and Glutathione peroxidase,,2023-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14745,NCT02053584,BGMS Accuracy Assessment When Used by Layperson,Evaluation of the Ease of Use of the Dario BGMS by the Lay-person,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
14746,NCT02169999,Patients' change in knowledge about diabetes and its treatments,Patients' Change in Decisional Conflict Scores,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
14747,NCT03722199,FMD -Flow mediated dilatation test,blood pressure analysis,exercise test with hand held dynamometer,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
14748,NCT02657018,Change from baseline daily physical activity at 24 weeks,Adherence to the intervention,Perceived acceptance of intervention,2016-08,COMPLETED,INTERVENTIONAL,['NA']
14749,NCT03298009,Change to be observed with canagliflozin on whole-body partitioning.,plasma NEFA turnover,body composition,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
14750,NCT03406910,Risk for Type 2 Diabetes (T2D) in subjects who consume different frequencies/amounts of eggs and meat.,,,2015-02-13,COMPLETED,OBSERVATIONAL,['NA']
14751,NCT03499223,Change from baseline in BCVA,Withdrawal from repeat study treatment and reason for withdrawal,,2018-04-20,COMPLETED,INTERVENTIONAL,['PHASE2']
14752,NCT04810780,Primery Effectivness Endpoint,,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
14753,NCT06185465,Difference in scoring the positive rate of bacterial biofilm before the first treatment and on the 7th day of treatment in Group A and Group B,Detection rate of bacteria/drug-resistant bacteria on the wound and their correlation with the detection rate of bacterial biofilm,,2024-01-03,RECRUITING,INTERVENTIONAL,['NA']
14754,NCT02234947,Ultrasound of Pancreatic volume,Blood Test will be done for pancreatic function and diabetes markers,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
14755,NCT04150926,Insulin concentration,,,2019-08-15,COMPLETED,INTERVENTIONAL,['NA']
14756,NCT03084822,Physical activity self-efficacy (using Self-Efficacy and Exercise Habits Survey),Cardiovascular health knowledge,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
14757,NCT04572165,Occurrence of first time malignant neoplasm of pancreas,,,2021-01-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14758,NCT03066570,"Quality of Life as measured with Norfolk Quality of Life Questionnaire, Diabetic Neuropathy Version (Norfolk-QOL-DN)",,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
14759,NCT00688974,Glucose control,Diabetes remission,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
14760,NCT03824002,Change from Baseline Reactive Hyperemia Index at 3 and 9 months,Change from Baseline Pulse Wave Velocity at 3 and 9 months,,2017-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14761,NCT03869931,Triglyceride concentration following 30 days of fenofibrate treatment,Change in ETDRS scale following 30 days of fenofibrate treatment,,2019-03-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
14762,NCT03862963,Usage of diabetes medications,Waist circumference,,2006-06-01,COMPLETED,INTERVENTIONAL,['NA']
14763,NCT00172796,,,,2005-04,UNKNOWN,OBSERVATIONAL,['NA']
14764,NCT03039075,Changes of HbA1c,"Changes of LDL, HDL, TG, TC",,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14765,NCT05620225,Comparison of therapy-related AEs between the 2 Study arms,Neurological Exam - percentage of treatment arm with a change in neurological status,,2022-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14766,NCT01237522,Renal clearance of metformin,,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14767,NCT05191160,Liver fat,Glucose tolerance - 2-hour plasma glucose (2h-PG),Adherence biomarkers - Objective biomarkers of SSBs (urinary fructose),2021-11-02,RECRUITING,INTERVENTIONAL,['NA']
14768,NCT00272831,Fatal or severe bleeding,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
14769,NCT05930210,The ulcer complete closure rate,The proportion of subjects with complete ulcer closure,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE3']
14770,NCT02880592,Time to initial closure of diabetic foot ulcer,Incidence of adverse events,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
14771,NCT01803126,To study the role of biofilm in the hardening of the arteries. The study will evaluate the hardening of the arteries found in legs that have been amputated because of vascular disease and/or diabetes.,,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
14772,NCT03316508,Change of Copeptin concentrations,Complexity of procedures,,2017-06-14,COMPLETED,OBSERVATIONAL,['NA']
14773,NCT02716610,Maximum glucose infusion rate (GIRmax),Bioavailability,,2013-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14774,NCT05973799,Glucose infusion rate,Peripheral glucose uptake,Growth Hormone,2019-10-10,RECRUITING,INTERVENTIONAL,['NA']
14775,NCT01396941,Insulin sensitivity,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
14776,NCT04823208,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Body Weight,,2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
14777,NCT00828425,evolution of diabetic retinopathy,concomitant medication,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
14778,NCT02139254,Number of women with gestational diabetes,Delivery Mode,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
14779,NCT06318442,Difference in Glucose tolerance,Difference in insulin sensitivity,Tissue specific changes in AMPK determined from adipose and muscle biopsies,2024-04-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14780,NCT05256706,Changes in prescriptions of participants with type 2 diabetes (T2D) in concordance with SSCVD results over a 6-month period,Change in medication possession ratio,,2022-02-03,COMPLETED,INTERVENTIONAL,['NA']
14781,NCT00489190,Dynamics compared with the initial level of glycemia and insulin dosages.,"Evaluation of frequency of glycemia episodes. Also undesirable events, Influence on indexes of general clinical analysis of blood and biochemical analysis of blood.",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14782,NCT05228561,The effect of mobile application supported diabetes education on blood sugar,,,2022-03-15,UNKNOWN,INTERVENTIONAL,['NA']
14783,NCT00312780,Reduction in albumin excretion relative to creatinine,Pharmacokinetics and renal elimination,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14784,NCT00071526,"Plasma, neutrophil and RBC Vitamin C concentrates",Determine the renal threshold and relative bioavailability for vitamin C,,2006-04-11,RECRUITING,OBSERVATIONAL,['NA']
14785,NCT02345057,Change from baseline in urinary albumin to creatine ratio (UACR),Change in serum potassium,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14786,NCT00853619,Compliance with guideline,Patient outcomes,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
14787,NCT00351767,Skin re-epithelialization without drainage or dressing requirements,Number of debridements performed,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14788,NCT01503008,Self-efficacy,Device-related and -unrelated adverse events,,2012-02,WITHDRAWN,INTERVENTIONAL,['NA']
14789,NCT00850239,"Primary objective is to demonstrate the efficacy of dutogliptin, as evidenced by placebo-corrected changes in HbA1c relative to baseline.",• Demonstrate changes in fasting plasma glucose,,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3']
14790,NCT06076720,Comparison of changes in the Low Vision Quality-of-Life Questionnaire (LVQOL) scores at different time points,Comparison of changes in visual scanning test at different time points,,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14791,NCT05083013,Need for ventilatory support,Incidence of other complications,,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA']
14792,NCT00301249,,,,1999-10,COMPLETED,OBSERVATIONAL,['NA']
14793,NCT01101867,Mean Glucose,"1,5-anhydroglucitol Change",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14794,NCT04067999,Change in Glycated Haemoglobin A1c (HbA1c) (measured in mmol/mol),Patient completed the study under treatment with semaglutide (yes/no),,2019-08-05,COMPLETED,OBSERVATIONAL,['NA']
14795,NCT02361931,Number of participants with the reduction of wound area by 75%$ or more,Recurrence of closed wounds,,2016-03-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14796,NCT02280486,Proportion of subjects achieving glycemic response defined as Glycosylated hemoglobin (HbA1c) < 7.0%,"Safety and tolerability of saxagliptin vs. glimepiride measured by adverse events, serious adverse events (SAEs); laboratory assessments (biochemistry, lipids, blood and urine routine tests",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14797,NCT05063253,Changes in glycosylated hemoglobin (HbA1c) from baseline to week 20,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).,,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
14798,NCT05226416,hospitalization for any cause,rate of demand for medical care,,2022-02-21,COMPLETED,OBSERVATIONAL,['NA']
14799,NCT03793855,GC,DQ,ADD,2019-05-06,COMPLETED,INTERVENTIONAL,['NA']
14800,NCT01194882,Change in glycosylated hemoglobin (HbA1c),Antibody assessments (anti-Insulin antibodies),,2010-11-16,COMPLETED,INTERVENTIONAL,['PHASE3']
14801,NCT02737527,Difference in Procedure time (I1),A 5-pointed Likert satisfaction scale related to the procedure,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
14802,NCT05023993,Feasibility of a nutrition and exercise program in childhood cancer survivors (CCS),,,2022-06-23,RECRUITING,INTERVENTIONAL,['NA']
14803,NCT04657783,Major adverse cardiovascular events (MACE),All cause mortality,,2020-06-10,RECRUITING,OBSERVATIONAL,['NA']
14804,NCT01452113,plasma glucagon concentration,GIP,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14805,NCT06268145,ECC5004 PK parameters: tmax,ECC5004 PK parameters: AUC(extr),,2024-02-06,RECRUITING,INTERVENTIONAL,['PHASE1']
14806,NCT01755351,The influence of diabetes distress on treatment sdherence,,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
14807,NCT01174303,Area under the Glucose Infusion Rate curve (only for NN5401),Area under the glucose infusion rate curve (only for biphasic insulin aspart 30),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14808,NCT00381992,"The prevalence of hepatitis B, hepatitis C, hypertension, hyperlipidemia, diabetes and obesity, HIV, N. gonorrhoeae, and C. trachomatis",,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
14809,NCT05440591,Carotid Femoral Pulse Wave Velocity,Advanced glycation end products,,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE4']
14810,NCT01316341,Fasting Plasma Glucose (FPG) Change From Baseline,"Clinical Relevant Abnormalities for Protocol-Specified Significant Adverse Events, Hypoglycaemic Events, Vital Signs, Blood Chemistry, Rescue Therapy, Body Weight and Waist Circumference",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14811,NCT03219320,Numeric Rating Scale (NRS) Average Pain Intensity,Numeric Rating Scale (NRS) Average Pain Intensity in Patients Who Did Not Use a Concomitant Medication at Baseline,,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE2']
14812,NCT00612625,insulin secretion rate (ISR) were derived by deconvolution of c-peptide. ISR is expressed as pmol/kg/min,The calculated ISR values was plotted against the ambient plasma glucose. The slopes of this linear relationships were calculated by cross-correlation analysis and is and estimation of beta-cell responsiveness (pmol/kg/min)/mmol/l,,2004-02,COMPLETED,INTERVENTIONAL,['NA']
14813,NCT04689958,Improvement in Brief Pain inventory at week 8,,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14814,NCT02402933,Number of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration,Percentage of Participants With Adverse Events Through the Nasal Score Questionnaire,Change in Blood Glucose Level Over Time,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14815,NCT04235959,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.,PK: Cmax of Tirzepatide (Cohort 2),,2020-10-21,COMPLETED,INTERVENTIONAL,['PHASE1']
14816,NCT00472953,To evaluate pulmonary safety comparing inhaled insulin to subcutaneous injections,Preprandial Insulin Doses,,2007-05-15,TERMINATED,INTERVENTIONAL,['PHASE3']
14817,NCT03658512,Glycemic control (HbA1C),,Nasal and skin swab,2018-08-13,RECRUITING,OBSERVATIONAL,['NA']
14818,NCT00922649,Number of daily basal rates at Week 16,Change from baseline to week 16 in Patient Reported Outcomes (PROs),,2008-02-01,COMPLETED,INTERVENTIONAL,['NA']
14819,NCT04332302,Genotyping of HLA (rs2854275),Change from Baseline Balance at 12 weeks,,2020-01-15,UNKNOWN,INTERVENTIONAL,['NA']
14820,NCT00332085,Hemoglobin A1c,Oral Glucose Tolerance Test,,2006-01,TERMINATED,INTERVENTIONAL,['PHASE1']
14821,NCT00042458,- To investigate the safety of pramlintide treatment employing dose titration upon initiation of pramlintide followed by insulin dose optimization in subjects with type 1 diabetes.,- To examine the pattern of daily insulin use over the course of the study.,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14822,NCT05691738,Falling Risk,Diaposan (Vibration) Evaluation,,2022-10-03,COMPLETED,INTERVENTIONAL,['NA']
14823,NCT00454233,"Safety and tolerability (adverse events; biochemical, hematological and urine analysis tests; vital signs, 12-lead ECG, physical examination)","Efficacy and pharmacodynamics (change in HbA1c and fasting plasma glucose; change in urinary glucose excretion; plasma levels of YM543; C-peptide, insulin, fructosamine, non-esterified fatty acids, triglyceride, cholesterol-panel)",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14824,NCT04902638,Hyperglycaemia time,,,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA']
14825,NCT02694796,Achievement of Physical activity recommendations,Captured physical activity,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
14826,NCT03769870,"AUCτ,ss(Area under the concentration-time curve at steady state)",,,2019-01-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14827,NCT06065098,Fidelity summary score,Sustainability (Participants),Difference in quality of life (QoL),2023-11-18,RECRUITING,INTERVENTIONAL,['NA']
14828,NCT04369664,Change in platelet activity (LTA) before and after cholesterol reduction,,,2020-08-12,COMPLETED,INTERVENTIONAL,['PHASE4']
14829,NCT02429024,A1c change from baseline in subjects using the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system compared to subjects using only the OneTouch Verio® Flex (without Bluetooth) for 24 weeks.,OneTouch Reveal Mobile APP interaction and usage via APP analytics over 24wks.,Healthcare efficiency survey by the HCP,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14830,NCT02189395,difference in glycemic control between treatment groups as measured by the mean daily blood glucose,number of hypoglycemic events,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4']
14831,NCT01736930,Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 3,Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 3,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14832,NCT01076478,To determine the relationship of peripheral neuropathy with peripheral vascular disease using the WIQ and the ABI from baseline to W12.,To assess the safety of Cilostazol therapy.,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14833,NCT05644730,Primary Efficacy Outcome,Percent Time in the Desired Control Range,Glucose readings from CGM's versus from blood,2022-11-08,RECRUITING,INTERVENTIONAL,['NA']
14834,NCT02347709,Measure the degree of loss of epidermal nerve fibers near a lower extremity diabetic wound using Intra-epidermal Nerve Fiber Density analysis.,,,2014-12,WITHDRAWN,OBSERVATIONAL,['NA']
14835,NCT01648296,The Primary Endpoint is to Determine if PET/CT Measurements of Myocardial FA Metabolism Performed With [18F]FluorbetaOx Correlated With Those Performed With [11C]Palmitate and Calculation of Human Dosimetry.,To Determine Human Dosimetry Based on the Human Biodistribution of [18F](+/-)NOS in Both Normal Healthy Volunteers and Dilated Non-ischemic Cardiomyopathy Patients.,,2012-09-13,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14836,NCT03370497,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Subjective ratings of appetite (au),,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
14837,NCT02869659,Chang in Epigengene score (and related individual transcriptional and methylation measures),change in homeostatic model assessment (HOMA) estimates of insulin resistance,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
14838,NCT00501592,Insulin Resistance and Glucose Homeostasis,Hepatocellular Function,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
14839,NCT04279587,Change in Hemoglobin A1c,Change in Behavioral Pediatrics Feeding Assessment,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14840,NCT00278980,Change in sensory nerve conduction velocity from baseline to 6 mo of treatment,- Safety and tolerability of C-peptide,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14841,NCT05760456,Change from Baseline at Week 12 in Hemoglobin A1c (HbA1c),Safety assessments,,2023-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14842,NCT03479866,Hunger and appetite assessment,,Carotid plaque,2018-06-04,UNKNOWN,INTERVENTIONAL,['NA']
14843,NCT03864562,Gastric emptying rate,Recruitment rate,,2019-03-01,COMPLETED,OBSERVATIONAL,['NA']
14844,NCT00624364,HbA1c,Adverse events,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14845,NCT00123136,improve quality of life,"serial changes in EDX, QST, autonomic functions, biopsy",,2005-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
14846,NCT03925519,"Analysis of blood sugar, glycated hemoglobin (HbA1c)",Analysis of Nitric Oxide,,2013-01-25,COMPLETED,OBSERVATIONAL,['NA']
14847,NCT00915200,Urinary Albumin excretion,tolerance and safety,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14848,NCT05668442,Adverse events,Questionnaires,,2020-11-21,COMPLETED,OBSERVATIONAL,['NA']
14849,NCT04619303,Difference in best corrected visual acuity change between treatment arms,Adverse Events,,2017-02-07,COMPLETED,INTERVENTIONAL,['PHASE4']
14850,NCT02623465,(Part B) PK: AUC of Insulin Lispro Glucose Following a Mixed Meal,(Part B) PD: AUC of Glucose Following a Meal,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14851,NCT00676819,Glucose infusion rate,"Cmax,ins: the maximal serum insulin (or serum insulin aspart) concentration",,2002-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
14852,NCT03182972,Medication reconciliation: Percentage unreconciled medications,,,2016-08-02,COMPLETED,INTERVENTIONAL,['NA']
14853,NCT02409238,Primary cognitive endpoint (Neuropsychological Performance),Secondary adherence endpoints Fasting Lipids,,2015-03-11,TERMINATED,INTERVENTIONAL,['PHASE4']
14854,NCT05628090,Proportion of patients persisting on insulin glargine (Lantus® or Toujeo®) at the end of 6th month,Proportion of patients on Toujeo® who switched to other therapy at the end of 6th month,,2022-11-30,COMPLETED,OBSERVATIONAL,['NA']
14855,NCT02996539,Association between HRV and renal function (eGFR and UACR),Clinical characteristics of patients,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
14856,NCT00129259,Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT),Change in Average Total Insulin Dose Per Body Weight,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14857,NCT01150955,Metabolic parameters,Pathways of substrate metabolism.,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
14858,NCT04420845,Change in mean HbA1c (NGSP%) from baseline to 12 weeks post-intervention,Change in diabetes-related quality of life from baseline to 12 weeks post-intervention,,2022-03-25,WITHDRAWN,INTERVENTIONAL,['NA']
14859,NCT05346679,BMI,,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
14860,NCT02451436,Sleep Duration,hs-CRP,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
14861,NCT00734591,Rate of Primary Lung Cancer Mortality,Rate of Primary Lung Cancer Diagnosis,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
14862,NCT04134143,Number of participants with adverse events through study completion,,,2019-11-07,TERMINATED,INTERVENTIONAL,['PHASE1']
14863,NCT00847327,Glycemic variability,Hemoglobin A1C,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
14864,NCT02299050,Glucose Metabolism During Mixed Meal Tolerance Test,Arterial Stiffness (AS),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14865,NCT00827853,Rate of binary restenosis as determined by duplex ultrasound.,Resting ankle-brachial index,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
14866,NCT03061214,Change in HbA1c,Occurence of Cross Reacting Antibodies With in Vitro Neutralising Effect to Endogenous GLP-1 (Yes/no),,2017-08-28,COMPLETED,INTERVENTIONAL,['PHASE3']
14867,NCT03281083,Liver fat content,Abdominal fat,,2014-03-28,TERMINATED,INTERVENTIONAL,['PHASE2']
14868,NCT01081834,Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy),Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy),,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14869,NCT04102657,Difference in body-fat percentage before and after 12-14 days of designated diet,Time below range (Interstitial BG <70 mg/dL) between designated diet groups,,2019-09-20,UNKNOWN,INTERVENTIONAL,['NA']
14870,NCT04074954,Amount of activity conducted by the patient after receiving surgery,,,2023-03-23,WITHDRAWN,OBSERVATIONAL,['NA']
14871,NCT01642108,HbA1c,Glucagon secretion,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
14872,NCT02462785,Change in Carbohydrate Counting Accuracy Measured Using a Standardized Meal & Snack Tray Test at Baseline and 3-months Post-Education,Change in Carbohydrate Counting Knowledge Tested Using the PedCarbQuiz (PCQ) at Baseline and 3-months Post-Education,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
14873,NCT01221467,Primary Efficacy Outcome,Secondary outcomes,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14874,NCT03447080,Change in postprandial blood glucose over 180 minutes period,Change in postprandial plasma insulin over 180 minutes period,,2017-06-02,COMPLETED,INTERVENTIONAL,['NA']
14875,NCT04000789,Conjunctival Goblet Cell Density,,,2019-07,UNKNOWN,INTERVENTIONAL,['NA']
14876,NCT01386801,,,,2009-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14877,NCT05683990,"Number of Clinically Significant Abnormal Results From Laboratory measurements, including hematology, clinical chemistry, metabolic status parameters (fasting C-peptide, HbA1c, fasting glucose) and urine analysis",Variables that indicate effects on the immune system,,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE2']
14878,NCT02089438,Postprandial glucose,Postprandial glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14879,NCT04628481,Change from baseline in HbA1c,Estimated Glucose Disposal Rate (eGDR),,2020-12-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14880,NCT04929379,Baseline-adjusted levels of serum biomarkers of increased ESKD risk at the end of the drug wash-out period,Levels of serum biomarkers of increased ESKD risk at the end of treatment,,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE2']
14881,NCT02544568,Maximum plasma concentration [Cmax] of glucose and triglycerides,Maximum plasma concentration [Cmax] of glucagon,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
14882,NCT02334137,Change from Baseline in Patient Knowledge about Diabetes at 3 months (via multiple-choice surveys),Change from Baseline in Patient Knowledge about Diabetes Immediately after using Educational Services (via multiple-choice surveys),,2014-11,COMPLETED,OBSERVATIONAL,['NA']
14883,NCT01707784,Markers of stress,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
14884,NCT04564846,Difference in Area Under the Curve (AUC(0-16)) of endogenous glucose production between placebo and ORMD-0801,Mean changes in ketones from baseline to Day 29 of the treatment period.,,2020-11-23,COMPLETED,INTERVENTIONAL,['PHASE2']
14885,NCT03343730,Rate of Diabetic Retinopathy Detection,,,2018-02-27,UNKNOWN,INTERVENTIONAL,['NA']
14886,NCT00169624,Flow dependent and independent Brachial artery vasoreactivity assessed using Doppler technology at 3 month vs baseline,Myocardial perfusion improvement following improved vasoreactivity assessed using myocardial perfusion imaging at 3 month vs baseline,,2005-10,TERMINATED,INTERVENTIONAL,['PHASE3']
14887,NCT00501072,Clinical effectiveness: percentage of time spent in euglycaemia,"Incidence of hypoglycaemia; Number of SMBG performed, Number of adjustments of insulin therapy, Patient satisfaction, agreement of paired SMBG and RT-CGMS measurements.",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
14888,NCT02742597,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,Evaluation of Intervention Effectiveness - Change in Demographics,,2016-01-12,COMPLETED,INTERVENTIONAL,['NA']
14889,NCT04160988,Specificity,Percentage of Participant Images With Insufficient Quality as Judged by VeriSee DR,,2019-12-16,COMPLETED,OBSERVATIONAL,['NA']
14890,NCT01054118,GLP-1 levels after a standard meal,Assess incremental glucose changes after a meal tolerance test (MTT),,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
14891,NCT01112709,Muscular Strength,Body Composition,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14892,NCT05505773,To evaluate the systemic metabolic rate of diabetic patients before and after bariatric gastric bypass surgery using the Breezing® device.,,,2017-01-06,COMPLETED,OBSERVATIONAL,['NA']
14893,NCT05237128,Change in HbA1c,Change in HbA1c,,2022-03-22,RECRUITING,INTERVENTIONAL,['NA']
14894,NCT03609294,AUClast,,,2018-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
14895,NCT02034045,Hospital admissions per patient,Cost Effectiveness,Trial Fidelity and Safety,2013-06,COMPLETED,INTERVENTIONAL,['NA']
14896,NCT01841697,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants Achieving an A1C Goal <6.5% After 24 Weeks of Treatment,,2013-06-13,COMPLETED,INTERVENTIONAL,['PHASE3']
14897,NCT01782261,Increase of regulatory FOXP3+ T cells,Immunophenotyping,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14898,NCT06002048,Montreal Cognitive Assessment (MoCA),,,2023-07-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14899,NCT01680978,Cardiac energetics: Change in PCr/ATP ratio using phosphorus magnetic resonance spectroscopy (MRS),Change in cardiac/hepatic triglyceride content assessed my MRS,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14900,NCT01277432,Depression and psychological well-being,Quality of life,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
14901,NCT03709108,Safety and feasibility of the SI-informed bolus calculator: Low Blood Glucose Index,,,2018-11-19,COMPLETED,INTERVENTIONAL,['NA']
14902,NCT00599885,Comparison of telmisartan and valsartan on neointima volume with IVUS at 8 months after zotarolimus-eluting stent implantation.,"Comparison of telmisartan and valsartan on the levels of RBP-4 and inflammatory markers (hsCRP, IL-6, TNF-α, adiponectin).",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
14903,NCT03997396,Changes in Gesell developmental scale test results within 6 months of age,Changes in percentage of RBC width distribution(RDW%),,2019-06-01,RECRUITING,OBSERVATIONAL,['NA']
14904,NCT05773677,incidence of maternal obstetric complications:,differences in early or late enrollment of patients,,2022-10-10,RECRUITING,INTERVENTIONAL,['NA']
14905,NCT00134264,The time to first occurrence of a major cardiovascular disease event,Various composites of major cardiovascular disease events and other lipid parameters,,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3']
14906,NCT01468675,Number of Subjects Who Discussed Disease Risk With Primary Care Provider,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
14907,NCT02635646,Individual Insulin Resistance and Insulin Secretion,2h OGTT Glucose,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
14908,NCT03449251,Sub-study 5: Change in hand vein diameter after relaxin infusion in healthy participants,Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (TNF alpha),,2018-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14909,NCT04745780,Glycated hemoglobin,Hypoglycemic events,,2021-02-10,COMPLETED,INTERVENTIONAL,['NA']
14910,NCT05846802,Measure of symptom severity of gastroparesis and functional dyspepsia using the change in total score from the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI SYM) from baseline to 48 weeks.,"Changes in gastric emptying, as measured by gastric emptying scintigraphy (GES) at baseline and 48 weeks",Presence or absence of Carnett's sign for abdominal wall pain at baseline.,2024-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14911,NCT04057677,Mitochondrial Respiration,Physical function,,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14912,NCT05543850,Time in range,Satisfaction,Glucagon dose,2022-10-28,COMPLETED,INTERVENTIONAL,['NA']
14913,NCT06170905,Postprandial glucose excursion,Glicentin course,,2024-02-01,RECRUITING,INTERVENTIONAL,['NA']
14914,NCT04079881,AUC Postprandial Glucagon,AUC Postprandial Glucose,,2020-02-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14915,NCT01048268,The difference in glucagon secretion quantified as the difference in plasma glucagon concentration and incremental baseline-subtracted area under the curve (AUC) for plasma glucagon,The difference between the amount of infused glucose and the insulin responses,,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14916,NCT06310356,a composite of pregnancy outcomes,day glucose time in range >180mg/dl,,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14917,NCT02435862,Observation of pharmacologic induction of PVD.,The secondary endpoints of this study is the observation of a complete stage 4 PVD to the equator including vitreopapillary release as seen by B-scan ultrasound and confirmed by OCT where possible by study day 90 as determined by the reading center.,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14918,NCT01469104,Change in plasma glucose concentration,Change in serum insulin concentrations,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
14919,NCT01425359,Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment,Patient's Global Impression of Change (PGIC) Scale Score,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
14920,NCT06137586,Total glucagon response,Difference in heart rate,,2022-08-10,RECRUITING,INTERVENTIONAL,['NA']
14921,NCT00819091,Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18,Change From Baseline in Fasting Plasma Glucose at Week 12,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14922,NCT06237322,Blood Glucose Measurement taken with alternate PPG software device,,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14923,NCT00997178,Change in Glycosylated Hemoglobin (HbA1c),Need for Diabetes Rescue Therapy,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14924,NCT01912170,Fasting insulin,"birth weight, length of children","blood lipids, inflammatory markers",2013-08,UNKNOWN,INTERVENTIONAL,['NA']
14925,NCT05946785,microvascular insulin-mediated dilation,endothelial cell insulin-stimulated eNOS phosphorylation,,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
14926,NCT00013975,,,,2001-03,COMPLETED,OBSERVATIONAL,['NA']
14927,NCT03297762,CGM use,Hgb A1c,,2018-05-07,TERMINATED,INTERVENTIONAL,['NA']
14928,NCT01542242,Hemoglobin A1C,Total Body Adipose Tissue Distribution (whole body Computed Tomography),,2012-02,TERMINATED,INTERVENTIONAL,['PHASE4']
14929,NCT03276312,Healing time,Quality of Life using the Short Form 36 (SF-36) questionnaire,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
14930,NCT00105755,Reduce the risk for lower extremity ulceration and amputation in veterans at high risk for these complications.; Incidence of diabetic foot ulcers over 18 months. Incidence of foot infections over 18 months. Incidence of Charcot fractures.,Improve quality of life. Health Related Quality of Life (change over 18 months),,2003-01,COMPLETED,INTERVENTIONAL,['NA']
14931,NCT02440061,β-cell function (DI-meal),,,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14932,NCT03629704,28 day prognosis,Incidence of hypoglycemia,,2018-08-03,UNKNOWN,OBSERVATIONAL,['NA']
14933,NCT01720303,Change in HbA1c,Change in body weight,,2002-09-19,COMPLETED,INTERVENTIONAL,['PHASE4']
14934,NCT05449795,Number of results from the Contour Next and Contour Plus Elite BGMSs reference values within ±20% of reference values,,,2022-11-29,COMPLETED,OBSERVATIONAL,['NA']
14935,NCT00987285,"Improvement in health behaviors (e.g., dietary patterns, physical activity, medication taking) and biologic outcomes (HbA1c, lipid ratio, blood pressure, and smoking status).","Diabetes-specific quality of life (Diabetes Distress Scale), patient activation (PAM scale), and perceived social-environmental support (the Chronic Illness Resources Survey) at 4- and 12-month follow-ups.",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
14936,NCT02159638,Difference between the two CGM systems compared to capillary glucose value,Evaluation of two CGM systems from questionnaire,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
14937,NCT00915486,Percentage reduction in ulcer surface area,"Changes in vital signs, body weight, physical examination and laboratory parameters",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14938,NCT05145673,Variation of blood glucose maximum concentration,Antioxidant activity,,2016-01-19,COMPLETED,INTERVENTIONAL,['NA']
14939,NCT00313313,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14940,NCT01599442,duration of survival without major amputation,total mortality,,2010-06,TERMINATED,OBSERVATIONAL,['NA']
14941,NCT02561130,Number of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group,Number of Participants With Severe Hypoglycemic Episodes,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
14942,NCT03225339,Weight loss,Patient reported outcomes,Waist Circumference,2017-07-16,COMPLETED,INTERVENTIONAL,['NA']
14943,NCT01548222,Percentage of time CGM glucose is <70mg/dl,Weight gain,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
14944,NCT05133973,Incidence and severity of device related adverse events (ADE),User satisfaction questionnaire score,,2022-10-10,RECRUITING,INTERVENTIONAL,['NA']
14945,NCT04554199,Cognitive function assessment in controlled type 2 diabetic patients wearing RPD.,,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
14946,NCT01495052,changes from baseline in insulin resistance Hematology index detection Hematology index detection Hematology index detection Hematology index detection Hematology index detection,changes from baseline in WHR,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
14947,NCT04787952,The potential associations between BAT activity and transcriptome profile,The potential associations between BAT activity and fT4 concentrations,,2016-10-01,COMPLETED,OBSERVATIONAL,['NA']
14948,NCT04709120,death,Rate of cases of health status worsening occured during hospitalisation,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
14949,NCT05566717,Primary Endpoint,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
14950,NCT01341587,Change in HbA1c,,,2011-04,TERMINATED,INTERVENTIONAL,['NA']
14951,NCT06135987,Number of patients with complete healed chronic wound (venous leg ulcer and Diabetic foot ulcer) at 12 weeks,Defectuosity of the device,,2022-06-24,RECRUITING,OBSERVATIONAL,['NA']
14952,NCT04521049,to classify renal responders to saxagliptin using tubular markers,,,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14953,NCT01271023,Overall frequency of hyperglycemia,Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14954,NCT01786408,Non-Inferiority of Analyte Levels,,,2013-03,WITHDRAWN,INTERVENTIONAL,['NA']
14955,NCT06079463,Beck Anxiety Scale,World Health Organization Quality of Life Scale,,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14956,NCT02696252,"proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a diabetes accuracy measurement of %20/20 mg/dL",,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
14957,NCT05816057,The observed mean change in Glycosylated Haemoglobin A1c (HbA1c) values from baseline after 32 weeks of treatment.,Change From Baseline to Week 32 in Fasting Blood Lipids: Total Cholesterol、Low-density Lipoprotein (LDL) Cholesterol、 High-density Lipoprotein (HDL) Cholesterol 、Triglycerides (Ratio to Baseline).,,2022-07-25,COMPLETED,INTERVENTIONAL,['PHASE3']
14958,NCT01710540,"Cmax, Tmax, AUC0-t, AUC0-∞, AUC%_Extrap, Kel and t1/2",Safety profile,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14959,NCT04201600,Aggregate Language Score,Instrumental Activities of Daily Living (IADL) total score,,2022-03-01,RECRUITING,OBSERVATIONAL,['NA']
14960,NCT04233229,Time in range (TIR),Body Weight,,2019-12-30,COMPLETED,INTERVENTIONAL,['NA']
14961,NCT02893306,Changes in insulin pancreatic reserve,Changes in insulin requirement,Number of patients with grade 3 through grade 5 adverse events (CTCAE v3.0),2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
14962,NCT00838825,resource utilization,metabolic outcome,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14963,NCT03648424,Composite Cardiovascular (CV) Outcome,,,2011-05-01,COMPLETED,OBSERVATIONAL,['NA']
14964,NCT00970099,insulin sensitivity and insulin signaling,,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1']
14965,NCT01047982,difference in HOMA values,"incidence of pregnancy complications: hypertension, preterm delivery. macrosomia, shoulder dystocia, etc.",,2010-03,COMPLETED,INTERVENTIONAL,['NA']
14966,NCT03234322,Difference of participant's physical activity at twelve months after the routine health check between the groups.,Acceptance of participants according to the application of a diabetes risk score for routine use in clinical practice.,Change on participant's individual diabetes risk.,2017-09-13,COMPLETED,INTERVENTIONAL,['NA']
14967,NCT01745900,Continuing validation of near infrared spectroscopy-based glucose meter algorithm,,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
14968,NCT05512871,Mobile health application feasibility,Change in intake of meals,,2022-09-19,COMPLETED,INTERVENTIONAL,['NA']
14969,NCT03958838,Change from Baseline HbA1c and at 12 months,Change in Peer Support Engagement and Health Care Utilization and 12 months,,2019-05-25,COMPLETED,INTERVENTIONAL,['NA']
14970,NCT00939939,incremental area under the triglyceride curve (iAUC-TG),hs-CRP,,2010-03,TERMINATED,INTERVENTIONAL,['PHASE4']
14971,NCT00608439,Total Symptom Score,Quantitative Sensory Test,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14972,NCT05921019,the Brief Pain Inventory-Short Form,Nerve conduction velocity (NCV),,2022-08-31,RECRUITING,INTERVENTIONAL,['NA']
14973,NCT01501032,Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,,2013-10,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14974,NCT03495102,Change in Hemoglobin A1c (HbA1c) From Baseline,Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State,,2018-04-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14975,NCT02725593,Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24,Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24,,2016-06-22,COMPLETED,INTERVENTIONAL,['PHASE3']
14976,NCT02274740,Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min),Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction,,2015-04,TERMINATED,INTERVENTIONAL,['PHASE2']
14977,NCT00795860,Insulin sensitivity,whole body and skeletal muscle oxidative capacity,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
14978,NCT01358435,Mean AUC0-24h and Cmax,"PK endpts: AUC0-4h, AUC0-6h, AUC0-12h, AUC6-12h, AUC6-24h,tmax,and elimination rate constant. PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR0-12h,AUCGIR0-24h, AUCGIR6-12h, AUCGIR6-24h, GIRmax and tGIRmax Safety : AEs,haematology,biochem,phy exam",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14979,NCT03018028,Change in HbA1c (Week 26),Change From Baseline in DTR-QOL: Sub-domains,,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14980,NCT03407989,estimated GFR decline ml/min/y,"Diabetes-specific health-related quality of life baseline measures, CKD stage, and eGFR decline.",,2014-01-01,UNKNOWN,OBSERVATIONAL,['NA']
14981,NCT04942756,Evaluate CGM by using FSL2 in preventing severe hyperglycemia peaks,,,2021-06-30,UNKNOWN,INTERVENTIONAL,['NA']
14982,NCT01969318,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 12,"Change From Baseline in Body Weight at Week 4,8,12",,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14983,NCT05883072,Internet Speed,Analyzing Chat response generated by AI Chatbot,,2023-01-05,RECRUITING,OBSERVATIONAL,['NA']
14984,NCT01293669,Changes in fasting plasma glucose (FPG),Change in AUC insulin from Day 1 (Baseline) at Week 4,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14985,NCT05571878,"The change in brain imaging outcomes, measuring brain insulin resistance, following intranasal insulin or placebo challenges, compared between the participants with depression and healthy controls.",Correlation between brain insulin resistance with cognitive functioning at baseline and 6-month study follow up,"Correlation between brain insulin resistance, and hepatic and visceral adiposity",2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
14986,NCT02750774,Gestational Diabetes Mellitus (GDM) occurrence,Neonatal Intensive Care Unit (NICU) admission,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
14987,NCT03244241,Difference in mean daily plasma glucose between the two groups,Number of post-discharge infections or re-admissions 1 month after discharge,,2017-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14988,NCT06305195,deep breath test interpretation,Framingham risk score (FRS),,2023-08-23,RECRUITING,OBSERVATIONAL,['NA']
14989,NCT00817778,Clinically Relevant Change of Laboratory Variables,"S-C-Peptide (AUC0-24)/24, Change From Baseline to End of Treatment",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14990,NCT00011206,,,,2001-01,COMPLETED,OBSERVATIONAL,['NA']
14991,NCT01102673,"PK Endpoints: AUC(0-inf), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2), as the data permit.",none-see my comment,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14992,NCT02875704,"Aqueous levels of oxidized adducts on protein (i.e. oxidative biomarker) in patients with stargardt disease, AMD, DR and controls",,,2017-01-03,TERMINATED,OBSERVATIONAL,['NA']
14993,NCT05667051,Percentage of bleeding on probing sites (BOP%),,,2022-04-05,COMPLETED,OBSERVATIONAL,['NA']
14994,NCT03782129,Mortality rate 5 years after DFU diagnosis,Risks factors correlated to mortality rate among DFU patients diagnosed in 2010,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
14995,NCT01594801,Safety,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14996,NCT02768935,level of expression markers,,,2017-10-30,COMPLETED,INTERVENTIONAL,['NA']
14997,NCT05039970,Number of Sessions Attended,Participants' game rating/Net Promoter Score or questionnaire.,Fitness tracker integration with the game.,2021-09-07,COMPLETED,INTERVENTIONAL,['NA']
14998,NCT05424965,Activity of Wnt signaling pathway in placental tissue,,,2018-03-23,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14999,NCT01493258,Change in CERSG Knowledge Score from baseline to 24-hr and to 6-month follow up,CERSG Acceptance,,2010-08,WITHDRAWN,INTERVENTIONAL,['NA']
15000,NCT05386849,Primary Efficacy Outcome,Time in desired control range,Glucose readings from CGM's versus from blood,2022-05-09,COMPLETED,INTERVENTIONAL,['NA']
15001,NCT04868851,Drop out,Parent survey on intervention acceptability (Here for Health),,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
15002,NCT02744300,Weight loss,Number of participants with either: a HbA1c value greater than or equal to 5.7; or a 2 hour value on a 75 g oral glucose tolerance test of greater than or equal to 140,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
15003,NCT02682342,change in mitochondrial network complexity of endothelial cells as measured by mitochondrial network fragment ratio,,,2016-03-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15004,NCT00722917,Change from Baseline in Glycosylated Hemoglobin,Plasma concentrations of TAK-379 and its metabolite M-I via a sparse sampling population approach.,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE2']
15005,NCT00779363,Device Functionality Evaluation,Percentage of body weight loss,,2004-06,COMPLETED,INTERVENTIONAL,['NA']
15006,NCT01771042,Change in whole-body norepinephrine kinetics,Change in muscle sympathetic nerve activity,Change in insulin sensitivity,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
15007,NCT04427189,Change of HbA1c level,DKA rate,,2008-04,RECRUITING,OBSERVATIONAL,['NA']
15008,NCT06034548,Clinical outcomes - BP,Behavioral outcome - exercise; questions,,2018-08-27,COMPLETED,INTERVENTIONAL,['NA']
15009,NCT01257334,the change from baseline in HbA1c,,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
15010,NCT05431296,Primary outcome: Percent time spent in glucose target range (3.9-10mmol/L),Audit of Diabetes Dependent Quality of Life questionnaire domain.,"Changes in care, measured by changes in diabetes medication usage.",2023-02-07,RECRUITING,INTERVENTIONAL,['NA']
15011,NCT00970723,"The primary outcome will be the percentage of patients having a sustained 50% or more-decrease in retinal thickening at 1 year, assessed with OCT in the study eye.",Comparison of blood pressure in each group at one year,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
15012,NCT04864977,Percentage of Participants with Type 2 Diabetes Who Achieve Nadir Glucose in Range 70-125 milligram/deciliter (mg/dL),Percentage of Participants who successfully use Continuous Glucose Monitoring (CGM),,2021-08-16,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15013,NCT02462369,microalbuminuria improvement in T2DM treated with saxagliptin,incidence of hypoglycaemia of saxagliptin or glimepiride,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
15014,NCT02524938,Change in estimated glomerular filtration rate (eGFR),Change in 8hydroxy 2'deoxyguanoside (8OhdG),,2016-06-01,TERMINATED,INTERVENTIONAL,['NA']
15015,NCT02026024,mean amplitude of glycaemic excursions (MAGE),,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
15016,NCT02919397,Weight (kg),Sleep duration (average hours per night),,2016-10-01,COMPLETED,INTERVENTIONAL,['NA']
15017,NCT05407454,The Diabetes Quality of Life - Brief Clinical Inventory,,,2022-06-07,COMPLETED,OBSERVATIONAL,['NA']
15018,NCT03528811,"Coincidence rate of ""5 points test of Tongji university""",,,2016-08-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
15019,NCT02596204,Change in Hemoglobin A1c,Change in Hemoglobin A1c,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
15020,NCT01155050,Change in Waist Circumference,Change in Fasting Plasma Glucose,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
15021,NCT03760965,Change in hemoglobin A1c (HbA1c),Adverse events,,2018-11-27,TERMINATED,INTERVENTIONAL,['PHASE3']
15022,NCT02106364,Change from Baseline in Hemoglobin A1c (HbA1c) at 26 Week Endpoint,Change from Baseline in Lipid Profile,,2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15023,NCT02565706,Quantity of Fruit and Vegetable Intake,Response to Survey Items Assessing Knowledge of Area Farmers' Markets,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
15024,NCT02415556,Verbal Memory Composite z Score,Weight (kg).,Cerebral Blood Flow on Magnetic Resonance Imaging (MRI).,2015-10-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15025,NCT05347420,The quantitative Neuropad test,The visual Neuropad test,,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA']
15026,NCT03444142,Blood pressure,Waist Circumference,,2017-11-17,UNKNOWN,INTERVENTIONAL,['PHASE4']
15027,NCT01467414,Area under the glucose infusion rate curve during one dosing interval at steady state,Maximum observed serum insulin degludec concentration at steady state,,2011-10,TERMINATED,INTERVENTIONAL,['PHASE1']
15028,NCT00502008,"Fasting and Post Prandial Blood Glucose, Glycosylated Hemoglobin",Serum Lipid levels,,2005-11,COMPLETED,INTERVENTIONAL,['NA']
15029,NCT03102424,Change in HbA1c values to evaluate of the effect of DW1330,Change from baseline in OAD drugs description,Change from baseline of inflammatory biomarkers,2017-04-10,COMPLETED,INTERVENTIONAL,['NA']
15030,NCT03922932,Structural OCT Retinal Thickening Area,,,2017-08-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15031,NCT00226902,Change in pulse wave velocity at the three different haemoglobin levels,,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
15032,NCT01006590,Absolute Change From Baseline in HbA1c at Week 24,Change From Baseline to Week 24 in Beta-cell Function as Measured by Homeostasis Model Assessment-2-beta,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15033,NCT01375803,Mean changes in blood HbA1c values from baseline to end of study,"Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]",,2009-06,COMPLETED,INTERVENTIONAL,['NA']
15034,NCT06074731,Morphological changes using Swept Source Optical Coherence Tomography,,,2017-06-01,RECRUITING,OBSERVATIONAL,['NA']
15035,NCT01571622,Glucose response,"Insulin GLP-1, GIP and DPP4",,2012-04,COMPLETED,INTERVENTIONAL,['NA']
15036,NCT02617654,"The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production",Change in QoL between after and prior to treatment with liraglutide,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15037,NCT03208686,Blood glucose levels,,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
15038,NCT04914819,Number of Participants Losing 5 Percent or More of Weight From Baseline to 16-week Follow-up,Intervention Arm: Number of Weeks With Daily Data Reporting for at Least 5 of 7 Days,,2021-06-18,COMPLETED,INTERVENTIONAL,['NA']
15039,NCT00487240,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,Insulin Dose (Total and By Component [Basal and Bolus]),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15040,NCT03737188,Analysis of system accuracy based on ISO 15197,,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA']
15041,NCT00237549,"Amputations, non traumatic","Neuropathy, periphery and autonomy",,2001-01,COMPLETED,INTERVENTIONAL,['NA']
15042,NCT05231642,Glucose AUC,PAI-1,,2021-11-30,COMPLETED,INTERVENTIONAL,['NA']
15043,NCT00372957,Glucose Weighted Mean AUCs at Baseline (Day -1) and Day 7,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2006-03-22,COMPLETED,INTERVENTIONAL,['PHASE2']
15044,NCT03785886,Change from Baseline Fasting Blood Glucose at 3 months,Time and Frequency of Adverse Reactions and Serious Adverse Events through the study completion,,2019-03,UNKNOWN,INTERVENTIONAL,['NA']
15045,NCT05394519,Achievement of greater than or equal to (≥) 5% weight reduction,"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2023-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15046,NCT00987662,Reduction of 24h BP and arterial stiffness in obese hypertensives,Drug specific effect on reduction in central fat deposition and the leptin to adiponectin ratio,,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15047,NCT03338517,Ulcer surface area,,,2016-08-04,COMPLETED,INTERVENTIONAL,['NA']
15048,NCT02413385,Average steps per day,Body mass index,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
15049,NCT05333185,Blood Glucose Levels,Regulating the Nutrition of Children according to their blood sugar level,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
15050,NCT05601583,Total Scan Time,,,2023-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
15051,NCT03273140,Better Sense of Coherence,Better Quality of life,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
15052,NCT03590223,occurence of Major adverse cardiac events,mortality,,2017-12-29,COMPLETED,OBSERVATIONAL,['NA']
15053,NCT01024218,Device preference,Comparison of the frequency of adverse events (needle stick injuries),,2004-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15054,NCT00121667,Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC),Confirmed Hypoglycemia During the ST + LT Treatment Period,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
15055,NCT00658099,Change in weight,"The satisfaction of physicians who treat the subjects with either insulin detemir or NPH insulin by using 4 questions, which are included in CRF, at the final visit.",,2007-11,COMPLETED,OBSERVATIONAL,['NA']
15056,NCT00143104,"To assess in patients with type 1 diabetes mellitus the effects, if any, on lung lining, fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.","(1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.",,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
15057,NCT03904485,Assessment of myocardial injury,,,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA']
15058,NCT02076542,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in self-care behaviors at the 2-week and 6-month follow-up,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
15059,NCT06124586,effect of an immediate (within first 48h) PTA intervention on microbiome composition,Effect of the immediate PTA intervention on related complications,,2024-02-01,RECRUITING,INTERVENTIONAL,['NA']
15060,NCT04123093,Wound Surface Area,Adverse Events - Wound Care Subjects,,2019-08-09,TERMINATED,INTERVENTIONAL,['NA']
15061,NCT00537264,Health-related quality of life outcomes,,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
15062,NCT01933529,Insulin secretion,Inflammation,Clinical chemistry parameter,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15063,NCT05529589,Change of visual acuity,B-mode ultrasound imaging,,2023-02-10,RECRUITING,OBSERVATIONAL,['NA']
15064,NCT04222348,Baby wellness,LBP profile and oxidativge stress as well as in lipid profile,,2016-10-26,UNKNOWN,INTERVENTIONAL,['PHASE3']
15065,NCT00422253,,,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
15066,NCT05596747,Incidence and Severity of Hypoglycemia,PD: Change from Baseline in 7-Point Glucose,,2022-11-30,COMPLETED,INTERVENTIONAL,['PHASE1']
15067,NCT00985114,Percent (%) of Subjects Who Achieve a ≥ 0.5% Reduction in HbA1C at 24 Weeks or Last Visit From Baseline.,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
15068,NCT02706821,Fasting and postprandial plasma glucose,Monocyte chemoattractant protein-1 (MCP-1),,2014-02,COMPLETED,INTERVENTIONAL,['NA']
15069,NCT06256419,Genotype identification in patients with T2DM,Incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
15070,NCT02039245,Plasma concentration of metformin following the dose of 2 CANA/MET XR FDC tablets,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15071,NCT04592107,progression of chronic kidney disease,,,2017-12-12,COMPLETED,OBSERVATIONAL,['NA']
15072,NCT00357955,"Percentage of Participans With A1c<7%, LDL Cholesterol <100mg/dL, Systolic Blood Pressure <130mm Hg and Diastolic Blood Pressure <80 mm Hg",,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
15073,NCT06077708,Periodontal Clinical Parameters,Biochemical Data,,2022-08-23,COMPLETED,INTERVENTIONAL,['NA']
15074,NCT02117765,Primary Safety Endpoints (composite outcome measure),Exploratory (composite outcome measure),,2015-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15075,NCT03198832,Probing depth change,Clinical Attachment Level,,2016-05-02,COMPLETED,INTERVENTIONAL,['NA']
15076,NCT02585505,Increase in glucagon stimulated C peptide level,,,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15077,NCT00327574,the three intervention arms,Cost outcomes: the total cost per intervention and cost per subjects,,2004-06,UNKNOWN,INTERVENTIONAL,['NA']
15078,NCT01206582,Gastric Emptying Half-time,Leukocyte and Platelet Counts,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15079,NCT03528226,Change in percent flow-mediated dilation (FMD) values,Body composition (DEXA),,2019-11-12,RECRUITING,INTERVENTIONAL,['NA']
15080,NCT02242149,Evidence of improvement in glycemic control and improvement in liver steatosis,Changes of adipocytokines and cytokeratin-18,,2014-10-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15081,NCT01768546,Change from Baseline Weight Measure at Week 16,Change from Baseline Weight Measure at Month 12,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
15082,NCT04835493,HbA1c,Telehealth Acceptability,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
15083,NCT03355040,number of Neonatal death,Number of Anal sphincter tear for the patient,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
15084,NCT02043405,Change in insulin sensitivity,Change in membrane localized diacylglycerol species,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15085,NCT00658021,Number of Participants With Post-Treatment Adverse Events of Special Interest (AESI) During Safety Follow-up Period,Percentage of Participants Discontinuing the Study Due to Failure to Maintain Glycemic Control Through Week 28,,2008-05-30,COMPLETED,INTERVENTIONAL,['PHASE3']
15086,NCT04958980,Concentration of participants at increased risk for diabetes complications related to increased waist circumference,,,2021-08,UNKNOWN,INTERVENTIONAL,['NA']
15087,NCT04466904,To assess the number and incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of IBI362 compared with placebo,Number of Participants With Anti-IBI362 Antibodies,,2020-09-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15088,NCT00725036,Long term pulmonary safety profiles,Treatment satisfaction,,2002-09-02,COMPLETED,INTERVENTIONAL,['PHASE3']
15089,NCT02394314,Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382,Proportion of subjects with ADA to MEDI0382,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15090,NCT06284681,Response to weight-neutral health coaching measurement,Change in Metabolic Syndrome Severity Score,Change in Metabolic Syndrome Severity Score,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15091,NCT05749679,Change in annual glomerular filtration rate (GFR) slope,change of Albuminuria,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15092,NCT05271864,Oxygen Saturation,Heart rate,,2022-11-01,COMPLETED,OBSERVATIONAL,['NA']
15093,NCT04286399,Combined endpoint based on the first occurrence of cardiovascular death or major adverse cardiovascular event,,,2019-07-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15094,NCT00287066,18F-labeled glucose uptake in muscle,Glucose turnover overnight Insulin pharmacokinetics,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3']
15095,NCT05433415,Change from Block Kids 2004 Food Frequency Questionnaire (BKFFQ) at 12 and 24 weeks,Change fron Quality of Mother Interaction at 12 and 24 weeks,Change from Weight Efficacy Lifestyle Questionnaire at 12 and 24 weeks,2023-03-06,RECRUITING,INTERVENTIONAL,['NA']
15096,NCT03770767,Birth weight standard deviation score,"Neonatal morbidity (neonatal hypoglycaemia, jaundice, respiratory distress and duration of stay in neonatal intensive care unit) and infant morbidity evaluated as hospitalization during the first 3 months of life (after discharge in the neonatal period)",,2019-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15097,NCT02006459,plasma Glucagon,"Satiety, hunger, appetite",,2013-09,COMPLETED,OBSERVATIONAL,['NA']
15098,NCT03248271,Nadir of diastolic blood pressure during the Tilt Table Test,Presence or absence of a positive Tilt Table Test (vasovagal syncope),,2017-10-01,WITHDRAWN,OBSERVATIONAL,['NA']
15099,NCT02629952,Improvement in Glucose Tolerance after 4 weeks of drinking blueberry tea.,Improvement in large artery stiffness after 4 weeks of drinking blueberry tea.,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
15100,NCT03807440,Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist,Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication,,2019-08-26,COMPLETED,OBSERVATIONAL,['NA']
15101,NCT00184613,Variation in morning FPG,Variation of pre-dinner plasma glucose collected in hospital on the last 3 days,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15102,NCT03819634,Time to Infusion Set Failure,,,2019-01-25,COMPLETED,INTERVENTIONAL,['NA']
15103,NCT04905628,Dexcom Continuous Glucose Monitoring (CGM) System Performance,System Related Adverse Device Effects,,2021-07-08,UNKNOWN,OBSERVATIONAL,['NA']
15104,NCT03923205,AUC for postprandial glucose,Urine glucose concentration,,2019-03-07,UNKNOWN,INTERVENTIONAL,['NA']
15105,NCT01724515,Mitochondrial Respiration,Phosphorylation of proteins,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15106,NCT04801485,the incidence of gestational diabetes,the perinatal outcomes-3,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
15107,NCT03330756,glycaemic control,Cardiac / ventricular hypertrophy,,2017-10-23,UNKNOWN,INTERVENTIONAL,['NA']
15108,NCT01787903,Time spent in the euglycemic range,Changes in hypoglycemia awareness score,RT-CGM satisfaction,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15109,NCT03250533,Rate of ulcer healing - Digital photography,Bioimpedance,,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15110,NCT00609895,Compare % of subjects with glucose > or = to 56 mg/dL at any point of 8-point glucose profiles during 3 consecutive days,"To evaluate overall safety and tolerability based on adverse event reporting, laboratory tests, and clinical examinations",,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15111,NCT00966407,"Genotype for specific genes related to obesity, metabolic syndrome, and/or type 2 diabetes; Fasting serum biomarkers; Hand grip strength, muscle strength of upper and lower extremities; Fitness measurements; Body composition measures",Perception of physical fitness; Relationship between physiological measures and genotype variation,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
15112,NCT02538848,"Incidence, severity and causality of adverse events",,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15113,NCT02453555,Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline),Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus All Placebo),,2015-05-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15114,NCT00032864,,,,1997-01,COMPLETED,OBSERVATIONAL,['NA']
15115,NCT02667964,FGF-21 change after physical activity,,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
15116,NCT02612714,serum testosterone,sexual function evaluation,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15117,NCT01530789,Percentage of patient using the system,satisfaction level of the telemedecin nurse,,2011-05,TERMINATED,OBSERVATIONAL,['NA']
15118,NCT03112538,between group difference of HbA1c changes from baseline to 6 months,Treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire DTSQs,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15119,NCT02687776,myocardial injury in non-cardiac surgery (MINS),composite events composed of all-cause mortality and/or major adverse cardiac and cerebrovascular events (MACCE),,2016-02,UNKNOWN,OBSERVATIONAL,['NA']
15120,NCT02230501,HbA1c,antidiabetic medication,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
15121,NCT01530165,Incidence of Type 2 Diabetes,The impact of city planning on prevalence of obesity and type 2 diabetes,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
15122,NCT01223547,Change in HbA1c,Weight,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
15123,NCT02163278,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Pharmacodynamic parameters,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15124,NCT01623882,Percentage of wounds closed,,,2012-06,WITHDRAWN,OBSERVATIONAL,['NA']
15125,NCT01426737,Mean amplitude of glycemic excursion as described by Service et al. (1970) calculated from the glucose excursions of the CGMS profiles using MiniMedSolution Software (MedtronicMiniMed).,,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
15126,NCT00532935,Change From Baseline in A1C at Week 32,Percent of Participants With A1C <7.0% at Week 32,,2008-01-26,COMPLETED,INTERVENTIONAL,['PHASE3']
15127,NCT05258292,Mean glucose levels during the late luteal phase,Total insulin delivery,,2022-05-02,RECRUITING,OBSERVATIONAL,['NA']
15128,NCT01354288,HbA1c 12 months after therapeutic education,Evolution of the parental and child quality of life 12 and 24 months after therapeutic education (evaluated by questionnaire),,2011-12-07,COMPLETED,INTERVENTIONAL,['NA']
15129,NCT00723853,"Biochemical markers (glucose tolerance, lipid panel, insulin, hemoglobin A-1-C)","Cost Assessment (costs incurred to attend meetings, eat healthier, exercise more)",,2008-04,COMPLETED,INTERVENTIONAL,['NA']
15130,NCT00858351,Subjective Pain,Temperature,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
15131,NCT01775878,glycosylated hemoglobin,blood pressure,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
15132,NCT02097316,"Time spent in glycemic area 70-180 mg / dl, measured continuously for 5 days with a continuous glucose monitoring (CGM) DEXCOM G4",Time spent in the strict glycemic area 80-140 mg / dl,Time spent above 180mg/dl;,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15133,NCT01474889,Endogenous Glucose Production,Autonomic Symptom Response to Hypoglycemia,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
15134,NCT04088981,Rate of glycemic control,Body weight,Endothelial function,2024-07,SUSPENDED,INTERVENTIONAL,['NA']
15135,NCT01602913,"Incidence of T2DM defined as having at least 2 diagnostic codes indicating T2DM after the index date, or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date",,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
15136,NCT02382757,Long-term complications,Percentage of children lost to follow-up,,2011-09,TERMINATED,OBSERVATIONAL,['NA']
15137,NCT04216303,cause specific mortality from infection/sepsis,,,2019-09-12,WITHDRAWN,OBSERVATIONAL,['NA']
15138,NCT01936025,lowest dose of DXM,additive BG lowering effects,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
15139,NCT00297635,Magnitude of glucose excursions and fluctuations as indicated by the standard deviation between glucose tests to indicate relative glucose control and the mean daily glucose value over the 3 month period following the initiation of pump therapy,Whether use of the technology results in perceived improvement in the quality of care and improved satisfaction for all involved,,2006-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15140,NCT01936935,Matsuda Insulin Sensitivity Index (MISI),Plasma high-sensitivity C-reactive protein (hs-CRP),Mean peak postprandial glucose,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15141,NCT03258918,Percentage of participants who achieve weight loss goal,Study attrition,Change in physical symptoms,2017-09-11,COMPLETED,INTERVENTIONAL,['NA']
15142,NCT00960661,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30,Minor Hypoglycemia Rate Per Year,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15143,NCT00276406,Ascending Colon Emptying Half-time (AC t1/2) Measured in Hours,QTc Interval Before and After Treatment,,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15144,NCT00238524,Investigate the efficacy of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy will be determined by pain score ratings assessed in a patient's diary and at clinic visits.,"Investigate effect of lacosmide on subjects' perception of sleep, activity, quality of life, and safety, determined by rating scales assessed in a patient's diary and at the clinic visits.",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15145,NCT01221090,HbA1c,Quality of Life (QOL),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15146,NCT02410499,Change from Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) at Day 85,Change from Baseline in Urinary Protein:Creatinine Ratio (UPCR) Over Time,,2015-05-20,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15147,NCT00139763,Will availability of inhaled insulin result in more type 2 diabetes patients choosing a treatment that involves insulin (if now on >2 OAs) or a more intensive insulin regimen (if now on OAs + glargine) compared to only standard therapies available,Determine both patient and MD reasons for treatment choices made. Determine if treatment choice is influenced by physician specialty or patient ethnicity. Determine how cost impacts patient treatment choice.,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15148,NCT01536236,Visual Analog Scale (VAS),Short Form 36 (SF-36) Quality of Life Questionnaire,,2011-10,WITHDRAWN,INTERVENTIONAL,['NA']
15149,NCT01480843,"Change in Frequency of Hypoglycemia Episodes From Baseline, 5 Months, 8 Months",,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
15150,NCT01536665,Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) ),Time from termination of insulin infusion at nadir to reach plasma glucose 4.0,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15151,NCT01751321,glucose variability,,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
15152,NCT04591457,Anti-insulin antibodies (AIAs),Adverse events,,2020-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15153,NCT03244449,Whole-body glucose disposal,HOMA-IR (Homeostasis Model Assessment - Insulin Resistance),,2014-08-26,COMPLETED,OBSERVATIONAL,['NA']
15154,NCT03164200,"Respiratory quotient (RQ, a measure of substrate oxidation)",,,2011-12-14,COMPLETED,INTERVENTIONAL,['NA']
15155,NCT03734887,Change of Medication Adherence Rate,Program Acceptability assessed by a random sub-sample of interviews,,2019-10-31,TERMINATED,INTERVENTIONAL,['NA']
15156,NCT01516320,Difference in insulin secretion between groups.,Difference in Body composition between groups,,2009-05-13,COMPLETED,INTERVENTIONAL,['NA']
15157,NCT01319656,Evaluation of effects,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
15158,NCT01582139,Hypoglycemic Events,Time in Range,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
15159,NCT03987191,Time Spent With CGM Glucose Levels >180mg/dl Between Two Groups,Work Productivity and Activity Impairment (WPAI:SHP Version 2 Questionnaire) Between Two Groups,,2020-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15160,NCT05752045,Referable Diabetic Retinopathy screening sensitivity/specificity,Laterality determination algorithm accuracy for laterality assessment,,2023-06-28,RECRUITING,INTERVENTIONAL,['NA']
15161,NCT04881019,Gylcemic response profiles,,,2021-06-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15162,NCT05641337,Compound adverse events,Incidence rate of complications of liver cirrhosis within six months,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE3']
15163,NCT03980574,Hospital Readmission Rates,,Serological Assessment,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
15164,NCT01288144,Rate of screening,,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
15165,NCT01938365,Deterioration of pancreatic islet function,"Insulin dosage, HbA1c levels and evaluation of chronic complications",,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
15166,NCT03063515,First phase insulin response to IV glucose infusion,Glucose excursion after IV glucose infusion,,2017-04-19,COMPLETED,INTERVENTIONAL,['PHASE1']
15167,NCT00240370,Compare change from basline in HbA1c after 24 weeks and 50 weeks of treatment with muraglitazar + metformin vs. pioglitazone + metformin,hs-CRP from baseline to W24,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15168,NCT01706289,,,,2009-03,UNKNOWN,OBSERVATIONAL,['NA']
15169,NCT03875729,The area under the time-concentration curve (AUC) of C-peptide after a mixed meal tolerance test (MMTT) at Week 78,Incidence and titers of anti-teplizumab antibodies after treatment courses,,2019-04-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15170,NCT05396898,Difference in insulin secretion,Drug concentration/dose ratio,,2020-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
15171,NCT00458497,Oxygenation levels of blood in the feet will be compared between Holofiber and placebo socks at several time points using standard nonparametric t-test statistics.,,,2007-04,TERMINATED,INTERVENTIONAL,['NA']
15172,NCT03730480,Fingerstick Contour Next BGMS and Contour TV3 Results Compared to the Reference Analyzer,Subjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMS,,2018-09-06,COMPLETED,INTERVENTIONAL,['NA']
15173,NCT02081573,Acceptability Questionnaire.,Body Mass Index,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15174,NCT04258813,Diversity supplement primary outcome: 90-day postoperative cardiovascular complications,Provider-reported care coordination,PCP-reported care coordination,2021-06-14,RECRUITING,INTERVENTIONAL,['NA']
15175,NCT02328235,Metabolic Flexibility measured ex vivo in skeletal muscle using radio labeled carbon isotopes,Intestinal Permeability using a 4 sugar probe test and mass spectrometry,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15176,NCT00726440,Comparison of HbA1c mean between the 3 groups,comparison of the sensors consumption in group 1 and 2 and the evolution in time of this consumption,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
15177,NCT03512119,"Measure of 2 hours plasma glucose value (mmol/l) of OGTT, change from baseline at one year of Lumacaftor-Ivacaftor treatment",Number of cures of antibiotics IV and per os /year and interval between 2 cures (week),,2016-02-11,COMPLETED,OBSERVATIONAL,['NA']
15178,NCT03028506,large for gestational age infants,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
15179,NCT01026675,oral glucose challenge test plasma glucose value,oral glucose challenge test plasma glucose cut-off value,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
15180,NCT01055626,Differences in body fat,Differences in cardiovascular risk factors,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
15181,NCT02558296,Change in HbA1c From Baseline to Week 24,Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline,Proportion of Participants With Incidence of Hospitalization for Heart Failure,2015-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15182,NCT03191396,Change in HbA1c,Change in Pulse Rate,,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE3']
15183,NCT00340132,24-hour metabolic rate,,,1983-01-01,COMPLETED,OBSERVATIONAL,['NA']
15184,NCT06013228,Fatigue,,,2023-08-30,RECRUITING,OBSERVATIONAL,['NA']
15185,NCT01188863,Half-life of the drug in plasma,Glucagon-like Peptide 1,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
15186,NCT03504046,Percent time in glucose range 70-180 mg/dL,Connectivity Analysis (Number of Connection Errors Between devices),,2018-02-28,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15187,NCT04623567,Change from Baseline Triglyceride at 12 weeks,Change from Baseline TCM Symptom Score at 12 weeks,Compositional and Functional Changes from Baseline Metabolites in blood and feces at 12 weeks,2021-12-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15188,NCT04722991,DRSS improvement ≥2 steps at 48 weeks of treatment in the study eye,Frequency of treatment emergent adverse events,,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15189,NCT04078516,"Diagnostic value of CCM, PTT, AF and MRI",Validation of PainDETECT in diabetes,Exploratory measures,2019-08-12,COMPLETED,OBSERVATIONAL,['NA']
15190,NCT03629912,Timed Up and Go (TUG) Test: Change in Dynamic Balance,Diastolic Blood Pressure,,2018-08-13,COMPLETED,INTERVENTIONAL,['NA']
15191,NCT00430742,"Body weight at 36 weeks, HbA1c at 36 weeks","Body weight at 24 and 52 weeks, HbA1c at 24 and 52 weeks",,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3']
15192,NCT05883098,Healing by 12 weeks,Infection rate,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA']
15193,NCT00492700,improvement in steatosis,improvement in transaminase levels; improvement/less worsening in necrosis and inflammatory activity and /or fibrosis,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15194,NCT00491400,Brachial Artery Flow-mediated Dilation,Serum Lipids,,2005-09,TERMINATED,INTERVENTIONAL,['NA']
15195,NCT01840189,nocturnal hypoglycemic events,o Subjective health status,,2013-04-24,TERMINATED,INTERVENTIONAL,['PHASE2']
15196,NCT01594762,Number of Participants With Clinical Response,Number of Participants With Treatment-Emergent Adverse Events (TEAE),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15197,NCT03367351,Adherence to CGM,CGM Self-Efficacy,,2018-03-09,COMPLETED,INTERVENTIONAL,['NA']
15198,NCT05260879,Adoption of the recommended diet and exercise behavior,Reduction in number of participants with hyperglycemia,,2021-11-26,COMPLETED,INTERVENTIONAL,['NA']
15199,NCT04196348,Change in GIP dynamic profile,,,2019-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15200,NCT00539448,Evaluating the Glycemic control of the regimen : Change in A1C levels,Average daily dose : - For both insulin Glulisine & insulin Glargine. - FBG and PPBG if possible ?,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15201,NCT01662921,show that insulin glulisine is non-inferior to insulin lispro in a basal/bolus regimen to treat hyperglycemia in patient with gestational diabetes mellitus,Compare incidence of hypoglycemic episodes <60 mg/dL with symptoms,Compare incidence of primary cesarean section,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15202,NCT02527265,Insulin Maximum Observed Concentration (Cmax),Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2),,2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2']
15203,NCT06213337,Development of foot care self-efficacy in diabetic patients,,,2023-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15204,NCT04183413,Systolic blood pressure among adults with hypertension,"21. Knowledge on diabetes and hypertension among adults with diabetes, prediabetes, or hypertension",,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
15205,NCT01338376,HbA1c,The incidence of Hypoglycemia,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
15206,NCT02198989,HbA1c,Insulin resistance measured as HOMA-IR,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15207,NCT02967224,Change in HbA1c (percentage %),Change in fasting plasma glucose,,2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15208,NCT05737810,Attitudes regarding insulin icodec,,,2023-03-27,COMPLETED,OBSERVATIONAL,['NA']
15209,NCT04990427,Serious Adverse Events,UACR & UPCR,,2022-01-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15210,NCT03155087,the incidence of T2DM,metformin efficacy----the decrease level of HbA1c,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
15211,NCT03711383,Plasma acetate concentrations (microM),"Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK)",,2018-02-20,COMPLETED,INTERVENTIONAL,['NA']
15212,NCT04041375,Change in Diabetes Distress Screening Scale (DDS17),Change in Use of community resources,Change in Use of VHA resources,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
15213,NCT00162240,compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + metformin vs placebo + metformin,"change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15214,NCT00659165,Calories Consumed After Fast.,,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
15215,NCT03292315,Homeostatic Model Assessment of Beta-Cell Function (HOMA-B),Glycated Hemoglobin (HbA1C),,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE4']
15216,NCT02061969,Mean Fasting Blood Glucose Level,Mortality,,2014-04-25,COMPLETED,INTERVENTIONAL,['PHASE4']
15217,NCT05510583,"Assessment of the non-inferiority of the occurrence of maternal, fetal, and neonatal complications for patients of both groups",Comparison of the rate of patients put on insulin in both groups,,2022-08-02,COMPLETED,OBSERVATIONAL,['NA']
15218,NCT05543265,Rate of primary care provider visit attendance,Rate of patient-reported primary care visit attendance,,2022-11-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15219,NCT05467514,To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus.,"To assess the effect of liraglutide on cardiovascular risk factors, cardiometabolic markers. eGDR (Estimated glucose disposal rate)",,2022-07-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15220,NCT04602650,Fecal Microbial Gene Sequencing,Neurological History Questionnaire,,2021-01-14,COMPLETED,OBSERVATIONAL,['NA']
15221,NCT04131257,Change in the incidence of diabetes among individuals with pre-diabetes,"Change in the ""Adoption at the clinic level""",,2019-12,UNKNOWN,INTERVENTIONAL,['NA']
15222,NCT00396851,,,,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
15223,NCT05519501,Percent of subjects with study wound deemed closed at 12 weeks,,,2021-10-10,RECRUITING,INTERVENTIONAL,['NA']
15224,NCT02384889,Number of Participants with Dose Limiting Toxicities,,Changes in Serum Markers of Beta Cell Stress,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
15225,NCT04741074,Kidney Transplant Eligibility,Receipt of Kidney Transplant,Proportion Experiencing Acute Pancreatitis Events,2021-07-23,TERMINATED,INTERVENTIONAL,['PHASE3']
15226,NCT06125561,oral health-related quality of life,Clinical attachment loss,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
15227,NCT00105404,,,,2005-03-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15228,NCT04723134,Number of Wounds with Complete Healing,,,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
15229,NCT05691452,Changes of sit-to-stand transitions,Changes of 24-hour glucose levels assessed by continuous glucose monitors,,2023-01-24,RECRUITING,INTERVENTIONAL,['NA']
15230,NCT01335763,The change in HbA1c from baseline to week 26,Health economic evaluation,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
15231,NCT05360056,Change in DTSQc scores,,,2022-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15232,NCT03496298,Time to First Occurrence of Major Adverse Cardiovascular Events (MACE): Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular (CV) Event - Non-Inferiority Analysis,Time to First Occurrence of Composite Renal Endpoint: Event Rate Per 100 Participant-years for First Occurrence of Composite Renal Endpoint,,2018-04-27,TERMINATED,INTERVENTIONAL,['PHASE3']
15233,NCT04073927,Intestinal inflammation,Kidney function,,2019-08-05,UNKNOWN,INTERVENTIONAL,['NA']
15234,NCT01167231,"Safety, tolerability of acarbose and its effect on body weight, waist circumference and blood pressure","Effect of acarbose on HbA1c, fasting and postprandial glycemia and on lipid profile",,2007-05,COMPLETED,OBSERVATIONAL,['NA']
15235,NCT05543967,Longitudinal changes of odor-induced brain fMRI activation,Longitudinal changes of functional MRI scan,,2022-10-18,RECRUITING,OBSERVATIONAL,['NA']
15236,NCT05427682,Plasma concentrations of rongliflozin,Incidence of Adverse Events [safety],,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
15237,NCT03964428,hepicidin concentration,,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
15238,NCT03348280,Renin production by monocytes,Renin production by monocyte media,,2017-09-01,RECRUITING,OBSERVATIONAL,['NA']
15239,NCT03360058,"Measure the effectiveness of an online training programme, practice implementation toolkit and face to face training for primary care staff",Training uptake,,2017-10-07,COMPLETED,INTERVENTIONAL,['NA']
15240,NCT04445181,Proportion of patients with CKD in a large T2D population,"Proportion of healthcare provider prescriptions of SGLT2i used to treat glycemia management, hypertension, heart failure, coronary artery disease, CKD or other condition",,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
15241,NCT03916601,(Cohort 2) Assessment of PK parameter: Maximum insulin concentration (INS-Cmax),Assessment of PD parameter: Time to GIRmax (GIR-tmax),,2017-12-13,COMPLETED,INTERVENTIONAL,['PHASE1']
15242,NCT03656744,Absolute Change in Liver Fat Content (LFC) as Measured by MRI-PDFF,Number of Participants Reporting an Adverse Events From Baseline Through Week 18,,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE2']
15243,NCT01786421,Determination of diurnal triglyceridemia depend on alcohol intake,Gender differences in diurnal triglyceridemia by alcohol consumption,,na,COMPLETED,OBSERVATIONAL,['NA']
15244,NCT05543434,Clinical attachment level gain,Radiographic Evaluation,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
15245,NCT05564728,Qualitative perspective on a conversational agent/chatbot app usage experience among patients and carers at the end of the trial (1 month).,Usability of a conversational agent/chatbot among patients and carers at the end of the trial (1 month).,,2023-06-23,COMPLETED,OBSERVATIONAL,['NA']
15246,NCT02583438,gut microbiota,The change of inflammatory markers,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
15247,NCT00813215,Incremental AUC og the triglyceride response,Gene expression of genes involved in lipid metabolism and inflammation,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
15248,NCT02119572,"Change from Baseline HbA1c at 6 months,12 months",cost,,na,UNKNOWN,INTERVENTIONAL,['NA']
15249,NCT02225457,Change from baseline in insulin sensitivity,Change from baseline in muscle and adipose tissue gene expression,,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
15250,NCT01461577,Efficacy assessment of insulin glargine measured by changes of HbA1c levels from baseline,Number of patients with treatment-emergent adverse events,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
15251,NCT05801627,HbA1c change from baseline at week 24,eatic β-cell function change (calculated by HOMA-β ) from baseline at week 24 and week 52,,2020-05-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15252,NCT05305794,Percentage of time spent within glycemic target range (0.70-1.80 g/l),,,2022-07-12,RECRUITING,INTERVENTIONAL,['PHASE3']
15253,NCT05501093,Bacterial composition,Gingival inflammation,,2019-03-11,RECRUITING,OBSERVATIONAL,['NA']
15254,NCT05804565,Power Calculation for Definitive RTC,Patient-Reported Quality of Life,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
15255,NCT06316544,admission to ICU,,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
15256,NCT01881074,Local Inflammatory Markers,Systemic Inflammatory Markers,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
15257,NCT01353937,Quality of Life,cEPCs by FACS analysis,,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE1']
15258,NCT03195153,"Assessment of platelet reaction units Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay [Accumetrics, San Diego, California] After 30 days of treatment with each drug",,,2017-03-28,UNKNOWN,INTERVENTIONAL,['PHASE4']
15259,NCT00005754,Progression of coronary artery calcification,,,1999-09,COMPLETED,OBSERVATIONAL,['NA']
15260,NCT03644238,Blood glucose,,,2017-08-21,COMPLETED,INTERVENTIONAL,['NA']
15261,NCT01002209,Time to complete healing of operative wounds,"HBO complications (confinement anxiety, barotrauma, oxygen convulsions)",,2019-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15262,NCT05222633,Central subfield thickness,,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
15263,NCT05706298,Change in time in target glycaemic range,Change in carbohydrate intake,,2022-12-07,RECRUITING,INTERVENTIONAL,['NA']
15264,NCT01485913,"Compare the intermediate evolution of the HbA1c (3, 6 and 12 months)","Compare the evolution of the bio-clinical parameters at 3.6, and 12 months: weight, BMI, blood pressure, waist measurement",,2011-07-01,COMPLETED,INTERVENTIONAL,['NA']
15265,NCT05831059,Numeric Rating Scale,,,2022-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15266,NCT01235026,Plasmatic Interleukin-6 (IL-6),Plasmatic usCRP,,2010-11,UNKNOWN,INTERVENTIONAL,['NA']
15267,NCT05274009,Core temperature (AUC),Change in plasma volume,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15268,NCT02783196,Clock Gene expression,Overall glycemia,,2016-07,UNKNOWN,INTERVENTIONAL,['NA']
15269,NCT03766256,Choice of evidence-based diabetes prevention (lifestyle change or metformin),Decisional conflict,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
15270,NCT03583593,Time of healing,Insulin control,,2014-05-23,COMPLETED,INTERVENTIONAL,['PHASE2']
15271,NCT04666636,Change in glycohemoglobin,,,2020-12-07,RECRUITING,INTERVENTIONAL,['PHASE2']
15272,NCT00597545,Number of Participants With Improved Neuropsychometric Changes,,,2007-03,TERMINATED,INTERVENTIONAL,['NA']
15273,NCT02992431,15D,visits to physician,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
15274,NCT04577274,Change from baseline Insulin at 240 minutes,Creatinine concentration analysis,,2020-11-04,COMPLETED,INTERVENTIONAL,['NA']
15275,NCT06060392,Change in liver fat content,Change in LDL-cholesterol,,2023-10-30,RECRUITING,INTERVENTIONAL,['NA']
15276,NCT01433419,Adverse events,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15277,NCT05429229,Change from baseline in lipoperoxides levels in tear film at 30 days.,Change from baseline in tear secretion in mm with Schirmer I test at 30 days.,Change from baseline severity of dry eye symptoms according the punctuation in Ocular Surface Disease Index (OSDI) at 30 days,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
15278,NCT02530840,Diabetes Control as Expressed by the Change in HbA1c %,,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
15279,NCT01349374,"Nothing will be measured, the aim of the study is the obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines.",,,2011-01,TERMINATED,INTERVENTIONAL,['NA']
15280,NCT01772446,Compare the percentage of patients in the intervention group versus the control group who get a HbA1c below 7%,"Evaluate whether the intervention is more effective (reducing HbA1c below 7%) in patients with predictive risk index <1.5, or in patients with predictive risk index> 1.5.",,2013-06,COMPLETED,INTERVENTIONAL,['NA']
15281,NCT02325193,"average AUC/day in hypoglycaemic range < 70mg/dl (3,9mmo/l)",Number of PLGM activities,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
15282,NCT01382264,Improved glycemic control as determined by A1C in a population of patients with inadequately controlled type 2 diabetes mellitus.,Satisfaction with treatment and quality of life.,,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
15283,NCT02284425,Incidence and severity of treatment emergent adverse events (TEAEs),Concentration of REGN1193 in serum over time,,2014-10,TERMINATED,INTERVENTIONAL,['PHASE1']
15284,NCT00729898,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Weight changes,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
15285,NCT01177709,Weight (wt) in Pounds (Lbs)..,Insulin Level,,2008-05,TERMINATED,INTERVENTIONAL,['NA']
15286,NCT06176495,Percentage change in glycemic control determined by HbA1C (in percent) in participants with diabetes pre and post intervention.,Assessment of Changes in Anxiety Screening score (in percentage pre and post intervention),,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15287,NCT05852626,Number of patients who achieved individualized target HbA1c,Foot evaluation,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15288,NCT03179332,AUCGIR(0-60min),Clinical safety laboratory,,2017-06-20,COMPLETED,INTERVENTIONAL,['PHASE1']
15289,NCT01861860,The incidence of MACE composite criteria among patients who received a TAXUS long stent deployed using IVUS according to the OPERA criteria according to the LPPR during a 12 months period after inclusion in the trial.,Medico-economics data at 12 months including,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
15290,NCT05254002,"Mean ratio of change from baseline to Day 180 in UACR for the combination therapy group, to finerenone alone",Total number of urosepsis and pyelonephritis events,,2022-06-23,RECRUITING,INTERVENTIONAL,['PHASE2']
15291,NCT02947503,Development of T2D and obesity during Phase C,Secondary outcome measures phase C,,2019-11-26,RECRUITING,INTERVENTIONAL,['PHASE3']
15292,NCT01613755,Peak plasma concentration (Cmax) of metformin,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15293,NCT00843609,"Reduction in time spent in hypoglycaemia, defined as continuous glucose <3.5mmol/l (63mg/dl) (with or without symptomatic hypoglycaemia).",Quality of Life measures (Fear of Hypoglycaemia score and subject satisfaction questionnaire);,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
15294,NCT01609881,"Vitreous and anterior chamber levels of prostaglandins, other cytokines, and Acuvail",Secondary Outcome,,2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
15295,NCT05241262,Maximum tolerated dose (MTD) of NAC,Change in Brain glutathione (GSH) level,,2023-04,RECRUITING,INTERVENTIONAL,['PHASE1']
15296,NCT04094194,LDL-cholesterol (randomized and non-randomized controlled trials),Incident Stroke (Prospective Cohort Studies),,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
15297,NCT02939768,Mitochondrial superoxide dismutase (MnSOD) activity,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
15298,NCT02074540,Insulin adherence,,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
15299,NCT00069446,Incidence of clinically significant hypotension.,Percent reduction in total ulcer surface area.,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1']
15300,NCT05134987,"AUCPG,0.5-2h Area under the plasma glucose-time curve at steady concentrations",Number of adverse events,,2021-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15301,NCT03118336,epicardial adipose tissue volume,myocardial PCr/ATP ratio,,2017-06-16,COMPLETED,INTERVENTIONAL,['PHASE3']
15302,NCT03080337,Compliance with glucose testing over time,Cost-effectiveness (dollars per hour),,2017-03-17,TERMINATED,INTERVENTIONAL,['NA']
15303,NCT00142974,Reduction in weekly mean of a daily composite diabetic gastropathy dyspeptic symptom severity score throughout 6 weeks of treatment.,"Weekly mean severity of individual dyspeptic symptoms (nausea, vomiting, retching, epigastric/stomach, discomfort/pain, postprandial fullness, bloating, early satiety).",,2004-05,TERMINATED,INTERVENTIONAL,['PHASE2']
15304,NCT01508806,Area under the Curve (AUC),Adverse events,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
15305,NCT01704261,Percentage of Participants Who Discontinued From the Study Due to an AE,Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% at Week 24,,2012-10-18,COMPLETED,INTERVENTIONAL,['PHASE3']
15306,NCT05892341,Effectiveness of AQUACEL® Ag+ Extra™ and Cutimed® Sorbact® on wound management,Safety assesment,Quality of Life assesment,2022-12-05,COMPLETED,INTERVENTIONAL,['NA']
15307,NCT05585190,Insulin sensitivity (HOMA-IR),vascular endothelial function (superficial femoral and brachial arteries) and resilience to a high-glucose load,Acceptability Questionnaire,2023-02-06,RECRUITING,INTERVENTIONAL,['NA']
15308,NCT02999867,response to the dietary intervention by the change from baseline in insulin resistance at 30-day,response to the dietary intervention by the change from baseline in iron absorption at 30-day,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
15309,NCT03758144,change in glycemic control,Gastrointestinal symptom questionnaire,change in weight,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA']
15310,NCT06293417,major adverse cardiovascular events and diabetic microvascular events for 48 months,change in TC/HDL-C ratio at 48month from baseline,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15311,NCT00474838,Change of pancreatic beta cell function,Time to reach target goal of blood glucose level,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15312,NCT04971889,Change from Baseline HbA1c,Change from baseline Systolic Blood Pressure,Change from baseline Situational Obstacles to Dietary Adherence Questionnaire,2021-08-03,RECRUITING,INTERVENTIONAL,['NA']
15313,NCT01947556,T-BG≥10,T-INSAUC50%,time exogenous glucose requirement,2014-03,COMPLETED,INTERVENTIONAL,['NA']
15314,NCT02169050,Oral Glucose Insulin Sensitivity (OGIS),Inflammatory markers in plasma,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
15315,NCT01269580,post revascularization cardiovascualr mortality,post revascularization amputation,post revascularization restenosis,2009-02,UNKNOWN,OBSERVATIONAL,['NA']
15316,NCT00198146,"Area under the curve, Glucagon Stimulation Testing for c-peptide measurements at 0, +6min and +10min intervals over 2 years",Insulin requirements (units/kg/day),,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15317,NCT01037647,VLDL-TG production and clearance rates,VLDL-TG subcutaneous adipose tissue storage,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
15318,NCT03313661,The level of fasting and post prandial BG level,,,2017-10-14,UNKNOWN,INTERVENTIONAL,['PHASE3']
15319,NCT04841291,The number of participants who believed in the practicality of the virtual simulation-based foot care education.,The participants' level of foot self-care efficacy to perform recommended diabetic foot self-care activities.,,2022-01-25,RECRUITING,INTERVENTIONAL,['NA']
15320,NCT04334109,"Change in mean HbA1c (NGSP%) from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention","Change in diabetes-related quality of life from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention",,2021-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15321,NCT02750501,Change From Baseline of Erythrocyte Omega-3 Index % (DHA+EPA),Plasma Composition (%) Ratio of n6/n3 Fatty Acids.,GI Symptoms,2016-07-20,COMPLETED,INTERVENTIONAL,['NA']
15322,NCT04715776,"From baseline to 3 months after using dietary supplements (compare yourself with yourself), follow up for a total of 12 months",,,2018-12-10,UNKNOWN,INTERVENTIONAL,['NA']
15323,NCT04982575,Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide),"Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)",,2021-08-02,COMPLETED,INTERVENTIONAL,['PHASE2']
15324,NCT04743778,Regimen Adherence,Diabetes Quality of Life,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
15325,NCT03878459,Decrease in HbA1c,insulin dose,,2019-08-08,RECRUITING,INTERVENTIONAL,['PHASE4']
15326,NCT03673904,statistical significant elevation of high sensitive CRP in diabetics and prediabetes,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15327,NCT01006057,Area under the insulin degludec concentration-time curve,Renal clearance of insulin degludec after single-dose,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15328,NCT04387058,the cumulative incidence,,,2019-06-16,UNKNOWN,INTERVENTIONAL,['NA']
15329,NCT01472159,"Change in glycemic control, assessed by hemoglobin A1c","Change in psychosocial factors (e.g., self-efficacy, fear of hypoglycemia, quality of life, diabetes-specific family conflict, diabetes responsibility sharing, diabetes-specific burden, anxiety, depressive symptoms)",,2011-10,COMPLETED,INTERVENTIONAL,['NA']
15330,NCT02681588,birthweight,,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
15331,NCT01991093,Multiple electrode aggregometry in detection of clopidogrel resistance,,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
15332,NCT03881540,Change in Glycated haemoglobin (A1C),Change in exercise minutes,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
15333,NCT05471986,Sensitivity and Specificity of EyeCheckup to detect vision-threatening diabetic retinopathy,Negative Predictive Value,,2024-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15334,NCT04753294,Change in wound progress,Wear time,,2021-06-14,COMPLETED,INTERVENTIONAL,['NA']
15335,NCT03463629,Change in glucose level as indicated by HbA1c levels,Change in blood pressure,Glucose level as indicated by HbA1c levels,2018-03-21,COMPLETED,INTERVENTIONAL,['NA']
15336,NCT06245980,Heart failure readmission,cardiovascular death,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
15337,NCT02477969,HbA1c,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2014-02-27,UNKNOWN,INTERVENTIONAL,['PHASE3']
15338,NCT04682795,Time In Range,Insulin dose,Insulin treatment compliance,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15339,NCT00428532,,,,2007-03,UNKNOWN,INTERVENTIONAL,['NA']
15340,NCT05674799,BMI in early pregnancy,Glycemia in early pregnancy,Rate of neonatal hypoglycemia requiring treatment,2023-04-08,RECRUITING,INTERVENTIONAL,['NA']
15341,NCT00960635,,,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15342,NCT04617275,Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity,CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity),,2021-01-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15343,NCT05525364,Variables of interests - Blood glucose and hyperglycemia data,,,2019-06-20,COMPLETED,OBSERVATIONAL,['NA']
15344,NCT02609633,Change From Baseline in Diabetes-Related Distress Among Parents/Caregivers According to the Problem Areas in Diabetes (PAID) Child and Teen (C&T) Parent Questionnaire Score at Month 6,Percentage of Participants With Overall Treatment Satisfaction With the Use of Accu-Chek® CONNECT Diabetes Management System According to a Questionnaire,,2015-12-28,COMPLETED,INTERVENTIONAL,['NA']
15345,NCT05186519,All non-traumatic amputate events,Length of stay in hospital,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
15346,NCT00393770,Insulin sensitivity,Lipid profile.,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
15347,NCT05681533,Epicardial fat volume,,,2021-03-31,RECRUITING,OBSERVATIONAL,['NA']
15348,NCT06264427,Number of participants with obstructive sleep apnea,CPAP treatment effect on daytime sleepiness measured with the functional outcome of sleep questionnaire (FOSQ-10).,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
15349,NCT00673296,Interval between the treatment and clearing of premacular hemorrhage,"Snellen best-corrected visual acuity measurements, intraocular pressure, slit-lamp examination and non-contact lens biomicroscopic examination.",,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
15350,NCT01838083,Area under the serum insulin concentration curve within 24 hours (INS-AUC0-24) after dosing on Day 6,"Safety as measured by adverse events/serious adverse events, ohypoglycemia events, physical examinations, clinical laboratory, electrocardiograms, vital signs, injection site reactions and anti-insulin antibodies.",,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
15351,NCT05102071,Occurrence of first hospitalization for congestive heart failure (HHF),All cause cost,,2021-11-01,WITHDRAWN,OBSERVATIONAL,['NA']
15352,NCT03022721,Development of diabetic complications,,,2016-09,RECRUITING,OBSERVATIONAL,['NA']
15353,NCT00795691,Change in Body Weight at month 12,Quality of life as assessed using the Diabetes Quality of Life Scale at month 12,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
15354,NCT02162407,Steady state glucose infusion rate (GIR) / interstitial insulin steady state concentration,Insulin concentration profiles,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15355,NCT00440440,Mean absolute change in visceral adipose tissue mass in type 2 diabetic subjects with hypogonadism after 6 months of androgel therapy.,Mean absolute change in spine BMC and lumbar spine (L1-L4) BMD,,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15356,NCT02811055,Difference from baseline in Plasma aldosterone concentration,Difference from baseline in HOMA index,,2017-07-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
15357,NCT00824395,,,,2006-01,WITHDRAWN,OBSERVATIONAL,['NA']
15358,NCT01096940,To evaluate the effect of AZD1656 on the steady state pharmacokinetics of simvastatin (including simvastatin acid) and vice versa by assessment of AUC(0-24) and Cmax.,"To evaluate the safety and tolerability of AZD1656 alone and in combination with simvastatin by assessments of adverse events, laboratory variables, electrocardiogram, blood pressure, pulse, results of physical examination, and weight.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15359,NCT06061861,6-month change in glycosylated hemoglobin level,Change in self-reported readiness to change,,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE3']
15360,NCT01905020,Percentage of time in target range,Number of hypoglycemic events requiring treatment,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15361,NCT03222284,Device usability as assessed by the System Usability Scale (SUS),,,2017-07-17,UNKNOWN,INTERVENTIONAL,['NA']
15362,NCT01492166,Change in prandial glucose increment (PGI),Occurrence of Adverse Drug Reactions (ADR),,2006-11,COMPLETED,OBSERVATIONAL,['NA']
15363,NCT03980353,Identification of community integration obstacles for children with type 1 diabetes,,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
15364,NCT00878605,Hemoglobin A1C,,,2010-04-01,TERMINATED,INTERVENTIONAL,['PHASE2']
15365,NCT02889172,Beck Depression Inventory,Simplified Medication Adherence Questionnaire,,2015-02,TERMINATED,INTERVENTIONAL,['NA']
15366,NCT01722266,Change in Mean Weekly Glucose Concentrations,Change in Glucagon Concentrations,,2012-11-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15367,NCT00812032,An exploratory study with three co-primary response variables which are directly related to platelet COX-1 inhibition: arachidonic acid-induced platelet aggregation in whole blood and PRP and in the Cone-and-Plate(let) Assay (CPA),"Indirectly COX-related platelet aggregation induced by collagen or ADP, and thromboxane metabolite excretion.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15368,NCT03368209,Calibration models for device predictive purposes,,,2015-12-04,TERMINATED,INTERVENTIONAL,['NA']
15369,NCT00358254,,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
15370,NCT05308836,Safety measure,Insulin dose,,2021-10-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
15371,NCT01892319,"Proportion of pregnancies (Levemir® treatment), compared to pregnancies (other basal insulin treatment regimens), resulting in none of the following events: Major congenital malformations, Perinatal death, Neonatal death",Proportion with changes (progression/regression) of major congenital malformations,,2013-09-30,COMPLETED,OBSERVATIONAL,['NA']
15372,NCT04707157,Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm),,2021-05-06,TERMINATED,INTERVENTIONAL,['PHASE2']
15373,NCT05645419,Number of Participants with myocardial infarction,,,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15374,NCT04625088,Time course change in plasma HISS levels,Time course change in Meal Induced Glycemia (MIG) scores (Molar Units),,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
15375,NCT01545570,"pharmacokinetic parameters of GSK2374697, after ascending single or titrated multiple subcutaneous doses, in healthy subjects",dose proportionality of GSK2374697,,2011-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15376,NCT02498119,"Composite measure of patient physical observations to include weight, height and BMI",The effect of LTB4 and LTC4 of eicosanoids,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
15377,NCT05612698,fasting plasma glucose,body composition (measured by bioimpedance),,2023-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15378,NCT05409924,Safety analyses after multiple doses of ATR-258,PK analyses will be performed after PK of ATR-258 multiple dose,,2022-04-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15379,NCT01165684,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 32,Hypoglycaemic Episodes (Rate of All Treatment Emergent Hypoglycaemia Episodes),,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15380,NCT01890993,Change in HbA1c (glycosylated haemoglobin),Change in systolic blood pressure,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
15381,NCT04259801,Number of treatment emergent adverse events (TEAE) in Part 2,The maximum concentration of semaglutide after administration of the 12th dose of semaglutide,,2020-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
15382,NCT05980026,change in UACR (mg/g creatinine) level,change in HbA1c(%),,2022-01-10,COMPLETED,INTERVENTIONAL,['NA']
15383,NCT01954459,Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use.,,,2013-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
15384,NCT01277471,Change in Insulin Resistance,Oxidative stress markers and AGEs,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
15385,NCT01098539,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Plasma Concentrations (Conc.) of Albiglutide at Week 8 and Week 16,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15386,NCT04218734,Change in HbA1c (%) from baseline to week 24,Change in body weight from baseline to week 12 and week 24,,2020-01-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15387,NCT00431717,,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
15388,NCT02002130,Compare the effect of oral GABA or oral GABA/GAD combination administration on pancreatic beta cell function by quantitative C-peptide secretion,Compare the effect of oral GABA or oral GABA/GAD administration on diabetes related autoantibodies,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15389,NCT01482481,HbA1c level,Body Mass Index (BMI),,2008-01,COMPLETED,OBSERVATIONAL,['NA']
15390,NCT01626586,Diabetes-related Outcomes,Diabetes-related medical outcome data,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
15391,NCT01993121,Changes from baseline in cardiovascular exercise performance,Changes from baseline in diastolic function will be measured,,2002-09,COMPLETED,INTERVENTIONAL,['NA']
15392,NCT00918879,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients (Expressed in Percentage of Total Participants) Achieving a Therapeutic Glycemic Response Defined as HbA1c < 7.0% at Week 24,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15393,NCT03341117,"Modification in the antioxidant enzymatic system activity (total antioxidant capacity, catalase, glutathione peroxidase , superoxide dismutase) in patients with type 2 diabetes after the administration of acetylsalicylic acid",Modification in fasting glucose in patients with type 2 diabetes after the administration of Acetylsalicylic acid,,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
15394,NCT06038968,assess functional outcomes by multifocal electroretinogram,visual acuity,,2022-09-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15395,NCT02752828,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,,2016-05-23,COMPLETED,INTERVENTIONAL,['PHASE3']
15396,NCT05198544,Evaluate Wound healing in Wagner 1 and 2 grade DFUs by wound size,Occurrence of adverse events through case report forms,Bacterial burden measured by Imaging,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15397,NCT04080596,AUClast,,,2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE1']
15398,NCT05153564,"Area under the levonorgestrel plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state (AUC0-24h,LN,SS)","Maximum observed paracetamol concentration following a standardised meal (Cmax,para)",,2021-12-13,COMPLETED,INTERVENTIONAL,['PHASE1']
15399,NCT01871324,the efficacy will be evaluated using Diabetes Quality of Life questionnaire before and after the program.,the efficacy will be evaluated using behavioral changes related to diabetes questionnaire before and after the program.,"the efficacy will be evaluated using HbA1c values, glucose levels before and after the program",2013-09,WITHDRAWN,INTERVENTIONAL,['NA']
15400,NCT00325429,Adverse events profile after 52 weeks of treatment,Change from baseline to endpoint in body weight at 52 weeks,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15401,NCT03025919,area under the ROC curve,sensitivity and specificity of screening,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
15402,NCT03530176,18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes,,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
15403,NCT02586129,Change in HbA1c,,,2015-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15404,NCT03898206,Postprandial glucose,Blood pressure,,2019-02-26,UNKNOWN,INTERVENTIONAL,['NA']
15405,NCT01174901,"Differentiation between serious secondary non-traumatic headache as opposed to benign, self-limiting non-traumatic headache by copeptin level measurement",Comparison of copeptin with other potential biomarkers in non-traumatic headache,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
15406,NCT04058951,Urine albumin creatinine ratio (UACR),,,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA']
15407,NCT00909051,"Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)",,,2009-03-24,COMPLETED,OBSERVATIONAL,['NA']
15408,NCT04461236,Change in whole-body protein metabolism in type 2 diabetic obese subjects,Changes in quality of life as measured by Short Form (36) Health Survey (SF36) in type 2 diabetics obese subjects,Group differences in Bi-manual Coordination Task between type 2 diabetics and non-diabetic subjects,2019-05-30,UNKNOWN,INTERVENTIONAL,['NA']
15409,NCT03648307,Glucose tolerance,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
15410,NCT00738907,Pancreatic tracer binding as standardized uptake value (SUV) or binding potential (BPnd),,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
15411,NCT04627272,Specificity,,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
15412,NCT01681173,Change of 2h-postprandial blood glucose from IGT to diabetes mellitus type 2 or normal glucose tolerance (NGT),Determination of gene expression in adipose tissue,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
15413,NCT00770653,The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.,Change From Baseline in Erythrocyte Deformability (60.00).,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15414,NCT04741685,TIR,Hypoglycemia perception 2,,2021-02-15,COMPLETED,OBSERVATIONAL,['NA']
15415,NCT00090506,,,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15416,NCT04873232,To evaluate the efficacy of IM administration of Engensis on pain in Participants with painful DPN in the feet and lower legs as compared to Placebo,To evaluate the safety of IM administration of Engensis in Participants with painful DPN in the feet and lower legs,,2021-05-17,RECRUITING,INTERVENTIONAL,['PHASE3']
15417,NCT02625649,Number of patients with HbA1c<48 mmol/mol.,Number of patients with two-step change from preoperative level on the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) scale,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
15418,NCT01792323,tmax(GIR); time to maximum glucose infusion rate,"GIRmax, maximum glucose infusion rate","tmax(ins), time to maximum observed plasma insulin lispro concentration",2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
15419,NCT02204384,Area Under the Curve (AUC 0-180min) for glycemic and insulinemic responses,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
15420,NCT02575599,The Patient Activation Measure (PAM),Glycosylated haemoglobin (HbA1c),,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15421,NCT05659368,changing in insulin production,change in HbA1c,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
15422,NCT05173025,Angiotensin(1-7),HbA1c,,2018-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15423,NCT00803920,Characterize glucose control using periodic CGM in subjects participating in protocol 2993LAR-105 at the International Diabetes Center study site.,,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
15424,NCT01707979,near infrared spectroscopy,,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
15425,NCT05541237,remission rate,blood lipid profile,,2022-08-17,RECRUITING,INTERVENTIONAL,['NA']
15426,NCT01089166,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
15427,NCT00813085,Comparison of change in diabetes quality of care between intervention and usual care group.,"Change in diabetes risk factor variables, satisfaction with care and technology, quality of life and health care utilization, health data privacy issues.",,2002-04,COMPLETED,INTERVENTIONAL,['NA']
15428,NCT00645268,The IIEF Erectile Function (EF) Domain score,Flow mediated brachial artery dilation (FMD) as an index of generalized endothelial function,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15429,NCT03563456,Antioxydants,Personal history as independent factor,,2017-06-05,COMPLETED,INTERVENTIONAL,['NA']
15430,NCT00540462,"Measure sugar levels, HbA1c levels, and medication needed. OGTT, MGTT.","Comparing the DM controls between Medical and Surgical treatment In surgery groups, compare the bypass surgery and sleeve gastrectomy",,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
15431,NCT05341388,BDNF concentrations,36 item Short Form Survey (SF-36),,2021-03-01,TERMINATED,OBSERVATIONAL,['NA']
15432,NCT02249871,Area under the semaglutide plasma concentration time curve,Number of hypoglycaemic episodes,,2014-09-24,COMPLETED,INTERVENTIONAL,['PHASE1']
15433,NCT04592601,Weight Loss,Adverse Events,,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA']
15434,NCT00282945,"This study will examine whether biomarkers of B-cell function measured early in the study (1, 3, and/or 6 months) will predict long-term changes in B-cell function (as represented by HOMA-B).",,,2006-01,TERMINATED,INTERVENTIONAL,['NA']
15435,NCT05054361,blood MAIT cells frequency,16 S sequencing in the Subjects stools,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
15436,NCT01624259,Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),Percent Change From Baseline in Lipid Parameters at 26 Weeks,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15437,NCT04612933,Change from baseline of Time in Range (TiR),Change from baseline of time spent below target glucose range (TbR) level 2,Semi-structured interviews,2021-06-28,RECRUITING,INTERVENTIONAL,['NA']
15438,NCT03367455,Associations of serum potassium and KCNJ11 variants with incident diabetes as represented by odds ratio,,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
15439,NCT05899439,Genetic risk of type 1 diabetes,,,2005-01-01,RECRUITING,OBSERVATIONAL,['NA']
15440,NCT02488785,Hemoglobin A1c,,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
15441,NCT03168867,Glycemic Control,Household Chaos (Self-reported),,2017-09-25,COMPLETED,INTERVENTIONAL,['NA']
15442,NCT04611737,height,Depression Anxiety Stress Scales,,2020-11-03,COMPLETED,INTERVENTIONAL,['NA']
15443,NCT01871870,Verification of the Automation and Telemetry Components,Deviation From Target Blood Glucose,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15444,NCT05464407,Foot ulcer healing,Number of new foot ulcers,,2022-02-24,TERMINATED,INTERVENTIONAL,['NA']
15445,NCT03169959,Maximum observed plasma concentration (Cmax),Laboratory assessments of urinalysis,,2017-05-29,COMPLETED,INTERVENTIONAL,['PHASE1']
15446,NCT05819151,Tongue image features,Symptom patterns,,2022-10-12,RECRUITING,OBSERVATIONAL,['NA']
15447,NCT04611152,Changes in BCVA to Assess Non-inferiority of KSI-301 to Aflibercept.,Safety and Tolerability of KSI-301 mg compared to aflibercept 2 mg measured by the number of ocular and systemic adverse events.,,2020-09-30,TERMINATED,INTERVENTIONAL,['PHASE3']
15448,NCT05579561,Change from baseline of triglycerides,Change in the microbiome,,2022-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15449,NCT03973762,Se and Sp under investigation target 3,Se and Sp under investigation target 1/2/4/5,,2019-05-31,COMPLETED,INTERVENTIONAL,['NA']
15450,NCT01319734,improving the renal function,Vitamin C can improve the visual fields,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
15451,NCT03584217,Glomerular filtration rate (GFR),Renal perfusion,Epigenetic profiling,2018-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15452,NCT03407677,rotation of insulin injections,Accuracy of the ROTO track® injection log,glycaemic control,2018-08-27,COMPLETED,INTERVENTIONAL,['NA']
15453,NCT02632292,In-stent late lumen loss,Anginal status assessed by the Seattle Angina Questionnaire,,2016-01,TERMINATED,INTERVENTIONAL,['NA']
15454,NCT05349903,Postprandial plasma gut hormone response,Breath hydrogen (fermentability),,2021-11-10,COMPLETED,INTERVENTIONAL,['NA']
15455,NCT00662831,Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing,Transcutaneous Local Tissue Oxygenation (pO2),Number of Clinically Relevant Minor Hemorrhages and Trivial Hemorrhages,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15456,NCT01029639,"Questionnaires completed by subjects at baseline quarterly to assess ability to sense low blood sugar. Tracking incidences requiring outside assistance including paramedics, ER visits and hospitalizations due to low blood sugar incidences.",,,2007-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15457,NCT02127047,Change in beta-cell function as derived from change in C-peptide and glucose levels during the mixed meal test,Change in fractalkine,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15458,NCT02846545,Active Treatment Period: C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) at Week 52,Titers of Antibodies to Golimumab,,2016-08-26,COMPLETED,INTERVENTIONAL,['PHASE2']
15459,NCT04891159,"Adoption of a shared decision making measured by the total score obtained on the 9 items of the shared decision making questionnaire (SDM-Q-9), translated into French.",,,2021-09,UNKNOWN,OBSERVATIONAL,['NA']
15460,NCT03421119,HbA1c,Liver enzymes,,2019-06-20,UNKNOWN,INTERVENTIONAL,['PHASE3']
15461,NCT04504045,Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 12.,Change from Baseline in High Sensitivity C-Reactive Protein at Week 12.,,2020-09-01,TERMINATED,INTERVENTIONAL,['PHASE1']
15462,NCT02890745,"Urinary excretion of 8-oxo-7,8-dihydroguanosine (nmol/24h)","Plasma levels of iron, ferritin, transferrin and transferrin saturation",,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15463,NCT05709444,"To determine the incidence of overall adverse events, related adverse events, a composite of adverse events of special interest, serious adverse events, and the incidence of BMT discontinuation.",To measure the efficacy of SQ BMT in combination with RAAS inhibition therapy to achieve a <1.0 ml/min/year drop in eGFR after six months,,2022-12-26,RECRUITING,INTERVENTIONAL,['PHASE2']
15464,NCT02161588,Area under the semaglutide plasma concentration-time curve,Number of treatment emergent adverse events (TEAEs) recorded,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15465,NCT05716724,Change in glycated haemoglobin (HbA1c),Timing of intake of oral semaglutide as reported in patient diary,,2023-01-25,COMPLETED,OBSERVATIONAL,['NA']
15466,NCT02364323,percentage of patients attaining ≥ 3 pre-defined treatment targets from the following treatment targets: 1) BP <130/80 mm Hg 2) HbA1c <7% 3) Calculated LDL-cholesterol <2.6mmol/l 4) Fasting TG <2mmol/l 5) Use of ACEI or ARB,Patient behavior measured on the Summary of Diabetes Self-care Activities (SDSCA),,2015-02-17,COMPLETED,INTERVENTIONAL,['NA']
15467,NCT00790530,Completion of dilated eye examination,Completion of microalbumin testing,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
15468,NCT02563015,Lean mass,25(OH)D,,2016-03-07,TERMINATED,INTERVENTIONAL,['NA']
15469,NCT00640549,Changes in concentration of LDL subfractions LDL-5 and LDL-6 compared with screening (visit 1),Changes in size of LDL subfractions compared with screening (visit 1),,2003-03,TERMINATED,INTERVENTIONAL,['PHASE4']
15470,NCT01378117,Mean Blood Glucose Levels Among the Three Groups at the Time of Hospitalization to 1st Day After Therapy,Percent of Blood Glucose Readings Within Target Range Between 70 and 140 mg/dL Among the Three Groups After 24 Hrs of Randomized Treatment,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15471,NCT02496000,Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.,The Effect of ORMD-0801 on the Percent Change in HbA1c,,2015-07-27,COMPLETED,INTERVENTIONAL,['PHASE2']
15472,NCT02216955,Disease-specific survival,Overall survival,Disease-free survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
15473,NCT00847899,Glucose dynamics and insulin sensitivity,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15474,NCT03664726,Reinforcing Value of Food,Change in Working Memory Span,,2018-02-12,COMPLETED,INTERVENTIONAL,['NA']
15475,NCT05629117,Changes in Blood Pressure Level including Systolic blood pressure (SBP) and Diastolic blood pressure (DBP),Changes in Quality of Life,,2022-12-26,COMPLETED,INTERVENTIONAL,['NA']
15476,NCT00643773,Body Composition,Muscle characteristics,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15477,NCT02320253,Percent Weight Change From Baseline,Depression Score: Change From Baseline.,Health Economics,2014-11,COMPLETED,INTERVENTIONAL,['NA']
15478,NCT01144091,The purpose of the study is to examine the potential renal protective effect of pentoxyphylline in high-risk patients undergoing angiography,The purpose of the study is to examine the potential renal protective effect of pentoxyphylline in patients with elevated base line creatinin level > 2 undergoing angiography,,2012-12,WITHDRAWN,INTERVENTIONAL,['NA']
15479,NCT04757233,Change in score on Summary of Diabetes Self-Care Activities Questionnaire (SDSCA),,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
15480,NCT02432924,Change in physical activity level (PAL),QIntervention: Change in cardiovascular disease and type 2 diabetes risk,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
15481,NCT01593774,Change from baseline in weight at week eight,Changes from baseline in HOMA-IR values at week 8,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15482,NCT00659295,"Incidence of Serious Adverse Reactions, Including Major Hypoglycaemic Events",,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
15483,NCT05666479,Accuracy of Real-Time Continuous Glucose Monitoring,Assess Irreversible Damage/Interference of Real-Time Continuous Glucose Monitoring Devices Caused by Electrocautery,,2022-09-09,RECRUITING,OBSERVATIONAL,['NA']
15484,NCT04326166,Change in HbA1c,Change in FPG,,2020-03-25,UNKNOWN,OBSERVATIONAL,['NA']
15485,NCT02028091,"Pulse wave arrival time difference between finger and toe, duration of diabetes",,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
15486,NCT03095846,5. Difference in brown adipose tissue (BAT) activity after cooling between Winter Swimmers (WS) and No-Winter Swimmers (NWS).,Difference in resting energy expenditure after cooling versus no cooling,,2017-04-02,COMPLETED,INTERVENTIONAL,['NA']
15487,NCT02619487,glycemic control assessed by HbA1C level.,number of hospitalizations related to T1D,,2019-03,WITHDRAWN,INTERVENTIONAL,['NA']
15488,NCT03577184,Change from baseline in Random blood sugar (RBS) and fasting blood sugar (FBS) levels at week 12 in participants receiving Vildagliptin combination with Metformin,Number of participants who experienced an Adverse Event,,2018-07,WITHDRAWN,OBSERVATIONAL,['NA']
15489,NCT00889226,Proportion of Patients Achieving LDL- C<100mg/dL,The Change of LDL-C,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15490,NCT01009021,Pain recorded using a Visual Analog Scale,,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
15491,NCT00945659,Glycated Hemoglobin (HbA1c),Hypoglycemia Fear Survey-Parent,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
15492,NCT05965973,"Change in the expression of key genes in hepatic fibrogenesis including transforming growth factor beta 1, a-smooth muscle actin, type-1 collagen, connective tissue growth factor",Identify bacteria strains involved in the control of blood glucose such as C elegans.,,2023-06-09,RECRUITING,INTERVENTIONAL,['NA']
15493,NCT01526720,Genetic basis of beta cell function,Genetic basis of insulin sensitivity,,2003-10,UNKNOWN,OBSERVATIONAL,['NA']
15494,NCT06145542,Continuous glucose monitoring at follow-up,Ambulatory Blood Pressure at follow-up,,2023-12-11,RECRUITING,INTERVENTIONAL,['NA']
15495,NCT00097877,HbA1c,other glycemic variables,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15496,NCT03474731,Hemoglobin A1c,Total cholesterol,,2018-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15497,NCT02077179,Metabolic Syndrome Z Score,Adherence to the HIP Program; Percent of Dietary Logs Completed,,2014-09,TERMINATED,INTERVENTIONAL,['NA']
15498,NCT02564926,Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan,Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52,,2016-01-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15499,NCT04163055,The rate of CWH of DFUs will be estimated as a proportion and compared between the two groups using a chi square test. The superiority of AF-guided intervention (Arm 2) will be established if the null hypothesis is rejected.,Quality of Life improvement due to the device as assessed Diabetic Foot Ulcer Scale,,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15500,NCT03506230,Differences in HbA1c after six months,Whether or not HbA1c test was performed at 3 months,Differences in the number of GP visits,2018-11-25,UNKNOWN,INTERVENTIONAL,['NA']
15501,NCT05962372,Cardiometabolic Improvement Score (CIS),Change in levels of metabolic risk factors,,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15502,NCT03261895,Self-management,,,2017-05-04,COMPLETED,INTERVENTIONAL,['NA']
15503,NCT00589134,osmotic regulation of AVP,temperature responses,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
15504,NCT02031081,Change In Cumulative Meal-related Symptoms,Gastric Emptying Rate,,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15505,NCT01269502,Recurrency of diabetic foot ulcer,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
15506,NCT03774095,Gastrointestinal tolerability,,,2018-06-11,UNKNOWN,INTERVENTIONAL,['NA']
15507,NCT02936843,Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh,,,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15508,NCT00476151,Placebo vs. Active Comparison of the Change From Average Pain at Baseline to Average Pain at 4 Weeks.,,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15509,NCT03449654,Change in vascular inflammation,Carotid intima media thickness,Autonomic nervous system function,2017-10-26,COMPLETED,INTERVENTIONAL,['PHASE4']
15510,NCT03509324,fasting plasma glucose after insulin therapy,,,2015-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15511,NCT03034226,Insulin sensitivity,Symptoms during hypoglycemia,,2017-02-23,COMPLETED,INTERVENTIONAL,['NA']
15512,NCT04701424,Time in the target glucose range (3.9 to 10.0 mmol/l),Total insulin dose,Percentage of time of CGM availability,2020-12-16,COMPLETED,INTERVENTIONAL,['NA']
15513,NCT03887936,Finite element analysis of bone to measure bone strength,Osteoblast and osteoclast progenitor cells which are cells found in bone,,2019-10-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15514,NCT03760068,Treatment Emergent Antibody Response (TEAR),Change in 7-point Self-monitored Blood Glucose (SMBG) Profile From Baseline,,2018-11-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15515,NCT01086319,"Hospitalizations with any hypersensitivity reaction, including anaphylaxis, angioedema, generalized urticaria, SJS, TEN, and other severe skin reactions (i.e., acute generalized exanthematous pustulosis and drug rash with eosinophilia/systemic symptoms)",Hospitalized for for toxic epidermal necrolysis (TEN),,2009-08,COMPLETED,OBSERVATIONAL,['NA']
15516,NCT03520972,Change of glycosylated hemoglobin(HbA1c),Self-monitoring of blood glucose (SMBG),Blood lipid,2018-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15517,NCT01136785,Change in Mean Serum Insulin Derived From 24 Hour Blood Sampling,Change in 24-h Mean Level of Plasma Norepinephrine,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
15518,NCT02350374,"The individual variation of CHO amount at each main meal : Breakfast, Lunch, Snacks, Dinner",,,2014-11-17,COMPLETED,INTERVENTIONAL,['NA']
15519,NCT01357109,Peripheral endothelial function,Myocardial perfusion,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15520,NCT00377676,Subjects Experiencing Serious Adverse Events,Change in HbA1c From Baseline to Week 24 for Subjects With a Baseline HbA1c of ≥ 7.5% Who Were Taking at Least One Oral Hypoglycemia Agent (OHA) at Baseline.,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15521,NCT02779452,Change in neurodevelopment,Change in DHA level in cord blood,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
15522,NCT02138097,Subsequent Insulin Initiation for MarketScan Patients,Persistence at 12 Months for MarketScan Patients,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
15523,NCT05110404,fasting lipid profile,,,2021-12-25,COMPLETED,INTERVENTIONAL,['NA']
15524,NCT01939522,Pneumococcal serotype-specific (SpVS) antibody concentrations at 3 months following a single dose of 13-valent pneumococcal conjugate vaccine (PCV13),Blood glucose control in the week preceding and the week following immunisation with PCV13,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15525,NCT01817569,Adverse event incidence.,Mean change in lipid metabolism.,,2011-02-13,COMPLETED,OBSERVATIONAL,['NA']
15526,NCT01643811,Proportion of patients who quit previous medication for hypertension because of improved disease,"difference of serum levels of c-peptide, Ghrelin, GIP, GLP-1, glucagon, insulin between before and after operation",,2012-04,COMPLETED,OBSERVATIONAL,['NA']
15527,NCT02726217,Acceptability of the intervention protocol will be evaluated using a satisfaction survey.,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
15528,NCT00511875,Change in Early Treatment Diabetic Retinopathy Study (ETDRS),Change in Arteriovenous Ratio Diameter,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15529,NCT04820270,Immunization,PRA level,,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA']
15530,NCT04924686,NOD2 ligands in fecal and plasma,,,2020-05-10,UNKNOWN,OBSERVATIONAL,['NA']
15531,NCT05739214,percent of wound size measurement methods,percent of wounds complete closure,,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
15532,NCT00717457,Change in HbA1c,Beta cell function (proinsulin/insulin ratio),,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15533,NCT00001723,Change in BMI Standard Deviation Score,Effect of Race on Change in Weight (kg),,1998-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15534,NCT05282641,Chronic glucose metabolism,Cerebral blood flow (CBF),Exploratory objective micro-albuminuria and kidney function,2021-05-26,COMPLETED,INTERVENTIONAL,['NA']
15535,NCT02624817,Metabolic control,Insulin secretory response to a glucagon test,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15536,NCT06098729,Accuracy,Interview themes,,2023-11-02,RECRUITING,INTERVENTIONAL,['NA']
15537,NCT01715090,Mean change in HbA1c,Detection of important factors for patient compliance to internet-based self-care interventions,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
15538,NCT05094986,Rate of use of services,Outliers registries,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
15539,NCT01603121,Safety and Tolerability of Study Drug,Evaluation of Early Efficacy of Study Drug,,2012-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15540,NCT02675335,mean ulcer size after a treatment period of 12 weeks,,,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15541,NCT01630980,Metabolic syndrome measures,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
15542,NCT02088034,Body Weight,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4']
15543,NCT05429359,CGM outcomes during and after morning exercise,Change in growth hormone concentration in venous blood during and after morning exercise test,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15544,NCT01703221,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,Change From Baseline for Fasting Plasma Glucose (FPG) at Week 24,,2012-10-24,COMPLETED,INTERVENTIONAL,['PHASE3']
15545,NCT02442024,Change from baseline fructosamine after 1 and 2 months of diet,Change from baseline lipid profile after 1 and 2 months of diet,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
15546,NCT02882737,"The primary endpoint is peak plasma glucose achieved within 2 hours after the 200 μg subcutaneous glucagon injection. In the primary analysis, the investigators will compare the peak plasma glucose after exercise and after resting.",The fused data from the two sensors.,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
15547,NCT00775216,The primary outcome will be assessed by the short version of the International Physical Activity Questionnaire and the 6-minute Walk Test.,"Questions regarding readiness to change, self-efficacy, knowledge of and access to physical activity centers, basic demographics, height/weight, and blood pressure will be assessed.",,2008-10,TERMINATED,INTERVENTIONAL,['NA']
15548,NCT02015780,Change from Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Change from Baseline in Total Daily Dose of Insulin at Week 52,,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15549,NCT00608387,Glycosylated hemoglobin (HbgA1c),Overall cost-effectiveness,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
15550,NCT06227650,Percentage of time spent in the target,Microangiopathic events,,2024-02-06,RECRUITING,OBSERVATIONAL,['NA']
15551,NCT04731272,Early-phase insulin secretion,Glucose tolerance,,2021-04-20,RECRUITING,INTERVENTIONAL,['PHASE2']
15552,NCT01512849,Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284,Clinical Laboratory Tests,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15553,NCT05756361,Change in Weight for parent and child,"In parents, change in medication dosing",,2023-04-26,RECRUITING,INTERVENTIONAL,['NA']
15554,NCT02229383,Change in HbA1c From Baseline to Week 28,Change in Seated Systolic Blood Pressure From Baseline to Week 28,,2014-09-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15555,NCT00015626,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
15556,NCT01524874,Change in mean serum 25-hydroxycholecalciferol concentration,Change in mean cardiometabolic risk factors,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
15557,NCT01679210,Dietary Intake,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15558,NCT01485614,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During Weeks 0-54 (Analysis of Selected Arms: Sitagliptin and Placebo/Metformin),Participants With Worsening in Dental Status at Week 54,,2012-02-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15559,NCT03380325,Capillary recruitment,Continous cardiovascular monitoring,,2016-05-11,COMPLETED,INTERVENTIONAL,['NA']
15560,NCT00986349,Change in Anti-diabetes Medications,Total Weight Change (kg) at Week 52 Compared to Baseline Weight,Fasting Plasma Glucose Over Time for All Subjects,2010-06,COMPLETED,INTERVENTIONAL,['NA']
15561,NCT03997656,body weight,health-related quality of life,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15562,NCT00103857,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 104,,2005-03-17,COMPLETED,INTERVENTIONAL,['PHASE3']
15563,NCT01831154,The Effect of Intraoperative Tight Glycemic Control on Postoperative C-Reactive Protein Plasma Levels in Patients Undergoing Open Heart Surgery,Intraoperative Glycemic Stability in Patients Undergoing Open Heart Surgery Compared Between Three Glycemic Protocols.,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
15564,NCT01368328,Insulin Sensitivity as assessed with homeostatic model assessment (HOMA),urea and creatinine,,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
15565,NCT04324229,Incidence of type 2 diabetes,,,2020-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15566,NCT01854463,glycemic control,arterial stiffenss,non-alcoholic fatty liver diseases and bone turnover marker,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15567,NCT00806338,"Safety and Tolerance of multiple intravenous doses of trodusquemine (MSI-1436) in obese or overweight type 2 diabetics. Safety will be evaluated by physical exams, vital signs assessments, 12-lead ECGs, clinical lab tests and adverse event profile.",Effect on exploratory biomarkers,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15568,NCT00725257,Hemoglobin A1c,Time to introduction of an oral hypoglycemic agent,,2004-06,COMPLETED,INTERVENTIONAL,['NA']
15569,NCT00573781,"Changes in glucose metabolism, changes in transcriptomic and metabolomic profiles",Interaction between the diet and genetic factors within treatment groups,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
15570,NCT01503112,Glycaemic response (HbA1c change post treatment),Weight change over 6 months treatment,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
15571,NCT01883258,Change in vascular endothelial function,Change in maximal oxygen consumption,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
15572,NCT02723110,Calculated Incretin Effect,PAM enzyme activity assay,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
15573,NCT05166382,Prescription rates of cardioprotective medications in the informed group vs uniformed group at Month 6,Standard of care risk assessment: Atherosclerotic Cardiovascular Disease risk calculator (ASCVD) at 6 months,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15574,NCT00006438,,,,1997-01,COMPLETED,INTERVENTIONAL,['NA']
15575,NCT00288236,Absolute change in HbA1C from baseline to Week 48,"Fasting glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides, safety (physical examination, vital signs, laboratory tests, adverse events).",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15576,NCT00147758,To assess the additional lowering of HbA1c achieved by addition of colesevelam hydrochloride to current antidiabetic therapy,To assess the safety and tolerability of colesevelam hydrochloride as add-on therapy,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15577,NCT03808376,Safety Endpoint - Incidence of device-related or sensor insertion/removal procedure-related serious adverse,,,2018-12-27,COMPLETED,INTERVENTIONAL,['NA']
15578,NCT00097786,Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide,,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15579,NCT03549754,6. Provide real world data on renal outcomes and other microvascular complications in patients with type 2 diabetes and Heart Failure,,,2018-02-17,RECRUITING,OBSERVATIONAL,['NA']
15580,NCT03656887,Number of hypoglycemic events (<70 mg/dl) detected by capillary blood glucose measurement or clinical signs suggestive of hypoglycemia.,,,2019-01-08,COMPLETED,OBSERVATIONAL,['NA']
15581,NCT04136067,Number of treatment-emergent adverse events (AEs),Maximum observed serum NNC0268-0965 concentration after the last dose,,2019-10-29,COMPLETED,INTERVENTIONAL,['PHASE1']
15582,NCT00707447,Waist Circumference,Emotional Well-being/ Depression (CES-D),,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15583,NCT00603291,Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52,Percent Change in Body Weight From Baseline to Week 52,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15584,NCT01849731,Glycosylated Haemoglobin levels,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
15585,NCT00350779,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 18,Change From Baseline in 2-hour PMG (Post-meal Glucose) at Week 54,,2006-06-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15586,NCT01103622,"evaluate the pharmacokinetics of digoxin after a single dose when administered alone and in combination with AZD1656 at steady state, by assessment of AUC and Cmax of digoxin",describe the pharmacokinetics of digoxin when administered alone or in combination with AZD1656 by assessment of tmax and t1/2.,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15587,NCT01574820,"major cardiovascular events, including myocardial infarction, overt heart failure, and surgery or coronary intervention for CAD",Biomarkers measurements,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15588,NCT00592670,Catecholamine measures,,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
15589,NCT01509157,Parental fear of hypoglycemia,Hypoglycemic events-number and severity of episodes,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15590,NCT03267264,Overall User Preference -Combined Groups,User Experience - Each Individual Study Group,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
15591,NCT02863328,Change in HbA1c,Change in CoEQ: Scores From the 4 Domains and the 19 Items,,2016-08-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15592,NCT04935554,Change in HbA1c from baseline until week 12,Change in mental health by questionnaire SCL-90r until week 12,,2020-08-17,COMPLETED,INTERVENTIONAL,['NA']
15593,NCT03439345,Progression to referable diabetic retinopathy/maculopathy,Cost-effectiveness (incremental cost per QALY gained),Minor and major non-traumatic lower limb amputation (minor [defined as distal to the ankle] or major [defined as through or proximal to the ankle]),2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE4']
15594,NCT03060694,controlled attenuation parameter; liver stiffness measure,,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
15595,NCT03593694,Change from Baseline Hemoglobin A1c (HbA1c) at 3 and 6 months,,,2017-11-06,TERMINATED,INTERVENTIONAL,['NA']
15596,NCT01810952,Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol.,Glucose Values <70 mg/dL.,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
15597,NCT05589467,height in centimeters,,,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15598,NCT06010004,Number of Participants with Treatment Emergent Adverse Events (TEAEs),Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG),,2023-09-28,RECRUITING,INTERVENTIONAL,['PHASE3']
15599,NCT02143765,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Diabetes Treatment Satisfaction,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15600,NCT00574782,,,,2003-09,COMPLETED,OBSERVATIONAL,['NA']
15601,NCT01898923,Number of Participants With Complete Ulcer Closure,Incidence of Infection of the Target Ulcer,,2012-11-23,COMPLETED,INTERVENTIONAL,['PHASE3']
15602,NCT03955289,Improved healing rate to time to healing,"Decreased complications in diabetic foot ulcers, i.e. infection, hospital admission, amputation",,2019-01-15,COMPLETED,OBSERVATIONAL,['NA']
15603,NCT01302028,Effect of grade of renal impairment on the pharmacokinetics of ASP1941,"Assessment of safety through evaluation of adverse events, physical examination, vital sins, lab-tests and 12-lead ECG",,2010-01-22,COMPLETED,INTERVENTIONAL,['PHASE1']
15604,NCT02722239,Adverse Events,,,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE1']
15605,NCT02092051,Difference in HbA1c between week 26 and week 69,Difference in the mean number of severe hypoglycaemic events between weeks 1-26 and weeks 43-69 defined as unconsciousness due to hypoglycaemia or need of assistance from another person to resolve the hypoglycaemia,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15606,NCT03490747,Change in cardiorespiratory fitness,Change in patient health care utilisation costs,Exercise referral practitioner (ERP) interviews (intervention group only),2018-03-12,COMPLETED,INTERVENTIONAL,['NA']
15607,NCT00741923,"body weight, waist circumference, blood glucose, satiety hormones, and blood lipids, inflammation factor, and glycated haemoglobin",,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
15608,NCT03211832,Partnerships to Support EBDM,Inter-agency Connectedness,,2017-07-05,COMPLETED,INTERVENTIONAL,['NA']
15609,NCT02906319,HbA1c levels,,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
15610,NCT00928889,Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4),Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4),,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15611,NCT00607867,Change in Overnight Fasting Glucose Concentration at 5 Weeks From Baseline,Change in Fasting Triglycerides at 5 Weeks From Baseline,,2008-04,TERMINATED,INTERVENTIONAL,['NA']
15612,NCT00655044,HbA1C,Safety,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
15613,NCT01157403,C peptide release test,,,2010-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15614,NCT02184455,Percentage of Wound Area Reduction Compared to Baseline,Percent Change in Wound Area From Baseline,,2016-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15615,NCT01867216,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline in C-Peptide Area Under the Effective Concentration Curve (AUEC₀-₁₂) During Mixed Meal Tolerance Test at Day 28,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15616,NCT02929355,Rate of vascular events between day one and the last day of follow-up reviewed by patient examination,Rate of carotid atherosclerosis progression measured by duplex ultrasonography in percentage of stenosis,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
15617,NCT03681249,24H urine total protein,,,2018-11-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15618,NCT01559181,Pubertal development,PCOS,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
15619,NCT03520855,Diapason questionnaire (Aide aux Jeunes Diabètes),Evaluation of well-being with DQOLY,,2019-04-03,RECRUITING,INTERVENTIONAL,['NA']
15620,NCT03202277,Fasting glucose,Dietary quality measured by the NCI dietary factor screener,,2017-09-17,COMPLETED,INTERVENTIONAL,['NA']
15621,NCT04503551,Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 52,Reported incidence of device deficiencies,,2020-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15622,NCT01177163,The number of patients with symptomatic hypoglycemia and severe hypoglycemia,Change in urine glucose excretion (pharmacodynamics parameter),,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15623,NCT05127538,Dynamic Balance,,,2021-12-10,COMPLETED,INTERVENTIONAL,['NA']
15624,NCT01996228,Autoimmune control,Metabolic control,,2013-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15625,NCT01467674,HbA1c,Clinical Periodontal Status,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
15626,NCT01086280,"Major cardiovascular events defined as a composite of acute MI, stroke or death due to acute MI, stroke, CHF, dysrhythmia, sudden death, or coronary revascularization. Alternative outcomes include DVT, PE, and arterial vascular disease",All-cause death,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
15627,NCT02806960,PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax),,,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1']
15628,NCT01422590,AUC of DPP-4 activity,,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15629,NCT06082063,MACE + HHF,"Diabetic ketoacidosis, safety",Long term risk of DKA,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15630,NCT05221359,Safety: Percentage of patients who will experience at least one relevant adverse event (AE) judged by the investigator as probably or highly probably related to ExOlin® for the whole duration of the study (extension phase included),Quality of Life: Overall score and subscores of the Diabetes Quality of Life (DQOL) questionnaire,,2022-05-05,RECRUITING,INTERVENTIONAL,['NA']
15631,NCT02980627,Metabolic Control (Change in HbA1c),Decrease in Overall Eating Disorder symptomatology,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
15632,NCT00727779,euglycemic clamp steady state glucose infusion rate (clamp GIR),GLUT4 content of muscle,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
15633,NCT05132335,To evaluate the repeatability of the ratio of subcutaneous adipose tissue (SAT) to skeletal muscle fatty acid uptake rates,,,2021-03-29,COMPLETED,INTERVENTIONAL,['NA']
15634,NCT00035984,Change in HbA1c from Baseline to Week 30,Change in body weight from Baseline to each intermediate visit and Week 30,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15635,NCT04714762,Change in fasting glucose,Costs,,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15636,NCT03128320,Change in transcutaneous oxygen pressure (TcPO2),Number of subjects with TEAEs in different severity,,2017-05-25,COMPLETED,INTERVENTIONAL,['PHASE2']
15637,NCT02500485,The number of volunteers with adverse events as a measure of safety and tolerability.,,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
15638,NCT05915975,Change in Glycemic Control,Change in Diabetes Self-Management,,2023-11-07,RECRUITING,INTERVENTIONAL,['NA']
15639,NCT03311724,Change From Baseline in Haemoglobin A1c (HbA1c),Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide,,2017-10-19,COMPLETED,INTERVENTIONAL,['PHASE2']
15640,NCT03362528,Generation and validation of predictive algorithms for determining blood glucose levels,,,2017-09-25,COMPLETED,INTERVENTIONAL,['NA']
15641,NCT01137474,Adjusted Mean Change From Baseline in Hemoglobin (HbA1c) at Week 12,Adjusted Mean Change From Baseline in Serum Uric Acid Levels at Week 12,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15642,NCT03734718,Blood glucose,Number of symptomatic hypoglycemic events,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
15643,NCT05936203,Insulin doses delivered,,,2023-01-11,COMPLETED,INTERVENTIONAL,['NA']
15644,NCT05140694,Changes of CAP score,Changes of inflammation biomarker,Changes of gut microbiota,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
15645,NCT01261494,HbA1c,Insulin resistance Index [fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR)],,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
15646,NCT00409461,,,,na,TERMINATED,INTERVENTIONAL,['NA']
15647,NCT03468283,hemoglobin A1c levels,the Problem Areas in Diabetes,,2012-08-07,COMPLETED,INTERVENTIONAL,['NA']
15648,NCT00675311,"The primary study measures for this study include glycemic control and LDL levels, satisfaction with diabetes care, and adherence to diabetes medications and self-monitoring recommendations",Secondary measures include diabetes-related health-care utilization and physiologic data.,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
15649,NCT01371318,Lower extremity amputation secondary to diabetic foot ulcer,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
15650,NCT01406262,QTc interval,Number of participants with adverse events,,2011-07-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15651,NCT03539133,Rehospitalization due to heart failure,Restenosis rate,,2017-10-18,RECRUITING,OBSERVATIONAL,['NA']
15652,NCT05104437,Neutralizing antibody level,Adverse events following vaccination,,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
15653,NCT00676741,Metabolic control measured as HbA1c,Number of adverse drug reactions (ADR),,2008-02,COMPLETED,OBSERVATIONAL,['NA']
15654,NCT05309057,Body weight,Markers of inflammation - CRP,,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA']
15655,NCT02298192,Change From Baseline in HbA1c,Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes,,2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE3']
15656,NCT04833413,Change in HbA1c,Impact on body weight,,2021-04-15,RECRUITING,OBSERVATIONAL,['NA']
15657,NCT01974674,restoration of normal glycemic control without insulin,degenerative complications of diabetes,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
15658,NCT01274052,,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
15659,NCT05093569,to determine the accuracy of K'Watch Release 0.x CGM system glucose readings at day 1 as compared to standard references.,Safety of the K'Watch system characterizing device-related pain intensity (Visual Analogue Scale scores from 0-10) recorded during the study.,,2021-11-15,UNKNOWN,OBSERVATIONAL,['NA']
15660,NCT03721848,Health Behavior-Amount of Red Meat Intake (Assessing Change),Primary Care PTSD (Assessing Change),,2017-04-30,COMPLETED,INTERVENTIONAL,['NA']
15661,NCT04791826,Frequency of prescription of SGLT-2i medication at outpatient clinic visits,Adherence of prescription of SGLT-2i medication at outpatient clinic visit,Frequency of incident HF,2021-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15662,NCT00869076,Hgb A1c change,Percent of patients with a 1 point decrease in A1c by ethnicity,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15663,NCT02536950,Mean glucose,% time < 60 mg/dl,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
15664,NCT06018844,Moderate to Vigorous Physical Activity (MVPA) levels,Change in participant HbA1c,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15665,NCT02877355,Area under the semaglutide plasma concentration-time curve,Maximum observed SNAC plasma concentration,,2016-08-22,COMPLETED,INTERVENTIONAL,['PHASE1']
15666,NCT04531462,Change in HbA1c From Baseline After 52 Weeks of Treatment,Change of Time in the 5-time Chair Stand Test From Baseline to Week 52,,2020-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15667,NCT00375388,"To investigate the quality of the metabolic control of diabetes and related variables (daily dose of insulin, body weight).",To perform a socio-economic evaluation.,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15668,NCT01761318,Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion),Myocardial T1 - mapping,Hypoglycaemic episodes,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
15669,NCT05261776,Blood glucose level,,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
15670,NCT02501746,Change in Systolic Blood Pressure,Change in cardiovascular disease (CVD) risk Score,,2017-02-06,COMPLETED,INTERVENTIONAL,['NA']
15671,NCT00812487,Hospital Readmission,Mean Glucose,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15672,NCT01276106,Change in HbA1c From Baseline,,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15673,NCT03658980,Number of Participants Who Had Successful Referrals,Increase in Knowledge About Diabetic Retinopathy,,2018-12-15,COMPLETED,INTERVENTIONAL,['NA']
15674,NCT01309698,Pharmacokinetics of vildagliptin,"Pharmacodynamic parameters (dipeptidyl peptidase IV (DPP-4) activity, glucagon-like peptide-1(GLP-1), glucose, insulin, glucagon)",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4']
15675,NCT03766308,HbA1c,Change in Waist circumference,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
15676,NCT03150199,Number of PP-MI Sessions Completed by Participants,Change in Diabetes Self-Care,Change in Hemoglobin A1c,2017-07-25,COMPLETED,INTERVENTIONAL,['NA']
15677,NCT04667143,Mean change from baseline in HbA1c at Week 24,,,2021-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
15678,NCT03659383,Rate of reaching target of glucose,Time of reaching target of glucose,,2018-09-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
15679,NCT00138606,Change from baseline in HbA1c at 52 weeks,Change from baseline in mean daily number of insulin injections at 52 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15680,NCT05200819,"Risk-marker signatures for severe COVID-19 disease, longer-term complications in patients surviving COVID-19.",,,2020-12-02,COMPLETED,OBSERVATIONAL,['NA']
15681,NCT02693964,Difference in carotid intima media thickness between postmenopausal women with type 1 diabetes and controls,Correlation between biomarkers with cardiovascular risk measures (carotid intima media thickness),,2016-03,COMPLETED,OBSERVATIONAL,['NA']
15682,NCT05613556,Frequency and location of high-pressure plantar areas,,,2022-04-01,COMPLETED,OBSERVATIONAL,['NA']
15683,NCT01864174,"Number of Participants With Death, Serious Adverse Events (SAEs), SAEs Related to Study Therapy, SAEs Leading to Discontinuation, Adverse Events (AEs) Related to Study Therapy, and AEs Leading to Discontinuation",Percent of Participants With HbA1c < 7%,,2013-06-20,COMPLETED,INTERVENTIONAL,['PHASE4']
15684,NCT05630417,Blood Parameters Follow-up Form,Blood Parameters Follow-up Form,,2022-03-15,COMPLETED,INTERVENTIONAL,['NA']
15685,NCT00879970,Number of Participants With the Indicated Components of the Composite Outcome for Vitamin D,"Mean Score on Montreal Cognitive Assessment (MoCA) Test, as an Assessment of Cognitive Function (CF)",,2009-05,TERMINATED,INTERVENTIONAL,['PHASE4']
15686,NCT01515202,"Safety and tolerability, as measured by the number, frequency and intensity of adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests","Pharmacodynamics, as measured by Serum concentration of cortisol and cortisone after an oral dose of cortisone and biomarkers for HPA axis activity (urinary free cortisol and cortisone, salivary cortisol, ACTH, DHEA-S and 4-androstenedione)",,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15687,NCT00715624,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15688,NCT03367663,Serum atherogenicity,,,2018-01-17,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15689,NCT03502174,FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects,,,2018-04-05,COMPLETED,OBSERVATIONAL,['NA']
15690,NCT06293664,Difference in the total or incremental area under the curve of glucose and insulin concentration at an OGTT during saline vs. α-MSH infusion,"Difference in the total or incremental area under the curve of the concentration of metabolites (C-peptide, Glucagon, Gut hormones, α-MSH) during OGTT with saline or α-MSH infusion.",Adverse events (including flushing),2024-03-04,RECRUITING,INTERVENTIONAL,['NA']
15691,NCT03761615,Time in range glucose levels as determined by CGM,Carbohydrate consumption,Length of hospital stay,2018-11-13,COMPLETED,OBSERVATIONAL,['NA']
15692,NCT05041621,Comparison of 5 hours postprandial percentage of time below 3.9 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations,Mobile app usability questionnaire: score is the average of 16 items and each item scores ranges 0-6 (average of higher scores means higher usability),,2021-07-07,COMPLETED,INTERVENTIONAL,['NA']
15693,NCT03928379,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug,PD: Change from Baseline in Fasting Plasma Insulin,,2019-10-27,COMPLETED,INTERVENTIONAL,['PHASE1']
15694,NCT03958591,the proportions of treatment simplification,,,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15695,NCT01882036,Measure homeostasis model assessment i.e. estimated change in insulin resistance (HOMA-IR) index,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
15696,NCT02361437,Rate of healing of diabetic ulcers measured by ulcer size,lower extremity skin oxygenation measured by trancutaneous oximetry,,2015-02,TERMINATED,INTERVENTIONAL,['NA']
15697,NCT04548232,Hepatic steatosis,Fertility,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15698,NCT01364129,Proportion of Participants that Receive Annual Eye Exam,,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
15699,NCT04926623,HbA1c (%) changes at 24 weeks compared to baseline,,,2021-06-17,COMPLETED,INTERVENTIONAL,['NA']
15700,NCT01493895,To assess the efficacy of b-cure laser in patients with diabetes mellitus induced lower leg skin ulcers,safety,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15701,NCT01007097,Change from Baseline in Glycosylated Hemoglobin at Week 12.,Incidence of Hypoglycemia During Double-Blind Treatment Period.,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
15702,NCT03073343,Change in alanine aminotransferase (ALT) level in all study participants,Compare changes in alanine aminotransferase (ALT) level in both cohorts,,2013-11-12,UNKNOWN,INTERVENTIONAL,['NA']
15703,NCT05413005,Clinically important hypoglycemic episodes,Serum IgM levels,,2022-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15704,NCT01063374,plaque volume,retinal photography,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15705,NCT01709201,Percent days abstinent,Medical complications,Medical complications 90 days post baseline,2013-07,WITHDRAWN,INTERVENTIONAL,['NA']
15706,NCT02634528,"PK: Cins.max, maximum observed insulin concentration",Changes in Electrocardiogram recordings,,2016-11-16,COMPLETED,INTERVENTIONAL,['PHASE1']
15707,NCT02247271,Patient Activation Measure (PAM),Self-reported healthcare utilization,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
15708,NCT00279240,Reduction in conversion of IGT to diabetes,Benefits of the drug on anthropometric variables and biochemical parameters,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15709,NCT00435981,To evaluate the efficacy of Diamyd® 20ug versus placebo with respect to preserving residual insulin secretion as measured by C-peptide levels. The effect of intervention will be evaluated at month 15 (main study period) and at month 30 (Extension phase).,To evaluate the safety of Diamyd® 20ug.,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15710,NCT05716607,glycemic variability,immunoglobulins,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15711,NCT03932721,Difference in the percentage change in flow mediated dilation (FMD),Difference in the percentage change in FMD reserve,Difference in Plasma C-Reactive Protein Change in mg/dL from randomization to 16 weeks of treatment.,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15712,NCT00974272,Triglyceride concentration in serum,"serum or plasma lipoproteins, apolipoproteins and inflammatory markers; endothelial function",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15713,NCT04347252,hepatic glucose production,Change in Beta-hydroxybutyrate concentrations,,2019-09-24,COMPLETED,INTERVENTIONAL,['PHASE1']
15714,NCT01818674,Temporally investigate the causal induction of cascading changes in body weight between follow-ups on subsequent weight changes in other participants.,Relative changes in blood pressure between individual trial arms,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
15715,NCT05148897,Evaluate general knowledge of women about different aspects of Gestational Diabetes: Questionnaire,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
15716,NCT04126291,Change in knowledge,Change in practice related to pediatric weight management,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
15717,NCT03185689,Proportion of T2D patients with controlled BGL as measured by a change in HbA1c,Proportion of T2D patients with a recommended level of diabetes self-care behavior as measured by summary of diabetes self-care activities (SDSCA) questionnaire,Change in the level of depressive symptoms as measured by patient health questionnaire depression scale (PHQ-9),2016-04-04,COMPLETED,INTERVENTIONAL,['NA']
15718,NCT05587348,Odds of attending 1 DSMES class,Change in Diabetes Self-Efficacy from baseline to 6 months,,2023-09-12,RECRUITING,INTERVENTIONAL,['NA']
15719,NCT05540132,Time to completion of distance bike challenge,Glycemic variability in the 12 hours following the exercise test,,2023-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15720,NCT02804698,Framingham cardiovascular disease risk,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
15721,NCT03230175,Number of Subjects With Complete Wound Healing,Percent Change in Wound Surface Area,,2017-10-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15722,NCT02455011,"Number of treatment emergent adverse events per subject, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGs","Geometric mean ratio to baseline over time of AST, ALT, ALP and total bilirubin.",,2015-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15723,NCT03478306,"Progression of diabetic retinopathy, oscillary potential",Retinal structure,,2018-03-27,COMPLETED,INTERVENTIONAL,['PHASE3']
15724,NCT03602950,changes in wound healing,morbidly wound healing,,2018-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15725,NCT06291766,Adverse Pregnancy Outcome,Week of delivery,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
15726,NCT05396378,Increase of blood glucose following the oral glucose dose,Maternal subjective well being after oral glucose dose during the preoperative fasting period,,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15727,NCT00891995,C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.,BMI Percentile,,2010-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15728,NCT01978704,mean plasma glucose concentrations,postprandial plasma glucose concentrations,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15729,NCT01645995,Changes in body weight and body composition,"Changes in cardiovascular risk factors (blood pressure, inflammatory markers)",,2012-03,COMPLETED,INTERVENTIONAL,['NA']
15730,NCT03359629,Percentage of Measurements With < 15% Error,,,2017-09-27,COMPLETED,OBSERVATIONAL,['NA']
15731,NCT01154413,Reduction in hypo/hyperglycemia episodes,"Lower mean glycemia, reduced time of stay in hospital",,2007-12,COMPLETED,INTERVENTIONAL,['NA']
15732,NCT00191178,Instruments used/tests performed:hand held computers to rate a series of 13 symptoms;hand held computers to administer a series of cognitive-motor performance tests;blood glucose testing,"blood glucose rate of change;eight-point self-monitored blood glucose profile;episodes of hypoglycemia, including episodes of severe hypoglycemia",,2003-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15733,NCT01780051,AUCt and Cmax of repaglinide and metformin,"AUC∞, Tmax, t1/2, CL/F and Vd/F of repaglinide and metformin",,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15734,NCT06318611,Chronotype,Glycemic control,,2022-05-01,COMPLETED,OBSERVATIONAL,['NA']
15735,NCT03282136,"all cause mortality, and cardiac cause mortality.",hospital admissions for HF,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15736,NCT05935839,Visualization of tissue changes in diabetic patients using MSOT.,,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15737,NCT01899274,Changes in Hemoglobin A1C levels,bant Component Usage,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
15738,NCT01830569,Pre- to post-implementation change in HbA1c.,Pre- to post-implementation change in a composite process score.,Actual use of the EBMeDS system,2017-03-29,COMPLETED,INTERVENTIONAL,['NA']
15739,NCT02430870,Percentage of Participants Who Have Severe Hypoglycemia at Least Once Post-dose During Dosing For Part 2,AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 Over the Dosing Interval for TAK-648 for Part 2,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
15740,NCT04585581,Plasma glucose concentration,Infant bone mass,Infant bone mass,2020-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15741,NCT00546728,Change in Reactive Hyperemic Index Over the 3-month Treatment Period,,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15742,NCT05290233,Lean mass,processing speed,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
15743,NCT00308139,Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose),Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With Non-SU Use at Screening,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15744,NCT05181631,Echographic cardiomyopathy,,,2022-01-15,UNKNOWN,INTERVENTIONAL,['NA']
15745,NCT00639964,fetal weight corrected by gestational age,erythrocytary and plasmatic fatty acid distribution,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
15746,NCT00343343,Deposition of sterile air depositions.,Amount of backflow,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15747,NCT00315952,"To perform positron emission tomography (PET) imaging of [18F]-fluoro-deoxy-glucose (FDG) uptake by muscle, following administration of a single dose of inhaled compared to infused insulin in volunteers with type 1 diabetes",To determine overnight rates of glucose production and plasma glucose after a single pre-dinner dose of inhaled compared to IV infused insulin in volunteers with type 1 diabetes,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15748,NCT04832464,Berg Balance Scale,Michigan Neuropathy Screening Instrument,,2021-03-30,UNKNOWN,INTERVENTIONAL,['NA']
15749,NCT00848705,Self-management behaviors,Self-management Problem solving,,2007-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15750,NCT02749435,Mean Change from baseline to Month 6 in HbA1c,Proportion of patients in both cohorts who intensify antihyperglycaemic treatment from Visit 1,Change from baseline to Month 6 in Morisky 8-item scale (adherence),2016-05-03,TERMINATED,OBSERVATIONAL,['NA']
15751,NCT01486888,Maximum serum insulin concentration (Cmax),Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15752,NCT01820715,Number of Subjects or Incidence with Adverse Events including Adverse Drug Event and Serious Adverse Event,overnight pain score,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15753,NCT05483777,Wound Observation and Evaluation Form,,,2023-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15754,NCT03512665,Homeostasis Model Assessment - Insulin Resistance (HOMA-IR),Change in plasma FGF-21,,2018-04-07,COMPLETED,INTERVENTIONAL,['NA']
15755,NCT03602378,"Stress in parents of children with developmental disability and chronic disease, and healthy children.","Advanced glycation end products in parents of children with developmental disability, chronic disease and parents of healthy children.",,2018-04-02,UNKNOWN,OBSERVATIONAL,['NA']
15756,NCT04001283,Metabolic protein expression in cardiac biopsies and vascular offcuts,,,2013-01-21,UNKNOWN,INTERVENTIONAL,['PHASE2']
15757,NCT00376870,In-Segment Late Loss,Stent thrombosis,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
15758,NCT05587413,Change of HbA1C between the control group and interventional group.,,,2022-11-02,RECRUITING,INTERVENTIONAL,['NA']
15759,NCT05841225,diet adherence,,,2023-06-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15760,NCT06333977,"Incidence, severity of adverse events",Renal Clearance (CLR) in urine,HbA1c,2022-03-25,COMPLETED,INTERVENTIONAL,['PHASE1']
15761,NCT02079805,Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12),Number of Participants With Treatment-Emergent Adverse Events,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
15762,NCT03766854,"AUCI287τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state","GIRmax,0-24h,SS - Maximum observed glucose infusion rate at steady state",,2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15763,NCT02842554,Pain Assessment Training,Predicted Response to Training,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15764,NCT02344082,Change in hemoglobin A1c,Telemedicine Adherence (Percent of telephone encounters completed in intervention arm),,2015-01,COMPLETED,INTERVENTIONAL,['NA']
15765,NCT04953221,The change in the average weekly NRS score of pain from baseline,The change from baseline in the SF-36 Quality of Life Scale score,,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA']
15766,NCT01973400,"Total Symptoms Score (TSS) (pain, paresthesia, burning, and numbness)of patients with diabetes type 1 and 2 neuropathy.",Neuropathy Impairment Score (NIS) of patients with diabetes type 1 and 2 neuropathy,"Mini Mental State Examination (MMSE) score, Montreal Cognitive Assessment (MoCA) test.",2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15767,NCT04537637,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2020-08-28,COMPLETED,OBSERVATIONAL,['NA']
15768,NCT01554020,Fasting glucose,Blood pressure,,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15769,NCT03549845,Healthcare Utilization Composite - Change in CVD-related emergency department visits and hospitalizations,Participant experience of the CHAP intervention,Cardiovascular Risk - Change in diabetes risk score,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
15770,NCT05921344,Consensus Error Grid (CEG) for venous plasma glucose and glucose values measured by mμSORS at each time point of OGTT.,Incidence of Treatment-Emergent Adverse Events,,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15771,NCT02617693,Difference in waist circumference,"Change in stress levels, as measured by the Depression Anxiety and Stress Scale 21-items (DASS-21) used in National Health Surveys in Malaysia",,2015-11-23,COMPLETED,INTERVENTIONAL,['PHASE4']
15772,NCT01623934,Diagnosis of gestational diabetes mellitus,,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
15773,NCT01096277,Endothelial function,Effect on EPCs,,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
15774,NCT04593173,Analysis of Value of 2D and 3D Left Ventricular Strains in Echocardiography in Type 2 of diabetic Patients,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
15775,NCT01770639,Treatment failure within the first year after surgery,Foot angles,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
15776,NCT05581966,Data Collection,,,2023-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15777,NCT04141761,Effect of Multistrain Probiotic on Immune System Inflammation as measured by plasma transcription analysis,System-wide Effects as measured by systemic microbial antigen (a marker of intestinal permeability) as measured by plasma analysis,,2019-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15778,NCT03283774,Cost analysis,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
15779,NCT04215328,Weight change between groups,Changes in gut hormone levels,,2014-11-01,COMPLETED,INTERVENTIONAL,['NA']
15780,NCT04805970,Measure and characterize organ volume change in patients with and without diabetes through use of summary statistics.,,,2021-03-24,RECRUITING,OBSERVATIONAL,['NA']
15781,NCT01556984,The changes of endothelial function,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
15782,NCT05952739,Diabetes mellitus complicating pregnancy,,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
15783,NCT00329862,"Reduction and or elimination of co-morbidities @ 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 weeks",,,2006-05,TERMINATED,INTERVENTIONAL,['NA']
15784,NCT02377388,changes on platelet aggregability.,platelet aggregability differences by two point-of-care methods.,"measure of safety, Number of participants with adverse effects by analysis on changes of serum level",2017-02-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15785,NCT03249077,Weight,HbA1c (24-month for digital DPP),Motivation for continuing,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
15786,NCT00849316,Incidence of major hypoglycaemic episodes,Number of all minor (daytime and nocturnal) hypoglycaemic events,,2009-02,WITHDRAWN,OBSERVATIONAL,['NA']
15787,NCT02084654,First-phase insulin response,glucose lowering effect,insulin-mediated glucose uptake (insulin sensitivity),2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15788,NCT01704612,the duration of sensory block in hours,the duration of motor sciatic block,"occurrence of neurological omplications, yes/no",2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15789,NCT01037582,Number and severity of adverse events (AEs) recorded,The uptake in blood of oral NN9924 compared to i.v. and s.c. administration of the same compound,,2009-12-17,COMPLETED,INTERVENTIONAL,['PHASE1']
15790,NCT01183715,Single dose pharmacokinetics of PF-05161704 and its metabolite PF-05200145,Preliminary pharmacodynamics of PF-05161704,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15791,NCT03269084,Clinical diagnosis of type 1 diabetes,,,1994-11-07,RECRUITING,OBSERVATIONAL,['NA']
15792,NCT01304836,Diagnosis of new onset Diabetes Mellitus as per ADA criteria at any point up to 24 weeks after kidney transplantation,Change from Baseline in HbA1C levels,,2011-01-22,COMPLETED,INTERVENTIONAL,['PHASE4']
15793,NCT03740074,App utility,Personal Activity Intelligence (PAI) Score,,2018-10-02,COMPLETED,INTERVENTIONAL,['NA']
15794,NCT03341793,Changes in myokine (muscle secretome) secretion induced by bariatric surgery,,,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA']
15795,NCT04057261,Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months,Differences in circulation inflammatory cell composition by flow cytometry analyses (FACS) between Liraglutide treatment group and placebo group,,2020-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15796,NCT06147414,% of inconclusive results,Estimated delay for result in standard care diagnosis condition,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15797,NCT01839344,Glucose tolerance following a maltose tolerance test,Area under the Glucose Curve (AUC),Reactive Hyperemia Index (RHI),2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15798,NCT03318601,Correlation between copetine and other biomarkers,Copetine concentrations,,2016-05-09,UNKNOWN,INTERVENTIONAL,['NA']
15799,NCT00743808,Systolic blood pressure,Measure changes in action taken related to improving blood pressure management as percent of providers reporting changing (initiating or adjusting) blood pressure medication,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
15800,NCT01002521,Genetic Phenotyping (Haptoglobin and TRAPS),Quality of Life,,2009-12,UNKNOWN,OBSERVATIONAL,['NA']
15801,NCT00642174,Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay,Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15802,NCT04186195,Children's type 1 diabetes glycemic control,Parent's type 1 diabetes glycemic status,,2020-11-03,COMPLETED,OBSERVATIONAL,['NA']
15803,NCT03064347,Difference in AUC of GLP-1 on meal tolerance tests Enteric Coated vs. Uncoated Nutrient.,Difference in Peak GLP-1 on meal tolerance tests Enteric Coated vs. Uncoated Nutrient.,,2017-02-22,COMPLETED,INTERVENTIONAL,['NA']
15804,NCT03961854,Adverse Event and/or Serious Adverse Event,,,2019-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
15805,NCT02065310,Percentage of quality controls that fall within 15% of the nominal value for a analytical run of the CEdG assay.,Correlation of Hemoglobin A1c and CEdG levels,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
15806,NCT03774511,Homeostatic Model Assessment of Insulin Resistance (HOMA-IR),Visceral adipose fat,,2017-07-09,COMPLETED,INTERVENTIONAL,['NA']
15807,NCT00823849,"Primary Efficacy Evaluation: Comparing with the basic line information, the change value of arteriosclerosis related biomarker in 4 groups after 12 weeks of treatment.",,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15808,NCT05887999,Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia,Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT,,2023-06-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15809,NCT03817749,Glucose control,Change from baseline caspase-1 activation at 14 days,,2019-02-06,COMPLETED,INTERVENTIONAL,['NA']
15810,NCT03977727,1-Hour Change in Postprandial Plasma Glucose (PPG),Pump Occlusions,,2019-06-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15811,NCT06336486,Visual Analog Scale(VAS),36-Item Short Form Health Survey(SF-36),,2018-12-04,COMPLETED,INTERVENTIONAL,['NA']
15812,NCT06146322,Food intake,,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
15813,NCT06111586,Change from baseline to W52 in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration,Change from baseline to W52 and W104 in DTSQs Total and item scores (caregivers of all participants 12-17 y.o.),,2023-12-11,RECRUITING,INTERVENTIONAL,['PHASE2']
15814,NCT05292833,The percentage of patients adhering to the Mediterranean Diet,Describe the difficulties/barriers to the initiation of the Mediterranean Diet,,2023-07-06,RECRUITING,OBSERVATIONAL,['NA']
15815,NCT01617434,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26,Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15816,NCT03254524,Emergency Deparrtment (ED) visit by a patient,Hospital Selection,,2014-08-20,COMPLETED,OBSERVATIONAL,['NA']
15817,NCT06132334,Physical activity level,Upper extremity functional exercise capacity (percentage of the expected value (%)),,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15818,NCT05434559,Time in range,Body mass index,Glycemic consensus targets,2022-02-20,COMPLETED,OBSERVATIONAL,['NA']
15819,NCT02634333,Change in Visual Acuity From Baseline,Development of PDR and/or DME (Whichever Came First),,2016-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15820,NCT03279107,Change in plasma blood insulin from fasting baseline value (Time Frame: Up to 180 minutes).,Change in subjective appetite ratings from fasting baseline value (Time Frame: Up to 180 minutes).,,2017-08-25,COMPLETED,INTERVENTIONAL,['NA']
15821,NCT01588418,Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism,Effect of Exenatide on the Liver and Adipose Tissue Glucose Uptake,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15822,NCT02028195,Functional capacity,,Health economy assessment,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
15823,NCT03865381,Mean Change in Hemoglobin A1c,Mean Change in A1c,,2019-02-08,COMPLETED,INTERVENTIONAL,['NA']
15824,NCT00683735,To assess the effect of co-administration of sitagliptin and metformin compared to placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load),To assess the effect of sitagliptin compared with placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load),,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15825,NCT04428645,Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl,Change in Coefficient of Variation of Sensor Glucose Based on the Dexcom G6 CGM Data.,,2020-07-21,COMPLETED,INTERVENTIONAL,['NA']
15826,NCT01088451,Differences in mean blood glucose concentrations and the pattern of fluctuation on control and study days; and changes in the glycated hemoglobin A1c after the study period. Occurrence of side effects especially hypoglycemic episodes.,"The difference in postprandial areas under the curve when comparing conventional therapy and experimental combined prandial insulin therapy in the 5 to 6 hours following meal ingestion, taking into account the glycemic index profile of the meal.",,2009-12,UNKNOWN,INTERVENTIONAL,['NA']
15827,NCT04105608,Changes in serum GLP-1 concentration,Hunger-satiety scores (millimeters),,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
15828,NCT03987438,The risk of diabetes mellitus (DM) in patients with impaired glucose tolerance,Changes in glycosylated hemoglobin levels.,,2019-08-03,UNKNOWN,INTERVENTIONAL,['NA']
15829,NCT03033849,Acceptance criteria defined by ISO 15197:2013 (E) will be applied,,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
15830,NCT03661177,Lipid panel,Cultural identity change,,2020-01-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15831,NCT00893425,Flow mediated dilatation,ADMA CD95,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15832,NCT03602638,coronary calcification score,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15833,NCT00767884,Changes in optic nerve head topography before and after panretinal photocoagulation,,,2008-10-29,TERMINATED,OBSERVATIONAL,['NA']
15834,NCT02123563,plaque and gingival indices,,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
15835,NCT00879710,Changes in LDL Cholesterol,Changes in Cholesterol Absorption or Synthesis Rates From the Baseline,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
15836,NCT05622630,Vibration sensation test,,,2019-08-13,COMPLETED,INTERVENTIONAL,['NA']
15837,NCT06273124,Primary Outcome,,,2024-03-07,RECRUITING,INTERVENTIONAL,['NA']
15838,NCT01429818,%ΔMBF,Adverse effects,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15839,NCT01895712,Target Vessel Failure (TVF),Target lesion revascularization (TLR),,2013-08,COMPLETED,OBSERVATIONAL,['NA']
15840,NCT04499820,density of the deep capillary plexus in optical coherence tomography angiography (OCTA),Diet questionnaire,,2020-06-26,RECRUITING,INTERVENTIONAL,['NA']
15841,NCT00645424,Percentage of subjects with low-density lipoprotein cholesterol (LDL-C) levels of <100 mg/dL (LDL-C responders) at Week 12,"Percentage of subjects with total cholesterol (TC) levels of <160 mg/dL (TC responders) at Weeks 4, 8, and 12",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15842,NCT03594344,Intact skin with no abnormal openings at the site of primary amputation,The Foot and Ankle Ability Measure (FAAM),,2018-07-04,RECRUITING,INTERVENTIONAL,['NA']
15843,NCT02040571,Continuous glucose monitoring (CGM) time spent in target glycaemic range (4.0-8.0 mmol/L) from 2000h-0800h in clinical trial centre (phase 1 of the study).,Cognitive Assessment: CogState assessment battery outcome measures will be generated. Each battery test point will record participant response times and accuracy rates for all tasks performed.,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15844,NCT00184600,HbA1c (Glycosylated Haemoglobin) at Month 36,Number of Participants Having an 'Other' Adverse Event,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15845,NCT05317455,PDH flux in the frontal lobe,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15846,NCT00006165,,,,na,COMPLETED,INTERVENTIONAL,['NA']
15847,NCT01377155,Days to reach the titration target,The frequency of reported and documented (<70 mg/dl) hypoglycemic events per 24 hour period,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
15848,NCT05517863,percent of wounds complete closure,percent of days needed for surface area reduction,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
15849,NCT00798161,HbA1c Change From Baseline at Week 24,Use of Rescue Therapy,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15850,NCT04795531,Change in HbA1c (glycated haemoglobin),Mean weekly insulin dose,,2021-03-24,COMPLETED,INTERVENTIONAL,['PHASE3']
15851,NCT00148304,diabetes self-care/attitudes,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
15852,NCT02569060,Change from Baseline HbA1c at 6 Months,Change from Baseline Food stability,Change from Baseline Diabetes Self-Care,2015-10,COMPLETED,INTERVENTIONAL,['NA']
15853,NCT01616433,Glucose,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15854,NCT06192121,Diabetes Self-Care Activities,,,2023-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15855,NCT00857870,Area under the curve (AUC) after a testmeal measured CGM.,"HbA1C, glycemic variability, glycemic load, insulin secretion after testmeal, free fatty acids, biomarkers of low grade inflammation, endothelial dysfunction.",,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
15856,NCT05782881,"Composite cardiovascular disease (cardiovascular death, non fatal myocardial infarction, non fatal stroke, hospitalization for heart failure, and readmission for acute coronary syndrome)",Blood pressure( both diastolic and systolic will be measured),,2023-01-15,RECRUITING,INTERVENTIONAL,['NA']
15857,NCT04878393,Number of adverse event (AEs),Number of serious adverse reactions (SARs),,2021-04-30,COMPLETED,OBSERVATIONAL,['NA']
15858,NCT00005905,,,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15859,NCT03222245,Change in quality of life,Change in HbA1c,,2017-06-30,COMPLETED,OBSERVATIONAL,['NA']
15860,NCT03398902,Change in % time glucose is ≥ 140mg/dL,,,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15861,NCT02397447,Insulin Sensitivity (Matsuda Index) After 90 Days,AUC-insulin After 90 Days,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15862,NCT00471926,,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA']
15863,NCT00348725,Quotation by Visual Numeric Rating Scale before and after 4-week treatment,Assessment of safety by reporting of Adverse Events,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15864,NCT03591081,"The proportion of patients who self-refer for recurrence of diabetic foot-ulcer over a twelve-month period, compared with the current National diabetes foot audit average of 33.3%",Changes in cardiovascular markers,,2018-06-22,COMPLETED,INTERVENTIONAL,['NA']
15865,NCT06121856,Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument using arterial blood,,,2023-02-07,COMPLETED,OBSERVATIONAL,['NA']
15866,NCT03024944,Amount of Tau Accumulation by Measuring Standardized Uptake Value Ratio (SUVR),,,2017-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15867,NCT00743002,"To evaluate the safety and tolerability of TT223 as a treatment for Type 2 diabetes at 1 mg, 2 mg and 3 mg.",To determine the pharmacokinetic (PK) parameter profile of TT223 in a subset of patients.,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
15868,NCT01906359,6-hour postprandial changes from fasting in glucose-dependent insulinotropic polypeptide (GIP),6-hour changes from fasting hunger rating using visual analogue scale (VAS),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15869,NCT06160063,Evaluation of Literacy Scale for Acute Complications of Diabetesfor Children with Type 1 Diabetes (8-12 years),,,2023-01-16,COMPLETED,INTERVENTIONAL,['NA']
15870,NCT04167761,Rate of isoproterenol-stimulated lipolysis to measure metabolic flexibility in epicardial adipose tissue samples.,Distribution of adipose cell size in epicardial tissue.,,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15871,NCT05773495,Change in Diabetic Screening Rate,Follow Up Rate For In-Person Eye Care Among Screen Positives,,2024-03-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
15872,NCT01212913,Change in hemoglobin A1c level (HbA1c),Continuous Glucose Monitoring System (CGMS) data,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15873,NCT05599893,Glycemic level,Health related quality of life,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
15874,NCT02144441,Trial feasibility metric: reasons for disenrollment,Hypoglycemia,,2014-06,WITHDRAWN,INTERVENTIONAL,['NA']
15875,NCT01847144,Change in fasting glucose,Additional changes in biochemical results,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15876,NCT01963130,"This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on portal hemodynamics.","This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on hepatosteatosis.",,2012-07,COMPLETED,OBSERVATIONAL,['NA']
15877,NCT03010475,Area under the rosuvastatin plasma concentration-time curve,Maximum observed rosuvastatin plasma concentration,,2017-01-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15878,NCT01825148,pancreatic uptake of radiolabeled Exendin,,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
15879,NCT01827735,The primary endpoint is based upon the percentage of CD4+T regulatory (defined as CD3+CD4+CD25highCD127low) cells within the CD3+CD4+T cell gate following treatment with IL-2.,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15880,NCT05041673,Change in steatosis as measured using CAP score (fibroscan) and MRI,Changes in fibrosis grade,,2021-02-23,UNKNOWN,INTERVENTIONAL,['NA']
15881,NCT02230488,Prevent <31 day readmission,improve overall glycemic management,Patient satisfaction,2014-09,TERMINATED,INTERVENTIONAL,['NA']
15882,NCT02382159,Variation of the Lipid parameter pattern patients who are treated by lipid-lowering drug.,Variation for lipid parameter when the patients who are treated for 3±1 months by lipid-lowering drug.,Setting the sub-group by the result of lipid parameter,2010-10,COMPLETED,OBSERVATIONAL,['NA']
15883,NCT04418908,Change in quantitative immunuofluorescence of endothelial cell proteins,,,2010-11-24,COMPLETED,INTERVENTIONAL,['NA']
15884,NCT01649219,Glucose and lipid metabolism,Changes in muscle metabolism,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15885,NCT02250222,Number of participants with one or more drug related adverse events or serious adverse events,PK profile (maximum concentration (Cmax) of LGD-6972 after repeat oral doses in NHS and in subjects with T2DM,"Change from baseline in fasting plasma active and total GLP-1 measured during an OGTT on Day 14 of treatment with LGD-6972 at 0.5, 1, 1.5, 2, 3, and 4 hours post-glucose load in one dose group of subjects with T2DM",2014-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15886,NCT03767699,Gestational Weight Gain,,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
15887,NCT05035082,Change in Glycosylated hemoglobin A1c (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, change version (DTSQc), Relative treatment satisfaction total score",,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15888,NCT01461499,Reduction in Albuminuria,Change in the Serum Insulin Level,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15889,NCT04466501,"Evaluate the performance agreement of the ACR |LAB compared to the comparator device, tested by professional users.",,,2019-06-30,COMPLETED,INTERVENTIONAL,['NA']
15890,NCT05216172,peripheral regulatory T cells,incidence of treatment emergent adverse events (with particular reference to episodes of infection),regulatory T cells: functional assay,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15891,NCT03914326,"Time to first occurrence of a major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death/non-fatal myocardial infarction/non-fatal stroke",Time to first occurrence of a severe hypoglycaemic episode,,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15892,NCT02167243,To assess if the intervention reduces A1c,,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
15893,NCT01637727,Long term effects of gestational diabetes mellitus in a population of parous women,Long term effects of gestational diabetes mellitus in a population of parous women,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
15894,NCT00544934,glycated albumimin concentration,urine albumin,,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15895,NCT01223560,,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
15896,NCT01869790,Area under the curve (AUC),,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
15897,NCT01547403,Primary Endpoint for CUSTOM Trial,,,2012-08,WITHDRAWN,OBSERVATIONAL,['NA']
15898,NCT00241124,Change from baseline in systolic 24 hour blood pressure after 12 weeks,"Adverse events, serious adverse events, laboratory values, physical examinations, vital signs for up to 26 weeks",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15899,NCT02302508,"Pharmacokinetics (AUC0-t metabolites and parent drug) of clopidogrel, prasugrel and ticagrelor.",Platelet function activities,,2019-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15900,NCT05392166,pancreatic enzymes elevation in diabetic children .,,,2022-05-13,RECRUITING,INTERVENTIONAL,['NA']
15901,NCT04618406,Change in the number of wound complications,Number of participants requiring re-amputation,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
15902,NCT04346524,Maternal complications during pregnancy,Fetal complications during pregnancy,,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
15903,NCT05613920,Changes in blood glucose levels over time,pregnancy outcomes,Apgar score of newborn,2022-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15904,NCT01146314,Improvement of health status of overweight children,Improvement of health behaviors and psychosocial adjustment,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
15905,NCT00892151,Number of Participants Rated Successful (<=3) at Performing Specific Tasks,Number of Participants Who Rated Clarity and Usefulness of User Instructions as >=3,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
15906,NCT05195567,Analysis of system accuracy based on DIN EN ISO 15197,,,2022-02-17,COMPLETED,INTERVENTIONAL,['NA']
15907,NCT05449782,Macrovascular endothelial function,Leg perfusion pressure,Photoplethysmography (PPG) blood flow,2021-05-17,COMPLETED,INTERVENTIONAL,['NA']
15908,NCT03610412,The effect of cinnamomum cassia on body weight,The effect of cinnamomum cassia potentiates the IGF1 insulin response on body fat%.,,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15909,NCT02152852,Improvement in HbA1c,Physical and mental functioning,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
15910,NCT01268488,Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 15mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Numbers of Forearm Blood Glucose (BG) Results Within +/- 5 to 15 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
15911,NCT02832739,Level of and potential changes in technology acceptance in participants,Level of and potential changes in eHealth Literacy in participants,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
15912,NCT03490136,Prevalence of type 2 diabetes,Changes in dietary habits,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
15913,NCT05911256,Change in participant HbA1c values,Change in Glycemic variability from baseline,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15914,NCT00564668,Safety,HbA1c,,2004-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
15915,NCT01832311,level of vascular endothelial growth factor in aqueous humor,degree of corneal edema,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15916,NCT01307917,"compare endothelial function by studying reactive hyperemia, nitric oxide, and proinflammatory factors in adolescents (12-21 years old) with diabetes vs. healthy sex- and age-matched control subjects.","examine the effects of flavonoids on vascular function, urine nitric oxide, and proinflammatory factors in patients with diabetes mellitus",,2009-07,WITHDRAWN,INTERVENTIONAL,['NA']
15917,NCT01290575,"Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.",AUC(0-24 h) and postprandial AUC(0-4h) for biomarkers of glucose homeostasis,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15918,NCT03085550,Degree of wound healing,Patient reported outcome measures,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
15919,NCT01072708,Describe the natural history of the glucose tolerance in cystic fibrosis patients and to identify the predictive factors of the reversibility or the aggravation in the disorders of the glucidic metabolism.,"Estimate the probability of arisen the complications associated to the disorders of the glucidic metabolism : - deterioration of the respiratory function, - lung exacerbations - alteration of the nutritional state",,2009-04,COMPLETED,INTERVENTIONAL,['NA']
15920,NCT02174562,"Percent of Participants With Improvement in Hemoglobin A1c by 0.5%""",Adherence as Measured By Percentage of Doses Taken as Prescribed,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
15921,NCT05295329,IMR improvementcompared with baseline.,,,2022-04-01,UNKNOWN,INTERVENTIONAL,['NA']
15922,NCT00870454,Mean of the last 7 daily average diabetic peripheral neuropathy (DPN) pain scores,The mean of the last 7 Daily Sleep Interference scores.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15923,NCT02387749,Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.,Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
15924,NCT03668808,Continuous Glucose Monitoring - Time in Range (70-140 mg/dl),Sleep Efficiency Measured by ActiGraph,,2018-11-16,COMPLETED,INTERVENTIONAL,['PHASE4']
15925,NCT04867785,Change From Baseline in Hemoglobin A1c (HbA1c),"Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943",,2021-05-13,COMPLETED,INTERVENTIONAL,['PHASE2']
15926,NCT01094054,Disposition Index,Gastric emptying and intestinal transit,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15927,NCT02402985,Variance of glucose metabolism after different diet intervention,Variance of intestinal hormones,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
15928,NCT05880810,Mean daily glucose,Percentage of subjects to continue use of continuous glucose monitor,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15929,NCT03289494,"Mean postprandial incremental Area Under the Curve (iAUC), measured by CGMS",Charaterisation of acceptability to H-SDS diet in free living conditions,,2017-08-30,COMPLETED,INTERVENTIONAL,['NA']
15930,NCT03811470,All cancers,Cost-effectiveness,,2017-05-31,RECRUITING,OBSERVATIONAL,['NA']
15931,NCT01685502,Decrease rate of HbA1c,Body weight,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
15932,NCT03672409,Change in knowledge measurements in diabetes by questionnaire,,,2018-09-05,UNKNOWN,INTERVENTIONAL,['NA']
15933,NCT01805245,Diabetes Distress,Mean Night Diastolic Ambulatory Blood Pressure,Mindfulness,2012-01,COMPLETED,INTERVENTIONAL,['NA']
15934,NCT03436212,Relationships between glucose levels and insulin doses,,,2017-09-05,UNKNOWN,INTERVENTIONAL,['NA']
15935,NCT01508858,AUC of levonorgestrel,Adverse events,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15936,NCT06209411,Number of participants who completed OGTT during the first year postpartum,"Number of women with abnormal OGTT who get tests including hemoglobin, lipid profile, creatinine.",,2024-03-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15937,NCT00337337,"Changes in glycemic parameters including fasting plasma glucose, postprandial plasma glucose, insulin sensitivity and lipid profile",Acceptabiliy and tolerability,,2005-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
15938,NCT04025801,Confocal microscopy exam of sub-basal corneal nerve fibre tortuosity (NFT) by using the CCMetrics software,,,2019-07-31,UNKNOWN,OBSERVATIONAL,['NA']
15939,NCT04796779,Time in Range,CGM-measured Percent Below 54 mg/dL,"CGM-measured % >300 mg/dL During the Four Hours Following the Announced Meal, or Until the Next Meal Bolus is Given, for the Missed Meal Bolus Challenge",2021-04-21,COMPLETED,INTERVENTIONAL,['NA']
15940,NCT00263939,"Health related quality of life (HRQoL) at 2wks and 4wks during the intervention, immediately post intervention and at 6 months and 1 year post intervention","self-care self-efficacy at 2wks and 4wks during the intervention, immediately post intervention and at 6 months and 1 year post intervention",,2004-07,COMPLETED,INTERVENTIONAL,['NA']
15941,NCT03553680,Change in Diabetes Distress,Change in Diabetes Self-Care,,2017-10-20,COMPLETED,INTERVENTIONAL,['NA']
15942,NCT01727661,exercise testing with near-infrared spectroscopy,quality of life,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
15943,NCT02970656,Glycosylated Hemoglobin (HbA1c),DNA Methylation,,2017-02-08,COMPLETED,INTERVENTIONAL,['NA']
15944,NCT02876744,Detection and measure of ischemic territories in central and peripheral retina,,,2017-04-04,COMPLETED,OBSERVATIONAL,['NA']
15945,NCT00855010,Bone Turnover Marker - Plasma 25-hydroxyvitamin D,Disposition Index,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
15946,NCT03334318,iGFR at the end of the PERL trial,HBGI (High blood glucose index),,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
15947,NCT04190160,The Diabetes Treatment Satisfaction (DTSQ),Cognitive function (MMSE),,2018-11-19,COMPLETED,INTERVENTIONAL,['NA']
15948,NCT02114554,Prognostic factors for poor outcome,,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
15949,NCT00931879,Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot.,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15950,NCT04779645,Change in Cardiovascular Disease (CVD) Risk Markers.,,,2021-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15951,NCT03371940,Change in depression status - Diagnosis of Major Depressive Disorder,Cost effectiveness analyses,,2012-01-01,COMPLETED,INTERVENTIONAL,['NA']
15952,NCT02955875,Medications knowledge at 9 months,Cost-effectiveness of pharmaceutical care at 9 months,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
15953,NCT01555164,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15954,NCT03089333,Change in Systolic Blood Pressure,Change in microalbuminuria,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15955,NCT05247437,Changes in weight from baseline (week 0) to posttreatment (week 9),Changes in the scores on the Weight loss self-efficacy scale,,2022-02-19,UNKNOWN,INTERVENTIONAL,['NA']
15956,NCT02079870,Ad libitum energy intake during a lunch meal (following a standardised breakfast meal),Incidence of adverse events,,2014-03-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15957,NCT02883751,Wound closure,Cost-benefit ratio of ulcer treatment following minor amputations,,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
15958,NCT03647306,MI-IS,,,2018-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15959,NCT00231660,The percent change in body weight and change in HbA1c from baseline (Week 0) to one year after maintenance therapy (Week 60).,"Changes from baseline or from enrollment to Week 60 in BMI and HRQOL measures; safety evaluations, such as adverse events and vital signs throughout study.",,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15960,NCT03091686,Participants' intentions to reduce occupational sitting time,Participants confidence to reduce occupational sitting time,,2017-08-17,COMPLETED,INTERVENTIONAL,['NA']
15961,NCT05516576,"Remission of diabetes after endoscopic gastroplasty with endomina, in patients with type-2 diabetes and class I obesity",,,2023-09-29,RECRUITING,INTERVENTIONAL,['NA']
15962,NCT01787214,Within-day glucose variability,Net glycemia at 4 hours,,2013-06,TERMINATED,INTERVENTIONAL,['NA']
15963,NCT00097071,HbA1c,"Measurements of glycaemic control, safety parameters including frequency of hypoglycaemia, laboratory tests, clinical evaluations and adverse events",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15964,NCT01910727,Change in percent of total calories from fat from baseline through 12 months follow-up,Increased numbers of individuals having been screen for diabetes between baseline and 12 months follow-up,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
15965,NCT02744963,Appropriate medicine adherence,Healthcare costs including medication costs,Count of healthcare encounters,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
15966,NCT03068273,CGM patient acceptability questionnaire - patient-reported outcome,Hyperglycemia (>250 mg/dL): rate comparison (type 2 diabetes),,2015-05,COMPLETED,INTERVENTIONAL,['NA']
15967,NCT00653302,% of responders with HbA1c<7% and/or a final decrease of HbA1c>15% compare to the basal value (HbA1c final - HbA1c basal).,AE/SAE evaluation,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15968,NCT00269646,insulin sensitivity,Flow-mediated dilation,,2004-11,UNKNOWN,INTERVENTIONAL,['NA']
15969,NCT05132179,Time to healing,"Change of diabetic foot ulcer´s, DFU´s, depth",,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
15970,NCT05015894,"AUC0-∞,NNC0480-0389,SD, area under the NNC0480-0389 plasma concentration time curve after a single dose","Cmax,NNC0480-0389,SD, Maximum observed NNC0480-0389 plasma concentration after a single dose",,2021-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
15971,NCT04209075,Gastrointestinal (GI) Tolerability Score,Stool Short Chain Fatty Acids (SCFA),,2020-03-10,COMPLETED,INTERVENTIONAL,['PHASE2']
15972,NCT00762684,Change from baseline in glycosylated hemoglobin.,Change from baseline in urinary albumin to creatinine ratio.,,2004-11,TERMINATED,INTERVENTIONAL,['PHASE3']
15973,NCT00700622,Change From Baseline in HbA1c to Week 16,,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3']
15974,NCT03877783,retention rate,Memory function,,2020-10-19,UNKNOWN,INTERVENTIONAL,['NA']
15975,NCT02513875,fasting glucose (mg/dL),TC (mg/dL),,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15976,NCT01783275,Splanchnic glucose uptake,Endogenous glucose production,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15977,NCT05745441,24-hour total fat oxidation,14-hour post-dinner cumulative dietary fat oxidation,,2023-07-05,RECRUITING,INTERVENTIONAL,['NA']
15978,NCT03199638,"HbA1c, Glycated Hemoglobin",Insulin Sensitivity Score (ISS),,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
15979,NCT03703869,Change in HbA1c at month 6,Body weight,,2018-03-06,COMPLETED,OBSERVATIONAL,['NA']
15980,NCT01587599,drug-drug-interactions,improved overall health status,,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
15981,NCT02291874,Fasting plasma glucose,"Adverse events (AEs), vital signs, and laboratory tests",,2014-10-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15982,NCT03204799,Metagenomic profile change,blood glucose change,,2016-12-17,UNKNOWN,OBSERVATIONAL,['NA']
15983,NCT02889510,Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1),Changes From Baseline on Measurements of Respiratory Function Defined by Residual Functional Capacity (RFC),,2016-10-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15984,NCT00703612,"Lowering of blood glucose be it fasting, random or post prandial",Lowering of glycosylated hemoglobin (HbA1C).,,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15985,NCT02856113,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in CD26 (CD8+T Cells) Surface Antigen Levels at Weeks 26 and 52,,2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15986,NCT00931372,Area under the insulin secretion curve,Area under the insulin secretion curve,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15987,NCT03312179,MACE,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15988,NCT05544266,"Phenotypic and genotypic characterization of previously unknown forms of diabetes using Whole Genome Sequencing (WGS), and deeper phenotyping methods",,,2020-09-30,RECRUITING,OBSERVATIONAL,['NA']
15989,NCT05310916,"Evaluation of the study biomarkers, IL-6, and VEGF",Occurrence of adverse events,,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE3']
15990,NCT02813343,Glucose control (HbA1c levels),Standardized PROMs/PREMs,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
15991,NCT05236660,Foot ulcer recurrence during the 12-months follow-up (as the primary clinical outcome),Quality-adjusted life years,,2022-03-02,RECRUITING,INTERVENTIONAL,['NA']
15992,NCT05418699,HbA1c level,Coefficient of variation,,2022-09-26,RECRUITING,OBSERVATIONAL,['NA']
15993,NCT02197520,Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value),Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15994,NCT01877603,The relation between plasma irisin and endothelium-dependent vasodilation,,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
15995,NCT01413035,To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus,To evaluate the incidence and severity of adverse events of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus,,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15996,NCT01065948,"monitor safety and performance of FAS response in two different body sites (abdomen, forearm)","assess comfort level during FAS insertion, when worn during normal activities, and during FAS removal",,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15997,NCT06253351,HbA1c after HCL,nephropathy,,2024-03-13,RECRUITING,OBSERVATIONAL,['NA']
15998,NCT01614613,MAD Mean Absolute Value of the Difference Between Blood Glucose Meter (BGMS) Results and Corresponding YSI Blood Glucose (BG) Results in the Low BG Range(<70 mg/dL),Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
15999,NCT02582736,Hospitalization for a hyperglycemic emergency,,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
16000,NCT05262387,Change From Baseline in Plasma Glucose (PG) From the Start to the End of Exercise for Each Treatment Arm,Change From Baseline in Postprandial Plasma Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) for Each Treatment Arm,,2022-02-14,COMPLETED,INTERVENTIONAL,['PHASE1']
16001,NCT04025762,Time spent in the target sensor glucose range,"Total, basal and bolus insulin dose",Sleep quality assessment,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
16002,NCT04698018,"AUCIAsp,0-30min, area under the serum insulin aspart concentration-time curve from 0 to 30 minutes",Number of treatment emergent hypoglycaemic episodes,,2021-04-20,COMPLETED,INTERVENTIONAL,['PHASE1']
16003,NCT05790681,"Time to maximum observed serum insulin icodec concentration after a single dose (tmax,Ico,SD)","Model-based area under the serum insulin icodec concentration-time curve during one dosing interval at steady state (AUC,Ico,τ,SS,model)",,2023-04-25,RECRUITING,INTERVENTIONAL,['PHASE1']
16004,NCT05691985,The association of fibrinogen to albumin ratio (FAR) with DKD type 2.,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16005,NCT04096989,Health-related quality of life of short form 36 (SF-36),Body mass index (BMI),,2020-02-17,COMPLETED,INTERVENTIONAL,['NA']
16006,NCT04279613,Adverse Events,Change in the area under the plasma C-peptide concentration-time curve,,2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
16007,NCT01987258,Glycemic control,Excess post-exercise oxygen consumption (EPOC),,2013-06,COMPLETED,INTERVENTIONAL,['NA']
16008,NCT05714059,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),,2023-02-28,COMPLETED,INTERVENTIONAL,['NA']
16009,NCT04234373,Effect of a low-carb dietary intervention on glycemic control as defined by blood glucose level at 2h after an oral glucose tolerance test.,Effect of a low-carb dietary intervention on liver fat fraction as measured with MRI,,2020-07-01,RECRUITING,INTERVENTIONAL,['NA']
16010,NCT01609582,Time to First Occurrence of Any Component of Primary Major Adverse Cardiovascular Event (MACE) Composite,Time to First Occurrence of Any Component of Secondary Major Adverse Cardiovascular Event (MACE) Composite,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE3']
16011,NCT01163591,"The optimal eZscan unit to detect the presence of diabetic nephropathy as defined by eGFR and ACR using ROC analysis, sensitivity and specificity values.","A prediction algorithm using age, sex, body mass index and eZcan score will be developed to predict eGFR as continuous and categorical variables using Cox regression analysis.",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
16012,NCT04342845,Problem Areas in Diabetes Questionnaire,Stages of Change score,,2016-05-01,COMPLETED,INTERVENTIONAL,['NA']
16013,NCT03119142,Adherence to the Mediterranean diet,Inflammation,,2017-05-02,COMPLETED,OBSERVATIONAL,['NA']
16014,NCT04388280,Major adverse cardiovascular events (MACE),Differences in the outcome between functional and angiographic imaging in imaging arm,,2021-01-28,UNKNOWN,INTERVENTIONAL,['NA']
16015,NCT03771066,Change in rate of glucose appearance,Change in concentration of clostridia,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
16016,NCT04939753,Nephrogenic Diabetes Insipidus prevalence,Timing of symptoms of NDI,,2021-05-26,COMPLETED,OBSERVATIONAL,['NA']
16017,NCT01121276,Area under the blood glucose concentration-time curve,Area under the blood glucose concentration-time curve,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
16018,NCT00095446,Treatment satisfaction with insulin pump therapy,infusion set in-use times,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16019,NCT03922022,Rate of recruitment,EQ-5D-5L,,2019-05-21,COMPLETED,INTERVENTIONAL,['NA']
16020,NCT03869411,maximum rate of oxygen consumption,blood cholesterol,,2019-08-15,COMPLETED,INTERVENTIONAL,['NA']
16021,NCT05716503,Patient satisfaction of aesthetic outcome,,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
16022,NCT05247840,diagnostic accuracy of peripheral nerve conduction test 3.6,clinical symptoms of diabetic patients will be measured and compared to healthy children. 8.6,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16023,NCT05392959,the longitudinal change of the Index of Microvascular Resistance (IMR).,,,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE4']
16024,NCT02065349,"Change in mean of 24-hour average pain intensity, Numeric pain rating scale (NPRS)","Composite of pharmacokinetics of ASP8477 concentration: Trough concentration (Ctrough), observed maximum concentration (Cmax), Area under the curve (AUC)0-6",,2014-02-24,COMPLETED,INTERVENTIONAL,['PHASE2']
16025,NCT00660764,"Effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who hadn't been treated with cholesterol lowering drugs in the past 3 months.",Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.,,2003-05,COMPLETED,OBSERVATIONAL,['NA']
16026,NCT02132676,Change in Glycemic Control,Endocrinology Visits,,2016-04-25,COMPLETED,OBSERVATIONAL,['NA']
16027,NCT03740919,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values at Week 26,,2019-04-07,COMPLETED,INTERVENTIONAL,['PHASE3']
16028,NCT01493050,glucose metabolism,serum phosphate level,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
16029,NCT01247558,All-Cause Health Plan Costs,Demographics of Patients Taking Metanx®,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
16030,NCT00898534,Hemoglobin A1c,Number of phone and/or email contacts between practitioner and patient,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE4']
16031,NCT00171119,Change from baseline in urine albumin excretion rate after 24 weeks,Percent of patients returning to normal urine albumin excretion rate after 24 weeks,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE4']
16032,NCT03757910,Brain Tau SUVR,White Matter Hyper Intensity Volume,,2019-10-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
16033,NCT01333176,Does the HbA1c identify the same individuals as fasting and 2-hr pc glucose tests to identify diabetes and pre-diabetes in a First Nation community,"To identify the response rate of ""gold standard"" diabetes testing in a First nation community",,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
16034,NCT00419562,Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo,Rate of Type 1 Diabetes in Secondary Stratum (Stratum 3+4) When Treated With Oral Insulin Versus Placebo,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
16035,NCT00851903,HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period),Change in Body Weight From Baseline to Study Endpoint,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3']
16036,NCT03555734,Cardiovascular disease (CVD),Obesity,,2017-11-21,UNKNOWN,OBSERVATIONAL,['NA']
16037,NCT01566006,proteinuria,,,2012-04,UNKNOWN,INTERVENTIONAL,['NA']
16038,NCT03215953,Severe adverse events related to use of offloading device,Lifestyle limitation,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
16039,NCT05957055,The frequency of adverse events - lisdexamphetamine arm,"Percentage of trial participants achieving an improvement in ADHD symptom severity on the basis of Conners 3 ""hyperactivity/impulsivity"" scale",,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
16040,NCT00349362,The effect of 6 months of testosterone replacement on diabetes control measured by HbA1c in hypogonadal men with type 2 diabetes treated with insulin.,The effect of the CAG repeat polymorphism in exon 1 of the androgen receptor gene on the response of the study population to testosterone.,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16041,NCT02429232,Change from baseline in bone turnover markers,Change from baseline in urine biomarkers,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
16042,NCT05282602,Timed Up and Go Test,,,2022-02-20,COMPLETED,INTERVENTIONAL,['NA']
16043,NCT04354090,Incidence of adverse events and serious adverse events related to JY09,Immunogenicity,,2018-04-26,COMPLETED,INTERVENTIONAL,['PHASE1']
16044,NCT03448367,Safety of the FreeStyle Libre Flash Glucose Monitoring System,,,2018-02-27,TERMINATED,OBSERVATIONAL,['NA']
16045,NCT02276196,"Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF)",Blood Pressure,Arterial stiffness,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
16046,NCT02472236,Composite measure the plasma concentrations of Digoxin.,Incidence of adverse events and serious adverse events,,2015-06-08,COMPLETED,INTERVENTIONAL,['PHASE1']
16047,NCT00005124,,,,1969-07,COMPLETED,OBSERVATIONAL,['NA']
16048,NCT00699790,Change in HbA1c,"Other glycemic, atherosclerosis, lipid and mechanism-based biomarkers will be measured",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
16049,NCT01656850,Plasma Vitamin E Level at the Baseline and at the End of 3-month Dietary Intervention,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
16050,NCT02318706,Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain,Change in Visual Analog Scale From Baseline (Week 14) to Week 66 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
16051,NCT04782128,"The proportion of subjects who have improved by ≥2 steps from baseline in DRSS score at week 24, 52",Safety of RC28-E injection,,2021-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
16052,NCT01812811,Fraction of missed pulse wave analysis,Reproducibility of pulse wave analysis parameters,"Diurnal variation of brachial blood pressure, central blood pressure and pulse wave velocity",2012-09,COMPLETED,OBSERVATIONAL,['NA']
16053,NCT02954601,Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM),Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2']
16054,NCT02498002,ACADM Gene Expression in Subcutaneous Adipose Tissue,Post-Prandial Protein Oxidation,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
16055,NCT02506972,Incremental area under the blood glucose response curve,Time to baseline,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
16056,NCT04446026,Hb1Ac,Fasting glucose,,2020-07-08,COMPLETED,INTERVENTIONAL,['PHASE4']
16057,NCT03150654,Change macular pigment optical density from baseline at 6 months,Correlation analysis between macular pigment optical density and panretinal laser photocoagulation parameters during 6 months,,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
16058,NCT04141787,Clinical cure rate of deep-seated methicillin sensitive Staphylococcal infections,Adverse event rate,Duration of therapy,2019-07-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
16059,NCT06327191,"To determine whether treatment with metformin during pregnancy, in women with GDM, leads to a reduction in adiposity in the offspring at follow up as measured by anthropometric measurements and sum of skinfolds.",,,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16060,NCT05478525,Number of participants with adverse events [safety and tolerability of GLY-200],Change from baseline in 3-hours postprandial plasma insulin profile,,2022-08-03,COMPLETED,INTERVENTIONAL,['PHASE2']
16061,NCT00547183,Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in the SEP diary,"Change in the GAQ, SEP, IIEF, SEAR, and RSE scores.",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16062,NCT00537498,"Number of patients being alive, having no major amputation and healed ulceration","Each of overall survival, major amputation rate, survival free of major amputation rate, rate of ulcer healing, and safety",,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
16063,NCT04240652,Diabetic macular edema,Albumin-creatinine-ratio (mg/mmol),,2018-06-05,RECRUITING,OBSERVATIONAL,['NA']
16064,NCT02373319,Pre-post changes in blood lipid levels,Pre-post changes in body mass index,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
16065,NCT00528372,Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Last Observation Carried Forward [LOCF]): Group 2,Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Findings (Last Observation Carried Forward {LOCF]),,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
16066,NCT03378765,BMI,,,2018-01-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16067,NCT00403741,"Score on Treatment Self-Regulation Questionnaire(TSRQ)at Treatment Self-Regulation Questionnaire (TSRQ) at 3 months, 9 months and 15 months after assesment's day of the education period.","HbA1c et lipid profile at 3 months, 9 months and 15 months after assesment's day of the education period.",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
16068,NCT05949281,Change in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L),Safety-related events,Change in interleukin messenger ribonucleic acid (mRNA) expression measured by quantitative polymerase chain reaction,2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE2']
16069,NCT03839511,Peak Epinephrine Levels,CGM Glucose,,2018-11-28,COMPLETED,OBSERVATIONAL,['NA']
16070,NCT00185601,HbA1c,Health care utilization,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
16071,NCT00118976,albuminuria,Tertiary: differences in response to treatment in patients with different ACE/ID and other renin angiotensin system genotypes.,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
16072,NCT05237076,Chemosensitivity of carotid bodies during baseline and euglycemic clamp,HRV during baseline and euglycemic clamp,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
16073,NCT03627182,Change from baseline in Glycosylated Hemoglobin (HbA1c),Evaluate safety of CKD-501 from number of participants with adverse events,,2018-04-26,UNKNOWN,INTERVENTIONAL,['PHASE3']
16074,NCT01542060,HbA1c (glycosylated haemoglobin),Incidence of hypoglycaemic episodes,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
16075,NCT01257373,Cumulative major adverse cardiovascular events（MACE）,Stroke,,2010-04,UNKNOWN,OBSERVATIONAL,['NA']
16076,NCT04277598,Wound area reduction after 4 weeks treatment with APO-2,Evaluation of Quality of Life: questionnaire,,2020-10-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16077,NCT04567225,Time to Anion Gap Closure,Incidence of Hypoglycemia,,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE4']
16078,NCT06003634,Number of Participants with Change in A1c,Social Network Scale,,2023-11-20,RECRUITING,OBSERVATIONAL,['NA']
16079,NCT04445168,Moderate to vigorous physical activity (MVPA),Health-related quality of life,,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA']
16080,NCT03909555,Difference in the proportions of chronic complications,Difference of quality of life,New biomarkers which may indicate the occurrence of chronic complications of diabetes,2019-06-01,UNKNOWN,OBSERVATIONAL,['NA']
16081,NCT02378493,Antibiogram results,The capacity of the S. aureus strains isolated to create biofilms in the presence of antibiotics,Perception threshold for vibrations at the ankle (Hz),2015-12-16,COMPLETED,OBSERVATIONAL,['NA']
16082,NCT05782192,HbA1c change from baseline at week 24,Pancreatic β-cell function change (calculated by HOMA-β ) from baseline at week 24 and week 52,,2019-06-13,COMPLETED,INTERVENTIONAL,['PHASE3']
16083,NCT00237250,Change in area under the 0-2 hour prandial glucose curve at 12 weeks,Change in fasting proinsulin/insulin ratio at 12 weeks,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16084,NCT00469287,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
16085,NCT04531111,Impact of COVID-19 pandemic and lockdown on glycemic control among a sample of Egyptian children and adolescents with type 1 diabetes,Impact of COVID-19 pandemic and lockdown on insulin dosage among a sample of Egyptian children and adolescents with type 1 diabetes,,2020-07-07,UNKNOWN,OBSERVATIONAL,['NA']
16086,NCT03064321,Average Glucose Control for Last 3 Months Assessed by A!C level,Sleep Quality,Insomnia Severity,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
16087,NCT03847129,Static two-point discrimination (S2PD) test,,,2015-08-20,COMPLETED,INTERVENTIONAL,['NA']
16088,NCT01525992,Hemoglobin A1c,Blood pressure,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
16089,NCT00198900,,,,2000-01,COMPLETED,OBSERVATIONAL,['NA']
16090,NCT00609986,Acute/Active Rejection,Severe Hyperglycemia,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
16091,NCT01456650,Change in plasma fasting glucose,HbA1c levels,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4']
16092,NCT00123435,Weight loss,Quality of life and participant satisfaction,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
16093,NCT00554671,Hemoglobin A1c,Health-care Costs to the VHA,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
16094,NCT03476460,Incidence of contrast nephropathy during the first 48 hours after contrast administration,Determination of biomarkers of contrast nephropathy during the first 48 hours after contrast administration,,2014-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
16095,NCT02747277,Frequency of CD19 and IgM low B cells in cord blood of babies born from autoimmune mothers,,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
16096,NCT03740698,% Time in Target Range Defined as 3.9-10mmol/l,,,2021-02-01,TERMINATED,INTERVENTIONAL,['NA']
16097,NCT02162212,Arm elevation.,"Disability of the Arm, Shoulder, and Hand (DASH) questionnaire",,2014-09,COMPLETED,INTERVENTIONAL,['NA']
16098,NCT06137222,Incidence of adverse events (AEs) and serious adverse events (SAEs). Primary safety endpoint,Wound size (area in cm2) reduction from baseline/treatment initiation,,2023-12-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16099,NCT00509223,HbA1c Change,,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
16100,NCT02023320,Change in HbA1c from baseline,Change in serum C-peptide from baseline,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
16101,NCT01897688,To demonstrate the safety and efficacy of islet transplantation under alemtuzumab induction for treatment of Type-1 Diabetes (T1D) in subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes.,To relate clinical transplant outcomes based upon islet quantity/quality to organ donor characteristics.,,2012-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
16102,NCT05684406,evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabetic patients,evaluate the potential of leukocyte telomere length as biomarker in type 2 diabetic patients,,2023-01,RECRUITING,OBSERVATIONAL,['NA']
16103,NCT00992537,Area under the glucose infusion rate curve,Maximum observed insulin aspart concentration,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
16104,NCT02833415,Change in Glycerol Enrichment,,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4']
16105,NCT05680207,improvement in The Diabetes Empowerment Scale scores,improvement in triglyceride,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
16106,NCT05375656,Glycemic variability during Inuit diet,Glycemic variability during habitual diet,Fecal proteomics.,2022-01-08,COMPLETED,INTERVENTIONAL,['NA']
16107,NCT04762719,Uptake of 11C-ER 176 in the Stomach Muscle,Percentage of Immune Cells With CD45 Expression,,2021-05-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16108,NCT02643251,Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score,Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE2']
16109,NCT05322551,Changes in lipid related biochemical parameters,Dietary Intake changes,,2022-06-24,RECRUITING,OBSERVATIONAL,['NA']
16110,NCT05977465,Change in HbA1c %,,,2022-01-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16111,NCT05067270,"Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas",,,2021-10-22,COMPLETED,INTERVENTIONAL,['PHASE1']
16112,NCT05293808,Effects of different doses of aspirin on platelet aggregation,Valuation of RAC1 levels in platelets,,2014-05-01,COMPLETED,INTERVENTIONAL,['PHASE4']
16113,NCT03779139,Clarke score,,,2019-08-01,RECRUITING,INTERVENTIONAL,['NA']
16114,NCT04753099,parental competence with managing child's care,,,2020-10-09,COMPLETED,INTERVENTIONAL,['NA']
16115,NCT00484419,Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint,Mean Percentage of Change in LDL-C Levels From Week 0(Baseline) to Week 16 (Least Squares Mean),,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
16116,NCT05544825,75-g Oral Glucose Tolerance Test (120 minute glucose),High-density lipoprotein cholesterol,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA']
16117,NCT05427084,TBR (Tissue-to-blood ratio) of the most-diseased segment (MDS) of the ascending aorta,Change in monocyte marker expression,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16118,NCT01700075,full recovery from atherosclerotic diseases,normalised laboratory and instrumental data,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
16119,NCT03766334,Average blood glucose fluctuations at endpoint and baseline,Waist circumference(endpoint)-Waist circumference(baseline),,2018-12-05,WITHDRAWN,INTERVENTIONAL,['NA']
16120,NCT02087826,Response to the Mixed Meal Tolerance Test,Response to Metformin,Response to a Mixed Meal Tolerance Test after Metformin,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16121,NCT05386927,Urine metabolomics,,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
16122,NCT05597709,Analysis of risk factors for clinical outcomes in patients with T2DM,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
16123,NCT03295578,Wellbeing,Qualitative user experiences,BMI,2017-10-02,COMPLETED,INTERVENTIONAL,['NA']
16124,NCT02701569,Glycated hemoglobin,Treatment satisfaction as measured by the World Health Organization-Diabetes Treatment Satisfaction Questionnaire,Depressive symptoms as measured by the Beck's Depression Inventory,2014-07,COMPLETED,INTERVENTIONAL,['NA']
16125,NCT03778580,Bone formation in serum by P1NP,Advanced glycation endproducts,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
16126,NCT05231174,AUROC of the self-evaluation tool,,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA']
16127,NCT01337141,Optimise metabolic control,Treatment adherence,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
16128,NCT06141811,Evaluation of incidence of adverse events,,,2023-04-25,RECRUITING,OBSERVATIONAL,['NA']
16129,NCT04120844,Problem Areas in Diabetic (PAID) Questionnaire,Stages of Change score,,2016-05-01,COMPLETED,INTERVENTIONAL,['NA']
16130,NCT00407771,"The magnitude of platelet aggregation inhibition before randomization, 10 minutes (t=0) and 8 hours (t=8) post tirofiban administration using the Ultegra RPFA assay.",Major adverse cardiac events (MACE) at 24 hours and 30 days post PCI.,,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
16131,NCT00231023,,,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
16132,NCT02756117,Change in plasma 2-AAA from baseline to peak post-lysine ingestion (anticipated 2-4 hours post-ingestion),Change in urinary 2-AAA from baseline to peak post-lysine ingestion (anticipated 2-4 hours post-ingestion),,2016-05,COMPLETED,INTERVENTIONAL,['PHASE1']
16133,NCT05791929,Area Under ROC curve generated by the statistical model able to discriminate between healing and not healing ulcers,The AUC of the models estimated according to different sites of ulcers.,,2023-04-13,WITHDRAWN,OBSERVATIONAL,['NA']
16134,NCT06060743,insulin information sheet,Insulin Injection Skill Observation Form,,2022-11-01,COMPLETED,INTERVENTIONAL,['NA']
16135,NCT01145599,"Identify ""progressors""","Identify correlations between ""progressors"" and study outcomes.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
16136,NCT05900505,"To compare participant satisfaction with NSRCH (social navigator) vs. standard care (social worker), as measured by the Client Satisfaction Questionnaire (CSQ).","To compare change in Quality of Life (QOL) of participants (pre/post intervention) referred to NSRCH (social navigator) vs standard care (social worker), as measured by the WHOQOL-BREF.",To compare the resource cost of the social navigator compared to the social worker.,2023-06-26,RECRUITING,INTERVENTIONAL,['NA']
16137,NCT00997282,Changes in HbA1C from baseline,Changes in 3 hour PPG AUC from baseline,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16138,NCT03565809,Diabetes control,hospitalization for falls and femoral fracture,,2017-05-02,COMPLETED,OBSERVATIONAL,['NA']
16139,NCT06317584,Diabetes Empowerment scale,Albumin to Creatinine Ratio (ACR),,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16140,NCT02131272,Change in HbA1c (Glycosylated Haemoglobin),Incidence of Adverse Events (AEs),,2014-06-11,TERMINATED,INTERVENTIONAL,['PHASE3']
16141,NCT02941874,Normal values of IRAP concentration will be calculated by making the average of the three dosages of IRAP measured at base line.,Temporal reproducibility of the concentration of IRAP,kinetic profile of the concentration of IRAP during OGTT,2017-04-07,COMPLETED,OBSERVATIONAL,['NA']
16142,NCT04430608,Time In Range (TIR) for blood glucose,Course of hospital stay.,,2020-05-25,UNKNOWN,INTERVENTIONAL,['NA']
16143,NCT02425410,Delay between viral events and T1D diagnosis,Age at T1D diagnosis as a quantitative trait,,2010-03,UNKNOWN,OBSERVATIONAL,['NA']
16144,NCT03661684,AUC for glucose during OGTT,AUC for Insulin during OGTT,,2016-06-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
16145,NCT03022682,Complete recruitment of IDEO cohort participants to spur novel and creative interactions between investigators that have transformative potential in obesity research.,Adipose tissue inflammation and fibrosis,,2015-02,RECRUITING,OBSERVATIONAL,['NA']
16146,NCT03936062,"Relative hazard of composite outcome of ACS/unstable angina, Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
16147,NCT00933881,Improvement in heart rate control post-GDM,Improvement in SDB post-GDM,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
16148,NCT04328207,Percentage of participants that adhere to referral appointment,,,2020-11-18,RECRUITING,INTERVENTIONAL,['NA']
16149,NCT01051089,"HbA1c, serum adipokine levels",VO2max,,2009-06,UNKNOWN,INTERVENTIONAL,['NA']
16150,NCT01353066,Measurement of the progression carotid intima media thickness (CIMT) at 24 months after entry into the trial relative to baseline,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16151,NCT06003153,Insulin response to oral semaglutide treatment,Baseline incretin level,,2024-03-12,RECRUITING,INTERVENTIONAL,['PHASE4']
16152,NCT04025489,Investigation of gene polymorphism and other markers in 500 subjects,Effect of vitamin d supplementation on raging and other metabolic measures.,,2020-03-01,RECRUITING,INTERVENTIONAL,['NA']
16153,NCT01847092,Changes in Urine Albumin to Creatinine Ratio (UACR),Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
16154,NCT04613700,Duration of ad libitum meal,Gallbladder motility,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
16155,NCT02824510,Subcutaneous glucose evolution,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
16156,NCT05624970,insulin sensitivity,A body shape index (ABSI),,2022-11-09,RECRUITING,INTERVENTIONAL,['NA']
16157,NCT00477204,Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor.,,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
16158,NCT04507347,Primary composite endpoint consisting of incidence of cardiac mortality and/or number of worsening of heart failure and/or change from baseline to week 48 in functional capacity,,,2021-06,WITHDRAWN,INTERVENTIONAL,['PHASE3']
16159,NCT01713764,Hemoglobin A1c,Hemoglobin A1c,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
16160,NCT00935805,Blood pressure,Fasting blood glucose,,2006-07,UNKNOWN,OBSERVATIONAL,['NA']
16161,NCT01525238,Geometric Mean of Apparent Volume of Distribution at Terminal Phase After Extravascular Administration (Vz/F) of Dapagliflozin,Number of Participants With Marked Urinalysis Abnormalities,,2012-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
16162,NCT04924504,Association between insulin sensitivity Versus structural and functional changes in the placenta,Changes from baseline in the central aortic pressure waveform,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
16163,NCT01357603,Pharmacokinetic Parameters: Maximum concentration (Cmax),Pharmacodynamic parameter: GIR max and tGIR max,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16164,NCT05151770,Algorithm efficacy,Influence of the insulin administration on algorithm results,,2021-12-30,COMPLETED,OBSERVATIONAL,['NA']
16165,NCT04643171,superoxide dismutase,lipid hydroperoxidase,,2020-11-19,UNKNOWN,INTERVENTIONAL,['NA']
16166,NCT01014884,Determine the impact of multidisciplinary team interventions in reducing the rate of non-elective hospitalizations over a 12 month period compared to usual care,Determine the impact of multidisciplinary team interventions versus usual care on the length of stay (LOS) of each non-elective hospitalization,,2009-11,TERMINATED,INTERVENTIONAL,['NA']
16167,NCT05307172,the rate of annual decline in glomerular filtration rate (GFR year n+1 - GFR year n) measured by iohexol clearance,The occurrence of severe liver damage,,2022-05-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16168,NCT04219462,the Five-Version of International Index of Erectile function,,,2019-12-02,UNKNOWN,INTERVENTIONAL,['NA']
16169,NCT03231709,Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period,Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group),,2017-08-18,COMPLETED,INTERVENTIONAL,['PHASE4']
16170,NCT01513473,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory),"Insulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)",,2012-01-16,COMPLETED,INTERVENTIONAL,['PHASE3']
16171,NCT03138174,To meet the requirements of ISO 15197:2015,,,2017-03-23,COMPLETED,OBSERVATIONAL,['NA']
16172,NCT02063321,Prevalence of Diabetic Macular Edema or clinically significant Diabetic Macular Edema,Range of visual deterioration and occurence of blindness in relation to general treatment (insulin vs. OAD or combination therapy),,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
16173,NCT04626453,Oxyhemoglobin differences,blood glucose level in mg/dL,,2020-10-29,COMPLETED,INTERVENTIONAL,['NA']
16174,NCT00703989,prostacyclin synthase activity,,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
16175,NCT05854069,Gaps in CGM use,CGM satisfaction during the intervention period,Satisfaction with data-sharing relationships,2023-04-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
16176,NCT04441216,Between-group differences in glycemic excursion during 75g OGTT as indicated by area under the curve (AUC) plasma glucose concentration during 12-week on-treatment and 12-week off treatment period,Prevalence of euglycaemic chinese subject after 12-week on-treatment and 12-week off treatment period,,2020-08-02,RECRUITING,INTERVENTIONAL,['NA']
16177,NCT00545857,C-peptide response to a Sustacal meal,Hemoglobin A1c,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16178,NCT04902378,Glycemic control as reflected by percent glucose time-in-range,Proportion of participants who experience device-related adverse events,,2021-06-15,RECRUITING,INTERVENTIONAL,['NA']
16179,NCT04642534,Correlation of in vitro circadian parameters (amplitude and magnitude) with clinical metabolic health outcomes (body weight),"Glucose excursion (time-in-range, coefficient of variation)",Metabolomic parameters of energy metabolism,2020-02-12,COMPLETED,OBSERVATIONAL,['NA']
16180,NCT02591576,Long term excess mortality,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
16181,NCT02923089,Postprandial plasma insulin,,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
16182,NCT05762783,Daytime time-in-range (TIR),,,2023-03-27,RECRUITING,OBSERVATIONAL,['NA']
16183,NCT01708096,Insulin sensitivity,Weight reduction,Insulin signaling and glucose transport in skeletal muscle,2009-10,COMPLETED,INTERVENTIONAL,['NA']
16184,NCT04758364,gait speed,,,2021-02-20,COMPLETED,OBSERVATIONAL,['NA']
16185,NCT00934414,To compare the relative bioavailability and bioeffect of TI Inhalation Powder in subjects with type 2 diabetes who smoke and who do not smoke to determine relative insulin bioavailability,,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2']
16186,NCT02412852,Reporting of Adverse Events During 12 Week Study Period,Assessment of Blood Oxygenation. (Pulse Oximetry),,2015-04-28,COMPLETED,INTERVENTIONAL,['PHASE2']
16187,NCT00042471,Effect of varying needle length on bioavailability of Pramlintide,Effect of varying needle length on safety and tolerability of Pramlintide,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2']
16188,NCT05619198,Percentage of time spent in sensor-derived time in range (3.9-10.0 mmol/L) during and after a bout of exercise,Physical activity level assessed by Actigraph GT3x,,2022-12-19,RECRUITING,INTERVENTIONAL,['NA']
16189,NCT02202668,Transcutaneous Raman spectra of subcutaneous deep wound soft tissue and underlying bone,Wound temperature post-Transcutaneous Raman Spectroscope,,2014-09,TERMINATED,INTERVENTIONAL,['NA']
16190,NCT01982253,Change From Baseline in HbA1c at Week 12.,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12,,2013-10,TERMINATED,INTERVENTIONAL,['PHASE2']
16191,NCT04460885,Change in HbA1c,"Time spent > 10 mmol/L (180 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6",,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3']
16192,NCT00046501,to measure change in glycemic control as measured by hemoglobin A1c (A1c).,"Clinical values: physical examination, vital signs, change in age-adjusted body mass index (BMI)",,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
16193,NCT05297110,rate of fasting glycemia level reduction,rate of adverse effects,,2021-08-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16194,NCT01257464,Insulin release,Incretin Response,,2010-09,TERMINATED,INTERVENTIONAL,['PHASE2']
16195,NCT05354947,Number of Hepatic Adverse Events - Elevation of liver transaminases AST / ALT.,Number of Metabolism and nutrition disorders - Hypoglycemia,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
16196,NCT01365507,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
16197,NCT01933256,The safety and tolerability of repeat doses of HIP2B in subjects with type 2 diabetes mellitus.,Glucose-stimulated insulin secretion.,Pharmacodynamic (PD) effects of repeat doses of HIP2B on measures of glycemic control and β-cell function,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
16198,NCT03781102,Change in Body Mass Index (BMI) Percentile,Change in demographic and social and environmental risk factors for T2D,,2019-07-01,SUSPENDED,INTERVENTIONAL,['NA']
16199,NCT05479435,Hearth Rate,Body Mass Index (BMI),,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
16200,NCT01185496,,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
16201,NCT06192940,Insulin Injection,Acute Diabetes Events,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16202,NCT02420392,Difference of incretin sensitivity of pancreatic beta cell measured by hyperglycemic clamp with GLP-1 and GIP infusion,Difference of Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
16203,NCT00223782,Plantar Pressure,,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
16204,NCT00067886,,,,2003-03,COMPLETED,OBSERVATIONAL,['NA']
16205,NCT01653899,To assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant,2. To obtain preliminary data on the efficacy of IDN-6556 to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.,,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16206,NCT00060918,Change from baseline in HbA1c at 5 months,"Blood pressure at 3 and 5 months. Body weight at 3 and 5 months. Lab values (glucose, insulin, triglycerides, cholesterol, and albumin:creatinine ratio) at 3 and 5 months.",,2001-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16207,NCT00619983,Visual Analog Scale for Pain,,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE4']
16208,NCT01677104,skin blood flow,,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
16209,NCT05245110,Changes from baseline Health-related quality of life at 12 weeks,,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
16210,NCT03890991,Diabetes self-care activities measured using the Revised Summary of Diabetes Self-care Activities,Proportion of participants who adhere to yearly eye and foot screening,,2019-02-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16211,NCT01669473,Medication adherence,"Clinical outcomes-systolic blood pressure, HbA1, and LDL cholesterol.",,2013-06,COMPLETED,INTERVENTIONAL,['NA']
16212,NCT04463277,Serum Lipid Profile.,,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
16213,NCT04005261,Correlations of fasting C-peptide concentrations with patients characteristics and biochemical findings,,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
16214,NCT03127852,Quality of Life as Measured by SF-36,Self-efficacy as Measured by the SEMCD6.,,2016-08-23,COMPLETED,INTERVENTIONAL,['NA']
16215,NCT04041492,Insulin,HOMA Index,,2017-02-14,COMPLETED,INTERVENTIONAL,['NA']
16216,NCT01934608,Medication adherence to each of the chronic medications as measured by the proportion of days covered (PDC) measure,"Secondary outcomes will be continuous gaps (e.g. 15, 30, or 60 days) in medication use.",,2013-09,COMPLETED,INTERVENTIONAL,['NA']
16217,NCT00775541,"MRI, mRS, urine and blood samples",7 day food and DHQ food questionnaire,,2007-10,TERMINATED,INTERVENTIONAL,['NA']
16218,NCT04797208,Time in range,Level 2 hypoglycaemia,Usability,2023-01-09,RECRUITING,INTERVENTIONAL,['NA']
16219,NCT05503303,"Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols",,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
16220,NCT01040806,HbA1c level,LDL cholesterol level,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
16221,NCT03027934,Aggregation Response,Reticulated Platelet Reactivity Index (PRI),,2017-08-28,WITHDRAWN,INTERVENTIONAL,['PHASE4']
16222,NCT02089152,Culture-confirmed melioidosis,Overall melioidosis,,2014-04-01,COMPLETED,INTERVENTIONAL,['NA']
16223,NCT04322240,measurement of Compound Muscle Action Potential (CMAP) distal latency,,,2020-04-02,COMPLETED,INTERVENTIONAL,['NA']
16224,NCT05822349,change in anxiety level,,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
16225,NCT04878419,Recruitment Rate,Correlation of outcome expectation on degree of change in participants Time in Range after the educational intervention.,Correlation of childhood opportunity index (COI) with degree of change in participants' Time In Range after the educational intervention.,2021-06-17,COMPLETED,INTERVENTIONAL,['NA']
16226,NCT00013208,,,,na,COMPLETED,INTERVENTIONAL,['NA']
16227,NCT05570162,Adherence to Flash 1,Percentage of patients attaining the the International Consensus on Time in Range (ICTR),,2022-11-01,COMPLETED,INTERVENTIONAL,['NA']
16228,NCT00765817,Change in Glycosylated Hemoglobin (HbA1c),Percentage of Subjects Experiencing Minor Hypoglycemia,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16229,NCT06224803,Concentration of HbA1c,Concentration of Blood Sugar,,2020-08-26,COMPLETED,INTERVENTIONAL,['NA']
16230,NCT00536965,HbA1c profile,,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
16231,NCT00550979,endothelial function,,,2007-09,UNKNOWN,OBSERVATIONAL,['NA']
16232,NCT04420728,Effect of Auto vs. Manual Mode of MiniMed 670G on Time in Target Range Assessed via CGM,"Assess Feasibility of Auto-mode MiniMed 670G via study recruitment, retention and completion rates.",Impact of Weaning on Total Daily Insulin Requirement Assessed by Child Food and Liquid Intake Questionnaire,2020-07-15,COMPLETED,INTERVENTIONAL,['NA']
16233,NCT01722643,HbA1c at 12 Months,Daily Frequency of Self Monitoring of Blood Glucose Checks 12 Months Following Enrollment,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
16234,NCT03547960,Gestational diabetes,Insulin secretion,,2018-05-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
16235,NCT04889859,diabetes remission rate (%),changes in gut microbiota,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
16236,NCT03817099,Rate of participants completed the study,Efficacy potential on body mass index,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
16237,NCT02913703,Effect of preprandial ghrelin on glucose tolerance,Effect of preprandial ghrelin on insulin sensitivity (as measured by Matsuda index),,2017-01-11,COMPLETED,INTERVENTIONAL,['PHASE1']
16238,NCT04776239,Post-PCI coronary artery endothelial function as assessed via FFR,Number of participants with Target Vessel Failure,,2021-08-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16239,NCT04035044,Analytical verification of Allegro - Urine Albumin comparison,,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
16240,NCT00639808,12-lead ECG data,Scintigraphy to measure rate of gastric emptying after ingestion of a radio-labeled meal,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
16241,NCT03362580,Educational level,,,2017-12-12,COMPLETED,OBSERVATIONAL,['NA']
16242,NCT00006068,,,,na,UNKNOWN,INTERVENTIONAL,['NA']
16243,NCT01840982,"1. Glycemic index(GI) 2. Glucose, insulin AUC(incremental area under the curve) 3. C-peptide","Homeostatic model assessment-insulin resistance(HOMA-IR), quantitative insulin sensitivity check index(QUICKI), Insulinogenic index(IGI)",,2010-10,COMPLETED,INTERVENTIONAL,['NA']
16244,NCT01045447,Change in Glycosylated Haemoglobin (HbA1c),Mean of 9-point Self Measured Plasma Glucose Profile (SMPG),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
16245,NCT02885428,diagnostic of the silent myocardial ischemia,,,2015-04-15,TERMINATED,OBSERVATIONAL,['NA']
16246,NCT01576887,Number of Adverse Events,Area under the curve,,2012-07-31,WITHDRAWN,INTERVENTIONAL,['PHASE2']
16247,NCT04106440,Connected Health Survey,Hemoglobin A1c values,,2019-10-18,COMPLETED,INTERVENTIONAL,['NA']
16248,NCT04495972,Insulin sensitivity,Level of 2-hour blood glucose Area Under the Curve (AUC),,2021-01-15,COMPLETED,INTERVENTIONAL,['NA']
16249,NCT04838743,Change in local laboratory measured HbA1c (Glycated haemoglobin ),Change in daily dose of Xultophy®,,2021-04-23,COMPLETED,OBSERVATIONAL,['NA']
16250,NCT03196687,percentage of Frequency of asymptomatic left ventricular diastolic dysfunction in diabetes mellitus type 2,,,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA']
16251,NCT00968708,Percentage of Participants With Primary Major Adverse Cardiac Events (MACE),Percentage of Participants With Secondary Major Adverse Cardiac Events (MACE),,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
16252,NCT02366481,Change in beta-cell function,Change in endothelial function (FMD),,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
16253,NCT03498534,Development of active TB,,,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE4']
16254,NCT03392961,Glucose concentration (Tmin) will be assessed. (Cohort 3),Number of Participants With Adverse Events as a Measure of Safety and Tolerability,,2014-03-27,COMPLETED,INTERVENTIONAL,['PHASE1']
16255,NCT06057454,Measurement of adverse events from the date of the first dose through 12 weeks of R-5280 tolerance,Measurement of clinical activity and to determine the gut microbiome profile in youth with recently diagnosed Type 1 Diabetes,,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE1']
16256,NCT02399332,Change in HbA1C from baseline at one year,Change in medication adherence from baseline at one year,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
16257,NCT02213159,Total dose of morphine consumed in Post Anesthesia Care Unit (PACU),overall satisfaction at one month,,2014-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16258,NCT03887403,Assess the effectiveness of the intervention to increase adherence to OAD treatment.,,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
16259,NCT00154414,HbA1c,Safety and tolerability,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
16260,NCT06067022,Temporomandibular Dysfunction,Pain assessment,,2023-01-05,COMPLETED,OBSERVATIONAL,['NA']
16261,NCT03057444,Change of short chain fatty acid concentration in the gut,Change from baseline in anthropometry at four weeks and eight weeks after consumption resistant starch type III,Change from baseline in GLP-1 (Glucagon-like peptide-1) at four weeks and eight weeks after consumption resistant starch type III,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
16262,NCT00171743,,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
16263,NCT03703999,HbA1c,insulin use,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
16264,NCT04267367,Change in HbA1c level,,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
16265,NCT01076634,"Area under the glucose infusion rate curve during one dosing interval at steady-date""",Area under the serum Insulin Degludec concentration-time curve,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
16266,NCT00854984,The obstacles to providing access and support to a generic online self help computerised cognitive behavioural therapy (CBT) programme for such patients.,"A change in depression (BDI-2), anxiety , social function (WASAS), quality of life (Euroqol 5D) or illness perception (IPQ-R) from participation in a self help programme.",,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
16267,NCT04623086,Mean Change in Percent Time in Range,Correction Boluses,,2020-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
16268,NCT01328561,,,,2011-03-17,TERMINATED,OBSERVATIONAL,['NA']
16269,NCT02351466,Changes in total and regional gray and white matter volumes and white matter microstructure.,Changes in Neurocognitive metrics including IQ as well as executive and visual-spatial memory.,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
16270,NCT02192450,Symptomatic nocturnal hypoglycaemia,Quality of life incl. pre-depression scale,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
16271,NCT01430143,Change from baseline in insulin sensitivity at 12 weeks,Diameter of t-tubuli in skeletal muscle,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
16272,NCT00447382,Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies,Adverse Events,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16273,NCT04565418,Change in 24 rhythm in whole-body energy metabolism (fat oxidation),Change in 24h rhythm in serum cholesterol,,2021-01-26,COMPLETED,INTERVENTIONAL,['NA']
16274,NCT04650646,Hypoglycaemia and QTc interval prolongation,"Type 1 diabetes, healthy controls and coagulability",,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
16275,NCT00857376,This study will provide information on the effect of a dose range of ALA on oxidative stress biomarkers.,To determine whether ALA improves vascular function through its effects on oxidative stress,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
16276,NCT01573897,Transcutaneous oxygen tension (PtcO2),,,2012-06-04,TERMINATED,OBSERVATIONAL,['NA']
16277,NCT04793165,To evaluate the effectiveness and safety of AP treatment without CHO counting in an outpatient setting.,"To determine, as a safety parameter, the percentage of time with glycemic levels less than 70 mg/dl.",,2021-03-08,COMPLETED,INTERVENTIONAL,['NA']
16278,NCT04761016,Blood pressure,Medication use,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16279,NCT01155206,Triglyceride-rich lipoprotein production rate,,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16280,NCT00894270,Assess the safety and effectiveness of 5 mm needles using either thigh or abdomen and either a pinched or unpinched skin fold.,Examine pain/discomfort of injections using the different techniques and the different injection sites.,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
16281,NCT01500850,Fasting Intact Proinsulin,Hypoglycemic events.,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
16282,NCT02258932,Eating behaviours of adult patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy measured using food diaries and food surveys.,Cardiometabolic risks of adult patients with Type 1 diabetes who are using insulin pump therapy.,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
16283,NCT05611541,Postprandial 2 hour blood glucose value,Level of compliance with the weekly diet,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
16284,NCT06119737,Thyroid Stimulating Hormone,,,2021-05-02,COMPLETED,INTERVENTIONAL,['NA']
16285,NCT03096392,"The amount of time, in minutes, glucose levels are within range (70-180 mg/dL)",Total doses of insulin used (in number of units of insulin injected) during the study,,2017-04-18,COMPLETED,INTERVENTIONAL,['PHASE2']
16286,NCT01315977,Activation of Antioxidant Response Element After Consumption of Green Tea,,,2011-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16287,NCT02199834,Change of HbA1c,Change in depressive symptom,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
16288,NCT00823953,serum fructosamine at end of trial phase in each of the groups,"Insulin resistance by the hyperinsulinemic, euglycemic clamp in a subset at the end of trial phase",,2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
16289,NCT01941290,Target Lesion Failure (TLF),Clinical Procedure Success,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
16290,NCT00799435,"Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity","Changes in Left Ventricular Diastolic Stiffness, Serum Levels of Advanced Glycation End Products, Serum Biomarkers of Collagen Synthesis, and Serum Levels of Brain Natriuretic Peptide",,2009-07,TERMINATED,INTERVENTIONAL,['PHASE4']
16291,NCT05347862,Change from Baseline Glycated Hemoglobin at 3 and 6 months,Short Form Health Survey (SF-36),Handgrip strength,2022-12-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16292,NCT00522158,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
16293,NCT02688218,Mean Change in Sensor Glucose in Subjects With Type 1 Diabetes,,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
16294,NCT01296100,The proportion of patients who reach normal levels of all glycaemic parameters.,Difference in reduction of 10 year-estimated cardiovascular risk score of 10% between the standard therapy control group and the lifestyle intervention groups (WHO CVD prediction chart).,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
16295,NCT00133809,The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation,The Number of Subjects Exhibiting Fasting C-peptide Levels ≥ 0.5 ng/mL,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
16296,NCT04558710,Coefficient of variation,Time Above Range,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
16297,NCT01057628,change from baseline in HbA1c,"safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-01-13,COMPLETED,INTERVENTIONAL,['PHASE3']
16298,NCT03232983,Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) Following LY900014 Administration,Total Amount of Glucose Infused (Gtot) Over Duration of the Clamp Procedure,,2017-08-14,COMPLETED,INTERVENTIONAL,['PHASE1']
16299,NCT03088410,Homeo-static Model Assessment-Insulin Resistance (HOMA-IR),,,2016-08-22,COMPLETED,INTERVENTIONAL,['PHASE4']
16300,NCT03226457,The Effect of Empagliflozin Versus Placebo on the Change in Urine Output.,"The Effect of Empagliflozin Versus Placebo on the Change to the Renal Biomarker, Cystatin C.",,2017-12-11,COMPLETED,INTERVENTIONAL,['PHASE4']
16301,NCT00121641,A1C Changes From Baseline at Week 24 - Open Label Cohort,Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC) - Open Label Cohort,Changes From Baseline in Heart Rate During the ST + LT Period - Open Label Cohort,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
16302,NCT00771069,Attainment rate to the target blood pressure.,Treatment pattern and factors that affect BP control,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
16303,NCT04420507,the gut and oral microbiome of healthy pregnant women,The glucose level during pregnancy,,2017-05-15,COMPLETED,OBSERVATIONAL,['NA']
16304,NCT00605189,Compare Energy Charge Between Wound Treatment Therapies,,,2007-07,TERMINATED,INTERVENTIONAL,['NA']
16305,NCT06297603,Change from Baseline in Hemoglobin A1c (HbA1c) (%),Change from Baseline in Systolic Blood Pressure (SBP),,2024-04-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
16306,NCT00349986,HgbA1c measurement,,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE4']
16307,NCT03354806,Foot tissue oxygenation on day 2,Foot tissue oxygenation in hyperaemia-induced condition on day 2,,2018-06,WITHDRAWN,INTERVENTIONAL,['NA']
16308,NCT06208618,Diabetes management self-efficacy,Belief in a healthy lifestyle,,2024-01-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
16309,NCT02117518,"Identification, isolation, propagation and targeting of autoreactive T cells from T1D patients",,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
16310,NCT05960565,Area under the glucose curve,Pharmacokinetics of glucagon,,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2']
16311,NCT01251016,Patient Selection,,,2010-07,UNKNOWN,OBSERVATIONAL,['NA']
16312,NCT05264376,"Change over time in Perceived Well-Being as assessed by the World Health Organization Well-Being Index (WHO-5; deWit et al., 2007).",,,2022-03-21,COMPLETED,INTERVENTIONAL,['NA']
16313,NCT03999385,Change in diabetes self-management,Change in Eating Disorder Symptomatology,,2019-06-24,UNKNOWN,INTERVENTIONAL,['NA']
16314,NCT01459809,Change in HbA1c,Frequence and incidence of hypoglycemia,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
16315,NCT04734132,Glycated hemoglobin (HbA1C),Conversion rate from prediabetes to normal,Microbiota composition,2019-01-22,COMPLETED,INTERVENTIONAL,['NA']
16316,NCT03670225,Determine if Invia Motion Endure supports acceptable progress towards the goal of therapy for DFU and PI/PU wounds,Evaluation of ease of use and satisfaction,Adequate management of the exudate,2018-10-16,COMPLETED,INTERVENTIONAL,['NA']
16317,NCT02178787,To Compare Profiles of TCD-blood Flow Velocities (TCD_BFV).,To Compare Profiles of UTlight Blood Flow (UT_BF) and Regional Oximetry (UT_Ox).,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
16318,NCT03415256,Skin blood flow,balance,,2018-11,WITHDRAWN,INTERVENTIONAL,['NA']
16319,NCT01134224,Area under the glucose infusion rate curve (only for IDegAsp),Area under the insulin aspart concentration-time curve (only for BIAsp 30),,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
16320,NCT02164279,Identify predictive non-invasive urinary biomarkers,Relation of urinary markers with patient characteristics,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
16321,NCT03730662,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia,,2018-11-20,COMPLETED,INTERVENTIONAL,['PHASE3']
16322,NCT00478127,,,,na,COMPLETED,OBSERVATIONAL,['NA']
16323,NCT04236895,PD endpoint,Safety endpoints,,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE1']
16324,NCT04109235,Change in HbA1C,Physical Activity (minutes per week),,2020-02-13,RECRUITING,INTERVENTIONAL,['NA']
16325,NCT04653961,Sensor glucose percentage of time in hyperglycemia above 250 mg/dl,Number of Serious Adverse Events,The amount of bolus insulin dose,2020-06-01,RECRUITING,INTERVENTIONAL,['NA']
16326,NCT04428723,Analysis of hormonal responses during mixed meal testing.,Relationship between hormonal responses and microbiome.,Safety outcome- hyperglycemia and hypoglycemia during the study,2020-08-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16327,NCT03748420,Mean Change in A1c,Clinic-based Medical Care Costs,,2020-08-19,COMPLETED,INTERVENTIONAL,['NA']
16328,NCT02798172,"The primary endpoints were changes from baseline to week 26 in pulmonary function parameters [VC%, FVC%, FEV1%, PEF%, MVV%, TLC%, FEV1/FVC%, DLCO%, and DLCO/VA%] between pretherapy and posttreatment.","In addition, safety endpoints were assessed (AEs, clinical laboratory tests, vital signs, and electrocardiographic readings)",The changes of BMI from baseline to week 26 in intervention group (n=44) and control group (n=37).,2014-05,COMPLETED,INTERVENTIONAL,['NA']
16329,NCT00101478,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
16330,NCT02762708,Changes in the Gut Microbiome Following RYGB or Caloric Restriction,,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
16331,NCT04069234,Coronary Flow Velocity Reserve (CFR),Coronary flow parameter-LAD resting mean diastolic flow velocity,,2019-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE3']
16332,NCT01083043,Serum levels of endothelial dysfunction biomarkers and glycemic variability,Metabolic parameters and glycemic variability,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
16333,NCT04073524,Level of quality of life - total score,Level of self perceived stress,,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA']
16334,NCT05890950,Proportion of participants who discontinued study medication due to an AE,t1/2 of plasma K-833,,2023-03-13,COMPLETED,INTERVENTIONAL,['PHASE1']
16335,NCT06014879,Demographic and Medical Information Questionnaire,,,2023-08-07,RECRUITING,INTERVENTIONAL,['NA']
16336,NCT01963663,Serum concentration of YKL-40,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
16337,NCT00878813,Major disability or death,"severe cerebrovascular re-event (i.e. new TIA, and stroke)",,2009-03,COMPLETED,OBSERVATIONAL,['NA']
16338,NCT01618214,Change From Baseline in HbA1c (Glycosylated Haemoglobin),"Incidence of Hypoglycaemic Episodes (All, Major, Minor and Symptoms Only)",,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16339,NCT03319784,Change in blood glucose level,American Shoulder and Elbow Surgeon (ASES) Shoulder Score,,2018-09-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
16340,NCT04468152,We hypothesize that neck circumference correlated significantly with DME.,We hypothesize that the sRAGE levels were higher in the DME group.,,2018-07-07,COMPLETED,INTERVENTIONAL,['NA']
16341,NCT04269070,Change in 2-hour postprandial area-under-the-curve blood glucose at 2 weeks,Change in baseline workplace stepping time at 2 weeks,Change in central aortic diastolic and systolic blood pressure at 2 weeks,2021-03-25,COMPLETED,INTERVENTIONAL,['NA']
16342,NCT00891943,"Changes in weight, waist circumference and percent body fat at 12 months.","BMI, blood pressure, resting heart rate; obesity and weight related quality of life, Rosenberg measure of self-esteem changes at 12 months.",,2009-06,UNKNOWN,INTERVENTIONAL,['NA']
16343,NCT04230382,OGTT,,S-Magnesium,2020-01-20,COMPLETED,OBSERVATIONAL,['NA']
16344,NCT04997512,Mortality at 2 years,Scores from GOLD score,,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16345,NCT01614262,change in glycosylated hemoglobin using intensive periodic CGM monitoring vs traditional monitoring,quality of life data evaluation,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
16346,NCT01555008,Change from baseline in postprandial glucose,Area Under Curve (AUC),,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16347,NCT00833846,,,,2009-01-27,COMPLETED,OBSERVATIONAL,['NA']
16348,NCT05864183,comparison between the measurement of HbA1c in normal non prediabetics and prediabetics at Sohag university hospital .,,,2023-04-15,RECRUITING,OBSERVATIONAL,['NA']
16349,NCT06087679,change in resting PPS,Problem Areas In Diabetes (PAID-20),Kidney function measured as creatinine,2022-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16350,NCT03857802,Change of glycated hemoglobin levels.,Change in sleep quality: Pittsburgh Sleep Quality Index,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
16351,NCT01520831,Area under the GIR (Glucose Infusion Rate) profile (AUC GIR) in the interval 0-120 minutes,"t½, terminal half-life",,1999-04,COMPLETED,INTERVENTIONAL,['PHASE1']
16352,NCT02652026,Change from baseline in Glycosylated Hemoglobin (HbA1c),,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
16353,NCT03625752,Changes in pain as measured by the Visual Analog Scale (VAS),Adverse events,,2019-06-06,RECRUITING,INTERVENTIONAL,['NA']
16354,NCT01464437,To evaluate the dose-effect relationship of AMG 151 compared to placebo on fasting plasma glucose in subjects with type 2 diabetes treated with metformin,Adverse events,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
16355,NCT04639414,Histological resolution of NASH without worsening of fibrosis,Hepatic steatosis grade,,2021-03-26,RECRUITING,INTERVENTIONAL,['PHASE4']
16356,NCT01607294,assess the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes,"assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters",,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
16357,NCT00445003,Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks,Change in Optical Coherence Tomography Retinal Volume,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16358,NCT06096935,exom,exome variations,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16359,NCT03674866,Change in Glycated Haemoglobin (HbA1c),Reason(s) for discontinuing insulin degludec,,2018-10-29,COMPLETED,OBSERVATIONAL,['NA']
16360,NCT02463097,Change in A1C,Number of Diabetic Ketoacidosis (DKA) Events,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
16361,NCT04233801,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24,Number of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events,,2020-04-15,COMPLETED,INTERVENTIONAL,['PHASE3']
16362,NCT01549444,Renin and Aldosterone levels corelated to BP measurements,Blood pressure measurements,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
16363,NCT00108225,"IGF-1, GH, Body Composition",,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
16364,NCT04484779,Total and Domain Specific Score of the mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients,Likelihood of Site to Recommend the IIM System,,2020-07-14,COMPLETED,INTERVENTIONAL,['NA']
16365,NCT03013985,Mean Daily Blood Glucose Concentration After Hospital Discharge,Hospital Mortality,,2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE4']
16366,NCT01606397,Number of participants with one or more drug related adverse events (AEs) or any serious AEs,Change in fasting glucagon-like peptide-1 (GLP-1) level,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16367,NCT01170039,"Efficacy, Measured by the Average Number of Spontaneous Bowel Movements (SBMs) Per Week",Change in Scores on the Patient Assessment of Constipation Quality of Life (PAC-QOL) Questionnaire,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
16368,NCT02456922,Harmony 1 Sensor accuracy,,,2018-07,WITHDRAWN,INTERVENTIONAL,['NA']
16369,NCT05144360,Systolic blood pressure (SBP),Adverse events,,2022-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
16370,NCT03690778,Cmax of Metformin and rosuvastatin,,,2018-10-04,COMPLETED,INTERVENTIONAL,['PHASE1']
16371,NCT02409017,Mean maternal glucose,,,2015-04,TERMINATED,INTERVENTIONAL,['NA']
16372,NCT01795833,Number of Participants With Progression to Type 2 Diabetes,Total Physical Activity,,2013-06-03,COMPLETED,INTERVENTIONAL,['NA']
16373,NCT02049359,Change From Baseline A1C,"Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes",,2014-01,COMPLETED,INTERVENTIONAL,['NA']
16374,NCT05620927,Impaired awareness of hypoglycemia (IAH) - Clarke's Questionnaire,occurrence of cognitive impairment,,2022-11-24,RECRUITING,OBSERVATIONAL,['NA']
16375,NCT04830969,Change in Probing Pocket Depth at the 6-month Post-SRP Completed at Baseline,Change in Distance to the Healthy Plane Based on the Subgingival Plaque Microbiome at 6 Months,,2016-11-08,COMPLETED,INTERVENTIONAL,['PHASE2']
16376,NCT04181424,Glycemic control (HbA1c),Blood Pressure,,2019-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16377,NCT01471275,Glycosylated hemoglobin,Adverse events recorded,,2011-11,UNKNOWN,INTERVENTIONAL,['NA']
16378,NCT06197906,accuracy,,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16379,NCT03499704,Mean Change from Baseline in HbA1c at Week 26,Number of Participants who Achieved an HbA1c Goal Target of Less than (<) 6.5 Percent (%) at Week 26,,2020-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
16380,NCT05607160,Proportion of participants achieving the HbA1c target value,"Absolute change in HbA1c (%), from baseline to month 3 and 6",,2022-10-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16381,NCT01513369,reduction in HBA1c-levels,Change in used insulin dosage during study,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
16382,NCT01168076,,,,2001-12,COMPLETED,OBSERVATIONAL,['NA']
16383,NCT00986375,physical activity fruit & vegetable consumption,intervention engagement,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
16384,NCT06113588,Diabetes-related distress (patient and family member),Patient medical outcomes,,2023-06-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
16385,NCT02411578,Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment,CGM Coefficient of Variation,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
16386,NCT00276939,Hemoglobin A1c,Dietary Acceptability,,2003-09,COMPLETED,INTERVENTIONAL,['NA']
16387,NCT02637622,The importance of medication cost from patient perspective,,Self-reported difficulty in understanding and answering the survey questions,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
16388,NCT03940183,HbA1c,Body Mass Index,,2019-07-08,COMPLETED,INTERVENTIONAL,['PHASE3']
16389,NCT02035371,Area under the serum insulin aspart concentration-time curve,Maximum observed serum insulin aspart concentration,,2014-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
16390,NCT01626053,Changes in A1c levels for pretest and post test (Preset baseline and post-test 2 years,,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
16391,NCT05845242,"Correlation of the above features with the chance of developing ulcers (Risk 0, Risk 1, Risk 2 and Risk 3).","Assessing the practical needs for transferring measurements to a different environment (e.g., home) by interviewing the clinicians involved in the consortium.",,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16392,NCT06057623,Change of the isometric force,Change of Rate of Perceived Exertion,,2023-06-15,RECRUITING,OBSERVATIONAL,['NA']
16393,NCT00389896,HDL-C raising effects after 6 weeks,Effect on other lipids and lipoproteins at 6 weeks,,2001-07-26,COMPLETED,INTERVENTIONAL,['PHASE3']
16394,NCT04308291,Time in range (TIR),Glycemic parameters changes,,2021-02-15,COMPLETED,OBSERVATIONAL,['NA']
16395,NCT03437044,P2Y12 Reaction Units (PRU),Platelet Reactivity Index (PRI),,2018-03-14,COMPLETED,INTERVENTIONAL,['PHASE4']
16396,NCT03266952,Incidence of Stroke,Scoring cognitive impairment,Incidence of diabetes,1993-01,COMPLETED,OBSERVATIONAL,['NA']
16397,NCT00771004,Incidence of Cardiac Troponin I elevation (greater than 1 upper limit of normal) post-percutaneous coronary intervention with stent implantation.,Time course of Adiponectin Laboratory Procedure.,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
16398,NCT00502138,Fasting and postprandial pramlintide pharmacokinetics,Hemoglobin A1c,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16399,NCT03931434,Progression rates of low attenuation plaque under influence of Aged Garlic Extract (AGE) as compared to placebo.,Rate of change in endothelial function,,2016-02-23,COMPLETED,INTERVENTIONAL,['NA']
16400,NCT02037321,Non-alcoholic fatty liver disease (NAFLD) analysis,,,2013-05,UNKNOWN,OBSERVATIONAL,['NA']
16401,NCT04455633,Change from Baseline in Average Daily Pain Score (ADPS),Safety: # of AEs reported,,2020-07-07,COMPLETED,INTERVENTIONAL,['PHASE2']
16402,NCT04207619,Percent 13C enrichment of bicarbonate measured via carbon-13 magnetic resonance spectroscopy (13C-MRS),Change in serum epinephrine levels,,2020-02-19,RECRUITING,INTERVENTIONAL,['NA']
16403,NCT03385135,Endothelium-dependent vasodilation,Major adverse cardiac events (MACE),,2017-12,UNKNOWN,INTERVENTIONAL,['NA']
16404,NCT04378114,Bias (mg/dL) Between the Guardian™ Sensor (3) Values and Yellow Springs Instrument™ (YSI™) Plasma Glucose,Percentage of Guardian™ Sensor (3) Values That Were Within 20% of YSI™ Plasma Glucose Values,,2020-05-18,COMPLETED,INTERVENTIONAL,['NA']
16405,NCT00993304,"AUC0-8h (triglyceride), the area under the triglyceride-concentration-time curve in the interval 0-8 hours following a meal with a high fat content","Glucose, insulin, C-peptide and glucagon: AUC0-8 hours after meal with a high fat content",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
16406,NCT00634543,Change From Baseline in Pain Intensity Score at Day 43,Change From Baseline in Short Form-36 (SF-36) Score at Day 43,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
16407,NCT04062890,Blood Pressure,,,2019-12-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
16408,NCT00369148,glycohemoglobin,blood pressure,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16409,NCT01245166,The changes from baseline in HbA1c to the end of treatment period,"the change from baseline to the end of treatment in FBG, PBG, lipid profiles, and body weight. The safety evaluation will include: 1) Adverse events; 2) Laboratory data; 3) Physical examination; 4) Vital signs; 5) 12- lead ECG",,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
16410,NCT00446264,Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year,Number of Adverse Events,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2']
16411,NCT04515758,Participant and Instructor Age,Change in Exercise-related Self-Efficacy,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
16412,NCT05887544,Concentration of Indole-3-lactic acid in blood,Concentration of 3-Phenyllactic acid in urine,Exploratory analyses,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
16413,NCT03076528,Balance change from Baseline to 4 weeks quantified by body sway,Change of Incidents of foot problems,,2016-11-06,COMPLETED,INTERVENTIONAL,['PHASE2']
16414,NCT00396071,Change in C-peptide IAUC (0-4hr),Change in postprandial GLP-1,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16415,NCT01498276,Intergenerational transfer of diet-related behaviors,Efficacy of utilizing mothers to educate family members of disease risk and motivate healthy behaviors.,,2012-01-03,COMPLETED,OBSERVATIONAL,['NA']
16416,NCT03263494,Change in HbA1c from baseline to 26 weeks adjusted for baseline,Pittsburgh Sleep Quality Index,,2018-01-25,COMPLETED,INTERVENTIONAL,['PHASE3']
16417,NCT04331535,Time-to-new diagnosis of common complex disease,Medication adherence,Health status and quality of life,2020-07-17,RECRUITING,INTERVENTIONAL,['NA']
16418,NCT01042977,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16419,NCT04602754,Percentual reduction of LDL-c levels measured between the first visit and the last visit.,Incidence and severity of adverse events recorded during the study.,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE3']
16420,NCT01859793,Brachial Artery Flow Mediated Dilation,Circulating Inflammatory Markers VCAM-1,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16421,NCT05031871,AUC0-inf：Area under the curve from time 0 to infinity；,ADA：anti-drug antibody,,2021-09-02,COMPLETED,INTERVENTIONAL,['PHASE1']
16422,NCT04470635,Vascular endothelial growth factor level,Thiol/disulphide measurement,,2020-07-25,COMPLETED,OBSERVATIONAL,['NA']
16423,NCT04495114,Preoperative glucose,,,2017-08-31,COMPLETED,INTERVENTIONAL,['NA']
16424,NCT01386541,Assessment of the safety/tolerability of multiple dosing of BYK324677 given once daily (SID) or twice daily (BID) in healthy volunteers.,Exploratory assessment of the pharmacodynamics (PD) of multiple dosing of BYK324677 (SID or BID) under steady state conditions in healthy volunteers.,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16425,NCT01453751,Number of adverse events reported,reduction in requirement of insulin dosage compared to baseline,,2014-03,WITHDRAWN,INTERVENTIONAL,['NA']
16426,NCT02660476,"Diabetes Complications (Nephropathy, Neuropathy, Retinopathy)",Physical activity,,2014-10,TERMINATED,OBSERVATIONAL,['NA']
16427,NCT05902650,OCTA data,,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
16428,NCT04531163,Systolic blood pressure,,,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16429,NCT04389775,Number of treatment emergent adverse events (TEAEs),Trough plasma XW003 concentrations before next dosing (Day 1 to last dosing),,2020-03-29,COMPLETED,INTERVENTIONAL,['PHASE1']
16430,NCT05165693,Glucose positive area under the curve (AUC),Insulin Concentrations,Sensory Questionnaire,2022-02-23,COMPLETED,INTERVENTIONAL,['NA']
16431,NCT03366168,"To demonstrate that in humans, epithelial stem cells isolated from the base of human taste buds can be propagated.",To investigate if differentiation capability of the stem cells changes as a factor of age.,,2017-12-18,RECRUITING,OBSERVATIONAL,['NA']
16432,NCT03502109,Quality of Life (QoL) by visual analog scale (VAS),ACR (albumin-creatinine ratio),,2018-01-05,COMPLETED,INTERVENTIONAL,['NA']
16433,NCT01839370,Percent of Glucose Measurements within Target Range,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
16434,NCT00879801,The rate of conversion to diabetes of IGR subjects carrier of type 2 diabetes susceptibility genes,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
16435,NCT00099892,Change from baseline in HbA1c after 24 weeks,Change from baseline in fasting lipids at 24 weeks,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
16436,NCT02459535,"change in combined blood levels of glucose and insulin, expressed in calculated indices for insulin sensitivity",,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
16437,NCT03686722,Maximum excretion rate (Urate max),Maximum Glucose concentration(Gmax),,2017-09-09,COMPLETED,INTERVENTIONAL,['PHASE1']
16438,NCT00967629,serum AGE levels,inflammatory markers,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16439,NCT00856986,Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.,Hypoglycaemic Episodes Weeks 0-52,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16440,NCT01361594,Hospital Mortality,Cerebrovascular Events,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
16441,NCT00435786,,,,na,COMPLETED,OBSERVATIONAL,['NA']
16442,NCT01797601,Insulin effect on regional brain activity assessed by fMRI,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
16443,NCT01383304,"Combined primary endpoint: Cardiovascular death, acute myocardial infarction, ischaemic stroke",Single endpoints:cardiovascular death; acute myocardial infarction; ischemic stroke; stent thrombosis; all-cause death,Genotype according to pre-specified genetic single nucleotide polymorphisms (SNPs),2007-11,UNKNOWN,OBSERVATIONAL,['NA']
16444,NCT03445065,Cohort 2: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 90 to Day 120,Change From Baseline in the Partner Diabetes Distress Scale (Partner-DDS) Questionnaire Total and Subscale Scores at Day 60 and Day 180,,2018-02-28,COMPLETED,INTERVENTIONAL,['NA']
16445,NCT00516958,"To compare the rates of clinical success (cure + improvement) of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in patients with mild diabetic foot infections in non ischemic ulcers",To compare the treatment groups with respect to microbiological outcome. Incidence of adverse events and other safety outcomes,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
16446,NCT05452525,AUClast,,,2022-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
16447,NCT02317211,Glycemic Control,Blood lipids,,2014-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
16448,NCT04189510,Efficacy of Artificial Pancreas system,,,2021-04-01,WITHDRAWN,INTERVENTIONAL,['NA']
16449,NCT05147883,Score of Quality of Life,Depression,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
16450,NCT00130806,The difference in daily dose requirements of insulin after 24 weeks,"(a) HbA1C; (b) FPG; (c) Percent of patients with HbA1C <7.0%; (d) TG, HDL-C, non-HDL-C and apolipoprotein B; (e) Free Fatty Acids (FFA); (f) the incidence of hypoglycemic events at 24 weeks",,2005-09,TERMINATED,INTERVENTIONAL,['PHASE3']
16451,NCT05776420,Hemoglobin A1c,Carotenoid level,,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE3']
16452,NCT02367066,Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma C-Peptide,"Apparent Oral Plasma AZD1981 at Steady-State, CL_ss/F",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16453,NCT04234867,time to development of DKA,time to decrease of ph level,,2022-05-18,TERMINATED,INTERVENTIONAL,['PHASE1']
16454,NCT03746392,Documentation of goals of care,,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
16455,NCT01763567,Device Performance: Accuracy of HGMS,,Functionality of HGMS: Alerts and Alarms - % of Hyper False Alert,2012-03,COMPLETED,OBSERVATIONAL,['NA']
16456,NCT01342874,altered OGTT,delivery and neonatal outcomes,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
16457,NCT01449747,"Change in AUC of Active GLP-1, Total GLP-1 and Total GIP Between Before and After Sitagliptin Treatment",Differences of DPP-4 Activity After Sitagliptin Treatment Between Responder and Non-responder Groups,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
16458,NCT01629862,Absolute Change in Brachial Artery Flow-mediated Dilation (FMD).,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
16459,NCT02115555,Glycemic Control using HBA1C,Treatment Adherence Behaviors,Satisfaction,2014-05,COMPLETED,INTERVENTIONAL,['NA']
16460,NCT01404078,Tolerability of a Double Dose of Half Strength Polycap,Blood Pressure Reduction and Lipid Lowering in Type 2 Diabetics,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
16461,NCT01941238,Incidence of hypoglycemia,Rate of acute complications,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
16462,NCT00341237,Disease,,,2010-05-26,RECRUITING,OBSERVATIONAL,['NA']
16463,NCT03923114,Pituitary uptake of Ga-68-NODAGA-exendin,Metabolic status (ACTH),,2019-05-23,UNKNOWN,INTERVENTIONAL,['NA']
16464,NCT05390892,"Total (first and recurrent) cardiovascular, kidney, and death events",,,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE4']
16465,NCT04948931,Spielberger State-Trait Anxiety Scale (STAI),,,2021-07-28,COMPLETED,INTERVENTIONAL,['NA']
16466,NCT06057246,Post-prandial glucose response,Sleep duration,,2023-05-15,RECRUITING,INTERVENTIONAL,['NA']
